{
  "category": "Anatomic Pathology",
  "subject": {
    "name": "Breast",
    "url": "https://app.pathprimer.com/curriculum/a34ff663-5c88-4096-8685-f69f6bed7955",
    "lessons": {
      "Normal Breast, Disorders of Development, and Specimen Processing": {
        "name": "Normal Breast, Disorders of Development, and Specimen Processing",
        "url": "https://app.pathprimer.com/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
        "topics": {
          "Histology of Normal Breast": {
            "name": "Histology of Normal Breast",
            "url": "https://app.pathprimer.com/document/6f8be0e4-fbc3-4ce7-987f-d0102283bc75/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Introduction": {
                "Breast Origin and Function": [
                  {
                    "text": "The breast is a highly evolved modified skin appendageBreasts are the defining feature of the class Mammalia",
                    "sub_points": [
                      "Breasts are the defining feature of the class Mammalia"
                    ]
                  },
                  {
                    "text": "Multiple cell types are present: Epithelial, fibroblasts, adipocytes, endothelial, and immune cells"
                  },
                  {
                    "text": "There are many important differences in comparison to other organsProvides source of nourishment and immunologic protection for a different individual (infant)Undergoes continuous change over the life cycle in response to menarche, pregnancy, lactation, and menopauseTarget organ for a variety of hormones that regulate development and physiologic functionResults in a broad range of normal breast histologyDue to the superficial location, the breast has social, sexual, and cultural significanceBreast cancer is the only cancer with > 3,000-year history of 1st-person accounts by patientsPatients are often the 1st to diagnose their carcinoma in populations without screeningOften has an important influence on selecting treatment options",
                    "sub_points": [
                      "Provides source of nourishment and immunologic protection for a different individual (infant)",
                      "Undergoes continuous change over the life cycle in response to menarche, pregnancy, lactation, and menopauseTarget organ for a variety of hormones that regulate development and physiologic functionResults in a broad range of normal breast histology",
                      "Target organ for a variety of hormones that regulate development and physiologic function",
                      "Results in a broad range of normal breast histology",
                      "Due to the superficial location, the breast has social, sexual, and cultural significanceBreast cancer is the only cancer with > 3,000-year history of 1st-person accounts by patientsPatients are often the 1st to diagnose their carcinoma in populations without screeningOften has an important influence on selecting treatment options",
                      "Breast cancer is the only cancer with > 3,000-year history of 1st-person accounts by patients",
                      "Patients are often the 1st to diagnose their carcinoma in populations without screening",
                      "Often has an important influence on selecting treatment options"
                    ]
                  }
                ],
                "Embryologic Development": [
                  {
                    "text": "Mammary glands are a highly specialized and modified type of sweat gland2 ventral bands of thickened ectoderm (mammary ridges) form at the 5th or 6th week of fetal developmentAs an embryo develops, mammary ridges disappear except for a small portion that persists in the pectoral region and gives rise to mammary budsMammary buds begin to develop as solid downgrowths of the epidermis into the underlying mesenchymePrimary buds lead to the development of each breastThe primary bud leads to the development of secondary buds that develop into lactiferous ducts and their branchesOnly the main lactiferous ducts are formed at birth, and the remainder of the duct/lobular system remains underdeveloped until puberty",
                    "sub_points": [
                      "2 ventral bands of thickened ectoderm (mammary ridges) form at the 5th or 6th week of fetal developmentAs an embryo develops, mammary ridges disappear except for a small portion that persists in the pectoral region and gives rise to mammary buds",
                      "As an embryo develops, mammary ridges disappear except for a small portion that persists in the pectoral region and gives rise to mammary buds",
                      "Mammary buds begin to develop as solid downgrowths of the epidermis into the underlying mesenchymePrimary buds lead to the development of each breastThe primary bud leads to the development of secondary buds that develop into lactiferous ducts and their branches",
                      "Primary buds lead to the development of each breastThe primary bud leads to the development of secondary buds that develop into lactiferous ducts and their branches",
                      "The primary bud leads to the development of secondary buds that develop into lactiferous ducts and their branches",
                      "Only the main lactiferous ducts are formed at birth, and the remainder of the duct/lobular system remains underdeveloped until puberty"
                    ]
                  }
                ],
                "Normal Breast (Rule of 2s)": [
                  {
                    "text": "The breast has 2 types of epithelial cells, 2 types of stroma, and 2 main structuresEpithelial cellsLuminal cells and myoepithelial cells (MECs)StromaInterlobular stroma and intralobular stromaStructuresLarge ducts and terminal duct lobular units (TDLUs)",
                    "sub_points": [
                      "Epithelial cellsLuminal cells and myoepithelial cells (MECs)",
                      "Luminal cells and myoepithelial cells (MECs)",
                      "StromaInterlobular stroma and intralobular stroma",
                      "Interlobular stroma and intralobular stroma",
                      "StructuresLarge ducts and terminal duct lobular units (TDLUs)",
                      "Large ducts and terminal duct lobular units (TDLUs)"
                    ]
                  }
                ]
              },
              "Gross Anatomy": {
                "Anatomic Boundaries": [
                  {
                    "text": "Breasts rest on the anterior chest wall overlying the pectoralis major and minor musclesSuperior border at ~ 2nd rib; inferior border at 6th rib; lateral border at midaxillary line; medial border at edge of sternumThe deep margin of the breast rests on the fascia of the pectoralis major muscleBreast tissue often extends into the axilla (tail of Spence)",
                    "sub_points": [
                      "Superior border at ~ 2nd rib; inferior border at 6th rib; lateral border at midaxillary line; medial border at edge of sternum",
                      "The deep margin of the breast rests on the fascia of the pectoralis major muscle",
                      "Breast tissue often extends into the axilla (tail of Spence)"
                    ]
                  },
                  {
                    "text": "In some women, breast tissue is present in superficial subcutaneous tissue and can extend beyond grossly evident border of the breastMastectomies remove the majority of fibroglandular breast tissue but may not remove all epithelial cellsSuperficially located lobules can be left in the subcutaneous tissue of breast flaps",
                    "sub_points": [
                      "Mastectomies remove the majority of fibroglandular breast tissue but may not remove all epithelial cells",
                      "Superficially located lobules can be left in the subcutaneous tissue of breast flaps"
                    ]
                  }
                ],
                "Suspensory (Cooper) Ligaments": [
                  {
                    "text": "Cooper ligaments attach to the fascia of the skin and the pectoralis muscle"
                  },
                  {
                    "text": "Provide support and allow for mobility"
                  },
                  {
                    "text": "Swelling and edema of breast tissue around these ligaments causes a pitted orange peel appearance of the skin (peau d'orange)"
                  },
                  {
                    "text": "Carcinoma involving these ligaments results in skin retraction &/or dimpling"
                  }
                ],
                "Nipple": [
                  {
                    "text": "Positioned slightly medial and inferior to the center of the breastCone-shaped; average height: 10-12 mm",
                    "sub_points": [
                      "Cone-shaped; average height: 10-12 mm"
                    ]
                  },
                  {
                    "text": "10-15 major lactiferous duct orifices open on the surface of the nippleArranged radially in nipple papillaSome major ducts bifurcate below nipple and are distributed in widely separated areas of the breast",
                    "sub_points": [
                      "Arranged radially in nipple papillaSome major ducts bifurcate below nipple and are distributed in widely separated areas of the breast",
                      "Some major ducts bifurcate below nipple and are distributed in widely separated areas of the breast"
                    ]
                  },
                  {
                    "text": "The nipple-areolar complex is supported by a subdermal layer of circumferential smooth muscleFacilitates nipple erection and functions during nursingRare leiomyomas can arise from this muscle",
                    "sub_points": [
                      "Facilitates nipple erection and functions during nursingRare leiomyomas can arise from this muscle",
                      "Rare leiomyomas can arise from this muscle"
                    ]
                  }
                ]
              },
              "Microscopic Anatomy": {
                "Nipple": [
                  {
                    "text": "Covered by pigmented squamous epithelium"
                  },
                  {
                    "text": "Toker cells are a normal epidermal componentPresent in the majority of nipples if identified by cytokeratin 7 studiesUsually present as single cells near nipple orificesCan also form small clusters or glandular structuresThese cells have the appearance and immunoprofile of normal luminal cellsBland cells with clear or pale cytoplasmUsually positive for hormone receptorsIncidental findingNot associated with scaling exudate of nipple skin as is seen in ductal carcinoma in situ (DCIS) involving nipple skin (Paget disease)There is an insufficient number of Toker cells to disrupt the normal tight junctions of epithelial cellsMust be distinguished from Paget diseaseThe majority of cases of Paget disease overexpress HER2, whereas Toker cells are HER2(-)An increase in Toker cells can be seen in some conditions (Toker cell hyperplasia)Rare cases of Toker cell hyperplasia with nuclear atypia occur; may be the cell of origin of rare cases of Paget disease without DCIS identified deeper in the breast",
                    "sub_points": [
                      "Present in the majority of nipples if identified by cytokeratin 7 studies",
                      "Usually present as single cells near nipple orificesCan also form small clusters or glandular structures",
                      "Can also form small clusters or glandular structures",
                      "These cells have the appearance and immunoprofile of normal luminal cellsBland cells with clear or pale cytoplasmUsually positive for hormone receptors",
                      "Bland cells with clear or pale cytoplasm",
                      "Usually positive for hormone receptors",
                      "Incidental findingNot associated with scaling exudate of nipple skin as is seen in ductal carcinoma in situ (DCIS) involving nipple skin (Paget disease)There is an insufficient number of Toker cells to disrupt the normal tight junctions of epithelial cells",
                      "Not associated with scaling exudate of nipple skin as is seen in ductal carcinoma in situ (DCIS) involving nipple skin (Paget disease)",
                      "There is an insufficient number of Toker cells to disrupt the normal tight junctions of epithelial cells",
                      "Must be distinguished from Paget diseaseThe majority of cases of Paget disease overexpress HER2, whereas Toker cells are HER2(-)An increase in Toker cells can be seen in some conditions (Toker cell hyperplasia)Rare cases of Toker cell hyperplasia with nuclear atypia occur; may be the cell of origin of rare cases of Paget disease without DCIS identified deeper in the breast",
                      "The majority of cases of Paget disease overexpress HER2, whereas Toker cells are HER2(-)",
                      "An increase in Toker cells can be seen in some conditions (Toker cell hyperplasia)",
                      "Rare cases of Toker cell hyperplasia with nuclear atypia occur; may be the cell of origin of rare cases of Paget disease without DCIS identified deeper in the breast"
                    ]
                  },
                  {
                    "text": "Clear cells of nipple epidermis are keratinocytes with prominent glycogenated cytoplasmCells can mimic cells of Paget diseaseKeratinocytes are positive for high molecular weight keratins and HER2(-)",
                    "sub_points": [
                      "Cells can mimic cells of Paget disease",
                      "Keratinocytes are positive for high molecular weight keratins and HER2(-)"
                    ]
                  },
                  {
                    "text": "Ducts dilate to form lactiferous sinuses beneath nippleSinuses have serrated contours and are supported by smooth muscle, collagen, and elastic fibersMost common lesions are large duct papillomas and nipple adenomasFunction to assist as a milk reservoir during breastfeeding",
                    "sub_points": [
                      "Sinuses have serrated contours and are supported by smooth muscle, collagen, and elastic fibers",
                      "Most common lesions are large duct papillomas and nipple adenomas",
                      "Function to assist as a milk reservoir during breastfeeding"
                    ]
                  },
                  {
                    "text": "The basement membrane of the ducts is continuous with the basement membrane of the skinThe basement membrane surrounds the entire mammary ductal/lobular system and separates epithelial cells from breast stromaConsists of type IV collagen and lamininElastic fibers are normally present in varying amounts around mammary ducts but not lobulesWith age, the supporting structures of major ducts can weaken, allowing extravasation of contentsThe resulting chronic inflammation may cause nipple discharge and fibrosis (duct ectasia)",
                    "sub_points": [
                      "The basement membrane surrounds the entire mammary ductal/lobular system and separates epithelial cells from breast stromaConsists of type IV collagen and laminin",
                      "Consists of type IV collagen and laminin",
                      "Elastic fibers are normally present in varying amounts around mammary ducts but not lobules",
                      "With age, the supporting structures of major ducts can weaken, allowing extravasation of contentsThe resulting chronic inflammation may cause nipple discharge and fibrosis (duct ectasia)",
                      "The resulting chronic inflammation may cause nipple discharge and fibrosis (duct ectasia)"
                    ]
                  },
                  {
                    "text": "Keratin-producing squamous cells of the epidermis extend into the major duct orifices for 1-2 mmOutside of lactation, a keratin plug may be present in the nipple orificeThere is an abrupt transition from squamous cells to the normal luminal/myoepithelial lining of ductsIf keratin-producing cells extend deeper, keratin becomes trapped and the rupture of involved ducts can result in a subareolar abscess in response to extravasated keratin [squamous metaplasia of lactiferous ducts (SMOLD)]",
                    "sub_points": [
                      "Outside of lactation, a keratin plug may be present in the nipple orifice",
                      "There is an abrupt transition from squamous cells to the normal luminal/myoepithelial lining of ductsIf keratin-producing cells extend deeper, keratin becomes trapped and the rupture of involved ducts can result in a subareolar abscess in response to extravasated keratin [squamous metaplasia of lactiferous ducts (SMOLD)]",
                      "If keratin-producing cells extend deeper, keratin becomes trapped and the rupture of involved ducts can result in a subareolar abscess in response to extravasated keratin [squamous metaplasia of lactiferous ducts (SMOLD)]"
                    ]
                  }
                ],
                "Areola": [
                  {
                    "text": "Lacks pilosebaceous units and hair except at periphery"
                  },
                  {
                    "text": "Numerous sensory nerve endings are present"
                  }
                ],
                "Skin Appendages": [
                  {
                    "text": "Montgomery tuberclesNumerous sebaceous glands are present in the areolaOpen through small prominences at the periphery of the areolaBecome more prominent during pregnancy and lactation",
                    "sub_points": [
                      "Numerous sebaceous glands are present in the areola",
                      "Open through small prominences at the periphery of the areola",
                      "Become more prominent during pregnancy and lactation"
                    ]
                  },
                  {
                    "text": "Eccrine sweat glands and ductsPresent in breast dermis and skinAt other sites, syringomas arise from these glandsIn the breast, syringomatous tumors of the nipple are more closely related to breast epithelial cells",
                    "sub_points": [
                      "Present in breast dermis and skin",
                      "At other sites, syringomas arise from these glands",
                      "In the breast, syringomatous tumors of the nipple are more closely related to breast epithelial cells"
                    ]
                  },
                  {
                    "text": "Apocrine sweat glands and ductsPresent in axillary skin and areolaApocrine metaplasia in breast cysts has the same appearance as the cells in sweat glandsCharacterized by apocrine secretion due to the presence of apocrine snouts that are pinched off to form secretions (decapitation secretion)Nuclei are large and round with large, single nucleoliCytoplasm is abundant, eosinophilic, and often has cytoplasmic granules",
                    "sub_points": [
                      "Present in axillary skin and areola",
                      "Apocrine metaplasia in breast cysts has the same appearance as the cells in sweat glandsCharacterized by apocrine secretion due to the presence of apocrine snouts that are pinched off to form secretions (decapitation secretion)",
                      "Characterized by apocrine secretion due to the presence of apocrine snouts that are pinched off to form secretions (decapitation secretion)",
                      "Nuclei are large and round with large, single nucleoli",
                      "Cytoplasm is abundant, eosinophilic, and often has cytoplasmic granules"
                    ]
                  }
                ],
                "Large Duct System": [
                  {
                    "text": "15-20 major duct systems empty at the nippleAdditional smaller ductal systems open onto areola",
                    "sub_points": [
                      "Additional smaller ductal systems open onto areola"
                    ]
                  },
                  {
                    "text": "Ducts ramify until they form TDLUs"
                  },
                  {
                    "text": "Ductal systems vary considerably in size and extent and often overlapRarely confined to a single quadrantSize and extent vary greatly in different individualsSome large ducts branch and fill widely separate areas of the breastCannot be recognized grossly; requires duct injection or serial section reconstructionAnastomoses between ductal systems may be present",
                    "sub_points": [
                      "Rarely confined to a single quadrant",
                      "Size and extent vary greatly in different individuals",
                      "Some large ducts branch and fill widely separate areas of the breastCannot be recognized grossly; requires duct injection or serial section reconstruction",
                      "Cannot be recognized grossly; requires duct injection or serial section reconstruction",
                      "Anastomoses between ductal systems may be present"
                    ]
                  },
                  {
                    "text": "Significance for breast carcinomaDuctal carcinoma in situ (DCIS) is clonal population and usually involves a single duct systemThe distribution of DCIS generally follows the ductal systemFan-shaped with apex toward nippleMultiple duct systems may be involved whenDCIS grows into a 2nd duct system by crossing into another duct orifice at the nipple2 separate clonal neoplastic populations of DCIS are presentSome studies have reported anastomoses between ductal systemsIf these exist, DCIS could involve a 2nd ductal system via an anastomosis",
                    "sub_points": [
                      "Ductal carcinoma in situ (DCIS) is clonal population and usually involves a single duct system",
                      "The distribution of DCIS generally follows the ductal systemFan-shaped with apex toward nipple",
                      "Fan-shaped with apex toward nipple",
                      "Multiple duct systems may be involved whenDCIS grows into a 2nd duct system by crossing into another duct orifice at the nipple2 separate clonal neoplastic populations of DCIS are presentSome studies have reported anastomoses between ductal systemsIf these exist, DCIS could involve a 2nd ductal system via an anastomosis",
                      "DCIS grows into a 2nd duct system by crossing into another duct orifice at the nipple",
                      "2 separate clonal neoplastic populations of DCIS are present",
                      "Some studies have reported anastomoses between ductal systemsIf these exist, DCIS could involve a 2nd ductal system via an anastomosis",
                      "If these exist, DCIS could involve a 2nd ductal system via an anastomosis"
                    ]
                  }
                ],
                "Lobules": [
                  {
                    "text": "Formed when the terminal duct branches into multiple rounded acini (TDLU)This is the functional unit for milk production",
                    "sub_points": [
                      "This is the functional unit for milk production"
                    ]
                  },
                  {
                    "text": "Lobulocentric architecture consists of the terminal duct branching into multiple acini and surrounded by intralobular stromaImportant in distinguishing benign lesions that maintain this architecture from malignant lesions that do not",
                    "sub_points": [
                      "Important in distinguishing benign lesions that maintain this architecture from malignant lesions that do not"
                    ]
                  },
                  {
                    "text": "TDLU can unfold with coalescence of acini to form structures resembling ducts"
                  },
                  {
                    "text": "50% of all glandular tissue is located in the upper outer quadrantNearly 1/2 of all breast carcinomas occur in this quadrant",
                    "sub_points": [
                      "Nearly 1/2 of all breast carcinomas occur in this quadrant"
                    ]
                  },
                  {
                    "text": "The majority of breast lesions are thought to arise from the TDLUCysts, epithelial hyperplasia, sclerosing adenosis, and, most likely, carcinomas",
                    "sub_points": [
                      "Cysts, epithelial hyperplasia, sclerosing adenosis, and, most likely, carcinomas"
                    ]
                  }
                ]
              },
              "Epithelial Cells": {
                "Epithelial Cell Types": [
                  {
                    "text": "2 types of epithelial cells are present in breast: Luminal cells and MECsPrecursor/progenitor or stem cells are presumed to be present but are not morphologically recognizableSometimes referred to as intermediate or basal cellsMay give rise to both luminal cells and MECsSupported by occurrence of clonal neoplasms composed of both cell types (e.g., myoepitheliomas, adenoid cystic carcinoma)Patchy immunoreactivity for high molecular weight cytokeratins 5/6 and ER in epithelial hyperplasia supports a polyclonal proliferation of multiple cells types",
                    "sub_points": [
                      "Precursor/progenitor or stem cells are presumed to be present but are not morphologically recognizableSometimes referred to as intermediate or basal cellsMay give rise to both luminal cells and MECsSupported by occurrence of clonal neoplasms composed of both cell types (e.g., myoepitheliomas, adenoid cystic carcinoma)",
                      "Sometimes referred to as intermediate or basal cells",
                      "May give rise to both luminal cells and MECsSupported by occurrence of clonal neoplasms composed of both cell types (e.g., myoepitheliomas, adenoid cystic carcinoma)",
                      "Supported by occurrence of clonal neoplasms composed of both cell types (e.g., myoepitheliomas, adenoid cystic carcinoma)",
                      "Patchy immunoreactivity for high molecular weight cytokeratins 5/6 and ER in epithelial hyperplasia supports a polyclonal proliferation of multiple cells types"
                    ]
                  },
                  {
                    "text": "Normal ducts and lobules are lined by a 2-cell-layer epitheliumRecognition of the normal 2 cell layers is an important feature to distinguish benign lesions from invasive carcinomas",
                    "sub_points": [
                      "Recognition of the normal 2 cell layers is an important feature to distinguish benign lesions from invasive carcinomas"
                    ]
                  }
                ],
                "Luminal Cells": [
                  {
                    "text": "Form innermost layer lining ducts and aciniLuminal cells in TDLU produce milkLuminal cells in larger ducts do not undergo lactational change nor produce milk",
                    "sub_points": [
                      "Luminal cells in TDLU produce milk",
                      "Luminal cells in larger ducts do not undergo lactational change nor produce milk"
                    ]
                  },
                  {
                    "text": "Cells are cuboidal to columnar in shapeNuclei are small, round to oval, and usually have inconspicuous nucleoliCells have a moderate amount of eosinophilic cytoplasm",
                    "sub_points": [
                      "Nuclei are small, round to oval, and usually have inconspicuous nucleoli",
                      "Cells have a moderate amount of eosinophilic cytoplasm"
                    ]
                  },
                  {
                    "text": "Luminal cell phenotypeExpress luminal low molecular weight keratins, including 7, 8, 18, 19May also express basal keratinsSome, but not all, luminal cells express ERα &/or PR at any given timeHormone receptors are not expressed in normal proliferating luminal cellsReceptor (+) cells are present in both large duct system and TDLU but may be more frequent in latterExpress E-cadherin and other cateninsSome luminal cells express mammaglobin &/or gross cystic disease fluid protein 15 (GCDFP-15)Luminal cells are thought to be the precursor cells for the majority of breast carcinomasLineage fidelity loss in luminal epithelial cells is a hallmark of agingMarked by reduced luminal epithelial cell-specific transcriptomes and gain of MEC-like features",
                    "sub_points": [
                      "Express luminal low molecular weight keratins, including 7, 8, 18, 19May also express basal keratins",
                      "May also express basal keratins",
                      "Some, but not all, luminal cells express ERα &/or PR at any given timeHormone receptors are not expressed in normal proliferating luminal cellsReceptor (+) cells are present in both large duct system and TDLU but may be more frequent in latter",
                      "Hormone receptors are not expressed in normal proliferating luminal cells",
                      "Receptor (+) cells are present in both large duct system and TDLU but may be more frequent in latter",
                      "Express E-cadherin and other catenins",
                      "Some luminal cells express mammaglobin &/or gross cystic disease fluid protein 15 (GCDFP-15)",
                      "Luminal cells are thought to be the precursor cells for the majority of breast carcinomas",
                      "Lineage fidelity loss in luminal epithelial cells is a hallmark of agingMarked by reduced luminal epithelial cell-specific transcriptomes and gain of MEC-like features",
                      "Marked by reduced luminal epithelial cell-specific transcriptomes and gain of MEC-like features"
                    ]
                  }
                ],
                "Myoepithelial Cells (MECs)": [
                  {
                    "text": "Form the outermost layer between luminal cells and the basement membrane"
                  },
                  {
                    "text": "Cells form a contractile meshwork that does not cover the entire basement membraneThis results in gaps between MEC processes, resulting in luminal cells resting on the basement membrane",
                    "sub_points": [
                      "This results in gaps between MEC processes, resulting in luminal cells resting on the basement membrane"
                    ]
                  },
                  {
                    "text": "Multiple functionsHelp produce and maintain basement membraneLesions of MECs are often associated with matrix productionAid in maintaining luminal cell polarityInhibit angiogenesisContract for milk ejection during breastfeeding",
                    "sub_points": [
                      "Help produce and maintain basement membraneLesions of MECs are often associated with matrix production",
                      "Lesions of MECs are often associated with matrix production",
                      "Aid in maintaining luminal cell polarity",
                      "Inhibit angiogenesis",
                      "Contract for milk ejection during breastfeeding"
                    ]
                  },
                  {
                    "text": "Often flattened with small, round nucleiCytoplasm can be abundant and clear; may mimic lobular neoplasiaWith aging, cells can become prominent and spindled in shape (MEC atrophy)",
                    "sub_points": [
                      "Cytoplasm can be abundant and clear; may mimic lobular neoplasia",
                      "With aging, cells can become prominent and spindled in shape (MEC atrophy)"
                    ]
                  },
                  {
                    "text": "MECphenotypeExpress high molecular weight basal keratins 5/6, 14, 17May also express luminal keratinsExpress contractile proteins: Smooth muscle actin, calponin, smooth muscle myosin heavy chainAlso express p63, CD10, P-cadherin, S100, mapsinDo not express hormone receptorsMEC associated with carcinoma in situ may diminish in number and become displaced from basement membraneMay have altered phenotype and fail to express some MEC markersStains for multiple MEC markers may be helpfulComplete loss of MEC is a useful diagnostic feature to help recognize invasive carcinomaMay be precursors of some hormone receptor (-) carcinomasBasal used to describe carcinomas that may arise from MEC or MEC-like cellMany of these carcinomas express MEC markers",
                    "sub_points": [
                      "Express high molecular weight basal keratins 5/6, 14, 17May also express luminal keratins",
                      "May also express luminal keratins",
                      "Express contractile proteins: Smooth muscle actin, calponin, smooth muscle myosin heavy chain",
                      "Also express p63, CD10, P-cadherin, S100, mapsin",
                      "Do not express hormone receptors",
                      "MEC associated with carcinoma in situ may diminish in number and become displaced from basement membraneMay have altered phenotype and fail to express some MEC markersStains for multiple MEC markers may be helpfulComplete loss of MEC is a useful diagnostic feature to help recognize invasive carcinoma",
                      "May have altered phenotype and fail to express some MEC markers",
                      "Stains for multiple MEC markers may be helpful",
                      "Complete loss of MEC is a useful diagnostic feature to help recognize invasive carcinoma",
                      "May be precursors of some hormone receptor (-) carcinomasBasal used to describe carcinomas that may arise from MEC or MEC-like cellMany of these carcinomas express MEC markers",
                      "Basal used to describe carcinomas that may arise from MEC or MEC-like cell",
                      "Many of these carcinomas express MEC markers"
                    ]
                  }
                ],
                "Metaplastic Changes": [
                  {
                    "text": "Epithelial cells can take on different appearances due to injury, hormonal influences, or other unknown factors"
                  },
                  {
                    "text": "Cells look monomorphic due to metaplasiaIt can be very difficult to distinguish some cases of metaplasia from carcinomas with a metaplastic appearance",
                    "sub_points": [
                      "It can be very difficult to distinguish some cases of metaplasia from carcinomas with a metaplastic appearance"
                    ]
                  },
                  {
                    "text": "Squamous metaplasiaA squamous phenotype can occur in response to injury or inflammationThe different appearance can often raise concern for atypia or neoplasiaRare squamous carcinomas arise from areas of squamous metaplasia in cystsCarcinomas can have the appearance of atypical mitotically active, spindle-shaped cells in stroma, which can be shown to be epithelial in type by immunohistochemical studies",
                    "sub_points": [
                      "A squamous phenotype can occur in response to injury or inflammation",
                      "The different appearance can often raise concern for atypia or neoplasia",
                      "Rare squamous carcinomas arise from areas of squamous metaplasia in cystsCarcinomas can have the appearance of atypical mitotically active, spindle-shaped cells in stroma, which can be shown to be epithelial in type by immunohistochemical studies",
                      "Carcinomas can have the appearance of atypical mitotically active, spindle-shaped cells in stroma, which can be shown to be epithelial in type by immunohistochemical studies"
                    ]
                  },
                  {
                    "text": "Apocrine metaplasiaVery common change in cells lining cystic spaces and in papillomasResemble apocrine sweat glandsApocrine cells often express androgen receptor and show immunoreactivity for HER2Mixed apocrine and nonapocrine populations favor a benign lesionNuclei are large and round with prominent single nucleoliCytoplasm is abundant and eosinophilicRed cytoplasmic granules often presentApocrine snouts common",
                    "sub_points": [
                      "Very common change in cells lining cystic spaces and in papillomasResemble apocrine sweat glandsApocrine cells often express androgen receptor and show immunoreactivity for HER2",
                      "Resemble apocrine sweat glands",
                      "Apocrine cells often express androgen receptor and show immunoreactivity for HER2",
                      "Mixed apocrine and nonapocrine populations favor a benign lesion",
                      "Nuclei are large and round with prominent single nucleoli",
                      "Cytoplasm is abundant and eosinophilicRed cytoplasmic granules often presentApocrine snouts common",
                      "Red cytoplasmic granules often present",
                      "Apocrine snouts common"
                    ]
                  },
                  {
                    "text": "Clear cell changeCytoplasm is abundant and clearNuclei often small, hyperchromatic, and roundCan be present in either luminal cells or MECs",
                    "sub_points": [
                      "Cytoplasm is abundant and clear",
                      "Nuclei often small, hyperchromatic, and round",
                      "Can be present in either luminal cells or MECs"
                    ]
                  },
                  {
                    "text": "Columnar cell changeLuminal cells have a tall, columnar shape rather than cuboidalIf > 2 cell layers are present, termed columnar cell hyperplasia",
                    "sub_points": [
                      "Luminal cells have a tall, columnar shape rather than cuboidal",
                      "If > 2 cell layers are present, termed columnar cell hyperplasia"
                    ]
                  },
                  {
                    "text": "Paneth cell-like changeLuminal cells have brightly eosinophilic cytoplasmic granulesMay be related to apocrine metaplasiaAssociated with eosinophilic colloid-like secretionsCan be associated with microglandular adenosis and rare carcinomas",
                    "sub_points": [
                      "Luminal cells have brightly eosinophilic cytoplasmic granulesMay be related to apocrine metaplasia",
                      "May be related to apocrine metaplasia",
                      "Associated with eosinophilic colloid-like secretions",
                      "Can be associated with microglandular adenosis and rare carcinomas"
                    ]
                  }
                ]
              },
              "Mammary Stroma": {
                "Composition": [
                  {
                    "text": "Breast stromal composition depends on age, menstrual status, pregnancy history, and lactationComposed of varying amount of fibrous connective tissue and adipose tissueDuctal/fibrous tissue:adipose tissue ratio varies between individuals and changes over timeImportant determinant of mammographic densityMammographic appearanceIn young women, breast tissue is predominantly fibrous (radiodense or white)Mammography has low sensitivity due to difficulty detecting lesionsWith age, fibrous stroma is replaced by adipose tissueIn older women, breast tissue may be predominantly adipose tissue (radiolucent or black)Mammography has greater sensitivity as calcifications and small masses are detected more easilyObesity and postmenopausal hormone use can act to maintain breast tissue density",
                    "sub_points": [
                      "Composed of varying amount of fibrous connective tissue and adipose tissue",
                      "Ductal/fibrous tissue:adipose tissue ratio varies between individuals and changes over timeImportant determinant of mammographic density",
                      "Important determinant of mammographic density",
                      "Mammographic appearanceIn young women, breast tissue is predominantly fibrous (radiodense or white)Mammography has low sensitivity due to difficulty detecting lesionsWith age, fibrous stroma is replaced by adipose tissueIn older women, breast tissue may be predominantly adipose tissue (radiolucent or black)Mammography has greater sensitivity as calcifications and small masses are detected more easilyObesity and postmenopausal hormone use can act to maintain breast tissue density",
                      "In young women, breast tissue is predominantly fibrous (radiodense or white)Mammography has low sensitivity due to difficulty detecting lesions",
                      "Mammography has low sensitivity due to difficulty detecting lesions",
                      "With age, fibrous stroma is replaced by adipose tissue",
                      "In older women, breast tissue may be predominantly adipose tissue (radiolucent or black)Mammography has greater sensitivity as calcifications and small masses are detected more easilyObesity and postmenopausal hormone use can act to maintain breast tissue density",
                      "Mammography has greater sensitivity as calcifications and small masses are detected more easily",
                      "Obesity and postmenopausal hormone use can act to maintain breast tissue density"
                    ]
                  }
                ],
                "Interlobular Stroma": [
                  {
                    "text": "Responsible for the majority of breast volume"
                  },
                  {
                    "text": "The increase in breast size at puberty is primarily due to the increase in interlobular stromaHormonal influences on this stroma are poorly understood",
                    "sub_points": [
                      "Hormonal influences on this stroma are poorly understood"
                    ]
                  },
                  {
                    "text": "Cellular components of stroma include fibroblasts, myofibroblasts, adipocytes, blood vessels, and lymphaticsThe majority of fibroblasts and myofibroblasts are CD34(+)Some myofibroblasts are ER &/or PR (+)",
                    "sub_points": [
                      "The majority of fibroblasts and myofibroblasts are CD34(+)",
                      "Some myofibroblasts are ER &/or PR (+)"
                    ]
                  },
                  {
                    "text": "Large, hyperchromatic, multinucleated stromal cells can be seen and may be due to degenerative changesShould not be confused with atypia &/or neoplasia",
                    "sub_points": [
                      "Should not be confused with atypia &/or neoplasia"
                    ]
                  },
                  {
                    "text": "A variety of lesions that can occur in and outside of the breast arise from this stromaBreast and other sites: Lipoma, angiolipoma, hemangioma, nodular fasciitis, fibromatosisMost common in breast: Myofibroblastoma, pseudoangiomatous stromal hyperplasia (PASH), angiosarcoma",
                    "sub_points": [
                      "Breast and other sites: Lipoma, angiolipoma, hemangioma, nodular fasciitis, fibromatosis",
                      "Most common in breast: Myofibroblastoma, pseudoangiomatous stromal hyperplasia (PASH), angiosarcoma"
                    ]
                  }
                ],
                "Intralobular Stroma": [
                  {
                    "text": "Surrounds and supports the acini of the TDLU"
                  },
                  {
                    "text": "Looser and more cellular appearance compared with interlobular stroma"
                  },
                  {
                    "text": "Often has scattered lymphocytes and plasma cellsMay be myxoid in appearance",
                    "sub_points": [
                      "May be myxoid in appearance"
                    ]
                  },
                  {
                    "text": "Lesions of this stroma are specific to the breast and are biphasic (consist of stroma and epithelium)Hyperplasias are due to the increased growth of both stroma and epitheliumNeoplasias are due to a proliferation of clonal stromal cells that stimulates growth of nonclonal epitheliumFibroadenomas and phyllodes tumors",
                    "sub_points": [
                      "Hyperplasias are due to the increased growth of both stroma and epithelium",
                      "Neoplasias are due to a proliferation of clonal stromal cells that stimulates growth of nonclonal epitheliumFibroadenomas and phyllodes tumors",
                      "Fibroadenomas and phyllodes tumors"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Breast Specimens Overview": {
            "name": "Breast Specimens Overview",
            "url": "https://app.pathprimer.com/document/13e2a016-f898-4a07-9ac5-ed34382a5dbd/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Breast Specimen Processing: General Considerations": {
                "Introduction": [
                  {
                    "text": "Breast specimens are more complicated than many other types of specimensMultiple procedures are often performed for the same lesion, multiple lesions, or for recurrence of lesionsBiopsy sites and changes related to prior therapy are often presentMultiple lesions may be present in a single specimenNeoadjuvant therapy is often utilized to treat breast carcinomas (BCs)Because of mammographic screening, many lesions are small and not evident grosslySpecimen radiography is often required to identify the lesion for which the surgery was performed",
                    "sub_points": [
                      "Multiple procedures are often performed for the same lesion, multiple lesions, or for recurrence of lesionsBiopsy sites and changes related to prior therapy are often present",
                      "Biopsy sites and changes related to prior therapy are often present",
                      "Multiple lesions may be present in a single specimen",
                      "Neoadjuvant therapy is often utilized to treat breast carcinomas (BCs)",
                      "Because of mammographic screening, many lesions are small and not evident grossly",
                      "Specimen radiography is often required to identify the lesion for which the surgery was performed"
                    ]
                  },
                  {
                    "text": "Gross evaluation is often either the only or the best method to determine important features of BCsSize of BCSingle or multiple BCsStatus of marginsExtent of lymph node involvement",
                    "sub_points": [
                      "Size of BC",
                      "Single or multiple BCs",
                      "Status of margins",
                      "Extent of lymph node involvement"
                    ]
                  },
                  {
                    "text": "Thus, the appropriate processing of breast specimens requires good multidisciplinary communication among radiologists, pathologists, and surgeonsClinical history and imaging results are important to create a safety net to ensure breast specimens are optimally evaluated and interpreted",
                    "sub_points": [
                      "Clinical history and imaging results are important to create a safety net to ensure breast specimens are optimally evaluated and interpreted"
                    ]
                  }
                ],
                "Requisition Forms": [
                  {
                    "text": "These forms need to include information necessary for optimal processing and interpretation of the specimen"
                  },
                  {
                    "text": "Customized forms can be developed to ensure that appropriate information is provided and to facilitate the completion of the form"
                  },
                  {
                    "text": "e.g., forms submitted with core needle biopsies can include checklists for information related to the procedure and the targeted lesionImaging modality: Stereotactic, ultrasound, MRType of lesionMass, including size and borders (circumscribed, spiculated, ill defined)Calcifications, including if the specimen radiograph showed calcificationsArchitectural distortion or asymmetryEnhancing mass on MR or nonmass enhancement",
                    "sub_points": [
                      "Imaging modality: Stereotactic, ultrasound, MR",
                      "Type of lesionMass, including size and borders (circumscribed, spiculated, ill defined)Calcifications, including if the specimen radiograph showed calcificationsArchitectural distortion or asymmetryEnhancing mass on MR or nonmass enhancement",
                      "Mass, including size and borders (circumscribed, spiculated, ill defined)",
                      "Calcifications, including if the specimen radiograph showed calcifications",
                      "Architectural distortion or asymmetry",
                      "Enhancing mass on MR or nonmass enhancement"
                    ]
                  }
                ],
                "Specimen Types": [
                  {
                    "text": "The type of specimen must be clearly indicatedDetermines how margins are inked and evaluatedTerminology has not been standardized, and multiple names can be applied to similar or identical specimens",
                    "sub_points": [
                      "Determines how margins are inked and evaluatedTerminology has not been standardized, and multiple names can be applied to similar or identical specimens",
                      "Terminology has not been standardized, and multiple names can be applied to similar or identical specimens"
                    ]
                  },
                  {
                    "text": "Procedures intended to sample, but not remove, a lesionIncisional biopsiesCore needle biopsies",
                    "sub_points": [
                      "Incisional biopsies",
                      "Core needle biopsies"
                    ]
                  },
                  {
                    "text": "Procedures intended to remove the lesion but conserve the breastExcision, quadrantectomy, lumpectomy, partial mastectomy, oncoplastic surgeryIf the lesion is not palpable, wires or localization devices may be used to identify the lesion",
                    "sub_points": [
                      "Excision, quadrantectomy, lumpectomy, partial mastectomy, oncoplastic surgery",
                      "If the lesion is not palpable, wires or localization devices may be used to identify the lesion"
                    ]
                  },
                  {
                    "text": "Procedures intended to reduce the size of the breastReduction mammaplasties and oncoplastic surgery",
                    "sub_points": [
                      "Reduction mammaplasties and oncoplastic surgery"
                    ]
                  },
                  {
                    "text": "Procedures intended to remove the entire breastMastectomyRadical mastectomies remove pectoralis muscles and are rarely performed\"Modified radical\" mastectomies do not remove pectoralis musclesMay remove skin and nipple, just nipple (skin sparing), or no skin or nipple (skin and nipple sparing)Prophylactic mastectomies are performed for risk reductionSubcutaneous mastectomies are generally used for gynecomastia and do not remove skin or nippleTop surgery and male chest contouring surgery are used for gender-confirmation proceduresThe nipple is generally not removed, but some skin is typically resectedThe amount of breast tissue removed is not as extensive as for a mastectomy",
                    "sub_points": [
                      "MastectomyRadical mastectomies remove pectoralis muscles and are rarely performed\"Modified radical\" mastectomies do not remove pectoralis muscles",
                      "Radical mastectomies remove pectoralis muscles and are rarely performed",
                      "\"Modified radical\" mastectomies do not remove pectoralis muscles",
                      "May remove skin and nipple, just nipple (skin sparing), or no skin or nipple (skin and nipple sparing)Prophylactic mastectomies are performed for risk reduction",
                      "Prophylactic mastectomies are performed for risk reduction",
                      "Subcutaneous mastectomies are generally used for gynecomastia and do not remove skin or nipple",
                      "Top surgery and male chest contouring surgery are used for gender-confirmation proceduresThe nipple is generally not removed, but some skin is typically resectedThe amount of breast tissue removed is not as extensive as for a mastectomy",
                      "The nipple is generally not removed, but some skin is typically resected",
                      "The amount of breast tissue removed is not as extensive as for a mastectomy"
                    ]
                  },
                  {
                    "text": "Lymph nodesSentinel lymph nodes: Identified by dye, radioactive tracer, or bothDissection: Should include extent of dissection (how many anatomic levels) to determine the number of nodes expected",
                    "sub_points": [
                      "Sentinel lymph nodes: Identified by dye, radioactive tracer, or both",
                      "Dissection: Should include extent of dissection (how many anatomic levels) to determine the number of nodes expected"
                    ]
                  }
                ],
                "Orientation": [
                  {
                    "text": "Specimens must have adequate orientation in order to identify sites of possible margin involvement"
                  },
                  {
                    "text": "Sutures, inks, clips, or other methods may be used"
                  },
                  {
                    "text": "Because breast specimens are pliable and can change shape after excision, it is preferable for the surgeon to ink the margins or to send separate shave margins"
                  }
                ],
                "Specimen Radiography": [
                  {
                    "text": "Excisions containing radiographic lesions should be imaged before transfer to the pathology departmentThe radiologist should document that the targeted lesion was removedThe specimen radiograph and the radiologist's report should be available to the pathologist",
                    "sub_points": [
                      "The radiologist should document that the targeted lesion was removed",
                      "The specimen radiograph and the radiologist's report should be available to the pathologist"
                    ]
                  },
                  {
                    "text": "If a mastectomy contains a nonpalpable radiographic lesion, the specimen should be radiographed prior to processingBecause the specimen radiograph is not required for the surgery, the radiograph may need to be performed in the pathology department or be requested to be performed in the radiology department",
                    "sub_points": [
                      "Because the specimen radiograph is not required for the surgery, the radiograph may need to be performed in the pathology department or be requested to be performed in the radiology department"
                    ]
                  }
                ]
              },
              "Intraoperative Consultations": {
                "Overview": [
                  {
                    "text": "Intraoperative consultation is requested on breast specimens for the following purposesPrimary diagnosis, evaluation of margins, evaluation of sentinel lymph nodes, radioactive seed recovery, and collection of fresh tissue for research and biobanking",
                    "sub_points": [
                      "Primary diagnosis, evaluation of margins, evaluation of sentinel lymph nodes, radioactive seed recovery, and collection of fresh tissue for research and biobanking"
                    ]
                  }
                ],
                "Primary Diagnosis": [
                  {
                    "text": "The use of frozen sections for the 1st diagnosis of cancer followed by immediate definitive surgery is not recommendedPatients with carcinoma should have the opportunity to consider surgical and treatment optionsThere is a small probability of false-positive or false-negative diagnosis",
                    "sub_points": [
                      "Patients with carcinoma should have the opportunity to consider surgical and treatment options",
                      "There is a small probability of false-positive or false-negative diagnosis"
                    ]
                  },
                  {
                    "text": "In almost all cases, core needle biopsy is the preferred technique for 1st diagnosis"
                  }
                ],
                "Evaluation of Margins": [
                  {
                    "text": "Margins are difficult to evaluate by frozen section due to the large surface area of breast biopsies, the difficulty of freezing fatty tissue well, and the frequent presence of cautery artifactCytologic scrape preparations from intact specimens can be used, but cautery on the outer surface can limit this technique",
                    "sub_points": [
                      "Cytologic scrape preparations from intact specimens can be used, but cautery on the outer surface can limit this technique"
                    ]
                  },
                  {
                    "text": "The specimen radiograph can be helpful to evaluate margins when the carcinoma can be seen as a mass or calcifications"
                  },
                  {
                    "text": "The gross distance of palpable cancers to margins can be determined and may be helpful"
                  },
                  {
                    "text": "Ductal carcinoma in situ (DCIS) is rarely grossly apparent and may be present at margins in grossly normal-appearing tissue"
                  },
                  {
                    "text": "If intraoperative assessment is attempted, the surgeon must be aware of the possibility of different results on permanent sections"
                  }
                ],
                "Evaluation of Sentinel Lymph Nodes": [
                  {
                    "text": "Sentinel nodes may undergo intraoperative evaluation if the detection of a positive node will result in the surgeon removing additional nodes"
                  },
                  {
                    "text": "Nodes are thinly sliced at ~ 2 mm and completely frozenThe most common source of false-negative results is the failure to freeze all slices",
                    "sub_points": [
                      "The most common source of false-negative results is the failure to freeze all slices"
                    ]
                  },
                  {
                    "text": "This method will detect all macrometastases > 0.2 cm"
                  }
                ],
                "Recovery of Radioactive Seeds": [
                  {
                    "text": "It is imperative to recover radioactive seeds and to safely store them until they can be returned and undergo appropriate disposal"
                  },
                  {
                    "text": "This procedure is often best performed in the intraoperative consultation room to limit the area that must be searched if a seed is misplaced"
                  }
                ],
                "Allocation of Fresh Tissue for Research or Biobanking": [
                  {
                    "text": "Immediate allocation of tissue for special processing can be requested for diagnosis, as part of the patient's enrollment in a clinical trial, or for research studies and biobanking"
                  },
                  {
                    "text": "Rapid identification of lesional tissue is important because ischemic time has detrimental effects on potential mRNA and protein biomarkers"
                  },
                  {
                    "text": "Appropriate permission from the patient and from the institutional review board must be obtained"
                  },
                  {
                    "text": "The pathologist plays a key role to ensure that the tissue allocation is in the best interest of the patient and does not compromise diagnosis"
                  }
                ]
              },
              "Specimen Radiography": {
                "Core Needle Biopsies": [
                  {
                    "text": "Biopsies performed for calcifications should be radiographed to document that representative calcifications have been sampledThese cores can be separated from cores without calcifications to aid in correlation with the pathologic findingsCores with calcifications may be cut at shallower levels to ensure all calcifications are seen on tissue sections",
                    "sub_points": [
                      "These cores can be separated from cores without calcifications to aid in correlation with the pathologic findings",
                      "Cores with calcifications may be cut at shallower levels to ensure all calcifications are seen on tissue sections"
                    ]
                  },
                  {
                    "text": "It is helpful for cores to be wrapped in paper and placed in a cassette to ensure all tissue and calcifications are preserved for optimal evaluation"
                  }
                ],
                "Localized Excisions": [
                  {
                    "text": "Multiple methods are available to identify the site of a nonpalpable lesion for surgical removalWire, radioactive seed, radar reflector, magnetic seed, RFID tag",
                    "sub_points": [
                      "Wire, radioactive seed, radar reflector, magnetic seed, RFID tag"
                    ]
                  },
                  {
                    "text": "The specimen must be radiographed to ensure that the localization device and the targeted lesion have been removedUsing a grid for the radiograph can help identify the site of the lesion",
                    "sub_points": [
                      "Using a grid for the radiograph can help identify the site of the lesion"
                    ]
                  },
                  {
                    "text": "The radiologist evaluates the radiograph and determines whether or not the targeted lesion or lesions have been removedThe radiologist also documents when a targeted lesion has not been removedFor subtle lesions (ill-defined masses, architectural distortion, or faint calcifications), it is helpful for the radiologist to circle the lesion on the radiographSome findings in a specimen radiograph can be incidental to the targeted lesion",
                    "sub_points": [
                      "The radiologist also documents when a targeted lesion has not been removed",
                      "For subtle lesions (ill-defined masses, architectural distortion, or faint calcifications), it is helpful for the radiologist to circle the lesion on the radiograph",
                      "Some findings in a specimen radiograph can be incidental to the targeted lesion"
                    ]
                  },
                  {
                    "text": "The specimen radiograph and the radiologist's interpretation should be available to the pathologistIt is helpful to include this information in the pathology report",
                    "sub_points": [
                      "It is helpful to include this information in the pathology report"
                    ]
                  },
                  {
                    "text": "If a carcinoma is present in a specimen, it is at the site of the imaging lesion or in the immediate vicinity in > 95% of casesIn rare cases, lobular carcinoma in situ (LCIS), low-grade DCIS, or small invasive carcinomas may be present as incidental findings",
                    "sub_points": [
                      "In rare cases, lobular carcinoma in situ (LCIS), low-grade DCIS, or small invasive carcinomas may be present as incidental findings"
                    ]
                  },
                  {
                    "text": "Multiple localization device excisions2 or more markers are used in 2 settings2 separate lesions are present (e.g., 2 carcinomas)Markers are used to bracket an area of tissue for excision, most commonly an area of calcifications or a region of architectural distortion",
                    "sub_points": [
                      "2 or more markers are used in 2 settings2 separate lesions are present (e.g., 2 carcinomas)Markers are used to bracket an area of tissue for excision, most commonly an area of calcifications or a region of architectural distortion",
                      "2 separate lesions are present (e.g., 2 carcinomas)",
                      "Markers are used to bracket an area of tissue for excision, most commonly an area of calcifications or a region of architectural distortion"
                    ]
                  },
                  {
                    "text": "Intraoperative ultrasound localized excisionThe surgeon can use ultrasound to identify a mass &/or an echogenic clip embedded in biodegradable carrier material (gel)",
                    "sub_points": [
                      "The surgeon can use ultrasound to identify a mass &/or an echogenic clip embedded in biodegradable carrier material (gel)"
                    ]
                  }
                ],
                "Pathology/Radiology Correlation": [
                  {
                    "text": "For each type of lesion detected by imaging, there is a pathologic differential diagnoses"
                  },
                  {
                    "text": "Mass with spiculated borders97% invasive carcinoma2% surgical or trauma-related scarring1% rare lesions, such as radial sclerosing lesion, fibromatosis, granular cell tumor",
                    "sub_points": [
                      "97% invasive carcinoma",
                      "2% surgical or trauma-related scarring",
                      "1% rare lesions, such as radial sclerosing lesion, fibromatosis, granular cell tumor"
                    ]
                  },
                  {
                    "text": "Mass with circumscribed borders65% fibroadenoma20% cysts or clusters of cysts9% other benign lesions, such as nodular sclerosing adenosis, myofibroblastoma, hamartoma, angiolipoma3% DCIS (DCIS involving fibroadenoma or papilloma, DCIS with surrounding stromal fibrosis)< 1% encapsulated papillary carcinoma and solid papillary carcinoma3% invasive carcinoma (especially medullary pattern, mucinous, solid lobular, and triple negative)",
                    "sub_points": [
                      "65% fibroadenoma",
                      "20% cysts or clusters of cysts",
                      "9% other benign lesions, such as nodular sclerosing adenosis, myofibroblastoma, hamartoma, angiolipoma",
                      "3% DCIS (DCIS involving fibroadenoma or papilloma, DCIS with surrounding stromal fibrosis)",
                      "< 1% encapsulated papillary carcinoma and solid papillary carcinoma",
                      "3% invasive carcinoma (especially medullary pattern, mucinous, solid lobular, and triple negative)"
                    ]
                  },
                  {
                    "text": "Mass with ill-defined marginsThese masses may actually have ill-defined margins or may have margins obscured by adjacent fibrous tissue20% fibroadenoma15% invasive carcinoma, 2% DCIS65% other benign lesions",
                    "sub_points": [
                      "These masses may actually have ill-defined margins or may have margins obscured by adjacent fibrous tissue",
                      "20% fibroadenoma",
                      "15% invasive carcinoma, 2% DCIS",
                      "65% other benign lesions"
                    ]
                  },
                  {
                    "text": "CalcificationsRadiologically suspicious calcifications are clustered, linear, or segmental with amorphous or pleomorphic morphologyAdditional nonsuspicious calcifications can be seenSome calcifications seen on radiography are likely multiple overlapping calcifications in 3 dimensionsCalcifications seen in tissue sections are essentially in 2 dimensions; it can be difficult to correlate imaging and pathologic calcifications by number or sizeIt is essential to be certain that suspicious radiologic calcifications are sampled for microscopic examination75% are benign and associated with apocrine cysts, sclerosing adenosis, hyalinized fibroadenomas20% DCIS5% invasive carcinomaGenerally small (< 1 cm)",
                    "sub_points": [
                      "Radiologically suspicious calcifications are clustered, linear, or segmental with amorphous or pleomorphic morphologyAdditional nonsuspicious calcifications can be seen",
                      "Additional nonsuspicious calcifications can be seen",
                      "Some calcifications seen on radiography are likely multiple overlapping calcifications in 3 dimensions",
                      "Calcifications seen in tissue sections are essentially in 2 dimensions; it can be difficult to correlate imaging and pathologic calcifications by number or size",
                      "It is essential to be certain that suspicious radiologic calcifications are sampled for microscopic examination",
                      "75% are benign and associated with apocrine cysts, sclerosing adenosis, hyalinized fibroadenomas",
                      "20% DCIS",
                      "5% invasive carcinomaGenerally small (< 1 cm)",
                      "Generally small (< 1 cm)"
                    ]
                  },
                  {
                    "text": "Architectural distortionLocalized alteration in the typical uniform breast texture, characterized by lines radiating from a central pointA definable central area of solid density is not present33% benign changes, including radial sclerosing lesion33% diffusely invasive carcinoma, especially lobular carcinoma33% DCIS",
                    "sub_points": [
                      "Localized alteration in the typical uniform breast texture, characterized by lines radiating from a central pointA definable central area of solid density is not present",
                      "A definable central area of solid density is not present",
                      "33% benign changes, including radial sclerosing lesion",
                      "33% diffusely invasive carcinoma, especially lobular carcinoma",
                      "33% DCIS"
                    ]
                  },
                  {
                    "text": "Masses on USThe appearance on US is the best correlate for size and borders with the lesion on pathologyUS is very good at distinguishing solid and cystic massesThe majority of lesions are hypoechoic with respect to subcutaneous adipose tissueHyperechoic lesions contain closely interdigitated tissues of different echogenicity (fibrous tissue, fat, fluid, hemosiderin) and are usually benign",
                    "sub_points": [
                      "The appearance on US is the best correlate for size and borders with the lesion on pathology",
                      "US is very good at distinguishing solid and cystic masses",
                      "The majority of lesions are hypoechoic with respect to subcutaneous adipose tissue",
                      "Hyperechoic lesions contain closely interdigitated tissues of different echogenicity (fibrous tissue, fat, fluid, hemosiderin) and are usually benign"
                    ]
                  },
                  {
                    "text": "MR lesionsMR detects blood flow, making correlation with pathologic findings more difficultMass with spiculated margins: 18% invasive carcinoma, 10% DCIS, 16% fibroadenoma, 56% other benign lesionsMass with circumscribed margins: 11% invasive carcinoma, 3% DCIS, 43% fibroadenoma, 43% other benign lesionsLinear/clumped enhancement: 5% invasive carcinoma, 19% DCIS, 12% fibroadenoma, 64% other benign lesionsNonmass enhancement: Majority are benign",
                    "sub_points": [
                      "MR detects blood flow, making correlation with pathologic findings more difficultMass with spiculated margins: 18% invasive carcinoma, 10% DCIS, 16% fibroadenoma, 56% other benign lesionsMass with circumscribed margins: 11% invasive carcinoma, 3% DCIS, 43% fibroadenoma, 43% other benign lesionsLinear/clumped enhancement: 5% invasive carcinoma, 19% DCIS, 12% fibroadenoma, 64% other benign lesionsNonmass enhancement: Majority are benign",
                      "Mass with spiculated margins: 18% invasive carcinoma, 10% DCIS, 16% fibroadenoma, 56% other benign lesions",
                      "Mass with circumscribed margins: 11% invasive carcinoma, 3% DCIS, 43% fibroadenoma, 43% other benign lesions",
                      "Linear/clumped enhancement: 5% invasive carcinoma, 19% DCIS, 12% fibroadenoma, 64% other benign lesions",
                      "Nonmass enhancement: Majority are benign"
                    ]
                  }
                ]
              },
              "Fixation": {
                "Transport to Pathology Department": [
                  {
                    "text": "Specimens should be sent as rapidly as possible to minimize ischemic time"
                  },
                  {
                    "text": "Tissue can be transported without fixation if within 1-2 hours from removalPreferred if frozen sections, flow cytometry, some types of molecular studies, bacterial culture, or tissue banking are planned",
                    "sub_points": [
                      "Preferred if frozen sections, flow cytometry, some types of molecular studies, bacterial culture, or tissue banking are planned"
                    ]
                  },
                  {
                    "text": "Intact specimens can be placed into formalin if a longer time to specimen processing is anticipatedFormalin penetrates tissues slowlyCross linking of proteins is required for tissue stabilization and appropriate antigenicityOuter surfaces of specimens are often cauterized, which creates barrier to diffusionThus, inner portions of a specimen will not be fixed for many hoursIn some cases, the surgeon may ink the specimen and bisect it to allow better fixation, if necessary, for long transport times",
                    "sub_points": [
                      "Formalin penetrates tissues slowlyCross linking of proteins is required for tissue stabilization and appropriate antigenicity",
                      "Cross linking of proteins is required for tissue stabilization and appropriate antigenicity",
                      "Outer surfaces of specimens are often cauterized, which creates barrier to diffusionThus, inner portions of a specimen will not be fixed for many hours",
                      "Thus, inner portions of a specimen will not be fixed for many hours",
                      "In some cases, the surgeon may ink the specimen and bisect it to allow better fixation, if necessary, for long transport times"
                    ]
                  },
                  {
                    "text": "Optimal fixation is required for histologic detail, preservation of antigenic markers (e.g., ER, PR, and HER2), and preservation of other biomarkers"
                  },
                  {
                    "text": "Refrigeration may be helpful to delay tissue deterioration, if transport is delayed"
                  }
                ],
                "Ischemic Time": [
                  {
                    "text": "Tissue starts to deteriorate as soon as it is removed from the blood supply"
                  },
                  {
                    "text": "Ischemic time is defined as the length of time from the blood supply being cut off to the time sliced tissue is placed into fixative (i.e., when formalin touches the tumor)"
                  },
                  {
                    "text": "Prolonged ischemic time (> 1 hour) can have deleterious effects on studies for mRNA and protein biomarkers"
                  },
                  {
                    "text": "Ischemic time should be minimized whenever possibleIt is helpful to document unusually long ischemic times to help with interpretation of molecular studiesIf results are negative for such specimens, it may be appropriate to use other specimens for analysisCore needle biopsies generally have very short ischemic times and may be preferable for many types of studiesLimitations of using needle core biopsies for ancillary studies include tumor sampling issues due to heterogeneity and potentially a small sample size",
                    "sub_points": [
                      "It is helpful to document unusually long ischemic times to help with interpretation of molecular studies",
                      "If results are negative for such specimens, it may be appropriate to use other specimens for analysis",
                      "Core needle biopsies generally have very short ischemic times and may be preferable for many types of studiesLimitations of using needle core biopsies for ancillary studies include tumor sampling issues due to heterogeneity and potentially a small sample size",
                      "Limitations of using needle core biopsies for ancillary studies include tumor sampling issues due to heterogeneity and potentially a small sample size"
                    ]
                  }
                ],
                "Fixation Time": [
                  {
                    "text": "Defined as time from tissue being placed into formalin to the time processing begins in preparation for paraffin embedding"
                  },
                  {
                    "text": "10% neutral buffered (phosphate) formalin is recommendedCross linking occurs, which stabilizes tissue, inhibits deterioration, and is important for antigenicityOptimal fixation time is at least 6-72 hoursShorter fixation times result in suboptimal antigen preservation for IHCLonger fixation times may result in excessive protein cross linking and diminished antigenicity after prolonged period (weeks to months)",
                    "sub_points": [
                      "Cross linking occurs, which stabilizes tissue, inhibits deterioration, and is important for antigenicity",
                      "Optimal fixation time is at least 6-72 hoursShorter fixation times result in suboptimal antigen preservation for IHCLonger fixation times may result in excessive protein cross linking and diminished antigenicity after prolonged period (weeks to months)",
                      "Shorter fixation times result in suboptimal antigen preservation for IHC",
                      "Longer fixation times may result in excessive protein cross linking and diminished antigenicity after prolonged period (weeks to months)"
                    ]
                  }
                ],
                "Type of Fixatives": [
                  {
                    "text": "Clinical assays are generally optimized for tissue fixed in 10% neutral buffered (phosphate) formalin"
                  },
                  {
                    "text": "Other types of fixatives can alter results of assaysBouin fixation: Diminishes hormone receptor positivity and degrades DNAAlcohol fixation: May alter results for PR and HER2",
                    "sub_points": [
                      "Bouin fixation: Diminishes hormone receptor positivity and degrades DNA",
                      "Alcohol fixation: May alter results for PR and HER2"
                    ]
                  },
                  {
                    "text": "If other types of fixatives are used for clinical assays, results must be validated as being accurate"
                  }
                ]
              },
              "Tissue for Special Studies": {
                "Clinical Assays": [
                  {
                    "text": "Assays for hormone receptors and HER2 are performed on routine formalin-fixed tissue"
                  },
                  {
                    "text": "Proprietary assays can also be performed on routine formalin-fixed tissue"
                  }
                ],
                "Research Studies and Biobanking": [
                  {
                    "text": "Only tissue that is not required for pathologic diagnosis can be taken for other purposes"
                  },
                  {
                    "text": "Tissue from specimens without a diagnosis of invasive carcinoma should not be taken for research unless the procedure is performed for cosmetic reasons and no gross lesions are present"
                  },
                  {
                    "text": "Tissue from lymph nodes without gross metastases should not be taken for research studiesSmall macrometastases are not grossly apparentMetastases are not evenly distributed in nodesRemoval of 1/2 node will result in missing macrometastases in up to 30% of cases",
                    "sub_points": [
                      "Small macrometastases are not grossly apparent",
                      "Metastases are not evenly distributed in nodes",
                      "Removal of 1/2 node will result in missing macrometastases in up to 30% of cases"
                    ]
                  }
                ]
              },
              "Errors in Specimen Processing": {
                "Completely Freezing Small Lesions": [
                  {
                    "text": "Primary diagnosis by frozen section is not recommended"
                  },
                  {
                    "text": "Rarely benefits patient"
                  },
                  {
                    "text": "Can harm patients if lesion cannot be interpreted due to freezing artifact &/or tissue loss during performance of frozen section"
                  },
                  {
                    "text": "False-positive/negative results are rare but do occur"
                  }
                ],
                "Failure to Find Lesion": [
                  {
                    "text": "Lesions are rarely missed in small biopsy specimens that are entirely examined microscopicallyOnly occurs if a very small carcinoma is smaller than the width of a tissue section",
                    "sub_points": [
                      "Only occurs if a very small carcinoma is smaller than the width of a tissue section"
                    ]
                  },
                  {
                    "text": "Lesions may be missed if the entire specimen is not submitted for microscopic examinationPathologist should be aware of the number and types of lesions identified clinically and radiologically in order to find and sample themAdditional examination of specimens by radiography may be helpful to locate lesions",
                    "sub_points": [
                      "Pathologist should be aware of the number and types of lesions identified clinically and radiologically in order to find and sample them",
                      "Additional examination of specimens by radiography may be helpful to locate lesions"
                    ]
                  },
                  {
                    "text": "The targeted calcifications should be identified in excisions for calcificationsThe specimen radiograph must document that the targeted calcifications were removedTissue containing radiologic calcifications must be sampled, as this is the most likely location of the cancerTissue and blocks can be radiographed to find the radiologic calcificationsThere are many incidental calcifications present in tissue that are too small to be seen by radiographyTherefore, merely seeing a calcification is not sufficient to ensure that the targeted calcifications have been identifiedReasons for not finding the targeted calcificationsTissue with radiologic calcifications not sampledCalcifications are located deeper in block and can be detected with deeper sectionsCalcium oxalate not seen; consist of flat pale rhomboid or needle-shaped crystals in apocrine cysts; more easily visible under polarized lightSubtle stromal calcifications in hyalinized stroma of a fibroadenoma or papilloma are not seenVery prolonged fixation results in dissolution of calcificationsCalcifications are lost from tissue during formalin fixationCan be minimized for core needle biopsies if the radiologist wraps cores in paper and places them in a cassette prior to fixation in formalinLarge calcifications chip out from sections; however, large calcifications are generally not those targetedMost common when calcifications or heterotopic bone are present in fatty tissue due to fat necrosis\"Calcifications\" are actually surgical debris or other radiodense material (e.g., gold or tattoo pigment)",
                    "sub_points": [
                      "The specimen radiograph must document that the targeted calcifications were removed",
                      "Tissue containing radiologic calcifications must be sampled, as this is the most likely location of the cancerTissue and blocks can be radiographed to find the radiologic calcificationsThere are many incidental calcifications present in tissue that are too small to be seen by radiographyTherefore, merely seeing a calcification is not sufficient to ensure that the targeted calcifications have been identified",
                      "Tissue and blocks can be radiographed to find the radiologic calcifications",
                      "There are many incidental calcifications present in tissue that are too small to be seen by radiographyTherefore, merely seeing a calcification is not sufficient to ensure that the targeted calcifications have been identified",
                      "Therefore, merely seeing a calcification is not sufficient to ensure that the targeted calcifications have been identified",
                      "Reasons for not finding the targeted calcificationsTissue with radiologic calcifications not sampledCalcifications are located deeper in block and can be detected with deeper sectionsCalcium oxalate not seen; consist of flat pale rhomboid or needle-shaped crystals in apocrine cysts; more easily visible under polarized lightSubtle stromal calcifications in hyalinized stroma of a fibroadenoma or papilloma are not seenVery prolonged fixation results in dissolution of calcificationsCalcifications are lost from tissue during formalin fixationCan be minimized for core needle biopsies if the radiologist wraps cores in paper and places them in a cassette prior to fixation in formalinLarge calcifications chip out from sections; however, large calcifications are generally not those targetedMost common when calcifications or heterotopic bone are present in fatty tissue due to fat necrosis\"Calcifications\" are actually surgical debris or other radiodense material (e.g., gold or tattoo pigment)",
                      "Tissue with radiologic calcifications not sampled",
                      "Calcifications are located deeper in block and can be detected with deeper sections",
                      "Calcium oxalate not seen; consist of flat pale rhomboid or needle-shaped crystals in apocrine cysts; more easily visible under polarized light",
                      "Subtle stromal calcifications in hyalinized stroma of a fibroadenoma or papilloma are not seen",
                      "Very prolonged fixation results in dissolution of calcifications",
                      "Calcifications are lost from tissue during formalin fixationCan be minimized for core needle biopsies if the radiologist wraps cores in paper and places them in a cassette prior to fixation in formalin",
                      "Can be minimized for core needle biopsies if the radiologist wraps cores in paper and places them in a cassette prior to fixation in formalin",
                      "Large calcifications chip out from sections; however, large calcifications are generally not those targetedMost common when calcifications or heterotopic bone are present in fatty tissue due to fat necrosis",
                      "Most common when calcifications or heterotopic bone are present in fatty tissue due to fat necrosis",
                      "\"Calcifications\" are actually surgical debris or other radiodense material (e.g., gold or tattoo pigment)"
                    ]
                  }
                ],
                "Failure to Find Lymph Nodes": [
                  {
                    "text": "It is important for the surgeon to communicate the extent of axillary dissection"
                  },
                  {
                    "text": "All tissue potentially containing nodes should be sliced thinly and palpated to identify nodesCareful examination can reliably identify nodes down to 2-3 mm in size",
                    "sub_points": [
                      "Careful examination can reliably identify nodes down to 2-3 mm in size"
                    ]
                  },
                  {
                    "text": "If the expected number of nodes is not found, additional axillary tissue can be submitted for microscopic examinationVery small nodes may not be grossly apparentSmall nodes are sometimes adjacent to blood vesselsNodes with extensive fatty replacement can be difficult to identifyIn mastectomy specimens, problems with orientation of specimen &/or identification of axillary tissue should be considered",
                    "sub_points": [
                      "Very small nodes may not be grossly apparentSmall nodes are sometimes adjacent to blood vessels",
                      "Small nodes are sometimes adjacent to blood vessels",
                      "Nodes with extensive fatty replacement can be difficult to identify",
                      "In mastectomy specimens, problems with orientation of specimen &/or identification of axillary tissue should be considered"
                    ]
                  },
                  {
                    "text": "If no nodes or only very few nodes are found, this should be documented in the pathology reportExtent of tissue sampling should be describedClinical reasons for lower than expected numbers should be considered (prior treatment, prior axillary surgery)May be indication for additional surgery to identify more nodes",
                    "sub_points": [
                      "Extent of tissue sampling should be described",
                      "Clinical reasons for lower than expected numbers should be considered (prior treatment, prior axillary surgery)",
                      "May be indication for additional surgery to identify more nodes"
                    ]
                  }
                ]
              },
              "Reporting": {
                "Reporting Malignant Results": [
                  {
                    "text": "Guidelines for reporting invasive carcinoma and DCIS are issued by the College of American Pathologists (www.cap.org; accessed 11/25/2024) and the International Collaboration on Cancer Reporting (ICCR) (https://www.iccr-cancer.org/datasets/published-datasets/breast/; accessed 11/25/2024)The use of checklists has been shown to improve completeness of pathology reports",
                    "sub_points": [
                      "The use of checklists has been shown to improve completeness of pathology reports"
                    ]
                  }
                ],
                "Reporting Benign Results": [
                  {
                    "text": "It is important to document the lesion that prompted the biopsy"
                  },
                  {
                    "text": "In addition, other lesions that increase the risk of invasive carcinoma should be reported"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Core Needle Biopsies": {
            "name": "Core Needle Biopsies",
            "url": "https://app.pathprimer.com/document/0623781d-5287-487d-aafc-0eafbdff7373/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Features of High-Quality Core Needle Biopsy Programs": {
                "Advantages of Core Needle Biopsies (CNBs)": [
                  {
                    "text": "CNBs can be used for the initial evaluation of almost all breast lesions"
                  },
                  {
                    "text": "Patients with benign findings benefit because they can be spared surgerySurgery is associated with skin scarring and possible loss of volumeThe resulting fibrotic scar and fat necrosis can complicate subsequent imaging",
                    "sub_points": [
                      "Surgery is associated with skin scarring and possible loss of volume",
                      "The resulting fibrotic scar and fat necrosis can complicate subsequent imaging"
                    ]
                  },
                  {
                    "text": "Patients with malignant findings benefit because the optimal sequence of treatment can be plannedThe findings help determine the best subsequent surgeryPatients who require mastectomy can be identifiedMultiple lesions can be sampled to determine the extent of the cancerPatients have the option of neoadjuvant therapyFor the majority of patients, only 1 subsequent surgical procedure is required to remove the cancer and sample lymph nodes if necessaryIf lymphoma or metastasis is diagnosed, the patient is spared excisionOptimal preservation of biomolecules for molecular assays can be achievedMinimal ischemic time and precise fixation timeIncreased ischemic time associated with excisions can have significant effects on mRNA and protein and can make it difficult to distinguish changes due to sampling technique from treatment or tumor alterations",
                    "sub_points": [
                      "The findings help determine the best subsequent surgeryPatients who require mastectomy can be identifiedMultiple lesions can be sampled to determine the extent of the cancerPatients have the option of neoadjuvant therapy",
                      "Patients who require mastectomy can be identified",
                      "Multiple lesions can be sampled to determine the extent of the cancer",
                      "Patients have the option of neoadjuvant therapy",
                      "For the majority of patients, only 1 subsequent surgical procedure is required to remove the cancer and sample lymph nodes if necessary",
                      "If lymphoma or metastasis is diagnosed, the patient is spared excision",
                      "Optimal preservation of biomolecules for molecular assays can be achievedMinimal ischemic time and precise fixation timeIncreased ischemic time associated with excisions can have significant effects on mRNA and protein and can make it difficult to distinguish changes due to sampling technique from treatment or tumor alterations",
                      "Minimal ischemic time and precise fixation time",
                      "Increased ischemic time associated with excisions can have significant effects on mRNA and protein and can make it difficult to distinguish changes due to sampling technique from treatment or tumor alterations"
                    ]
                  },
                  {
                    "text": "Severe complications after CNB are very rare (< 1% of procedures)"
                  }
                ],
                "Quality Assurance": [
                  {
                    "text": "Radiology-pathology communicationIn an ideal program, cancers will be detected, biopsied, diagnosed, and then excised with high accuracyBecause lesions are sampled rather than removed, close communication between the radiologist and pathologist is essentialCustomized requisition forms can facilitate communication of essential informationThe radiologist must communicate features of the lesion being sampled to the pathologistMode of detection (mammography, US, MR)Type of lesion (mass, calcifications, architectural distortion, asymmetry, type of enhancement on MR)Size and margins of masses (spiculated, circumscribed, or ill defined/obscured)Distance between lesions if multiple lesions are presentDistance from prior excisional sites, if presentThe pathologist must communicate whether or not the pathologic findings could correlate with the imaging lesionCases with known or suspected discordance should be flagged for reviewUltimately, the radiologist makes the decision as to whether the targeted lesion was adequately sampled",
                    "sub_points": [
                      "In an ideal program, cancers will be detected, biopsied, diagnosed, and then excised with high accuracy",
                      "Because lesions are sampled rather than removed, close communication between the radiologist and pathologist is essentialCustomized requisition forms can facilitate communication of essential information",
                      "Customized requisition forms can facilitate communication of essential information",
                      "The radiologist must communicate features of the lesion being sampled to the pathologistMode of detection (mammography, US, MR)Type of lesion (mass, calcifications, architectural distortion, asymmetry, type of enhancement on MR)Size and margins of masses (spiculated, circumscribed, or ill defined/obscured)Distance between lesions if multiple lesions are presentDistance from prior excisional sites, if present",
                      "Mode of detection (mammography, US, MR)",
                      "Type of lesion (mass, calcifications, architectural distortion, asymmetry, type of enhancement on MR)",
                      "Size and margins of masses (spiculated, circumscribed, or ill defined/obscured)",
                      "Distance between lesions if multiple lesions are present",
                      "Distance from prior excisional sites, if present",
                      "The pathologist must communicate whether or not the pathologic findings could correlate with the imaging lesion",
                      "Cases with known or suspected discordance should be flagged for review",
                      "Ultimately, the radiologist makes the decision as to whether the targeted lesion was adequately sampled"
                    ]
                  },
                  {
                    "text": "Radiology-pathology conferencesPeriodic review of cases is an excellent opportunity for obtaining additional opinions, discussion of difficult cases with possible discordance, follow-up of CNBs with subsequent excision, and education (cross training in other discipline)With good radiology/pathology communication, only 1-8% of biopsies are considered discordant or potentially discordantThese patients can be followed closely, undergo repeat CNB, or be recommended for excisionWhen vacuum-assisted cores are used, < 10% of women with discordant findings have a missed malignancy",
                    "sub_points": [
                      "Periodic review of cases is an excellent opportunity for obtaining additional opinions, discussion of difficult cases with possible discordance, follow-up of CNBs with subsequent excision, and education (cross training in other discipline)",
                      "With good radiology/pathology communication, only 1-8% of biopsies are considered discordant or potentially discordantThese patients can be followed closely, undergo repeat CNB, or be recommended for excisionWhen vacuum-assisted cores are used, < 10% of women with discordant findings have a missed malignancy",
                      "These patients can be followed closely, undergo repeat CNB, or be recommended for excision",
                      "When vacuum-assisted cores are used, < 10% of women with discordant findings have a missed malignancy"
                    ]
                  }
                ]
              },
              "Modalities": {
                "Palpation": [
                  {
                    "text": "Palpable masses can be sampled using freehand (Tru-cut) CNBA fine-needle aspiration (FNA) with a smaller needle is more likely to pierce the lesion and obtain lesional cells",
                    "sub_points": [
                      "A fine-needle aspiration (FNA) with a smaller needle is more likely to pierce the lesion and obtain lesional cells"
                    ]
                  },
                  {
                    "text": "However, CNBs performed without imaging assistance tend to push lesions away rather than piercing them"
                  },
                  {
                    "text": "If the CNB does not show a definite mass-forming lesion (e.g., fibroadenoma or carcinoma), the possibility of the biopsy not sampling the lesion must be considered"
                  },
                  {
                    "text": "It is preferable to perform CNB using US in order to document that a lesion has been sampled"
                  }
                ],
                "Mammography (Stereotactic)": [
                  {
                    "text": "Detects lesions on mammogram due to variable penetration of x-rays into tissueAdipose tissue: Penetrated well; dark grayFibrous tissue: Poorly penetrated; whiteNormal tissue: Intermingled adipose and fibrous tissue; variable areas of gray and whiteMasses: Replace adipose tissue; whiteCalcifications: Not penetrated; very whiteMetal: Not penetrated; more densely white than calcifications",
                    "sub_points": [
                      "Adipose tissue: Penetrated well; dark gray",
                      "Fibrous tissue: Poorly penetrated; white",
                      "Normal tissue: Intermingled adipose and fibrous tissue; variable areas of gray and white",
                      "Masses: Replace adipose tissue; white",
                      "Calcifications: Not penetrated; very white",
                      "Metal: Not penetrated; more densely white than calcifications"
                    ]
                  },
                  {
                    "text": "Used for masses (~ 45% of lesions), calcifications (~ 45% of lesions), and architectural distortion/asymmetry (~ 10% of lesions)"
                  },
                  {
                    "text": "Tomosynthesis (3D mammography)Additional images are taken from multiple different anglesThe types of lesions seen more easily on tomosynthesis are those that cause subtle changes in parenchymal texture (described as architectural distortion or asymmetry)Commonly found lesions are diffusely invasive carcinomas and radial sclerosing lesions",
                    "sub_points": [
                      "Additional images are taken from multiple different angles",
                      "The types of lesions seen more easily on tomosynthesis are those that cause subtle changes in parenchymal texture (described as architectural distortion or asymmetry)Commonly found lesions are diffusely invasive carcinomas and radial sclerosing lesions",
                      "Commonly found lesions are diffusely invasive carcinomas and radial sclerosing lesions"
                    ]
                  }
                ],
                "US": [
                  {
                    "text": "Detects lesions due to different echo patterns generated by sound waves interacting with fibrous tissue, adipose tissue, and fluid"
                  },
                  {
                    "text": "Excellent modality for size and shape of masses and identifying fluid-filled cystsIn general, calcifications cannot be seen",
                    "sub_points": [
                      "In general, calcifications cannot be seen"
                    ]
                  },
                  {
                    "text": "Useful for additional evaluation of lesions identified by mammography or MR"
                  },
                  {
                    "text": "Preferred modality for biopsy when possible due to ease of use and minimal required equipment"
                  }
                ],
                "MR": [
                  {
                    "text": "Detects lesions due to increased blood flow after injection of gadolinium"
                  },
                  {
                    "text": "MR-guided CNBs are only performed for lesions that cannot be identified by other methodsRequire open coil and compatible needles and are more difficult to perform",
                    "sub_points": [
                      "Require open coil and compatible needles and are more difficult to perform"
                    ]
                  },
                  {
                    "text": "Lesions are typically smallShapes of small lesions are due to the pattern of blood flow and do not correlate well with the actual shape",
                    "sub_points": [
                      "Shapes of small lesions are due to the pattern of blood flow and do not correlate well with the actual shape"
                    ]
                  }
                ]
              },
              "Types of Needle Biopsies": {
                "Fine-Needle Aspiration (FNA)": [
                  {
                    "text": "Usually uses 22-gauge or smaller needles"
                  },
                  {
                    "text": "Can be performed on palpable masses or under image guidanceSlides can be interpreted immediately",
                    "sub_points": [
                      "Slides can be interpreted immediately"
                    ]
                  },
                  {
                    "text": "Single cells, rather than large tissue cores, are removedTherefore, invasive carcinoma and carcinoma in situ cannot be distinguished with certaintyThis information is important in deciding if lymph nodes need to be sampled",
                    "sub_points": [
                      "Therefore, invasive carcinoma and carcinoma in situ cannot be distinguished with certaintyThis information is important in deciding if lymph nodes need to be sampled",
                      "This information is important in deciding if lymph nodes need to be sampled"
                    ]
                  },
                  {
                    "text": "Useful for distinguishing solid from cystic lesionsMasses that can be aspirated to completion need no further evaluation",
                    "sub_points": [
                      "Masses that can be aspirated to completion need no further evaluation"
                    ]
                  },
                  {
                    "text": "Very useful for sampling lymph nodes prior to planned neoadjuvant therapyDocuments metastasis but leaves it in place to be evaluated for treatment responseResponse in nodal metastases has more prognostic importance than response in breast",
                    "sub_points": [
                      "Documents metastasis but leaves it in place to be evaluated for treatment response",
                      "Response in nodal metastases has more prognostic importance than response in breast"
                    ]
                  }
                ],
                "Cutting Core Needle": [
                  {
                    "text": "14-, 11-, or 8-gauge needles are typically used"
                  },
                  {
                    "text": "Nonvacuum assistedNeedle is advanced to the target, and multiple passes are made for samplingMay be designated as 3:00, 6:00, 9:00, and 12:00 o'clock positions relative to areas of the lesionThese designations should not be confused with positions relative to the nipple (i.e., they do not indicate 4 separate lesions)",
                    "sub_points": [
                      "Needle is advanced to the target, and multiple passes are made for samplingMay be designated as 3:00, 6:00, 9:00, and 12:00 o'clock positions relative to areas of the lesionThese designations should not be confused with positions relative to the nipple (i.e., they do not indicate 4 separate lesions)",
                      "May be designated as 3:00, 6:00, 9:00, and 12:00 o'clock positions relative to areas of the lesion",
                      "These designations should not be confused with positions relative to the nipple (i.e., they do not indicate 4 separate lesions)"
                    ]
                  },
                  {
                    "text": "Vacuum assistedNeedle is inserted into or immediately adjacent to the targeted lesionVacuum draws tissue into a trough, and an inner rotating cutting cannula is advanced and cuts a core of tissueTissue is delivered through the barrel of the probe into a collection chamberMultiple biopsies are taken by rotating the needle without the need for multiple insertionsCores are generally larger than nonvacuum-assisted cores14-gauge, vacuum-assisted CNB is ~ 2x size of 14-gauge, nonvacuum-assisted CNBVacuum assistance offers higher diagnostic accuracy for breast nodules < 5 mm compared with CNBMay remove entire lesion if numerous cores are taken",
                    "sub_points": [
                      "Needle is inserted into or immediately adjacent to the targeted lesion",
                      "Vacuum draws tissue into a trough, and an inner rotating cutting cannula is advanced and cuts a core of tissue",
                      "Tissue is delivered through the barrel of the probe into a collection chamber",
                      "Multiple biopsies are taken by rotating the needle without the need for multiple insertions",
                      "Cores are generally larger than nonvacuum-assisted cores14-gauge, vacuum-assisted CNB is ~ 2x size of 14-gauge, nonvacuum-assisted CNB",
                      "14-gauge, vacuum-assisted CNB is ~ 2x size of 14-gauge, nonvacuum-assisted CNB",
                      "Vacuum assistance offers higher diagnostic accuracy for breast nodules < 5 mm compared with CNB",
                      "May remove entire lesion if numerous cores are taken"
                    ]
                  }
                ],
                "Very Large Bore Needle": [
                  {
                    "text": "An oscillating circular knife is used to cut 1- to 2-cm, large cores (e.g., Advanced Breast Biopsy Instrumentation (ABBI), United States Surgical; Norwalk, CT)Cautery snare cuts tissue at tip1.0- to 2.5-cm skin incision is required, which must be sutured after procedureRemoves large amounts of nontarget tissue, including subcutaneous tissue",
                    "sub_points": [
                      "Cautery snare cuts tissue at tip",
                      "1.0- to 2.5-cm skin incision is required, which must be sutured after procedure",
                      "Removes large amounts of nontarget tissue, including subcutaneous tissue"
                    ]
                  },
                  {
                    "text": "No longer available commercially"
                  }
                ],
                "Cryobiopsy": [
                  {
                    "text": "A thin, 19-gauge solid needle is introduced into the middle of the target"
                  },
                  {
                    "text": "The tip is cooled with a CO₂ cartridge, which freezes the surrounding tissue"
                  },
                  {
                    "text": "Outer rotating cutting 10-gauge cannula is advanced over 1st needle to remove biopsyMultiple passes must be made for additional samples",
                    "sub_points": [
                      "Multiple passes must be made for additional samples"
                    ]
                  },
                  {
                    "text": "In theory, freezing might stabilize tissue and facilitate performance of biopsy"
                  },
                  {
                    "text": "Uncontrolled freezing and thawing in biopsy, and in residual lesion in breast, can have detrimental effects on morphology as well as on biomolecules"
                  },
                  {
                    "text": "Disadvantages far outweigh any theoretical benefits"
                  }
                ],
                "Intact Biopsies": [
                  {
                    "text": "Methods have been devised to remove the target as a single fragment of tissue rather than as multiple cores"
                  },
                  {
                    "text": "This requires using heat, which can introduce thermal damage into the lesion and surrounding breast tissueHeat in the core sample, as well as in surrounding breast, can have deleterious effects on biomolecules needed to guide treatment (ER, PR, HER2)",
                    "sub_points": [
                      "Heat in the core sample, as well as in surrounding breast, can have deleterious effects on biomolecules needed to guide treatment (ER, PR, HER2)"
                    ]
                  },
                  {
                    "text": "Detrimental possible effects on morphology and biomolecules outweigh possible advantages of having single fragment of tissue"
                  },
                  {
                    "text": "Types1-2 cm: Intact Breast Lesion Excision System (Intact Medical Corporation; Natick, MA)Uses radiofrequency energy to cut through breast tissue to lesion5 wires deploy to surround and remove the lesion as a spheroidal-shaped fragment using radiofrequency energyOvation (Rubicor Medical, Inc.; Redwood City, CA)Uses cautery with cutting wire loop to remove a spheroidal-shaped fragment of tissuePlastic bag surrounds specimen in order to remove it",
                    "sub_points": [
                      "1-2 cm: Intact Breast Lesion Excision System (Intact Medical Corporation; Natick, MA)Uses radiofrequency energy to cut through breast tissue to lesion5 wires deploy to surround and remove the lesion as a spheroidal-shaped fragment using radiofrequency energy",
                      "Uses radiofrequency energy to cut through breast tissue to lesion",
                      "5 wires deploy to surround and remove the lesion as a spheroidal-shaped fragment using radiofrequency energy",
                      "Ovation (Rubicor Medical, Inc.; Redwood City, CA)Uses cautery with cutting wire loop to remove a spheroidal-shaped fragment of tissuePlastic bag surrounds specimen in order to remove it",
                      "Uses cautery with cutting wire loop to remove a spheroidal-shaped fragment of tissue",
                      "Plastic bag surrounds specimen in order to remove it"
                    ]
                  }
                ],
                "Clips, Biodegradable Carrier Material (BCM), and Localizing Devices": [
                  {
                    "text": "ClipsDeployed to mark the site of biopsy in case excision is later requiredClips marketed by different manufacturers have different shapesIf > 1 lesion is biopsied, it is preferable to use clips of different shapes to ensure that each site can be identifiedClips are essential to mark cancers that undergo neoadjuvant therapyThis can be the only method to identify the tumor bed when there is a marked response",
                    "sub_points": [
                      "Deployed to mark the site of biopsy in case excision is later required",
                      "Clips marketed by different manufacturers have different shapesIf > 1 lesion is biopsied, it is preferable to use clips of different shapes to ensure that each site can be identified",
                      "If > 1 lesion is biopsied, it is preferable to use clips of different shapes to ensure that each site can be identified",
                      "Clips are essential to mark cancers that undergo neoadjuvant therapyThis can be the only method to identify the tumor bed when there is a marked response",
                      "This can be the only method to identify the tumor bed when there is a marked response"
                    ]
                  },
                  {
                    "text": "BCMBCM may be deployed with a clip to fill the cavity left by the biopsyA variety of materials are usedCollagen, polylactic acid, polyglycolic acid, starch pellets, hydrogel, othersAbsorbs water to fill void left by biopsyCan aid in holding clip within biopsy sitePlugs/gel: Consist of a single massThe gross appearance can look like a small white lozenge or as viscous clear gelA pseudosynovial lining forms around the plugBCM in the form of a gel can leak out during surgery (if the core site is transected) or during processingThe empty space can collapse, making it difficult to identify the core site, especially if transected at the marginPellets: Consist of multiple rice-shaped, white massesThe gross appearance has been confused with a papillary lesion or large calcificationsMicroscopically, they are usually arrayed in a circle surrounded by chronic active inflammation with a giant cell responseCollagen: Dense eosinophilic materialCan calcify over time if not resorbedSuture-like material: Multiple thin fibrils",
                    "sub_points": [
                      "BCM may be deployed with a clip to fill the cavity left by the biopsy",
                      "A variety of materials are usedCollagen, polylactic acid, polyglycolic acid, starch pellets, hydrogel, others",
                      "Collagen, polylactic acid, polyglycolic acid, starch pellets, hydrogel, others",
                      "Absorbs water to fill void left by biopsyCan aid in holding clip within biopsy site",
                      "Can aid in holding clip within biopsy site",
                      "Plugs/gel: Consist of a single massThe gross appearance can look like a small white lozenge or as viscous clear gelA pseudosynovial lining forms around the plugBCM in the form of a gel can leak out during surgery (if the core site is transected) or during processingThe empty space can collapse, making it difficult to identify the core site, especially if transected at the margin",
                      "The gross appearance can look like a small white lozenge or as viscous clear gel",
                      "A pseudosynovial lining forms around the plug",
                      "BCM in the form of a gel can leak out during surgery (if the core site is transected) or during processingThe empty space can collapse, making it difficult to identify the core site, especially if transected at the margin",
                      "The empty space can collapse, making it difficult to identify the core site, especially if transected at the margin",
                      "Pellets: Consist of multiple rice-shaped, white massesThe gross appearance has been confused with a papillary lesion or large calcificationsMicroscopically, they are usually arrayed in a circle surrounded by chronic active inflammation with a giant cell response",
                      "The gross appearance has been confused with a papillary lesion or large calcifications",
                      "Microscopically, they are usually arrayed in a circle surrounded by chronic active inflammation with a giant cell response",
                      "Collagen: Dense eosinophilic materialCan calcify over time if not resorbed",
                      "Can calcify over time if not resorbed",
                      "Suture-like material: Multiple thin fibrils"
                    ]
                  },
                  {
                    "text": "Localization devicesThese devices are placed via needle to identify the location of a lesion during surgical excisionRadioactive seeds, radar reflectors (Savi Scout), magnetic seeds (Magseed), and radiofrequency identification (RFID) tags are usedThese are larger than clips placed during biopsy and have specific shapesRadioactive seeds must be identified, documented, and disposed as for radioactive waste",
                    "sub_points": [
                      "These devices are placed via needle to identify the location of a lesion during surgical excisionRadioactive seeds, radar reflectors (Savi Scout), magnetic seeds (Magseed), and radiofrequency identification (RFID) tags are used",
                      "Radioactive seeds, radar reflectors (Savi Scout), magnetic seeds (Magseed), and radiofrequency identification (RFID) tags are used",
                      "These are larger than clips placed during biopsy and have specific shapes",
                      "Radioactive seeds must be identified, documented, and disposed as for radioactive waste"
                    ]
                  }
                ]
              },
              "Specimen Processing": {
                "Radiology": [
                  {
                    "text": "CNBs for calcifications are radiographed to ensure that calcifications have been sampledCores may be separated into those containing and those not containing calcificationsThe radiologist must notify the pathologist if the biopsy did not sample the targeted calcificationsIf no carcinoma is seen, repeat biopsy is generally warranted",
                    "sub_points": [
                      "Cores may be separated into those containing and those not containing calcifications",
                      "The radiologist must notify the pathologist if the biopsy did not sample the targeted calcificationsIf no carcinoma is seen, repeat biopsy is generally warranted",
                      "If no carcinoma is seen, repeat biopsy is generally warranted"
                    ]
                  },
                  {
                    "text": "It is helpful for the radiologist to wrap cores in thin paper and submit in a tissue cassette in a container of formalinEnsures all tissue fragments are removed from the formalin containerMore likely to keep cores intactMore likely to preserve calcifications in tissueAs many cassettes as necessary for multiple cores can be used to ensure adequate formalin penetration and fixation",
                    "sub_points": [
                      "Ensures all tissue fragments are removed from the formalin container",
                      "More likely to keep cores intact",
                      "More likely to preserve calcifications in tissue",
                      "As many cassettes as necessary for multiple cores can be used to ensure adequate formalin penetration and fixation"
                    ]
                  },
                  {
                    "text": "The time cores are placed in formalin should be recorded to ensure they are fixed for a sufficient amount of time prior to processingThis ensures specimens meet standards for fixation for biomarker testing",
                    "sub_points": [
                      "This ensures specimens meet standards for fixation for biomarker testing"
                    ]
                  }
                ],
                "Pathology: Gross Examination": [
                  {
                    "text": "Cores submitted in a volume of formalin need to be gently removed and placed in a cassetteThe sides and lid of the container must be examined for small adherent tissue fragments",
                    "sub_points": [
                      "The sides and lid of the container must be examined for small adherent tissue fragments"
                    ]
                  },
                  {
                    "text": "Cores in a paper packet can be transferred directly to a labeled cassette"
                  },
                  {
                    "text": "Cores should be distributed into additional cassettes if necessary to allow adequate flow of reagents during processing"
                  },
                  {
                    "text": "Cores excised late in the day should be held in fixative until the following day to ensure there are at least 6-8 hours of fixation"
                  }
                ],
                "Histology": [
                  {
                    "text": "Multiple levels are usually obtained on each biopsy to ensure each core has been well sampled3 levels are generally adequate for diagnosis3rd level should be ~ 1/2 through thickness of tissueAllows for additional sections should additional studies be necessaryFor masses and MR biopsies, diagnosis is usually apparent on 1st levelAdditional levels may be required for diagnoses associated with calcifications",
                    "sub_points": [
                      "3 levels are generally adequate for diagnosis3rd level should be ~ 1/2 through thickness of tissueAllows for additional sections should additional studies be necessary",
                      "3rd level should be ~ 1/2 through thickness of tissue",
                      "Allows for additional sections should additional studies be necessary",
                      "For masses and MR biopsies, diagnosis is usually apparent on 1st levelAdditional levels may be required for diagnoses associated with calcifications",
                      "Additional levels may be required for diagnoses associated with calcifications"
                    ]
                  },
                  {
                    "text": "Cores with calcifications may have more superficial sections taken during slide preparation to ensure they are not missed"
                  }
                ]
              },
              "Challenges in Needle Biopsy Specimens": {
                "Artifacts in Needle Biopsies": [
                  {
                    "text": "Displacement of epitheliumEpithelium can be pushed into vascular spaces or stroma during biopsyLymphovascular invasion should only be reported when definitive features are seen",
                    "sub_points": [
                      "Epithelium can be pushed into vascular spaces or stroma during biopsy",
                      "Lymphovascular invasion should only be reported when definitive features are seen"
                    ]
                  },
                  {
                    "text": "SwirliesSmall eddies of tissue are seen in vacuum-assisted biopsiesOnly involve small foci of tissue and do not interfere with interpretation",
                    "sub_points": [
                      "Small eddies of tissue are seen in vacuum-assisted biopsies",
                      "Only involve small foci of tissue and do not interfere with interpretation"
                    ]
                  },
                  {
                    "text": "GauzeDry gauze creates an empty hatch mark artifact in fresh tissue that can preclude optimal evaluationTissue should only be placed on saline-moistened material",
                    "sub_points": [
                      "Dry gauze creates an empty hatch mark artifact in fresh tissue that can preclude optimal evaluationTissue should only be placed on saline-moistened material",
                      "Tissue should only be placed on saline-moistened material"
                    ]
                  },
                  {
                    "text": "CrushSqueezing cores with forceps during handling can introduce marked distortion of tissueDefinitive diagnosis may not be possible or may be suboptimalMay not be able to determine type or grade of invasive carcinomaMay not be able to distinguish atypical lobular hyperplasia from artifact",
                    "sub_points": [
                      "Squeezing cores with forceps during handling can introduce marked distortion of tissue",
                      "Definitive diagnosis may not be possible or may be suboptimalMay not be able to determine type or grade of invasive carcinomaMay not be able to distinguish atypical lobular hyperplasia from artifact",
                      "May not be able to determine type or grade of invasive carcinoma",
                      "May not be able to distinguish atypical lobular hyperplasia from artifact"
                    ]
                  },
                  {
                    "text": "Cautery or freezingOnly present in intact or cryobiopsy systemsDevices that use these techniques should be avoided due to tissue damage in the core biopsy and the surrounding tissue",
                    "sub_points": [
                      "Only present in intact or cryobiopsy systems",
                      "Devices that use these techniques should be avoided due to tissue damage in the core biopsy and the surrounding tissue"
                    ]
                  }
                ],
                "Missing Calcifications": [
                  {
                    "text": "When specimens are wrapped in paper by the radiologist, recovery of calcifications is > 98%"
                  },
                  {
                    "text": "Failure to detect calcifications documented to be present by specimen radiography can be due to multiple causes"
                  },
                  {
                    "text": "Calcifications deeper in blockRadiography of block can identify calcifications that have not yet been sampledDeeper levels can be obtained until all tissue has been sampled for evaluation",
                    "sub_points": [
                      "Radiography of block can identify calcifications that have not yet been sampled",
                      "Deeper levels can be obtained until all tissue has been sampled for evaluation"
                    ]
                  },
                  {
                    "text": "Large calcifications chipping out of specimenMost commonly occurs for large calcifications in adipose tissue, such as those associated with heterotopic bone formation or fat necrosisLess likely to occur with small calcifications associated with carcinomasOnly small fragments of calcification may be evident on slides",
                    "sub_points": [
                      "Most commonly occurs for large calcifications in adipose tissue, such as those associated with heterotopic bone formation or fat necrosisLess likely to occur with small calcifications associated with carcinomas",
                      "Less likely to occur with small calcifications associated with carcinomas",
                      "Only small fragments of calcification may be evident on slides"
                    ]
                  },
                  {
                    "text": "Calcifications present but difficult to seeCalcium oxalate crystals are clear to yellow and form translucent flat crystalsOnly seen in association with apocrine cysts or in adjacent tissue associated with giant cellsMore easily appreciated using polarized lightCalcifications forming directly on hyalinized stroma of fibroadenomas or papillary cores can appear as minute blue bubbles and can be difficult to see",
                    "sub_points": [
                      "Calcium oxalate crystals are clear to yellow and form translucent flat crystalsOnly seen in association with apocrine cysts or in adjacent tissue associated with giant cellsMore easily appreciated using polarized light",
                      "Only seen in association with apocrine cysts or in adjacent tissue associated with giant cells",
                      "More easily appreciated using polarized light",
                      "Calcifications forming directly on hyalinized stroma of fibroadenomas or papillary cores can appear as minute blue bubbles and can be difficult to see"
                    ]
                  },
                  {
                    "text": "\"Calcifications\" are not calcificationsMetallic fragments from prior surgery or trauma can appear as calcificationsGold from injections for rheumatoid arthritis and tattoo pigments are radiodenseHemosiderin from prior surgery or trauma can be radiopaque",
                    "sub_points": [
                      "Metallic fragments from prior surgery or trauma can appear as calcifications",
                      "Gold from injections for rheumatoid arthritis and tattoo pigments are radiodense",
                      "Hemosiderin from prior surgery or trauma can be radiopaque"
                    ]
                  },
                  {
                    "text": "Calcifications have dissolved in fixativeProlonged time in formalin over several days can result in disappearance of calcificationsShould be prevented by prompt processing",
                    "sub_points": [
                      "Prolonged time in formalin over several days can result in disappearance of calcifications",
                      "Should be prevented by prompt processing"
                    ]
                  },
                  {
                    "text": "Calcifications fell out of specimenLoss of calcifications can occur from cystic lesionsCan be prevented or minimized by the radiologist wrapping cores in paper before placing them in formalin\"Milk of calcium\" is used by radiologists to describe calcifications in cystic spaces and may be more prone to lossThis term describes calcifications that change in spatial arrangement depending on whether gravity acts on the lesion (e.g., in a medial-lateral oblique or lateral view) or does not act on the lesion (craniocaudal view)When gravity acts on the lesion, the calcifications layer out on the bottom of the cyst creating a pattern on mammography that looks like a tea cup",
                    "sub_points": [
                      "Loss of calcifications can occur from cystic lesions",
                      "Can be prevented or minimized by the radiologist wrapping cores in paper before placing them in formalin",
                      "\"Milk of calcium\" is used by radiologists to describe calcifications in cystic spaces and may be more prone to lossThis term describes calcifications that change in spatial arrangement depending on whether gravity acts on the lesion (e.g., in a medial-lateral oblique or lateral view) or does not act on the lesion (craniocaudal view)When gravity acts on the lesion, the calcifications layer out on the bottom of the cyst creating a pattern on mammography that looks like a tea cup",
                      "This term describes calcifications that change in spatial arrangement depending on whether gravity acts on the lesion (e.g., in a medial-lateral oblique or lateral view) or does not act on the lesion (craniocaudal view)",
                      "When gravity acts on the lesion, the calcifications layer out on the bottom of the cyst creating a pattern on mammography that looks like a tea cup"
                    ]
                  },
                  {
                    "text": "Specimen misidentificationIf a cluster of definitive calcifications is present in the specimen radiograph, but not seen in the cores, the possibility of specimen mix-up should be considered",
                    "sub_points": [
                      "If a cluster of definitive calcifications is present in the specimen radiograph, but not seen in the cores, the possibility of specimen mix-up should be considered"
                    ]
                  },
                  {
                    "text": "Vascular calcificationsCalcifications in blood vessel walls have a distinct train-track appearance by mammographyRadiologists will not biopsy these deliberately because they are benign and could lead to bleedingTherefore, if only vascular calcifications are seen, this does not correlate with the targeted lesion",
                    "sub_points": [
                      "Calcifications in blood vessel walls have a distinct train-track appearance by mammography",
                      "Radiologists will not biopsy these deliberately because they are benign and could lead to bleedingTherefore, if only vascular calcifications are seen, this does not correlate with the targeted lesion",
                      "Therefore, if only vascular calcifications are seen, this does not correlate with the targeted lesion"
                    ]
                  }
                ],
                "Missed Lesions": [
                  {
                    "text": "It is important to detect cancers that have been missed to avoid delays in diagnosisThe false-negative rate is < 1% in most reports",
                    "sub_points": [
                      "The false-negative rate is < 1% in most reports"
                    ]
                  },
                  {
                    "text": "Factors that can contribute to missing a lesionTargeting errors due to poor lesion or needle visualizationLesion mobilityDeeply located lesionsCentral lesions in large breastDense fibrotic tissue resistant to needle penetrationSmall lesions (≤ 5 mm)Inability of patient to remain immobile",
                    "sub_points": [
                      "Targeting errors due to poor lesion or needle visualization",
                      "Lesion mobility",
                      "Deeply located lesions",
                      "Central lesions in large breast",
                      "Dense fibrotic tissue resistant to needle penetration",
                      "Small lesions (≤ 5 mm)",
                      "Inability of patient to remain immobile"
                    ]
                  },
                  {
                    "text": "Radiologic/pathologic correlation is essential to ensure the targeted lesion has been sampled"
                  },
                  {
                    "text": "Definite correlationIn many cases, a definite correlation can be establishedLarge masses, clusters of calcifications",
                    "sub_points": [
                      "In many cases, a definite correlation can be establishedLarge masses, clusters of calcifications",
                      "Large masses, clusters of calcifications"
                    ]
                  },
                  {
                    "text": "Possible correlationIn some cases, there may be a correlation, but it is not certainPseudoangiomatous stromal hyperplasia (PASH), lipoma, hamartoma, rare calcificationsThe radiologist must ensure that the targeted lesion was sampled",
                    "sub_points": [
                      "In some cases, there may be a correlation, but it is not certainPseudoangiomatous stromal hyperplasia (PASH), lipoma, hamartoma, rare calcifications",
                      "Pseudoangiomatous stromal hyperplasia (PASH), lipoma, hamartoma, rare calcifications",
                      "The radiologist must ensure that the targeted lesion was sampled"
                    ]
                  },
                  {
                    "text": "No correlationIn some cases, it is highly likely the target was not sampledCores for calcifications without calcifications, cores for a mass-forming lesion with only normal breast tissue identified",
                    "sub_points": [
                      "In some cases, it is highly likely the target was not sampledCores for calcifications without calcifications, cores for a mass-forming lesion with only normal breast tissue identified",
                      "Cores for calcifications without calcifications, cores for a mass-forming lesion with only normal breast tissue identified"
                    ]
                  },
                  {
                    "text": "Ultimately, the radiologist must decide if the targeted lesion has been adequately sampledRepeat imaging &/or biopsy should be performed in cases for which lesions might have been missed",
                    "sub_points": [
                      "Repeat imaging &/or biopsy should be performed in cases for which lesions might have been missed"
                    ]
                  }
                ],
                "Specimen Misidentification": [
                  {
                    "text": "Multiple methods have been devised to help minimize the possibility of specimen mix-upIn radiology, specimen containers are only labeled at time of biopsyThe radiologist can place specimens from different patients in cassettes of different colorsThe pathologist matches the color listed on the requisition form with the actual color of the cassetteProsector inks specimens from different patients in different colorsTissue on slide can be matched with correct color from the gross descriptionA commercial test is available in which a cheek swab taken from the patient at time of CNB is compared to the CNB by DNA testing if malignancy is diagnosed",
                    "sub_points": [
                      "In radiology, specimen containers are only labeled at time of biopsy",
                      "The radiologist can place specimens from different patients in cassettes of different colorsThe pathologist matches the color listed on the requisition form with the actual color of the cassette",
                      "The pathologist matches the color listed on the requisition form with the actual color of the cassette",
                      "Prosector inks specimens from different patients in different colorsTissue on slide can be matched with correct color from the gross description",
                      "Tissue on slide can be matched with correct color from the gross description",
                      "A commercial test is available in which a cheek swab taken from the patient at time of CNB is compared to the CNB by DNA testing if malignancy is diagnosed"
                    ]
                  },
                  {
                    "text": "However, with good communication between radiologists and pathologists, the likelihood of not detecting specimen misidentification is very small"
                  }
                ]
              },
              "Reporting Core Biopsy Results": {
                "Benign Findings": [
                  {
                    "text": "The pathologist should always attempt to correlate the findings with the targeted lesion"
                  },
                  {
                    "text": "When correlation cannot be made, or is uncertain, it is helpful to suggest review by the radiologist"
                  }
                ],
                "Lobular Carcinoma In Situ": [
                  {
                    "text": "Classic lobular carcinoma in situ (LCIS) is most often seen as an incidental finding"
                  },
                  {
                    "text": "Pleomorphic and florid LCIS are usually the source of the targeted lesion due to calcifications in necrosis or the formation of a small mass"
                  },
                  {
                    "text": "It is helpful for the pathologist to indicate when atypical lobular hyperplasia &/or LCIS are incidental findings, as this finding alone does not mandate excision"
                  }
                ],
                "Ductal Carcinoma In Situ": [
                  {
                    "text": "It is sometimes difficult to distinguish ductal carcinoma in situ (DCIS) from atypical ductal hyperplasia on CNBDiagnosis should be deferred to excision for borderline lesions",
                    "sub_points": [
                      "Diagnosis should be deferred to excision for borderline lesions"
                    ]
                  }
                ],
                "Invasive Carcinoma": [
                  {
                    "text": "It is useful to report the maximum size as seen on CNBGenerally smaller than the actual sizeHowever, size on excision may be smaller than on CNB for small carcinomasThis information will be necessary for assigning the appropriate T categorySize is helpful to judge the reliability of special studiesIf only a small area of carcinoma is present on CNB, and results of studies are negative, repeat studies on excision may be warrantedClinicians must understand that size on core should not be added to size on excision",
                    "sub_points": [
                      "Generally smaller than the actual sizeHowever, size on excision may be smaller than on CNB for small carcinomasThis information will be necessary for assigning the appropriate T category",
                      "However, size on excision may be smaller than on CNB for small carcinomas",
                      "This information will be necessary for assigning the appropriate T category",
                      "Size is helpful to judge the reliability of special studiesIf only a small area of carcinoma is present on CNB, and results of studies are negative, repeat studies on excision may be warranted",
                      "If only a small area of carcinoma is present on CNB, and results of studies are negative, repeat studies on excision may be warranted",
                      "Clinicians must understand that size on core should not be added to size on excision"
                    ]
                  },
                  {
                    "text": "Histologic type and grade are helpful for counseling patients about likely prognosis and treatmentGrade may be underscored in ~ 1/3 of cores compared to excisions; rarely overscoredClassification as a special histologic type needs to be reevaluated after excision",
                    "sub_points": [
                      "Grade may be underscored in ~ 1/3 of cores compared to excisions; rarely overscored",
                      "Classification as a special histologic type needs to be reevaluated after excision"
                    ]
                  },
                  {
                    "text": "Papillary carcinomas are difficult to classify on core biopsyCarcinomas are typically fragmentedStromal invasion may be difficult or impossible to evaluateIn some cases, a differential diagnosis of papillary DCIS, encapsulated papillary carcinoma, or invasive papillary carcinoma is appropriateLymph node sampling may be deferred until definitive invasive carcinoma is seen",
                    "sub_points": [
                      "Carcinomas are typically fragmented",
                      "Stromal invasion may be difficult or impossible to evaluate",
                      "In some cases, a differential diagnosis of papillary DCIS, encapsulated papillary carcinoma, or invasive papillary carcinoma is appropriateLymph node sampling may be deferred until definitive invasive carcinoma is seen",
                      "Lymph node sampling may be deferred until definitive invasive carcinoma is seen"
                    ]
                  },
                  {
                    "text": "ER, PR, and HER2 can be evaluatedThis information is used to determine eligibility for and type of neoadjuvant therapyCNBs usually have minimal ischemic time and optimal formalin fixationHowever, amount of tumor available may be limitedIn other cases, tissue disruption and crushing may make evaluation difficult or impossibleMinimum time for fixation is 6 hours for adequate antigen preservation; shorter times may result in false-negative resultsRepeat of negative results on larger areas of carcinoma on excision should be consideredStudies on larger areas of carcinoma may also be better for detecting cases of heterogeneous expression",
                    "sub_points": [
                      "This information is used to determine eligibility for and type of neoadjuvant therapy",
                      "CNBs usually have minimal ischemic time and optimal formalin fixationHowever, amount of tumor available may be limitedIn other cases, tissue disruption and crushing may make evaluation difficult or impossible",
                      "However, amount of tumor available may be limited",
                      "In other cases, tissue disruption and crushing may make evaluation difficult or impossible",
                      "Minimum time for fixation is 6 hours for adequate antigen preservation; shorter times may result in false-negative results",
                      "Repeat of negative results on larger areas of carcinoma on excision should be considered",
                      "Studies on larger areas of carcinoma may also be better for detecting cases of heterogeneous expression"
                    ]
                  },
                  {
                    "text": "CNB and FNA are suitable for high-throughput genomic and proteomic analysisCould be used to identify and quantify novel cancer biomarkers",
                    "sub_points": [
                      "Could be used to identify and quantify novel cancer biomarkers"
                    ]
                  },
                  {
                    "text": "For patients undergoing neoadjuvant treatment, results on CNB may be the only documentation of their carcinomaTumor necrosis and lymphocytic infiltrate are predictive of response to therapy and should be reportedDefinitive diagnosis of invasive carcinoma and adequate evaluation of tumor markers are essential, as some patients will have a pathologic complete response",
                    "sub_points": [
                      "Tumor necrosis and lymphocytic infiltrate are predictive of response to therapy and should be reported",
                      "Definitive diagnosis of invasive carcinoma and adequate evaluation of tumor markers are essential, as some patients will have a pathologic complete response"
                    ]
                  },
                  {
                    "text": "Most likely lesion to be misinterpreted as invasive carcinoma is sclerosing adenosisClose mimic of invasive carcinoma when involved by apocrine metaplasia, LCIS, or DCISThis possibility should always be considered and excluded by IHC studies for myoepithelial cells when warranted",
                    "sub_points": [
                      "Close mimic of invasive carcinoma when involved by apocrine metaplasia, LCIS, or DCIS",
                      "This possibility should always be considered and excluded by IHC studies for myoepithelial cells when warranted"
                    ]
                  }
                ],
                "Lymph Nodes": [
                  {
                    "text": "Masses in the axilla are often assumed to be lymph nodes"
                  },
                  {
                    "text": "If nodal architecture can be identified, this should be specifically stated"
                  },
                  {
                    "text": "If metastatic carcinoma is definitely in a node (i.e., a capsule is present), this should be stated"
                  },
                  {
                    "text": "If carcinoma is in breast tissue &/or DCIS is present showing that it is a primary carcinoma, this should be statedCarcinomas with a medullary pattern can closely resemble a lymph node metastasis due to the lymphocytic infiltrate",
                    "sub_points": [
                      "Carcinomas with a medullary pattern can closely resemble a lymph node metastasis due to the lymphocytic infiltrate"
                    ]
                  },
                  {
                    "text": "In some cases, the entire core consists of carcinoma, and it cannot be determined with certainty if it is a metastasis or a primary carcinoma"
                  },
                  {
                    "text": "Metastases are assumed to be macrometastases if large enough to be sampled by needle biopsyHelpful to document size of metastasis, particularly if special studies are performed",
                    "sub_points": [
                      "Helpful to document size of metastasis, particularly if special studies are performed"
                    ]
                  }
                ]
              },
              "Challenges in Excisions": {
                "Finding the Core Site": [
                  {
                    "text": "Imaging to identify the site of the clip is recommendedMastectomies are often not routinely radiographed",
                    "sub_points": [
                      "Mastectomies are often not routinely radiographed"
                    ]
                  },
                  {
                    "text": "Core sites marked by BCM are easier to see grossly"
                  },
                  {
                    "text": "In ~ 20% of cases, the clip is displaced from the actual biopsy siteThe radiologist must document the location of the clip with respect to the lesion",
                    "sub_points": [
                      "The radiologist must document the location of the clip with respect to the lesion"
                    ]
                  }
                ],
                "Epithelial Displacement": [
                  {
                    "text": "Benign or malignant cells can be pushed into stroma, lymphatic spaces, or lymph nodes by needle biopsiesMore likely to occur with papillary lesions",
                    "sub_points": [
                      "More likely to occur with papillary lesions"
                    ]
                  },
                  {
                    "text": "Likelihood of finding tumor cells diminishes over timeArtifactually displaced tumor cells may not surviveMay be due to dissociation from normal vasculature",
                    "sub_points": [
                      "Artifactually displaced tumor cells may not survive",
                      "May be due to dissociation from normal vasculature"
                    ]
                  },
                  {
                    "text": "In general, carcinoma should not be diagnosed when findings are only present within biopsy site changesIHC can sometimes document the presence of associated myoepithelial cellsInterpretation of these cells as showing malignant behavior should be made with great caution",
                    "sub_points": [
                      "IHC can sometimes document the presence of associated myoepithelial cells",
                      "Interpretation of these cells as showing malignant behavior should be made with great caution"
                    ]
                  }
                ],
                "Reactive Spindle Cell Nodules": [
                  {
                    "text": "Florid myofibroblastic spindle cell reaction can occur in breast or lymph nodes after CNBMore common when the targeted lesion was associated with myofibroblasts (e.g., papilloma or complex sclerosing lesion)",
                    "sub_points": [
                      "More common when the targeted lesion was associated with myofibroblasts (e.g., papilloma or complex sclerosing lesion)"
                    ]
                  },
                  {
                    "text": "Size varies from 0.1-1.0 cm"
                  },
                  {
                    "text": "Spindle cells can have mild to moderate nuclear pleomorphism, mitoses, and infiltrative pattern"
                  },
                  {
                    "text": "Should not be mistaken for a spindle cell neoplasmThe probability of finding a malignant spindle cell tumor adjacent to another lesion is highly unlikelyMajority can be confirmed as benign with correlation with CNB findings and IHC studies to exclude carcinoma",
                    "sub_points": [
                      "The probability of finding a malignant spindle cell tumor adjacent to another lesion is highly unlikely",
                      "Majority can be confirmed as benign with correlation with CNB findings and IHC studies to exclude carcinoma"
                    ]
                  }
                ],
                "Carcinomas With Core Needle Biopsy Sites Used for Ancillary Testing": [
                  {
                    "text": "Invasive carcinomas may be sent for additional testing by gene expression profiling"
                  },
                  {
                    "text": "The entire site of the carcinoma, including the biopsy site, may be sampled for the assay"
                  },
                  {
                    "text": "Results may not be representative of the cancerFew tumor cells may be present relative to the size of biopsy site, especially when cancer is of low cellularity (lobular carcinoma)Stromal cells and inflammatory cells contribute to expression of proliferation-related genes and are negative for ER and PR",
                    "sub_points": [
                      "Few tumor cells may be present relative to the size of biopsy site, especially when cancer is of low cellularity (lobular carcinoma)",
                      "Stromal cells and inflammatory cells contribute to expression of proliferation-related genes and are negative for ER and PR"
                    ]
                  },
                  {
                    "text": "Blocks with biopsy sites should not be used for these studies when possibleWhen not possible, recommendation for microdissection can be made",
                    "sub_points": [
                      "When not possible, recommendation for microdissection can be made"
                    ]
                  }
                ],
                "Infarction": [
                  {
                    "text": "Masses, particularly papillomas, can undergo infarction after needle biopsy"
                  },
                  {
                    "text": "Benign lesions can be mistaken for malignancy due to necrosis, possibly complicated by reactive squamous metaplasia and stromal cells"
                  },
                  {
                    "text": "Malignant lesions can be mistaken for benign lesions due to loss of cellularity and difficulty in interpreting necrotic cells"
                  }
                ],
                "Failure to Find Cancer After Excision": [
                  {
                    "text": "Rarely, cancer documented by CNB is not identified in the excision"
                  },
                  {
                    "text": "The following possibilities should be consideredEntire cancer was removed by core (responsible for majority of cases)This is only likely if the targeted lesion was calcifications or the mass was < 1 cmPatient received neoadjuvant therapy with a pathologic complete responseExcision did not remove site of cancerCan occur if clip has migrated from site or wrong clip is removedCan occur with mastectomy if cancer was located very deep, superficially (in the skin flap), or laterallyRadiography of mastectomies can be helpful to document the presence and location of clipsPathologist did not identify the cancer in the excisionDiagnosis on CNB was incorrectCNB was misidentified",
                    "sub_points": [
                      "Entire cancer was removed by core (responsible for majority of cases)This is only likely if the targeted lesion was calcifications or the mass was < 1 cm",
                      "This is only likely if the targeted lesion was calcifications or the mass was < 1 cm",
                      "Patient received neoadjuvant therapy with a pathologic complete response",
                      "Excision did not remove site of cancerCan occur if clip has migrated from site or wrong clip is removedCan occur with mastectomy if cancer was located very deep, superficially (in the skin flap), or laterallyRadiography of mastectomies can be helpful to document the presence and location of clips",
                      "Can occur if clip has migrated from site or wrong clip is removed",
                      "Can occur with mastectomy if cancer was located very deep, superficially (in the skin flap), or laterallyRadiography of mastectomies can be helpful to document the presence and location of clips",
                      "Radiography of mastectomies can be helpful to document the presence and location of clips",
                      "Pathologist did not identify the cancer in the excision",
                      "Diagnosis on CNB was incorrect",
                      "CNB was misidentified"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Excisions and Oncoplastic Surgery": {
            "name": "Excisions and Oncoplastic Surgery",
            "url": "https://app.pathprimer.com/document/fcc9a508-18c7-4090-9104-954013f6b1bc/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Introduction": {
                "Breast Excisions": [
                  {
                    "text": "Breast excisions are performed for the initial diagnosis of lesions, the treatment of symptoms, and for the removal of breast carcinomas (BCs)"
                  },
                  {
                    "text": "Excisions include all procedures with the intent to remove entire lesion but not the entire breast"
                  },
                  {
                    "text": "Many other terms are used for these specimensBiopsy: Refers to excisions but also includes special types of specimens, such as fine-needle biopsies, core needle biopsies, and incisional biopsiesThe intent of some biopsies is to sample, but not completely remove, a lesionLumpectomy: Literally means a procedure to remove a \"lump\" (a palpable mass) but also refers to excisions for palpable lesionsTraditionally used by surgeons to refer to excisions of BCsPartial mastectomy: Used synonymously with excisionsQuadrantectomy: Removes entire quadrant of the breast",
                    "sub_points": [
                      "Biopsy: Refers to excisions but also includes special types of specimens, such as fine-needle biopsies, core needle biopsies, and incisional biopsiesThe intent of some biopsies is to sample, but not completely remove, a lesion",
                      "The intent of some biopsies is to sample, but not completely remove, a lesion",
                      "Lumpectomy: Literally means a procedure to remove a \"lump\" (a palpable mass) but also refers to excisions for palpable lesionsTraditionally used by surgeons to refer to excisions of BCs",
                      "Traditionally used by surgeons to refer to excisions of BCs",
                      "Partial mastectomy: Used synonymously with excisions",
                      "Quadrantectomy: Removes entire quadrant of the breast"
                    ]
                  },
                  {
                    "text": "Excisions for breast-conserving therapy (BCT) usually result in better cosmetic results than mastectomy"
                  }
                ],
                "Excision for Primary Diagnosis": [
                  {
                    "text": "The majority of breast lesions are currently evaluated first by using core needle biopsy"
                  },
                  {
                    "text": "Some lesions are not amenable to needle biopsy and require excision for diagnosisLocation near nipple or deep in breastPatient unable to remain immobile during procedureLesion difficult to visualize using digital mammographyPatient chooses to not have clip placed to mark a lesion that may not be easily visualized after biopsy",
                    "sub_points": [
                      "Location near nipple or deep in breast",
                      "Patient unable to remain immobile during procedure",
                      "Lesion difficult to visualize using digital mammography",
                      "Patient chooses to not have clip placed to mark a lesion that may not be easily visualized after biopsy"
                    ]
                  }
                ],
                "Excision for Treatment of Symptoms": [
                  {
                    "text": "Some patients have symptoms that may be treated with excisionPalpable masses causing cosmetic changes or pain, nipple discharge, or inflammatory lesion causing pain ± fistula tracts",
                    "sub_points": [
                      "Palpable masses causing cosmetic changes or pain, nipple discharge, or inflammatory lesion causing pain ± fistula tracts"
                    ]
                  }
                ],
                "Excision for Breast-Conserving Therapy (BCT) for Tumors": [
                  {
                    "text": "Patients with tumors can generally be treated with BCTEligibility depends on size and location of tumorMust be able to maintain acceptable cosmesisFor BCs, patients should be candidates for radiation therapySurvival outcomes of BCT with radiation therapy are similar to those of mastectomyHowever, some patients at low risk for recurrence may be followed without radiation treatmentPatients who are currently pregnant, have some types of collagen vascular disease, or have had prior chest wall radiation are not good candidates and may have a better outcome with mastectomyPatient preference is an important consideration",
                    "sub_points": [
                      "Eligibility depends on size and location of tumor",
                      "Must be able to maintain acceptable cosmesis",
                      "For BCs, patients should be candidates for radiation therapySurvival outcomes of BCT with radiation therapy are similar to those of mastectomyHowever, some patients at low risk for recurrence may be followed without radiation treatmentPatients who are currently pregnant, have some types of collagen vascular disease, or have had prior chest wall radiation are not good candidates and may have a better outcome with mastectomy",
                      "Survival outcomes of BCT with radiation therapy are similar to those of mastectomy",
                      "However, some patients at low risk for recurrence may be followed without radiation treatment",
                      "Patients who are currently pregnant, have some types of collagen vascular disease, or have had prior chest wall radiation are not good candidates and may have a better outcome with mastectomy",
                      "Patient preference is an important consideration"
                    ]
                  },
                  {
                    "text": "Initial diagnosis of tumor by core needle biopsy aids in surgical planningSubsequent excision is often larger and more likely to achieve negative margins if a diagnosis of malignancy has been establishedFor invasive BCs, lymph node sampling can be performed in the same procedure",
                    "sub_points": [
                      "Subsequent excision is often larger and more likely to achieve negative margins if a diagnosis of malignancy has been established",
                      "For invasive BCs, lymph node sampling can be performed in the same procedure"
                    ]
                  }
                ],
                "Oncoplastic Surgery": [
                  {
                    "text": "Oncoplastic surgery is a combination of surgery to remove BC combined with plastic surgery to improve cosmetic outcome"
                  },
                  {
                    "text": "Large &/or multiple BCs can be removed without the need for mastectomy"
                  },
                  {
                    "text": "A major advantage over mastectomy is that sensation to the breast is maintained"
                  },
                  {
                    "text": "The specimen typically consists of multiple fragments of breast tissue (which can be irregular in shape) ± skin"
                  },
                  {
                    "text": "Requires careful attention to the identification of the true surgical margins"
                  }
                ],
                "Methods to Localize Lesions": [
                  {
                    "text": "Lesions that are nonpalpable must be localized by the radiologist for the surgeon and pathologistIf > 1 lesion is present, a localization device is placed at each lesionIf an area of abnormal tissue is present (e.g., an area of calcifications), 2 or more devices are placed to bracket the area",
                    "sub_points": [
                      "If > 1 lesion is present, a localization device is placed at each lesion",
                      "If an area of abnormal tissue is present (e.g., an area of calcifications), 2 or more devices are placed to bracket the area"
                    ]
                  },
                  {
                    "text": "The 6 main methods used to localize lesionsWires, radioactive seeds, radar reflectors, radiofrequency identification (RFID) tags, magnetic seeds, and intraoperative ultrasound localization of masses or lesions marked by echogenic clips",
                    "sub_points": [
                      "Wires, radioactive seeds, radar reflectors, radiofrequency identification (RFID) tags, magnetic seeds, and intraoperative ultrasound localization of masses or lesions marked by echogenic clips"
                    ]
                  },
                  {
                    "text": "WiresThis was the 1st method developed to localize breast lesionsThe radiologist places a wire at the site of the lesion on the morning of surgeryThe wire has hook at the end to lodge the tip in tissue near the targeted lesionThe wire can enter breast from any margin except posteriorIdeally, the wire is removed intact without dislodging it from the lesion or cutting itThe wire and the specimen radiograph are used to locate the lesionWires have several disadvantagesThe wire must be placed the morning of the surgery, which can complicate schedulingA wire protruding from the skin can be uncomfortable for the patientIt can be difficult for the surgeon to locate the tip of the wire during surgeryThe wire can become displaced during surgery or during transfer of the specimen",
                    "sub_points": [
                      "This was the 1st method developed to localize breast lesions",
                      "The radiologist places a wire at the site of the lesion on the morning of surgery",
                      "The wire has hook at the end to lodge the tip in tissue near the targeted lesion",
                      "The wire can enter breast from any margin except posterior",
                      "Ideally, the wire is removed intact without dislodging it from the lesion or cutting it",
                      "The wire and the specimen radiograph are used to locate the lesion",
                      "Wires have several disadvantagesThe wire must be placed the morning of the surgery, which can complicate schedulingA wire protruding from the skin can be uncomfortable for the patientIt can be difficult for the surgeon to locate the tip of the wire during surgeryThe wire can become displaced during surgery or during transfer of the specimen",
                      "The wire must be placed the morning of the surgery, which can complicate scheduling",
                      "A wire protruding from the skin can be uncomfortable for the patient",
                      "It can be difficult for the surgeon to locate the tip of the wire during surgery",
                      "The wire can become displaced during surgery or during transfer of the specimen"
                    ]
                  },
                  {
                    "text": "Radioactive seedsThe radioactive seed consists of a titanium capsule surrounding an internal core filament containing iodine-1254.5 x 0.8 mm cylinder (slightly larger and longer than clips used to mark core needle biopsy sites)0.1-0.3 mCi; 60-day half-lifeThe seed is placed by the radiologist using a needle up to 5 days prior to surgeryThis simplifies surgical scheduling and is more comfortable for the patientAlthough the seed can be detected for weeks, removal is recommended within 5-7 days of placement to minimize losing patients to follow-up or seed migrationStates may have specific regulations concerning how long a seed can be left in a patientThe surgeon uses a handheld gamma detection probe to locate the seedSimilar to the technique used to identify sentinel lymph nodesRadioactivity from the seed can be distinguished from radioactive Tc-99m used to locate a sentinel nodeA specimen radiograph documents the presence and location of seedThe seed must be identified by the pathologist and placed in specific secure metal containerThe pathologist should have access to a gamma detection probe, which can localize a seed to within 1 cmGeiger counters can be used to detect seeds, but the exact location is less certain (+/- several centimeters)All personnel involved in handling seeds must be trained in radiation safetyAll seeds must be logged and returned to the Radiation Safety Officer to ensure appropriate disposalThe tissue associated with the seed and any clips present are identified by the pathologistNo significant radiation exposure to staff occursDoes not require special protective equipment or monitoringDamage to a seed could theoretically result in increased exposureDamage to titanium shell only occurs if seed is deliberately cut with a blade while held on a hard surfaceIt is recommended that scissors not be used for these specimens, as they could potentially provide more forceShould the shell be damaged, leakage of radioactive iodine is minimized, as iodine is affixed to a silver rod within the seedIn the very unlikely event of damage to the seed, a protocol for containment should be in placeDisadvantagesThe program requires special licensing and must follow strict regulationsRadioactivity requires additional training of pathology staff and close attention to finding, retrieving, securing, and returning the seedsLoss of a seed could result in consequences for a localization program and licensureIn some states, radioactive seeds must be removed by a set period of timeAlthough radioactive seeds can be placed prior to neoadjuvant therapy and can be detected afterward, this is not allowable in all locationsThe 60-day half-life limits the time during which the seed can be detectedIf a seed migrates after placement, a separate surgical procedure may be required to remove it",
                    "sub_points": [
                      "The radioactive seed consists of a titanium capsule surrounding an internal core filament containing iodine-1254.5 x 0.8 mm cylinder (slightly larger and longer than clips used to mark core needle biopsy sites)0.1-0.3 mCi; 60-day half-life",
                      "4.5 x 0.8 mm cylinder (slightly larger and longer than clips used to mark core needle biopsy sites)",
                      "0.1-0.3 mCi; 60-day half-life",
                      "The seed is placed by the radiologist using a needle up to 5 days prior to surgeryThis simplifies surgical scheduling and is more comfortable for the patientAlthough the seed can be detected for weeks, removal is recommended within 5-7 days of placement to minimize losing patients to follow-up or seed migrationStates may have specific regulations concerning how long a seed can be left in a patient",
                      "This simplifies surgical scheduling and is more comfortable for the patient",
                      "Although the seed can be detected for weeks, removal is recommended within 5-7 days of placement to minimize losing patients to follow-up or seed migrationStates may have specific regulations concerning how long a seed can be left in a patient",
                      "States may have specific regulations concerning how long a seed can be left in a patient",
                      "The surgeon uses a handheld gamma detection probe to locate the seedSimilar to the technique used to identify sentinel lymph nodesRadioactivity from the seed can be distinguished from radioactive Tc-99m used to locate a sentinel node",
                      "Similar to the technique used to identify sentinel lymph nodes",
                      "Radioactivity from the seed can be distinguished from radioactive Tc-99m used to locate a sentinel node",
                      "A specimen radiograph documents the presence and location of seed",
                      "The seed must be identified by the pathologist and placed in specific secure metal containerThe pathologist should have access to a gamma detection probe, which can localize a seed to within 1 cmGeiger counters can be used to detect seeds, but the exact location is less certain (+/- several centimeters)All personnel involved in handling seeds must be trained in radiation safetyAll seeds must be logged and returned to the Radiation Safety Officer to ensure appropriate disposal",
                      "The pathologist should have access to a gamma detection probe, which can localize a seed to within 1 cmGeiger counters can be used to detect seeds, but the exact location is less certain (+/- several centimeters)",
                      "Geiger counters can be used to detect seeds, but the exact location is less certain (+/- several centimeters)",
                      "All personnel involved in handling seeds must be trained in radiation safety",
                      "All seeds must be logged and returned to the Radiation Safety Officer to ensure appropriate disposal",
                      "The tissue associated with the seed and any clips present are identified by the pathologist",
                      "No significant radiation exposure to staff occursDoes not require special protective equipment or monitoring",
                      "Does not require special protective equipment or monitoring",
                      "Damage to a seed could theoretically result in increased exposureDamage to titanium shell only occurs if seed is deliberately cut with a blade while held on a hard surfaceIt is recommended that scissors not be used for these specimens, as they could potentially provide more forceShould the shell be damaged, leakage of radioactive iodine is minimized, as iodine is affixed to a silver rod within the seedIn the very unlikely event of damage to the seed, a protocol for containment should be in place",
                      "Damage to titanium shell only occurs if seed is deliberately cut with a blade while held on a hard surface",
                      "It is recommended that scissors not be used for these specimens, as they could potentially provide more force",
                      "Should the shell be damaged, leakage of radioactive iodine is minimized, as iodine is affixed to a silver rod within the seed",
                      "In the very unlikely event of damage to the seed, a protocol for containment should be in place",
                      "DisadvantagesThe program requires special licensing and must follow strict regulationsRadioactivity requires additional training of pathology staff and close attention to finding, retrieving, securing, and returning the seedsLoss of a seed could result in consequences for a localization program and licensureIn some states, radioactive seeds must be removed by a set period of timeAlthough radioactive seeds can be placed prior to neoadjuvant therapy and can be detected afterward, this is not allowable in all locationsThe 60-day half-life limits the time during which the seed can be detectedIf a seed migrates after placement, a separate surgical procedure may be required to remove it",
                      "The program requires special licensing and must follow strict regulations",
                      "Radioactivity requires additional training of pathology staff and close attention to finding, retrieving, securing, and returning the seedsLoss of a seed could result in consequences for a localization program and licensure",
                      "Loss of a seed could result in consequences for a localization program and licensure",
                      "In some states, radioactive seeds must be removed by a set period of timeAlthough radioactive seeds can be placed prior to neoadjuvant therapy and can be detected afterward, this is not allowable in all locationsThe 60-day half-life limits the time during which the seed can be detected",
                      "Although radioactive seeds can be placed prior to neoadjuvant therapy and can be detected afterward, this is not allowable in all locations",
                      "The 60-day half-life limits the time during which the seed can be detected",
                      "If a seed migrates after placement, a separate surgical procedure may be required to remove it"
                    ]
                  },
                  {
                    "text": "Radar reflectorThe Savi Scout (Cianna Medical Inc.) uses infrared light and a micropulse radar reflector to mark the site of lesions1.2 x 0.16 cm device with a central 0.4-cm-long cylinder with 2 slender rods (antennae) extending from each endThe reflector is placed by the radiologist using a 16-gauge needle a few days prior to surgeryThe surgeon uses a handheld device to detect the reflector intraoperativelyThe specimen radiograph is used to identify the reflector and the targeted lesion in the specimenDisadvantageInactivated if directly touched by cautery",
                    "sub_points": [
                      "The Savi Scout (Cianna Medical Inc.) uses infrared light and a micropulse radar reflector to mark the site of lesions1.2 x 0.16 cm device with a central 0.4-cm-long cylinder with 2 slender rods (antennae) extending from each end",
                      "1.2 x 0.16 cm device with a central 0.4-cm-long cylinder with 2 slender rods (antennae) extending from each end",
                      "The reflector is placed by the radiologist using a 16-gauge needle a few days prior to surgery",
                      "The surgeon uses a handheld device to detect the reflector intraoperatively",
                      "The specimen radiograph is used to identify the reflector and the targeted lesion in the specimen",
                      "DisadvantageInactivated if directly touched by cautery",
                      "Inactivated if directly touched by cautery"
                    ]
                  },
                  {
                    "text": "Magnetic seedMagseed (Endomagnetics Inc.) is a paramagnetic surgical grade stainless steel device used to localize breast lesions0.5 x 0.09 cm cylinderA radiologist introduces the seed using an 18-gauge needle a few days before the surgical procedureThe surgeon uses a Sentimag detector probe that magnetizes the iron in the seed, which transiently creates a magnetic field that is detected by the probeThe specimen radiograph is used to identify the seed and the targeted lesion in the specimenDisadvantagesCauses a 4-cm artifact on MR, which can limit clinical useStainless steel surgical instruments can interfere with the use of the probe to detect the seed",
                    "sub_points": [
                      "Magseed (Endomagnetics Inc.) is a paramagnetic surgical grade stainless steel device used to localize breast lesions0.5 x 0.09 cm cylinder",
                      "0.5 x 0.09 cm cylinder",
                      "A radiologist introduces the seed using an 18-gauge needle a few days before the surgical procedure",
                      "The surgeon uses a Sentimag detector probe that magnetizes the iron in the seed, which transiently creates a magnetic field that is detected by the probe",
                      "The specimen radiograph is used to identify the seed and the targeted lesion in the specimen",
                      "DisadvantagesCauses a 4-cm artifact on MR, which can limit clinical useStainless steel surgical instruments can interfere with the use of the probe to detect the seed",
                      "Causes a 4-cm artifact on MR, which can limit clinical use",
                      "Stainless steel surgical instruments can interfere with the use of the probe to detect the seed"
                    ]
                  },
                  {
                    "text": "Radiofrequency identification (RFID) tagsRFID tag (LOCalizer, Hologic) is a ferrite rod covered with copper and wrapped by a glass casing and microprocessor1.2 cm in cylinderEach RFID tag has a unique identification number that can be read by the detectorThe device is placed at the lesion site by the radiologist using an 8-gauge needle a few days before the surgical procedureThe surgeon uses a probe to identify the deviceThe specimen radiograph is used to identify the seed and the targeted lesion in the specimenDisadvantagesCauses a 2-cm artifact on MR, which can limit useIf 2 tags are placed < 2 cm apart, interference can make it difficult to identify and localize the tags separately",
                    "sub_points": [
                      "RFID tag (LOCalizer, Hologic) is a ferrite rod covered with copper and wrapped by a glass casing and microprocessor1.2 cm in cylinderEach RFID tag has a unique identification number that can be read by the detector",
                      "1.2 cm in cylinder",
                      "Each RFID tag has a unique identification number that can be read by the detector",
                      "The device is placed at the lesion site by the radiologist using an 8-gauge needle a few days before the surgical procedure",
                      "The surgeon uses a probe to identify the device",
                      "The specimen radiograph is used to identify the seed and the targeted lesion in the specimen",
                      "DisadvantagesCauses a 2-cm artifact on MR, which can limit useIf 2 tags are placed < 2 cm apart, interference can make it difficult to identify and localize the tags separately",
                      "Causes a 2-cm artifact on MR, which can limit use",
                      "If 2 tags are placed < 2 cm apart, interference can make it difficult to identify and localize the tags separately"
                    ]
                  },
                  {
                    "text": "Intraoperative ultrasound localization (IOUSL)IOUSL can be used by the surgeon to identify masses detectable by ultrasound as well as lesions that have been previously marked by a large echogenic clip embedded in gel biodegradable carrier materialThis method does not require a 2nd needle placement of a localization deviceDisadvantageIf the biopsy site is transected, the gel and clip may leak out of the specimen, making the target area difficult to identify",
                    "sub_points": [
                      "IOUSL can be used by the surgeon to identify masses detectable by ultrasound as well as lesions that have been previously marked by a large echogenic clip embedded in gel biodegradable carrier material",
                      "This method does not require a 2nd needle placement of a localization device",
                      "DisadvantageIf the biopsy site is transected, the gel and clip may leak out of the specimen, making the target area difficult to identify",
                      "If the biopsy site is transected, the gel and clip may leak out of the specimen, making the target area difficult to identify"
                    ]
                  }
                ]
              },
              "Specimen Processing": {
                "Requisition Form": [
                  {
                    "text": "In addition to information that should be provided for all breast specimens, the following information is necessary for optimal gross examination of specimensType of lesion(s) targeted for removalPalpable massImaging finding (mammographic, ultrasound, or MR)MassArchitectural distortion/asymmetryCalcificationsEnhancement on MRClips from prior core needle biopsiesDuct excision for nipple dischargeOrientation of specimenDesignations using sutures or clips to mark specific margins (all 6 margins should be identifiable)If all margins are submitted as separate specimens, the main specimen need not be oriented by surgeonNeoadjuvant (presurgical) therapyIf patient has been treated, it is important to know the size of the lesion prior to treatment and to know if a clip or clips were placed to mark the site",
                    "sub_points": [
                      "Type of lesion(s) targeted for removalPalpable massImaging finding (mammographic, ultrasound, or MR)MassArchitectural distortion/asymmetryCalcificationsEnhancement on MRClips from prior core needle biopsiesDuct excision for nipple discharge",
                      "Palpable mass",
                      "Imaging finding (mammographic, ultrasound, or MR)MassArchitectural distortion/asymmetryCalcificationsEnhancement on MRClips from prior core needle biopsies",
                      "Mass",
                      "Architectural distortion/asymmetry",
                      "Calcifications",
                      "Enhancement on MR",
                      "Clips from prior core needle biopsies",
                      "Duct excision for nipple discharge",
                      "Orientation of specimenDesignations using sutures or clips to mark specific margins (all 6 margins should be identifiable)If all margins are submitted as separate specimens, the main specimen need not be oriented by surgeon",
                      "Designations using sutures or clips to mark specific margins (all 6 margins should be identifiable)",
                      "If all margins are submitted as separate specimens, the main specimen need not be oriented by surgeon",
                      "Neoadjuvant (presurgical) therapyIf patient has been treated, it is important to know the size of the lesion prior to treatment and to know if a clip or clips were placed to mark the site",
                      "If patient has been treated, it is important to know the size of the lesion prior to treatment and to know if a clip or clips were placed to mark the site"
                    ]
                  },
                  {
                    "text": "The type of localization device should be specifiedRadioactive seeds require special handling",
                    "sub_points": [
                      "Radioactive seeds require special handling"
                    ]
                  },
                  {
                    "text": "If adequate information is not provided, additional information should be requested from surgeon"
                  }
                ],
                "Specimen Radiograph": [
                  {
                    "text": "If the specimen was excised for a radiologic lesion, a specimen radiograph should be received with the specimen or available to the pathologistIf BC is present in a specimen, it is present at or within 1 cm of the radiologic lesion in > 95% of casesBCs incidental to the radiologic lesion are generally lobular carcinoma in situ or small low-grade ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "If BC is present in a specimen, it is present at or within 1 cm of the radiologic lesion in > 95% of casesBCs incidental to the radiologic lesion are generally lobular carcinoma in situ or small low-grade ductal carcinoma in situ (DCIS)",
                      "BCs incidental to the radiologic lesion are generally lobular carcinoma in situ or small low-grade ductal carcinoma in situ (DCIS)"
                    ]
                  },
                  {
                    "text": "The radiologist's interpretation should be available to the pathologistStates whether or not the targeted lesion or lesions are presentIdentifies type of lesion(s) (e.g., mass, calcifications, distortion, clip, wire, localization device)It is often helpful for radiologist to circle or otherwise indicate the location of the lesion, especially if subtleIn some cases, nontargeted lesions may be removed in addition to the targeted lesionIt is important for the pathologist to know which lesion was the one intended for excision",
                    "sub_points": [
                      "States whether or not the targeted lesion or lesions are present",
                      "Identifies type of lesion(s) (e.g., mass, calcifications, distortion, clip, wire, localization device)",
                      "It is often helpful for radiologist to circle or otherwise indicate the location of the lesion, especially if subtle",
                      "In some cases, nontargeted lesions may be removed in addition to the targeted lesionIt is important for the pathologist to know which lesion was the one intended for excision",
                      "It is important for the pathologist to know which lesion was the one intended for excision"
                    ]
                  },
                  {
                    "text": "Some pathology departments are capable of radiographing specimensUseful for identifying biopsy clips, surgical clips, and obvious lesions (e.g., large masses)May not be adequate to identify architectural distortion, asymmetry, or subtle calcificationsA specimen radiograph can only be interpreted fully if it is known what was targeted and if it can be identified in the specimen",
                    "sub_points": [
                      "Useful for identifying biopsy clips, surgical clips, and obvious lesions (e.g., large masses)",
                      "May not be adequate to identify architectural distortion, asymmetry, or subtle calcifications",
                      "A specimen radiograph can only be interpreted fully if it is known what was targeted and if it can be identified in the specimen"
                    ]
                  },
                  {
                    "text": "The radiograph should be oriented with respect to the specimen4 margins can be identified on the radiographOften provides useful information about the closest margin to the targeted lesionIf the lesion can be identified on the radiograph, surgeons can use the radiologic distance to margins to perform reexcision if a diagnosis of BC has been made previously by needle biopsyThe radiograph can be annotated to designate margins and sites for tissue sampling",
                    "sub_points": [
                      "4 margins can be identified on the radiograph",
                      "Often provides useful information about the closest margin to the targeted lesion",
                      "If the lesion can be identified on the radiograph, surgeons can use the radiologic distance to margins to perform reexcision if a diagnosis of BC has been made previously by needle biopsy",
                      "The radiograph can be annotated to designate margins and sites for tissue sampling"
                    ]
                  },
                  {
                    "text": "The likely location of the targeted lesion in the specimen can be approximated using the shape of the specimen and the location of the wire or other localization deviceCommercial specimen holders with grids are available; these help localize lesions in specimens",
                    "sub_points": [
                      "Commercial specimen holders with grids are available; these help localize lesions in specimens"
                    ]
                  },
                  {
                    "text": "If the specimen is transected along the plane of the wire, the gross appearance is similar to that of specimen radiographUsually helpful in identifying location of lesion, particularly when lesion is small or difficult to see grossly",
                    "sub_points": [
                      "Usually helpful in identifying location of lesion, particularly when lesion is small or difficult to see grossly"
                    ]
                  },
                  {
                    "text": "Radiographs of sliced specimens help identify lesionsEasier to locate lesions within slicesMay be more difficult to interpret if lesions are in > 1 slice (e.g., calcification clusters) or if clips are dislodged from specimenRadiographs of blocks of paraffin-embedded tissue can identify calcifications or clips",
                    "sub_points": [
                      "Easier to locate lesions within slices",
                      "May be more difficult to interpret if lesions are in > 1 slice (e.g., calcification clusters) or if clips are dislodged from specimen",
                      "Radiographs of blocks of paraffin-embedded tissue can identify calcifications or clips"
                    ]
                  },
                  {
                    "text": "Lesions localized by intraoperative ultrasound should also be radiographed to document the presence of the lesion and clipThe radiologist's report stating that lesion is present should be providedThe sonograph is generally not useful to locate lesion in specimen and not provided to pathologistLesions are generally > 1 cm and should be grossly evident",
                    "sub_points": [
                      "The radiologist's report stating that lesion is present should be provided",
                      "The sonograph is generally not useful to locate lesion in specimen and not provided to pathologist",
                      "Lesions are generally > 1 cm and should be grossly evident"
                    ]
                  },
                  {
                    "text": "Specimens cannot be imaged by MR due to absence of vascular blood flowSpecimen radiograph may be performed but rarely shows targeted lesionUnrelated calcifications should not be misinterpreted as targeted lesionMost MR lesions are 1st sampled by core needle biopsy; clip can be identified by radiography",
                    "sub_points": [
                      "Specimen radiograph may be performed but rarely shows targeted lesion",
                      "Unrelated calcifications should not be misinterpreted as targeted lesion",
                      "Most MR lesions are 1st sampled by core needle biopsy; clip can be identified by radiography"
                    ]
                  }
                ],
                "Gross Description": [
                  {
                    "text": "Description of intact specimen includesLabeling of specimen as provided by surgeonSize of specimen in 3 dimensionsIf oriented, dimensions should be designated as superior to inferior, medial to lateral, and anterior to posteriorIf there are multiple fragments, number and size of each fragment is recordedPresence of localization device (wire, seed, reflector, RFID tag) and clipsPresent within specimen or dislodgedPresence of skin (color, size, presence of scars)Presence of muscle (size and location)Sutures or other means of orientationIf specimen has been inked by surgeon, correct orientation should be confirmedPresence of any lesions visible on surface of specimenPresence of defects in surface that could lead to ink leaking into specimen",
                    "sub_points": [
                      "Labeling of specimen as provided by surgeon",
                      "Size of specimen in 3 dimensionsIf oriented, dimensions should be designated as superior to inferior, medial to lateral, and anterior to posteriorIf there are multiple fragments, number and size of each fragment is recorded",
                      "If oriented, dimensions should be designated as superior to inferior, medial to lateral, and anterior to posterior",
                      "If there are multiple fragments, number and size of each fragment is recorded",
                      "Presence of localization device (wire, seed, reflector, RFID tag) and clipsPresent within specimen or dislodged",
                      "Present within specimen or dislodged",
                      "Presence of skin (color, size, presence of scars)",
                      "Presence of muscle (size and location)",
                      "Sutures or other means of orientationIf specimen has been inked by surgeon, correct orientation should be confirmed",
                      "If specimen has been inked by surgeon, correct orientation should be confirmed",
                      "Presence of any lesions visible on surface of specimen",
                      "Presence of defects in surface that could lead to ink leaking into specimen"
                    ]
                  },
                  {
                    "text": "Description of sliced specimen should includeAppearance of any gross lesions: Size (3 dimensions), shape (irregular, circumscribed, ill defined), color, and consistency (rubbery, firm, hard, mucinous)Distance from each marginIf 2 lesions present, distance between lesions is recordedBiopsy sitesClips &/or biodegradable carrier material, indicating prior core needle biopsyRelationship to other gross lesionsProximity to marginsIf there is a specimen radiograph, relationship of gross lesion to radiologic lesionIf radioactive seed is present, documentation of identification by handheld gamma probe and appropriate handling for subsequent disposal",
                    "sub_points": [
                      "Appearance of any gross lesions: Size (3 dimensions), shape (irregular, circumscribed, ill defined), color, and consistency (rubbery, firm, hard, mucinous)",
                      "Distance from each margin",
                      "If 2 lesions present, distance between lesions is recorded",
                      "Biopsy sitesClips &/or biodegradable carrier material, indicating prior core needle biopsyRelationship to other gross lesionsProximity to margins",
                      "Clips &/or biodegradable carrier material, indicating prior core needle biopsy",
                      "Relationship to other gross lesions",
                      "Proximity to margins",
                      "If there is a specimen radiograph, relationship of gross lesion to radiologic lesion",
                      "If radioactive seed is present, documentation of identification by handheld gamma probe and appropriate handling for subsequent disposal"
                    ]
                  },
                  {
                    "text": "Extent to which specimen is sampled should be recordedEntire specimen, all fibrous tissue, or percentage of specimenA specimen diagram can be helpful to show where sections were taken",
                    "sub_points": [
                      "Entire specimen, all fibrous tissue, or percentage of specimen",
                      "A specimen diagram can be helpful to show where sections were taken"
                    ]
                  },
                  {
                    "text": "Cassette keyType of tissue in each cassette should be annotatedSections of lesions and tissue between lesions; margin sections, including designationsSections with skin or muscle",
                    "sub_points": [
                      "Type of tissue in each cassette should be annotatedSections of lesions and tissue between lesions; margin sections, including designationsSections with skin or muscle",
                      "Sections of lesions and tissue between lesions; margin sections, including designations",
                      "Sections with skin or muscle"
                    ]
                  }
                ],
                "Inking Specimen Margins": [
                  {
                    "text": "6 margins can generally be identified (anterior, posterior, superior, inferior, medial, and lateral)"
                  },
                  {
                    "text": "Different colors of ink can be used to identify specific marginsIt is helpful to establish an institutional system of specific colors for each margin",
                    "sub_points": [
                      "It is helpful to establish an institutional system of specific colors for each margin"
                    ]
                  },
                  {
                    "text": "If < 6 ink colors are used, sections should be taken and annotated as to locations of each margin"
                  },
                  {
                    "text": "Outer surface should be blotted dry before sectioning to avoid smearing ink onto interior surfacesHelpful to change gloves and clean any ink from workspace before proceeding",
                    "sub_points": [
                      "Helpful to change gloves and clean any ink from workspace before proceeding"
                    ]
                  },
                  {
                    "text": "If all margins are taken as separately submitted shave margins, the main specimen need not be inkedIf not all margins have been taken separately, some margins on main specimen may need to be evaluated",
                    "sub_points": [
                      "If not all margins have been taken separately, some margins on main specimen may need to be evaluated"
                    ]
                  }
                ],
                "Sectioning": [
                  {
                    "text": "Specimen is thinly sectioned into 2- to 5-mm-thick parallel slices, usually perpendicular to its long axis"
                  }
                ],
                "Sampling": [
                  {
                    "text": "Lesions should be sampled in their entirety when practicalVery large lesions should be sampled with at least 1 section per centimeter of greatest dimension",
                    "sub_points": [
                      "Very large lesions should be sampled with at least 1 section per centimeter of greatest dimension"
                    ]
                  },
                  {
                    "text": "If multiple lesions are present, tissue between lesions is sampled"
                  },
                  {
                    "text": "Margins generally taken as perpendicular sectionsEn face margins must be specified in description, as interpretation is different than for perpendicular marginsEn face margins are not recommended for BCs because distance to margin cannot be determined2 perpendicular sections per margin (12 total sections) form a reasonable initial evaluationSubmitting additional tissue sections may be considered if some of these initial sections are positive for BC",
                    "sub_points": [
                      "En face margins must be specified in description, as interpretation is different than for perpendicular marginsEn face margins are not recommended for BCs because distance to margin cannot be determined",
                      "En face margins are not recommended for BCs because distance to margin cannot be determined",
                      "2 perpendicular sections per margin (12 total sections) form a reasonable initial evaluationSubmitting additional tissue sections may be considered if some of these initial sections are positive for BC",
                      "Submitting additional tissue sections may be considered if some of these initial sections are positive for BC"
                    ]
                  },
                  {
                    "text": "If the targeted lesion is present in the specimen radiograph, but not identified grossly, it is preferable to submit all fibrous tissue if practicalSubmitting additional sections should also be considered if only atypical ductal hyperplasia or DCIS is identified or if expected lesions are not present (e.g., prior core needle biopsy site)",
                    "sub_points": [
                      "Submitting additional sections should also be considered if only atypical ductal hyperplasia or DCIS is identified or if expected lesions are not present (e.g., prior core needle biopsy site)"
                    ]
                  }
                ]
              },
              "Difficult Cases": {
                "Excisions for Known Ductal Carcinoma In Situ": [
                  {
                    "text": "It is preferable to completely sample excisions for a known case of DCIS for several reasonsImportant to determine if there are any foci of invasionMargin status important to evaluateExtent can be determined if completely sampled in systematic fashione.g., sampling can be carried out from medial to lateralLocation of sections on specimen radiograph or thickness of slices can be used to estimate extentExtent can also be estimated by number of blocks with DCIS when area of DCIS has been adequately sampledThis method is very similar to linear extent (determined by mapping tissue slices) up to 3 cmFor areas of DCIS > 3 cm, block method tends to give larger sizes compared with linear extent because DCIS involves 3D spaceFor clinical utility, an estimate is sufficient, and exact measurement is not practical to obtain or necessary",
                    "sub_points": [
                      "Important to determine if there are any foci of invasion",
                      "Margin status important to evaluate",
                      "Extent can be determined if completely sampled in systematic fashione.g., sampling can be carried out from medial to lateralLocation of sections on specimen radiograph or thickness of slices can be used to estimate extent",
                      "e.g., sampling can be carried out from medial to lateral",
                      "Location of sections on specimen radiograph or thickness of slices can be used to estimate extent",
                      "Extent can also be estimated by number of blocks with DCIS when area of DCIS has been adequately sampledThis method is very similar to linear extent (determined by mapping tissue slices) up to 3 cmFor areas of DCIS > 3 cm, block method tends to give larger sizes compared with linear extent because DCIS involves 3D spaceFor clinical utility, an estimate is sufficient, and exact measurement is not practical to obtain or necessary",
                      "This method is very similar to linear extent (determined by mapping tissue slices) up to 3 cm",
                      "For areas of DCIS > 3 cm, block method tends to give larger sizes compared with linear extent because DCIS involves 3D space",
                      "For clinical utility, an estimate is sufficient, and exact measurement is not practical to obtain or necessary"
                    ]
                  }
                ],
                "Excisions for Nipple Discharge": [
                  {
                    "text": "Nipple discharge is usually due to a large duct papillomaLess commonly, discharge is associated with papillary/micropapillary DCIS or benign changesDuct injections may reveal a filling defect but are difficult to perform",
                    "sub_points": [
                      "Less commonly, discharge is associated with papillary/micropapillary DCIS or benign changes",
                      "Duct injections may reveal a filling defect but are difficult to perform"
                    ]
                  },
                  {
                    "text": "A papilloma responsible for nipple discharge may be difficult to locate, as they can be small and friable"
                  },
                  {
                    "text": "If the lesion can be identified by mammography or ultrasound, the site may be marked by a localization device"
                  },
                  {
                    "text": "The involved duct may be marked with sutureThe ends of the duct can be taken as en face margins if they can be identified as small tubular structuresThe remainder of the duct may be opened with fine scissorsIf a papilloma is present, it may be seen as polypoid mass on stalk in wall",
                    "sub_points": [
                      "The ends of the duct can be taken as en face margins if they can be identified as small tubular structures",
                      "The remainder of the duct may be opened with fine scissors",
                      "If a papilloma is present, it may be seen as polypoid mass on stalk in wall"
                    ]
                  }
                ],
                "Excisions After Neoadjuvant Therapy": [
                  {
                    "text": "Clip should be placed prior to treatment to mark site of invasive BC"
                  },
                  {
                    "text": "A gross lesion may not be evident after complete or near-complete response"
                  },
                  {
                    "text": "The tumor bed may be an ill-defined fibrous area in the vicinity of the clip"
                  },
                  {
                    "text": "At least 1 section of tissue per centimeter of the largest dimension of tumor bed or size of BC prior to treatment should be sampled"
                  },
                  {
                    "text": "If initial sections do not show residual invasive BC, additional sampling should be considered to document a pathologic complete response"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Margins and Reexcisions": {
            "name": "Margins and Reexcisions",
            "url": "https://app.pathprimer.com/document/fdfb8338-9f1d-4ded-9e09-268ec282bb7c/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Introduction": {
                "Margins and Local Recurrence Rates": [
                  {
                    "text": "Positive margins [ink on invasive breast carcinoma (BC) or ductal carcinoma in situ (DCIS)] correlate with higher likelihood of residual disease in the breastCarcinoma close to margins also increases the likelihood of residual disease, but magnitude of risk is dependent on type of BC (invasive or in situ), distance from margin, and extent",
                    "sub_points": [
                      "Carcinoma close to margins also increases the likelihood of residual disease, but magnitude of risk is dependent on type of BC (invasive or in situ), distance from margin, and extent"
                    ]
                  },
                  {
                    "text": "Residual BC in breast is associated with increased risk of local recurrence"
                  },
                  {
                    "text": "Minimizing risk of local recurrence is an important goalCan improve survival for patients whose initial BC is likely curable [carcinoma in situ and small node (-) invasive BCs]Recurrent BC could be of a higher stageReduces the need for additional surgery and treatmentReduces the possibility of uncontrolled local disease in skin and chest wall (carcinoma en cuirasse)Recurrence is often very psychologically difficult for patientsMastectomy is usually required for treatment, as radiation cannot be delivered to the chest a 2nd time",
                    "sub_points": [
                      "Can improve survival for patients whose initial BC is likely curable [carcinoma in situ and small node (-) invasive BCs]Recurrent BC could be of a higher stage",
                      "Recurrent BC could be of a higher stage",
                      "Reduces the need for additional surgery and treatment",
                      "Reduces the possibility of uncontrolled local disease in skin and chest wall (carcinoma en cuirasse)",
                      "Recurrence is often very psychologically difficult for patientsMastectomy is usually required for treatment, as radiation cannot be delivered to the chest a 2nd time",
                      "Mastectomy is usually required for treatment, as radiation cannot be delivered to the chest a 2nd time"
                    ]
                  },
                  {
                    "text": "Margins for palpable invasive BCs are generally negativeSurgeon palpates BC and excises rim of grossly normal tissueApparently positive margin on microscopic examination may be due to ink leakage or inadvertent incision into BCGenerally, several mm of cauterized tissue are present within the patient's biopsy cavityResidual BC at edge of biopsy site will not be viableTherefore, a focally positive margin for invasive BC usually does not correlate with residual invasive BC in patient",
                    "sub_points": [
                      "Surgeon palpates BC and excises rim of grossly normal tissue",
                      "Apparently positive margin on microscopic examination may be due to ink leakage or inadvertent incision into BC",
                      "Generally, several mm of cauterized tissue are present within the patient's biopsy cavityResidual BC at edge of biopsy site will not be viable",
                      "Residual BC at edge of biopsy site will not be viable",
                      "Therefore, a focally positive margin for invasive BC usually does not correlate with residual invasive BC in patient"
                    ]
                  },
                  {
                    "text": "Margins for nonpalpable invasive BCs (due to small size or diffusely invasive pattern) may be positiveSurgeon cannot palpate BC and, therefore, must make an educated guess as to how much tissue to removeIf BC is transected, it will be present at the margin over a broad frontCautery artifact on BC supports that margin is true surgical marginExtensive residual BC may be present in breast",
                    "sub_points": [
                      "Surgeon cannot palpate BC and, therefore, must make an educated guess as to how much tissue to remove",
                      "If BC is transected, it will be present at the margin over a broad frontCautery artifact on BC supports that margin is true surgical marginExtensive residual BC may be present in breast",
                      "Cautery artifact on BC supports that margin is true surgical margin",
                      "Extensive residual BC may be present in breast"
                    ]
                  },
                  {
                    "text": "Margins may be positive or close for DCISDCIS is rarely grossly evidentExtent of DCIS cannot be determined with certainty by clinical examination or imagingSurgeon cannot definitively know how much tissue to removeMargins can only be evaluated with certainty microscopically on permanent sections",
                    "sub_points": [
                      "DCIS is rarely grossly evident",
                      "Extent of DCIS cannot be determined with certainty by clinical examination or imaging",
                      "Surgeon cannot definitively know how much tissue to remove",
                      "Margins can only be evaluated with certainty microscopically on permanent sections"
                    ]
                  }
                ],
                "Prediction of Residual Breast Carcinoma": [
                  {
                    "text": "Even under the best conditions, the likelihood of residual BC can only be estimated"
                  },
                  {
                    "text": "The presence of BC at margins does not predict residual BC in the patient with certaintyThere may not be breast tissue beyond the edge of the specimenParticularly relevant for margins adjacent to skin and pectoralis muscleOften several mm of cauterized tissue are in the biopsy cavity in patientCautery may destroy small amounts of residual BCMargins may be falsely positive due to ink leakage into cracks or specimen fragmentationCan be gaps between areas of involvement by DCISDuct at margin can appear free of DCIS, but DCIS can be present further along in ductMargins can be falsely negative if areas of involvement are not sampled or if areas are too small to be present within width of section",
                    "sub_points": [
                      "There may not be breast tissue beyond the edge of the specimenParticularly relevant for margins adjacent to skin and pectoralis muscle",
                      "Particularly relevant for margins adjacent to skin and pectoralis muscle",
                      "Often several mm of cauterized tissue are in the biopsy cavity in patientCautery may destroy small amounts of residual BC",
                      "Cautery may destroy small amounts of residual BC",
                      "Margins may be falsely positive due to ink leakage into cracks or specimen fragmentation",
                      "Can be gaps between areas of involvement by DCISDuct at margin can appear free of DCIS, but DCIS can be present further along in duct",
                      "Duct at margin can appear free of DCIS, but DCIS can be present further along in duct",
                      "Margins can be falsely negative if areas of involvement are not sampled or if areas are too small to be present within width of section"
                    ]
                  }
                ],
                "Risk Factors for Local Recurrence": [
                  {
                    "text": "~ 10% of patients will have a local recurrence at 10 years"
                  },
                  {
                    "text": "Risk factors for recurrence includeYoung patient agePoorly differentiated BCsPositive marginsExtensive intraductal component (EIC) with DCIS located away from invasive BCExtensive lymphovascular invasion",
                    "sub_points": [
                      "Young patient age",
                      "Poorly differentiated BCs",
                      "Positive margins",
                      "Extensive intraductal component (EIC) with DCIS located away from invasive BC",
                      "Extensive lymphovascular invasion"
                    ]
                  },
                  {
                    "text": "Subtypes of BC have different local recurrence rates at 5 yearsLuminal A BC: ER/PR (+), HER2(-): 1-2%Luminal B BC: ER/PR (+), HER2(+): 1-3%HER2 BC: ER/PR (-), HER2(+): 10%Triple negative BC (TNBC)/basal: ER, PR, and HER2 (-): 10%",
                    "sub_points": [
                      "Luminal A BC: ER/PR (+), HER2(-): 1-2%",
                      "Luminal B BC: ER/PR (+), HER2(+): 1-3%",
                      "HER2 BC: ER/PR (-), HER2(+): 10%",
                      "Triple negative BC (TNBC)/basal: ER, PR, and HER2 (-): 10%"
                    ]
                  },
                  {
                    "text": "Growth rate of luminal ER/PR (+) BCs can be inhibited by hormonal therapy over many years"
                  },
                  {
                    "text": "Patients with HER2(+)BCs are now being treated with HER2-targeted therapy over many yearsTreatment reduces likelihood of local recurrence",
                    "sub_points": [
                      "Treatment reduces likelihood of local recurrence"
                    ]
                  },
                  {
                    "text": "Targeted therapy for TNBCs is being developed and studied in clinical trials and is available for select cases"
                  }
                ],
                "Consensus Guidelines on Margins for Invasive Breast Carcinoma": [
                  {
                    "text": "A multidisciplinary panel of experts was convened by the Society of Surgical Oncology (SSO) and the American Society for Radiation Oncology (ASTRO) in 2013"
                  },
                  {
                    "text": "Guidelines pertain to early-stage invasive BC treated with breast conservation followed by whole-breast irradiationNot applicable to patients with only DCISNot applicable for patients with invasive BC undergoing partial breast irradiation or no radiationNot applicable for patients after neoadjuvant chemotherapy",
                    "sub_points": [
                      "Not applicable to patients with only DCIS",
                      "Not applicable for patients with invasive BC undergoing partial breast irradiation or no radiation",
                      "Not applicable for patients after neoadjuvant chemotherapy"
                    ]
                  },
                  {
                    "text": "Panel used metaanalysis of margin width and ipsilateral breast tumor recurrence (IBTR) based on 33 studies to derive recommendationsPositive marginsPositive margins (ink on invasive BC or DCIS) are associated with 2x increased risk of IBTR compared with negative marginsPositive margins after breast-conserving surgery signify possibility of residual disease in breastIncreased risk is not mitigated by favorable biology, endocrine therapy, or radiation boostTherefore, positive margin would, in general, be indication for additional surgery to obtain negative marginWider marginsDo not significantly decrease rate of IBTR compared with no ink on tumorNo evidence that wider margins reduced IBTR for younger patients, unfavorable biology, lobular BCs, or BCs with EIC",
                    "sub_points": [
                      "Positive marginsPositive margins (ink on invasive BC or DCIS) are associated with 2x increased risk of IBTR compared with negative marginsPositive margins after breast-conserving surgery signify possibility of residual disease in breastIncreased risk is not mitigated by favorable biology, endocrine therapy, or radiation boostTherefore, positive margin would, in general, be indication for additional surgery to obtain negative margin",
                      "Positive margins (ink on invasive BC or DCIS) are associated with 2x increased risk of IBTR compared with negative margins",
                      "Positive margins after breast-conserving surgery signify possibility of residual disease in breast",
                      "Increased risk is not mitigated by favorable biology, endocrine therapy, or radiation boost",
                      "Therefore, positive margin would, in general, be indication for additional surgery to obtain negative margin",
                      "Wider marginsDo not significantly decrease rate of IBTR compared with no ink on tumorNo evidence that wider margins reduced IBTR for younger patients, unfavorable biology, lobular BCs, or BCs with EIC",
                      "Do not significantly decrease rate of IBTR compared with no ink on tumor",
                      "No evidence that wider margins reduced IBTR for younger patients, unfavorable biology, lobular BCs, or BCs with EIC"
                    ]
                  },
                  {
                    "text": "Panel conclusionsPositive margins are reported when there is ink on invasive BC or DCISNo ink on tumor is standard for adequate marginUse of additional surgery to obtain wider margins is not supportedHowever, panel emphasized that guidelines are not substitutes for clinical judgmentThere may be patients who would benefit from wider marginsExample provided is a young woman with invasive BC with extensive DCIS and tumor < 1 mm from margin over a broad front",
                    "sub_points": [
                      "Positive margins are reported when there is ink on invasive BC or DCIS",
                      "No ink on tumor is standard for adequate marginUse of additional surgery to obtain wider margins is not supported",
                      "Use of additional surgery to obtain wider margins is not supported",
                      "However, panel emphasized that guidelines are not substitutes for clinical judgmentThere may be patients who would benefit from wider marginsExample provided is a young woman with invasive BC with extensive DCIS and tumor < 1 mm from margin over a broad front",
                      "There may be patients who would benefit from wider marginsExample provided is a young woman with invasive BC with extensive DCIS and tumor < 1 mm from margin over a broad front",
                      "Example provided is a young woman with invasive BC with extensive DCIS and tumor < 1 mm from margin over a broad front"
                    ]
                  },
                  {
                    "text": "Implications of guidelines for pathologistsPathologists should continue to report positive margins defined by ink on tumorIf margin is negative, distance to margin should be reportedGuidelines for reporting invasive BC and DCIS are issued by the College of American Pathologists (CAP) (www.cap.org; accessed 11/25/2024) and the International Collaboration on Cancer Reporting (ICCR) (https://www.iccr-cancer.org/datasets/published-datasets/breast/; accessed 11/25/2024)For breast-conserving surgery, specimen should be oriented, and all margins should be sampled and reportedThis includes anterior, posterior, superior, inferior, medial, and lateral marginsRelationship of both DCIS and invasive BC to each margin should be givenSpecimen should be adequately sampled so that margins are as accurate as possibleMargins should not be given an interpretation, such as \"close\"",
                    "sub_points": [
                      "Pathologists should continue to report positive margins defined by ink on tumor",
                      "If margin is negative, distance to margin should be reportedGuidelines for reporting invasive BC and DCIS are issued by the College of American Pathologists (CAP) (www.cap.org; accessed 11/25/2024) and the International Collaboration on Cancer Reporting (ICCR) (https://www.iccr-cancer.org/datasets/published-datasets/breast/; accessed 11/25/2024)For breast-conserving surgery, specimen should be oriented, and all margins should be sampled and reportedThis includes anterior, posterior, superior, inferior, medial, and lateral marginsRelationship of both DCIS and invasive BC to each margin should be givenSpecimen should be adequately sampled so that margins are as accurate as possible",
                      "Guidelines for reporting invasive BC and DCIS are issued by the College of American Pathologists (CAP) (www.cap.org; accessed 11/25/2024) and the International Collaboration on Cancer Reporting (ICCR) (https://www.iccr-cancer.org/datasets/published-datasets/breast/; accessed 11/25/2024)",
                      "For breast-conserving surgery, specimen should be oriented, and all margins should be sampled and reportedThis includes anterior, posterior, superior, inferior, medial, and lateral marginsRelationship of both DCIS and invasive BC to each margin should be given",
                      "This includes anterior, posterior, superior, inferior, medial, and lateral margins",
                      "Relationship of both DCIS and invasive BC to each margin should be given",
                      "Specimen should be adequately sampled so that margins are as accurate as possible",
                      "Margins should not be given an interpretation, such as \"close\""
                    ]
                  }
                ],
                "Consensus Guidelines on Margins for Ductal Carcinoma In Situ": [
                  {
                    "text": "A multidisciplinary panel of experts was convened by SSO, ASTRO, and the American Society of Clinical Oncology in 2016"
                  },
                  {
                    "text": "The guidelines are for DCIS treated with breast-conserving surgery and whole-breast radiationIncludes cases of DCIS with microinvasionThe optimal margins for women not receiving radiation were not included",
                    "sub_points": [
                      "Includes cases of DCIS with microinvasion",
                      "The optimal margins for women not receiving radiation were not included"
                    ]
                  },
                  {
                    "text": "The recommended distance from all margins is at least 0.2 cm"
                  },
                  {
                    "text": "The distance to all margins should be provided"
                  }
                ]
              },
              "Types of Margins": {
                "En Face (Shave)": [
                  {
                    "text": "A thin (2- to 4-mm) slice of tissue is taken from the surface of the specimenThis is similar to a portion of an orange peel relative to the orangeAny cancer seen in the tissue section on the glass slide is, by definition, at the marginThe actual distance from margin cannot be determinedEvaluates a larger area than can be examined in a perpendicular sectionAn en face margin of the base of the nipple is sometimes submitted by the surgeonAll of the major lactiferous sinuses can be evaluatedMultiple perpendicular sections and multiple levels would be necessary in order to visualize the same surface included in an en face section",
                    "sub_points": [
                      "This is similar to a portion of an orange peel relative to the orange",
                      "Any cancer seen in the tissue section on the glass slide is, by definition, at the marginThe actual distance from margin cannot be determined",
                      "The actual distance from margin cannot be determined",
                      "Evaluates a larger area than can be examined in a perpendicular sectionAn en face margin of the base of the nipple is sometimes submitted by the surgeonAll of the major lactiferous sinuses can be evaluatedMultiple perpendicular sections and multiple levels would be necessary in order to visualize the same surface included in an en face section",
                      "An en face margin of the base of the nipple is sometimes submitted by the surgeon",
                      "All of the major lactiferous sinuses can be evaluatedMultiple perpendicular sections and multiple levels would be necessary in order to visualize the same surface included in an en face section",
                      "Multiple perpendicular sections and multiple levels would be necessary in order to visualize the same surface included in an en face section"
                    ]
                  },
                  {
                    "text": "Not recommended for evaluation of other breast marginsA positive margin may be an indication for additional surgery, whereas a negative margin may notEn face margins result in higher rates of positive marginsMay result in additional unnecessary surgery",
                    "sub_points": [
                      "A positive margin may be an indication for additional surgery, whereas a negative margin may not",
                      "En face margins result in higher rates of positive margins",
                      "May result in additional unnecessary surgery"
                    ]
                  }
                ],
                "Perpendicular (Radial)": [
                  {
                    "text": "A section of tissue extending from the lesion to the margin is takenThe distance to the margin can be measuredInk leakage into tissue cracks can be difficult to evaluateCare should be taken to carefully dry the specimen and blot ink before sectioningCautery artifact on BC is additional evidence of true margin involvementExamines a smaller amount of margin than is seen in en face marginsMultiple sections are required to thoroughly examine all margins",
                    "sub_points": [
                      "The distance to the margin can be measuredInk leakage into tissue cracks can be difficult to evaluateCare should be taken to carefully dry the specimen and blot ink before sectioningCautery artifact on BC is additional evidence of true margin involvement",
                      "Ink leakage into tissue cracks can be difficult to evaluate",
                      "Care should be taken to carefully dry the specimen and blot ink before sectioning",
                      "Cautery artifact on BC is additional evidence of true margin involvement",
                      "Examines a smaller amount of margin than is seen in en face margins",
                      "Multiple sections are required to thoroughly examine all margins"
                    ]
                  },
                  {
                    "text": "At least 2 sections from each of the 6 margins are suggested for initial samplingAdditional sampling may be indicated in some situationsIf initial sections show DCIS at some, but not all, margins, additional sampling of negative margins may be helpful to guide subsequent surgery",
                    "sub_points": [
                      "Additional sampling may be indicated in some situationsIf initial sections show DCIS at some, but not all, margins, additional sampling of negative margins may be helpful to guide subsequent surgery",
                      "If initial sections show DCIS at some, but not all, margins, additional sampling of negative margins may be helpful to guide subsequent surgery"
                    ]
                  }
                ],
                "Cavity Biopsies": [
                  {
                    "text": "After removal of main specimen, the surgeon takes biopsies of designated marginsGenerally small and not orientedRemoves problems with ink leakage and orientationMay not be possible to determine distance to marginCrush and cautery artifacts can complicate interpretation of small specimensIn general, a positive cavity margin suggests that there is residual BC in breast",
                    "sub_points": [
                      "Generally small and not oriented",
                      "Removes problems with ink leakage and orientation",
                      "May not be possible to determine distance to margin",
                      "Crush and cautery artifacts can complicate interpretation of small specimens",
                      "In general, a positive cavity margin suggests that there is residual BC in breast"
                    ]
                  }
                ],
                "Separate Shave Margins": [
                  {
                    "text": "Taken by surgeon either at the time of main excision or in later procedure"
                  },
                  {
                    "text": "Usually oriented with suture to identify new marginBest inked in 2 colors to show old and new marginsIf oriented and inked in 6 colors, the location and clinical significance of many of the margins becomes problematic (e.g., interpreting the location of the \"inferior margin of the medial shave margin\")",
                    "sub_points": [
                      "Best inked in 2 colors to show old and new margins",
                      "If oriented and inked in 6 colors, the location and clinical significance of many of the margins becomes problematic (e.g., interpreting the location of the \"inferior margin of the medial shave margin\")"
                    ]
                  },
                  {
                    "text": "Generally thick enough to take perpendicular margins1 section per cm of longest dimension is suggested for initial sampling",
                    "sub_points": [
                      "1 section per cm of longest dimension is suggested for initial sampling"
                    ]
                  },
                  {
                    "text": "Removes problems with ink leakage and orientation"
                  }
                ]
              },
              "Radiologic Evaluation of Margins": {
                "Oriented Specimen Radiographs": [
                  {
                    "text": "4 margins can be identified on specimen radiographSpecimen can be repositioned, and 2nd radiograph may be performed to show remaining 2 margins",
                    "sub_points": [
                      "Specimen can be repositioned, and 2nd radiograph may be performed to show remaining 2 margins"
                    ]
                  },
                  {
                    "text": "Distance of radiologically evident lesions to margins (calcifications or masses) can be determinedSome BCs (especially DCIS) are not evident radiographicallyThus, all margins need to be evaluated microscopically",
                    "sub_points": [
                      "Some BCs (especially DCIS) are not evident radiographically",
                      "Thus, all margins need to be evaluated microscopically"
                    ]
                  },
                  {
                    "text": "If the surgeon can view the specimen radiograph intraoperatively, a radiologically close margin can be reexcisedCan reduce the need for subsequent surgery",
                    "sub_points": [
                      "Can reduce the need for subsequent surgery"
                    ]
                  },
                  {
                    "text": "Radiographs can change shape of specimenBreast tissue normally \"slumps\" after excision, resulting in pancake shapeCompression for specimen radiography can also flatten specimensMay change distance of BC to margins",
                    "sub_points": [
                      "Breast tissue normally \"slumps\" after excision, resulting in pancake shape",
                      "Compression for specimen radiography can also flatten specimens",
                      "May change distance of BC to margins"
                    ]
                  }
                ]
              },
              "Immediate Gross Assessment of Margins": {
                "Intraoperative Gross Assessment": [
                  {
                    "text": "Specimen can be oriented, inked, and sectioned at time of surgery"
                  },
                  {
                    "text": "If gross lesion is present, relationship to margins can be assessed, measured, and reported as an intraoperative consultation"
                  },
                  {
                    "text": "If gross lesion is close to a specific margin, additional tissue from that area can be excised during surgery"
                  },
                  {
                    "text": "Immediate gross assessment facilitates rapid tissue fixation and can help minimize cold ischemic time for tissue"
                  }
                ]
              },
              "Sampling Margins": {
                "Margins of Initial Excisions": [
                  {
                    "text": "At least 1 perpendicular section of each of 6 margins should be examined"
                  },
                  {
                    "text": "Additional sampling should be considered for cases with extensive DCIS or diffusely infiltrating BCs (e.g., invasive lobular BCs)"
                  },
                  {
                    "text": "En face margins are not generally recommendedIf an en face margin is submitted, this must be stated in the gross description, as the interpretation differs from the interpretation of a perpendicular margin",
                    "sub_points": [
                      "If an en face margin is submitted, this must be stated in the gross description, as the interpretation differs from the interpretation of a perpendicular margin"
                    ]
                  },
                  {
                    "text": "Margins should be sampled in the area most likely to show involvement by BCAreas grossly suspicious for BCAreas of biopsy site changes (fat necrosis, hemorrhage)Fibrous tissueAreas with radiologic findings suspicious for BC (e.g., calcifications)",
                    "sub_points": [
                      "Areas grossly suspicious for BC",
                      "Areas of biopsy site changes (fat necrosis, hemorrhage)",
                      "Fibrous tissue",
                      "Areas with radiologic findings suspicious for BC (e.g., calcifications)"
                    ]
                  },
                  {
                    "text": "Margin sampled should be designated for each block of tissueInk colors that are evident grossly may be more difficult to determine in a 4-μm section when there has been some smearing of colorsThe specimen radiograph or a diagram can be used to map the specimen and show location of tissue blocks",
                    "sub_points": [
                      "Ink colors that are evident grossly may be more difficult to determine in a 4-μm section when there has been some smearing of colors",
                      "The specimen radiograph or a diagram can be used to map the specimen and show location of tissue blocks"
                    ]
                  }
                ],
                "Separate Margin Excisions": [
                  {
                    "text": "Should be inked in 2 colors, designating new and old margin"
                  },
                  {
                    "text": "1-2 sections per cm of greatest dimension may be taken"
                  },
                  {
                    "text": "These margins should not be oriented with 2 sutures, implying that 6 different margins must be identifiedSignificance of margins other than designated new margin (e.g., inferior portion of medial margin) is unclearPotentially confusing (e.g., inferior portion of medial margin could be confused with true inferior margin)",
                    "sub_points": [
                      "Significance of margins other than designated new margin (e.g., inferior portion of medial margin) is unclear",
                      "Potentially confusing (e.g., inferior portion of medial margin could be confused with true inferior margin)"
                    ]
                  }
                ]
              },
              "Orientation of Margins": {
                "Designation": [
                  {
                    "text": "Breast specimens have 6 marginsAnterior, posterior, superior, inferior, medial, and lateral",
                    "sub_points": [
                      "Anterior, posterior, superior, inferior, medial, and lateral"
                    ]
                  },
                  {
                    "text": "If other names are used, then it may not be possible to orient remaining marginsFor example, designations, such as \"next to nipple,\" should also include name of specific margin",
                    "sub_points": [
                      "For example, designations, such as \"next to nipple,\" should also include name of specific margin"
                    ]
                  },
                  {
                    "text": "Surgeon should be called if specimen orientation is unclear"
                  },
                  {
                    "text": "Posterior margin may be next to muscle fasciaBreast tissue is almost never found deep to muscle fascia as identified by surgeonClose posterior margins are unlikely to correlate with residual diseaseBC invading into skeletal muscle is the most important finding at this margin and could be an indication of residual disease in chest wall",
                    "sub_points": [
                      "Breast tissue is almost never found deep to muscle fascia as identified by surgeon",
                      "Close posterior margins are unlikely to correlate with residual disease",
                      "BC invading into skeletal muscle is the most important finding at this margin and could be an indication of residual disease in chest wall"
                    ]
                  },
                  {
                    "text": "One of the margins may be below skinOften correlates with anterior margin but may be other designated marginsBreast tissue is usually not present in dermisIn rare cases, particularly close to nipple, ducts and lobules are present in dermisThe significance of close or positive margins below the skin is often unclearAdditional surgery would need to remove skin and subcutaneous tissue",
                    "sub_points": [
                      "Often correlates with anterior margin but may be other designated margins",
                      "Breast tissue is usually not present in dermisIn rare cases, particularly close to nipple, ducts and lobules are present in dermis",
                      "In rare cases, particularly close to nipple, ducts and lobules are present in dermis",
                      "The significance of close or positive margins below the skin is often unclear",
                      "Additional surgery would need to remove skin and subcutaneous tissue"
                    ]
                  }
                ],
                "Methods": [
                  {
                    "text": "Sutures2 perpendicular sutures can identify all 6 marginsShort suture for superior margin and long suture for lateral margin is easy to rememberAdditional sutures can be used to mark other margins if more specific identification is desirable (e.g., whipstitch marking deep margin)If sutures are placed at opposing margins (e.g., medial and lateral), the remaining margins cannot be identifiedIf sutures are placed at edges (e.g., inferior/posterior margin), location of remaining margins is more difficult to identify",
                    "sub_points": [
                      "2 perpendicular sutures can identify all 6 marginsShort suture for superior margin and long suture for lateral margin is easy to rememberAdditional sutures can be used to mark other margins if more specific identification is desirable (e.g., whipstitch marking deep margin)",
                      "Short suture for superior margin and long suture for lateral margin is easy to remember",
                      "Additional sutures can be used to mark other margins if more specific identification is desirable (e.g., whipstitch marking deep margin)",
                      "If sutures are placed at opposing margins (e.g., medial and lateral), the remaining margins cannot be identified",
                      "If sutures are placed at edges (e.g., inferior/posterior margin), location of remaining margins is more difficult to identify"
                    ]
                  },
                  {
                    "text": "InksSurgeons can identify margins using colored inksSurgeon has the advantage of seeing the specimen in situ before it may change in shape due to specimen handling and radiographyEspecially helpful for specimens of unusual shapeUsing both sutures and colored inks is helpfulWhen a specimen is inked by the surgeon, the prosector should recheck orientation for accuracyInks must be applied carefully to avoid smearingDetermination of edges of each margin are subjective when only 2 sutures are providedMore specific orientation beyond the 6 margins is not possible due to specimen malleability",
                    "sub_points": [
                      "Surgeons can identify margins using colored inks",
                      "Surgeon has the advantage of seeing the specimen in situ before it may change in shape due to specimen handling and radiography",
                      "Especially helpful for specimens of unusual shape",
                      "Using both sutures and colored inks is helpfulWhen a specimen is inked by the surgeon, the prosector should recheck orientation for accuracy",
                      "When a specimen is inked by the surgeon, the prosector should recheck orientation for accuracy",
                      "Inks must be applied carefully to avoid smearingDetermination of edges of each margin are subjective when only 2 sutures are providedMore specific orientation beyond the 6 margins is not possible due to specimen malleability",
                      "Determination of edges of each margin are subjective when only 2 sutures are provided",
                      "More specific orientation beyond the 6 margins is not possible due to specimen malleability"
                    ]
                  }
                ]
              },
              "Reporting Margins": {
                "En Face Margins": [
                  {
                    "text": "Any BC in the tissue section on the glass slide is reported as positive"
                  },
                  {
                    "text": "Invasive BC is reported separately from DCIS"
                  },
                  {
                    "text": "Extent of involvement can be conveyed by size, number of foci, &/or number of blocks"
                  },
                  {
                    "text": "Results in a larger number of margins reported as positiveIn general, should not be used for breast specimens",
                    "sub_points": [
                      "In general, should not be used for breast specimens"
                    ]
                  }
                ],
                "Perpendicular Margins": [
                  {
                    "text": "Positive margins are reported when ink is on invasive BC or DCIS"
                  },
                  {
                    "text": "Distance to designated negative margins is reported in mm"
                  },
                  {
                    "text": "Invasive BC is reported separately from DCIS"
                  },
                  {
                    "text": "Extent of involvement can be conveyed by size, number of foci, &/or number of blocks"
                  }
                ],
                "Determining Need for Reexcision": [
                  {
                    "text": "Often a complex decision based on many factors"
                  },
                  {
                    "text": "Intent of surgery: Cure vs. reduction in local recurrence riskPatients with DCIS and small node (-) BCs may benefit the most from more extensive surgeryMinimizes risk of developing subsequent BC at higher stageSurvival of patients with node (+) or larger BCs is unlikely to be diminished by local recurrence",
                    "sub_points": [
                      "Patients with DCIS and small node (-) BCs may benefit the most from more extensive surgery",
                      "Minimizes risk of developing subsequent BC at higher stage",
                      "Survival of patients with node (+) or larger BCs is unlikely to be diminished by local recurrence"
                    ]
                  },
                  {
                    "text": "Status of marginsPositive margins are generally an indication for additional surgeryDefinitions of need to reexcise margins based on proximity of BC to margin varies widelyInvasive BC focally at or close to margin does not correlate well with residual disease; there is usually additional margin of cauterized tissue in patientDCIS close to margins can be used to make an educated guess as to likelihood of residual diseaseLarger margins may be recommended for patients who decline or who are not eligible for radiation therapy",
                    "sub_points": [
                      "Positive margins are generally an indication for additional surgery",
                      "Definitions of need to reexcise margins based on proximity of BC to margin varies widelyInvasive BC focally at or close to margin does not correlate well with residual disease; there is usually additional margin of cauterized tissue in patientDCIS close to margins can be used to make an educated guess as to likelihood of residual diseaseLarger margins may be recommended for patients who decline or who are not eligible for radiation therapy",
                      "Invasive BC focally at or close to margin does not correlate well with residual disease; there is usually additional margin of cauterized tissue in patient",
                      "DCIS close to margins can be used to make an educated guess as to likelihood of residual disease",
                      "Larger margins may be recommended for patients who decline or who are not eligible for radiation therapy"
                    ]
                  },
                  {
                    "text": "Patient preferenceSome patients' highest priority will be to diminish risk of recurrence as much as possibleHowever, other patients may accept a slightly higher risk of recurrence to achieve a more favorable cosmetic result",
                    "sub_points": [
                      "Some patients' highest priority will be to diminish risk of recurrence as much as possible",
                      "However, other patients may accept a slightly higher risk of recurrence to achieve a more favorable cosmetic result"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mastectomies": {
            "name": "Mastectomies",
            "url": "https://app.pathprimer.com/document/489d485d-da7b-4641-9ed0-304b5d948c93/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Overview": {
                "Surgical Procedure": [
                  {
                    "text": "The goal of a mastectomy is to remove all breast tissue"
                  },
                  {
                    "text": "However, in some patients, this goal will not be accomplished because of breast tissue that is not removed in the skin flaps, at the far edges of the breast, or in the axilla (tail of Spence)In some women, breast epithelium with or without carcinoma is present in dermis or subcutaneous tissueThicker skin flaps result in an improved cosmetic result but are more likely to leave behind breast tissueIn some women, normal breast tissue is located very close to the deep dermisVery superficially located carcinomas may invade into the dermisThe nipple may not be excised if there is a low risk of involvement by carcinoma",
                    "sub_points": [
                      "In some women, breast epithelium with or without carcinoma is present in dermis or subcutaneous tissueThicker skin flaps result in an improved cosmetic result but are more likely to leave behind breast tissueIn some women, normal breast tissue is located very close to the deep dermisVery superficially located carcinomas may invade into the dermis",
                      "Thicker skin flaps result in an improved cosmetic result but are more likely to leave behind breast tissue",
                      "In some women, normal breast tissue is located very close to the deep dermis",
                      "Very superficially located carcinomas may invade into the dermis",
                      "The nipple may not be excised if there is a low risk of involvement by carcinoma"
                    ]
                  },
                  {
                    "text": "Therefore, a mastectomy is expected to remove most, but possibly not all, breast cellsProphylactic mastectomies reduce the risk of breast cancer by 90%, but not 100%",
                    "sub_points": [
                      "Prophylactic mastectomies reduce the risk of breast cancer by 90%, but not 100%"
                    ]
                  },
                  {
                    "text": "Rarely, new primary breast carcinomas arise in residual normal breast tissue after mastectomyThese carcinomas should be distinguished from true recurrent carcinomas that are treatment resistant and have a poorer prognosis",
                    "sub_points": [
                      "These carcinomas should be distinguished from true recurrent carcinomas that are treatment resistant and have a poorer prognosis"
                    ]
                  }
                ],
                "Indications": [
                  {
                    "text": "The majority of women can be successfully treated with breast-conserving therapy (BCT) and radiation therapyThe rate of local recurrence is higher with BCT, but survival is similarLocal recurrence is high for triple negative breast carcinomas (TNBCs) (hormone receptor and HER2 negative) regardless of extent of surgery (BCT or mastectomy)Presumably due to tumor burden within lymphaticsThese patients may have a greater benefit from BCT with radiation to chest wall",
                    "sub_points": [
                      "The rate of local recurrence is higher with BCT, but survival is similar",
                      "Local recurrence is high for triple negative breast carcinomas (TNBCs) (hormone receptor and HER2 negative) regardless of extent of surgery (BCT or mastectomy)Presumably due to tumor burden within lymphaticsThese patients may have a greater benefit from BCT with radiation to chest wall",
                      "Presumably due to tumor burden within lymphatics",
                      "These patients may have a greater benefit from BCT with radiation to chest wall"
                    ]
                  },
                  {
                    "text": "Mastectomy specimens are often complicated to evaluate, as these procedures are typically performed when BCT is not possible"
                  },
                  {
                    "text": "Indications for mastectomy rather than BCTExtensive carcinoma or multiple carcinomas that cannot be removed with cosmetically acceptable resultsCentrally located carcinomasCarcinomas involving the skin or chest wallMany patients are treated with neoadjuvant chemotherapy to identify carcinomas that respond wellRecurrent carcinoma after prior radiation treatmentHigh risk of subsequent carcinoma (e.g.,BRCA1/BRCA2germline mutation carriers)After neoadjuvant therapy for locally advanced carcinomas, carcinomas with minimal response, or inflammatory carcinomaPatients not eligible for radiation due to previous treatment or collagen vascular disease",
                    "sub_points": [
                      "Extensive carcinoma or multiple carcinomas that cannot be removed with cosmetically acceptable results",
                      "Centrally located carcinomas",
                      "Carcinomas involving the skin or chest wallMany patients are treated with neoadjuvant chemotherapy to identify carcinomas that respond well",
                      "Many patients are treated with neoadjuvant chemotherapy to identify carcinomas that respond well",
                      "Recurrent carcinoma after prior radiation treatment",
                      "High risk of subsequent carcinoma (e.g.,BRCA1/BRCA2germline mutation carriers)",
                      "After neoadjuvant therapy for locally advanced carcinomas, carcinomas with minimal response, or inflammatory carcinoma",
                      "Patients not eligible for radiation due to previous treatment or collagen vascular disease"
                    ]
                  }
                ],
                "Importance of Gross Evaluation": [
                  {
                    "text": "The possibility of sampling error is greater for mastectomies than for other breast specimens because only a small portion of the entire specimen can be examined microscopically"
                  },
                  {
                    "text": "Close correlation with clinical and imaging information is critical"
                  },
                  {
                    "text": "Radiography of the intact specimen is an important practice when clips or calcifications are present"
                  },
                  {
                    "text": "Diagrams provided by the surgeon or developed by the prosector based on imaging and clinical information are very helpful to ensure all lesions are identified grossly and adequately sampled"
                  }
                ],
                "Types of Mastectomy": [
                  {
                    "text": "Simple (total mastectomy)Removes breast tissue and skin ellipse, including nippleA small amount of pectoralis muscle may be removed if the carcinoma is close to the deep marginAxillary dissection is not performedSentinel lymph node biopsy may be performedHowever, some lower lymph nodes may be present; the lateral tissue should always be examined for nodes",
                    "sub_points": [
                      "Removes breast tissue and skin ellipse, including nipple",
                      "A small amount of pectoralis muscle may be removed if the carcinoma is close to the deep margin",
                      "Axillary dissection is not performedSentinel lymph node biopsy may be performed",
                      "Sentinel lymph node biopsy may be performed",
                      "However, some lower lymph nodes may be present; the lateral tissue should always be examined for nodes"
                    ]
                  },
                  {
                    "text": "RadicalA simple mastectomy that also removes the pectoralis major and minor muscles and includes an axillary lymph node dissectionCurrently rarely performed except for carcinomas that invade into chest wall",
                    "sub_points": [
                      "A simple mastectomy that also removes the pectoralis major and minor muscles and includes an axillary lymph node dissection",
                      "Currently rarely performed except for carcinomas that invade into chest wall"
                    ]
                  },
                  {
                    "text": "Modified radicalA simple mastectomy that does not remove the pectoralis muscles but does include an axillary dissection",
                    "sub_points": [
                      "A simple mastectomy that does not remove the pectoralis muscles but does include an axillary dissection"
                    ]
                  },
                  {
                    "text": "Skin sparingA simple mastectomy that removes the nipple with a small amount of surrounding skin",
                    "sub_points": [
                      "A simple mastectomy that removes the nipple with a small amount of surrounding skin"
                    ]
                  },
                  {
                    "text": "Nipple sparingA simple mastectomy that does not remove skin or nippleThe base of the nipple is a margin that may be sampled separately and submitted by the surgeonEligibility criteria for this procedure may include a certain distance of the carcinoma from the nippleMay leave more tissue in skin flaps due to the difficulty in dissecting breast tissue far from the skin incision",
                    "sub_points": [
                      "A simple mastectomy that does not remove skin or nipple",
                      "The base of the nipple is a margin that may be sampled separately and submitted by the surgeon",
                      "Eligibility criteria for this procedure may include a certain distance of the carcinoma from the nipple",
                      "May leave more tissue in skin flaps due to the difficulty in dissecting breast tissue far from the skin incision"
                    ]
                  },
                  {
                    "text": "SubcutaneousRemoves 85-90% of breast tissueDoes not remove nipple or skin; flaps are usually thickSimilar to nipple-sparing mastectomy but removes less breast tissueMost common indication is gynecomastia in men",
                    "sub_points": [
                      "Removes 85-90% of breast tissue",
                      "Does not remove nipple or skin; flaps are usually thick",
                      "Similar to nipple-sparing mastectomy but removes less breast tissueMost common indication is gynecomastia in men",
                      "Most common indication is gynecomastia in men"
                    ]
                  },
                  {
                    "text": "ProphylacticA mastectomy performed for risk reduction in the absence of a known carcinoma at the time of surgeryOccult invasive carcinomas are found in 3-15% of cases; generally < 1 cmMost commonly found when the patient has known contralateral carcinoma",
                    "sub_points": [
                      "A mastectomy performed for risk reduction in the absence of a known carcinoma at the time of surgery",
                      "Occult invasive carcinomas are found in 3-15% of cases; generally < 1 cmMost commonly found when the patient has known contralateral carcinoma",
                      "Most commonly found when the patient has known contralateral carcinoma"
                    ]
                  },
                  {
                    "text": "Mastectomy for gender-affirming therapyThe goal is to leave sufficient breast tissue and skin, and usually the nipple, to create the appearance of a male breastThese procedures are also termed chest contouring surgery and female-to-male top surgery",
                    "sub_points": [
                      "The goal is to leave sufficient breast tissue and skin, and usually the nipple, to create the appearance of a male breast",
                      "These procedures are also termed chest contouring surgery and female-to-male top surgery"
                    ]
                  }
                ],
                "Lymph Node Sampling With Mastectomy": [
                  {
                    "text": "Sentinel node biopsySentinel nodes are identified by dye or radioactive tracerThe average number of nodes is 2, but more may be identified in some patientsMetastases are most often found at pole of node stained with blue dye",
                    "sub_points": [
                      "Sentinel nodes are identified by dye or radioactive tracer",
                      "The average number of nodes is 2, but more may be identified in some patients",
                      "Metastases are most often found at pole of node stained with blue dye"
                    ]
                  },
                  {
                    "text": "Axillary dissectionExtent of dissection may include levels I, II, &/or IIISurgeon should indicate extent of dissectionIdeally, at least 10 nodes are foundIf fewer nodes are present, additional examination of specimen &/or additional submission of axillary tissue should be considered",
                    "sub_points": [
                      "Extent of dissection may include levels I, II, &/or III",
                      "Surgeon should indicate extent of dissection",
                      "Ideally, at least 10 nodes are foundIf fewer nodes are present, additional examination of specimen &/or additional submission of axillary tissue should be considered",
                      "If fewer nodes are present, additional examination of specimen &/or additional submission of axillary tissue should be considered"
                    ]
                  },
                  {
                    "text": "Internal mammary nodeMay be removed as part of a reconstruction procedureNode will be submitted as a separate specimen",
                    "sub_points": [
                      "May be removed as part of a reconstruction procedure",
                      "Node will be submitted as a separate specimen"
                    ]
                  }
                ]
              },
              "Specimen Processing": {
                "Requisition Form": [
                  {
                    "text": "In addition to information germane to all types of breast specimens, additional information is required for mastectomiesNumber and type of lesions present (masses, calcifications, clips, etc.)Often multiple, thus requiring mastectomy for removalKnown or suspected involvement of skin or muscleDistance between lesions and distance from nipplePresence and extent of axillary dissectionSpecimens should always be examined for lymph nodes even if axillary dissection was not performedThe extent of additional gross examination and tissue sampling if lymph nodes are not initially found is influenced by the number of nodes expected in specimen",
                    "sub_points": [
                      "Number and type of lesions present (masses, calcifications, clips, etc.)Often multiple, thus requiring mastectomy for removalKnown or suspected involvement of skin or muscle",
                      "Often multiple, thus requiring mastectomy for removal",
                      "Known or suspected involvement of skin or muscle",
                      "Distance between lesions and distance from nipple",
                      "Presence and extent of axillary dissectionSpecimens should always be examined for lymph nodes even if axillary dissection was not performedThe extent of additional gross examination and tissue sampling if lymph nodes are not initially found is influenced by the number of nodes expected in specimen",
                      "Specimens should always be examined for lymph nodes even if axillary dissection was not performed",
                      "The extent of additional gross examination and tissue sampling if lymph nodes are not initially found is influenced by the number of nodes expected in specimen"
                    ]
                  }
                ],
                "Specimen Radiograph": [
                  {
                    "text": "Mastectomies are generally not sent for radiologic examination by surgeon, as this information is not necessary for the surgical procedure"
                  },
                  {
                    "text": "Radiographs can be very helpful prior to sectioning to identify small lesions or lesions that are not apparent on gross examination (e.g., calcifications)Lesions may be lost (e.g., clips) after sectioning or more difficult to identify if transectedIn rare cases, carcinomas (typically marked by clip) are not removed by mastectomy due to superficial, deep, or far lateral locationAn intact specimen radiograph is very helpful to document the clip/carcinoma was not removed",
                    "sub_points": [
                      "Lesions may be lost (e.g., clips) after sectioning or more difficult to identify if transected",
                      "In rare cases, carcinomas (typically marked by clip) are not removed by mastectomy due to superficial, deep, or far lateral location",
                      "An intact specimen radiograph is very helpful to document the clip/carcinoma was not removed"
                    ]
                  },
                  {
                    "text": "Specimen radiographs reduce the amount of tissue sampling required, as lesions are more easily identified"
                  },
                  {
                    "text": "Radiographs can be performed in the radiology department or the pathology department if equipment is available"
                  }
                ],
                "Gross Description": [
                  {
                    "text": "Size of breast tissue measured in 3 dimensionsSize of attached axillary tail",
                    "sub_points": [
                      "Size of attached axillary tail"
                    ]
                  },
                  {
                    "text": "Size of skin ellipseSize of nipple and areola (note if retracted or if skin lesions are present)Ulceration &/or satellite skin lesions change American Joint Committee on Cancer (AJCC) T classificationEnlargement and erythema of inflammatory carcinoma are not seen in excised specimensScaling crust of the nipple due to Paget disease is usually removed by cleansing during preparation for surgeryAny lesions on the remainder of the skin, including scars (may be difficult to see if circumareolar) are notedA surgical clamp site at the edge of the skin can mimic a skin lesion",
                    "sub_points": [
                      "Size of nipple and areola (note if retracted or if skin lesions are present)Ulceration &/or satellite skin lesions change American Joint Committee on Cancer (AJCC) T classificationEnlargement and erythema of inflammatory carcinoma are not seen in excised specimensScaling crust of the nipple due to Paget disease is usually removed by cleansing during preparation for surgery",
                      "Ulceration &/or satellite skin lesions change American Joint Committee on Cancer (AJCC) T classification",
                      "Enlargement and erythema of inflammatory carcinoma are not seen in excised specimens",
                      "Scaling crust of the nipple due to Paget disease is usually removed by cleansing during preparation for surgery",
                      "Any lesions on the remainder of the skin, including scars (may be difficult to see if circumareolar) are notedA surgical clamp site at the edge of the skin can mimic a skin lesion",
                      "A surgical clamp site at the edge of the skin can mimic a skin lesion"
                    ]
                  },
                  {
                    "text": "Sutures or other markings for orientationA nipple-sparing mastectomy should have the area of the nipple marked with a suture",
                    "sub_points": [
                      "A nipple-sparing mastectomy should have the area of the nipple marked with a suture"
                    ]
                  },
                  {
                    "text": "All lesions are describedLocation (quadrant, distance from nipple)Size, color, borders, texture (soft, rubbery, hard)Distance &/or involvement of skin or muscleDistance between lesions",
                    "sub_points": [
                      "Location (quadrant, distance from nipple)",
                      "Size, color, borders, texture (soft, rubbery, hard)",
                      "Distance &/or involvement of skin or muscle",
                      "Distance between lesions"
                    ]
                  },
                  {
                    "text": "Cassette keyType of tissue in each cassette should be notedLesionsSkin, nipple, and deep marginLymph nodes (number &/or ink designations)",
                    "sub_points": [
                      "Type of tissue in each cassette should be notedLesionsSkin, nipple, and deep marginLymph nodes (number &/or ink designations)",
                      "Lesions",
                      "Skin, nipple, and deep margin",
                      "Lymph nodes (number &/or ink designations)"
                    ]
                  }
                ],
                "Inking Specimen Margins": [
                  {
                    "text": "The deep margin is a smooth fascial plane that lies on top of the pectoralis muscleUsually inked blackAny skeletal muscle or defects in fascia are noted if present; if so, these are potential areas of tumor invasion and should be specifically sampled",
                    "sub_points": [
                      "Usually inked black",
                      "Any skeletal muscle or defects in fascia are noted if present; if so, these are potential areas of tumor invasion and should be specifically sampled"
                    ]
                  },
                  {
                    "text": "Anterior/superficial breast tissue is adjacent to skin flapsThis is not a true margin in the majority of patients, as breast tissue is usually not present in skin flapsHowever, this will depend on the thickness of the flap and ductal anatomy of patientIf anterior tissue is grossly abnormal or if an invasive carcinoma is very close to this surface (e.g., < 1 cm), then this area can be differentially inked and sampledLocal recurrence after mastectomy is rare (< 5%)Close or positive anterior tissue edges are not highly predictive of residual tumor or recurrenceThe majority of patients do not have residual carcinoma in reexcisions> 90% do not recur in the absence of additional surgery or radiationHowever, local recurrences after nipple-sparing mastectomy can rarely occur in the region of the carcinomaA better surgical approach to attempt to reduce rare local recurrences would be to identify superficially located carcinomas and remove additional subcutaneous tissue in this areaIntraoperative ultrasound has been used for this purposeIf the anterior surface is inked and evaluated, this should be clearly distinguished from the deep margin",
                    "sub_points": [
                      "This is not a true margin in the majority of patients, as breast tissue is usually not present in skin flapsHowever, this will depend on the thickness of the flap and ductal anatomy of patient",
                      "However, this will depend on the thickness of the flap and ductal anatomy of patient",
                      "If anterior tissue is grossly abnormal or if an invasive carcinoma is very close to this surface (e.g., < 1 cm), then this area can be differentially inked and sampled",
                      "Local recurrence after mastectomy is rare (< 5%)Close or positive anterior tissue edges are not highly predictive of residual tumor or recurrenceThe majority of patients do not have residual carcinoma in reexcisions> 90% do not recur in the absence of additional surgery or radiationHowever, local recurrences after nipple-sparing mastectomy can rarely occur in the region of the carcinomaA better surgical approach to attempt to reduce rare local recurrences would be to identify superficially located carcinomas and remove additional subcutaneous tissue in this areaIntraoperative ultrasound has been used for this purpose",
                      "Close or positive anterior tissue edges are not highly predictive of residual tumor or recurrenceThe majority of patients do not have residual carcinoma in reexcisions> 90% do not recur in the absence of additional surgery or radiation",
                      "The majority of patients do not have residual carcinoma in reexcisions",
                      "> 90% do not recur in the absence of additional surgery or radiation",
                      "However, local recurrences after nipple-sparing mastectomy can rarely occur in the region of the carcinomaA better surgical approach to attempt to reduce rare local recurrences would be to identify superficially located carcinomas and remove additional subcutaneous tissue in this areaIntraoperative ultrasound has been used for this purpose",
                      "A better surgical approach to attempt to reduce rare local recurrences would be to identify superficially located carcinomas and remove additional subcutaneous tissue in this area",
                      "Intraoperative ultrasound has been used for this purpose",
                      "If the anterior surface is inked and evaluated, this should be clearly distinguished from the deep margin"
                    ]
                  },
                  {
                    "text": "Skin is usually not involved by carcinoma, and skin margins need not be evaluatedIf skin is involved (by direct invasion, Paget disease, or angiosarcoma), then skin margins should be evaluated grosslyIn the absence of gross involvement of margins, microscopic tumor is very unlikelyGrossly abnormal skin edges should be evaluated microscopically",
                    "sub_points": [
                      "If skin is involved (by direct invasion, Paget disease, or angiosarcoma), then skin margins should be evaluated grossly",
                      "In the absence of gross involvement of margins, microscopic tumor is very unlikely",
                      "Grossly abnormal skin edges should be evaluated microscopically"
                    ]
                  },
                  {
                    "text": "The base of the nipple is a margin for nipple-sparing mastectomiesSurgeon should remove base of nipple as an en face section and submit this as a separate specimenMajor ducts retract after nipple is removed, making it difficult to sample this margin on the specimenLocation of nipple base should be marked with sutureIf the nipple base is not received as a separate specimen, then the area of the nipple can be inked and perpendicular sections taken",
                    "sub_points": [
                      "Surgeon should remove base of nipple as an en face section and submit this as a separate specimenMajor ducts retract after nipple is removed, making it difficult to sample this margin on the specimen",
                      "Major ducts retract after nipple is removed, making it difficult to sample this margin on the specimen",
                      "Location of nipple base should be marked with suture",
                      "If the nipple base is not received as a separate specimen, then the area of the nipple can be inked and perpendicular sections taken"
                    ]
                  }
                ],
                "Sectioning": [
                  {
                    "text": "Breast is serially sectioned from posterior aspectSections are not quite completed at anterior aspect in order to keep specimen intact",
                    "sub_points": [
                      "Sections are not quite completed at anterior aspect in order to keep specimen intact"
                    ]
                  },
                  {
                    "text": "Axillary tail palpated and thinly sliced to identify all nodesThe most lateral portion of the breast should also be carefully examined for nodesAxillary lymph nodes can be present in simple mastectomies without formal node dissectionIf < 10 nodes are found in full dissection, additional examination and sampling should be considered",
                    "sub_points": [
                      "The most lateral portion of the breast should also be carefully examined for nodesAxillary lymph nodes can be present in simple mastectomies without formal node dissection",
                      "Axillary lymph nodes can be present in simple mastectomies without formal node dissection",
                      "If < 10 nodes are found in full dissection, additional examination and sampling should be considered"
                    ]
                  }
                ],
                "Sampling": [
                  {
                    "text": "LesionsSample all lesions with at least 1 section per cmSmaller lesions are sampled in their entirety",
                    "sub_points": [
                      "Sample all lesions with at least 1 section per cm",
                      "Smaller lesions are sampled in their entirety"
                    ]
                  },
                  {
                    "text": "MarginsPerpendicular section of deep margin closest to carcinomasBase of nipple margin for nipple-sparing mastectomies",
                    "sub_points": [
                      "Perpendicular section of deep margin closest to carcinomas",
                      "Base of nipple margin for nipple-sparing mastectomies"
                    ]
                  },
                  {
                    "text": "Skin and nipple1 representative perpendicular sectionMore extensive sampling if gross lesions are present or there is history of inflammatory carcinoma or ductal carcinoma in situ (DCIS) involving nipple skin (Paget disease)If nipple involvement is suspected, the base of nipple may be taken en face and the superficial nipple as perpendicular sections",
                    "sub_points": [
                      "1 representative perpendicular section",
                      "More extensive sampling if gross lesions are present or there is history of inflammatory carcinoma or ductal carcinoma in situ (DCIS) involving nipple skin (Paget disease)",
                      "If nipple involvement is suspected, the base of nipple may be taken en face and the superficial nipple as perpendicular sections"
                    ]
                  },
                  {
                    "text": "Lymph nodesAll nodes are thinly sliced (~ 2 mm) and completely submitted for microscopic examinationEach node must be separately identifiedSlices of nodes placed in same cassette should be inked different colors in order to be able to count the number of nodes with metastases",
                    "sub_points": [
                      "All nodes are thinly sliced (~ 2 mm) and completely submitted for microscopic examination",
                      "Each node must be separately identifiedSlices of nodes placed in same cassette should be inked different colors in order to be able to count the number of nodes with metastases",
                      "Slices of nodes placed in same cassette should be inked different colors in order to be able to count the number of nodes with metastases"
                    ]
                  }
                ],
                "Difficult Cases": [
                  {
                    "text": "Mastectomy after core needle biopsyLesions are usually small and may not be grossly evidentBiopsy sites can heal after 1 month, making it difficult to locate lesionA specimen radiograph prior to sectioning is very helpful to identify the site of a core needle biopsy and any radiologic findings (mass, calcifications, or clip)Clips can be dislodged during sectioningIf specimen is sliced and core site/lesion is not found, slices can be radiographed",
                    "sub_points": [
                      "Lesions are usually small and may not be grossly evident",
                      "Biopsy sites can heal after 1 month, making it difficult to locate lesion",
                      "A specimen radiograph prior to sectioning is very helpful to identify the site of a core needle biopsy and any radiologic findings (mass, calcifications, or clip)Clips can be dislodged during sectioning",
                      "Clips can be dislodged during sectioning",
                      "If specimen is sliced and core site/lesion is not found, slices can be radiographed"
                    ]
                  },
                  {
                    "text": "Mastectomy after neoadjuvant chemotherapySite of carcinoma should be marked with a core needle biopsy clip before treatmentIf there is marked or complete response, the clip may be the only means of identifying the tumor bedThe size and location of carcinoma prior to treatment should be known to the prosectorThe tumor bed can be very difficult to identify grossly, may be an ill-defined fibrotic area difficult to distinguish from normal breast tissueInitial sampling of tumor bed should be at least 1 section per cm of greatest dimension of carcinoma prior to treatment or grossly evident tumor bedIf no residual carcinoma is seen in the tumor bed or lymph nodes, additional sampling should be considered to document a pathologic complete responseIf tumor bed is not identified after evaluation of initial slides, additional sampling is necessaryIf tumor bed is not found, pathologic complete response cannot be determined with certainty",
                    "sub_points": [
                      "Site of carcinoma should be marked with a core needle biopsy clip before treatmentIf there is marked or complete response, the clip may be the only means of identifying the tumor bed",
                      "If there is marked or complete response, the clip may be the only means of identifying the tumor bed",
                      "The size and location of carcinoma prior to treatment should be known to the prosectorThe tumor bed can be very difficult to identify grossly, may be an ill-defined fibrotic area difficult to distinguish from normal breast tissue",
                      "The tumor bed can be very difficult to identify grossly, may be an ill-defined fibrotic area difficult to distinguish from normal breast tissue",
                      "Initial sampling of tumor bed should be at least 1 section per cm of greatest dimension of carcinoma prior to treatment or grossly evident tumor bedIf no residual carcinoma is seen in the tumor bed or lymph nodes, additional sampling should be considered to document a pathologic complete response",
                      "If no residual carcinoma is seen in the tumor bed or lymph nodes, additional sampling should be considered to document a pathologic complete response",
                      "If tumor bed is not identified after evaluation of initial slides, additional sampling is necessaryIf tumor bed is not found, pathologic complete response cannot be determined with certainty",
                      "If tumor bed is not found, pathologic complete response cannot be determined with certainty"
                    ]
                  },
                  {
                    "text": "Mastectomy for women with positive axillary lymph node and no primarycarcinomaby imagingRarely, women present with a palpable axillary node with metastatic breast carcinomaPrognosis is similar to women with same extent of nodal involvementPrognosis is not changed by presence or absence of primary carcinoma documented in breastMajority of carcinomas are found with mammography, ultrasound, &/or MRIf no lesions are detected by these modalities, it is unlikely primary will be found by gross examinationGross examination is best performed shortly after removal of breast and before fixationNormal tissue is softer, making detection of small invasive carcinomas easierIf no gross lesions are found, it is unlikely that sampling of normal-appearing tissue will identify the primary carcinomaExtensive sampling is unnecessary, as finding cancer will not alter stage or treatment of patientPrimary carcinomas may not be evident for several possible reasonsCarcinoma is very smallCarcinoma regressed (no evidence for this phenomenon but theoretically possible)Metastasis in lymph node is actually the primary carcinomaSome carcinomas can closely mimic nodes due to circumscribed borders and a dense lymphocytic infiltrateCarcinoma arose in benign inclusion in lymph node (very rare but reported)The metastasis in the axillary node is not breast carcinomaThe most common alternative sites for carcinoma are skin (ipsilateral torso and arm) and ipsilateral lung; metastatic melanoma and lymphoma should also be considered",
                    "sub_points": [
                      "Rarely, women present with a palpable axillary node with metastatic breast carcinomaPrognosis is similar to women with same extent of nodal involvementPrognosis is not changed by presence or absence of primary carcinoma documented in breast",
                      "Prognosis is similar to women with same extent of nodal involvement",
                      "Prognosis is not changed by presence or absence of primary carcinoma documented in breast",
                      "Majority of carcinomas are found with mammography, ultrasound, &/or MRIf no lesions are detected by these modalities, it is unlikely primary will be found by gross examination",
                      "If no lesions are detected by these modalities, it is unlikely primary will be found by gross examination",
                      "Gross examination is best performed shortly after removal of breast and before fixationNormal tissue is softer, making detection of small invasive carcinomas easierIf no gross lesions are found, it is unlikely that sampling of normal-appearing tissue will identify the primary carcinomaExtensive sampling is unnecessary, as finding cancer will not alter stage or treatment of patient",
                      "Normal tissue is softer, making detection of small invasive carcinomas easier",
                      "If no gross lesions are found, it is unlikely that sampling of normal-appearing tissue will identify the primary carcinoma",
                      "Extensive sampling is unnecessary, as finding cancer will not alter stage or treatment of patient",
                      "Primary carcinomas may not be evident for several possible reasonsCarcinoma is very smallCarcinoma regressed (no evidence for this phenomenon but theoretically possible)Metastasis in lymph node is actually the primary carcinomaSome carcinomas can closely mimic nodes due to circumscribed borders and a dense lymphocytic infiltrateCarcinoma arose in benign inclusion in lymph node (very rare but reported)The metastasis in the axillary node is not breast carcinomaThe most common alternative sites for carcinoma are skin (ipsilateral torso and arm) and ipsilateral lung; metastatic melanoma and lymphoma should also be considered",
                      "Carcinoma is very small",
                      "Carcinoma regressed (no evidence for this phenomenon but theoretically possible)",
                      "Metastasis in lymph node is actually the primary carcinomaSome carcinomas can closely mimic nodes due to circumscribed borders and a dense lymphocytic infiltrate",
                      "Some carcinomas can closely mimic nodes due to circumscribed borders and a dense lymphocytic infiltrate",
                      "Carcinoma arose in benign inclusion in lymph node (very rare but reported)",
                      "The metastasis in the axillary node is not breast carcinomaThe most common alternative sites for carcinoma are skin (ipsilateral torso and arm) and ipsilateral lung; metastatic melanoma and lymphoma should also be considered",
                      "The most common alternative sites for carcinoma are skin (ipsilateral torso and arm) and ipsilateral lung; metastatic melanoma and lymphoma should also be considered"
                    ]
                  },
                  {
                    "text": "Mastectomy with extensive DCISDCIS can extensively involve all 4 quadrants of breastMay be impractical to microscopically examine all involved tissue to look for invasionSentinel lymph node biopsy can be helpful in such cases to exclude metastasis from undetected area of invasionAll grossly firm to hard areas that could harbor invasive carcinoma should be sampled",
                    "sub_points": [
                      "DCIS can extensively involve all 4 quadrants of breast",
                      "May be impractical to microscopically examine all involved tissue to look for invasionSentinel lymph node biopsy can be helpful in such cases to exclude metastasis from undetected area of invasion",
                      "Sentinel lymph node biopsy can be helpful in such cases to exclude metastasis from undetected area of invasion",
                      "All grossly firm to hard areas that could harbor invasive carcinoma should be sampled"
                    ]
                  },
                  {
                    "text": "Mastectomy for inflammatory carcinomaClinical signs of enlarged erythematous breast are due to obstruction of dermal lymphatics by tumor cellsThese findings are not apparent in excised breast due to absence of blood flowPatients typically do not have an easily definable mass by palpation or imagingMajority of patients will undergo neoadjuvant chemotherapy prior to surgerySkin findings are often 1st to respond to treatmentIt may be difficult to determine site of tumor bedIf mass was present before treatment, this area should be sampledIf biopsy was performed and clip deployed, clip must be identifiedIn addition to nipple skin, other areas of skin should be sampled to look for skin involvement",
                    "sub_points": [
                      "Clinical signs of enlarged erythematous breast are due to obstruction of dermal lymphatics by tumor cellsThese findings are not apparent in excised breast due to absence of blood flow",
                      "These findings are not apparent in excised breast due to absence of blood flow",
                      "Patients typically do not have an easily definable mass by palpation or imaging",
                      "Majority of patients will undergo neoadjuvant chemotherapy prior to surgerySkin findings are often 1st to respond to treatment",
                      "Skin findings are often 1st to respond to treatment",
                      "It may be difficult to determine site of tumor bedIf mass was present before treatment, this area should be sampledIf biopsy was performed and clip deployed, clip must be identifiedIn addition to nipple skin, other areas of skin should be sampled to look for skin involvement",
                      "If mass was present before treatment, this area should be sampled",
                      "If biopsy was performed and clip deployed, clip must be identified",
                      "In addition to nipple skin, other areas of skin should be sampled to look for skin involvement"
                    ]
                  },
                  {
                    "text": "Mastectomy with missing clip &/or carcinomaClips marking carcinomas may not be removed if located very superficially, very laterally, or in the high upper outer quadrant/axillaA specimen radiograph taken prior to sectioning is very helpful to identify that a clip and carcinoma are not presentAfter sectioning, a clip may be missing because it was dislodged during specimen processingIf the lesion marked by the clip cannot be identified in the specimen, additional imaging of the patient may be necessary",
                    "sub_points": [
                      "Clips marking carcinomas may not be removed if located very superficially, very laterally, or in the high upper outer quadrant/axilla",
                      "A specimen radiograph taken prior to sectioning is very helpful to identify that a clip and carcinoma are not present",
                      "After sectioning, a clip may be missing because it was dislodged during specimen processing",
                      "If the lesion marked by the clip cannot be identified in the specimen, additional imaging of the patient may be necessary"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Reduction Mammoplasties": {
            "name": "Reduction Mammoplasties",
            "url": "https://app.pathprimer.com/document/7f0133ee-e153-479c-a42f-00d04e44109c/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Reduction mammoplasty or mammaplasty (RM)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Breast reduction surgery"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Surgical procedure to reduce size of breast; skin and breast tissue (but not nipple) are removed"
                  }
                ]
              },
              "BREAST REDUCTION SURGERY": {
                "Overview": [
                  {
                    "text": "IndicationsCongenital breast asymmetrySymptomatic macromastiaAsymmetry following breast carcinoma (BC) surgery",
                    "sub_points": [
                      "Congenital breast asymmetry",
                      "Symptomatic macromastia",
                      "Asymmetry following breast carcinoma (BC) surgery"
                    ]
                  },
                  {
                    "text": "Insurance plans usually only reimburse RM for physical symptoms and not for cosmetic reasonsGenerally require that a certain amount of breast tissue is removed (typically, at least 300 g)Insurance carriers have different methods of determining the required amount of tissue",
                    "sub_points": [
                      "Generally require that a certain amount of breast tissue is removed (typically, at least 300 g)",
                      "Insurance carriers have different methods of determining the required amount of tissue"
                    ]
                  },
                  {
                    "text": "RM has proven to be safe and relieves symptoms due to macromastiaAssociated with overall excellent patient satisfaction",
                    "sub_points": [
                      "Associated with overall excellent patient satisfaction"
                    ]
                  },
                  {
                    "text": "Follow-up studies after breast reduction surgery reveal multiple benefitsSignificantly better quality of lifeFewer breast-associated symptomsLess depression and anxiety; better self-esteem when compared with preoperative evaluation",
                    "sub_points": [
                      "Significantly better quality of life",
                      "Fewer breast-associated symptoms",
                      "Less depression and anxiety; better self-esteem when compared with preoperative evaluation"
                    ]
                  },
                  {
                    "text": "Risk factors that predispose to postoperative complications after RMObesity, smoking, diabetes, unilateral reduction weight of tissue removed > 1,000 g, preoperative radiation",
                    "sub_points": [
                      "Obesity, smoking, diabetes, unilateral reduction weight of tissue removed > 1,000 g, preoperative radiation"
                    ]
                  }
                ],
                "Macromastia": [
                  {
                    "text": "Benign condition of breast hypertrophy"
                  },
                  {
                    "text": "Defined as disproportionately heavy breastsWomen may seek consultation for RM due to psychological reasons, physical reasons, or bothObesity may be a contraindication for surgeryMay increase postoperative complication rates",
                    "sub_points": [
                      "Women may seek consultation for RM due to psychological reasons, physical reasons, or both",
                      "Obesity may be a contraindication for surgeryMay increase postoperative complication rates",
                      "May increase postoperative complication rates"
                    ]
                  },
                  {
                    "text": "Symptomatic macromastia has multiple presentationsBack and shoulder painKyphosisExcoriation from bra strapsChronic intertrigo in breast skin folds",
                    "sub_points": [
                      "Back and shoulder pain",
                      "Kyphosis",
                      "Excoriation from bra straps",
                      "Chronic intertrigo in breast skin folds"
                    ]
                  },
                  {
                    "text": "Severe breast hypertrophy can severely limit normal activity of daily livingMay limit exercise abilityMay cause difficulty sleeping",
                    "sub_points": [
                      "May limit exercise ability",
                      "May cause difficulty sleeping"
                    ]
                  },
                  {
                    "text": "Conservative measures, such as weight loss, physical therapy, and special brassieres, may provide some relief of symptoms"
                  },
                  {
                    "text": "Some patients may suffer from low self-esteem or depression due to unhappiness with body imageCounseling and psychological assessment may be appropriate in some cases",
                    "sub_points": [
                      "Counseling and psychological assessment may be appropriate in some cases"
                    ]
                  }
                ],
                "Bilateral Reduction Mammoplasties for Women Without a History of Breast Carcinoma": [
                  {
                    "text": "Aesthetic or functional RM are mainly performed on younger patients with no history of BC"
                  },
                  {
                    "text": "Incidence of occult BC will depend on whether or not imaging was performed prior to procedureScreening according to age and degree of risk should be performed prior to surgeryEspecially important for high-risk patients, as clinically important lesions may not be grossly evidentScreening is not always performed in all centers",
                    "sub_points": [
                      "Screening according to age and degree of risk should be performed prior to surgeryEspecially important for high-risk patients, as clinically important lesions may not be grossly evident",
                      "Especially important for high-risk patients, as clinically important lesions may not be grossly evident",
                      "Screening is not always performed in all centers"
                    ]
                  },
                  {
                    "text": "Occult malignant and premalignant lesions are rarely found in RMIncidence of invasive BC is very low (~ 0.06-1%)BCs are usually small (< 1 cm), grades 1-2, and ER(+)≤ 1% have ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)≤ 4% have atypical ductal or lobular hyperplasiaT-cell lymphocytic lobulitis may be seen in patients with germlineBRCA1orBRCA2mutationsLikelihood of finding an occult BC increases with ageYounger patients (< 40 years) are highly unlikely to have occult BCs",
                    "sub_points": [
                      "Incidence of invasive BC is very low (~ 0.06-1%)BCs are usually small (< 1 cm), grades 1-2, and ER(+)",
                      "BCs are usually small (< 1 cm), grades 1-2, and ER(+)",
                      "≤ 1% have ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)",
                      "≤ 4% have atypical ductal or lobular hyperplasia",
                      "T-cell lymphocytic lobulitis may be seen in patients with germlineBRCA1orBRCA2mutations",
                      "Likelihood of finding an occult BC increases with ageYounger patients (< 40 years) are highly unlikely to have occult BCs",
                      "Younger patients (< 40 years) are highly unlikely to have occult BCs"
                    ]
                  }
                ],
                "Contralateral Reduction Mammoplasties in Women With a History of Breast Carcinoma": [
                  {
                    "text": "Women who have undergone surgical treatment for BC may benefit from contralateral RM to provide bilateral symmetryProcedure can be performed at same time as partial mastectomy of cancerous breast or during immediate or delayed reconstruction",
                    "sub_points": [
                      "Procedure can be performed at same time as partial mastectomy of cancerous breast or during immediate or delayed reconstruction"
                    ]
                  },
                  {
                    "text": "Women with a history of BC are more likely to have BC in the contralateral RMReported incidence for occult breast BC is ~ 1-5%A similar incidence of occult BC is found for women in the same age groupOccult BCs are significantly more likely to be invasive lobular BC or DCIS than other BC types",
                    "sub_points": [
                      "Reported incidence for occult breast BC is ~ 1-5%",
                      "A similar incidence of occult BC is found for women in the same age group",
                      "Occult BCs are significantly more likely to be invasive lobular BC or DCIS than other BC types"
                    ]
                  }
                ],
                "Breast Imaging After Reduction Mammoplasties": [
                  {
                    "text": "RM can produce mammographic and histologic changesSkin thickening and retroareolar fibrosis may developFat necrosis, formation of oil cysts, fibrosis, and calcifications are common",
                    "sub_points": [
                      "Skin thickening and retroareolar fibrosis may develop",
                      "Fat necrosis, formation of oil cysts, fibrosis, and calcifications are common"
                    ]
                  },
                  {
                    "text": "Postoperative breast changes following RM do not significantly hinder assessment of screening mammographyRecall rates for further imaging assessment are similar between patients who have undergone RM compared to patients without prior surgery",
                    "sub_points": [
                      "Recall rates for further imaging assessment are similar between patients who have undergone RM compared to patients without prior surgery"
                    ]
                  }
                ],
                "Screen-Detected Cancer After Reduction Mammoplasties": [
                  {
                    "text": "Lower age-adjusted BC rates have been reported for women who have undergone RMRelative risk: 0.2-0.7Associated with removal of > 800 g of tissueReason for decreased BC risk hypothesized to be due to removal of potential epithelial precursor cells",
                    "sub_points": [
                      "Relative risk: 0.2-0.7",
                      "Associated with removal of > 800 g of tissue",
                      "Reason for decreased BC risk hypothesized to be due to removal of potential epithelial precursor cells"
                    ]
                  }
                ]
              },
              "Specimen Evaluation": {
                "Controversies in Specimen Sampling": [
                  {
                    "text": "Although the number of BCs found is quite small, there are very rare cases of BCs found in RMs that metastasize to lymph nodes &/or result in the death of the patient (~ 1 per 1,000 RMs)The majority of studies do not specify whether or not these invasive BCs were identified grossly or were found in normal-appearing tissueIn a study from an institution in which only grossly evident lesions were sampled, the number of BCs that subsequently developed in women whose specimens were not sampled was similar to the expected number in that populationSuggests that clinically significant BCs were not being missed",
                    "sub_points": [
                      "The majority of studies do not specify whether or not these invasive BCs were identified grossly or were found in normal-appearing tissue",
                      "In a study from an institution in which only grossly evident lesions were sampled, the number of BCs that subsequently developed in women whose specimens were not sampled was similar to the expected number in that populationSuggests that clinically significant BCs were not being missed",
                      "Suggests that clinically significant BCs were not being missed"
                    ]
                  },
                  {
                    "text": "Concern has been raised that sampling of grossly normal tissue finds BCs that would never have been detected otherwise in the woman's lifetimeFor example, it is estimated that at least 10% of mammographically screen-detected invasive BCs would not otherwise have become evident in the absence of screening and, thus, are not clinically significantThe majority of invasive BCs reported in studies of RMs are ≤ 1 cm, grade 1 or 2, and ER(+)Although sampling additional blocks of grossly normal tissue (e.g., 7 vs. 3 blocks) may detect more BCs, the BCs found are typically small and low gradeThere is concern that finding such small BCs could lead to treatment that potentially has greater morbidity than the cancer itself",
                    "sub_points": [
                      "For example, it is estimated that at least 10% of mammographically screen-detected invasive BCs would not otherwise have become evident in the absence of screening and, thus, are not clinically significant",
                      "The majority of invasive BCs reported in studies of RMs are ≤ 1 cm, grade 1 or 2, and ER(+)",
                      "Although sampling additional blocks of grossly normal tissue (e.g., 7 vs. 3 blocks) may detect more BCs, the BCs found are typically small and low grade",
                      "There is concern that finding such small BCs could lead to treatment that potentially has greater morbidity than the cancer itself"
                    ]
                  },
                  {
                    "text": "Therefore, there are differing opinions on the value of sampling RMs and the extent of sampling"
                  }
                ],
                "Specimen Processing": [
                  {
                    "text": "The most important goal of sampling RMs is to find grossly evident invasive BCsTherefore, there is general agreement that breast tissue from RMs should be sent for pathologic examination",
                    "sub_points": [
                      "Therefore, there is general agreement that breast tissue from RMs should be sent for pathologic examination"
                    ]
                  },
                  {
                    "text": "Right and left breast tissue should be received as separate specimensIn most cases, specimens are received as multiple fragments of breast tissue ± skin and are not orientedSurgeons have the option of marking specimens as to location in order to identify the site of a BC should one be foundHowever, this is rarely done due to BCs being very infrequent in these specimensIn very rare cases, this could facilitate margin assessment, making it possible to perform breast conservation rather than mastectomy",
                    "sub_points": [
                      "In most cases, specimens are received as multiple fragments of breast tissue ± skin and are not oriented",
                      "Surgeons have the option of marking specimens as to location in order to identify the site of a BC should one be foundHowever, this is rarely done due to BCs being very infrequent in these specimensIn very rare cases, this could facilitate margin assessment, making it possible to perform breast conservation rather than mastectomy",
                      "However, this is rarely done due to BCs being very infrequent in these specimens",
                      "In very rare cases, this could facilitate margin assessment, making it possible to perform breast conservation rather than mastectomy"
                    ]
                  },
                  {
                    "text": "Tissue is weighed and measured in aggregate for each breastTissue is usually weighed in the operating room because minimal weight is often required for insurance reimbursementOperating room weight and pathology weight are usually concordant; differences may be due to fluid lossOperating weight should be documented in pathology report if providedOn average, pathology weight is slightly lowerThis can result in insurance companies not reimbursing the cost of the surgery in a subset of cases if the pathology weight is used",
                    "sub_points": [
                      "Tissue is usually weighed in the operating room because minimal weight is often required for insurance reimbursement",
                      "Operating room weight and pathology weight are usually concordant; differences may be due to fluid lossOperating weight should be documented in pathology report if providedOn average, pathology weight is slightly lowerThis can result in insurance companies not reimbursing the cost of the surgery in a subset of cases if the pathology weight is used",
                      "Operating weight should be documented in pathology report if provided",
                      "On average, pathology weight is slightly lowerThis can result in insurance companies not reimbursing the cost of the surgery in a subset of cases if the pathology weight is used",
                      "This can result in insurance companies not reimbursing the cost of the surgery in a subset of cases if the pathology weight is used"
                    ]
                  },
                  {
                    "text": "Tissue segments are thinly sectioned and grossly examined by visual inspection and palpationAll grossly suspicious areas are sampled",
                    "sub_points": [
                      "All grossly suspicious areas are sampled"
                    ]
                  },
                  {
                    "text": "For patients < 35 years, and without risk factors for BC, not submitting grossly normal tissue for microscopic evaluation is an optionThe likelihood of finding a BC is very small in this group",
                    "sub_points": [
                      "The likelihood of finding a BC is very small in this group"
                    ]
                  },
                  {
                    "text": "For patients > 35 years, or with risk factors for BC (e.g., prior history of BC, family history, known germline mutation, radiation to the chest wall), representative fibrous tissue may be sampled2-4 blocks of representative breast tissue with at least 1 fragment of skin from each breast is generally recommended",
                    "sub_points": [
                      "2-4 blocks of representative breast tissue with at least 1 fragment of skin from each breast is generally recommended"
                    ]
                  },
                  {
                    "text": "If BC is found on initial slides, additional examination is indicated"
                  },
                  {
                    "text": "Specimen should be reexamined grossly and additional samples taken"
                  },
                  {
                    "text": "Specimen radiography can be considered if the patient has not undergone recent screeningMay reveal suspicious calcifications or small densitiesCould help guide additional sampling of specimen",
                    "sub_points": [
                      "May reveal suspicious calcifications or small densities",
                      "Could help guide additional sampling of specimen"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Breast Life Cycle Changes": {
            "name": "Breast Life Cycle Changes",
            "url": "https://app.pathprimer.com/document/f95d76c4-a1f3-4423-80bc-3f1b81d10d58/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "Female Breast": {
                "Introduction": [
                  {
                    "text": "Unlike other organs, breast changes over life cycle in response to menarche, pregnancy, lactation, and menopause"
                  },
                  {
                    "text": "Hormonal influences and growth factor effects regulate development and physiologic function"
                  },
                  {
                    "text": "Cyclical changes over the life cycle result in a broad range of normal breast histology"
                  },
                  {
                    "text": "It is important to recognize normal histologic patterns resulting from physiologic changes seen in specimens submitted for pathologic examination"
                  }
                ],
                "Embryologic and Fetal Development": [
                  {
                    "text": "Breast tissue development begins with mesenchymal-stromal differentiationStromal tissue differentiates firstInduces downgrowth of overlying epithelium forming 15-20 epithelial stripsPlacental hormones initiate canalization of epithelium and increasing mammary tissue",
                    "sub_points": [
                      "Stromal tissue differentiates first",
                      "Induces downgrowth of overlying epithelium forming 15-20 epithelial strips",
                      "Placental hormones initiate canalization of epithelium and increasing mammary tissue"
                    ]
                  },
                  {
                    "text": "Milk lines appear as 2 thickened ventral bands of ectoderm during 5th week of gestationInitially, the milk line extends from axilla to groinThe majority of the milk line regresses except for a segment in the thoracic-pectoral region, which forms the mammary ridge",
                    "sub_points": [
                      "Initially, the milk line extends from axilla to groin",
                      "The majority of the milk line regresses except for a segment in the thoracic-pectoral region, which forms the mammary ridge"
                    ]
                  },
                  {
                    "text": "Rarely, supernumerary nipples &/or subcutaneous breast tissue can develop in other areas along the milk lineThese areas can enlarge and produce milk during pregnancy and lactationMay give rise to benign &/or malignant lesions, similar to those seen in the breast",
                    "sub_points": [
                      "These areas can enlarge and produce milk during pregnancy and lactation",
                      "May give rise to benign &/or malignant lesions, similar to those seen in the breast"
                    ]
                  }
                ],
                "Childhood and Puberty": [
                  {
                    "text": "At birth, the breasts consist of the nipples and large ductsInfants (both male and female), especially breastfed infants, can transiently produce milk under the influence of maternal hormonesGalactorrhea of the newborn or \"witch's milk\"Rarely develop breast infections",
                    "sub_points": [
                      "Infants (both male and female), especially breastfed infants, can transiently produce milk under the influence of maternal hormonesGalactorrhea of the newborn or \"witch's milk\"",
                      "Galactorrhea of the newborn or \"witch's milk\"",
                      "Rarely develop breast infections"
                    ]
                  },
                  {
                    "text": "At puberty in females, the main mammary ducts branch, giving rise to terminal duct budsThese are precursors of future terminal ductal lobular units (TDLUs)",
                    "sub_points": [
                      "These are precursors of future terminal ductal lobular units (TDLUs)"
                    ]
                  },
                  {
                    "text": "Connective tissue elements also proliferateAdipose tissue increases in volume below breast skinPeriductal stromal tissue and the vascular supply also proliferate",
                    "sub_points": [
                      "Adipose tissue increases in volume below breast skin",
                      "Periductal stromal tissue and the vascular supply also proliferate"
                    ]
                  },
                  {
                    "text": "Tanner phases of pubertal breast developmentTanner phase 1Nipple elevation but no palpable glandular tissueTanner phase 2Mound of nipple and breast tissue begins to project from chest wallPalpable tissue present in subareolar regionTanner phase 3Increased glandular tissue elementsIncreased areolar size with development of pigmentationTanner phase 4Development of separate nipple-areolar complex and secondary mound anterior to breast tissueTanner phase 5Final adolescent development, smooth breast contour",
                    "sub_points": [
                      "Tanner phase 1Nipple elevation but no palpable glandular tissue",
                      "Nipple elevation but no palpable glandular tissue",
                      "Tanner phase 2Mound of nipple and breast tissue begins to project from chest wallPalpable tissue present in subareolar region",
                      "Mound of nipple and breast tissue begins to project from chest wall",
                      "Palpable tissue present in subareolar region",
                      "Tanner phase 3Increased glandular tissue elementsIncreased areolar size with development of pigmentation",
                      "Increased glandular tissue elements",
                      "Increased areolar size with development of pigmentation",
                      "Tanner phase 4Development of separate nipple-areolar complex and secondary mound anterior to breast tissue",
                      "Development of separate nipple-areolar complex and secondary mound anterior to breast tissue",
                      "Tanner phase 5Final adolescent development, smooth breast contour",
                      "Final adolescent development, smooth breast contour"
                    ]
                  },
                  {
                    "text": "Lesions in childhood and pubertyBenign lesions very rareSurgery should be avoided as the breast bud can be damaged, which can prevent subsequent developmentMalignant lesions are exceedingly rareSecretory carcinoma occurring in this age group has a relatively favorable prognosis",
                    "sub_points": [
                      "Benign lesions very rareSurgery should be avoided as the breast bud can be damaged, which can prevent subsequent development",
                      "Surgery should be avoided as the breast bud can be damaged, which can prevent subsequent development",
                      "Malignant lesions are exceedingly rareSecretory carcinoma occurring in this age group has a relatively favorable prognosis",
                      "Secretory carcinoma occurring in this age group has a relatively favorable prognosis"
                    ]
                  },
                  {
                    "text": "Male breast tissueAt puberty in males, the breast usually does not develop beyond a rudimentary large duct systemLobules are only very rarely presentIf present, an endogenous or exogenous hormonal influence should be considered",
                    "sub_points": [
                      "At puberty in males, the breast usually does not develop beyond a rudimentary large duct systemLobules are only very rarely presentIf present, an endogenous or exogenous hormonal influence should be considered",
                      "Lobules are only very rarely present",
                      "If present, an endogenous or exogenous hormonal influence should be considered"
                    ]
                  },
                  {
                    "text": "Lesions in malesThe most common is gynecomastia (typically at puberty or at older ages)2/3 of males may experience some breast tissue enlargement (gynecomastia) that does not persistCan be the result of steroids taken for sports performance or bodybuildingAlmost all lesions seen in females can occur in males (but at much lower frequency)The only lesion seen in similar frequency is myofibroblastoma",
                    "sub_points": [
                      "The most common is gynecomastia (typically at puberty or at older ages)2/3 of males may experience some breast tissue enlargement (gynecomastia) that does not persistCan be the result of steroids taken for sports performance or bodybuilding",
                      "2/3 of males may experience some breast tissue enlargement (gynecomastia) that does not persist",
                      "Can be the result of steroids taken for sports performance or bodybuilding",
                      "Almost all lesions seen in females can occur in males (but at much lower frequency)The only lesion seen in similar frequency is myofibroblastoma",
                      "The only lesion seen in similar frequency is myofibroblastoma"
                    ]
                  }
                ],
                "Adult": [
                  {
                    "text": "Menstrual cycle changesProliferative phase of menstrual cycleEarly breast changes prior to ovulation (days 3-14)Increase in ovarian estrogen productionMammary lobules are relatively quiescentDecreased stromal densityDecreased breast volume and water contentBreast MR examination should be scheduled during the early phase of the cycleSecretory phase of menstrual cycleLater breast changes after ovulation (days 15-28)Due to estrogen production with increased progesterone levels (luteal phase)Proliferation of mammary duct epithelium, increased numbers of aciniIncreased stromal density (tissue edema)Increased breast volume and water contentSome women may experience symptoms due to increased interlobular fluid and epithelial cell proliferationMenstruationDecreasing estrogen and progesterone levelsRegression of lobules and disappearance of stromal edema",
                    "sub_points": [
                      "Proliferative phase of menstrual cycleEarly breast changes prior to ovulation (days 3-14)Increase in ovarian estrogen productionMammary lobules are relatively quiescentDecreased stromal densityDecreased breast volume and water contentBreast MR examination should be scheduled during the early phase of the cycle",
                      "Early breast changes prior to ovulation (days 3-14)Increase in ovarian estrogen productionMammary lobules are relatively quiescentDecreased stromal densityDecreased breast volume and water contentBreast MR examination should be scheduled during the early phase of the cycle",
                      "Increase in ovarian estrogen production",
                      "Mammary lobules are relatively quiescent",
                      "Decreased stromal density",
                      "Decreased breast volume and water content",
                      "Breast MR examination should be scheduled during the early phase of the cycle",
                      "Secretory phase of menstrual cycleLater breast changes after ovulation (days 15-28)Due to estrogen production with increased progesterone levels (luteal phase)Proliferation of mammary duct epithelium, increased numbers of aciniIncreased stromal density (tissue edema)Increased breast volume and water contentSome women may experience symptoms due to increased interlobular fluid and epithelial cell proliferation",
                      "Later breast changes after ovulation (days 15-28)Due to estrogen production with increased progesterone levels (luteal phase)Proliferation of mammary duct epithelium, increased numbers of aciniIncreased stromal density (tissue edema)Increased breast volume and water contentSome women may experience symptoms due to increased interlobular fluid and epithelial cell proliferation",
                      "Due to estrogen production with increased progesterone levels (luteal phase)",
                      "Proliferation of mammary duct epithelium, increased numbers of acini",
                      "Increased stromal density (tissue edema)",
                      "Increased breast volume and water content",
                      "Some women may experience symptoms due to increased interlobular fluid and epithelial cell proliferation",
                      "MenstruationDecreasing estrogen and progesterone levelsRegression of lobules and disappearance of stromal edema",
                      "Decreasing estrogen and progesterone levelsRegression of lobules and disappearance of stromal edema",
                      "Regression of lobules and disappearance of stromal edema"
                    ]
                  },
                  {
                    "text": "Pregnancy-related changesPhysiologic functionBreast tissue is responsible for milk secretion for nourishment and immunologic protection of young during postpartum lactationWith onset of pregnancy, breast tissue becomes fully mature and functionalLobules progressively increase in size and numberHormones influencing changes include estrogen, progesterone, growth hormone, prolactin, and placental hormonesEarly pregnancy changesGeneralized breast tissue enlargementMarked ductal and lobular proliferation (high mitotic rate)Increase in number of lobules and acinar units within each lobuleStromal elements of breast gradually replaced by proliferating glandular epitheliumIncreased nipple-areolar complex pigmentationMontgomery tubercles (sebaceous glands of areola) become prominent; appear as rounded papules on skin surfaceFunction in nipple lubrication during breastfeedingLater pregnancy changesProgressive stimulation of lobular developmentCytoplasm of luminal cells becomes vacuolatedNucleoli are prominent due to protein productionStimulation of milk secretion into expanded TDLUsOxytocin induces myoepithelial proliferation and differentiationProliferation rate slowsIncrease in stromal fat elementsPostpartum enlargement of breast due to distention of lobular acini and accumulation of colostrumAfter delivery, estrogen and progesterone levels fall, resulting in lactationProlactin, growth hormones, and insulin induce production and secretion of milkLuminal cells show cytoplasmic vacuolization with bulbous or hobnail projections into aciniMilk production occurs in TDLUs and is transferred to nipple via the large duct systemMilk ejection reflex (let-down) is mediated by oxytocin, which causes myoepithelial cell contractionOxytocin is released in response to neural reflexes activated by suckling, seeing, or hearing an infantMilk traverses large duct system and distends lactiferous sinusesLuminal cells of the large duct system do not undergo secretory changesRegression after cessation of lactationLobules decrease in size and numberIncomplete regression back to prepregnancy stateAverage lobule size is related to number of pregnanciesA mild lymphocytic infiltrate is associated with regressing lobulesCytologic changes return to nonpregnant state",
                    "sub_points": [
                      "Physiologic functionBreast tissue is responsible for milk secretion for nourishment and immunologic protection of young during postpartum lactationWith onset of pregnancy, breast tissue becomes fully mature and functionalLobules progressively increase in size and numberHormones influencing changes include estrogen, progesterone, growth hormone, prolactin, and placental hormones",
                      "Breast tissue is responsible for milk secretion for nourishment and immunologic protection of young during postpartum lactation",
                      "With onset of pregnancy, breast tissue becomes fully mature and functionalLobules progressively increase in size and numberHormones influencing changes include estrogen, progesterone, growth hormone, prolactin, and placental hormones",
                      "Lobules progressively increase in size and number",
                      "Hormones influencing changes include estrogen, progesterone, growth hormone, prolactin, and placental hormones",
                      "Early pregnancy changesGeneralized breast tissue enlargementMarked ductal and lobular proliferation (high mitotic rate)Increase in number of lobules and acinar units within each lobuleStromal elements of breast gradually replaced by proliferating glandular epitheliumIncreased nipple-areolar complex pigmentationMontgomery tubercles (sebaceous glands of areola) become prominent; appear as rounded papules on skin surfaceFunction in nipple lubrication during breastfeeding",
                      "Generalized breast tissue enlargementMarked ductal and lobular proliferation (high mitotic rate)Increase in number of lobules and acinar units within each lobuleStromal elements of breast gradually replaced by proliferating glandular epithelium",
                      "Marked ductal and lobular proliferation (high mitotic rate)",
                      "Increase in number of lobules and acinar units within each lobule",
                      "Stromal elements of breast gradually replaced by proliferating glandular epithelium",
                      "Increased nipple-areolar complex pigmentationMontgomery tubercles (sebaceous glands of areola) become prominent; appear as rounded papules on skin surfaceFunction in nipple lubrication during breastfeeding",
                      "Montgomery tubercles (sebaceous glands of areola) become prominent; appear as rounded papules on skin surface",
                      "Function in nipple lubrication during breastfeeding",
                      "Later pregnancy changesProgressive stimulation of lobular developmentCytoplasm of luminal cells becomes vacuolatedNucleoli are prominent due to protein productionStimulation of milk secretion into expanded TDLUsOxytocin induces myoepithelial proliferation and differentiationProliferation rate slowsIncrease in stromal fat elementsPostpartum enlargement of breast due to distention of lobular acini and accumulation of colostrumAfter delivery, estrogen and progesterone levels fall, resulting in lactationProlactin, growth hormones, and insulin induce production and secretion of milkLuminal cells show cytoplasmic vacuolization with bulbous or hobnail projections into aciniMilk production occurs in TDLUs and is transferred to nipple via the large duct systemMilk ejection reflex (let-down) is mediated by oxytocin, which causes myoepithelial cell contractionOxytocin is released in response to neural reflexes activated by suckling, seeing, or hearing an infantMilk traverses large duct system and distends lactiferous sinusesLuminal cells of the large duct system do not undergo secretory changes",
                      "Progressive stimulation of lobular developmentCytoplasm of luminal cells becomes vacuolatedNucleoli are prominent due to protein productionStimulation of milk secretion into expanded TDLUsOxytocin induces myoepithelial proliferation and differentiation",
                      "Cytoplasm of luminal cells becomes vacuolated",
                      "Nucleoli are prominent due to protein production",
                      "Stimulation of milk secretion into expanded TDLUs",
                      "Oxytocin induces myoepithelial proliferation and differentiation",
                      "Proliferation rate slows",
                      "Increase in stromal fat elements",
                      "Postpartum enlargement of breast due to distention of lobular acini and accumulation of colostrumAfter delivery, estrogen and progesterone levels fall, resulting in lactationProlactin, growth hormones, and insulin induce production and secretion of milkLuminal cells show cytoplasmic vacuolization with bulbous or hobnail projections into aciniMilk production occurs in TDLUs and is transferred to nipple via the large duct system",
                      "After delivery, estrogen and progesterone levels fall, resulting in lactation",
                      "Prolactin, growth hormones, and insulin induce production and secretion of milk",
                      "Luminal cells show cytoplasmic vacuolization with bulbous or hobnail projections into acini",
                      "Milk production occurs in TDLUs and is transferred to nipple via the large duct system",
                      "Milk ejection reflex (let-down) is mediated by oxytocin, which causes myoepithelial cell contractionOxytocin is released in response to neural reflexes activated by suckling, seeing, or hearing an infantMilk traverses large duct system and distends lactiferous sinusesLuminal cells of the large duct system do not undergo secretory changes",
                      "Oxytocin is released in response to neural reflexes activated by suckling, seeing, or hearing an infant",
                      "Milk traverses large duct system and distends lactiferous sinuses",
                      "Luminal cells of the large duct system do not undergo secretory changes",
                      "Regression after cessation of lactationLobules decrease in size and numberIncomplete regression back to prepregnancy stateAverage lobule size is related to number of pregnanciesA mild lymphocytic infiltrate is associated with regressing lobulesCytologic changes return to nonpregnant state",
                      "Lobules decrease in size and numberIncomplete regression back to prepregnancy stateAverage lobule size is related to number of pregnancies",
                      "Incomplete regression back to prepregnancy state",
                      "Average lobule size is related to number of pregnancies",
                      "A mild lymphocytic infiltrate is associated with regressing lobules",
                      "Cytologic changes return to nonpregnant state"
                    ]
                  },
                  {
                    "text": "Lesions related to pregnancy &/or lactationLactational change with calcificationsLobules can undergo sporadic lactational change in the absence of pregnancy or other hormonal triggersMay be associated with prominent large psammoma body calcificationsCan form a cluster of calcifications that appear suspicious by mammographyLactational adenomaPresents as a palpable circumscribed mass during pregnancy or lactationMay wax and wane in size with breastfeedingConsists of normal-appearing lactational tissueMore likely a localized hyperplasia than neoplasiaRegresses after pregnancy and lactationLactational abscessLactation is the most common period for breast infectionsCracks in the nipple can lead to infection by skin bacteriaStaphylococcusspecies are most common bacterial cause, followed by streptococciUsually adequately treated with antibiotics and expression of milkGalactocelePresents as a palpable massRupture of ducts leads to extravasation of milk into mammary stromaMilk causes a chronic inflammatory responseInfarction of benign lesionsIncreased proliferation of tissues occurs during 1st and 2nd trimestersBenign lesions, such as fibroadenomas, can grow in size and may infarctMitotic activity and necrosis can mimic malignant changes in benign lesionsConsider pregnancy-related changes before making a diagnosis of malignancyBloody nipple dischargeMay occur during pregnancyLikely related to rapid tissue remodeling and growthCarcinoma diagnosed during pregnancyRegardless of age at childbirth, women face a transient increased risk for breast carcinoma during pregnancy and postpartum periodCarcinoma diagnosed during this period confers significantly poorer outcome due to presentation at higher stagesDiagnosis is often delayed due to rarity of diagnosisIncreased risk of cancer persists for a period of time after pregnancy; longer for older individualsRare: In only 1 of 3,000-10,000 pregnancies is cancer diagnosed during or within 1st year after deliveryTime during pregnancy is too brief for de novo development of cancerPatients likely have preexisting carcinoma in situ, possibly with a small area of invasionTransition to invasive carcinoma may be facilitated by stromal changes and tissue remodeling during pregnancy and postpregnancy involutionSimilar gene expression pattern as seen in wound healingPostpartum tissue remodeling involving collagen deposition and macrophage infiltrates demonstrate tumor promotional attributes in models of breast carcinomaIn rodent models, postpartum mammary involution has been identified as a key mediator of tumor progressionHormone levels during pregnancy may promote rapid tumor growthOver a longer period of time, cancer risk decreasedThought to be due to terminal differentiation of milk-producing epithelial cells, reducing potential pool of precursor cellsFor young women (late teens to early 20s), protective effects of pregnancy outweigh increased riskEarly pregnancy reduces lifetime risk for ER(+) carcinoma by ~ 1/2Additional pregnancies further decreases cancer risk (~ 7%)For older women (≥ 35 years), increased risk is greater than protective benefitFalse diagnosis of carcinoma during pregnancy is a major possible pitfallProminent nucleoli, high mitotic rate, and necrosis can closely mimic malignancyPathologists are often not informed that a patient is pregnant or lactatingIn some cases, the patient and clinician may not be aware of early pregnancyIncorrect diagnosis can lead to diagnostic procedures that put fetus at risk &/or termination of desired pregnancyLactational changes after skin and nipple sparing mastectomy~ 1/2 of women who become pregnant experience nipple discharge &/or nodularityLactational adenomas can occur due to residual breast tissue",
                    "sub_points": [
                      "Lactational change with calcificationsLobules can undergo sporadic lactational change in the absence of pregnancy or other hormonal triggersMay be associated with prominent large psammoma body calcificationsCan form a cluster of calcifications that appear suspicious by mammography",
                      "Lobules can undergo sporadic lactational change in the absence of pregnancy or other hormonal triggers",
                      "May be associated with prominent large psammoma body calcifications",
                      "Can form a cluster of calcifications that appear suspicious by mammography",
                      "Lactational adenomaPresents as a palpable circumscribed mass during pregnancy or lactationMay wax and wane in size with breastfeedingConsists of normal-appearing lactational tissueMore likely a localized hyperplasia than neoplasiaRegresses after pregnancy and lactation",
                      "Presents as a palpable circumscribed mass during pregnancy or lactation",
                      "May wax and wane in size with breastfeeding",
                      "Consists of normal-appearing lactational tissue",
                      "More likely a localized hyperplasia than neoplasia",
                      "Regresses after pregnancy and lactation",
                      "Lactational abscessLactation is the most common period for breast infectionsCracks in the nipple can lead to infection by skin bacteriaStaphylococcusspecies are most common bacterial cause, followed by streptococciUsually adequately treated with antibiotics and expression of milk",
                      "Lactation is the most common period for breast infections",
                      "Cracks in the nipple can lead to infection by skin bacteriaStaphylococcusspecies are most common bacterial cause, followed by streptococci",
                      "Staphylococcusspecies are most common bacterial cause, followed by streptococci",
                      "Usually adequately treated with antibiotics and expression of milk",
                      "GalactocelePresents as a palpable massRupture of ducts leads to extravasation of milk into mammary stromaMilk causes a chronic inflammatory response",
                      "Presents as a palpable mass",
                      "Rupture of ducts leads to extravasation of milk into mammary stroma",
                      "Milk causes a chronic inflammatory response",
                      "Infarction of benign lesionsIncreased proliferation of tissues occurs during 1st and 2nd trimestersBenign lesions, such as fibroadenomas, can grow in size and may infarctMitotic activity and necrosis can mimic malignant changes in benign lesionsConsider pregnancy-related changes before making a diagnosis of malignancy",
                      "Increased proliferation of tissues occurs during 1st and 2nd trimestersBenign lesions, such as fibroadenomas, can grow in size and may infarct",
                      "Benign lesions, such as fibroadenomas, can grow in size and may infarct",
                      "Mitotic activity and necrosis can mimic malignant changes in benign lesionsConsider pregnancy-related changes before making a diagnosis of malignancy",
                      "Consider pregnancy-related changes before making a diagnosis of malignancy",
                      "Bloody nipple dischargeMay occur during pregnancyLikely related to rapid tissue remodeling and growth",
                      "May occur during pregnancy",
                      "Likely related to rapid tissue remodeling and growth",
                      "Carcinoma diagnosed during pregnancyRegardless of age at childbirth, women face a transient increased risk for breast carcinoma during pregnancy and postpartum periodCarcinoma diagnosed during this period confers significantly poorer outcome due to presentation at higher stagesDiagnosis is often delayed due to rarity of diagnosisIncreased risk of cancer persists for a period of time after pregnancy; longer for older individualsRare: In only 1 of 3,000-10,000 pregnancies is cancer diagnosed during or within 1st year after deliveryTime during pregnancy is too brief for de novo development of cancerPatients likely have preexisting carcinoma in situ, possibly with a small area of invasionTransition to invasive carcinoma may be facilitated by stromal changes and tissue remodeling during pregnancy and postpregnancy involutionSimilar gene expression pattern as seen in wound healingPostpartum tissue remodeling involving collagen deposition and macrophage infiltrates demonstrate tumor promotional attributes in models of breast carcinomaIn rodent models, postpartum mammary involution has been identified as a key mediator of tumor progressionHormone levels during pregnancy may promote rapid tumor growthOver a longer period of time, cancer risk decreasedThought to be due to terminal differentiation of milk-producing epithelial cells, reducing potential pool of precursor cellsFor young women (late teens to early 20s), protective effects of pregnancy outweigh increased riskEarly pregnancy reduces lifetime risk for ER(+) carcinoma by ~ 1/2Additional pregnancies further decreases cancer risk (~ 7%)For older women (≥ 35 years), increased risk is greater than protective benefitFalse diagnosis of carcinoma during pregnancy is a major possible pitfallProminent nucleoli, high mitotic rate, and necrosis can closely mimic malignancyPathologists are often not informed that a patient is pregnant or lactatingIn some cases, the patient and clinician may not be aware of early pregnancyIncorrect diagnosis can lead to diagnostic procedures that put fetus at risk &/or termination of desired pregnancy",
                      "Regardless of age at childbirth, women face a transient increased risk for breast carcinoma during pregnancy and postpartum periodCarcinoma diagnosed during this period confers significantly poorer outcome due to presentation at higher stagesDiagnosis is often delayed due to rarity of diagnosisIncreased risk of cancer persists for a period of time after pregnancy; longer for older individuals",
                      "Carcinoma diagnosed during this period confers significantly poorer outcome due to presentation at higher stages",
                      "Diagnosis is often delayed due to rarity of diagnosis",
                      "Increased risk of cancer persists for a period of time after pregnancy; longer for older individuals",
                      "Rare: In only 1 of 3,000-10,000 pregnancies is cancer diagnosed during or within 1st year after delivery",
                      "Time during pregnancy is too brief for de novo development of cancerPatients likely have preexisting carcinoma in situ, possibly with a small area of invasionTransition to invasive carcinoma may be facilitated by stromal changes and tissue remodeling during pregnancy and postpregnancy involutionSimilar gene expression pattern as seen in wound healingPostpartum tissue remodeling involving collagen deposition and macrophage infiltrates demonstrate tumor promotional attributes in models of breast carcinomaIn rodent models, postpartum mammary involution has been identified as a key mediator of tumor progression",
                      "Patients likely have preexisting carcinoma in situ, possibly with a small area of invasion",
                      "Transition to invasive carcinoma may be facilitated by stromal changes and tissue remodeling during pregnancy and postpregnancy involution",
                      "Similar gene expression pattern as seen in wound healing",
                      "Postpartum tissue remodeling involving collagen deposition and macrophage infiltrates demonstrate tumor promotional attributes in models of breast carcinoma",
                      "In rodent models, postpartum mammary involution has been identified as a key mediator of tumor progression",
                      "Hormone levels during pregnancy may promote rapid tumor growth",
                      "Over a longer period of time, cancer risk decreasedThought to be due to terminal differentiation of milk-producing epithelial cells, reducing potential pool of precursor cells",
                      "Thought to be due to terminal differentiation of milk-producing epithelial cells, reducing potential pool of precursor cells",
                      "For young women (late teens to early 20s), protective effects of pregnancy outweigh increased riskEarly pregnancy reduces lifetime risk for ER(+) carcinoma by ~ 1/2Additional pregnancies further decreases cancer risk (~ 7%)",
                      "Early pregnancy reduces lifetime risk for ER(+) carcinoma by ~ 1/2",
                      "Additional pregnancies further decreases cancer risk (~ 7%)",
                      "For older women (≥ 35 years), increased risk is greater than protective benefit",
                      "False diagnosis of carcinoma during pregnancy is a major possible pitfallProminent nucleoli, high mitotic rate, and necrosis can closely mimic malignancyPathologists are often not informed that a patient is pregnant or lactatingIn some cases, the patient and clinician may not be aware of early pregnancyIncorrect diagnosis can lead to diagnostic procedures that put fetus at risk &/or termination of desired pregnancy",
                      "Prominent nucleoli, high mitotic rate, and necrosis can closely mimic malignancy",
                      "Pathologists are often not informed that a patient is pregnant or lactating",
                      "In some cases, the patient and clinician may not be aware of early pregnancy",
                      "Incorrect diagnosis can lead to diagnostic procedures that put fetus at risk &/or termination of desired pregnancy",
                      "Lactational changes after skin and nipple sparing mastectomy~ 1/2 of women who become pregnant experience nipple discharge &/or nodularityLactational adenomas can occur due to residual breast tissue",
                      "~ 1/2 of women who become pregnant experience nipple discharge &/or nodularity",
                      "Lactational adenomas can occur due to residual breast tissue"
                    ]
                  },
                  {
                    "text": "Involutional changesInvolution of mammary epithelium and stroma begins prior to menopause at ~ 4th decadeDecreased hormonal stimulation occurs after menopauseMultiple changes occurProgressive atrophy of tissue elements and involutionMyoepithelial cells become more prominent and spindled in shape (so-called myoepithelial atrophy)May mimic lobular neoplasiaReduction in size and complexity of TDLUsIn older women, only mammary ducts may remainMastitis obliterans has appearance of fibrotic ducts with regrowth of ductal structures at peripheryProgressive loss of specialized intralobular stromaGeneralized fatty replacement of breast parenchymaBreast tissue becomes less dense on mammographyIncreases sensitivity of mammography to detect faint calcifications and small massesVascular changesWalls of blood vessels frequently calcify and can be seen on mammographyIn younger women (≤ 40 years), associated with other risk factors for heart diseaseIn older women (≥ 60 years), vascular calcification is commonCalcifications have specific appearance on mammographyForm parallel linear arrays (train tracks)Will not be targeted for biopsy by radiologists, as they are not associated with malignancyThus, vascular calcifications in biopsy almost never correlate with the targeted lesionPostmenopausal hormone replacement therapy stimulates breast tissueFor women with obesity, hormone production from fat after menopause can also stimulate breast tissueFailure to undergo involution may cause the observed continuing increase in breast carcinoma incidence at advanced ages",
                    "sub_points": [
                      "Involution of mammary epithelium and stroma begins prior to menopause at ~ 4th decadeDecreased hormonal stimulation occurs after menopause",
                      "Decreased hormonal stimulation occurs after menopause",
                      "Multiple changes occurProgressive atrophy of tissue elements and involutionMyoepithelial cells become more prominent and spindled in shape (so-called myoepithelial atrophy)May mimic lobular neoplasiaReduction in size and complexity of TDLUsIn older women, only mammary ducts may remainMastitis obliterans has appearance of fibrotic ducts with regrowth of ductal structures at peripheryProgressive loss of specialized intralobular stroma",
                      "Progressive atrophy of tissue elements and involutionMyoepithelial cells become more prominent and spindled in shape (so-called myoepithelial atrophy)May mimic lobular neoplasia",
                      "Myoepithelial cells become more prominent and spindled in shape (so-called myoepithelial atrophy)",
                      "May mimic lobular neoplasia",
                      "Reduction in size and complexity of TDLUsIn older women, only mammary ducts may remainMastitis obliterans has appearance of fibrotic ducts with regrowth of ductal structures at periphery",
                      "In older women, only mammary ducts may remain",
                      "Mastitis obliterans has appearance of fibrotic ducts with regrowth of ductal structures at periphery",
                      "Progressive loss of specialized intralobular stroma",
                      "Generalized fatty replacement of breast parenchymaBreast tissue becomes less dense on mammographyIncreases sensitivity of mammography to detect faint calcifications and small masses",
                      "Breast tissue becomes less dense on mammography",
                      "Increases sensitivity of mammography to detect faint calcifications and small masses",
                      "Vascular changesWalls of blood vessels frequently calcify and can be seen on mammographyIn younger women (≤ 40 years), associated with other risk factors for heart diseaseIn older women (≥ 60 years), vascular calcification is commonCalcifications have specific appearance on mammographyForm parallel linear arrays (train tracks)Will not be targeted for biopsy by radiologists, as they are not associated with malignancyThus, vascular calcifications in biopsy almost never correlate with the targeted lesion",
                      "Walls of blood vessels frequently calcify and can be seen on mammographyIn younger women (≤ 40 years), associated with other risk factors for heart diseaseIn older women (≥ 60 years), vascular calcification is common",
                      "In younger women (≤ 40 years), associated with other risk factors for heart disease",
                      "In older women (≥ 60 years), vascular calcification is common",
                      "Calcifications have specific appearance on mammographyForm parallel linear arrays (train tracks)Will not be targeted for biopsy by radiologists, as they are not associated with malignancyThus, vascular calcifications in biopsy almost never correlate with the targeted lesion",
                      "Form parallel linear arrays (train tracks)",
                      "Will not be targeted for biopsy by radiologists, as they are not associated with malignancy",
                      "Thus, vascular calcifications in biopsy almost never correlate with the targeted lesion",
                      "Postmenopausal hormone replacement therapy stimulates breast tissueFor women with obesity, hormone production from fat after menopause can also stimulate breast tissueFailure to undergo involution may cause the observed continuing increase in breast carcinoma incidence at advanced ages",
                      "For women with obesity, hormone production from fat after menopause can also stimulate breast tissue",
                      "Failure to undergo involution may cause the observed continuing increase in breast carcinoma incidence at advanced ages"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Juvenile Papillomatosis": {
            "name": "Juvenile Papillomatosis",
            "url": "https://app.pathprimer.com/document/f195ad4c-8697-499f-a51a-cb3d395167b8/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Rare, mass-forming lesion of breast, composed of cysts and epithelial proliferation, occurring in young patients"
                  },
                  {
                    "text": "Also termed Swiss cheese disease due to multiple cysts"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "~ 20% of women with juvenile papillomatosis (JP) have a family history of breast cancer"
                  },
                  {
                    "text": "Rare cases associated with hereditary tumor syndromes"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare: < 1% of all excised breast masses"
                  },
                  {
                    "text": "Mean age: 26 years (range: 7 months to 81 years)"
                  },
                  {
                    "text": "Occurs in both females and males"
                  },
                  {
                    "text": "Presents as palpable, circumscribed, mobile mass"
                  },
                  {
                    "text": "Can recur if not completely excised~ 10-15% of patients have concurrent cancer, and ~ 10% may subsequently develop cancer",
                    "sub_points": [
                      "~ 10-15% of patients have concurrent cancer, and ~ 10% may subsequently develop cancer"
                    ]
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "1-8 cm (average: 4 cm)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Several different histologic lesions are generally presentCystsOften with inspissated secretions and foamy histiocytesEpithelial hyperplasiaUsually floridNecrosis present in ~ 15%Apocrine metaplasiaPapillomasAtypical architectural patterns (cribriform or micropapillary) are present in ~ 40%",
                    "sub_points": [
                      "CystsOften with inspissated secretions and foamy histiocytes",
                      "Often with inspissated secretions and foamy histiocytes",
                      "Epithelial hyperplasiaUsually floridNecrosis present in ~ 15%",
                      "Usually florid",
                      "Necrosis present in ~ 15%",
                      "Apocrine metaplasia",
                      "Papillomas",
                      "Atypical architectural patterns (cribriform or micropapillary) are present in ~ 40%"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Proliferative changes"
                  },
                  {
                    "text": "Papillomas"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Juvenile papillomatosis (JP)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Swiss cheese disease (not recommended as the diagnostic term)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare, mass-forming lesion of breast, composed of cysts and epithelial proliferation, occurring in young patients"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular": [
                  {
                    "text": "PIK3CAmutations (50%) orAKT1mutations (20%) are reported in JP"
                  },
                  {
                    "text": "These are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityPIK3CAandAKT1mutations are also reported in many other breast proliferative lesions as well as in normal breast tissueThus, these somatic mutations likely predispose to the development of multiple types of proliferative lesions but are not specific to any particular lesion",
                    "sub_points": [
                      "PIK3CAandAKT1mutations are also reported in many other breast proliferative lesions as well as in normal breast tissueThus, these somatic mutations likely predispose to the development of multiple types of proliferative lesions but are not specific to any particular lesion",
                      "Thus, these somatic mutations likely predispose to the development of multiple types of proliferative lesions but are not specific to any particular lesion"
                    ]
                  }
                ],
                "Family History": [
                  {
                    "text": "~ 20% of women with JP have a family history of breast cancer, including both 1st- and 2nd-degree relativesAffected relatives are usually mothers and maternal aunts",
                    "sub_points": [
                      "Affected relatives are usually mothers and maternal aunts"
                    ]
                  },
                  {
                    "text": "Rare cases are associated with hereditary tumor syndromes3 out of 4 male infants with JP had features associated with neurofibromatosis 11 had neurofibromatosis, 1 likely had neurofibromatosis-Noonan syndrome, and 1 had café au lait spotsSuggests a possible genetic basis for some cases in male patients1 case of Cowden syndrome and 1 case of Proteus syndrome in female patients",
                    "sub_points": [
                      "3 out of 4 male infants with JP had features associated with neurofibromatosis 11 had neurofibromatosis, 1 likely had neurofibromatosis-Noonan syndrome, and 1 had café au lait spotsSuggests a possible genetic basis for some cases in male patients",
                      "1 had neurofibromatosis, 1 likely had neurofibromatosis-Noonan syndrome, and 1 had café au lait spots",
                      "Suggests a possible genetic basis for some cases in male patients",
                      "1 case of Cowden syndrome and 1 case of Proteus syndrome in female patients"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare: < 1% of all excised breast masses"
                  }
                ],
                "Age": [
                  {
                    "text": "Mean: 26 years (range: 7 months to 81 years)70% are under 26 years",
                    "sub_points": [
                      "70% are under 26 years"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Occurs in both females and males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Presents as palpable, circumscribed, mobile massThe clinical impression is often fibroadenoma",
                    "sub_points": [
                      "The clinical impression is often fibroadenoma"
                    ]
                  },
                  {
                    "text": "Can be multiple and bilateral"
                  },
                  {
                    "text": "Not associated with nipple discharge"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Can recur if not completely excised~ 7% of patients have concurrent cancer, and ~ 3% may subsequently develop cancer",
                    "sub_points": [
                      "~ 7% of patients have concurrent cancer, and ~ 3% may subsequently develop cancer"
                    ]
                  },
                  {
                    "text": "The following features have been suggested as risk factors for developing carcinoma, but cases are rare and little information is availableFamily history, epithelial atypia, bilateral &/or multiple lesions, recurrent lesions, diagnosis at older age (> 25 years)",
                    "sub_points": [
                      "Family history, epithelial atypia, bilateral &/or multiple lesions, recurrent lesions, diagnosis at older age (> 25 years)"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Patients should be followed clinically due to a possible increased risk of carcinoma"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Mass with circumscribed margins: Resembles fibroadenomaSome not apparent on mammography",
                    "sub_points": [
                      "Some not apparent on mammography"
                    ]
                  },
                  {
                    "text": "Occasionally shows microcalcifications"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Ill-defined mass with multiple cysts"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Focal enhancement with internal cystic areas"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Firm, discrete mass; borders are not well defined"
                  },
                  {
                    "text": "Multiple small (1- to 2-mm) cystsCysts confer Swiss cheese appearance on gross examination",
                    "sub_points": [
                      "Cysts confer Swiss cheese appearance on gross examination"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "1-8 cm (average: 2-4 cm)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Several histologic lesions are generally presentCystsOften with inspissated secretions and foamy histiocytesEpithelial hyperplasiaUsually floridNecrosis present in ~ 15%Apocrine metaplasiaPapillomas",
                    "sub_points": [
                      "CystsOften with inspissated secretions and foamy histiocytes",
                      "Often with inspissated secretions and foamy histiocytes",
                      "Epithelial hyperplasiaUsually floridNecrosis present in ~ 15%",
                      "Usually florid",
                      "Necrosis present in ~ 15%",
                      "Apocrine metaplasia",
                      "Papillomas"
                    ]
                  },
                  {
                    "text": "Atypical architectural patterns (cribriform or micropapillary) are present in ~ 40%"
                  },
                  {
                    "text": "Fibroadenomas are often present as separate lesions"
                  },
                  {
                    "text": "Concurrent carcinoma is present in 10-15% of patients; several types are reportedInvasive lobular carcinomaInvasive secretory carcinomaInvasive carcinoma of no special type (ductal)Lobular carcinoma in situ",
                    "sub_points": [
                      "Invasive lobular carcinoma",
                      "Invasive secretory carcinoma",
                      "Invasive carcinoma of no special type (ductal)",
                      "Lobular carcinoma in situ"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Proliferative Changes": [
                  {
                    "text": "Any findings associated with JP can be present as multiple small lesions in breast"
                  },
                  {
                    "text": "The essential diagnostic criterion for JP is the presence of changes within a grossly defined palpable mass in a young person"
                  }
                ],
                "Papillomas": [
                  {
                    "text": "Papillomas are often associated with JP"
                  },
                  {
                    "text": "JP is not synonymous with finding of 1 or multiple papillomas in young patientA discrete palpable mass with cysts must be present",
                    "sub_points": [
                      "A discrete palpable mass with cysts must be present"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Gynecomastia in Men and Gynecomastia-Like Changes in Women": {
            "name": "Gynecomastia in Men and Gynecomastia-Like Changes in Women",
            "url": "https://app.pathprimer.com/document/a6b63556-6846-4d7c-9c67-478dda206202/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nonneoplastic enlargement of male breast due to hyperplasia of epithelium and stroma"
                  },
                  {
                    "text": "Similar findings in females are termed gynecomastia-like changes"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Gynecomastia develops due to imbalance in free androgen:estrogen ratio (variety of etiologies)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "3 distinct peaks in occurrence of gynecomastia in malesMale infants (60-90%), transientMales at puberty (48-64%, peak age: 13-14 years)Highest prevalence in older males (50-80 years)",
                    "sub_points": [
                      "Male infants (60-90%), transient",
                      "Males at puberty (48-64%, peak age: 13-14 years)",
                      "Highest prevalence in older males (50-80 years)"
                    ]
                  },
                  {
                    "text": "In females, can occur as a discrete finding or associated with bilateral breast enlargement"
                  },
                  {
                    "text": "Gynecomastia is benign, usually self-limitedFor persistent or symptomatic lesions, pharmacologic and surgical options are available",
                    "sub_points": [
                      "For persistent or symptomatic lesions, pharmacologic and surgical options are available"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Hormonal imbalance stimulates stromal and glandular tissue in gynecomastia"
                  },
                  {
                    "text": "Early changes(active or florid phase)Proliferation of periductal connective tissue, edema, inflammationEpithelial hyperplasia with tapering micropapillae",
                    "sub_points": [
                      "Proliferation of periductal connective tissue, edema, inflammation",
                      "Epithelial hyperplasia with tapering micropapillae"
                    ]
                  },
                  {
                    "text": "Later changes(inactive fibrous phase)Flattening of ductal epitheliumProgressive fibrosis of adjacent stroma",
                    "sub_points": [
                      "Flattening of ductal epithelium",
                      "Progressive fibrosis of adjacent stroma"
                    ]
                  },
                  {
                    "text": "The histologic appearance of gynecomastia is the same, regardless of underlying cause"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Ductal carcinoma in situ, micropapillary pattern"
                  },
                  {
                    "text": "Myofibroblastoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Nonneoplastic, diffuse or focal enlargement of male breast due to hyperplasia of both epithelium and stroma"
                  },
                  {
                    "text": "Similar findings in females are termed gynecomastia-like changes or gynecomastoid hyperplasia"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Endocrine Alterations and Pathogenesis": [
                  {
                    "text": "Gynecomastia develops due to alterations in free androgen:estrogen ratioAffected by serum levels of sex hormone-binding globulin",
                    "sub_points": [
                      "Affected by serum levels of sex hormone-binding globulin"
                    ]
                  },
                  {
                    "text": "Many causes are recognizedObesity resulting in enhanced peripheral aromatization of androgen to estrogenDue to displacement of estrogen from sex hormone-binding globulin or decreased metabolismDeclining androgen synthesis with ageMedications (~ 25% of cases of gynecomastia)Most common group are antiretroviral treatments (~ 25%)Anabolic steroid use in body buildersNonsteroidal antiandrogen monotherapy treatment in patients with prostate cancerMany others (including herbal medicines, lavender, tea tree oil, etc.)Digitalis, tricyclic antidepressants, amiodarone, simvastatin, atorvastatin, omeprazole, marijuana, topical agents, spironolactone, many antihypertensive medicationsLiver disease (cirrhosis, liver transplantation)Renal disease (chronic renal failure, dialysis, kidney transplantation)Hormone deficiency (hypogonadism, pituitary adenoma) and prostate cancerGonadal failure: Decreased testosteronePrimary gonadal failure includes Klinefelter syndrome (47,XXY; 50% of affected men develop gynecomastia), mumps orchitis, castrationSecondary gonadal failure includes hypothalamic and pituitary diseaseHormone-producing tumorsLeydig, Sertoli, and granulosa cell tumors",
                    "sub_points": [
                      "Obesity resulting in enhanced peripheral aromatization of androgen to estrogenDue to displacement of estrogen from sex hormone-binding globulin or decreased metabolism",
                      "Due to displacement of estrogen from sex hormone-binding globulin or decreased metabolism",
                      "Declining androgen synthesis with age",
                      "Medications (~ 25% of cases of gynecomastia)Most common group are antiretroviral treatments (~ 25%)Anabolic steroid use in body buildersNonsteroidal antiandrogen monotherapy treatment in patients with prostate cancerMany others (including herbal medicines, lavender, tea tree oil, etc.)Digitalis, tricyclic antidepressants, amiodarone, simvastatin, atorvastatin, omeprazole, marijuana, topical agents, spironolactone, many antihypertensive medications",
                      "Most common group are antiretroviral treatments (~ 25%)",
                      "Anabolic steroid use in body builders",
                      "Nonsteroidal antiandrogen monotherapy treatment in patients with prostate cancer",
                      "Many others (including herbal medicines, lavender, tea tree oil, etc.)Digitalis, tricyclic antidepressants, amiodarone, simvastatin, atorvastatin, omeprazole, marijuana, topical agents, spironolactone, many antihypertensive medications",
                      "Digitalis, tricyclic antidepressants, amiodarone, simvastatin, atorvastatin, omeprazole, marijuana, topical agents, spironolactone, many antihypertensive medications",
                      "Liver disease (cirrhosis, liver transplantation)",
                      "Renal disease (chronic renal failure, dialysis, kidney transplantation)",
                      "Hormone deficiency (hypogonadism, pituitary adenoma) and prostate cancer",
                      "Gonadal failure: Decreased testosteronePrimary gonadal failure includes Klinefelter syndrome (47,XXY; 50% of affected men develop gynecomastia), mumps orchitis, castrationSecondary gonadal failure includes hypothalamic and pituitary disease",
                      "Primary gonadal failure includes Klinefelter syndrome (47,XXY; 50% of affected men develop gynecomastia), mumps orchitis, castration",
                      "Secondary gonadal failure includes hypothalamic and pituitary disease",
                      "Hormone-producing tumorsLeydig, Sertoli, and granulosa cell tumors",
                      "Leydig, Sertoli, and granulosa cell tumors"
                    ]
                  },
                  {
                    "text": "In ≥ 25% of cases, no cause is identified"
                  },
                  {
                    "text": "Persons during female sex reassignment undergo estrogen treatment, which results in breast enlargementLobule formation is present in the majority, rather than gynecomastia",
                    "sub_points": [
                      "Lobule formation is present in the majority, rather than gynecomastia"
                    ]
                  }
                ],
                "Gynecomastia-Like Changes in Women (Gynecomastoid Hyperplasia)": [
                  {
                    "text": "Occurs in 4 main settingsPrepubertal breastLobules develop during menarche and pregnancyMammographic mass or asymmetric densityUsually younger women (19-42 years)Some have a history of infertility or amenorrheaRare cases associated with antiretroviral therapyBiopsies show a focal area of gynecomastia-like changesJuvenile hypertrophyOccurs at onset of puberty (typically 11-14 years of age)Characterized by massive bilateral breast enlargementGynecomastia-like changes are often presentPersons undergoing male sex reassignment treatment and surgeryMajority have undergone androgen treatmentMastectomies show changes similar to the fibrous stage of gynecomastia in ~ 40%",
                    "sub_points": [
                      "Prepubertal breastLobules develop during menarche and pregnancy",
                      "Lobules develop during menarche and pregnancy",
                      "Mammographic mass or asymmetric densityUsually younger women (19-42 years)Some have a history of infertility or amenorrheaRare cases associated with antiretroviral therapyBiopsies show a focal area of gynecomastia-like changes",
                      "Usually younger women (19-42 years)",
                      "Some have a history of infertility or amenorrhea",
                      "Rare cases associated with antiretroviral therapy",
                      "Biopsies show a focal area of gynecomastia-like changes",
                      "Juvenile hypertrophyOccurs at onset of puberty (typically 11-14 years of age)Characterized by massive bilateral breast enlargementGynecomastia-like changes are often present",
                      "Occurs at onset of puberty (typically 11-14 years of age)",
                      "Characterized by massive bilateral breast enlargement",
                      "Gynecomastia-like changes are often present",
                      "Persons undergoing male sex reassignment treatment and surgeryMajority have undergone androgen treatmentMastectomies show changes similar to the fibrous stage of gynecomastia in ~ 40%",
                      "Majority have undergone androgen treatment",
                      "Mastectomies show changes similar to the fibrous stage of gynecomastia in ~ 40%"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Gynecomastia is common finding in malesPalpable breast tissue can be detected in 36% of healthy young adult males57% of healthy older males and 70% of hospitalized older males show evidence of gynecomastia",
                    "sub_points": [
                      "Palpable breast tissue can be detected in 36% of healthy young adult males",
                      "57% of healthy older males and 70% of hospitalized older males show evidence of gynecomastia"
                    ]
                  },
                  {
                    "text": "3 peaks of gynecomastia occur during male lifespanInfancy: 60-90% of male infants show transient gynecomastia due to maternal estrogens; may produce milk (\"witch's milk\")Puberty: 48-64% of males develop gynecomastia (peak incidence: 13-14 years); > 1/2 have family history of gynecomastiaIncidence begins to diminish in late adolescenceOlder age: Highest prevalence seen in males between 50-80 years of age",
                    "sub_points": [
                      "Infancy: 60-90% of male infants show transient gynecomastia due to maternal estrogens; may produce milk (\"witch's milk\")",
                      "Puberty: 48-64% of males develop gynecomastia (peak incidence: 13-14 years); > 1/2 have family history of gynecomastia",
                      "Incidence begins to diminish in late adolescence",
                      "Older age: Highest prevalence seen in males between 50-80 years of age"
                    ]
                  },
                  {
                    "text": "Incidence of symptomatic gynecomastia is lower"
                  },
                  {
                    "text": "Majority of female patients are premenopausal"
                  }
                ],
                "Site": [
                  {
                    "text": "Subareolar and just superior to nipple in males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most often presents as a palpable, tender, firm, mobile, disc-shaped mound of tissue"
                  },
                  {
                    "text": "May be painful; most common in first 6 months; possibly associated with stromal edema"
                  },
                  {
                    "text": "May be unilateral or bilateral"
                  },
                  {
                    "text": "Can be localized or diffuse"
                  },
                  {
                    "text": "Pseudogynecomastia occurs when there is an increase in adipose tissue in the absence of breast epitheliumUsually in older obese males",
                    "sub_points": [
                      "Usually in older obese males"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Benign condition and is usually self-limited in malesOver time, fibrotic tissue gradually replaces symptomatic proliferation of glandular tissue, and tenderness resolvesIf regression occurs, no therapeutic intervention is necessaryWhen work-up is negative for other underlying pathology, reassurance and periodic follow-up are recommended",
                    "sub_points": [
                      "Over time, fibrotic tissue gradually replaces symptomatic proliferation of glandular tissue, and tenderness resolvesIf regression occurs, no therapeutic intervention is necessary",
                      "If regression occurs, no therapeutic intervention is necessary",
                      "When work-up is negative for other underlying pathology, reassurance and periodic follow-up are recommended"
                    ]
                  },
                  {
                    "text": "If gynecomastia persists and is associated with pain, pharmacologic and surgical options are available"
                  },
                  {
                    "text": "Gynecomastia associated with specific drug use can be treated by withdrawing the causative agentMay result in regression and decrease pain",
                    "sub_points": [
                      "May result in regression and decrease pain"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Simple surgical excision may be indicated for symptomatic lesions that are persistentCommonly used technique is subcutaneous mastectomySurgical treatment typically produces good cosmesis and is well tolerated",
                    "sub_points": [
                      "Commonly used technique is subcutaneous mastectomy",
                      "Surgical treatment typically produces good cosmesis and is well tolerated"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Symptomatic gynecomastia of recent onset may respond to antiestrogen therapyShort course of ER modifiers (tamoxifen or raloxifene)Reported to lead to reductions in pain and nodule size without long-term adverse effects",
                    "sub_points": [
                      "Short course of ER modifiers (tamoxifen or raloxifene)",
                      "Reported to lead to reductions in pain and nodule size without long-term adverse effects"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign condition: Only necessary to treat due to concerns with pain &/or cosmetic appearance"
                  },
                  {
                    "text": "Some studies show a small increased risk of developing breast cancer in males"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "3 patterns depending on duration and causeEarly (< 1 year)Discrete, subareolar mass extending posteriorly in fan-shaped patternLate (> 1 year)Flame-shaped central mass with linear projections into peripheral tissueDiffuse (related to exogenous estrogen treatment, e.g., males with prostate cancer or transgender females)Dense nodular parenchyma resembling female breastLacks Cooper ligaments",
                    "sub_points": [
                      "Early (< 1 year)Discrete, subareolar mass extending posteriorly in fan-shaped pattern",
                      "Discrete, subareolar mass extending posteriorly in fan-shaped pattern",
                      "Late (> 1 year)Flame-shaped central mass with linear projections into peripheral tissue",
                      "Flame-shaped central mass with linear projections into peripheral tissue",
                      "Diffuse (related to exogenous estrogen treatment, e.g., males with prostate cancer or transgender females)Dense nodular parenchyma resembling female breastLacks Cooper ligaments",
                      "Dense nodular parenchyma resembling female breast",
                      "Lacks Cooper ligaments"
                    ]
                  },
                  {
                    "text": "In females, gynecomastia-like changes usually present as asymmetry and, less commonly, as a mass with circumscribed margins"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Usually ill-defined, soft, rubbery to firm area of fibrous breast tissue; 2-6 cm in size"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Normal adult male breast tissue consists of nipple and rudimentary large ducts"
                  },
                  {
                    "text": "In gynecomastia, there is an increase in glandular elements, fibrous stroma, and adipose tissueEpithelial component consists primarily of branching ducts and terminal ductulesAbsent or minimal lobule formationReceptors for androgens and estrogens are present",
                    "sub_points": [
                      "Epithelial component consists primarily of branching ducts and terminal ductulesAbsent or minimal lobule formationReceptors for androgens and estrogens are present",
                      "Absent or minimal lobule formation",
                      "Receptors for androgens and estrogens are present"
                    ]
                  },
                  {
                    "text": "Histologic appearance changes over time"
                  },
                  {
                    "text": "Early changes(active florid phase)Increase in proliferation of periductal connective tissue, edema, and inflammationMyxoid stroma contains fibroblasts, myofibroblasts, lymphocytes, and plasma cellsPseudoangiomatous stromal hyperplasia (PASH) may be presentMultinucleated stromal cells as seen in female breasts have been reportedMitotic activity is variableEpithelial hyperplasia commonCan be florid with papillary tuftsPapillae have broad base and narrow, pinched apexNarrow-based papillae with bulging tips &/or complex architecture are not seenArise from a hyperplastic lining of the ductsAtypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), ductal carcinoma in situ (DCIS), and lobular carcinoma in situ (LCIS) are uncommon and should be diagnosed with cautionThe clinical significance of these findings, especially in young men, is unclear",
                    "sub_points": [
                      "Increase in proliferation of periductal connective tissue, edema, and inflammationMyxoid stroma contains fibroblasts, myofibroblasts, lymphocytes, and plasma cellsPseudoangiomatous stromal hyperplasia (PASH) may be presentMultinucleated stromal cells as seen in female breasts have been reportedMitotic activity is variable",
                      "Myxoid stroma contains fibroblasts, myofibroblasts, lymphocytes, and plasma cells",
                      "Pseudoangiomatous stromal hyperplasia (PASH) may be present",
                      "Multinucleated stromal cells as seen in female breasts have been reported",
                      "Mitotic activity is variable",
                      "Epithelial hyperplasia commonCan be florid with papillary tuftsPapillae have broad base and narrow, pinched apexNarrow-based papillae with bulging tips &/or complex architecture are not seenArise from a hyperplastic lining of the ductsAtypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), ductal carcinoma in situ (DCIS), and lobular carcinoma in situ (LCIS) are uncommon and should be diagnosed with cautionThe clinical significance of these findings, especially in young men, is unclear",
                      "Can be florid with papillary tufts",
                      "Papillae have broad base and narrow, pinched apexNarrow-based papillae with bulging tips &/or complex architecture are not seen",
                      "Narrow-based papillae with bulging tips &/or complex architecture are not seen",
                      "Arise from a hyperplastic lining of the ducts",
                      "Atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), ductal carcinoma in situ (DCIS), and lobular carcinoma in situ (LCIS) are uncommon and should be diagnosed with cautionThe clinical significance of these findings, especially in young men, is unclear",
                      "The clinical significance of these findings, especially in young men, is unclear"
                    ]
                  },
                  {
                    "text": "Later changes(inactive fibrous phase)Gradual resolution of inflammatory reactionFlattening of ductal epitheliumSquamous metaplasia may be presentProgressive fibrosis of adjacent stromal elementsHyalinized periductal stromaLesions may regress completely, or there may be a residual fibrous nodule",
                    "sub_points": [
                      "Gradual resolution of inflammatory reactionFlattening of ductal epitheliumSquamous metaplasia may be presentProgressive fibrosis of adjacent stromal elementsHyalinized periductal stroma",
                      "Flattening of ductal epithelium",
                      "Squamous metaplasia may be present",
                      "Progressive fibrosis of adjacent stromal elements",
                      "Hyalinized periductal stroma",
                      "Lesions may regress completely, or there may be a residual fibrous nodule"
                    ]
                  },
                  {
                    "text": "Histologic appearance of gynecomastia is the same, regardless of underlying cause"
                  },
                  {
                    "text": "Incidental carcinoma in subcutaneous mastectomies for gynecomastia is very unusual< 1% of males < 21 years~ 6% of mastectomies have lesions that would be classified as ADH if in a female breastThe significance of this finding as a risk factor for developing breast cancer is unknown for males",
                    "sub_points": [
                      "< 1% of males < 21 years",
                      "~ 6% of mastectomies have lesions that would be classified as ADH if in a female breastThe significance of this finding as a risk factor for developing breast cancer is unknown for males",
                      "The significance of this finding as a risk factor for developing breast cancer is unknown for males"
                    ]
                  },
                  {
                    "text": "Gynecomastia-like changes in womenBreast tissue in women can have the appearance of gynecomastia in menDiscrete or ill-defined mass or can be diffusely present",
                    "sub_points": [
                      "Breast tissue in women can have the appearance of gynecomastia in men",
                      "Discrete or ill-defined mass or can be diffusely present"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptorsEstrogen, progesterone, and androgen receptor expression is seen in virtually all cases of gynecomastiaPatients with Klinefelter syndrome and gynecomastia exhibit markedly elevated expression of ER and PR in ductal epitheliumCases of gynecomastia due to other causes do not demonstrate such significant elevation of these receptors",
                    "sub_points": [
                      "Estrogen, progesterone, and androgen receptor expression is seen in virtually all cases of gynecomastia",
                      "Patients with Klinefelter syndrome and gynecomastia exhibit markedly elevated expression of ER and PR in ductal epitheliumCases of gynecomastia due to other causes do not demonstrate such significant elevation of these receptors",
                      "Cases of gynecomastia due to other causes do not demonstrate such significant elevation of these receptors"
                    ]
                  },
                  {
                    "text": "Prostate-specific antigen (PSA)Gynecomastia induced by antiandrogen therapy may show strong focal PSA reactivity in ductal epitheliumShould not be misinterpreted as evidence of metastasis to breast from an underlying prostate cancerProstatic acid phosphatase is negative",
                    "sub_points": [
                      "Gynecomastia induced by antiandrogen therapy may show strong focal PSA reactivity in ductal epitheliumShould not be misinterpreted as evidence of metastasis to breast from an underlying prostate cancerProstatic acid phosphatase is negative",
                      "Should not be misinterpreted as evidence of metastasis to breast from an underlying prostate cancer",
                      "Prostatic acid phosphatase is negative"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ductal Carcinoma In Situ, Micropapillary Pattern": [
                  {
                    "text": "Micropapillae typically arise on a flat 2- to 3-cell layer lining involved ductsCells are monomorphic in appearancePapillae have a narrow base and bulbous, expanded tipsComplex architectural patterns may be present, such as rigid arches and cribriform spacesOften associated with calcifications and secretionsRarely associated with necrosis",
                    "sub_points": [
                      "Cells are monomorphic in appearance",
                      "Papillae have a narrow base and bulbous, expanded tips",
                      "Complex architectural patterns may be present, such as rigid arches and cribriform spaces",
                      "Often associated with calcifications and secretions",
                      "Rarely associated with necrosis"
                    ]
                  },
                  {
                    "text": "Low-grade epithelial atypia in males, particularly young males, should be interpreted with caution as the clinical significance is unclear"
                  },
                  {
                    "text": "These findings are more problematic when present in females in gynecomastia-like changesIHC studies for cytokeratin 5/6 and ER showing a heterogeneous pattern may help confirm changes as usual ductal hyperplasia",
                    "sub_points": [
                      "IHC studies for cytokeratin 5/6 and ER showing a heterogeneous pattern may help confirm changes as usual ductal hyperplasia"
                    ]
                  }
                ],
                "Myofibroblastoma": [
                  {
                    "text": "Clinical presentation (older man, palpable nodule) may overlap with gynecomastia"
                  },
                  {
                    "text": "Both myofibroblastoma and PASH (which is frequently present in gynecomastia) are proliferations of myofibroblasts"
                  },
                  {
                    "text": "Myofibroblastoma forms a discrete, circumscribed mass without epithelial elementsPASH can be ill-defined or form a mass but typically surrounds normal epithelial elements",
                    "sub_points": [
                      "PASH can be ill-defined or form a mass but typically surrounds normal epithelial elements"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mammary Hamartoma (Fibroadenolipoma)": {
            "name": "Mammary Hamartoma (Fibroadenolipoma)",
            "url": "https://app.pathprimer.com/document/3f3b8df9-73a8-4d80-9348-3692d9684526/lesson/dab5d75c-3874-464d-ad72-54d595a81e68",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mammary hamartoma (MH) (adenolipoma, fibroadenolipoma, adenolipofibroma, chondrolipoma)"
                  },
                  {
                    "text": "Well-circumscribed mass consisting of disorganized overgrowth of mature benign mammary tissues"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "1-5% of benign breast masses"
                  },
                  {
                    "text": "Does not progress to or increase risk of malignancy"
                  },
                  {
                    "text": "No treatment is necessary for majority of cases"
                  },
                  {
                    "text": "Surgical excision can be considered for symptomatic lesions or if imaging appearance is atypical"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Classic appearance has been described as breast within breast on mammography"
                  },
                  {
                    "text": "Well-circumscribed, encapsulated mass containing adipose tissue is most likely to be MH"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Stroma of MH can consist of a variety of different mesenchymal tissuesDifferent stromal elements can coexist in single lesionAdipose tissue is typically seen in variable amountsCases with prominent myoid changes are referred to as myoid hamartomas",
                    "sub_points": [
                      "Different stromal elements can coexist in single lesion",
                      "Adipose tissue is typically seen in variable amounts",
                      "Cases with prominent myoid changes are referred to as myoid hamartomas"
                    ]
                  },
                  {
                    "text": "Findings on core needle biopsy are not diagnostic, as findings are not specific for MHTypically shows mixture of benign breast tissue elementsCorrelation of benign breast tissue with characteristic imaging findings support diagnosis of MH",
                    "sub_points": [
                      "Typically shows mixture of benign breast tissue elements",
                      "Correlation of benign breast tissue with characteristic imaging findings support diagnosis of MH"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Fibroadenoma"
                  },
                  {
                    "text": "Phyllodes tumor"
                  },
                  {
                    "text": "Myofibroblastoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mammary hamartoma (MH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Adenolipoma, fibroadenolipoma, adenolipofibroma, chondrolipoma, myoid hamartoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "MH consists of a benign proliferation of stromal and epithelial cells that show normal differentiation but are disorganized with respect to architecture"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genomic Changes": [
                  {
                    "text": "Few MHs have been investigated for genomic changes"
                  },
                  {
                    "text": "1 mammary myoid hamartoma is reported to have a translocation ofHMGA2Other benign tumors also haveHMGA2rearrangements, such asLipomas, leiomyomas, myolipomas, and pulmonary hamartomas",
                    "sub_points": [
                      "Other benign tumors also haveHMGA2rearrangements, such asLipomas, leiomyomas, myolipomas, and pulmonary hamartomas",
                      "Lipomas, leiomyomas, myolipomas, and pulmonary hamartomas"
                    ]
                  },
                  {
                    "text": "2 MHs are reported to have chromosome 12 breakpointsSimilar breakpoints are also found in other benign tumors, such asLipomas, uterine leiomyomas, and pleomorphic adenomas of the salivary gland",
                    "sub_points": [
                      "Similar breakpoints are also found in other benign tumors, such asLipomas, uterine leiomyomas, and pleomorphic adenomas of the salivary gland",
                      "Lipomas, uterine leiomyomas, and pleomorphic adenomas of the salivary gland"
                    ]
                  },
                  {
                    "text": "MH, similar to these other benign lesions, is characterized by a benign proliferation of adipose tissue, smooth muscle/myofibroblasts, and stroma"
                  }
                ],
                "PTEN Hamartoma Tumor Syndromes": [
                  {
                    "text": "Cowden syndrome is caused by an autosomal dominant germline mutation in tumor suppressor genePTENPatients usually present in their 20s with macrocephaly, trichilemmomas, and papillomatous papulesLoss ofPTENincreases activation and signaling of PI3K/Akt/mTOR pathwayIncreases risk for developing benign and malignant tumors, including MHBreast, thyroid, skin, central nervous system, and GI tract are most frequently affectedHamartomas probably result from dysgenesis of mesenchymal cells, leading to abnormal growth resulting from altered cellular signaling50-75% of women develop benign breast lesionsMHs, papillomas, fibroadenomas (FAs), cysts, adenosis, epithelial hyperplasiaIncreased likelihood of multiple ipsilateral and contralateral lesionsLifetime risk of developing breast cancer is 25-50%",
                    "sub_points": [
                      "Patients usually present in their 20s with macrocephaly, trichilemmomas, and papillomatous papules",
                      "Loss ofPTENincreases activation and signaling of PI3K/Akt/mTOR pathway",
                      "Increases risk for developing benign and malignant tumors, including MHBreast, thyroid, skin, central nervous system, and GI tract are most frequently affectedHamartomas probably result from dysgenesis of mesenchymal cells, leading to abnormal growth resulting from altered cellular signaling",
                      "Breast, thyroid, skin, central nervous system, and GI tract are most frequently affected",
                      "Hamartomas probably result from dysgenesis of mesenchymal cells, leading to abnormal growth resulting from altered cellular signaling",
                      "50-75% of women develop benign breast lesionsMHs, papillomas, fibroadenomas (FAs), cysts, adenosis, epithelial hyperplasiaIncreased likelihood of multiple ipsilateral and contralateral lesions",
                      "MHs, papillomas, fibroadenomas (FAs), cysts, adenosis, epithelial hyperplasia",
                      "Increased likelihood of multiple ipsilateral and contralateral lesions",
                      "Lifetime risk of developing breast cancer is 25-50%"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 1-5% of benign breast tumorsMH may be underdiagnosed due to overlap with other benign lesions",
                    "sub_points": [
                      "MH may be underdiagnosed due to overlap with other benign lesions"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Mean: 45 years with wide range (20-80 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Almost exclusively seen in women"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Typical presentation is painless, soft to firm, palpable massClinical impression is often that of FA",
                    "sub_points": [
                      "Clinical impression is often that of FA"
                    ]
                  },
                  {
                    "text": "May be detected on screening mammogramMHs may be solitary or multipleMay occur in ectopic breast tissue in axilla or groin",
                    "sub_points": [
                      "MHs may be solitary or multiple",
                      "May occur in ectopic breast tissue in axilla or groin"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No treatment is necessary for most patientsTypical imaging appearance and benign breast tissue on core needle biopsy support diagnosis of MHSurgical excision may be considered for lesions with atypical appearance on imaging or symptomatic massesMHs are well demarcated and easily enucleatedSuspicious calcifications or a density with spiculated margins would be unusual for typical MHSome MHs can reach a large size, causing breast asymmetry and requiring surgical excision",
                    "sub_points": [
                      "Typical imaging appearance and benign breast tissue on core needle biopsy support diagnosis of MH",
                      "Surgical excision may be considered for lesions with atypical appearance on imaging or symptomatic massesMHs are well demarcated and easily enucleatedSuspicious calcifications or a density with spiculated margins would be unusual for typical MH",
                      "MHs are well demarcated and easily enucleated",
                      "Suspicious calcifications or a density with spiculated margins would be unusual for typical MH",
                      "Some MHs can reach a large size, causing breast asymmetry and requiring surgical excision"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MH is benign lesionNo increased risk for progression to malignancy",
                    "sub_points": [
                      "No increased risk for progression to malignancy"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Classic appearance is described as a breast within breast"
                  },
                  {
                    "text": "Ovoid to round or lobulated, well-circumscribed massMixed heterogeneous density with mottled centerDegree of mammographic density will depend upon fat component of lesionOther benign mass-forming breast lesions typically do not include fat",
                    "sub_points": [
                      "Mixed heterogeneous density with mottled center",
                      "Degree of mammographic density will depend upon fat component of lesion",
                      "Other benign mass-forming breast lesions typically do not include fat"
                    ]
                  },
                  {
                    "text": "A thin, smooth pseudocapsule with peripheral radiolucent zones is a common finding"
                  },
                  {
                    "text": "MH displaces adjacent normal breast tissue mammographically"
                  },
                  {
                    "text": "Benign-appearing calcifications may be present"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Well-encapsulated mass lesion with variably echogenic rimHeterogeneous internal echogenicityMixture of sonolucent fat and echogenic glandular elements",
                    "sub_points": [
                      "Heterogeneous internal echogenicityMixture of sonolucent fat and echogenic glandular elements",
                      "Mixture of sonolucent fat and echogenic glandular elements"
                    ]
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Well-encapsulated mass with dark, smooth, thin rimOvoid in shape with internal heterogenicityHeterogeneous gadolinium enhancement",
                    "sub_points": [
                      "Ovoid in shape with internal heterogenicity",
                      "Heterogeneous gadolinium enhancement"
                    ]
                  },
                  {
                    "text": "Internal fat intensity is demonstrated in most lesions"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Variable size range from 1 cm to > 14 cmTypically 3-6 cm at diagnosis",
                    "sub_points": [
                      "Typically 3-6 cm at diagnosis"
                    ]
                  },
                  {
                    "text": "Gross examination shows nodular masses that are rounded and possess smooth pushing contoursSome lesions are shelled out or marginally excised at time of surgery because of encapsulated nature of MHsMay be difficult to appreciate mass if no surrounding tissue is presentSoft to firm on palpationCut surface shows variable fatty areas within fibrotic stroma, tan-white to yellow in colorClefts and fronds within lesion are typically not present",
                    "sub_points": [
                      "Some lesions are shelled out or marginally excised at time of surgery because of encapsulated nature of MHsMay be difficult to appreciate mass if no surrounding tissue is present",
                      "May be difficult to appreciate mass if no surrounding tissue is present",
                      "Soft to firm on palpation",
                      "Cut surface shows variable fatty areas within fibrotic stroma, tan-white to yellow in color",
                      "Clefts and fronds within lesion are typically not present"
                    ]
                  },
                  {
                    "text": "Macroscopic nodules are well demarcated from adjacent breast tissue"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "HMGA2translocations1 myoid hamartoma is reported to have a fusion ofHMGA2(12q14) (high mobility group AT-hook 2) with a sequence from 5p13RT-PCR and Sanger sequencing verified theHMGA2fusion transcript",
                    "sub_points": [
                      "1 myoid hamartoma is reported to have a fusion ofHMGA2(12q14) (high mobility group AT-hook 2) with a sequence from 5p13RT-PCR and Sanger sequencing verified theHMGA2fusion transcript",
                      "RT-PCR and Sanger sequencing verified theHMGA2fusion transcript"
                    ]
                  },
                  {
                    "text": "Chromosome 12 breakpoints2 MHs reported to have chromosome 12 breakpointsChromosome 12 translocation breakpoints map within a \"multiple aberration region\" found in multiple tumorsGenes involved are under investigation",
                    "sub_points": [
                      "2 MHs reported to have chromosome 12 breakpointsChromosome 12 translocation breakpoints map within a \"multiple aberration region\" found in multiple tumorsGenes involved are under investigation",
                      "Chromosome 12 translocation breakpoints map within a \"multiple aberration region\" found in multiple tumors",
                      "Genes involved are under investigation"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "MHs are lobulated and composed of a mixture of glandular structures and different stromal elements in varying proportionsDisproportionate growth of these tissue components will show disorganization of mature mammary tissuesStromal component may spread around and through lobular structures",
                    "sub_points": [
                      "Disproportionate growth of these tissue components will show disorganization of mature mammary tissues",
                      "Stromal component may spread around and through lobular structures"
                    ]
                  },
                  {
                    "text": "Stromal componentsStroma elements consist of a variety of different mesenchymal tissuesOften several different types seen in single lesionVarying degrees of dense hyalinized stroma are seen between individual lobules in most casesFibrotic stroma may show areas of pseudoangiomatous stromal hyperplasia due to prominent myofibroblastsSome lesions will show predominance of dense fibrotic stromaVariable adipose tissue is noted within stromaAdipose tissue can account for 5-90% of stromal areaAdipocytes may occur singly and be encased by dense fibrous stroma (encapsulated fat)Less common stromal changes can occurCases with prominent myoid changes have been referred to as myoid or muscular hamartomasMorphologically, the stroma has the appearance of smooth muscleCells are positive for smooth muscle actin, desmin, and other muscle markersMay be myofibroblastsBizarre stromal giant cellsOften multinucleated, degenerative in appearanceShould not be considered evidence of malignancyFoci of cartilaginous or osseous metaplasiaLesions with predominant cartilaginous metaplasia may be termed chondrolipomas",
                    "sub_points": [
                      "Stroma elements consist of a variety of different mesenchymal tissuesOften several different types seen in single lesion",
                      "Often several different types seen in single lesion",
                      "Varying degrees of dense hyalinized stroma are seen between individual lobules in most casesFibrotic stroma may show areas of pseudoangiomatous stromal hyperplasia due to prominent myofibroblastsSome lesions will show predominance of dense fibrotic stroma",
                      "Fibrotic stroma may show areas of pseudoangiomatous stromal hyperplasia due to prominent myofibroblasts",
                      "Some lesions will show predominance of dense fibrotic stroma",
                      "Variable adipose tissue is noted within stromaAdipose tissue can account for 5-90% of stromal areaAdipocytes may occur singly and be encased by dense fibrous stroma (encapsulated fat)",
                      "Adipose tissue can account for 5-90% of stromal area",
                      "Adipocytes may occur singly and be encased by dense fibrous stroma (encapsulated fat)",
                      "Less common stromal changes can occurCases with prominent myoid changes have been referred to as myoid or muscular hamartomasMorphologically, the stroma has the appearance of smooth muscleCells are positive for smooth muscle actin, desmin, and other muscle markersMay be myofibroblastsBizarre stromal giant cellsOften multinucleated, degenerative in appearanceShould not be considered evidence of malignancyFoci of cartilaginous or osseous metaplasiaLesions with predominant cartilaginous metaplasia may be termed chondrolipomas",
                      "Cases with prominent myoid changes have been referred to as myoid or muscular hamartomasMorphologically, the stroma has the appearance of smooth muscleCells are positive for smooth muscle actin, desmin, and other muscle markersMay be myofibroblasts",
                      "Morphologically, the stroma has the appearance of smooth muscle",
                      "Cells are positive for smooth muscle actin, desmin, and other muscle markers",
                      "May be myofibroblasts",
                      "Bizarre stromal giant cellsOften multinucleated, degenerative in appearanceShould not be considered evidence of malignancy",
                      "Often multinucleated, degenerative in appearance",
                      "Should not be considered evidence of malignancy",
                      "Foci of cartilaginous or osseous metaplasiaLesions with predominant cartilaginous metaplasia may be termed chondrolipomas",
                      "Lesions with predominant cartilaginous metaplasia may be termed chondrolipomas"
                    ]
                  },
                  {
                    "text": "Epithelial componentsThe glandular component can exhibit a range of different appearancesTypical lesions include normal-appearing terminal duct lobular unitsHave normal luminal and myoepithelial layersMild epithelial hyperplasia without atypia may be seen but is uncommonRare lesions have been reported to contain foci of atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), or invasive carcinomaSome lesions show cystic changes, apocrine metaplasia, and adenosis",
                    "sub_points": [
                      "The glandular component can exhibit a range of different appearancesTypical lesions include normal-appearing terminal duct lobular unitsHave normal luminal and myoepithelial layers",
                      "Typical lesions include normal-appearing terminal duct lobular units",
                      "Have normal luminal and myoepithelial layers",
                      "Mild epithelial hyperplasia without atypia may be seen but is uncommonRare lesions have been reported to contain foci of atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), or invasive carcinoma",
                      "Rare lesions have been reported to contain foci of atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), or invasive carcinoma",
                      "Some lesions show cystic changes, apocrine metaplasia, and adenosis"
                    ]
                  },
                  {
                    "text": "Core needle biopsyMH typically cannot be diagnosed on core needle biopsyThere are no specific features to identify breast tissue as being in MHThe presence of fibrous tissue within lobules, or admixed fibrous tissue, muscle/myoid change, and fat in stroma, should raise the possibility of MHBenign breast tissue on core needle biopsy correlated with an imaging finding of a lesion with circumscribed borders containing adipose tissue can support a diagnosis of MH",
                    "sub_points": [
                      "MH typically cannot be diagnosed on core needle biopsyThere are no specific features to identify breast tissue as being in MHThe presence of fibrous tissue within lobules, or admixed fibrous tissue, muscle/myoid change, and fat in stroma, should raise the possibility of MH",
                      "There are no specific features to identify breast tissue as being in MH",
                      "The presence of fibrous tissue within lobules, or admixed fibrous tissue, muscle/myoid change, and fat in stroma, should raise the possibility of MH",
                      "Benign breast tissue on core needle biopsy correlated with an imaging finding of a lesion with circumscribed borders containing adipose tissue can support a diagnosis of MH"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptorsER and PR expression in epithelial cells is similar to that of normal breast tissue",
                    "sub_points": [
                      "ER and PR expression in epithelial cells is similar to that of normal breast tissue"
                    ]
                  },
                  {
                    "text": "Muscle markers: Smooth muscle actin, desmin, othersPositive in stromal cells with smooth muscle appearance",
                    "sub_points": [
                      "Positive in stromal cells with smooth muscle appearance"
                    ]
                  },
                  {
                    "text": "Myoepithelial cell markers: p63, CK5/6, calponin, muscle-specific actinPositive in myoepithelial cells associated with epithelium",
                    "sub_points": [
                      "Positive in myoepithelial cells associated with epithelium"
                    ]
                  },
                  {
                    "text": "S100: Positive in areas of cartilaginous metaplasia and adipose tissue"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Fibroadenoma (FA)": [
                  {
                    "text": "FAs are proliferations of stromal intralobular fibroblasts that may be hyperplastic or neoplasticFAs typically cause distortion and elongation of epithelial component, resulting in cleftsIn MH, there is a more varied appearance of epithelial elements, which are irregularly dispersed in stroma",
                    "sub_points": [
                      "FAs typically cause distortion and elongation of epithelial component, resulting in cleftsIn MH, there is a more varied appearance of epithelial elements, which are irregularly dispersed in stroma",
                      "In MH, there is a more varied appearance of epithelial elements, which are irregularly dispersed in stroma"
                    ]
                  },
                  {
                    "text": "FAs only rarely include adipose tissueWhen present, the area should be evaluated carefully to exclude an infiltrative pattern in adipose tissue or heterologous well-differentiated liposarcomaMH may be softer than FA, depending on amount of adipose tissue",
                    "sub_points": [
                      "When present, the area should be evaluated carefully to exclude an infiltrative pattern in adipose tissue or heterologous well-differentiated liposarcoma",
                      "MH may be softer than FA, depending on amount of adipose tissue"
                    ]
                  }
                ],
                "Phyllodes Tumor (PT)": [
                  {
                    "text": "PTs are clonal neoplastic proliferations"
                  },
                  {
                    "text": "The stromal component of PTs is usually distorted and elongated by tumor cells, resulting in clefts"
                  },
                  {
                    "text": "Benign adipose tissue may be invaded by PT"
                  },
                  {
                    "text": "PT can include liposarcoma as a heterologous elementStromal adipose tissue component of MH will appear mature and benign",
                    "sub_points": [
                      "Stromal adipose tissue component of MH will appear mature and benign"
                    ]
                  },
                  {
                    "text": "Nuclear atypia and mitoses are usually present in PTMH is benign lesion and should not show these features",
                    "sub_points": [
                      "MH is benign lesion and should not show these features"
                    ]
                  }
                ],
                "Myofibroblastoma (MYB)": [
                  {
                    "text": "Like MH, MYB can consist of combinations of myofibroblasts, adipose tissue, and cartilageHowever, epithelial elements should be absent or, if present, only focally present at the periphery",
                    "sub_points": [
                      "However, epithelial elements should be absent or, if present, only focally present at the periphery"
                    ]
                  },
                  {
                    "text": "MYB usually has a prominent myofibroblastic component that distinguishes it histologically from MH"
                  },
                  {
                    "text": "Lesions with prominent components of adipose tissue and cartilage are termed chrondrolipomasAt least some chondrolipomas have features supporting that they are MYBsHormone receptor positivity in stromal cells, loss of Rb",
                    "sub_points": [
                      "At least some chondrolipomas have features supporting that they are MYBsHormone receptor positivity in stromal cells, loss of Rb",
                      "Hormone receptor positivity in stromal cells, loss of Rb"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Core needle biopsy usually shows nonspecific mixture of benign breast tissue elements"
                  },
                  {
                    "text": "Correlation with imaging findings is often necessary for definitive diagnosis"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Hamartomas should be correlated with clinical or imaging findings when reported"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Benign Epithelial Lesions": {
        "name": "Benign Epithelial Lesions",
        "url": "https://app.pathprimer.com/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
        "topics": {
          "Nonproliferative Changes": {
            "name": "Nonproliferative Changes",
            "url": "https://app.pathprimer.com/document/a4bbef58-f06f-4226-8795-10ecfbfb6ca5/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Benign breast disease (BBD) with nonproliferative changes includes a number of commonly encountered pathologic findingsCystsApocrine metaplasiaCalcificationsStromal fibrosisAdenosis",
                    "sub_points": [
                      "Cysts",
                      "Apocrine metaplasia",
                      "Calcifications",
                      "Stromal fibrosis",
                      "Adenosis"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "May be related to excess hormonal stimulation &/or hypersensitivity of breast tissue"
                  },
                  {
                    "text": "Clinical factors are associated with an increased risk of BBDLate age at menopause, estrogen replacement therapy, nulliparity, low body mass index, and family history of breast cancer",
                    "sub_points": [
                      "Late age at menopause, estrogen replacement therapy, nulliparity, low body mass index, and family history of breast cancer"
                    ]
                  },
                  {
                    "text": "Tamoxifen, when used for breast cancer prevention, is associated with a reduction in prevalence of BBD"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Frequent findings: Evident in up to 50-60% of female patients of reproductive age"
                  },
                  {
                    "text": "Nonproliferative changes do not increase cancer risk"
                  },
                  {
                    "text": "Often presents as palpable masses (cysts) or mammographic lesions (densities or calcifications)Only importance is to exclude carcinoma",
                    "sub_points": [
                      "Only importance is to exclude carcinoma"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Includes cysts, apocrine metaplasia, fibrosis, and adenosisChanges are usually bilateral and multifocal",
                    "sub_points": [
                      "Changes are usually bilateral and multifocal"
                    ]
                  },
                  {
                    "text": "Cysts may rupture contents into surrounding stroma inciting inflammatory response"
                  },
                  {
                    "text": "Number of epithelial cells are not increased or only mildly increased"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Proliferative breast disease"
                  },
                  {
                    "text": "Atypical hyperplasia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Fibrocystic breast disease"
                  },
                  {
                    "text": "Fibrocystic changes (FCCs)"
                  },
                  {
                    "text": "Benign breast conditions"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Commonly encountered constellation of benign breast changes, including cysts, apocrine metaplasia, stromal fibrosis, and adenosis"
                  },
                  {
                    "text": "Does not increase risk of subsequent carcinoma"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Benign breast disease (BBD) includes nonproliferative changes, proliferative changes, and atypical hyperplasia"
                  },
                  {
                    "text": "Nonproliferative changes are the most common (~ 70%) and are defined as those not increasing the risk of subsequent breast carcinoma (BC)Includes cysts, apocrine metaplasia, stromal fibrosis, and adenosis",
                    "sub_points": [
                      "Includes cysts, apocrine metaplasia, stromal fibrosis, and adenosis"
                    ]
                  }
                ],
                "Fibrocystic Change (FCC)": [
                  {
                    "text": "This is a nonspecific term that can be used to describe findings on clinical breast examination, breast imaging, or microscopic evaluationClinically, FCC can refer to a \"lumpy, bumpy\" breastBy imaging, FCC can be used to refer to nonspecific densities and calcificationsMicroscopically, FCC may be used for lesions included, or not included, in the definition of nonproliferative BBD",
                    "sub_points": [
                      "Clinically, FCC can refer to a \"lumpy, bumpy\" breast",
                      "By imaging, FCC can be used to refer to nonspecific densities and calcifications",
                      "Microscopically, FCC may be used for lesions included, or not included, in the definition of nonproliferative BBD"
                    ]
                  },
                  {
                    "text": "It is more useful to report the specific types of lesions that are present rather than to use FCC as a description"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hormonal Effects": [
                  {
                    "text": "Responsiveness of breast tissues to monthly changes of estrogen and progesterone levels plays an important role in the pathogenesis of BBDMay be related to excess hormonal stimulation &/or hypersensitivity of breast tissue",
                    "sub_points": [
                      "May be related to excess hormonal stimulation &/or hypersensitivity of breast tissue"
                    ]
                  },
                  {
                    "text": "Clinical factors are associated with an increased risk of BBDLate age at menopause, estrogen replacement therapy, nulliparity, low body mass index, and family history of BC",
                    "sub_points": [
                      "Late age at menopause, estrogen replacement therapy, nulliparity, low body mass index, and family history of BC"
                    ]
                  },
                  {
                    "text": "Clinical factors are associated with a decreased risk of BBDHigh parity, oral contraceptives, physical activityTamoxifen, when used for BC prevention, is associated with a 28% reduction in the prevalence of BBD (relative risk is 0.72)",
                    "sub_points": [
                      "High parity, oral contraceptives, physical activity",
                      "Tamoxifen, when used for BC prevention, is associated with a 28% reduction in the prevalence of BBD (relative risk is 0.72)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very commonSome elements of BBD are evident in up to 50-60% of female patients of reproductive age",
                    "sub_points": [
                      "Some elements of BBD are evident in up to 50-60% of female patients of reproductive age"
                    ]
                  },
                  {
                    "text": "Increased incidence of BBD is seen in postmenopausal women receiving estrogens ± progestins for > 8 years (relative risk increased by 1.70)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Mammographic screeningMay present with densities or calcifications",
                    "sub_points": [
                      "May present with densities or calcifications"
                    ]
                  },
                  {
                    "text": "Palpable lumpsDiffuse symmetrical lumpiness is commonly found on physical examinationSize and symptoms may fluctuate over the course of the menstrual cycle",
                    "sub_points": [
                      "Diffuse symmetrical lumpiness is commonly found on physical examination",
                      "Size and symptoms may fluctuate over the course of the menstrual cycle"
                    ]
                  },
                  {
                    "text": "Cyclic breast pain may occur during late luteal phase of menstrual cycle"
                  }
                ],
                "Natural History": [
                  {
                    "text": "BBD with nonproliferative changes does not increase risk of BC"
                  },
                  {
                    "text": "Some prefer using condition or changes rather than disease, as described breast lesions are probably within the spectrum of normality"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "MassesMay be circumscribed or ill definedMay also be associated with calcifications",
                    "sub_points": [
                      "May be circumscribed or ill definedMay also be associated with calcifications",
                      "May also be associated with calcifications"
                    ]
                  },
                  {
                    "text": "Calcifications: Usually clustered"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "BBD has wide spectrum of morphologic and kinetic features on MRTypically presents as mass or nonmass-like regional enhancement with benign kinetics",
                    "sub_points": [
                      "Typically presents as mass or nonmass-like regional enhancement with benign kinetics"
                    ]
                  },
                  {
                    "text": "MR should preferably be performed in first 1/2 of menstrual cycle to minimize false-positive findings"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Cut surface has whitish, firm, rubbery appearance"
                  },
                  {
                    "text": "Unopened, larger, blue dome cysts contain turbid fluid that is brown or blue in color"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "BBD includes cysts, apocrine metaplasia, fibrosis, and adenosisChanges are usually bilateral and multifocal",
                    "sub_points": [
                      "Changes are usually bilateral and multifocal"
                    ]
                  },
                  {
                    "text": "FibrosisStromal fibrosis contributes to palpable densities on breast exam and increased density on imagingDue to repeated cyst rupture, inflammation, and scarringMust be distinguished from normal dense breast tissue in young women not associated with cysts and inflammation",
                    "sub_points": [
                      "Stromal fibrosis contributes to palpable densities on breast exam and increased density on imaging",
                      "Due to repeated cyst rupture, inflammation, and scarring",
                      "Must be distinguished from normal dense breast tissue in young women not associated with cysts and inflammation"
                    ]
                  },
                  {
                    "text": "Apocrine metaplasiaCells have abundant granular, eosinophilic cytoplasm; may be vacuolatedResembles normal apocrine sweat glandsEnlarged, round nuclei contain prominent nucleoliSome cells are tetraploidModerate degrees of nuclear variation may be present but not true cytologic atypiaApocrine cells are ER(-)/PR(-) and AR(+)/GCDFP-15(+)May show membrane enhancement for HER2Architecture can be flat or papillaryApocrine changes can be seen in both benign and malignant breast lesionsLesions with apocrine change are difficult to evaluate, as cells are monomorphic due to metaplasia rather than neoplasiaFocal apocrine metaplasia is more common in benign lesionsMalignancies with apocrine features show this change in all tumor cellsCytologic atypia, necrosis, mitoses, or complex architecture raise the possibility of an apocrine neoplasm",
                    "sub_points": [
                      "Cells have abundant granular, eosinophilic cytoplasm; may be vacuolatedResembles normal apocrine sweat glands",
                      "Resembles normal apocrine sweat glands",
                      "Enlarged, round nuclei contain prominent nucleoliSome cells are tetraploidModerate degrees of nuclear variation may be present but not true cytologic atypia",
                      "Some cells are tetraploid",
                      "Moderate degrees of nuclear variation may be present but not true cytologic atypia",
                      "Apocrine cells are ER(-)/PR(-) and AR(+)/GCDFP-15(+)May show membrane enhancement for HER2",
                      "May show membrane enhancement for HER2",
                      "Architecture can be flat or papillary",
                      "Apocrine changes can be seen in both benign and malignant breast lesionsLesions with apocrine change are difficult to evaluate, as cells are monomorphic due to metaplasia rather than neoplasiaFocal apocrine metaplasia is more common in benign lesionsMalignancies with apocrine features show this change in all tumor cellsCytologic atypia, necrosis, mitoses, or complex architecture raise the possibility of an apocrine neoplasm",
                      "Lesions with apocrine change are difficult to evaluate, as cells are monomorphic due to metaplasia rather than neoplasia",
                      "Focal apocrine metaplasia is more common in benign lesionsMalignancies with apocrine features show this change in all tumor cells",
                      "Malignancies with apocrine features show this change in all tumor cells",
                      "Cytologic atypia, necrosis, mitoses, or complex architecture raise the possibility of an apocrine neoplasm"
                    ]
                  },
                  {
                    "text": "CystsCommon findingMay be due to unfolding of lobulesMay be microscopic or grossly visibleCan present clinically as a large, firm, palpable massClusters of cysts can form lobulated massesTypically lined by a single layer of luminal epithelial cellsApocrine cells (type I cysts)Flattened luminal cells (type II cysts)Mild epithelial hyperplasia may be presentContents variableClear fluidBlood and fibrin: May appear as solid mass on imagingSecretory debris: Often associated with calcificationsMucin: Associated with mucocele formationCysts may rupture contents into surrounding stromaIncites chronic inflammatory reaction to secretory materialOchrocytes are histiocytes with brown, granular cytoplasm due to phagocytosis of lipidsMay be associated with fat necrosis and fibrosisFibrosis can form irregular mass by palpation or imagingCalcifications may be found in surrounding stroma associated with giant cell response",
                    "sub_points": [
                      "Common findingMay be due to unfolding of lobules",
                      "May be due to unfolding of lobules",
                      "May be microscopic or grossly visibleCan present clinically as a large, firm, palpable massClusters of cysts can form lobulated masses",
                      "Can present clinically as a large, firm, palpable mass",
                      "Clusters of cysts can form lobulated masses",
                      "Typically lined by a single layer of luminal epithelial cellsApocrine cells (type I cysts)Flattened luminal cells (type II cysts)Mild epithelial hyperplasia may be present",
                      "Apocrine cells (type I cysts)",
                      "Flattened luminal cells (type II cysts)",
                      "Mild epithelial hyperplasia may be present",
                      "Contents variableClear fluidBlood and fibrin: May appear as solid mass on imagingSecretory debris: Often associated with calcificationsMucin: Associated with mucocele formation",
                      "Clear fluid",
                      "Blood and fibrin: May appear as solid mass on imaging",
                      "Secretory debris: Often associated with calcifications",
                      "Mucin: Associated with mucocele formation",
                      "Cysts may rupture contents into surrounding stromaIncites chronic inflammatory reaction to secretory materialOchrocytes are histiocytes with brown, granular cytoplasm due to phagocytosis of lipidsMay be associated with fat necrosis and fibrosisFibrosis can form irregular mass by palpation or imagingCalcifications may be found in surrounding stroma associated with giant cell response",
                      "Incites chronic inflammatory reaction to secretory material",
                      "Ochrocytes are histiocytes with brown, granular cytoplasm due to phagocytosis of lipids",
                      "May be associated with fat necrosis and fibrosis",
                      "Fibrosis can form irregular mass by palpation or imaging",
                      "Calcifications may be found in surrounding stroma associated with giant cell response"
                    ]
                  },
                  {
                    "text": "CalcificationsOnly calcifications with suspicious imaging features (e.g., numerous, clustered, irregular, or linear and branching) are associated with malignancyMammography detects calcifications 50-100 μm in size (0.05-0.10 mm) or multiple clustered, overlapping calcificationsSmaller calcifications not related to the mammographic calcifications are seen as incidental microscopic findingsIt is imperative pathologists examine the tissue harboring the suspicious mammographic calcificationsOften difficult to correlate calcifications seen microscopically with those seen by imaging according to number or sizeImaging visualizes calcifications in 3D; tissue sections on slides are essentially 2DThus, it is essential to be certain that the tissue harboring the radiologic calcifications has been examined and not rely on number or sizeCalcifications may be calcium phosphate or calcium oxalateCalcium phosphate appears as granular, dark purple crystalsMay be associated with secretory and necrotic debris, mucin, or dense, collagenized stroma in fibroadenomasDo not polarizeCalcium oxalate crystals are flat rhomboid- or needle-shaped crystalsTranslucent or yellowMore easily seen under polarized lightOnly found in association with cysts with apocrine metaplasia; if there has been cyst rupture, crystals may be present in surrounding stromaNever associated with malignancyMilk of calcium is a radiology term used to describe calcifications that change in relative position in 2 different mammographic viewsOn a horizontal view [cranial-caudal (CC)], cysts are flattened, and calcifications are not influenced by gravityOn upright views [medial-lateral-oblique (MLO) or true lateral], calcifications appear to line bottom of cysts under influence of gravity in a tea cup patternCorrelates with calcifications in large cysts that layer out on bottom of cystSpecial stains can be used to identify calcium depositsIf calcifications are not evident by light microscopy, they are very small and unlikely to correlate with mammographic calcificationsTherefore, special stains are rarely useful in practiceIf calcifications cannot be identified, the following should be consideredCalcifications not biopsied by radiologist or surgeonAll specimens removed to evaluate calcifications should be radiographed to ensure calcifications are presentTissue with calcifications not sampled by pathologistTissue and paraffin blocks can be radiographed to identify location of calcificationsCalcifications present but deeper in blockDeeper levels can be obtained until calcifications are seenCalcifications dissolved: Can occur if tissue is left in formalin for multiple daysCalcifications lost from small specimens, particularly core needle biopsiesIt is helpful for radiologists to wrap cores in paper and place them in a cassette prior to placing in formalinThis practice also ensures that all tissue removed by the radiologist is examined microscopically by the pathologistCalcifications not present: Other radiodense materials can mimic calcificationsMetallic debris from prior surgery or traumaGold treatments for rheumatoid arthritisHeterotopic boneSome types of pigments used in tattoosCalcifications dislodged from tissue during preparation of slidesUsually occurs with very large calcificationsOnly remnants of calcification may remainTrack may be seen in tissue where calcification was dragged by microtome bladeUsually occurs when surrounding tissue is adipose tissue",
                    "sub_points": [
                      "Only calcifications with suspicious imaging features (e.g., numerous, clustered, irregular, or linear and branching) are associated with malignancyMammography detects calcifications 50-100 μm in size (0.05-0.10 mm) or multiple clustered, overlapping calcificationsSmaller calcifications not related to the mammographic calcifications are seen as incidental microscopic findingsIt is imperative pathologists examine the tissue harboring the suspicious mammographic calcifications",
                      "Mammography detects calcifications 50-100 μm in size (0.05-0.10 mm) or multiple clustered, overlapping calcificationsSmaller calcifications not related to the mammographic calcifications are seen as incidental microscopic findings",
                      "Smaller calcifications not related to the mammographic calcifications are seen as incidental microscopic findings",
                      "It is imperative pathologists examine the tissue harboring the suspicious mammographic calcifications",
                      "Often difficult to correlate calcifications seen microscopically with those seen by imaging according to number or sizeImaging visualizes calcifications in 3D; tissue sections on slides are essentially 2DThus, it is essential to be certain that the tissue harboring the radiologic calcifications has been examined and not rely on number or size",
                      "Imaging visualizes calcifications in 3D; tissue sections on slides are essentially 2D",
                      "Thus, it is essential to be certain that the tissue harboring the radiologic calcifications has been examined and not rely on number or size",
                      "Calcifications may be calcium phosphate or calcium oxalateCalcium phosphate appears as granular, dark purple crystalsMay be associated with secretory and necrotic debris, mucin, or dense, collagenized stroma in fibroadenomasDo not polarizeCalcium oxalate crystals are flat rhomboid- or needle-shaped crystalsTranslucent or yellowMore easily seen under polarized lightOnly found in association with cysts with apocrine metaplasia; if there has been cyst rupture, crystals may be present in surrounding stromaNever associated with malignancy",
                      "Calcium phosphate appears as granular, dark purple crystalsMay be associated with secretory and necrotic debris, mucin, or dense, collagenized stroma in fibroadenomasDo not polarize",
                      "May be associated with secretory and necrotic debris, mucin, or dense, collagenized stroma in fibroadenomas",
                      "Do not polarize",
                      "Calcium oxalate crystals are flat rhomboid- or needle-shaped crystalsTranslucent or yellowMore easily seen under polarized lightOnly found in association with cysts with apocrine metaplasia; if there has been cyst rupture, crystals may be present in surrounding stromaNever associated with malignancy",
                      "Translucent or yellow",
                      "More easily seen under polarized light",
                      "Only found in association with cysts with apocrine metaplasia; if there has been cyst rupture, crystals may be present in surrounding stroma",
                      "Never associated with malignancy",
                      "Milk of calcium is a radiology term used to describe calcifications that change in relative position in 2 different mammographic viewsOn a horizontal view [cranial-caudal (CC)], cysts are flattened, and calcifications are not influenced by gravityOn upright views [medial-lateral-oblique (MLO) or true lateral], calcifications appear to line bottom of cysts under influence of gravity in a tea cup patternCorrelates with calcifications in large cysts that layer out on bottom of cyst",
                      "On a horizontal view [cranial-caudal (CC)], cysts are flattened, and calcifications are not influenced by gravity",
                      "On upright views [medial-lateral-oblique (MLO) or true lateral], calcifications appear to line bottom of cysts under influence of gravity in a tea cup pattern",
                      "Correlates with calcifications in large cysts that layer out on bottom of cyst",
                      "Special stains can be used to identify calcium depositsIf calcifications are not evident by light microscopy, they are very small and unlikely to correlate with mammographic calcificationsTherefore, special stains are rarely useful in practice",
                      "If calcifications are not evident by light microscopy, they are very small and unlikely to correlate with mammographic calcifications",
                      "Therefore, special stains are rarely useful in practice",
                      "If calcifications cannot be identified, the following should be consideredCalcifications not biopsied by radiologist or surgeonAll specimens removed to evaluate calcifications should be radiographed to ensure calcifications are presentTissue with calcifications not sampled by pathologistTissue and paraffin blocks can be radiographed to identify location of calcificationsCalcifications present but deeper in blockDeeper levels can be obtained until calcifications are seenCalcifications dissolved: Can occur if tissue is left in formalin for multiple daysCalcifications lost from small specimens, particularly core needle biopsiesIt is helpful for radiologists to wrap cores in paper and place them in a cassette prior to placing in formalinThis practice also ensures that all tissue removed by the radiologist is examined microscopically by the pathologistCalcifications not present: Other radiodense materials can mimic calcificationsMetallic debris from prior surgery or traumaGold treatments for rheumatoid arthritisHeterotopic boneSome types of pigments used in tattoosCalcifications dislodged from tissue during preparation of slidesUsually occurs with very large calcificationsOnly remnants of calcification may remainTrack may be seen in tissue where calcification was dragged by microtome bladeUsually occurs when surrounding tissue is adipose tissue",
                      "Calcifications not biopsied by radiologist or surgeonAll specimens removed to evaluate calcifications should be radiographed to ensure calcifications are present",
                      "All specimens removed to evaluate calcifications should be radiographed to ensure calcifications are present",
                      "Tissue with calcifications not sampled by pathologistTissue and paraffin blocks can be radiographed to identify location of calcifications",
                      "Tissue and paraffin blocks can be radiographed to identify location of calcifications",
                      "Calcifications present but deeper in blockDeeper levels can be obtained until calcifications are seen",
                      "Deeper levels can be obtained until calcifications are seen",
                      "Calcifications dissolved: Can occur if tissue is left in formalin for multiple days",
                      "Calcifications lost from small specimens, particularly core needle biopsiesIt is helpful for radiologists to wrap cores in paper and place them in a cassette prior to placing in formalinThis practice also ensures that all tissue removed by the radiologist is examined microscopically by the pathologist",
                      "It is helpful for radiologists to wrap cores in paper and place them in a cassette prior to placing in formalin",
                      "This practice also ensures that all tissue removed by the radiologist is examined microscopically by the pathologist",
                      "Calcifications not present: Other radiodense materials can mimic calcificationsMetallic debris from prior surgery or traumaGold treatments for rheumatoid arthritisHeterotopic boneSome types of pigments used in tattoos",
                      "Metallic debris from prior surgery or trauma",
                      "Gold treatments for rheumatoid arthritis",
                      "Heterotopic bone",
                      "Some types of pigments used in tattoos",
                      "Calcifications dislodged from tissue during preparation of slidesUsually occurs with very large calcificationsOnly remnants of calcification may remainTrack may be seen in tissue where calcification was dragged by microtome bladeUsually occurs when surrounding tissue is adipose tissue",
                      "Usually occurs with very large calcifications",
                      "Only remnants of calcification may remain",
                      "Track may be seen in tissue where calcification was dragged by microtome blade",
                      "Usually occurs when surrounding tissue is adipose tissue"
                    ]
                  },
                  {
                    "text": "AdenosisIncreased number of acini compared to average lobule size in surrounding breast tissueSize of lobules varies greatly depending on age and prior pregnancy historyAcini are often enlarged or dilated but not distorted, as is seen in sclerosing adenosisOften associated with columnar cell change ± flat epithelial atypiaLarge involuting lobules may overlap in appearance with sclerosing adenosis",
                    "sub_points": [
                      "Increased number of acini compared to average lobule size in surrounding breast tissueSize of lobules varies greatly depending on age and prior pregnancy history",
                      "Size of lobules varies greatly depending on age and prior pregnancy history",
                      "Acini are often enlarged or dilated but not distorted, as is seen in sclerosing adenosis",
                      "Often associated with columnar cell change ± flat epithelial atypia",
                      "Large involuting lobules may overlap in appearance with sclerosing adenosis"
                    ]
                  },
                  {
                    "text": "Chronic inflammation (mastitis)Scattering of lymphocytes is normal findingChronic inflammation is increased at end of each menstrual cycle and after pregnancy or lactationInflammatory response after cyst rupture and spillage of secretory material into stroma may contribute to fibrosis",
                    "sub_points": [
                      "Scattering of lymphocytes is normal finding",
                      "Chronic inflammation is increased at end of each menstrual cycle and after pregnancy or lactation",
                      "Inflammatory response after cyst rupture and spillage of secretory material into stroma may contribute to fibrosis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Proliferative Breast Disease": [
                  {
                    "text": "Defined as benign changes that increase subsequent risk of developing BC in either breastModerate to florid epithelial hyperplasia, sclerosing adenosis, radial sclerosing lesions (radial scar), papillomas, fibroadenoma",
                    "sub_points": [
                      "Moderate to florid epithelial hyperplasia, sclerosing adenosis, radial sclerosing lesions (radial scar), papillomas, fibroadenoma"
                    ]
                  },
                  {
                    "text": "All of these changes increase number of epithelial cells"
                  },
                  {
                    "text": "Relative risk is increased 1.5-2.0xThis translates into 4-6% lifetime risk of invasive BC",
                    "sub_points": [
                      "This translates into 4-6% lifetime risk of invasive BC"
                    ]
                  }
                ],
                "Atypical Hyperplasia": [
                  {
                    "text": "Clonal epithelial proliferation with abnormal architecture"
                  },
                  {
                    "text": "Atypical lobular hyperplasia and atypical ductal hyperplasia increase bilateral relative risk of invasive BC by 4-5x12-15% lifetime risk of invasive BC",
                    "sub_points": [
                      "12-15% lifetime risk of invasive BC"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Columnar Cell Change, Columnar Cell Hyperplasia, and Flat Epithelial Atypia": {
            "name": "Columnar Cell Change, Columnar Cell Hyperplasia, and Flat Epithelial Atypia",
            "url": "https://app.pathprimer.com/document/8094e4d9-7c48-4bd6-8411-e1321bed08fb/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Columnar cell change (CCC), columnar cell hyperplasia (CCH), and flat epithelial atypia (FEA) are frequently found in breast biopsies performed to evaluate mammographic calcifications"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "CCC, CCH, and FEA are the earliest recognized clonal proliferations in the low-grade breast neoplasia pathwayClonality is supported by uniform morphology and the expression of low molecular weight keratinsThe most common genomic change is loss of heterozygosity at 16q, which is also seen in other members of this familyCCC, CCH, and FEA show upregulation of hormone receptors, shown by diffuse strong immunoreactivity",
                    "sub_points": [
                      "Clonality is supported by uniform morphology and the expression of low molecular weight keratins",
                      "The most common genomic change is loss of heterozygosity at 16q, which is also seen in other members of this family",
                      "CCC, CCH, and FEA show upregulation of hormone receptors, shown by diffuse strong immunoreactivity"
                    ]
                  },
                  {
                    "text": "Current evidence suggests that CCC, CCH, and FEA are likely nonobligate precursors of atypical ductal hyperplasia"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most commonly detected as calcifications on imaging"
                  },
                  {
                    "text": "When FEA is found, the surrounding tissue should be carefully examined for lesions conferring greater riskExamination of more tissue or levels on blocks may be appropriate",
                    "sub_points": [
                      "Examination of more tissue or levels on blocks may be appropriate"
                    ]
                  },
                  {
                    "text": "The risk of subsequent breast carcinoma associated with CCC, CCH, and FEA is the same as other types of proliferative disease without atypia (e.g., usual ductal hyperplasia, sclerosing adenosis)Relative risk is ~ 1.5x, translating into a 5-7% lifetime riskRisk is to both breastsNot considered sufficiently high to recommend additional screening or chemoprevention",
                    "sub_points": [
                      "Relative risk is ~ 1.5x, translating into a 5-7% lifetime risk",
                      "Risk is to both breasts",
                      "Not considered sufficiently high to recommend additional screening or chemoprevention"
                    ]
                  },
                  {
                    "text": "When FEA is found on core needle biopsy, and there is good radiologic/pathologic correlation, the likelihood of carcinoma on excision is < 5%Carcinomas are generally small (< 0.5 cm) and low grade",
                    "sub_points": [
                      "Carcinomas are generally small (< 0.5 cm) and low grade"
                    ]
                  },
                  {
                    "text": "Presence of FEA should alert pathologist to search for other frequently associated lesions"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Apocrine metaplasia"
                  },
                  {
                    "text": "Atypical ductal hyperplasia"
                  },
                  {
                    "text": "Ductal carcinoma in situ, clinging type"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Columnar cell change (CCC)"
                  },
                  {
                    "text": "Columnar cell hyperplasia (CCH)"
                  },
                  {
                    "text": "Flat epithelial atypia (FEA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Terms CCC, CCH, and FEA are preferred"
                  },
                  {
                    "text": "Other terms that are no longer recommended includeColumnar alteration of lobules or columnar metaplasiaAtypical cystic lobulesHyperplastic unfolded lobulesBlunt duct adenosisClinging carcinoma (monomorphic type)Ductal intraepithelial neoplasia of flat monomorphic type",
                    "sub_points": [
                      "Columnar alteration of lobules or columnar metaplasia",
                      "Atypical cystic lobules",
                      "Hyperplastic unfolded lobules",
                      "Blunt duct adenosis",
                      "Clinging carcinoma (monomorphic type)",
                      "Ductal intraepithelial neoplasia of flat monomorphic type"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "CCC and CCH are clonal proliferations of columnar epithelial cells lining dilated lobular units> 2 cell layers are present in CCH",
                    "sub_points": [
                      "> 2 cell layers are present in CCH"
                    ]
                  },
                  {
                    "text": "Cystic spaces frequently contain luminal secretions and flocculent materialFrequently associated with microcalcifications",
                    "sub_points": [
                      "Frequently associated with microcalcifications"
                    ]
                  },
                  {
                    "text": "FEA is characterized by a clonal monomorphic population of cuboidal to columnar cells with round, mildly atypical nuclei lining enlarged, dilated acini1 to several cell layers",
                    "sub_points": [
                      "1 to several cell layers"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "CCC, CCH, and FEA are the earliest recognized clonal proliferations in the low-grade breast neoplasia pathwayThe most common genomic change is loss of heterozygosity at 16q, which is also seen in other members of this familyCurrent evidence suggests that CCC, CCH, and FEA are likely nonobligate precursors of atypical ductal hyperplasia (ADH)May coexist with other entities with additional genetic changes in the low-grade breast neoplasia pathway",
                    "sub_points": [
                      "The most common genomic change is loss of heterozygosity at 16q, which is also seen in other members of this family",
                      "Current evidence suggests that CCC, CCH, and FEA are likely nonobligate precursors of atypical ductal hyperplasia (ADH)",
                      "May coexist with other entities with additional genetic changes in the low-grade breast neoplasia pathway"
                    ]
                  },
                  {
                    "text": "Clonality is supported by uniform morphology and the expression of low molecular weight (LMW) keratinsThe heterogeneous pattern of expression for LMW and high molecular weight (HMW) keratins in usual ductal hyperplasia is not seen",
                    "sub_points": [
                      "The heterogeneous pattern of expression for LMW and high molecular weight (HMW) keratins in usual ductal hyperplasia is not seen"
                    ]
                  },
                  {
                    "text": "CCC, CCH, and FEA show upregulation of hormone receptors shown by diffuse strong immunoreactivityHormone-induced field effects are thought to play a role in development and possible disease progression",
                    "sub_points": [
                      "Hormone-induced field effects are thought to play a role in development and possible disease progression"
                    ]
                  },
                  {
                    "text": "The overall risk of breast cancer is the same as for proliferative breast disease without atypia"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "FEA: 1-2% of core needle biopsies (excluding cases with lesions of higher risk)"
                  }
                ],
                "Age": [
                  {
                    "text": "~ 50 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most commonly detected as calcifications on mammographic screeningLess commonly detected as MR enhancement or mass",
                    "sub_points": [
                      "Less commonly detected as MR enhancement or mass"
                    ]
                  },
                  {
                    "text": "Encountered with increasing frequency in breast core needle biopsiesMost frequently seen in biopsies performed for grouped, amorphous mammographic calcificationsDoes not form palpable masses or cause clinical symptoms",
                    "sub_points": [
                      "Most frequently seen in biopsies performed for grouped, amorphous mammographic calcifications",
                      "Does not form palpable masses or cause clinical symptoms"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Core needle biopsyCCC or CCHExcision not required based on the presence of these lesionsFEAIf FEA is the most advanced lesion, cancers are found in < 5% of casesCancers are typically small (< 0.5 cm) and low gradeThe likelihood of cancer is diminished if the target was calcifications, and all calcifications are removed by the core needle biopsyExcision is not required based on the finding of FEA aloneCareful correlation with radiologic findings is required",
                    "sub_points": [
                      "CCC or CCHExcision not required based on the presence of these lesions",
                      "Excision not required based on the presence of these lesions",
                      "FEAIf FEA is the most advanced lesion, cancers are found in < 5% of casesCancers are typically small (< 0.5 cm) and low gradeThe likelihood of cancer is diminished if the target was calcifications, and all calcifications are removed by the core needle biopsyExcision is not required based on the finding of FEA alone",
                      "If FEA is the most advanced lesion, cancers are found in < 5% of cases",
                      "Cancers are typically small (< 0.5 cm) and low grade",
                      "The likelihood of cancer is diminished if the target was calcifications, and all calcifications are removed by the core needle biopsy",
                      "Excision is not required based on the finding of FEA alone",
                      "Careful correlation with radiologic findings is required"
                    ]
                  },
                  {
                    "text": "ExcisionNo additional surgery is necessary if only CCC, CCH, and FEA are present",
                    "sub_points": [
                      "No additional surgery is necessary if only CCC, CCH, and FEA are present"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "CCC, CCH, and FEA are often found in association with other lesions in the low-grade neoplasia familyADH, atypical lobular hyperplasia (ALH)Low-grade ductal carcinoma in situ (DCIS), lobular carcinoma in situInvasive low-grade ductal carcinomas (tubular carcinoma), invasive lobular carcinomaRosen triad: FEA, lobular carcinoma in situ, and tubular carcinomaPrognosis is driven by lesions of higher risk when present",
                    "sub_points": [
                      "ADH, atypical lobular hyperplasia (ALH)",
                      "Low-grade ductal carcinoma in situ (DCIS), lobular carcinoma in situ",
                      "Invasive low-grade ductal carcinomas (tubular carcinoma), invasive lobular carcinomaRosen triad: FEA, lobular carcinoma in situ, and tubular carcinoma",
                      "Rosen triad: FEA, lobular carcinoma in situ, and tubular carcinoma",
                      "Prognosis is driven by lesions of higher risk when present"
                    ]
                  },
                  {
                    "text": "CCC and FEA in isolation increase risk of subsequent cancer to the same extent as proliferative disease without atypia: ~ 1.5x relative riskTranslates to a 5-7% lifetime risk of invasive carcinomaRisk is to both breastsAs an isolated finding, FEA is not equivalent to ADH or ALH in regard to cancer riskWomen with FEA are not considered to be at \"high risk\" for breast carcinomaRisk is similar to that of usual ductal hyperplasia, papillomas, and sclerosing adenosisNo additional screening or treatment is recommended for a finding of FEA alone",
                    "sub_points": [
                      "Translates to a 5-7% lifetime risk of invasive carcinomaRisk is to both breasts",
                      "Risk is to both breasts",
                      "As an isolated finding, FEA is not equivalent to ADH or ALH in regard to cancer riskWomen with FEA are not considered to be at \"high risk\" for breast carcinoma",
                      "Women with FEA are not considered to be at \"high risk\" for breast carcinoma",
                      "Risk is similar to that of usual ductal hyperplasia, papillomas, and sclerosing adenosis",
                      "No additional screening or treatment is recommended for a finding of FEA alone"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "CCC, CCH, and FEA are detected on mammography due to the association with calcifications"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "These lesions do not form grossly evident lesions"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "The lesion responsible for the mammographic calcifications must be identifiedThe area should be located on the specimen radiograph and specifically sampled in designated cassettesThe microscopic findings should be correlated with the mammographic appearance",
                    "sub_points": [
                      "The area should be located on the specimen radiograph and specifically sampled in designated cassettes",
                      "The microscopic findings should be correlated with the mammographic appearance"
                    ]
                  },
                  {
                    "text": "When FEA is present as the most advanced lesion in an excision, the surrounding tissue should be carefully evaluated for lesions of greater riskWhen possible, all fibrous tissue should be examined microscopicallyAdditional levels should be considered on the block with FEA to look for lesions of greater risk",
                    "sub_points": [
                      "When possible, all fibrous tissue should be examined microscopically",
                      "Additional levels should be considered on the block with FEA to look for lesions of greater risk"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA Copy Number Changes": [
                  {
                    "text": "Loss at 16q and gains of 1q are the most frequently detected recurrent changesLosses at 9q, 10q, 14q, and 17p, and gains at 15q, 16p, and 19p have also been reported",
                    "sub_points": [
                      "Losses at 9q, 10q, 14q, and 17p, and gains at 15q, 16p, and 19p have also been reported"
                    ]
                  },
                  {
                    "text": "Similar chromosomal aberrations (especially 16q loss) may occur over the spectrum of FEA, ADH, and low-grade DCIS"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "CCCTerminal duct lobular units (TDLUs) have expanded acinar spaces lined by 1 or 2 layers of columnar cellsEnlargement and variable cystic dilatation of TDLUs are commonFlat growth pattern by lining epithelial cells; may show some stratificationMore irregular contours of acini compared with FEACells are uniform with ovoid to elongated nucleiNuclei show polarity, oriented in regular fashion perpendicular to the basement membraneEvenly dispersed chromatin without conspicuous nucleoli or atypiaMitotic figures rarely encounteredApical cytoplasmic blebs or snouts often present at the luminal surface of epithelial cellsFlocculent secretions typically present in luminaMucin production may be presentLuminal calcifications are frequently present and may be prominent",
                    "sub_points": [
                      "Terminal duct lobular units (TDLUs) have expanded acinar spaces lined by 1 or 2 layers of columnar cellsEnlargement and variable cystic dilatation of TDLUs are commonFlat growth pattern by lining epithelial cells; may show some stratificationMore irregular contours of acini compared with FEA",
                      "Enlargement and variable cystic dilatation of TDLUs are common",
                      "Flat growth pattern by lining epithelial cells; may show some stratification",
                      "More irregular contours of acini compared with FEA",
                      "Cells are uniform with ovoid to elongated nucleiNuclei show polarity, oriented in regular fashion perpendicular to the basement membrane",
                      "Nuclei show polarity, oriented in regular fashion perpendicular to the basement membrane",
                      "Evenly dispersed chromatin without conspicuous nucleoli or atypiaMitotic figures rarely encountered",
                      "Mitotic figures rarely encountered",
                      "Apical cytoplasmic blebs or snouts often present at the luminal surface of epithelial cells",
                      "Flocculent secretions typically present in luminaMucin production may be present",
                      "Mucin production may be present",
                      "Luminal calcifications are frequently present and may be prominent"
                    ]
                  },
                  {
                    "text": "CCHCytologic features similar to CCCEpithelial lining cells show varying cellular stratification, > 2 cell layersNuclei ovoid to elongated and, for the most part, oriented perpendicular to basement membraneLack conspicuous nucleoli or atypiaCells proliferate to varying degrees to form small mounds or tapering micropapillaeTufts and mounds are broader at base than at tipsThere should be no true micropapillary architecture",
                    "sub_points": [
                      "Cytologic features similar to CCC",
                      "Epithelial lining cells show varying cellular stratification, > 2 cell layers",
                      "Nuclei ovoid to elongated and, for the most part, oriented perpendicular to basement membraneLack conspicuous nucleoli or atypia",
                      "Lack conspicuous nucleoli or atypia",
                      "Cells proliferate to varying degrees to form small mounds or tapering micropapillaeTufts and mounds are broader at base than at tipsThere should be no true micropapillary architecture",
                      "Tufts and mounds are broader at base than at tips",
                      "There should be no true micropapillary architecture"
                    ]
                  },
                  {
                    "text": "FEASimilar lobular involvement as seen in CCC and CCHApical snouts and secretions frequentCalcifications in secretions typicalMore rounded and rigid-appearing acini compared with CCCEpithelial cells demonstrate low-grade, monomorphic cytologic atypiaCuboidal cells with round enlarged nucleiLess common are oval-shaped nuclei that can be oriented to basement membraneThese cases show greater degree of nuclear atypia, allowing them to be distinguished from CCC and CCHIncreased nuclear:cytoplasmic ratio: Confers basophilic appearance to lesionSimilar to cytologic features of low-grade DCISNuclei can show stratificationLoss of polarity with respect to basement membraneLoss of perpendicular orientation to basement membraneNuclear chromatin may be evenly dispersed or slightly marginatedNucleoli may be present and variably prominentThe cells do not form architectural structures (arcades, cribriform spaces, micropapillae)Lesions with complex architecture are best classified as ADH or low-grade DCISFEA may coexist with areas that fulfill diagnostic criteria for ADH or low-grade DCISFinding of FEA should prompt diligent search for areas of greater clinical significanceMay require careful examination of deeper levels &/or additional sectionsReproducibilityClassification of FEA shows good reproducibility when diagnostic criteria are agreed upon by a panel and a specific designated lesion is classifiedA study to measure reproducibility of classifying atypical lesions (including both FEA and ADH) showed only 48% agreement with an expert panelThe study was more typical of clinical practice and included more pathologistsHowever, a limitation to this study is that the conditions of the study did not completely duplicate normal pathologic practice",
                    "sub_points": [
                      "Similar lobular involvement as seen in CCC and CCHApical snouts and secretions frequentCalcifications in secretions typicalMore rounded and rigid-appearing acini compared with CCC",
                      "Apical snouts and secretions frequent",
                      "Calcifications in secretions typical",
                      "More rounded and rigid-appearing acini compared with CCC",
                      "Epithelial cells demonstrate low-grade, monomorphic cytologic atypiaCuboidal cells with round enlarged nucleiLess common are oval-shaped nuclei that can be oriented to basement membraneThese cases show greater degree of nuclear atypia, allowing them to be distinguished from CCC and CCHIncreased nuclear:cytoplasmic ratio: Confers basophilic appearance to lesionSimilar to cytologic features of low-grade DCIS",
                      "Cuboidal cells with round enlarged nucleiLess common are oval-shaped nuclei that can be oriented to basement membraneThese cases show greater degree of nuclear atypia, allowing them to be distinguished from CCC and CCH",
                      "Less common are oval-shaped nuclei that can be oriented to basement membrane",
                      "These cases show greater degree of nuclear atypia, allowing them to be distinguished from CCC and CCH",
                      "Increased nuclear:cytoplasmic ratio: Confers basophilic appearance to lesion",
                      "Similar to cytologic features of low-grade DCIS",
                      "Nuclei can show stratificationLoss of polarity with respect to basement membraneLoss of perpendicular orientation to basement membrane",
                      "Loss of polarity with respect to basement membrane",
                      "Loss of perpendicular orientation to basement membrane",
                      "Nuclear chromatin may be evenly dispersed or slightly marginatedNucleoli may be present and variably prominent",
                      "Nucleoli may be present and variably prominent",
                      "The cells do not form architectural structures (arcades, cribriform spaces, micropapillae)",
                      "Lesions with complex architecture are best classified as ADH or low-grade DCIS",
                      "FEA may coexist with areas that fulfill diagnostic criteria for ADH or low-grade DCIS",
                      "Finding of FEA should prompt diligent search for areas of greater clinical significanceMay require careful examination of deeper levels &/or additional sections",
                      "May require careful examination of deeper levels &/or additional sections",
                      "ReproducibilityClassification of FEA shows good reproducibility when diagnostic criteria are agreed upon by a panel and a specific designated lesion is classifiedA study to measure reproducibility of classifying atypical lesions (including both FEA and ADH) showed only 48% agreement with an expert panelThe study was more typical of clinical practice and included more pathologistsHowever, a limitation to this study is that the conditions of the study did not completely duplicate normal pathologic practice",
                      "Classification of FEA shows good reproducibility when diagnostic criteria are agreed upon by a panel and a specific designated lesion is classified",
                      "A study to measure reproducibility of classifying atypical lesions (including both FEA and ADH) showed only 48% agreement with an expert panelThe study was more typical of clinical practice and included more pathologistsHowever, a limitation to this study is that the conditions of the study did not completely duplicate normal pathologic practice",
                      "The study was more typical of clinical practice and included more pathologists",
                      "However, a limitation to this study is that the conditions of the study did not completely duplicate normal pathologic practice"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "CCC and FEA are frequent findings in core needle biopsies for calcificationsMore important associated neoplastic epithelial lesions are often present and would be an indication for excision (ADH, low-grade DCIS, tubular carcinoma)",
                    "sub_points": [
                      "More important associated neoplastic epithelial lesions are often present and would be an indication for excision (ADH, low-grade DCIS, tubular carcinoma)"
                    ]
                  },
                  {
                    "text": "Careful correlation between imaging studies and pathologic findings is essential"
                  },
                  {
                    "text": "As in other cases, if there is pathologic/radiologic discordance (e.g., the lesion was a large mass or area of architectural distortion), an excision should be considered"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "ER strongly positive throughout lesionStrongly and diffusely positive in CCC, CCH, and FEAHowever, the smaller the lesion, the more likely the cells will all show ER positivity regardless of clonalityThis finding alone should not be used for classification",
                    "sub_points": [
                      "Strongly and diffusely positive in CCC, CCH, and FEA",
                      "However, the smaller the lesion, the more likely the cells will all show ER positivity regardless of clonalityThis finding alone should not be used for classification",
                      "This finding alone should not be used for classification"
                    ]
                  },
                  {
                    "text": "LMW keratins (e.g., CK8/18)Positive in CCC, CCH, and FEAHowever, the smaller the lesion, the more likely the cells will show only LMW keratin positivityThis finding alone should not be used for classification",
                    "sub_points": [
                      "Positive in CCC, CCH, and FEA",
                      "However, the smaller the lesion, the more likely the cells will show only LMW keratin positivityThis finding alone should not be used for classification",
                      "This finding alone should not be used for classification"
                    ]
                  },
                  {
                    "text": "HMW keratins (e.g., CK5/6)CCC, CCH, and FEA are negative",
                    "sub_points": [
                      "CCC, CCH, and FEA are negative"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Apocrine Metaplasia": [
                  {
                    "text": "May show cystically dilated spaces and calcifications similar to CCC"
                  },
                  {
                    "text": "Has a low nuclear:cytoplasmic ratio, eosinophilic granular cytoplasm, and round nuclei with nucleoli"
                  },
                  {
                    "text": "May have a flat growth pattern or a micropapillary growth pattern"
                  }
                ],
                "Columnar Cell Lesions Lacking Myoepithelial Cells": [
                  {
                    "text": "Rare lesions have the appearance of CCC, CCH, or FEA but lack myoepithelial cells and may appear to infiltrate around normal structures"
                  },
                  {
                    "text": "Surrounding stroma is desmoplastic"
                  },
                  {
                    "text": "Nuclei are small and monomorphic and show minimal atypia"
                  },
                  {
                    "text": "Moderate cytoplasm"
                  },
                  {
                    "text": "Associated with adjacent areas of conventional CCC and FEA"
                  },
                  {
                    "text": "Clinical significance not yet knownMajority of breast epithelial lesions without myoepithelial cells are carcinomas with some potential of metastasisHowever, microglandular adenosis and some apocrine lesions are important exceptionsMay be a lesion that can be locally infiltrative but without metastasis (\"macroglandular adenosis\")",
                    "sub_points": [
                      "Majority of breast epithelial lesions without myoepithelial cells are carcinomas with some potential of metastasisHowever, microglandular adenosis and some apocrine lesions are important exceptionsMay be a lesion that can be locally infiltrative but without metastasis (\"macroglandular adenosis\")",
                      "However, microglandular adenosis and some apocrine lesions are important exceptions",
                      "May be a lesion that can be locally infiltrative but without metastasis (\"macroglandular adenosis\")"
                    ]
                  },
                  {
                    "text": "These lesions are typically small and completely excisedClinical significance of larger lesions is unknown",
                    "sub_points": [
                      "Clinical significance of larger lesions is unknown"
                    ]
                  }
                ],
                "Atypical Ductal Hyperplasia/Low-Grade Ductal Carcinoma In Situ": [
                  {
                    "text": "ADH and DCIS have complex architectural patternsPunched-out fenestrations (cribriform or cookie-cutter pattern)Well-developed micropapillaeRigid cellular bridges, bars, and arcades",
                    "sub_points": [
                      "Punched-out fenestrations (cribriform or cookie-cutter pattern)",
                      "Well-developed micropapillae",
                      "Rigid cellular bridges, bars, and arcades"
                    ]
                  },
                  {
                    "text": "Complex architectural patterns formed by a monomorphic cell population should be classified as either ADH or DCISBy definition, FEA is flat and should not have architectural atypia",
                    "sub_points": [
                      "By definition, FEA is flat and should not have architectural atypia"
                    ]
                  },
                  {
                    "text": "FEA may coexist with ADH and DCISCurrent evidence suggests that CCC and FEA are likely precursors of ADH",
                    "sub_points": [
                      "Current evidence suggests that CCC and FEA are likely precursors of ADH"
                    ]
                  }
                ],
                "High-Grade Ductal Carcinoma In Situ, Flat or Clinging Pattern": [
                  {
                    "text": "Very rare examples of DCIS consist entirely of a single layer of cells with high-grade nuclei lining lobules and ductsThis pattern is most commonly seen adjacent to more conventional areas of DCIS",
                    "sub_points": [
                      "This pattern is most commonly seen adjacent to more conventional areas of DCIS"
                    ]
                  },
                  {
                    "text": "High-grade cytologic atypia with marked nuclear pleomorphism is not a feature of FEA"
                  },
                  {
                    "text": "High-grade nuclear features merit designation as high-grade DCISClassified as DCIS, even when neoplastic cells comprise only a single cell layer (flat or clinging pattern)",
                    "sub_points": [
                      "Classified as DCIS, even when neoplastic cells comprise only a single cell layer (flat or clinging pattern)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Presence of FEA should alert pathologist to search for other frequently associated lesionsADH, DCIS, lobular neoplasiaInvasive carcinomaTubular carcinoma and classic lobular carcinoma",
                    "sub_points": [
                      "ADH, DCIS, lobular neoplasia",
                      "Invasive carcinomaTubular carcinoma and classic lobular carcinoma",
                      "Tubular carcinoma and classic lobular carcinoma"
                    ]
                  },
                  {
                    "text": "If FEA is the lesion of highest risk in an excisional specimenPerform multiple levels to look for architectural changes of ADH or low-grade DCISSubmit all tissue for microscopic examination when clinically relevant and practical",
                    "sub_points": [
                      "Perform multiple levels to look for architectural changes of ADH or low-grade DCIS",
                      "Submit all tissue for microscopic examination when clinically relevant and practical"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "CCC, CCH, and FEA should be reported when they are the lesions responsible for calcifications seen on imaging or the lesions conferring the greatest risk"
                  },
                  {
                    "text": "These lesions need not be specifically reported when lesions of greater risk are present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Mucocele-Like Lesions": {
            "name": "Mucocele-Like Lesions",
            "url": "https://app.pathprimer.com/document/086ae4df-da9f-4f7a-8f33-2a4cff0cf5ae/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mucocele-like lesion (MLL)Uncommon lesion composed of mucin-containing cysts that may rupture",
                    "sub_points": [
                      "Uncommon lesion composed of mucin-containing cysts that may rupture"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most commonly presents as a mammographic lesionCalcifications ± smoothly circumscribed mass",
                    "sub_points": [
                      "Calcifications ± smoothly circumscribed mass"
                    ]
                  },
                  {
                    "text": "Less commonly, forms a palpable mass"
                  },
                  {
                    "text": "MLL without associated carcinoma is a benign lesion~ 50% associated with atypical hyperplasia or carcinoma",
                    "sub_points": [
                      "~ 50% associated with atypical hyperplasia or carcinoma"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Cystically dilated ducts contain luminal mucinSpaces lined by cuboidal to attenuated epitheliumHistocytes and inflammatory cells may be present",
                    "sub_points": [
                      "Spaces lined by cuboidal to attenuated epithelium",
                      "Histocytes and inflammatory cells may be present"
                    ]
                  },
                  {
                    "text": "Epithelium may show a spectrum of proliferative changes, including hyperplasia, atypical ductal hyperplasia (ADH), or ductal carcinoma in situ (DCIS)"
                  },
                  {
                    "text": "Ruptured ducts with extravasated mucin in surrounding stroma are commonContributes to formation of mass",
                    "sub_points": [
                      "Contributes to formation of mass"
                    ]
                  },
                  {
                    "text": "Strips or clusters of epithelial cells may become detached from wall, floating free in mucinMultiple H&E levels may be necessary to exclude invasive mucinous carcinoma",
                    "sub_points": [
                      "Multiple H&E levels may be necessary to exclude invasive mucinous carcinoma"
                    ]
                  },
                  {
                    "text": "Distinction between MLL and mucinous carcinoma is often not possible on core needle biopsy when there is extravasated mucinExcision may be necessary for final classification",
                    "sub_points": [
                      "Excision may be necessary for final classification"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "MLL with ADH or DCIS"
                  },
                  {
                    "text": "Invasive mucinous carcinoma"
                  },
                  {
                    "text": "Mucinous cystadenocarcinoma"
                  },
                  {
                    "text": "Nodular mucinosis"
                  },
                  {
                    "text": "Cystic hypersecretory breast lesions"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mucocele-like lesion (MLL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Mucocele-like tumor"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Uncommon breast lesion composed of mucin-containing cystsRupture results in extravasated mucin in periductal stroma creating a mass",
                    "sub_points": [
                      "Rupture results in extravasated mucin in periductal stroma creating a mass"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Breast lesions associated with mucin range from benign cysts containing mucin, mucocele-like lesions (MLLs) (which can be associated with atypia), ductal carcinoma in situ (DCIS) with mucin production, and invasive mucinous carcinoma (IMC)"
                  },
                  {
                    "text": "MLL is composed of mucin-containing cysts, often associated with rupture resulting in extravasated mucin"
                  },
                  {
                    "text": "Although the majority (~ 2/3) are benign, MLLs can be associated with atypia and, occasionally, carcinoma"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Relationship to Invasive Mucinous Carcinoma (IMC)": [
                  {
                    "text": "Several lines of evidence suggest that at least some MLLs may be related to IMCADH is reported in up to 50% of patients with MLLSome may later develop IMCSome MLLs contain areas of DCIS and IMC at initial diagnosisThe type of mucin found in MLL is identical to that found in IMC",
                    "sub_points": [
                      "ADH is reported in up to 50% of patients with MLLSome may later develop IMC",
                      "Some may later develop IMC",
                      "Some MLLs contain areas of DCIS and IMC at initial diagnosis",
                      "The type of mucin found in MLL is identical to that found in IMC"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Wide range at presentation: 27-79 years (mean: 48 years)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most commonly detected on screening mammograms due to calcifications or a mass"
                  },
                  {
                    "text": "Less commonly, MLL is detected as palpable mass"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Diagnosis of MLL on core needle biopsy may warrant excision for further evaluationCareful evaluation of excised tissue sample for atypia or carcinoma is requiredMultiple H&E levels on tissue with mucin in stroma may be helpful to evaluate the possibility of IMC",
                    "sub_points": [
                      "Careful evaluation of excised tissue sample for atypia or carcinoma is required",
                      "Multiple H&E levels on tissue with mucin in stroma may be helpful to evaluate the possibility of IMC"
                    ]
                  },
                  {
                    "text": "If no carcinoma is found after complete excision, no additional treatment is necessary"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "MLL without associated carcinoma is a benign lesion"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Pleomorphic &/or amorphous coarse calcifications are the most common finding in ~ 50% of casesLess common is a lobulated mass with smooth bordersThe mass may have indistinct margins due to extravasated mucin in stroma",
                    "sub_points": [
                      "Less common is a lobulated mass with smooth bordersThe mass may have indistinct margins due to extravasated mucin in stroma",
                      "The mass may have indistinct margins due to extravasated mucin in stroma"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Multiple cysts with calcified or noncalcified solid components, often multiple, may suggest a diagnosis of MLLHypoechoic, round, oval, or lobulated solid masses may be present",
                    "sub_points": [
                      "Hypoechoic, round, oval, or lobulated solid masses may be present"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Cysts and dilated ducts contain luminal mucinSpaces are lined by cuboidal to attenuated (flattened) epitheliumEpithelium may show a spectrum of proliferative changes, including hyperplasia, ADH, or DCIS",
                    "sub_points": [
                      "Spaces are lined by cuboidal to attenuated (flattened) epithelium",
                      "Epithelium may show a spectrum of proliferative changes, including hyperplasia, ADH, or DCIS"
                    ]
                  },
                  {
                    "text": "Ruptured ducts may be associated with extravasated mucin in surrounding stromaHistologic picture resembles mucocele of minor salivary glands found in oral cavityHistocytes and inflammatory cells may be seen in extravasated mucinDistinctive large granular calcifications may be present within mucin and are characteristicStrips or clusters of epithelial cells may become detached from wall and float free in mucinIt is important not to overinterpret detached free-floating lining epithelium as mucinous carcinomaMultiple levels of areas of mucin extravasation may be helpful to look for possible areas of invasionFeatures favoring MLL with epithelial detachmentLinear configuration of epithelial cells (resembling lining)Associated myoepithelial cells; in some cases, IHC studies for myoepithelial markers may be helpfulAssociated findings that suggest presence of core needle biopsy track",
                    "sub_points": [
                      "Histologic picture resembles mucocele of minor salivary glands found in oral cavity",
                      "Histocytes and inflammatory cells may be seen in extravasated mucin",
                      "Distinctive large granular calcifications may be present within mucin and are characteristic",
                      "Strips or clusters of epithelial cells may become detached from wall and float free in mucinIt is important not to overinterpret detached free-floating lining epithelium as mucinous carcinomaMultiple levels of areas of mucin extravasation may be helpful to look for possible areas of invasion",
                      "It is important not to overinterpret detached free-floating lining epithelium as mucinous carcinoma",
                      "Multiple levels of areas of mucin extravasation may be helpful to look for possible areas of invasion",
                      "Features favoring MLL with epithelial detachmentLinear configuration of epithelial cells (resembling lining)Associated myoepithelial cells; in some cases, IHC studies for myoepithelial markers may be helpfulAssociated findings that suggest presence of core needle biopsy track",
                      "Linear configuration of epithelial cells (resembling lining)",
                      "Associated myoepithelial cells; in some cases, IHC studies for myoepithelial markers may be helpful",
                      "Associated findings that suggest presence of core needle biopsy track"
                    ]
                  },
                  {
                    "text": "Epithelial lining consists of uniform, flattened to low cuboidal cellsUniform, oval nuclei, absence of cytologic atypiaAssociated with underlying myoepithelial cell layer",
                    "sub_points": [
                      "Uniform, oval nuclei, absence of cytologic atypia",
                      "Associated with underlying myoepithelial cell layer"
                    ]
                  },
                  {
                    "text": "Low columnar epithelium and minor papillary elements may be present in some lesions"
                  },
                  {
                    "text": "Atypical epithelial alterations may be associated with MLLADH, columnar cell change ± atypiaDCIS (micropapillary and cribriform patterns)Awareness of association with atypia should prompt close histologic scrutiny of any epithelial proliferative changes accompanying MLL",
                    "sub_points": [
                      "ADH, columnar cell change ± atypia",
                      "DCIS (micropapillary and cribriform patterns)",
                      "Awareness of association with atypia should prompt close histologic scrutiny of any epithelial proliferative changes accompanying MLL"
                    ]
                  },
                  {
                    "text": "In background of MLL, diagnosis of ADH and DCIS relies on conventionally described cytoarchitectural criteria"
                  },
                  {
                    "text": "Distinction between MLL and IMC is often difficult on core needle biopsy when there is extravasated mucinMucin neovascularization is more common in IMC (~ 70%) compared to MLL (~ 14%)The microvessels are present in mucin and are not associated with fibrous septaCD31 identifies more vessels than morphology alone in IMC (~ 90% of MCs)",
                    "sub_points": [
                      "Mucin neovascularization is more common in IMC (~ 70%) compared to MLL (~ 14%)",
                      "The microvessels are present in mucin and are not associated with fibrous septa",
                      "CD31 identifies more vessels than morphology alone in IMC (~ 90% of MCs)"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Rare: < 1% of diagnoses by core needle biopsy"
                  },
                  {
                    "text": "~ 2/3 do not show atypiaLikelihood of carcinoma on excision is very low (< 5%)Clinical surveillance can be appropriate for MLL without atypia when identified on a core needle biopsy for a nonmass lesionClinicopathologic correlation and radiologic concordance requiredIf lesion is a mass, &/or lesion is not well sampled, excision might be considered",
                    "sub_points": [
                      "Likelihood of carcinoma on excision is very low (< 5%)",
                      "Clinical surveillance can be appropriate for MLL without atypia when identified on a core needle biopsy for a nonmass lesionClinicopathologic correlation and radiologic concordance required",
                      "Clinicopathologic correlation and radiologic concordance required",
                      "If lesion is a mass, &/or lesion is not well sampled, excision might be considered"
                    ]
                  },
                  {
                    "text": "~ 1/3 are associated with atypiaExcision is recommended for further classification",
                    "sub_points": [
                      "Excision is recommended for further classification"
                    ]
                  },
                  {
                    "text": "Areas of mucin extravasation raise concern for IMC, and examination of additional levels may be helpfulIf minimal extent (< 0.5 cm), and imaging lesion is calcifications, likelihood of IMC is lowIf extravasated mucin is extensive, and imaging lesion is a mass, excision may be advised, as possibility of IMC is higher",
                    "sub_points": [
                      "If minimal extent (< 0.5 cm), and imaging lesion is calcifications, likelihood of IMC is low",
                      "If extravasated mucin is extensive, and imaging lesion is a mass, excision may be advised, as possibility of IMC is higher"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Mucin is generally readily identifiable on H&ELargely composed of neutral and nonsulfated acid mucinSpecial stains are rarely necessary",
                    "sub_points": [
                      "Largely composed of neutral and nonsulfated acid mucin",
                      "Special stains are rarely necessary"
                    ]
                  },
                  {
                    "text": "Mucicarmine: PositiveDiffuse strong staining of extracellular mucin",
                    "sub_points": [
                      "Diffuse strong staining of extracellular mucin"
                    ]
                  },
                  {
                    "text": "PAS diastase: PositiveDiffuse strong staining of extracellular mucin",
                    "sub_points": [
                      "Diffuse strong staining of extracellular mucin"
                    ]
                  },
                  {
                    "text": "Alcian blue at pH 2.7: PositiveDiffuse strong staining of extracellular mucin",
                    "sub_points": [
                      "Diffuse strong staining of extracellular mucin"
                    ]
                  },
                  {
                    "text": "Alcian blue at pH 0.9: EquivocalWeak to absent staining of extracellular mucin",
                    "sub_points": [
                      "Weak to absent staining of extracellular mucin"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Mucin is generally readily identifiable on H&EIHC to identify type of mucin is rarely necessary or helpful",
                    "sub_points": [
                      "IHC to identify type of mucin is rarely necessary or helpful"
                    ]
                  },
                  {
                    "text": "MUC2 and MUC6 are predominant mucins in MLLSame mucins are found in IMCs",
                    "sub_points": [
                      "Same mucins are found in IMCs"
                    ]
                  },
                  {
                    "text": "Vascular markers (e.g., CD31) may be helpful for the evaluation of neovascularization"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mucocele-Like Lesions With Atypical Ductal Hyperplasia or Ductal Carcinoma In Situ": [
                  {
                    "text": "Up to 50% of MLLs are associated with ADH &/or DCISAssociated DCIS is low grade and often demonstrates cribriform or micropapillary patterns",
                    "sub_points": [
                      "Associated DCIS is low grade and often demonstrates cribriform or micropapillary patterns"
                    ]
                  },
                  {
                    "text": "Specimens with MLL should be completely examined microscopically, when feasible, to determine if ADH or DCIS is presentIf architectural complexity &/or low-grade nuclear atypia in epithelium are present, levels can be helpful",
                    "sub_points": [
                      "If architectural complexity &/or low-grade nuclear atypia in epithelium are present, levels can be helpful"
                    ]
                  },
                  {
                    "text": "No appreciable differences in age, tumor size, or laterality between patients with MLL vs. MLL with ADH or DCIS"
                  }
                ],
                "Invasive Mucinous Carcinoma": [
                  {
                    "text": "Can be paucicellular with large quantities of stromal mucin and only a few floating nests of neoplastic epitheliumClusters, solid clumps, and nests of tumor cells are usually grade 1 and, sometimes, grade 2Nuclear atypia favors diagnosis of IMC",
                    "sub_points": [
                      "Clusters, solid clumps, and nests of tumor cells are usually grade 1 and, sometimes, grade 2Nuclear atypia favors diagnosis of IMC",
                      "Nuclear atypia favors diagnosis of IMC"
                    ]
                  },
                  {
                    "text": "Myoepithelial cells should not be seen in association with epithelial nests of IMCDemonstration of associated myoepithelial cells supports diagnosis of MLL with detached epitheliumChanges of previous core or needle biopsy in vicinity (e.g., granulation tissue, fat necrosis, or hemorrhage) increase likelihood of epithelial displacement",
                    "sub_points": [
                      "Demonstration of associated myoepithelial cells supports diagnosis of MLL with detached epithelium",
                      "Changes of previous core or needle biopsy in vicinity (e.g., granulation tissue, fat necrosis, or hemorrhage) increase likelihood of epithelial displacement"
                    ]
                  },
                  {
                    "text": "Mucin neovascularization favors IMC"
                  },
                  {
                    "text": "Distinction between IMC and mucin extravasation in MLL can be difficult on core needle biopsyExcision may be necessary for final classification",
                    "sub_points": [
                      "Excision may be necessary for final classification"
                    ]
                  }
                ],
                "Mucinous Cystadenocarcinoma": [
                  {
                    "text": "Very rare breast neoplasm"
                  },
                  {
                    "text": "Histologically reminiscent of mucinous cystadenocarcinomas in pancreas and ovaryMultilocular cystic appearance can mimic MLLLining cells are tall and columnar with cytoplasmic mucin and basally oriented nuclei, differing from MLLTumor cells are ER(-), unlike MLL, which is ER(+)",
                    "sub_points": [
                      "Multilocular cystic appearance can mimic MLL",
                      "Lining cells are tall and columnar with cytoplasmic mucin and basally oriented nuclei, differing from MLL",
                      "Tumor cells are ER(-), unlike MLL, which is ER(+)"
                    ]
                  },
                  {
                    "text": "Mucin extravasation has also been described in mucinous cystadenocarcinoma"
                  }
                ],
                "Nodular Mucinosis": [
                  {
                    "text": "Very rare lesion consisting of accumulation of stromal mucin"
                  },
                  {
                    "text": "Lesions typically located under or near nipplePoorly circumscribed and unencapsulatedSoft and gelatinous consistency",
                    "sub_points": [
                      "Poorly circumscribed and unencapsulated",
                      "Soft and gelatinous consistency"
                    ]
                  },
                  {
                    "text": "Mucinous tissue consists of acid mucopolysaccharidesStain positive with Alcian blue and Hale colloidal ironMucicarmine stain may be faintly positive; PAS(-)",
                    "sub_points": [
                      "Stain positive with Alcian blue and Hale colloidal iron",
                      "Mucicarmine stain may be faintly positive; PAS(-)"
                    ]
                  },
                  {
                    "text": "Can be distinguished from MLL by location and staining properties of mucous substancesNot associated with mucin-producing epithelium",
                    "sub_points": [
                      "Not associated with mucin-producing epithelium"
                    ]
                  }
                ],
                "Cystic Hypersecretory Breast Lesions": [
                  {
                    "text": "Includes both cystic hypersecretory hyperplasia and cystic hypersecretory carcinomaMay bear superficial similarity to MLL due to presence of cystically dilated duct spacesLuminal contents from cystic hypersecretory lesion differ from MLLContain dense gelatinous eosinophilic material resembling colloid of thyroid",
                    "sub_points": [
                      "May bear superficial similarity to MLL due to presence of cystically dilated duct spaces",
                      "Luminal contents from cystic hypersecretory lesion differ from MLLContain dense gelatinous eosinophilic material resembling colloid of thyroid",
                      "Contain dense gelatinous eosinophilic material resembling colloid of thyroid"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "MLL is typically benign, although it can be associated with atypia &/or malignancy"
                  },
                  {
                    "text": "Differentiating MLL from IMC can be difficult on core needle biopsySurgical excision is often recommended to exclude possibility of ADH, DCIS, or IMCExamination of entire pathologic specimen is necessary to exclude a more advanced lesion",
                    "sub_points": [
                      "Surgical excision is often recommended to exclude possibility of ADH, DCIS, or IMC",
                      "Examination of entire pathologic specimen is necessary to exclude a more advanced lesion"
                    ]
                  },
                  {
                    "text": "MLL may represent one end of the pathologic spectrum of low-grade mucinous breast neoplasiaA specific description of the associated epithelium should be provided when reportingStrips or clusters of epithelium in mucin of MLL may raise consideration for IMCEpithelial displacement is favored if floating epithelium is scant, associated with myoepithelial cells, or contiguous with cyst liningNeovascularization of the mucin is uncommon",
                    "sub_points": [
                      "A specific description of the associated epithelium should be provided when reporting",
                      "Strips or clusters of epithelium in mucin of MLL may raise consideration for IMC",
                      "Epithelial displacement is favored if floating epithelium is scant, associated with myoepithelial cells, or contiguous with cyst lining",
                      "Neovascularization of the mucin is uncommon"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Collagenous Spherulosis": {
            "name": "Collagenous Spherulosis",
            "url": "https://app.pathprimer.com/document/cd65714d-e5dd-43c1-af88-bc329618d0fe/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Collagenous spherulosis (CS)Mucinous spherulosis is a variant of CS",
                    "sub_points": [
                      "Mucinous spherulosis is a variant of CS"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Majority of lesions are incidental findings in 1-2% of biopsies; less commonly, CS calcifies and is detected by mammography"
                  },
                  {
                    "text": "Benign lesion, no additional treatment requiredNo evidence that CS is directly associated with precancerous lesions or is a risk factor for breast cancer",
                    "sub_points": [
                      "No evidence that CS is directly associated with precancerous lesions or is a risk factor for breast cancer"
                    ]
                  },
                  {
                    "text": "Only importance of CS is that it can resemble cribriform ductal carcinoma in situ (DCIS) or adenoid cystic carcinoma (AdCC)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Almost always small lesion involving 1 or only a few spaces"
                  },
                  {
                    "text": "CS is proliferation of luminal cells and basement membrane-producing myoepithelial cellsOften involves other lesions, such as papillomas and sclerosing adenosis",
                    "sub_points": [
                      "Often involves other lesions, such as papillomas and sclerosing adenosis"
                    ]
                  },
                  {
                    "text": "Spherules of basement membrane-like material creates cribriform or fenestrated pattern"
                  },
                  {
                    "text": "Basement membrane-like material has variety of appearancesDense eosinophilic hyaline spherulesPink fibrillar materialMucoid or myxoid materialThese lesions are termed mucinous spherulosis",
                    "sub_points": [
                      "Dense eosinophilic hyaline spherules",
                      "Pink fibrillar material",
                      "Mucoid or myxoid materialThese lesions are termed mucinous spherulosis",
                      "These lesions are termed mucinous spherulosis"
                    ]
                  },
                  {
                    "text": "IHC studies are helpful to identify mixed luminal and myoepithelial cell populations"
                  },
                  {
                    "text": "CS involved by lobular neoplasia is a close mimic for DCIS"
                  },
                  {
                    "text": "Dyscohesive pattern and intracytoplasmic vacuoles of lobular neoplasia are helpful for recognition"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "DCIS, cribriform pattern"
                  },
                  {
                    "text": "AdCC"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Collagenous spherulosis (CS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Mucinous spherulosis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign epithelial proliferation of luminal cells and matrix-producing myoepithelial cellsImportant to recognize because CS resembles the cribriform pattern of ductal carcinoma in situ (DCIS) and adenoid cystic carcinoma (AdCC)",
                    "sub_points": [
                      "Important to recognize because CS resembles the cribriform pattern of ductal carcinoma in situ (DCIS) and adenoid cystic carcinoma (AdCC)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Rare finding in 1-2% of breast biopsies"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Incidental finding in majority of casesTypically seen in breast tissue containing other benign proliferative lesionsSclerosing adenosis, papilloma, usual ductal hyperplasia, and atypical ductal hyperplasia",
                    "sub_points": [
                      "Typically seen in breast tissue containing other benign proliferative lesionsSclerosing adenosis, papilloma, usual ductal hyperplasia, and atypical ductal hyperplasia",
                      "Sclerosing adenosis, papilloma, usual ductal hyperplasia, and atypical ductal hyperplasia"
                    ]
                  },
                  {
                    "text": "Rare cases are associated with calcifications detected by mammography"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign lesion that does not require any clinical action"
                  },
                  {
                    "text": "No evidence that CS is directly associated with precancerous lesions or predisposes to future development of breast cancer"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Arises from the epithelium of ducts and lobulesOften seen in association with papillomas, sclerosing adenosis, and ductal hyperplasia",
                    "sub_points": [
                      "Often seen in association with papillomas, sclerosing adenosis, and ductal hyperplasia"
                    ]
                  },
                  {
                    "text": "Typically small (< 0.5 cm), restricted to a few ductal spaces"
                  },
                  {
                    "text": "Myoepithelial cells produce acellular extracellular basement membrane-like material (matrix)Composed of polysaccharides, laminin, and type IV collagenPositive for PAS and Alcian blueMay calcify and be detected mammographically",
                    "sub_points": [
                      "Composed of polysaccharides, laminin, and type IV collagenPositive for PAS and Alcian blueMay calcify and be detected mammographically",
                      "Positive for PAS and Alcian blue",
                      "May calcify and be detected mammographically"
                    ]
                  },
                  {
                    "text": "Spherules of basement membrane-like material are surrounded by myoepithelial cells (\"pseudolumina\")Myoepithelial cells may be small, attenuated, &/or compressed and difficult to appreciate in H&E sectionsIHC studies (calponin, p63, myosin heavy chain) to highlight myoepithelial cells may be helpful diagnostically",
                    "sub_points": [
                      "Myoepithelial cells may be small, attenuated, &/or compressed and difficult to appreciate in H&E sections",
                      "IHC studies (calponin, p63, myosin heavy chain) to highlight myoepithelial cells may be helpful diagnostically"
                    ]
                  },
                  {
                    "text": "Basement membrane-like material can have different morphologic appearancesDense eosinophilic hyaline or collagenous spherulesPink fibrillar materialA denser cuticle of material lines the inner surface of spaces formed by myoepithelial cellsMay have a mucoid or myxoid appearanceThese lesions are termed mucinous spherulosis",
                    "sub_points": [
                      "Dense eosinophilic hyaline or collagenous spherules",
                      "Pink fibrillar materialA denser cuticle of material lines the inner surface of spaces formed by myoepithelial cells",
                      "A denser cuticle of material lines the inner surface of spaces formed by myoepithelial cells",
                      "May have a mucoid or myxoid appearanceThese lesions are termed mucinous spherulosis",
                      "These lesions are termed mucinous spherulosis"
                    ]
                  },
                  {
                    "text": "Luminal cells form solid nests or true luminaLumina appear empty or contain secretory materialLining cells often have apical blebs that project into lumen",
                    "sub_points": [
                      "Lumina appear empty or contain secretory material",
                      "Lining cells often have apical blebs that project into lumen"
                    ]
                  },
                  {
                    "text": "The true lumina formed by luminal cells and the pseudolumina formed by myoepithelial cells together mimic the cribriform pattern of DCIS"
                  },
                  {
                    "text": "CS involved bylobular neoplasia(LN)LN (lobular carcinoma in situ or atypical lobular hyperplasia) can involve the areas between the pseudoluminaLN replaces, or partially replaces, the area typically occupied by luminal cellsDyscohesive pattern and intracytoplasmic vacuoles of LN are helpful for recognitionMay be difficult to appreciate when cells are densely packedThe combination of the monomorphic population of LN and the cribriform pattern closely mimics DCISImmunoperoxidase studies to demonstrate the absence of E-cadherin or other adhesion proteins in LN are helpful in recognizing this lesionLN usually involves adjacent breast tissue as well as CSLN is more easily recognized in areas not involved by CS",
                    "sub_points": [
                      "LN (lobular carcinoma in situ or atypical lobular hyperplasia) can involve the areas between the pseudoluminaLN replaces, or partially replaces, the area typically occupied by luminal cellsDyscohesive pattern and intracytoplasmic vacuoles of LN are helpful for recognitionMay be difficult to appreciate when cells are densely packed",
                      "LN replaces, or partially replaces, the area typically occupied by luminal cells",
                      "Dyscohesive pattern and intracytoplasmic vacuoles of LN are helpful for recognitionMay be difficult to appreciate when cells are densely packed",
                      "May be difficult to appreciate when cells are densely packed",
                      "The combination of the monomorphic population of LN and the cribriform pattern closely mimics DCIS",
                      "Immunoperoxidase studies to demonstrate the absence of E-cadherin or other adhesion proteins in LN are helpful in recognizing this lesion",
                      "LN usually involves adjacent breast tissue as well as CSLN is more easily recognized in areas not involved by CS",
                      "LN is more easily recognized in areas not involved by CS"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Incidental CS detected on core needle biopsy is a benign finding and need not be excised"
                  },
                  {
                    "text": "Distinction from cribriform DCIS or AdCC can be more difficult in limited specimensCorrelation with imaging findings is helpfulDCIS is usually detected as calcificationsAdCC is usually detected as mass",
                    "sub_points": [
                      "Correlation with imaging findings is helpfulDCIS is usually detected as calcificationsAdCC is usually detected as mass",
                      "DCIS is usually detected as calcifications",
                      "AdCC is usually detected as mass"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ductal Carcinoma In Situ, Cribriform Pattern": [
                  {
                    "text": "DCIS is a clonal proliferation of luminal cellsTumor cells are monomorphic in appearanceNormal myoepithelial cells are only seen adjacent to basement membrane at periphery",
                    "sub_points": [
                      "Tumor cells are monomorphic in appearance",
                      "Normal myoepithelial cells are only seen adjacent to basement membrane at periphery"
                    ]
                  },
                  {
                    "text": "Tumor cells are polarized around spherical luminaRigid or punched-out (cookie cutter) appearanceSpaces may be empty, contain secretions, mucin, necrotic cells, or calcifications",
                    "sub_points": [
                      "Rigid or punched-out (cookie cutter) appearance",
                      "Spaces may be empty, contain secretions, mucin, necrotic cells, or calcifications"
                    ]
                  },
                  {
                    "text": "Immunoperoxidase studies will confirm the presence of myoepithelial cells only at the periphery of the lesion"
                  }
                ],
                "Adenoid Cystic Carcinoma (AdCC)": [
                  {
                    "text": "AdCC is a neoplastic proliferation of luminal and myoepithelial cells with matrix productionThe cribriform pattern seen in AdCC consists of true lumina (formed by luminal cells) and pseudolumina (formed by myoepithelial cells)",
                    "sub_points": [
                      "The cribriform pattern seen in AdCC consists of true lumina (formed by luminal cells) and pseudolumina (formed by myoepithelial cells)"
                    ]
                  },
                  {
                    "text": "Unlike CS, AdCC is usually detected as a > 1-cm mass by palpation or imaging and has an infiltrative growth pattern"
                  },
                  {
                    "text": "Differences in immunoreactivity patterns have been reported for AdCC and CS but may vary from case to caseCD117 (C-kit) is positive in epithelial cell population in AdCCReported to be negative or scant in CSResults may vary with specific antibodies to CD117Smooth muscle myosin heavy chain, CD10, and HHF35 are reported to be positive in myoepithelial cells in CS but negative in AdCCHowever, immunoreactivity may be seen in some cases of AdCCHormone receptors positive in luminal cell population of CS but negative in the majority of cases of AdCCGATA3 shows stronger positivity in CS",
                    "sub_points": [
                      "CD117 (C-kit) is positive in epithelial cell population in AdCCReported to be negative or scant in CSResults may vary with specific antibodies to CD117",
                      "Reported to be negative or scant in CS",
                      "Results may vary with specific antibodies to CD117",
                      "Smooth muscle myosin heavy chain, CD10, and HHF35 are reported to be positive in myoepithelial cells in CS but negative in AdCCHowever, immunoreactivity may be seen in some cases of AdCC",
                      "However, immunoreactivity may be seen in some cases of AdCC",
                      "Hormone receptors positive in luminal cell population of CS but negative in the majority of cases of AdCC",
                      "GATA3 shows stronger positivity in CS"
                    ]
                  },
                  {
                    "text": "In one study, 37% of AdCCs had a MYB rearrangement, whereas none of the CS cases had a rearrangement"
                  },
                  {
                    "text": "The distinction between AdCC and CS is best made on gross and microscopic evaluation"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "CS is only important due to its mimicry of DCIS and AdCCIt is important to be aware of features of CS to avoid misdiagnosis of cancer",
                    "sub_points": [
                      "It is important to be aware of features of CS to avoid misdiagnosis of cancer"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Syringomatous Tumor of the Nipple": {
            "name": "Syringomatous Tumor of the Nipple",
            "url": "https://app.pathprimer.com/document/04f4786d-715f-4bcd-a093-c9187ab053a0/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Benign neoplasm of nipple consisting of a mixed cell population forming tubules and solid nests with squamous metaplasia"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Very rare: < 1% of breast biopsies"
                  },
                  {
                    "text": "Presents as a palpable, solitary, firm dermal mass in subareolar or nipple region"
                  },
                  {
                    "text": "Management is complete local excision to achieve negative margins; local recurrence ~ 30% if margins positiveLocal recurrences ~ 30% if incompletely excised",
                    "sub_points": [
                      "Local recurrences ~ 30% if incompletely excised"
                    ]
                  },
                  {
                    "text": "Does not metastasize"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "3 types of cells presentMyoepithelial-like cells: p63(+) and high molecular weight keratin (+)Luminal-like cells: p63(-) and low molecular weight keratin (+)Squamoid cells: p63(+) and high molecular weight keratin (+)",
                    "sub_points": [
                      "Myoepithelial-like cells: p63(+) and high molecular weight keratin (+)",
                      "Luminal-like cells: p63(-) and low molecular weight keratin (+)",
                      "Squamoid cells: p63(+) and high molecular weight keratin (+)"
                    ]
                  },
                  {
                    "text": "Cells have small uniform nuclei"
                  },
                  {
                    "text": "Mitotic figures absent or rare"
                  },
                  {
                    "text": "Infiltrates into dermis and smooth muscle of areola"
                  },
                  {
                    "text": "Overlying epidermis is usually normal in appearance but can be acanthotic"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Variable pattern of p63 and markers for myoepithelial markers can aid in recognition"
                  },
                  {
                    "text": "Negative for hormone receptors and HER2"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Low-grade adenosquamous carcinoma"
                  },
                  {
                    "text": "Tubular carcinoma"
                  },
                  {
                    "text": "Squamous cell carcinoma of nipple"
                  },
                  {
                    "text": "Nipple adenoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Syringomatous tumor (SyT)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign, locally infiltrative neoplasm of probable lactiferous duct origin that arises in the dermis of nipple and areolaComposed of luminal-like cells, myoepithelial-like cells, and squamous cells",
                    "sub_points": [
                      "Composed of luminal-like cells, myoepithelial-like cells, and squamous cells"
                    ]
                  },
                  {
                    "text": "Other terms for this tumor are not recommendedSyringomatous adenoma, infiltrating syringomatous adenoma, nipple syringoma",
                    "sub_points": [
                      "Syringomatous adenoma, infiltrating syringomatous adenoma, nipple syringoma"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Syringomatous tumors (SyTs) only occur in the dermis of the breast and smooth muscle of the areola"
                  },
                  {
                    "text": "It has been proposed that SyTs likely arise from progenitor cells in the lactiferous ducts based on the types of keratins expressedTumor cells have more features in common with large duct epithelial cells rather than dermal eccrine sweat glandsSupports origin from lactiferous sinusesDistinguishes SyT of the nipple from SyTs of skinSkin tumors are thought to arise from eccrine ductsLack luminal-like cell component of SyTCorrelates breast SyT only present in the nipple rather than being distributed at other skin sites",
                    "sub_points": [
                      "Tumor cells have more features in common with large duct epithelial cells rather than dermal eccrine sweat glands",
                      "Supports origin from lactiferous sinuses",
                      "Distinguishes SyT of the nipple from SyTs of skinSkin tumors are thought to arise from eccrine ductsLack luminal-like cell component of SyT",
                      "Skin tumors are thought to arise from eccrine ducts",
                      "Lack luminal-like cell component of SyT",
                      "Correlates breast SyT only present in the nipple rather than being distributed at other skin sites"
                    ]
                  },
                  {
                    "text": "Although SyTs have an infiltrative pattern and can recur locally, the ability to metastasize has never been definitively demonstrated"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare: < 1% of breast biopsies (only ~ 80 cases reported)"
                  }
                ],
                "Age": [
                  {
                    "text": "Mean: 40-50 years (range: 11-76 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Almost all of these tumors have occurred in femalesOnly 2 cases reported in males",
                    "sub_points": [
                      "Only 2 cases reported in males"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Palpable solitary firm mass in the dermis of the nipple and areolaRare cases are bilateral",
                    "sub_points": [
                      "Rare cases are bilateral"
                    ]
                  },
                  {
                    "text": "May be associated with pain or tenderness, skin irritation (crusting &/or pruritus), and nipple retraction or inversion"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Should be completely excised with negative marginsMay recur locally if not completely excised (~ 30% of cases with positive margins)",
                    "sub_points": [
                      "May recur locally if not completely excised (~ 30% of cases with positive margins)"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign lesion that invades locally but does not metastasizeNo well-documented cases of regional or distant metastasisOne case report of possible isolated tumor cells in a lymph node could be due to epithelial displacement related to a prior excision",
                    "sub_points": [
                      "No well-documented cases of regional or distant metastasisOne case report of possible isolated tumor cells in a lymph node could be due to epithelial displacement related to a prior excision",
                      "One case report of possible isolated tumor cells in a lymph node could be due to epithelial displacement related to a prior excision"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Can be difficult to detect due to superficial location and presence within dense areolar smooth muscle"
                  },
                  {
                    "text": "Mass-forming lesion in subareolar regionBorders more often irregular than circumscribed",
                    "sub_points": [
                      "Borders more often irregular than circumscribed"
                    ]
                  },
                  {
                    "text": "Large calcifications may be present localized to the nippleThese correlate with superficial squamous cysts with calcified keratin debris formed by tumor cells",
                    "sub_points": [
                      "These correlate with superficial squamous cysts with calcified keratin debris formed by tumor cells"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Can be difficult to detect due to location"
                  },
                  {
                    "text": "Ill-defined mass with heterogeneous internal echoes"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Ill-defined, firm, white mass with minute cystic spaces in dermis of nipple and areola"
                  }
                ],
                "Size": [
                  {
                    "text": "Usually 0.5-4 cm but rarely can be larger"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "SyTs consist of at least 3 types of cellsLuminal-like cellsp63(-) and low molecular weight cytokeratin (+)Generally located in the center of cell nests and form luminaMyoepithelial-like cellsp63 and high molecular weight cytokeratin 5/14 (+)Variably express other proteins expressed by myoepithelial cellsGenerally located at the periphery of tumor cell nestsSquamous cellsp63 and high molecular weight cytokeratin 10 (+)May produce keratin and form cystsTypically found forming solid nests or in center of tumor cell nests",
                    "sub_points": [
                      "Luminal-like cellsp63(-) and low molecular weight cytokeratin (+)Generally located in the center of cell nests and form lumina",
                      "p63(-) and low molecular weight cytokeratin (+)",
                      "Generally located in the center of cell nests and form lumina",
                      "Myoepithelial-like cellsp63 and high molecular weight cytokeratin 5/14 (+)Variably express other proteins expressed by myoepithelial cellsGenerally located at the periphery of tumor cell nests",
                      "p63 and high molecular weight cytokeratin 5/14 (+)Variably express other proteins expressed by myoepithelial cells",
                      "Variably express other proteins expressed by myoepithelial cells",
                      "Generally located at the periphery of tumor cell nests",
                      "Squamous cellsp63 and high molecular weight cytokeratin 10 (+)May produce keratin and form cystsTypically found forming solid nests or in center of tumor cell nests",
                      "p63 and high molecular weight cytokeratin 10 (+)May produce keratin and form cysts",
                      "May produce keratin and form cysts",
                      "Typically found forming solid nests or in center of tumor cell nests"
                    ]
                  },
                  {
                    "text": "The 3 types of cells are seen in different combinations in tubules and solid nestsTubules are lined by > 1 cell layerCells at periphery are typically flattened and p63(+)Rarely positive for other myoepithelial markers, such as actinInner cells can be either cuboidal (glandular or luminal) or flattened (squamous)Lumina may contain granular eosinophilic secretionsMay show complex branching patternsSquamous nests may be solid or cysticOften comma- or tadpole-shapedCysts contain keratin, may be calcifiedCells are p63(+)",
                    "sub_points": [
                      "Tubules are lined by > 1 cell layerCells at periphery are typically flattened and p63(+)Rarely positive for other myoepithelial markers, such as actinInner cells can be either cuboidal (glandular or luminal) or flattened (squamous)Lumina may contain granular eosinophilic secretionsMay show complex branching patterns",
                      "Cells at periphery are typically flattened and p63(+)Rarely positive for other myoepithelial markers, such as actin",
                      "Rarely positive for other myoepithelial markers, such as actin",
                      "Inner cells can be either cuboidal (glandular or luminal) or flattened (squamous)",
                      "Lumina may contain granular eosinophilic secretions",
                      "May show complex branching patterns",
                      "Squamous nests may be solid or cysticOften comma- or tadpole-shapedCysts contain keratin, may be calcifiedCells are p63(+)",
                      "Often comma- or tadpole-shaped",
                      "Cysts contain keratin, may be calcified",
                      "Cells are p63(+)"
                    ]
                  },
                  {
                    "text": "Nuclei are small and uniform"
                  },
                  {
                    "text": "Mitoses are absent or rare, and necrosis is absent"
                  },
                  {
                    "text": "Tumor infiltrates around and within smooth muscle and lactiferous sinuses of nippleExtent can be difficult to define, as portions of tumor can appear to be located at a distance, separated by normal-appearing dermis",
                    "sub_points": [
                      "Extent can be difficult to define, as portions of tumor can appear to be located at a distance, separated by normal-appearing dermis"
                    ]
                  },
                  {
                    "text": "Tumor cells should not invade into epidermis or deeply into subcutaneous adipose tissueCan very focally involve subcutaneous tissue",
                    "sub_points": [
                      "Can very focally involve subcutaneous tissue"
                    ]
                  },
                  {
                    "text": "Perineural invasion may be presentShould be distinguished from involvement of smooth muscleBundles of smooth muscle can be mistaken for nervesNo lymphovascular invasion is seen",
                    "sub_points": [
                      "Should be distinguished from involvement of smooth muscleBundles of smooth muscle can be mistaken for nerves",
                      "Bundles of smooth muscle can be mistaken for nerves",
                      "No lymphovascular invasion is seen"
                    ]
                  },
                  {
                    "text": "Stroma may be fibrous or loosely cellularMay be denser around tumor cell nestsCan show myxoid or hyaline changeSpindle cells in stroma are reactive fibroblasts",
                    "sub_points": [
                      "May be denser around tumor cell nests",
                      "Can show myxoid or hyaline change",
                      "Spindle cells in stroma are reactive fibroblasts"
                    ]
                  },
                  {
                    "text": "Neoplastic epithelial spindle cells would be highly unusualIf present, another diagnosis should be consideredKeratin (+) stromal cells can sometimes be seen in association with benign sclerosing lesionsMost common with the antibody MNF116Other keratins and p63 are more reliable for identifying neoplastic spindle cells",
                    "sub_points": [
                      "If present, another diagnosis should be considered",
                      "Keratin (+) stromal cells can sometimes be seen in association with benign sclerosing lesionsMost common with the antibody MNF116Other keratins and p63 are more reliable for identifying neoplastic spindle cells",
                      "Most common with the antibody MNF116",
                      "Other keratins and p63 are more reliable for identifying neoplastic spindle cells"
                    ]
                  },
                  {
                    "text": "Pseudoepitheliomatous hyperplasia can occur in the overlying skinTumor does not invade into epidermis and does not cause ulceration",
                    "sub_points": [
                      "Tumor does not invade into epidermis and does not cause ulceration"
                    ]
                  },
                  {
                    "text": "A mild lymphocytic infiltrate is usually present"
                  },
                  {
                    "text": "Often associated with sclerosing lesions (sclerosing adenosis and sclerosing papilloma)"
                  }
                ],
                "Skin Punch Biopsy": [
                  {
                    "text": "The initial diagnostic specimen is typically a punch biopsy of nipple/areolar skinThe small size and crush artifact can make diagnosis difficult",
                    "sub_points": [
                      "The small size and crush artifact can make diagnosis difficult"
                    ]
                  },
                  {
                    "text": "Correlation with the clinical lesion and imaging is helpful to distinguish SyT from low-grade adenosquamous carcinoma (LGASC)"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "p63: Positive in subsets of cellsPeripheral myoepithelial-like cells and squamous cells are positiveLuminal-like cells forming tubules are negative",
                    "sub_points": [
                      "Peripheral myoepithelial-like cells and squamous cells are positive",
                      "Luminal-like cells forming tubules are negative"
                    ]
                  },
                  {
                    "text": "Other myoepithelial markers: May be positive in a subset of cells but often negativep63(+) population of cells shows variable immunoreactivity for other myoepithelial markers",
                    "sub_points": [
                      "p63(+) population of cells shows variable immunoreactivity for other myoepithelial markers"
                    ]
                  },
                  {
                    "text": "High molecular weight keratinsCytokeratins 5 and 14: Usually present in myoepithelial-like cellsCytokeratin 10: Usually present in squamous cells",
                    "sub_points": [
                      "Cytokeratins 5 and 14: Usually present in myoepithelial-like cells",
                      "Cytokeratin 10: Usually present in squamous cells"
                    ]
                  },
                  {
                    "text": "Low molecular weight keratins (e.g., 8 and 18): Positive in luminal-like cells"
                  },
                  {
                    "text": "Hormone receptors: Usually negative (focal weak immunoreactivity sometimes present)"
                  },
                  {
                    "text": "HER2: Negative"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Low-Grade Adenosquamous Carcinoma (LGASC)": [
                  {
                    "text": "SyT is histologically very similar to LGASCBoth are associated with sclerosing lesions",
                    "sub_points": [
                      "Both are associated with sclerosing lesions"
                    ]
                  },
                  {
                    "text": "Major distinguishing feature is locationLGASC arises within breast parenchymaHowever, some tumors arise in retroareolar tissueLarger tumors can secondarily invade into dermisMay be difficult or impossible to distinguish LGASC from SyT in small &/or superficial biopsies",
                    "sub_points": [
                      "LGASC arises within breast parenchymaHowever, some tumors arise in retroareolar tissue",
                      "However, some tumors arise in retroareolar tissue",
                      "Larger tumors can secondarily invade into dermisMay be difficult or impossible to distinguish LGASC from SyT in small &/or superficial biopsies",
                      "May be difficult or impossible to distinguish LGASC from SyT in small &/or superficial biopsies"
                    ]
                  },
                  {
                    "text": "Multiple cell types and variable immunoreactivity for p63 and keratins, and myoepithelial markers, are seen in both tumorsSome LGASCs are associated with a neoplastic spindle cell component positive for p63 &/or keratinsNeoplastic spindle cells would be very unusual for SyT",
                    "sub_points": [
                      "Some LGASCs are associated with a neoplastic spindle cell component positive for p63 &/or keratins",
                      "Neoplastic spindle cells would be very unusual for SyT"
                    ]
                  }
                ],
                "Tubular Carcinoma (TC)": [
                  {
                    "text": "TCs are very well-differentiated carcinomas usually involving breast parenchyma and only rarely involving dermis"
                  },
                  {
                    "text": "Tubules are typically angulated rather than rounded and have a single cell layerTubules of SyT have multiple cell layers",
                    "sub_points": [
                      "Tubules of SyT have multiple cell layers"
                    ]
                  },
                  {
                    "text": "Apical snouts are common"
                  },
                  {
                    "text": "Frequently associated with flat epithelial atypia, atypical ductal hyperplasia, &/or ductal carcinoma in situ"
                  },
                  {
                    "text": "Not associated with squamous metaplasia, and tumor cells are p63(-)SyT shows p63 positivity in squamous cells and peripherally located cells",
                    "sub_points": [
                      "SyT shows p63 positivity in squamous cells and peripherally located cells"
                    ]
                  },
                  {
                    "text": "TCs could potentially invade into epidermisSyT does not invade into epidermis",
                    "sub_points": [
                      "SyT does not invade into epidermis"
                    ]
                  },
                  {
                    "text": "TC is almost always strongly positive for ERIf negative, other diagnoses (e.g., microglandular adenosis) or problems with assay should be consideredSyT is negative for hormone receptors",
                    "sub_points": [
                      "If negative, other diagnoses (e.g., microglandular adenosis) or problems with assay should be considered",
                      "SyT is negative for hormone receptors"
                    ]
                  }
                ],
                "Squamous Cell Carcinoma of Nipple": [
                  {
                    "text": "Arises from nipple skin and presents as a clinically evident epidermal lesionSyT presents as mass in dermis but does not directly involve epidermisOverlying benign reactive changes in epidermis (e.g., acanthosis) associated with SyT might mimic squamous cell carcinoma",
                    "sub_points": [
                      "SyT presents as mass in dermis but does not directly involve epidermis",
                      "Overlying benign reactive changes in epidermis (e.g., acanthosis) associated with SyT might mimic squamous cell carcinoma"
                    ]
                  },
                  {
                    "text": "Squamous cell carcinoma in situ is generally present"
                  },
                  {
                    "text": "Tumor cells invade as large nests of cellsNuclear pleomorphism and mitoses are generally presentLymphovascular invasion could be present",
                    "sub_points": [
                      "Nuclear pleomorphism and mitoses are generally present",
                      "Lymphovascular invasion could be present"
                    ]
                  },
                  {
                    "text": "Tubule (glandular) component is not present"
                  }
                ],
                "Nipple Adenoma": [
                  {
                    "text": "Nipple adenomas are benign proliferative lesions that arise near the orifices of lactiferous ducts at the skin"
                  },
                  {
                    "text": "Form nodular palpable masses contiguous with skinIf overlying surface is involved by glandular epithelium, epidermis can appear eroded or ulceratedSyT forms plaque-like area of firmness in nipple dermis",
                    "sub_points": [
                      "If overlying surface is involved by glandular epithelium, epidermis can appear eroded or ulcerated",
                      "SyT forms plaque-like area of firmness in nipple dermis"
                    ]
                  },
                  {
                    "text": "Some adenomas have areas of squamous metaplasiaBoth nipple adenomas and SyTs are associated with superficial keratin cysts",
                    "sub_points": [
                      "Both nipple adenomas and SyTs are associated with superficial keratin cysts"
                    ]
                  },
                  {
                    "text": "An infiltrative pattern of small nests of cells in dermis is not seenIf present, SyT associated with an adenoma should be considered",
                    "sub_points": [
                      "If present, SyT associated with an adenoma should be considered"
                    ]
                  }
                ],
                "Skin Adnexal Tumors": [
                  {
                    "text": "Syringoma and microcystic adnexal carcinoma can share features with SyT"
                  },
                  {
                    "text": "The glandular differentiation in SyT distinguishes this lesion as a tumor arising from the nipple"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "It may not be possible to distinguish SyT from LGASC in small superficial biopsiesClassification should be deferred to after complete excision",
                    "sub_points": [
                      "Classification should be deferred to after complete excision"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sclerosing Adenosis": {
            "name": "Sclerosing Adenosis",
            "url": "https://app.pathprimer.com/document/a5783e8b-3c01-43e0-bd17-d5ebc3029d43/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Can present as mammographic calcifications or a mass, a palpable mass, or an incidental finding"
                  },
                  {
                    "text": "Classified as proliferative disease without atypia1.5-2.0x increased risk for development of invasive carcinoma in either breast",
                    "sub_points": [
                      "1.5-2.0x increased risk for development of invasive carcinoma in either breast"
                    ]
                  },
                  {
                    "text": "Most common benign lesion mistaken for invasive carcinomaClosely mimics carcinoma when involved by apocrine metaplasia, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS)Can be difficult to diagnose on core needle biopsiesShould always be considered in the differential diagnosis of invasive carcinomas",
                    "sub_points": [
                      "Closely mimics carcinoma when involved by apocrine metaplasia, lobular carcinoma in situ (LCIS), or ductal carcinoma in situ (DCIS)",
                      "Can be difficult to diagnose on core needle biopsies",
                      "Should always be considered in the differential diagnosis of invasive carcinomas"
                    ]
                  }
                ],
                "Imaging": [
                  {
                    "text": "Microcalcifications (clustered, amorphous) most common finding"
                  },
                  {
                    "text": "Also forms rounded or smoothly lobulated masses"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Circumscribed lobulocentric architecture"
                  },
                  {
                    "text": "Lumina distorted and compressed by dense stroma"
                  },
                  {
                    "text": "Frequently associated with papillomas, complex sclerosing lesions, and fibroadenomas"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "IHC to detect myoepithelial cells is helpful to distinguish sclerosing adenosis from invasive carcinoma"
                  },
                  {
                    "text": "Expression of some myoepithelial markers is reducedSmooth muscle actin, calponin, and p63 are least affected; reduced in < 10%",
                    "sub_points": [
                      "Smooth muscle actin, calponin, and p63 are least affected; reduced in < 10%"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Normal physiologic adenosis and involution"
                  },
                  {
                    "text": "Invasive ductal carcinoma"
                  },
                  {
                    "text": "Microglandular adenosis"
                  },
                  {
                    "text": "Adenomyoepithelioma"
                  },
                  {
                    "text": "Tubular adenoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Sclerosing adenosis (SA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Lobulocentric benign proliferation of acini around a central duct with stromal sclerosis and compression of lumina"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Adenosis": [
                  {
                    "text": "Defined as an increase in the number of acini per lobulePhysiologic adenosisoccurs as a response to pregnancy during which the number of acini in each lobule increasesBlunt duct adenosisrefers to a lobule with rounded dilated acini, often lined by columnar cell changeSAis a lobulocentric proliferative lesion in which the number of acini in a lobule is increased, and the acini also show sclerosing changesSA has increased expression of ER and Ki-67 (indicating increased proliferation) over normal benign breast epitheliumSA and other proliferative lesions are more common in women receiving hormone replacement therapyAssociated with obesity (increased endogenous estrogen levels)Hormone imbalance and dysregulation of ER may play a role in the development of SARisk for developing SA and other proliferative lesions may be increased in women who have > 25% fibroglandular breast tissue density",
                    "sub_points": [
                      "Physiologic adenosisoccurs as a response to pregnancy during which the number of acini in each lobule increases",
                      "Blunt duct adenosisrefers to a lobule with rounded dilated acini, often lined by columnar cell change",
                      "SAis a lobulocentric proliferative lesion in which the number of acini in a lobule is increased, and the acini also show sclerosing changesSA has increased expression of ER and Ki-67 (indicating increased proliferation) over normal benign breast epitheliumSA and other proliferative lesions are more common in women receiving hormone replacement therapyAssociated with obesity (increased endogenous estrogen levels)Hormone imbalance and dysregulation of ER may play a role in the development of SARisk for developing SA and other proliferative lesions may be increased in women who have > 25% fibroglandular breast tissue density",
                      "SA has increased expression of ER and Ki-67 (indicating increased proliferation) over normal benign breast epitheliumSA and other proliferative lesions are more common in women receiving hormone replacement therapyAssociated with obesity (increased endogenous estrogen levels)",
                      "SA and other proliferative lesions are more common in women receiving hormone replacement therapy",
                      "Associated with obesity (increased endogenous estrogen levels)",
                      "Hormone imbalance and dysregulation of ER may play a role in the development of SA",
                      "Risk for developing SA and other proliferative lesions may be increased in women who have > 25% fibroglandular breast tissue density"
                    ]
                  },
                  {
                    "text": "Tubular adenosisdescribes a lesion in which the acini have a wandering pattern in fibroadipose tissue rather than forming a discrete cluster around a ductThe acini can be rounded and open (\"tubular\") or sclerotic (angular and compressed)",
                    "sub_points": [
                      "The acini can be rounded and open (\"tubular\") or sclerotic (angular and compressed)"
                    ]
                  }
                ],
                "Stromal Fibrosis in Sclerosing Adenosis": [
                  {
                    "text": "Fibrosis in SA suggests combined stimulation of epithelial, myoepithelial, and mesenchymal cellsThese are likely phenotypic changes resulting from microenvironmental signals that stimulate proliferationThe nature of these signals has not been determined",
                    "sub_points": [
                      "These are likely phenotypic changes resulting from microenvironmental signals that stimulate proliferationThe nature of these signals has not been determined",
                      "The nature of these signals has not been determined"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Frequent incidental finding in breast biopsiesPresent in 12% of breast biopsies without cancer",
                    "sub_points": [
                      "Present in 12% of breast biopsies without cancer"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Most common in perimenopausal women"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most commonly detected by screening mammography"
                  },
                  {
                    "text": "Less commonly presents as a palpable massThese cases can be termed nodular SAMay be associated with pain and tenderness",
                    "sub_points": [
                      "These cases can be termed nodular SA",
                      "May be associated with pain and tenderness"
                    ]
                  },
                  {
                    "text": "Also a frequent incidental finding in breast specimens removed for other indications"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No treatment is necessary for SA detected by core needle biopsy or on excision"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Classified as proliferative disease without atypia (the same category as usual ductal hyperplasia)1.5-2.0x increased relative risk for development of invasive carcinoma or 5-7% actual lifetime riskIncreased risk for both breasts",
                    "sub_points": [
                      "1.5-2.0x increased relative risk for development of invasive carcinoma or 5-7% actual lifetime risk",
                      "Increased risk for both breasts"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Calcifications are the most common findingClustered amorphous calcifications typicalPleomorphic &/or punctate calcifications less common",
                    "sub_points": [
                      "Clustered amorphous calcifications typical",
                      "Pleomorphic &/or punctate calcifications less common"
                    ]
                  },
                  {
                    "text": "Less commonly forms a mass, generally with circumscribed or smoothly lobulated marginsThe borders are less likely to be ill defined or irregularMay be associated with calcifications (occasionally, calcifications can be extensive)",
                    "sub_points": [
                      "The borders are less likely to be ill defined or irregular",
                      "May be associated with calcifications (occasionally, calcifications can be extensive)"
                    ]
                  },
                  {
                    "text": "SA can also present as architectural distortionThis finding has become more common with the use of tomosynthesis",
                    "sub_points": [
                      "This finding has become more common with the use of tomosynthesis"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Solid hypoechoic mass with circumscribed margins"
                  },
                  {
                    "text": "Unlikely to show posterior acoustic changes"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "May show enhancement in up to 30% of cases or can be an incidental finding"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "SA presenting as a mass by palpation or imaging may be grossly evidentA rubbery, circumscribed nodule may be seen (nodular adenosis)",
                    "sub_points": [
                      "A rubbery, circumscribed nodule may be seen (nodular adenosis)"
                    ]
                  },
                  {
                    "text": "The majority are small (< 1 cm) and not grossly apparent"
                  },
                  {
                    "text": "In rare cases, associated microcalcifications are plentiful and may impart a gritty cut surface"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "No consistent genetic changes have been reported"
                  }
                ],
                "Protein": [
                  {
                    "text": "Homogeneous strong positivity for hormone receptors is seen"
                  },
                  {
                    "text": "Ki-67 is increased with respect to uninvolved breast epithelium"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Arises within terminal duct lobular unit (TDLU)Consist of enlarged and distorted TDLUs, containing crowded back-to-back acini, prominent myoepithelium, and associated stromal fibrosisMust be at least 2x larger than adjacent lobulesAt least 50% of the lobule should be involved by the sclerosing changesHowever, lobules can vary greatly in size in the same breast, making this requirement difficult to assessThe cellular composition may be difficult to appreciate in some cases due to distortion and compression of the acini",
                    "sub_points": [
                      "Consist of enlarged and distorted TDLUs, containing crowded back-to-back acini, prominent myoepithelium, and associated stromal fibrosis",
                      "Must be at least 2x larger than adjacent lobulesAt least 50% of the lobule should be involved by the sclerosing changes",
                      "At least 50% of the lobule should be involved by the sclerosing changes",
                      "However, lobules can vary greatly in size in the same breast, making this requirement difficult to assess",
                      "The cellular composition may be difficult to appreciate in some cases due to distortion and compression of the acini"
                    ]
                  },
                  {
                    "text": "A lobulocentric pattern is an important diagnostic featureRefers to a cluster of tubules or acini around a central larger duct or ductsLobulocentric growth pattern is best appreciated at low magnification",
                    "sub_points": [
                      "Refers to a cluster of tubules or acini around a central larger duct or ducts",
                      "Lobulocentric growth pattern is best appreciated at low magnification"
                    ]
                  },
                  {
                    "text": "Acini appear to swirl around a central ductAcini are lined by luminal cells and myoepithelial cellsTightly clustered acini conform in shape to one another (back-to-back pattern)The acini at the periphery can be open and round in shapeLuminal cells lack atypia and may appear cuboidal or flattened and compressedMyoepithelial cells may be spindled in shape and can be prominentThe 2 cell layers are best appreciated at peripheryMay be difficult to see in the center of the lesionThis can make SA difficult to evaluate on core needle biopsies that partially sample the lesion",
                    "sub_points": [
                      "Acini are lined by luminal cells and myoepithelial cells",
                      "Tightly clustered acini conform in shape to one another (back-to-back pattern)The acini at the periphery can be open and round in shape",
                      "The acini at the periphery can be open and round in shape",
                      "Luminal cells lack atypia and may appear cuboidal or flattened and compressed",
                      "Myoepithelial cells may be spindled in shape and can be prominent",
                      "The 2 cell layers are best appreciated at peripheryMay be difficult to see in the center of the lesionThis can make SA difficult to evaluate on core needle biopsies that partially sample the lesion",
                      "May be difficult to see in the center of the lesionThis can make SA difficult to evaluate on core needle biopsies that partially sample the lesion",
                      "This can make SA difficult to evaluate on core needle biopsies that partially sample the lesion"
                    ]
                  },
                  {
                    "text": "Sclerosis refers to stromal hyalinization that compresses and distorts aciniLuminal spaces can be completely closed by thickened and eosinophilic basement membraneAcini may have the appearance of solid cords arranged in a swirling patternGlandular compression and distortion may be most marked in the center of lesions",
                    "sub_points": [
                      "Luminal spaces can be completely closed by thickened and eosinophilic basement membrane",
                      "Acini may have the appearance of solid cords arranged in a swirling pattern",
                      "Glandular compression and distortion may be most marked in the center of lesions"
                    ]
                  },
                  {
                    "text": "Microcalcifications within either the stroma or the glandular lumina are present in > 50% of cases and may be prominent"
                  },
                  {
                    "text": "Multiple confluent areas of SA can be termed \"nodular SA\"Nodular SA is preferred over \"adenosis tumor\" as \"tumor\" may raise an unwarranted concern for malignancyCan form a palpable mass &/or a mammographic density",
                    "sub_points": [
                      "Nodular SA is preferred over \"adenosis tumor\" as \"tumor\" may raise an unwarranted concern for malignancy",
                      "Can form a palpable mass &/or a mammographic density"
                    ]
                  },
                  {
                    "text": "Pseudoperineural invasion may be seenTubules are present within nervesMyoepithelial cells are present as demonstrated by IHCNot an indication of malignancy",
                    "sub_points": [
                      "Tubules are present within nerves",
                      "Myoepithelial cells are present as demonstrated by IHC",
                      "Not an indication of malignancy"
                    ]
                  },
                  {
                    "text": "SA is frequently associated with other proliferative lesionsSclerosing papilloma, complex sclerosing lesion, fibroadenoma, usual ductal hyperplasiaOther benign lesions can be seen within or at the periphery of SAs",
                    "sub_points": [
                      "Sclerosing papilloma, complex sclerosing lesion, fibroadenoma, usual ductal hyperplasia",
                      "Other benign lesions can be seen within or at the periphery of SAs"
                    ]
                  },
                  {
                    "text": "Tubular adenosis is a pattern in which acini are located farther apart instead of forming a discrete massAcini can be rounded and open or sclerotic",
                    "sub_points": [
                      "Acini can be rounded and open or sclerotic"
                    ]
                  },
                  {
                    "text": "Apocrine adenosis and atypical apocrine adenosisTerm used for SA involved by apocrine metaplasiaMay be mistaken for carcinoma due to the monomorphic appearance of cells with enlarged nucleiIf nuclei are enlarged (3x larger in size) and atypical, may be termed atypical apocrine adenosisNot shown to increase risk of cancer or likelihood of finding cancer on excision after core needle biopsy if imaging is concordant and atypical ductal hyperplasia is not presentHowever, the risk for finding cancer on excision may be greater if the imaging lesion was a mass",
                    "sub_points": [
                      "Term used for SA involved by apocrine metaplasia",
                      "May be mistaken for carcinoma due to the monomorphic appearance of cells with enlarged nuclei",
                      "If nuclei are enlarged (3x larger in size) and atypical, may be termed atypical apocrine adenosisNot shown to increase risk of cancer or likelihood of finding cancer on excision after core needle biopsy if imaging is concordant and atypical ductal hyperplasia is not presentHowever, the risk for finding cancer on excision may be greater if the imaging lesion was a mass",
                      "Not shown to increase risk of cancer or likelihood of finding cancer on excision after core needle biopsy if imaging is concordant and atypical ductal hyperplasia is not presentHowever, the risk for finding cancer on excision may be greater if the imaging lesion was a mass",
                      "However, the risk for finding cancer on excision may be greater if the imaging lesion was a mass"
                    ]
                  },
                  {
                    "text": "SA involved by lobular carcinoma in situ (LCIS) andductal carcinoma in situ(DCIS)The combination of neoplastic cells and a complex glandular pattern can closely mimic an invasive carcinomaFeatures supporting SA includeMyoepithelial cells on H&E or by IHCLobulocentric architecture with pushing bordersArchitecture is best appreciated on low powerLobulocentric pattern may not be easily evaluated on core needle biopsyDense, rather than desmoplastic, stromaSwirling back-to-back glands in concentric arraysUsually does not involve adipose tissueIf SA does involve adipose tissue, the acini appear to not disturb the adipocytesNo true infiltration around normal ducts and lobulesIdentifying SA in adjacent breast tissue may be helpful",
                    "sub_points": [
                      "The combination of neoplastic cells and a complex glandular pattern can closely mimic an invasive carcinoma",
                      "Features supporting SA includeMyoepithelial cells on H&E or by IHCLobulocentric architecture with pushing bordersArchitecture is best appreciated on low powerLobulocentric pattern may not be easily evaluated on core needle biopsyDense, rather than desmoplastic, stromaSwirling back-to-back glands in concentric arraysUsually does not involve adipose tissueIf SA does involve adipose tissue, the acini appear to not disturb the adipocytesNo true infiltration around normal ducts and lobules",
                      "Myoepithelial cells on H&E or by IHC",
                      "Lobulocentric architecture with pushing bordersArchitecture is best appreciated on low powerLobulocentric pattern may not be easily evaluated on core needle biopsy",
                      "Architecture is best appreciated on low power",
                      "Lobulocentric pattern may not be easily evaluated on core needle biopsy",
                      "Dense, rather than desmoplastic, stroma",
                      "Swirling back-to-back glands in concentric arrays",
                      "Usually does not involve adipose tissueIf SA does involve adipose tissue, the acini appear to not disturb the adipocytes",
                      "If SA does involve adipose tissue, the acini appear to not disturb the adipocytes",
                      "No true infiltration around normal ducts and lobules",
                      "Identifying SA in adjacent breast tissue may be helpful"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "The benign features of SA are more difficult to appreciate on partially sampled lesions on core needle biopsyBorders and lobulocentric pattern may not be evaluableCentral sclerosed acini can closely mimic invasive carcinomaThe center of the lesion may be mistaken for periphery of the lesion on core needle biopsyIf the center of the lesion shows sclerosis, this can be mistaken for invasion into adjacent stroma",
                    "sub_points": [
                      "Borders and lobulocentric pattern may not be evaluable",
                      "Central sclerosed acini can closely mimic invasive carcinomaThe center of the lesion may be mistaken for periphery of the lesion on core needle biopsyIf the center of the lesion shows sclerosis, this can be mistaken for invasion into adjacent stroma",
                      "The center of the lesion may be mistaken for periphery of the lesion on core needle biopsyIf the center of the lesion shows sclerosis, this can be mistaken for invasion into adjacent stroma",
                      "If the center of the lesion shows sclerosis, this can be mistaken for invasion into adjacent stroma"
                    ]
                  },
                  {
                    "text": "SA is the most common benign lesion mistaken for invasive carcinomaClosely mimics carcinoma when involved by apocrine metaplasia, LCIS, or DCIS",
                    "sub_points": [
                      "Closely mimics carcinoma when involved by apocrine metaplasia, LCIS, or DCIS"
                    ]
                  },
                  {
                    "text": "Must always be considered in the differential diagnosis of invasive carcinomaIHC for myoepithelial markers is helpful to confirm a diagnosis of SA",
                    "sub_points": [
                      "IHC for myoepithelial markers is helpful to confirm a diagnosis of SA"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Myoepithelial markersSA is always associated with a myoepithelial cell layerMost useful markers are p63 and smooth muscle myosin heavy chainUse of > 1 myoepithelial marker or a multiplex IHC study can be helpfulA diagnosis of malignancy should not be based on the absence of only 1 markerExpression of some markers is reduced in sclerosing lesionsExpression of CK5/6 is reduced to greatest extent; absent in ~ 1/3Smooth muscle actin, calponin, and p63 are least affected; reduced in < 10%In interpreting muscle markers, the nucleus of the cell should be seen above the basement membraneBlood vessels and myofibroblasts can mimic myoepithelial cells when closely apposed to the base of epithelial cells",
                    "sub_points": [
                      "SA is always associated with a myoepithelial cell layer",
                      "Most useful markers are p63 and smooth muscle myosin heavy chain",
                      "Use of > 1 myoepithelial marker or a multiplex IHC study can be helpfulA diagnosis of malignancy should not be based on the absence of only 1 marker",
                      "A diagnosis of malignancy should not be based on the absence of only 1 marker",
                      "Expression of some markers is reduced in sclerosing lesionsExpression of CK5/6 is reduced to greatest extent; absent in ~ 1/3Smooth muscle actin, calponin, and p63 are least affected; reduced in < 10%",
                      "Expression of CK5/6 is reduced to greatest extent; absent in ~ 1/3",
                      "Smooth muscle actin, calponin, and p63 are least affected; reduced in < 10%",
                      "In interpreting muscle markers, the nucleus of the cell should be seen above the basement membraneBlood vessels and myofibroblasts can mimic myoepithelial cells when closely apposed to the base of epithelial cells",
                      "Blood vessels and myofibroblasts can mimic myoepithelial cells when closely apposed to the base of epithelial cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Normal Physiologic Adenosis": [
                  {
                    "text": "Breast lobules normally enlarge during pregnancy"
                  },
                  {
                    "text": "Lobules partially regress after pregnancy and end of lactation and undergo involution with age"
                  },
                  {
                    "text": "Involuting lobules may be difficult to distinguish from SAMyoepithelial cells are prominent, and basement membranes are thickenedLuminal cells diminish in size and appear atrophicThus, involuting lobules appear more eosinophilic than SA, which is dominated by luminal cells with plump blue nucleiAn involuting lobule looks predominantly pink at low powerSA looks predominantly blue at low power",
                    "sub_points": [
                      "Myoepithelial cells are prominent, and basement membranes are thickened",
                      "Luminal cells diminish in size and appear atrophic",
                      "Thus, involuting lobules appear more eosinophilic than SA, which is dominated by luminal cells with plump blue nucleiAn involuting lobule looks predominantly pink at low powerSA looks predominantly blue at low power",
                      "An involuting lobule looks predominantly pink at low power",
                      "SA looks predominantly blue at low power"
                    ]
                  }
                ],
                "Invasive Ductal Carcinoma (IDC)": [
                  {
                    "text": "SA can mimic IDC, especially when involved by apocrine metaplasia, LCIS, or DCIS"
                  },
                  {
                    "text": "IDC shows a haphazard infiltrating growth patternDoes not conform to lobulocentric architecture (best appreciated on low-power examination)Tubules are more widely spaced, not in parallel arraysBorders are irregular and infiltrating rather than circumscribed and pushingOften invades around normal ducts and lobules and into adipose tissueInfiltration around normal structures is often easily seen on IHC studies for myoepithelial cellsIn contrast, SA generally forms a single expansile lesion without an infiltrative pattern",
                    "sub_points": [
                      "Does not conform to lobulocentric architecture (best appreciated on low-power examination)",
                      "Tubules are more widely spaced, not in parallel arrays",
                      "Borders are irregular and infiltrating rather than circumscribed and pushing",
                      "Often invades around normal ducts and lobules and into adipose tissueInfiltration around normal structures is often easily seen on IHC studies for myoepithelial cellsIn contrast, SA generally forms a single expansile lesion without an infiltrative pattern",
                      "Infiltration around normal structures is often easily seen on IHC studies for myoepithelial cells",
                      "In contrast, SA generally forms a single expansile lesion without an infiltrative pattern"
                    ]
                  },
                  {
                    "text": "IDC consists of angulated glands with open lumina or solid tumor cell nestsTubules lack surrounding myoepithelial cellsIHC can be helpful to confirm lack of myoepithelial cellsMyofibroblasts and blood vessels adjacent to malignant tubules are positive for muscle markers and should not be mistaken for myoepithelial cells",
                    "sub_points": [
                      "Tubules lack surrounding myoepithelial cells",
                      "IHC can be helpful to confirm lack of myoepithelial cellsMyofibroblasts and blood vessels adjacent to malignant tubules are positive for muscle markers and should not be mistaken for myoepithelial cells",
                      "Myofibroblasts and blood vessels adjacent to malignant tubules are positive for muscle markers and should not be mistaken for myoepithelial cells"
                    ]
                  },
                  {
                    "text": "IDC is associated with more cellular desmoplastic stromaRarely associated with dense stromaWhen SA is associated with dense stroma, the stroma appears to compress and distort the epithelium",
                    "sub_points": [
                      "Rarely associated with dense stroma",
                      "When SA is associated with dense stroma, the stroma appears to compress and distort the epithelium"
                    ]
                  },
                  {
                    "text": "IDC often invades into adipose tissue with a destructive pattern"
                  }
                ],
                "Microglandular Adenosis (MGA)": [
                  {
                    "text": "Composed of small round tubules scattered around normal breast structuresCuboidal-shaped cells, may show clear cell changeLuminal spaces are open with round contours and contain eosinophilic secretionsSecretions are PAS and mucicarmine (+)Little or no stromal response",
                    "sub_points": [
                      "Cuboidal-shaped cells, may show clear cell change",
                      "Luminal spaces are open with round contours and contain eosinophilic secretionsSecretions are PAS and mucicarmine (+)",
                      "Secretions are PAS and mucicarmine (+)",
                      "Little or no stromal response"
                    ]
                  },
                  {
                    "text": "MGA can closely mimic a low-grade invasive carcinomaAbsence of hormone receptors in a lesion thought to be grade 1 carcinoma should raise the possibility of MGA",
                    "sub_points": [
                      "Absence of hormone receptors in a lesion thought to be grade 1 carcinoma should raise the possibility of MGA"
                    ]
                  },
                  {
                    "text": "MGA can be distinguished from SA and invasive carcinoma by IHCMGA: Tubules are ER(-), strongly S100(+), and no myoepithelial cells are presentSA: Luminal cells show variable positivity for ER, are S100(-) (although myoepithelial cells can be positive), and myoepithelial cells are presentIDC: Tubules are ER(+) (strong and diffuse), S100(-), and no myoepithelial cells are presentThere are very rare tubule-forming IDCs that are ER(-) but androgen receptor (+)",
                    "sub_points": [
                      "MGA: Tubules are ER(-), strongly S100(+), and no myoepithelial cells are present",
                      "SA: Luminal cells show variable positivity for ER, are S100(-) (although myoepithelial cells can be positive), and myoepithelial cells are present",
                      "IDC: Tubules are ER(+) (strong and diffuse), S100(-), and no myoepithelial cells are presentThere are very rare tubule-forming IDCs that are ER(-) but androgen receptor (+)",
                      "There are very rare tubule-forming IDCs that are ER(-) but androgen receptor (+)"
                    ]
                  },
                  {
                    "text": "MGA can recur and be associated with invasive carcinoma"
                  }
                ],
                "Adenomyoepithelioma": [
                  {
                    "text": "Rare benign lesion due to proliferation of both myoepithelial and luminal cells"
                  },
                  {
                    "text": "Myoepithelial cells are increased in number with respect to the number of luminal cellsIn SA, the myoepithelial cells are not increased in number with respect to the luminal cells",
                    "sub_points": [
                      "In SA, the myoepithelial cells are not increased in number with respect to the luminal cells"
                    ]
                  },
                  {
                    "text": "Lumina are generally round and open"
                  },
                  {
                    "text": "Myoepithelial cells can be spindled or round"
                  }
                ],
                "Tubular Adenoma": [
                  {
                    "text": "Forms well-circumscribed masses"
                  },
                  {
                    "text": "Benign proliferation of uniform, round acini in a lobulocentric patternAcini are back-to-back with little intervening stroma",
                    "sub_points": [
                      "Acini are back-to-back with little intervening stroma"
                    ]
                  },
                  {
                    "text": "Acini are not compressed and surrounded by dense stroma, as in SALumina are round and open",
                    "sub_points": [
                      "Lumina are round and open"
                    ]
                  },
                  {
                    "text": "Single normal myoepithelial cell layer is present"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Always consider SA in the differential diagnosis of invasive carcinomaEspecially important for core needle biopsies",
                    "sub_points": [
                      "Especially important for core needle biopsies"
                    ]
                  },
                  {
                    "text": "SA should be suspected in younger patients with small-sized lesions with distinct margins"
                  },
                  {
                    "text": "Myoepithelial markers are helpful to confirm that a normal single myoepithelial cell layer is present"
                  },
                  {
                    "text": "Distinction is especially challenging when SA is involved by apocrine metaplasia, LCIS, or DCIS"
                  }
                ]
              },
              "REPORTING": {
                "Features to Include": [
                  {
                    "text": "If SA is the lesion for which a biopsy or excision is performed, the presence of SA should be correlated with clinical or imaging findings"
                  },
                  {
                    "text": "SA slightly increases the risk of breast cancer"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Usual Ductal Hyperplasia": {
            "name": "Usual Ductal Hyperplasia",
            "url": "https://app.pathprimer.com/document/57b2128f-e79b-43fe-9a95-af31374e6040/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Usual ductal hyperplasia (UDH)An intraductal heterogeneous polyclonal population of luminal cells",
                    "sub_points": [
                      "An intraductal heterogeneous polyclonal population of luminal cells"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Hormonal stimulation &/or estrogen hypersensitivity likely play an important role in the pathogenesis of UDH"
                  },
                  {
                    "text": "Few genetic changes are found in UDH compared to atypical ductal hyperplasia or ductal carcinoma in situ (DCIS)"
                  },
                  {
                    "text": "Not considered to be a direct precursor for breast neoplasia"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Found in up to 25% of breast biopsies"
                  },
                  {
                    "text": "Associated with 1.5-2.0x increased relative risk of developing invasive carcinoma in the same or contralateral breastTranslates into actual 5-7% lifetime risk of developing invasive carcinomaDegree of risk not generally considered to be sufficient to recommend enhanced screening or chemoprevention",
                    "sub_points": [
                      "Translates into actual 5-7% lifetime risk of developing invasive carcinoma",
                      "Degree of risk not generally considered to be sufficient to recommend enhanced screening or chemoprevention"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Heterogeneous microscopic appearance correlates with polyclonal cell population"
                  },
                  {
                    "text": "Cells fill and bridge duct spaces, vary in shape and size"
                  },
                  {
                    "text": "Do not show polarization around luminal spaces"
                  },
                  {
                    "text": "Arranged in haphazard pattern and appear to be overlapping"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Heterogeneous immunoreactivity for hormone receptors and high molecular weight keratins correlate with UDH being composed of mixed polyclonal proliferation"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Atypical ductal hyperplasia"
                  },
                  {
                    "text": "DCIS, low grade"
                  },
                  {
                    "text": "Solid papillary carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Usual ductal hyperplasia (UDH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Ductal epithelial hyperplasia, ductal hyperplasia without atypia"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign intraductal polyclonal epithelial proliferation consisting of an increased number of luminal cellsCharacterized by varying degrees of solid or fenestrated epithelial proliferation that tends to fill and bridge across involved spacesOften showing streaming growth, especially in center of proliferationFlorid UDH must be distinguished from atypical ductal hyperplasia (ADH) and low-grade ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "Characterized by varying degrees of solid or fenestrated epithelial proliferation that tends to fill and bridge across involved spacesOften showing streaming growth, especially in center of proliferation",
                      "Often showing streaming growth, especially in center of proliferation",
                      "Florid UDH must be distinguished from atypical ductal hyperplasia (ADH) and low-grade ductal carcinoma in situ (DCIS)"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hormonal": [
                  {
                    "text": "Hormonal stimulation &/or estrogen hypersensitivity likely play an important role in the etiology of UDH"
                  },
                  {
                    "text": "Intraductal proliferative lesions, including UDH, are extremely rare before puberty; when they occur, they are generally the result of exogenous or abnormal endogenous hormonal stimulation"
                  },
                  {
                    "text": "In UDH, ER expression is associated with a lack of expression of the proliferation marker Ki-67In contrast, in atypical ductal hyperplasia (ADH) and low-grade ductal carcinoma in situ (DCIS), there is a positive association between ER and Ki-67These findings suggest that UDH and ADH are different entities rather than part of a spectrum of disease",
                    "sub_points": [
                      "In contrast, in atypical ductal hyperplasia (ADH) and low-grade ductal carcinoma in situ (DCIS), there is a positive association between ER and Ki-67",
                      "These findings suggest that UDH and ADH are different entities rather than part of a spectrum of disease"
                    ]
                  }
                ],
                "Genetics": [
                  {
                    "text": "Most studies have found no consistent genetic alterations associated with UDHGenetic alterations that have been described in ADH and low-grade DCIS are not seen in UDH",
                    "sub_points": [
                      "Genetic alterations that have been described in ADH and low-grade DCIS are not seen in UDH"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "UDH is present in ~ 25% of benign breast biopsies"
                  },
                  {
                    "text": "Incidence is not easily determined since UDH is almost always an incidental finding"
                  }
                ],
                "Age": [
                  {
                    "text": "Majority: 35-60 years (average: ~ 53 years); less frequent in women > 60 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Frequently found as a component of lesions that come to attention clinically or by imagingOften admixed with other benign epithelial changes, including sclerosing adenosis, papillomas, or apocrine metaplasia and cysts",
                    "sub_points": [
                      "Often admixed with other benign epithelial changes, including sclerosing adenosis, papillomas, or apocrine metaplasia and cysts"
                    ]
                  },
                  {
                    "text": "UDH is a microscopic findingNot clinically apparent as a palpable mass or causing other symptomsNot associated with imaging findingsFrequent constituent of \"fibrocystic changes\" (sclerosing adenosis, cystic apocrine metaplasia, etc.) that may be detected by mammography",
                    "sub_points": [
                      "Not clinically apparent as a palpable mass or causing other symptoms",
                      "Not associated with imaging findings",
                      "Frequent constituent of \"fibrocystic changes\" (sclerosing adenosis, cystic apocrine metaplasia, etc.) that may be detected by mammography"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "UDH is a benign process requiring no further treatment"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "UDH is associated with a 1.5-2.0x increased relative risk of developing subsequent invasive carcinoma~ 5-7% are expected to develop breast cancer during their lifetimesCancer risk applies to both breastsUDH is not thought to be a direct precursor; local surgery would not lower riskSubsequent cancer risk is higher in women with UDH and a family history of breast cancer",
                    "sub_points": [
                      "~ 5-7% are expected to develop breast cancer during their lifetimes",
                      "Cancer risk applies to both breastsUDH is not thought to be a direct precursor; local surgery would not lower risk",
                      "UDH is not thought to be a direct precursor; local surgery would not lower risk",
                      "Subsequent cancer risk is higher in women with UDH and a family history of breast cancer"
                    ]
                  },
                  {
                    "text": "UDH alone is not a reason for enhanced breast cancer surveillanceFollow-up should include physician examinations and routine mammographic screening",
                    "sub_points": [
                      "Follow-up should include physician examinations and routine mammographic screening"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "UDH alone does not result in findings by imaging"
                  },
                  {
                    "text": "Often found as a component of other mass-forming lesions or lesions forming calcifications"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "UDH does not form grossly evident lesions"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Few overall genomic changes have been detected"
                  },
                  {
                    "text": "MutationsPIK3CA(~ 45%) andAKT1(~ 15%) point mutationsThese are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityMutations in these genes are found in many other breast lesionsPapillomas, adenomyoepitheliomas, nipple adenomas, juvenile papillomatosis, columnar cell change, and normal breast tissueThus, these mutations may occur early in development and predispose to the formation of multiple types of proliferative lesions but are not specific to any particular lesionFrequent discordant genotypes are reported in UDH and concurrent carcinomas from the same patientPIK3CApoint mutations in proliferative lesions are often paired with wild-type alleles in adjacent carcinomasSupports other studies that UDH is not a direct precursor for carcinoma",
                    "sub_points": [
                      "PIK3CA(~ 45%) andAKT1(~ 15%) point mutationsThese are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityMutations in these genes are found in many other breast lesionsPapillomas, adenomyoepitheliomas, nipple adenomas, juvenile papillomatosis, columnar cell change, and normal breast tissueThus, these mutations may occur early in development and predispose to the formation of multiple types of proliferative lesions but are not specific to any particular lesionFrequent discordant genotypes are reported in UDH and concurrent carcinomas from the same patientPIK3CApoint mutations in proliferative lesions are often paired with wild-type alleles in adjacent carcinomasSupports other studies that UDH is not a direct precursor for carcinoma",
                      "These are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motility",
                      "Mutations in these genes are found in many other breast lesionsPapillomas, adenomyoepitheliomas, nipple adenomas, juvenile papillomatosis, columnar cell change, and normal breast tissue",
                      "Papillomas, adenomyoepitheliomas, nipple adenomas, juvenile papillomatosis, columnar cell change, and normal breast tissue",
                      "Thus, these mutations may occur early in development and predispose to the formation of multiple types of proliferative lesions but are not specific to any particular lesion",
                      "Frequent discordant genotypes are reported in UDH and concurrent carcinomas from the same patientPIK3CApoint mutations in proliferative lesions are often paired with wild-type alleles in adjacent carcinomasSupports other studies that UDH is not a direct precursor for carcinoma",
                      "PIK3CApoint mutations in proliferative lesions are often paired with wild-type alleles in adjacent carcinomas",
                      "Supports other studies that UDH is not a direct precursor for carcinoma"
                    ]
                  },
                  {
                    "text": "Copy number changesLoss of heterozygosity in ~ 10% of UDHFewer genetic abnormalities compared with those seen in ADH (~ 50% of cases)Far fewer changes than low-grade DCIS (50-80% of cases, numerous loci with similar pattern to invasive carcinoma) and invasive carcinoma from same patients",
                    "sub_points": [
                      "Loss of heterozygosity in ~ 10% of UDHFewer genetic abnormalities compared with those seen in ADH (~ 50% of cases)Far fewer changes than low-grade DCIS (50-80% of cases, numerous loci with similar pattern to invasive carcinoma) and invasive carcinoma from same patients",
                      "Fewer genetic abnormalities compared with those seen in ADH (~ 50% of cases)",
                      "Far fewer changes than low-grade DCIS (50-80% of cases, numerous loci with similar pattern to invasive carcinoma) and invasive carcinoma from same patients"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "The number of luminal cells is increased beyond the normal single cell layer"
                  },
                  {
                    "text": "The cells are haphazardly oriented to one another in a cohesive growth patternMild proliferation: 2-4 cell layersFlorid proliferation: > 4 cell layers filling and distending duct spacesFlorid UDH may show solid, fenestrated, or short tapering micropapillae",
                    "sub_points": [
                      "Mild proliferation: 2-4 cell layers",
                      "Florid proliferation: > 4 cell layers filling and distending duct spaces",
                      "Florid UDH may show solid, fenestrated, or short tapering micropapillae"
                    ]
                  },
                  {
                    "text": "Architectural patternsCells fill and bridge across duct spacesSolid patternHeterogeneity in cell size, shape, and placementMay demonstrate peripheral slit-like luminal spacesNormal myoepithelial layer is maintainedFenestrated patternLuminal spaces are irregular and variable in size and shapeFrequently slit-like and located peripherallyRounded, punched-out spaces (\"cookie cutter\") are seen in ADH and DCISMicropapillary patternTuft-like papillary projections with broad base and tapered at tips (pinched tips)Epithelium between micropapillae also shows hyperplasiaSame pattern of hyperplasia is seen in gynecomastia and gynecomastia-like changesMicropapillae associated with DCIS have a narrow base and a bulbous tip and arise from a flat lining",
                    "sub_points": [
                      "Cells fill and bridge across duct spaces",
                      "Solid patternHeterogeneity in cell size, shape, and placementMay demonstrate peripheral slit-like luminal spacesNormal myoepithelial layer is maintained",
                      "Heterogeneity in cell size, shape, and placement",
                      "May demonstrate peripheral slit-like luminal spaces",
                      "Normal myoepithelial layer is maintained",
                      "Fenestrated patternLuminal spaces are irregular and variable in size and shapeFrequently slit-like and located peripherallyRounded, punched-out spaces (\"cookie cutter\") are seen in ADH and DCIS",
                      "Luminal spaces are irregular and variable in size and shape",
                      "Frequently slit-like and located peripherallyRounded, punched-out spaces (\"cookie cutter\") are seen in ADH and DCIS",
                      "Rounded, punched-out spaces (\"cookie cutter\") are seen in ADH and DCIS",
                      "Micropapillary patternTuft-like papillary projections with broad base and tapered at tips (pinched tips)Epithelium between micropapillae also shows hyperplasiaSame pattern of hyperplasia is seen in gynecomastia and gynecomastia-like changesMicropapillae associated with DCIS have a narrow base and a bulbous tip and arise from a flat lining",
                      "Tuft-like papillary projections with broad base and tapered at tips (pinched tips)",
                      "Epithelium between micropapillae also shows hyperplasia",
                      "Same pattern of hyperplasia is seen in gynecomastia and gynecomastia-like changes",
                      "Micropapillae associated with DCIS have a narrow base and a bulbous tip and arise from a flat lining"
                    ]
                  },
                  {
                    "text": "Cytologic featuresMay have syncytial appearance with inconspicuous cell bordersFeatures favor polyclonal rather than monoclonal proliferationCells vary in size, shape, and nuclear orientationDo not show polarization around luminal spacesArranged in haphazard pattern and appear to be overlappingSome cases show spindle-shaped cells with prominent streaming or swirling patternRare mitoses do not preclude a diagnosis of UDH",
                    "sub_points": [
                      "May have syncytial appearance with inconspicuous cell borders",
                      "Features favor polyclonal rather than monoclonal proliferationCells vary in size, shape, and nuclear orientationDo not show polarization around luminal spacesArranged in haphazard pattern and appear to be overlappingSome cases show spindle-shaped cells with prominent streaming or swirling patternRare mitoses do not preclude a diagnosis of UDH",
                      "Cells vary in size, shape, and nuclear orientation",
                      "Do not show polarization around luminal spaces",
                      "Arranged in haphazard pattern and appear to be overlapping",
                      "Some cases show spindle-shaped cells with prominent streaming or swirling pattern",
                      "Rare mitoses do not preclude a diagnosis of UDH"
                    ]
                  },
                  {
                    "text": "Central necrosis can occasionally be presentTypically in areas of very florid hyperplasiaMost commonly seen in florid UDH in nipple adenomas",
                    "sub_points": [
                      "Typically in areas of very florid hyperplasia",
                      "Most commonly seen in florid UDH in nipple adenomas"
                    ]
                  },
                  {
                    "text": "Frequent constituent of benign epithelial lesionsApocrine cysts, sclerosing adenosis, complex sclerosing lesions, papillomas, nipple adenomas",
                    "sub_points": [
                      "Apocrine cysts, sclerosing adenosis, complex sclerosing lesions, papillomas, nipple adenomas"
                    ]
                  },
                  {
                    "text": "Metaplastic changesNormal epithelial cells can undergo apocrine or clear cell metaplasiaMetaplastic changes are more common in benign changes than in ADH or DCISResults in a monomorphic-appearing cell populationIt is very difficult to distinguish monomorphism of metaplasia from neoplasiaDiagnosis of atypia or malignancy in the setting of metaplasia requiresArchitectural atypiaHigh-grade nucleiAssociation with invasive carcinoma of the same histologic appearance",
                    "sub_points": [
                      "Normal epithelial cells can undergo apocrine or clear cell metaplasiaMetaplastic changes are more common in benign changes than in ADH or DCIS",
                      "Metaplastic changes are more common in benign changes than in ADH or DCIS",
                      "Results in a monomorphic-appearing cell populationIt is very difficult to distinguish monomorphism of metaplasia from neoplasia",
                      "It is very difficult to distinguish monomorphism of metaplasia from neoplasia",
                      "Diagnosis of atypia or malignancy in the setting of metaplasia requiresArchitectural atypiaHigh-grade nucleiAssociation with invasive carcinoma of the same histologic appearance",
                      "Architectural atypia",
                      "High-grade nuclei",
                      "Association with invasive carcinoma of the same histologic appearance"
                    ]
                  },
                  {
                    "text": "StromaSurrounding stroma usually does not show changes, such as periductal fibrosis or a lymphocytic infiltrate",
                    "sub_points": [
                      "Surrounding stroma usually does not show changes, such as periductal fibrosis or a lymphocytic infiltrate"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Florid UDH must be distinguished from ADH, as ADH is an indication for excisionIHC for high molecular weight (HMW) cytokeratins and ER can be helpful in difficult casesHeterogeneous pattern supports UDHA homogeneous pattern in small foci should not be overinterpreted as supporting ADH",
                    "sub_points": [
                      "IHC for high molecular weight (HMW) cytokeratins and ER can be helpful in difficult casesHeterogeneous pattern supports UDHA homogeneous pattern in small foci should not be overinterpreted as supporting ADH",
                      "Heterogeneous pattern supports UDH",
                      "A homogeneous pattern in small foci should not be overinterpreted as supporting ADH"
                    ]
                  },
                  {
                    "text": "Core biopsy finding must be correlated with clinical imagingUDH alone is an unlikely correlate for a lesion seen by imaging and is usually an incidental finding",
                    "sub_points": [
                      "UDH alone is an unlikely correlate for a lesion seen by imaging and is usually an incidental finding"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "UDH exhibits a mixed cellular immunophenotype as evidenced by heterogeneous ER and high molecular weight (HMW) keratin expressionUDH is a true hyperplasia with polyclonal proliferation of multiple cell typesHowever, very small lesions may show a monomorphic pattern due to the limited amount of cells and not due to clonality",
                    "sub_points": [
                      "UDH is a true hyperplasia with polyclonal proliferation of multiple cell types",
                      "However, very small lesions may show a monomorphic pattern due to the limited amount of cells and not due to clonality"
                    ]
                  },
                  {
                    "text": "Hormone receptorsER expression is generally present but typically patchyUp to 60% of florid UDH cases demonstrate diffuse expression of ER",
                    "sub_points": [
                      "ER expression is generally present but typically patchyUp to 60% of florid UDH cases demonstrate diffuse expression of ER",
                      "Up to 60% of florid UDH cases demonstrate diffuse expression of ER"
                    ]
                  },
                  {
                    "text": "HMW keratins (CK5/6, CK14, or 34BE12)Diffuse or mosaic patternConsistent with mixed cellular phenotype of polyclonal hyperplasiaFlat epithelial atypia, ADH, and DCIS are negative for HMW cytokeratinsER(-) DCIS can be diffusely and strongly positive for HMW cytokeratinsSurrounding myoepithelial cells are positive",
                    "sub_points": [
                      "Diffuse or mosaic patternConsistent with mixed cellular phenotype of polyclonal hyperplasia",
                      "Consistent with mixed cellular phenotype of polyclonal hyperplasia",
                      "Flat epithelial atypia, ADH, and DCIS are negative for HMW cytokeratinsER(-) DCIS can be diffusely and strongly positive for HMW cytokeratinsSurrounding myoepithelial cells are positive",
                      "ER(-) DCIS can be diffusely and strongly positive for HMW cytokeratins",
                      "Surrounding myoepithelial cells are positive"
                    ]
                  },
                  {
                    "text": "Ki-67 proliferative index is very lowUsually < 5% of cells",
                    "sub_points": [
                      "Usually < 5% of cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Atypical Ductal Hyperplasia": [
                  {
                    "text": "ADH is a small monoclonal population of cells but insufficient for diagnosis of DCISUniform population of monotonous cells typically only partially fills duct spacesArchitectural features (e.g., cribriform spaces and papillae) are focal or not as well formed as in DCISIn contrast, UDH consists of multiple cell types and does not appear clonal",
                    "sub_points": [
                      "Uniform population of monotonous cells typically only partially fills duct spaces",
                      "Architectural features (e.g., cribriform spaces and papillae) are focal or not as well formed as in DCISIn contrast, UDH consists of multiple cell types and does not appear clonal",
                      "In contrast, UDH consists of multiple cell types and does not appear clonal"
                    ]
                  },
                  {
                    "text": "ADH is negative for HMW cytokeratins and is strongly positive for ERThe mixed cell population in UDH usually shows patchy positivity for HMW cytokeratin and ER",
                    "sub_points": [
                      "The mixed cell population in UDH usually shows patchy positivity for HMW cytokeratin and ER"
                    ]
                  },
                  {
                    "text": "If a lesion is difficult to classify as ADH or UDH, UDH should be favored"
                  }
                ],
                "Ductal Carcinoma In Situ, Low Grade": [
                  {
                    "text": "Involved ductal spaces are expanded and filled with a monotonous clonal population of cellsComplex architectural patterns are well formed (cribriform, solid, micropapillary, papillary)Uniform involvement of duct spacesTypically involves multiple adjacent duct spaces",
                    "sub_points": [
                      "Complex architectural patterns are well formed (cribriform, solid, micropapillary, papillary)",
                      "Uniform involvement of duct spaces",
                      "Typically involves multiple adjacent duct spaces"
                    ]
                  },
                  {
                    "text": "Low-grade DCIS is negative for HMW cytokeratins and is strongly positive for ER"
                  },
                  {
                    "text": "Composed of monotonous uniform cells that stand apartCells do not overlap; frequent sharp cellular boundaries",
                    "sub_points": [
                      "Cells do not overlap; frequent sharp cellular boundaries"
                    ]
                  },
                  {
                    "text": "UDH does not have a uniform appearance and does not have well-formed architectural features"
                  }
                ],
                "Solid Papillary Carcinoma": [
                  {
                    "text": "Usually forms a solid mass or masses with fibrovascular coresUDH is most often an incidental finding",
                    "sub_points": [
                      "UDH is most often an incidental finding"
                    ]
                  },
                  {
                    "text": "Cells fill multiple circumscribed spacesSpaces are much larger than those typically involved by UDH",
                    "sub_points": [
                      "Spaces are much larger than those typically involved by UDH"
                    ]
                  },
                  {
                    "text": "Myoepithelial cells may be sparse or absentWhen present, the lesion is classified as DCISWhen absent, classification depends on patternLesions composed of circumscribed nests of cells resembling DCIS are classified as carcinoma in situ (AJCC Tis)Lesions composed of irregular nests of cells with an infiltrative pattern are classified as invasive solid papillary carcinoma (SPC)",
                    "sub_points": [
                      "When present, the lesion is classified as DCIS",
                      "When absent, classification depends on patternLesions composed of circumscribed nests of cells resembling DCIS are classified as carcinoma in situ (AJCC Tis)Lesions composed of irregular nests of cells with an infiltrative pattern are classified as invasive solid papillary carcinoma (SPC)",
                      "Lesions composed of circumscribed nests of cells resembling DCIS are classified as carcinoma in situ (AJCC Tis)",
                      "Lesions composed of irregular nests of cells with an infiltrative pattern are classified as invasive solid papillary carcinoma (SPC)"
                    ]
                  },
                  {
                    "text": "Presence of spindle-shaped cells in a whirling pattern can mimic UDH"
                  },
                  {
                    "text": "Solid papillary carcinoma (SPC) is negative for HMW cytokeratins and is strongly positive for EROften positive for neuroendocrine markers (synaptophysin or chromogranin)",
                    "sub_points": [
                      "Often positive for neuroendocrine markers (synaptophysin or chromogranin)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Epithelial lesions form a histologic continuum from UDH to ADH to low-grade DCIS"
                  },
                  {
                    "text": "When borderline lesions are encountered, it is recommended to classify as the one of lower importance"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Should be reported when UDH is the only lesion conferring a slightly higher risk of carcinoma"
                  },
                  {
                    "text": "Not essential to report when lesions of greater importance for prognosis are present (e.g., ADH or carcinoma)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Radial Sclerosing Lesion/Radial Scar": {
            "name": "Radial Sclerosing Lesion/Radial Scar",
            "url": "https://app.pathprimer.com/document/cbcc0cd3-d949-4e67-8f26-514af064c120/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Radial sclerosing lesion (RSL) is the only benign lesion that commonly mimics invasive carcinoma by imaging and microscopically"
                  },
                  {
                    "text": "Large lesions can form masses with spiculated margins or cause architectural distortion on imagingSome lesions are palpable",
                    "sub_points": [
                      "Some lesions are palpable"
                    ]
                  },
                  {
                    "text": "Gross lesions are firm irregular masses"
                  },
                  {
                    "text": "Microscopic findings can mimic carcinomaCentral nidus resembles invasive carcinomaProliferative changes in nidus can mimic atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "Central nidus resembles invasive carcinoma",
                      "Proliferative changes in nidus can mimic atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS)"
                    ]
                  },
                  {
                    "text": "Small lesions are common incidental findings"
                  },
                  {
                    "text": "RSL is classified as proliferative breast disease without atypia"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Masses with long slender spicules"
                  },
                  {
                    "text": "Center of mass is relatively small compared to the length of the spicules and may be lucent (black star appearance)"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Central nidusEntrapped and distorted small glands in cellular or collagenized stroma",
                    "sub_points": [
                      "Entrapped and distorted small glands in cellular or collagenized stroma"
                    ]
                  },
                  {
                    "text": "CoronaRadiating epithelial components appear to expand or enlarge away from the central nidusVarying degrees of proliferative epithelial changes are present",
                    "sub_points": [
                      "Radiating epithelial components appear to expand or enlarge away from the central nidus",
                      "Varying degrees of proliferative epithelial changes are present"
                    ]
                  },
                  {
                    "text": "Rarely, RSL can be involved by atypical hyperplasia, carcinoma in situ, or invasive carcinoma"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Tubular carcinoma"
                  },
                  {
                    "text": "Low-grade adenosquamous carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Radial sclerosing lesion (RSL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Radial scar"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Radial Sclerosing Lesion (RSL) and Complex Sclerosing Lesion (CSL)": [
                  {
                    "text": "RSL and CSL are often used as synonyms but are best viewed as 2 different but closely related lesions"
                  },
                  {
                    "text": "RSL has a very specific architecture that forms a mass with elongated spiculesThere is a central fibroelastotic core or nidus containing entrapped glandular structuresOutwardly radiating ductal structures create the irregular stellate appearance",
                    "sub_points": [
                      "There is a central fibroelastotic core or nidus containing entrapped glandular structures",
                      "Outwardly radiating ductal structures create the irregular stellate appearance"
                    ]
                  },
                  {
                    "text": "In contrast, CSLs consist of multiple architectural patterns in a background of fibrotic stromaThe epithelial component can include usual ductal hyperplasia, adenosis, papillomas/sclerosing papillomas, and cysts as well as RSLsThe epithelium is at least partially compressed and distorted by stroma (i.e., \"sclerosed\")The overall borders of CSLs are typically circumscribed or lobulated rather than spiculated",
                    "sub_points": [
                      "The epithelial component can include usual ductal hyperplasia, adenosis, papillomas/sclerosing papillomas, and cysts as well as RSLs",
                      "The epithelium is at least partially compressed and distorted by stroma (i.e., \"sclerosed\")",
                      "The overall borders of CSLs are typically circumscribed or lobulated rather than spiculated"
                    ]
                  },
                  {
                    "text": "Both RSL and CSL are classified as proliferative breast disease without atypia"
                  }
                ],
                "Proposed Origin of RSLs": [
                  {
                    "text": "It has been proposed that RSL may be result of injury, vascular obliteration and ischemia, &/or inflammationThe central fibrotic area could be area of resolving and resolved tissue damageThe term scar is used to describe RSL, as it resembles a scar that \"pulls in\" surrounding breast tissueHowever, RSL is not associated with prior surgery or traumaAlthough RSL and radial scar are synonyms, the term RSL is less likely to be confused with a true surgical scar",
                    "sub_points": [
                      "The central fibrotic area could be area of resolving and resolved tissue damage",
                      "The term scar is used to describe RSL, as it resembles a scar that \"pulls in\" surrounding breast tissueHowever, RSL is not associated with prior surgery or traumaAlthough RSL and radial scar are synonyms, the term RSL is less likely to be confused with a true surgical scar",
                      "However, RSL is not associated with prior surgery or trauma",
                      "Although RSL and radial scar are synonyms, the term RSL is less likely to be confused with a true surgical scar"
                    ]
                  },
                  {
                    "text": "No specific cause has been identified"
                  }
                ],
                "Relationship to Adenosquamous Proliferation": [
                  {
                    "text": "The compressed glands in the center of RSL are morphologically similar to low-grade adenosquamous carcinoma (LGASC)Adenosquamous proliferation is defined as a proliferative lesion with both squamous and glandular features",
                    "sub_points": [
                      "Adenosquamous proliferation is defined as a proliferative lesion with both squamous and glandular features"
                    ]
                  },
                  {
                    "text": "It has been proposed that RSL, and other sclerosing lesions, may be precursor lesions for LGASCMany LGASCs are present adjacent to, or involve, sclerosing lesionsHowever, genetic evidence linking these lesions has not been reportedIt is unclear whether there is a true precursor relationship or if there is just a histologic resemblance",
                    "sub_points": [
                      "Many LGASCs are present adjacent to, or involve, sclerosing lesions",
                      "However, genetic evidence linking these lesions has not been reported",
                      "It is unclear whether there is a true precursor relationship or if there is just a histologic resemblance"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very common, 14-28% of females in autopsy studiesMajority had multiple lesions, and almost 1/2 had bilateral RSL",
                    "sub_points": [
                      "Majority had multiple lesions, and almost 1/2 had bilateral RSL"
                    ]
                  },
                  {
                    "text": "Reported increase in diagnosis of RSLs on core biopsy due in part to the integration of digital breast tomosynthesis (DBT) into standard practiceHas increased the frequency of certain imaging findings, particularly architectural distortionNo significant increase in rate of upgrade of RSL detected by DBT",
                    "sub_points": [
                      "Has increased the frequency of certain imaging findings, particularly architectural distortion",
                      "No significant increase in rate of upgrade of RSL detected by DBT"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Majority are incidental microscopic findings"
                  },
                  {
                    "text": "Larger RSLs may be detected as imaging finding"
                  },
                  {
                    "text": "Very rarely present as palpable mass"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Diagnosis on core needle biopsyRSL can be difficult to diagnose when only a portion of the lesion is presentMasses with spiculated margins are more often invasive carcinomas than RSLsHowever, with good radiologic/pathologic correlation, the likelihood of finding carcinoma on excision of RSL identified in a core needle biopsy is very low",
                    "sub_points": [
                      "RSL can be difficult to diagnose when only a portion of the lesion is present",
                      "Masses with spiculated margins are more often invasive carcinomas than RSLs",
                      "However, with good radiologic/pathologic correlation, the likelihood of finding carcinoma on excision of RSL identified in a core needle biopsy is very low"
                    ]
                  },
                  {
                    "text": "Diagnosis on excisional specimensRSL is a benign lesion, and no additional treatment is necessary",
                    "sub_points": [
                      "RSL is a benign lesion, and no additional treatment is necessary"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "For RSL without atypical hyperplasia, the relative risk for developing subsequent invasive carcinoma is increased ~ 1.5-2.0xClassified as proliferative breast disease without atypiaAbsolute lifetime risk of carcinoma in either breast is ~ 5-7%",
                    "sub_points": [
                      "Classified as proliferative breast disease without atypia",
                      "Absolute lifetime risk of carcinoma in either breast is ~ 5-7%"
                    ]
                  },
                  {
                    "text": "Atypical hyperplasia is more commonly associated with larger RSLs (> 1 cm) and in women > 50 years of ageFor these lesions the risk is related to the atypical hyperplasia",
                    "sub_points": [
                      "For these lesions the risk is related to the atypical hyperplasia"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Mass with spiculated margins most commonLength of spicules (radiating arms) is long in relation to the central area of massCarcinomas have a larger central area with shorter spiculesCenter of mass may be lucentCan be described as a \"black star\"",
                    "sub_points": [
                      "Length of spicules (radiating arms) is long in relation to the central area of massCarcinomas have a larger central area with shorter spicules",
                      "Carcinomas have a larger central area with shorter spicules",
                      "Center of mass may be lucentCan be described as a \"black star\"",
                      "Can be described as a \"black star\""
                    ]
                  },
                  {
                    "text": "Architectural distortion is a more subtle finding of radiating arms from central point without a definite massTomosynthesis detects more areas of architectural distortion~ 1/3 of architectural distortion undergoing core needle biopsy are RSLs and other sclerosing lesions",
                    "sub_points": [
                      "Tomosynthesis detects more areas of architectural distortion",
                      "~ 1/3 of architectural distortion undergoing core needle biopsy are RSLs and other sclerosing lesions"
                    ]
                  },
                  {
                    "text": "Microcalcifications are present in some lesionsTypically seen in association with accompanying sclerosing adenosis or atypical ductal hyperplasia (ADH)",
                    "sub_points": [
                      "Typically seen in association with accompanying sclerosing adenosis or atypical ductal hyperplasia (ADH)"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "RSL most commonly seen as a hypoechoic area/mass"
                  },
                  {
                    "text": "Parenchymal distortion without a mass may be seen"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Irregular, enhancing lesion by MR"
                  },
                  {
                    "text": "RSLs tend to show less enhancement by MR, compared with invasive carcinoma"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Larger lesions form an irregular, firm massYellow-white color, indurated with central retractionLesions are usually firm but not as hard as invasive carcinomasCentral nidus is firmer than the area of radiating armsHowever, lesions may grossly be indistinguishable from invasive carcinoma",
                    "sub_points": [
                      "Yellow-white color, indurated with central retraction",
                      "Lesions are usually firm but not as hard as invasive carcinomasCentral nidus is firmer than the area of radiating arms",
                      "Central nidus is firmer than the area of radiating arms",
                      "However, lesions may grossly be indistinguishable from invasive carcinoma"
                    ]
                  },
                  {
                    "text": "The majority of RSLs are small and not detectable grossly"
                  }
                ],
                "Size": [
                  {
                    "text": "Most lesions are < 2 cmAverage: < 1 cm",
                    "sub_points": [
                      "Average: < 1 cm"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "PIK3CAmutations are present in ~ 2/3 of RSLsCommon hotspot mutations are His1047Arg (H1047R) and Glu545Lys (E545K)",
                    "sub_points": [
                      "Common hotspot mutations are His1047Arg (H1047R) and Glu545Lys (E545K)"
                    ]
                  },
                  {
                    "text": "Activating point mutations inPIK3CAare common in many other benign lesions, including columnar cell change, usual ductal hyperplasia, papillomas, juvenile papillomatosis, and adenomyoepitheliomas as well as in normal breast tissueThis is an important gene in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityIt is possible that the somatic mutations occur early in development and predispose to the formation of multiple types of lesions but are not specific to any particular lesionCarcinomas occurring in patients with mutations in proliferative lesions often do not have the samePIK3CAmutationSuggests that mutations are a common change contributing to proliferation, but lesions with mutations rarely progress to carcinoma",
                    "sub_points": [
                      "This is an important gene in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motility",
                      "It is possible that the somatic mutations occur early in development and predispose to the formation of multiple types of lesions but are not specific to any particular lesionCarcinomas occurring in patients with mutations in proliferative lesions often do not have the samePIK3CAmutationSuggests that mutations are a common change contributing to proliferation, but lesions with mutations rarely progress to carcinoma",
                      "Carcinomas occurring in patients with mutations in proliferative lesions often do not have the samePIK3CAmutation",
                      "Suggests that mutations are a common change contributing to proliferation, but lesions with mutations rarely progress to carcinoma"
                    ]
                  },
                  {
                    "text": "No other mutations were detected in a panel of 52 genes"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Essential features of RSL are a central fibrotic nidus surrounded by radiating arms (corona), creating an overall mass with spiculated margins"
                  },
                  {
                    "text": "Central nidus\"Early\" RSLNumerous small, entrapped, and distorted ductsDistorted ducts appear angulated, giving rise to a pseudoinfiltrative appearanceHowever, the pseudoinfiltrative area is confined to the central nidus and does not actually infiltrate into the surrounding normal breast epitheliumSquamous metaplasia can be presentEntrapped ducts retain a normal myoepithelial layerAppearance may mimic tubular carcinoma (TC), especially on core needle biopsyIHC is helpful to confirm the presence of myoepithelial cells in difficult casesStroma may be cellular or collagenizedMild inflammation can be present\"Late\" RSLUsually hypocellular with fewer ducts presentDense, granular eosinophilic stroma, sometimes showing weakly basophilic qualityElastic component of stroma can be highlighted by a van Gieson stain, which will show dense curvilinear elastic fibrils",
                    "sub_points": [
                      "\"Early\" RSLNumerous small, entrapped, and distorted ductsDistorted ducts appear angulated, giving rise to a pseudoinfiltrative appearanceHowever, the pseudoinfiltrative area is confined to the central nidus and does not actually infiltrate into the surrounding normal breast epitheliumSquamous metaplasia can be presentEntrapped ducts retain a normal myoepithelial layerAppearance may mimic tubular carcinoma (TC), especially on core needle biopsyIHC is helpful to confirm the presence of myoepithelial cells in difficult casesStroma may be cellular or collagenizedMild inflammation can be present",
                      "Numerous small, entrapped, and distorted ductsDistorted ducts appear angulated, giving rise to a pseudoinfiltrative appearanceHowever, the pseudoinfiltrative area is confined to the central nidus and does not actually infiltrate into the surrounding normal breast epitheliumSquamous metaplasia can be presentEntrapped ducts retain a normal myoepithelial layerAppearance may mimic tubular carcinoma (TC), especially on core needle biopsyIHC is helpful to confirm the presence of myoepithelial cells in difficult cases",
                      "Distorted ducts appear angulated, giving rise to a pseudoinfiltrative appearance",
                      "However, the pseudoinfiltrative area is confined to the central nidus and does not actually infiltrate into the surrounding normal breast epithelium",
                      "Squamous metaplasia can be present",
                      "Entrapped ducts retain a normal myoepithelial layer",
                      "Appearance may mimic tubular carcinoma (TC), especially on core needle biopsy",
                      "IHC is helpful to confirm the presence of myoepithelial cells in difficult cases",
                      "Stroma may be cellular or collagenized",
                      "Mild inflammation can be present",
                      "\"Late\" RSLUsually hypocellular with fewer ducts presentDense, granular eosinophilic stroma, sometimes showing weakly basophilic qualityElastic component of stroma can be highlighted by a van Gieson stain, which will show dense curvilinear elastic fibrils",
                      "Usually hypocellular with fewer ducts present",
                      "Dense, granular eosinophilic stroma, sometimes showing weakly basophilic quality",
                      "Elastic component of stroma can be highlighted by a van Gieson stain, which will show dense curvilinear elastic fibrils"
                    ]
                  },
                  {
                    "text": "CoronaRadiating epithelial components appear to expand or enlarge farther away from the central nidusDemonstrate varying degrees of proliferative changesFlorid usual ductal hyperplasia and sclerosing adenosisCysts can also be a component",
                    "sub_points": [
                      "Radiating epithelial components appear to expand or enlarge farther away from the central nidus",
                      "Demonstrate varying degrees of proliferative changesFlorid usual ductal hyperplasia and sclerosing adenosis",
                      "Florid usual ductal hyperplasia and sclerosing adenosis",
                      "Cysts can also be a component"
                    ]
                  },
                  {
                    "text": "RSL involved by other lesionsIn rare cases, RSL can be involved by ADH, atypical lobular hyperplasia, in situ carcinoma, or invasive carcinomaAtypical hyperplasias and carcinomas are more common in larger lesions and in women > 50 years",
                    "sub_points": [
                      "In rare cases, RSL can be involved by ADH, atypical lobular hyperplasia, in situ carcinoma, or invasive carcinomaAtypical hyperplasias and carcinomas are more common in larger lesions and in women > 50 years",
                      "Atypical hyperplasias and carcinomas are more common in larger lesions and in women > 50 years"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "RSL on core needle biopsy may be difficult to distinguish from invasive carcinomasDemonstration of myoepithelial markers by IHC is helpful to make this distinctionHowever, myoepithelial cells can be scant in small foci in the central nidusA lesion difficult to classify can be diagnosed as an \"atypical glandular proliferation\" with a recommendation to classify lesion after excision",
                    "sub_points": [
                      "Demonstration of myoepithelial markers by IHC is helpful to make this distinctionHowever, myoepithelial cells can be scant in small foci in the central nidus",
                      "However, myoepithelial cells can be scant in small foci in the central nidus",
                      "A lesion difficult to classify can be diagnosed as an \"atypical glandular proliferation\" with a recommendation to classify lesion after excision"
                    ]
                  },
                  {
                    "text": "The likelihood of an upgrade after excision is decreased with vacuum-assisted biopsies compared to biopsies without vacuum assistance"
                  },
                  {
                    "text": "Lesions presenting as a mass with spiculated marginsIn general, the majority of these lesions are invasive carcinomas (> 90%)If RSL is present, it is important to determine if the RSL is a good correlate for the mass or could be an incidental findingThe size of the RSL on core should be compared with the size of mass by imaging to help determine likelihood of RSL being the targeted lesionIf RSL is concordant with the imaging lesion, the likelihood of finding carcinoma on excision is low (< 5%)The majority of carcinomas in this setting are small, well-differentiated invasive carcinomas and low-grade ductal carcinoma in situ (DCIS)If there is uncertainty as to whether or not the targeted mass was biopsied, excision may be recommended",
                    "sub_points": [
                      "In general, the majority of these lesions are invasive carcinomas (> 90%)",
                      "If RSL is present, it is important to determine if the RSL is a good correlate for the mass or could be an incidental finding",
                      "The size of the RSL on core should be compared with the size of mass by imaging to help determine likelihood of RSL being the targeted lesion",
                      "If RSL is concordant with the imaging lesion, the likelihood of finding carcinoma on excision is low (< 5%)The majority of carcinomas in this setting are small, well-differentiated invasive carcinomas and low-grade ductal carcinoma in situ (DCIS)",
                      "The majority of carcinomas in this setting are small, well-differentiated invasive carcinomas and low-grade ductal carcinoma in situ (DCIS)",
                      "If there is uncertainty as to whether or not the targeted mass was biopsied, excision may be recommended"
                    ]
                  },
                  {
                    "text": "Lesions presenting as a mass with circumscribed margins or calcificationsRSL in such biopsy may be an incidental finding or part of a CSLRadiologic and pathologic correlation is necessary to ensure targeted lesion was sampledSmall incidental RSLs (< 0.5 cm) are unlikely to be associated with adjacent carcinoma",
                    "sub_points": [
                      "RSL in such biopsy may be an incidental finding or part of a CSLRadiologic and pathologic correlation is necessary to ensure targeted lesion was sampled",
                      "Radiologic and pathologic correlation is necessary to ensure targeted lesion was sampled",
                      "Small incidental RSLs (< 0.5 cm) are unlikely to be associated with adjacent carcinoma"
                    ]
                  },
                  {
                    "text": "RSL with associated atypia on core biopsyUpgrade to malignancy in surgical specimen is ~ 20%Upgrade rate is highly dependent on the type of atypia present on coreThe presence of ADH shows highest upgrade rate (~ 35% for malignancy, ~ 7% for invasive carcinoma)The presence of flat epithelial atypia (FEA) shows a negligible upgrade rate (< 5%)",
                    "sub_points": [
                      "Upgrade to malignancy in surgical specimen is ~ 20%",
                      "Upgrade rate is highly dependent on the type of atypia present on core",
                      "The presence of ADH shows highest upgrade rate (~ 35% for malignancy, ~ 7% for invasive carcinoma)",
                      "The presence of flat epithelial atypia (FEA) shows a negligible upgrade rate (< 5%)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Myoepithelial markers identify the normal myoepithelial cell layerHelpful to exclude invasive carcinoma, particularly when evaluating compressed glands in the central nidus on core needle biopsyResults must be interpreted with cautionMyoepithelial cells may only be identified around some of entrapped glandsMyoepithelial cells may not be present in the plane of section used for IHCUse of > 1 marker is recommended to improve likelihood of detectionNormal myoepithelial cells in sclerosing lesions may not express all markersp63, calponin, and smooth muscle actin have good sensitivity and specificityMultiplex studies using > 1 myoepithelial marker may be helpful",
                    "sub_points": [
                      "Helpful to exclude invasive carcinoma, particularly when evaluating compressed glands in the central nidus on core needle biopsy",
                      "Results must be interpreted with cautionMyoepithelial cells may only be identified around some of entrapped glandsMyoepithelial cells may not be present in the plane of section used for IHC",
                      "Myoepithelial cells may only be identified around some of entrapped glands",
                      "Myoepithelial cells may not be present in the plane of section used for IHC",
                      "Use of > 1 marker is recommended to improve likelihood of detectionNormal myoepithelial cells in sclerosing lesions may not express all markersp63, calponin, and smooth muscle actin have good sensitivity and specificityMultiplex studies using > 1 myoepithelial marker may be helpful",
                      "Normal myoepithelial cells in sclerosing lesions may not express all markers",
                      "p63, calponin, and smooth muscle actin have good sensitivity and specificity",
                      "Multiplex studies using > 1 myoepithelial marker may be helpful"
                    ]
                  },
                  {
                    "text": "p63 (nuclear location)Advantage: Very specific for myoepithelial cells; can rarely be positive in tumor cellsDisadvantage: The nucleus of a cell may not be present on every level",
                    "sub_points": [
                      "Advantage: Very specific for myoepithelial cells; can rarely be positive in tumor cells",
                      "Disadvantage: The nucleus of a cell may not be present on every level"
                    ]
                  },
                  {
                    "text": "Muscle markers (cytoplasmic location)Advantage: A portion of the cell is usually present on every level; typically provides continuous stainingDisadvantage: Also positive in blood vessels and myofibroblasts",
                    "sub_points": [
                      "Advantage: A portion of the cell is usually present on every level; typically provides continuous staining",
                      "Disadvantage: Also positive in blood vessels and myofibroblasts"
                    ]
                  },
                  {
                    "text": "Basal cytokeratins (cytoplasmic location)Advantage: Very specific for epithelial cells; typically provides continuous stainingDisadvantage: Not all myoepithelial cells are positive, and some luminal cells and tumor cells can be positive",
                    "sub_points": [
                      "Advantage: Very specific for epithelial cells; typically provides continuous staining",
                      "Disadvantage: Not all myoepithelial cells are positive, and some luminal cells and tumor cells can be positive"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Tubular Carcinoma (TC)": [
                  {
                    "text": "The imaging, macroscopic, and histologic appearances of RSLs and TC can be similar"
                  },
                  {
                    "text": "TC is associated with a cellular desmoplastic stromaEntrapped ducts of RSL are usually surrounded by hyalinized fibroelastotic stroma of low cellularity",
                    "sub_points": [
                      "Entrapped ducts of RSL are usually surrounded by hyalinized fibroelastotic stroma of low cellularity"
                    ]
                  },
                  {
                    "text": "Tubules of TC are composed of a single cell layer and lack surrounding myoepithelial cellsMyofibroblasts and blood vessels positive for muscle markers can closely appose the ducts of TC and mimic myoepithelial cellsEntrapped ducts of RSL demonstrate surrounding myoepithelial cellsMay show usual ductal hyperplasia with multiple layersMay be associated with squamous metaplasia",
                    "sub_points": [
                      "Myofibroblasts and blood vessels positive for muscle markers can closely appose the ducts of TC and mimic myoepithelial cells",
                      "Entrapped ducts of RSL demonstrate surrounding myoepithelial cellsMay show usual ductal hyperplasia with multiple layersMay be associated with squamous metaplasia",
                      "May show usual ductal hyperplasia with multiple layers",
                      "May be associated with squamous metaplasia"
                    ]
                  },
                  {
                    "text": "Tubules of TC generally have open lumina, and cells have apocrine snoutsEntrapped ducts of RSL are often compressed and distorted with absent or slit-like lumina",
                    "sub_points": [
                      "Entrapped ducts of RSL are often compressed and distorted with absent or slit-like lumina"
                    ]
                  },
                  {
                    "text": "TC grows as haphazard tubules invading around normal ducts and lobulesEntrapped ducts of RSL are limited to the central fibroelastotic nidus of lesion",
                    "sub_points": [
                      "Entrapped ducts of RSL are limited to the central fibroelastotic nidus of lesion"
                    ]
                  },
                  {
                    "text": "TC is more commonly associated with adjacent FEA, DCIS, &/or lobular carcinoma in situ"
                  }
                ],
                "Low-Grade Adenosquamous Carcinoma": [
                  {
                    "text": "LGASC is often seen associated with sclerosing lesions, such as RSL"
                  },
                  {
                    "text": "The central nidus of RSL can closely resemble LGASC, especially when squamous metaplasia is presentThese areas are typically small (0.1-0.2 cm) and limited to the central area of RSL",
                    "sub_points": [
                      "These areas are typically small (0.1-0.2 cm) and limited to the central area of RSL"
                    ]
                  },
                  {
                    "text": "Diagnosis of LGASC would be supported byGlands and squamous cell nests in an infiltrative pattern around normal ducts and lobulesDensely cellular stromaMixed tumor cell populations of luminal-like, myoepithelial-like, and squamous cellsNormal myoepithelial cells as demonstrated by positivity for multiple markers are absentNeoplastic spindle cell population positive for keratins or p63Lymphocytic aggregates at periphery",
                    "sub_points": [
                      "Glands and squamous cell nests in an infiltrative pattern around normal ducts and lobules",
                      "Densely cellular stroma",
                      "Mixed tumor cell populations of luminal-like, myoepithelial-like, and squamous cellsNormal myoepithelial cells as demonstrated by positivity for multiple markers are absent",
                      "Normal myoepithelial cells as demonstrated by positivity for multiple markers are absent",
                      "Neoplastic spindle cell population positive for keratins or p63",
                      "Lymphocytic aggregates at periphery"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "RSLs on core needle biopsy without atypia and with good radiologic/pathologic correlation are unlikely to be associated with carcinoma on excision"
                  },
                  {
                    "text": "If ADH is present, the upgrade rate on excision is similar to that of ADH without an RSL"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "RSL is the only benign lesion that closely mimics invasive carcinoma by imaging, grossly, and microscopically"
                  },
                  {
                    "text": "Immunoperoxidase studies to identify the normal myoepithelial cell layer are helpful"
                  },
                  {
                    "text": "Any RSL with atypia or those that are benign but with radiological discordance should undergo excision"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Papilloma, Large Duct and Small Duct": {
            "name": "Papilloma, Large Duct and Small Duct",
            "url": "https://app.pathprimer.com/document/0275f7a7-9020-4cd4-a047-2594b5c75234/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Large duct papilloma (LDP)Usually centrally located in lactiferous duct; often solitary",
                    "sub_points": [
                      "Usually centrally located in lactiferous duct; often solitary"
                    ]
                  },
                  {
                    "text": "Small duct papilloma (SDP)Usually multiple and peripherally locatedMore likely to be involved by atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) than LDP",
                    "sub_points": [
                      "Usually multiple and peripherally located",
                      "More likely to be involved by atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) than LDP"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "LDP may present with pathologic nipple dischargeLarger lesions may be palpable",
                    "sub_points": [
                      "Larger lesions may be palpable"
                    ]
                  },
                  {
                    "text": "Standard treatment for symptomatic LDP is complete excision; benign lesions on excision need no further surgical treatment"
                  },
                  {
                    "text": "Papillomas without atypia on core needle biopsy have a low likelihood of carcinoma on excision if there is good radiologic/pathologic correlationRisk factors for upgrade on excision include older age, size > 1 cm, and clinical symptoms",
                    "sub_points": [
                      "Risk factors for upgrade on excision include older age, size > 1 cm, and clinical symptoms"
                    ]
                  },
                  {
                    "text": "Papillomas are proliferative lesions that increase the likelihood of subsequent carcinomaLDP: Relative risk 1.5-2.0xSDP: Relative risk ~ 3x",
                    "sub_points": [
                      "LDP: Relative risk 1.5-2.0x",
                      "SDP: Relative risk ~ 3x"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Arborizing fronds lined by epithelial and myoepithelial cells with central fibrovascular coresMay show usual ductal hyperplasia (UDH) or be involved by ADH or DCIS",
                    "sub_points": [
                      "May show usual ductal hyperplasia (UDH) or be involved by ADH or DCIS"
                    ]
                  },
                  {
                    "text": "IHC for myoepithelial markers can be helpful in diagnosis"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Myoepithelial markers to confirm myoepithelial cells in fronds and at periphery"
                  },
                  {
                    "text": "CK5/6 and ER to distinguish UDH from ADH/DCIS"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "DCIS, papillary pattern"
                  },
                  {
                    "text": "Encapsulated papillary carcinoma"
                  },
                  {
                    "text": "Solid papillary carcinoma"
                  },
                  {
                    "text": "Nipple adenoma"
                  },
                  {
                    "text": "Tall cell carcinoma with reversed polarity"
                  },
                  {
                    "text": "Locally recurrent invasive carcinoma in skin or chest wall"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Large duct papilloma (LDP), a.k.a. central papilloma"
                  },
                  {
                    "text": "Small duct papilloma (SDP), a.k.a. peripheral papilloma"
                  },
                  {
                    "text": "Ductal carcinoma in situ (DCIS)"
                  },
                  {
                    "text": "Atypical ductal hyperplasia (ADH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Intraductal papilloma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign epithelial proliferative lesions characterized by papillary ingrowths into central major ducts (LDP) or peripheral smaller ducts (SDP)"
                  },
                  {
                    "text": "Characterized by fronds with fibrovascular cores lined by epithelial and myoepithelial cell layers"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Papillary lesions of the breast include benign papillomas, papillomas with atypia, ductal carcinoma in situ (DCIS) with a papillary pattern, encapsulated papillary carcinoma (EPC), and invasive papillary carcinomaAll are characterized by papillary fronds with fibrovascular cores growing into a cystic space",
                    "sub_points": [
                      "All are characterized by papillary fronds with fibrovascular cores growing into a cystic space"
                    ]
                  },
                  {
                    "text": "Benign papillomas are enclosed by a normal basement membrane lined by myoepithelial cells at the periphery of the involved duct and lining the fibrovascular coresLarge duct papillomas (LDPs), a.k.a. central papillomas, are usually solitary and located at the nippleSmall duct papillomas (SDPs), a.k.a. peripheral papillomas, are usually multiple and located deeper in the breast",
                    "sub_points": [
                      "Large duct papillomas (LDPs), a.k.a. central papillomas, are usually solitary and located at the nipple",
                      "Small duct papillomas (SDPs), a.k.a. peripheral papillomas, are usually multiple and located deeper in the breast"
                    ]
                  },
                  {
                    "text": "Papillomas can be difficult to evaluate, as they can be partially involved by usual ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH), or carcinoma in situ (CIS)"
                  },
                  {
                    "text": "Papillomas are included in the category of proliferative benign breast disease (BBD)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Common lesions in women and rarely occur in men"
                  }
                ],
                "Age": [
                  {
                    "text": "LDP: Most frequent in women 35-50 years old"
                  },
                  {
                    "text": "SDP: Usually younger women"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Large duct papilloma (LDP)Nipple discharge associated with pathologic lesions is unilateral and spontaneousSanguinous or serosanguineous: 70%Bloody (less common): May be due to papilloma twisting on stalk and infarctionOther causes of discharge: Duct ectasia, mastitis, cysts, carcinoma (most commonly extensive papillary and micropapillary DCIS)Nipple discharge is present in 80% of cases of LDPIn women < 60 years, 7% of cases with discharge are associated with malignancyIn women > 60 years, 30% of cases with discharge are associated with malignancyCan also present as a palpable subareolar mass or as a mass on imaging",
                    "sub_points": [
                      "Nipple discharge associated with pathologic lesions is unilateral and spontaneousSanguinous or serosanguineous: 70%Bloody (less common): May be due to papilloma twisting on stalk and infarctionOther causes of discharge: Duct ectasia, mastitis, cysts, carcinoma (most commonly extensive papillary and micropapillary DCIS)",
                      "Sanguinous or serosanguineous: 70%",
                      "Bloody (less common): May be due to papilloma twisting on stalk and infarction",
                      "Other causes of discharge: Duct ectasia, mastitis, cysts, carcinoma (most commonly extensive papillary and micropapillary DCIS)",
                      "Nipple discharge is present in 80% of cases of LDPIn women < 60 years, 7% of cases with discharge are associated with malignancyIn women > 60 years, 30% of cases with discharge are associated with malignancy",
                      "In women < 60 years, 7% of cases with discharge are associated with malignancy",
                      "In women > 60 years, 30% of cases with discharge are associated with malignancy",
                      "Can also present as a palpable subareolar mass or as a mass on imaging"
                    ]
                  },
                  {
                    "text": "Small duct papilloma (SDP)SDPs are usually detected on screening mammography or as an incidental findingCan form small masses &/or present as calcificationsRarely associated with nipple discharge or palpable mass",
                    "sub_points": [
                      "SDPs are usually detected on screening mammography or as an incidental findingCan form small masses &/or present as calcifications",
                      "Can form small masses &/or present as calcifications",
                      "Rarely associated with nipple discharge or palpable mass"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Core needle biopsyMany papillomas are diagnosed 1st by core needle biopsyBenign papilloma: Likelihood of carcinoma on excision with good radiologic/pathologic correlation is low (< 5%)Factors that increase the risk of carcinoma include larger size (> 1 cm), older patient age, and association with symptoms (palpable mass or nipple discharge)Other factors associated with upgrade of benign papilloma on core after excisionPersonal or family breast cancer history, multiple papillomas, calcification on imagingIncidental papillomas found adjacent to another lesion are not an indication for excisionPapilloma with atypia: 20-60% are associated with carcinoma on excisionSurgical excision is usually recommendedThe majority of carcinomas on excision are DCISCorrelation of clinical findings, diagnostic imaging, and core biopsy findings is critical for subsequent management decisionsSymptomatic papillomas are excised for diagnosis and treatment of nipple discharge",
                    "sub_points": [
                      "Many papillomas are diagnosed 1st by core needle biopsy",
                      "Benign papilloma: Likelihood of carcinoma on excision with good radiologic/pathologic correlation is low (< 5%)Factors that increase the risk of carcinoma include larger size (> 1 cm), older patient age, and association with symptoms (palpable mass or nipple discharge)Other factors associated with upgrade of benign papilloma on core after excisionPersonal or family breast cancer history, multiple papillomas, calcification on imagingIncidental papillomas found adjacent to another lesion are not an indication for excision",
                      "Factors that increase the risk of carcinoma include larger size (> 1 cm), older patient age, and association with symptoms (palpable mass or nipple discharge)",
                      "Other factors associated with upgrade of benign papilloma on core after excisionPersonal or family breast cancer history, multiple papillomas, calcification on imaging",
                      "Personal or family breast cancer history, multiple papillomas, calcification on imaging",
                      "Incidental papillomas found adjacent to another lesion are not an indication for excision",
                      "Papilloma with atypia: 20-60% are associated with carcinoma on excisionSurgical excision is usually recommendedThe majority of carcinomas on excision are DCIS",
                      "Surgical excision is usually recommended",
                      "The majority of carcinomas on excision are DCIS",
                      "Correlation of clinical findings, diagnostic imaging, and core biopsy findings is critical for subsequent management decisions",
                      "Symptomatic papillomas are excised for diagnosis and treatment of nipple discharge"
                    ]
                  },
                  {
                    "text": "Surgical excisionFor benign lesions on excision, no further surgical treatment is necessary",
                    "sub_points": [
                      "For benign lesions on excision, no further surgical treatment is necessary"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Classified as proliferative disease without atypia"
                  },
                  {
                    "text": "Mild increased risk of subsequent breast carcinoma (BC): 1.5-2.0x relative risk or ~ 5-7% lifetime riskBC risk is slightly higher (3x) for women with multiple peripheral SDPBCs can occur in either breast and at any site",
                    "sub_points": [
                      "BC risk is slightly higher (3x) for women with multiple peripheral SDP",
                      "BCs can occur in either breast and at any site"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "LDP can present as a lobulated mass ± calcificationsSome are not seen by imaging",
                    "sub_points": [
                      "Some are not seen by imaging"
                    ]
                  },
                  {
                    "text": "SDP can present as a lobulated mass or cluster of calcifications"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "LDP: Intraductal, well-defined, mass near nippleMay have both solid and cystic componentsAdjacent ducts often dilated",
                    "sub_points": [
                      "May have both solid and cystic components",
                      "Adjacent ducts often dilated"
                    ]
                  },
                  {
                    "text": "SDP: Small circumscribed or lobulated masses"
                  }
                ],
                "Ductography": [
                  {
                    "text": "LDP associated with nipple discharge may be diagnosed by ductographyInvolved ductal orifice is often dilatedIt may be very difficult to cannulate the duct in the absence of dischargeContrast agent can show 1 or multiple filling defects with smooth contours in ductPapilloma interrupts flow of contrast",
                    "sub_points": [
                      "Involved ductal orifice is often dilatedIt may be very difficult to cannulate the duct in the absence of discharge",
                      "It may be very difficult to cannulate the duct in the absence of discharge",
                      "Contrast agent can show 1 or multiple filling defects with smooth contours in ductPapilloma interrupts flow of contrast",
                      "Papilloma interrupts flow of contrast"
                    ]
                  },
                  {
                    "text": "Ductography may help localize lesion for excision"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "LDP may be visible macroscopicallyUsually < 2 cm but can be as large as 4-5 cmAppears as a tan-pink, circumscribed nodule protruding into dilated duct or cystically dilated spaceCystic spaces may be filled with serosanguineous fluid and hemorrhageVerrucous, bosselated, or frankly papillary appearance",
                    "sub_points": [
                      "Usually < 2 cm but can be as large as 4-5 cm",
                      "Appears as a tan-pink, circumscribed nodule protruding into dilated duct or cystically dilated spaceCystic spaces may be filled with serosanguineous fluid and hemorrhage",
                      "Cystic spaces may be filled with serosanguineous fluid and hemorrhage",
                      "Verrucous, bosselated, or frankly papillary appearance"
                    ]
                  },
                  {
                    "text": "However, many papillomas are soft to palpation and not evident as a gross lesion"
                  },
                  {
                    "text": "SDP is usually < 1 cm and not evident grossly"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "Excisions for nipple dischargeThe subareolar tissue beneath the duct orifice with discharge is excisedIt is helpful if the dilated duct is marked with a suture by the surgeonIf grossly identified, the involved duct is opened longitudinally and examined for gross lesionsIf a gross lesion is not detectable by palpation or imaging, in general, the entire specimen should be examined microscopically",
                    "sub_points": [
                      "The subareolar tissue beneath the duct orifice with discharge is excisedIt is helpful if the dilated duct is marked with a suture by the surgeon",
                      "It is helpful if the dilated duct is marked with a suture by the surgeon",
                      "If grossly identified, the involved duct is opened longitudinally and examined for gross lesions",
                      "If a gross lesion is not detectable by palpation or imaging, in general, the entire specimen should be examined microscopically"
                    ]
                  },
                  {
                    "text": "Excisions for palpable massesPapillomas that are palpable grossly may not be palpable in the specimenAn associated cystic fluid space can contribute to the size of the mass but deflate after excisionPapillomas can be friable and may be disaggregated after excisionIf the lesion cannot be reliably identified grossly, in general, the entire specimen should be examined microscopically",
                    "sub_points": [
                      "Papillomas that are palpable grossly may not be palpable in the specimenAn associated cystic fluid space can contribute to the size of the mass but deflate after excisionPapillomas can be friable and may be disaggregated after excision",
                      "An associated cystic fluid space can contribute to the size of the mass but deflate after excision",
                      "Papillomas can be friable and may be disaggregated after excision",
                      "If the lesion cannot be reliably identified grossly, in general, the entire specimen should be examined microscopically"
                    ]
                  },
                  {
                    "text": "Mammographically localized excisionsThe specimen radiograph should be used to identify the site of the lesion and to guide samplingThe entire lesion should be examined microscopically",
                    "sub_points": [
                      "The specimen radiograph should be used to identify the site of the lesion and to guide sampling",
                      "The entire lesion should be examined microscopically"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Genetics": [
                  {
                    "text": "Papillomas are monoclonal proliferations"
                  },
                  {
                    "text": "Loss of heterozygosity (LOH)LOH at locus 16q21.1-16q22.2 detected in both benign and malignant papillary lesionsLOH at locus16q23.3-16q24.1 detected only in malignant papillary lesionsTP53deletion and possibly LOH at 16q23 appear to be associated with malignant lesions and may play role as progression factors",
                    "sub_points": [
                      "LOH at locus 16q21.1-16q22.2 detected in both benign and malignant papillary lesionsLOH at locus16q23.3-16q24.1 detected only in malignant papillary lesions",
                      "LOH at locus16q23.3-16q24.1 detected only in malignant papillary lesions",
                      "TP53deletion and possibly LOH at 16q23 appear to be associated with malignant lesions and may play role as progression factors"
                    ]
                  },
                  {
                    "text": "MutationsActivating point mutations ofPIK3CA(~ 30-40%) andAKT1(~ 20-30%) are common: ~ 50-60% of papillomas have 1 of these mutationsThese are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityIn one study, the same mutation was found in both myoepithelial and epithelial cells of papillomas, supporting that the mutation occurred in a precursor cellPIK3CAandAKT1mutations are also reported in many other breast proliferative lesions as well as in normal breast tissueThus, these somatic mutations likely occur early in development and predispose to the development of multiple types of proliferative lesions but are not specific to any particular lesion",
                    "sub_points": [
                      "Activating point mutations ofPIK3CA(~ 30-40%) andAKT1(~ 20-30%) are common: ~ 50-60% of papillomas have 1 of these mutationsThese are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityIn one study, the same mutation was found in both myoepithelial and epithelial cells of papillomas, supporting that the mutation occurred in a precursor cellPIK3CAandAKT1mutations are also reported in many other breast proliferative lesions as well as in normal breast tissueThus, these somatic mutations likely occur early in development and predispose to the development of multiple types of proliferative lesions but are not specific to any particular lesion",
                      "These are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityIn one study, the same mutation was found in both myoepithelial and epithelial cells of papillomas, supporting that the mutation occurred in a precursor cell",
                      "In one study, the same mutation was found in both myoepithelial and epithelial cells of papillomas, supporting that the mutation occurred in a precursor cell",
                      "PIK3CAandAKT1mutations are also reported in many other breast proliferative lesions as well as in normal breast tissue",
                      "Thus, these somatic mutations likely occur early in development and predispose to the development of multiple types of proliferative lesions but are not specific to any particular lesion"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Large duct papilloma (LDP)Originates in lactiferous sinus or large mammary ducts below nippleGrows as arborizing finger-like fronds with centrally located fibrovascular coresEach frond is lined by luminal epithelial cells with associated myoepithelial cellsMyoepithelial and epithelial cells also line the surrounding duct wallIHC for myoepithelial markers can aid in diagnostic evaluation in problematic casesApocrine metaplasia may be present and is supportive of a heterogeneous benign cell proliferationRare papillomas with apocrine changes can lack myoepithelial cellsUsual ductal hyperplasia (UDH) can be present and may be floridMitoses are generally absent or rareGloboid cells are prominent epithelial cells with rounded contours and pale cytoplasm that can be seen in some papillary lesionsOften positive for GCDFP-15In malignant papillary lesions, care must be taken to not mistake them for myoepithelial cellsFibrovascular cores are generally thick and of varying sizesDense collagen in the cores may calcifyIn contrast, the fibrovascular cores of BCs are usually uniform in size and thin and delicateInfarction with extensive coagulative necrosis and hemorrhage may be seenCan be associated with prior needle biopsies of the papilloma or twisting of stalk causing ischemiaCan result in clinical hemorrhagic dischargeNot an indication of malignancy if other features of malignancy are not presentSquamous metaplasia may be present and can be associated with infarctionRarely, spindle or squamous cell BCs can arise in association with squamous metaplasia",
                    "sub_points": [
                      "Originates in lactiferous sinus or large mammary ducts below nipple",
                      "Grows as arborizing finger-like fronds with centrally located fibrovascular coresEach frond is lined by luminal epithelial cells with associated myoepithelial cellsMyoepithelial and epithelial cells also line the surrounding duct wallIHC for myoepithelial markers can aid in diagnostic evaluation in problematic cases",
                      "Each frond is lined by luminal epithelial cells with associated myoepithelial cells",
                      "Myoepithelial and epithelial cells also line the surrounding duct wall",
                      "IHC for myoepithelial markers can aid in diagnostic evaluation in problematic cases",
                      "Apocrine metaplasia may be present and is supportive of a heterogeneous benign cell proliferationRare papillomas with apocrine changes can lack myoepithelial cells",
                      "Rare papillomas with apocrine changes can lack myoepithelial cells",
                      "Usual ductal hyperplasia (UDH) can be present and may be floridMitoses are generally absent or rare",
                      "Mitoses are generally absent or rare",
                      "Globoid cells are prominent epithelial cells with rounded contours and pale cytoplasm that can be seen in some papillary lesionsOften positive for GCDFP-15In malignant papillary lesions, care must be taken to not mistake them for myoepithelial cells",
                      "Often positive for GCDFP-15",
                      "In malignant papillary lesions, care must be taken to not mistake them for myoepithelial cells",
                      "Fibrovascular cores are generally thick and of varying sizesDense collagen in the cores may calcifyIn contrast, the fibrovascular cores of BCs are usually uniform in size and thin and delicate",
                      "Dense collagen in the cores may calcify",
                      "In contrast, the fibrovascular cores of BCs are usually uniform in size and thin and delicate",
                      "Infarction with extensive coagulative necrosis and hemorrhage may be seenCan be associated with prior needle biopsies of the papilloma or twisting of stalk causing ischemiaCan result in clinical hemorrhagic dischargeNot an indication of malignancy if other features of malignancy are not present",
                      "Can be associated with prior needle biopsies of the papilloma or twisting of stalk causing ischemia",
                      "Can result in clinical hemorrhagic discharge",
                      "Not an indication of malignancy if other features of malignancy are not present",
                      "Squamous metaplasia may be present and can be associated with infarctionRarely, spindle or squamous cell BCs can arise in association with squamous metaplasia",
                      "Rarely, spindle or squamous cell BCs can arise in association with squamous metaplasia"
                    ]
                  },
                  {
                    "text": "Small duct papilloma (SDP)Usually peripherally located small lesions involving terminal duct lobular unitsOften multipleThe term papillomatosis for multiple SDPs is not recommended by WHOThe same histologic features seen in LDP are present in SDP, although infarction uncommon",
                    "sub_points": [
                      "Usually peripherally located small lesions involving terminal duct lobular units",
                      "Often multipleThe term papillomatosis for multiple SDPs is not recommended by WHO",
                      "The term papillomatosis for multiple SDPs is not recommended by WHO",
                      "The same histologic features seen in LDP are present in SDP, although infarction uncommon"
                    ]
                  },
                  {
                    "text": "Myoepithelial hyperplasiaIn rare cases, the myoepithelial cells are increased in number and can appear atypicalThey can have epithelioid morphology with abundant clear cytoplasm or spindle-shapedThis type of papilloma can overlap in appearance with a small adenomyoepithelioma",
                    "sub_points": [
                      "In rare cases, the myoepithelial cells are increased in number and can appear atypicalThey can have epithelioid morphology with abundant clear cytoplasm or spindle-shaped",
                      "They can have epithelioid morphology with abundant clear cytoplasm or spindle-shaped",
                      "This type of papilloma can overlap in appearance with a small adenomyoepithelioma"
                    ]
                  },
                  {
                    "text": "Collagenous spherulosis (CS)In CS, myoepithelial cells surround basement membrane-like material to create a pseudocribriform patternThis pattern should not be mistaken for a true cribriform pattern and atypia in a papillomaIHC to demonstrate the myoepithelial cells can be helpful",
                    "sub_points": [
                      "In CS, myoepithelial cells surround basement membrane-like material to create a pseudocribriform pattern",
                      "This pattern should not be mistaken for a true cribriform pattern and atypia in a papilloma",
                      "IHC to demonstrate the myoepithelial cells can be helpful"
                    ]
                  },
                  {
                    "text": "Sclerosing papillomaLesions with a prominent component of stromal sclerosis, fibrosis, &/or sclerosing adenosisThese lesions overlap with complex sclerosing lesions, which can have a papillary componentEntrapped glands may be distorted by stroma and mimic an invasive patternMyoepithelial cells may be sparse or absentRare lesions with absent myoepithelial cells have been termed \"infiltrating epitheliosis\"This benign lesion shows a heterogeneous staining pattern for high molecular weight keratins and estrogen receptor (ER), similar to UDH",
                    "sub_points": [
                      "Lesions with a prominent component of stromal sclerosis, fibrosis, &/or sclerosing adenosis",
                      "These lesions overlap with complex sclerosing lesions, which can have a papillary component",
                      "Entrapped glands may be distorted by stroma and mimic an invasive patternMyoepithelial cells may be sparse or absent",
                      "Myoepithelial cells may be sparse or absent",
                      "Rare lesions with absent myoepithelial cells have been termed \"infiltrating epitheliosis\"This benign lesion shows a heterogeneous staining pattern for high molecular weight keratins and estrogen receptor (ER), similar to UDH",
                      "This benign lesion shows a heterogeneous staining pattern for high molecular weight keratins and estrogen receptor (ER), similar to UDH"
                    ]
                  },
                  {
                    "text": "Epithelial displacementEntrapment of benign epithelium in core needle biopsy sites, surgical sites, or other areas of stromal disturbance occurs most frequently with papillary lesionsBenign cells can also be pushed into lymphatics and lymph nodesUsually, only a few cells are present (< < 100 cells)IHC can be helpful in many cases to demonstrate the presence of both myoepithelial and epithelial cellsEven if myoepithelial cells are absent, a diagnosis of invasion or metastasis should be made only with great caution",
                    "sub_points": [
                      "Entrapment of benign epithelium in core needle biopsy sites, surgical sites, or other areas of stromal disturbance occurs most frequently with papillary lesions",
                      "Benign cells can also be pushed into lymphatics and lymph nodesUsually, only a few cells are present (< < 100 cells)",
                      "Usually, only a few cells are present (< < 100 cells)",
                      "IHC can be helpful in many cases to demonstrate the presence of both myoepithelial and epithelial cells",
                      "Even if myoepithelial cells are absent, a diagnosis of invasion or metastasis should be made only with great caution"
                    ]
                  },
                  {
                    "text": "Papilloma with atypiaPapillomas can be partially involved by either ADH or DCISIHC for high molecular weight cytokeratins (CK5/6) and ER can be helpful to distinguish UDH from ADH/DCISCriteria for distinguishing ADH from DCIS within a papilloma have been recommended by WHOADH is diagnosed if the area is < 0.3 cm and nuclei are low gradeIf nuclear grade is intermediate or high, classification as DCIS is favoredDCIS is diagnosed if involved area is ≥ 0.3 cmDCIS in surrounding breast tissue is helpful to support a diagnosis of DCIS and is more significant for determining the risk of subsequent BCThe clinical significance of DCIS limited to a papilloma and completely excised is unclear",
                    "sub_points": [
                      "Papillomas can be partially involved by either ADH or DCISIHC for high molecular weight cytokeratins (CK5/6) and ER can be helpful to distinguish UDH from ADH/DCIS",
                      "IHC for high molecular weight cytokeratins (CK5/6) and ER can be helpful to distinguish UDH from ADH/DCIS",
                      "Criteria for distinguishing ADH from DCIS within a papilloma have been recommended by WHOADH is diagnosed if the area is < 0.3 cm and nuclei are low gradeIf nuclear grade is intermediate or high, classification as DCIS is favoredDCIS is diagnosed if involved area is ≥ 0.3 cmDCIS in surrounding breast tissue is helpful to support a diagnosis of DCIS and is more significant for determining the risk of subsequent BCThe clinical significance of DCIS limited to a papilloma and completely excised is unclear",
                      "ADH is diagnosed if the area is < 0.3 cm and nuclei are low gradeIf nuclear grade is intermediate or high, classification as DCIS is favored",
                      "If nuclear grade is intermediate or high, classification as DCIS is favored",
                      "DCIS is diagnosed if involved area is ≥ 0.3 cmDCIS in surrounding breast tissue is helpful to support a diagnosis of DCIS and is more significant for determining the risk of subsequent BC",
                      "DCIS in surrounding breast tissue is helpful to support a diagnosis of DCIS and is more significant for determining the risk of subsequent BC",
                      "The clinical significance of DCIS limited to a papilloma and completely excised is unclear"
                    ]
                  },
                  {
                    "text": "Spindle cell carcinoma arising in a papillomaSquamous metaplasia may occur in papillomas, especially if associated with infarction and inflammationSpindle cell/squamous carcinomas can arise adjacent to these areasSpindle cells may be difficult to distinguish from reactive fibroblasts in the fibrous capsule of a papillomaNuclear atypia and mitoses are usually presentIHC for keratin (particularly basal types) and p63 is helpful to establish the epithelial origin of spindle cells",
                    "sub_points": [
                      "Squamous metaplasia may occur in papillomas, especially if associated with infarction and inflammation",
                      "Spindle cell/squamous carcinomas can arise adjacent to these areas",
                      "Spindle cells may be difficult to distinguish from reactive fibroblasts in the fibrous capsule of a papillomaNuclear atypia and mitoses are usually present",
                      "Nuclear atypia and mitoses are usually present",
                      "IHC for keratin (particularly basal types) and p63 is helpful to establish the epithelial origin of spindle cells"
                    ]
                  },
                  {
                    "text": "Associated lesionsRare lesions, including adenomyoepitheliomas, pleomorphic adenomas, adenosquamous carcinomas, and metaplastic carcinomas, may be found associated with sclerosing papillomasThey may also be found associated with other fibrosclerotic lesions",
                    "sub_points": [
                      "Rare lesions, including adenomyoepitheliomas, pleomorphic adenomas, adenosquamous carcinomas, and metaplastic carcinomas, may be found associated with sclerosing papillomasThey may also be found associated with other fibrosclerotic lesions",
                      "They may also be found associated with other fibrosclerotic lesions"
                    ]
                  }
                ],
                "Lymph Nodes": [
                  {
                    "text": "Benign epithelial inclusions, sometimes with a papillary architecture, can rarely be found in lymph nodesMay be associated with multiple papillomas in the breast",
                    "sub_points": [
                      "May be associated with multiple papillomas in the breast"
                    ]
                  },
                  {
                    "text": "The inclusions have a benign appearance and usually have myoepithelial cells by morphology and IHC"
                  },
                  {
                    "text": "ADH, DCIS, and, very rarely, invasive BC can arise in these inclusionsThis is a very rare etiology for invasive BC present in a lymph node in the absence of a primary BCHowever, in the majority of cases, a primary BC is found with more extensive imaging (e.g., MR)",
                    "sub_points": [
                      "This is a very rare etiology for invasive BC present in a lymph node in the absence of a primary BC",
                      "However, in the majority of cases, a primary BC is found with more extensive imaging (e.g., MR)"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Papillary lesions are usually fragmented and can be difficult to evaluateAn attempt should be made to classify as benign, involved by ADH or DCIS, or malignantIf features are not clearly benign, the lesion can be described as having atypical features and classification after excision recommended",
                    "sub_points": [
                      "An attempt should be made to classify as benign, involved by ADH or DCIS, or malignantIf features are not clearly benign, the lesion can be described as having atypical features and classification after excision recommended",
                      "If features are not clearly benign, the lesion can be described as having atypical features and classification after excision recommended"
                    ]
                  },
                  {
                    "text": "The size of the greatest extent of a papillary lesion is helpful information to provide to determine if the lesion might correlate with a mass seen by imagingFor example, a < 0.2-cm SDP is more likely an incidental finding than the source of a mass seen by imaging",
                    "sub_points": [
                      "For example, a < 0.2-cm SDP is more likely an incidental finding than the source of a mass seen by imaging"
                    ]
                  },
                  {
                    "text": "IHC can be helpful in difficult cases and can increase diagnostic concordanceMyoepithelial markers confirming these cells are at periphery and in fibrovascular cores favor a benign papillomaCK5/6 and ER are helpful to evaluate UDH vs. ADH/DCIS involving a papillomaIf myoepithelial cells are absent in the fibrovascular cores but present or at the periphery, the most likely diagnosis is DCISIf myoepithelial cells are absent in the fibrovascular cores and at the periphery, possible diagnoses include DCIS, EPC, and invasive papillary BC",
                    "sub_points": [
                      "Myoepithelial markers confirming these cells are at periphery and in fibrovascular cores favor a benign papillomaCK5/6 and ER are helpful to evaluate UDH vs. ADH/DCIS involving a papilloma",
                      "CK5/6 and ER are helpful to evaluate UDH vs. ADH/DCIS involving a papilloma",
                      "If myoepithelial cells are absent in the fibrovascular cores but present or at the periphery, the most likely diagnosis is DCIS",
                      "If myoepithelial cells are absent in the fibrovascular cores and at the periphery, possible diagnoses include DCIS, EPC, and invasive papillary BC"
                    ]
                  },
                  {
                    "text": "The likelihood of finding malignancy on excision of a benign papilloma is very low if there is good radiologic/pathologic correlationRisk factors for carcinoma on excision include older age, size > 1 cm, and symptoms (palpable mass or nipple discharge)",
                    "sub_points": [
                      "Risk factors for carcinoma on excision include older age, size > 1 cm, and symptoms (palpable mass or nipple discharge)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Myoepithelial markersThe presence and location of myoepithelial cells are very helpful in the classification of papillary lesionsBenign papillomas usually have a prominent myoepithelial cell layer at the periphery and in fibrovascular coresp63Very helpful for the evaluation of fibrovascular cores, as only myoepithelial cells will be positiveIn rare carcinomas, some tumor cells are positive for p63 but will not be located basallyMuscle markersBoth myoepithelial cells and endothelial cells are positive for muscle markersBlood vessels can be closely opposed to the basal portion of epithelial cells of papillary carcinomas in fibrovascular stalks and can be misidentified as myoepithelial cells",
                    "sub_points": [
                      "The presence and location of myoepithelial cells are very helpful in the classification of papillary lesions",
                      "Benign papillomas usually have a prominent myoepithelial cell layer at the periphery and in fibrovascular cores",
                      "p63Very helpful for the evaluation of fibrovascular cores, as only myoepithelial cells will be positiveIn rare carcinomas, some tumor cells are positive for p63 but will not be located basally",
                      "Very helpful for the evaluation of fibrovascular cores, as only myoepithelial cells will be positive",
                      "In rare carcinomas, some tumor cells are positive for p63 but will not be located basally",
                      "Muscle markersBoth myoepithelial cells and endothelial cells are positive for muscle markersBlood vessels can be closely opposed to the basal portion of epithelial cells of papillary carcinomas in fibrovascular stalks and can be misidentified as myoepithelial cells",
                      "Both myoepithelial cells and endothelial cells are positive for muscle markers",
                      "Blood vessels can be closely opposed to the basal portion of epithelial cells of papillary carcinomas in fibrovascular stalks and can be misidentified as myoepithelial cells"
                    ]
                  },
                  {
                    "text": "CK5/6 and ERThese markers are useful to distinguish usual ductal hyperplasia (UDH) from ADH and DCISUDH: Patchy heterogeneous positivity for CK5/6 and ERADH and DCIS: Negative for CK5/6, diffusely and strongly positive for ERThe findings must be interpreted in the context of the H&E findingsSome nonatypical papillomas can be negative for CK5/6 and strongly positive for ER, especially if involved by columnar cell change",
                    "sub_points": [
                      "These markers are useful to distinguish usual ductal hyperplasia (UDH) from ADH and DCISUDH: Patchy heterogeneous positivity for CK5/6 and ERADH and DCIS: Negative for CK5/6, diffusely and strongly positive for ER",
                      "UDH: Patchy heterogeneous positivity for CK5/6 and ER",
                      "ADH and DCIS: Negative for CK5/6, diffusely and strongly positive for ER",
                      "The findings must be interpreted in the context of the H&E findingsSome nonatypical papillomas can be negative for CK5/6 and strongly positive for ER, especially if involved by columnar cell change",
                      "Some nonatypical papillomas can be negative for CK5/6 and strongly positive for ER, especially if involved by columnar cell change"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ductal Carcinoma In Situ, Papillary Pattern": [
                  {
                    "text": "DCIS with a papillary pattern often also involves preexisting papillomasSome fibrovascular cores may have myoepithelial cells, and others lack them",
                    "sub_points": [
                      "Some fibrovascular cores may have myoepithelial cells, and others lack them"
                    ]
                  },
                  {
                    "text": "The epithelial cells are monomorphic in appearance, and nuclei may be hyperchromatic"
                  },
                  {
                    "text": "Architectural complexity, such as solid, cribriform, or micropapillary patterns, is also helpful to identify the lesion as DCIS"
                  },
                  {
                    "text": "May present as nipple discharge when very extensive"
                  }
                ],
                "Encapsulated Papillary Carcinoma": [
                  {
                    "text": "Usually presents as a central mass with circumscribed borders but located deeper in breast than LDP"
                  },
                  {
                    "text": "May be associated with nipple discharge"
                  },
                  {
                    "text": "Fibrovascular cores are usually thin and delicate"
                  },
                  {
                    "text": "Epithelial cells are monomorphic in appearanceEither lacks apocrine metaplasia or entire lesion appears apocrine",
                    "sub_points": [
                      "Either lacks apocrine metaplasia or entire lesion appears apocrine"
                    ]
                  },
                  {
                    "text": "Myoepithelial cells are absent within fibrovascular cores and at periphery"
                  },
                  {
                    "text": "If completely excised and no frank stromal invasion is present, clinical behavior is similar to DCIS"
                  }
                ],
                "Solid Papillary Carcinoma (SPC)": [
                  {
                    "text": "Presents as multiple solid circumscribed nodules of tumor cells with inconspicuous fibrovascular coresSome foci may have sparse myoepithelial cells at the periphery, and others lack myoepithelial cellsLacks the frond-like architectures seen in other papillary lesions",
                    "sub_points": [
                      "Some foci may have sparse myoepithelial cells at the periphery, and others lack myoepithelial cells",
                      "Lacks the frond-like architectures seen in other papillary lesions"
                    ]
                  },
                  {
                    "text": "The tumor cells can appear to have a heterogeneous appearance due to the possible presence of epithelioid cells with finely granular cytoplasm, spindle cells (neuroendocrine appearance), and cells with intracellular mucin (signet-ring cells)IHC for CK5/6 is usually negative and ER strongly positivePositivity for chromogranin and synaptophysin is present in ~ 50% of cases",
                    "sub_points": [
                      "IHC for CK5/6 is usually negative and ER strongly positive",
                      "Positivity for chromogranin and synaptophysin is present in ~ 50% of cases"
                    ]
                  },
                  {
                    "text": "Some SPCs are associated with extracellular mucin"
                  },
                  {
                    "text": "Prognosis similar to DCIS if frank stromal invasion is not present"
                  }
                ],
                "Nipple Adenoma": [
                  {
                    "text": "These benign lesions occur very superficially at duct orifices and often extend out on to the epidermal surfaceLDP involves a single large duct located below nipple skin",
                    "sub_points": [
                      "LDP involves a single large duct located below nipple skin"
                    ]
                  },
                  {
                    "text": "Typically presents as a palpable dermal mass or focal erosion of nipple skin"
                  },
                  {
                    "text": "Consists of a complex pattern of papillary areas, solid areas, sclerosing adenosis, and superficial keratin cysts"
                  },
                  {
                    "text": "Myoepithelial cells are present throughout the lesion"
                  }
                ],
                "Tall Cell Carcinoma With Reversed Polarity (TTCRP)": [
                  {
                    "text": "A very rare type of BC that has solid, solid papillary, and papillary patterns of growth and typically forms a mass with circumscribed borders"
                  },
                  {
                    "text": "Papillae may have foamy histiocytes in the centers of fibrovascular cores"
                  },
                  {
                    "text": "No myoepithelial cells are present"
                  },
                  {
                    "text": "Areas of \"reversed polarity\" are columnar cells lining fibrovascular cores with the nuclei located at the apex, rather than the base, of the cell"
                  },
                  {
                    "text": "Most are negative for hormone receptors and HER2 or show only weak ER expression"
                  },
                  {
                    "text": "The majority haveIDH2p.Arg172 hotspot mutations"
                  }
                ],
                "Skin and Chest Wall Recurrent Invasive Carcinoma": [
                  {
                    "text": "Invasive BC occurring in the skin or chest wall (skeletal muscle) can have a papillary appearance"
                  },
                  {
                    "text": "Recurrent carcinoma can form masses with circumscribed bordersNo myoepithelial cells are presentThe circumscribed borders may be due to origin in a lymphatic space",
                    "sub_points": [
                      "No myoepithelial cells are present",
                      "The circumscribed borders may be due to origin in a lymphatic space"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Papillary lesions are challenging to diagnose due to the number of benign and malignant lesionsPresence and location of myoepithelial cells are very helpful for classification",
                    "sub_points": [
                      "Presence and location of myoepithelial cells are very helpful for classification"
                    ]
                  },
                  {
                    "text": "LDP can twist and infarct, resulting in extensive necrosis, which should not be used as evidence for malignancy"
                  },
                  {
                    "text": "Beware of overinterpretation of epithelial displacement of papillary fronds into stroma, vascular spaces, or lymph nodes as evidence of malignancy"
                  },
                  {
                    "text": "Routine excision in all cases of papilloma diagnosed on core biopsy may be unnecessary when there is good radiologic/pathologic concordance, as the likelihood of upgrade is very low"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Papillomas responsible for clinical or imaging lesions are reported in order that concordance can be determined (e.g., size of lesion)"
                  },
                  {
                    "text": "Incidental papillomas need not be reported, unless the papilloma is the most significant proliferative lesion"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nipple Adenoma": {
            "name": "Nipple Adenoma",
            "url": "https://app.pathprimer.com/document/5ea7806e-e9a5-41a3-ba24-0c7cbd11491a/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Benign proliferative lesion arising in major duct orifices of nipple"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Usually present clinically as a palpable dermal nodule at nippleLarge lesions can distort nipple or protrude from surface",
                    "sub_points": [
                      "Large lesions can distort nipple or protrude from surface"
                    ]
                  },
                  {
                    "text": "Epidermis can appear eroded ± hemorrhage"
                  },
                  {
                    "text": "Skin changes (crusting, erosion) can raise concern for malignancy"
                  },
                  {
                    "text": "Local excision is necessary for diagnosis and treatment"
                  },
                  {
                    "text": "Occasional recurrences have been described after incomplete excision"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diverse array of possible histologic patternsSclerosing papillomatosis, papillomatosis, adenosis, or mixed patterns",
                    "sub_points": [
                      "Sclerosing papillomatosis, papillomatosis, adenosis, or mixed patterns"
                    ]
                  },
                  {
                    "text": "Some features can be difficult to distinguish from malignancyFlorid usual ductal hyperplasiaFocal necrosis in areas of florid hyperplasiaSclerosing adenosis resembling invasive carcinoma",
                    "sub_points": [
                      "Florid usual ductal hyperplasia",
                      "Focal necrosis in areas of florid hyperplasia",
                      "Sclerosing adenosis resembling invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Glandular cells replacing epidermis can mimic skin ulceration"
                  },
                  {
                    "text": "Toker cell hyperplasia may be present in epidermis"
                  },
                  {
                    "text": "A normal myoepithelial cell layer is present"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Large duct papilloma"
                  },
                  {
                    "text": "Syringomatous tumor"
                  },
                  {
                    "text": "Squamous cell carcinoma of the nipple"
                  },
                  {
                    "text": "Invasive ductal carcinoma"
                  },
                  {
                    "text": "Ductal carcinoma in situ involving large ducts"
                  },
                  {
                    "text": "Encapsulated papillary carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nipple adenoma (NA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Nipple duct adenoma"
                  },
                  {
                    "text": "Not recommended by WHO: Erosive adenomatosis, florid papillomatosis, papillary adenoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign glandular proliferation of superficial lactiferous ducts, arising at orifices of nipple ducts at skin and characterized by florid epithelial hyperplasia"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Nipple adenomas (NAs) are benign proliferative lesions that occur just below, and often involve, the nipple epidermis"
                  },
                  {
                    "text": "Due to their superficial location, they typically present with the clinical symptom of a mass ± skin erosion"
                  },
                  {
                    "text": "Erosion of the epidermis occurs when the glandular epithelium of the adenoma overgrows the squamous epitheliumThis is the finding that gives rise to the term \"erosive adenomatosis\" for NAsGlandular tissue is easily abraded, and this can result in bleeding",
                    "sub_points": [
                      "This is the finding that gives rise to the term \"erosive adenomatosis\" for NAs",
                      "Glandular tissue is easily abraded, and this can result in bleeding"
                    ]
                  },
                  {
                    "text": "Skin erosion and bleeding often raise clinical concern for an invasive carcinoma or Paget disease of the nipple"
                  },
                  {
                    "text": "If untreated, NAs can become quite large and form a polypoid mass attached to the nipple by a stalk"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "~ 1-2% of breast excisions"
                  }
                ],
                "Age": [
                  {
                    "text": "Wide range at presentation"
                  },
                  {
                    "text": "Most often seen in 4th or 5th decade"
                  }
                ],
                "Sex": [
                  {
                    "text": "Occurs in females; with rare cases in males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Palpable subcutaneous mass or superficial protruding mass of nipple skinUsually < 1 cmSlowly growing over many years",
                    "sub_points": [
                      "Usually < 1 cm",
                      "Slowly growing over many years"
                    ]
                  },
                  {
                    "text": "Erosion of skin and hemorrhage can mimic Paget disease and invasive carcinomaCan be tender and swollen",
                    "sub_points": [
                      "Can be tender and swollen"
                    ]
                  },
                  {
                    "text": "Hyperkeratosis due to irritation can clinically mimic the scaling crust of Paget disease"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete excision is necessary for definitive diagnosis and treatment"
                  },
                  {
                    "text": "Minimal surgical techniques can be used that preserve the nipple"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign lesion but can recur locally if not completely excised"
                  },
                  {
                    "text": "Association with carcinoma can occur but is very rare"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Imaging studies frequently are inconclusive"
                  },
                  {
                    "text": "May not be seen by imaging due to superficial location"
                  },
                  {
                    "text": "Ultrasound may show a dermal massNo specific features distinguish adenoma from carcinoma",
                    "sub_points": [
                      "No specific features distinguish adenoma from carcinoma"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Firm mass under nipple epidermis with irregular or lobulated bordersMacroscopic features similar to invasive carcinoma",
                    "sub_points": [
                      "Macroscopic features similar to invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Overlying epidermis may have a scale crust &/or appear to be eroded"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "PIK3CAmutations are reported in ~ 50% of NAsThis is an important gene in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilityMutations are found in many breast proliferative lesions, such as papillomas and adenomyoepitheliomas, as well as in normal breast tissueTherefore, this mutation may occur early in development and predispose to the development of multiple types of proliferative lesions but not be specific to any particular lesion",
                    "sub_points": [
                      "This is an important gene in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motility",
                      "Mutations are found in many breast proliferative lesions, such as papillomas and adenomyoepitheliomas, as well as in normal breast tissue",
                      "Therefore, this mutation may occur early in development and predispose to the development of multiple types of proliferative lesions but not be specific to any particular lesion"
                    ]
                  },
                  {
                    "text": "There is little information on other genomic changes in NAs"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Located just below the epidermis and is associated with the superficial lactiferous sinuses of the nippleMay be in continuity with overlying squamous epitheliumTraumatized glandular cells on skin surface can give appearance of ulcerationA normal myoepithelial layer is present",
                    "sub_points": [
                      "May be in continuity with overlying squamous epithelium",
                      "Traumatized glandular cells on skin surface can give appearance of ulceration",
                      "A normal myoepithelial layer is present"
                    ]
                  },
                  {
                    "text": "Forms a nodular mass that can include multiple morphologic patterns"
                  },
                  {
                    "text": "4 major patterns were defined by Rosen; different patterns often coexist in the same caseSclerosing papillomatosis patternPapillary growth within ductsPapillary growth can be distorted by prominent stromal proliferationTypically associated with collagenous bands, myxoid change, or elastosisOverlying skin is intact but thickenedSquamous cysts are often present in duct orificesFocal central necrosis can be present in areas of florid epithelial hyperplasiaUsually presents as mass with serous dischargePapillomatosis patternPapillary growth within large ductsLess prominent stromal proliferationEpidermis replaced by glandular epitheliumCreates a clinical appearance of erythematous granular surface on the nippleFocal necrosis can be presentUsually presents with skin erosion and bloody discharge in indurated area of nippleMay be mistaken for ductal carcinoma in situ (DCIS) involving nipple epidermis (Paget disease) clinicallyAdenosis patternProliferation of small glands in a sclerosing adenosis patternEntrapped ducts can have a pseudoinfiltrative patternMay closely mimic invasive carcinomaApocrine metaplasia is common in this patternA normal myoepithelial cell layer is presentIHC can be helpful to demonstrate presence in difficult casesNecrosis is uncommonUsually presents with bloody or serous dischargeMixed patternAny combination of these patterns can be seenFlorid epithelial hyperplasia is commonNuclei lack significant pleomorphism or low-grade monomorphic appearanceHigh molecular weight keratins show patchy or checkerboard pattern of stainingSupports that cells are a heterogeneous population and not a clonal proliferation of atypical or malignant cellsToker cell hyperplasia may be present in epidermisIn a superficial biopsy, the presence of Toker cells in association with clinically evident skin changes can be mistaken for Paget diseaseInvasive carcinoma and DCIS are very rarely present within NA",
                    "sub_points": [
                      "Sclerosing papillomatosis patternPapillary growth within ductsPapillary growth can be distorted by prominent stromal proliferationTypically associated with collagenous bands, myxoid change, or elastosisOverlying skin is intact but thickenedSquamous cysts are often present in duct orificesFocal central necrosis can be present in areas of florid epithelial hyperplasiaUsually presents as mass with serous discharge",
                      "Papillary growth within ducts",
                      "Papillary growth can be distorted by prominent stromal proliferationTypically associated with collagenous bands, myxoid change, or elastosis",
                      "Typically associated with collagenous bands, myxoid change, or elastosis",
                      "Overlying skin is intact but thickened",
                      "Squamous cysts are often present in duct orifices",
                      "Focal central necrosis can be present in areas of florid epithelial hyperplasia",
                      "Usually presents as mass with serous discharge",
                      "Papillomatosis patternPapillary growth within large ductsLess prominent stromal proliferationEpidermis replaced by glandular epitheliumCreates a clinical appearance of erythematous granular surface on the nippleFocal necrosis can be presentUsually presents with skin erosion and bloody discharge in indurated area of nippleMay be mistaken for ductal carcinoma in situ (DCIS) involving nipple epidermis (Paget disease) clinically",
                      "Papillary growth within large ducts",
                      "Less prominent stromal proliferation",
                      "Epidermis replaced by glandular epitheliumCreates a clinical appearance of erythematous granular surface on the nipple",
                      "Creates a clinical appearance of erythematous granular surface on the nipple",
                      "Focal necrosis can be present",
                      "Usually presents with skin erosion and bloody discharge in indurated area of nippleMay be mistaken for ductal carcinoma in situ (DCIS) involving nipple epidermis (Paget disease) clinically",
                      "May be mistaken for ductal carcinoma in situ (DCIS) involving nipple epidermis (Paget disease) clinically",
                      "Adenosis patternProliferation of small glands in a sclerosing adenosis patternEntrapped ducts can have a pseudoinfiltrative patternMay closely mimic invasive carcinomaApocrine metaplasia is common in this patternA normal myoepithelial cell layer is presentIHC can be helpful to demonstrate presence in difficult casesNecrosis is uncommonUsually presents with bloody or serous discharge",
                      "Proliferation of small glands in a sclerosing adenosis pattern",
                      "Entrapped ducts can have a pseudoinfiltrative patternMay closely mimic invasive carcinomaApocrine metaplasia is common in this patternA normal myoepithelial cell layer is presentIHC can be helpful to demonstrate presence in difficult cases",
                      "May closely mimic invasive carcinoma",
                      "Apocrine metaplasia is common in this pattern",
                      "A normal myoepithelial cell layer is present",
                      "IHC can be helpful to demonstrate presence in difficult cases",
                      "Necrosis is uncommon",
                      "Usually presents with bloody or serous discharge",
                      "Mixed patternAny combination of these patterns can be seen",
                      "Any combination of these patterns can be seen",
                      "Florid epithelial hyperplasia is commonNuclei lack significant pleomorphism or low-grade monomorphic appearanceHigh molecular weight keratins show patchy or checkerboard pattern of stainingSupports that cells are a heterogeneous population and not a clonal proliferation of atypical or malignant cells",
                      "Nuclei lack significant pleomorphism or low-grade monomorphic appearance",
                      "High molecular weight keratins show patchy or checkerboard pattern of staining",
                      "Supports that cells are a heterogeneous population and not a clonal proliferation of atypical or malignant cells",
                      "Toker cell hyperplasia may be present in epidermisIn a superficial biopsy, the presence of Toker cells in association with clinically evident skin changes can be mistaken for Paget disease",
                      "In a superficial biopsy, the presence of Toker cells in association with clinically evident skin changes can be mistaken for Paget disease",
                      "Invasive carcinoma and DCIS are very rarely present within NA"
                    ]
                  }
                ],
                "Skin Biopsy": [
                  {
                    "text": "Initial diagnostic biopsy is usually a skin biopsyClinical features of skin erosion with bleeding &/or scale crust can be very suspicious for malignancy",
                    "sub_points": [
                      "Clinical features of skin erosion with bleeding &/or scale crust can be very suspicious for malignancy"
                    ]
                  },
                  {
                    "text": "Biopsies are generally small and limited due to cosmetic concerns for nippleCrush artifact is common",
                    "sub_points": [
                      "Crush artifact is common"
                    ]
                  },
                  {
                    "text": "Florid usual ductal hyperplasia combined with a central area of necrosis should not be overinterpreted as malignancy"
                  },
                  {
                    "text": "Toker cell hyperplasia associated with scale crust due to irritation from the NA should not be overinterpreted as Paget disease"
                  },
                  {
                    "text": "A misdiagnosis of malignancy can result in inappropriate mastectomy due to location at nippleSmall biopsies should be interpreted very conservativelyIn some cases, a final diagnosis should be reserved until entire lesion has been excised",
                    "sub_points": [
                      "Small biopsies should be interpreted very conservatively",
                      "In some cases, a final diagnosis should be reserved until entire lesion has been excised"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Large Duct Papilloma": [
                  {
                    "text": "Arise in lactiferous sinuses located below skin surfaceNAs are similar lesions but are located more superficially",
                    "sub_points": [
                      "NAs are similar lesions but are located more superficially"
                    ]
                  },
                  {
                    "text": "Usually present as nipple discharge or lobulated mass identified by imagingUnlikely to present as a palpable subdermal mass",
                    "sub_points": [
                      "Unlikely to present as a palpable subdermal mass"
                    ]
                  }
                ],
                "Syringomatous Tumor (SyT)": [
                  {
                    "text": "SyT presents as a plaque-like area of subdermal firmness at nippleIn contrast, NAs form a discrete mass at duct orifice",
                    "sub_points": [
                      "In contrast, NAs form a discrete mass at duct orifice"
                    ]
                  },
                  {
                    "text": "Tumor cells infiltrate as small nests in dermis around normal structures and in areolar smooth muscleNAs form contiguous nodular masses within ductal system",
                    "sub_points": [
                      "NAs form contiguous nodular masses within ductal system"
                    ]
                  },
                  {
                    "text": "Both SyT and NA are associated with superficial keratin cysts"
                  },
                  {
                    "text": "A normal myoepithelial cell layer is not present in SyT"
                  }
                ],
                "Squamous Cell Carcinoma of Nipple": [
                  {
                    "text": "Initial lesion involves epidermis of the nipple as squamous cell carcinoma in situIn contrast, NAs arise in ducts below the epidermis",
                    "sub_points": [
                      "In contrast, NAs arise in ducts below the epidermis"
                    ]
                  },
                  {
                    "text": "Squamous cells show nuclear atypia, and necrosis may be present"
                  },
                  {
                    "text": "Squamous cell nests in dermis have an infiltrative pattern and surround normal structures"
                  }
                ],
                "Invasive Carcinoma": [
                  {
                    "text": "Invasive carcinomas rarely arise within the nipple"
                  },
                  {
                    "text": "These carcinomas can also form subdermal masses or thickening of the nipple"
                  },
                  {
                    "text": "Invasive carcinomas are very rarely associated with an NA"
                  },
                  {
                    "text": "In difficult cases, IHC can be used to confirm the absence of a myoepithelial cell layer"
                  }
                ],
                "Ductal Carcinoma In Situ Involving Large Ducts": [
                  {
                    "text": "DCIS involving a lactiferous sinus of nipple is usually clinically occult"
                  },
                  {
                    "text": "Formation of a palpable mass would be very unusual"
                  },
                  {
                    "text": "DCIS involving nipple epidermis (Paget disease) presents as scaling crust of the skin"
                  },
                  {
                    "text": "DCIS typically involves single lactiferous sinusMultinodular pattern, as seen in NA, would be unusual, unless DCIS involves the adenoma",
                    "sub_points": [
                      "Multinodular pattern, as seen in NA, would be unusual, unless DCIS involves the adenoma"
                    ]
                  },
                  {
                    "text": "Generally high grade and positive for HER2"
                  }
                ],
                "Encapsulated Papillary Carcinoma": [
                  {
                    "text": "These carcinomas generally form a solitary mass with circumscribed margins below the nipple"
                  },
                  {
                    "text": "Typically present as nipple discharge or a circumscribed mass by imagingFound deeper in breast (2-3 cm below nipple) compared with NAsMore superficial involvement would be unusual",
                    "sub_points": [
                      "Found deeper in breast (2-3 cm below nipple) compared with NAsMore superficial involvement would be unusual",
                      "More superficial involvement would be unusual"
                    ]
                  },
                  {
                    "text": "Tumor grows as delicate papillary fronds"
                  },
                  {
                    "text": "Myoepithelial cells are absent in papillary fronds and at the peripheryImmunoperoxidase studies may be helpful to support absence of myoepithelial cells",
                    "sub_points": [
                      "Immunoperoxidase studies may be helpful to support absence of myoepithelial cells"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "NAs are benign lesions that can be associated with clinical and pathologic features raising concern for malignancy"
                  },
                  {
                    "text": "Due to location, misdiagnosis can result in inappropriate mastectomy"
                  },
                  {
                    "text": "IHC studies are helpful to demonstrate a normal myoepithelial cell layer and to exclude invasive carcinoma"
                  },
                  {
                    "text": "Florid usual ductal hyperplasia with central necrosis can be present, which can mimic DCISImmunoperoxidase studies for high molecular keratins can be helpful in difficult cases to support classification as florid hyperplasia",
                    "sub_points": [
                      "Immunoperoxidase studies for high molecular keratins can be helpful in difficult cases to support classification as florid hyperplasia"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Microglandular Adenosis": {
            "name": "Microglandular Adenosis",
            "url": "https://app.pathprimer.com/document/04ca10c8-1fc9-4ede-8421-ef486bacd901/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Microglandular adenosis (MGA) is a proliferation of small tubules in a scattered pattern in breast tissue"
                  },
                  {
                    "text": "Atypical MGA (AMGA) shows nuclear and architectural atypia"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Genomic changes vary whether or not MGA is associated with carcinomaPure MGA may show copy number alterations or may not show any genomic changes by the technique usedMGA and AMGA usually show multiple genomic changes also found in the associated invasive carcinomaTP53mutations are found in > 80% when associated with carcinoma",
                    "sub_points": [
                      "Pure MGA may show copy number alterations or may not show any genomic changes by the technique used",
                      "MGA and AMGA usually show multiple genomic changes also found in the associated invasive carcinomaTP53mutations are found in > 80% when associated with carcinoma",
                      "TP53mutations are found in > 80% when associated with carcinoma"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Can present as a palpable mass, mammographic density, or be an incidental finding"
                  },
                  {
                    "text": "Pure MGA has never been reported to metastasize but may recur locally"
                  },
                  {
                    "text": "Associated with invasive carcinoma in ~ 25% of cases (at presentation or after recurrence)Nonobligate precursor of some triple negative carcinomas",
                    "sub_points": [
                      "Nonobligate precursor of some triple negative carcinomas"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Proliferation of small, round tubules surrounded by basement membrane material"
                  },
                  {
                    "text": "Negative for hormone receptorsConsider MGA if a lesion thought to be grade 1 carcinoma is ER(-)",
                    "sub_points": [
                      "Consider MGA if a lesion thought to be grade 1 carcinoma is ER(-)"
                    ]
                  },
                  {
                    "text": "Strong cytoplasmic positivity for S100"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Tubular adenosis"
                  },
                  {
                    "text": "Carcinoma arising in MGA"
                  },
                  {
                    "text": "Acinic cell carcinoma"
                  },
                  {
                    "text": "Invasive tubular carcinoma"
                  },
                  {
                    "text": "Adenomyoepithelioma, tubular type"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Microglandular adenosis (MGA)"
                  },
                  {
                    "text": "Atypical MGA (AMGA)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Proliferation of small, round tubules with a single cell layer distributed in an infiltrative pattern, negative for ER and positive for S100"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Microglandular Adenosis Without Associated Carcinoma": [
                  {
                    "text": "In its pure form (i.e., not associated with carcinoma), MGA has a consistent morphologic appearance, but lesions show genomic heterogeneity"
                  },
                  {
                    "text": "Although some cases recur locally, pure MGA has never been reported to metastasizeIt is the only benign epithelial lesion that lacks a myoepithelial cell layerThe tubules are surrounded by a structure similar to basement membrane by IHC studies and electron microscopy",
                    "sub_points": [
                      "It is the only benign epithelial lesion that lacks a myoepithelial cell layer",
                      "The tubules are surrounded by a structure similar to basement membrane by IHC studies and electron microscopy"
                    ]
                  },
                  {
                    "text": "Some cases of pure MGA show copy number aberrations, whereas other cases do not have demonstrable genetic changes by the techniques usedBecause some cases show clonality, microglandular adenoma has been suggested as an alternative nameMGA is the current preferred term by WHO",
                    "sub_points": [
                      "Because some cases show clonality, microglandular adenoma has been suggested as an alternative nameMGA is the current preferred term by WHO",
                      "MGA is the current preferred term by WHO"
                    ]
                  },
                  {
                    "text": "It is unknown if all of these lesions are clonal or if they consist of multiple clones"
                  },
                  {
                    "text": "Risk factors to predict the potential for progression to carcinoma have not been definedIt has been proposed that aTP53mutation is the driver event for additional genomic changes, as these mutations have only been reported in MGA associated with carcinoma",
                    "sub_points": [
                      "It has been proposed that aTP53mutation is the driver event for additional genomic changes, as these mutations have only been reported in MGA associated with carcinoma"
                    ]
                  }
                ],
                "Microglandular Adenosis With Associated Carcinoma": [
                  {
                    "text": "MGA is associated with invasive carcinoma in ~ 25% of casesCarcinoma may be present at presentation or after local recurrence",
                    "sub_points": [
                      "Carcinoma may be present at presentation or after local recurrence"
                    ]
                  },
                  {
                    "text": "In these cases, MGA typically has a range of appearances with some areas designated AMGA"
                  },
                  {
                    "text": "MGA and AMGA often share many features with the associated carcinomaMorphologically similarTriple negative for hormone receptors and HER2 and positive for S100AMGA and carcinoma share some genomic changes with the carcinoma often showing additional changes",
                    "sub_points": [
                      "Morphologically similar",
                      "Triple negative for hormone receptors and HER2 and positive for S100",
                      "AMGA and carcinoma share some genomic changes with the carcinoma often showing additional changes"
                    ]
                  },
                  {
                    "text": "MGA is considered a nonobligate precursor for some triple negative breast carcinomas (TNBCs)"
                  }
                ],
                "Low-Grade Triple Negative Breast Neoplasia Family": [
                  {
                    "text": "The association of MGA with invasive carcinoma has provided evidence for a family of low-grade TNBCs"
                  },
                  {
                    "text": "Some associated TNBCs are also low grade, and deaths due to these cancers are rareAdenoid cystic carcinoma (AdCC)Acinic cell carcinoma (AcCC)",
                    "sub_points": [
                      "Adenoid cystic carcinoma (AdCC)",
                      "Acinic cell carcinoma (AcCC)"
                    ]
                  },
                  {
                    "text": "However, other TNBCs associated with MGA are high grade and can lead to the death of patientsGrade 3 invasive ductal carcinomaMetaplastic matrix producing carcinoma",
                    "sub_points": [
                      "Grade 3 invasive ductal carcinoma",
                      "Metaplastic matrix producing carcinoma"
                    ]
                  },
                  {
                    "text": "MGA shares complex patterns of copy number alterations (e.g., 5q losses and 8q and 2q gains) and frequentTP53mutations that are also found in TNBCs"
                  },
                  {
                    "text": "Although MGA may be a precursor for some TNBCs, it is highly unlikely to be a precursor for all TNBCsMGA is very rare compared to TNBCsCarcinomas with associated MGA are very rareIt is possible that in some cases, the carcinoma overgrows MGANot all TNBCs have features associated with MGA",
                    "sub_points": [
                      "MGA is very rare compared to TNBCs",
                      "Carcinomas with associated MGA are very rareIt is possible that in some cases, the carcinoma overgrows MGA",
                      "It is possible that in some cases, the carcinoma overgrows MGA",
                      "Not all TNBCs have features associated with MGA"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare: Found in < 0.2% of breast biopsies"
                  }
                ],
                "Age": [
                  {
                    "text": "Wide range: 20-80 years (median: 50-60 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Not reported in male patients"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most common clinical finding is a palpable mass"
                  },
                  {
                    "text": "Can be an incidental microscopic finding"
                  },
                  {
                    "text": "There are no known risk factors for MGA"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "If diagnosed on core needle biopsy, complete excision is recommended to evaluate for associated carcinoma"
                  },
                  {
                    "text": "If diagnosed on excisional specimen, margins should be reportedMay recur locally if margins are involvedWhether or not reexcision to obtain margins free of MGA is required is debatedIf AMGA is present, complete excision is recommended",
                    "sub_points": [
                      "May recur locally if margins are involved",
                      "Whether or not reexcision to obtain margins free of MGA is required is debated",
                      "If AMGA is present, complete excision is recommended"
                    ]
                  },
                  {
                    "text": "Risk of subsequent carcinoma is unclear due to rarity of lesion"
                  },
                  {
                    "text": "Value of genomic testing to predict risk has not been evaluated (e.g., testing forTP53mutations)"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "No additional therapy indicated if carcinoma is not present"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Pure MGA does not metastasize and has not been reported to invade outside breast"
                  },
                  {
                    "text": "If invasive carcinoma is present, prognosis is dependent on the type of carcinomaUnknown if these carcinomas have different outcomes compared to similar carcinomas in absence of MGASome have metastasized and caused death of patients",
                    "sub_points": [
                      "Unknown if these carcinomas have different outcomes compared to similar carcinomas in absence of MGA",
                      "Some have metastasized and caused death of patients"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "No specific features"
                  },
                  {
                    "text": "Masses can have spiculated or indistinct margins"
                  },
                  {
                    "text": "May appear as architectural distortion without mass"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "May form ill-defined or indurated mass or not be apparent grossly"
                  }
                ],
                "Size": [
                  {
                    "text": "Range: < 1 cm to > 20 cm"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "If MGA is present, the entire specimen should be examined microscopically, if possible, to evaluate for associated carcinoma"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Molecular analyses have demonstrated that MGA lesions are heterogeneous at the genetic levelThe types of genomic changes detected vary depending on whether or not carcinoma is present",
                    "sub_points": [
                      "The types of genomic changes detected vary depending on whether or not carcinoma is present"
                    ]
                  },
                  {
                    "text": "MGA not associated with carcinomaSome have copy number alterations, whereas others do not show genomic changes by the techniques usedDo not haveTP53mutations",
                    "sub_points": [
                      "Some have copy number alterations, whereas others do not show genomic changes by the techniques used",
                      "Do not haveTP53mutations"
                    ]
                  },
                  {
                    "text": "MGA and AMGA associated with carcinomasMajority show complex copy number alterationsGains of 1q, 2q, 7p, and 8qLosses of 1p, 3p, 5q, 6q, 8p, 14q, 16q, 17p, and 17qTP53mutations (> 80%)The remaining wildtype allele is lostPIK3CAmutations (~ 12%)BRCA1mutations (~ 12%)Other mutations at lower frequenciesAMGA can show additional changes compared to MGA in the same lesionAssociated carcinomas can also show the same changes as well as additional changesA minority of MGA associated with carcinoma lack genomic changes",
                    "sub_points": [
                      "Majority show complex copy number alterationsGains of 1q, 2q, 7p, and 8qLosses of 1p, 3p, 5q, 6q, 8p, 14q, 16q, 17p, and 17q",
                      "Gains of 1q, 2q, 7p, and 8q",
                      "Losses of 1p, 3p, 5q, 6q, 8p, 14q, 16q, 17p, and 17q",
                      "TP53mutations (> 80%)The remaining wildtype allele is lost",
                      "The remaining wildtype allele is lost",
                      "PIK3CAmutations (~ 12%)",
                      "BRCA1mutations (~ 12%)",
                      "Other mutations at lower frequencies",
                      "AMGA can show additional changes compared to MGA in the same lesionAssociated carcinomas can also show the same changes as well as additional changes",
                      "Associated carcinomas can also show the same changes as well as additional changes",
                      "A minority of MGA associated with carcinoma lack genomic changes"
                    ]
                  }
                ],
                "mRNA": [
                  {
                    "text": "Small size and sparse cellularity limit ability to perform gene expression profiling"
                  }
                ],
                "Protein": [
                  {
                    "text": "The pattern of protein expression is not typical for mature luminal or myoepithelial cellsExpress both low and high molecular weight keratinsStrongly expresses S100Lacks ER, PR, and AR expression",
                    "sub_points": [
                      "Express both low and high molecular weight keratins",
                      "Strongly expresses S100",
                      "Lacks ER, PR, and AR expression"
                    ]
                  },
                  {
                    "text": "It has been proposed that the cells might be a type of ER(-) luminal progenitor cell"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "MGADispersed pattern of small, round tubules in and around normal ducts and lobulesNot lobulocentricSome disorganized clusters of tubules may be presentTubules can be widely separatedLittle or no stromal reactionTubules are present in adipose tissue as well as fibrotic stromaNormal ducts and lobules are not altered by the surrounding MGATubules are round with open lumina and consist of single cell layerUniform in shape and size: About the size or slightly larger than a normal acinusA basement membrane may be seen or demonstrated by IHCTubules lack surrounding myoepithelial layerLumina contain characteristic darkly eosinophilic secretory materialPositive for PAS-D, mucicarmine, and Alcian blueCalcifications are occasionally presentNuclei are round with small nucleoli and minimal pleomorphismCells are cuboidal and have clear &/or foamy cytoplasmFine cytoplasmic granules reported in some casesHowever, AcCC should be considered in such casesApical snouts are not presentMitoses absent or rareOncocytic differentiation and chondroid metaplasia may be present",
                    "sub_points": [
                      "Dispersed pattern of small, round tubules in and around normal ducts and lobulesNot lobulocentricSome disorganized clusters of tubules may be presentTubules can be widely separated",
                      "Not lobulocentricSome disorganized clusters of tubules may be present",
                      "Some disorganized clusters of tubules may be present",
                      "Tubules can be widely separated",
                      "Little or no stromal reactionTubules are present in adipose tissue as well as fibrotic stromaNormal ducts and lobules are not altered by the surrounding MGA",
                      "Tubules are present in adipose tissue as well as fibrotic stroma",
                      "Normal ducts and lobules are not altered by the surrounding MGA",
                      "Tubules are round with open lumina and consist of single cell layerUniform in shape and size: About the size or slightly larger than a normal acinusA basement membrane may be seen or demonstrated by IHCTubules lack surrounding myoepithelial layerLumina contain characteristic darkly eosinophilic secretory materialPositive for PAS-D, mucicarmine, and Alcian blueCalcifications are occasionally present",
                      "Uniform in shape and size: About the size or slightly larger than a normal acinusA basement membrane may be seen or demonstrated by IHC",
                      "A basement membrane may be seen or demonstrated by IHC",
                      "Tubules lack surrounding myoepithelial layer",
                      "Lumina contain characteristic darkly eosinophilic secretory materialPositive for PAS-D, mucicarmine, and Alcian blueCalcifications are occasionally present",
                      "Positive for PAS-D, mucicarmine, and Alcian blue",
                      "Calcifications are occasionally present",
                      "Nuclei are round with small nucleoli and minimal pleomorphism",
                      "Cells are cuboidal and have clear &/or foamy cytoplasmFine cytoplasmic granules reported in some casesHowever, AcCC should be considered in such casesApical snouts are not present",
                      "Fine cytoplasmic granules reported in some casesHowever, AcCC should be considered in such cases",
                      "However, AcCC should be considered in such cases",
                      "Apical snouts are not present",
                      "Mitoses absent or rare",
                      "Oncocytic differentiation and chondroid metaplasia may be present"
                    ]
                  },
                  {
                    "text": "AMGALesions are classified as AMGA due to both architectural and nuclear featuresIntraluminal secretions are often reduced or absentArchitectural featuresIncreased numbers of cells instead of single cell layerCribriform, solid nests, or single cellsNuclear featuresPleomorphic nuclei with large nucleoliFrequent &/or atypical mitoses",
                    "sub_points": [
                      "Lesions are classified as AMGA due to both architectural and nuclear featuresIntraluminal secretions are often reduced or absent",
                      "Intraluminal secretions are often reduced or absent",
                      "Architectural featuresIncreased numbers of cells instead of single cell layerCribriform, solid nests, or single cells",
                      "Increased numbers of cells instead of single cell layer",
                      "Cribriform, solid nests, or single cells",
                      "Nuclear featuresPleomorphic nuclei with large nucleoliFrequent &/or atypical mitoses",
                      "Pleomorphic nuclei with large nucleoli",
                      "Frequent &/or atypical mitoses"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "MGA can mimic well-differentiated invasive carcinoma when sampling is limitedSince MGA lacks myoepithelial cells, it is not possible to differentiate from carcinoma using myoepithelial markers aloneThe absence of hormone receptors is an important clue that the lesion is not a well-differentiated carcinoma",
                    "sub_points": [
                      "Since MGA lacks myoepithelial cells, it is not possible to differentiate from carcinoma using myoepithelial markers alone",
                      "The absence of hormone receptors is an important clue that the lesion is not a well-differentiated carcinoma"
                    ]
                  },
                  {
                    "text": "AMGA can closely mimic TNBC on core needle biopsyMisdiagnosis could lead to inappropriate neoadjuvant chemotherapy (NAT)AMGA and MGA can be more prominent after NAT because of the lack of response compared to TNBC",
                    "sub_points": [
                      "Misdiagnosis could lead to inappropriate neoadjuvant chemotherapy (NAT)",
                      "AMGA and MGA can be more prominent after NAT because of the lack of response compared to TNBC"
                    ]
                  },
                  {
                    "text": "If diagnosed on core needle biopsy, excision of MGA and AMGA is recommended to evaluate for possible synchronous carcinoma"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptors: Negative"
                  },
                  {
                    "text": "HER2: Negative"
                  },
                  {
                    "text": "S100: Strongly positive"
                  },
                  {
                    "text": "Myoepithelial markers: Negative"
                  },
                  {
                    "text": "Basement membrane markers: PositiveCollagen IV, laminin, reticulinNot necessary for diagnosis",
                    "sub_points": [
                      "Collagen IV, laminin, reticulin",
                      "Not necessary for diagnosis"
                    ]
                  },
                  {
                    "text": "Keratin: PositiveLuminal keratins (e.g., CK8/18): PositiveBasal keratins (e.g., CK14, CK17, CK5/6): Variably positive",
                    "sub_points": [
                      "Luminal keratins (e.g., CK8/18): Positive",
                      "Basal keratins (e.g., CK14, CK17, CK5/6): Variably positive"
                    ]
                  },
                  {
                    "text": "EMA: Negative or only focal"
                  },
                  {
                    "text": "GATA3: Can be reduced or lost"
                  },
                  {
                    "text": "GCDFP-15: Usually negative"
                  },
                  {
                    "text": "Cathepsin-D: Positive"
                  },
                  {
                    "text": "EGFR: Positive"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Tubular Adenosis": [
                  {
                    "text": "Tubular adenosis is an area of adenosis that has a pseudoinfiltrative pattern in stromaIt can be seen in association with more conventional sclerosing adenosisSurrounding stroma can be denseUsually does not involve adipose tissue",
                    "sub_points": [
                      "It can be seen in association with more conventional sclerosing adenosis",
                      "Surrounding stroma can be dense",
                      "Usually does not involve adipose tissue"
                    ]
                  },
                  {
                    "text": "Tubules can be sclerotic (compressed and slit-like), or they can be round and resemble MGASecretions generally absentCalcifications often present",
                    "sub_points": [
                      "Secretions generally absent",
                      "Calcifications often present"
                    ]
                  },
                  {
                    "text": "The myoepithelial cell layer may be difficult to see on H&EIHC will confirm the presence of a myoepithelial cell layer",
                    "sub_points": [
                      "IHC will confirm the presence of a myoepithelial cell layer"
                    ]
                  },
                  {
                    "text": "ER shows variable positivity"
                  }
                ],
                "Carcinoma Arising in Microglandular Adenosis": [
                  {
                    "text": "Carcinoma may be present at first presentation or develop after local recurrenceUsually present with a palpable mass measuring from 1-11 cm (mean: ~ 3 cm)Irregular nests of cells associated with desmoplastic response identify areas of carcinomaAMGA is also present in the majority of casesTypical MGA and AMGA often merge into areas of more frank malignancySimilar genomic changes (e.g., shared mutations) for MGA, AMGA, and carcinoma have been shown in some cases",
                    "sub_points": [
                      "Usually present with a palpable mass measuring from 1-11 cm (mean: ~ 3 cm)",
                      "Irregular nests of cells associated with desmoplastic response identify areas of carcinoma",
                      "AMGA is also present in the majority of casesTypical MGA and AMGA often merge into areas of more frank malignancy",
                      "Typical MGA and AMGA often merge into areas of more frank malignancy",
                      "Similar genomic changes (e.g., shared mutations) for MGA, AMGA, and carcinoma have been shown in some cases"
                    ]
                  },
                  {
                    "text": "Majority are grade 3 (~ 70%) or grade 2 (~ 25%)"
                  },
                  {
                    "text": "IHC profile typically similar to MGAER, PR, and HER2: Negative (> 95%)S100: Positive (~ 95%)",
                    "sub_points": [
                      "ER, PR, and HER2: Negative (> 95%)",
                      "S100: Positive (~ 95%)"
                    ]
                  },
                  {
                    "text": "Increased incidence of unusual histologic types40-60% are invasive ductal carcinoma~ 30-40% are metaplastic, including carcinomas with matrix production~ 20% are AdCC~ 10% are AcCC",
                    "sub_points": [
                      "40-60% are invasive ductal carcinoma",
                      "~ 30-40% are metaplastic, including carcinomas with matrix production",
                      "~ 20% are AdCC",
                      "~ 10% are AcCC"
                    ]
                  }
                ],
                "Acinic Cell Carcinoma (AcCC)": [
                  {
                    "text": "AcCC can have an infiltrative pattern very similar to MGAGreater variation in size and shape of tubules and solid nests",
                    "sub_points": [
                      "Greater variation in size and shape of tubules and solid nests"
                    ]
                  },
                  {
                    "text": "A distinctive feature of AcCC is the presence of serous differentiationBrightly eosinophilic cytoplasmic zymogen-type granulesPositivity for amylase, lysozyme, and α-1-chymotrypsinThere are lesions that focally display these features that are difficult to classify as either MGA or AcCC",
                    "sub_points": [
                      "Brightly eosinophilic cytoplasmic zymogen-type granules",
                      "Positivity for amylase, lysozyme, and α-1-chymotrypsin",
                      "There are lesions that focally display these features that are difficult to classify as either MGA or AcCC"
                    ]
                  },
                  {
                    "text": "Both AcCC and MGA are ER negative and S100 positive"
                  },
                  {
                    "text": "AcCC is EMA positive and MGA negative"
                  },
                  {
                    "text": "MGA more consistently stains for basement membrane markers compared to AcCC"
                  },
                  {
                    "text": "Both AcCC and MGA often have 8q gains and 5q losses as well asTP53mutations"
                  },
                  {
                    "text": "In general, AcCC has a favorable prognosis but does have metastatic capacityCan be associated with higher grade areas with a solid infiltrative pattern",
                    "sub_points": [
                      "Can be associated with higher grade areas with a solid infiltrative pattern"
                    ]
                  }
                ],
                "Invasive Tubular Carcinoma (TC)": [
                  {
                    "text": "Tubules are angulated, and cells often have apocrine snoutsTubules vary in shape and sizeIn contrast, tubules of MGA are uniform in size, round in shape, and do not have apocrine snouts",
                    "sub_points": [
                      "Tubules vary in shape and size",
                      "In contrast, tubules of MGA are uniform in size, round in shape, and do not have apocrine snouts"
                    ]
                  },
                  {
                    "text": "Tubules are in a contiguous area surrounded by a desmoplastic stromal reactionIn MGA, tubules appear to be randomly scattered and may be located far from each other",
                    "sub_points": [
                      "In MGA, tubules appear to be randomly scattered and may be located far from each other"
                    ]
                  },
                  {
                    "text": "TCs are always strongly ER positive and S100 negative"
                  },
                  {
                    "text": "TCs are frequently associated with atypical hyperplasia or carcinoma in situ"
                  }
                ],
                "Adenomyoepithelioma (AME), Tubular Type": [
                  {
                    "text": "AMEs are rare neoplasms consisting of distinct luminal and myoepithelial neoplastic populations"
                  },
                  {
                    "text": "The tubular type of AME infiltrates as tubules and solid nests of cells"
                  },
                  {
                    "text": "The double cell population and multiple cell layers distinguish this neoplasm from MGA"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Absence of myoepithelial cells should always be documented to exclude tubular adenosis"
                  },
                  {
                    "text": "Absence of hormone receptors in well-differentiated carcinoma should raise possibility of MGA"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Presence of MGA, AMGA, extent, and relationship to margins"
                  },
                  {
                    "text": "Correlate with finding for which excision was performed (imaging lesion or clinical mass)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Atypical Ductal Hyperplasia": {
            "name": "Atypical Ductal Hyperplasia",
            "url": "https://app.pathprimer.com/document/db3e27dd-97d4-4d9c-9fc8-cfccea090207/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Atypical ductal hyperplasia (ADH) is an intraductal clonal proliferation with some, but not all, features of ductal carcinoma in situ (DCIS)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "ADH and DCIS are genetically related"
                  },
                  {
                    "text": "ADH likely represents an early stage in the low-grade breast neoplasia pathway"
                  },
                  {
                    "text": "However, the majority do not progress to carcinoma"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Marker of increased risk of carcinoma in both breasts and a nonobligate precursor of carcinomaIncreased relative risk is 4-5x; absolute risk is ~ 13-17% at ~ 10 years",
                    "sub_points": [
                      "Increased relative risk is 4-5x; absolute risk is ~ 13-17% at ~ 10 years"
                    ]
                  }
                ],
                "Imaging": [
                  {
                    "text": "ADH most often presents with calcifications detected on mammographic screeningPresent in 15-20% of breast biopsies performed to evaluate calcifications",
                    "sub_points": [
                      "Present in 15-20% of breast biopsies performed to evaluate calcifications"
                    ]
                  },
                  {
                    "text": "Excision is currently recommended when detected on core needle biopsy"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "ADH consists of a monomorphic population of cells that are ER(+) and high molecular weight keratins (-)"
                  },
                  {
                    "text": "Cells appear to stand apart with well-defined borders"
                  },
                  {
                    "text": "Diagnosis is based on qualitative and quantitative findings"
                  },
                  {
                    "text": "Can be present in papillomas, fibroadenomas, sclerosing adenosis, and other benign lesions"
                  },
                  {
                    "text": "Borderline lesions may be described as ADH bordering on DCIS"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Usual ductal hyperplasia"
                  },
                  {
                    "text": "DCIS"
                  },
                  {
                    "text": "Collagenous spherulosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Atypical ductal hyperplasia (ADH)"
                  },
                  {
                    "text": "Low-grade ductal carcinoma in situ (LG-DCIS)"
                  },
                  {
                    "text": "Low-grade invasive breast carcinoma of no special type (LG-IBC-NST)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Ductal intraepithelial neoplasia type 1b or 1c is a proposed alternative nomenclature but is not widely used"
                  }
                ],
                "Definitions": [
                  {
                    "text": "A clonal intraductal proliferation with architectural and cytologic features approaching those seen in LG-DCIS, but less developed in degree and extent"
                  },
                  {
                    "text": "Associated with a 3-5x increased relative risk of developing breast carcinoma (invasive or in situ) in either breast (equivalent to ~ 13-17% risk at ~ 10 years)With long-term follow-up, the cumulative risk of carcinoma at 25 years is ~ 30%",
                    "sub_points": [
                      "With long-term follow-up, the cumulative risk of carcinoma at 25 years is ~ 30%"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Atypical Ductal Hyperplasia as a Nonobligate Precursor": [
                  {
                    "text": "ADH likely represents an early stage in the low-grade breast neoplasia pathwayIncreases the risk of invasive carcinoma in both breastsSome studies have shown a slightly increased risk in the ipsilateral breastOften associated with LG-DCIS and LG-IBC-NSTADH shares a pattern of losses and gains in DNA also seen in low-grade carcinomas",
                    "sub_points": [
                      "Increases the risk of invasive carcinoma in both breastsSome studies have shown a slightly increased risk in the ipsilateral breast",
                      "Some studies have shown a slightly increased risk in the ipsilateral breast",
                      "Often associated with LG-DCIS and LG-IBC-NST",
                      "ADH shares a pattern of losses and gains in DNA also seen in low-grade carcinomas"
                    ]
                  },
                  {
                    "text": "The strong, uniform expression of estrogen receptor (ER) suggests a hormonal roleIncreased ER expression &/or increased sensitivity to estrogen likely plays a role in the pathogenesis and progression of ADHFor women with ADH, chemoprevention with tamoxifen reduces the risk of ER(+) cancers",
                    "sub_points": [
                      "Increased ER expression &/or increased sensitivity to estrogen likely plays a role in the pathogenesis and progression of ADH",
                      "For women with ADH, chemoprevention with tamoxifen reduces the risk of ER(+) cancers"
                    ]
                  },
                  {
                    "text": "However, the majority of ADH does not progress to carcinomaThe factors responsible for progression from ADH to LG-DCIS and LG-IBC-NST are not yet completely understood",
                    "sub_points": [
                      "The factors responsible for progression from ADH to LG-DCIS and LG-IBC-NST are not yet completely understood"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Present in 15-20% of breast biopsies performed to evaluate mammographic microcalcifications"
                  }
                ],
                "Age": [
                  {
                    "text": "Peak: Women in mid-40s"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most commonly detected as clustered calcifications on screening mammography"
                  }
                ],
                "Treatment": [
                  {
                    "text": "ChemopreventionTamoxifen reduces the risk of ER(+) carcinomasHowever, the majority of women opt for careful active surveillance with imaging",
                    "sub_points": [
                      "Tamoxifen reduces the risk of ER(+) carcinomas",
                      "However, the majority of women opt for careful active surveillance with imaging"
                    ]
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Risk reduction by surgery would require bilateral mastectomiesADH in an excisional specimen does not require additional surgery",
                    "sub_points": [
                      "ADH in an excisional specimen does not require additional surgery"
                    ]
                  },
                  {
                    "text": "Core needle biopsyDCIS is found in adjacent tissue in ~ 15-20% of casesInvasive carcinoma is present in < 5% of casesLikelihood of DCIS found on excision is less for larger bore core needle biopsiesADH on core needle biopsy is currently an indication for excisionFactors associated with increased likelihood of malignant diagnosis on surgical excision includePalpable mass on clinical exam or imagingMultiple foci of ADH may increase risk compared to a single focus; however, size and number of core needle biopsies vary for different patientsResidual calcifications after the biopsyHowever, the likelihood of a malignant diagnosis is not increased in patients with high-risk germline breast cancer predisposition genesThe association with age has been inconsistent over multiple studies",
                    "sub_points": [
                      "DCIS is found in adjacent tissue in ~ 15-20% of casesInvasive carcinoma is present in < 5% of casesLikelihood of DCIS found on excision is less for larger bore core needle biopsies",
                      "Invasive carcinoma is present in < 5% of cases",
                      "Likelihood of DCIS found on excision is less for larger bore core needle biopsies",
                      "ADH on core needle biopsy is currently an indication for excision",
                      "Factors associated with increased likelihood of malignant diagnosis on surgical excision includePalpable mass on clinical exam or imagingMultiple foci of ADH may increase risk compared to a single focus; however, size and number of core needle biopsies vary for different patientsResidual calcifications after the biopsyHowever, the likelihood of a malignant diagnosis is not increased in patients with high-risk germline breast cancer predisposition genesThe association with age has been inconsistent over multiple studies",
                      "Palpable mass on clinical exam or imaging",
                      "Multiple foci of ADH may increase risk compared to a single focus; however, size and number of core needle biopsies vary for different patients",
                      "Residual calcifications after the biopsy",
                      "However, the likelihood of a malignant diagnosis is not increased in patients with high-risk germline breast cancer predisposition genes",
                      "The association with age has been inconsistent over multiple studies"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "ADH is a marker of increased risk for developing carcinoma and a nonobligate precursor of carcinomaAssociated with a 3-5x increased relative risk or ~ 13-17% risk of carcinoma (invasive and in situ) at ~ 10 yearsCancer risk is approximately equal in both breastsHowever, ipsilateral cancer is more common (~ 2/3 vs. ~ 1/3) in the first 5 years after diagnosis of ADHThe long-term cumulative incidence of breast cancer after 25 years for either breast is ~ 30%",
                    "sub_points": [
                      "Associated with a 3-5x increased relative risk or ~ 13-17% risk of carcinoma (invasive and in situ) at ~ 10 yearsCancer risk is approximately equal in both breastsHowever, ipsilateral cancer is more common (~ 2/3 vs. ~ 1/3) in the first 5 years after diagnosis of ADHThe long-term cumulative incidence of breast cancer after 25 years for either breast is ~ 30%",
                      "Cancer risk is approximately equal in both breastsHowever, ipsilateral cancer is more common (~ 2/3 vs. ~ 1/3) in the first 5 years after diagnosis of ADH",
                      "However, ipsilateral cancer is more common (~ 2/3 vs. ~ 1/3) in the first 5 years after diagnosis of ADH",
                      "The long-term cumulative incidence of breast cancer after 25 years for either breast is ~ 30%"
                    ]
                  },
                  {
                    "text": "The effect of family history on breast cancer risk is controversialSome studies have shown increased risk with positive family history, while others have shown no significant difference",
                    "sub_points": [
                      "Some studies have shown increased risk with positive family history, while others have shown no significant difference"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Calcifications are the most common findingClustered distributionOther calcification morphologies (punctate, pleomorphic, fine linear) favor DCIS",
                    "sub_points": [
                      "Clustered distribution",
                      "Other calcification morphologies (punctate, pleomorphic, fine linear) favor DCIS"
                    ]
                  },
                  {
                    "text": "ADH may be an incidental microscopic finding associated with other benign lesionsPapilloma, fibroadenoma, apocrine cysts, radial sclerosing lesion, gynecomastia",
                    "sub_points": [
                      "Papilloma, fibroadenoma, apocrine cysts, radial sclerosing lesion, gynecomastia"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Gross Findings": [
                  {
                    "text": "ADH does not form grossly apparent lesions"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Common genomic patterns of alterations occur in ADH, LG-DCIS, and invasive carcinoma from the same breast"
                  },
                  {
                    "text": "Shared alterations include gains of 1q and losses of 16qLosses at 16q are particularly frequent16q loss is the most common cytogenetic event in pure ADH followed by 1q gainLoss of heterozygosity at 17p and 11q13 also reported",
                    "sub_points": [
                      "Losses at 16q are particularly frequent16q loss is the most common cytogenetic event in pure ADH followed by 1q gain",
                      "16q loss is the most common cytogenetic event in pure ADH followed by 1q gain",
                      "Loss of heterozygosity at 17p and 11q13 also reported"
                    ]
                  },
                  {
                    "text": "However, few studies have examined ADH in the absence of associated carcinoma"
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "ADH, LG-DCIS, and LG-IBC-NST have similar gene expression patternsDominated by expression of ER and ER-regulated genesDifferences are in quantitative levels of expressionNo significant qualitative differences in expression patterns",
                    "sub_points": [
                      "Dominated by expression of ER and ER-regulated genes",
                      "Differences are in quantitative levels of expression",
                      "No significant qualitative differences in expression patterns"
                    ]
                  },
                  {
                    "text": "Low-grade carcinomas express a unique set of genes rarely seen in high-grade carcinomas"
                  }
                ],
                "Protein": [
                  {
                    "text": "ADH has protein expression patterns supporting that it is a clonal populationDiffuse expression of low molecular weight keratins and absence of expression of high molecular weight keratinsDiffuse strong expression of hormone receptors in majority of cases",
                    "sub_points": [
                      "Diffuse expression of low molecular weight keratins and absence of expression of high molecular weight keratins",
                      "Diffuse strong expression of hormone receptors in majority of cases"
                    ]
                  },
                  {
                    "text": "Usual ductal hyperplasia (UDH) shows variable expression of ER and variable expression of high molecular weight cytokeratins (mosaic pattern), supporting that it is a polyclonal population of cells"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "ADH is a proliferation of luminal-type cellsMay involve terminal duct lobular units or interlobular ductsDiagnosis is based on both qualitative and quantitative assessmentMain differential diagnosis is between ADH and LG-DCISLG-DCIS requires cytologic, architectural, and size criteria to be met for diagnosisADH demonstrates some, but not all, features of LG-DCISThere are borderline lesions that cannot be consistently classified by all pathologists as either ADH or DCISAdditional opinions may be helpful to reach a consensusConveying the difficulty in making a definitive classification to the clinician can be helpful for clinical managementIf the case is reviewed and a different classification favored by the consultant, the result can be placed into the context of a borderline lesionIt is generally recommended to classify truly borderline lesions as ADH to avoid overtreatmentHowever, if a borderline lesion is close to a margin in an excision for DCIS, ADH bordering on DCIS may be preferredReexcision of this area may reveal adjacent DCIS",
                    "sub_points": [
                      "May involve terminal duct lobular units or interlobular ducts",
                      "Diagnosis is based on both qualitative and quantitative assessment",
                      "Main differential diagnosis is between ADH and LG-DCISLG-DCIS requires cytologic, architectural, and size criteria to be met for diagnosisADH demonstrates some, but not all, features of LG-DCIS",
                      "LG-DCIS requires cytologic, architectural, and size criteria to be met for diagnosis",
                      "ADH demonstrates some, but not all, features of LG-DCIS",
                      "There are borderline lesions that cannot be consistently classified by all pathologists as either ADH or DCISAdditional opinions may be helpful to reach a consensusConveying the difficulty in making a definitive classification to the clinician can be helpful for clinical managementIf the case is reviewed and a different classification favored by the consultant, the result can be placed into the context of a borderline lesionIt is generally recommended to classify truly borderline lesions as ADH to avoid overtreatmentHowever, if a borderline lesion is close to a margin in an excision for DCIS, ADH bordering on DCIS may be preferredReexcision of this area may reveal adjacent DCIS",
                      "Additional opinions may be helpful to reach a consensus",
                      "Conveying the difficulty in making a definitive classification to the clinician can be helpful for clinical managementIf the case is reviewed and a different classification favored by the consultant, the result can be placed into the context of a borderline lesion",
                      "If the case is reviewed and a different classification favored by the consultant, the result can be placed into the context of a borderline lesion",
                      "It is generally recommended to classify truly borderline lesions as ADH to avoid overtreatmentHowever, if a borderline lesion is close to a margin in an excision for DCIS, ADH bordering on DCIS may be preferredReexcision of this area may reveal adjacent DCIS",
                      "However, if a borderline lesion is close to a margin in an excision for DCIS, ADH bordering on DCIS may be preferred",
                      "Reexcision of this area may reveal adjacent DCIS"
                    ]
                  },
                  {
                    "text": "Qualitative assessment in diagnosis of ADHArchitectural featuresMost common: Cribriform spaces or arched bridges; spaces often not as uniform as those seen in DCISBridges across cribriform spaces may be thin and show streaming of cellsMicropapillae may be present but are generally not extensiveOften associated with columnar cell change and flat epithelial atypiaFocal necrosis is rarely presentPagetoid spread in ducts can be present but is uncommonCytologic featuresCells are all luminal in typeLack expression of high molecular weight keratins 5/6Uniformly and strongly express ERThese findings support that ADH is a clonal proliferation and distinguish it from UDHCells appear to stand apart from one another with well-defined bordersUsually uniform in appearance with polarization around cribriform spacesHowever, cell populations of different morphologies may be present (cuboidal, spindle, columnar)Involved spaces usually contain > 1 cell population; monomorphic-appearing cells may merge with areas of UDHHigh-grade nuclei are not seen in ADH",
                    "sub_points": [
                      "Architectural featuresMost common: Cribriform spaces or arched bridges; spaces often not as uniform as those seen in DCISBridges across cribriform spaces may be thin and show streaming of cellsMicropapillae may be present but are generally not extensiveOften associated with columnar cell change and flat epithelial atypiaFocal necrosis is rarely presentPagetoid spread in ducts can be present but is uncommon",
                      "Most common: Cribriform spaces or arched bridges; spaces often not as uniform as those seen in DCIS",
                      "Bridges across cribriform spaces may be thin and show streaming of cells",
                      "Micropapillae may be present but are generally not extensive",
                      "Often associated with columnar cell change and flat epithelial atypia",
                      "Focal necrosis is rarely present",
                      "Pagetoid spread in ducts can be present but is uncommon",
                      "Cytologic featuresCells are all luminal in typeLack expression of high molecular weight keratins 5/6Uniformly and strongly express ERThese findings support that ADH is a clonal proliferation and distinguish it from UDHCells appear to stand apart from one another with well-defined bordersUsually uniform in appearance with polarization around cribriform spacesHowever, cell populations of different morphologies may be present (cuboidal, spindle, columnar)Involved spaces usually contain > 1 cell population; monomorphic-appearing cells may merge with areas of UDHHigh-grade nuclei are not seen in ADH",
                      "Cells are all luminal in typeLack expression of high molecular weight keratins 5/6Uniformly and strongly express ERThese findings support that ADH is a clonal proliferation and distinguish it from UDH",
                      "Lack expression of high molecular weight keratins 5/6",
                      "Uniformly and strongly express ER",
                      "These findings support that ADH is a clonal proliferation and distinguish it from UDH",
                      "Cells appear to stand apart from one another with well-defined borders",
                      "Usually uniform in appearance with polarization around cribriform spaces",
                      "However, cell populations of different morphologies may be present (cuboidal, spindle, columnar)",
                      "Involved spaces usually contain > 1 cell population; monomorphic-appearing cells may merge with areas of UDH",
                      "High-grade nuclei are not seen in ADH"
                    ]
                  },
                  {
                    "text": "Quantitative assessment in diagnosis of ADHSize &/or extent of involvement is used by some to distinguish ADH from LG-DCIS when qualitative criteria for DCIS are metDifferent definitions required for diagnosis of DCIS have been proposedAt least 2 duct spaces must be involvedLesion must be > 0.2 cm in sizeSize is not universally accepted criterion for diagnosis of ADH by allNo minimum size requirement for high-grade DCISIf there are multiple foci of ADH, each with varying morphologies, this is more characteristic of ADH than DCIS",
                    "sub_points": [
                      "Size &/or extent of involvement is used by some to distinguish ADH from LG-DCIS when qualitative criteria for DCIS are met",
                      "Different definitions required for diagnosis of DCIS have been proposedAt least 2 duct spaces must be involvedLesion must be > 0.2 cm in size",
                      "At least 2 duct spaces must be involved",
                      "Lesion must be > 0.2 cm in size",
                      "Size is not universally accepted criterion for diagnosis of ADH by allNo minimum size requirement for high-grade DCIS",
                      "No minimum size requirement for high-grade DCIS",
                      "If there are multiple foci of ADH, each with varying morphologies, this is more characteristic of ADH than DCIS"
                    ]
                  },
                  {
                    "text": "CalcificationsADH is often associated with secretionsSecretory material with membrane fragments provides a regular repeating structure for crystallization of calcificationsCalcifications are calcium phosphate in typeCalcium oxalate has not been described in ADH but may be present in adjacent cystsADH may also be associated with columnar cell change with apical snouts and secretionsCalcifications may be found in adjacent dilated lobules/cystsLess commonly, ADH is associated with mucin production with calcificationsIf mucinous cysts rupture, it may be difficult to distinguish findings from invasive mucinous carcinomaIn very rare cases, focal necrosis can be seenGenerally too limited in extent to form mammographic calcifications",
                    "sub_points": [
                      "ADH is often associated with secretionsSecretory material with membrane fragments provides a regular repeating structure for crystallization of calcificationsCalcifications are calcium phosphate in typeCalcium oxalate has not been described in ADH but may be present in adjacent cysts",
                      "Secretory material with membrane fragments provides a regular repeating structure for crystallization of calcifications",
                      "Calcifications are calcium phosphate in type",
                      "Calcium oxalate has not been described in ADH but may be present in adjacent cysts",
                      "ADH may also be associated with columnar cell change with apical snouts and secretionsCalcifications may be found in adjacent dilated lobules/cysts",
                      "Calcifications may be found in adjacent dilated lobules/cysts",
                      "Less commonly, ADH is associated with mucin production with calcificationsIf mucinous cysts rupture, it may be difficult to distinguish findings from invasive mucinous carcinoma",
                      "If mucinous cysts rupture, it may be difficult to distinguish findings from invasive mucinous carcinoma",
                      "In very rare cases, focal necrosis can be seenGenerally too limited in extent to form mammographic calcifications",
                      "Generally too limited in extent to form mammographic calcifications"
                    ]
                  },
                  {
                    "text": "Distribution of ADHTypically presents as single focus or involves a small areaIf multiple foci are present, foci typically differ in appearance; suggests presence of multiple different clonesSupports classification as ADH rather than LG-DCISIf ADH appears extensive, and foci are morphologically similar in appearance, a diagnosis of an unusual type of DCIS should be considered",
                    "sub_points": [
                      "Typically presents as single focus or involves a small area",
                      "If multiple foci are present, foci typically differ in appearance; suggests presence of multiple different clonesSupports classification as ADH rather than LG-DCIS",
                      "Supports classification as ADH rather than LG-DCIS",
                      "If ADH appears extensive, and foci are morphologically similar in appearance, a diagnosis of an unusual type of DCIS should be considered"
                    ]
                  },
                  {
                    "text": "Examination of multiple levelsADH and DCIS are often found in close proximityDeeper levels through paraffin blocks are often helpful to identify areas that may be diagnostic of DCIS associated with ADHIf a specimen has not been completely sampled, additional sampling is generally warranted",
                    "sub_points": [
                      "ADH and DCIS are often found in close proximity",
                      "Deeper levels through paraffin blocks are often helpful to identify areas that may be diagnostic of DCIS associated with ADH",
                      "If a specimen has not been completely sampled, additional sampling is generally warranted"
                    ]
                  },
                  {
                    "text": "ADH involving other lesionsADH can be present in papillomas, fibroadenomas, sclerosing adenosis, and other benign lesionsADH in a papilloma can be difficult to classifyDifficult cases can be classified as a papilloma with atypiaIf on core needle biopsy, excision should be considered for definitive classificationDiagnosis is more challenging when the underlying architecture is distortedThe clinical significance with respect to the subsequent risk of cancer is unclear if ADH is only found within another lesionAreas of ADH outside the lesion should be sought",
                    "sub_points": [
                      "ADH can be present in papillomas, fibroadenomas, sclerosing adenosis, and other benign lesionsADH in a papilloma can be difficult to classifyDifficult cases can be classified as a papilloma with atypiaIf on core needle biopsy, excision should be considered for definitive classification",
                      "ADH in a papilloma can be difficult to classify",
                      "Difficult cases can be classified as a papilloma with atypiaIf on core needle biopsy, excision should be considered for definitive classification",
                      "If on core needle biopsy, excision should be considered for definitive classification",
                      "Diagnosis is more challenging when the underlying architecture is distorted",
                      "The clinical significance with respect to the subsequent risk of cancer is unclear if ADH is only found within another lesionAreas of ADH outside the lesion should be sought",
                      "Areas of ADH outside the lesion should be sought"
                    ]
                  },
                  {
                    "text": "ADH and lobular neoplasiaADH in combination with lobular neoplasia (atypical lobular hyperplasia or lobular carcinoma in situ) can closely mimic LG-DCISIf a monomorphic population of cells appears dyscohesive, IHC studies for E-cadherin may reveal 2 separate populations",
                    "sub_points": [
                      "ADH in combination with lobular neoplasia (atypical lobular hyperplasia or lobular carcinoma in situ) can closely mimic LG-DCIS",
                      "If a monomorphic population of cells appears dyscohesive, IHC studies for E-cadherin may reveal 2 separate populations"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "ADH on core needle biopsy is currently an indication for excisionDCIS is found in adjacent tissue in ~ 15-20% of cases",
                    "sub_points": [
                      "DCIS is found in adjacent tissue in ~ 15-20% of cases"
                    ]
                  },
                  {
                    "text": "Histologic factors associated with increased likelihood of malignant diagnosis on surgical excision may includeMicropapillary architectureThe extent of ADH has had variable success in predicting an upgradeThis factor varies by the number and size of the cores taken by the radiologist, resulting in difficulty in quantificationThe presence of other lesions of risk, such as atypical lobular hyperplasia or lobular carcinoma in situ, may increase risk",
                    "sub_points": [
                      "Micropapillary architecture",
                      "The extent of ADH has had variable success in predicting an upgradeThis factor varies by the number and size of the cores taken by the radiologist, resulting in difficulty in quantification",
                      "This factor varies by the number and size of the cores taken by the radiologist, resulting in difficulty in quantification",
                      "The presence of other lesions of risk, such as atypical lobular hyperplasia or lobular carcinoma in situ, may increase risk"
                    ]
                  },
                  {
                    "text": "However, clearly defined criteria have not been developed for ADH of sufficiently low risk for upgrade after core needle biopsy such that excision would not be recommended"
                  },
                  {
                    "text": "It can be difficult to classify lesions as ADH or LG-DCIS based on the limited sampling on core needle biopsyThese lesions can be reported as having \"borderline\" features of ADH and LG-DCIS if additional levels and opinions do not aid in classificationThe risk of upgrade on excision to breast carcinoma is higher than for ADH alone (~ 40%)If the excision does not show carcinoma, these lesions can be classified as ADH",
                    "sub_points": [
                      "These lesions can be reported as having \"borderline\" features of ADH and LG-DCIS if additional levels and opinions do not aid in classification",
                      "The risk of upgrade on excision to breast carcinoma is higher than for ADH alone (~ 40%)If the excision does not show carcinoma, these lesions can be classified as ADH",
                      "If the excision does not show carcinoma, these lesions can be classified as ADH"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "High molecular weight keratins 5/6ADH and LG-DCIS are generally negative for keratins 5/6UDH shows patchy positivity",
                    "sub_points": [
                      "ADH and LG-DCIS are generally negative for keratins 5/6",
                      "UDH shows patchy positivity"
                    ]
                  },
                  {
                    "text": "Low molecular weight keratinsADH and LG-DCIS consist of a uniform population of luminal cells expressing low molecular weight keratins (e.g., CK8, CK18, and CK19)",
                    "sub_points": [
                      "ADH and LG-DCIS consist of a uniform population of luminal cells expressing low molecular weight keratins (e.g., CK8, CK18, and CK19)"
                    ]
                  },
                  {
                    "text": "Hormone receptorsADH typically shows uniform high levels of ER expression",
                    "sub_points": [
                      "ADH typically shows uniform high levels of ER expression"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Usual Ductal Hyperplasia (UDH)": [
                  {
                    "text": "Mixed nonclonal proliferation of luminal-type cells, myoepithelial-type cells, and intermediate cellsCells are variable in shape (epithelioid, spindle, columnar)Cells vary in sizeCells often overlap with uneven nuclear spacingOften show streaming or swirling pattern of growth and disorganized appearance",
                    "sub_points": [
                      "Cells are variable in shape (epithelioid, spindle, columnar)",
                      "Cells vary in size",
                      "Cells often overlap with uneven nuclear spacing",
                      "Often show streaming or swirling pattern of growth and disorganized appearance"
                    ]
                  },
                  {
                    "text": "Metaplastic changes in UDH can complicate interpretationIncludes apocrine metaplasia, clear cell change, and columnar cell changeResults in cells that appear monomorphic and clonal",
                    "sub_points": [
                      "Includes apocrine metaplasia, clear cell change, and columnar cell change",
                      "Results in cells that appear monomorphic and clonal"
                    ]
                  },
                  {
                    "text": "ArchitectureOften has solid pattern of duct involvementWhen spaces are present, they are typically located peripherallyIrregular shape in 3 dimensions (similar to spaces in recanalized thrombus)Cells are not oriented around edge of spacePapillae, when present, are broad based and taper at ends (\"pinched tips\")",
                    "sub_points": [
                      "Often has solid pattern of duct involvement",
                      "When spaces are present, they are typically located peripherallyIrregular shape in 3 dimensions (similar to spaces in recanalized thrombus)Cells are not oriented around edge of space",
                      "Irregular shape in 3 dimensions (similar to spaces in recanalized thrombus)",
                      "Cells are not oriented around edge of space",
                      "Papillae, when present, are broad based and taper at ends (\"pinched tips\")"
                    ]
                  },
                  {
                    "text": "ImmunohistochemistryA mixed or mosaic pattern of staining with high molecular weight cytokeratins 5/6 is seenER is positive but typically in a heterogeneous patchy distribution with varying intensityHowever, it is important to note that the smaller a lesion is, the more likely it is to show homogeneous immunoreactivity for these markersA homogeneous pattern should not be used to diagnose ADH in the absence of histologic features",
                    "sub_points": [
                      "A mixed or mosaic pattern of staining with high molecular weight cytokeratins 5/6 is seen",
                      "ER is positive but typically in a heterogeneous patchy distribution with varying intensity",
                      "However, it is important to note that the smaller a lesion is, the more likely it is to show homogeneous immunoreactivity for these markersA homogeneous pattern should not be used to diagnose ADH in the absence of histologic features",
                      "A homogeneous pattern should not be used to diagnose ADH in the absence of histologic features"
                    ]
                  }
                ],
                "Low-Grade Ductal Carcinoma In Situ (LG-DCIS)": [
                  {
                    "text": "A monomorphic cell population of luminal-type cells filling and distending duct spacesCells have uniform monomorphic appearanceStand apart from one another; do not overlapThe bridges in the cribriform pattern or in arches appear rigid due to cuboidal cell shapeComplex architecture with micropapillary, papillary, cribriform, or solid patterns is usually presentCribriform spaces are spherical in 3 dimensionsUniform in size and shape and evenly distributedNuclei are oriented and polarized toward spaces",
                    "sub_points": [
                      "Cells have uniform monomorphic appearanceStand apart from one another; do not overlapThe bridges in the cribriform pattern or in arches appear rigid due to cuboidal cell shape",
                      "Stand apart from one another; do not overlap",
                      "The bridges in the cribriform pattern or in arches appear rigid due to cuboidal cell shape",
                      "Complex architecture with micropapillary, papillary, cribriform, or solid patterns is usually presentCribriform spaces are spherical in 3 dimensionsUniform in size and shape and evenly distributedNuclei are oriented and polarized toward spaces",
                      "Cribriform spaces are spherical in 3 dimensions",
                      "Uniform in size and shape and evenly distributed",
                      "Nuclei are oriented and polarized toward spaces"
                    ]
                  },
                  {
                    "text": "Usually involves multiple duct spacesRarely < 2-3 mm in size and may be very extensive",
                    "sub_points": [
                      "Rarely < 2-3 mm in size and may be very extensive"
                    ]
                  },
                  {
                    "text": "LG-DCIS may be associated with ADH &/or LG-IBC-NST"
                  }
                ],
                "Collagenous Spherulosis (CS)": [
                  {
                    "text": "CS can mimic ADH due to the formation of cribriform spaces in some casesSpherules formed by basement membrane-like material and the cellular arrangement can give rise to the appearance of a cribriform or fenestrated proliferation when viewed at low powerThe basement membrane-like material is Alcian blue/PAS positive",
                    "sub_points": [
                      "Spherules formed by basement membrane-like material and the cellular arrangement can give rise to the appearance of a cribriform or fenestrated proliferation when viewed at low power",
                      "The basement membrane-like material is Alcian blue/PAS positive"
                    ]
                  },
                  {
                    "text": "IHC will demonstrate the presence of myoepithelial cells lining the pseudoluminal spaces formed by the basement membrane-like materialIn ADH, myoepithelial cells are only present at the periphery of the lesion",
                    "sub_points": [
                      "In ADH, myoepithelial cells are only present at the periphery of the lesion"
                    ]
                  },
                  {
                    "text": "Rarely, CS can be involved by lobular neoplasiaNeoplastic lobular cells displace the luminal cells and surround the spherules of basement membrane-like material ringed by myoepithelial cellsThe monomorphic appearance of the lobular cell population in combination with the pseudoluminal spaces closely mimics ADH or LG-DCISThe recognition of the basement membrane-like material and the dyshesive quality of lobular cells are helpful cluesIHC for E-cadherin and myoepithelial cells will identify the 2 cell types",
                    "sub_points": [
                      "Neoplastic lobular cells displace the luminal cells and surround the spherules of basement membrane-like material ringed by myoepithelial cellsThe monomorphic appearance of the lobular cell population in combination with the pseudoluminal spaces closely mimics ADH or LG-DCISThe recognition of the basement membrane-like material and the dyshesive quality of lobular cells are helpful cluesIHC for E-cadherin and myoepithelial cells will identify the 2 cell types",
                      "The monomorphic appearance of the lobular cell population in combination with the pseudoluminal spaces closely mimics ADH or LG-DCIS",
                      "The recognition of the basement membrane-like material and the dyshesive quality of lobular cells are helpful clues",
                      "IHC for E-cadherin and myoepithelial cells will identify the 2 cell types"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "ADH resembles LG-DCISDemonstrates similar architectural and cytologic atypiaPartial involvement of ducts &/or small size favors classification as ADH",
                    "sub_points": [
                      "Demonstrates similar architectural and cytologic atypiaPartial involvement of ducts &/or small size favors classification as ADH",
                      "Partial involvement of ducts &/or small size favors classification as ADH"
                    ]
                  },
                  {
                    "text": "Because biologic and histologic changes are on a continuum, rare lesions cannot be classified consistently as UDH, ADH, and LG-DCIS by pathologistsIn general, borderline lesions should be classified as the lesion of lower clinical significanceA conservative approach is favored for borderline lesions between ADH or LG-DCIS on core needle biopsies, as the majority of patients will not have cancer on excision",
                    "sub_points": [
                      "In general, borderline lesions should be classified as the lesion of lower clinical significance",
                      "A conservative approach is favored for borderline lesions between ADH or LG-DCIS on core needle biopsies, as the majority of patients will not have cancer on excision"
                    ]
                  },
                  {
                    "text": "Accurate diagnosis of ADH is essential, given the clinical significance and implications (surveillance and chemoprevention)Application of standardized morphologic criterion is necessary to help improve concordance between pathologists",
                    "sub_points": [
                      "Application of standardized morphologic criterion is necessary to help improve concordance between pathologists"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "ADH is important to report when it is the lesion conferring the greatest risk of breast cancer for a patientReporting is optional when carcinoma is presentBorderline lesions difficult to classify as ADH or LG-DCIS may be reported when close to marginsReexcision may be considered",
                    "sub_points": [
                      "Reporting is optional when carcinoma is present",
                      "Borderline lesions difficult to classify as ADH or LG-DCIS may be reported when close to marginsReexcision may be considered",
                      "Reexcision may be considered"
                    ]
                  },
                  {
                    "text": "For core needle biopsies showing ADH, multifocality and micropapillary architecture may be reported"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Atypical Lobular Hyperplasia": {
            "name": "Atypical Lobular Hyperplasia",
            "url": "https://app.pathprimer.com/document/63511ccc-02c1-4f9b-8932-9f75cdc67337/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Atypical lobular hyperplasia (ALH) is cytologically identical to lobular carcinoma in situ (LCIS) but is more limited in extent"
                  },
                  {
                    "text": "The term lobular neoplasia (LN) includes both ALH and LCIS"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "The hallmark feature of ALH, LCIS, and invasive lobular carcinoma (ILC) is loss of cell adhesionThis is predominantly due to loss of E-cadherin expression",
                    "sub_points": [
                      "This is predominantly due to loss of E-cadherin expression"
                    ]
                  },
                  {
                    "text": "Loss of heterozygosity at loci frequently observed in LCIS and ILC has also been reported in ALH"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "ALH is a marker of bilateral increased risk of invasive carcinoma and is a nonobligate precursor lesion~ 2/3 of cancers develop in the same breast and ~ 1/3 in contralateral breast",
                    "sub_points": [
                      "~ 2/3 of cancers develop in the same breast and ~ 1/3 in contralateral breast"
                    ]
                  },
                  {
                    "text": "Increases relative risk by 4-5x (0.5-1.0% of patients develop invasive cancer per year; 13-17% lifetime risk)"
                  },
                  {
                    "text": "Incidental finding in breast biopsies performed for other indicationsMost commonly detected in biopsies for calcifications",
                    "sub_points": [
                      "Most commonly detected in biopsies for calcifications"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Monomorphic population of polygonal or cuboidal cells that are small and round"
                  },
                  {
                    "text": "Cells are dyscohesive and regularly spaced"
                  },
                  {
                    "text": "Overall lobular architecture is maintained"
                  },
                  {
                    "text": "May secondarily involve other benign lesions"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "LCIS"
                  },
                  {
                    "text": "Poor tissue preservation or crush artifact"
                  },
                  {
                    "text": "Myoepithelial cells"
                  },
                  {
                    "text": "Histiocytes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Atypical lobular hyperplasia (ALH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Lobular intraepithelial neoplasia 1"
                  }
                ],
                "Definitions": [
                  {
                    "text": "ALH is a clonal proliferation, cytologically identical to lobular carcinoma in situ (LCIS) but more limited in extentCharacterized by proliferation of small, noncohesive cells with low to moderate nuclear grade ± pagetoid involvement of ducts< 1/2 of the lobular unit is involved by lobular neoplasia (LN)",
                    "sub_points": [
                      "Characterized by proliferation of small, noncohesive cells with low to moderate nuclear grade ± pagetoid involvement of ducts",
                      "< 1/2 of the lobular unit is involved by lobular neoplasia (LN)"
                    ]
                  },
                  {
                    "text": "Lobular neoplasia (LN) includes both ALH and LCIS"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "ALH is thought to represent an early stage in the low-grade breast neoplasia pathway for multiple reasonsIncreases the risk of invasive carcinoma in both breasts",
                    "sub_points": [
                      "Increases the risk of invasive carcinoma in both breasts"
                    ]
                  },
                  {
                    "text": "Often found with LCIS and invasive lobular carcinoma (ILC)Clonal neoplastic proliferation that shares a pattern of losses and gains in DNA also seen in LCIS and ILC",
                    "sub_points": [
                      "Clonal neoplastic proliferation that shares a pattern of losses and gains in DNA also seen in LCIS and ILC"
                    ]
                  },
                  {
                    "text": "The hallmark feature of ALH, LCIS, and ILC is loss of cellular adhesionIn the majority of cases, this is due to loss of expression of the E-cadherin protein, which is encoded by theCDH1geneMechanisms for loss of expression include combinations of genetic, epigenetic, and transcriptional alterationsLoss of heterozygosity (LOH) at 16q22, an area that includesCDH1, occurs in ALH, LCIS, and ILCMutations inCDH1are found in LCIS and invasive carcinoma but were not detected in one study of ALHPromoter methylation ofCDH1occurs in ALH, LCIS, and ILCUpregulation of other genes can lead to decreased expression ofCDH1",
                    "sub_points": [
                      "In the majority of cases, this is due to loss of expression of the E-cadherin protein, which is encoded by theCDH1gene",
                      "Mechanisms for loss of expression include combinations of genetic, epigenetic, and transcriptional alterationsLoss of heterozygosity (LOH) at 16q22, an area that includesCDH1, occurs in ALH, LCIS, and ILCMutations inCDH1are found in LCIS and invasive carcinoma but were not detected in one study of ALHPromoter methylation ofCDH1occurs in ALH, LCIS, and ILCUpregulation of other genes can lead to decreased expression ofCDH1",
                      "Loss of heterozygosity (LOH) at 16q22, an area that includesCDH1, occurs in ALH, LCIS, and ILC",
                      "Mutations inCDH1are found in LCIS and invasive carcinoma but were not detected in one study of ALH",
                      "Promoter methylation ofCDH1occurs in ALH, LCIS, and ILC",
                      "Upregulation of other genes can lead to decreased expression ofCDH1"
                    ]
                  },
                  {
                    "text": "ALH may be a true precursor lesion in rare casesIt is a nonobligate precursor, as the majority of women with ALH do not develop invasive carcinomaShared genetic changes suggest that ALH and LCIS represent a similar stage of genetic evolutionALH and LCIS are genomically related to adjacent ILC in some cases, supporting their role as true precursor lesions",
                    "sub_points": [
                      "It is a nonobligate precursor, as the majority of women with ALH do not develop invasive carcinoma",
                      "Shared genetic changes suggest that ALH and LCIS represent a similar stage of genetic evolution",
                      "ALH and LCIS are genomically related to adjacent ILC in some cases, supporting their role as true precursor lesions"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "ALH and LCIS without invasive carcinoma are found in only 0.5-4.0% of breast biopsies and reduction mammoplasty specimens"
                  },
                  {
                    "text": "They are usually detected as incidental findings in biopsies performed for other indications"
                  },
                  {
                    "text": "The true incidence of ALH in the general population is unknown"
                  }
                ],
                "Age": [
                  {
                    "text": "ALH is more common in premenopausal women (peak incidence: Mid-40s to 50 years of age)"
                  }
                ],
                "Site": [
                  {
                    "text": "ALH can be multicentric and is frequently bilateral"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Asymptomatic"
                  },
                  {
                    "text": "Most commonly detected as an incidental finding in biopsies for calcifications"
                  }
                ],
                "Treatment": [
                  {
                    "text": "In order to reduce risk, both breasts would require treatmentChemoprevention with tamoxifen reduces the risk of ER(+) invasive carcinomaBilateral mastectomy reduces risk",
                    "sub_points": [
                      "Chemoprevention with tamoxifen reduces the risk of ER(+) invasive carcinoma",
                      "Bilateral mastectomy reduces risk"
                    ]
                  },
                  {
                    "text": "However, the majority of women will not develop invasive carcinoma, and most choose surveillance by imaging"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "ALH increases the relative risk of developing invasive carcinoma by 4-5x0.5-1.0% of patients develop invasive cancer per year, resulting in a ~ 13-17% lifetime riskSome studies have shown an increased risk when other features are presentMultiple foci of ALH (e.g., > 3 foci vs. < 3 foci)Strong family history of breast carcinoma (may double the risk)Younger age at diagnosis of ALHDiminished age-related involution",
                    "sub_points": [
                      "0.5-1.0% of patients develop invasive cancer per year, resulting in a ~ 13-17% lifetime risk",
                      "Some studies have shown an increased risk when other features are presentMultiple foci of ALH (e.g., > 3 foci vs. < 3 foci)Strong family history of breast carcinoma (may double the risk)Younger age at diagnosis of ALHDiminished age-related involution",
                      "Multiple foci of ALH (e.g., > 3 foci vs. < 3 foci)",
                      "Strong family history of breast carcinoma (may double the risk)",
                      "Younger age at diagnosis of ALH",
                      "Diminished age-related involution"
                    ]
                  },
                  {
                    "text": "If ductal involvement by ALH (pagetoid extension) is also present, the relative risk is 8x"
                  },
                  {
                    "text": "The subsequent risk of invasive carcinoma for women with LN applies to both breasts~ 2/3 of cancers develop in the same breast and ~ 1/3 in the contralateral breastIpsilateral cancers may not be present at the same site as LNCarcinomas that occur in women after a diagnosis of LN average > 10 years to diagnosisUp to 1/2 of subsequent cancers show classic or variant patterns of special-type histology with a good prognosisThe likelihood of developing ILC is 3x higher than in the general populationHowever, the majority of subsequent carcinomas are not lobular in type",
                    "sub_points": [
                      "~ 2/3 of cancers develop in the same breast and ~ 1/3 in the contralateral breast",
                      "Ipsilateral cancers may not be present at the same site as LN",
                      "Carcinomas that occur in women after a diagnosis of LN average > 10 years to diagnosisUp to 1/2 of subsequent cancers show classic or variant patterns of special-type histology with a good prognosisThe likelihood of developing ILC is 3x higher than in the general populationHowever, the majority of subsequent carcinomas are not lobular in type",
                      "Up to 1/2 of subsequent cancers show classic or variant patterns of special-type histology with a good prognosisThe likelihood of developing ILC is 3x higher than in the general populationHowever, the majority of subsequent carcinomas are not lobular in type",
                      "The likelihood of developing ILC is 3x higher than in the general population",
                      "However, the majority of subsequent carcinomas are not lobular in type"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "ALH does not cause mammographically detected lesionsMore commonly present in biopsies for calcifications than in biopsies for massesCalcifications are often present in areas adjacent to ALHFrequently associated with adjacent apocrine cysts, columnar cell change, flat epithelial atypia, or atypical ductal hyperplasia with calcifications",
                    "sub_points": [
                      "More commonly present in biopsies for calcifications than in biopsies for masses",
                      "Calcifications are often present in areas adjacent to ALHFrequently associated with adjacent apocrine cysts, columnar cell change, flat epithelial atypia, or atypical ductal hyperplasia with calcifications",
                      "Frequently associated with adjacent apocrine cysts, columnar cell change, flat epithelial atypia, or atypical ductal hyperplasia with calcifications"
                    ]
                  },
                  {
                    "text": "The incidence of ALH is reported to be higher in women with increased mammographic breast density"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "ALH and LCIS do not form gross lesions"
                  }
                ]
              },
              "MOLECULAR": {
                "Cell Adhesion Molecules": [
                  {
                    "text": "Like other members of the lobular family, ALH lacks cellular adhesionIn the majority of cases, this is due to loss of membrane expression of the E-cadherin protein, which is encoded by theCDH1geneE-cadherin is a transmembrane protein that plays a major role in intercellular adhesion and cell polarityThe cytoplasmic portion of E-cadherin is attached to actin cytoskeleton by binding β- or γ-cateninLoss of E-cadherin expression can be shown by IHCThe majority of cases also lack β-catenin expression and show aberrant cytoplasmic p120CDH1DNA alterations are found in LCIS but were not reported in one study of ALHALH may lack expression due to methylation of theCDH1gene promoter region",
                    "sub_points": [
                      "In the majority of cases, this is due to loss of membrane expression of the E-cadherin protein, which is encoded by theCDH1gene",
                      "E-cadherin is a transmembrane protein that plays a major role in intercellular adhesion and cell polarityThe cytoplasmic portion of E-cadherin is attached to actin cytoskeleton by binding β- or γ-catenin",
                      "The cytoplasmic portion of E-cadherin is attached to actin cytoskeleton by binding β- or γ-catenin",
                      "Loss of E-cadherin expression can be shown by IHCThe majority of cases also lack β-catenin expression and show aberrant cytoplasmic p120",
                      "The majority of cases also lack β-catenin expression and show aberrant cytoplasmic p120",
                      "CDH1DNA alterations are found in LCIS but were not reported in one study of ALH",
                      "ALH may lack expression due to methylation of theCDH1gene promoter region"
                    ]
                  },
                  {
                    "text": "In a small subset of lesions, E-cadherin is expressed, but other associated adhesion proteins are nonfunctionalLoss or abnormal expression of catenins can be demonstrated by IHC",
                    "sub_points": [
                      "Loss or abnormal expression of catenins can be demonstrated by IHC"
                    ]
                  },
                  {
                    "text": "Classification of lesions as \"lobular\" is based on morphology rather than specific protein expressionIHC studies are not necessary when loss of cohesion can be identified morphologically",
                    "sub_points": [
                      "IHC studies are not necessary when loss of cohesion can be identified morphologically"
                    ]
                  }
                ],
                "DNA Copy Number Alterations": [
                  {
                    "text": "ALH and LCIS share other similar losses and gains of DNALOH at loci frequently observed in ILC has been reported in ALH and LCISLOH at 16q21-q23.1 (location ofCDH1)LOH at 11q13, 16q, 17p, and 17q, 7p, 16p, 22qCopy number gain at 14q32.33 (site ofAKT1gene) (involved in luminal morphogenesis), 2p, 6q",
                    "sub_points": [
                      "LOH at loci frequently observed in ILC has been reported in ALH and LCISLOH at 16q21-q23.1 (location ofCDH1)LOH at 11q13, 16q, 17p, and 17q, 7p, 16p, 22q",
                      "LOH at 16q21-q23.1 (location ofCDH1)",
                      "LOH at 11q13, 16q, 17p, and 17q, 7p, 16p, 22q",
                      "Copy number gain at 14q32.33 (site ofAKT1gene) (involved in luminal morphogenesis), 2p, 6q"
                    ]
                  }
                ],
                "Germline Mutations": [
                  {
                    "text": "GermlineCDH1mutations are present in 30% of patients with hereditary diffuse (signet-ring cell) gastric carcinomaSome patients in these kindreds develop lobular carcinomas",
                    "sub_points": [
                      "Some patients in these kindreds develop lobular carcinomas"
                    ]
                  },
                  {
                    "text": "However, kindreds with germline mutations inCDH1with only lobular carcinomas and not gastric carcinomas are exceedingly rare"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Architectural featuresCells are loosely cohesive, regularly spaced, and fill and slightly distend acini of lobules< 50% of the acini per lobule are distendedIf > 50% are widely distended, a diagnosis of LCIS is renderedThe overall lobular architecture is maintained, but the acini should be larger than in adjacent lobules> 8 cells across an acinus has been proposed as a definition of distentionCells are dyscohesive and cannot form cribriform spaces, micropapillae, or arcadesCalcifications and necrosis are not associated with ALH",
                    "sub_points": [
                      "Cells are loosely cohesive, regularly spaced, and fill and slightly distend acini of lobules< 50% of the acini per lobule are distendedIf > 50% are widely distended, a diagnosis of LCIS is renderedThe overall lobular architecture is maintained, but the acini should be larger than in adjacent lobules> 8 cells across an acinus has been proposed as a definition of distention",
                      "< 50% of the acini per lobule are distendedIf > 50% are widely distended, a diagnosis of LCIS is rendered",
                      "If > 50% are widely distended, a diagnosis of LCIS is rendered",
                      "The overall lobular architecture is maintained, but the acini should be larger than in adjacent lobules",
                      "> 8 cells across an acinus has been proposed as a definition of distention",
                      "Cells are dyscohesive and cannot form cribriform spaces, micropapillae, or arcades",
                      "Calcifications and necrosis are not associated with ALH"
                    ]
                  },
                  {
                    "text": "Cytologic featuresCells are small, uniform, round, or cuboidalType A cells: Small, round nuclei (1-1.5x the size of a lymphocyte nucleus) with inconspicuous nucleoli and scant cytoplasmType B cells: Larger, more variable nuclei (2x the size of a lymphocyte nucleus) with more abundant cytoplasmBoth types of cells can be presentIntracytoplasmic lumina (signet-ring cells) may be seenCells stain positive for mucinCells have low nuclear grade with inconspicuous nucleiMitotic figures would be highly unusual",
                    "sub_points": [
                      "Cells are small, uniform, round, or cuboidalType A cells: Small, round nuclei (1-1.5x the size of a lymphocyte nucleus) with inconspicuous nucleoli and scant cytoplasmType B cells: Larger, more variable nuclei (2x the size of a lymphocyte nucleus) with more abundant cytoplasmBoth types of cells can be present",
                      "Type A cells: Small, round nuclei (1-1.5x the size of a lymphocyte nucleus) with inconspicuous nucleoli and scant cytoplasm",
                      "Type B cells: Larger, more variable nuclei (2x the size of a lymphocyte nucleus) with more abundant cytoplasm",
                      "Both types of cells can be present",
                      "Intracytoplasmic lumina (signet-ring cells) may be seenCells stain positive for mucin",
                      "Cells stain positive for mucin",
                      "Cells have low nuclear grade with inconspicuous nucleiMitotic figures would be highly unusual",
                      "Mitotic figures would be highly unusual"
                    ]
                  },
                  {
                    "text": "Pagetoid spreadALH is often seen as pagetoid spread in ductsDefined as the presence of neoplastic cells spreading between the basement membrane and overlying normal epithelial cellsCan form a cloverleaf appearance in large ductsMay be difficult to distinguish from prominent myoepithelial cells or histiocytes in ducts",
                    "sub_points": [
                      "ALH is often seen as pagetoid spread in ductsDefined as the presence of neoplastic cells spreading between the basement membrane and overlying normal epithelial cells",
                      "Defined as the presence of neoplastic cells spreading between the basement membrane and overlying normal epithelial cells",
                      "Can form a cloverleaf appearance in large ducts",
                      "May be difficult to distinguish from prominent myoepithelial cells or histiocytes in ducts"
                    ]
                  },
                  {
                    "text": "ALH involvement of benign lesionsSclerosing adenosis, radial sclerosing lesions, fibroadenoma, or collagenous spherulosis may be entirely or completely involved by LNMay present as a mass-forming lesion or mammographic calcificationsCan mimic either invasive or in situ carcinomaCareful attention to cytologic detail and IHC for myoepithelial cell markers and E-cadherin are helpful for correct diagnosis",
                    "sub_points": [
                      "Sclerosing adenosis, radial sclerosing lesions, fibroadenoma, or collagenous spherulosis may be entirely or completely involved by LNMay present as a mass-forming lesion or mammographic calcifications",
                      "May present as a mass-forming lesion or mammographic calcifications",
                      "Can mimic either invasive or in situ carcinomaCareful attention to cytologic detail and IHC for myoepithelial cell markers and E-cadherin are helpful for correct diagnosis",
                      "Careful attention to cytologic detail and IHC for myoepithelial cell markers and E-cadherin are helpful for correct diagnosis"
                    ]
                  },
                  {
                    "text": "ALH subtypesUnlike LCIS, variants of ALH are not recognizedLesions with the appearance of ALH but associated with pleomorphic nuclei or necrosis are highly unusualSuch lesions can be described, and the possibility that they are a limited form of pleomorphic LCIS suggestedIf seen on core needle biopsy, excision should be considered",
                    "sub_points": [
                      "Unlike LCIS, variants of ALH are not recognized",
                      "Lesions with the appearance of ALH but associated with pleomorphic nuclei or necrosis are highly unusual",
                      "Such lesions can be described, and the possibility that they are a limited form of pleomorphic LCIS suggested",
                      "If seen on core needle biopsy, excision should be considered"
                    ]
                  },
                  {
                    "text": "Core needle biopsyALH may be found as an incidental finding in core needle biopsiesALH does not cause masses or provide a substrate for calcifications (i.e., necrosis or secretions)When there is good radiologic/pathologic correlation (i.e., the targeted lesion underlying the calcifications, mass, or architectural distortion is identified), the ALH can be reported as an incidental findingIf radiologic/pathologic correlation is poor, excision may be recommended to ensure the targeted lesion has not been missedIn this setting, the likelihood of finding carcinoma on excision is very low (< 5%)Cancers found are generally small, well-differentiated, invasive carcinomas or small foci of low-grade ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "ALH may be found as an incidental finding in core needle biopsiesALH does not cause masses or provide a substrate for calcifications (i.e., necrosis or secretions)",
                      "ALH does not cause masses or provide a substrate for calcifications (i.e., necrosis or secretions)",
                      "When there is good radiologic/pathologic correlation (i.e., the targeted lesion underlying the calcifications, mass, or architectural distortion is identified), the ALH can be reported as an incidental findingIf radiologic/pathologic correlation is poor, excision may be recommended to ensure the targeted lesion has not been missed",
                      "If radiologic/pathologic correlation is poor, excision may be recommended to ensure the targeted lesion has not been missed",
                      "In this setting, the likelihood of finding carcinoma on excision is very low (< 5%)Cancers found are generally small, well-differentiated, invasive carcinomas or small foci of low-grade ductal carcinoma in situ (DCIS)",
                      "Cancers found are generally small, well-differentiated, invasive carcinomas or small foci of low-grade ductal carcinoma in situ (DCIS)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "E-cadherin (membrane immunoreactivity): NegativeOften difficult to evaluate, as, by definition, few cells are presentThe adjacent and often intermingled luminal cells are E-cadherin positiveMyoepithelial cells show weaker granular staining due to expression of P-cadherinEvaluated best when clusters of cells are presentMay show aberrant cytoplasmic expression rather than membrane expression",
                    "sub_points": [
                      "Often difficult to evaluate, as, by definition, few cells are presentThe adjacent and often intermingled luminal cells are E-cadherin positiveMyoepithelial cells show weaker granular staining due to expression of P-cadherin",
                      "The adjacent and often intermingled luminal cells are E-cadherin positive",
                      "Myoepithelial cells show weaker granular staining due to expression of P-cadherin",
                      "Evaluated best when clusters of cells are presentMay show aberrant cytoplasmic expression rather than membrane expression",
                      "May show aberrant cytoplasmic expression rather than membrane expression"
                    ]
                  },
                  {
                    "text": "Catenins: May be negative or aberrantAberrant cytoplasmic expression of p120 when E-cadherin is absent is easier to evaluate when few cells are presentThis finding is not affected by the normal expression pattern of neighboring cellsIn rare cases, E-cadherin expression is present in LN, but catenin expression is lostCells show the same morphologic loss of adhesion as when E-cadherin expression is absentAdditional studies showing abnormal loss of catenin may be helpful for classification when there is dyscohesive morphology but the cells are positive for E-cadherin",
                    "sub_points": [
                      "Aberrant cytoplasmic expression of p120 when E-cadherin is absent is easier to evaluate when few cells are presentThis finding is not affected by the normal expression pattern of neighboring cells",
                      "This finding is not affected by the normal expression pattern of neighboring cells",
                      "In rare cases, E-cadherin expression is present in LN, but catenin expression is lostCells show the same morphologic loss of adhesion as when E-cadherin expression is absentAdditional studies showing abnormal loss of catenin may be helpful for classification when there is dyscohesive morphology but the cells are positive for E-cadherin",
                      "Cells show the same morphologic loss of adhesion as when E-cadherin expression is absent",
                      "Additional studies showing abnormal loss of catenin may be helpful for classification when there is dyscohesive morphology but the cells are positive for E-cadherin"
                    ]
                  },
                  {
                    "text": "High molecular weight keratins (34BE12): ~ 80% have cytoplasmic perinuclear patternSuggested that this pattern may be useful to distinguish LN from solid, low-grade DCIS, which is usually negativeSome cases of DCIS may also be positiveThis finding has not been reproducible in all studies",
                    "sub_points": [
                      "Suggested that this pattern may be useful to distinguish LN from solid, low-grade DCIS, which is usually negativeSome cases of DCIS may also be positiveThis finding has not been reproducible in all studies",
                      "Some cases of DCIS may also be positive",
                      "This finding has not been reproducible in all studies"
                    ]
                  },
                  {
                    "text": "High molecular weight keratins (CK5/6): Majority negativeADH and DCIS are also negative",
                    "sub_points": [
                      "ADH and DCIS are also negative"
                    ]
                  },
                  {
                    "text": "Estrogen and progesterone receptors: PositiveMay be useful in some cases to distinguish ALH from myoepithelial cells",
                    "sub_points": [
                      "May be useful in some cases to distinguish ALH from myoepithelial cells"
                    ]
                  },
                  {
                    "text": "HER2: NegativeRare cases of pleomorphic LCIS express HER2Variant forms of ALH are not currently recognized",
                    "sub_points": [
                      "Rare cases of pleomorphic LCIS express HER2",
                      "Variant forms of ALH are not currently recognized"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Lobular Carcinoma In Situ": [
                  {
                    "text": "ALH is distinguished from LCIS based on the extent of the lesion (degree of distention of lobules)"
                  },
                  {
                    "text": "LCIS is diagnosed when at least 1/2 of a lobular unit is filled and distorted by neoplastic cell populationDistention of acini can be defined as ≥ 8 cells present across diameter of acinus",
                    "sub_points": [
                      "Distention of acini can be defined as ≥ 8 cells present across diameter of acinus"
                    ]
                  },
                  {
                    "text": "Extent is a continuum; some cases can be difficult to classify"
                  },
                  {
                    "text": "Some favor the term LN to include both ALH and LCIS"
                  },
                  {
                    "text": "However, multiple studies have shown that risk of subsequently developing breast cancer is greater for patients diagnosed with LCIS as compared to ALH"
                  }
                ],
                "Poor Tissue Preservation or Crush Artifact": [
                  {
                    "text": "May give the impression of loss of cohesion of luminal cellsDyscohesive cells can mimic LNUsually involves all cells within the affected areaPoor preservation may also alter expression of IHC markers",
                    "sub_points": [
                      "Dyscohesive cells can mimic LN",
                      "Usually involves all cells within the affected area",
                      "Poor preservation may also alter expression of IHC markers"
                    ]
                  },
                  {
                    "text": "Careful attention to quality of morphology and cytologic appearance of cells can help in making the correct interpretation"
                  },
                  {
                    "text": "ALH should not be diagnosed if diagnostic features are not definitive"
                  }
                ],
                "Myoepithelial Cells": [
                  {
                    "text": "May be more prominent during menstrual cycle or if involved by metaplastic changesNuclei are generally smaller, rounder, and more hyperchromatic than those of ALHCytoplasm may be clear, whereas ALH usually has eosinophilic cytoplasm",
                    "sub_points": [
                      "Nuclei are generally smaller, rounder, and more hyperchromatic than those of ALH",
                      "Cytoplasm may be clear, whereas ALH usually has eosinophilic cytoplasm"
                    ]
                  },
                  {
                    "text": "Appearance can mimic pagetoid spread by ALHCells should not be dyscohesive, and gaps between cells should not be seen",
                    "sub_points": [
                      "Cells should not be dyscohesive, and gaps between cells should not be seen"
                    ]
                  },
                  {
                    "text": "IHC may be difficult to perform, as there is typically a single layer of cellsMyoepithelial markers may be helpful to identify cells as myoepithelialMay be difficult to document absence of E-cadherin if only a single layer of cells is present",
                    "sub_points": [
                      "Myoepithelial markers may be helpful to identify cells as myoepithelial",
                      "May be difficult to document absence of E-cadherin if only a single layer of cells is present"
                    ]
                  },
                  {
                    "text": "ALH should not be diagnosed if diagnostic features are not definitive"
                  }
                ],
                "Histiocytic Infiltrate in Ducts": [
                  {
                    "text": "Histiocytes can be present in ductal epithelium around areas of chronic inflammation"
                  },
                  {
                    "text": "Presence of dyscohesive cells with clear cytoplasm can mimic LN"
                  },
                  {
                    "text": "Cells are generally scatteredLN is generally present as contiguous cords and nests of cells",
                    "sub_points": [
                      "LN is generally present as contiguous cords and nests of cells"
                    ]
                  },
                  {
                    "text": "Cytoplasm is generally abundant and often foamyCytoplasm of LN is uniform and dense",
                    "sub_points": [
                      "Cytoplasm of LN is uniform and dense"
                    ]
                  },
                  {
                    "text": "Nuclei often have lobulated and folded appearanceNuclei of LN are usually very uniformly round",
                    "sub_points": [
                      "Nuclei of LN are usually very uniformly round"
                    ]
                  }
                ],
                "Low-Grade Ductal Carcinoma In Situ, Solid Type": [
                  {
                    "text": "Distinction of LN from solid low-grade DCIS can be challenging on morphologic grounds aloneDCIS can involve lobules without unfolding lobule into single space (so-called cancerization of lobules)",
                    "sub_points": [
                      "DCIS can involve lobules without unfolding lobule into single space (so-called cancerization of lobules)"
                    ]
                  },
                  {
                    "text": "Solid DCIS can be composed of small monomorphic cells similar to those of LN"
                  },
                  {
                    "text": "Presence of secondary lumen formation or rosette-like arrangement of cells and cellular cohesion suggests a ductal lesion rather than LN"
                  },
                  {
                    "text": "IHC for E-cadherin may be helpful in difficult casesMembrane positivity for E-cadherin is typically absent in LN but present in DCISCareful analysis of staining and morphology should be used to make this distinctionResidual normal ductal epithelial cells (E-cadherin positive) may be admixed with neoplastic lobular cells (E-cadherin negative)",
                    "sub_points": [
                      "Membrane positivity for E-cadherin is typically absent in LN but present in DCIS",
                      "Careful analysis of staining and morphology should be used to make this distinction",
                      "Residual normal ductal epithelial cells (E-cadherin positive) may be admixed with neoplastic lobular cells (E-cadherin negative)"
                    ]
                  },
                  {
                    "text": "In occasional cases, LN and DCIS can be present in the same ductal &/or lobular spaces"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "ALH has the same cytologic appearance as LCIS and ILCDistinguished by extent and location",
                    "sub_points": [
                      "Distinguished by extent and location"
                    ]
                  },
                  {
                    "text": "ALH is an incidental finding in biopsies performed for other indications"
                  },
                  {
                    "text": "The presence of ALH identifies women at higher risk of subsequent invasive carcinomaShould not be overdiagnosed in cases without definitive diagnostic features",
                    "sub_points": [
                      "Should not be overdiagnosed in cases without definitive diagnostic features"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "General Guidelines": [
                  {
                    "text": "ALH is important to report when it is the lesion of greatest risk in biopsyIf LCIS, DCIS, or invasive carcinoma are present, ALH does not have additional clinical significance",
                    "sub_points": [
                      "If LCIS, DCIS, or invasive carcinoma are present, ALH does not have additional clinical significance"
                    ]
                  },
                  {
                    "text": "Relationship of ALH to margins should not be reported"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Overview of Risk Factors for Developing Breast Carcinoma": {
            "name": "Overview of Risk Factors for Developing Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/25aa27ad-9497-4499-bccf-61dac445301d/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "Breast Cancer Risk": {
                "Introduction": [
                  {
                    "text": "Breast cancer is the most common nondermal malignancy affecting women and is the 2nd most common cause of cancer death"
                  },
                  {
                    "text": "All women are considered to be at risk, but the level of risk varies in different populations"
                  },
                  {
                    "text": "Lifetime risk of developing invasive breast cancer ranges from ~ 3% (for women without risk factors) to > 80% (for women with highly penetrant germline mutations)Average lifetime risk of developing breast cancer is 1 in 8 women (~ 12%)",
                    "sub_points": [
                      "Average lifetime risk of developing breast cancer is 1 in 8 women (~ 12%)"
                    ]
                  },
                  {
                    "text": "Measuring the degree of risk aids in providing help withIndividual choices about risk reductionRisk reduction strategies may include chemoprevention or prophylactic surgeryLifestyle and dietary changesOptimal screening strategyDecisions about testing for single-gene mutationsStratification of patients for enrollment in trialsUnderstanding the biology of breast cancer",
                    "sub_points": [
                      "Individual choices about risk reductionRisk reduction strategies may include chemoprevention or prophylactic surgeryLifestyle and dietary changes",
                      "Risk reduction strategies may include chemoprevention or prophylactic surgery",
                      "Lifestyle and dietary changes",
                      "Optimal screening strategy",
                      "Decisions about testing for single-gene mutations",
                      "Stratification of patients for enrollment in trials",
                      "Understanding the biology of breast cancer"
                    ]
                  },
                  {
                    "text": "The majority of risk factors cannot be modified (e.g., age, sex, ethnicity, family history)"
                  },
                  {
                    "text": "There are also risk factors that would be difficult to modify, including age at 1st pregnancy and age at menopause"
                  },
                  {
                    "text": "Risk factors for developing estrogen receptor (ER)-positive or ER-negative breast cancer can be different and are beginning to be identified"
                  }
                ],
                "Breast Cancer Risk Assessment Tools": [
                  {
                    "text": "There are many methods to assess breast cancer risk, but 2 are the most widely used in the USANational Cancer Institute Breast Cancer Risk Assessment Tool (BCRAT or Gail model)Available at https://bcrisktool.cancer.gov/ (accessed December 2, 2024)Not used for women with highly penetrant germline mutations (e.g.,BRCA1,BRCA2, orTP53)Not used for women who have received chest wall radiationTyrer-Cuzick model [International Breast Intervention Study (IBIS)]Available at https://ibis.ikonopedia.com/ (accessed December 2, 2024)Useful to quantify magnitude of risk for individualsNot applicable for women who have been diagnosed with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or invasive carcinoma",
                    "sub_points": [
                      "National Cancer Institute Breast Cancer Risk Assessment Tool (BCRAT or Gail model)Available at https://bcrisktool.cancer.gov/ (accessed December 2, 2024)Not used for women with highly penetrant germline mutations (e.g.,BRCA1,BRCA2, orTP53)Not used for women who have received chest wall radiation",
                      "Available at https://bcrisktool.cancer.gov/ (accessed December 2, 2024)",
                      "Not used for women with highly penetrant germline mutations (e.g.,BRCA1,BRCA2, orTP53)",
                      "Not used for women who have received chest wall radiation",
                      "Tyrer-Cuzick model [International Breast Intervention Study (IBIS)]Available at https://ibis.ikonopedia.com/ (accessed December 2, 2024)",
                      "Available at https://ibis.ikonopedia.com/ (accessed December 2, 2024)",
                      "Useful to quantify magnitude of risk for individualsNot applicable for women who have been diagnosed with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or invasive carcinoma",
                      "Not applicable for women who have been diagnosed with ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or invasive carcinoma"
                    ]
                  },
                  {
                    "text": "BCRATprovides risk estimates for the next 5 years and for lifetime and incorporates the following informationPatient age (must be 35-85 years), ethnicity, age at menarche, age at 1st live birth, number of 1st-degree relatives with invasive breast cancerNumber of prior breast biopsies and diagnosis of atypical hyperplasiaValidated for European Americans (EA), African Americans (AA), Hispanic Americans (HA), Asian Americans, and Pacific Islander AmericansRisk may be underestimated for AA with prior biopsiesRisk for AA and Pacific Islander Americans may be inaccurate due to the low number of women used to create modelWomen with risk of ≥ 1.66% in the next 5 years are eligible for chemoprevention with hormonal agents",
                    "sub_points": [
                      "Patient age (must be 35-85 years), ethnicity, age at menarche, age at 1st live birth, number of 1st-degree relatives with invasive breast cancer",
                      "Number of prior breast biopsies and diagnosis of atypical hyperplasiaValidated for European Americans (EA), African Americans (AA), Hispanic Americans (HA), Asian Americans, and Pacific Islander AmericansRisk may be underestimated for AA with prior biopsiesRisk for AA and Pacific Islander Americans may be inaccurate due to the low number of women used to create model",
                      "Validated for European Americans (EA), African Americans (AA), Hispanic Americans (HA), Asian Americans, and Pacific Islander AmericansRisk may be underestimated for AA with prior biopsiesRisk for AA and Pacific Islander Americans may be inaccurate due to the low number of women used to create model",
                      "Risk may be underestimated for AA with prior biopsies",
                      "Risk for AA and Pacific Islander Americans may be inaccurate due to the low number of women used to create model",
                      "Women with risk of ≥ 1.66% in the next 5 years are eligible for chemoprevention with hormonal agents"
                    ]
                  },
                  {
                    "text": "Tyrer-Cuzick modelincludes more information about family history and incorporates the following informationPatient age, height, weight, breast density, parity, age at 1st birth, menopause, hormone replacement therapy (HRT)BRCA1/BRCA2, ovarian cancer history, biopsy, atypical hyperplasia, LCIS, Ashkenazi heritage1st- and 2nd-degree relatives with breast or ovarian cancer, age of onset in relatives",
                    "sub_points": [
                      "Patient age, height, weight, breast density, parity, age at 1st birth, menopause, hormone replacement therapy (HRT)",
                      "BRCA1/BRCA2, ovarian cancer history, biopsy, atypical hyperplasia, LCIS, Ashkenazi heritage",
                      "1st- and 2nd-degree relatives with breast or ovarian cancer, age of onset in relatives"
                    ]
                  },
                  {
                    "text": "These models perform better for predicting ER(+) cancer than ER(-) cancer"
                  }
                ]
              },
              "Factors Associated With Breast Cancer Risk": {
                "Sex": [
                  {
                    "text": "Women are at much higher risk than menOnly 1 of every 100 breast cancers occur in malesMost likely due to larger pool of potential cancer precursor cellsThe periodic bursts of proliferation throughout a female's reproductive life and during pregnancy and other estrogenic effects could increase likelihood of neoplasia",
                    "sub_points": [
                      "Only 1 of every 100 breast cancers occur in males",
                      "Most likely due to larger pool of potential cancer precursor cellsThe periodic bursts of proliferation throughout a female's reproductive life and during pregnancy and other estrogenic effects could increase likelihood of neoplasia",
                      "The periodic bursts of proliferation throughout a female's reproductive life and during pregnancy and other estrogenic effects could increase likelihood of neoplasia"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Age-specific incidence rates for breast cancer increase dramatically after age 40Increase with age is primarily for ER(+) cancers",
                    "sub_points": [
                      "Increase with age is primarily for ER(+) cancers"
                    ]
                  },
                  {
                    "text": "Peak incidence for breast cancer among women occurs between 75-79 yearsIncidence peaks for ER(+) cancers are not as pronounced among non-European populationsMedian age at diagnosis in USA: 61 years",
                    "sub_points": [
                      "Incidence peaks for ER(+) cancers are not as pronounced among non-European populations",
                      "Median age at diagnosis in USA: 61 years"
                    ]
                  },
                  {
                    "text": "Lifetime probability of being diagnosed with breast cancer diminishes as increased age ranges are achievedAge 30, lifetime risk of breast cancer: 12.5%Age 50, lifetime risk of breast cancer: 11.1%Age 70, lifetime risk of breast cancer: 6.6%",
                    "sub_points": [
                      "Age 30, lifetime risk of breast cancer: 12.5%",
                      "Age 50, lifetime risk of breast cancer: 11.1%",
                      "Age 70, lifetime risk of breast cancer: 6.6%"
                    ]
                  }
                ],
                "Estrogen Exposure": [
                  {
                    "text": "Exposure to higher levels of estrogen increases lifetime risk of developing breast cancer"
                  },
                  {
                    "text": "Factors that reduce risk of breast cancerLate menarche, early natural menopause, or oophorectomyEarly pregnancy (late teens to early 20s)Multiple pregnanciesProlonged breastfeeding (4.3% reduction in risk for each year of breastfeeding)Populations with high breastfeeding rates have lower incidences of breast cancerMay be largely responsible for differences between developed and developing countriesThe absence or short duration of breastfeeding is associated with ER(-) and HER2(-) breast carcinoma [triple negative breast carcinoma (TNBC)]Hypothesized that abrupt involution after pregnancy results in the expansion of luminal progenitor cellsUse of estrogen antagonists, such as tamoxifenLow endogenous estradiol levelsObesity in premenopausal women",
                    "sub_points": [
                      "Late menarche, early natural menopause, or oophorectomy",
                      "Early pregnancy (late teens to early 20s)",
                      "Multiple pregnancies",
                      "Prolonged breastfeeding (4.3% reduction in risk for each year of breastfeeding)Populations with high breastfeeding rates have lower incidences of breast cancerMay be largely responsible for differences between developed and developing countriesThe absence or short duration of breastfeeding is associated with ER(-) and HER2(-) breast carcinoma [triple negative breast carcinoma (TNBC)]Hypothesized that abrupt involution after pregnancy results in the expansion of luminal progenitor cells",
                      "Populations with high breastfeeding rates have lower incidences of breast cancerMay be largely responsible for differences between developed and developing countries",
                      "May be largely responsible for differences between developed and developing countries",
                      "The absence or short duration of breastfeeding is associated with ER(-) and HER2(-) breast carcinoma [triple negative breast carcinoma (TNBC)]",
                      "Hypothesized that abrupt involution after pregnancy results in the expansion of luminal progenitor cells",
                      "Use of estrogen antagonists, such as tamoxifen",
                      "Low endogenous estradiol levels",
                      "Obesity in premenopausal women"
                    ]
                  },
                  {
                    "text": "Factors that increase risk of breast cancerEarly menarche and late menopause {early age at menarche [relative risk (RR) = 1.3], late menopause [RR = 1.5]}A greater number of menstrual cycles increases riskEarly age menarche (RR = 1.3) and late menopause (RR = 1.5)NulliparityParous women have a lower risk of ER(+) cancerWomen of increased parity (≥ 3 children) and who do not breastfeed may have an increased risk of TNBCLate age at 1st live birth (RR = 1.7-1.9)Obesity in postmenopausal women (elevated estradiol levels compared with women of normal weight)Adult weight gain and abdominal fatnessExcess body fat may influence steroid hormone levels and inflammatory responsesSome, but not all, studies have shown obese women have a higher risk of TNBCHRTAfter publication of Women's Health initiative trial in 2002, the number of women using HRT decreasedThe incidence of invasive breast carcinoma and DCIS dropped 10-15% in women > age 50 but not in younger age groupsDecrease occurred for ER(+) cancersIt is not known if HRT causes cancer, increases the rate of growth of existing cancers, stimulates angiogenesis, &/or has effects on breast cancer detectionSome of the decrease in breast carcinoma diagnosis during the same time is attributed to leveling off and a slight decline in the number of women undergoing mammographic screeningMore recent literature suggests little or no increased breast cancer risk from HRT",
                    "sub_points": [
                      "Early menarche and late menopause {early age at menarche [relative risk (RR) = 1.3], late menopause [RR = 1.5]}A greater number of menstrual cycles increases risk",
                      "A greater number of menstrual cycles increases risk",
                      "Early age menarche (RR = 1.3) and late menopause (RR = 1.5)",
                      "NulliparityParous women have a lower risk of ER(+) cancerWomen of increased parity (≥ 3 children) and who do not breastfeed may have an increased risk of TNBC",
                      "Parous women have a lower risk of ER(+) cancer",
                      "Women of increased parity (≥ 3 children) and who do not breastfeed may have an increased risk of TNBC",
                      "Late age at 1st live birth (RR = 1.7-1.9)",
                      "Obesity in postmenopausal women (elevated estradiol levels compared with women of normal weight)Adult weight gain and abdominal fatnessExcess body fat may influence steroid hormone levels and inflammatory responsesSome, but not all, studies have shown obese women have a higher risk of TNBC",
                      "Adult weight gain and abdominal fatness",
                      "Excess body fat may influence steroid hormone levels and inflammatory responses",
                      "Some, but not all, studies have shown obese women have a higher risk of TNBC",
                      "HRTAfter publication of Women's Health initiative trial in 2002, the number of women using HRT decreasedThe incidence of invasive breast carcinoma and DCIS dropped 10-15% in women > age 50 but not in younger age groupsDecrease occurred for ER(+) cancersIt is not known if HRT causes cancer, increases the rate of growth of existing cancers, stimulates angiogenesis, &/or has effects on breast cancer detectionSome of the decrease in breast carcinoma diagnosis during the same time is attributed to leveling off and a slight decline in the number of women undergoing mammographic screeningMore recent literature suggests little or no increased breast cancer risk from HRT",
                      "After publication of Women's Health initiative trial in 2002, the number of women using HRT decreased",
                      "The incidence of invasive breast carcinoma and DCIS dropped 10-15% in women > age 50 but not in younger age groups",
                      "Decrease occurred for ER(+) cancers",
                      "It is not known if HRT causes cancer, increases the rate of growth of existing cancers, stimulates angiogenesis, &/or has effects on breast cancer detectionSome of the decrease in breast carcinoma diagnosis during the same time is attributed to leveling off and a slight decline in the number of women undergoing mammographic screening",
                      "Some of the decrease in breast carcinoma diagnosis during the same time is attributed to leveling off and a slight decline in the number of women undergoing mammographic screening",
                      "More recent literature suggests little or no increased breast cancer risk from HRT"
                    ]
                  },
                  {
                    "text": "How estrogen exposure increases cancer risk is unknownEstrogen increases mitotic rate of breast cellsIncreased mitogenic stimulus may increase risk of mutationEstrogen mitogenic drive may act as a cancer promoter and contribute to disease progressionEstrogen can act as a carcinogen when converted to mutagenic metabolites",
                    "sub_points": [
                      "Estrogen increases mitotic rate of breast cellsIncreased mitogenic stimulus may increase risk of mutationEstrogen mitogenic drive may act as a cancer promoter and contribute to disease progression",
                      "Increased mitogenic stimulus may increase risk of mutation",
                      "Estrogen mitogenic drive may act as a cancer promoter and contribute to disease progression",
                      "Estrogen can act as a carcinogen when converted to mutagenic metabolites"
                    ]
                  }
                ],
                "Pregnancy": [
                  {
                    "text": "Both increases and decreases risk of breast cancerTransiently increases risk of breast cancer; over many years, risk declines and eventually becomes lower than for nulliparous women (crossover effect)",
                    "sub_points": [
                      "Transiently increases risk of breast cancer; over many years, risk declines and eventually becomes lower than for nulliparous women (crossover effect)"
                    ]
                  },
                  {
                    "text": "For young women (< 20 years), protective effect predominates, and lifetime risk of ER(+) breast cancer is reduced by 50%Terminal differentiation of epithelial cells may occur, thus reducing potential pool of cancer precursorsAdditional pregnancies further reduce risk (~ 7% per pregnancy)Pregnancy permanently changes gene expression profiles of breast tissue",
                    "sub_points": [
                      "Terminal differentiation of epithelial cells may occur, thus reducing potential pool of cancer precursorsAdditional pregnancies further reduce risk (~ 7% per pregnancy)",
                      "Additional pregnancies further reduce risk (~ 7% per pregnancy)",
                      "Pregnancy permanently changes gene expression profiles of breast tissue"
                    ]
                  },
                  {
                    "text": "For older women (> 35 years), increased risk predominates and extends for a longer period of time"
                  },
                  {
                    "text": "Cancers diagnosed during pregnancy or postpartum usually present at higher stages and have poor prognosisIn only 1 of 3,000-10,000 pregnancies is breast cancer diagnosed during or within 1 year of parturition",
                    "sub_points": [
                      "In only 1 of 3,000-10,000 pregnancies is breast cancer diagnosed during or within 1 year of parturition"
                    ]
                  },
                  {
                    "text": "Many proposed mechanisms for increase in riskHigh hormonal levels could stimulate proliferation of precursor lesions, increasing risk of cancerHigh hormonal levels may stimulate preexisting cancers to proliferateHowever, many pregnancy-associated carcinomas are TNBCStroma may become more permissive to allow lobular expansion and branching during pregnancy and regression after pregnancy, which could facilitate progression from carcinoma in situ to invasive carcinomaStroma during postpregnancy involution is similar to that of wound healing and could promote cancer growth and metastasisChange in immune surveillance may promote progression of preexisting cancers",
                    "sub_points": [
                      "High hormonal levels could stimulate proliferation of precursor lesions, increasing risk of cancer",
                      "High hormonal levels may stimulate preexisting cancers to proliferateHowever, many pregnancy-associated carcinomas are TNBC",
                      "However, many pregnancy-associated carcinomas are TNBC",
                      "Stroma may become more permissive to allow lobular expansion and branching during pregnancy and regression after pregnancy, which could facilitate progression from carcinoma in situ to invasive carcinoma",
                      "Stroma during postpregnancy involution is similar to that of wound healing and could promote cancer growth and metastasis",
                      "Change in immune surveillance may promote progression of preexisting cancers"
                    ]
                  },
                  {
                    "text": "There is a clear protective link between breastfeeding and reduced breast cancer riskOvulation is suppressed during breastfeeding, which reduces the repeated stimulation of epithelial proliferation premensesMay be related to changes in mammographic density following breastfeeding",
                    "sub_points": [
                      "Ovulation is suppressed during breastfeeding, which reduces the repeated stimulation of epithelial proliferation premenses",
                      "May be related to changes in mammographic density following breastfeeding"
                    ]
                  }
                ],
                "Mammographic Density": [
                  {
                    "text": "Mammographic appearance depends on tissue composition of breastStromal tissue and glandular epithelium attenuate x-rays more than fat and increase mammographic density",
                    "sub_points": [
                      "Stromal tissue and glandular epithelium attenuate x-rays more than fat and increase mammographic density"
                    ]
                  },
                  {
                    "text": "Mammographic density is a strong risk factor for breast cancer4-5x greater risk in women with density in > 75% of breastRisk for breast cancer greater than for women with little or no density",
                    "sub_points": [
                      "4-5x greater risk in women with density in > 75% of breastRisk for breast cancer greater than for women with little or no density",
                      "Risk for breast cancer greater than for women with little or no density"
                    ]
                  },
                  {
                    "text": "Density of breast tissue is influenced by age, parity, body mass index, and menopauseThese factors account for only 20-30% of variation in density in populationStudies of twins suggest that percentage of mammographic density, at given age, is heritableHereditary factors may explain up to 63% of variance in breast densityInvestigation of genes associated with breast density is an active area of researchGenes that influence mammographic density may also be associated with breast cancer riskGene profile associated with density may help identify potential targets for breast cancer prevention",
                    "sub_points": [
                      "These factors account for only 20-30% of variation in density in population",
                      "Studies of twins suggest that percentage of mammographic density, at given age, is heritableHereditary factors may explain up to 63% of variance in breast density",
                      "Hereditary factors may explain up to 63% of variance in breast density",
                      "Investigation of genes associated with breast density is an active area of researchGenes that influence mammographic density may also be associated with breast cancer riskGene profile associated with density may help identify potential targets for breast cancer prevention",
                      "Genes that influence mammographic density may also be associated with breast cancer risk",
                      "Gene profile associated with density may help identify potential targets for breast cancer prevention"
                    ]
                  }
                ],
                "Family History": [
                  {
                    "text": "10-20% of patients with breast cancer have a 1st-degree relative with breast cancerOnly 1% have > 1 affected 1st-degree relative~ 50% are thought to be due to heredity and ~ 50% due to coincidental cases in same family",
                    "sub_points": [
                      "Only 1% have > 1 affected 1st-degree relative",
                      "~ 50% are thought to be due to heredity and ~ 50% due to coincidental cases in same family"
                    ]
                  },
                  {
                    "text": "Therefore, 5-10% of breast cancer is primarily due to inheritance of susceptibility gene(s)~ 4% of hereditary breast cancers are due to a single, highly penetrant gene~ 2/3 areBRCA1orBRCA2germline mutations; lifetime risk is 40-80%Remainder are due toTP53,CHEK2,PTEN, and others~ 6% of hereditary breast cancers are thought to be due to combinations of genes &/or genes of lower penetrance",
                    "sub_points": [
                      "~ 4% of hereditary breast cancers are due to a single, highly penetrant gene~ 2/3 areBRCA1orBRCA2germline mutations; lifetime risk is 40-80%Remainder are due toTP53,CHEK2,PTEN, and others",
                      "~ 2/3 areBRCA1orBRCA2germline mutations; lifetime risk is 40-80%",
                      "Remainder are due toTP53,CHEK2,PTEN, and others",
                      "~ 6% of hereditary breast cancers are thought to be due to combinations of genes &/or genes of lower penetrance"
                    ]
                  },
                  {
                    "text": "Only some types of family history confer significant risk≥ 2 affected individuals on the same side of the family with the same or related cancersAge of cancer diagnosis earlier than average age of onset in general population in at least 1 individualRR = 1.8 for woman with 1st-degree relative aged 50 years or older with postmenopausal breast cancerRR = 3.3 for woman with 1st-degree relative with premenopausal breast cancerRR = 1.5 for woman with 2nd-degree relative with breast cancerRR = 3.6 for woman with two 1st-degree relatives with breast cancerPresence of > 1 primary cancer in individual (not including metastases)History of medical conditions associated with increased risk of developing certain types of cancer",
                    "sub_points": [
                      "≥ 2 affected individuals on the same side of the family with the same or related cancers",
                      "Age of cancer diagnosis earlier than average age of onset in general population in at least 1 individualRR = 1.8 for woman with 1st-degree relative aged 50 years or older with postmenopausal breast cancerRR = 3.3 for woman with 1st-degree relative with premenopausal breast cancerRR = 1.5 for woman with 2nd-degree relative with breast cancerRR = 3.6 for woman with two 1st-degree relatives with breast cancer",
                      "RR = 1.8 for woman with 1st-degree relative aged 50 years or older with postmenopausal breast cancer",
                      "RR = 3.3 for woman with 1st-degree relative with premenopausal breast cancer",
                      "RR = 1.5 for woman with 2nd-degree relative with breast cancer",
                      "RR = 3.6 for woman with two 1st-degree relatives with breast cancer",
                      "Presence of > 1 primary cancer in individual (not including metastases)",
                      "History of medical conditions associated with increased risk of developing certain types of cancer"
                    ]
                  },
                  {
                    "text": "Genetic testing is available for families with a high likelihood of a germline mutationCounseling is highly recommended to consider ramifications of results before requesting test",
                    "sub_points": [
                      "Counseling is highly recommended to consider ramifications of results before requesting test"
                    ]
                  },
                  {
                    "text": "Majority (> 85%) of women with a family history will not develop breast cancerA history of a mother developing postmenopausal breast cancer does not alter risk significantly",
                    "sub_points": [
                      "A history of a mother developing postmenopausal breast cancer does not alter risk significantly"
                    ]
                  },
                  {
                    "text": "Direct-to-consumer testing is available but is not as comprehensive or as reliable as testing by certified laboratoriesUsually, only the most common mutations are evaluatedMany results cannot be confirmed when repeated",
                    "sub_points": [
                      "Usually, only the most common mutations are evaluated",
                      "Many results cannot be confirmed when repeated"
                    ]
                  }
                ],
                "Radiation Exposure": [
                  {
                    "text": "Radiation to the breasts during puberty increases the risk of breast cancer"
                  },
                  {
                    "text": "Female survivors of Hodgkin disease treated with mantle radiation are at increased riskRisk for breast cancer is proportional to radiation dose and age at time of treatmentFor young patients treated with > 40 Gy to chest wall, estimated cumulative breast cancer risk of 19.1% over the next 30 yearsSurveillance guidelines recommend annual mammograms beginning 8 years following treatmentThese women do not have an elevated risk of angiosarcomaAngiosarcoma risk is only increased in older women undergoing radiation for breast carcinomaIt is unknown why radiation has different effects at different age",
                    "sub_points": [
                      "Risk for breast cancer is proportional to radiation dose and age at time of treatment",
                      "For young patients treated with > 40 Gy to chest wall, estimated cumulative breast cancer risk of 19.1% over the next 30 years",
                      "Surveillance guidelines recommend annual mammograms beginning 8 years following treatment",
                      "These women do not have an elevated risk of angiosarcomaAngiosarcoma risk is only increased in older women undergoing radiation for breast carcinomaIt is unknown why radiation has different effects at different age",
                      "Angiosarcoma risk is only increased in older women undergoing radiation for breast carcinoma",
                      "It is unknown why radiation has different effects at different age"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Incidence and types of breast cancer vary in different ethnic groups (2018-2020)EA women in USA: Highest incidence of breast cancer (130 per 100,000), ~ 11% TNBCDeath rate: 20.6 per 100,000 (1 in 39)AA women in USA: Slightly lower incidence (127 per 100,000), ~ 25% TNBCDeath rate: 28.9 per 100,000 (1 in 32)HA women in USA: Lower incidence (93 per 100,000), ~ 17% TNBCDeath rate: 14.3 per 100,000Asian/Pacific Islander American women in USA: Lower incidence (92.9 per 100,000), ~ 11% TNBCDeath rate: 11.3 per 100,000Native American women in USA: Lower incidence (100.9 per 100,000)Death rate: 14.5 per 100,000",
                    "sub_points": [
                      "EA women in USA: Highest incidence of breast cancer (130 per 100,000), ~ 11% TNBCDeath rate: 20.6 per 100,000 (1 in 39)",
                      "Death rate: 20.6 per 100,000 (1 in 39)",
                      "AA women in USA: Slightly lower incidence (127 per 100,000), ~ 25% TNBCDeath rate: 28.9 per 100,000 (1 in 32)",
                      "Death rate: 28.9 per 100,000 (1 in 32)",
                      "HA women in USA: Lower incidence (93 per 100,000), ~ 17% TNBCDeath rate: 14.3 per 100,000",
                      "Death rate: 14.3 per 100,000",
                      "Asian/Pacific Islander American women in USA: Lower incidence (92.9 per 100,000), ~ 11% TNBCDeath rate: 11.3 per 100,000",
                      "Death rate: 11.3 per 100,000",
                      "Native American women in USA: Lower incidence (100.9 per 100,000)Death rate: 14.5 per 100,000",
                      "Death rate: 14.5 per 100,000"
                    ]
                  },
                  {
                    "text": "The greatest difference among the groups is the much higher number of ER(+) breast cancers with age for EA womenThe number of TNBCs and HER2(+) cancers remains relatively constant with age and across ethnic groups",
                    "sub_points": [
                      "The number of TNBCs and HER2(+) cancers remains relatively constant with age and across ethnic groups"
                    ]
                  },
                  {
                    "text": "Differences support a major role for genetic etiology for breast cancerHowever, the incidence of breast cancer increases over several generations in groups migrating to USA, supporting an environmental role as well",
                    "sub_points": [
                      "However, the incidence of breast cancer increases over several generations in groups migrating to USA, supporting an environmental role as well"
                    ]
                  },
                  {
                    "text": "Variation in death rates is likely due to contributions from genetic susceptibility to different types of cancer, access to medical care, as well as other factors"
                  }
                ],
                "Benign Breast Disease": [
                  {
                    "text": "> 1 million breast biopsies performed annually in USA for mammographic abnormalities are found to be benignHistologic findings can stratify benign biopsy findings into groups with significantly different risks of later breast cancer development",
                    "sub_points": [
                      "Histologic findings can stratify benign biopsy findings into groups with significantly different risks of later breast cancer development"
                    ]
                  },
                  {
                    "text": "Nashville study, Nurses' Health study, and Mayo Clinic study linked benign breast lesions with subsequent risk for developing carcinoma"
                  },
                  {
                    "text": "Nonproliferative diseaseis not associated with increased risk of cancerIncludes mild epithelial hyperplasia, duct ectasia, and apocrine cysts",
                    "sub_points": [
                      "Includes mild epithelial hyperplasia, duct ectasia, and apocrine cysts"
                    ]
                  },
                  {
                    "text": "Proliferative disease without atypiaincreases RR by 1.5-2.0xIncludes moderate to florid epithelial hyperplasia, papillomas, sclerosing adenosis, radial sclerosing lesions, and fibroadenomas with complex histologyColumnar cell hyperplasia and flat epithelial atypiaFrequently seen in association with lobular neoplasia and tubular carcinoma (Rosen triad) or with atypical ductal hyperplasia (ADH)Most are clonal and share the same loss of 16q as atypical hyperplasia and carcinoma in situRisk of subsequent invasive carcinoma is only slightly elevated",
                    "sub_points": [
                      "Includes moderate to florid epithelial hyperplasia, papillomas, sclerosing adenosis, radial sclerosing lesions, and fibroadenomas with complex histology",
                      "Columnar cell hyperplasia and flat epithelial atypiaFrequently seen in association with lobular neoplasia and tubular carcinoma (Rosen triad) or with atypical ductal hyperplasia (ADH)Most are clonal and share the same loss of 16q as atypical hyperplasia and carcinoma in situRisk of subsequent invasive carcinoma is only slightly elevated",
                      "Frequently seen in association with lobular neoplasia and tubular carcinoma (Rosen triad) or with atypical ductal hyperplasia (ADH)",
                      "Most are clonal and share the same loss of 16q as atypical hyperplasia and carcinoma in situ",
                      "Risk of subsequent invasive carcinoma is only slightly elevated"
                    ]
                  },
                  {
                    "text": "Proliferative disease with atypiaincreases RR by 4-5xAtypical hyperplasia is a clonal proliferation but lacks sufficient criteria for diagnosis as carcinoma in situADH and atypical lobular hyperplasia (ALH)ALH with pagetoid spread increases RR by 8xThe cumulative incidence of breast cancer in patients diagnosed with atypical hyperplasia approaches 30% at 25 years of follow-up",
                    "sub_points": [
                      "Atypical hyperplasia is a clonal proliferation but lacks sufficient criteria for diagnosis as carcinoma in situADH and atypical lobular hyperplasia (ALH)ALH with pagetoid spread increases RR by 8x",
                      "ADH and atypical lobular hyperplasia (ALH)",
                      "ALH with pagetoid spread increases RR by 8x",
                      "The cumulative incidence of breast cancer in patients diagnosed with atypical hyperplasia approaches 30% at 25 years of follow-up"
                    ]
                  },
                  {
                    "text": "DCIS and LCISincrease RR by 10x~ 1% risk of invasive carcinoma per yearFor rare cases of non-high-grade DCIS treated with only diagnostic biopsy, subsequent invasive carcinomas most commonly occur at the same siteMany of these cancers are diagnosed years or decades laterNo series of untreated high-grade DCISPresumed that number of cases progressing to invasion would be higherIf DCIS is treated with surgery, radiation, &/or hormonal therapy, the risk of developing invasive carcinoma is low (< 10%)Subsequent invasive cancers are found at the same site (1/3), at a separate site in the same breast (1/3), and in the contralateral breast (1/3)Subsequent carcinomas after LCIS are more equally distributed in both breasts~ 3/5 in the same breast and 2/5 in the contralateral breastChemoprevention reduces risk by ~ 50%",
                    "sub_points": [
                      "~ 1% risk of invasive carcinoma per year",
                      "For rare cases of non-high-grade DCIS treated with only diagnostic biopsy, subsequent invasive carcinomas most commonly occur at the same siteMany of these cancers are diagnosed years or decades later",
                      "Many of these cancers are diagnosed years or decades later",
                      "No series of untreated high-grade DCISPresumed that number of cases progressing to invasion would be higher",
                      "Presumed that number of cases progressing to invasion would be higher",
                      "If DCIS is treated with surgery, radiation, &/or hormonal therapy, the risk of developing invasive carcinoma is low (< 10%)Subsequent invasive cancers are found at the same site (1/3), at a separate site in the same breast (1/3), and in the contralateral breast (1/3)",
                      "Subsequent invasive cancers are found at the same site (1/3), at a separate site in the same breast (1/3), and in the contralateral breast (1/3)",
                      "Subsequent carcinomas after LCIS are more equally distributed in both breasts~ 3/5 in the same breast and 2/5 in the contralateral breastChemoprevention reduces risk by ~ 50%",
                      "~ 3/5 in the same breast and 2/5 in the contralateral breast",
                      "Chemoprevention reduces risk by ~ 50%"
                    ]
                  }
                ],
                "Diet and Exercise": [
                  {
                    "text": "Lifestyle and diet have small effects on breast cancer risk"
                  },
                  {
                    "text": "Alcohol intake raises risk of ER(+) breast cancer at all agesMenopausal status and type of alcoholic drink do not seem to modify this association",
                    "sub_points": [
                      "Menopausal status and type of alcoholic drink do not seem to modify this association"
                    ]
                  },
                  {
                    "text": "Tobacco use is associated with small increased risk of ER(+) breast cancer"
                  },
                  {
                    "text": "Limited evidence suggests that diet and overall nutrition may influence overall breast cancer riskDietary fat, carbohydrates, and red meat intake have been associated with increased riskEvidence from large cohort and case-control studies has been used to draw inferences about causal relationshipsDifficult to draw firm conclusion from these types of analysesFruits, vegetables, micronutrients, soy, and phytoestrogens have been associated with protective effect for breast cancerVitamin D intake and high serum levels of vitamin D are inversely related to risk of breast cancerHigh soy intake (containing phytoestrogens) may decrease risk of breast cancerDietary intake may interact with a variety of other genetic and environmental factors to impact risk for individual",
                    "sub_points": [
                      "Dietary fat, carbohydrates, and red meat intake have been associated with increased riskEvidence from large cohort and case-control studies has been used to draw inferences about causal relationshipsDifficult to draw firm conclusion from these types of analyses",
                      "Evidence from large cohort and case-control studies has been used to draw inferences about causal relationships",
                      "Difficult to draw firm conclusion from these types of analyses",
                      "Fruits, vegetables, micronutrients, soy, and phytoestrogens have been associated with protective effect for breast cancerVitamin D intake and high serum levels of vitamin D are inversely related to risk of breast cancerHigh soy intake (containing phytoestrogens) may decrease risk of breast cancer",
                      "Vitamin D intake and high serum levels of vitamin D are inversely related to risk of breast cancer",
                      "High soy intake (containing phytoestrogens) may decrease risk of breast cancer",
                      "Dietary intake may interact with a variety of other genetic and environmental factors to impact risk for individual"
                    ]
                  },
                  {
                    "text": "Exercise has been associated with a small protective effect for breast cancer risk"
                  }
                ],
                "Screening": [
                  {
                    "text": "Screening increases the likelihood of being diagnosed with breast cancer but is not thought to significantly cause cancer"
                  },
                  {
                    "text": "More invasive carcinomas are detected in screened populations compared to nonscreened populationsEstimated to be ~ 10-25% of invasive cancersThese are cancers that may not have been detected in patient's lifetime without screeningPrimarily well-differentiated ER(+) cancers",
                    "sub_points": [
                      "Estimated to be ~ 10-25% of invasive cancers",
                      "These are cancers that may not have been detected in patient's lifetime without screening",
                      "Primarily well-differentiated ER(+) cancers"
                    ]
                  },
                  {
                    "text": "MR detects additional foci of carcinoma in 10-30%Significance of these very small cancers is debated",
                    "sub_points": [
                      "Significance of these very small cancers is debated"
                    ]
                  },
                  {
                    "text": "Not currently possible to definitively distinguish clinically important cancers from those that would not cause harm"
                  }
                ],
                "Microbiota": [
                  {
                    "text": "The breast has a normal microbiotaMultiple bacterial species have been identified in the breast tissue of women prior to breastfeeding",
                    "sub_points": [
                      "Multiple bacterial species have been identified in the breast tissue of women prior to breastfeeding"
                    ]
                  },
                  {
                    "text": "The role of the microbiota in inflammation, estrogen metabolism, and epigenetic alterations is under investigation"
                  },
                  {
                    "text": "Although changes have been identified in breast tissue ± cancer, a definite link to breast cancer risk has not been established"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Strategies for Breast Cancer Risk Reduction": [
                  {
                    "text": "Numerous interventions have been used to modify breast cancer risk &/or improve detection in high-risk populationsRisk is assessed using assessment tools and, when applicable, genetic testingManagement of risk reduction is based on assessment of individual's risk compared with general populationRisk reduction strategies may include lifestyle changes, screening, chemoprevention, and prophylactic surgery",
                    "sub_points": [
                      "Risk is assessed using assessment tools and, when applicable, genetic testing",
                      "Management of risk reduction is based on assessment of individual's risk compared with general population",
                      "Risk reduction strategies may include lifestyle changes, screening, chemoprevention, and prophylactic surgery"
                    ]
                  }
                ],
                "Screening": [
                  {
                    "text": "Mammographic screening reduces deaths from breast cancer in women 40-70 years of age"
                  },
                  {
                    "text": "At 50 years of age, ~ 4 women need to undergo biopsy to detect cancer in 1 woman"
                  },
                  {
                    "text": "At 40 years of age, ~ 10 women need to undergo biopsy to detect cancer in 1 womanConcern has been raised as to cost to 9 women vs. benefit; however, most organizations continue to recommend routine screening starting at age 40",
                    "sub_points": [
                      "Concern has been raised as to cost to 9 women vs. benefit; however, most organizations continue to recommend routine screening starting at age 40"
                    ]
                  },
                  {
                    "text": "Screening has had a small effect on death rate from cancer due to limitations with techniqueThe majority (70-75%) of carcinomas are detected when already invasive and metastasis could have taken placeCarcinomas most likely to cause death are rapidly growing and are more likely to present as interval cancers detected between screens",
                    "sub_points": [
                      "The majority (70-75%) of carcinomas are detected when already invasive and metastasis could have taken place",
                      "Carcinomas most likely to cause death are rapidly growing and are more likely to present as interval cancers detected between screens"
                    ]
                  },
                  {
                    "text": "Women at very high risk of breast cancer (typically withBRCA1andBRCA2mutations) may undergo additional screening with MRMR is not adversely affected by dense breast tissue in these (generally young) womenMR is highly sensitive but not very specific and is therefore not suitable for screening women of average risk",
                    "sub_points": [
                      "MR is not adversely affected by dense breast tissue in these (generally young) women",
                      "MR is highly sensitive but not very specific and is therefore not suitable for screening women of average risk"
                    ]
                  }
                ],
                "Pharmacotherapy/Chemoprevention": [
                  {
                    "text": "Selective ER modulators and aromatase inhibitors have been shown to reduce breast cancer riskTamoxifen, raloxifene, exemestane, and anastrozole have been used for chemoprevention",
                    "sub_points": [
                      "Tamoxifen, raloxifene, exemestane, and anastrozole have been used for chemoprevention"
                    ]
                  },
                  {
                    "text": "5 years of treatment reduces number of ER(+) cancers, but not ER(-) cancers, by ~ 50%Has not been shown to decrease deaths from breast cancer",
                    "sub_points": [
                      "Has not been shown to decrease deaths from breast cancer"
                    ]
                  },
                  {
                    "text": "Tamoxifen and raloxifene can increase risk of fractures and and venous thromboembolic events"
                  },
                  {
                    "text": "Breast Cancer Prevention Trial investigated value of tamoxifen in reducing risk of primary invasive breast cancer13,388 women aged 35 years or older who were at increased risk for breast cancerParticipants randomly assigned to receive tamoxifen 20 mg or placebo daily for 5 yearsTamoxifen reduced risk of developing invasive breast cancer by 49% (RR = 0.51)Follow-up analysis demonstrated that tamoxifen had persisting effect on breast cancer incidenceIncidence of ER(+) breast cancers reduced 69% in tamoxifen group (RR = 0.31)No significant change in incidence of ER(-) breast cancers (RR = 1.22)",
                    "sub_points": [
                      "13,388 women aged 35 years or older who were at increased risk for breast cancerParticipants randomly assigned to receive tamoxifen 20 mg or placebo daily for 5 yearsTamoxifen reduced risk of developing invasive breast cancer by 49% (RR = 0.51)Follow-up analysis demonstrated that tamoxifen had persisting effect on breast cancer incidenceIncidence of ER(+) breast cancers reduced 69% in tamoxifen group (RR = 0.31)No significant change in incidence of ER(-) breast cancers (RR = 1.22)",
                      "Participants randomly assigned to receive tamoxifen 20 mg or placebo daily for 5 years",
                      "Tamoxifen reduced risk of developing invasive breast cancer by 49% (RR = 0.51)",
                      "Follow-up analysis demonstrated that tamoxifen had persisting effect on breast cancer incidence",
                      "Incidence of ER(+) breast cancers reduced 69% in tamoxifen group (RR = 0.31)",
                      "No significant change in incidence of ER(-) breast cancers (RR = 1.22)"
                    ]
                  }
                ],
                "Prophylactic Surgery": [
                  {
                    "text": "Reduces but does not eliminate risk of developing cancerBreast tissue in subcutaneous tissue or in axilla may not be removedAfter oophorectomy, patients can develop primary peritoneal carcinomas",
                    "sub_points": [
                      "Breast tissue in subcutaneous tissue or in axilla may not be removed",
                      "After oophorectomy, patients can develop primary peritoneal carcinomas"
                    ]
                  },
                  {
                    "text": "Surgical options for risk reduction include prophylactic mastectomy and salpingo-oophorectomyWomen at markedly increased risk have greatest benefit from these proceduresRisk usually based on presence of inherited genetic mutations (BRCA1,BRCA2,TP53,PTEN)Mastectomy reduces risk of breast cancer by 90%Salpingo-oophorectomy reduces risk of ovarian cancer by 85-90%Breast cancer risk is reduced by 50%",
                    "sub_points": [
                      "Women at markedly increased risk have greatest benefit from these proceduresRisk usually based on presence of inherited genetic mutations (BRCA1,BRCA2,TP53,PTEN)",
                      "Risk usually based on presence of inherited genetic mutations (BRCA1,BRCA2,TP53,PTEN)",
                      "Mastectomy reduces risk of breast cancer by 90%",
                      "Salpingo-oophorectomy reduces risk of ovarian cancer by 85-90%Breast cancer risk is reduced by 50%",
                      "Breast cancer risk is reduced by 50%"
                    ]
                  }
                ],
                "Lifestyle Modification": [
                  {
                    "text": "Some lifestyle modifications will slightly reduce breast cancer risk; these changes are also recommended for other health benefitsReduction or elimination of alcohol and tobacco useMaintenance of normal weight after menopause",
                    "sub_points": [
                      "Reduction or elimination of alcohol and tobacco use",
                      "Maintenance of normal weight after menopause"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Benign Breast Disease as a Risk Factor for Developing Breast Carcinoma": {
            "name": "Benign Breast Disease as a Risk Factor for Developing Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/b3535aa6-8a56-4945-9e26-f77af3d74080/lesson/f42eb460-554c-4833-83f9-766d6e1bfae4",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Benign breast disease (BBD) is classified according to the subsequent risk of developing invasive breast carcinoma"
                  },
                  {
                    "text": "BBD consists of a spectrum of nonmalignant conditions characterized by various histologic features and clinical manifestations"
                  }
                ]
              },
              "Overview": {
                "Introduction": [
                  {
                    "text": "The widespread use of mammographic screening has led to the increased detection of BBD~ 10% of women undergoing screening mammography are recalled for additional diagnostic imaging8-10% will have a finding that prompts image-guided core needle biopsyMany of these biopsies show a variety of different types of BBD",
                    "sub_points": [
                      "~ 10% of women undergoing screening mammography are recalled for additional diagnostic imaging8-10% will have a finding that prompts image-guided core needle biopsyMany of these biopsies show a variety of different types of BBD",
                      "8-10% will have a finding that prompts image-guided core needle biopsy",
                      "Many of these biopsies show a variety of different types of BBD"
                    ]
                  },
                  {
                    "text": "BBD comprises a large, diverse group of different histologic entities that were originally classified according to morphology (nonproliferative vs. proliferative)"
                  },
                  {
                    "text": "Analyzing these groups according to biologic changes and subsequent risk of carcinoma has led to insights into the origins of cancer"
                  }
                ],
                "Morphologic Studies": [
                  {
                    "text": "BBD was originally classified according to the histologic appearance"
                  },
                  {
                    "text": "An association with carcinoma was postulated based on similarities in appearance and adjacent location"
                  },
                  {
                    "text": "BBD can resemble carcinomaAtypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are cytologically identical to invasive lobular carcinomaUsual ductal hyperplasia (UDH) resembles atypical ductal hyperplasia (ADH), which resembles ductal carcinoma in situ (DCIS)Radial sclerosing lesions (RSLs) are similar in appearance to tubular carcinoma",
                    "sub_points": [
                      "Atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) are cytologically identical to invasive lobular carcinoma",
                      "Usual ductal hyperplasia (UDH) resembles atypical ductal hyperplasia (ADH), which resembles ductal carcinoma in situ (DCIS)",
                      "Radial sclerosing lesions (RSLs) are similar in appearance to tubular carcinoma"
                    ]
                  },
                  {
                    "text": "BBD is frequently seen adjacent to invasive carcinomasALH is often associated with LCIS and invasive lobular carcinomaADH is often associated with DCIS and invasive ductal carcinomaColumnar cell change, flat epithelial atypia (FEA), ALH, LCIS, and tubular carcinoma are frequently seen together (combinations are described as Rosen triad)",
                    "sub_points": [
                      "ALH is often associated with LCIS and invasive lobular carcinoma",
                      "ADH is often associated with DCIS and invasive ductal carcinoma",
                      "Columnar cell change, flat epithelial atypia (FEA), ALH, LCIS, and tubular carcinoma are frequently seen together (combinations are described as Rosen triad)"
                    ]
                  }
                ],
                "Epidemiologic Studies": [
                  {
                    "text": "Large, long-term studies followed women with BBD to assess the risk for developing cancer"
                  },
                  {
                    "text": "Similar results were found in 3 main studiesNashville study, Nurse's Health study, Mayo Clinic study",
                    "sub_points": [
                      "Nashville study, Nurse's Health study, Mayo Clinic study"
                    ]
                  },
                  {
                    "text": "3 main morphologic classes of BBD are defined based on these studiesNonproliferative breast disease (NPD)Does not increase risk of subsequent carcinomaProliferative disease without atypia (PDWA)1.5-2.0x increased relative risk of carcinoma in either breast (absolute lifetime risk: ~ 5-7%)Atypical hyperplasia (AH)4-5x increased relative risk of carcinoma (absolute lifetime risk: ~ 13-17%)Risk is higher for ipsilateral (60%) compared to contralateral carcinoma (40%)Suggests that AH is both indicator of bilateral risk and can also act as a nonobligate precursor in same breast",
                    "sub_points": [
                      "Nonproliferative breast disease (NPD)Does not increase risk of subsequent carcinoma",
                      "Does not increase risk of subsequent carcinoma",
                      "Proliferative disease without atypia (PDWA)1.5-2.0x increased relative risk of carcinoma in either breast (absolute lifetime risk: ~ 5-7%)",
                      "1.5-2.0x increased relative risk of carcinoma in either breast (absolute lifetime risk: ~ 5-7%)",
                      "Atypical hyperplasia (AH)4-5x increased relative risk of carcinoma (absolute lifetime risk: ~ 13-17%)Risk is higher for ipsilateral (60%) compared to contralateral carcinoma (40%)Suggests that AH is both indicator of bilateral risk and can also act as a nonobligate precursor in same breast",
                      "4-5x increased relative risk of carcinoma (absolute lifetime risk: ~ 13-17%)",
                      "Risk is higher for ipsilateral (60%) compared to contralateral carcinoma (40%)Suggests that AH is both indicator of bilateral risk and can also act as a nonobligate precursor in same breast",
                      "Suggests that AH is both indicator of bilateral risk and can also act as a nonobligate precursor in same breast"
                    ]
                  }
                ],
                "Biologic Studies": [
                  {
                    "text": "BBD has been investigated using multiple techniquesIHC studies for protein expressionGene expression profiling (mRNA)Loss of heterozygosity for selected markersComparative genomic hybridization",
                    "sub_points": [
                      "IHC studies for protein expression",
                      "Gene expression profiling (mRNA)",
                      "Loss of heterozygosity for selected markers",
                      "Comparative genomic hybridization"
                    ]
                  },
                  {
                    "text": "These studies have successfullyIdentified biologic changes responsible for BBDIdentified true precursor lesions for invasive carcinoma",
                    "sub_points": [
                      "Identified biologic changes responsible for BBD",
                      "Identified true precursor lesions for invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Very few genetic changes are seen in NPD and PDWA compared with AHStrong expression of ER suggests role for hormonal influence during developmentLack of genetic changes supports that the majority of these lesions are not true precursors",
                    "sub_points": [
                      "Strong expression of ER suggests role for hormonal influence during development",
                      "Lack of genetic changes supports that the majority of these lesions are not true precursors"
                    ]
                  },
                  {
                    "text": "Potential precursor lesions for ER(+) cancer"
                  },
                  {
                    "text": "A low-grade breast neoplasia family has been identifiedCharacterized by clonality, strong diffuse expression of ER, and characteristic loss at 16q and gain at 1pIncludes some columnar cell lesions, FEA, ADH, and ALHBiologically related to LCIS and low-grade DCISOften associated with invasive tubular carcinoma, invasive cribriform carcinoma, grades 1 and 2 lobular carcinomas, and grade 1 invasive ductal carcinomaSupports that these lesions can be nonobligate precursors of low-grade carcinomasNevertheless, the majority do not progress during patients' lifetimesHigh-grade ER(+) carcinomas also show 16q deletions and are likely etiologically related to low-grade ER(+) carcinomas",
                    "sub_points": [
                      "Characterized by clonality, strong diffuse expression of ER, and characteristic loss at 16q and gain at 1p",
                      "Includes some columnar cell lesions, FEA, ADH, and ALHBiologically related to LCIS and low-grade DCISOften associated with invasive tubular carcinoma, invasive cribriform carcinoma, grades 1 and 2 lobular carcinomas, and grade 1 invasive ductal carcinoma",
                      "Biologically related to LCIS and low-grade DCIS",
                      "Often associated with invasive tubular carcinoma, invasive cribriform carcinoma, grades 1 and 2 lobular carcinomas, and grade 1 invasive ductal carcinoma",
                      "Supports that these lesions can be nonobligate precursors of low-grade carcinomasNevertheless, the majority do not progress during patients' lifetimes",
                      "Nevertheless, the majority do not progress during patients' lifetimes",
                      "High-grade ER(+) carcinomas also show 16q deletions and are likely etiologically related to low-grade ER(+) carcinomas"
                    ]
                  },
                  {
                    "text": "Potential precursor lesions for ER(-) carcinoma"
                  },
                  {
                    "text": "Precursors for ER(-) carcinoma have not been establishedCarcinomas are heterogeneous and include triple negative (basal-like), HER2(+), apocrine, metaplastic, and other typesMajority show aneuploidy and numerous genetic changesMost frequent changes are losses at 1p, 8p, and 17p and gains at 1q and 8qAmplifications are common and include 1q, 8q, 17q (site of HER2), and 20qMinority have deletion of 16q, characteristic of low-grade carcinomas",
                    "sub_points": [
                      "Carcinomas are heterogeneous and include triple negative (basal-like), HER2(+), apocrine, metaplastic, and other types",
                      "Majority show aneuploidy and numerous genetic changesMost frequent changes are losses at 1p, 8p, and 17p and gains at 1q and 8qAmplifications are common and include 1q, 8q, 17q (site of HER2), and 20qMinority have deletion of 16q, characteristic of low-grade carcinomas",
                      "Most frequent changes are losses at 1p, 8p, and 17p and gains at 1q and 8q",
                      "Amplifications are common and include 1q, 8q, 17q (site of HER2), and 20q",
                      "Minority have deletion of 16q, characteristic of low-grade carcinomas"
                    ]
                  },
                  {
                    "text": "Several possible precursor lesions have been proposedMyoepithelial precursor lesionMyoepithelial cells are normally ER(-)Some carcinomas have features very similar to myoepithelial cellsHowever, histologically recognizable neoplastic myoepithelial lesions are quite rareA myoepithelial precursor lesion might progress rapidly to invasive carcinoma, as normal myoepithelial cells supporting the basement membrane would not be presentA brief in situ phase could explain why ER(-) carcinomas are rarely associated with extensive ER(-) DCISER(+) ADHER(-) carcinomas may arise from ER(+) ADH or DCIS that loses ER expressionSome cases of DCIS show markedly heterogeneous expression of ER (less common in ADH)Could explain reduction of subsequent carcinomas due to tamoxifen treatment or oophorectomy for women with carcinoma who haveBRCA1germline mutationsHowever, genetic changes in ER(+) precursors differ from ER(-) carcinomasFor example, loss of 16q is very unusualIn addition, ER(-) carcinomas are almost never associated with ER(+) precursors in adjacent tissueApocrine metaplasiaShares morphologic features with cases of apocrine DCIS and invasive apocrine carcinomaNormally, ER(-) and AR(+)Increased immunoreactivity for HER2 is present in ~ 50% of cases of metaplasia but is not associated with gene amplification~ 1/2 of apocrine carcinomas show gene amplification and HER2 overexpressionMyoepithelial cells may be diminished in numberSome lesions are clonal; may share genetic gains and losses with adjacent DCIS and invasive carcinomaApocrine metaplasia without atypia associated with cysts is not associated with increased cancer riskIt is possible that there are apocrine precursors with nuclear or architectural (complex papillary hyperplasia) atypia that can act as precursor lesionsMicroglandular adenosis (MGA)Very rare infiltrative lesion of breast that is ER(-)Much less common than ER(-) invasive carcinomasMGA is associated with synchronous or metachronous invasive carcinoma in ~ 25% of casesShares genetic changes with the invasive carcinoma, which may have additional changesMGA can be a precursor lesion for rare invasive carcinomas",
                    "sub_points": [
                      "Myoepithelial precursor lesionMyoepithelial cells are normally ER(-)Some carcinomas have features very similar to myoepithelial cellsHowever, histologically recognizable neoplastic myoepithelial lesions are quite rareA myoepithelial precursor lesion might progress rapidly to invasive carcinoma, as normal myoepithelial cells supporting the basement membrane would not be presentA brief in situ phase could explain why ER(-) carcinomas are rarely associated with extensive ER(-) DCIS",
                      "Myoepithelial cells are normally ER(-)",
                      "Some carcinomas have features very similar to myoepithelial cells",
                      "However, histologically recognizable neoplastic myoepithelial lesions are quite rare",
                      "A myoepithelial precursor lesion might progress rapidly to invasive carcinoma, as normal myoepithelial cells supporting the basement membrane would not be present",
                      "A brief in situ phase could explain why ER(-) carcinomas are rarely associated with extensive ER(-) DCIS",
                      "ER(+) ADHER(-) carcinomas may arise from ER(+) ADH or DCIS that loses ER expressionSome cases of DCIS show markedly heterogeneous expression of ER (less common in ADH)Could explain reduction of subsequent carcinomas due to tamoxifen treatment or oophorectomy for women with carcinoma who haveBRCA1germline mutationsHowever, genetic changes in ER(+) precursors differ from ER(-) carcinomasFor example, loss of 16q is very unusualIn addition, ER(-) carcinomas are almost never associated with ER(+) precursors in adjacent tissue",
                      "ER(-) carcinomas may arise from ER(+) ADH or DCIS that loses ER expression",
                      "Some cases of DCIS show markedly heterogeneous expression of ER (less common in ADH)",
                      "Could explain reduction of subsequent carcinomas due to tamoxifen treatment or oophorectomy for women with carcinoma who haveBRCA1germline mutations",
                      "However, genetic changes in ER(+) precursors differ from ER(-) carcinomasFor example, loss of 16q is very unusual",
                      "For example, loss of 16q is very unusual",
                      "In addition, ER(-) carcinomas are almost never associated with ER(+) precursors in adjacent tissue",
                      "Apocrine metaplasiaShares morphologic features with cases of apocrine DCIS and invasive apocrine carcinomaNormally, ER(-) and AR(+)Increased immunoreactivity for HER2 is present in ~ 50% of cases of metaplasia but is not associated with gene amplification~ 1/2 of apocrine carcinomas show gene amplification and HER2 overexpressionMyoepithelial cells may be diminished in numberSome lesions are clonal; may share genetic gains and losses with adjacent DCIS and invasive carcinomaApocrine metaplasia without atypia associated with cysts is not associated with increased cancer riskIt is possible that there are apocrine precursors with nuclear or architectural (complex papillary hyperplasia) atypia that can act as precursor lesions",
                      "Shares morphologic features with cases of apocrine DCIS and invasive apocrine carcinoma",
                      "Normally, ER(-) and AR(+)",
                      "Increased immunoreactivity for HER2 is present in ~ 50% of cases of metaplasia but is not associated with gene amplification~ 1/2 of apocrine carcinomas show gene amplification and HER2 overexpression",
                      "~ 1/2 of apocrine carcinomas show gene amplification and HER2 overexpression",
                      "Myoepithelial cells may be diminished in number",
                      "Some lesions are clonal; may share genetic gains and losses with adjacent DCIS and invasive carcinoma",
                      "Apocrine metaplasia without atypia associated with cysts is not associated with increased cancer risk",
                      "It is possible that there are apocrine precursors with nuclear or architectural (complex papillary hyperplasia) atypia that can act as precursor lesions",
                      "Microglandular adenosis (MGA)Very rare infiltrative lesion of breast that is ER(-)Much less common than ER(-) invasive carcinomasMGA is associated with synchronous or metachronous invasive carcinoma in ~ 25% of casesShares genetic changes with the invasive carcinoma, which may have additional changesMGA can be a precursor lesion for rare invasive carcinomas",
                      "Very rare infiltrative lesion of breast that is ER(-)Much less common than ER(-) invasive carcinomas",
                      "Much less common than ER(-) invasive carcinomas",
                      "MGA is associated with synchronous or metachronous invasive carcinoma in ~ 25% of casesShares genetic changes with the invasive carcinoma, which may have additional changesMGA can be a precursor lesion for rare invasive carcinomas",
                      "Shares genetic changes with the invasive carcinoma, which may have additional changes",
                      "MGA can be a precursor lesion for rare invasive carcinomas"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "BBD in breast biopsies without carcinomaNPD: 40-70%PDWA: 30-60%AH: 10-15%ADH is more common than ALH due to association with mammographic calcifications",
                    "sub_points": [
                      "NPD: 40-70%",
                      "PDWA: 30-60%",
                      "AH: 10-15%ADH is more common than ALH due to association with mammographic calcifications",
                      "ADH is more common than ALH due to association with mammographic calcifications"
                    ]
                  }
                ],
                "Overall Risk forAtypical Hyperplasia": [
                  {
                    "text": "Cohort studies or case-control study designs (Nashville and Mayo) have consistently shown that the relative risk associated with AH is ~ 4-5x"
                  },
                  {
                    "text": "Updated data from the Mayo breast cohort study has shown that absolute risk after diagnosis of AH at 25 years is 30%Breast carcinomas that developed included both invasive and in situ carcinomasCumulative risk was higher for women with multiple atypical foci (1 focus vs. 2 foci vs. ≥ 3 foci)Risk can vary with age of patientHowever, other studies have not shown age is a factor",
                    "sub_points": [
                      "Breast carcinomas that developed included both invasive and in situ carcinomas",
                      "Cumulative risk was higher for women with multiple atypical foci (1 focus vs. 2 foci vs. ≥ 3 foci)",
                      "Risk can vary with age of patientHowever, other studies have not shown age is a factor",
                      "However, other studies have not shown age is a factor"
                    ]
                  },
                  {
                    "text": "Relative and absolute breast carcinoma risks after a diagnosis of AH highlight importance of accurate diagnosisNeed to insure good quality control and application of standardized pathologic criteria for diagnosis",
                    "sub_points": [
                      "Need to insure good quality control and application of standardized pathologic criteria for diagnosis"
                    ]
                  },
                  {
                    "text": "Cumulative incidence of breast carcinoma appears to increase linearly over time"
                  },
                  {
                    "text": "Risk increased for women whose subsequent biopsies showed more proliferation and decreased for women whose biopsies showed less proliferation"
                  },
                  {
                    "text": "Women with AH are eligible for risk-reducing strategies, including enhanced surveillance and chemoprevention"
                  }
                ],
                "Histologic Factors": [
                  {
                    "text": "2 histologic features stratify risk among women with diagnosis of AHQuantification of number of separate foci of AHIncreased number of foci of atypia is associated with higher riskExtent of normal regression or involution of background lobular unitsGreater degree of involution = lower riskThis pattern has been seen with other types of BBD",
                    "sub_points": [
                      "Quantification of number of separate foci of AHIncreased number of foci of atypia is associated with higher risk",
                      "Increased number of foci of atypia is associated with higher risk",
                      "Extent of normal regression or involution of background lobular unitsGreater degree of involution = lower riskThis pattern has been seen with other types of BBD",
                      "Greater degree of involution = lower risk",
                      "This pattern has been seen with other types of BBD"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Significance of Lesions of Risk": [
                  {
                    "text": "Lesions conferring increased risk of breast carcinoma are useful in counseling patientsFamily history in addition to BBD may slightly elevate risk",
                    "sub_points": [
                      "Family history in addition to BBD may slightly elevate risk"
                    ]
                  },
                  {
                    "text": "Many models of risk incorporate types of BBDAH is used to calculate risk using Gail modelPDWA and AH are used in Rosner and Colditz model",
                    "sub_points": [
                      "AH is used to calculate risk using Gail model",
                      "PDWA and AH are used in Rosner and Colditz model"
                    ]
                  },
                  {
                    "text": "Women at very high risk can consider options for risk reductionChemopreventionRisk of ≥ 1.66% within next 5 years using Gail model is used for eligibility for chemoprevention with tamoxifen or raloxifeneReduces risk of ER(+) carcinomas but not ER(-) carcinomasReduces BBD and likelihood of undergoing breast biopsyIncreases risk of thromboembolic events (pulmonary embolism and deep vein thrombosis) and endometrial hyperplasia or cancerHot flashes and vaginal discharge are common side effectsA metaanalysis showed a reduction in the number of breast carcinomas and deaths from breast carcinomaRandomized, controlled trials have shown pharmacologic risk reduction to be effective in women with AHTrials have evaluated use of selective ER modulators and aromatase inhibitors for prevention of breast carcinomaRelative risk reductions in AH subgroup ranged from 41-79%Women with higher risk status are most likely to benefitSurveillanceIncreased surveillance at shorter intervals or using additional modalities (e.g., MR) may detect cancers earlier for women at increased riskAmerican Cancer Society and National Comprehensive Cancer Network recommend screening with mammography combined with MR for only very high-risk patient groups with a > 20% lifetime risk of breast carcinomaKnown germline mutation or 1st-degree relative with known mutation (BRCA1,BRCA2, Li-Fraumeni (TP53), Cowden (PTEN), Bannayan-Riley-Ruvalcaba syndromes)Strong family history of breast or ovarian cancer in 2 or more 1st-degree relativesRadiation treatment to chest < 30 years of ageSurgeryBilateral mastectomy reduces risk by > 90%Usually only considered for women with known germline mutations, strong family history, prior chest radiation, or possibly LCISBilateral salpingo-oophorectomy decreases risk of breast and ovarian cancerUsually recommended only for women withBRCA1orBRCA2mutationsLifestyle changesWeight reduction, exercise, and dietary changes may have a small effect, but primary benefit is reduced risk of cardiovascular diseaseFor young women, breastfeeding after childbirth reduces risk and should be encouraged",
                    "sub_points": [
                      "Chemoprevention",
                      "Risk of ≥ 1.66% within next 5 years using Gail model is used for eligibility for chemoprevention with tamoxifen or raloxifeneReduces risk of ER(+) carcinomas but not ER(-) carcinomasReduces BBD and likelihood of undergoing breast biopsyIncreases risk of thromboembolic events (pulmonary embolism and deep vein thrombosis) and endometrial hyperplasia or cancerHot flashes and vaginal discharge are common side effectsA metaanalysis showed a reduction in the number of breast carcinomas and deaths from breast carcinoma",
                      "Reduces risk of ER(+) carcinomas but not ER(-) carcinomasReduces BBD and likelihood of undergoing breast biopsy",
                      "Reduces BBD and likelihood of undergoing breast biopsy",
                      "Increases risk of thromboembolic events (pulmonary embolism and deep vein thrombosis) and endometrial hyperplasia or cancer",
                      "Hot flashes and vaginal discharge are common side effects",
                      "A metaanalysis showed a reduction in the number of breast carcinomas and deaths from breast carcinoma",
                      "Randomized, controlled trials have shown pharmacologic risk reduction to be effective in women with AHTrials have evaluated use of selective ER modulators and aromatase inhibitors for prevention of breast carcinomaRelative risk reductions in AH subgroup ranged from 41-79%Women with higher risk status are most likely to benefit",
                      "Trials have evaluated use of selective ER modulators and aromatase inhibitors for prevention of breast carcinoma",
                      "Relative risk reductions in AH subgroup ranged from 41-79%",
                      "Women with higher risk status are most likely to benefit",
                      "SurveillanceIncreased surveillance at shorter intervals or using additional modalities (e.g., MR) may detect cancers earlier for women at increased riskAmerican Cancer Society and National Comprehensive Cancer Network recommend screening with mammography combined with MR for only very high-risk patient groups with a > 20% lifetime risk of breast carcinomaKnown germline mutation or 1st-degree relative with known mutation (BRCA1,BRCA2, Li-Fraumeni (TP53), Cowden (PTEN), Bannayan-Riley-Ruvalcaba syndromes)Strong family history of breast or ovarian cancer in 2 or more 1st-degree relativesRadiation treatment to chest < 30 years of age",
                      "Increased surveillance at shorter intervals or using additional modalities (e.g., MR) may detect cancers earlier for women at increased risk",
                      "American Cancer Society and National Comprehensive Cancer Network recommend screening with mammography combined with MR for only very high-risk patient groups with a > 20% lifetime risk of breast carcinomaKnown germline mutation or 1st-degree relative with known mutation (BRCA1,BRCA2, Li-Fraumeni (TP53), Cowden (PTEN), Bannayan-Riley-Ruvalcaba syndromes)Strong family history of breast or ovarian cancer in 2 or more 1st-degree relativesRadiation treatment to chest < 30 years of age",
                      "Known germline mutation or 1st-degree relative with known mutation (BRCA1,BRCA2, Li-Fraumeni (TP53), Cowden (PTEN), Bannayan-Riley-Ruvalcaba syndromes)",
                      "Strong family history of breast or ovarian cancer in 2 or more 1st-degree relatives",
                      "Radiation treatment to chest < 30 years of age",
                      "SurgeryBilateral mastectomy reduces risk by > 90%Usually only considered for women with known germline mutations, strong family history, prior chest radiation, or possibly LCISBilateral salpingo-oophorectomy decreases risk of breast and ovarian cancerUsually recommended only for women withBRCA1orBRCA2mutations",
                      "Bilateral mastectomy reduces risk by > 90%Usually only considered for women with known germline mutations, strong family history, prior chest radiation, or possibly LCIS",
                      "Usually only considered for women with known germline mutations, strong family history, prior chest radiation, or possibly LCIS",
                      "Bilateral salpingo-oophorectomy decreases risk of breast and ovarian cancerUsually recommended only for women withBRCA1orBRCA2mutations",
                      "Usually recommended only for women withBRCA1orBRCA2mutations",
                      "Lifestyle changesWeight reduction, exercise, and dietary changes may have a small effect, but primary benefit is reduced risk of cardiovascular diseaseFor young women, breastfeeding after childbirth reduces risk and should be encouraged",
                      "Weight reduction, exercise, and dietary changes may have a small effect, but primary benefit is reduced risk of cardiovascular disease",
                      "For young women, breastfeeding after childbirth reduces risk and should be encouraged"
                    ]
                  }
                ],
                "Core Needle Biopsies": [
                  {
                    "text": "BBD is often detected on core needle biopsies due to association with mammographic abnormalities"
                  },
                  {
                    "text": "Excision is indicated when there is sufficient risk of adjacent DCIS or invasive carcinomaADH and papillomas with atypia show DCIS on excision in up to ~ 15%FEA and incidental ALH or LCIS are associated with a < 5% risk of carcinoma on excision, and a decision to excise should be made based on radiologic/pathologic correlation",
                    "sub_points": [
                      "ADH and papillomas with atypia show DCIS on excision in up to ~ 15%",
                      "FEA and incidental ALH or LCIS are associated with a < 5% risk of carcinoma on excision, and a decision to excise should be made based on radiologic/pathologic correlation"
                    ]
                  }
                ],
                "Relative Risk and Absolute Risk": [
                  {
                    "text": "Relative risk is determined by comparison to a group of women without any risk factors"
                  },
                  {
                    "text": "Absolute risk is the percentage of women expected to develop invasive carcinoma over their lifetime if untreatedThe absolute risk for women without risk factors is ~ 1 in 30 or 3.3%; therefore, a lesion conferring 2x increased relative risk increases the absolute risk to 6.6%",
                    "sub_points": [
                      "The absolute risk for women without risk factors is ~ 1 in 30 or 3.3%; therefore, a lesion conferring 2x increased relative risk increases the absolute risk to 6.6%"
                    ]
                  }
                ],
                "Imaging Findings": [
                  {
                    "text": "BBD is often detected by mammographic screeningSclerosing adenosis: Calcifications, focal asymmetry, architectural distortionColumnar cell change ± FEA: CalcificationsPapilloma: Mass, calcificationsRSL: Architectural distortion, calcificationsLobular neoplasia (ALH, LCIS): Typically incidental findings in biopsies for other lesionsPleomorphic and florid LCIS can be associated with necrosis and calcificationsADH: Calcifications",
                    "sub_points": [
                      "Sclerosing adenosis: Calcifications, focal asymmetry, architectural distortion",
                      "Columnar cell change ± FEA: Calcifications",
                      "Papilloma: Mass, calcifications",
                      "RSL: Architectural distortion, calcifications",
                      "Lobular neoplasia (ALH, LCIS): Typically incidental findings in biopsies for other lesionsPleomorphic and florid LCIS can be associated with necrosis and calcifications",
                      "Pleomorphic and florid LCIS can be associated with necrosis and calcifications",
                      "ADH: Calcifications"
                    ]
                  },
                  {
                    "text": "Mammographic density (MD) and breast cancer riskMD refers to the amount of dense breast tissue (epithelial or stromal) seen on a mammogramWomen with > 75% breast density on mammography have 4-6x greater breast cancer risk than women with little density (< 5% density)43% of women who are 40-74 years of age have extremely or heterogeneously dense breastsBiology underlying increase MD is poorly understoodStudies suggest that MD is influenced by exogenous hormones that also influence breast cancer riskMD may be a surrogate for effects of exogenous hormones and risk of breast cancerTwin studies suggest that ~ 60% of variation in MD risk is explained by genetic factors",
                    "sub_points": [
                      "MD refers to the amount of dense breast tissue (epithelial or stromal) seen on a mammogram",
                      "Women with > 75% breast density on mammography have 4-6x greater breast cancer risk than women with little density (< 5% density)43% of women who are 40-74 years of age have extremely or heterogeneously dense breasts",
                      "43% of women who are 40-74 years of age have extremely or heterogeneously dense breasts",
                      "Biology underlying increase MD is poorly understoodStudies suggest that MD is influenced by exogenous hormones that also influence breast cancer riskMD may be a surrogate for effects of exogenous hormones and risk of breast cancerTwin studies suggest that ~ 60% of variation in MD risk is explained by genetic factors",
                      "Studies suggest that MD is influenced by exogenous hormones that also influence breast cancer riskMD may be a surrogate for effects of exogenous hormones and risk of breast cancer",
                      "MD may be a surrogate for effects of exogenous hormones and risk of breast cancer",
                      "Twin studies suggest that ~ 60% of variation in MD risk is explained by genetic factors"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Classification ofBenign Breast Disease": [
                  {
                    "text": "NPD: No increased risk(~ 3% lifetime risk of invasive carcinoma)Mild hyperplasia: 3-4 cell layersGross or microscopic cystsApocrine metaplasiaDuct ectasiaSquamous metaplasiaFibroadenomaParenchymal atrophy and fibrosisMastitis",
                    "sub_points": [
                      "Mild hyperplasia: 3-4 cell layers",
                      "Gross or microscopic cysts",
                      "Apocrine metaplasia",
                      "Duct ectasia",
                      "Squamous metaplasia",
                      "Fibroadenoma",
                      "Parenchymal atrophy and fibrosis",
                      "Mastitis"
                    ]
                  },
                  {
                    "text": "PDWA: 1.5-2x increased risk(~ 5-7% lifetime risk of invasive carcinoma)Lesions are proliferative because they increase number of epithelial cellsModerate to florid UDHSclerosing adenosisComplex sclerosing lesionRSL (radial scar)PapillomaColumnar cell changeFEAComplex fibroadenomas were originally included but were shown to not be an independent risk factor when associated BBD was consideredComplex fibroadenomas are defined as having cysts > 3 mm, sclerosing adenosis, epithelial calcifications, or papillary apocrine metaplasia",
                    "sub_points": [
                      "Lesions are proliferative because they increase number of epithelial cells",
                      "Moderate to florid UDH",
                      "Sclerosing adenosis",
                      "Complex sclerosing lesion",
                      "RSL (radial scar)",
                      "Papilloma",
                      "Columnar cell change",
                      "FEA",
                      "Complex fibroadenomas were originally included but were shown to not be an independent risk factor when associated BBD was consideredComplex fibroadenomas are defined as having cysts > 3 mm, sclerosing adenosis, epithelial calcifications, or papillary apocrine metaplasia",
                      "Complex fibroadenomas are defined as having cysts > 3 mm, sclerosing adenosis, epithelial calcifications, or papillary apocrine metaplasia"
                    ]
                  },
                  {
                    "text": "AH (proliferative disease with atypia): 4-5x increased risk(~ 13-17% lifetime risk of invasive carcinoma)ADH: Multifocality may increase riskALH: Risk is higher in premenopausal women or if pagetoid spread is present",
                    "sub_points": [
                      "ADH: Multifocality may increase risk",
                      "ALH: Risk is higher in premenopausal women or if pagetoid spread is present"
                    ]
                  }
                ],
                "Features of Breast Cancers Developing After Atypical Hyperplasia": [
                  {
                    "text": "Data from Mayo Clinic cohort81% developed invasive carcinoma, 19% developed DCISWomen with AH developed carcinoma at ~ 1% per yearWomen with AH were more likely to develop ER(+) carcinoma (91%) compared to women with PDWA (80%) or NPD (85%)HER2 expression did not vary by categoryIpsilateral carcinomas were slightly more common than contralateral carcinomasMost pronounced for AH group (65% vs. 35%)Among women with ADH who later developed carcinoma78% of later carcinomas were no special type (ductal), 22% were lobular or other histologic typesAmong women with ALH who later developed carcinoma77% of later carcinomas were no special type (ductal), 23% were lobular or other histologic typesAmong women with invasive breast carcinoma and known nodal status75% had node (-) carcinoma, 25% had node (+) carcinoma",
                    "sub_points": [
                      "81% developed invasive carcinoma, 19% developed DCISWomen with AH developed carcinoma at ~ 1% per year",
                      "Women with AH developed carcinoma at ~ 1% per year",
                      "Women with AH were more likely to develop ER(+) carcinoma (91%) compared to women with PDWA (80%) or NPD (85%)HER2 expression did not vary by category",
                      "HER2 expression did not vary by category",
                      "Ipsilateral carcinomas were slightly more common than contralateral carcinomasMost pronounced for AH group (65% vs. 35%)",
                      "Most pronounced for AH group (65% vs. 35%)",
                      "Among women with ADH who later developed carcinoma78% of later carcinomas were no special type (ductal), 22% were lobular or other histologic types",
                      "78% of later carcinomas were no special type (ductal), 22% were lobular or other histologic types",
                      "Among women with ALH who later developed carcinoma77% of later carcinomas were no special type (ductal), 23% were lobular or other histologic types",
                      "77% of later carcinomas were no special type (ductal), 23% were lobular or other histologic types",
                      "Among women with invasive breast carcinoma and known nodal status75% had node (-) carcinoma, 25% had node (+) carcinoma",
                      "75% had node (-) carcinoma, 25% had node (+) carcinoma"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "In Situ Carcinoma": {
        "name": "In Situ Carcinoma",
        "url": "https://app.pathprimer.com/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
        "topics": {
          "Lobular Carcinoma In Situ": {
            "name": "Lobular Carcinoma In Situ",
            "url": "https://app.pathprimer.com/document/8ab8b7c6-62e2-476a-bc3c-9320798ae466/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "The \"lobular\" family of breast lesions, atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and invasive lobular carcinoma (ILC), are all characterized by loss of cellular cohesionAlterations in the E-cadherin gene (CDH1), resulting in the absence of protein expression, is the etiology in almost all cases",
                    "sub_points": [
                      "Alterations in the E-cadherin gene (CDH1), resulting in the absence of protein expression, is the etiology in almost all cases"
                    ]
                  },
                  {
                    "text": "LCIS is both a risk factor for the development of invasive carcinoma in either breast and can be a direct precursor of ILCLCIS and associated ILC often share genetic changes",
                    "sub_points": [
                      "LCIS and associated ILC often share genetic changes"
                    ]
                  },
                  {
                    "text": "Pleomorphic LCIS (P-LCIS) and florid LCIS (F-LCIS) are genomically more advanced lesions with increased copy number changes and mutations"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Women with classic LCIS (C-LCIS) have an 8-10x increased relative risk of developing invasive carcinoma"
                  },
                  {
                    "text": "The absolute risk is ~ 1-2% per year; lifetime risk is ~ 30-40%"
                  },
                  {
                    "text": "The magnitude of risk for P-LCIS and F-LCIS is unknown but is presumed to be higher"
                  },
                  {
                    "text": "C-LCIS is found as an incidental lesion"
                  },
                  {
                    "text": "P-LCIS and F-LCIS typically present on imaging as calcifications (associated with necrosis) or small masses"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "C-LCIS: Monomorphic proliferation of small, dyscohesive cells expanding at least 1/2 the acini of a lobuleMonomorphic proliferation of small, dyscohesive cells expanding at least 1/2 the acini of a lobule",
                    "sub_points": [
                      "Monomorphic proliferation of small, dyscohesive cells expanding at least 1/2 the acini of a lobule"
                    ]
                  },
                  {
                    "text": "P-LCIS: Enlarged atypical nuclei with variation in size and shapeEnlarged atypical nuclei with variation in size and shape",
                    "sub_points": [
                      "Enlarged atypical nuclei with variation in size and shape"
                    ]
                  },
                  {
                    "text": "F-LCIS: Marked distention of spaces, often with necrosisMarked distention of spaces, often with necrosis",
                    "sub_points": [
                      "Marked distention of spaces, often with necrosis"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "ALH"
                  },
                  {
                    "text": "Ductal carcinoma in situ, solid pattern"
                  },
                  {
                    "text": "Invasive carcinoma"
                  },
                  {
                    "text": "Crush artifact, myoepithelial cells, histiocytes"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Lobular carcinoma in situ (LCIS)Classic LCIS (C-LCIS), pleomorphic LCIS (P-LCIS), florid LCIS (F-LCIS)Nonclassic LCIS (NC-LCIS): P-LCIS, F-LCIS",
                    "sub_points": [
                      "Classic LCIS (C-LCIS), pleomorphic LCIS (P-LCIS), florid LCIS (F-LCIS)",
                      "Nonclassic LCIS (NC-LCIS): P-LCIS, F-LCIS"
                    ]
                  },
                  {
                    "text": "Atypical lobular hyperplasia (ALH)"
                  },
                  {
                    "text": "Lobular neoplasia (LN) : ALH and LCIS"
                  },
                  {
                    "text": "Invasive lobular carcinoma (ILC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "\"Lobular\" as a descriptive term refers to monoclonal neoplastic proliferations of epithelial cells lacking cell adhesion"
                  },
                  {
                    "text": "LCIS is both a risk factor and a nonobligate precursor of invasive breast carcinoma"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "Lobular carcinoma in situ (LCIS) is a clonal neoplastic proliferation and an early lesion in the low-grade neoplasia pathway"
                  },
                  {
                    "text": "LCIS is both a risk factor for the development of invasive carcinoma in either breast and can be a direct precursor of invasive lobular carcinoma (ILC)Identical mutations can be found in LCIS and adjacent ILCLCIS associated with ILC has more genetic alterations than pure LCIS",
                    "sub_points": [
                      "Identical mutations can be found in LCIS and adjacent ILCLCIS associated with ILC has more genetic alterations than pure LCIS",
                      "LCIS associated with ILC has more genetic alterations than pure LCIS"
                    ]
                  },
                  {
                    "text": "The hallmark molecular feature of all lobular lesions, atypical lobular hyperplasia (ALH), LCIS, and ILC, is loss of cellular cohesionIn ~ 95% of lesions, this is due to loss of expression of E-cadherinE-cadherin plays a major role in intercellular adhesion and cell polarity",
                    "sub_points": [
                      "In ~ 95% of lesions, this is due to loss of expression of E-cadherinE-cadherin plays a major role in intercellular adhesion and cell polarity",
                      "E-cadherin plays a major role in intercellular adhesion and cell polarity"
                    ]
                  },
                  {
                    "text": "The World Health Organization (WHO) recognizes 3 types of LCIS: Classic (C-LCIS), florid (F-LCIS), and pleomorphic (P-LCIS)The majority of information about LCIS is from studies of C-LCISLess is known about nonclassic LCIS (NC-LCIS) because they are rare (< 5% of all LCIS) and usually detected in association with ILCMany would have been classified and treated as ductal carcinoma in situ (DCIS) prior to immunohistochemical (IHC) testing for E-cadherinWhen C-LCIS, NC-LCIS, and ILC are found together, they all share common mutationsA higher number of DNA alterations are typically found in NC-LCIS and ILC compared to C-LCIS",
                    "sub_points": [
                      "The majority of information about LCIS is from studies of C-LCIS",
                      "Less is known about nonclassic LCIS (NC-LCIS) because they are rare (< 5% of all LCIS) and usually detected in association with ILCMany would have been classified and treated as ductal carcinoma in situ (DCIS) prior to immunohistochemical (IHC) testing for E-cadherin",
                      "Many would have been classified and treated as ductal carcinoma in situ (DCIS) prior to immunohistochemical (IHC) testing for E-cadherin",
                      "When C-LCIS, NC-LCIS, and ILC are found together, they all share common mutationsA higher number of DNA alterations are typically found in NC-LCIS and ILC compared to C-LCIS",
                      "A higher number of DNA alterations are typically found in NC-LCIS and ILC compared to C-LCIS"
                    ]
                  }
                ],
                "Nomenclature and Cell of Origin": [
                  {
                    "text": "LCIS was first described by Dr. Foote and Dr. Stewart in 1941"
                  },
                  {
                    "text": "The name LCIS was chosen because involved lobules typically continue to look like lobules"
                  },
                  {
                    "text": "In contrast, the cohesive growth pattern of DCIS often unfolds lobules such that they form larger spaces resembling ducts"
                  },
                  {
                    "text": "They selected the name \"lobular\" instead of \"acinar\" carcinoma in situ (CIS) as they did not want the name to imply that the lesion arose only from acinar cells"
                  },
                  {
                    "text": "They recognized that LCIS and DCIS both involve lobules and ductsThe invasive carcinomas associated with the 2 types of CIS were given the same names, \"lobular\" and \"ductal\"",
                    "sub_points": [
                      "The invasive carcinomas associated with the 2 types of CIS were given the same names, \"lobular\" and \"ductal\""
                    ]
                  },
                  {
                    "text": "The cell of origin of breast carcinomas is currently unknown but is thought to likely be a stem or precursor cell in the terminal ducts"
                  }
                ],
                "Risk Factors": [
                  {
                    "text": "Hormone exposureIncidence is increased in postmenopausal hormone replacement therapy (HRT) usersThe incidence of LCIS decreased between 2001 and 2004, possibly due to decreased use of HRT after the results of the Women's Health Initiative trial in 2002Majority of LCIS shows strong diffuse expression of ER",
                    "sub_points": [
                      "Incidence is increased in postmenopausal hormone replacement therapy (HRT) users",
                      "The incidence of LCIS decreased between 2001 and 2004, possibly due to decreased use of HRT after the results of the Women's Health Initiative trial in 2002",
                      "Majority of LCIS shows strong diffuse expression of ER"
                    ]
                  },
                  {
                    "text": "Germline mutationsFewer than 5% of patients with lobular carcinoma have a germline mutationCDH1Hereditary diffuse gastric cancer(HDGC)syndrome is predominantly associated with signet-ring cell gastric carcinoma (GC) with fewer cases of ILCHereditary lobular breast cancer(HLBC)syndrome is associated predominantly with ILC with fewer cases of GCLess common than HDGCPatients with ILC are more commonly ≤ 45 years old and usually have a family history of breast carcinomaAlthough some mutations are preferentially associated with either GC or ILC, the reasons for the differences in risk are not yet knownBRCA2Associated carcinomas are most often estrogen receptor (ER) positive and can be of no special type as well as ILCGuidelines for patients with lobular carcinoma who should be screened have been proposedBilateral lobular breast carcinoma with age of onset < 50 years, orUnilateral lobular breast carcinoma with age of onset < 45 years and a family history of lobular breast carcinomaPersonal or family history of diffuse gastric cancer and lobular breast carcinoma with at least 1 diagnosed at < 50 years of age",
                    "sub_points": [
                      "Fewer than 5% of patients with lobular carcinoma have a germline mutation",
                      "CDH1Hereditary diffuse gastric cancer(HDGC)syndrome is predominantly associated with signet-ring cell gastric carcinoma (GC) with fewer cases of ILCHereditary lobular breast cancer(HLBC)syndrome is associated predominantly with ILC with fewer cases of GCLess common than HDGCPatients with ILC are more commonly ≤ 45 years old and usually have a family history of breast carcinomaAlthough some mutations are preferentially associated with either GC or ILC, the reasons for the differences in risk are not yet known",
                      "Hereditary diffuse gastric cancer(HDGC)syndrome is predominantly associated with signet-ring cell gastric carcinoma (GC) with fewer cases of ILC",
                      "Hereditary lobular breast cancer(HLBC)syndrome is associated predominantly with ILC with fewer cases of GCLess common than HDGCPatients with ILC are more commonly ≤ 45 years old and usually have a family history of breast carcinoma",
                      "Less common than HDGC",
                      "Patients with ILC are more commonly ≤ 45 years old and usually have a family history of breast carcinoma",
                      "Although some mutations are preferentially associated with either GC or ILC, the reasons for the differences in risk are not yet known",
                      "BRCA2Associated carcinomas are most often estrogen receptor (ER) positive and can be of no special type as well as ILC",
                      "Associated carcinomas are most often estrogen receptor (ER) positive and can be of no special type as well as ILC",
                      "Guidelines for patients with lobular carcinoma who should be screened have been proposedBilateral lobular breast carcinoma with age of onset < 50 years, orUnilateral lobular breast carcinoma with age of onset < 45 years and a family history of lobular breast carcinomaPersonal or family history of diffuse gastric cancer and lobular breast carcinoma with at least 1 diagnosed at < 50 years of age",
                      "Bilateral lobular breast carcinoma with age of onset < 50 years, or",
                      "Unilateral lobular breast carcinoma with age of onset < 45 years and a family history of lobular breast carcinoma",
                      "Personal or family history of diffuse gastric cancer and lobular breast carcinoma with at least 1 diagnosed at < 50 years of age"
                    ]
                  },
                  {
                    "text": "Other risk factors are similar to those for all breast carcinomas (e.g., nulliparity, older age at first birth and at menopause, high breast density, family history)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "ALH and C-LCIS in the absence of ILC are found in 0.5-4% of breast biopsies and < 1-2% of reduction mammoplasty specimens"
                  },
                  {
                    "text": "Because these are incidental lesions, the true incidence is not known"
                  },
                  {
                    "text": "P-LCIS and F-LCIS are < 5% of LCIS"
                  },
                  {
                    "text": "The incidence of LCIS decreased from 2001-2004, possibly due to decreased use of postmenopausal HRT"
                  }
                ],
                "Age": [
                  {
                    "text": "C-LCIS: Mean: 44-46 years; 80-90% are premenopausal"
                  },
                  {
                    "text": "P-LCIS and F-LCIS: Mean: ~ 60 years; majority are postmenopausal"
                  }
                ],
                "Sex": [
                  {
                    "text": "Almost all patients are female"
                  },
                  {
                    "text": "Very rare cases reported in males"
                  }
                ],
                "Site": [
                  {
                    "text": "C-LCIS is frequently observed as multiple foci within the same or both breasts; multicentric in ~ 80% of mastectomies; bilateral in ~ 30-70% of patients"
                  },
                  {
                    "text": "NC-LCIS is more often present at a single site within an area of C-LCIS"
                  }
                ],
                "Presentation": [
                  {
                    "text": "C-LCIS is an incidental findingUsually identified in biopsy or surgical excision specimens targeting another lesionSometimes involves ducts and lobules that have preexisting calcifications",
                    "sub_points": [
                      "Usually identified in biopsy or surgical excision specimens targeting another lesion",
                      "Sometimes involves ducts and lobules that have preexisting calcifications"
                    ]
                  },
                  {
                    "text": "P-LCIS and F-LCIS are usually detected on screening mammography as calcifications in areas of necrosis ± a small mass"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Prophylactic mastectomiesBecause the increased risk of invasive carcinoma associated with LCIS is to both breasts, bilateral mastectomies are required for risk reductionHowever, the majority of women with LCIS will never develop invasive carcinoma, and most do not choose mastectomies",
                    "sub_points": [
                      "Because the increased risk of invasive carcinoma associated with LCIS is to both breasts, bilateral mastectomies are required for risk reduction",
                      "However, the majority of women with LCIS will never develop invasive carcinoma, and most do not choose mastectomies"
                    ]
                  },
                  {
                    "text": "Systemic treatmentAdjuvant endocrine therapy (chemoprevention) reduces the subsequent risk of ER(+) carcinomasTamoxifen results in a 56% reductionNot shown to reduce the risk of breast cancer-related death",
                    "sub_points": [
                      "Adjuvant endocrine therapy (chemoprevention) reduces the subsequent risk of ER(+) carcinomasTamoxifen results in a 56% reduction",
                      "Tamoxifen results in a 56% reduction",
                      "Not shown to reduce the risk of breast cancer-related death"
                    ]
                  },
                  {
                    "text": "SurveillanceWomen can be followed with close imaging surveillance",
                    "sub_points": [
                      "Women can be followed with close imaging surveillance"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Women with C-LCIS have an 8-10x increased relative risk of developing invasive carcinomaThe absolute risk is ~ 1-2% per year for a lifetime risk of 30-40%The magnitude of risk for NC-LCIS is unknown but is presumed to be higher",
                    "sub_points": [
                      "The absolute risk is ~ 1-2% per year for a lifetime risk of 30-40%",
                      "The magnitude of risk for NC-LCIS is unknown but is presumed to be higher"
                    ]
                  },
                  {
                    "text": "~ 2/3 of carcinomas develop in the same breast, ~ 1/3 in the contralateral breastThe majority occurring in the same breast are in a site away from the original LCIS",
                    "sub_points": [
                      "The majority occurring in the same breast are in a site away from the original LCIS"
                    ]
                  },
                  {
                    "text": "The risk for developing a contralateral carcinoma is low and is similar for both LCIS and DCIS"
                  },
                  {
                    "text": "The time to an invasive carcinoma diagnosis from a diagnosis of LCIS ranges from 5-30 yearsThe subsequent invasive carcinomas are 3x more likely to be ILC (~ 25-75%) than in the general population, but many are of no special typeIpsilateral carcinomas may be more common in the first 5-10 years",
                    "sub_points": [
                      "The subsequent invasive carcinomas are 3x more likely to be ILC (~ 25-75%) than in the general population, but many are of no special type",
                      "Ipsilateral carcinomas may be more common in the first 5-10 years"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "C-LCIS is not specifically associated with mammographic findings but may involve areas of preexisting calcifications"
                  },
                  {
                    "text": "P-LCIS and F-LCIS are usually detected on mammography as calcifications in areas of necrosis ± a small mass"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "LCIS may be present in core needle biopsies for non-mass enhancement or for a mass"
                  },
                  {
                    "text": "However, it is difficult to know whether or not the LCIS was responsible for the enhancement"
                  },
                  {
                    "text": "Upgrades for C-LCIS on excision are low and are usually DCIS"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "LCIS does not form grossly apparent lesions"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "In the absence of data on the natural history of NC-LCIS, as well as long-term follow-up for the risk of recurrence, processing specimens and reporting results similar to DCIS can provide information to assist patients and clinicians to make informed decisions"
                  },
                  {
                    "text": "All grossly abnormal tissue and tissue corresponding to radiologic findings should be completely sampledWhen feasible, all fibrous tissue should be sampledThere is a high likelihood of finding foci of invasion",
                    "sub_points": [
                      "When feasible, all fibrous tissue should be sampled",
                      "There is a high likelihood of finding foci of invasion"
                    ]
                  },
                  {
                    "text": "Each margin should be sampled"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA Mutations": [
                  {
                    "text": "All types of LCISCDH1(E-cadherin) (> 80%),PIK3CA(~ 40%),CBFB(~ 12%)",
                    "sub_points": [
                      "CDH1(E-cadherin) (> 80%),PIK3CA(~ 40%),CBFB(~ 12%)"
                    ]
                  },
                  {
                    "text": "NC-LCISTP53(~ 30%)ERBB2(HER2)(~ 20-70%)More frequent in cases with apocrine featuresERBB3(HER3) (~ 20%)",
                    "sub_points": [
                      "TP53(~ 30%)",
                      "ERBB2(HER2)(~ 20-70%)More frequent in cases with apocrine features",
                      "More frequent in cases with apocrine features",
                      "ERBB3(HER3) (~ 20%)"
                    ]
                  }
                ],
                "DNA Copy Number Alterations": [
                  {
                    "text": "All types of LCISMost common changes are loss at 16q and gain at 1qAlso seen in the low-grade breast neoplasia familyLoss at 16q21-23.1 is the site ofCDH1(E-cadherin)",
                    "sub_points": [
                      "Most common changes are loss at 16q and gain at 1qAlso seen in the low-grade breast neoplasia familyLoss at 16q21-23.1 is the site ofCDH1(E-cadherin)",
                      "Also seen in the low-grade breast neoplasia family",
                      "Loss at 16q21-23.1 is the site ofCDH1(E-cadherin)"
                    ]
                  },
                  {
                    "text": "NC-LCISAmplification ofHER2(~ 15-40%)Mutations and amplifications are mutually exclusiveHER2alterations are more common in ER(-) lesionsAmplification ofCCND1(cyclin-D1) (~ 20-30%)",
                    "sub_points": [
                      "Amplification ofHER2(~ 15-40%)Mutations and amplifications are mutually exclusiveHER2alterations are more common in ER(-) lesions",
                      "Mutations and amplifications are mutually exclusive",
                      "HER2alterations are more common in ER(-) lesions",
                      "Amplification ofCCND1(cyclin-D1) (~ 20-30%)"
                    ]
                  }
                ],
                "Cell Adhesion": [
                  {
                    "text": "Loss of functional E-cadherin is due to combinations of mechanisms leading to biallelic inactivation ofCDH1In ILC, ~ 85% have aCDH1mutation combined with a deletion of the 2nd allele~ 7% have aCDH1mutation combined with hypermethylation of the promoter of the 2nd allele~ 7% do not have aCDH1mutationSome have promoter methylation of 1 allele and deletion of the other alleleSome have alterations of other genes, including α-catenin, p120 catenin, or AIN2",
                    "sub_points": [
                      "In ILC, ~ 85% have aCDH1mutation combined with a deletion of the 2nd allele",
                      "~ 7% have aCDH1mutation combined with hypermethylation of the promoter of the 2nd allele",
                      "~ 7% do not have aCDH1mutationSome have promoter methylation of 1 allele and deletion of the other alleleSome have alterations of other genes, including α-catenin, p120 catenin, or AIN2",
                      "Some have promoter methylation of 1 allele and deletion of the other allele",
                      "Some have alterations of other genes, including α-catenin, p120 catenin, or AIN2"
                    ]
                  },
                  {
                    "text": "Different combinations of alterations result in different patterns of immunoreactivity~ 85% have complete loss of E-cadherin~ 10% have aberrant patternsComplete but weak, incomplete and beaded, cytoplasmic, perinuclear in a dot-like pattern, or nuclear< 5% have compete membrane staining, but the protein is nonfunctionalHowever, a type of LCIS with retained E-cadherin positivity has not yet been definedAdditional studies may be helpful to support that adhesion is abnormalβ-catenin and α-catenin expression may be absentp120 catenin may localize to the cytoplasm",
                    "sub_points": [
                      "~ 85% have complete loss of E-cadherin",
                      "~ 10% have aberrant patternsComplete but weak, incomplete and beaded, cytoplasmic, perinuclear in a dot-like pattern, or nuclear",
                      "Complete but weak, incomplete and beaded, cytoplasmic, perinuclear in a dot-like pattern, or nuclear",
                      "< 5% have compete membrane staining, but the protein is nonfunctional",
                      "However, a type of LCIS with retained E-cadherin positivity has not yet been definedAdditional studies may be helpful to support that adhesion is abnormalβ-catenin and α-catenin expression may be absentp120 catenin may localize to the cytoplasm",
                      "Additional studies may be helpful to support that adhesion is abnormal",
                      "β-catenin and α-catenin expression may be absent",
                      "p120 catenin may localize to the cytoplasm"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Classic LCIS (C-LCIS)Monomorphic proliferation of small, dyscohesive cells2 types of nucleiType A cells: Nuclei are small to slightly enlarged (1-1.5x size of lymphocyte) with uniform round nuclei and inconspicuous nucleoliType B cells: Nuclei larger (2x size of lymphocyte), more abundant cytoplasm, and more prominent nucleoliType A and B cells often coexist in the same lesionThe criterion to distinguish LCIS from ALH is based on extentAt least 50% of acini in a lobular unit must be filled and distended (≤ 8 cells across)Involved lobules may be compared to uninvolved lobules to estimate degree of distentionMitotic activity is absent to exceedingly rareThere is generally a moderate amount of pale pink cytoplasmIntracytoplasmic vacuoles and signet-ring cells are variably present; may occasionally be prominentSpecial stains (PAS or mucicarmine) can be used to demonstrate cytoplasmic mucin vacuoles",
                    "sub_points": [
                      "Monomorphic proliferation of small, dyscohesive cells",
                      "2 types of nucleiType A cells: Nuclei are small to slightly enlarged (1-1.5x size of lymphocyte) with uniform round nuclei and inconspicuous nucleoliType B cells: Nuclei larger (2x size of lymphocyte), more abundant cytoplasm, and more prominent nucleoliType A and B cells often coexist in the same lesion",
                      "Type A cells: Nuclei are small to slightly enlarged (1-1.5x size of lymphocyte) with uniform round nuclei and inconspicuous nucleoli",
                      "Type B cells: Nuclei larger (2x size of lymphocyte), more abundant cytoplasm, and more prominent nucleoli",
                      "Type A and B cells often coexist in the same lesion",
                      "The criterion to distinguish LCIS from ALH is based on extentAt least 50% of acini in a lobular unit must be filled and distended (≤ 8 cells across)Involved lobules may be compared to uninvolved lobules to estimate degree of distention",
                      "At least 50% of acini in a lobular unit must be filled and distended (≤ 8 cells across)",
                      "Involved lobules may be compared to uninvolved lobules to estimate degree of distention",
                      "Mitotic activity is absent to exceedingly rare",
                      "There is generally a moderate amount of pale pink cytoplasm",
                      "Intracytoplasmic vacuoles and signet-ring cells are variably present; may occasionally be prominentSpecial stains (PAS or mucicarmine) can be used to demonstrate cytoplasmic mucin vacuoles",
                      "Special stains (PAS or mucicarmine) can be used to demonstrate cytoplasmic mucin vacuoles"
                    ]
                  },
                  {
                    "text": "Pleomorphic LCIS (P-LCIS; ~ 75% of cases of NC-LCIS)High nuclear grade: Some nuclei > 4x size of lymphocyteIrregular membranes, prominent nucleoliCan be multinucleatedVariation in nuclear size: ~ 2-3xNo requirement for extentLesions that do not completely fill or distend a lobule should be classified as P-LCIS rather than ALHApocrine features can be present (~ 20% of cases)Abundant eosinophilic, granular cytoplasmLarge, rounded nuclei with prominent nucleoliCentral necrosis with calcifications can be presentOften seen in cases with apocrine featuresMitoses may be present and frequentOften found as a contiguous focus surrounded by C-LCIS",
                    "sub_points": [
                      "High nuclear grade: Some nuclei > 4x size of lymphocyteIrregular membranes, prominent nucleoliCan be multinucleated",
                      "Irregular membranes, prominent nucleoli",
                      "Can be multinucleated",
                      "Variation in nuclear size: ~ 2-3x",
                      "No requirement for extentLesions that do not completely fill or distend a lobule should be classified as P-LCIS rather than ALH",
                      "Lesions that do not completely fill or distend a lobule should be classified as P-LCIS rather than ALH",
                      "Apocrine features can be present (~ 20% of cases)Abundant eosinophilic, granular cytoplasmLarge, rounded nuclei with prominent nucleoli",
                      "Abundant eosinophilic, granular cytoplasm",
                      "Large, rounded nuclei with prominent nucleoli",
                      "Central necrosis with calcifications can be presentOften seen in cases with apocrine features",
                      "Often seen in cases with apocrine features",
                      "Mitoses may be present and frequent",
                      "Often found as a contiguous focus surrounded by C-LCIS"
                    ]
                  },
                  {
                    "text": "Florid LCIS (F-LCIS; ~ 25% of cases of NC-LCIS)The cells have the same appearance as C-LCISIf significant nuclear atypia is present, the lesion should be classified as P-LCISThe involved spaces are markedly distended (at least 40-50 cells across)Multiple spaces are usually involved with little to no intervening stromaCentral necrosis and calcifications may be present (~ 60% of cases)Typically found as a contiguous focus with C-LCIS at the periphery",
                    "sub_points": [
                      "The cells have the same appearance as C-LCISIf significant nuclear atypia is present, the lesion should be classified as P-LCIS",
                      "If significant nuclear atypia is present, the lesion should be classified as P-LCIS",
                      "The involved spaces are markedly distended (at least 40-50 cells across)",
                      "Multiple spaces are usually involved with little to no intervening stroma",
                      "Central necrosis and calcifications may be present (~ 60% of cases)",
                      "Typically found as a contiguous focus with C-LCIS at the periphery"
                    ]
                  },
                  {
                    "text": "Myoepithelial cellsIn any subtype, myoepithelial cells are often seen in an abnormal location above the basement membraneThis is more common in LCIS than in DCIS and can be a clue that a low-grade lesion is LCIS",
                    "sub_points": [
                      "In any subtype, myoepithelial cells are often seen in an abnormal location above the basement membrane",
                      "This is more common in LCIS than in DCIS and can be a clue that a low-grade lesion is LCIS"
                    ]
                  },
                  {
                    "text": "Pagetoid spreadPagetoid spread in ducts (growth of cells between luminal and myoepithelial layers) may be presentDuctal involvement can give cloverleaf patternCan be seen with any subtypeInvolvement of nipple skin by LCIS has not been clearly demonstratedSingle cells in the epidermis adjacent to duct orifices are likely Toker cellsLCIS can involve lactiferous ducts but usually does not extend to the epidermis",
                    "sub_points": [
                      "Pagetoid spread in ducts (growth of cells between luminal and myoepithelial layers) may be presentDuctal involvement can give cloverleaf pattern",
                      "Ductal involvement can give cloverleaf pattern",
                      "Can be seen with any subtype",
                      "Involvement of nipple skin by LCIS has not been clearly demonstratedSingle cells in the epidermis adjacent to duct orifices are likely Toker cellsLCIS can involve lactiferous ducts but usually does not extend to the epidermis",
                      "Single cells in the epidermis adjacent to duct orifices are likely Toker cells",
                      "LCIS can involve lactiferous ducts but usually does not extend to the epidermis"
                    ]
                  },
                  {
                    "text": "Difficult to classify LCISSome cases are difficult to classify into the 3 subtypesCentral necrosis but insufficient features for P-LCIS or F-LCISIf detected on core needle biopsy, excision should be performed, as this is not incidental LCISUnusual abundant cytoplasmic changes: Apocrine, histiocytoid, clear, foamyNuclear pleomorphism but insufficient for P-LCISIt is suggested to classify these cases as C-LCIS but with the unusual features noted",
                    "sub_points": [
                      "Some cases are difficult to classify into the 3 subtypesCentral necrosis but insufficient features for P-LCIS or F-LCISIf detected on core needle biopsy, excision should be performed, as this is not incidental LCISUnusual abundant cytoplasmic changes: Apocrine, histiocytoid, clear, foamyNuclear pleomorphism but insufficient for P-LCIS",
                      "Central necrosis but insufficient features for P-LCIS or F-LCISIf detected on core needle biopsy, excision should be performed, as this is not incidental LCIS",
                      "If detected on core needle biopsy, excision should be performed, as this is not incidental LCIS",
                      "Unusual abundant cytoplasmic changes: Apocrine, histiocytoid, clear, foamy",
                      "Nuclear pleomorphism but insufficient for P-LCIS",
                      "It is suggested to classify these cases as C-LCIS but with the unusual features noted"
                    ]
                  },
                  {
                    "text": "LCIS and atypical ductal hyperplasia (ADH)LCIS and ADH in the same space can mimic DCISLCIS provides a monomorphic population; ADH provides architectural complexity and atypiaE-cadherin helps identify 2 separate populations",
                    "sub_points": [
                      "LCIS and ADH in the same space can mimic DCIS",
                      "LCIS provides a monomorphic population; ADH provides architectural complexity and atypia",
                      "E-cadherin helps identify 2 separate populations"
                    ]
                  },
                  {
                    "text": "LCIS and collagenous spherulosis (CS)LCIS in CS can closely mimic DCISLCIS provides a monomorphic population, and CS provides cribriform spacesE-cadherin identifies LCISp63 identifies myoepithelial cells lining the spaces that are filled with basement membrane-like material",
                    "sub_points": [
                      "LCIS in CS can closely mimic DCIS",
                      "LCIS provides a monomorphic population, and CS provides cribriform spaces",
                      "E-cadherin identifies LCIS",
                      "p63 identifies myoepithelial cells lining the spaces that are filled with basement membrane-like material"
                    ]
                  },
                  {
                    "text": "LCIS in sclerosing adenosis (SA)LCIS in SA can closely mimic invasive carcinomaBack to back glands, a rounded border, and the absence of infiltration around normal epithelial strongly suggest SAMultiplex IHC studies for keratin and myoepithelial markers are the most helpful to evaluate the possibility of invasive carcinoma",
                    "sub_points": [
                      "LCIS in SA can closely mimic invasive carcinoma",
                      "Back to back glands, a rounded border, and the absence of infiltration around normal epithelial strongly suggest SA",
                      "Multiplex IHC studies for keratin and myoepithelial markers are the most helpful to evaluate the possibility of invasive carcinoma"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "C-LCIS: If LCIS is an incidental finding and there is good radiologic/pathologic correlation, the risk of finding invasive carcinoma on excision is very low (< 5 %)Cancers are typically small, low-grade invasive carcinomas or DCISExcision is generally not recommended",
                    "sub_points": [
                      "Cancers are typically small, low-grade invasive carcinomas or DCIS",
                      "Excision is generally not recommended"
                    ]
                  },
                  {
                    "text": "F-LCIS and P-LCIS: Excision is recommended because the risk of an upgrade is high (> 40%)P-LCIS and F-LCIS are usually the source of the imaging finding and not incidentalThe most common finding is calcifications (~ 80%) followed by small masses",
                    "sub_points": [
                      "P-LCIS and F-LCIS are usually the source of the imaging finding and not incidental",
                      "The most common finding is calcifications (~ 80%) followed by small masses"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "E-cadherin> 95% of cases of LCIS show complete absence of E-cadherinNot required or recommended for diagnosis if a lesion has classic morphologic featuresβ-catenin and α-catenin are typically also lost, and p120 shows cytoplasmic positivityIn lesions with intermingled nonneoplastic cells, their cadherin positivity can make interpretation difficultE-cadherin is positive in luminal cells, and myoepithelial cells show weaker positivity due to cross reaction with P-cadherin~ 5-10% of cases show aberrant patternsDot-like discontinuous weak membrane staining or patchy cytoplasmic positivity may be seenOverstaining can lead to a false-positive resultStaining results should always be interpreted in the context of morphologic findingsIn cases with dyscohesive morphology but E-cadherin positivity, IHC for other cell adhesion proteins may help support the correct diagnosisThe most common abnormal finding is aberrant cytoplasmic localization of p120 cateninIn some cases, p120 staining can be seen in the nucleusThe pattern of p120 staining can be difficult to interpret if LCIS is intermingled with residual luminal and myoepithelial cells",
                    "sub_points": [
                      "> 95% of cases of LCIS show complete absence of E-cadherinNot required or recommended for diagnosis if a lesion has classic morphologic featuresβ-catenin and α-catenin are typically also lost, and p120 shows cytoplasmic positivityIn lesions with intermingled nonneoplastic cells, their cadherin positivity can make interpretation difficultE-cadherin is positive in luminal cells, and myoepithelial cells show weaker positivity due to cross reaction with P-cadherin",
                      "Not required or recommended for diagnosis if a lesion has classic morphologic features",
                      "β-catenin and α-catenin are typically also lost, and p120 shows cytoplasmic positivity",
                      "In lesions with intermingled nonneoplastic cells, their cadherin positivity can make interpretation difficultE-cadherin is positive in luminal cells, and myoepithelial cells show weaker positivity due to cross reaction with P-cadherin",
                      "E-cadherin is positive in luminal cells, and myoepithelial cells show weaker positivity due to cross reaction with P-cadherin",
                      "~ 5-10% of cases show aberrant patternsDot-like discontinuous weak membrane staining or patchy cytoplasmic positivity may be seenOverstaining can lead to a false-positive resultStaining results should always be interpreted in the context of morphologic findings",
                      "Dot-like discontinuous weak membrane staining or patchy cytoplasmic positivity may be seen",
                      "Overstaining can lead to a false-positive result",
                      "Staining results should always be interpreted in the context of morphologic findings",
                      "In cases with dyscohesive morphology but E-cadherin positivity, IHC for other cell adhesion proteins may help support the correct diagnosisThe most common abnormal finding is aberrant cytoplasmic localization of p120 cateninIn some cases, p120 staining can be seen in the nucleusThe pattern of p120 staining can be difficult to interpret if LCIS is intermingled with residual luminal and myoepithelial cells",
                      "The most common abnormal finding is aberrant cytoplasmic localization of p120 cateninIn some cases, p120 staining can be seen in the nucleusThe pattern of p120 staining can be difficult to interpret if LCIS is intermingled with residual luminal and myoepithelial cells",
                      "In some cases, p120 staining can be seen in the nucleus",
                      "The pattern of p120 staining can be difficult to interpret if LCIS is intermingled with residual luminal and myoepithelial cells"
                    ]
                  },
                  {
                    "text": "High molecular weight cytokeratins~ 80% of LCIS show weak to moderate 34βE12 positivity (cytokeratins 1, 5, 10, and 14) in a cytoplasmic perinuclear patternPositivity is also seen in a subset of DCIS and therefore has limited usefulness for diagnosisMajority of DCIS and LCIS are negative for cytokeratins 5 and 6; usual ductal hyperplasia typically shows positivityLCIS can partially involve ducts with residual normal luminal cells, which can make interpretation difficult",
                    "sub_points": [
                      "~ 80% of LCIS show weak to moderate 34βE12 positivity (cytokeratins 1, 5, 10, and 14) in a cytoplasmic perinuclear patternPositivity is also seen in a subset of DCIS and therefore has limited usefulness for diagnosis",
                      "Positivity is also seen in a subset of DCIS and therefore has limited usefulness for diagnosis",
                      "Majority of DCIS and LCIS are negative for cytokeratins 5 and 6; usual ductal hyperplasia typically shows positivityLCIS can partially involve ducts with residual normal luminal cells, which can make interpretation difficult",
                      "LCIS can partially involve ducts with residual normal luminal cells, which can make interpretation difficult"
                    ]
                  },
                  {
                    "text": "ER and PRC-LCIS and F-LCIS: > 95% positivityNot usually evaluated on a clinical basisP-LCIS: ~ 60-80% positive (~ 40% if apocrine)Because there is limited information on ER(-) NC-LCIS, reporting ER status can be helpful for patients and clinicians in decision making",
                    "sub_points": [
                      "C-LCIS and F-LCIS: > 95% positivityNot usually evaluated on a clinical basis",
                      "Not usually evaluated on a clinical basis",
                      "P-LCIS: ~ 60-80% positive (~ 40% if apocrine)",
                      "Because there is limited information on ER(-) NC-LCIS, reporting ER status can be helpful for patients and clinicians in decision making"
                    ]
                  },
                  {
                    "text": "AR> 95% positivity",
                    "sub_points": [
                      "> 95% positivity"
                    ]
                  },
                  {
                    "text": "HER2C-LCIS: NegativeWeak edge enhancement can mimic true immunoreactivityP-LCIS and F-LCIS: 15-40% positive, particularly in those with apocrine appearance",
                    "sub_points": [
                      "C-LCIS: NegativeWeak edge enhancement can mimic true immunoreactivity",
                      "Weak edge enhancement can mimic true immunoreactivity",
                      "P-LCIS and F-LCIS: 15-40% positive, particularly in those with apocrine appearance"
                    ]
                  },
                  {
                    "text": "GCDFP-15C-LCIS: > 90% positiveP-LCIS and F-LCIS: 10-40% positive (higher if apocrine)",
                    "sub_points": [
                      "C-LCIS: > 90% positive",
                      "P-LCIS and F-LCIS: 10-40% positive (higher if apocrine)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "ALH": [
                  {
                    "text": "Cytologically identical to LCIS and negative for E-cadherin"
                  },
                  {
                    "text": "Defined by its limited extentNeoplastic cells only partially fill lobular acini with residual lumina presentNumber of distended acini per lobule is < 50%",
                    "sub_points": [
                      "Neoplastic cells only partially fill lobular acini with residual lumina present",
                      "Number of distended acini per lobule is < 50%"
                    ]
                  },
                  {
                    "text": "Distinction from LCIS is subjective but important for risk stratificationALH alone confers a lower 4-5x relative increased risk of invasive carcinoma compared to LCIS",
                    "sub_points": [
                      "ALH alone confers a lower 4-5x relative increased risk of invasive carcinoma compared to LCIS"
                    ]
                  }
                ],
                "DCIS, Solid Pattern": [
                  {
                    "text": "DCIS with a solid pattern can closely resemble LCIS"
                  },
                  {
                    "text": "Cribriform spaces, papillae, or micropapillae require cell adhesion and are only seen with DCIS"
                  },
                  {
                    "text": "In difficult cases, IHC to demonstrate the presence of E-cadherin can be helpful"
                  }
                ],
                "Invasive Carcinoma Mimicking LCIS": [
                  {
                    "text": "Alveolar or solid ILC can be difficult to distinguish from LCISIHC studies can be used to confirm the absence of myoepithelial cells",
                    "sub_points": [
                      "IHC studies can be used to confirm the absence of myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Rare metastatic tumors, such as carcinoid, can also mimic LCIS"
                  }
                ],
                "Artifacts Leading to Cellular Dyscohesion": [
                  {
                    "text": "Poor preservation or crushing can result in rounding up of cells and loss of cohesion, which mimics LCISUsually occurs at the edge of specimens or in specimens that have not been well fixedOnly single cell layer typically presentLCIS or ALH should not be diagnosed unless cells are well preserved",
                    "sub_points": [
                      "Usually occurs at the edge of specimens or in specimens that have not been well fixedOnly single cell layer typically present",
                      "Only single cell layer typically present",
                      "LCIS or ALH should not be diagnosed unless cells are well preserved"
                    ]
                  }
                ],
                "Benign Cells": [
                  {
                    "text": "Prominent myoepithelial cells with clear cytoplasm can mimic pagetoid spread by LCISThese cells will not be increased in numberSimilar changes in myoepithelial cells are typically seen throughout specimenIHC for myoepithelial markers can be helpful in problematic cases",
                    "sub_points": [
                      "These cells will not be increased in number",
                      "Similar changes in myoepithelial cells are typically seen throughout specimen",
                      "IHC for myoepithelial markers can be helpful in problematic cases"
                    ]
                  },
                  {
                    "text": "Histiocytic infiltration into large ducts can mimic pagetoid spread by LCISHistiocytes typically have abundant cytoplasm and small nucleiIHC for histiocytic markers can be helpful in problematic cases",
                    "sub_points": [
                      "Histiocytes typically have abundant cytoplasm and small nuclei",
                      "IHC for histiocytic markers can be helpful in problematic cases"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "IHC is not required for the diagnosis of C-LCIS"
                  },
                  {
                    "text": "LCIS involving other lesions can be mistaken for invasive carcinoma or DCIS"
                  },
                  {
                    "text": "Finding dyscohesive growth, lack of microacinar formation, and signet-ring cells in a solid intraductal proliferation should raise the possibility of LCIS"
                  }
                ]
              },
              "REPORTING": {
                "Protocols": [
                  {
                    "text": "There is general agreement that the extent and margins for C-LCIS need not be reported"
                  },
                  {
                    "text": "There is not a current consensus on reporting NC-LCISProviding information similar to that provided for DCIS may be advisable to assist clinicians and patients in making informed decisions",
                    "sub_points": [
                      "Providing information similar to that provided for DCIS may be advisable to assist clinicians and patients in making informed decisions"
                    ]
                  },
                  {
                    "text": "College of American Pathologists (CAP) cancer protocol templatesNC-LCIS is not included as a reporting element in the breast cancer templates",
                    "sub_points": [
                      "NC-LCIS is not included as a reporting element in the breast cancer templates"
                    ]
                  },
                  {
                    "text": "International Collaboration on Cancer Reporting (ICCR)Recommends reporting NC-LCIS, including size and distance to margins",
                    "sub_points": [
                      "Recommends reporting NC-LCIS, including size and distance to margins"
                    ]
                  },
                  {
                    "text": "World Health Organization (WHO)Recommends reporting margins for P-LCIS and F-LCIS",
                    "sub_points": [
                      "Recommends reporting margins for P-LCIS and F-LCIS"
                    ]
                  }
                ],
                "Cancer Staging": [
                  {
                    "text": "Union for International Cancer Control (UICC) TNM classification(8th edition, 2017)Continues to recommend that LCIS be classified as pTis",
                    "sub_points": [
                      "Continues to recommend that LCIS be classified as pTis"
                    ]
                  },
                  {
                    "text": "American Joint Committee on Cancer (AJCC) TNM classification(8th edition, 2017)LCIS (including C-LCIS, P-LCIS, and F-LCIS) is no longer staged as TisThe reason provided is that \"LCIS is a benign condition and is not treated as a carcinoma. It is properly considered a proliferative disease with associated risk for developing a breast cancer in the future and, therefore, is no longer included in this cancer staging system.\"This recommendation was not based on any new understanding of the biology of LCIS",
                    "sub_points": [
                      "LCIS (including C-LCIS, P-LCIS, and F-LCIS) is no longer staged as Tis",
                      "The reason provided is that \"LCIS is a benign condition and is not treated as a carcinoma. It is properly considered a proliferative disease with associated risk for developing a breast cancer in the future and, therefore, is no longer included in this cancer staging system.\"",
                      "This recommendation was not based on any new understanding of the biology of LCIS"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ductal Carcinoma In Situ": {
            "name": "Ductal Carcinoma In Situ",
            "url": "https://app.pathprimer.com/document/907275d8-8971-4709-b7c1-1d01f83eb50d/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {
              "KEY FACTS": {
                "Classification": [
                  {
                    "text": "Ductal carcinoma in situ (DCIS) is a clonal proliferation of epithelial cells confined to the ductal/lobular system"
                  },
                  {
                    "text": "The same genomic changes found in invasive carcinoma are also found in DCIS"
                  },
                  {
                    "text": "Diagnosis can be difficult due to a number of factorsLarge number of morphologic patternsGrade ranging from low to highSpectrum of biologic changes in single lesionsHistologic mimics",
                    "sub_points": [
                      "Large number of morphologic patterns",
                      "Grade ranging from low to high",
                      "Spectrum of biologic changes in single lesions",
                      "Histologic mimics"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Majority detected due to calcifications on mammographic screening"
                  },
                  {
                    "text": "Less commonly presents as nipple discharge, Paget disease of nipple, or palpable mass"
                  },
                  {
                    "text": "Usually treated with complete excision of lesion ± radiation ± tamoxifen"
                  },
                  {
                    "text": "Surveillance rather than treatment may be appropriate for limited in extent, low-grade lesions"
                  },
                  {
                    "text": "Prognosis is excellent: > 95% survivalWith treatment, recurrence is < 10%If untreated, ~ 1% of patients per year develop invasive carcinoma at same site",
                    "sub_points": [
                      "With treatment, recurrence is < 10%",
                      "If untreated, ~ 1% of patients per year develop invasive carcinoma at same site"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Usual ductal hyperplasia"
                  },
                  {
                    "text": "Nonsclerosing lymphocytic lobulitis"
                  },
                  {
                    "text": "Gynecomastoid hyperplasia"
                  },
                  {
                    "text": "Collagenous spherulosis"
                  },
                  {
                    "text": "Radiation atypia"
                  },
                  {
                    "text": "Atypical ductal hyperplasia"
                  },
                  {
                    "text": "Lobular carcinoma in situ"
                  },
                  {
                    "text": "Invasive carcinoma"
                  },
                  {
                    "text": "Lymphovascular invasion"
                  },
                  {
                    "text": "Chest wall recurrence of invasive carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Ductal carcinoma in situ (DCIS)"
                  },
                  {
                    "text": "Lobular carcinoma in situ (LCIS)"
                  },
                  {
                    "text": "Atypical ductal hyperplasia (ADH)"
                  },
                  {
                    "text": "Flat epithelial atypia (FEA)"
                  },
                  {
                    "text": "Usual ductal hyperplasia (UDH)"
                  },
                  {
                    "text": "Invasive breast carcinoma (IBC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Intraductal carcinoma (IDC)Not recommended as an abbreviation, as it can be confused with invasive ductal carcinoma",
                    "sub_points": [
                      "Not recommended as an abbreviation, as it can be confused with invasive ductal carcinoma"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "A clonal neoplastic proliferation of epithelial cells confined to ducts and lobules"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "DCIS describes clonal proliferations of tumor cells that share the same biologic changes also present in IBCs"
                  },
                  {
                    "text": "However, unlike IBC, DCIS is confined to the ductal/lobular system by the basement membrane, usually lined by an intact layer of myoepithelial cells"
                  },
                  {
                    "text": "The majority of cases of DCIS, especially low-grade lesions, do not progress to invasion during the patients' lifetimes"
                  },
                  {
                    "text": "For those that do progress, the underlying reasons are likely multifactorialGene expression changes in the surrounding myoepithelial and stromal cells may impact the capacity of these cells to maintain the basement membraneMyoepithelial cells associated with DCIS may be reduced in number, can be in an abnormal location above the basement membrane, and may have aberrant expression of proteinsChanges in the microenvironment, particularly in regard to tumor-infiltrating lymphocytes, may be permissive for invasion",
                    "sub_points": [
                      "Gene expression changes in the surrounding myoepithelial and stromal cells may impact the capacity of these cells to maintain the basement membraneMyoepithelial cells associated with DCIS may be reduced in number, can be in an abnormal location above the basement membrane, and may have aberrant expression of proteins",
                      "Myoepithelial cells associated with DCIS may be reduced in number, can be in an abnormal location above the basement membrane, and may have aberrant expression of proteins",
                      "Changes in the microenvironment, particularly in regard to tumor-infiltrating lymphocytes, may be permissive for invasion"
                    ]
                  },
                  {
                    "text": "The acquisition of genetic changes in the tumor cells has not been identified as a main determinant of invasionDCIS and IBC have similar patterns, and genomic studies cannot distinguish between themDCIS can only be diagnosed by morphologic examination",
                    "sub_points": [
                      "DCIS and IBC have similar patterns, and genomic studies cannot distinguish between them",
                      "DCIS can only be diagnosed by morphologic examination"
                    ]
                  },
                  {
                    "text": "DCIS adjacent to IBC typically shares many, but not all, genomic changes with the IBCThese findings support that all grades of DCIS can be direct precursors to IBCDCIS is not thought to pass through a progression of low- to high-grade DCIS before progressing to invasionGenomic diversity can occur in DCIS, and associated IBC may consist of a subclone of the tumor cellsThe most common example is HER2(+) DCIS associated with HER2(-) IBC",
                    "sub_points": [
                      "These findings support that all grades of DCIS can be direct precursors to IBCDCIS is not thought to pass through a progression of low- to high-grade DCIS before progressing to invasion",
                      "DCIS is not thought to pass through a progression of low- to high-grade DCIS before progressing to invasion",
                      "Genomic diversity can occur in DCIS, and associated IBC may consist of a subclone of the tumor cellsThe most common example is HER2(+) DCIS associated with HER2(-) IBC",
                      "The most common example is HER2(+) DCIS associated with HER2(-) IBC"
                    ]
                  }
                ],
                "Precursor Lesions for DCIS": [
                  {
                    "text": "Flat epithelial atypia (FEA) and atypical ductal hyperplasia (ADH) are thought to be nonobligate precursors of low- to intermediate-grade DCISThese lesions have losses at 16q and gains at 1q that are also found in DCIS as well as in other members of the low-grade breast neoplasia pathway",
                    "sub_points": [
                      "These lesions have losses at 16q and gains at 1q that are also found in DCIS as well as in other members of the low-grade breast neoplasia pathway"
                    ]
                  },
                  {
                    "text": "FEA, ADH, and low-/intermediate-grade DCIS strongly express ER (~ 70-80%)Typically, almost all tumor cells show strong expressionEstrogen likely stimulates proliferation and plays a role in pathogenesis and progression",
                    "sub_points": [
                      "Typically, almost all tumor cells show strong expression",
                      "Estrogen likely stimulates proliferation and plays a role in pathogenesis and progression"
                    ]
                  },
                  {
                    "text": "A precursor lesion for high-grade DCIS has not been identifiedSome cases of high-grade DCIS are ER(-)Increased genomic alterations are associated with increasing nuclear gradeHigh-grade DCIS shows marked inter- and intratumoral heterogeneity and is most likely part of distinct and separate pathway to neoplasia",
                    "sub_points": [
                      "Some cases of high-grade DCIS are ER(-)",
                      "Increased genomic alterations are associated with increasing nuclear grade",
                      "High-grade DCIS shows marked inter- and intratumoral heterogeneity and is most likely part of distinct and separate pathway to neoplasia"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "The true incidence of DCIS is unknown because not all cases can be detected clinically or by screeningDCIS is present in ~ 10-15% of women at autopsy, but this is an underestimate as only a small amount of tissue is examined",
                    "sub_points": [
                      "DCIS is present in ~ 10-15% of women at autopsy, but this is an underestimate as only a small amount of tissue is examined"
                    ]
                  },
                  {
                    "text": "DCIS comprises < 5% of breast carcinomas (BCs) in populations without mammographic screeningOnly rare cases of DCIS presenting clinically as a palpable mass or nipple discharge are diagnosed",
                    "sub_points": [
                      "Only rare cases of DCIS presenting clinically as a palpable mass or nipple discharge are diagnosed"
                    ]
                  },
                  {
                    "text": "DCIS comprises 20-30% of BCs detected by mammographic screeningThe majority are detected as mammographic calcifications",
                    "sub_points": [
                      "The majority are detected as mammographic calcifications"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "In screened populations, incidence increases ~ 2x from age 40-80 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Very rare in menInvolves large retroareolar ducts and typically presents as nipple discharge",
                    "sub_points": [
                      "Involves large retroareolar ducts and typically presents as nipple discharge"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "~ 90% of cases of DCIS are detected by mammographic screening"
                  },
                  {
                    "text": "< 5% are detected as a palpable mass or nipple discharge"
                  },
                  {
                    "text": "< 1% are detected as Paget disease of nipple (eczematous scale crust of the skin)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "The risk of developing IBC is modified by treatmentComplete excision with negative margins &/or radiation therapy &/or hormonal therapy reduces risk to < 10%~ 1/2 of recurrences are DCIS, and 1/2 are IBCRisk of recurrence after mastectomy is < 5%Local recurrence may be due to breast tissue left behind in chest wallSome recurrences are true recurrences (related to DCIS), and some are new primary carcinomasRisk of contralateral IBC is ~ 1/2 the risk for ipsilateral IBC20-30% of subsequent breast cancer deaths are from contralateral IBCSuggests 1/2 of ipsilateral IBCs may be due to new primary IBCsMay explain why surgery with wide margins without radiation therapy does not eliminate the possibility of subsequent IBC in the same breast",
                    "sub_points": [
                      "Complete excision with negative margins &/or radiation therapy &/or hormonal therapy reduces risk to < 10%~ 1/2 of recurrences are DCIS, and 1/2 are IBC",
                      "~ 1/2 of recurrences are DCIS, and 1/2 are IBC",
                      "Risk of recurrence after mastectomy is < 5%Local recurrence may be due to breast tissue left behind in chest wall",
                      "Local recurrence may be due to breast tissue left behind in chest wall",
                      "Some recurrences are true recurrences (related to DCIS), and some are new primary carcinomasRisk of contralateral IBC is ~ 1/2 the risk for ipsilateral IBC20-30% of subsequent breast cancer deaths are from contralateral IBCSuggests 1/2 of ipsilateral IBCs may be due to new primary IBCsMay explain why surgery with wide margins without radiation therapy does not eliminate the possibility of subsequent IBC in the same breast",
                      "Risk of contralateral IBC is ~ 1/2 the risk for ipsilateral IBC20-30% of subsequent breast cancer deaths are from contralateral IBC",
                      "20-30% of subsequent breast cancer deaths are from contralateral IBC",
                      "Suggests 1/2 of ipsilateral IBCs may be due to new primary IBCsMay explain why surgery with wide margins without radiation therapy does not eliminate the possibility of subsequent IBC in the same breast",
                      "May explain why surgery with wide margins without radiation therapy does not eliminate the possibility of subsequent IBC in the same breast"
                    ]
                  },
                  {
                    "text": "Neoadjuvant chemotherapy (NAT)For IBCs associated with DCIS on the initial core needle biopsy, in ~ 40% of cases, there is no residual DCIS after NATThe highest response rate is for HER2(+) DCIS (~ 50%)Absence of DCIS is higher when there has been a pathologic complete response for the IBCThis demonstrates that DCIS can respond to chemotherapy, which could modify surgical planning after NATFor example, although calcifications associated with DCIS remain after NAT, viable DCIS may not be present",
                    "sub_points": [
                      "For IBCs associated with DCIS on the initial core needle biopsy, in ~ 40% of cases, there is no residual DCIS after NATThe highest response rate is for HER2(+) DCIS (~ 50%)Absence of DCIS is higher when there has been a pathologic complete response for the IBC",
                      "The highest response rate is for HER2(+) DCIS (~ 50%)",
                      "Absence of DCIS is higher when there has been a pathologic complete response for the IBC",
                      "This demonstrates that DCIS can respond to chemotherapy, which could modify surgical planning after NATFor example, although calcifications associated with DCIS remain after NAT, viable DCIS may not be present",
                      "For example, although calcifications associated with DCIS remain after NAT, viable DCIS may not be present"
                    ]
                  },
                  {
                    "text": "SurveillanceMultiple ongoing trials are evaluated using surveillance rather than excision and radiation therapy for patients with good prognosis DCISThe patients may or may not receive tamoxifenLow-risk DCIS is generally defined as presenting as calcifications (without symptoms) and with non-high-grade nucleiHowever, diagnostic concordance among pathologists for nuclear grade can be difficult to achieve~ 6-24% of women eligible for these studies will likely have undiagnosed IBCThese IBCs are usually small and well differentiatedThe endpoint of these trials is the diagnosis of IBC during follow-up",
                    "sub_points": [
                      "Multiple ongoing trials are evaluated using surveillance rather than excision and radiation therapy for patients with good prognosis DCISThe patients may or may not receive tamoxifen",
                      "The patients may or may not receive tamoxifen",
                      "Low-risk DCIS is generally defined as presenting as calcifications (without symptoms) and with non-high-grade nucleiHowever, diagnostic concordance among pathologists for nuclear grade can be difficult to achieve",
                      "However, diagnostic concordance among pathologists for nuclear grade can be difficult to achieve",
                      "~ 6-24% of women eligible for these studies will likely have undiagnosed IBCThese IBCs are usually small and well differentiated",
                      "These IBCs are usually small and well differentiated",
                      "The endpoint of these trials is the diagnosis of IBC during follow-up"
                    ]
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "Surgery is used to attempt to remove the area of breast tissue involved by DCIS"
                  },
                  {
                    "text": "Risk of recurrence is lower if DCIS is ≥ 0.2 cm from margins"
                  },
                  {
                    "text": "Lymph node biopsy is not necessary in the majority of cases if IBC is unlikelyIBC on excision is more likely if the presentation is as a palpable mass, there is extensive high-grade DCIS, or the patient is youngIf a macrometastasis is found, it is highly likely there is an undetected area of invasionAdditional sampling should be considered",
                    "sub_points": [
                      "IBC on excision is more likely if the presentation is as a palpable mass, there is extensive high-grade DCIS, or the patient is young",
                      "If a macrometastasis is found, it is highly likely there is an undetected area of invasionAdditional sampling should be considered",
                      "Additional sampling should be considered"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Tamoxifen reduces recurrence of ER(+) DCIS by ~ 30-50% but does not improve survival over the already high survival rate (98% at 10 years)"
                  }
                ],
                "Radiation": [
                  {
                    "text": "Radiation therapy reduces recurrence by ~ 50% but does not improve survival"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Patients with DCIS undergoing standard of care treatment have an excellent prognosis"
                  },
                  {
                    "text": "The risk of dying of breast cancer is < 5% at 20 yearsThe death rate from all causes for women with DCIS is lower than that for women without BCMajority of women with DCIS have had mammograms and therefore access to medical careMany women in the general population may not have similar access and therefore have a higher death rate than women with DCISIt is difficult to improve the already excellent survival by additional treatmentThe causes of breast cancer-related death after a diagnosis of DCIS are difficult to study because this event is so rareSome are due to subsequent ipsilateral or contralateral IBCSome may be due to undetected IBC at the time of DCIS diagnosis",
                    "sub_points": [
                      "The death rate from all causes for women with DCIS is lower than that for women without BCMajority of women with DCIS have had mammograms and therefore access to medical careMany women in the general population may not have similar access and therefore have a higher death rate than women with DCISIt is difficult to improve the already excellent survival by additional treatment",
                      "Majority of women with DCIS have had mammograms and therefore access to medical careMany women in the general population may not have similar access and therefore have a higher death rate than women with DCIS",
                      "Many women in the general population may not have similar access and therefore have a higher death rate than women with DCIS",
                      "It is difficult to improve the already excellent survival by additional treatment",
                      "The causes of breast cancer-related death after a diagnosis of DCIS are difficult to study because this event is so rareSome are due to subsequent ipsilateral or contralateral IBCSome may be due to undetected IBC at the time of DCIS diagnosis",
                      "Some are due to subsequent ipsilateral or contralateral IBC",
                      "Some may be due to undetected IBC at the time of DCIS diagnosis"
                    ]
                  },
                  {
                    "text": "Prognosis is diminished for women who recur with IBCWomen with untreated DCIS have an 8-10x increased relative risk of developing IBCCorresponds to ~ 1% of patients per year (or ~ 20-30% with IBC at 20-30 years)The majority of subsequent IBCs are detected early and are small with negative nodes",
                    "sub_points": [
                      "Women with untreated DCIS have an 8-10x increased relative risk of developing IBCCorresponds to ~ 1% of patients per year (or ~ 20-30% with IBC at 20-30 years)",
                      "Corresponds to ~ 1% of patients per year (or ~ 20-30% with IBC at 20-30 years)",
                      "The majority of subsequent IBCs are detected early and are small with negative nodes"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "20-30% of screen-detected cancers are DCIS"
                  },
                  {
                    "text": "Calcifications (85%)20-30% of biopsies for suspicious calcifications will reveal DCISCalcifications show clusters, linear and branching distribution, large number, small size, irregular or pleomorphic shape, &/or increasing number over timeExtent of DCIS is generally greater than that suggested by distribution of calcifications",
                    "sub_points": [
                      "20-30% of biopsies for suspicious calcifications will reveal DCIS",
                      "Calcifications show clusters, linear and branching distribution, large number, small size, irregular or pleomorphic shape, &/or increasing number over time",
                      "Extent of DCIS is generally greater than that suggested by distribution of calcifications"
                    ]
                  },
                  {
                    "text": "Radiologic density (10%)Usually associated with extensive high-grade DCIS, periductal stromal fibrosis, or DCIS involving other benign lesions",
                    "sub_points": [
                      "Usually associated with extensive high-grade DCIS, periductal stromal fibrosis, or DCIS involving other benign lesions"
                    ]
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Majority of cases of DCIS are associated with enhancementAlthough sensitive, findings are not specific enough for MR to be used for screening general population",
                    "sub_points": [
                      "Although sensitive, findings are not specific enough for MR to be used for screening general population"
                    ]
                  },
                  {
                    "text": "Most common pattern is linear clumped enhancementDCIS is typically surrounded by a collarette of small capillariesAssociated increased blood flow is detected by MR",
                    "sub_points": [
                      "DCIS is typically surrounded by a collarette of small capillaries",
                      "Associated increased blood flow is detected by MR"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Most cases of DCIS cannot be seen or palpated grosslyExtensive sampling is necessary to determine extent and margins",
                    "sub_points": [
                      "Extensive sampling is necessary to determine extent and margins"
                    ]
                  },
                  {
                    "text": "Minority (generally high grade) produce gross lesionsMasses due to periductal fibrosis usually form an ill-defined firm area without discrete bordersColor may be gray and texture grittyComedo-type necrosis can be seen as minute extruded plugs of necrotic cells when tissue is gently squeezed",
                    "sub_points": [
                      "Masses due to periductal fibrosis usually form an ill-defined firm area without discrete borders",
                      "Color may be gray and texture gritty",
                      "Comedo-type necrosis can be seen as minute extruded plugs of necrotic cells when tissue is gently squeezed"
                    ]
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "Tissue corresponding to the clinical or radiologic lesion must be examinedCorrelation with the specimen radiograph or reimaging of tissue or blocks is often necessary to localize calcifications",
                    "sub_points": [
                      "Correlation with the specimen radiograph or reimaging of tissue or blocks is often necessary to localize calcifications"
                    ]
                  },
                  {
                    "text": "All grossly abnormal tissue should be examined microscopically"
                  },
                  {
                    "text": "All margins must be examined with perpendicular sectionsThe surgeon should orient specimens such that 6 margins can be identified",
                    "sub_points": [
                      "The surgeon should orient specimens such that 6 margins can be identified"
                    ]
                  },
                  {
                    "text": "Evaluation of all tissue and mapping the location of sections can help determine the extent of DCIS"
                  },
                  {
                    "text": "Ideally, the entire specimen, or at least all fibrous tissue, is evaluated to ensure no foci of invasion are missedTissue consisting of only adipose tissue is very unlikely to show IBC",
                    "sub_points": [
                      "Tissue consisting of only adipose tissue is very unlikely to show IBC"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "The most common mutations arePIK3CA(~ 15-25%),TP53(~ 10%), andGATA3(~ 10%)The same genetic changes found in DCIS are found in IBC",
                    "sub_points": [
                      "The same genetic changes found in DCIS are found in IBC"
                    ]
                  },
                  {
                    "text": "More biologic heterogeneity can be seen in DCIS than in IBCIncreased numbers of genomic changes correlate with increased nuclear grade",
                    "sub_points": [
                      "Increased numbers of genomic changes correlate with increased nuclear grade"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "The same biologic subtypes according to protein expression patterns found in IBC are also found in DCISER(+)/HER2(-) (similar to luminal A and some B IBCs): ~ 70% of casesER(+)/HER2(+) (similar to some luminal B IBCs): ~ 10-20% of casesER(-)/HER2(+) (similar to HER2-enriched IBCs): ~ 20-30% of casesER(-)/HER2(-) (\"triple negative cancer\"; similar to basal-like IBCs): ~ 5-10% of cases",
                    "sub_points": [
                      "ER(+)/HER2(-) (similar to luminal A and some B IBCs): ~ 70% of cases",
                      "ER(+)/HER2(+) (similar to some luminal B IBCs): ~ 10-20% of cases",
                      "ER(-)/HER2(+) (similar to HER2-enriched IBCs): ~ 20-30% of cases",
                      "ER(-)/HER2(-) (\"triple negative cancer\"; similar to basal-like IBCs): ~ 5-10% of cases"
                    ]
                  },
                  {
                    "text": "HER2(+) DCIS is slightly more frequent than HER2(+) IBCGreater extent in breast than other subtypes when associated with invasive IBCMost likely type of DCIS to cause Paget disease of nippleIn rare cases, associated invasive IBC is HER2(-)",
                    "sub_points": [
                      "Greater extent in breast than other subtypes when associated with invasive IBC",
                      "Most likely type of DCIS to cause Paget disease of nipple",
                      "In rare cases, associated invasive IBC is HER2(-)"
                    ]
                  },
                  {
                    "text": "\"Triple negative\" DCIS is less common than \"triple negative\" IBCCan be difficult to recognize when limited in extent and in a clinging pattern in lobulesMay transition quickly to invasion and is then overgrown by IBC",
                    "sub_points": [
                      "Can be difficult to recognize when limited in extent and in a clinging pattern in lobules",
                      "May transition quickly to invasion and is then overgrown by IBC"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "DCIS grows within the ductal/lobular system and is usually seen as multiple well-circumscribed nests of tumor cellsInvolved lobules are often \"unfolded\" into a single large space, resembling a ductIn contrast, lobules involved by lobular carcinoma in situ (LCIS) are usually recognizable as a lobuleThe terms \"ductal\" and \"lobular\" are related to these morphologic appearances and not to the cell of originMore complex patterns are seen when DCIS involves sclerosing adenosis (SA) or other lesions",
                    "sub_points": [
                      "Involved lobules are often \"unfolded\" into a single large space, resembling a ductIn contrast, lobules involved by lobular carcinoma in situ (LCIS) are usually recognizable as a lobuleThe terms \"ductal\" and \"lobular\" are related to these morphologic appearances and not to the cell of origin",
                      "In contrast, lobules involved by lobular carcinoma in situ (LCIS) are usually recognizable as a lobule",
                      "The terms \"ductal\" and \"lobular\" are related to these morphologic appearances and not to the cell of origin",
                      "More complex patterns are seen when DCIS involves sclerosing adenosis (SA) or other lesions"
                    ]
                  },
                  {
                    "text": "The most important features for predicting behavior are nuclear grade and necrosisArchitectural patterns have less significance but are important to recognize for diagnosisTumor-infiltrating lymphocytes are most commonly seen in association with high-grade DCIS with central necrosis",
                    "sub_points": [
                      "Architectural patterns have less significance but are important to recognize for diagnosis",
                      "Tumor-infiltrating lymphocytes are most commonly seen in association with high-grade DCIS with central necrosis"
                    ]
                  },
                  {
                    "text": "Cytologic appearanceDCIS is a clonal proliferation, resulting in a population of monotonous, similar-appearing cells if low grade or cells with pleomorphic nuclei if high gradeIn contrast, UDH consists of a mixture of luminal, myoepithelial, and intermediate-type cellsThe cells generally have distinct cell membranes and form complex architectural shapes with a rigid appearance (e.g., arcades, micropapillae, or cribriform spaces)Shapes formed by UDH are generally irregular in shape, and the cells forming them can appear to be streaming rather than rigidMetaplastic changes can make a diagnosis of DCIS difficult as cells can appear monomorphic due to the metaplasiaIncludes apocrine, clear cell, and foamy cell changesIn these cases, architectural changes may be essential for a diagnosis of DCIS, unless cells with high nuclear grade are present",
                    "sub_points": [
                      "DCIS is a clonal proliferation, resulting in a population of monotonous, similar-appearing cells if low grade or cells with pleomorphic nuclei if high gradeIn contrast, UDH consists of a mixture of luminal, myoepithelial, and intermediate-type cells",
                      "In contrast, UDH consists of a mixture of luminal, myoepithelial, and intermediate-type cells",
                      "The cells generally have distinct cell membranes and form complex architectural shapes with a rigid appearance (e.g., arcades, micropapillae, or cribriform spaces)Shapes formed by UDH are generally irregular in shape, and the cells forming them can appear to be streaming rather than rigid",
                      "Shapes formed by UDH are generally irregular in shape, and the cells forming them can appear to be streaming rather than rigid",
                      "Metaplastic changes can make a diagnosis of DCIS difficult as cells can appear monomorphic due to the metaplasiaIncludes apocrine, clear cell, and foamy cell changesIn these cases, architectural changes may be essential for a diagnosis of DCIS, unless cells with high nuclear grade are present",
                      "Includes apocrine, clear cell, and foamy cell changes",
                      "In these cases, architectural changes may be essential for a diagnosis of DCIS, unless cells with high nuclear grade are present"
                    ]
                  },
                  {
                    "text": "Nuclear gradeThe same 3-tier nuclear grading system used for IBC is also used for DCISThere is often a mixture of nuclear grades; the highest grade present should be reportedDiagnostic agreement among pathologists is only moderate due to the biologic continuum in nuclear grade and the heterogeneity of lesions",
                    "sub_points": [
                      "The same 3-tier nuclear grading system used for IBC is also used for DCIS",
                      "There is often a mixture of nuclear grades; the highest grade present should be reported",
                      "Diagnostic agreement among pathologists is only moderate due to the biologic continuum in nuclear grade and the heterogeneity of lesions"
                    ]
                  },
                  {
                    "text": "Architectural patternsThe majority of cases of DCIS consist of > 1 architectural patternCribriformCribriform spaces appear punched out and very round (cookie cutter; spherical in 3 dimensions)Cells and nuclei show polarization around the luminal spaceSpaces are distributed evenlySpaces associated with UDH are typically sinuous in shape and peripherally locatedSecretory material in spaces often calcifiesNecrosis is less likely to be associated with this typePapillaryPapillary fronds have a central fibrovascular coreMyoepithelial cells are present around periphery of spaces but not within papillary coresIf present, indicates involvement of a preexisting papillomaEndothelial cells lining blood vessels can be apposed to base of tumor cells in thin fibrovascular coresCan be difficult to distinguish endothelial cells from myoepithelial cells using IHC muscle-type markersp63 is the best marker to confirm the absence of myoepithelial cells in papillary coresMicropapillaryMicropapillae have narrow bases that expand to bulbous ends or more complex areas of architectureAppearance has been compared to a light bulb or drumstickPapillae associated with hyperplasia or gynecomastia are short and tapering and usually arise on a background of hyperplasiaMicropapillae do not have fibrovascular coresThe adjacent epithelium is usually flat and often has the appearance of FEAComedoThis is sometimes considered an architectural pattern, but central necrosis can be seen in any architectural patternThere is central necrosis surrounded by a rim of tumor cellsPathologists vary in the degree of necrosis required to be considered comedonecrosis, and a specific definition has not been setA strict definition of comedo-pattern DCIS requires both central necrosis and high nuclear gradeCalcifications are almost always present in necrosis and are usually numerousThe central necrotic core can form linear and branching calcifications on mammography that outline ductal systemThe mammographic lesion is often close to the actual extent of DCISThere is often associated circumferential stromal fibrosis, often with a lymphocytic infiltrateCan form a mammographic density with calcificationsSome cases form a grossly palpable mass consisting of grayish fibrotic tissue with punctate foci of necrosisSolidCells completely fill ductal spacesClingingCells with high-grade nuclei line spaces without forming architectural patternsUsually only seen adjacent to other architectural patterns of DCISPagetoid spreadMost commonly seen in nipple epidermis as Paget disease of nippleDCIS can extend from the lactiferous sinuses to the epidermis without crossing a basement membrane~ 80% of cases are HER2(+)Uncommonly seen in breast ducts, as DCIS tends to displace normal luminal cells rather than infiltrate in the space between luminal and myoepithelial cells",
                    "sub_points": [
                      "The majority of cases of DCIS consist of > 1 architectural pattern",
                      "CribriformCribriform spaces appear punched out and very round (cookie cutter; spherical in 3 dimensions)Cells and nuclei show polarization around the luminal spaceSpaces are distributed evenlySpaces associated with UDH are typically sinuous in shape and peripherally locatedSecretory material in spaces often calcifiesNecrosis is less likely to be associated with this type",
                      "Cribriform spaces appear punched out and very round (cookie cutter; spherical in 3 dimensions)",
                      "Cells and nuclei show polarization around the luminal space",
                      "Spaces are distributed evenlySpaces associated with UDH are typically sinuous in shape and peripherally located",
                      "Spaces associated with UDH are typically sinuous in shape and peripherally located",
                      "Secretory material in spaces often calcifiesNecrosis is less likely to be associated with this type",
                      "Necrosis is less likely to be associated with this type",
                      "PapillaryPapillary fronds have a central fibrovascular coreMyoepithelial cells are present around periphery of spaces but not within papillary coresIf present, indicates involvement of a preexisting papillomaEndothelial cells lining blood vessels can be apposed to base of tumor cells in thin fibrovascular coresCan be difficult to distinguish endothelial cells from myoepithelial cells using IHC muscle-type markersp63 is the best marker to confirm the absence of myoepithelial cells in papillary cores",
                      "Papillary fronds have a central fibrovascular core",
                      "Myoepithelial cells are present around periphery of spaces but not within papillary coresIf present, indicates involvement of a preexisting papilloma",
                      "If present, indicates involvement of a preexisting papilloma",
                      "Endothelial cells lining blood vessels can be apposed to base of tumor cells in thin fibrovascular cores",
                      "Can be difficult to distinguish endothelial cells from myoepithelial cells using IHC muscle-type markers",
                      "p63 is the best marker to confirm the absence of myoepithelial cells in papillary cores",
                      "MicropapillaryMicropapillae have narrow bases that expand to bulbous ends or more complex areas of architectureAppearance has been compared to a light bulb or drumstickPapillae associated with hyperplasia or gynecomastia are short and tapering and usually arise on a background of hyperplasiaMicropapillae do not have fibrovascular coresThe adjacent epithelium is usually flat and often has the appearance of FEA",
                      "Micropapillae have narrow bases that expand to bulbous ends or more complex areas of architectureAppearance has been compared to a light bulb or drumstickPapillae associated with hyperplasia or gynecomastia are short and tapering and usually arise on a background of hyperplasia",
                      "Appearance has been compared to a light bulb or drumstick",
                      "Papillae associated with hyperplasia or gynecomastia are short and tapering and usually arise on a background of hyperplasia",
                      "Micropapillae do not have fibrovascular cores",
                      "The adjacent epithelium is usually flat and often has the appearance of FEA",
                      "ComedoThis is sometimes considered an architectural pattern, but central necrosis can be seen in any architectural patternThere is central necrosis surrounded by a rim of tumor cellsPathologists vary in the degree of necrosis required to be considered comedonecrosis, and a specific definition has not been setA strict definition of comedo-pattern DCIS requires both central necrosis and high nuclear gradeCalcifications are almost always present in necrosis and are usually numerousThe central necrotic core can form linear and branching calcifications on mammography that outline ductal systemThe mammographic lesion is often close to the actual extent of DCISThere is often associated circumferential stromal fibrosis, often with a lymphocytic infiltrateCan form a mammographic density with calcificationsSome cases form a grossly palpable mass consisting of grayish fibrotic tissue with punctate foci of necrosis",
                      "This is sometimes considered an architectural pattern, but central necrosis can be seen in any architectural pattern",
                      "There is central necrosis surrounded by a rim of tumor cellsPathologists vary in the degree of necrosis required to be considered comedonecrosis, and a specific definition has not been set",
                      "Pathologists vary in the degree of necrosis required to be considered comedonecrosis, and a specific definition has not been set",
                      "A strict definition of comedo-pattern DCIS requires both central necrosis and high nuclear grade",
                      "Calcifications are almost always present in necrosis and are usually numerousThe central necrotic core can form linear and branching calcifications on mammography that outline ductal systemThe mammographic lesion is often close to the actual extent of DCIS",
                      "The central necrotic core can form linear and branching calcifications on mammography that outline ductal system",
                      "The mammographic lesion is often close to the actual extent of DCIS",
                      "There is often associated circumferential stromal fibrosis, often with a lymphocytic infiltrateCan form a mammographic density with calcifications",
                      "Can form a mammographic density with calcifications",
                      "Some cases form a grossly palpable mass consisting of grayish fibrotic tissue with punctate foci of necrosis",
                      "SolidCells completely fill ductal spaces",
                      "Cells completely fill ductal spaces",
                      "ClingingCells with high-grade nuclei line spaces without forming architectural patternsUsually only seen adjacent to other architectural patterns of DCIS",
                      "Cells with high-grade nuclei line spaces without forming architectural patterns",
                      "Usually only seen adjacent to other architectural patterns of DCIS",
                      "Pagetoid spreadMost commonly seen in nipple epidermis as Paget disease of nippleDCIS can extend from the lactiferous sinuses to the epidermis without crossing a basement membrane~ 80% of cases are HER2(+)Uncommonly seen in breast ducts, as DCIS tends to displace normal luminal cells rather than infiltrate in the space between luminal and myoepithelial cells",
                      "Most commonly seen in nipple epidermis as Paget disease of nippleDCIS can extend from the lactiferous sinuses to the epidermis without crossing a basement membrane~ 80% of cases are HER2(+)",
                      "DCIS can extend from the lactiferous sinuses to the epidermis without crossing a basement membrane",
                      "~ 80% of cases are HER2(+)",
                      "Uncommonly seen in breast ducts, as DCIS tends to displace normal luminal cells rather than infiltrate in the space between luminal and myoepithelial cells"
                    ]
                  },
                  {
                    "text": "NecrosisNecrosis ranges from single cells to almost involving an entire involved spaceNecrosis can be seen in any architectural pattern; extensive necrosis is associated with high nuclear gradeComedonecrosis is generally agreed to involve a large area of an involved space, but the exact extent has not been definedThe area that must be involved varies 10-70% among pathologistsA strict definition of necrosis requires the presence of cellular debrisThick, eosinophilic secretory material with calcifications can resemble necrosis",
                    "sub_points": [
                      "Necrosis ranges from single cells to almost involving an entire involved space",
                      "Necrosis can be seen in any architectural pattern; extensive necrosis is associated with high nuclear grade",
                      "Comedonecrosis is generally agreed to involve a large area of an involved space, but the exact extent has not been definedThe area that must be involved varies 10-70% among pathologists",
                      "The area that must be involved varies 10-70% among pathologists",
                      "A strict definition of necrosis requires the presence of cellular debrisThick, eosinophilic secretory material with calcifications can resemble necrosis",
                      "Thick, eosinophilic secretory material with calcifications can resemble necrosis"
                    ]
                  },
                  {
                    "text": "MucinMucin in lumina can be associated with DCIS and may calcifyCan be associated with cribriform, micropapillary, papillary, or clinging patternsWhen extravasated, it can be difficult to distinguish from microinvasionSignet-ring cells with intracytoplasmic mucin can be present, but these cells are more common in LCIS",
                    "sub_points": [
                      "Mucin in lumina can be associated with DCIS and may calcifyCan be associated with cribriform, micropapillary, papillary, or clinging patternsWhen extravasated, it can be difficult to distinguish from microinvasion",
                      "Can be associated with cribriform, micropapillary, papillary, or clinging patterns",
                      "When extravasated, it can be difficult to distinguish from microinvasion",
                      "Signet-ring cells with intracytoplasmic mucin can be present, but these cells are more common in LCIS"
                    ]
                  },
                  {
                    "text": "CalcificationsCalcification occurs in DCIS on membrane fragments due to apocrine secretion or necrosisCalcium and phosphate crystallize on regular repeating structuresIt is important to identify calcifications to correlate with the mammographic lesionCrystalloids are brightly eosinophilic structures with an angulated shape that have only been reported in association with DCISCalcium oxalate is seen in apocrine cysts and has not been associated with malignancy",
                    "sub_points": [
                      "Calcification occurs in DCIS on membrane fragments due to apocrine secretion or necrosisCalcium and phosphate crystallize on regular repeating structures",
                      "Calcium and phosphate crystallize on regular repeating structures",
                      "It is important to identify calcifications to correlate with the mammographic lesion",
                      "Crystalloids are brightly eosinophilic structures with an angulated shape that have only been reported in association with DCIS",
                      "Calcium oxalate is seen in apocrine cysts and has not been associated with malignancy"
                    ]
                  },
                  {
                    "text": "DCIS involving other lesionsDCIS can involve fibroadenomas, papillomas, and other benign lesions, which can make classification difficultDCIS in SA can closely mimic IBCA circumscribed border, lobulocentric growth, back to back glands, lack of infiltration around normal epithelium, and dense stroma are important cluesMultiplex IHC for keratin and myoepithelial markers are helpful for diagnosis",
                    "sub_points": [
                      "DCIS can involve fibroadenomas, papillomas, and other benign lesions, which can make classification difficult",
                      "DCIS in SA can closely mimic IBCA circumscribed border, lobulocentric growth, back to back glands, lack of infiltration around normal epithelium, and dense stroma are important cluesMultiplex IHC for keratin and myoepithelial markers are helpful for diagnosis",
                      "A circumscribed border, lobulocentric growth, back to back glands, lack of infiltration around normal epithelium, and dense stroma are important clues",
                      "Multiplex IHC for keratin and myoepithelial markers are helpful for diagnosis"
                    ]
                  },
                  {
                    "text": "Extent of DCISExtent refers to volume of breast occupied by DCISExtent can vary from 0.2 cm to > 20 cm or all 4 quadrants of breastAverage extent of DCIS is 2-3 cmIt is recommended that DCIS only be diagnosed if at least 2 spaces are involved or if it is present in an area at least 0.2 cm in sizeSmaller lesions are classified as ADHThe size criteria does not apply to DCIS with high-grade nucleiAn estimate of extent is useful clinicallySmall (< 2 cm): Can be completely excised with wide margins; likelihood of associated IBC is very smallAverage (2-3 cm): Can usually be completely excised and completely evaluated microscopically; the likelihood of missed IBC is smallLarge (> 3 cm): May be difficult or impractical to completely evaluate microscopically; a focus of IBC could be missedExtent can only be estimatedBreast tissue is highly compressibleThe shape of breast specimens changes after excisionSpecimen radiography also compresses and distorts shape (size) of excisionsMorphologic gaps in ductal involvement are reported to occur, particularly in lower grades of DCISDCIS is often removed in multiple specimensMultiple methods are available to estimate extentMeasurement of DCIS on glass slide: Only accurate if DCIS is only present on 1 slideMargins: If 2 opposing margins are positive or close to DCIS, the extent can be estimated by using specimen sizeComplete serial sequential sectioning (SSS) and mapping of sections with DCIS to give linear measurementBlock method (BM) multiplies number of blocks with DCIS by 0.4 cm (or average width of sliced tissue in cassettes, if known)SSS correlates well with BM up to ~ 3 cmBecause BM is related to volume as well as to linear dimension, it usually gives larger estimate compared with SSS for very extensive DCIS",
                    "sub_points": [
                      "Extent refers to volume of breast occupied by DCISExtent can vary from 0.2 cm to > 20 cm or all 4 quadrants of breastAverage extent of DCIS is 2-3 cm",
                      "Extent can vary from 0.2 cm to > 20 cm or all 4 quadrants of breast",
                      "Average extent of DCIS is 2-3 cm",
                      "It is recommended that DCIS only be diagnosed if at least 2 spaces are involved or if it is present in an area at least 0.2 cm in sizeSmaller lesions are classified as ADHThe size criteria does not apply to DCIS with high-grade nuclei",
                      "Smaller lesions are classified as ADH",
                      "The size criteria does not apply to DCIS with high-grade nuclei",
                      "An estimate of extent is useful clinicallySmall (< 2 cm): Can be completely excised with wide margins; likelihood of associated IBC is very smallAverage (2-3 cm): Can usually be completely excised and completely evaluated microscopically; the likelihood of missed IBC is smallLarge (> 3 cm): May be difficult or impractical to completely evaluate microscopically; a focus of IBC could be missed",
                      "Small (< 2 cm): Can be completely excised with wide margins; likelihood of associated IBC is very small",
                      "Average (2-3 cm): Can usually be completely excised and completely evaluated microscopically; the likelihood of missed IBC is small",
                      "Large (> 3 cm): May be difficult or impractical to completely evaluate microscopically; a focus of IBC could be missed",
                      "Extent can only be estimatedBreast tissue is highly compressibleThe shape of breast specimens changes after excisionSpecimen radiography also compresses and distorts shape (size) of excisionsMorphologic gaps in ductal involvement are reported to occur, particularly in lower grades of DCISDCIS is often removed in multiple specimens",
                      "Breast tissue is highly compressible",
                      "The shape of breast specimens changes after excision",
                      "Specimen radiography also compresses and distorts shape (size) of excisions",
                      "Morphologic gaps in ductal involvement are reported to occur, particularly in lower grades of DCIS",
                      "DCIS is often removed in multiple specimens",
                      "Multiple methods are available to estimate extentMeasurement of DCIS on glass slide: Only accurate if DCIS is only present on 1 slideMargins: If 2 opposing margins are positive or close to DCIS, the extent can be estimated by using specimen sizeComplete serial sequential sectioning (SSS) and mapping of sections with DCIS to give linear measurementBlock method (BM) multiplies number of blocks with DCIS by 0.4 cm (or average width of sliced tissue in cassettes, if known)SSS correlates well with BM up to ~ 3 cmBecause BM is related to volume as well as to linear dimension, it usually gives larger estimate compared with SSS for very extensive DCIS",
                      "Measurement of DCIS on glass slide: Only accurate if DCIS is only present on 1 slide",
                      "Margins: If 2 opposing margins are positive or close to DCIS, the extent can be estimated by using specimen size",
                      "Complete serial sequential sectioning (SSS) and mapping of sections with DCIS to give linear measurement",
                      "Block method (BM) multiplies number of blocks with DCIS by 0.4 cm (or average width of sliced tissue in cassettes, if known)",
                      "SSS correlates well with BM up to ~ 3 cm",
                      "Because BM is related to volume as well as to linear dimension, it usually gives larger estimate compared with SSS for very extensive DCIS"
                    ]
                  },
                  {
                    "text": "Core needle biopsyBorderline lesions between ADH and DCIS are generally best classified as ADH on core needle biopsyFinal classification is best made on excisionIf the patient has undergone radiation, nuclear atypia can mimic DCISDiagnosis of malignancy will likely be treated with mastectomyIHC for myoepithelial cells can be helpful if invasion is suspectedIf invasion is present, a sentinel lymph node will likely be performedDCIS involving SA can closely mimic invasive carcinoma, especially in a core needle biopsyMore likely if the lesion is a small circumscribed or lobulated mass and involved spaces are back to back and in a swirling patternIn true invasion, infiltration around normal epithelium is usually seenIHC for myoepithelial cells may be helpful when this is a possibility",
                    "sub_points": [
                      "Borderline lesions between ADH and DCIS are generally best classified as ADH on core needle biopsyFinal classification is best made on excision",
                      "Final classification is best made on excision",
                      "If the patient has undergone radiation, nuclear atypia can mimic DCISDiagnosis of malignancy will likely be treated with mastectomy",
                      "Diagnosis of malignancy will likely be treated with mastectomy",
                      "IHC for myoepithelial cells can be helpful if invasion is suspectedIf invasion is present, a sentinel lymph node will likely be performed",
                      "If invasion is present, a sentinel lymph node will likely be performed",
                      "DCIS involving SA can closely mimic invasive carcinoma, especially in a core needle biopsyMore likely if the lesion is a small circumscribed or lobulated mass and involved spaces are back to back and in a swirling patternIn true invasion, infiltration around normal epithelium is usually seenIHC for myoepithelial cells may be helpful when this is a possibility",
                      "More likely if the lesion is a small circumscribed or lobulated mass and involved spaces are back to back and in a swirling pattern",
                      "In true invasion, infiltration around normal epithelium is usually seen",
                      "IHC for myoepithelial cells may be helpful when this is a possibility"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Myoepithelial markersVery helpful to distinguish DCIS from IBC and to identify microinvasionMyoepithelial cells may be displaced from normal location on basement membranePitfalls in interpretationThe number of myoepithelial cells can be reduced and may only express some markersA panel of multiple markers, including p63, is recommendedBlood vessels surrounding circumscribed nests of IBC or abutting neoplastic cells in neoplastic papillae can mimic myoepithelial cellsSome high-grade cancers express p63Multiplex IHC for myoepithelial marker and cytokeratin can be very helpful for detecting microinvasive carcinomaA focus of invasion seen on H&E may be absent on deeper level, but another focus may appear that will be difficult to recognize without keratin positivity",
                    "sub_points": [
                      "Very helpful to distinguish DCIS from IBC and to identify microinvasion",
                      "Myoepithelial cells may be displaced from normal location on basement membrane",
                      "Pitfalls in interpretationThe number of myoepithelial cells can be reduced and may only express some markersA panel of multiple markers, including p63, is recommendedBlood vessels surrounding circumscribed nests of IBC or abutting neoplastic cells in neoplastic papillae can mimic myoepithelial cellsSome high-grade cancers express p63",
                      "The number of myoepithelial cells can be reduced and may only express some markersA panel of multiple markers, including p63, is recommended",
                      "A panel of multiple markers, including p63, is recommended",
                      "Blood vessels surrounding circumscribed nests of IBC or abutting neoplastic cells in neoplastic papillae can mimic myoepithelial cells",
                      "Some high-grade cancers express p63",
                      "Multiplex IHC for myoepithelial marker and cytokeratin can be very helpful for detecting microinvasive carcinomaA focus of invasion seen on H&E may be absent on deeper level, but another focus may appear that will be difficult to recognize without keratin positivity",
                      "A focus of invasion seen on H&E may be absent on deeper level, but another focus may appear that will be difficult to recognize without keratin positivity"
                    ]
                  },
                  {
                    "text": "ERMajority of DCIS (~ 70-80%) is strongly positive for ERUDH is often heterogeneously positiveER testing is recommended to help make decisions about hormonal therapyER(+) DCIS is almost always PR(+) as well",
                    "sub_points": [
                      "Majority of DCIS (~ 70-80%) is strongly positive for ERUDH is often heterogeneously positive",
                      "UDH is often heterogeneously positive",
                      "ER testing is recommended to help make decisions about hormonal therapy",
                      "ER(+) DCIS is almost always PR(+) as well"
                    ]
                  },
                  {
                    "text": "E-cadherinDCIS is E-cadherin (+)The majority of LCIS is E-cadherin (-), although rare cases express E-cadherin but show defects in other cell adhesion molecules",
                    "sub_points": [
                      "DCIS is E-cadherin (+)The majority of LCIS is E-cadherin (-), although rare cases express E-cadherin but show defects in other cell adhesion molecules",
                      "The majority of LCIS is E-cadherin (-), although rare cases express E-cadherin but show defects in other cell adhesion molecules"
                    ]
                  },
                  {
                    "text": "HER2~ 30% of DCIS overexpress HER2HER2(+) DCIS tends to be larger and correlates with higher nuclear gradeRoutine evaluation is not usually requested or recommended at this timeIn rare cases, DCIS may overexpress HER2, whereas associated IBC does notCan lead to erroneous results for gene expression profiling, FISH, or other tests if DCIS is not clearly distinguished from IBC",
                    "sub_points": [
                      "~ 30% of DCIS overexpress HER2",
                      "HER2(+) DCIS tends to be larger and correlates with higher nuclear grade",
                      "Routine evaluation is not usually requested or recommended at this time",
                      "In rare cases, DCIS may overexpress HER2, whereas associated IBC does notCan lead to erroneous results for gene expression profiling, FISH, or other tests if DCIS is not clearly distinguished from IBC",
                      "Can lead to erroneous results for gene expression profiling, FISH, or other tests if DCIS is not clearly distinguished from IBC"
                    ]
                  },
                  {
                    "text": "High molecular weight (HMW) CK5/6Negative in the majority of DCIS, as well as ADHSome high-grade ER(-) DCIS can be positiveUDH is heterogeneously positive for HMW keratins",
                    "sub_points": [
                      "Negative in the majority of DCIS, as well as ADH",
                      "Some high-grade ER(-) DCIS can be positive",
                      "UDH is heterogeneously positive for HMW keratins"
                    ]
                  }
                ],
                "Multigene mRNA Prognostic Score": [
                  {
                    "text": "Several assays using mRNA profiling (including from 6 to 812 genes) have been developed to predict the likelihood of recurrence as either DCIS or IBC"
                  },
                  {
                    "text": "The Oncotype DX breast DCIS score evaluates 7 DCIS-related genes, including PR and Ki-67 (and 4 other genes related to proliferation)"
                  },
                  {
                    "text": "Retrospective tests were performed on 327 patient samples from ECOG E5194Low- or intermediate-grade DCIS ≤ 2.5 cm (66% of patients) or high-grade DCIS ≤ 1 cm (34% of patients)Surgical margins were at least 0.3 cmPatients were not treated with radiation~ 30% received tamoxifenOnly 2.8% were ER(-), and only 7.6% HER2(+)",
                    "sub_points": [
                      "Low- or intermediate-grade DCIS ≤ 2.5 cm (66% of patients) or high-grade DCIS ≤ 1 cm (34% of patients)",
                      "Surgical margins were at least 0.3 cm",
                      "Patients were not treated with radiation~ 30% received tamoxifen",
                      "~ 30% received tamoxifen",
                      "Only 2.8% were ER(-), and only 7.6% HER2(+)"
                    ]
                  },
                  {
                    "text": "At 10 years, ipsilateral recurrence rates were 6% for invasive carcinoma and 8% for DCIS for entire group"
                  },
                  {
                    "text": "Patients were divided into 3 groups according to recurrence score (RS)Low risk (70% of patients): 3.7% invasive carcinoma and 7.2% DCISIntermediate risk (16% of patients): 12.3% invasive carcinoma and 16.1% DCISHigh risk (13% of patients): 19.2% invasive carcinoma and 7.9% DCIS",
                    "sub_points": [
                      "Low risk (70% of patients): 3.7% invasive carcinoma and 7.2% DCIS",
                      "Intermediate risk (16% of patients): 12.3% invasive carcinoma and 16.1% DCIS",
                      "High risk (13% of patients): 19.2% invasive carcinoma and 7.9% DCIS"
                    ]
                  },
                  {
                    "text": "The risk of recurrence at 10 years uses age (< 50 or ≥ 50 years), size (≤ 1 cm, 1.1-2.5 cm, > 2.5 cm), and RS to predict recurrence as DCIS or IBCFor example, a ≥ 50 year old woman with a 1.1- to 2.5-cm DCIS has a ~ 10% recurrence risk with low RS, ~ 14% with an intermediate RS, and ~ 20% with high RSSingle gene scores for ER and PR are also provided",
                    "sub_points": [
                      "For example, a ≥ 50 year old woman with a 1.1- to 2.5-cm DCIS has a ~ 10% recurrence risk with low RS, ~ 14% with an intermediate RS, and ~ 20% with high RS",
                      "Single gene scores for ER and PR are also provided"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Usual Ductal Hyperplasia (UDH)": [
                  {
                    "text": "Composed of a mixed population of luminal-like, myoepithelial-like, and intermediate cells, resulting in a heterogeneous appearance"
                  },
                  {
                    "text": "Spaces, when present, are generally irregular in shape and arrayed near periphery"
                  },
                  {
                    "text": "HMW keratin and ER reveal a heterogeneous pattern correlating with multiple cell types present"
                  },
                  {
                    "text": "Central necrosis is very rare but can occur in cases of florid UDHMost commonly seen in florid hyperplasia in nipple adenomas",
                    "sub_points": [
                      "Most commonly seen in florid hyperplasia in nipple adenomas"
                    ]
                  }
                ],
                "Nonsclerosing Lymphocytic Lobulitis (NSLL)": [
                  {
                    "text": "NSLL consists of a dense lymphocytic infiltrate centered on normal-appearing lobules and is strongly associated with risk factors for developing IBC"
                  },
                  {
                    "text": "Unlike sclerosing lymphocytic lobulitis (diabetic mastopathy), the infiltrate is predominantly composed of T cells, and there are no stromal changes"
                  },
                  {
                    "text": "The acinar cells are normal in appearance"
                  },
                  {
                    "text": "NSLL can mimic DCIS with a lymphocytic infiltrate at low power and can also be seen in breast tissue adjacent to IBCs"
                  }
                ],
                "Gynecomastoid Hyperplasia": [
                  {
                    "text": "Gynecomastia in males and gynecomastoid hyperplasia in females can mimic micropapillary pattern DCIS"
                  },
                  {
                    "text": "The cells lining ducts can have short, tapering papillae arising on a background of hyperplasiaIn micropapillary pattern DCIS, the lining cells between the micropapillae are usually flat",
                    "sub_points": [
                      "In micropapillary pattern DCIS, the lining cells between the micropapillae are usually flat"
                    ]
                  }
                ],
                "Collagenous Spherulosis (CS)": [
                  {
                    "text": "CS consists of a proliferation of both luminal and myoepithelial cells"
                  },
                  {
                    "text": "Myoepithelial cells surround round spaces filled with basement membrane-like material"
                  },
                  {
                    "text": "The pattern mimics cribriform pattern DCIS"
                  },
                  {
                    "text": "This resemblance is more striking when CS is involved by LCIS"
                  },
                  {
                    "text": "IHC reveals myoepithelial cells surrounding the spaces"
                  }
                ],
                "Radiation Atypia": [
                  {
                    "text": "Radiation treatment can cause nuclear enlargement in benign cells"
                  },
                  {
                    "text": "Affected cells are generally scattered among normal-appearing cells"
                  },
                  {
                    "text": "Should not form proliferative lesions (e.g., fill ducts, form papillae or cribriform spaces)"
                  },
                  {
                    "text": "Can be very difficult to distinguish from recurrent DCISDCIS should not be diagnosed unless diagnosis is certainDiagnosis of recurrent carcinoma may be treated with mastectomy",
                    "sub_points": [
                      "DCIS should not be diagnosed unless diagnosis is certain",
                      "Diagnosis of recurrent carcinoma may be treated with mastectomy"
                    ]
                  }
                ],
                "Atypical Ductal Hyperplasia (ADH)": [
                  {
                    "text": "ADH is a small clonal population that resembles DCIS but is more limited in extentIf only a single space is involved or the lesion is < 0.2 cm, classification as ADH is recommended",
                    "sub_points": [
                      "If only a single space is involved or the lesion is < 0.2 cm, classification as ADH is recommended"
                    ]
                  },
                  {
                    "text": "IHC is not helpful, as both ADH and DCIS are negative for HMW keratin and show strong, diffuse ER positivity"
                  },
                  {
                    "text": "If a lesion is borderline between ADH and DCIS, classification as ADH is recommended"
                  }
                ],
                "Lobular Carcinoma In Situ (LCIS)": [
                  {
                    "text": "LCIS and DCIS with a solid pattern can morphologically resemble each other"
                  },
                  {
                    "text": "It is important to make this distinction, as treatment recommendations differ"
                  },
                  {
                    "text": "Absence of E-cadherin supports classification as LCISIn very rare cases, E-cadherin may be present, but other cell adhesion molecules are nonfunctional",
                    "sub_points": [
                      "In very rare cases, E-cadherin may be present, but other cell adhesion molecules are nonfunctional"
                    ]
                  },
                  {
                    "text": "LCIS involving ADH can also closely mimic DCIS"
                  }
                ],
                "Solid Papillary Carcinoma (SPC)": [
                  {
                    "text": "SPC forms circumscribed nests of cells surrounding fibrovascular cores and may or may not be associated with myoepithelial cellsMay occur as a single or multiple circumscribed nests of tumor cellsSome have spindle cell patterns that can be difficult to distinguish from usual hyperplasia",
                    "sub_points": [
                      "May occur as a single or multiple circumscribed nests of tumor cells",
                      "Some have spindle cell patterns that can be difficult to distinguish from usual hyperplasia"
                    ]
                  },
                  {
                    "text": "If myoepithelial cells are absent, and there is no definite area of stromal invasion, WHO recommends classifying as Tis"
                  }
                ],
                "Encapsulated Papillary Carcinoma (EPC)": [
                  {
                    "text": "EPC generally involves a single space with circumscribed margins, usually located deep to nipple"
                  },
                  {
                    "text": "Myoepithelial cells are absent at the periphery and in fibrovascular cores"
                  },
                  {
                    "text": "Prognosis is excellent, and WHO recommends classification as Tis"
                  }
                ],
                "Microinvasive Carcinoma": [
                  {
                    "text": "Most commonly associated with high-grade and extensive DCISAssociated stromal fibrosis and lymphocytic infiltrate can make evaluation of invasion difficult",
                    "sub_points": [
                      "Associated stromal fibrosis and lymphocytic infiltrate can make evaluation of invasion difficult"
                    ]
                  },
                  {
                    "text": "Microinvasive carcinoma is defined as tumor cells in stroma in an area measuring ≤ 0.1 cm"
                  },
                  {
                    "text": "Multiplex IHC for both keratin and myoepithelial markers is very helpful for evaluation"
                  },
                  {
                    "text": "Artifactual displacement of DCIS after core needle biopsy or excision can mimic invasionOften associated with an inflammatory stromal reaction (but not true desmoplasia) in a linear pattern along a needle trackThe cells can appear degenerative with smudged chromatinMyoepithelial cells may or may not be present",
                    "sub_points": [
                      "Often associated with an inflammatory stromal reaction (but not true desmoplasia) in a linear pattern along a needle track",
                      "The cells can appear degenerative with smudged chromatin",
                      "Myoepithelial cells may or may not be present"
                    ]
                  }
                ],
                "Invasive Carcinoma": [
                  {
                    "text": "Some BCs invade as circumscribed nests of cells that can closely mimic DCIS"
                  },
                  {
                    "text": "Arrangement is generally haphazard in stroma rather than following the normal pattern of ducts and lobules"
                  },
                  {
                    "text": "The desmoplastic response generally extends beyond cells rather than being circumferential, as in DCIS"
                  },
                  {
                    "text": "In difficult cases, IHC is helpful to demonstrate absence of myoepithelial cells in IBC"
                  }
                ],
                "Lymphovascular Invasion (LVI)": [
                  {
                    "text": "Both DCIS and LVI can be present as circumscribed nests of tumor cells without a stromal response"
                  },
                  {
                    "text": "LVI follows a linear vascular pattern and is often present between lobules and adjacent to veins and arteriolesLocation of DCIS will be in the normal pattern of ducts and lobulesA space with sharp branching is more typical for LVI than DCISA space between the tumor cells and the wall of the space is more common in LVI than in DCIS",
                    "sub_points": [
                      "Location of DCIS will be in the normal pattern of ducts and lobules",
                      "A space with sharp branching is more typical for LVI than DCIS",
                      "A space between the tumor cells and the wall of the space is more common in LVI than in DCIS"
                    ]
                  },
                  {
                    "text": "Some (not all) endothelial cells of lymphatics can be identified with IHC for CD31 or podoplanin (D2-40)Podoplanin (D2-40) is also positive in some myoepithelial cellsMuscle markers are present in myoepithelial cells and some endothelial cells",
                    "sub_points": [
                      "Podoplanin (D2-40) is also positive in some myoepithelial cells",
                      "Muscle markers are present in myoepithelial cells and some endothelial cells"
                    ]
                  },
                  {
                    "text": "DCIS can be identified by IHC for p63, which will be negative in endothelial cells"
                  }
                ],
                "Chest Wall Recurrence of Invasive Carcinoma": [
                  {
                    "text": "Recurrent invasive carcinoma in the chest wall or a reconstructed breast often grows as circumscribed nests and can closely mimic DCIS"
                  },
                  {
                    "text": "Recurrence as DCIS only occurs when all breast tissue has not been removedNormal breast tissue may be present",
                    "sub_points": [
                      "Normal breast tissue may be present"
                    ]
                  },
                  {
                    "text": "IHC for myoepithelial cells should always be used to evaluate for myoepithelial cells if the carcinoma has a circumscribed pattern"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "DCIS is challenging to diagnose due to the wide variety of architectural patterns, low- to high-grade nuclear features, and the spectrum of underlying biologic changes"
                  },
                  {
                    "text": "Borderline lesions are generally best classified as ADH to avoid overtreatment"
                  },
                  {
                    "text": "DCIS mimics can usually be identified using IHC markers"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "DCIS is reported according to the College of American Pathologists DCIS protocol"
                  }
                ],
                "Staging": [
                  {
                    "text": "In the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) TNM classifications, DCIS is classified as Tis (8th edition)"
                  },
                  {
                    "text": "The stage is not altered by grade or the expression of ER, PR, and HER2"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Ductal Carcinoma In Situ, Paget Disease": {
            "name": "Ductal Carcinoma In Situ, Paget Disease",
            "url": "https://app.pathprimer.com/document/5c6fe645-94b6-4923-a3bb-29ac9c32f682/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mammary Paget disease (MPD) is an uncommon presentation of breast cancer as skin changes due to tumor cells involving the nipple epidermis~ 50% of cases are ductal carcinoma in situ (DCIS) alone and ~ 50% are DCIS and invasive carcinoma",
                    "sub_points": [
                      "~ 50% of cases are ductal carcinoma in situ (DCIS) alone and ~ 50% are DCIS and invasive carcinoma"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Occurs in 1-4% of women and 1-2% of men with breast carcinoma"
                  },
                  {
                    "text": "The most common clinical appearance is a scaling crust with erythema of nipple skinOften mistaken for skin inflammatory disease or infection, leading to delayed diagnosis",
                    "sub_points": [
                      "Often mistaken for skin inflammatory disease or infection, leading to delayed diagnosis"
                    ]
                  },
                  {
                    "text": "Rarely presents as a darkly pigmented macule of the nipple"
                  },
                  {
                    "text": "Excellent prognosis for patients with only MPD and no invasion: > 95% survival at 20 yearsIf invasion is present, prognosis depends on the size of the invasive carcinoma and lymph node status",
                    "sub_points": [
                      "If invasion is present, prognosis depends on the size of the invasive carcinoma and lymph node status"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Tumor cells, singly and in clusters, are present within the epidermis"
                  },
                  {
                    "text": "Tumor cells can extend from the orifice of a lactiferous duct to nipple skin without crossing the basement membrane"
                  },
                  {
                    "text": "A moderate to intense lichenoid lymphocytic infiltrate is typically present in the underlying superficial dermis"
                  },
                  {
                    "text": "Majority are positive for HER2 (~ 80%)"
                  },
                  {
                    "text": "Immunohistochemical studies are helpful in distinguishing MPD from melanoma and squamous cell carcinoma"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Toker cell hyperplasia"
                  },
                  {
                    "text": "Clear cell change in keratinocytes"
                  },
                  {
                    "text": "Squamous cell carcinoma in situ/Bowen disease"
                  },
                  {
                    "text": "Sebaceous carcinoma"
                  },
                  {
                    "text": "Melanoma"
                  },
                  {
                    "text": "Carcinoma directly invading nipple skin"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Mammary Paget disease (MPD) is an uncommon clinical presentation of breast carcinoma (BC) as a scaling crust or erosion of the nipple skin or (very rarely) a darkly pigmented macule due to tumor cells involving nipple epidermis~ 50% are ductal carcinoma in situ (DCIS) alone and ~ 50% DCIS and invasive BC",
                    "sub_points": [
                      "~ 50% are ductal carcinoma in situ (DCIS) alone and ~ 50% DCIS and invasive BC"
                    ]
                  },
                  {
                    "text": "\"Pagetoid spread\" is used to describe tumor cells located between a normal basement membrane and an overlying normal cell layerOccurs with multiple types of tumors and at multiple sites in the body",
                    "sub_points": [
                      "Occurs with multiple types of tumors and at multiple sites in the body"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "Mammary Paget Disease (MPD)": [
                  {
                    "text": "1st described by Sir James Paget (1874)He noted skin changes on the nipple and areola with characteristics of chronic eczema in women who later developed ipsilateral invasive BCAlthough he hypothesized that the skin changes were an inflammatory condition that increased the risk of BC, they are actually due to tumor cells infiltrating in the epidermis",
                    "sub_points": [
                      "He noted skin changes on the nipple and areola with characteristics of chronic eczema in women who later developed ipsilateral invasive BC",
                      "Although he hypothesized that the skin changes were an inflammatory condition that increased the risk of BC, they are actually due to tumor cells infiltrating in the epidermis"
                    ]
                  },
                  {
                    "text": "In the majority of cases, the skin changes result from DCIS arising in the breast and spreading into the nipple epidermis at the orifice of a lactiferous ductNo invasion is necessary as the basement membranes of the ductal system and the epidermis are continuous",
                    "sub_points": [
                      "No invasion is necessary as the basement membranes of the ductal system and the epidermis are continuous"
                    ]
                  },
                  {
                    "text": "The tumor cells disrupt the tight junctions of the squamous cells, allowing intercellular fluid to escape, thus resulting in the scaling crust on the skinThe changes are often pruritic, resulting in excoriation, which can cause skin erosion",
                    "sub_points": [
                      "The changes are often pruritic, resulting in excoriation, which can cause skin erosion"
                    ]
                  },
                  {
                    "text": "The skin lesions are often misinterpreted as an inflammatory condition, and diagnosis can be delayed for months or years"
                  },
                  {
                    "text": "The majority of MPD (~ 80%) shows HER2 overexpression, and it has been suggested this plays an important role in the skin involvementEpidermotropism may be mediated by interactions of HER2 on tumor cells and heregulin-α motility factor released from keratinocytes, promoting a chemotactic action",
                    "sub_points": [
                      "Epidermotropism may be mediated by interactions of HER2 on tumor cells and heregulin-α motility factor released from keratinocytes, promoting a chemotactic action"
                    ]
                  },
                  {
                    "text": "Very rare cases without underlying DCIS may arise from Toker cells residing in the epidermisThese are normal glandular cells found at the orifices of nipple ducts",
                    "sub_points": [
                      "These are normal glandular cells found at the orifices of nipple ducts"
                    ]
                  },
                  {
                    "text": "MPD can also arise in the areola from rudimentary ductal systems and in supernumerary nipples along the milk line"
                  },
                  {
                    "text": "There are 3 additional presentations of MPDPigmented MPDMPD rarely forms a darkly pigmented macule of the nipple that closely resembles melanomaTumor cells are associated with a markedly increased number of melanocytes, resulting in the pigmentationThe tumor cells are basally located and do not disrupt the overlying keratinocytes; thus, the typical scaling crust is not presentClinically occult (incidental) MPDMPD can be an incidental finding in mastectomiesFocal nipple involvement can be insufficient to produce clinically detected symptomsIatrogenic MPD3 cases of MPD arising at the site of a core needle biopsy of the breast have been reportedThe original carcinoma was microinvasive carcinoma and DCISThe patients presented with a scaling crust at the skin entrance site of the prior core needle biopsyLocated far from original nipple and areolaNot located on milk lineThe MPD was limited to the epidermis with no invasion present",
                    "sub_points": [
                      "Pigmented MPDMPD rarely forms a darkly pigmented macule of the nipple that closely resembles melanomaTumor cells are associated with a markedly increased number of melanocytes, resulting in the pigmentationThe tumor cells are basally located and do not disrupt the overlying keratinocytes; thus, the typical scaling crust is not present",
                      "MPD rarely forms a darkly pigmented macule of the nipple that closely resembles melanoma",
                      "Tumor cells are associated with a markedly increased number of melanocytes, resulting in the pigmentation",
                      "The tumor cells are basally located and do not disrupt the overlying keratinocytes; thus, the typical scaling crust is not present",
                      "Clinically occult (incidental) MPDMPD can be an incidental finding in mastectomiesFocal nipple involvement can be insufficient to produce clinically detected symptoms",
                      "MPD can be an incidental finding in mastectomies",
                      "Focal nipple involvement can be insufficient to produce clinically detected symptoms",
                      "Iatrogenic MPD3 cases of MPD arising at the site of a core needle biopsy of the breast have been reportedThe original carcinoma was microinvasive carcinoma and DCISThe patients presented with a scaling crust at the skin entrance site of the prior core needle biopsyLocated far from original nipple and areolaNot located on milk lineThe MPD was limited to the epidermis with no invasion present",
                      "3 cases of MPD arising at the site of a core needle biopsy of the breast have been reportedThe original carcinoma was microinvasive carcinoma and DCIS",
                      "The original carcinoma was microinvasive carcinoma and DCIS",
                      "The patients presented with a scaling crust at the skin entrance site of the prior core needle biopsyLocated far from original nipple and areolaNot located on milk line",
                      "Located far from original nipple and areola",
                      "Not located on milk line",
                      "The MPD was limited to the epidermis with no invasion present"
                    ]
                  },
                  {
                    "text": "\"Paget disease\" as a diagnostic termThe term \"Paget disease\" does not specify whether the carcinoma is only DCIS or if invasive BC is also present~ 50% of cases of MPD are associated with invasive BC deeper in the breastIf no invasion is present, \"DCIS involving nipple epidermis (Paget disease of the nipple)\" is a clearer description to communicate that only DCIS is present",
                    "sub_points": [
                      "The term \"Paget disease\" does not specify whether the carcinoma is only DCIS or if invasive BC is also present~ 50% of cases of MPD are associated with invasive BC deeper in the breast",
                      "~ 50% of cases of MPD are associated with invasive BC deeper in the breast",
                      "If no invasion is present, \"DCIS involving nipple epidermis (Paget disease of the nipple)\" is a clearer description to communicate that only DCIS is present"
                    ]
                  },
                  {
                    "text": "Pagetoid spread in breast ductsIn breast tissue away from the nipple, pagetoid spread in ducts is most commonly associated with atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS)Unlike ALH and LCIS, DCIS typically overgrows or pushes aside overlying luminal cells and fills involved ducts",
                    "sub_points": [
                      "In breast tissue away from the nipple, pagetoid spread in ducts is most commonly associated with atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS)",
                      "Unlike ALH and LCIS, DCIS typically overgrows or pushes aside overlying luminal cells and fills involved ducts"
                    ]
                  }
                ],
                "Other Types of Paget Disease": [
                  {
                    "text": "ExtramammaryPaget disease(EMPD)Arises from apocrine sweat glands in axilla, perianal region, penis, or scrotum",
                    "sub_points": [
                      "Arises from apocrine sweat glands in axilla, perianal region, penis, or scrotum"
                    ]
                  },
                  {
                    "text": "EctopicPaget disease(EPD)Arises in skin devoid of apocrine glands in male and female patientsCan involve the trunk, face, scalp, and limbsMay arise from eccrine glandsOnly 1 reported case of lymph node involvementWhen EPD arises on the skin of the breast away from the nipple, it can be confused clinically with MPDPatients may undergo unnecessary breast biopsy or mastectomy",
                    "sub_points": [
                      "Arises in skin devoid of apocrine glands in male and female patientsCan involve the trunk, face, scalp, and limbsMay arise from eccrine glands",
                      "Can involve the trunk, face, scalp, and limbs",
                      "May arise from eccrine glands",
                      "Only 1 reported case of lymph node involvement",
                      "When EPD arises on the skin of the breast away from the nipple, it can be confused clinically with MPD",
                      "Patients may undergo unnecessary breast biopsy or mastectomy"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Occurs in 1-4% of women and 1-2% of men with breast cancer"
                  }
                ],
                "Age": [
                  {
                    "text": "No predilection seen"
                  }
                ],
                "Sex": [
                  {
                    "text": "Occurs in both female and male patients"
                  },
                  {
                    "text": "MPD in male patients is very similar to MPD in female patientsHER2 positivity may be lower, but only a few cases have been tested",
                    "sub_points": [
                      "HER2 positivity may be lower, but only a few cases have been tested"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Scaling crust and erythema of nipple epidermis is the presenting symptom in > 90% of casesMay be limited to nipple or extend to areola and adjacent skinErosion of epidermis or serosanguineous/bloody discharge may be present in more advanced casesPain and pruritus are frequent symptomsMay result in excoriation of nipple, which exacerbates the skin changesA delay in diagnosis can be related to an initial diagnosis of eczema or inflammatory skin disorderPatients often treated topically for suspected skin disease for prolonged periods (months to years)",
                    "sub_points": [
                      "May be limited to nipple or extend to areola and adjacent skin",
                      "Erosion of epidermis or serosanguineous/bloody discharge may be present in more advanced cases",
                      "Pain and pruritus are frequent symptomsMay result in excoriation of nipple, which exacerbates the skin changes",
                      "May result in excoriation of nipple, which exacerbates the skin changes",
                      "A delay in diagnosis can be related to an initial diagnosis of eczema or inflammatory skin disorderPatients often treated topically for suspected skin disease for prolonged periods (months to years)",
                      "Patients often treated topically for suspected skin disease for prolonged periods (months to years)"
                    ]
                  },
                  {
                    "text": "A rare presentation is as a darkly pigmented macule involving the nipple epidermisPigmentation is due to an increased number of melanocytes near tumor cellsMelanocytes intermingle in nests of tumor cellsTumor cells are located in the lower epidermis and do not disrupt the epidermis sufficiently to cause a scale crust",
                    "sub_points": [
                      "Pigmentation is due to an increased number of melanocytes near tumor cellsMelanocytes intermingle in nests of tumor cellsTumor cells are located in the lower epidermis and do not disrupt the epidermis sufficiently to cause a scale crust",
                      "Melanocytes intermingle in nests of tumor cells",
                      "Tumor cells are located in the lower epidermis and do not disrupt the epidermis sufficiently to cause a scale crust"
                    ]
                  },
                  {
                    "text": "~ 1/2 of patients also have a palpable massMost of these patients have associated invasive BC deeper in the breast",
                    "sub_points": [
                      "Most of these patients have associated invasive BC deeper in the breast"
                    ]
                  },
                  {
                    "text": "MPD can be the site of recurrence after breast-conserving therapy or nipple-sparing mastectomyThe risk is increased if the original carcinoma was HER2(+)",
                    "sub_points": [
                      "The risk is increased if the original carcinoma was HER2(+)"
                    ]
                  },
                  {
                    "text": "Benign lesions can clinically mimic MPDNipple adenomas growing out onto the nipple epidermis can produce erosion and bleedingNipple hyperkeratosis causing thickening and pigmentation associated with pregnancy, drug use (BRAF inhibitors, hormone use in men), other diseasesContact or allergic eczema can involve the nipple, causing irritation and erythema",
                    "sub_points": [
                      "Nipple adenomas growing out onto the nipple epidermis can produce erosion and bleeding",
                      "Nipple hyperkeratosis causing thickening and pigmentation associated with pregnancy, drug use (BRAF inhibitors, hormone use in men), other diseases",
                      "Contact or allergic eczema can involve the nipple, causing irritation and erythema"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Systemic treatmentPatients with both MPD and invasive MPD may receive neoadjuvant therapyComplete response of the MPD and other areas of DCIS are reported in ~ 40-50%, especially for HER2(+) carcinomas",
                    "sub_points": [
                      "Patients with both MPD and invasive MPD may receive neoadjuvant therapy",
                      "Complete response of the MPD and other areas of DCIS are reported in ~ 40-50%, especially for HER2(+) carcinomas"
                    ]
                  }
                ],
                "Surgical approaches": [
                  {
                    "text": "The extent of surgery is determined by presence and extent of the underlying BCThe entire nipple must be excised",
                    "sub_points": [
                      "The entire nipple must be excised"
                    ]
                  },
                  {
                    "text": "Breast-conserving therapy is often possible"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis is determined by the presence and extent of the underlying invasive BC"
                  },
                  {
                    "text": "When invasion occurs directly from MPD in the epidermis, the BCs are typically small, as they are detected earlyThe AJCC T classification is based on tumor sizeSkin erosion and hemorrhage are typically due to DCIS and should not be classified as AJCC T4bThe presence of tumor cells in the superficial dermis are not associated with a greater likelihood of metastasisLymph node metastases are rare",
                    "sub_points": [
                      "The AJCC T classification is based on tumor size",
                      "Skin erosion and hemorrhage are typically due to DCIS and should not be classified as AJCC T4b",
                      "The presence of tumor cells in the superficial dermis are not associated with a greater likelihood of metastasis",
                      "Lymph node metastases are rare"
                    ]
                  },
                  {
                    "text": "For MPD with DCIS only, survival is similar to cases of DCIS (> 95% survival at 20 years)"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "MPD with only DCIS is not detectable by imaging in 20-50% of patients"
                  },
                  {
                    "text": "Imaging is most useful in detecting the presence of abnormal findings elsewhere in breastIf a mammographic density or distortion with nipple retraction are present, invasion is more likely to be presentCalcifications may be associated with underlying DCIS",
                    "sub_points": [
                      "If a mammographic density or distortion with nipple retraction are present, invasion is more likely to be present",
                      "Calcifications may be associated with underlying DCIS"
                    ]
                  }
                ],
                "MR Findings": [
                  {
                    "text": "May or may not show abnormal nipple enhancement &/or ill-defined, thickened nipple-areolar complexBlood vessel density is increased in MPD, which may result in increased enhancementMay be related to associated inflammation",
                    "sub_points": [
                      "Blood vessel density is increased in MPD, which may result in increased enhancementMay be related to associated inflammation",
                      "May be related to associated inflammation"
                    ]
                  },
                  {
                    "text": "MR can be useful in the detection of the extent of disease and other areas of disease in underlying breast tissue"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "The skin preparation prior to surgery usually removes the scaling crust seen clinicallyIn advanced cases, the skin may show erosion or erythema",
                    "sub_points": [
                      "In advanced cases, the skin may show erosion or erythema"
                    ]
                  },
                  {
                    "text": "A palpable mass may be present in the underlying breast if invasive BC is present"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "The extent of epidermal involvement usually does not extend beyond the clinically evident lesion"
                  },
                  {
                    "text": "The nipple should be excised with a rim of normal skin around the area of skin changes"
                  },
                  {
                    "text": "Skin margins should be taken, but the likelihood of skin margin involvement is very small"
                  },
                  {
                    "text": "If no invasive BC has been documented, the entire nipple should be examinedNipple is truncated at baseAn en face section of the nipple base shows cross sections of all lactiferous sinusesThe upper part of the nipple is sectioned perpendicularlyThese sections will show many of the duct orifices",
                    "sub_points": [
                      "Nipple is truncated at baseAn en face section of the nipple base shows cross sections of all lactiferous sinusesThe upper part of the nipple is sectioned perpendicularlyThese sections will show many of the duct orifices",
                      "An en face section of the nipple base shows cross sections of all lactiferous sinuses",
                      "The upper part of the nipple is sectioned perpendicularlyThese sections will show many of the duct orifices",
                      "These sections will show many of the duct orifices"
                    ]
                  },
                  {
                    "text": "If there is known invasive BC, examination of the entire nipple is unlikely to reveal additional prognostic informationA representative perpendicular section of nipple can document MPD",
                    "sub_points": [
                      "A representative perpendicular section of nipple can document MPD"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "Protein Expression": [
                  {
                    "text": "The distribution of molecular types of MPD is different from that observed in invasive BCs in generalER(+)/HER2(-) (similar to luminal cancers identified by mRNA profiling): ~ 5%ER(+)/HER2(+) (similar to some luminal B cancers identified by mRNA profiling): ~ 24%ER(-)/HER2(+) (similar to HER2-enriched cancers identified by mRNA profiling): ~ 66%ER(-)/HER2(-) (similar to basal-like cancers identified by mRNA profiling): ~ 5%",
                    "sub_points": [
                      "ER(+)/HER2(-) (similar to luminal cancers identified by mRNA profiling): ~ 5%",
                      "ER(+)/HER2(+) (similar to some luminal B cancers identified by mRNA profiling): ~ 24%",
                      "ER(-)/HER2(+) (similar to HER2-enriched cancers identified by mRNA profiling): ~ 66%",
                      "ER(-)/HER2(-) (similar to basal-like cancers identified by mRNA profiling): ~ 5%"
                    ]
                  },
                  {
                    "text": "Thus, ER(+) and HER2(-) carcinomas are less common, and HER2(+) carcinomas are more common"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Paget cells are large and atypical in appearance and stand out from surrounding keratinocytesTumor cells contain enlarged pleomorphic nuclei often with prominent nucleoliExhibit variable mitotic activityThe cells have abundant pale or eosinophilic cytoplasmMay contain diastase-resistant PAS(+) globules, consistent with mucinTumor cells can take up melanin from the adjacent normal melanocytesThis finding is not equivalent to pigmented MPD, as pigmentation is not seen clinically and the number of melanocytes is not increasedImmunohistochemical studies can identify pigmented cells as carcinoma and not melanoma",
                    "sub_points": [
                      "Tumor cells contain enlarged pleomorphic nuclei often with prominent nucleoli",
                      "Exhibit variable mitotic activity",
                      "The cells have abundant pale or eosinophilic cytoplasmMay contain diastase-resistant PAS(+) globules, consistent with mucin",
                      "May contain diastase-resistant PAS(+) globules, consistent with mucin",
                      "Tumor cells can take up melanin from the adjacent normal melanocytesThis finding is not equivalent to pigmented MPD, as pigmentation is not seen clinically and the number of melanocytes is not increasedImmunohistochemical studies can identify pigmented cells as carcinoma and not melanoma",
                      "This finding is not equivalent to pigmented MPD, as pigmentation is not seen clinically and the number of melanocytes is not increasedImmunohistochemical studies can identify pigmented cells as carcinoma and not melanoma",
                      "Immunohistochemical studies can identify pigmented cells as carcinoma and not melanoma"
                    ]
                  },
                  {
                    "text": "Cells are intermingled with keratinocytesTypically present as single cells and in small clustersClusters are more common in basal portion of epidermisIn rare cases, the entire epidermis is replaced by Paget cellsCells are friable and loss can result in erosion of surfaceThe basal layer of the epidermis appears to be compressed or \"crushed\" by the tumor cells",
                    "sub_points": [
                      "Typically present as single cells and in small clustersClusters are more common in basal portion of epidermis",
                      "Clusters are more common in basal portion of epidermis",
                      "In rare cases, the entire epidermis is replaced by Paget cellsCells are friable and loss can result in erosion of surface",
                      "Cells are friable and loss can result in erosion of surface",
                      "The basal layer of the epidermis appears to be compressed or \"crushed\" by the tumor cells"
                    ]
                  },
                  {
                    "text": "A moderate to intense lichenoid lymphocytic infiltrate is typically present in the underlying superficial dermisInflammatory changes may obscure tumor cells and should not be mistaken for dermatitis",
                    "sub_points": [
                      "Inflammatory changes may obscure tumor cells and should not be mistaken for dermatitis"
                    ]
                  },
                  {
                    "text": "Varying degrees of hyperplasia and hyperkeratosis of the associated epidermis are commonThese changes can be a response to tumor or due to excoriation",
                    "sub_points": [
                      "These changes can be a response to tumor or due to excoriation"
                    ]
                  },
                  {
                    "text": "Associated DCIS ± invasion is present in the underlying breast in the majority of casesAssociated DCIS is typically high grade with a solid pattern and central necrosisCarcinoma deeper in the breast typically has the same morphologic appearance and receptor expression pattern as the MPD",
                    "sub_points": [
                      "Associated DCIS is typically high grade with a solid pattern and central necrosis",
                      "Carcinoma deeper in the breast typically has the same morphologic appearance and receptor expression pattern as the MPD"
                    ]
                  },
                  {
                    "text": "Pigmented MPDTumors present as a darkly pigmented macule of nipple epidermisPaget cells are associated with increased numbers of melanocytes in the epidermis that are intermingled in clusters of tumor cellsNumerous melanophages and melanin are present in the surrounding stromaTumor cells cluster at the lower portion of the epidermis and are not seen in the upper levelsThe keratinocytes are not disrupted and a scale crust is not present",
                    "sub_points": [
                      "Tumors present as a darkly pigmented macule of nipple epidermis",
                      "Paget cells are associated with increased numbers of melanocytes in the epidermis that are intermingled in clusters of tumor cells",
                      "Numerous melanophages and melanin are present in the surrounding stroma",
                      "Tumor cells cluster at the lower portion of the epidermis and are not seen in the upper levelsThe keratinocytes are not disrupted and a scale crust is not present",
                      "The keratinocytes are not disrupted and a scale crust is not present"
                    ]
                  },
                  {
                    "text": "MPD with dermal invasionIn rare cases, tumor cells in the epidermis directly invade into the underlying dermisAreas of invasion are often obscured by a dense lymphocytic infiltrateMultiplex assays for keratin and myoepithelial markers are often helpful to demonstrate tumor cells in stroma and not in underlying ductsDermal lymphovascular invasion has not been described; only a single case has been associated with lymph node metastases",
                    "sub_points": [
                      "In rare cases, tumor cells in the epidermis directly invade into the underlying dermis",
                      "Areas of invasion are often obscured by a dense lymphocytic infiltrate",
                      "Multiplex assays for keratin and myoepithelial markers are often helpful to demonstrate tumor cells in stroma and not in underlying ducts",
                      "Dermal lymphovascular invasion has not been described; only a single case has been associated with lymph node metastases"
                    ]
                  },
                  {
                    "text": "MPD of areolaCan arise from rudimentary ductal systems or apocrine glands of the areola",
                    "sub_points": [
                      "Can arise from rudimentary ductal systems or apocrine glands of the areola"
                    ]
                  },
                  {
                    "text": "Ectopic PD involving breast skinPD arising on the skin of the breast, but not associated with the nipple and areola, may be ectopic PDThe possibility of PD in a supernumerary nipple along the milk line or iatrogenic MPD at a needle biopsy site should also be consideredThe histologic appearance is identical to MPD, but lactiferous sinuses are not seen in the underlying tissueThought to arise from eccrine ducts",
                    "sub_points": [
                      "PD arising on the skin of the breast, but not associated with the nipple and areola, may be ectopic PD",
                      "The possibility of PD in a supernumerary nipple along the milk line or iatrogenic MPD at a needle biopsy site should also be considered",
                      "The histologic appearance is identical to MPD, but lactiferous sinuses are not seen in the underlying tissue",
                      "Thought to arise from eccrine ducts"
                    ]
                  }
                ],
                "Skin Punch Biopsy": [
                  {
                    "text": "The initial diagnosis is usually made with a skin punch biopsy"
                  },
                  {
                    "text": "Often, these biopsies are small due to concern about the cosmetic appearance of the nipple"
                  },
                  {
                    "text": "It is important for the pathologist to be aware if there is a clinical lesion that would correlate with MPDIdentification of Toker cells as an incidental finding could lead to overdiagnosis of MPDIHC for HER2 can be helpful in making the distinction between Toker cells and MPD",
                    "sub_points": [
                      "Identification of Toker cells as an incidental finding could lead to overdiagnosis of MPD",
                      "IHC for HER2 can be helpful in making the distinction between Toker cells and MPD"
                    ]
                  }
                ],
                "Cytologic Preparations": [
                  {
                    "text": "Tumor cells are often present on the surface of the epidermis and in the scale crust"
                  },
                  {
                    "text": "Skin scrapings can sometimes be used for diagnosis"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Mucin stains or PAS with diastase (+) in ~ 50%Helpful to demonstrate glandular origin of tumor cells",
                    "sub_points": [
                      "Helpful to demonstrate glandular origin of tumor cells"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "A panel of immunohistochemical studies are helpful in establishing the glandular origin of Paget cellsPaget cells have similar immunophenotype as underlying BC cells (if present)",
                    "sub_points": [
                      "Paget cells have similar immunophenotype as underlying BC cells (if present)"
                    ]
                  },
                  {
                    "text": "Low molecular weight (LMW) cytokeratins (cytokeratin 7, CAM5.2, others) (+) in > 90%Helpful to distinguish tumor cells (+) from squamous cell carcinoma (negative in ~ 90% but can be positive) and melanoma (-)Toker cells are positive and should not be mistaken for Paget cellsRare cases of MPD are CK7(-)",
                    "sub_points": [
                      "Helpful to distinguish tumor cells (+) from squamous cell carcinoma (negative in ~ 90% but can be positive) and melanoma (-)",
                      "Toker cells are positive and should not be mistaken for Paget cells",
                      "Rare cases of MPD are CK7(-)"
                    ]
                  },
                  {
                    "text": "High molecular weight (HMW) cytokeratins (cytokeratin 5/6, others)Helpful to distinguish tumor cells (-) from squamous cells (+)",
                    "sub_points": [
                      "Helpful to distinguish tumor cells (-) from squamous cells (+)"
                    ]
                  },
                  {
                    "text": "HER2(+): ~ 80-90%Helpful in distinguishing tumor cells from Toker cells",
                    "sub_points": [
                      "Helpful in distinguishing tumor cells from Toker cells"
                    ]
                  },
                  {
                    "text": "ER/PR: Variable (10-40%)Typically positive in Toker cells, but not helpful in distinguishing from Paget cells",
                    "sub_points": [
                      "Typically positive in Toker cells, but not helpful in distinguishing from Paget cells"
                    ]
                  },
                  {
                    "text": "GATA3(+): 70-95%Also positive in squamous cell carcinoma of the skin",
                    "sub_points": [
                      "Also positive in squamous cell carcinoma of the skin"
                    ]
                  },
                  {
                    "text": "Carcinoembryonic antigen (+) in ~ 50%May be helpful in distinguishing Paget cells from squamous cells and melanocytesHowever, variable staining patterns with different antibodies limits usefulness",
                    "sub_points": [
                      "May be helpful in distinguishing Paget cells from squamous cells and melanocytes",
                      "However, variable staining patterns with different antibodies limits usefulness"
                    ]
                  },
                  {
                    "text": "Epithelial membrane antigen/MUC1(+): ~ 90%Helpful in distinguishing Paget cells from melanocytesSquamous cell carcinomas sometimes reported to be positive",
                    "sub_points": [
                      "Helpful in distinguishing Paget cells from melanocytes",
                      "Squamous cell carcinomas sometimes reported to be positive"
                    ]
                  },
                  {
                    "text": "S100(+): ~ 25-50%If negative, excludes diagnosis of melanoma",
                    "sub_points": [
                      "If negative, excludes diagnosis of melanoma"
                    ]
                  },
                  {
                    "text": "TRPS1(+): ~ 100%Of note, squamous cell carcinoma is also positive",
                    "sub_points": [
                      "Of note, squamous cell carcinoma is also positive"
                    ]
                  },
                  {
                    "text": "Melanoma markers (Melan-A, HMB45, others) (-)Helpful to evaluate for melanomaMelanocytes can be increased in number in the area of Paget disease",
                    "sub_points": [
                      "Helpful to evaluate for melanoma",
                      "Melanocytes can be increased in number in the area of Paget disease"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Toker Cells and Toker Cell Hyperplasia": [
                  {
                    "text": "Toker cells are normal glandular epithelial cells found in nipple epidermis near duct orificesPresent in at least 70% of normal nipples when detected with immunohistochemical studiesMay be slightly more common in transmasculine individuals",
                    "sub_points": [
                      "Present in at least 70% of normal nipples when detected with immunohistochemical studies",
                      "May be slightly more common in transmasculine individuals"
                    ]
                  },
                  {
                    "text": "They are an incidental finding and do not cause clinical symptoms"
                  },
                  {
                    "text": "Cells have a benign appearance with bland, small, regular nuclei and inconspicuous nucleoliPresent as single cells, small nests, or may form tubules",
                    "sub_points": [
                      "Present as single cells, small nests, or may form tubules"
                    ]
                  },
                  {
                    "text": "Cells are similar to normal luminal cellsPositive for LMW keratins (CK7, CAM5.2), ER, and EMALess commonly positive for CEA and mucin",
                    "sub_points": [
                      "Positive for LMW keratins (CK7, CAM5.2), ER, and EMALess commonly positive for CEA and mucin",
                      "Less commonly positive for CEA and mucin"
                    ]
                  },
                  {
                    "text": "Toker cells can be distinguished from Paget cellsPaget cells have greater nuclear pleomorphism, are found in greater numbers, and the majority are HER2(+)",
                    "sub_points": [
                      "Paget cells have greater nuclear pleomorphism, are found in greater numbers, and the majority are HER2(+)"
                    ]
                  },
                  {
                    "text": "In Toker cell hyperplasia, cells are numerous and may show some evidence of nuclear atypiaUsually incidental finding; would be highly unusual to be associated with clinical findingsProposed to be precursor lesion for rare cases of MPD without an underlying breast cancer",
                    "sub_points": [
                      "Usually incidental finding; would be highly unusual to be associated with clinical findings",
                      "Proposed to be precursor lesion for rare cases of MPD without an underlying breast cancer"
                    ]
                  },
                  {
                    "text": "Toker cells in combination with an inflammatory condition of the skin can be diagnostically difficult"
                  }
                ],
                "Clear Cell Change in Keratinocytes (\"Pagetoid Dyskeratosis\")": [
                  {
                    "text": "Benign clear cells are often seen as an incidental finding in nipples of mastectomies"
                  },
                  {
                    "text": "Squamous cells have small bland nuclei and spiny processes"
                  },
                  {
                    "text": "More frequently seen in basal and midlayers of epidermis"
                  }
                ],
                "Squamous Cell Carcinoma In Situ/Bowen Disease": [
                  {
                    "text": "The clinical presentation of early disease is very similar to MPD as a pruritic scaly lesion, sometimes with a raised plaque &/or ulcerationLike MPD, skin symptoms can be present for months to years",
                    "sub_points": [
                      "Like MPD, skin symptoms can be present for months to years"
                    ]
                  },
                  {
                    "text": "Not associated with underlying BCThe squamous cell carcinoma can extend into lactiferous sinuses",
                    "sub_points": [
                      "The squamous cell carcinoma can extend into lactiferous sinuses"
                    ]
                  },
                  {
                    "text": "Extensive replacement of nipple epidermis by Paget cells can mimic squamous cell carcinoma in situ microscopically"
                  },
                  {
                    "text": "Squamous cell carcinoma is positive for HMW cytokeratins (e.g., CK5/6, CK14, CK17) (> 95%), p63 (> 95%), and GATA3 (~ 80%)Negative for LMW keratins (CK7, CAM5.2), GCDFP-15, and HER2",
                    "sub_points": [
                      "Negative for LMW keratins (CK7, CAM5.2), GCDFP-15, and HER2"
                    ]
                  }
                ],
                "Sebaceous Carcinoma": [
                  {
                    "text": "Usually occurs on the eyelids but rarely occurs elsewhere, including on the nipple"
                  },
                  {
                    "text": "There is a strong association with Muir-Torre syndrome"
                  },
                  {
                    "text": "Metastases occur in ~ 30%"
                  },
                  {
                    "text": "Presents as erythematous plaque, clinically mimicking MPD"
                  },
                  {
                    "text": "Basaloid and squamoid cells are intermingled with cells with sebaceous differentiationCytoplasm vacuolated due to lipids, which indent the nucleusSebaceous cells can be scant in poorly differentiated carcinomasA pagetoid pattern can be seen in the epidermis",
                    "sub_points": [
                      "Cytoplasm vacuolated due to lipids, which indent the nucleus",
                      "Sebaceous cells can be scant in poorly differentiated carcinomas",
                      "A pagetoid pattern can be seen in the epidermis"
                    ]
                  },
                  {
                    "text": "Like MPD, can be positive for LMW keratins, GATA3, ER (~ 30%), and HER2 (~ 35%)"
                  },
                  {
                    "text": "Unlike MPD, positive for HMW keratins (> 95%) and p63 (> 95%), and negative for GCDFP-15"
                  },
                  {
                    "text": "The most specific marker is adipophilin, which is positive in the lipid vacuolesThis antibody detects adipocyte differentiation-related protein (ADRP/ADFP)",
                    "sub_points": [
                      "This antibody detects adipocyte differentiation-related protein (ADRP/ADFP)"
                    ]
                  }
                ],
                "Melanoma": [
                  {
                    "text": "Melanoma involving the nipple is exceedingly rarePigmented Paget disease clinically resembles melanocytic lesion",
                    "sub_points": [
                      "Pigmented Paget disease clinically resembles melanocytic lesion"
                    ]
                  },
                  {
                    "text": "Cells show nesting at dermoepidermal junction and \"buck shot\" spread in epidermis"
                  },
                  {
                    "text": "Cells often have cytoplasmic melaninPaget cells may take up melanin pigment released by epidermal cells or melanocytes, mimicking melanoma",
                    "sub_points": [
                      "Paget cells may take up melanin pigment released by epidermal cells or melanocytes, mimicking melanoma"
                    ]
                  },
                  {
                    "text": "IHC staining pattern is helpful for confirming diagnosisPositive for S100, HMB-45, Melan-A, and other melanoma markersNegative for keratins, HER2, CEA, GATA3, and EMA",
                    "sub_points": [
                      "Positive for S100, HMB-45, Melan-A, and other melanoma markers",
                      "Negative for keratins, HER2, CEA, GATA3, and EMA"
                    ]
                  }
                ],
                "Carcinoma Directly Invading Nipple Skin": [
                  {
                    "text": "Large, locally advanced palpable invasive BCs can invade into skin, resulting in erythema &/or erosionMay involve dermis in a horizontal pattern for 1-2 mm",
                    "sub_points": [
                      "May involve dermis in a horizontal pattern for 1-2 mm"
                    ]
                  },
                  {
                    "text": "May resemble MPD in small skin punch biopsies"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "MPD is much more common than squamous cell carcinoma or melanoma involving the nipple"
                  },
                  {
                    "text": "In the absence of clinically evident skin changes, a diagnosis of MPD is highly unlikelyThe possibility of Toker cells should always be considered",
                    "sub_points": [
                      "The possibility of Toker cells should always be considered"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "A diagnosis of Paget disease could refer to either DCIS alone or DCIS and invasive BC"
                  },
                  {
                    "text": "A clearer diagnosis is \"DCIS involving nipple epidermis (Paget disease)\" when only DCIS is present"
                  },
                  {
                    "text": "The appropriate AJCC/UICC T category is Tis (Paget) if no underlying DCIS is present, Tis (DCIS) if underlying DCIS is present, or T based on invasive BC if present"
                  },
                  {
                    "text": "If there is invasion into the dermis, only the size of the invasion should be used as size for T classification"
                  },
                  {
                    "text": "Skin changes (erythema, edema, erosion) due to DCIS are not sufficient for classification as T4 disease"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Cystic Hypersecretory Lesions": {
            "name": "Cystic Hypersecretory Lesions",
            "url": "https://app.pathprimer.com/document/3fb5cf90-8d20-48f0-8ac4-f8f76471c80c/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Cystic hypersecretory hyperplasia (CHH) and atypical CHH (A-CHH) are benign lesions"
                  },
                  {
                    "text": "CHH is often an incidental finding but can present as mammographic calcifications, a mass, or nipple discharge"
                  },
                  {
                    "text": "If present on core needle biopsy, excision is recommended due to their occasional association with carcinoma"
                  },
                  {
                    "text": "Very rare finding; fewer than 100 cases reported"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "CHH: Cysts are filled with dense eosinophilic secretions, lined by flat to columnar cells without atypiaThe cytoplasm is frequently vacuolated~ 80% estrogen receptor positive",
                    "sub_points": [
                      "The cytoplasm is frequently vacuolated",
                      "~ 80% estrogen receptor positive"
                    ]
                  },
                  {
                    "text": "A-CHH: Similar to CHH but with areas of nuclear enlargement, hyperchromasia, and prominent nucleoli"
                  },
                  {
                    "text": "Cystic hypersecretory carcinoma in situ (CHC-IS): Similar to A-CHH but with micropapillary architecture"
                  },
                  {
                    "text": "CHC-IS with invasive carcinoma: Invasive carcinomas arising in a background of CHC-ISTypically does not show hypersecretory features but may be associated with eosinophilic secretions~50% estrogen receptor positive",
                    "sub_points": [
                      "Typically does not show hypersecretory features but may be associated with eosinophilic secretions",
                      "~50% estrogen receptor positive"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Pregnancy-like (pseudolactational) hyperplasia (PLH)Same histologic changes as during pregnancy or lactation",
                    "sub_points": [
                      "Same histologic changes as during pregnancy or lactation"
                    ]
                  },
                  {
                    "text": "Secretory carcinomaTypically low-grade invasive carcinomas, whereas carcinomas associated with CHC-IS are typically high gradeCysts are smaller (microcystic), giving a honeycomb appearanceNegative for estrogen receptor and positive for S100, and the majority have anETV6::NTRK3gene fusion",
                    "sub_points": [
                      "Typically low-grade invasive carcinomas, whereas carcinomas associated with CHC-IS are typically high grade",
                      "Cysts are smaller (microcystic), giving a honeycomb appearance",
                      "Negative for estrogen receptor and positive for S100, and the majority have anETV6::NTRK3gene fusion"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Cystic hypersecretory hyperplasia (CHH)"
                  },
                  {
                    "text": "Atypical CHH (A-CHH)"
                  },
                  {
                    "text": "Cystic hypersecretory carcinoma (CHC)It should be specified if CHC is in situ carcinoma (CHC-IS) or associated with invasion (CHC with invasion)",
                    "sub_points": [
                      "It should be specified if CHC is in situ carcinoma (CHC-IS) or associated with invasion (CHC with invasion)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Very rare finding: Fewer than 100 cases reported"
                  }
                ],
                "Age": [
                  {
                    "text": "~ 34-79 years (mean: ~ 60 years)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "CHH is often an incidental finding but can present as mammographic calcifications, a mass, or nipple discharge"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "CHH can be microscopic or up to 5 cm in sizeGrossly resembles juvenile papillomatosis (\"Swiss cheese disease\")Associated invasive carcinomas tend to be larger and can have solid areas",
                    "sub_points": [
                      "Grossly resembles juvenile papillomatosis (\"Swiss cheese disease\")",
                      "Associated invasive carcinomas tend to be larger and can have solid areas"
                    ]
                  },
                  {
                    "text": "Multiple coalescent cysts (0.1 cm to 1 cm) are filled with gelatinous, thick, yellow/green secretions"
                  },
                  {
                    "text": "CHC-IS has the same appearance but is generally larger; can be 10 cm in size"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "CHHCysts are filled with dense, homogeneous, eosinophilic secretionsColloid-like; resembles thyroid glandSecretions retract from the sides of cysts and often have scalloped edgeShatter artifact (parallel cracks) can be presentPAS positive and diastase resistantNegative for thyroglobulinIf there is cyst rupture, a chronic inflammatory reaction of lymphocytes and histiocytes resultsThe lining cells are flat to columnar with benign-appearing nucleoliThe cytoplasm is eosinophilic and frequently vacuolatedA myoepithelial layer is present~ 80% estrogen receptor positive by immunohistochemistry (IHC)In cases of A-CHH, CHC-IS, and CHC with invasion, CHH is typically present in the surrounding breast tissue",
                    "sub_points": [
                      "Cysts are filled with dense, homogeneous, eosinophilic secretionsColloid-like; resembles thyroid glandSecretions retract from the sides of cysts and often have scalloped edgeShatter artifact (parallel cracks) can be presentPAS positive and diastase resistantNegative for thyroglobulinIf there is cyst rupture, a chronic inflammatory reaction of lymphocytes and histiocytes results",
                      "Colloid-like; resembles thyroid gland",
                      "Secretions retract from the sides of cysts and often have scalloped edgeShatter artifact (parallel cracks) can be present",
                      "Shatter artifact (parallel cracks) can be present",
                      "PAS positive and diastase resistantNegative for thyroglobulin",
                      "Negative for thyroglobulin",
                      "If there is cyst rupture, a chronic inflammatory reaction of lymphocytes and histiocytes results",
                      "The lining cells are flat to columnar with benign-appearing nucleoliThe cytoplasm is eosinophilic and frequently vacuolated",
                      "The cytoplasm is eosinophilic and frequently vacuolated",
                      "A myoepithelial layer is present",
                      "~ 80% estrogen receptor positive by immunohistochemistry (IHC)",
                      "In cases of A-CHH, CHC-IS, and CHC with invasion, CHH is typically present in the surrounding breast tissue"
                    ]
                  },
                  {
                    "text": "A-CHHSame features as CHH but with nuclear enlargement, hyperchromasia, and prominent nucleoliCysts tend to be smaller than in CHHThe epithelium may be stratified with occasional tuftsIn one study, 1 of 2 cases tested had aTP53mutation and showed p53 overexpression by IHC",
                    "sub_points": [
                      "Same features as CHH but with nuclear enlargement, hyperchromasia, and prominent nucleoliCysts tend to be smaller than in CHH",
                      "Cysts tend to be smaller than in CHH",
                      "The epithelium may be stratified with occasional tufts",
                      "In one study, 1 of 2 cases tested had aTP53mutation and showed p53 overexpression by IHC"
                    ]
                  },
                  {
                    "text": "CHC-ISSame features as CHH and A-CHH but with micropapillary architectureNecrosis and calcifications may be presentNuclei are enlarged and vesicular with prominent nucleoliIn one study, 3 of 4 cases showedTP53alterations2 had mutations and abnormal p53 IHC expression and 1 had abnormal IHC (DNA testing could not be performed in this case)~ 80% estrogen receptor positive",
                    "sub_points": [
                      "Same features as CHH and A-CHH but with micropapillary architectureNecrosis and calcifications may be present",
                      "Necrosis and calcifications may be present",
                      "Nuclei are enlarged and vesicular with prominent nucleoli",
                      "In one study, 3 of 4 cases showedTP53alterations2 had mutations and abnormal p53 IHC expression and 1 had abnormal IHC (DNA testing could not be performed in this case)",
                      "2 had mutations and abnormal p53 IHC expression and 1 had abnormal IHC (DNA testing could not be performed in this case)",
                      "~ 80% estrogen receptor positive"
                    ]
                  },
                  {
                    "text": "CHC-IS with invasive carcinomaInvasive carcinomas are typically high grade and do not have the same cystic and secretory appearance as CHC-ISHowever, secretions can be present in areas of invasion and metastasesVery rare; fewer than 30 cases reported~ 50% estrogen receptor positiveSome cases reported to be HER2 positive~ 50% have positive axillary lymph nodesDistant metastases are also reported",
                    "sub_points": [
                      "Invasive carcinomas are typically high grade and do not have the same cystic and secretory appearance as CHC-ISHowever, secretions can be present in areas of invasion and metastasesVery rare; fewer than 30 cases reported",
                      "However, secretions can be present in areas of invasion and metastases",
                      "Very rare; fewer than 30 cases reported",
                      "~ 50% estrogen receptor positiveSome cases reported to be HER2 positive",
                      "Some cases reported to be HER2 positive",
                      "~ 50% have positive axillary lymph nodesDistant metastases are also reported",
                      "Distant metastases are also reported"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "If CHH or A-CHH are present on core needle biopsy, excision is recommended to evaluate for possible adjacent CHC-IS &/or invasive carcinoma"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Pregnancy-Like (Pseudolactational) Hyperplasia (PLH)": [
                  {
                    "text": "Same histologic changes as during pregnancy or lactationOften an incidental finding in a single lobule or scattered lobulesSome are detected as mammographic calcifications, which can be psammoma body-likePreserved lobular architectureCan occur in women who have never been pregnant and have not undergone hormonal treatments",
                    "sub_points": [
                      "Often an incidental finding in a single lobule or scattered lobules",
                      "Some are detected as mammographic calcifications, which can be psammoma body-like",
                      "Preserved lobular architecture",
                      "Can occur in women who have never been pregnant and have not undergone hormonal treatments"
                    ]
                  },
                  {
                    "text": "The cytoplasm is clear or vacuolated, and there may be cytoplasmic blebs"
                  },
                  {
                    "text": "Secretions are pale in color and bubbly"
                  },
                  {
                    "text": "Nuclei can be enlarged and hyperchromatic with prominent nucleoli"
                  },
                  {
                    "text": "CHH and PLH can merge in the same lesion"
                  }
                ],
                "Secretory Carcinoma": [
                  {
                    "text": "These invasive carcinomas are typically low grade, whereas carcinomas associated with CHC-IS are typically high grade"
                  },
                  {
                    "text": "Cysts are smaller (microcystic), giving a honeycomb appearanceCystic areas are a component of the invasive carcinoma and lack myoepithelial cellsSecretions are densely eosinophilic",
                    "sub_points": [
                      "Cystic areas are a component of the invasive carcinoma and lack myoepithelial cells",
                      "Secretions are densely eosinophilic"
                    ]
                  },
                  {
                    "text": "The tumor cells have vacuolated cytoplasm with typically mild to moderate nuclear atypia"
                  },
                  {
                    "text": "These cancers are negative for estrogen receptor and positive for S100, and the majority have anETV6::NTRK3gene fusion"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Encapsulated Papillary Carcinoma": {
            "name": "Encapsulated Papillary Carcinoma",
            "url": "https://app.pathprimer.com/document/389eb4c0-87e3-493f-a7ee-c16516be71eb/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Encapsulated papillary carcinoma (EPC) grows as delicate fibrovascular fronds present usually within a single well-circumscribed cystic space"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "0.5-2.0% of breast cancers in women"
                  },
                  {
                    "text": "Most common in older women (median age: 60-70 years)"
                  },
                  {
                    "text": "Often presents as a palpable mass or circumscribed mammographic density"
                  },
                  {
                    "text": "Definitive diagnosis cannot be made on core needle biopsyFinal classification should be made after excisionLymph node sampling generally not recommended as nodal involvement is rare",
                    "sub_points": [
                      "Final classification should be made after excision",
                      "Lymph node sampling generally not recommended as nodal involvement is rare"
                    ]
                  },
                  {
                    "text": "Absence of myoepithelial cells suggests EPC is form of indolent invasive carcinomaClinical behavior for low- to intermediate-grade EPC is similar to ductal carcinoma in situ (DCIS)Survival is > 95% at 10 yearsWHO recommends classifying as DCIS (Tis)",
                    "sub_points": [
                      "Clinical behavior for low- to intermediate-grade EPC is similar to ductal carcinoma in situ (DCIS)",
                      "Survival is > 95% at 10 years",
                      "WHO recommends classifying as DCIS (Tis)"
                    ]
                  },
                  {
                    "text": "Survival is > 95% at 10 years when no associated stromal invasion is identified"
                  },
                  {
                    "text": "Rare high-grade EPCs are recommended to be classified as invasive carcinoma"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ER and PR are positive in almost all cases"
                  },
                  {
                    "text": "HER2 is absent"
                  },
                  {
                    "text": "Myoepithelial markers confirm absence of myoepithelial cells in papillary fronds and in surrounding capsule"
                  },
                  {
                    "text": "p63 is the most useful marker for documenting the absence of myoepithelial cells in papillary fronds"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Large duct papilloma"
                  },
                  {
                    "text": "Ductal carcinoma in situ, papillary pattern"
                  },
                  {
                    "text": "Solid papillary carcinoma"
                  },
                  {
                    "text": "Invasive lobular carcinoma, solid pattern"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Encapsulated papillary carcinoma (EPC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Intracystic and encysted papillary carcinoma are not recommended terms by WHO (5th edition)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Papillary carcinoma with delicate fibrovascular fronds, usually growing in a single well-circumscribed cystic spaceNo, or only rare, myoepithelial cells are present at the periphery or in fibrovascular fronds",
                    "sub_points": [
                      "No, or only rare, myoepithelial cells are present at the periphery or in fibrovascular fronds"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Biology": [
                  {
                    "text": "EPC was originally classified as ductal carcinoma in situ (DCIS)"
                  },
                  {
                    "text": "However, unlike DCIS, there are no myoepithelial cells surrounding the periphery of the involved space or they are very sparse"
                  },
                  {
                    "text": "EPC is likely an indolent form of invasive carcinoma with expansile growth pattern and very low propensity for metastasis"
                  },
                  {
                    "text": "WHO recommends classification as DCIS (Tis) rather than invasive carcinoma for low- to intermediate-grade lesionsIf frank invasion beyond the fibrous capsule is present, the area of the invasive cancer (not including the EPC) is used for T classification",
                    "sub_points": [
                      "If frank invasion beyond the fibrous capsule is present, the area of the invasive cancer (not including the EPC) is used for T classification"
                    ]
                  },
                  {
                    "text": "Majority of patients do well with local excisionLymph node metastases are very rareMacrometastases have been reported in very rare cases; the associated EPC is often exceptionally largeIsolated tumor cells in nodes may be related to epithelial displacement by prior core needle biopsy",
                    "sub_points": [
                      "Lymph node metastases are very rareMacrometastases have been reported in very rare cases; the associated EPC is often exceptionally largeIsolated tumor cells in nodes may be related to epithelial displacement by prior core needle biopsy",
                      "Macrometastases have been reported in very rare cases; the associated EPC is often exceptionally large",
                      "Isolated tumor cells in nodes may be related to epithelial displacement by prior core needle biopsy"
                    ]
                  },
                  {
                    "text": "High-grade EPCs are recommended to be classified as invasive carcinomaThese lesions have nuclear pleomorphism, an increased mitotic rate, and may be ER(-) &/or HER2(+)",
                    "sub_points": [
                      "These lesions have nuclear pleomorphism, an increased mitotic rate, and may be ER(-) &/or HER2(+)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "0.5-2.0% of breast cancers in womenRare in men",
                    "sub_points": [
                      "Rare in men"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Most common in older women (60-70 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Majority postmenopausal women, but some cases reported in older men"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Usually presents as a central palpable or mammographic mass with circumscribed margins ± nipple dischargeUsually deeper in breast than large duct papillomas",
                    "sub_points": [
                      "Usually deeper in breast than large duct papillomas"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "When diagnosed on core needle biopsy, complete surgical excision is recommendedIt is generally not possible to classify papillary carcinomas with certainty due to fragmented nature of lesion on needle biopsy",
                    "sub_points": [
                      "It is generally not possible to classify papillary carcinomas with certainty due to fragmented nature of lesion on needle biopsy"
                    ]
                  },
                  {
                    "text": "Lymph node sampling is not required for EPC without stromal invasionRare lymph node involvement is reported but typically with unusually large tumors",
                    "sub_points": [
                      "Rare lymph node involvement is reported but typically with unusually large tumors"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Rate of local recurrence very low if there is no DCIS in adjacent tissue"
                  },
                  {
                    "text": "If EPC is associated with foci of DCIS in the surrounding tissue, the risk of recurrence is higher"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Survival is > 95% at 10 years when no associated stromal invasion is identified"
                  },
                  {
                    "text": "EPC can recur locally, and the recurrence can also be EPC"
                  },
                  {
                    "text": "Distant metastasis is very rare"
                  },
                  {
                    "text": "The Oncotype Dx recurrence scores for 9 cases of EPC (1 with 0.15 cm of invasion, 2 with isolated tumor cells, and 1 with a macrometastasis) had a median of 3 (range: 0-11)"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Often a retroareolar mass with circumscribed margins ± calcifications"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Soft, circumscribed, tan to brown mass"
                  },
                  {
                    "text": "Majority 1-2 cm"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Fewer genomic changes compared to grade and ER-matched nonpapillary carcinomasEPC, solid papillary carcinoma (SPC), and invasive papillary carcinoma are genetically similar",
                    "sub_points": [
                      "EPC, solid papillary carcinoma (SPC), and invasive papillary carcinoma are genetically similar"
                    ]
                  },
                  {
                    "text": "Gene copy changesChanges characteristic of low-grade breast neoplasia pathway frequently present16q losses,16p gains, 1q gainsDue to limited number of samples studied, prevalence or significance of these changes remains unclear",
                    "sub_points": [
                      "Changes characteristic of low-grade breast neoplasia pathway frequently present16q losses,16p gains, 1q gainsDue to limited number of samples studied, prevalence or significance of these changes remains unclear",
                      "16q losses,16p gains, 1q gains",
                      "Due to limited number of samples studied, prevalence or significance of these changes remains unclear"
                    ]
                  },
                  {
                    "text": "Mutations~ 20% have hotspotPIK3CAmutations",
                    "sub_points": [
                      "~ 20% have hotspotPIK3CAmutations"
                    ]
                  }
                ],
                "mRNA": [
                  {
                    "text": "Classified as luminal A"
                  },
                  {
                    "text": "EPC, invasive papillary carcinoma, and SPC all share similar gene expression patternsDownregulate genes involved in proliferation, cell assembly and organization, and cellular migrationOverexpress genes related to homeostasis and angiogenesis",
                    "sub_points": [
                      "Downregulate genes involved in proliferation, cell assembly and organization, and cellular migration",
                      "Overexpress genes related to homeostasis and angiogenesis"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "Classified as luminal A based on protein expression [ER(+), HER2(-), low proliferation]Low molecular weight keratins 8 and 18 present, high molecular weight keratins, such as 5 and 6, usually absent",
                    "sub_points": [
                      "Low molecular weight keratins 8 and 18 present, high molecular weight keratins, such as 5 and 6, usually absent"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "EPC is confined to 1 or occasionally multiple spaces with circumscribed margins"
                  },
                  {
                    "text": "Outer thickened capsule is generally fibrotic with scattering of lymphocytesFibrotic capsule is likely a reactive process, rather than a thickened native basement membraneEntrapment of epithelium within capsule may occur and should not be overinterpreted as invasion",
                    "sub_points": [
                      "Fibrotic capsule is likely a reactive process, rather than a thickened native basement membrane",
                      "Entrapment of epithelium within capsule may occur and should not be overinterpreted as invasion"
                    ]
                  },
                  {
                    "text": "Tumor grows as delicate papillary fronds with thin fibrovascular cores lined by a single layer of monomorphic columnar cells"
                  },
                  {
                    "text": "Tumor cells are low to intermediate nuclear gradeSome cases show apocrine features throughout",
                    "sub_points": [
                      "Some cases show apocrine features throughout"
                    ]
                  },
                  {
                    "text": "Occasional globoid cells may be presentMore abundant pale cytoplasm and rounded in shapeOften positive for GCDFP-15Should not be misinterpreted as myoepithelial cells",
                    "sub_points": [
                      "More abundant pale cytoplasm and rounded in shape",
                      "Often positive for GCDFP-15",
                      "Should not be misinterpreted as myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Majority lack myoepithelial cells~ 20% show reduced but focal myoepithelial cells",
                    "sub_points": [
                      "~ 20% show reduced but focal myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Epithelial displacementSmall foci of epithelial cells may be present in fibrous capsule and are not clearly evidence of invasionNormal or malignant cells can be displaced into stroma, vascular channels, or lymph nodes by prior core biopsyEpithelial displacement due to prior core needle biopsy should not be overinterpretedMyoepithelial cell markers are not helpful in identifying epithelial displacementFor diagnosis of invasion, definitive stromal invasion should be present in adjacent breast tissue, beyond area of concentric peritumoral fibrosis",
                    "sub_points": [
                      "Small foci of epithelial cells may be present in fibrous capsule and are not clearly evidence of invasionNormal or malignant cells can be displaced into stroma, vascular channels, or lymph nodes by prior core biopsyEpithelial displacement due to prior core needle biopsy should not be overinterpretedMyoepithelial cell markers are not helpful in identifying epithelial displacement",
                      "Normal or malignant cells can be displaced into stroma, vascular channels, or lymph nodes by prior core biopsy",
                      "Epithelial displacement due to prior core needle biopsy should not be overinterpreted",
                      "Myoepithelial cell markers are not helpful in identifying epithelial displacement",
                      "For diagnosis of invasion, definitive stromal invasion should be present in adjacent breast tissue, beyond area of concentric peritumoral fibrosis"
                    ]
                  }
                ],
                "Encapsulated Papillary Carcinoma With Invasive Carcinoma": [
                  {
                    "text": "~ 25% of EPC are associated with areas of frank stromal invasionInvasive carcinoma extends beyond capsule of lesionCarcinoma is generally of no special type and is not papillary in appearanceThe size of the invasive carcinoma used for AJCC T classification should not include the size of the associated EPC",
                    "sub_points": [
                      "Invasive carcinoma extends beyond capsule of lesion",
                      "Carcinoma is generally of no special type and is not papillary in appearance",
                      "The size of the invasive carcinoma used for AJCC T classification should not include the size of the associated EPC"
                    ]
                  }
                ],
                "High-Grade Carcinomas With Features of Encapsulated Papillary Carcinoma": [
                  {
                    "text": "~ 6% of carcinomas with the appearance of EPC have unusual high-grade features"
                  },
                  {
                    "text": "Usually larger in size (average: ~ 3 cm)"
                  },
                  {
                    "text": "Often have solid papillary areas"
                  },
                  {
                    "text": "Usually classified as poorly differentiatedNuclear pleomorphism and increased proliferation presentNecrosis may be presentPapillary pattern not considered tubule formation for grading (score 3)",
                    "sub_points": [
                      "Nuclear pleomorphism and increased proliferation present",
                      "Necrosis may be present",
                      "Papillary pattern not considered tubule formation for grading (score 3)"
                    ]
                  },
                  {
                    "text": "Recommended to be classified as invasive carcinomaHowever, due to their rarity, the likelihood of metastasis is unknown",
                    "sub_points": [
                      "However, due to their rarity, the likelihood of metastasis is unknown"
                    ]
                  },
                  {
                    "text": "~ 2/3 negative for ER, PR, and HER2; some cases may be HER2(+)May be positive for EMA or CK5/6",
                    "sub_points": [
                      "May be positive for EMA or CK5/6"
                    ]
                  },
                  {
                    "text": "Often associated with high-grade DCIS"
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Often difficult to provide a specific diagnosis because the nature of a papillary lesion leads to fragmentation"
                  },
                  {
                    "text": "IHC studies can be helpful to confirm the absence of myoepithelial cells in fibrovascular cores"
                  },
                  {
                    "text": "A diagnosis of only \"papillary carcinoma\" is insufficient to guide subsequent managementIt is generally appropriate to provide a differential diagnosis of DCIS with a papillary pattern, EPC, or invasive papillary carcinoma",
                    "sub_points": [
                      "It is generally appropriate to provide a differential diagnosis of DCIS with a papillary pattern, EPC, or invasive papillary carcinoma"
                    ]
                  },
                  {
                    "text": "Correlation with the imaging findings is very helpful to determine the most likely diagnosis"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "ER and PR positive in almost all cases; often negative in rare high-grade EPC"
                  },
                  {
                    "text": "HER2 negative in almost all cases; may be positive in high-grade lesions"
                  },
                  {
                    "text": "Myoepithelial markers: Confirm absence of myoepithelial cells in papillary fronds and at the periphery of the lesionRare myoepithelial cells can be presentp63 is most useful marker for detecting myoepithelial cells in papillary frondsMuscle markers are also positive in blood vessels, which can closely appose the base of tumor cells and be difficult to distinguish from myoepithelial cells",
                    "sub_points": [
                      "Rare myoepithelial cells can be present",
                      "p63 is most useful marker for detecting myoepithelial cells in papillary frondsMuscle markers are also positive in blood vessels, which can closely appose the base of tumor cells and be difficult to distinguish from myoepithelial cells",
                      "Muscle markers are also positive in blood vessels, which can closely appose the base of tumor cells and be difficult to distinguish from myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Low molecular weight keratins 8 and 18 present; high molecular weight CK5/6 usually absent unless high grade"
                  },
                  {
                    "text": "Collagen type IV is present around periphery of lesionThis finding is also present in some invasive carcinomas and metastatic carcinomasTherefore, not sufficient evidence for classification as carcinoma as in situ",
                    "sub_points": [
                      "This finding is also present in some invasive carcinomas and metastatic carcinomas",
                      "Therefore, not sufficient evidence for classification as carcinoma as in situ"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Large Duct Papilloma": [
                  {
                    "text": "Also occurs in central breast as a mass with circumscribed margins and often associated with nipple discharge"
                  },
                  {
                    "text": "Fibrovascular cores are generally thicker, more variable in size, and may show sclerosisLarge lesions may infarct due to torsion on the stalk",
                    "sub_points": [
                      "Large lesions may infarct due to torsion on the stalk"
                    ]
                  },
                  {
                    "text": "Cell population appears more heterogeneous, and apocrine metaplasia may be focally present"
                  },
                  {
                    "text": "A well-developed myoepithelial cell layer is present within papillary fronds and surrounding the outer portion of the lesion"
                  }
                ],
                "Ductal Carcinoma In Situ, Papillary Pattern": [
                  {
                    "text": "Usually involves multiple smaller ductal spaces"
                  },
                  {
                    "text": "Myoepithelial cells are present around periphery of involved ducts but not in fibrovascular cores"
                  },
                  {
                    "text": "If there are myoepithelial cells in the papillary cores, the lesion is interpreted as DCIS involving a papilloma"
                  }
                ],
                "Solid Papillary Carcinoma (SPC)": [
                  {
                    "text": "SPC has a solid growth pattern with small inconspicuous fibrovascular cores rather than a cystic growth pattern"
                  },
                  {
                    "text": "Multiple circumscribed nodules are usually present, rather than a single dilated space as in EPC"
                  },
                  {
                    "text": "Like EPC, myoepithelial cells may be present, present but sparse, or completely absent"
                  },
                  {
                    "text": "The tumor cell population can appear heterogeneous due to cells with finely granular cytoplasm, spindle cells, and cells with intracellular mucin (signet ring cells)"
                  },
                  {
                    "text": "~ 2/3 are positive for neuroendocrine markers (chromogranin or synaptophysin) and mucin is sometimes present"
                  },
                  {
                    "text": "Some carcinomas show mixed features of EPC and SPC and can be difficult to classify"
                  }
                ],
                "Invasive Lobular Carcinoma, Solid Pattern": [
                  {
                    "text": "The solid pattern of invasive lobular carcinoma forms mass with circumscribed margins, which can be traversed by thin fibrovascular bands"
                  },
                  {
                    "text": "The tumor cells can be so closely packed such that they do not appear to be dyscohesive"
                  },
                  {
                    "text": "The more typical single cell pattern of invasion may be present at the periphery"
                  },
                  {
                    "text": "IHC will confirm the absence of E-cadherin"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "In general, a differential diagnosis including DCIS, EPC, and invasive papillary carcinoma is appropriate for reporting core needle biopsies"
                  },
                  {
                    "text": "Classify as Tis unless clear areas of invasive carcinoma are present beyond fibrous capsule or the lesion is high grade"
                  },
                  {
                    "text": "Beware of overinterpretation of epithelial displacement into stroma, vascular spaces, or lymph nodes"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "EPC of low to intermediate grade is reported according to the College of American Pathology (CAP) DCIS protocol and the International Collaboration on Cancer Reporting (ICCR) dataset for pathology reporting of DCIS, variants of LCIS, and low-grade lesions"
                  },
                  {
                    "text": "EPC with associated invasive carcinoma and high-grade EPC are reported according to CAP Invasive Breast Cancer Protocol and the ICCR dataset for reporting invasive carcinoma"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Microinvasive Carcinoma": {
            "name": "Microinvasive Carcinoma",
            "url": "https://app.pathprimer.com/document/510f2092-2030-459b-8096-2044a816d19d/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {
              "KEY FACTS": {
                "Classification": [
                  {
                    "text": "Microinvasive carcinoma is defined by foci of tumor cells in periductal stroma, not connected to carcinoma in situ, and measuring ≤ 1 mm"
                  },
                  {
                    "text": "Classified as AJCC T1mi"
                  },
                  {
                    "text": "The most important goal of pathologic evaluation is to ensure a larger area of invasion has not been missed"
                  },
                  {
                    "text": "When feasible, all areas of grossly abnormal tissue &/or tissue with an imaging lesion (e.g., calcifications) should be sampled"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Uncommon, accounting for < 1% of all breast carcinomas"
                  },
                  {
                    "text": "Overall prognosis is favorable with survival generally similar to ductal carcinoma in situ (DCIS) (20-year disease-specific mortality 4%)"
                  },
                  {
                    "text": "< 5% of patients have macrometastases to lymph nodes or distant metastases, making it difficult to identify risk factors for these rare events"
                  },
                  {
                    "text": "Although outcome may be less favorable when more foci of microinvasive carcinoma are identified, results have varied in different studiesA specific number of foci that would warrant the use of systemic therapy has not been defined",
                    "sub_points": [
                      "A specific number of foci that would warrant the use of systemic therapy has not been defined"
                    ]
                  },
                  {
                    "text": "The number of foci of microinvasion are reported as well as the results of hormone receptor and HER2 testing in microinvasive carcinoma and DCIS, to assist in clinical decision making"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Typically occurs in an extensive area of high-grade DCIS"
                  },
                  {
                    "text": "Microinvasive carcinoma can be of any biologic type"
                  },
                  {
                    "text": "Multiplex immunoperoxidase studies for both keratin and myoepithelial markers can be helpful for diagnosis"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "DCIS with cancerization of lobules"
                  },
                  {
                    "text": "Small foci of invasive carcinoma (AJCC T1a)"
                  },
                  {
                    "text": "Artifactual displacement of tumor cells into stroma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Microinvasive carcinoma is defined as carcinoma invading in stroma ≤ 1 mm in size"
                  },
                  {
                    "text": "The majority of cases are associated with ductal carcinoma in situ (DCIS) with ~ 20% of cases associated with lobular carcinoma in situ (LCIS) or not associated with carcinoma in situ (CIS)"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Microinvasive carcinoma, defined as being ≤ 1 mm in size, is detected in ~ 5-10% of cases of ductal carcinoma in situ (DCIS) and in fewer cases of lobular carcinoma in situ (LCIS)However, there is wide variation in the reported frequency of microinvasion in different studies, as it can be influenced by the extent of sampling, evaluation of additional levels, the use of IHC, and diagnostic criteria",
                    "sub_points": [
                      "However, there is wide variation in the reported frequency of microinvasion in different studies, as it can be influenced by the extent of sampling, evaluation of additional levels, the use of IHC, and diagnostic criteria"
                    ]
                  },
                  {
                    "text": "Although lymph node macrometastases have been reported, and very rare patients develop distant metastases, risk factors for these events are difficult to study because these events are so rare (< 5% in most studies)Both overdiagnosis and underdiagnosis are important issues in the evaluation of microinvasionThe number of foci of microinvasion can be difficult to define and report",
                    "sub_points": [
                      "Both overdiagnosis and underdiagnosis are important issues in the evaluation of microinvasion",
                      "The number of foci of microinvasion can be difficult to define and report"
                    ]
                  },
                  {
                    "text": "The most important goal of pathologic evaluation is to ensure a larger area of invasion has not been missedWhen feasible, all areas of grossly abnormal tissue &/or tissue with an imaging lesion (e.g., calcifications) should be sampledMultiplex IHC studies for keratin and myoepithelial markers are helpful to identify microinvasionReporting should include the number of foci and the results of hormone receptor and HER2 testing for microinvasive carcinoma and DCIS to assist in clinical decision makingWhen there is insufficient microinvasive carcinoma for testing, the results for the associated DCIS are concordant in > 95% of cases",
                    "sub_points": [
                      "When feasible, all areas of grossly abnormal tissue &/or tissue with an imaging lesion (e.g., calcifications) should be sampled",
                      "Multiplex IHC studies for keratin and myoepithelial markers are helpful to identify microinvasion",
                      "Reporting should include the number of foci and the results of hormone receptor and HER2 testing for microinvasive carcinoma and DCIS to assist in clinical decision makingWhen there is insufficient microinvasive carcinoma for testing, the results for the associated DCIS are concordant in > 95% of cases",
                      "When there is insufficient microinvasive carcinoma for testing, the results for the associated DCIS are concordant in > 95% of cases"
                    ]
                  }
                ],
                "Origin of Stromal Invasion": [
                  {
                    "text": "The earliest changes in neoplasia occur in epithelial cells in ducts and lobules and eventually result in CISThe tumor cells are confined to ducts and lobules by surrounding basement membrane (BM)",
                    "sub_points": [
                      "The tumor cells are confined to ducts and lobules by surrounding basement membrane (BM)"
                    ]
                  },
                  {
                    "text": "The transition from carcinoma in situ (CIS) to invasive carcinoma is not yet completely understood"
                  },
                  {
                    "text": "CIS associated with invasive breast carcinoma (BC) has differences compared to CIS in the absence of invasionHigher proliferative rate and enhanced apoptosisHigher levels of expression of matrix metalloproteasesLess likely to be estrogen receptor (ER) (+)More likely to be HER2(+)",
                    "sub_points": [
                      "Higher proliferative rate and enhanced apoptosis",
                      "Higher levels of expression of matrix metalloproteases",
                      "Less likely to be estrogen receptor (ER) (+)",
                      "More likely to be HER2(+)"
                    ]
                  },
                  {
                    "text": "CIS and associated invasive BC are clonally related and very similar by DNA, mRNA, and protein analysisExtensive genomic heterogeneity occurs while the carcinoma is in situEither a single subclone, or multiple different subclones, occurring in DCIS can give rise to invasive BCNo gene expression patterns or mutations specific to invasive BC have been identified",
                    "sub_points": [
                      "Extensive genomic heterogeneity occurs while the carcinoma is in situ",
                      "Either a single subclone, or multiple different subclones, occurring in DCIS can give rise to invasive BC",
                      "No gene expression patterns or mutations specific to invasive BC have been identified"
                    ]
                  },
                  {
                    "text": "The transition to invasive BC may not be due to an alteration in CISMaintenance of normal duct and lobule architecture and the basement membrane (BM) requires cellular crosstalk among normal luminal, myoepithelial, and stromal cellsLoss of 1 of the normal epithelial cell populations as it is replaced by CIS could lead to changes in tissue structure and cellular interactionsMyoepithelial cells help produce components of the extracellular BM, secrete protease inhibitors, inhibit angiogenesis, and help maintain orientation of normal luminal cellsMyoepithelial cells associated with CIS are often sparse in number and may be in abnormal locations above the BMOften show abnormal loss of expression of myoepithelial cell markersGaps can appear in the BM, and epithelial cells may protrude through these gapsSurrounding stromal cells also help maintain normal structures and tissue architectureFibroblasts and inflammatory cells associated with carcinoma show changes in gene expression patternsThe tumor microenvironment is also likely to play an important roleMicroinvasive carcinoma and associated DCIS are more likely to be associated with tumor infiltrating lymphocytesTherefore, alterations in normal cells, loss of BM maintenance, and the microenvironment may be of primary importance in the transition to stromal invasion",
                    "sub_points": [
                      "Maintenance of normal duct and lobule architecture and the basement membrane (BM) requires cellular crosstalk among normal luminal, myoepithelial, and stromal cellsLoss of 1 of the normal epithelial cell populations as it is replaced by CIS could lead to changes in tissue structure and cellular interactions",
                      "Loss of 1 of the normal epithelial cell populations as it is replaced by CIS could lead to changes in tissue structure and cellular interactions",
                      "Myoepithelial cells help produce components of the extracellular BM, secrete protease inhibitors, inhibit angiogenesis, and help maintain orientation of normal luminal cellsMyoepithelial cells associated with CIS are often sparse in number and may be in abnormal locations above the BMOften show abnormal loss of expression of myoepithelial cell markersGaps can appear in the BM, and epithelial cells may protrude through these gaps",
                      "Myoepithelial cells associated with CIS are often sparse in number and may be in abnormal locations above the BM",
                      "Often show abnormal loss of expression of myoepithelial cell markers",
                      "Gaps can appear in the BM, and epithelial cells may protrude through these gaps",
                      "Surrounding stromal cells also help maintain normal structures and tissue architectureFibroblasts and inflammatory cells associated with carcinoma show changes in gene expression patterns",
                      "Fibroblasts and inflammatory cells associated with carcinoma show changes in gene expression patterns",
                      "The tumor microenvironment is also likely to play an important roleMicroinvasive carcinoma and associated DCIS are more likely to be associated with tumor infiltrating lymphocytes",
                      "Microinvasive carcinoma and associated DCIS are more likely to be associated with tumor infiltrating lymphocytes",
                      "Therefore, alterations in normal cells, loss of BM maintenance, and the microenvironment may be of primary importance in the transition to stromal invasion"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Uncommon: < 1% of all breast cancers"
                  }
                ],
                "Age": [
                  {
                    "text": "Range: 32-78 years (mean: 56 years)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Microinvasive carcinoma usually presents as mammographic calcifications, similar to extensive high-grade DCIS"
                  },
                  {
                    "text": "Some present with Paget disease of the nipple with skin changesMicroinvasion can occur in the dermis from the DCIS involving the epidermis",
                    "sub_points": [
                      "Microinvasion can occur in the dermis from the DCIS involving the epidermis"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Microinvasive carcinoma with DCIS requires surgical excision with free marginsMost common treatment is breast conservation, which includes wide local excision with negative marginsAxillary sentinel lymph node biopsy should be strongly considered, as additional larger foci of invasion may be detected on excision",
                    "sub_points": [
                      "Most common treatment is breast conservation, which includes wide local excision with negative margins",
                      "Axillary sentinel lymph node biopsy should be strongly considered, as additional larger foci of invasion may be detected on excision"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Additional adjuvant therapy beyond radiation should be based on presence or absence of lymph node metastasis"
                  }
                ],
                "Radiation": [
                  {
                    "text": "Radiation treatment is the current standard of care for patients undergoing breast conservation"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Overall prognosis is favorable with survival similar to DCIS (20-year disease-specific mortality 4%)"
                  },
                  {
                    "text": "Although outcome may be less favorable when more foci of microinvasive carcinoma are identified, results have varied in different studiesThe number of foci needed to alter clinical decisions on systemic therapy have not been definedThe number of foci can be highly variable depending on pathologic evaluation",
                    "sub_points": [
                      "The number of foci needed to alter clinical decisions on systemic therapy have not been defined",
                      "The number of foci can be highly variable depending on pathologic evaluation"
                    ]
                  },
                  {
                    "text": "Lymph node metastases are reported in < 10% of patientsMetastases are usually micrometastases to a single nodeIsolated tumor cells and micrometastases have little prognostic significance",
                    "sub_points": [
                      "Metastases are usually micrometastases to a single nodeIsolated tumor cells and micrometastases have little prognostic significance",
                      "Isolated tumor cells and micrometastases have little prognostic significance"
                    ]
                  },
                  {
                    "text": "Macrometastases are associated with more extensive DCIS, high nuclear grade, and very rare cases with lymphovascular invasionThe possibility of a missed area of invasion should be consideredAdditional sampling, if possible, may reveal a larger area of invasionThe possibility of misdiagnosis should be considered and investigatedSome invasive carcinomas, such as invasive cribriform carcinoma, can closely resemble DCISLymphovascular invasion completely filling vascular spaces can closely resemble DCISIn the rare circumstance of finding a macrometastasis, patients would be classified as at least AJCC anatomic stage II, depending on the number of metastases",
                    "sub_points": [
                      "The possibility of a missed area of invasion should be consideredAdditional sampling, if possible, may reveal a larger area of invasion",
                      "Additional sampling, if possible, may reveal a larger area of invasion",
                      "The possibility of misdiagnosis should be considered and investigatedSome invasive carcinomas, such as invasive cribriform carcinoma, can closely resemble DCISLymphovascular invasion completely filling vascular spaces can closely resemble DCIS",
                      "Some invasive carcinomas, such as invasive cribriform carcinoma, can closely resemble DCIS",
                      "Lymphovascular invasion completely filling vascular spaces can closely resemble DCIS",
                      "In the rare circumstance of finding a macrometastasis, patients would be classified as at least AJCC anatomic stage II, depending on the number of metastases"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Radiologic features of microinvasive carcinoma and DCIS are identical to pure DCIS of equivalent extent and grade"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Microinvasive carcinoma with DCIS is generally associated with a stromal response (periductal fibrosis, lymphocytic infiltrates) leading to an abnormal gross appearance"
                  },
                  {
                    "text": "Tissue is usually firm but without a discrete massColor is typically white or gray",
                    "sub_points": [
                      "Color is typically white or gray"
                    ]
                  },
                  {
                    "text": "If comedo DCIS is present, small punctate areas of necrosis may be seen if tissue is gently compressed"
                  },
                  {
                    "text": "Areas of firm to hard homogeneous appearance effacing normal breast texture are likely to be associated with stromal invasion"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "If possible, the entire area of grossly abnormal tissue should be examined microscopically"
                  },
                  {
                    "text": "Additional sampling may reveal larger areas of invasion &/or lymphovascular invasion"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Microinvasive carcinoma is defined by tumor cells within stroma measuring ≤ 1 mm~ 80% of cases occur adjacent to DCIS and ~ 20% of cases with LCISMultiple foci may be presentSizes of multiple separate foci shouldnotbe added together into a larger sizeNo myoepithelial cells are presentSome high-grade carcinomas are p63(+), and in these cases, this marker may not be helpful to identify myoepithelial cells",
                    "sub_points": [
                      "~ 80% of cases occur adjacent to DCIS and ~ 20% of cases with LCIS",
                      "Multiple foci may be presentSizes of multiple separate foci shouldnotbe added together into a larger size",
                      "Sizes of multiple separate foci shouldnotbe added together into a larger size",
                      "No myoepithelial cells are presentSome high-grade carcinomas are p63(+), and in these cases, this marker may not be helpful to identify myoepithelial cells",
                      "Some high-grade carcinomas are p63(+), and in these cases, this marker may not be helpful to identify myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Tumor cells protruding through a gap in the BM but still contiguous with DCIS are not classified as microinvasive carcinomaThe tumor cells must appear to be separate foci outside the duct on slides, even though they may be contiguous with the tumor cells in the duct if evaluated in 3 dimensions",
                    "sub_points": [
                      "The tumor cells must appear to be separate foci outside the duct on slides, even though they may be contiguous with the tumor cells in the duct if evaluated in 3 dimensions"
                    ]
                  },
                  {
                    "text": "Microinvasive carcinoma is often associated with stromal changesPeriductal fibrosisInvolved acini of associated DCIS can appear distorted and irregularOften requires immunoperoxidase studies to evaluate for myoepithelial cellsPeriductal dense lymphocytic infiltratesAreas of marked inflammation can obscure foci of microinvasive carcinoma",
                    "sub_points": [
                      "Periductal fibrosisInvolved acini of associated DCIS can appear distorted and irregularOften requires immunoperoxidase studies to evaluate for myoepithelial cells",
                      "Involved acini of associated DCIS can appear distorted and irregular",
                      "Often requires immunoperoxidase studies to evaluate for myoepithelial cells",
                      "Periductal dense lymphocytic infiltratesAreas of marked inflammation can obscure foci of microinvasive carcinoma",
                      "Areas of marked inflammation can obscure foci of microinvasive carcinoma"
                    ]
                  },
                  {
                    "text": "True microinvasive carcinoma infiltrates as single cells or small clusters with an angulated shapeRounded foci of carcinoma are more likely small acini involved by DCISDue to the small size, multiple markers may be required to identify myoepithelial cells",
                    "sub_points": [
                      "Rounded foci of carcinoma are more likely small acini involved by DCIS",
                      "Due to the small size, multiple markers may be required to identify myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Associated DCIS usually has high-grade nucleiComedonecrosis is often presentAssociation of microinvasive carcinoma with low-grade DCIS is very uncommonCytologic features of cells in the area of microinvasive carcinoma resemble the cells of the DCIS",
                    "sub_points": [
                      "Comedonecrosis is often present",
                      "Association of microinvasive carcinoma with low-grade DCIS is very uncommon",
                      "Cytologic features of cells in the area of microinvasive carcinoma resemble the cells of the DCIS"
                    ]
                  },
                  {
                    "text": "In rare cases, lymphovascular invasion can be present when only microinvasive carcinoma is seenThe possibility that a larger area of invasion has been missed should be consideredAdditional sampling, if possible, is warrantedThe possibility that lymphovascular invasion is an artifact due to epithelial displacement also should be considered",
                    "sub_points": [
                      "The possibility that a larger area of invasion has been missed should be consideredAdditional sampling, if possible, is warranted",
                      "Additional sampling, if possible, is warranted",
                      "The possibility that lymphovascular invasion is an artifact due to epithelial displacement also should be considered"
                    ]
                  },
                  {
                    "text": "DCIS with mucin production and microinvasive carcinomaDucts involved by DCIS can rupture, resulting in stromal extravasation of mucinNeither invasion nor microinvasive carcinoma should be diagnosed unless tumor cells are present within mucinEvaluation after core needle biopsy can be very difficult due to artifactual displacement of epithelial cellsAreas of mucin extravasation contiguous with ductal spaces lined by myoepithelial cells are more likely due to extravasation from DCIS rather than invasive mucinous carcinomaNeovascularization of mucin is more common in mucinous carcinomas than in extravasated mucin due to rupture",
                    "sub_points": [
                      "Ducts involved by DCIS can rupture, resulting in stromal extravasation of mucin",
                      "Neither invasion nor microinvasive carcinoma should be diagnosed unless tumor cells are present within mucin",
                      "Evaluation after core needle biopsy can be very difficult due to artifactual displacement of epithelial cells",
                      "Areas of mucin extravasation contiguous with ductal spaces lined by myoepithelial cells are more likely due to extravasation from DCIS rather than invasive mucinous carcinoma",
                      "Neovascularization of mucin is more common in mucinous carcinomas than in extravasated mucin due to rupture"
                    ]
                  },
                  {
                    "text": "DCIS involving nipple skin (Paget disease) with microinvasive carcinomaIn rare cases, invasion can occur directly from epidermal involvement into dermisExtent of invasion is generally limited to microinvasion or invasion < 1 cmAlthough invasion is into dermis, rather than breast tissue, prognosis is similar to equivalent areas of invasive carcinoma in the breast",
                    "sub_points": [
                      "In rare cases, invasion can occur directly from epidermal involvement into dermis",
                      "Extent of invasion is generally limited to microinvasion or invasion < 1 cm",
                      "Although invasion is into dermis, rather than breast tissue, prognosis is similar to equivalent areas of invasive carcinoma in the breast"
                    ]
                  },
                  {
                    "text": "LCIS with microinvasive carcinomaLess commonly seen with LCIS compared to DCISSingle cells next to LCIS can be difficult to detectImmunoperoxidase studies for both keratin and myoepithelial cell markers are very helpfulSmall foci of invasive lobular carcinoma are more commonly seen in stroma not associated with LCISMay be due to the pattern of lobular carcinomas invading along fibrovascular strands in breastA cross section of 1 of these strands would have the appearance of a small focus of microinvasive carcinoma",
                    "sub_points": [
                      "Less commonly seen with LCIS compared to DCIS",
                      "Single cells next to LCIS can be difficult to detectImmunoperoxidase studies for both keratin and myoepithelial cell markers are very helpful",
                      "Immunoperoxidase studies for both keratin and myoepithelial cell markers are very helpful",
                      "Small foci of invasive lobular carcinoma are more commonly seen in stroma not associated with LCISMay be due to the pattern of lobular carcinomas invading along fibrovascular strands in breastA cross section of 1 of these strands would have the appearance of a small focus of microinvasive carcinoma",
                      "May be due to the pattern of lobular carcinomas invading along fibrovascular strands in breast",
                      "A cross section of 1 of these strands would have the appearance of a small focus of microinvasive carcinoma"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Any area of invasion is important to identify, as this finding may change subsequent surgical management"
                  },
                  {
                    "text": "DCIS on core needle biopsies of masses is more likely to be associated with microinvasive carcinomaDiagnosis of microinvasive carcinoma should only be made when definitive features are present",
                    "sub_points": [
                      "Diagnosis of microinvasive carcinoma should only be made when definitive features are present"
                    ]
                  },
                  {
                    "text": "Invasive carcinoma (> 0.1 cm) should be distinguished from microinvasive carcinoma (≤ 0.1 cm)The size of the invasive component can impact decisions on lymph node samplingFor small carcinomas, the largest area of invasion may be seen on the core needle biopsyThis information is important for subsequent AJCC T classification if a smaller area is present in the excision",
                    "sub_points": [
                      "The size of the invasive component can impact decisions on lymph node sampling",
                      "For small carcinomas, the largest area of invasion may be seen on the core needle biopsyThis information is important for subsequent AJCC T classification if a smaller area is present in the excision",
                      "This information is important for subsequent AJCC T classification if a smaller area is present in the excision"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "ER, PR, and HER2 studiesMicroinvasive carcinoma can be of any biologic type\"Luminal\" ER(+)/HER2(-) = 50-60%\"Luminal/HER2\" ER(+)/HER2(+) = 5-20%\"HER2\" ER(-)/HER2(+) = 20-30%\"TNBC/basal\" ER(-)/HER2(-) = 5-10%HER2(+) microinvasive carcinoma may be associated with adverse pathologic features and increased local recurrence riskIn the majority of cases, the results are concordant for DCIS and microinvasive carcinoma (~ > 95%), but rare cases of microinvasive carcinoma being negative for a marker positive in DCIS may occurIf microinvasive carcinoma is only present as a few cells, expression may not be seen due to sampling or may be difficult to evaluateIf multiple foci of microinvasive carcinoma are present, it is possible other foci would be positiveIt is highly unusual for foci of microinvasive carcinoma to show expression of ER, PR, or HER2 not seen in the associated DCISIt is helpful to report the results of ER, PR, and HER2 for both DCIS and the microinvasive carcinoma, particularly when there is discordanceIf systemic treatment is being considered, the ER, PR, and HER2 status of DCIS may be more predictive of response to therapy than the absence of any of these markers in areas of microinvasive carcinomaIf treatment is to reduce risk of local recurrence, residual carcinoma is most likely to be DCISIf treatment is to reduce the small possibility of distant recurrence, the few cells present in the focus of microinvasive carcinoma may not be indicative of the cells that metastasizeUnfortunately, because these cases are so rare, data is lacking",
                    "sub_points": [
                      "Microinvasive carcinoma can be of any biologic type\"Luminal\" ER(+)/HER2(-) = 50-60%\"Luminal/HER2\" ER(+)/HER2(+) = 5-20%\"HER2\" ER(-)/HER2(+) = 20-30%\"TNBC/basal\" ER(-)/HER2(-) = 5-10%",
                      "\"Luminal\" ER(+)/HER2(-) = 50-60%",
                      "\"Luminal/HER2\" ER(+)/HER2(+) = 5-20%",
                      "\"HER2\" ER(-)/HER2(+) = 20-30%",
                      "\"TNBC/basal\" ER(-)/HER2(-) = 5-10%",
                      "HER2(+) microinvasive carcinoma may be associated with adverse pathologic features and increased local recurrence risk",
                      "In the majority of cases, the results are concordant for DCIS and microinvasive carcinoma (~ > 95%), but rare cases of microinvasive carcinoma being negative for a marker positive in DCIS may occurIf microinvasive carcinoma is only present as a few cells, expression may not be seen due to sampling or may be difficult to evaluateIf multiple foci of microinvasive carcinoma are present, it is possible other foci would be positiveIt is highly unusual for foci of microinvasive carcinoma to show expression of ER, PR, or HER2 not seen in the associated DCIS",
                      "If microinvasive carcinoma is only present as a few cells, expression may not be seen due to sampling or may be difficult to evaluate",
                      "If multiple foci of microinvasive carcinoma are present, it is possible other foci would be positive",
                      "It is highly unusual for foci of microinvasive carcinoma to show expression of ER, PR, or HER2 not seen in the associated DCIS",
                      "It is helpful to report the results of ER, PR, and HER2 for both DCIS and the microinvasive carcinoma, particularly when there is discordance",
                      "If systemic treatment is being considered, the ER, PR, and HER2 status of DCIS may be more predictive of response to therapy than the absence of any of these markers in areas of microinvasive carcinomaIf treatment is to reduce risk of local recurrence, residual carcinoma is most likely to be DCISIf treatment is to reduce the small possibility of distant recurrence, the few cells present in the focus of microinvasive carcinoma may not be indicative of the cells that metastasizeUnfortunately, because these cases are so rare, data is lacking",
                      "If treatment is to reduce risk of local recurrence, residual carcinoma is most likely to be DCIS",
                      "If treatment is to reduce the small possibility of distant recurrence, the few cells present in the focus of microinvasive carcinoma may not be indicative of the cells that metastasize",
                      "Unfortunately, because these cases are so rare, data is lacking"
                    ]
                  },
                  {
                    "text": "Myoepithelial cell markersDeeper levels and immunostudies for myoepithelial cells can be useful for confirming the diagnosis of microinvasive carcinomaA panel of myoepithelial markers (e.g., p63, calponin, smooth muscle myosin heavy chain) is recommendedMyoepithelial cells associated with DCIS may lose expression of 1 or more markersMuscle markers are more sensitive (as they detect any part of the cell body) but are less specificAlso present in myofibroblasts and vesselsp63 is more specific (as it is not seen in stromal cells) but less sensitive (only nuclei of myoepithelial cells detected)Can be present in some high-grade carcinomas, which makes interpretation difficultIf only a myoepithelial marker is used, it may be difficult to distinguish tumor cells from reactive stromal or endothelial cellsArea of microinvasive carcinoma seen on original H&E slide may not be present on deeper level used for IHC, but other foci may appearTumor cells may be obscured by dense lymphocytic infiltrateMultiplex studies for both a myoepithelial marker and keratin are very useful in this setting",
                    "sub_points": [
                      "Deeper levels and immunostudies for myoepithelial cells can be useful for confirming the diagnosis of microinvasive carcinoma",
                      "A panel of myoepithelial markers (e.g., p63, calponin, smooth muscle myosin heavy chain) is recommendedMyoepithelial cells associated with DCIS may lose expression of 1 or more markersMuscle markers are more sensitive (as they detect any part of the cell body) but are less specificAlso present in myofibroblasts and vesselsp63 is more specific (as it is not seen in stromal cells) but less sensitive (only nuclei of myoepithelial cells detected)Can be present in some high-grade carcinomas, which makes interpretation difficult",
                      "Myoepithelial cells associated with DCIS may lose expression of 1 or more markers",
                      "Muscle markers are more sensitive (as they detect any part of the cell body) but are less specificAlso present in myofibroblasts and vessels",
                      "Also present in myofibroblasts and vessels",
                      "p63 is more specific (as it is not seen in stromal cells) but less sensitive (only nuclei of myoepithelial cells detected)Can be present in some high-grade carcinomas, which makes interpretation difficult",
                      "Can be present in some high-grade carcinomas, which makes interpretation difficult",
                      "If only a myoepithelial marker is used, it may be difficult to distinguish tumor cells from reactive stromal or endothelial cellsArea of microinvasive carcinoma seen on original H&E slide may not be present on deeper level used for IHC, but other foci may appearTumor cells may be obscured by dense lymphocytic infiltrateMultiplex studies for both a myoepithelial marker and keratin are very useful in this setting",
                      "Area of microinvasive carcinoma seen on original H&E slide may not be present on deeper level used for IHC, but other foci may appear",
                      "Tumor cells may be obscured by dense lymphocytic infiltrate",
                      "Multiplex studies for both a myoepithelial marker and keratin are very useful in this setting"
                    ]
                  },
                  {
                    "text": "KeratinKeratin studies are helpful to detect small foci of epithelial cells beyond the BM in stromaIf only keratin is used, it can be difficult to distinguish microinvasion from DCIS in compressed and distorted acini",
                    "sub_points": [
                      "Keratin studies are helpful to detect small foci of epithelial cells beyond the BM in stroma",
                      "If only keratin is used, it can be difficult to distinguish microinvasion from DCIS in compressed and distorted acini"
                    ]
                  },
                  {
                    "text": "Multiplex IHC for keratin and myoepithelial markersStudies that combine keratin with a myoepithelial marker are more helpful for identifying microinvasive carcinoma than the studies performed separatelyEpithelial cell nests without myoepithelial cells are easily identified",
                    "sub_points": [
                      "Studies that combine keratin with a myoepithelial marker are more helpful for identifying microinvasive carcinoma than the studies performed separately",
                      "Epithelial cell nests without myoepithelial cells are easily identified"
                    ]
                  },
                  {
                    "text": "BM markersCollagen IV or laminin IHC can be used to demonstrate BMThese markers are less useful than myoepithelial markers, as they can sometimes be positive in areas of invasive carcinoma",
                    "sub_points": [
                      "Collagen IV or laminin IHC can be used to demonstrate BM",
                      "These markers are less useful than myoepithelial markers, as they can sometimes be positive in areas of invasive carcinoma"
                    ]
                  }
                ],
                "Multigene Assays": [
                  {
                    "text": "These assays are not appropriate for microinvasive carcinoma, as there are too few cells available for testing"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ductal Carcinoma In Situ (DCIS) With Cancerization of Lobules": [
                  {
                    "text": "DCIS involving small acinar spaces in lobules may be difficult to distinguish from microinvasive carcinomaCancerization of lobules maintains lobulocentric pattern best seen on low magnificationGroups of tumor cells within lobular acini typically show rounded contoursAreas of branching cut tangentially can mimic microinvasive carcinoma",
                    "sub_points": [
                      "Cancerization of lobules maintains lobulocentric pattern best seen on low magnification",
                      "Groups of tumor cells within lobular acini typically show rounded contours",
                      "Areas of branching cut tangentially can mimic microinvasive carcinoma"
                    ]
                  },
                  {
                    "text": "Cancerization of lobules can be distinguished from microinvasive carcinoma by architectural pattern and the presence of associated myoepithelial cells"
                  }
                ],
                "Small Invasive Carcinoma (T1a)": [
                  {
                    "text": "Foci of invasion measuring > 1 mm are classified as invasive breast cancer (T1a)"
                  },
                  {
                    "text": "If there are foci of microinvasive carcinoma, in addition to a larger area of invasion, smaller foci should be reported as additional areas of microinvasive carcinomaThe modifier \"m\" is not used for invasive carcinoma only detected microscopically in the absence of neoadjuvant therapy",
                    "sub_points": [
                      "The modifier \"m\" is not used for invasive carcinoma only detected microscopically in the absence of neoadjuvant therapy"
                    ]
                  }
                ],
                "Artifactual Displacement of Tumor Cells": [
                  {
                    "text": "Tumor cells of DCIS can be displaced into stroma due to prior core needle biopsy or surgical excision"
                  },
                  {
                    "text": "Cells will be surrounded by reactive stromal changes related to the core needle biopsy site or in the needle trackUsual desmoplastic and lymphocytic response associated with invasion is typically absent",
                    "sub_points": [
                      "Usual desmoplastic and lymphocytic response associated with invasion is typically absent"
                    ]
                  },
                  {
                    "text": "In some cases, myoepithelial cells may still be associated with tumor cells"
                  },
                  {
                    "text": "A diagnosis of invasive BC or microinvasive carcinoma should not be made if the histologic appearance suggests artifactual displacement (associated with biopsy tract changes)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Areas of microinvasive carcinoma present on the H&E slide may be absent on deeper levels used for IHCHowever, other areas of microinvasive carcinoma may appear",
                    "sub_points": [
                      "However, other areas of microinvasive carcinoma may appear"
                    ]
                  },
                  {
                    "text": "Multiplex immunoperoxidase studies, including antibodies for both keratin and myoepithelial markers, are very helpful for detecting microinvasive carcinoma"
                  }
                ]
              },
              "REPORTING": {
                "Key Elements to Report": [
                  {
                    "text": "\"Microinvasive carcinoma\" rather than \"DCIS with microinvasion\" is the terminology recommended by the World Health Organization"
                  },
                  {
                    "text": "The size of the largest focus of microinvasive carcinoma is reportedNumber of foci of microinvasive carcinoma (or number of blocks with microinvasive carcinoma) are reportedSizes of multiple foci should not be added togetherSize should not be rounded down (e.g., a 1.1-mm carcinoma should be classified as T1a)",
                    "sub_points": [
                      "Number of foci of microinvasive carcinoma (or number of blocks with microinvasive carcinoma) are reported",
                      "Sizes of multiple foci should not be added together",
                      "Size should not be rounded down (e.g., a 1.1-mm carcinoma should be classified as T1a)"
                    ]
                  },
                  {
                    "text": "Results of ER, PR, and HER2 should be reported for both DCIS and microinvasive carcinoma (especially if discordant)"
                  },
                  {
                    "text": "AJCC classification is T1miThe modifier \"m\" is not used if multiple foci of microinvasion are present",
                    "sub_points": [
                      "The modifier \"m\" is not used if multiple foci of microinvasion are present"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Checklist for the Reporting of Ductal Carcinoma In Situ": {
            "name": "Checklist for the Reporting of Ductal Carcinoma In Situ",
            "url": "https://app.pathprimer.com/document/f043ea78-27ef-4ff4-995a-555ee1ab42d4/lesson/cefe61cb-6637-4e35-b36c-0f780bf9f8d9",
            "content": {}
          }
        }
      },
      "Invasive Carcinoma": {
        "name": "Invasive Carcinoma",
        "url": "https://app.pathprimer.com/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
        "topics": {
          "Invasive Lobular Carcinoma": {
            "name": "Invasive Lobular Carcinoma",
            "url": "https://app.pathprimer.com/document/c1978466-bd49-45e7-90fc-e13668f3067c/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Invasive lobular carcinomas (ILCs) are characterized by loss of normal cell adhesion and actin cytoskeleton regulationUnderlies dyscohesive single cell morphology and diffuse pattern of infiltration in breast and at metastatic sites",
                    "sub_points": [
                      "Underlies dyscohesive single cell morphology and diffuse pattern of infiltration in breast and at metastatic sites"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "BiallelicCDH1(E-cadherin) alterations are present in > 95%, and ~ 95% show complete absence or aberrant expression of the proteinRare ILCs have alterations in other genes",
                    "sub_points": [
                      "Rare ILCs have alterations in other genes"
                    ]
                  },
                  {
                    "text": "CDH1germline mutations increase risk of gastric cancer and, to a lesser extent, ILCHowever, the majority of patients with ILC do not have E-cadherin germline mutations",
                    "sub_points": [
                      "However, the majority of patients with ILC do not have E-cadherin germline mutations"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most common special type of breast carcinoma: 10-15% of all breast cancers"
                  },
                  {
                    "text": "Majority present as an irregular mass, but the diffuse pattern of infiltration can make detection difficult"
                  },
                  {
                    "text": "Most common type of breast carcinoma to present as an occult primary with distant metastases"
                  },
                  {
                    "text": "Distinct pattern of metastases to serosal surfaces of GI and GYN tracts and leptomeninges"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Classic ILC: Linear files of dyscohesive cells, grade 1 or 2, ER(+), HER2(-)"
                  },
                  {
                    "text": "Nonclassic ILC: Variable cytologic and architectural features, usually grade 2 or 3, can be ER(-) &/or HER2(+)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Invasive carcinoma with ductal and lobular features"
                  },
                  {
                    "text": "Lymphoma and lymphocytes"
                  },
                  {
                    "text": "Metastatic melanoma"
                  },
                  {
                    "text": "Myofibroblastoma, epithelioid variant"
                  },
                  {
                    "text": "Gastric signet-ring cell carcinoma"
                  },
                  {
                    "text": "Hematopoietic cells"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive lobular carcinoma (ILC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "ILCs are characterized by loss of cell adhesion resulting in the morphologic appearance of dyscohesive cells"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Lobular and Ductal Terminology": [
                  {
                    "text": "The lobular family of breast lesions is defined by loss of normal cell adhesion and actin cytoskeleton regulationMembers include atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and ILC",
                    "sub_points": [
                      "Members include atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and ILC"
                    ]
                  },
                  {
                    "text": "LCIS typically expands, but does not distort, lobulesLCIS was given the name \"lobular\" because involved lobules continue to look like lobulesIn contrast, a lobule involved by ductal carcinoma in situ (DCIS) is often unfolded into a single space that resembles a duct, due to a cohesive tumor expansile growth pattern",
                    "sub_points": [
                      "LCIS was given the name \"lobular\" because involved lobules continue to look like lobules",
                      "In contrast, a lobule involved by ductal carcinoma in situ (DCIS) is often unfolded into a single space that resembles a duct, due to a cohesive tumor expansile growth pattern"
                    ]
                  },
                  {
                    "text": "Invasive carcinoma associated with LCIS was termed ILC, and invasive carcinoma associated with DCIS was termed invasive ductal carcinoma"
                  },
                  {
                    "text": "\"Lobular\" and \"ductal\" refer to growth patterns and do not indicate cell of originThe actual cell of origin for breast cancers (BCs) is unknown but is thought to likely be a stem or precursor cell in the terminal ductsSome carcinomas with ductal and lobular features have been shown to be clonally related, as they share the same mutations",
                    "sub_points": [
                      "The actual cell of origin for breast cancers (BCs) is unknown but is thought to likely be a stem or precursor cell in the terminal ducts",
                      "Some carcinomas with ductal and lobular features have been shown to be clonally related, as they share the same mutations"
                    ]
                  }
                ],
                "Diagnostic Criteria": [
                  {
                    "text": "ILC is the most common special histologic type of BC (~ 10-15%)~ 46,000 cases per year in the USA, which is a larger number than tumors of the kidney, brain, pancreas, liver, and ovaries in women",
                    "sub_points": [
                      "~ 46,000 cases per year in the USA, which is a larger number than tumors of the kidney, brain, pancreas, liver, and ovaries in women"
                    ]
                  },
                  {
                    "text": "The defining feature of ILC is the loss of cell cohesion, which is due to mutations and other alterations inCDH1(E-cadherin) in ~ 90-95% of cases"
                  },
                  {
                    "text": "The lack of cohesion alters the histologic appearanceCells are rounded and not attached to other cellsCannot form cribriform spaces, tubules, or papillaeCells invade along the areas of least resistance between collagen bundles (linear pattern), surrounding normal ducts (targetoid pattern), and along fibrovascular septa",
                    "sub_points": [
                      "Cells are rounded and not attached to other cells",
                      "Cannot form cribriform spaces, tubules, or papillae",
                      "Cells invade along the areas of least resistance between collagen bundles (linear pattern), surrounding normal ducts (targetoid pattern), and along fibrovascular septa"
                    ]
                  },
                  {
                    "text": "ILC is important to recognize, as there are distinct differences in imaging appearances, extent of disease at presentation, response to therapy, metastatic pattern, and long-term prognosis compared to other BCsOngoing studies are investigating therapies that could leverage biologic features specific to ILC",
                    "sub_points": [
                      "Ongoing studies are investigating therapies that could leverage biologic features specific to ILC"
                    ]
                  },
                  {
                    "text": "To assist in improving concordance in diagnosis, the European Lobular Breast Cancer Consortium (ELBCC) issued recommendations for morphologic and immunohistochemical (IHC) criteria for the diagnosis of ILCIf morphologic criteria for classic ILC are met, no IHC studies are necessaryIf morphologic features of ILC are present, but they do not fulfill the definition for classic ILC, additional IHC studies for E-cadherin, as well as other adhesion proteins, can be helpful for classification",
                    "sub_points": [
                      "If morphologic criteria for classic ILC are met, no IHC studies are necessary",
                      "If morphologic features of ILC are present, but they do not fulfill the definition for classic ILC, additional IHC studies for E-cadherin, as well as other adhesion proteins, can be helpful for classification"
                    ]
                  }
                ],
                "Risk Factors for Invasive Lobular Carcinoma": [
                  {
                    "text": "Lobular carcinoma in situ (LCIS)LCIS increases the risk of both ILCs and nonlobular BCs by ~ 10xBCs arising in women with a history of LCIS are 3x more likely to be ILC70-80% of cases of ILC are associated with LCISLCIS can share genetic alterations with an associated ILC, supporting its role as a true precursor lesion rather than only a risk factor",
                    "sub_points": [
                      "LCIS increases the risk of both ILCs and nonlobular BCs by ~ 10x",
                      "BCs arising in women with a history of LCIS are 3x more likely to be ILC",
                      "70-80% of cases of ILC are associated with LCIS",
                      "LCIS can share genetic alterations with an associated ILC, supporting its role as a true precursor lesion rather than only a risk factor"
                    ]
                  },
                  {
                    "text": "Germline mutations< 5% of patients with ILC have a germline mutationCDH1(E-cadherin)Hereditary diffuse gastric cancer (HDGC) syndrome is predominantly associated with signet-ring cell gastric carcinoma (GC) with fewer cases of ILCRisk of GC is ~ 40-80% before age of ~ 80Risk of ILC for females is ~ 40-50% before age of ~ 80Hereditary lobular BC (HLBC) syndrome is associated predominantly with ILC with fewer cases of GCLess common than HDGCPatients with ILC are more commonly ≤ 45 years old and usually have a family history of BCAlthough someCDH1mutations are more commonly associated with either ILC or GC, the reasons for the differences risk for the 2 types of carcinoma are not yet knownAlthough GC and ILC have morphologic similarities, they have important differences in the expression of other genesEach has organ-specific gene expression patternsBRCA2Women withBRCA2germline mutations develop ILCs at about the same incidence as women in general (~ 10%)Women withBRCA1orTP53germline mutations only very rarely develop ILC (< 2%)",
                    "sub_points": [
                      "< 5% of patients with ILC have a germline mutation",
                      "CDH1(E-cadherin)Hereditary diffuse gastric cancer (HDGC) syndrome is predominantly associated with signet-ring cell gastric carcinoma (GC) with fewer cases of ILCRisk of GC is ~ 40-80% before age of ~ 80Risk of ILC for females is ~ 40-50% before age of ~ 80Hereditary lobular BC (HLBC) syndrome is associated predominantly with ILC with fewer cases of GCLess common than HDGCPatients with ILC are more commonly ≤ 45 years old and usually have a family history of BCAlthough someCDH1mutations are more commonly associated with either ILC or GC, the reasons for the differences risk for the 2 types of carcinoma are not yet knownAlthough GC and ILC have morphologic similarities, they have important differences in the expression of other genesEach has organ-specific gene expression patterns",
                      "Hereditary diffuse gastric cancer (HDGC) syndrome is predominantly associated with signet-ring cell gastric carcinoma (GC) with fewer cases of ILCRisk of GC is ~ 40-80% before age of ~ 80Risk of ILC for females is ~ 40-50% before age of ~ 80",
                      "Risk of GC is ~ 40-80% before age of ~ 80",
                      "Risk of ILC for females is ~ 40-50% before age of ~ 80",
                      "Hereditary lobular BC (HLBC) syndrome is associated predominantly with ILC with fewer cases of GCLess common than HDGCPatients with ILC are more commonly ≤ 45 years old and usually have a family history of BC",
                      "Less common than HDGC",
                      "Patients with ILC are more commonly ≤ 45 years old and usually have a family history of BC",
                      "Although someCDH1mutations are more commonly associated with either ILC or GC, the reasons for the differences risk for the 2 types of carcinoma are not yet known",
                      "Although GC and ILC have morphologic similarities, they have important differences in the expression of other genesEach has organ-specific gene expression patterns",
                      "Each has organ-specific gene expression patterns",
                      "BRCA2Women withBRCA2germline mutations develop ILCs at about the same incidence as women in general (~ 10%)Women withBRCA1orTP53germline mutations only very rarely develop ILC (< 2%)",
                      "Women withBRCA2germline mutations develop ILCs at about the same incidence as women in general (~ 10%)",
                      "Women withBRCA1orTP53germline mutations only very rarely develop ILC (< 2%)"
                    ]
                  },
                  {
                    "text": "HormonalILC showed a higher rate of increase relative to nonlobular BC up until the early 2000sFollowing studies linking hormonal replacement therapy (HRT) to risk of BC, the use of HRT decreased, as did the rate of BCsThere was a relatively larger drop in cases of ILC compared to nonlobular BCsThis suggests a hormonal role in the development and growth of ILCs",
                    "sub_points": [
                      "ILC showed a higher rate of increase relative to nonlobular BC up until the early 2000s",
                      "Following studies linking hormonal replacement therapy (HRT) to risk of BC, the use of HRT decreased, as did the rate of BCs",
                      "There was a relatively larger drop in cases of ILC compared to nonlobular BCs",
                      "This suggests a hormonal role in the development and growth of ILCs"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "10-15% of invasive breast carcinomas"
                  }
                ],
                "Age": [
                  {
                    "text": "More common in older postmenopausal women (> 50 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Rare in males but does occurCan be associated withBRCA2germline mutations",
                    "sub_points": [
                      "Can be associated withBRCA2germline mutations"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "~ 50% of patients with ILC present with a palpable mass, which is similar to patients with nonlobular BCThe number of women presenting with palpable masses is dependent on the number of women undergoing mammographic screening",
                    "sub_points": [
                      "The number of women presenting with palpable masses is dependent on the number of women undergoing mammographic screening"
                    ]
                  },
                  {
                    "text": "The majority of ILCs present as masses on breast imaging with smaller numbers associated with other findings on imaging"
                  },
                  {
                    "text": "A greater number of ILCs (10-20%) are detected first as metastatic carcinoma with an occult primary compared to nonlobular BCs (5-10%)Due to the diffusely infiltrative pattern and minimal desmoplastic response, ILC can be difficult to detect clinically and by imagingMR is useful to detect the primary ILC in these cases",
                    "sub_points": [
                      "Due to the diffusely infiltrative pattern and minimal desmoplastic response, ILC can be difficult to detect clinically and by imaging",
                      "MR is useful to detect the primary ILC in these cases"
                    ]
                  },
                  {
                    "text": "ILC is reported to be more commonly multicentric and bilateral than nonlobular BCs, but these numbers could be inflated due to other factorsThe diffuse growth pattern, often in thin strands along lymphatic/vascular channels, could create the false impression of multiple foci in 2 dimensionsPatients with ILC may undergo additional imaging &/or surgery (e.g., bilateral mastectomy), which could lead to the discovery of more foci of BC compared to other patientsThe actual risk for a clinical diagnosis of contralateral BC is ~ 0.5-1% per year, which is similar to the risk for all patients with BC",
                    "sub_points": [
                      "The diffuse growth pattern, often in thin strands along lymphatic/vascular channels, could create the false impression of multiple foci in 2 dimensions",
                      "Patients with ILC may undergo additional imaging &/or surgery (e.g., bilateral mastectomy), which could lead to the discovery of more foci of BC compared to other patients",
                      "The actual risk for a clinical diagnosis of contralateral BC is ~ 0.5-1% per year, which is similar to the risk for all patients with BC"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgery and radiationLocal treatment for ILC is generally the same as for nonlobular BCs",
                    "sub_points": [
                      "Local treatment for ILC is generally the same as for nonlobular BCs"
                    ]
                  },
                  {
                    "text": "Endocrine therapyAlmost all ILCs are strongly positive for hormone receptors and negative for HER2Adjuvant endocrine therapy is usually recommendedAromatase inhibitors (AIs) are more effective compared to tamoxifen for ILC",
                    "sub_points": [
                      "Almost all ILCs are strongly positive for hormone receptors and negative for HER2",
                      "Adjuvant endocrine therapy is usually recommended",
                      "Aromatase inhibitors (AIs) are more effective compared to tamoxifen for ILC"
                    ]
                  },
                  {
                    "text": "ChemotherapyNeoadjuvant studies have shown that ILC shows minimal response to chemotherapy compared to nonlobular BCPathologic complete response (pCR) is < 5%Largely influenced by high hormone receptor expression and relatively low proliferative rates",
                    "sub_points": [
                      "Neoadjuvant studies have shown that ILC shows minimal response to chemotherapy compared to nonlobular BCPathologic complete response (pCR) is < 5%",
                      "Pathologic complete response (pCR) is < 5%",
                      "Largely influenced by high hormone receptor expression and relatively low proliferative rates"
                    ]
                  },
                  {
                    "text": "ILC-targeted therapyClinical trials are being conducted for E-cadherin-deficient carcinomase.g., the ROSALINE trial is evaluating the effectiveness of ROS1 inhibitors",
                    "sub_points": [
                      "Clinical trials are being conducted for E-cadherin-deficient carcinomase.g., the ROSALINE trial is evaluating the effectiveness of ROS1 inhibitors",
                      "e.g., the ROSALINE trial is evaluating the effectiveness of ROS1 inhibitors"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Similar to women with nonlobular BCs matched for grade and stageStage I: 46% of ILC compared to 54% of nonlobular BCStage II: 33% of ILC compared to 35% of nonlobular BCStage III: 17% of ILC compared to 8% of nonlobular BCStage IV: 4% of ILC compared to 2% of nonlobular BC",
                    "sub_points": [
                      "Stage I: 46% of ILC compared to 54% of nonlobular BC",
                      "Stage II: 33% of ILC compared to 35% of nonlobular BC",
                      "Stage III: 17% of ILC compared to 8% of nonlobular BC",
                      "Stage IV: 4% of ILC compared to 2% of nonlobular BC"
                    ]
                  },
                  {
                    "text": "Nonclassic patterns of ILC (e.g., solid, alveolar, pleomorphic) in general have worse prognosis compared to classic ILCMore likely to be high grade &/or hormone receptor low positive or negative &/or HER2(+)",
                    "sub_points": [
                      "More likely to be high grade &/or hormone receptor low positive or negative &/or HER2(+)"
                    ]
                  },
                  {
                    "text": "Survival for patients with ILC and nonlobular BC are very similar up to ~ 10 years, followed by slightly worse disease-free survival for ILCIncreased tumor size, nodal status, and proliferation (e.g., Ki-67 labeling index) are significantly associated with late recurrenceLate recurrences are enriched forESR1mutations (conferring resistance to endocrine therapy) andERBB2(HER2)-activating mutations (possibly promoting growth)",
                    "sub_points": [
                      "Increased tumor size, nodal status, and proliferation (e.g., Ki-67 labeling index) are significantly associated with late recurrence",
                      "Late recurrences are enriched forESR1mutations (conferring resistance to endocrine therapy) andERBB2(HER2)-activating mutations (possibly promoting growth)"
                    ]
                  },
                  {
                    "text": "ILC has a distinct pattern of metastatic spreadLess likely to metastasize to liver and lungs than nonlobular BCMore likely to metastasize to serosal surfaces (retroperitoneum, pleura, leptomeninges), GI, and GYN tractsCarcinomatous meningitis is usually due to ILCOccasionally detected in GI mucosal biopsies and endometrial curettingsMetastatic ILC to stomach can mimic linitis plastica due to primary GCDistant metastases can be difficult to detect by imaging due to the diffuse infiltrative pattern",
                    "sub_points": [
                      "Less likely to metastasize to liver and lungs than nonlobular BC",
                      "More likely to metastasize to serosal surfaces (retroperitoneum, pleura, leptomeninges), GI, and GYN tractsCarcinomatous meningitis is usually due to ILCOccasionally detected in GI mucosal biopsies and endometrial curettingsMetastatic ILC to stomach can mimic linitis plastica due to primary GC",
                      "Carcinomatous meningitis is usually due to ILC",
                      "Occasionally detected in GI mucosal biopsies and endometrial curettings",
                      "Metastatic ILC to stomach can mimic linitis plastica due to primary GC",
                      "Distant metastases can be difficult to detect by imaging due to the diffuse infiltrative pattern"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "ILCs have different imaging characteristics compared to nonlobular BCsMasses: 60-75% of ILCs (> 95% with spiculated borders) compared to 80-85% of nonlobular BCs (80% spiculated, 20% circumscribed)Solid and alveolar pattern ILCs form masses with circumscribed bordersArchitectural distortion: 25-40% of ILCs compared to 5-15% of nonlobular BCsDeveloping asymmetry: 10-20% of ILCs compared to 5-10% of nonlobular BCsAssociated calcifications: 10-15% of ILCs compared to 30-50% of nonlobular BCsOccult: 10-20% of ILC compared to 5-10% of nonlobular BCsILC is the most common type of BC to present as an occult primary with distant metastases",
                    "sub_points": [
                      "Masses: 60-75% of ILCs (> 95% with spiculated borders) compared to 80-85% of nonlobular BCs (80% spiculated, 20% circumscribed)Solid and alveolar pattern ILCs form masses with circumscribed borders",
                      "Solid and alveolar pattern ILCs form masses with circumscribed borders",
                      "Architectural distortion: 25-40% of ILCs compared to 5-15% of nonlobular BCs",
                      "Developing asymmetry: 10-20% of ILCs compared to 5-10% of nonlobular BCs",
                      "Associated calcifications: 10-15% of ILCs compared to 30-50% of nonlobular BCs",
                      "Occult: 10-20% of ILC compared to 5-10% of nonlobular BCsILC is the most common type of BC to present as an occult primary with distant metastases",
                      "ILC is the most common type of BC to present as an occult primary with distant metastases"
                    ]
                  },
                  {
                    "text": "Size may be underestimated by mammogram or ultrasound"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Mass with spiculated or circumscribed borders or area of enhancement"
                  },
                  {
                    "text": "Useful for detecting ILCs not imaged by mammography or ultrasound"
                  },
                  {
                    "text": "Size may be more accurate by MR examination but can overestimate size"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Majority form a discrete firm mass"
                  },
                  {
                    "text": "Subset are difficult to see grossly and are only slightly firmer on palpation"
                  },
                  {
                    "text": "ILC with a diffuse infiltrative pattern in adipose tissue may have pale yellow color, slightly firmer consistency"
                  }
                ],
                "Size": [
                  {
                    "text": "For grossly subtle ill-defined ILCs, assessment of tumor size for AJCC T classification can be difficult"
                  },
                  {
                    "text": "Requires correlation of imaging, gross, and microscopic information"
                  },
                  {
                    "text": "Number of blocks involved as mapped to the specimen can give an estimate of size"
                  }
                ]
              },
              "MOLECULAR": {
                "CDH1(E-Cadherin)": [
                  {
                    "text": "Loss or aberrant E-cadherin protein expression is observed in ~ 95% of ILCsE-cadherin: Calcium-dependent transmembrane proteinFunctional role in cellular adhesion and cell polarityBinds actin cytoskeleton through interactions with p120, α-, β-, and γ-cateninLoss of E-cadherin affects cellular adhesion, motility, and possibly cell division",
                    "sub_points": [
                      "E-cadherin: Calcium-dependent transmembrane proteinFunctional role in cellular adhesion and cell polarityBinds actin cytoskeleton through interactions with p120, α-, β-, and γ-catenin",
                      "Functional role in cellular adhesion and cell polarity",
                      "Binds actin cytoskeleton through interactions with p120, α-, β-, and γ-catenin",
                      "Loss of E-cadherin affects cellular adhesion, motility, and possibly cell division"
                    ]
                  },
                  {
                    "text": "To interfere with cell adhesion, bothCDH1alleles need to be altered~ 85% of ILCs have aCDH1mutation in 1 allele and a deletion in the other allele~ 7% of ILCs have aCDH1mutation in 1 allele, and the other allele has promoter methylation reducing transcription~ 7% of ILCs do not have aCDH1mutationSome have promoter methylation of 1 allele and a deletion of the other alleleSome have alterations in other genes, such as p120, α-catenin, or AIN2",
                    "sub_points": [
                      "~ 85% of ILCs have aCDH1mutation in 1 allele and a deletion in the other allele",
                      "~ 7% of ILCs have aCDH1mutation in 1 allele, and the other allele has promoter methylation reducing transcription",
                      "~ 7% of ILCs do not have aCDH1mutationSome have promoter methylation of 1 allele and a deletion of the other alleleSome have alterations in other genes, such as p120, α-catenin, or AIN2",
                      "Some have promoter methylation of 1 allele and a deletion of the other allele",
                      "Some have alterations in other genes, such as p120, α-catenin, or AIN2"
                    ]
                  },
                  {
                    "text": "CDH1mutations> 200 different mutations have been identifiedNonsense, frameshift, splice variant, missenseCan involve promoter or coding regionsCan be present in the extracellular or intracellular portions of the proteinThe locations of mutations inCDH1are shown at this website: https://www.oncokb.org/gene/CDH1 (accessed 11/27/2024)~ 10% of BCs withCDH1mutations would not be classified as ILC based on other criteria (e.g., 2nd allele is functional; morphology shows cell cohesion)",
                    "sub_points": [
                      "> 200 different mutations have been identifiedNonsense, frameshift, splice variant, missenseCan involve promoter or coding regionsCan be present in the extracellular or intracellular portions of the protein",
                      "Nonsense, frameshift, splice variant, missense",
                      "Can involve promoter or coding regions",
                      "Can be present in the extracellular or intracellular portions of the protein",
                      "The locations of mutations inCDH1are shown at this website: https://www.oncokb.org/gene/CDH1 (accessed 11/27/2024)",
                      "~ 10% of BCs withCDH1mutations would not be classified as ILC based on other criteria (e.g., 2nd allele is functional; morphology shows cell cohesion)"
                    ]
                  },
                  {
                    "text": "The type of mutation and the different combinations of alterations result in the absence of E-cadherin in ~ 85% of cases and aberrant expression in ~ 10-15%In ~ 5% of cases, E-cadherin membrane positivity is presentMay be due to mutations/deletions in extracellular domain that interfere with function but not protein production",
                    "sub_points": [
                      "In ~ 5% of cases, E-cadherin membrane positivity is present",
                      "May be due to mutations/deletions in extracellular domain that interfere with function but not protein production"
                    ]
                  }
                ],
                "Other DNA Alterations": [
                  {
                    "text": "ILC has fewer chromosomal abnormalities than nonlobular BCs"
                  },
                  {
                    "text": "Copy number changesThere are 3 frequent and consistent changes in ILCLoss at 16q (location of E-cadherin gene: 16q22.1) and gains at 1q and 16pThese changes are characteristic of the low-grade breast neoplasia family or pathwayRecurrent gains (8q), amplifications (1q32, 8p12-p11.2, 11q13), and losses (8p23-p21, 11q14.1-q25, 13q) are reportedERBB2(HER2) amplification is very rare in grades 1 and 2 ILCPresent in some grade 3 ILCs",
                    "sub_points": [
                      "There are 3 frequent and consistent changes in ILCLoss at 16q (location of E-cadherin gene: 16q22.1) and gains at 1q and 16pThese changes are characteristic of the low-grade breast neoplasia family or pathwayRecurrent gains (8q), amplifications (1q32, 8p12-p11.2, 11q13), and losses (8p23-p21, 11q14.1-q25, 13q) are reported",
                      "Loss at 16q (location of E-cadherin gene: 16q22.1) and gains at 1q and 16pThese changes are characteristic of the low-grade breast neoplasia family or pathway",
                      "These changes are characteristic of the low-grade breast neoplasia family or pathway",
                      "Recurrent gains (8q), amplifications (1q32, 8p12-p11.2, 11q13), and losses (8p23-p21, 11q14.1-q25, 13q) are reported",
                      "ERBB2(HER2) amplification is very rare in grades 1 and 2 ILCPresent in some grade 3 ILCs",
                      "Present in some grade 3 ILCs"
                    ]
                  },
                  {
                    "text": "Mutations in addition toCDH1PIK3CA~ 45%ERBB2~ 9% of newly diagnosed ILCs (compared to ~ 2% of all breast carcinomas)Present in ~ 18% of relapsed ILCsMajority activating mutationsHave not been associated with protein overexpressionMay be sensitive to tyrosine kinase inhibitorsESR1(ER): Rare in primary ILCs but occur in metastases (~ 10-15% of bone metastases)Confers resistance to endocrine therapyMore common in late recurrences after years of AI treatmentER protein continues to be expressed: DNA analysis is necessary to detect mutationsPTEN,TBX3,ERBB3,ARID1A,andFOXA1mutations are more common in ILC compared with nonlobular BCsTP53,MYC,MDM2: Mutation &/or amplification may be present in grade 3 ILC",
                    "sub_points": [
                      "PIK3CA~ 45%",
                      "ERBB2~ 9% of newly diagnosed ILCs (compared to ~ 2% of all breast carcinomas)Present in ~ 18% of relapsed ILCsMajority activating mutationsHave not been associated with protein overexpressionMay be sensitive to tyrosine kinase inhibitors",
                      "Present in ~ 18% of relapsed ILCs",
                      "Majority activating mutationsHave not been associated with protein overexpressionMay be sensitive to tyrosine kinase inhibitors",
                      "Have not been associated with protein overexpression",
                      "May be sensitive to tyrosine kinase inhibitors",
                      "ESR1(ER): Rare in primary ILCs but occur in metastases (~ 10-15% of bone metastases)Confers resistance to endocrine therapyMore common in late recurrences after years of AI treatmentER protein continues to be expressed: DNA analysis is necessary to detect mutations",
                      "Confers resistance to endocrine therapyMore common in late recurrences after years of AI treatment",
                      "More common in late recurrences after years of AI treatment",
                      "ER protein continues to be expressed: DNA analysis is necessary to detect mutations",
                      "PTEN,TBX3,ERBB3,ARID1A,andFOXA1mutations are more common in ILC compared with nonlobular BCs",
                      "TP53,MYC,MDM2: Mutation &/or amplification may be present in grade 3 ILC"
                    ]
                  },
                  {
                    "text": "Epigenetic changesILCs exhibit highest number of differentially methylated CpG sitesThere is a strong inverse correlation of aberrant DNA hypermethylation and copy number alterationsData support association between CpG island methylator phenotype and ILC",
                    "sub_points": [
                      "ILCs exhibit highest number of differentially methylated CpG sitesThere is a strong inverse correlation of aberrant DNA hypermethylation and copy number alterationsData support association between CpG island methylator phenotype and ILC",
                      "There is a strong inverse correlation of aberrant DNA hypermethylation and copy number alterations",
                      "Data support association between CpG island methylator phenotype and ILC"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "ILC of all grades are more similar to each other than to other BCsMajority have luminal A expression profile (~ 85%)Nonclassic ILC can be in luminal A, luminal B, HER2-enriched, or molecular apocrine groupsShare similar expression patterns related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signalingGrades 1 and 2 ILC have distinct gene expression patterns compared to grades 1 and 2 nonlobular BCs",
                    "sub_points": [
                      "Majority have luminal A expression profile (~ 85%)Nonclassic ILC can be in luminal A, luminal B, HER2-enriched, or molecular apocrine groups",
                      "Nonclassic ILC can be in luminal A, luminal B, HER2-enriched, or molecular apocrine groups",
                      "Share similar expression patterns related to cell adhesion, cell-to-cell signaling, and actin cytoskeleton signaling",
                      "Grades 1 and 2 ILC have distinct gene expression patterns compared to grades 1 and 2 nonlobular BCs"
                    ]
                  },
                  {
                    "text": "Most ILCs are classified as \"low-risk\" tumors by by multigene expression assaysILCs can have very low cellularity, which could lead to aberrant higher risk results for assays that do not utilize microdissectionmRNA is averaged over tumor cells and stromaResults should be interpreted with caution if discordant with tumor grade or single gene scores for estrogen and progesterone receptors",
                    "sub_points": [
                      "ILCs can have very low cellularity, which could lead to aberrant higher risk results for assays that do not utilize microdissection",
                      "mRNA is averaged over tumor cells and stroma",
                      "Results should be interpreted with caution if discordant with tumor grade or single gene scores for estrogen and progesterone receptors"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "The ELBCC issued recommendations for features identifying classic ILCSmall cells that lack cohesion and appear individually dispersed in stroma or in single-file cords; frequently form a concentric pattern around normal ductsNuclei are round or notched and ovoidThere is a thin rim of cytoplasm with occasional intracytoplasmic vacuoles, often with a central mucoid inclusion (signet-ring cell)Often little stromal response or alteration in normal breast architectureIf these features are present, a diagnosis of ILC can be made without the use of IHC",
                    "sub_points": [
                      "Small cells that lack cohesion and appear individually dispersed in stroma or in single-file cords; frequently form a concentric pattern around normal ducts",
                      "Nuclei are round or notched and ovoid",
                      "There is a thin rim of cytoplasm with occasional intracytoplasmic vacuoles, often with a central mucoid inclusion (signet-ring cell)",
                      "Often little stromal response or alteration in normal breast architecture",
                      "If these features are present, a diagnosis of ILC can be made without the use of IHC"
                    ]
                  },
                  {
                    "text": "The ELBCC recommends that BCs with features characteristic of ILC may warrant IHC to determine if classification as ILC is appropriateIntercellular dyscohesionLinear infiltration &/or single cell infiltration of tumor cellsCircumferential infiltration of tumor cells around ductsUniform, monomorphic nucleiIntracytoplasmic vacuolesSingle cells or small, loosely cohesive cells grouped in stromal mucin poolsInfiltration of adipose tissue without stromal reactionAssociated LCIS &/or ALH< 25% tubules in the Nottingham grading system, in conjunction with any of the above",
                    "sub_points": [
                      "Intercellular dyscohesion",
                      "Linear infiltration &/or single cell infiltration of tumor cells",
                      "Circumferential infiltration of tumor cells around ducts",
                      "Uniform, monomorphic nuclei",
                      "Intracytoplasmic vacuoles",
                      "Single cells or small, loosely cohesive cells grouped in stromal mucin pools",
                      "Infiltration of adipose tissue without stromal reaction",
                      "Associated LCIS &/or ALH",
                      "< 25% tubules in the Nottingham grading system, in conjunction with any of the above"
                    ]
                  },
                  {
                    "text": "Cytologic featuresClassicNuclei score 1 or 2 for gradingThere is typically scant or a moderate amount of cytoplasmOccasional signet-ring cells can be presentSignet-ring cellCells with cytoplasmic mucin vacuoles can be seen in any type of ILCSingle mucin vacuole with central dot is the most common appearanceMultiple vacuoles giving a foamy appearance is less common: This type is more characteristic of gastric signet-ring cell carcinomas (GSRCs)Signet-ring cells can also be seen in BCs of no special typePleomorphicCells have larger (> 4x the size of lymphocytes) nuclei with marked pleomorphism (\"equivalent to high-grade DCIS\")May have single or multiple prominent nucleoli\"Pleomorphic ILC\" includes both grades 2 and 3 ILCGrade provides more information than designation as \"pleomorphic ILC\"5-10% are ER(-)20-30% are HER2(+)20-60% are p53(+)Histiocytoid/apocrineCells have abundant eosinophilic &/or foamy cytoplasmCells can resemble histiocytes (ergo term \"histiocytoid\"), particularly in lymph nodes, metastatic sites, or in areas of inflammationMay resemble granular cell tumorTumors with both histiocytoid/apocrine and pleomorphic features are more likely to be HER2(+)",
                    "sub_points": [
                      "ClassicNuclei score 1 or 2 for gradingThere is typically scant or a moderate amount of cytoplasmOccasional signet-ring cells can be present",
                      "Nuclei score 1 or 2 for grading",
                      "There is typically scant or a moderate amount of cytoplasm",
                      "Occasional signet-ring cells can be present",
                      "Signet-ring cellCells with cytoplasmic mucin vacuoles can be seen in any type of ILCSingle mucin vacuole with central dot is the most common appearanceMultiple vacuoles giving a foamy appearance is less common: This type is more characteristic of gastric signet-ring cell carcinomas (GSRCs)Signet-ring cells can also be seen in BCs of no special type",
                      "Cells with cytoplasmic mucin vacuoles can be seen in any type of ILCSingle mucin vacuole with central dot is the most common appearanceMultiple vacuoles giving a foamy appearance is less common: This type is more characteristic of gastric signet-ring cell carcinomas (GSRCs)",
                      "Single mucin vacuole with central dot is the most common appearance",
                      "Multiple vacuoles giving a foamy appearance is less common: This type is more characteristic of gastric signet-ring cell carcinomas (GSRCs)",
                      "Signet-ring cells can also be seen in BCs of no special type",
                      "PleomorphicCells have larger (> 4x the size of lymphocytes) nuclei with marked pleomorphism (\"equivalent to high-grade DCIS\")May have single or multiple prominent nucleoli\"Pleomorphic ILC\" includes both grades 2 and 3 ILCGrade provides more information than designation as \"pleomorphic ILC\"5-10% are ER(-)20-30% are HER2(+)20-60% are p53(+)",
                      "Cells have larger (> 4x the size of lymphocytes) nuclei with marked pleomorphism (\"equivalent to high-grade DCIS\")May have single or multiple prominent nucleoli",
                      "May have single or multiple prominent nucleoli",
                      "\"Pleomorphic ILC\" includes both grades 2 and 3 ILCGrade provides more information than designation as \"pleomorphic ILC\"",
                      "Grade provides more information than designation as \"pleomorphic ILC\"",
                      "5-10% are ER(-)",
                      "20-30% are HER2(+)",
                      "20-60% are p53(+)",
                      "Histiocytoid/apocrineCells have abundant eosinophilic &/or foamy cytoplasmCells can resemble histiocytes (ergo term \"histiocytoid\"), particularly in lymph nodes, metastatic sites, or in areas of inflammationMay resemble granular cell tumorTumors with both histiocytoid/apocrine and pleomorphic features are more likely to be HER2(+)",
                      "Cells have abundant eosinophilic &/or foamy cytoplasm",
                      "Cells can resemble histiocytes (ergo term \"histiocytoid\"), particularly in lymph nodes, metastatic sites, or in areas of inflammation",
                      "May resemble granular cell tumor",
                      "Tumors with both histiocytoid/apocrine and pleomorphic features are more likely to be HER2(+)"
                    ]
                  },
                  {
                    "text": "Growth patternsClassic (most common)Single-file rows of cells, typically no more than 1-2 cells wide, between collagen cleftsOrientation in circular fashion around normal ducts gives targetoid, concentric, or bull's-eye appearanceDesmoplasia may be minimal or absent: Correlates with absence of discrete mass by imaging or by palpationAlveolar (5-10% of ILCs)Tumor forms rounded aggregates of 20 or more cells separated by fibrovascular septa or normal stromaClusters are smaller than those seen in the solid patternClusters of cells can resemble LCISThe classic pattern is usually focally presentSolid (5-10% of ILCs)Tumor forms large, usually circumscribed, nests of cells with little or no intervening stromaCells are dyscohesive within massThe classic pattern is usually focally present at the peripheryCan resemble lymphoma or metastatic melanomaSolid-papillary (< 1% of ILCs)Similar to the solid pattern, but thin fibrous trabeculae can mimic the fibrovascular cores of solid papillary carcinomaThe dyscohesive nature of the cells may not be apparent when packed togetherTubulolobular (< 1% of ILCs)The cells of classic ILC are intermingled with minute round tubules (smaller and rounder than the tubules in tubular carcinoma)All grade 1These cancers are generally positive for E-cadherinCan be associated with either DCIS or LCIS or bothThis pattern is not synonymous with BCs with ductal and lobular features or ductulolobular BCMucinous (ILC with extracellular mucin) (< 1% of ILCs)Single cells are present in extracellular mucinSignet-ring cell morphology may be focal or prominentTrabecularTumor cells are arranged in thicker cords or strandsPlexiformTumor cells are arranged in a more complex pattern of interconnecting cord or strandsWith tubular elements (much < 1%)Very rare ILCs withCDH1mutations and lack of E-cadherin show focal tubule formationThe tubule forming areas of the carcinoma aberrantly express p-cadherin",
                    "sub_points": [
                      "Classic (most common)Single-file rows of cells, typically no more than 1-2 cells wide, between collagen cleftsOrientation in circular fashion around normal ducts gives targetoid, concentric, or bull's-eye appearanceDesmoplasia may be minimal or absent: Correlates with absence of discrete mass by imaging or by palpation",
                      "Single-file rows of cells, typically no more than 1-2 cells wide, between collagen clefts",
                      "Orientation in circular fashion around normal ducts gives targetoid, concentric, or bull's-eye appearance",
                      "Desmoplasia may be minimal or absent: Correlates with absence of discrete mass by imaging or by palpation",
                      "Alveolar (5-10% of ILCs)Tumor forms rounded aggregates of 20 or more cells separated by fibrovascular septa or normal stromaClusters are smaller than those seen in the solid patternClusters of cells can resemble LCISThe classic pattern is usually focally present",
                      "Tumor forms rounded aggregates of 20 or more cells separated by fibrovascular septa or normal stromaClusters are smaller than those seen in the solid pattern",
                      "Clusters are smaller than those seen in the solid pattern",
                      "Clusters of cells can resemble LCIS",
                      "The classic pattern is usually focally present",
                      "Solid (5-10% of ILCs)Tumor forms large, usually circumscribed, nests of cells with little or no intervening stromaCells are dyscohesive within massThe classic pattern is usually focally present at the peripheryCan resemble lymphoma or metastatic melanoma",
                      "Tumor forms large, usually circumscribed, nests of cells with little or no intervening stroma",
                      "Cells are dyscohesive within mass",
                      "The classic pattern is usually focally present at the periphery",
                      "Can resemble lymphoma or metastatic melanoma",
                      "Solid-papillary (< 1% of ILCs)Similar to the solid pattern, but thin fibrous trabeculae can mimic the fibrovascular cores of solid papillary carcinomaThe dyscohesive nature of the cells may not be apparent when packed together",
                      "Similar to the solid pattern, but thin fibrous trabeculae can mimic the fibrovascular cores of solid papillary carcinoma",
                      "The dyscohesive nature of the cells may not be apparent when packed together",
                      "Tubulolobular (< 1% of ILCs)The cells of classic ILC are intermingled with minute round tubules (smaller and rounder than the tubules in tubular carcinoma)All grade 1These cancers are generally positive for E-cadherinCan be associated with either DCIS or LCIS or bothThis pattern is not synonymous with BCs with ductal and lobular features or ductulolobular BC",
                      "The cells of classic ILC are intermingled with minute round tubules (smaller and rounder than the tubules in tubular carcinoma)All grade 1",
                      "All grade 1",
                      "These cancers are generally positive for E-cadherin",
                      "Can be associated with either DCIS or LCIS or both",
                      "This pattern is not synonymous with BCs with ductal and lobular features or ductulolobular BC",
                      "Mucinous (ILC with extracellular mucin) (< 1% of ILCs)Single cells are present in extracellular mucinSignet-ring cell morphology may be focal or prominent",
                      "Single cells are present in extracellular mucinSignet-ring cell morphology may be focal or prominent",
                      "Signet-ring cell morphology may be focal or prominent",
                      "TrabecularTumor cells are arranged in thicker cords or strands",
                      "Tumor cells are arranged in thicker cords or strands",
                      "PlexiformTumor cells are arranged in a more complex pattern of interconnecting cord or strands",
                      "Tumor cells are arranged in a more complex pattern of interconnecting cord or strands",
                      "With tubular elements (much < 1%)Very rare ILCs withCDH1mutations and lack of E-cadherin show focal tubule formationThe tubule forming areas of the carcinoma aberrantly express p-cadherin",
                      "Very rare ILCs withCDH1mutations and lack of E-cadherin show focal tubule formation",
                      "The tubule forming areas of the carcinoma aberrantly express p-cadherin"
                    ]
                  },
                  {
                    "text": "GradeClassic ILC: 80-90% are grade 2; 10-20% are grade 1Nonclassic ILC: Usually grade 2 with some grade 3 cases",
                    "sub_points": [
                      "Classic ILC: 80-90% are grade 2; 10-20% are grade 1",
                      "Nonclassic ILC: Usually grade 2 with some grade 3 cases"
                    ]
                  },
                  {
                    "text": "Tumor-infiltrating lymphocytes (TILs)Only ~ 15% of ILCs show > 10% TILs; lower compared to nonlobular BCs",
                    "sub_points": [
                      "Only ~ 15% of ILCs show > 10% TILs; lower compared to nonlobular BCs"
                    ]
                  },
                  {
                    "text": "LCISPresent in 70-80% of cases, nuclear grade is similar to grade of ILCMore frequently associated with grades 1 and 2 ILCLess common in association with grade 3 and nonclassic patterns of ILC",
                    "sub_points": [
                      "Present in 70-80% of cases, nuclear grade is similar to grade of ILCMore frequently associated with grades 1 and 2 ILCLess common in association with grade 3 and nonclassic patterns of ILC",
                      "More frequently associated with grades 1 and 2 ILC",
                      "Less common in association with grade 3 and nonclassic patterns of ILC"
                    ]
                  },
                  {
                    "text": "Lymphovascular invasion (LVI)is very rarely observedCells of ILC lack cohesion to each other or to vascular wall: Cells are likely dispersed into lymphatic system and, thus, are rarely seen",
                    "sub_points": [
                      "Cells of ILC lack cohesion to each other or to vascular wall: Cells are likely dispersed into lymphatic system and, thus, are rarely seen"
                    ]
                  },
                  {
                    "text": "Multiple foci of invasion are commonMay be due to multiple separate foci of invasion associated with extensive LCIS or the appearance of multiple foci due to the growth pattern of ILCILC typically infiltrates along fibrovascular septa into adjacent stroma2D cross sections of periphery of tumor can create the appearance of multiple separate foci",
                    "sub_points": [
                      "May be due to multiple separate foci of invasion associated with extensive LCIS or the appearance of multiple foci due to the growth pattern of ILCILC typically infiltrates along fibrovascular septa into adjacent stroma2D cross sections of periphery of tumor can create the appearance of multiple separate foci",
                      "ILC typically infiltrates along fibrovascular septa into adjacent stroma",
                      "2D cross sections of periphery of tumor can create the appearance of multiple separate foci"
                    ]
                  }
                ],
                "Lymph Node Metastases": [
                  {
                    "text": "Metastases may be difficult to detect due to single cell dispersed patternEspecially true for nodes with partial involvement and scattered single cellsCells can closely resemble lymphocytes or histiocytesMay result in false-negative intraoperative assessmentTouch preparations in addition to frozen sections of lymph nodes may be helpful for detecting tumor cellsCytoplasmic mucin vacuoles (signet-ring cells) are helpful to recognize tumor cells",
                    "sub_points": [
                      "Especially true for nodes with partial involvement and scattered single cells",
                      "Cells can closely resemble lymphocytes or histiocytes",
                      "May result in false-negative intraoperative assessmentTouch preparations in addition to frozen sections of lymph nodes may be helpful for detecting tumor cellsCytoplasmic mucin vacuoles (signet-ring cells) are helpful to recognize tumor cells",
                      "Touch preparations in addition to frozen sections of lymph nodes may be helpful for detecting tumor cells",
                      "Cytoplasmic mucin vacuoles (signet-ring cells) are helpful to recognize tumor cells"
                    ]
                  },
                  {
                    "text": "Cytokeratin studies can be helpful in some casesCan aid in determining extent of involvement and evaluation of extranodal invasionCan help distinguish isolated tumor cells from micrometastases and macrometastasesIf numerous dispersed cells are present, need to use judgment to determine best classification",
                    "sub_points": [
                      "Can aid in determining extent of involvement and evaluation of extranodal invasion",
                      "Can help distinguish isolated tumor cells from micrometastases and macrometastasesIf numerous dispersed cells are present, need to use judgment to determine best classification",
                      "If numerous dispersed cells are present, need to use judgment to determine best classification"
                    ]
                  }
                ],
                "Distant Metastases": [
                  {
                    "text": "Often difficult to detect, as tumor cells can be scattered and resemble lymphocytes or histiocytesIt is always helpful to identify primary BCs with single cell infiltration as ILC or BCs with lobular features in order to trigger a high index of suspicion",
                    "sub_points": [
                      "It is always helpful to identify primary BCs with single cell infiltration as ILC or BCs with lobular features in order to trigger a high index of suspicion"
                    ]
                  },
                  {
                    "text": "StomachGastric signet-ring carcinoma and metastatic ILC to the stomach appear similar and can be difficult to distinguish morphologicallySome patients may have occult breast primaryGastric: Vacuole filled with foamy mucinBreast: Vacuole with distinct central mucin dropletHowever, many carcinomas have mixed patternsIHC: Typical patternsGastric: ER(-), CDX2(+), MUC1 rare, GATA3 and GCDFP-15 (-)Breast: ER(+), CDX2(-), MUC1(+), GATA3 and GCDFP-15 (+)",
                    "sub_points": [
                      "Gastric signet-ring carcinoma and metastatic ILC to the stomach appear similar and can be difficult to distinguish morphologicallySome patients may have occult breast primaryGastric: Vacuole filled with foamy mucinBreast: Vacuole with distinct central mucin dropletHowever, many carcinomas have mixed patterns",
                      "Some patients may have occult breast primaryGastric: Vacuole filled with foamy mucinBreast: Vacuole with distinct central mucin dropletHowever, many carcinomas have mixed patterns",
                      "Gastric: Vacuole filled with foamy mucin",
                      "Breast: Vacuole with distinct central mucin droplet",
                      "However, many carcinomas have mixed patterns",
                      "IHC: Typical patternsGastric: ER(-), CDX2(+), MUC1 rare, GATA3 and GCDFP-15 (-)Breast: ER(+), CDX2(-), MUC1(+), GATA3 and GCDFP-15 (+)",
                      "Gastric: ER(-), CDX2(+), MUC1 rare, GATA3 and GCDFP-15 (-)",
                      "Breast: ER(+), CDX2(-), MUC1(+), GATA3 and GCDFP-15 (+)"
                    ]
                  },
                  {
                    "text": "Bone marrowILC is very difficult to detect due to single cell pattern and resemblance to hematopoietic cellsKeratin IHC is helpful to detect, or exclude, tumor cellsER and PR may be artifactually negative due to use of nonformalin fixatives (e.g., Bouin) &/or decalcificationNegative results, if the primary carcinoma was positive, should be reported with great cautionRepeat studies on a nondecalcified specimen (e.g., a clot section) are warranted when possible",
                    "sub_points": [
                      "ILC is very difficult to detect due to single cell pattern and resemblance to hematopoietic cells",
                      "Keratin IHC is helpful to detect, or exclude, tumor cells",
                      "ER and PR may be artifactually negative due to use of nonformalin fixatives (e.g., Bouin) &/or decalcificationNegative results, if the primary carcinoma was positive, should be reported with great cautionRepeat studies on a nondecalcified specimen (e.g., a clot section) are warranted when possible",
                      "Negative results, if the primary carcinoma was positive, should be reported with great caution",
                      "Repeat studies on a nondecalcified specimen (e.g., a clot section) are warranted when possible"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "The possibility of ILC should always be considered when the imaging lesion is architectural distortion or asymmetry"
                  },
                  {
                    "text": "ILC can be a subtle finding due to the presence of single cells, dispersed growth pattern, and absence of desmoplasiaAreas of increased stromal cellularity should be carefully evaluated to rule out subtle ILCSmall foci of ILC in stroma are often not adjacent to LCISCytokeratin studies can be helpful in challenging casesMay reveal far more neoplastic cells than was appreciated from H&E section",
                    "sub_points": [
                      "Areas of increased stromal cellularity should be carefully evaluated to rule out subtle ILCSmall foci of ILC in stroma are often not adjacent to LCIS",
                      "Small foci of ILC in stroma are often not adjacent to LCIS",
                      "Cytokeratin studies can be helpful in challenging casesMay reveal far more neoplastic cells than was appreciated from H&E section",
                      "May reveal far more neoplastic cells than was appreciated from H&E section"
                    ]
                  },
                  {
                    "text": "If LCIS is not present and ER is negative, lymphoma and melanoma should be consideredSurgery would not be indicated for either of these alternative diagnoses",
                    "sub_points": [
                      "Surgery would not be indicated for either of these alternative diagnoses"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "MucicarmineMucin vacuoles will be positive when present",
                    "sub_points": [
                      "Mucin vacuoles will be positive when present"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "E-cadherinAbsent in ~ 85% of ILCsAlso absent in very rare nonlobular BCsAberrant patterns in ~ 10-15% of ILCsImmunoreactivity may be partial (granular) on membrane, cytoplasmic (diffuse or perinuclear dot-like), nuclear, complete but weak, &/or have a heterogeneous patternPositive in ~ 5% of ILCMay be due to loss or alteration of extracellular domain leading to defective function",
                    "sub_points": [
                      "Absent in ~ 85% of ILCsAlso absent in very rare nonlobular BCs",
                      "Also absent in very rare nonlobular BCs",
                      "Aberrant patterns in ~ 10-15% of ILCsImmunoreactivity may be partial (granular) on membrane, cytoplasmic (diffuse or perinuclear dot-like), nuclear, complete but weak, &/or have a heterogeneous pattern",
                      "Immunoreactivity may be partial (granular) on membrane, cytoplasmic (diffuse or perinuclear dot-like), nuclear, complete but weak, &/or have a heterogeneous pattern",
                      "Positive in ~ 5% of ILCMay be due to loss or alteration of extracellular domain leading to defective function",
                      "May be due to loss or alteration of extracellular domain leading to defective function"
                    ]
                  },
                  {
                    "text": "CateninsE-cadherin (-) ILC also lacks expression of α-, β-, and γ-cateninsp120 is upregulated and shows diffuse cytoplasmic expressionMajority of E-cadherin (+) ILC lacks membrane expression of 1 or more catenins but may show cytoplasmic expressionp120 shows cytoplasmic expression in most cases",
                    "sub_points": [
                      "E-cadherin (-) ILC also lacks expression of α-, β-, and γ-cateninsp120 is upregulated and shows diffuse cytoplasmic expression",
                      "p120 is upregulated and shows diffuse cytoplasmic expression",
                      "Majority of E-cadherin (+) ILC lacks membrane expression of 1 or more catenins but may show cytoplasmic expressionp120 shows cytoplasmic expression in most cases",
                      "p120 shows cytoplasmic expression in most cases"
                    ]
                  },
                  {
                    "text": "Hormone receptors> 90% of grade 1 and grade 2 ILC and ~ 80% of grade 3 ILC are ER(+)If ILC is ER(-), a false-negative result (e.g., due to assay failure or nonstandard treatment, such as decalcification) or different diagnosis (e.g., metastatic melanoma or lymphoma) should be considered",
                    "sub_points": [
                      "> 90% of grade 1 and grade 2 ILC and ~ 80% of grade 3 ILC are ER(+)",
                      "If ILC is ER(-), a false-negative result (e.g., due to assay failure or nonstandard treatment, such as decalcification) or different diagnosis (e.g., metastatic melanoma or lymphoma) should be considered"
                    ]
                  },
                  {
                    "text": "HER2HER2 overexpression is uncommon (< 5% of cases) in grade 1 or 2 classic ILC20-30% of nonclassic and grade 3 ILC are HER2(+)Edge enhancement can be seen in some cases and should not be overinterpreted as a 3+ resultISH for HER2 amplification is helpful for confirmation",
                    "sub_points": [
                      "HER2 overexpression is uncommon (< 5% of cases) in grade 1 or 2 classic ILC20-30% of nonclassic and grade 3 ILC are HER2(+)Edge enhancement can be seen in some cases and should not be overinterpreted as a 3+ resultISH for HER2 amplification is helpful for confirmation",
                      "20-30% of nonclassic and grade 3 ILC are HER2(+)",
                      "Edge enhancement can be seen in some cases and should not be overinterpreted as a 3+ result",
                      "ISH for HER2 amplification is helpful for confirmation"
                    ]
                  },
                  {
                    "text": "GCDFP-15Frequently positive, particularly in ILC with pleomorphic, apocrine, or signet-ring cell cytologic features",
                    "sub_points": [
                      "Frequently positive, particularly in ILC with pleomorphic, apocrine, or signet-ring cell cytologic features"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Invasive Carcinoma With Ductal and Lobular Features (Ductulolobular Carcinoma)": [
                  {
                    "text": "~ 3-5% of BCs have a heterogeneous appearance, including both single cell infiltrative pattern and areas of cohesive cell growth and tubule formation"
                  },
                  {
                    "text": "Studies support that these BCs result when a subclone of tumor cells acquires an additional alteration in E-cadherin or another cell adhesion proteinThe lobular component of the BC more commonly shows cytoplasmic E-cadherin compared to the pattern of complete absence in classic ILCThe nonlobular component is positive for E-cadherin",
                    "sub_points": [
                      "The lobular component of the BC more commonly shows cytoplasmic E-cadherin compared to the pattern of complete absence in classic ILC",
                      "The nonlobular component is positive for E-cadherin"
                    ]
                  },
                  {
                    "text": "These BCs are more commonly associated with DCIS than LCISIn some cases, the CIS also shows features of both DCIS and LCIS",
                    "sub_points": [
                      "In some cases, the CIS also shows features of both DCIS and LCIS"
                    ]
                  },
                  {
                    "text": "It is important to document single cell infiltration when presentThis pattern of tumor growth can be very difficult to identify at metastatic sites",
                    "sub_points": [
                      "This pattern of tumor growth can be very difficult to identify at metastatic sites"
                    ]
                  }
                ],
                "Lymphoma and Lymphocytes": [
                  {
                    "text": "Both ILC and lymphoma can appear as single cells, linear arrays, or clusters of tumor cellsILC typically has more cytoplasm than seen in lymphomaPlasma cells at low power can mimic ILC due to cytoplasm",
                    "sub_points": [
                      "ILC typically has more cytoplasm than seen in lymphoma",
                      "Plasma cells at low power can mimic ILC due to cytoplasm"
                    ]
                  },
                  {
                    "text": "Presence of LCIS supports diagnosis of ILC"
                  },
                  {
                    "text": "Aggregates or linear arrays of lymphocytes or plasma cells can also mimic ILC"
                  },
                  {
                    "text": "IHC studies are helpful in difficult casesKeratin is positive in ILC and absent in lymphomaLeukocyte common antigen is positive in lymphoma and absent in ILC",
                    "sub_points": [
                      "Keratin is positive in ILC and absent in lymphoma",
                      "Leukocyte common antigen is positive in lymphoma and absent in ILC"
                    ]
                  }
                ],
                "Metastatic Melanoma": [
                  {
                    "text": "Most common metastasis to breast in adult womenPrimary tumor may be occult at the time of metastasis",
                    "sub_points": [
                      "Primary tumor may be occult at the time of metastasis"
                    ]
                  },
                  {
                    "text": "Cells are dyscohesive and usually form sheets of cellsAppearance can mimic solid pattern of ILC",
                    "sub_points": [
                      "Appearance can mimic solid pattern of ILC"
                    ]
                  },
                  {
                    "text": "Should be suspected if LCIS is absent and tumor cells are negative for hormone receptors"
                  },
                  {
                    "text": "IHC for cytokeratins and melanoma markers are helpful"
                  }
                ],
                "Myofibroblastoma, Epithelioid Variant": [
                  {
                    "text": "Presents as a mass with circumscribed margins consisting of tumor cells without involvement of ducts and lobulesILC typically forms a mass with spiculated margins or architectural distortion, and the tumor cells infiltrate around ducts and lobules",
                    "sub_points": [
                      "ILC typically forms a mass with spiculated margins or architectural distortion, and the tumor cells infiltrate around ducts and lobules"
                    ]
                  },
                  {
                    "text": "Spindle cell areas are often present in addition to epithelioid cells that closely resemble ILCSpindle cells not seen in ILC",
                    "sub_points": [
                      "Spindle cells not seen in ILC"
                    ]
                  },
                  {
                    "text": "Myofibroblastomas are usually positive for ER and PR but are negative for keratin"
                  }
                ],
                "Gastric Signet-Ring Cell Carcinoma (GSRC)": [
                  {
                    "text": "ILC and GSRC can be identical in appearance"
                  },
                  {
                    "text": "Individuals with germline E-cadherin mutations are at risk for both types of carcinoma (~ 40-50% lifetime risk of BC)"
                  },
                  {
                    "text": "ILC may metastasize to stomach, and primary site may be occult"
                  },
                  {
                    "text": "GCs very rarely metastasize to breast"
                  },
                  {
                    "text": "The morphology of the signet-ring cells can be helpful, although both types can be seen in either carcinomaGSRC: The cells typically have abundant small vacuolesILC: The cells typically have a single vacuole with a central mucin droplet",
                    "sub_points": [
                      "GSRC: The cells typically have abundant small vacuoles",
                      "ILC: The cells typically have a single vacuole with a central mucin droplet"
                    ]
                  },
                  {
                    "text": "IHC may be necessary to identify source of carcinomaILC: Usually ER, GCDFP-15, MUC1 (+) and CDX2 and Hep-Par1 (-)Gastric: Usually CDX2 and Hep-Par1 (+) and ER, GCDFP-15, and MUC1 (-)",
                    "sub_points": [
                      "ILC: Usually ER, GCDFP-15, MUC1 (+) and CDX2 and Hep-Par1 (-)",
                      "Gastric: Usually CDX2 and Hep-Par1 (+) and ER, GCDFP-15, and MUC1 (-)"
                    ]
                  }
                ],
                "Hematopoietic Cells": [
                  {
                    "text": "ILC frequently metastasizes to bone marrow"
                  },
                  {
                    "text": "Tumor cells closely resemble hematopoietic cellsKeratin studies are generally indicated to ensure tumor cells are not present",
                    "sub_points": [
                      "Keratin studies are generally indicated to ensure tumor cells are not present"
                    ]
                  },
                  {
                    "text": "False-negative results for hormone receptors can occur due to fixation in nonformalin fixatives &/or decalcification"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnosis is made based on H&E appearance"
                  },
                  {
                    "text": "IHC for E-cadherin is not necessary to diagnose classic ILCPositive results do not preclude diagnosis of ILC",
                    "sub_points": [
                      "Positive results do not preclude diagnosis of ILC"
                    ]
                  },
                  {
                    "text": "If ILC is ER(-), a false-negative result or alternative diagnosis (e.g., lymphoma or melanoma) should be considered"
                  },
                  {
                    "text": "If ILC appears to be HER2(+), result should be confirmed by FISHEdge enhancement on dyscohesive cells can make immunoreactivity look positive",
                    "sub_points": [
                      "Edge enhancement on dyscohesive cells can make immunoreactivity look positive"
                    ]
                  },
                  {
                    "text": "Metastatic ILC in lymph nodes, bone marrow, and other sites can be easily missedKeratin IHC usually helpful",
                    "sub_points": [
                      "Keratin IHC usually helpful"
                    ]
                  },
                  {
                    "text": "Metastatic ILC to stomach can be mistaken for GSRCIHC can distinguish these 2 morphologically similar carcinomas",
                    "sub_points": [
                      "IHC can distinguish these 2 morphologically similar carcinomas"
                    ]
                  },
                  {
                    "text": "It is important to report BCs that infiltrate as single cells, as this pattern can be difficult to detect at other sites"
                  },
                  {
                    "text": "ILC is most common type of breast carcinoma presenting with distant metastases and occult primary carcinoma"
                  }
                ]
              },
              "GRADING": {
                "Nottingham Combined Histologic Grade": [
                  {
                    "text": "Graded using same system as used for all types of BC"
                  },
                  {
                    "text": "ILC can be of any grade, and grade is associated with survivalGrade 1 (10-15% of ILCs): Nuclear score 1, mitotic score 1, tubule score 3May resemble lymphocytes due to scant cytoplasmGrade 2 (70-80% of ILCs): Nuclear score 2, mitotic score 1 or 2, tubule score 3May resemble histiocytes when cytoplasm is abundantGrade 3 (10-15% of ILCs): Nuclear score 2 or 3, mitotic score 2 or 3, tubule score 3May not have distinguishing lobular features, except lack of cohesion",
                    "sub_points": [
                      "Grade 1 (10-15% of ILCs): Nuclear score 1, mitotic score 1, tubule score 3May resemble lymphocytes due to scant cytoplasm",
                      "May resemble lymphocytes due to scant cytoplasm",
                      "Grade 2 (70-80% of ILCs): Nuclear score 2, mitotic score 1 or 2, tubule score 3May resemble histiocytes when cytoplasm is abundant",
                      "May resemble histiocytes when cytoplasm is abundant",
                      "Grade 3 (10-15% of ILCs): Nuclear score 2 or 3, mitotic score 2 or 3, tubule score 3May not have distinguishing lobular features, except lack of cohesion",
                      "May not have distinguishing lobular features, except lack of cohesion"
                    ]
                  },
                  {
                    "text": "Mitotic index correlates better with clinical outcome than ILC type or nuclear gradeHigh mitotic count is associated with worse prognosis",
                    "sub_points": [
                      "High mitotic count is associated with worse prognosis"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "ILC is reported according to the College of American Pathology Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Tubular Carcinoma and Invasive Cribriform Carcinoma": {
            "name": "Invasive Tubular Carcinoma and Invasive Cribriform Carcinoma",
            "url": "https://app.pathprimer.com/document/2103637b-d249-4237-84de-d4a8ef34b4c1/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Tubular carcinoma (TC) and invasive cribriform carcinoma (ICC) are well-differentiated carcinomas"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Frequently associated with columnar cell change, flat epithelial atypia (FEA), low-grade ductal carcinoma in situ (LG-DCIS), and lobular neoplasiaSimilar genomic changes are seen in all of these members of the low-grade neoplasia familySuggests precursor roles and possible biologic progression",
                    "sub_points": [
                      "Similar genomic changes are seen in all of these members of the low-grade neoplasia family",
                      "Suggests precursor roles and possible biologic progression"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "60-70% present as nonpalpable, mammographically detected lesionsMajority of patients have small carcinomas and negative lymph nodes at presentation",
                    "sub_points": [
                      "Majority of patients have small carcinomas and negative lymph nodes at presentation"
                    ]
                  },
                  {
                    "text": "Pure TC and ICC have excellent prognosisVirtually always strongly estrogen receptor (ER) positivePatients may not require systemic treatment or be adequately treated with hormonal therapy alone",
                    "sub_points": [
                      "Virtually always strongly estrogen receptor (ER) positive",
                      "Patients may not require systemic treatment or be adequately treated with hormonal therapy alone"
                    ]
                  },
                  {
                    "text": "Very favorable prognosis restricted to tumors consisting almost entirely of tubular or cribriform patterns"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Myoepithelial markers may be helpful to distinguish TC and ICC from benign lesions and DCIS"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Sclerosing adenosis"
                  },
                  {
                    "text": "Radial sclerosing lesion"
                  },
                  {
                    "text": "Grade 1 invasive breast carcinoma"
                  },
                  {
                    "text": "Cribriform DCIS"
                  },
                  {
                    "text": "Microglandular adenosis"
                  },
                  {
                    "text": "Low-grade adenosquamous carcinoma"
                  },
                  {
                    "text": "Syringomatous adenoma"
                  },
                  {
                    "text": "Adenoid cystic carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Tubular carcinoma (TC)"
                  },
                  {
                    "text": "Invasive cribriform carcinoma (ICC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "TC and ICC are very well-differentiated carcinomas that have low metastatic potential and excellent prognosis"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Low-Grade Breast Neoplasia Pathway": [
                  {
                    "text": "Members of the \"low-grade neoplasia family\" are frequently found together"
                  },
                  {
                    "text": "TC and ICC are frequently (> 80% of cases) associated withColumnar cell change (95-100% of cases), flat epithelial atypia (FEA), and atypical ductal hyperplasia (ADH)Low-grade ductal carcinoma in situ (LG-DCIS) ~ 90%Lobular neoplasia ~ 15-55%Includes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS)",
                    "sub_points": [
                      "Columnar cell change (95-100% of cases), flat epithelial atypia (FEA), and atypical ductal hyperplasia (ADH)",
                      "Low-grade ductal carcinoma in situ (LG-DCIS) ~ 90%",
                      "Lobular neoplasia ~ 15-55%Includes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS)",
                      "Includes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS)"
                    ]
                  },
                  {
                    "text": "\"Rosen triad\" includes TC, columnar cell change/FEA/ADH, and lobular neoplasia"
                  },
                  {
                    "text": "The low-grade neoplasia family members often share similar biologic changesAll strongly express estrogen receptor (ER)Suggests that hormones likely play an important role in tumor development and disease progressionHave a relatively low number of chromosome alterationsChromosomal losses are more common than chromosomal gains16q loss (~ 80% of TC) and 1q gain (~ 55% of TC) are commonMay represent biologic progression along low-grade breast neoplasia pathwaySupports possible nonobligate precursor role for FEA and LG-DCIS progressing to TC",
                    "sub_points": [
                      "All strongly express estrogen receptor (ER)Suggests that hormones likely play an important role in tumor development and disease progression",
                      "Suggests that hormones likely play an important role in tumor development and disease progression",
                      "Have a relatively low number of chromosome alterationsChromosomal losses are more common than chromosomal gains16q loss (~ 80% of TC) and 1q gain (~ 55% of TC) are common",
                      "Chromosomal losses are more common than chromosomal gains",
                      "16q loss (~ 80% of TC) and 1q gain (~ 55% of TC) are common",
                      "May represent biologic progression along low-grade breast neoplasia pathway",
                      "Supports possible nonobligate precursor role for FEA and LG-DCIS progressing to TC"
                    ]
                  },
                  {
                    "text": "When one of the members of the low-grade family is identified, the surrounding tissue should be evaluated carefully for more advanced lesions"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "1-4% of breast cancers in unscreened populations"
                  },
                  {
                    "text": "10-30% of screen-detected breast cancers"
                  }
                ],
                "Age": [
                  {
                    "text": "Most common in women in their 50s-60s undergoing mammographic screening"
                  }
                ],
                "Sex": [
                  {
                    "text": "Rare in male patients"
                  }
                ],
                "Presentation": [
                  {
                    "text": "60-70% present as nonpalpable, mammographically detected masses with spiculated margins> 95% of patients have small carcinomas (< 2 cm) and negative lymph nodes at presentationMore likely to be detected by mammography than other cancers",
                    "sub_points": [
                      "> 95% of patients have small carcinomas (< 2 cm) and negative lymph nodes at presentation",
                      "More likely to be detected by mammography than other cancers"
                    ]
                  },
                  {
                    "text": "Multicentric involvement of ipsilateral breast is present in ~ 20% of patients"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete excision with negative margins recommended"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Endocrine therapy expected to be effective"
                  },
                  {
                    "text": "Little or no response to chemotherapy expected"
                  },
                  {
                    "text": "Small node-negative TC may not require any systemic treatment"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent prognosis compared with other types of breast cancer> 95% 10-year breast cancer-specific survival at 10 years for TCLymph node metastasis rate, overall and disease-free survival comparable to patients with DCIS",
                    "sub_points": [
                      "> 95% 10-year breast cancer-specific survival at 10 years for TC",
                      "Lymph node metastasis rate, overall and disease-free survival comparable to patients with DCIS"
                    ]
                  },
                  {
                    "text": "Restricted to TC and ICC that conform to strict histologic criteria for diagnosis> 90% of carcinoma must consist of well-formed tubules &/or cribriform areas",
                    "sub_points": [
                      "> 90% of carcinoma must consist of well-formed tubules &/or cribriform areas"
                    ]
                  },
                  {
                    "text": "Few patients (< 10% TC, 10-20% ICC) have positive nodes; limited nodal metastases may not impact overall survivalMultifocal and larger carcinomas are more likely to be associated with lymph node metastasesIn general, only 1-3 nodes are involvedUse of systemic adjuvant chemotherapy in patients with axillary metastases may not be warranted",
                    "sub_points": [
                      "Multifocal and larger carcinomas are more likely to be associated with lymph node metastases",
                      "In general, only 1-3 nodes are involved",
                      "Use of systemic adjuvant chemotherapy in patients with axillary metastases may not be warranted"
                    ]
                  },
                  {
                    "text": "Ongoing investigations are examining whether some patients with TC can avoid axillary surgical staging or omit radiotherapy"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Small mass with spiculated margins or architectural distortion"
                  },
                  {
                    "text": "Associated amorphous or pleomorphic microcalcifications in up to 50%May be due to calcified secretions in tubules or cribriform spaces in carcinomasAssociated columnar cell change, FEA, ADH, or DCIS may also have calcifications",
                    "sub_points": [
                      "May be due to calcified secretions in tubules or cribriform spaces in carcinomas",
                      "Associated columnar cell change, FEA, ADH, or DCIS may also have calcifications"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Irregular, gray-white mass"
                  }
                ],
                "Size": [
                  {
                    "text": "~ 75% of TCs are ≤ 1 cm, especially when mammographically detectedMean size: 8-12 mmRarely > 2 cm (< 5%)",
                    "sub_points": [
                      "Mean size: 8-12 mm",
                      "Rarely > 2 cm (< 5%)"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Low frequency of genetic alterationsMost frequent are 16q loss (~ 80%) and 1q gain (~ 55%)Frequently occur concomitantlySimilar alterations are shared by FEA, LG-DCIS, and TC",
                    "sub_points": [
                      "Most frequent are 16q loss (~ 80%) and 1q gain (~ 55%)Frequently occur concomitantly",
                      "Frequently occur concomitantly",
                      "Similar alterations are shared by FEA, LG-DCIS, and TC"
                    ]
                  },
                  {
                    "text": "Other alterations, 16p gain, loss of 8p, 3p (FHITgene locus), and 11q (ATMgene locus) have been reported17p loss (frequently found in other invasive breast cancers) is infrequent in TC",
                    "sub_points": [
                      "17p loss (frequently found in other invasive breast cancers) is infrequent in TC"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "Gene expression profiling classifies TC and ICC in the luminal A molecular class of breast cancer"
                  },
                  {
                    "text": "High expression of ER and ER-related genes"
                  },
                  {
                    "text": "Should show low recurrence score by Oncotype DX testIf not, problems with the assay should be consideredSmall carcinomas with relatively large core needle biopsy sites can yield falsely elevated scores due to low tumor cellularity and inflammatory reaction to biopsyThe single gene scores for ER and progesterone receptor (PR) should be checked to make sure they correlate with the immunoperoxidase resultsWhen a single gene score is discordant with the immunoperoxidase result, usually the positive result is the correct one",
                    "sub_points": [
                      "If not, problems with the assay should be considered",
                      "Small carcinomas with relatively large core needle biopsy sites can yield falsely elevated scores due to low tumor cellularity and inflammatory reaction to biopsyThe single gene scores for ER and progesterone receptor (PR) should be checked to make sure they correlate with the immunoperoxidase resultsWhen a single gene score is discordant with the immunoperoxidase result, usually the positive result is the correct one",
                      "The single gene scores for ER and progesterone receptor (PR) should be checked to make sure they correlate with the immunoperoxidase results",
                      "When a single gene score is discordant with the immunoperoxidase result, usually the positive result is the correct one"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "High expression of hormone receptors and related proteins"
                  },
                  {
                    "text": "Low expression of proliferation markers"
                  },
                  {
                    "text": "HER2 overexpression in TC and ICC would be highly unusualIf positive, consider repeat testing, a problem with the assay, or an alternative diagnosis",
                    "sub_points": [
                      "If positive, consider repeat testing, a problem with the assay, or an alternative diagnosis"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Tubular Carcinoma": [
                  {
                    "text": "Haphazard infiltrative proliferation of well-formed glandsSingle layer of epithelial cellsNo myoepithelial cell layerStromal myofibroblasts apposed to the base of glands can mimic myoepithelial cells on H&E and IHCCells are low gradeNuclei slightly larger than normal luminal nuclei (score 1 or 2 for grading)Nucleoli are small and uniformChromatin is uniformApical cytoplasmic snouts are commonMitoses are rareTubules have open lumina and angulated contours with tapering ends> 90% of tumor should demonstrate characteristic tubular morphology to be considered TCCalcifications may be associated with secretory material in luminaDesmoplastic stromal reaction should be present and may be quite prominentUsually cellularProminent stromal elastosis may be presentTubules typically invade around normal ducts and lobulesLymphovascular invasion would be highly unusualTC is frequently associated with LG-DCISDCIS typically has cribriform and micropapillary architectural patternsTC is also frequently associated with columnar cell changes, FEA, ALH, and LCIS",
                    "sub_points": [
                      "Single layer of epithelial cellsNo myoepithelial cell layerStromal myofibroblasts apposed to the base of glands can mimic myoepithelial cells on H&E and IHC",
                      "No myoepithelial cell layer",
                      "Stromal myofibroblasts apposed to the base of glands can mimic myoepithelial cells on H&E and IHC",
                      "Cells are low gradeNuclei slightly larger than normal luminal nuclei (score 1 or 2 for grading)Nucleoli are small and uniformChromatin is uniformApical cytoplasmic snouts are commonMitoses are rare",
                      "Nuclei slightly larger than normal luminal nuclei (score 1 or 2 for grading)",
                      "Nucleoli are small and uniform",
                      "Chromatin is uniform",
                      "Apical cytoplasmic snouts are common",
                      "Mitoses are rare",
                      "Tubules have open lumina and angulated contours with tapering ends> 90% of tumor should demonstrate characteristic tubular morphology to be considered TCCalcifications may be associated with secretory material in lumina",
                      "> 90% of tumor should demonstrate characteristic tubular morphology to be considered TC",
                      "Calcifications may be associated with secretory material in lumina",
                      "Desmoplastic stromal reaction should be present and may be quite prominentUsually cellularProminent stromal elastosis may be present",
                      "Usually cellular",
                      "Prominent stromal elastosis may be present",
                      "Tubules typically invade around normal ducts and lobules",
                      "Lymphovascular invasion would be highly unusual",
                      "TC is frequently associated with LG-DCISDCIS typically has cribriform and micropapillary architectural patterns",
                      "DCIS typically has cribriform and micropapillary architectural patterns",
                      "TC is also frequently associated with columnar cell changes, FEA, ALH, and LCIS"
                    ]
                  }
                ],
                "Cribriform Carcinoma": [
                  {
                    "text": "Haphazard infiltration of stroma by irregular cribriform nests imparting fenestrated appearanceResembles cribriform DCISUnlike DCIS, nests of tumor cells may infiltrate around normal ducts with a desmoplastic stromal reactionICC lacks myoepithelial cellsThe cells at the periphery of tumor cell nests can be \"crushed\" and can resemble myoepithelial cellsCytologic features are similar to those of TC",
                    "sub_points": [
                      "Resembles cribriform DCISUnlike DCIS, nests of tumor cells may infiltrate around normal ducts with a desmoplastic stromal reactionICC lacks myoepithelial cells",
                      "Unlike DCIS, nests of tumor cells may infiltrate around normal ducts with a desmoplastic stromal reaction",
                      "ICC lacks myoepithelial cells",
                      "The cells at the periphery of tumor cell nests can be \"crushed\" and can resemble myoepithelial cells",
                      "Cytologic features are similar to those of TC"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "TC and ICC may be difficult to distinguish from benign mimics of invasive cancer on limited core needle biopsy"
                  },
                  {
                    "text": "ICC can also be difficult to distinguish from cribriform LG-DCIS on core needle biopsyDesmoplastic stromal reaction and absence of myoepithelial cells by IHC is helpful",
                    "sub_points": [
                      "Desmoplastic stromal reaction and absence of myoepithelial cells by IHC is helpful"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptors: Strongly positiveER (> 95%) and PR (> 75%) expressionIf result is negative, test should be repeated to confirmOther diagnoses should be considered (e.g., luminal androgen receptor carcinoma, microglandular adenosis, or syringomatous adenoma)",
                    "sub_points": [
                      "ER (> 95%) and PR (> 75%) expression",
                      "If result is negative, test should be repeated to confirmOther diagnoses should be considered (e.g., luminal androgen receptor carcinoma, microglandular adenosis, or syringomatous adenoma)",
                      "Other diagnoses should be considered (e.g., luminal androgen receptor carcinoma, microglandular adenosis, or syringomatous adenoma)"
                    ]
                  },
                  {
                    "text": "HER2: Negative in vast majority of casesTC and ICC rarely (if ever) show HER2 overexpression orERBB2gene amplification",
                    "sub_points": [
                      "TC and ICC rarely (if ever) show HER2 overexpression orERBB2gene amplification"
                    ]
                  },
                  {
                    "text": "Ki-67: Low, typically 10% or lessUsually have low proliferative index (< 10% positive cells)",
                    "sub_points": [
                      "Usually have low proliferative index (< 10% positive cells)"
                    ]
                  },
                  {
                    "text": "Myoepithelial markers: AbsentIHC is often necessary to distinguish TC and ICC from benign adenosis lesionsBenign lesions have a myoepithelial layer, which is often prominentMicroglandular adenosis lacks myoepithelial cells but is negative for ER and PRMuscle markers are positive in stromal myofibroblasts and blood vesselsStromal cells apposed to the base of tumor cells can mimic myoepithelial cellsSmall blood vessels forming a circlet around cribriform nests can mimic myoepithelial cells",
                    "sub_points": [
                      "IHC is often necessary to distinguish TC and ICC from benign adenosis lesionsBenign lesions have a myoepithelial layer, which is often prominentMicroglandular adenosis lacks myoepithelial cells but is negative for ER and PR",
                      "Benign lesions have a myoepithelial layer, which is often prominent",
                      "Microglandular adenosis lacks myoepithelial cells but is negative for ER and PR",
                      "Muscle markers are positive in stromal myofibroblasts and blood vesselsStromal cells apposed to the base of tumor cells can mimic myoepithelial cellsSmall blood vessels forming a circlet around cribriform nests can mimic myoepithelial cells",
                      "Stromal cells apposed to the base of tumor cells can mimic myoepithelial cells",
                      "Small blood vessels forming a circlet around cribriform nests can mimic myoepithelial cells"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Sclerosing Adenosis": [
                  {
                    "text": "Circumscribed or nodular appearance with lobulocentric pattern, best appreciated at low magnificationHowever, in some cases, tubules can have a pseudoinfiltrative pattern in stroma and adipose tissueStroma is usually denseA loose desmoplastic stroma should not be presentUsually does not involve adipose tissue",
                    "sub_points": [
                      "However, in some cases, tubules can have a pseudoinfiltrative pattern in stroma and adipose tissue",
                      "Stroma is usually denseA loose desmoplastic stroma should not be present",
                      "A loose desmoplastic stroma should not be present",
                      "Usually does not involve adipose tissue"
                    ]
                  },
                  {
                    "text": "Ductal structures have compressed or obliterated luminaDuctal structures are usually back to back and typically have parallel or whirling patterns",
                    "sub_points": [
                      "Ductal structures are usually back to back and typically have parallel or whirling patterns"
                    ]
                  },
                  {
                    "text": "Myoepithelial cells are present and often prominentIHC can be helpful to document myoepithelial cellsMyoepithelial cells associated with sclerosing lesions may not express all IHC markersMultiple markers should be tried before concluding no myoepithelial cells are present",
                    "sub_points": [
                      "IHC can be helpful to document myoepithelial cells",
                      "Myoepithelial cells associated with sclerosing lesions may not express all IHC markersMultiple markers should be tried before concluding no myoepithelial cells are present",
                      "Multiple markers should be tried before concluding no myoepithelial cells are present"
                    ]
                  },
                  {
                    "text": "Perineural invasion can be present in some cases of sclerosing adenosis and is not an indication of malignancy"
                  },
                  {
                    "text": "Associated FEA, ADH, or DCIS are less common compared with cases of TC or ICC"
                  },
                  {
                    "text": "Sclerosing adenosis involved by apocrine metaplasia, LCIS, or DCIS can closely mimic invasive carcinoma"
                  }
                ],
                "Radial Sclerosing Lesion": [
                  {
                    "text": "Forms a mass with spiculated margins both radiographically and on gross examinationRadiating arms (spicules) are generally proportionally longer than central portion of lesionCarcinomas typically have irregular borders with shorter spiculesThere may be a lucent area at the center of the lesion on imaging",
                    "sub_points": [
                      "Radiating arms (spicules) are generally proportionally longer than central portion of lesionCarcinomas typically have irregular borders with shorter spicules",
                      "Carcinomas typically have irregular borders with shorter spicules",
                      "There may be a lucent area at the center of the lesion on imaging"
                    ]
                  },
                  {
                    "text": "Entrapped ducts in the central fibrotic zone can closely mimic TC, especially on core biopsiesDucts are limited to the center and do not infiltrate out into surrounding tissuesStroma is densely hyalinized and lacks desmoplasiaEntrapped ducts have a myoepithelial cell layer that may be difficult to see on H&E",
                    "sub_points": [
                      "Ducts are limited to the center and do not infiltrate out into surrounding tissues",
                      "Stroma is densely hyalinized and lacks desmoplasia",
                      "Entrapped ducts have a myoepithelial cell layer that may be difficult to see on H&E"
                    ]
                  }
                ],
                "Grade 1 Invasive Breast Carcinomas of No Special Type (IBC-NST)": [
                  {
                    "text": "TC isnotsynonymous with grade 1 IBC-NST"
                  },
                  {
                    "text": "Grade 1 carcinomas can have less tubule formation, more nuclear pleomorphism, &/or increased mitotic rate compared to TC"
                  },
                  {
                    "text": "TC has better prognosis than other grade 1 carcinomas"
                  }
                ],
                "Cribriform Ductal Carcinoma In Situ": [
                  {
                    "text": "DCIS with a cribriform pattern can resemble ICC"
                  },
                  {
                    "text": "Does not infiltrate around normal ducts and lobules"
                  },
                  {
                    "text": "IHC confirms the presence of myoepithelial cells in DCIS"
                  }
                ],
                "Microglandular Adenosis": [
                  {
                    "text": "May show nodular or diffuse architecture"
                  },
                  {
                    "text": "Little to no desmoplastic response"
                  },
                  {
                    "text": "Uniform, small, round luminal spacesEosinophilic secretions present in luminaLacks apocrine snouts typical of TC",
                    "sub_points": [
                      "Eosinophilic secretions present in lumina",
                      "Lacks apocrine snouts typical of TC"
                    ]
                  },
                  {
                    "text": "No myoepithelial cells are present"
                  },
                  {
                    "text": "Negative for ER and PR and positive for S100"
                  }
                ],
                "Low-Grade Adenosquamous Carcinoma": [
                  {
                    "text": "Consists of small, well-formed tubules or solid nests of cellsTumor cell nests frequently have comma-shaped tails",
                    "sub_points": [
                      "Tumor cell nests frequently have comma-shaped tails"
                    ]
                  },
                  {
                    "text": "At least focal areas of squamous differentiation are presentSquamous component is positive for p63",
                    "sub_points": [
                      "Squamous component is positive for p63"
                    ]
                  },
                  {
                    "text": "Negative for ER and PR"
                  }
                ],
                "Syringomatous Adenoma": [
                  {
                    "text": "Arises in dermis of nippleTC rarely involves dermis",
                    "sub_points": [
                      "TC rarely involves dermis"
                    ]
                  },
                  {
                    "text": "Squamoid areas positive for p63 are present"
                  },
                  {
                    "text": "Negative for ER and PR"
                  }
                ],
                "Adenoid Cystic Carcinoma (AdCC)": [
                  {
                    "text": "Both AdCC and ICC are invasive carcinomas with a cribriform growth pattern"
                  },
                  {
                    "text": "AdCC consists of both luminal and myoepithelial cells, whereas ICC consists of only luminal cellsIHC shows 2 distinct cell populations in AdCCNeoplastic myoepithelial cells are positive for p63 in classic AdCC but may be negative in solid-basaloid AdCCLuminal cells are positive for low molecular weight keratins and may be positive for CD117",
                    "sub_points": [
                      "IHC shows 2 distinct cell populations in AdCC",
                      "Neoplastic myoepithelial cells are positive for p63 in classic AdCC but may be negative in solid-basaloid AdCC",
                      "Luminal cells are positive for low molecular weight keratins and may be positive for CD117"
                    ]
                  },
                  {
                    "text": "2 types of spaces form the cribriform pattern of AdCCSpaces formed by luminal cells often contain secretory materialMyoepithelial cells surround pseudolumina filled with basement membrane-like materialThe cribriform pattern of ICC is formed by luminal cells surrounding true lumina",
                    "sub_points": [
                      "Spaces formed by luminal cells often contain secretory material",
                      "Myoepithelial cells surround pseudolumina filled with basement membrane-like material",
                      "The cribriform pattern of ICC is formed by luminal cells surrounding true lumina"
                    ]
                  },
                  {
                    "text": "AdCC is almost always negative for ER and PR"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "TC and ICC are special histologic types of breast carcinoma with a very favorable prognosisFavorable prognosis restricted to TC and ICC that conform to strict histologic criteria",
                    "sub_points": [
                      "Favorable prognosis restricted to TC and ICC that conform to strict histologic criteria"
                    ]
                  },
                  {
                    "text": "Important to recognize, as systemic therapy &/or sentinel node biopsy may not be necessary"
                  },
                  {
                    "text": "Diagnosis may be challenging on limited needle biopsyMyoepithelial markers can be helpful in difficult cases",
                    "sub_points": [
                      "Myoepithelial markers can be helpful in difficult cases"
                    ]
                  },
                  {
                    "text": "If ER is negative, alternative diagnoses and assay quality should be considered"
                  }
                ]
              },
              "GRADING": {
                "Nottingham Combined Histologic Grade": [
                  {
                    "text": "TC and ICC are always grade 1 carcinomasTubule score will always be 1Mitotic score will always be 1Nuclear grade score is usually 1 but may be 2",
                    "sub_points": [
                      "Tubule score will always be 1",
                      "Mitotic score will always be 1",
                      "Nuclear grade score is usually 1 but may be 2"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "TC and ICC can be reported according to College of American Pathology Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Triple Negative Breast Carcinoma and Basal-Like Breast Carcinoma": {
            "name": "Triple Negative Breast Carcinoma and Basal-Like Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/0427433e-8102-4983-8057-21cfb3961748/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Classification": [
                  {
                    "text": "Triple negative breast carcinoma (TNBC, defined by protein expression) and basal-like carcinoma (BLC, defined by mRNA profiling) encompass very similar (~ 70-80% overlap) groups of cancers"
                  },
                  {
                    "text": "10-15% of invasive carcinomas"
                  },
                  {
                    "text": "Characterized by high genomic instability and frequent dense lymphocytic infiltrates"
                  },
                  {
                    "text": "Differ from ER(+) &/or HER2(+) breast carcinomas (BCs) by biology, morphology, clinical features, response to therapy, time to recurrence, pattern of metastases, and prognosis"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "EpidemiologyRelatively more common in young women and African American and Hispanic American womenBRCA1-associated cancers are usually TNBC/BLC",
                    "sub_points": [
                      "Relatively more common in young women and African American and Hispanic American women",
                      "BRCA1-associated cancers are usually TNBC/BLC"
                    ]
                  },
                  {
                    "text": "PresentationTypically present as palpable masses at higher stages",
                    "sub_points": [
                      "Typically present as palpable masses at higher stages"
                    ]
                  },
                  {
                    "text": "Time to recurrenceHighest and earliest (4-5 years) rate of relapse or recurrence; recurrences after 10 years are very rare; survival at 10 years is similar to survival at 20 years",
                    "sub_points": [
                      "Highest and earliest (4-5 years) rate of relapse or recurrence; recurrences after 10 years are very rare; survival at 10 years is similar to survival at 20 years"
                    ]
                  },
                  {
                    "text": "Metastatic patternIncreased risk for metastasis to visceral organs and CNS",
                    "sub_points": [
                      "Increased risk for metastasis to visceral organs and CNS"
                    ]
                  },
                  {
                    "text": "PrognosisPoorer prognosis compared to ER(+) &/or HER2(+) carcinomasResponsible for ~ 30% of BC deathsHowever, complete response to chemotherapy in ~ 40% portends a favorable outcome",
                    "sub_points": [
                      "Poorer prognosis compared to ER(+) &/or HER2(+) carcinomasResponsible for ~ 30% of BC deaths",
                      "Responsible for ~ 30% of BC deaths",
                      "However, complete response to chemotherapy in ~ 40% portends a favorable outcome"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Typical features include a circumscribed border, high nuclear grade, syncytial growth pattern, and a dense lymphocytic infiltrate"
                  },
                  {
                    "text": "Special histologic types in this group include metaplastic, adenoid cystic, and secretory"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Luminal breast carcinoma (BC): Estrogen receptor (ER)(+) and HER2(-)"
                  },
                  {
                    "text": "Luminal HER2 BC: ER(+) and HER2(+)"
                  },
                  {
                    "text": "HER2 BC: ER(-) and HER2(+)"
                  },
                  {
                    "text": "Triple negative BC (TNBC): ER(-) and HER2(-)"
                  },
                  {
                    "text": "Basal-like carcinoma (BLC): Defined by gene expression profiling (GEP) studies using mRNA"
                  },
                  {
                    "text": "Note: The molecular groups of BC are defined in different ways in different contexts"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Molecular Types of Breast Carcinomas": [
                  {
                    "text": "GEP demonstrated that BCs can be sorted into molecular types based on the expression pattern of thousands of genes"
                  },
                  {
                    "text": "4 major groups identified by GEP are closely related to 4 groups of BCs classified based on expression of ER and HER2"
                  },
                  {
                    "text": "These 4 groups have important biologic, clinical, epidemiologic, and prognostic differences"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Comparison of Triple Negative and Basal-Like Carcinomas": [
                  {
                    "text": "TNBC and BLC describe overlapping groups of cancersTNBC is defined by IHC studies confirming the absence of ER, progesterone receptor (PR), and HER2 proteinsThese studies are routinely performed on all invasive carcinomasBLC is defined by mRNA expression using GEPThis assay is usually performed by a commercial laboratory at the request of the patient or clinicianTypically only performed for a few BCs outside of a research studyWhether or not a TNBC is also a BLC is not generally used for clinical decision making",
                    "sub_points": [
                      "TNBC is defined by IHC studies confirming the absence of ER, progesterone receptor (PR), and HER2 proteinsThese studies are routinely performed on all invasive carcinomas",
                      "These studies are routinely performed on all invasive carcinomas",
                      "BLC is defined by mRNA expression using GEPThis assay is usually performed by a commercial laboratory at the request of the patient or clinicianTypically only performed for a few BCs outside of a research studyWhether or not a TNBC is also a BLC is not generally used for clinical decision making",
                      "This assay is usually performed by a commercial laboratory at the request of the patient or clinician",
                      "Typically only performed for a few BCs outside of a research study",
                      "Whether or not a TNBC is also a BLC is not generally used for clinical decision making"
                    ]
                  },
                  {
                    "text": "TNBC and BLC are often used as interchangeable terms without regard to these definitions"
                  },
                  {
                    "text": "Cancers that are both TNBC and BLCThere is a 70-80% overlap in BCs classified as either TNBC or BLCHistologic types of BCs that are solely or predominantly in this group are medullary pattern BC,BRCA1BC (~ 80%), metaplastic squamous cell BC, metaplastic matrix-producing BC, and translocation BCs (adenoid cystic and secretory BC)",
                    "sub_points": [
                      "There is a 70-80% overlap in BCs classified as either TNBC or BLCHistologic types of BCs that are solely or predominantly in this group are medullary pattern BC,BRCA1BC (~ 80%), metaplastic squamous cell BC, metaplastic matrix-producing BC, and translocation BCs (adenoid cystic and secretory BC)",
                      "Histologic types of BCs that are solely or predominantly in this group are medullary pattern BC,BRCA1BC (~ 80%), metaplastic squamous cell BC, metaplastic matrix-producing BC, and translocation BCs (adenoid cystic and secretory BC)"
                    ]
                  },
                  {
                    "text": "Cancers that are TNBC but not BLC (~ 20-30% of TNBC)BCs that are TNBCs but not BLCs have differences compared to BCs that are bothLower incidence ofTP53overexpressionBetter overall survival compared with BLCsLuminal androgen receptor (AR) cancer~ 20-30% of TNBCsMay express low molecular weight keratinsLike luminal BCs, these BCs usually have a low proliferative rate and a low response rate to chemotherapyA pathologic complete response (pCR) is less likely (~ 15%) compared to TNBC that is AR(-) (~ 30-40%)May expressOften have apocrine morphology and a few exhibit tubule formationSome are rare examples of grade 1 TNBCClaudin-low cancerDefined by mRNA profiling as different from BLC but negative for hormone receptors and HER2Shows lower expression of epithelial adhesion proteins (claudins and E-cadherin) and increased expression of genes involved in immunity, tumor cell invasiveness, epithelial-mesenchymal transition, and related to cancer stem cellnessSimilar to both TNBC and BLC, they are associated with high tumor grade, larger tumor size, an extensive lymphocytic infiltrate, and circumscribed marginsIncludes cases of spindle cell metaplastic BC and fibromatosis-like metaplastic BC",
                    "sub_points": [
                      "BCs that are TNBCs but not BLCs have differences compared to BCs that are bothLower incidence ofTP53overexpressionBetter overall survival compared with BLCs",
                      "Lower incidence ofTP53overexpression",
                      "Better overall survival compared with BLCs",
                      "Luminal androgen receptor (AR) cancer~ 20-30% of TNBCsMay express low molecular weight keratinsLike luminal BCs, these BCs usually have a low proliferative rate and a low response rate to chemotherapyA pathologic complete response (pCR) is less likely (~ 15%) compared to TNBC that is AR(-) (~ 30-40%)May expressOften have apocrine morphology and a few exhibit tubule formationSome are rare examples of grade 1 TNBC",
                      "~ 20-30% of TNBCs",
                      "May express low molecular weight keratins",
                      "Like luminal BCs, these BCs usually have a low proliferative rate and a low response rate to chemotherapyA pathologic complete response (pCR) is less likely (~ 15%) compared to TNBC that is AR(-) (~ 30-40%)",
                      "A pathologic complete response (pCR) is less likely (~ 15%) compared to TNBC that is AR(-) (~ 30-40%)",
                      "May express",
                      "Often have apocrine morphology and a few exhibit tubule formationSome are rare examples of grade 1 TNBC",
                      "Some are rare examples of grade 1 TNBC",
                      "Claudin-low cancerDefined by mRNA profiling as different from BLC but negative for hormone receptors and HER2Shows lower expression of epithelial adhesion proteins (claudins and E-cadherin) and increased expression of genes involved in immunity, tumor cell invasiveness, epithelial-mesenchymal transition, and related to cancer stem cellnessSimilar to both TNBC and BLC, they are associated with high tumor grade, larger tumor size, an extensive lymphocytic infiltrate, and circumscribed marginsIncludes cases of spindle cell metaplastic BC and fibromatosis-like metaplastic BC",
                      "Defined by mRNA profiling as different from BLC but negative for hormone receptors and HER2",
                      "Shows lower expression of epithelial adhesion proteins (claudins and E-cadherin) and increased expression of genes involved in immunity, tumor cell invasiveness, epithelial-mesenchymal transition, and related to cancer stem cellness",
                      "Similar to both TNBC and BLC, they are associated with high tumor grade, larger tumor size, an extensive lymphocytic infiltrate, and circumscribed margins",
                      "Includes cases of spindle cell metaplastic BC and fibromatosis-like metaplastic BC"
                    ]
                  },
                  {
                    "text": "Cancers that are BLC but not TNBC (~ 15-20% of BLC)~ 5-10% of BLCs are ER(+)~ 85% of luminal BCs with low levels of ER expression (i.e., in 1-10% of cells) are classified as BLC< 10% of all luminal BCsClinical trials for TNBC often include these BCs~ 10% of BLCs are HER2(+)Patients with these BCs are eligible for HER2-targeted therapyTargeted treatment is based on protein expression and not classification as BLC",
                    "sub_points": [
                      "~ 5-10% of BLCs are ER(+)~ 85% of luminal BCs with low levels of ER expression (i.e., in 1-10% of cells) are classified as BLC< 10% of all luminal BCsClinical trials for TNBC often include these BCs",
                      "~ 85% of luminal BCs with low levels of ER expression (i.e., in 1-10% of cells) are classified as BLC< 10% of all luminal BCsClinical trials for TNBC often include these BCs",
                      "< 10% of all luminal BCs",
                      "Clinical trials for TNBC often include these BCs",
                      "~ 10% of BLCs are HER2(+)Patients with these BCs are eligible for HER2-targeted therapy",
                      "Patients with these BCs are eligible for HER2-targeted therapy",
                      "Targeted treatment is based on protein expression and not classification as BLC"
                    ]
                  }
                ],
                "Triple Negative and Basal-Like Carcinomas": [
                  {
                    "text": "Characteristics of TNBC and BLC are discussed together in this chapter due to the overlap between these groups"
                  },
                  {
                    "text": "TNBC/BLCs do not express ER due to epigenetic factorsER mutations in BCs are very rare except after extended aromatase inhibitor treatment of luminal BCs",
                    "sub_points": [
                      "ER mutations in BCs are very rare except after extended aromatase inhibitor treatment of luminal BCs"
                    ]
                  },
                  {
                    "text": "The absence of ER expression and the expression of proteins found in myoepithelial cells in many TNBCs and BLCs suggest that myoepithelial cells or their precursors could be the cell of originThe term \"basal\" was chosen to indicate the similarity of BLC to basally located myoepithelial cellsMammary stem cells have a basal-like gene expression profile",
                    "sub_points": [
                      "The term \"basal\" was chosen to indicate the similarity of BLC to basally located myoepithelial cells",
                      "Mammary stem cells have a basal-like gene expression profile"
                    ]
                  },
                  {
                    "text": "However, some observations suggest that the precursor cell may express ER, which is later silenced by epigenetic changes"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Association with germline mutationsBCs arising in carriers ofBRCA1are most commonly TNBC/BLC in type",
                    "sub_points": [
                      "BCs arising in carriers ofBRCA1are most commonly TNBC/BLC in type"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "10-15% of all invasive BCs"
                  }
                ],
                "Age": [
                  {
                    "text": "Incidence is relatively constant from 30-80 years"
                  },
                  {
                    "text": "However, because luminal BCs are less common in young women, TNBC/BLC is responsible for ~ 30% of BCs in young women but only ~ 10% of BCs in older women"
                  }
                ],
                "Sex": [
                  {
                    "text": "Uncommon in men"
                  },
                  {
                    "text": "The majority of male BCs are luminal BC"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "TNBC/BLC is more common in African American (20-25% of cancers) and Hispanic American (17% of cancers) women compared to all American women (10% of cancers)Luminal BCs show a marked increase with age in the entire population, but this increase is less pronounced in African American womenThis results in TNBC/BLC comprising a larger fraction of BCs in African American women due to both an absolute increase and a relative increase compared to the other molecular types",
                    "sub_points": [
                      "Luminal BCs show a marked increase with age in the entire population, but this increase is less pronounced in African American women",
                      "This results in TNBC/BLC comprising a larger fraction of BCs in African American women due to both an absolute increase and a relative increase compared to the other molecular types"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "TNBC/BLC presents as a palpable mass in ~ 2/3 of patientsIn part, this is due to TNBC/BLC occurring in young women with or withoutBRCA1mutationsAnother contributing factor is the rapid growth rate of many of these carcinomas, resulting in presentation as an \"interval BC\" detected within the screening interval",
                    "sub_points": [
                      "In part, this is due to TNBC/BLC occurring in young women with or withoutBRCA1mutations",
                      "Another contributing factor is the rapid growth rate of many of these carcinomas, resulting in presentation as an \"interval BC\" detected within the screening interval"
                    ]
                  },
                  {
                    "text": "When TNBC/BLC is detected on screening, it is usually as a mass that can have circumscribed or spiculated marginsThe DCIS associated with these cancers is generally limited in extent and often does not have calcificationsThis feature also contributes to TNBC/BLC presenting most commonly after invasion has occurred",
                    "sub_points": [
                      "The DCIS associated with these cancers is generally limited in extent and often does not have calcifications",
                      "This feature also contributes to TNBC/BLC presenting most commonly after invasion has occurred"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "ChemotherapyMost patients are treated with aggressive chemotherapyTNBC/BLC often shows a good response after neoadjuvant chemotherapy (NAT)~ 30-40% show pCRpCR is associated with good long-term survival outcomesTumors with a high content of tumor-infiltrating lymphocytes (TILs) and necrosis are more likely to show a good response to NATSome of these patients may be curedPatients without a pCR after NAT have a poor prognosis if BC is of higher stage",
                    "sub_points": [
                      "Most patients are treated with aggressive chemotherapy",
                      "TNBC/BLC often shows a good response after neoadjuvant chemotherapy (NAT)~ 30-40% show pCRpCR is associated with good long-term survival outcomesTumors with a high content of tumor-infiltrating lymphocytes (TILs) and necrosis are more likely to show a good response to NATSome of these patients may be curedPatients without a pCR after NAT have a poor prognosis if BC is of higher stage",
                      "~ 30-40% show pCRpCR is associated with good long-term survival outcomesTumors with a high content of tumor-infiltrating lymphocytes (TILs) and necrosis are more likely to show a good response to NAT",
                      "pCR is associated with good long-term survival outcomes",
                      "Tumors with a high content of tumor-infiltrating lymphocytes (TILs) and necrosis are more likely to show a good response to NAT",
                      "Some of these patients may be cured",
                      "Patients without a pCR after NAT have a poor prognosis if BC is of higher stage"
                    ]
                  },
                  {
                    "text": "Therapy targeting DNA repairHypersensitivity to DNA-damaging agents is due to abnormal DNA repair functionTargeted agents, such as inhibitors of poly (ADP-ribose) polymerase-1 (PARP) and mTOR, are in clinical testingThese agents target molecular signaling molecules that define TNBC/BLCImproved outcomes have been observed for patients with metastatic TNBC/BLC withBRCA1/BRCA2mutations treated with PARP inhibitors and platinum agents compared to standard chemotherapy",
                    "sub_points": [
                      "Hypersensitivity to DNA-damaging agents is due to abnormal DNA repair function",
                      "Targeted agents, such as inhibitors of poly (ADP-ribose) polymerase-1 (PARP) and mTOR, are in clinical testingThese agents target molecular signaling molecules that define TNBC/BLCImproved outcomes have been observed for patients with metastatic TNBC/BLC withBRCA1/BRCA2mutations treated with PARP inhibitors and platinum agents compared to standard chemotherapy",
                      "These agents target molecular signaling molecules that define TNBC/BLC",
                      "Improved outcomes have been observed for patients with metastatic TNBC/BLC withBRCA1/BRCA2mutations treated with PARP inhibitors and platinum agents compared to standard chemotherapy"
                    ]
                  },
                  {
                    "text": "Immune checkpoint blockade (ICB)TNBC/BLC shows robust immune cell infiltrates and higher programmed death ligand-1 (PD-L1) expression compared to other BCsTILs are predictive of response to chemotherapy and improved survivalHigh TIL tumors appear to correlate with response to ICBIn TNBC, expression of PD-L1 occurs mainly on tumor-infiltrating immune cells and can inhibit antitumor immune responseICB that disrupts PD1/PD-L1 interactions in combination with chemotherapy has shown promise in clinical trials for metastatic TNBCIMpassion 130 trial showed prolonged progression-free and overall survival with ICB + chemotherapy in 1st-line treatment of metastatic TNBCPatients whose tumors showed PD-L1 expression in tumor-infiltrating immune cells appeared to derive the most benefit",
                    "sub_points": [
                      "TNBC/BLC shows robust immune cell infiltrates and higher programmed death ligand-1 (PD-L1) expression compared to other BCs",
                      "TILs are predictive of response to chemotherapy and improved survivalHigh TIL tumors appear to correlate with response to ICBIn TNBC, expression of PD-L1 occurs mainly on tumor-infiltrating immune cells and can inhibit antitumor immune response",
                      "High TIL tumors appear to correlate with response to ICB",
                      "In TNBC, expression of PD-L1 occurs mainly on tumor-infiltrating immune cells and can inhibit antitumor immune response",
                      "ICB that disrupts PD1/PD-L1 interactions in combination with chemotherapy has shown promise in clinical trials for metastatic TNBCIMpassion 130 trial showed prolonged progression-free and overall survival with ICB + chemotherapy in 1st-line treatment of metastatic TNBCPatients whose tumors showed PD-L1 expression in tumor-infiltrating immune cells appeared to derive the most benefit",
                      "IMpassion 130 trial showed prolonged progression-free and overall survival with ICB + chemotherapy in 1st-line treatment of metastatic TNBC",
                      "Patients whose tumors showed PD-L1 expression in tumor-infiltrating immune cells appeared to derive the most benefit"
                    ]
                  },
                  {
                    "text": "Antibody drug conjugates (ADCs)ADCs are composed of a recombinant monoclonal antibody to a cell surface antigen conjugated to a cytoxic agentThe antibody allows selective targeting of tumor cells relative to normal cellsThe cytotoxic agent causes cell death when internalized and also kills neighboring tumor cells when released into the tumor microenvironment (bystander effect)Ongoing trials are investigating new types of ADCs and combining ADCs with other types of treatmentAs of August 2024, 2 ADCs are FDA approved for the treatment of TNBCSacituzumab govitecan-hziy (Trodelvy)SN-38 (an active metabolite of the topoisomerase I inhibitor irinotecan) is bound via a cleavable linker to Topo-2 (trophoblast cell surface antigen-2)All BC types express Topo-2, but the levels are highest in TNBCHowever, the benefit of this treatment does not appear to be related to the levels of Topo-2 on tumor cellsTratuzumab Deruxtecan (T-DXd or Enhertu)A topoisomerase I inhibitor is bound via a cleavable linker to a humanized anti-HER2 monoclonal antibodyAlmost all BCs express HER2 to some extentBCs negative for HER2 but expressing low levels (i.e., ultra low or 1+) are eligible for treatment, including ~ 30% of TNBCs",
                    "sub_points": [
                      "ADCs are composed of a recombinant monoclonal antibody to a cell surface antigen conjugated to a cytoxic agentThe antibody allows selective targeting of tumor cells relative to normal cellsThe cytotoxic agent causes cell death when internalized and also kills neighboring tumor cells when released into the tumor microenvironment (bystander effect)",
                      "The antibody allows selective targeting of tumor cells relative to normal cells",
                      "The cytotoxic agent causes cell death when internalized and also kills neighboring tumor cells when released into the tumor microenvironment (bystander effect)",
                      "Ongoing trials are investigating new types of ADCs and combining ADCs with other types of treatment",
                      "As of August 2024, 2 ADCs are FDA approved for the treatment of TNBC",
                      "Sacituzumab govitecan-hziy (Trodelvy)SN-38 (an active metabolite of the topoisomerase I inhibitor irinotecan) is bound via a cleavable linker to Topo-2 (trophoblast cell surface antigen-2)All BC types express Topo-2, but the levels are highest in TNBCHowever, the benefit of this treatment does not appear to be related to the levels of Topo-2 on tumor cells",
                      "SN-38 (an active metabolite of the topoisomerase I inhibitor irinotecan) is bound via a cleavable linker to Topo-2 (trophoblast cell surface antigen-2)",
                      "All BC types express Topo-2, but the levels are highest in TNBCHowever, the benefit of this treatment does not appear to be related to the levels of Topo-2 on tumor cells",
                      "However, the benefit of this treatment does not appear to be related to the levels of Topo-2 on tumor cells",
                      "Tratuzumab Deruxtecan (T-DXd or Enhertu)A topoisomerase I inhibitor is bound via a cleavable linker to a humanized anti-HER2 monoclonal antibodyAlmost all BCs express HER2 to some extentBCs negative for HER2 but expressing low levels (i.e., ultra low or 1+) are eligible for treatment, including ~ 30% of TNBCs",
                      "A topoisomerase I inhibitor is bound via a cleavable linker to a humanized anti-HER2 monoclonal antibody",
                      "Almost all BCs express HER2 to some extent",
                      "BCs negative for HER2 but expressing low levels (i.e., ultra low or 1+) are eligible for treatment, including ~ 30% of TNBCs"
                    ]
                  }
                ],
                "Response to Neoadjuvant Therapy (NAT)": [
                  {
                    "text": "~ 40% will undergo a pCR after NAT, which is predictive of a very favorable prognosis"
                  },
                  {
                    "text": "Patients with residual disease are eligible for additional treatment in an attempt to improve the relatively poor prognosis for higher stage carcinomas"
                  }
                ],
                "Time to Recurrence": [
                  {
                    "text": "TNBC/BLC is the molecular type most likely to recur and has the earliest peak of recurrence at ~ 4-5 years"
                  },
                  {
                    "text": "Recurrences after 8 years are very rareA diagnosis of BC after that time is most likely a new primary BCSome rare types of TNBC/BLC can recur after many years, such as adenoid cystic and secretory BC",
                    "sub_points": [
                      "A diagnosis of BC after that time is most likely a new primary BC",
                      "Some rare types of TNBC/BLC can recur after many years, such as adenoid cystic and secretory BC"
                    ]
                  }
                ],
                "Metastatic Pattern": [
                  {
                    "text": "Compared to luminal BC and luminal HER2 BC, TNBC/BLC and HER2 BC have higher rates of metastasis to viscera (35-40%) and brain (~ 20-25%) and lower rates of metastasis to bone (~ 40%)"
                  },
                  {
                    "text": "This pattern contributes to the higher rates of mortality in this group due to generally poor response rates for recurrent metastatic carcinoma and the location in vital organs"
                  },
                  {
                    "text": "Responsible for ~ 30% of BC deaths"
                  }
                ],
                "AJCC (8th Edition) Anatomic Stage": [
                  {
                    "text": "Anatomic staging (Tumor,Nodes,Metastasis) provides prognostic information for all types of BC"
                  },
                  {
                    "text": "Compared to the other luminal and luminal HER2 types, TNBC/BLC and HER2 BC are less likely to present at stage I (~ 30-35%)"
                  }
                ],
                "AJCC (8th Edition) Prognostic Stage": [
                  {
                    "text": "In the 8th edition, prognostic stage groups include anatomic stage as well as ER, PR, HER2, grade, and the result of a multigene prognostic test (if available)Stage I cancers have a relatively good prognosis, but these cancers are rarely detected this early (only ~ 35% compared to ≥ 50% of luminal BCs)",
                    "sub_points": [
                      "Stage I cancers have a relatively good prognosis, but these cancers are rarely detected this early (only ~ 35% compared to ≥ 50% of luminal BCs)"
                    ]
                  },
                  {
                    "text": "For each stage, TNBC/BLC has a less favorable prognosis than other types of BCs, but the difference is most pronounced at higher stagesTNBC/BLC is often moved to a higher prognostic stage compared to the anatomic stage due to poorer survival",
                    "sub_points": [
                      "TNBC/BLC is often moved to a higher prognostic stage compared to the anatomic stage due to poorer survival"
                    ]
                  },
                  {
                    "text": "The majority (~ 65%) of TNBC/BLCs present at stages II-IV and demonstrate an aggressive clinical course and poor prognosisHowever, because recurrences after 8 years are rare, survival curves plateau and survival at 10 years is similar to survival at 20 years",
                    "sub_points": [
                      "However, because recurrences after 8 years are rare, survival curves plateau and survival at 10 years is similar to survival at 20 years"
                    ]
                  },
                  {
                    "text": "Some histologic types of TNBC/BLC have a relatively good prognosisAdenoid cystic, secretory, fibromatosis-like metaplastic, low-grade adenosquamousFor these BCs, histologic classification is more important than classification as TNBC/BLC",
                    "sub_points": [
                      "Adenoid cystic, secretory, fibromatosis-like metaplastic, low-grade adenosquamous",
                      "For these BCs, histologic classification is more important than classification as TNBC/BLC"
                    ]
                  },
                  {
                    "text": "Other special histologic types of TNBC/BLC have a poorer than average prognosis for this groupSquamous cell and matrix-producing metaplastic carcinomasCarcinomas lacking a lymphocytic infiltrateThese carcinomas are less likely to respond to chemotherapy",
                    "sub_points": [
                      "Squamous cell and matrix-producing metaplastic carcinomas",
                      "Carcinomas lacking a lymphocytic infiltrate",
                      "These carcinomas are less likely to respond to chemotherapy"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Often ill-defined, oval, round, or lobulated mass lesionSome cancers (particularly those with a medullary pattern) have circumscribed margins and can mimic benign lesionsCalcifications are uncommon",
                    "sub_points": [
                      "Some cancers (particularly those with a medullary pattern) have circumscribed margins and can mimic benign lesions",
                      "Calcifications are uncommon"
                    ]
                  },
                  {
                    "text": "TNBC/BLC may grow rapidlyTumors are overrepresented among \"interval breast cancers\" (cancers becoming clinically evident between annual mammograms)",
                    "sub_points": [
                      "Tumors are overrepresented among \"interval breast cancers\" (cancers becoming clinically evident between annual mammograms)"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Hypoechoic mass, oval, or lobulatedMay show pseudocystic component due to necrosis in larger lesions",
                    "sub_points": [
                      "May show pseudocystic component due to necrosis in larger lesions"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Partially circumscribed or lobulated mass lesion"
                  },
                  {
                    "text": "Extensive necrosis may impart a cystic appearance"
                  }
                ]
              },
              "MOLECULAR": {
                "Genomic Instability": [
                  {
                    "text": "This group of BCs is characterized by greater genomic instability compared to the other typesNumerous mutations, complex patterns of copy number alterations, and structural rearrangements are present",
                    "sub_points": [
                      "Numerous mutations, complex patterns of copy number alterations, and structural rearrangements are present"
                    ]
                  },
                  {
                    "text": "Tumor mutation burden (TMB)Multiple pathways of DNA repair are defective, resulting in a high TMBMany sporadic TNBC/BLCs have alteredBRCA1activity and loss of functionBRCA1 plays an important role in DNA repair of double-strand breaks by homologous recombinationCells that lackBRCA1expression must rely on less reliable modes of repair and are genetically unstable~ 10-20% of TNBC/BLC have methylation of the gene promoter, resulting in decreased transcriptionMutations inBRCA1are rare in sporadic TNBC/BLC (~ 3-5%)TNBC/BLC associated with germlineBRCA1mutations are also susceptible to defective DNA repair~ 10-35% of patients with TNBC have germline mutations, depending on the population testedThe numerous mutations arising during carcinogenesis can result in altered proteins (neoantigens), which may prompt the brisk lymphocytic response associated with many of these BCs",
                    "sub_points": [
                      "Multiple pathways of DNA repair are defective, resulting in a high TMB",
                      "Many sporadic TNBC/BLCs have alteredBRCA1activity and loss of functionBRCA1 plays an important role in DNA repair of double-strand breaks by homologous recombinationCells that lackBRCA1expression must rely on less reliable modes of repair and are genetically unstable~ 10-20% of TNBC/BLC have methylation of the gene promoter, resulting in decreased transcriptionMutations inBRCA1are rare in sporadic TNBC/BLC (~ 3-5%)",
                      "BRCA1 plays an important role in DNA repair of double-strand breaks by homologous recombination",
                      "Cells that lackBRCA1expression must rely on less reliable modes of repair and are genetically unstable",
                      "~ 10-20% of TNBC/BLC have methylation of the gene promoter, resulting in decreased transcriptionMutations inBRCA1are rare in sporadic TNBC/BLC (~ 3-5%)",
                      "Mutations inBRCA1are rare in sporadic TNBC/BLC (~ 3-5%)",
                      "TNBC/BLC associated with germlineBRCA1mutations are also susceptible to defective DNA repair~ 10-35% of patients with TNBC have germline mutations, depending on the population tested",
                      "~ 10-35% of patients with TNBC have germline mutations, depending on the population tested",
                      "The numerous mutations arising during carcinogenesis can result in altered proteins (neoantigens), which may prompt the brisk lymphocytic response associated with many of these BCs"
                    ]
                  }
                ],
                "DNA: Mutations": [
                  {
                    "text": "The total number of somatic mutations is higher in TNBC/BLC (median: 49) compared with luminal cancers (median: 27)Mutations affect genes in numerous signaling pathways",
                    "sub_points": [
                      "Mutations affect genes in numerous signaling pathways"
                    ]
                  },
                  {
                    "text": "However, there is marked heterogeneity in the types of mutations in each tumorThe only cancer genes with mutations in ≥ 10% of TNBC/BLC areTP53andPIK3CAMutations in other cancer-driver genes are found at lower incidences",
                    "sub_points": [
                      "The only cancer genes with mutations in ≥ 10% of TNBC/BLC areTP53andPIK3CA",
                      "Mutations in other cancer-driver genes are found at lower incidences"
                    ]
                  },
                  {
                    "text": "TP53mutations (80%)More common than in the other 3 molecular types of BCUnlike ER(+) cancers, mutations are more likely to be non-sense single-nucleotide variants and indelsMutation is thought to be an early event in tumorigenesis and is related to both poor prognosis and resistance to chemotherapy",
                    "sub_points": [
                      "More common than in the other 3 molecular types of BCUnlike ER(+) cancers, mutations are more likely to be non-sense single-nucleotide variants and indels",
                      "Unlike ER(+) cancers, mutations are more likely to be non-sense single-nucleotide variants and indels",
                      "Mutation is thought to be an early event in tumorigenesis and is related to both poor prognosis and resistance to chemotherapy"
                    ]
                  },
                  {
                    "text": "PIK3CA-activating mutations (~ 10%)The incidence ofPIK3CAmutations (~ 10%) is lower than in the other 3 molecular types of BCAberrant activation of PIK3CA pathway occurs due to loss of negative regulators, such asPTEN, or activating mutations inPIK3CAPIK3CAmutations are increased in luminal AR TNBC",
                    "sub_points": [
                      "The incidence ofPIK3CAmutations (~ 10%) is lower than in the other 3 molecular types of BC",
                      "Aberrant activation of PIK3CA pathway occurs due to loss of negative regulators, such asPTEN, or activating mutations inPIK3CA",
                      "PIK3CAmutations are increased in luminal AR TNBC"
                    ]
                  },
                  {
                    "text": "Resulting neoantigens promote immune cell recruitment and expansion and are associated with local antitumor immunityPart of the rationale for immunotherapy for TNBC/BLC",
                    "sub_points": [
                      "Part of the rationale for immunotherapy for TNBC/BLC"
                    ]
                  }
                ],
                "DNA: Copy Number Alterations": [
                  {
                    "text": "Show complex patterns of copy number alternations with multiple gains and losses with fewer high-level amplificationsFound across all chromosomesGains of 1q, 8q, and 10pLosses of 5q and 8pEGFR,FGFR2, andVEGFA(VEGF) (vascular endothelial growth factor A) amplificationsVEGF overexpression drives angiogenesis and is associated with decreased survival",
                    "sub_points": [
                      "Found across all chromosomes",
                      "Gains of 1q, 8q, and 10p",
                      "Losses of 5q and 8p",
                      "EGFR,FGFR2, andVEGFA(VEGF) (vascular endothelial growth factor A) amplificationsVEGF overexpression drives angiogenesis and is associated with decreased survival",
                      "VEGF overexpression drives angiogenesis and is associated with decreased survival"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "BLC is defined by GEPPoor prognosis may be due to overexpression of genes promoting proliferation and migrationEGFR activates signaling pathways involved in cell proliferationα B-crystallin, a heat shock protein, inhibits apoptosisFascin, a cell motility protein, promotes invasionVEGF promotes angiogenesisAlterations in cell cycle regulation, including functional loss of RB and increased expression of cyclin E and p16INK4a, have been describedResulting high proliferation rates are involved in pathogenesis of BLCMay help to explain their especially poor prognosis",
                    "sub_points": [
                      "Poor prognosis may be due to overexpression of genes promoting proliferation and migrationEGFR activates signaling pathways involved in cell proliferationα B-crystallin, a heat shock protein, inhibits apoptosisFascin, a cell motility protein, promotes invasionVEGF promotes angiogenesisAlterations in cell cycle regulation, including functional loss of RB and increased expression of cyclin E and p16INK4a, have been describedResulting high proliferation rates are involved in pathogenesis of BLCMay help to explain their especially poor prognosis",
                      "EGFR activates signaling pathways involved in cell proliferation",
                      "α B-crystallin, a heat shock protein, inhibits apoptosis",
                      "Fascin, a cell motility protein, promotes invasion",
                      "VEGF promotes angiogenesis",
                      "Alterations in cell cycle regulation, including functional loss of RB and increased expression of cyclin E and p16INK4a, have been describedResulting high proliferation rates are involved in pathogenesis of BLCMay help to explain their especially poor prognosis",
                      "Resulting high proliferation rates are involved in pathogenesis of BLC",
                      "May help to explain their especially poor prognosis"
                    ]
                  },
                  {
                    "text": "Subsets of TNBC have been identified by GEPMultiple studies have used GEP to identify subsets of TNBCThe subsets in different studies have similarities but are not identicalIn general, GEP delineates 2 distinct categories of TNBCBLC (most common), associated with more aggressive disease and a worse prognosisNonbasal-like BLCLuminal AR subtype has been identified in multiple studiesLehmann classificationBLC subsets2 BLC subsets (BL1 and BL2)Basal-like 1: Increased cell cycle and DNA damage response signatureBasal-like 2: High expression of growth factor pathways and myoepithelial markersImmunomodulatory subtype (IM): Enriched immune cell processesMesenchymal subtype (M): Upregulated genes associated with differentiation and growth factor signalingNon-BLC subsetsMesenchymal stem-like subtype (MSL): Upregulated genes associated with differentiation and growth factor signalingLuminal AR subtype (LAR): Upregulated AR signalingTNBC subsets have different response rates to neoadjuvant chemotherapyHighest response rates for BL1Lower response rates for BL2, LAR, and M subsets",
                    "sub_points": [
                      "Multiple studies have used GEP to identify subsets of TNBCThe subsets in different studies have similarities but are not identical",
                      "The subsets in different studies have similarities but are not identical",
                      "In general, GEP delineates 2 distinct categories of TNBCBLC (most common), associated with more aggressive disease and a worse prognosisNonbasal-like BLCLuminal AR subtype has been identified in multiple studies",
                      "BLC (most common), associated with more aggressive disease and a worse prognosis",
                      "Nonbasal-like BLCLuminal AR subtype has been identified in multiple studies",
                      "Luminal AR subtype has been identified in multiple studies",
                      "Lehmann classification",
                      "BLC subsets2 BLC subsets (BL1 and BL2)Basal-like 1: Increased cell cycle and DNA damage response signatureBasal-like 2: High expression of growth factor pathways and myoepithelial markersImmunomodulatory subtype (IM): Enriched immune cell processesMesenchymal subtype (M): Upregulated genes associated with differentiation and growth factor signaling",
                      "2 BLC subsets (BL1 and BL2)Basal-like 1: Increased cell cycle and DNA damage response signatureBasal-like 2: High expression of growth factor pathways and myoepithelial markersImmunomodulatory subtype (IM): Enriched immune cell processesMesenchymal subtype (M): Upregulated genes associated with differentiation and growth factor signaling",
                      "Basal-like 1: Increased cell cycle and DNA damage response signature",
                      "Basal-like 2: High expression of growth factor pathways and myoepithelial markers",
                      "Immunomodulatory subtype (IM): Enriched immune cell processes",
                      "Mesenchymal subtype (M): Upregulated genes associated with differentiation and growth factor signaling",
                      "Non-BLC subsetsMesenchymal stem-like subtype (MSL): Upregulated genes associated with differentiation and growth factor signalingLuminal AR subtype (LAR): Upregulated AR signaling",
                      "Mesenchymal stem-like subtype (MSL): Upregulated genes associated with differentiation and growth factor signaling",
                      "Luminal AR subtype (LAR): Upregulated AR signaling",
                      "TNBC subsets have different response rates to neoadjuvant chemotherapyHighest response rates for BL1Lower response rates for BL2, LAR, and M subsets",
                      "Highest response rates for BL1",
                      "Lower response rates for BL2, LAR, and M subsets"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "General morphologic features of TNBC/BLCHigh nuclear gradeHigh mitotic rateCircumscription with pushing bordersBrisk lymphocytic stromal reaction; may be related to cytokine production by tumor cellsAreas of central geographic necrosis or fibrosisCentral fibrotic focus of > 30% associated with poorer prognosis compared to other TNBC/BLCSheets of pleomorphic tumor cells, syncytial-like growthIndicates broad clusters of tumor cells at least 7 cells across, not a true syncytium",
                    "sub_points": [
                      "High nuclear grade",
                      "High mitotic rate",
                      "Circumscription with pushing borders",
                      "Brisk lymphocytic stromal reaction; may be related to cytokine production by tumor cells",
                      "Areas of central geographic necrosis or fibrosisCentral fibrotic focus of > 30% associated with poorer prognosis compared to other TNBC/BLC",
                      "Central fibrotic focus of > 30% associated with poorer prognosis compared to other TNBC/BLC",
                      "Sheets of pleomorphic tumor cells, syncytial-like growthIndicates broad clusters of tumor cells at least 7 cells across, not a true syncytium",
                      "Indicates broad clusters of tumor cells at least 7 cells across, not a true syncytium"
                    ]
                  },
                  {
                    "text": "Medullary pattern of TNBC/BLCMedullary (referring to the soft marrow of bones) was applied to these tumors in the 19th century based on their gross appearanceDue to the lack of a desmoplastic (scirrhous) response, the cancers are softer on palpation\"Encephaloid\" was also used as a descriptor, again indicating their soft consistencyThis is a rare subtype of invasive BC that was originally defined by strict morphologic criteriaPredominant syncytial growth pattern in > 75% of the tumor (solid anastomosing cords of cells at least 7 cells across)Absence of gland formationMay have indistinct cell borders but are not a true syncytiumSharply circumscribed pushing bordersCells should not invade as single cells are small nestsCollagenous stroma is scantThere can be adjacent coalescent nodulesThe border is due to the pushing growth pattern of the carcinoma: Normal epithelium and adipose tissue should not be within the carcinomaModerate to frequently marked host lymphoplasmacytic inflammatory infiltrateTypically involves periphery of the tumor (interface of tumor and surrounding tissue)Predominantly CD3(+) and CD8(+) cytotoxic T cells intermingled with plasma cellsHigh nuclear grade and frequent mitotic figuresVesicular chromatin and multiple nucleoli commonMultinucleated giant cells may be presentAtypical mitoses frequently presentNo or very little ductal carcinoma in situ (DCIS) was originally a criterion but was later droppedCarcinomas fulfilling these criteria have a better prognosis compared to carcinomas of similar grade and sizeHowever, it was difficult to achieve diagnostic reproducibility~ 10-20% of cancers occurring inBRCA1carriers have this morphology, and ~ 60% have some of the featuresThis morphologic appearance, but more loosely defined, is now designated as invasive BC of no special type with a medullary pattern in the World Health Organization (WHO), 5th edition",
                    "sub_points": [
                      "Medullary (referring to the soft marrow of bones) was applied to these tumors in the 19th century based on their gross appearanceDue to the lack of a desmoplastic (scirrhous) response, the cancers are softer on palpation\"Encephaloid\" was also used as a descriptor, again indicating their soft consistency",
                      "Due to the lack of a desmoplastic (scirrhous) response, the cancers are softer on palpation",
                      "\"Encephaloid\" was also used as a descriptor, again indicating their soft consistency",
                      "This is a rare subtype of invasive BC that was originally defined by strict morphologic criteriaPredominant syncytial growth pattern in > 75% of the tumor (solid anastomosing cords of cells at least 7 cells across)Absence of gland formationMay have indistinct cell borders but are not a true syncytiumSharply circumscribed pushing bordersCells should not invade as single cells are small nestsCollagenous stroma is scantThere can be adjacent coalescent nodulesThe border is due to the pushing growth pattern of the carcinoma: Normal epithelium and adipose tissue should not be within the carcinomaModerate to frequently marked host lymphoplasmacytic inflammatory infiltrateTypically involves periphery of the tumor (interface of tumor and surrounding tissue)Predominantly CD3(+) and CD8(+) cytotoxic T cells intermingled with plasma cellsHigh nuclear grade and frequent mitotic figuresVesicular chromatin and multiple nucleoli commonMultinucleated giant cells may be presentAtypical mitoses frequently presentNo or very little ductal carcinoma in situ (DCIS) was originally a criterion but was later dropped",
                      "Predominant syncytial growth pattern in > 75% of the tumor (solid anastomosing cords of cells at least 7 cells across)Absence of gland formationMay have indistinct cell borders but are not a true syncytium",
                      "Absence of gland formation",
                      "May have indistinct cell borders but are not a true syncytium",
                      "Sharply circumscribed pushing bordersCells should not invade as single cells are small nestsCollagenous stroma is scantThere can be adjacent coalescent nodulesThe border is due to the pushing growth pattern of the carcinoma: Normal epithelium and adipose tissue should not be within the carcinoma",
                      "Cells should not invade as single cells are small nests",
                      "Collagenous stroma is scant",
                      "There can be adjacent coalescent nodules",
                      "The border is due to the pushing growth pattern of the carcinoma: Normal epithelium and adipose tissue should not be within the carcinoma",
                      "Moderate to frequently marked host lymphoplasmacytic inflammatory infiltrateTypically involves periphery of the tumor (interface of tumor and surrounding tissue)Predominantly CD3(+) and CD8(+) cytotoxic T cells intermingled with plasma cells",
                      "Typically involves periphery of the tumor (interface of tumor and surrounding tissue)",
                      "Predominantly CD3(+) and CD8(+) cytotoxic T cells intermingled with plasma cells",
                      "High nuclear grade and frequent mitotic figuresVesicular chromatin and multiple nucleoli commonMultinucleated giant cells may be presentAtypical mitoses frequently present",
                      "Vesicular chromatin and multiple nucleoli common",
                      "Multinucleated giant cells may be present",
                      "Atypical mitoses frequently present",
                      "No or very little ductal carcinoma in situ (DCIS) was originally a criterion but was later dropped",
                      "Carcinomas fulfilling these criteria have a better prognosis compared to carcinomas of similar grade and size",
                      "However, it was difficult to achieve diagnostic reproducibility",
                      "~ 10-20% of cancers occurring inBRCA1carriers have this morphology, and ~ 60% have some of the features",
                      "This morphologic appearance, but more loosely defined, is now designated as invasive BC of no special type with a medullary pattern in the World Health Organization (WHO), 5th edition"
                    ]
                  },
                  {
                    "text": "Metaplastic TNBC/BLCSquamous cell carcinoma and matrix-producing carcinoma are most commonly both TNBC and BLCSpindle cell metaplastic carcinomas and fibromatosis-like metaplastic carcinomas are more likely to be in the claudin-low group (TNBC but not BLC)",
                    "sub_points": [
                      "Squamous cell carcinoma and matrix-producing carcinoma are most commonly both TNBC and BLC",
                      "Spindle cell metaplastic carcinomas and fibromatosis-like metaplastic carcinomas are more likely to be in the claudin-low group (TNBC but not BLC)"
                    ]
                  },
                  {
                    "text": "Translocation carcinomasThe 2 types of BC that are associated with specific translocations have features of TNBC and BLCAdenoid cystic carcinoma (MYB::NFIB)Secretory carcinoma (ETV6::NTRK3)These carcinomas do not have the genomic instability observed in other members of this groupRelatively few genomic changes and lack ofTP53mutationsHave a more favorable prognosis",
                    "sub_points": [
                      "The 2 types of BC that are associated with specific translocations have features of TNBC and BLCAdenoid cystic carcinoma (MYB::NFIB)Secretory carcinoma (ETV6::NTRK3)",
                      "Adenoid cystic carcinoma (MYB::NFIB)",
                      "Secretory carcinoma (ETV6::NTRK3)",
                      "These carcinomas do not have the genomic instability observed in other members of this groupRelatively few genomic changes and lack ofTP53mutationsHave a more favorable prognosis",
                      "Relatively few genomic changes and lack ofTP53mutations",
                      "Have a more favorable prognosis"
                    ]
                  },
                  {
                    "text": "TNBC/BLC ductal carcinoma in situ (DCIS)This is the rarest type of DCIS (only ~ 8% of all cases of DCIS)DCIS is usually scant or absent adjacent to TNBC/BLCAlmost all have high nuclear grade and are often associated with necrosisAlmost all show expression of basal cytokeratinsOften seen as cancerization of lobules by cells with high-grade nuclei surrounded by a dense lymphocytic infiltrateCan be easily missed if not specifically sought outThe lymphocytic infiltrate is predominantly T cells",
                    "sub_points": [
                      "This is the rarest type of DCIS (only ~ 8% of all cases of DCIS)",
                      "DCIS is usually scant or absent adjacent to TNBC/BLC",
                      "Almost all have high nuclear grade and are often associated with necrosis",
                      "Almost all show expression of basal cytokeratins",
                      "Often seen as cancerization of lobules by cells with high-grade nuclei surrounded by a dense lymphocytic infiltrateCan be easily missed if not specifically sought outThe lymphocytic infiltrate is predominantly T cells",
                      "Can be easily missed if not specifically sought out",
                      "The lymphocytic infiltrate is predominantly T cells"
                    ]
                  },
                  {
                    "text": "TILsMedian percentage of TILs in TNBC: ~ 20%22% of TNBCs have > 50% TILs (lymphocyte-predominant BC)TILs are associated with favorable prognosis in TNBC/BLCFavorable when present both before and after NATTILs are significant predictor of better disease-free, distant disease-free, and overall survivalIndependent of age, nodal status, tumor size, grade, or vascular invasionTILs are associated with increased response to neoadjuvant chemotherapy",
                    "sub_points": [
                      "Median percentage of TILs in TNBC: ~ 20%22% of TNBCs have > 50% TILs (lymphocyte-predominant BC)",
                      "22% of TNBCs have > 50% TILs (lymphocyte-predominant BC)",
                      "TILs are associated with favorable prognosis in TNBC/BLCFavorable when present both before and after NAT",
                      "Favorable when present both before and after NAT",
                      "TILs are significant predictor of better disease-free, distant disease-free, and overall survivalIndependent of age, nodal status, tumor size, grade, or vascular invasion",
                      "Independent of age, nodal status, tumor size, grade, or vascular invasion",
                      "TILs are associated with increased response to neoadjuvant chemotherapy"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Patients with TNBC/BLC on core needle biopsy are eligible for neoadjuvant chemotherapyHigh nuclear grade, frequent mitoses, necrosis, and lymphocytic infiltrates may be prominent features",
                    "sub_points": [
                      "High nuclear grade, frequent mitoses, necrosis, and lymphocytic infiltrates may be prominent features"
                    ]
                  },
                  {
                    "text": "Accurate testing for ER, PR, and HER2 is essentialRepeat studies on subsequent excisions may be helpful to confirm negative results and evaluate for possible tumor heterogeneity",
                    "sub_points": [
                      "Repeat studies on subsequent excisions may be helpful to confirm negative results and evaluate for possible tumor heterogeneity"
                    ]
                  },
                  {
                    "text": "Necrosis and lymphocytic infiltrate noted on core needle biopsy are associated with a greater likelihood of a good response to treatment"
                  },
                  {
                    "text": "Upper outer quadrant masses that may be labeled as a lymph node by the radiologist can have the differential diagnosis of a primary TNBC vs. a metastasis to a lymph nodeA definite diagnosis of a metastasis should only be made when a lymph node capsule is present, especially when a primary carcinoma has not been identified",
                    "sub_points": [
                      "A definite diagnosis of a metastasis should only be made when a lymph node capsule is present, especially when a primary carcinoma has not been identified"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "ER and PRTNBC is defined as being negative for ER/PRLow levels of expression (≤ 10%) identify BCs similar to TNBC/BLCThese BCs may be eligible for TNBC trials~ 5-10% of BLCs are positive and are not TNBC",
                    "sub_points": [
                      "TNBC is defined as being negative for ER/PRLow levels of expression (≤ 10%) identify BCs similar to TNBC/BLCThese BCs may be eligible for TNBC trials",
                      "Low levels of expression (≤ 10%) identify BCs similar to TNBC/BLC",
                      "These BCs may be eligible for TNBC trials",
                      "~ 5-10% of BLCs are positive and are not TNBC"
                    ]
                  },
                  {
                    "text": "HER2TNBC is defined as being negative for HER2~ 30% have low levels of expression and are eligible for ADC treatment~ 10% of BLCs are HER2(+) by standard criteria and are not TNBC",
                    "sub_points": [
                      "TNBC is defined as being negative for HER2~ 30% have low levels of expression and are eligible for ADC treatment",
                      "~ 30% have low levels of expression and are eligible for ADC treatment",
                      "~ 10% of BLCs are HER2(+) by standard criteria and are not TNBC"
                    ]
                  },
                  {
                    "text": "CytokeratinHigh expression of basal high molecular weight cytokeratins 5, 14, and 17 (specific for BLC)Cytokeratin 5/6 present in majority in most studiesCytokeratin 17 present (50%) but may be focal/weakMost also express low molecular weight (luminal) cytokeratins 7, 8/18, and 19AR(+) TNBC is more likely to express low molecular weight keratins",
                    "sub_points": [
                      "High expression of basal high molecular weight cytokeratins 5, 14, and 17 (specific for BLC)Cytokeratin 5/6 present in majority in most studiesCytokeratin 17 present (50%) but may be focal/weak",
                      "Cytokeratin 5/6 present in majority in most studies",
                      "Cytokeratin 17 present (50%) but may be focal/weak",
                      "Most also express low molecular weight (luminal) cytokeratins 7, 8/18, and 19",
                      "AR(+) TNBC is more likely to express low molecular weight keratins"
                    ]
                  },
                  {
                    "text": "Ki-67High expression of proliferation-related genes",
                    "sub_points": [
                      "High expression of proliferation-related genes"
                    ]
                  },
                  {
                    "text": "EGFR (HER1)High expression (45%-75%)Less common in TNBC that is not BLC",
                    "sub_points": [
                      "High expression (45%-75%)Less common in TNBC that is not BLC",
                      "Less common in TNBC that is not BLC"
                    ]
                  },
                  {
                    "text": "p53Overexpression in 50-60%",
                    "sub_points": [
                      "Overexpression in 50-60%"
                    ]
                  },
                  {
                    "text": "CD117 (c-Kit)Positive in ~ 45%Does not correlate with mutations indicative of sensitivity to tyrosine kinase inhibitorsWhen positive in adenoid cystic carcinoma, only the luminal-like cells should be positive",
                    "sub_points": [
                      "Positive in ~ 45%",
                      "Does not correlate with mutations indicative of sensitivity to tyrosine kinase inhibitors",
                      "When positive in adenoid cystic carcinoma, only the luminal-like cells should be positive"
                    ]
                  }
                ],
                "Surrogate IHC Tests to Identify BLC": [
                  {
                    "text": "Panels of IHC markers have been developed to identify TNBC that is also BLC as defined by GEPMajority use basal keratin(s) and EGFRHowever, information based on this surrogate classification is not generally used clinically, and additional IHC for this purpose need not be performedSome studies have suggested that P-cadherin and vimentin could be adjunctive to commonly used IHC surrogates for BLC",
                    "sub_points": [
                      "Majority use basal keratin(s) and EGFR",
                      "However, information based on this surrogate classification is not generally used clinically, and additional IHC for this purpose need not be performed",
                      "Some studies have suggested that P-cadherin and vimentin could be adjunctive to commonly used IHC surrogates for BLC"
                    ]
                  },
                  {
                    "text": "(1) TNBC and positive for 1 basal cytokeratin, EGFR, &/or c-Kit (CD117)100% specific, 76% sensitive",
                    "sub_points": [
                      "100% specific, 76% sensitive"
                    ]
                  },
                  {
                    "text": "(2) TNBC and positive for either cytokeratin 5/6 or EGFR (\"5-marker method\" or \"core basal classification\")Any immunoreactivity for cytokeratin 5/6 or EGFR is considered positive result100% specific, 76% sensitive",
                    "sub_points": [
                      "Any immunoreactivity for cytokeratin 5/6 or EGFR is considered positive result",
                      "100% specific, 76% sensitive"
                    ]
                  },
                  {
                    "text": "(3) TNBC and positive for cytokeratin 14 and cytokeratin 34βE12 (cytokeratins 1, 4, 10, 14), and EGFR100% specific, 78% sensitiveCK5/6 was not used in this particular study, as < 10% of cases were positive, and EGFR positivity was not specific for BLCSuggests that it may be difficult to reproduce BLC classification across institutions due to differences in IHC results",
                    "sub_points": [
                      "100% specific, 78% sensitive",
                      "CK5/6 was not used in this particular study, as < 10% of cases were positive, and EGFR positivity was not specific for BLC",
                      "Suggests that it may be difficult to reproduce BLC classification across institutions due to differences in IHC results"
                    ]
                  },
                  {
                    "text": "TNBCs that are positive for CK5/6 or EGFR are more likely to have the following features than carcinomas that are negativeOccur more frequently in patients < 40 years of age (19% vs. 10%)More likely to be high grade (87% vs. 64%)Decreased 10-year BC survival (57% vs. 67%)",
                    "sub_points": [
                      "Occur more frequently in patients < 40 years of age (19% vs. 10%)",
                      "More likely to be high grade (87% vs. 64%)",
                      "Decreased 10-year BC survival (57% vs. 67%)"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Other High-Grade Malignancies": [
                  {
                    "text": "If a breast tumor is ER, PR, and HER2 (-) and lacks an in situ component, other types of malignancy should be consideredPrimary angiosarcomaCan have epithelioid or spindle cell morphologyCan occur in younger womenMetastatic melanoma or carcinomaPatients with another primary site usually have a well-documented prior history of metastasesDiffuse large B-cell lymphomaMost common lymphoma occurring in the breastHigh-grade nuclei and sheet-like growth can mimic TNBC/BLC",
                    "sub_points": [
                      "Primary angiosarcomaCan have epithelioid or spindle cell morphologyCan occur in younger women",
                      "Can have epithelioid or spindle cell morphology",
                      "Can occur in younger women",
                      "Metastatic melanoma or carcinomaPatients with another primary site usually have a well-documented prior history of metastases",
                      "Patients with another primary site usually have a well-documented prior history of metastases",
                      "Diffuse large B-cell lymphomaMost common lymphoma occurring in the breastHigh-grade nuclei and sheet-like growth can mimic TNBC/BLC",
                      "Most common lymphoma occurring in the breast",
                      "High-grade nuclei and sheet-like growth can mimic TNBC/BLC"
                    ]
                  }
                ],
                "Metastatic Carcinoma to a Lymph Node": [
                  {
                    "text": "The medullary pattern of TNBC can closely mimic a metastasis to a lymph node due to the circumscribed border and the dense lymphocytic infiltrate"
                  },
                  {
                    "text": "If an upper outer quadrant primary TNBC is mistaken for a lymph node metastasis, this raises concern for an occult primary BCIt would be very unusual for a TNBC to not be identified by imaging",
                    "sub_points": [
                      "It would be very unusual for a TNBC to not be identified by imaging"
                    ]
                  },
                  {
                    "text": "Core needle biopsies of upper outer quadrant masses should be interpreted as a lymph node metastasis only when a definite lymph node capsule is seenGerminal centers can be present in lymphocytic infiltrates associated with BCs and are not proof that the structure is a lymph nodeThe presence of DCIS &/or normal breast tissue would support that the mass is a primary BCWhen a definite diagnosis of a metastasis or a primary BC cannot be made, it is preferable to provide the differential diagnosis",
                    "sub_points": [
                      "Germinal centers can be present in lymphocytic infiltrates associated with BCs and are not proof that the structure is a lymph node",
                      "The presence of DCIS &/or normal breast tissue would support that the mass is a primary BC",
                      "When a definite diagnosis of a metastasis or a primary BC cannot be made, it is preferable to provide the differential diagnosis"
                    ]
                  }
                ],
                "T-Cell Lymphocytic Lobulitis (TCLL)": [
                  {
                    "text": "TCLL has been observed in 3 settingsFirst described as an incidental finding in prophylactic mastectomies, especially in women withBRCA1andBRCA2germline mutationsCan be present in tissue adjacent to TNBCAlso associated with enhancement by MR or masses",
                    "sub_points": [
                      "First described as an incidental finding in prophylactic mastectomies, especially in women withBRCA1andBRCA2germline mutations",
                      "Can be present in tissue adjacent to TNBC",
                      "Also associated with enhancement by MR or masses"
                    ]
                  },
                  {
                    "text": "The lesion consists of lymphocytic infiltrates composed predominantly of T cells centered on lobules that are otherwise normal in appearance"
                  },
                  {
                    "text": "TCLL is distinguished from triple negative DCIS by the absence of nuclear or architectural atypia"
                  },
                  {
                    "text": "When seen on core needle biopsy, especially if the imaging lesion is a mass, the possibility that a TNBC was missed by the biopsy should be considered"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "TNBC is identified by standard testing for ER, PR, and HER2~ 70-80% are BLC by GEPAdditional immunoperoxidase studies to identify cancers more likely to be BLC are not used clinically and are unnecessary",
                    "sub_points": [
                      "~ 70-80% are BLC by GEP",
                      "Additional immunoperoxidase studies to identify cancers more likely to be BLC are not used clinically and are unnecessary"
                    ]
                  },
                  {
                    "text": "Other malignancies should be considered when a poorly differentiated tumor is negative for hormone receptors and HER2 and no DCIS is identified"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Invasive carcinomas are reported according to College of American Pathology Invasive Breast Cancer protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Mucinous (Colloid) Carcinoma": {
            "name": "Invasive Mucinous (Colloid) Carcinoma",
            "url": "https://app.pathprimer.com/document/b108746a-3f3a-471b-a15e-6583f3e48925/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Mucinous carcinoma (MC) is characterized by abundant extracellular pools of stromal mucin"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "1-7% of all invasive mammary carcinomas; more common in older women"
                  },
                  {
                    "text": "Usually presents as a circumscribed/lobulated mass"
                  },
                  {
                    "text": "Pure MC (> 90% mucinous) is associated with favorable prognosis10-year survival > 80%",
                    "sub_points": [
                      "10-year survival > 80%"
                    ]
                  },
                  {
                    "text": "Mixed MC (> 10% nonmucinous areas) has prognosis dependent on non-MC component"
                  },
                  {
                    "text": "Mucinous micropapillary carcinoma is more commonly associated with lymph node and distant metastasis"
                  }
                ],
                "Macroscopic": [
                  {
                    "text": "Soft glistening cut surface, gelatinous appearance"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Hallmark of MC is abundant extracellular mucin production surrounding tumor cellsTumor cells typically show low histologic grade, but rare grade 3 cancers occur",
                    "sub_points": [
                      "Tumor cells typically show low histologic grade, but rare grade 3 cancers occur"
                    ]
                  },
                  {
                    "text": "Mucinous micropapillary carcinoma has micropapillary pattern in at least 50% of carcinoma"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "~ 95% are ER(+), and < 5% are HER2(+)But ~ 12% of mucinous micropapillary carcinomas are HER2(+)",
                    "sub_points": [
                      "But ~ 12% of mucinous micropapillary carcinomas are HER2(+)"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Mucocele-like lesion"
                  },
                  {
                    "text": "Myxoid fibroadenoma"
                  },
                  {
                    "text": "Matrix-producing carcinoma"
                  },
                  {
                    "text": "Invasive micropapillary carcinoma"
                  },
                  {
                    "text": "Invasive lobular carcinoma with extracellular mucin"
                  },
                  {
                    "text": "Mucinous cystadenocarcinoma"
                  },
                  {
                    "text": "Metastatic MC"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Mucinous carcinoma (MC)"
                  },
                  {
                    "text": "Mucinous micropapillary carcinoma (MMC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Colloid carcinoma"
                  },
                  {
                    "text": "Older terms: Mucoid or gelatinous carcinoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Special histologic type of invasive carcinoma characterized by abundant extracellular mucin surrounding tumor cellsPure MC; extracellular mucin production > 90% of tumorType A MC is paucicellular, and type B MC is highly cellular",
                    "sub_points": [
                      "Pure MC; extracellular mucin production > 90% of tumor",
                      "Type A MC is paucicellular, and type B MC is highly cellular"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "At the molecular level, MC represents a genetically distinct ER(+)/HER2(-) type of breast cancerDiffers from other types of breast cancer due to the low frequency of 1q gains and 16q losses as well asPIK3CGandTP53mutations",
                    "sub_points": [
                      "Differs from other types of breast cancer due to the low frequency of 1q gains and 16q losses as well asPIK3CGandTP53mutations"
                    ]
                  },
                  {
                    "text": "By mRNA profiling, type B MC shares a similar gene expression pattern with solid papillary carcinoma (SPC) and neuroendocrine breast carcinoma"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "1-7% of invasive carcinomasPrevalence is age related: < 1% in women under 35; 7% in women over 75Overall, ~ 2% incidence of pure MC",
                    "sub_points": [
                      "Prevalence is age related: < 1% in women under 35; 7% in women over 75",
                      "Overall, ~ 2% incidence of pure MC"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Older mean at diagnosis (~ 65-70 years)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most common presentation is as a palpable (soft) massSmaller cancers may be identified as circumscribed or lobulated masses on mammography",
                    "sub_points": [
                      "Smaller cancers may be identified as circumscribed or lobulated masses on mammography"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Pure MC is associated with favorable prognosisPatients typically have a lower incidence of axillary lymph node metastasis compared with no special type carcinomasAxillary nodal involvement is the most important prognostic factor for these patients10-year survival > 80%Late distant metastases have been reported in pure MCsIndolent behavior is likely associated with extracellular mucin, low proliferative activity, strong ER/PR expression, and infrequent HER2 overexpressionIn multivariate analyses, the most significant prognostic factors are nodal status, age, tumor size, PR status, and nuclear grade",
                    "sub_points": [
                      "Patients typically have a lower incidence of axillary lymph node metastasis compared with no special type carcinomasAxillary nodal involvement is the most important prognostic factor for these patients",
                      "Axillary nodal involvement is the most important prognostic factor for these patients",
                      "10-year survival > 80%",
                      "Late distant metastases have been reported in pure MCs",
                      "Indolent behavior is likely associated with extracellular mucin, low proliferative activity, strong ER/PR expression, and infrequent HER2 overexpression",
                      "In multivariate analyses, the most significant prognostic factors are nodal status, age, tumor size, PR status, and nuclear grade"
                    ]
                  },
                  {
                    "text": "Prognosis for MMC is intermediate between MC and invasive micropapillary carcinoma~ 12% HER2(+)Lymphovascular invasion in ~ 24%Lymph node metastasis in 20-40%Distant metastases in ~ 10%",
                    "sub_points": [
                      "~ 12% HER2(+)",
                      "Lymphovascular invasion in ~ 24%",
                      "Lymph node metastasis in 20-40%",
                      "Distant metastases in ~ 10%"
                    ]
                  },
                  {
                    "text": "Mixed tumors (carcinomas with only focal mucin production) have a worse prognosis than MCPrognosis for mixed tumors is determined by the nonmucinous component",
                    "sub_points": [
                      "Prognosis for mixed tumors is determined by the nonmucinous component"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Round, oval, or lobulated densityPortion of margin may be indistinctIrregular shape and spiculated margin may be seen in mixed tumors",
                    "sub_points": [
                      "Portion of margin may be indistinctIrregular shape and spiculated margin may be seen in mixed tumors",
                      "Irregular shape and spiculated margin may be seen in mixed tumors"
                    ]
                  },
                  {
                    "text": "Higher amount of mucin present in MC; correlates with circumscribed mass"
                  },
                  {
                    "text": "Calcifications are uncommonWhen present, calcification frequently corresponds to nonmucinous invasive carcinoma component of mixed mucinous tumorCalcifications can also occur directly in mucin",
                    "sub_points": [
                      "When present, calcification frequently corresponds to nonmucinous invasive carcinoma component of mixed mucinous tumor",
                      "Calcifications can also occur directly in mucin"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Round or oval massThey are isoechoic or hypoechoic to subcutaneous fat with posterior acoustic enhancement frequently presentSmall lesions typically isoechoic to fatLarger lesions or mixed tumors typically hypoechoic",
                    "sub_points": [
                      "They are isoechoic or hypoechoic to subcutaneous fat with posterior acoustic enhancement frequently present",
                      "Small lesions typically isoechoic to fat",
                      "Larger lesions or mixed tumors typically hypoechoic"
                    ]
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Homogeneous, high signal intensity on T2WI due to large quantities of mucoproteinsSignal intensity on T1WI varies from low to highThis is largely dependent on protein composition of tumor",
                    "sub_points": [
                      "Signal intensity on T1WI varies from low to highThis is largely dependent on protein composition of tumor",
                      "This is largely dependent on protein composition of tumor"
                    ]
                  },
                  {
                    "text": "Tumors typically show gradual and persistent enhancing pattern"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Pure MCs are well circumscribedCut surface is soft and typically glistening with gelatinous appearance",
                    "sub_points": [
                      "Cut surface is soft and typically glistening with gelatinous appearance"
                    ]
                  },
                  {
                    "text": "Consistency is firm rather than hardLack desmoplastic response",
                    "sub_points": [
                      "Lack desmoplastic response"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "Wide range: < 1 cm up to > 10 cmMedian: 2 cm",
                    "sub_points": [
                      "Median: 2 cm"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA Mutations and Fusion Genes": [
                  {
                    "text": "GATA3(~ 15-25%),KMT2C(~ 20%), andMAP3K1(~ 15%)Most frequently mutated genes in pure MC",
                    "sub_points": [
                      "Most frequently mutated genes in pure MC"
                    ]
                  },
                  {
                    "text": "PIK3CA(~ 10%)Less common than in other types of breast carcinomas~ 25-40% of carcinomas of no special type have mutations in this gene",
                    "sub_points": [
                      "Less common than in other types of breast carcinomas",
                      "~ 25-40% of carcinomas of no special type have mutations in this gene"
                    ]
                  },
                  {
                    "text": "OAZ1::CSNK1G2(~ 10%) andRFC4::LPP(~ 5%) fusion genesRecurrent but not pathognomonic for MC",
                    "sub_points": [
                      "Recurrent but not pathognomonic for MC"
                    ]
                  }
                ],
                "DNA Copy Number Alterations (CNAs)": [
                  {
                    "text": "In general, MC shows few CNAsInfrequent gain of 1q and 16p and loss of 16q (~ 10%)These changes are present in ~ 60% of grade- and ER status-matched no special type carcinomasRare recurrent amplifications",
                    "sub_points": [
                      "Infrequent gain of 1q and 16p and loss of 16q (~ 10%)These changes are present in ~ 60% of grade- and ER status-matched no special type carcinomas",
                      "These changes are present in ~ 60% of grade- and ER status-matched no special type carcinomas",
                      "Rare recurrent amplifications"
                    ]
                  },
                  {
                    "text": "MMC can have some CNAs also reported in invasive micropapillary carcinomaRecurrent gains in 1q, 6p, 8q, and 10q and recurrent losses in 16q, 11q, and 13qRecurrent 8p12-8p11.2 amplification encompassingFGFR1",
                    "sub_points": [
                      "Recurrent gains in 1q, 6p, 8q, and 10q and recurrent losses in 16q, 11q, and 13q",
                      "Recurrent 8p12-8p11.2 amplification encompassingFGFR1"
                    ]
                  }
                ],
                "mRNA Gene Expression Profiling": [
                  {
                    "text": "MC is in luminal type A group by transcriptional profilingMC is distinct from grade- and molecular subtype-matched invasive carcinomas of no special type (ductal)Gene expression profiles of type A MCs are distinct from type B MCsType B MC, neuroendocrine breast carcinoma, and SPC all have similar gene expression profilesThis includes type B MC ± expression of neuroendocrine markers by IHC",
                    "sub_points": [
                      "MC is distinct from grade- and molecular subtype-matched invasive carcinomas of no special type (ductal)",
                      "Gene expression profiles of type A MCs are distinct from type B MCs",
                      "Type B MC, neuroendocrine breast carcinoma, and SPC all have similar gene expression profilesThis includes type B MC ± expression of neuroendocrine markers by IHC",
                      "This includes type B MC ± expression of neuroendocrine markers by IHC"
                    ]
                  },
                  {
                    "text": "Gene expression profiles of mixed MCs are similar to those of pure MC"
                  }
                ],
                "Mucin Expression: MUC Genes": [
                  {
                    "text": "MC predominantly expresses mucin genesMUC2andMUC6MUC2 and MUC6, known as gel-forming mucins, are secreted into stroma that surrounds tumor cellsMUC2 and MUC6 may serve as a barrier to spread of tumor cellsMay help to explain indolent clinical behaviorExtracellular mucins may also increase cytotoxic T-lymphocyte activity",
                    "sub_points": [
                      "MUC2 and MUC6, known as gel-forming mucins, are secreted into stroma that surrounds tumor cellsMUC2 and MUC6 may serve as a barrier to spread of tumor cellsMay help to explain indolent clinical behaviorExtracellular mucins may also increase cytotoxic T-lymphocyte activity",
                      "MUC2 and MUC6 may serve as a barrier to spread of tumor cells",
                      "May help to explain indolent clinical behavior",
                      "Extracellular mucins may also increase cytotoxic T-lymphocyte activity"
                    ]
                  },
                  {
                    "text": "Differential methylation ofMUC2compared to other breast carcinomas may be related to its increased expression"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "There are 3 categories of MCPure MC, mixed MC, and MMC",
                    "sub_points": [
                      "Pure MC, mixed MC, and MMC"
                    ]
                  },
                  {
                    "text": "Pure MCPools of extracellular stromal mucin surround all tumor cells (at least 90% of carcinoma)Delicate fibrous septa divide pools or lakes of mucin into compartmentsDetached epithelial elements are present floating in pools of mucinDelicate blood vessels are present in the mucinPure MC should not contain areas of usual type of invasion of stroma in absence of mucinIf present, tumor should be designated as mixed mucinousAssociated non-MC is usually of no special type (ductal) but may be lobularMajority of cases have low-grade nuclei and would be classified as well or moderately differentiatedTypically with a low mitotic rateLumina formed by tumor cells in tumor clusters are included as glandular/tubule formationThere are rare cases of poorly differentiated MC (< 1% of total)WHO suggests reporting grade 3 MC as \"invasive breast carcinoma of no special type with mucin production\"Lymphovascular invasion is rare (~ 2%), and lymph node metastases are uncommon (~ 5-10%)Pure MC can be divided into 2 main subtypes based on architectural and cytologic featuresMucinous type APaucicellular with large quantities of extracellular mucin productionRibbon-like, annular, or cribriform growth patternsNeuroendocrine marker expression is not typicalMucinous type BGreater cellularity and larger clusters of tumor cells, sheet-like growthLess mucin in comparison to tumor cellsNeuroendocrine markers and argyrophilia are present in 25%Lower tumor nuclear gradeLower incidence of axillary node metastasisOlder patient ageMCs rarely show an association with tumor-infiltrating lymphocytes (< 20%)It is possible that extracellular mucin acts as a barrier to recognition by immune cells",
                    "sub_points": [
                      "Pools of extracellular stromal mucin surround all tumor cells (at least 90% of carcinoma)Delicate fibrous septa divide pools or lakes of mucin into compartmentsDetached epithelial elements are present floating in pools of mucinDelicate blood vessels are present in the mucinPure MC should not contain areas of usual type of invasion of stroma in absence of mucinIf present, tumor should be designated as mixed mucinousAssociated non-MC is usually of no special type (ductal) but may be lobularMajority of cases have low-grade nuclei and would be classified as well or moderately differentiatedTypically with a low mitotic rateLumina formed by tumor cells in tumor clusters are included as glandular/tubule formationThere are rare cases of poorly differentiated MC (< 1% of total)WHO suggests reporting grade 3 MC as \"invasive breast carcinoma of no special type with mucin production\"Lymphovascular invasion is rare (~ 2%), and lymph node metastases are uncommon (~ 5-10%)",
                      "Delicate fibrous septa divide pools or lakes of mucin into compartmentsDetached epithelial elements are present floating in pools of mucinDelicate blood vessels are present in the mucin",
                      "Detached epithelial elements are present floating in pools of mucin",
                      "Delicate blood vessels are present in the mucin",
                      "Pure MC should not contain areas of usual type of invasion of stroma in absence of mucinIf present, tumor should be designated as mixed mucinousAssociated non-MC is usually of no special type (ductal) but may be lobular",
                      "If present, tumor should be designated as mixed mucinous",
                      "Associated non-MC is usually of no special type (ductal) but may be lobular",
                      "Majority of cases have low-grade nuclei and would be classified as well or moderately differentiatedTypically with a low mitotic rateLumina formed by tumor cells in tumor clusters are included as glandular/tubule formation",
                      "Typically with a low mitotic rate",
                      "Lumina formed by tumor cells in tumor clusters are included as glandular/tubule formation",
                      "There are rare cases of poorly differentiated MC (< 1% of total)WHO suggests reporting grade 3 MC as \"invasive breast carcinoma of no special type with mucin production\"",
                      "WHO suggests reporting grade 3 MC as \"invasive breast carcinoma of no special type with mucin production\"",
                      "Lymphovascular invasion is rare (~ 2%), and lymph node metastases are uncommon (~ 5-10%)",
                      "Pure MC can be divided into 2 main subtypes based on architectural and cytologic featuresMucinous type APaucicellular with large quantities of extracellular mucin productionRibbon-like, annular, or cribriform growth patternsNeuroendocrine marker expression is not typicalMucinous type BGreater cellularity and larger clusters of tumor cells, sheet-like growthLess mucin in comparison to tumor cellsNeuroendocrine markers and argyrophilia are present in 25%Lower tumor nuclear gradeLower incidence of axillary node metastasisOlder patient age",
                      "Mucinous type APaucicellular with large quantities of extracellular mucin productionRibbon-like, annular, or cribriform growth patternsNeuroendocrine marker expression is not typical",
                      "Paucicellular with large quantities of extracellular mucin production",
                      "Ribbon-like, annular, or cribriform growth patterns",
                      "Neuroendocrine marker expression is not typical",
                      "Mucinous type BGreater cellularity and larger clusters of tumor cells, sheet-like growthLess mucin in comparison to tumor cellsNeuroendocrine markers and argyrophilia are present in 25%Lower tumor nuclear gradeLower incidence of axillary node metastasisOlder patient age",
                      "Greater cellularity and larger clusters of tumor cells, sheet-like growth",
                      "Less mucin in comparison to tumor cells",
                      "Neuroendocrine markers and argyrophilia are present in 25%",
                      "Lower tumor nuclear grade",
                      "Lower incidence of axillary node metastasis",
                      "Older patient age",
                      "MCs rarely show an association with tumor-infiltrating lymphocytes (< 20%)It is possible that extracellular mucin acts as a barrier to recognition by immune cells",
                      "It is possible that extracellular mucin acts as a barrier to recognition by immune cells"
                    ]
                  },
                  {
                    "text": "Mixed MCBreast cancer with both mucinous component and invasive carcinoma not surrounded by pools of mucin composing > 10% of total cancerPrognosis for mixed tumors is determined by nonmucinous component",
                    "sub_points": [
                      "Breast cancer with both mucinous component and invasive carcinoma not surrounded by pools of mucin composing > 10% of total cancer",
                      "Prognosis for mixed tumors is determined by nonmucinous component"
                    ]
                  },
                  {
                    "text": "MMCA micropapillary architectural pattern is seen in some MCsCarcinomas growing in fluids can form hollow spherules of cellsOn cross section, these spherules appear to be empty tubules (micropapillae)Results in \"inverted architecture\" (i.e., apical portions of cells point to outside of spherules or tubules)Immunohistochemical studies for EMA and MUC1 are positive on outer apical surfaceA subset (~ 20%) of MC with a micropapillary pattern in > 50% of carcinoma can be classified as MMCThe definition of a micropapillary pattern for this classification is restricted to the presence of clusters of cells with hollow centers (\"inverted tubules\") and does not include solid clustersSolid nests of cells seen in MCs can show outer apical immunoreactivity for EMA and MUC1Median patient age is ~ 10 years younger than for MCOften associated with psammoma body-like calcifications~ 90% are ER(+), similar to MCMajority have low to intermediate nuclear grade, but ~ 4% have high nuclear gradeCarcinomas with metastatic behavior may be more likely to be of higher gradeBiologic features are intermediate between MC and invasive micropapillary carcinoma~ 12% are HER2(+)Lymphovascular invasion in ~ 25%Lymph node metastases in 30-40%Distant metastases in ~ 10%Biologic features suggest a more aggressive behavior in these cases compared with pure MCSome tumors show somatic genetic alterations similar to those of MCOther tumors resemble invasive micropapillary carcinoma at the genetic levelMay represent a convergent phenotype that can stem from MC or invasive micropapillary carcinomaMetastases may have diminished mucin production or lack mucin productionLoss of mucin production may be a poor prognostic factor",
                    "sub_points": [
                      "A micropapillary architectural pattern is seen in some MCsCarcinomas growing in fluids can form hollow spherules of cellsOn cross section, these spherules appear to be empty tubules (micropapillae)Results in \"inverted architecture\" (i.e., apical portions of cells point to outside of spherules or tubules)Immunohistochemical studies for EMA and MUC1 are positive on outer apical surface",
                      "Carcinomas growing in fluids can form hollow spherules of cellsOn cross section, these spherules appear to be empty tubules (micropapillae)Results in \"inverted architecture\" (i.e., apical portions of cells point to outside of spherules or tubules)Immunohistochemical studies for EMA and MUC1 are positive on outer apical surface",
                      "On cross section, these spherules appear to be empty tubules (micropapillae)",
                      "Results in \"inverted architecture\" (i.e., apical portions of cells point to outside of spherules or tubules)",
                      "Immunohistochemical studies for EMA and MUC1 are positive on outer apical surface",
                      "A subset (~ 20%) of MC with a micropapillary pattern in > 50% of carcinoma can be classified as MMCThe definition of a micropapillary pattern for this classification is restricted to the presence of clusters of cells with hollow centers (\"inverted tubules\") and does not include solid clustersSolid nests of cells seen in MCs can show outer apical immunoreactivity for EMA and MUC1Median patient age is ~ 10 years younger than for MCOften associated with psammoma body-like calcifications~ 90% are ER(+), similar to MCMajority have low to intermediate nuclear grade, but ~ 4% have high nuclear gradeCarcinomas with metastatic behavior may be more likely to be of higher grade",
                      "The definition of a micropapillary pattern for this classification is restricted to the presence of clusters of cells with hollow centers (\"inverted tubules\") and does not include solid clustersSolid nests of cells seen in MCs can show outer apical immunoreactivity for EMA and MUC1",
                      "Solid nests of cells seen in MCs can show outer apical immunoreactivity for EMA and MUC1",
                      "Median patient age is ~ 10 years younger than for MC",
                      "Often associated with psammoma body-like calcifications",
                      "~ 90% are ER(+), similar to MC",
                      "Majority have low to intermediate nuclear grade, but ~ 4% have high nuclear gradeCarcinomas with metastatic behavior may be more likely to be of higher grade",
                      "Carcinomas with metastatic behavior may be more likely to be of higher grade",
                      "Biologic features are intermediate between MC and invasive micropapillary carcinoma~ 12% are HER2(+)Lymphovascular invasion in ~ 25%Lymph node metastases in 30-40%Distant metastases in ~ 10%",
                      "~ 12% are HER2(+)",
                      "Lymphovascular invasion in ~ 25%",
                      "Lymph node metastases in 30-40%",
                      "Distant metastases in ~ 10%",
                      "Biologic features suggest a more aggressive behavior in these cases compared with pure MCSome tumors show somatic genetic alterations similar to those of MCOther tumors resemble invasive micropapillary carcinoma at the genetic levelMay represent a convergent phenotype that can stem from MC or invasive micropapillary carcinoma",
                      "Some tumors show somatic genetic alterations similar to those of MC",
                      "Other tumors resemble invasive micropapillary carcinoma at the genetic level",
                      "May represent a convergent phenotype that can stem from MC or invasive micropapillary carcinoma",
                      "Metastases may have diminished mucin production or lack mucin productionLoss of mucin production may be a poor prognostic factor",
                      "Loss of mucin production may be a poor prognostic factor"
                    ]
                  },
                  {
                    "text": "Ductal carcinoma in situ (DCIS) associated with MCMay show papillary, micropapillary, cribriform, or solid patternsMajority also demonstrate prominent mucin productionMay be associated with calcifications in mucinMicroinvasion may be seen as tumor cells in pools of mucinMust be distinguished (if possible) from rupture of ducts with spillage of mucin and tumor cells into stroma",
                    "sub_points": [
                      "May show papillary, micropapillary, cribriform, or solid patterns",
                      "Majority also demonstrate prominent mucin productionMay be associated with calcifications in mucin",
                      "May be associated with calcifications in mucin",
                      "Microinvasion may be seen as tumor cells in pools of mucinMust be distinguished (if possible) from rupture of ducts with spillage of mucin and tumor cells into stroma",
                      "Must be distinguished (if possible) from rupture of ducts with spillage of mucin and tumor cells into stroma"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis of MC may be difficult on core needle biopsySome MCs are paucicellular with only a few dispersed clusters of tumor cellsThe core needle biopsy may contain stromal mucin devoid of tumor cells in the sample of the lesionAdditional levels may reveal tumor cellsExcision is advisable if the lesion is a mass",
                    "sub_points": [
                      "Some MCs are paucicellular with only a few dispersed clusters of tumor cells",
                      "The core needle biopsy may contain stromal mucin devoid of tumor cells in the sample of the lesionAdditional levels may reveal tumor cells",
                      "Additional levels may reveal tumor cells",
                      "Excision is advisable if the lesion is a mass"
                    ]
                  },
                  {
                    "text": "Mucin-filled cysts with adjacent extravasated stromal mucin should raise concern for MCMC more likely if atypical ductal hyperplasia or DCIS is presentDeeper levels may reveal diagnostic areas of MCMalignancy on excision is more common if the lesion is a mass rather than calcifications",
                    "sub_points": [
                      "MC more likely if atypical ductal hyperplasia or DCIS is present",
                      "Deeper levels may reveal diagnostic areas of MC",
                      "Malignancy on excision is more common if the lesion is a mass rather than calcifications"
                    ]
                  },
                  {
                    "text": "Evaluation of excisional specimens can be difficult after core needle biopsyMucin extravasation from cysts &/or DCIS can be caused by biopsy and may be difficult to distinguish from true invasionSeeding of needle track by MC has been reported in rare casesComparison to the lesion in the core needle biopsy can be helpful to determine the best classificationIf tumor cells in mucin are only seen in excision and are limited in extent, epithelial displacement should be considered",
                    "sub_points": [
                      "Mucin extravasation from cysts &/or DCIS can be caused by biopsy and may be difficult to distinguish from true invasionSeeding of needle track by MC has been reported in rare cases",
                      "Seeding of needle track by MC has been reported in rare cases",
                      "Comparison to the lesion in the core needle biopsy can be helpful to determine the best classificationIf tumor cells in mucin are only seen in excision and are limited in extent, epithelial displacement should be considered",
                      "If tumor cells in mucin are only seen in excision and are limited in extent, epithelial displacement should be considered"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptors: Majority positive (> 90%)MC more likely to be ER (94%) and PR (81%) (+) compared with carcinomas of no special typeTypically express high levels of both receptors",
                    "sub_points": [
                      "MC more likely to be ER (94%) and PR (81%) (+) compared with carcinomas of no special typeTypically express high levels of both receptors",
                      "Typically express high levels of both receptors"
                    ]
                  },
                  {
                    "text": "HER2: Majority negative (> 95%)HER2 overexpression may be present in MCs that are high grade &/or have micropapillary pattern ~ 12%EGFR overexpression is also very uncommon",
                    "sub_points": [
                      "HER2 overexpression may be present in MCs that are high grade &/or have micropapillary pattern ~ 12%",
                      "EGFR overexpression is also very uncommon"
                    ]
                  },
                  {
                    "text": "Neuroendocrine markers: May be positive in type B MCTumor cells show expression of 1 or more neuroendocrine markersChromogranin, synaptophysin, CD56Type A MC typically does not show neuroendocrine featuresNeuroendocrine features are associated with better prognosis in some reportsPrognostic significance is not well establishedNot considered a standard prognostic featureNot required for evaluation or classification of MC",
                    "sub_points": [
                      "Tumor cells show expression of 1 or more neuroendocrine markersChromogranin, synaptophysin, CD56",
                      "Chromogranin, synaptophysin, CD56",
                      "Type A MC typically does not show neuroendocrine features",
                      "Neuroendocrine features are associated with better prognosis in some reportsPrognostic significance is not well establishedNot considered a standard prognostic featureNot required for evaluation or classification of MC",
                      "Prognostic significance is not well establishedNot considered a standard prognostic featureNot required for evaluation or classification of MC",
                      "Not considered a standard prognostic feature",
                      "Not required for evaluation or classification of MC"
                    ]
                  },
                  {
                    "text": "Mucin expressionMUC1 expression, which is related to poor prognosis in gastric and colorectal cancers, is low in MCGel-forming secretory mucins (MUC2 and MUC6) are highly expressed in MC",
                    "sub_points": [
                      "MUC1 expression, which is related to poor prognosis in gastric and colorectal cancers, is low in MC",
                      "Gel-forming secretory mucins (MUC2 and MUC6) are highly expressed in MC"
                    ]
                  },
                  {
                    "text": "WT1 (nuclear) and β-catenin (membrane) expressionPure and mixed MC are reported to express WT1 (~ 65%) and β-cateninMay indicate that Wnt/β-catenin pathway is activated",
                    "sub_points": [
                      "Pure and mixed MC are reported to express WT1 (~ 65%) and β-cateninMay indicate that Wnt/β-catenin pathway is activated",
                      "May indicate that Wnt/β-catenin pathway is activated"
                    ]
                  },
                  {
                    "text": "EMA: PositiveTypically present on outer surface of tumor cell clusters (reverse polarity)Same pattern seen with MUC1Not sufficient to classify pattern as micropapillaryCell clusters with hollow cores and reverse polarity required",
                    "sub_points": [
                      "Typically present on outer surface of tumor cell clusters (reverse polarity)Same pattern seen with MUC1",
                      "Same pattern seen with MUC1",
                      "Not sufficient to classify pattern as micropapillaryCell clusters with hollow cores and reverse polarity required",
                      "Cell clusters with hollow cores and reverse polarity required"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "21-gene recurrence score (RS)There are significant differences in RSs for ER(+) breast cancer with different histologic subtypesPure MC is associated with a lower RS compared with invasive carcinoma of no special type (\"ductal\")Most cases of MC are classified into a low or intermediate RS category",
                    "sub_points": [
                      "There are significant differences in RSs for ER(+) breast cancer with different histologic subtypes",
                      "Pure MC is associated with a lower RS compared with invasive carcinoma of no special type (\"ductal\")",
                      "Most cases of MC are classified into a low or intermediate RS category"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mucocele-Like Lesion": [
                  {
                    "text": "Characterized by cystically dilated, mucin-filled ducts, lined by bland cells lining the spacesMay be associated with rupture and extravasated stromal mucinExtravasated mucin usually lacks blood vessels, whereas they are typically present in MCStrips or clusters of epithelial cells may become detached from liningMay be difficult to distinguish from MC on limited biopsy samplesDetached epithelial cell groups may be associated with myoepithelial cells",
                    "sub_points": [
                      "May be associated with rupture and extravasated stromal mucinExtravasated mucin usually lacks blood vessels, whereas they are typically present in MC",
                      "Extravasated mucin usually lacks blood vessels, whereas they are typically present in MC",
                      "Strips or clusters of epithelial cells may become detached from liningMay be difficult to distinguish from MC on limited biopsy samplesDetached epithelial cell groups may be associated with myoepithelial cells",
                      "May be difficult to distinguish from MC on limited biopsy samples",
                      "Detached epithelial cell groups may be associated with myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Mucocele-like lesions may be associated with atypical ductal hyperplasia or DCIS"
                  },
                  {
                    "text": "Disruption of a mucocele-like lesion by core needle biopsy can complicate interpretationPossibility of epithelial displacement into a needle track should be considered",
                    "sub_points": [
                      "Possibility of epithelial displacement into a needle track should be considered"
                    ]
                  }
                ],
                "Myxoid Fibroadenoma": [
                  {
                    "text": "Typically seen in a younger age group compared with MC"
                  },
                  {
                    "text": "Both present as circumscribed masses that are palpable or seen on imaging studies"
                  },
                  {
                    "text": "Myxoid stroma is associated with stromal spindle cells"
                  },
                  {
                    "text": "Epithelium of fibroadenoma has a normal layer of myoepithelial cells, whereas epithelium of MC lacks myoepithelial cells"
                  }
                ],
                "Invasive Micropapillary Carcinoma": [
                  {
                    "text": "Hollow and solid clusters of tumor cells are present in empty (serous) stromal spacesSome clusters have inverted (inside out) polarity with outer apical blebs forming a serrated surface",
                    "sub_points": [
                      "Some clusters have inverted (inside out) polarity with outer apical blebs forming a serrated surface"
                    ]
                  },
                  {
                    "text": "Less likely to be ER(+) (~ 85%) and more likely to be HER2(+) (~ 40-50%) than MC"
                  },
                  {
                    "text": "Frequently associated with lymphovascular invasion (~ 85%), lymph node metastasis (~ 80%), and distant metastasis (~ 40%)"
                  },
                  {
                    "text": "MMC has the same appearance as micropapillary carcinoma but is associated with mucin throughout the tumorBiologic and clinical features are intermediate between MC and invasive micropapillary carcinomaMucin may interfere with ability to metastasize",
                    "sub_points": [
                      "Biologic and clinical features are intermediate between MC and invasive micropapillary carcinoma",
                      "Mucin may interfere with ability to metastasize"
                    ]
                  },
                  {
                    "text": "It is important to recognize tumors with micropapillary pattern and to report presence or absence of mucin"
                  }
                ],
                "Matrix-Producing (Metaplastic) Carcinoma": [
                  {
                    "text": "Some metaplastic carcinomas produce abundant extracellular matrix"
                  },
                  {
                    "text": "Matrix often appears chondroid in appearanceTumor cells are located in lacunar spacesMore likely to be distributed toward periphery of lesionCells are individually dispersed or arranged in small trabeculaeHas more solid-appearing basophilic appearanceIn contrast, mucin is generally light pink to blue and wispy in appearance",
                    "sub_points": [
                      "Tumor cells are located in lacunar spaces",
                      "More likely to be distributed toward periphery of lesion",
                      "Cells are individually dispersed or arranged in small trabeculae",
                      "Has more solid-appearing basophilic appearanceIn contrast, mucin is generally light pink to blue and wispy in appearance",
                      "In contrast, mucin is generally light pink to blue and wispy in appearance"
                    ]
                  },
                  {
                    "text": "Almost always ER(-) and PR(-)Tumor cells are typically positive for basal cytokeratins (CK5/6, CK14) and p63",
                    "sub_points": [
                      "Tumor cells are typically positive for basal cytokeratins (CK5/6, CK14) and p63"
                    ]
                  },
                  {
                    "text": "Almost always high grade with high proliferative rate"
                  }
                ],
                "Invasive Lobular Carcinoma With Extracellular Mucin": [
                  {
                    "text": "Consists of dyscohesive signet-ring cells surrounded by extracellular mucin"
                  },
                  {
                    "text": "Shows loss of E-cadherin and cytoplasmic p120 positivity, as is seen in other lobular carcinomas"
                  },
                  {
                    "text": "The majority are positive for hormone receptors, and a few have been positive for HER2"
                  },
                  {
                    "text": "Genomic changes are similar to those of other lobular carcinomas"
                  }
                ],
                "Solid Papillary Carcinoma (SPC)": [
                  {
                    "text": "SPC is an indolent breast cancer found in older women"
                  },
                  {
                    "text": "Tumor is characterized by circumscribed expansile, cellular nodules with delicate fibrovascular cores"
                  },
                  {
                    "text": "SPC clusters with MC by gene expression profilingMucinous and neuroendocrine features are characteristic",
                    "sub_points": [
                      "Mucinous and neuroendocrine features are characteristic"
                    ]
                  },
                  {
                    "text": "Some carcinomas have mixed features between SPC and MC"
                  }
                ],
                "Mucinous Cystadenocarcinoma": [
                  {
                    "text": "Very rare breast carcinoma (< 30 cases) that consists of multiple well-circumscribed spaces filled with mucinThe spaces are lined by tall columnar cells that can be multilayered or tufted and form papillae with fibrovascular coresThe nuclei are located basally, and there is abundant intracytoplasmic mucinMyoepithelial cells are absent",
                    "sub_points": [
                      "The spaces are lined by tall columnar cells that can be multilayered or tufted and form papillae with fibrovascular coresThe nuclei are located basally, and there is abundant intracytoplasmic mucin",
                      "The nuclei are located basally, and there is abundant intracytoplasmic mucin",
                      "Myoepithelial cells are absent"
                    ]
                  },
                  {
                    "text": "The majority are negative for ER, PR, and HER2Rare cases have been HER2(+)",
                    "sub_points": [
                      "Rare cases have been HER2(+)"
                    ]
                  },
                  {
                    "text": "~ 15% metastasize to lymph nodes, but no distant metastases reported"
                  }
                ],
                "Metastatic Mucinous Carcinoma": [
                  {
                    "text": "In the absence of DCIS and positivity for ER, a metastasis to the breast should be considered"
                  },
                  {
                    "text": "Mucinous breast carcinoma: ER(+), GATA3(+), CK7(+), CK20(-), CDX2(-), TTF-1(-)"
                  },
                  {
                    "text": "Mucinous ovarian carcinoma: GATA3(-), CK20(+) (~ 66%), CDX2(+) (50%)Can be ER(+) (~ 25%)",
                    "sub_points": [
                      "Can be ER(+) (~ 25%)"
                    ]
                  },
                  {
                    "text": "Mucinous colon carcinoma: ER(-), CK7(-) (rare), CK20(+), CDX2(+)"
                  },
                  {
                    "text": "Mucinous lung carcinoma: ER(-), CK7(+), CK20(+/1) (~ 50%), TTF-1(+/-) (~ 35%)"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Pure MC is important to recognize due to low rates of local and distant recurrenceThese favorable prognostic features are only seen in tumors with > 90% mucinous histologyImmunoperoxidase studies for mucins or neuroendocrine markers are not necessary for diagnosis or classification",
                    "sub_points": [
                      "These favorable prognostic features are only seen in tumors with > 90% mucinous histology",
                      "Immunoperoxidase studies for mucins or neuroendocrine markers are not necessary for diagnosis or classification"
                    ]
                  },
                  {
                    "text": "Carcinomas with > 10% nonmucinous histology should be reported as mixed carcinomas"
                  },
                  {
                    "text": "MMCs should be recognized due to greater propensity for metastasisClassification is made with recognition of micropapillary pattern on H&EImmunoperoxidase studies are not helpful for this distinction",
                    "sub_points": [
                      "Classification is made with recognition of micropapillary pattern on H&E",
                      "Immunoperoxidase studies are not helpful for this distinction"
                    ]
                  },
                  {
                    "text": "Diagnosis of MC may be difficult on core needle biopsySome MCs are paucicellular with only a few dispersed clusters of tumor cellsA core needle biopsy may contain extensive stromal mucin devoid of tumor cellsExcision for definitive evaluation should be recommended if the lesion is a mass",
                    "sub_points": [
                      "Some MCs are paucicellular with only a few dispersed clusters of tumor cells",
                      "A core needle biopsy may contain extensive stromal mucin devoid of tumor cells",
                      "Excision for definitive evaluation should be recommended if the lesion is a mass"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Report the type of MCPure MC (> 90% mucinous histology)Mixed MC (> 10% nonmucinous histology)MMC",
                    "sub_points": [
                      "Pure MC (> 90% mucinous histology)",
                      "Mixed MC (> 10% nonmucinous histology)",
                      "MMC"
                    ]
                  },
                  {
                    "text": "MC is reported according to the College of American Pathologists Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Papillary Carcinoma": {
            "name": "Invasive Papillary Carcinoma",
            "url": "https://app.pathprimer.com/document/49236418-b54c-4d42-bfd0-c795193c19fc/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Invasive papillary carcinomas (IPCs) are very rare carcinomas consisting of > 90% papillary morphology"
                  },
                  {
                    "text": "Papillary carcinoma is a nonspecific termIncludes encapsulated papillary carcinoma (EPC), solid papillary carcinoma (SPC), and ductal carcinoma in situ (DCIS) with a papillary pattern",
                    "sub_points": [
                      "Includes encapsulated papillary carcinoma (EPC), solid papillary carcinoma (SPC), and ductal carcinoma in situ (DCIS) with a papillary pattern"
                    ]
                  },
                  {
                    "text": "Invasive carcinomas of no special type (\"ductal\") associated with EPC, SPC, or DCIS should not be classified as IPC"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Little is known about these carcinomas due to their rarity and studies often not clearly defining \"papillary carcinoma\""
                  },
                  {
                    "text": "~ 72% of IPC are luminal B molecular subtype"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "< 1% of breast carcinomas"
                  },
                  {
                    "text": "More common in postmenopausal women (typically 65-70 years of age)"
                  },
                  {
                    "text": "Presentation and imaging features are not specific to this tumor type"
                  },
                  {
                    "text": "Majority are grade 1 or 2Almost all are ER(+) and HER2(-)",
                    "sub_points": [
                      "Almost all are ER(+) and HER2(-)"
                    ]
                  },
                  {
                    "text": "Diagnosis on core needle biopsy may be difficult due to fragmentationA differential diagnosis should be included when appropriate",
                    "sub_points": [
                      "A differential diagnosis should be included when appropriate"
                    ]
                  },
                  {
                    "text": "Prognosis is likely similar to other grade- and size-matched ER(+) carcinomas"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "SPC"
                  },
                  {
                    "text": "Invasive SPC"
                  },
                  {
                    "text": "EPC"
                  },
                  {
                    "text": "Invasive carcinoma with tubulolobular features"
                  },
                  {
                    "text": "Invasive micropapillary carcinoma"
                  },
                  {
                    "text": "Skin or chest wall recurrence"
                  },
                  {
                    "text": "Metastatic papillary carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive papillary carcinoma (IPC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Invasive carcinomas consisting predominantly of papillae with fibrovascular cores (> 90%)"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Breast carcinomas (BCs) with papillary features include invasive papillary carcinoma (IPC), encapsulated papillary carcinoma (EPC), solid papillary carcinoma (SPC), and ductal carcinoma in situ (DCIS) with a papillary architectural patternThe term papillary carcinoma should not be used without further qualification &/or a differential diagnosis",
                    "sub_points": [
                      "The term papillary carcinoma should not be used without further qualification &/or a differential diagnosis"
                    ]
                  },
                  {
                    "text": "IPC refers to BCs with an infiltrative pattern consisting predominantly of papillae with fibrovascular cores (> 90%)Invasive BCs of no special type (\"ductal\") associated with EPC, SPC, or DCIS with a papillary pattern should not be classified as IPC",
                    "sub_points": [
                      "Invasive BCs of no special type (\"ductal\") associated with EPC, SPC, or DCIS with a papillary pattern should not be classified as IPC"
                    ]
                  },
                  {
                    "text": "IPC is very rare (< 1% of BCs) and, thus, there is little specific information about this type of BC~ 72% of IPCs are luminal B molecular subtype",
                    "sub_points": [
                      "~ 72% of IPCs are luminal B molecular subtype"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "< 1% of BCs"
                  }
                ],
                "Age": [
                  {
                    "text": "More common in postmenopausal women (> 50 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Majority occur in women but also reported in men"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Likely similar to other grade- and size-matched estrogen receptor (ER)(+)BCs"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Prominent pattern of papillae with fibrovascular cores in > 90% of IPCPapillae lack myoepithelial cells",
                    "sub_points": [
                      "Papillae lack myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Nuclear grade is generally low or intermediate"
                  },
                  {
                    "text": "Papillae are not considered glandular (acinar)/tubule formation in the Nottingham grading system"
                  },
                  {
                    "text": "Core needle biopsyPapillary neoplasms can be very difficult to classify on core needle biopsyPapillary pattern of growth often results in fragmentation of specimenImmunohistochemistry (IHC) for myoepithelial cells can be helpful to distinguish papillary carcinoma from benign papillomas",
                    "sub_points": [
                      "Papillary neoplasms can be very difficult to classify on core needle biopsyPapillary pattern of growth often results in fragmentation of specimen",
                      "Papillary pattern of growth often results in fragmentation of specimen",
                      "Immunohistochemistry (IHC) for myoepithelial cells can be helpful to distinguish papillary carcinoma from benign papillomas"
                    ]
                  },
                  {
                    "text": "The appropriate differential diagnosis should be provided, as this may alter subsequent surgery and lymph node samplingDetached papillae lacking myoepithelial cells may correspond to DCIS with a papillary pattern, EPC, or IPCA mass with circumscribed margins favors EPC, whereas a mass with spiculated margins favors IPC",
                    "sub_points": [
                      "Detached papillae lacking myoepithelial cells may correspond to DCIS with a papillary pattern, EPC, or IPC",
                      "A mass with circumscribed margins favors EPC, whereas a mass with spiculated margins favors IPC"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "ER and progesterone receptor (PR): Majority positive"
                  },
                  {
                    "text": "HER2: Majority negative"
                  },
                  {
                    "text": "Myoepithelial markers: Confirm the absence of myoepithelial cells"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Solid Papillary Carcinoma (SPC)": [
                  {
                    "text": "Usually consists of multiple masses with circumscribed borders filled with tumor cells with interspersed small fibrovascular cores"
                  },
                  {
                    "text": "Classified as AJCC Tis (DCIS) if features of invasion are not present"
                  },
                  {
                    "text": "Associated invasive BCs are usually of no special type (\"ductal\")These BCs should not be classified as IPC due to the association with SPC",
                    "sub_points": [
                      "These BCs should not be classified as IPC due to the association with SPC"
                    ]
                  }
                ],
                "Invasive SPC": [
                  {
                    "text": "These carcinomas have the appearance of SPC, but the tumor cell nests have irregular borders"
                  },
                  {
                    "text": "There is an infiltrative pattern around normal ducts and lobules associated with a desmoplastic response"
                  }
                ],
                "Encapsulated Papillary Carcinoma (EPC)": [
                  {
                    "text": "Usually forms a single well-circumscribed cystic space filled with delicate papillary fronds"
                  },
                  {
                    "text": "Classified as AJCC Tis (DCIS) if features of invasion are not present"
                  },
                  {
                    "text": "Associated invasive BCs are usually of no special type (\"ductal\")These BCs should not be classified as IPC due to the association with EPC",
                    "sub_points": [
                      "These BCs should not be classified as IPC due to the association with EPC"
                    ]
                  }
                ],
                "Invasive Carcinoma With Tubulolobular Features": [
                  {
                    "text": "This is a very rare type of BC with fewer than 20 reported cases"
                  },
                  {
                    "text": "These BCs infiltrate as interanastomosing tubules with papillary and micropapillary intratubular proliferation"
                  },
                  {
                    "text": "There is marked nuclear atypia in most cases"
                  },
                  {
                    "text": "~ 60% are triple negative BC and ~ 35% are HER2 positive"
                  }
                ],
                "Skin or Chest Wall Recurrence": [
                  {
                    "text": "Recurrent invasive BC in the skin or chest wall can have a papillary appearance and may form masses with circumscribed margins"
                  },
                  {
                    "text": "This may be due to recurrences originating in lymphatics"
                  }
                ],
                "Invasive Micropapillary Carcinoma": [
                  {
                    "text": "Consists of clusters or hollow balls of cells in clear spaces"
                  },
                  {
                    "text": "There are no true papillae with fibrovascular cores"
                  }
                ],
                "Metastatic Carcinoma": [
                  {
                    "text": "A metastasis should be considered if an in situ component is not apparent"
                  },
                  {
                    "text": "Ovary, lung, and thyroid would be the most likely primary sites with papillary morphology"
                  },
                  {
                    "text": "IHC studies can be used to determine the most likely primary site"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Micropapillary Carcinoma": {
            "name": "Invasive Micropapillary Carcinoma",
            "url": "https://app.pathprimer.com/document/b769152a-1c44-417a-ad96-c051f0f0eac6/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Invasive micropapillary carcinoma (IMPC) is a special histologic type of carcinoma showing anchorage-independent growth"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Uncommon breast cancer subtype (~ 5-10% of invasive carcinomas)"
                  },
                  {
                    "text": "Increased incidence of lymph node metastases, local recurrence, and distant metastasis"
                  },
                  {
                    "text": "40-50% of patients with IMPC present with ≥ 4 positive axillary nodesMicropapillary pattern on core needle biopsy is predictive of higher likelihood of lymph node metastasis",
                    "sub_points": [
                      "Micropapillary pattern on core needle biopsy is predictive of higher likelihood of lymph node metastasis"
                    ]
                  },
                  {
                    "text": "IMPC may have a more aggressive clinical course compared to breast cancers of no special typeSimilar overall survival, shorter recurrence-free survivalHigher likelihood of HER2 positivity compared to breast carcinomas in general",
                    "sub_points": [
                      "Similar overall survival, shorter recurrence-free survival",
                      "Higher likelihood of HER2 positivity compared to breast carcinomas in general"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Infiltrating clusters of tumor cells surrounded by spaces filled with clear (serous) fluidPeripherally located nuclei may bulge out with knobby appearance",
                    "sub_points": [
                      "Peripherally located nuclei may bulge out with knobby appearance"
                    ]
                  },
                  {
                    "text": "Micropapillary pattern may predominate or represent minor component of tumorImmunoreactivity for MUC1 at periphery of tumor cell clusters supports diagnosis",
                    "sub_points": [
                      "Immunoreactivity for MUC1 at periphery of tumor cell clusters supports diagnosis"
                    ]
                  },
                  {
                    "text": "Lymphovascular invasion is present in > 2/3Associated with increased likelihood and number of nodal metastases",
                    "sub_points": [
                      "Associated with increased likelihood and number of nodal metastases"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Mucinous carcinoma"
                  },
                  {
                    "text": "Mucinous carcinoma with micropapillary features"
                  },
                  {
                    "text": "Invasive ductal carcinoma with retraction artifact"
                  },
                  {
                    "text": "Metastatic micropapillary carcinoma (i.e., lung, ovary, bladder)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive micropapillary carcinoma (IMPC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Invasive carcinoma with a distinctive pattern of anchorage-independent growth, resulting in inverted tubule morphology"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Anchorage-Independent Growth Pattern": [
                  {
                    "text": "Anchorage to extracellular matrix via integrins is essential for the survival and proliferation of normal epithelial cells as well as many breast carcinomas (BCs)Separation from stroma triggers programmed cell death (anoikis)",
                    "sub_points": [
                      "Separation from stroma triggers programmed cell death (anoikis)"
                    ]
                  },
                  {
                    "text": "Alterations in signaling pathways allow some BCs to achieve anchorage-independent growthEnables BCs to survive in lymphatics, bloodstream, and other fluid-filled spaces",
                    "sub_points": [
                      "Enables BCs to survive in lymphatics, bloodstream, and other fluid-filled spaces"
                    ]
                  },
                  {
                    "text": "The growth pattern of IMPC is of tumor cells not attached to the surrounding stromaTumor cell clusters are seen in individual spaces surrounded by intercellular fluidThe apical aspect of the cells faces outward (inverted tubule morphology), some forming hollow balls of cells, a pattern also seen in metastatic BC in effusionsThe glycoprotein MUC1 is expressed on the apical surface facing the stroma and inhibits epithelial/stromal interactionAberrant expression of MUC1 is linked to tumor proliferation and nodal metastases",
                    "sub_points": [
                      "Tumor cell clusters are seen in individual spaces surrounded by intercellular fluid",
                      "The apical aspect of the cells faces outward (inverted tubule morphology), some forming hollow balls of cells, a pattern also seen in metastatic BC in effusions",
                      "The glycoprotein MUC1 is expressed on the apical surface facing the stroma and inhibits epithelial/stromal interactionAberrant expression of MUC1 is linked to tumor proliferation and nodal metastases",
                      "Aberrant expression of MUC1 is linked to tumor proliferation and nodal metastases"
                    ]
                  },
                  {
                    "text": "A high incidence of lymphovascular invasion (LVI), lymph node metastasis, and distant metastasis is observed for BCs arising at multiple sites showing any degree of micropapillary growth"
                  },
                  {
                    "text": "\"Micropapillary\" is used as a descriptor because the clusters of cells resemble the tips of micropapillae seen in ductal carcinoma in situ (DCIS)No true papillae are present",
                    "sub_points": [
                      "No true papillae are present"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare: ~ 5-10% of invasive BCs in large series80% show partial micropapillary patternPure IMPC is less frequent (~ 1-2%)Any amount of a micropapillary pattern confers a worse prognosis",
                    "sub_points": [
                      "80% show partial micropapillary pattern",
                      "Pure IMPC is less frequent (~ 1-2%)",
                      "Any amount of a micropapillary pattern confers a worse prognosis"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Broad range at presentation, but, overall, patients tend to be younger; mean: 55 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Reported in both females and males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most common presentation is as a palpable mass"
                  },
                  {
                    "text": "Smaller IMPCs present as mammographic masses with spiculated margins"
                  },
                  {
                    "text": "Increased incidence of axillary nodal involvement at presentation (> 2/3)Lymph node metastases occur in majority of IMPC even when < 1 cm in size",
                    "sub_points": [
                      "Lymph node metastases occur in majority of IMPC even when < 1 cm in size"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete surgical excision with clear marginsIncreased incidence of local recurrence, even after mastectomy",
                    "sub_points": [
                      "Increased incidence of local recurrence, even after mastectomy"
                    ]
                  }
                ],
                "Radiation": [
                  {
                    "text": "Postmastectomy chest wall radiation should be considered for patients with larger carcinomas"
                  },
                  {
                    "text": "Related to risk for local recurrence due to frequent LVI"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "IMPC may have a more aggressive clinical course compared to other BCs"
                  },
                  {
                    "text": "Increased incidence of local recurrence and shorter time to recurrenceRecurs in ~ 22% of patients compared to ~ 12% of patients with BCs of no special type (\"ductal\")",
                    "sub_points": [
                      "Recurs in ~ 22% of patients compared to ~ 12% of patients with BCs of no special type (\"ductal\")"
                    ]
                  },
                  {
                    "text": "Increased incidence of lymph node metastases40-50% of IMPCs present with ≥ 4 positive nodesLymph node metastases are common even with smaller tumors (< 1 cm)Higher percentage of IMPC cases (> 2/3) present with nodal metastases compared with BC of no special type (~ 1/3)Therefore, patients with IMPC are more likely to present at higher stages",
                    "sub_points": [
                      "40-50% of IMPCs present with ≥ 4 positive nodes",
                      "Lymph node metastases are common even with smaller tumors (< 1 cm)Higher percentage of IMPC cases (> 2/3) present with nodal metastases compared with BC of no special type (~ 1/3)Therefore, patients with IMPC are more likely to present at higher stages",
                      "Higher percentage of IMPC cases (> 2/3) present with nodal metastases compared with BC of no special type (~ 1/3)",
                      "Therefore, patients with IMPC are more likely to present at higher stages"
                    ]
                  },
                  {
                    "text": "Despite IMPC's higher propensity for lymph node metastasis, when matched by stage, the survival is similar to other BC types"
                  },
                  {
                    "text": "Pure IMPC displays more aggressive characteristics and is more often classified as the \"luminal-B subtype\" compared with mixed IMPC"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Does not have specific imaging findings"
                  },
                  {
                    "text": "Mass with spiculated or circumscribed borders"
                  },
                  {
                    "text": "Microcalcifications may be present"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Gross appearance is similar to other invasive BCs"
                  },
                  {
                    "text": "Typically form a solitary mass with ill-defined margins on gross examination"
                  },
                  {
                    "text": "Cut surface usually solid and white or white-grayMultifocal in ~ 30% of casesMay be related to propensity for LVI, resulting in intramammary metastasis",
                    "sub_points": [
                      "Multifocal in ~ 30% of cases",
                      "May be related to propensity for LVI, resulting in intramammary metastasis"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "0.7-10 cm (median: 2.8 cm)"
                  }
                ]
              },
              "MOLECULAR": {
                "Overview": [
                  {
                    "text": "No specific genomic changes or patterns of gene expression have been found to be unique to IMPC"
                  }
                ],
                "DNA": [
                  {
                    "text": "MutationsThe most common mutations are also found in other BCsPIK3CA,AKT1,TP53,GATA3,MAP2K4,NBPF10",
                    "sub_points": [
                      "The most common mutations are also found in other BCsPIK3CA,AKT1,TP53,GATA3,MAP2K4,NBPF10",
                      "PIK3CA,AKT1,TP53,GATA3,MAP2K4,NBPF10"
                    ]
                  },
                  {
                    "text": "Copy number changesThe overall repertoire of gene copy number changes is distinct from ER and grade-matched invasive BCAmplificationsMYC(8q24) (33%),CCND1(8%),FGFR1(17%)Gains in 8q, 17q (17p13.1 common), 20qLoss of heterozygosity6q, 8p, 13q",
                    "sub_points": [
                      "The overall repertoire of gene copy number changes is distinct from ER and grade-matched invasive BC",
                      "AmplificationsMYC(8q24) (33%),CCND1(8%),FGFR1(17%)Gains in 8q, 17q (17p13.1 common), 20q",
                      "MYC(8q24) (33%),CCND1(8%),FGFR1(17%)",
                      "Gains in 8q, 17q (17p13.1 common), 20q",
                      "Loss of heterozygosity6q, 8p, 13q",
                      "6q, 8p, 13q"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "IMPCs cluster together, indicating a common pattern of gene expressionTypically classified as luminal A or B subtype",
                    "sub_points": [
                      "Typically classified as luminal A or B subtype"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "Changes in expression of genes related to polarity, such as overexpression ofLIN7A"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "ArchitectureSmall clusters of tumor cells are present within separate clear lacunar or spheroidal spaces in stromaTumor cell clusters may be hollow without fibrovascular cores or solidApical blebs are present on the outer surface of clusters facing the stromaPeripherally located nuclei may bulge out with a knobby (hobnail) appearanceLack of cohesion between tumor cell clustersThe clusters of tumor cells are characterized by reversed polarity compared to tubules formed by adenocarcinomasApical (secretory) pole of cells is directed toward outside of cell groups (not into the central empty space)The cells are not attached to the adjacent extracellular matrixBase of cells directed toward the inner portion of cell groups or into the central empty spaceNo true papillae are presentPsammomatous calcifications present in ~ 50% of casesSpaces are usually clear (serous), but mucin can occasionally be presentThe presence of a micropapillary pattern, to any degree, increases the likelihood of LVI and nodal metastasesWHO recommends that > 90% of a BC should have a micropapillary pattern to be classified as pure IMPCLesser degrees of a micropapillary pattern should be reported, as these BCs also show a higher incidence of LVI and lymph node metastasis\"Micropapillary\" describes the similarity of the architecture to DCIS with micropapillaeThe hollow tips of micropapillae in DCIS have the same reversed polarity architecture",
                    "sub_points": [
                      "Small clusters of tumor cells are present within separate clear lacunar or spheroidal spaces in stromaTumor cell clusters may be hollow without fibrovascular cores or solidApical blebs are present on the outer surface of clusters facing the stromaPeripherally located nuclei may bulge out with a knobby (hobnail) appearanceLack of cohesion between tumor cell clusters",
                      "Tumor cell clusters may be hollow without fibrovascular cores or solid",
                      "Apical blebs are present on the outer surface of clusters facing the stroma",
                      "Peripherally located nuclei may bulge out with a knobby (hobnail) appearance",
                      "Lack of cohesion between tumor cell clusters",
                      "The clusters of tumor cells are characterized by reversed polarity compared to tubules formed by adenocarcinomasApical (secretory) pole of cells is directed toward outside of cell groups (not into the central empty space)The cells are not attached to the adjacent extracellular matrixBase of cells directed toward the inner portion of cell groups or into the central empty spaceNo true papillae are present",
                      "Apical (secretory) pole of cells is directed toward outside of cell groups (not into the central empty space)The cells are not attached to the adjacent extracellular matrix",
                      "The cells are not attached to the adjacent extracellular matrix",
                      "Base of cells directed toward the inner portion of cell groups or into the central empty space",
                      "No true papillae are present",
                      "Psammomatous calcifications present in ~ 50% of cases",
                      "Spaces are usually clear (serous), but mucin can occasionally be present",
                      "The presence of a micropapillary pattern, to any degree, increases the likelihood of LVI and nodal metastases",
                      "WHO recommends that > 90% of a BC should have a micropapillary pattern to be classified as pure IMPCLesser degrees of a micropapillary pattern should be reported, as these BCs also show a higher incidence of LVI and lymph node metastasis",
                      "Lesser degrees of a micropapillary pattern should be reported, as these BCs also show a higher incidence of LVI and lymph node metastasis",
                      "\"Micropapillary\" describes the similarity of the architecture to DCIS with micropapillaeThe hollow tips of micropapillae in DCIS have the same reversed polarity architecture",
                      "The hollow tips of micropapillae in DCIS have the same reversed polarity architecture"
                    ]
                  },
                  {
                    "text": "Cytologic featuresNeoplastic cells are predominantly polygonal in shape or pleomorphicFrequently intermediate to high nuclear gradeNuclear pleomorphism, hyperchromasia, and macronucleoli typicalAbundant finely granular, eosinophilic, or vacuolated cytoplasmDistinct cell bordersCan have an apocrine appearanceRare IMPCs are associated with osteoclast-like giant cells",
                    "sub_points": [
                      "Neoplastic cells are predominantly polygonal in shape or pleomorphicFrequently intermediate to high nuclear gradeNuclear pleomorphism, hyperchromasia, and macronucleoli typicalAbundant finely granular, eosinophilic, or vacuolated cytoplasmDistinct cell borders",
                      "Frequently intermediate to high nuclear grade",
                      "Nuclear pleomorphism, hyperchromasia, and macronucleoli typical",
                      "Abundant finely granular, eosinophilic, or vacuolated cytoplasm",
                      "Distinct cell borders",
                      "Can have an apocrine appearance",
                      "Rare IMPCs are associated with osteoclast-like giant cells"
                    ]
                  },
                  {
                    "text": "MucinIn typical IMPC, the cell spaces are filled with clear (\"serous\") fluidMucin can be seen in 3 settingsFocal mucin in a typical IMPCInvasive mucinous micropapillary carcinoma (IMMC) in which the entire carcinoma consists of abundant extracellular mucin with a prominent component of tumor cells having reversed polarityCarcinomas with mixed features of IMPC and IMMC",
                    "sub_points": [
                      "In typical IMPC, the cell spaces are filled with clear (\"serous\") fluid",
                      "Mucin can be seen in 3 settingsFocal mucin in a typical IMPCInvasive mucinous micropapillary carcinoma (IMMC) in which the entire carcinoma consists of abundant extracellular mucin with a prominent component of tumor cells having reversed polarityCarcinomas with mixed features of IMPC and IMMC",
                      "Focal mucin in a typical IMPC",
                      "Invasive mucinous micropapillary carcinoma (IMMC) in which the entire carcinoma consists of abundant extracellular mucin with a prominent component of tumor cells having reversed polarity",
                      "Carcinomas with mixed features of IMPC and IMMC"
                    ]
                  },
                  {
                    "text": "GradingTumor cell clusters with a central empty space (\"inverted tubules\") are considered glandular (acinar)/tubule formation in the Nottingham grading system",
                    "sub_points": [
                      "Tumor cell clusters with a central empty space (\"inverted tubules\") are considered glandular (acinar)/tubule formation in the Nottingham grading system"
                    ]
                  },
                  {
                    "text": "Ductal carcinoma in situ (DCIS)DCIS may be present in surrounding tissueAssociated DCIS often has high nuclear gradeIMPC can be associated with any architectural type of DCISThere is not a specific association with micropapillary DCIS",
                    "sub_points": [
                      "DCIS may be present in surrounding tissueAssociated DCIS often has high nuclear grade",
                      "Associated DCIS often has high nuclear grade",
                      "IMPC can be associated with any architectural type of DCISThere is not a specific association with micropapillary DCIS",
                      "There is not a specific association with micropapillary DCIS"
                    ]
                  },
                  {
                    "text": "Lymphovascular invasion (LVI)Common (> 2/3 of cases)Associated with increased incidence of nodal metastasesCan be difficult to distinguish from primary carcinomaInvolved lymphatics should be lined by endothelial cells, be outside the area of IMPC, and preferably associated with blood vesselsThe micropapillary pattern is usually seen in tumor that is present in lymphatics and lymph nodes",
                    "sub_points": [
                      "Common (> 2/3 of cases)Associated with increased incidence of nodal metastases",
                      "Associated with increased incidence of nodal metastases",
                      "Can be difficult to distinguish from primary carcinoma",
                      "Involved lymphatics should be lined by endothelial cells, be outside the area of IMPC, and preferably associated with blood vessels",
                      "The micropapillary pattern is usually seen in tumor that is present in lymphatics and lymph nodes"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "A micropapillary component present on core biopsy should be included in diagnosisIncreases likelihood of lymph node metastasis",
                    "sub_points": [
                      "Increases likelihood of lymph node metastasis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "MUC1MUC1 is a glycoprotein found at the apical portion of epithelial cells, induces tumor cell detachment from matrixEpithelial membrane antigen (EMA) is an epitope identified by antibodies, such as E29, and recognizes all forms of MUC1Other MUC1 antibodies recognize hypoglycosylated forms of MUC1 that are typically associated with cancersMUC1 antibodies are helpful to confirm a pattern of reversed polarity to distinguish IMPC from BCs with retraction artifactMUC1 is positive on the stromal-facing portion of tumor cells, highlighting the location of the apical portion of the cells",
                    "sub_points": [
                      "MUC1 is a glycoprotein found at the apical portion of epithelial cells, induces tumor cell detachment from matrixEpithelial membrane antigen (EMA) is an epitope identified by antibodies, such as E29, and recognizes all forms of MUC1Other MUC1 antibodies recognize hypoglycosylated forms of MUC1 that are typically associated with cancers",
                      "Epithelial membrane antigen (EMA) is an epitope identified by antibodies, such as E29, and recognizes all forms of MUC1",
                      "Other MUC1 antibodies recognize hypoglycosylated forms of MUC1 that are typically associated with cancers",
                      "MUC1 antibodies are helpful to confirm a pattern of reversed polarity to distinguish IMPC from BCs with retraction artifactMUC1 is positive on the stromal-facing portion of tumor cells, highlighting the location of the apical portion of the cells",
                      "MUC1 is positive on the stromal-facing portion of tumor cells, highlighting the location of the apical portion of the cells"
                    ]
                  },
                  {
                    "text": "E-cadherin and p120Positive in a basolateral patternThe apical portion of the cells is negativeThe pattern is a \"mirror image\" of that seen with MUC1 and confirms a pattern of reversed polarity",
                    "sub_points": [
                      "Positive in a basolateral pattern",
                      "The apical portion of the cells is negative",
                      "The pattern is a \"mirror image\" of that seen with MUC1 and confirms a pattern of reversed polarity"
                    ]
                  },
                  {
                    "text": "Hormone receptorsER expression (~ 80-90%), PR expression (~ 50-85%)",
                    "sub_points": [
                      "ER expression (~ 80-90%), PR expression (~ 50-85%)"
                    ]
                  },
                  {
                    "text": "HER2Overexpression in 40-50% of cases, as confirmed by in situ hybridizationMajority of cancers have a basolateral membrane staining pattern with sparing of the apical surfaceA positive 3+ result by IHC requires complete membrane staining, which would rarely be seen in IMPCModerate to intense partial membrane staining should trigger reflexERBB2(HER2) ISH analysisIntense basolateral membrane staining is highly correlated withERBB2(HER2) gene amplification",
                    "sub_points": [
                      "Overexpression in 40-50% of cases, as confirmed by in situ hybridization",
                      "Majority of cancers have a basolateral membrane staining pattern with sparing of the apical surfaceA positive 3+ result by IHC requires complete membrane staining, which would rarely be seen in IMPCModerate to intense partial membrane staining should trigger reflexERBB2(HER2) ISH analysisIntense basolateral membrane staining is highly correlated withERBB2(HER2) gene amplification",
                      "A positive 3+ result by IHC requires complete membrane staining, which would rarely be seen in IMPC",
                      "Moderate to intense partial membrane staining should trigger reflexERBB2(HER2) ISH analysis",
                      "Intense basolateral membrane staining is highly correlated withERBB2(HER2) gene amplification"
                    ]
                  },
                  {
                    "text": "Surrogate biologic types\"Luminal\" [ER(+)/HER2(-)]: 75%\"Luminal/HER2\" [ER(+)/HER2(+)]: 15%HER2 [ER(-)/HER2(+)]: 5%Triple negative BC (TNBC or basal-like) [ER(-)/HER2(-)]: 5%",
                    "sub_points": [
                      "\"Luminal\" [ER(+)/HER2(-)]: 75%",
                      "\"Luminal/HER2\" [ER(+)/HER2(+)]: 15%",
                      "HER2 [ER(-)/HER2(+)]: 5%",
                      "Triple negative BC (TNBC or basal-like) [ER(-)/HER2(-)]: 5%"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mucinous Carcinoma (MC)": [
                  {
                    "text": "MCs consist of clusters of tumor cells growing in abundant extracellular mucinForm circumscribed masses with expansile bordersIn contrast, IMPC involves multiple separate empty-appearing spaces filled with clear (serous) fluid",
                    "sub_points": [
                      "Form circumscribed masses with expansile borders",
                      "In contrast, IMPC involves multiple separate empty-appearing spaces filled with clear (serous) fluid"
                    ]
                  },
                  {
                    "text": "Tumor cell clusters have a mixed pattern of cell polarity, as shown morphologically and by IHC for MUC1Smooth rather than serrated outer bordersLumina within clustersMUC1 in ~ 80% of MCs shows mixed staining pattern of cytoplasm and membranesApical staining is present in ~ 20% in the absence of micropapillary morphologyThese cancers are usually hypocellular with low nuclear grade and are classified as MCIt is important to recognize that the majority of MCs do not have micropapillary features",
                    "sub_points": [
                      "Smooth rather than serrated outer borders",
                      "Lumina within clusters",
                      "MUC1 in ~ 80% of MCs shows mixed staining pattern of cytoplasm and membranesApical staining is present in ~ 20% in the absence of micropapillary morphologyThese cancers are usually hypocellular with low nuclear grade and are classified as MC",
                      "Apical staining is present in ~ 20% in the absence of micropapillary morphology",
                      "These cancers are usually hypocellular with low nuclear grade and are classified as MC",
                      "It is important to recognize that the majority of MCs do not have micropapillary features"
                    ]
                  },
                  {
                    "text": "Tumor features are generally favorableGrade 1 or 2> 90% ER and PR (+)< 5% HER2(+)LVI and lymph node metastasis uncommon",
                    "sub_points": [
                      "Grade 1 or 2",
                      "> 90% ER and PR (+)",
                      "< 5% HER2(+)",
                      "LVI and lymph node metastasis uncommon"
                    ]
                  }
                ],
                "Invasive Mucinous Micropapillary Carcinoma (IMMC)": [
                  {
                    "text": "Some BCs show intermediate features between IMPC and MC in which numerous cell clusters with reversed polarity are seen in a large area of contiguous extracellular mucin~ 20% of MCs have micropapillary features",
                    "sub_points": [
                      "~ 20% of MCs have micropapillary features"
                    ]
                  },
                  {
                    "text": "Different criteria have been proposed for the extent of the micropapillary pattern required for a designation as IMMCA specific percentage has not been defined, but > 50% of tumor cell clusters with reversed polarity by morphology and IHC has been suggested to identify IMMCs with a poorer prognosis",
                    "sub_points": [
                      "A specific percentage has not been defined, but > 50% of tumor cell clusters with reversed polarity by morphology and IHC has been suggested to identify IMMCs with a poorer prognosis"
                    ]
                  },
                  {
                    "text": "Grade and receptor positivity are intermediate between IMPC and MC~ 90% are ER(+)~ 10-30% HER2(+)Majority are grade 2 or grade 3",
                    "sub_points": [
                      "~ 90% are ER(+)",
                      "~ 10-30% HER2(+)",
                      "Majority are grade 2 or grade 3"
                    ]
                  },
                  {
                    "text": "Histologic features are intermediate between MC and IMPCLVI in ~ 25-50% (~ 10% in MC and > 2/3 in IMPC)Lymph node metastases in 30-45% (~ 20% in MC and > 2/3 in IMPC)",
                    "sub_points": [
                      "LVI in ~ 25-50% (~ 10% in MC and > 2/3 in IMPC)",
                      "Lymph node metastases in 30-45% (~ 20% in MC and > 2/3 in IMPC)"
                    ]
                  }
                ],
                "Invasive Carcinoma With Tissue Retraction Artifact": [
                  {
                    "text": "Retraction artifact associated with poor tissue preservation"
                  },
                  {
                    "text": "Cell nests do not have an inverted polarity patternSpaces within cell clusters are luminal spacesIHC for EMA or MUC1 can be helpful to demonstrate polarization of cells; central lumina is positive for these markers",
                    "sub_points": [
                      "Spaces within cell clusters are luminal spaces",
                      "IHC for EMA or MUC1 can be helpful to demonstrate polarization of cells; central lumina is positive for these markers"
                    ]
                  },
                  {
                    "text": "In one study, retraction was poor prognostic factor, suggesting that it may be due to significant altered carcinoma/stromal relationship"
                  }
                ],
                "Metastatic Micropapillary Carcinoma From Other Sites": [
                  {
                    "text": "Micropapillary carcinomas from bladder, lung, and ovary (serous) carcinoma have similar morphology"
                  },
                  {
                    "text": "A metastasis from another site should be considered when DCIS is absentAll express MUC1 on the surface of cell clusters",
                    "sub_points": [
                      "All express MUC1 on the surface of cell clusters"
                    ]
                  },
                  {
                    "text": "Correlation with clinical history and IHC evaluation may be needed to determine diagnosis"
                  },
                  {
                    "text": "Micropapillary carcinomas have site-specific markersLung IMPC: TTF-1(+) (100%), ER(+) (17%), negative for other markersBladder IMPC: Uroplakin (+) (92%), CK20(+) (54%), negative for other markersOvary IMPC: PAX8(+) (100%), ER(+) (92%), WT1(+) (91%), negative for other markersER expression cannot be used to distinguish breast from ovary primary sitesPsammomatous calcifications present in both ovarian and BCsBreast IMPC: ER(+) (88%), mammaglobin (+) (56%), WT1(+) (25%, usually only focally), negative for other markers",
                    "sub_points": [
                      "Lung IMPC: TTF-1(+) (100%), ER(+) (17%), negative for other markers",
                      "Bladder IMPC: Uroplakin (+) (92%), CK20(+) (54%), negative for other markers",
                      "Ovary IMPC: PAX8(+) (100%), ER(+) (92%), WT1(+) (91%), negative for other markersER expression cannot be used to distinguish breast from ovary primary sitesPsammomatous calcifications present in both ovarian and BCs",
                      "ER expression cannot be used to distinguish breast from ovary primary sites",
                      "Psammomatous calcifications present in both ovarian and BCs",
                      "Breast IMPC: ER(+) (88%), mammaglobin (+) (56%), WT1(+) (25%, usually only focally), negative for other markers"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "IMPC is important to recognize due to increased likelihood of lymph node metastases compared to other histologic types of BCs"
                  },
                  {
                    "text": "Must be distinguished from retraction artifact"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Invasive carcinomas with micropapillary component are reported according to College of American Pathologists Invasive Breast Cancer ProtocolReport percentage of micropapillary component for mixed tumors",
                    "sub_points": [
                      "Report percentage of micropapillary component for mixed tumors"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Metaplastic Breast Carcinoma": {
            "name": "Metaplastic Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/a7021458-ce63-4125-ac9c-a47c13c9b8ec/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Classification": [
                  {
                    "text": "Metaplastic breast carcinoma (MBC) encompasses a diverse group of carcinomas that consist entirely, or in part, of cells with squamous, spindle cell, or mesenchymal/matrix-producing differentiation"
                  },
                  {
                    "text": "Major patterns includeMetaplastic carcinoma with heterologous mesenchymal differentiation (MCHMD), spindle cell carcinoma (SpCC), squamous cell carcinoma (SqCC), high- and low-grade adenosquamous carcinoma (HGASC and LGASC), and fibromatosis-like metaplastic carcinoma (FLMC) as well as mixed patterns",
                    "sub_points": [
                      "Metaplastic carcinoma with heterologous mesenchymal differentiation (MCHMD), spindle cell carcinoma (SpCC), squamous cell carcinoma (SqCC), high- and low-grade adenosquamous carcinoma (HGASC and LGASC), and fibromatosis-like metaplastic carcinoma (FLMC) as well as mixed patterns"
                    ]
                  },
                  {
                    "text": "Must show at least focal evidence of origin as an epithelial malignancy by morphology or by expression of keratins and p63"
                  },
                  {
                    "text": "Majority are negative for hormone receptors and HER2 [triple negative breast carcinoma (TNBC)]"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "MBCs are uncommon (< 1% of all breast cancers)"
                  },
                  {
                    "text": "Usually present as a large palpable massLymph node metastases are less frequent compared with other carcinomas of similar sizeMetastases may preferentially be via blood vessels",
                    "sub_points": [
                      "Lymph node metastases are less frequent compared with other carcinomas of similar size",
                      "Metastases may preferentially be via blood vessels"
                    ]
                  },
                  {
                    "text": "Prognosis is generally poor, except for FLMC and LGASCTypically have a low response to chemotherapy",
                    "sub_points": [
                      "Typically have a low response to chemotherapy"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "SqCC of skin"
                  },
                  {
                    "text": "Phyllodes tumor"
                  },
                  {
                    "text": "Sarcoma"
                  },
                  {
                    "text": "Epithelial/myoepithelial tumors (including adenoid cystic carcinoma and pleomorphic adenoma)"
                  },
                  {
                    "text": "Fibromatosis"
                  },
                  {
                    "text": "Sclerosing adenosis and radial sclerosing lesions"
                  },
                  {
                    "text": "Syringomatous tumor of nipple"
                  },
                  {
                    "text": "Tubular carcinoma"
                  },
                  {
                    "text": "Metastasis to the breast"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Metaplastic breast carcinoma (MBC)"
                  },
                  {
                    "text": "Metaplastic carcinoma with heterologous mesenchymal differentiation (MCHMD)"
                  },
                  {
                    "text": "Spindle cell carcinoma (SpCC)"
                  },
                  {
                    "text": "Squamous cell carcinoma (SqCC)"
                  },
                  {
                    "text": "High-grade adenosquamous carcinoma (HGASC)"
                  },
                  {
                    "text": "Low-grade adenosquamous carcinoma (LGASC)"
                  },
                  {
                    "text": "Fibromatosis-like metaplastic carcinoma (FLMC)"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "MBC encompasses a diverse group of carcinomas that consist entirely, or in part, of cells with squamous, spindle cell, or mesenchymal/matrix-producing differentiationThese carcinomas may be composed primarily of metaplastic elements or a mixture of metaplastic areas and adenocarcinoma",
                    "sub_points": [
                      "These carcinomas may be composed primarily of metaplastic elements or a mixture of metaplastic areas and adenocarcinoma"
                    ]
                  },
                  {
                    "text": "All MBCs show at least focal evidence of origin as an epithelial malignancy"
                  },
                  {
                    "text": "Immunohistochemistry (IHC) is an essential tool for achieving the correct diagnosis, defining the histologic type, and differentiating MBC from other tumors with similar morphologyIf morphologic features of carcinoma and ductal carcinoma in situ (DCIS) are not present, expression of keratins (CKs) &/or p63 are important to establish an origin from epithelial cells",
                    "sub_points": [
                      "If morphologic features of carcinoma and ductal carcinoma in situ (DCIS) are not present, expression of keratins (CKs) &/or p63 are important to establish an origin from epithelial cells"
                    ]
                  },
                  {
                    "text": "\"Metaplasia\" in reference to MBCs describes tumor cells with differentiation not seen in the normal breast, including the following typesEpithelial spindle cellsSquamous cellsRhabdomyoid, neuroglial, or melanocytic cells (very rare)Cells forming bone or cartilageCells producing matrixIn some cases, it can be uncertain whether matrix is from mesenchymal differentiation (bone or cartilage) or from myoepithelial differentiation (basement membrane-like material)~ 1/3-2/3 of MBCs express markers typical of myoepithelial cells, including p63, smooth muscle actin, P-cadherin, napsin, &/or CD10",
                    "sub_points": [
                      "Epithelial spindle cells",
                      "Squamous cells",
                      "Rhabdomyoid, neuroglial, or melanocytic cells (very rare)",
                      "Cells forming bone or cartilage",
                      "Cells producing matrixIn some cases, it can be uncertain whether matrix is from mesenchymal differentiation (bone or cartilage) or from myoepithelial differentiation (basement membrane-like material)~ 1/3-2/3 of MBCs express markers typical of myoepithelial cells, including p63, smooth muscle actin, P-cadherin, napsin, &/or CD10",
                      "In some cases, it can be uncertain whether matrix is from mesenchymal differentiation (bone or cartilage) or from myoepithelial differentiation (basement membrane-like material)",
                      "~ 1/3-2/3 of MBCs express markers typical of myoepithelial cells, including p63, smooth muscle actin, P-cadherin, napsin, &/or CD10"
                    ]
                  },
                  {
                    "text": "The World Health Organization (WHO) recognizes 6 main patterns of MBC, which can be classified according to their different componentsPure epithelial pattern: SqCC, HGASC, LGASCPure sarcomatoid pattern: MCHMD, SpCC, FLMCNote that \"sarcomatoid\" is not recommended as a diagnostic term by WHO, as it can create confusion with a diagnosis of a true sarcomaMixed pattern: MBCs with both epithelial and sarcomatoid patterns",
                    "sub_points": [
                      "Pure epithelial pattern: SqCC, HGASC, LGASC",
                      "Pure sarcomatoid pattern: MCHMD, SpCC, FLMCNote that \"sarcomatoid\" is not recommended as a diagnostic term by WHO, as it can create confusion with a diagnosis of a true sarcoma",
                      "Note that \"sarcomatoid\" is not recommended as a diagnostic term by WHO, as it can create confusion with a diagnosis of a true sarcoma",
                      "Mixed pattern: MBCs with both epithelial and sarcomatoid patterns"
                    ]
                  },
                  {
                    "text": "MBCs are predominantly classified by genomic expression profiling (RNA) as basal-like and by protein expression as triple negative breast carcinoma (TNBC)"
                  },
                  {
                    "text": "MBCs are biologically and histologically diverse and have different patterns of clinical behaviorThe genomic changes found in different types of MBC likely correlate with these differences",
                    "sub_points": [
                      "The genomic changes found in different types of MBC likely correlate with these differences"
                    ]
                  },
                  {
                    "text": "For MBCs with mixed patterns, the areas of epithelial morphology and the areas with a metaplastic appearance have the same clonal originIn some cases, the metaplastic areas have additional mutationsIn MBCs in which both components are very similar genomically, epigenetic changes may play a role in the different morphology",
                    "sub_points": [
                      "In some cases, the metaplastic areas have additional mutations",
                      "In MBCs in which both components are very similar genomically, epigenetic changes may play a role in the different morphology"
                    ]
                  },
                  {
                    "text": "Although the majority of MBCs have aggressive behavior and poor prognosis, this group also includes types with a very favorable prognosis"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare; < 1% of breast carcinomas (BCs)"
                  }
                ],
                "Age": [
                  {
                    "text": "MBC: Similar to other types of invasive BC"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Higher grade types of MBC (SpCC, SqCC, HGASC, MCHMD): Majority present as a large palpable mass that can be associated with rapid growth"
                  },
                  {
                    "text": "LGASC and FLMC: Majority present as palpable masses, but some are detected as smaller masses on screening mammography"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Limited prognostic data are available due to the rarity of MBCs"
                  },
                  {
                    "text": "Axillary lymph node metastases are very uncommon in MBC compared with other BCs of similar sizeMetastatic route may be primarily hematogenous to lung, brain, and liver",
                    "sub_points": [
                      "Metastatic route may be primarily hematogenous to lung, brain, and liver"
                    ]
                  },
                  {
                    "text": "Higher grade types of MBC have a significantly worse prognosis than non-MBC in some studiesMay be related to higher stage at presentation> 90% MBCs are TNBCs; thus, hormonal or HER2-targeted therapy is not applicableRare HER2(+) MBC (~ 5% of MBC) have a better prognosis than other MBCsMBC may be more resistant to chemotherapy than other types of BCsOnly 10-15% have a pathologic complete response compared to ~ 30-40% for other TNBCsMBC is the most common type of TNBC to progress during treatment",
                    "sub_points": [
                      "May be related to higher stage at presentation",
                      "> 90% MBCs are TNBCs; thus, hormonal or HER2-targeted therapy is not applicableRare HER2(+) MBC (~ 5% of MBC) have a better prognosis than other MBCs",
                      "Rare HER2(+) MBC (~ 5% of MBC) have a better prognosis than other MBCs",
                      "MBC may be more resistant to chemotherapy than other types of BCsOnly 10-15% have a pathologic complete response compared to ~ 30-40% for other TNBCsMBC is the most common type of TNBC to progress during treatment",
                      "Only 10-15% have a pathologic complete response compared to ~ 30-40% for other TNBCs",
                      "MBC is the most common type of TNBC to progress during treatment"
                    ]
                  },
                  {
                    "text": "FLMC and LGASC have a more favorable prognosisThere is a low incidence of lymph node involvement and reports of distant metastases are rareMay be associated with very large tumors (> 4 cm)However, these are rare carcinomas, and the number of cases with follow-up is relatively small",
                    "sub_points": [
                      "There is a low incidence of lymph node involvement and reports of distant metastases are rareMay be associated with very large tumors (> 4 cm)",
                      "May be associated with very large tumors (> 4 cm)",
                      "However, these are rare carcinomas, and the number of cases with follow-up is relatively small"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Higher grade MBCLarge lobulated or irregular massUsually partially circumscribed and partially indistinct marginsCalcifications may be presentCan be prominent when associated with extracellular matrix production or ossification",
                    "sub_points": [
                      "Large lobulated or irregular massUsually partially circumscribed and partially indistinct margins",
                      "Usually partially circumscribed and partially indistinct margins",
                      "Calcifications may be presentCan be prominent when associated with extracellular matrix production or ossification",
                      "Can be prominent when associated with extracellular matrix production or ossification"
                    ]
                  },
                  {
                    "text": "FLMC and LGASC: May present as smaller masses on mammographic screeningCalcifications may be present, either in stroma or in sclerosing lesions associated with LGASC",
                    "sub_points": [
                      "Calcifications may be present, either in stroma or in sclerosing lesions associated with LGASC"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Higher grade MBC: Tend to be larger compared with other types of BCsMean: 2.5-4.5 cm (range: 1 cm to > 10 cm)",
                    "sub_points": [
                      "Mean: 2.5-4.5 cm (range: 1 cm to > 10 cm)"
                    ]
                  },
                  {
                    "text": "FLMC and LGASC: Tend to be smaller with a typical size of ~ 2-3 cm"
                  }
                ]
              },
              "MOLECULAR": {
                "Overview": [
                  {
                    "text": "MBC is genetically complex, and the observed changes vary for the different histologic types"
                  },
                  {
                    "text": "Genomic studies demonstrate that histologically distinct components of MBC are clonally relatedMBC is also clonally related to associated DCIS",
                    "sub_points": [
                      "MBC is also clonally related to associated DCIS"
                    ]
                  }
                ],
                "Higher Grade Metaplastic Breast Carcinoma (Not LGASC or FLMC)": [
                  {
                    "text": "MutationsMBC shows numerous mutations involving multiple pathwaysTP53is the most frequently mutated gene (~ 60-70%)Not found in SpCCsP13K/AKT pathway genes [PIK3CA(~ 30-60%),PIK3R1(~ 10%),PTEN(~ 11-17%),AKT1(~ 5%)]High frequency of mutation, amplification, and activationMost common in SpCCsNot seen in MBC with chondroid matrixMore common in MBC (~ 57%) than TNBC (~ 22%)PIK3CAmutations are only found in ~ 8% of TNBCWnt pathway genes [FAT1(~ 11%),CCN6(WISP3)]More common in MBC (~ 51%) than TNBC (~ 28%)Matrix-producing MBCs are more likely to harbor Wnt pathway alterationsChromatin-remodeling genes [ARID1A(~ 11%),KMT2C]MAPK pathway genes (NF1,KRAS,NRAS)TERTpromoter, related to telomerase activation and WNT pathway activation (~ 25-50%)More common in SpCCs and SqCCsNF1(~ 15%)6 cases of MBC in patients with neurofibromatosis have been reportedRB1-inactivating mutations",
                    "sub_points": [
                      "MBC shows numerous mutations involving multiple pathways",
                      "TP53is the most frequently mutated gene (~ 60-70%)Not found in SpCCs",
                      "Not found in SpCCs",
                      "P13K/AKT pathway genes [PIK3CA(~ 30-60%),PIK3R1(~ 10%),PTEN(~ 11-17%),AKT1(~ 5%)]High frequency of mutation, amplification, and activationMost common in SpCCsNot seen in MBC with chondroid matrixMore common in MBC (~ 57%) than TNBC (~ 22%)PIK3CAmutations are only found in ~ 8% of TNBC",
                      "High frequency of mutation, amplification, and activation",
                      "Most common in SpCCs",
                      "Not seen in MBC with chondroid matrix",
                      "More common in MBC (~ 57%) than TNBC (~ 22%)PIK3CAmutations are only found in ~ 8% of TNBC",
                      "PIK3CAmutations are only found in ~ 8% of TNBC",
                      "Wnt pathway genes [FAT1(~ 11%),CCN6(WISP3)]More common in MBC (~ 51%) than TNBC (~ 28%)Matrix-producing MBCs are more likely to harbor Wnt pathway alterations",
                      "More common in MBC (~ 51%) than TNBC (~ 28%)",
                      "Matrix-producing MBCs are more likely to harbor Wnt pathway alterations",
                      "Chromatin-remodeling genes [ARID1A(~ 11%),KMT2C]",
                      "MAPK pathway genes (NF1,KRAS,NRAS)",
                      "TERTpromoter, related to telomerase activation and WNT pathway activation (~ 25-50%)More common in SpCCs and SqCCs",
                      "More common in SpCCs and SqCCs",
                      "NF1(~ 15%)6 cases of MBC in patients with neurofibromatosis have been reported",
                      "6 cases of MBC in patients with neurofibromatosis have been reported",
                      "RB1-inactivating mutations"
                    ]
                  },
                  {
                    "text": "Copy number alterationsMBC has a pattern of copy number gains and losses distinct from basal-like BCs as well as other groupsGains of 1p/5p and loss of 3q most commonCDKN2A/CDKN2BandPTENloss reported in subgroupEGFR: Amplifications and polysomy (10-25% of cases)These changes are more prevalent in SpCCs and SqCCsMYCis most common amplified gene followed byEGFR",
                    "sub_points": [
                      "MBC has a pattern of copy number gains and losses distinct from basal-like BCs as well as other groupsGains of 1p/5p and loss of 3q most common",
                      "Gains of 1p/5p and loss of 3q most common",
                      "CDKN2A/CDKN2BandPTENloss reported in subgroup",
                      "EGFR: Amplifications and polysomy (10-25% of cases)These changes are more prevalent in SpCCs and SqCCs",
                      "These changes are more prevalent in SpCCs and SqCCs",
                      "MYCis most common amplified gene followed byEGFR"
                    ]
                  }
                ],
                "Low-Grade Adenosquamous Carcinoma (LGASC)": [
                  {
                    "text": "MutationsPIK3CAmutations in ~ 50%Kinase (H1047L and H1047R) and helical (E542K) domain missense mutations reportedNoTP53mutations reported",
                    "sub_points": [
                      "PIK3CAmutations in ~ 50%Kinase (H1047L and H1047R) and helical (E542K) domain missense mutations reported",
                      "Kinase (H1047L and H1047R) and helical (E542K) domain missense mutations reported",
                      "NoTP53mutations reported"
                    ]
                  },
                  {
                    "text": "Copy number alterations2 LGASCs analyzed showed complex copy number changes, including amplificationsEGFRamplification reported in a single case",
                    "sub_points": [
                      "2 LGASCs analyzed showed complex copy number changes, including amplifications",
                      "EGFRamplification reported in a single case"
                    ]
                  }
                ],
                "Fibromatosis-Like Metaplastic Carcinoma (FLMC)": [
                  {
                    "text": "Compared to other MBCs, there is low genomic instability and noTP53mutations"
                  },
                  {
                    "text": "TERTpromoter mutations in ~ 75%"
                  },
                  {
                    "text": "PIK3CAmutations in ~ 75%"
                  },
                  {
                    "text": "CDKN2A/CDKN2Bloss or mutation in ~ 60%"
                  }
                ],
                "Gene Expression Profiling (mRNA)": [
                  {
                    "text": "MBC has a distinctive molecular signature, separating it from other molecular classes of BCsMajority demonstrate a transcriptional profile similar to, but distinct from, basal-like BCsTranscriptional profile suggests cells undergoing epithelial-to-mesenchymal transition (EMT)Upregulation of genes related to stem cells and EMTProfile is most similar to claudin-low group of BCs (similar to so-called cancer stem cells)Claudin-low tumors show features similar to so-called cancer stem cells",
                    "sub_points": [
                      "Majority demonstrate a transcriptional profile similar to, but distinct from, basal-like BCsTranscriptional profile suggests cells undergoing epithelial-to-mesenchymal transition (EMT)Upregulation of genes related to stem cells and EMTProfile is most similar to claudin-low group of BCs (similar to so-called cancer stem cells)Claudin-low tumors show features similar to so-called cancer stem cells",
                      "Transcriptional profile suggests cells undergoing epithelial-to-mesenchymal transition (EMT)",
                      "Upregulation of genes related to stem cells and EMT",
                      "Profile is most similar to claudin-low group of BCs (similar to so-called cancer stem cells)",
                      "Claudin-low tumors show features similar to so-called cancer stem cells"
                    ]
                  },
                  {
                    "text": "Discriminator genes for MBC fall into several groupsDecreased expression of genes related to cell adhesion and increased expression of E-cadherin repressorsThese genes are hypothesized to play role in EMTE-cadherin can be present by IHC in epithelial component and absent in matrix-producing component of MBCDownregulation of genes related to maintaining epithelial phenotypeIncreased expression of genes involved in extracellular matrix formationIncreased expression of genes thought to be associated with stem cell-like patterns",
                    "sub_points": [
                      "Decreased expression of genes related to cell adhesion and increased expression of E-cadherin repressorsThese genes are hypothesized to play role in EMTE-cadherin can be present by IHC in epithelial component and absent in matrix-producing component of MBC",
                      "These genes are hypothesized to play role in EMT",
                      "E-cadherin can be present by IHC in epithelial component and absent in matrix-producing component of MBC",
                      "Downregulation of genes related to maintaining epithelial phenotype",
                      "Increased expression of genes involved in extracellular matrix formation",
                      "Increased expression of genes thought to be associated with stem cell-like patterns"
                    ]
                  },
                  {
                    "text": "Many MBCs are subclassified under the mesenchymal-like molecular subtype of TNBC"
                  },
                  {
                    "text": "Expression pattern for MBC is similar to that of residual BC not responding to chemotherapyMay indicate gene expression pattern associated with chemoresistance",
                    "sub_points": [
                      "May indicate gene expression pattern associated with chemoresistance"
                    ]
                  }
                ],
                "Tumor-Immune Microenvironment": [
                  {
                    "text": "MBCs show a lower rate of response to chemotherapy compared with other forms of TNBCStudies on the tumor immune microenvironment have revealed potential novel therapeutic approaches",
                    "sub_points": [
                      "Studies on the tumor immune microenvironment have revealed potential novel therapeutic approaches"
                    ]
                  },
                  {
                    "text": "MBCs demonstrate intermediate to high stromal tumor-infiltrating lymphocytes (TILs) (~ 34%)Intermediate to high TILs highest for SqCCs",
                    "sub_points": [
                      "Intermediate to high TILs highest for SqCCs"
                    ]
                  },
                  {
                    "text": "MBCs tend to have higher PD-L1 expression than TNBCs of no special typeRate of immune cell PD-L1 expression higher than tumor cell PD-L1 expressionTumor cells exhibit stem-like features that enable immune evasionSuggest tumor cell vulnerability to immune therapy",
                    "sub_points": [
                      "Rate of immune cell PD-L1 expression higher than tumor cell PD-L1 expression",
                      "Tumor cells exhibit stem-like features that enable immune evasion",
                      "Suggest tumor cell vulnerability to immune therapy"
                    ]
                  },
                  {
                    "text": "Immune checkpoint blockade may be effective therapy"
                  },
                  {
                    "text": "Results obtained in the KEYNOTE 522 clinical trial lead to the approval of pembrolizumab for treatment of high-risk early-stage TNBC, including MBC"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "MBC encompasses a very heterogeneous group of BCs"
                  },
                  {
                    "text": "The majority are grade 3 (~ 90%)"
                  },
                  {
                    "text": "WHO classification includes 6 types of MBC, but many show mixed or unusual patternsClassification is based on the specific metaplastic element within the carcinoma",
                    "sub_points": [
                      "Classification is based on the specific metaplastic element within the carcinoma"
                    ]
                  },
                  {
                    "text": "WHO recommends reporting the types of patterns present and the approximate percentage of each pattern"
                  }
                ],
                "Metaplastic Carcinoma With Heterologous Mesenchymal Differentiation (MCHMD) (~ 25%)": [
                  {
                    "text": "The majority are associated with abundant homogeneous extracellular matrix"
                  },
                  {
                    "text": "Other types of mesenchymal differentiation, including rhabdomyosarcomatous, neuroglial, and melanocytic, are exceedingly rare with only a few reported cases"
                  },
                  {
                    "text": "Heterologous matrix production is associated with chondrosarcoma or osteosarcoma"
                  },
                  {
                    "text": "In some cases, matrix may be difficult to distinguish from basement membrane-like material associated with myoepithelial-like cells"
                  },
                  {
                    "text": "Matrix can closely resemble extracellular mucin or dense collagenous stromaMatrix usually has a dense acellular cartilaginous appearance and surrounds small islands of cellsCarcinomas associated with mucin are almost always ER/PR(+)",
                    "sub_points": [
                      "Matrix usually has a dense acellular cartilaginous appearance and surrounds small islands of cells",
                      "Carcinomas associated with mucin are almost always ER/PR(+)"
                    ]
                  },
                  {
                    "text": "The epithelial component may have features of adenocarcinoma or be SpCC or SqCC"
                  },
                  {
                    "text": "Differential diagnosis can include other matrix-producing BCs (with myoepithelial differentiation), malignant phyllodes tumors (PTs), sarcomas, and pleomorphic adenoma"
                  }
                ],
                "Spindle Cell Carcinoma (SpCC) (~ 20% of MBCs)": [
                  {
                    "text": "Numerous architectural patterns can be present, ranging from short fascicles in a storiform pattern to long sweeping fasciclesMixed patterns are common",
                    "sub_points": [
                      "Mixed patterns are common"
                    ]
                  },
                  {
                    "text": "Spindle cells can range from having a bland, low-grade appearance to cells with highly pleomorphic nuclei and frequent mitoses"
                  },
                  {
                    "text": "A lymphocytic infiltrate is commonly present"
                  },
                  {
                    "text": "Frequently express myoepithelial markers, including p63, smooth muscle actin, and muscle-specific actinSome SpCCs overlap with carcinomas with myoepithelial features",
                    "sub_points": [
                      "Some SpCCs overlap with carcinomas with myoepithelial features"
                    ]
                  },
                  {
                    "text": "SpCC can arise adjacent to cysts lined by squamous metaplasia"
                  },
                  {
                    "text": "Differential diagnosis can include PT, sarcoma, fibromatosis, solitary fibrous tumor, and reactive stromal cells"
                  }
                ],
                "Squamous Cell Carcinoma (SqCC) (~ 10% of MBCs)": [
                  {
                    "text": "SqCC of the breast has the same histologic features of SqCCs at other sites"
                  },
                  {
                    "text": "These carcinomas can range from grade 1 to grade 3 and may be keratinizing or nonkeratinizing"
                  },
                  {
                    "text": "Often associated with a prominent spindle cell component"
                  },
                  {
                    "text": "SqCC is often located centrally and adjacent to a cystic cavityMay arise in areas of squamous metaplasia secondary to inflammation associated with a cyst or an intraductal papillomaIn situ SqCC may be present lining the cyst wallSqCC in this setting can mimic reactive stromal cellsShould be suspected if spindle cells show nuclear atypia or mitotic activity",
                    "sub_points": [
                      "May arise in areas of squamous metaplasia secondary to inflammation associated with a cyst or an intraductal papilloma",
                      "In situ SqCC may be present lining the cyst wall",
                      "SqCC in this setting can mimic reactive stromal cellsShould be suspected if spindle cells show nuclear atypia or mitotic activity",
                      "Should be suspected if spindle cells show nuclear atypia or mitotic activity"
                    ]
                  },
                  {
                    "text": "A rare acantholytic/angiomatoid growth pattern resembles angiosarcomaEpithelium degenerates and forms pseudovascular spaces",
                    "sub_points": [
                      "Epithelium degenerates and forms pseudovascular spaces"
                    ]
                  },
                  {
                    "text": "Differential diagnosis can include SqCC arising in the skin or metastatic from another site"
                  }
                ],
                "Fibromatosis-Like Metaplastic Carcinoma (FLMC)": [
                  {
                    "text": "Compared to SpCC, the spindle cells have very bland, small nuclei, and there is low cellularity resulting in the lesion typically resembling a benign process"
                  },
                  {
                    "text": "> 95% of the lesion should consist of spindle cells, but small foci of epithelioid or squamous cells may be present, which help to identify the lesion as a carcinoma"
                  },
                  {
                    "text": "Stromal collagen may be prominent"
                  },
                  {
                    "text": "Differential diagnosis often includes fibromatosis, nodular fasciitis, fascicular pseudoangiomatous stromal hyperplasia (PASH), or scarring"
                  }
                ],
                "Low-Grade Adenosquamous Carcinoma (LGASC)": [
                  {
                    "text": "LGASC is frequently associated with benign proliferative lesionsSclerosing papillomas, complex sclerosing lesions, radial sclerosing lesions, and adenomyoepitheliomasSmall foci (typically 1-2 mm) adjacent to benign lesions can have histologic and immunophenotypic similarity to LGASCThese have been termed adenosquamous proliferation (ASP) and have been proposed as a possible precursor for LGASC",
                    "sub_points": [
                      "Sclerosing papillomas, complex sclerosing lesions, radial sclerosing lesions, and adenomyoepitheliomas",
                      "Small foci (typically 1-2 mm) adjacent to benign lesions can have histologic and immunophenotypic similarity to LGASCThese have been termed adenosquamous proliferation (ASP) and have been proposed as a possible precursor for LGASC",
                      "These have been termed adenosquamous proliferation (ASP) and have been proposed as a possible precursor for LGASC"
                    ]
                  },
                  {
                    "text": "Usually smaller (~ 2 cm) than other types of MBC"
                  },
                  {
                    "text": "Nuclear pleomorphism is minimal, and mitoses are generally absent"
                  },
                  {
                    "text": "4 types of tumor cells are typically present in LGASC(1)Luminal-like cells: p63(-) and low molecular weight (LMW) CKs (+)Generally located in the center of cell nests and often form small, round, or compressed glandular structures(2)Squamous cells: p63 and high molecular weight (HMW) CKs (+)Typically found forming solid nests (sometimes comma-shaped) or within the center of cell nestsMay produce keratin and form cysts(3)Myoepithelial-like cells: p63 and HMW CKs (+)Generally located at the periphery of cell nestsThese cells variably express other proteins found in myoepithelial cellsNegative results for muscle markers can be used to help distinguish them from normal myoepithelial cells(4)Spindle cells: Variably positive for p63 &/or CKsLocated adjacent to epithelial cell nests and may appear to merge with themIt can be difficult to distinguish neoplastic spindle cells from reactive fibroblasts forming desmoplastic stromaStromal myofibroblasts around tumor cells nests can be strongly positive for muscle markers (lamellar pattern)",
                    "sub_points": [
                      "(1)Luminal-like cells: p63(-) and low molecular weight (LMW) CKs (+)Generally located in the center of cell nests and often form small, round, or compressed glandular structures",
                      "Generally located in the center of cell nests and often form small, round, or compressed glandular structures",
                      "(2)Squamous cells: p63 and high molecular weight (HMW) CKs (+)Typically found forming solid nests (sometimes comma-shaped) or within the center of cell nestsMay produce keratin and form cysts",
                      "Typically found forming solid nests (sometimes comma-shaped) or within the center of cell nests",
                      "May produce keratin and form cysts",
                      "(3)Myoepithelial-like cells: p63 and HMW CKs (+)Generally located at the periphery of cell nestsThese cells variably express other proteins found in myoepithelial cellsNegative results for muscle markers can be used to help distinguish them from normal myoepithelial cells",
                      "Generally located at the periphery of cell nests",
                      "These cells variably express other proteins found in myoepithelial cellsNegative results for muscle markers can be used to help distinguish them from normal myoepithelial cells",
                      "Negative results for muscle markers can be used to help distinguish them from normal myoepithelial cells",
                      "(4)Spindle cells: Variably positive for p63 &/or CKsLocated adjacent to epithelial cell nests and may appear to merge with themIt can be difficult to distinguish neoplastic spindle cells from reactive fibroblasts forming desmoplastic stromaStromal myofibroblasts around tumor cells nests can be strongly positive for muscle markers (lamellar pattern)",
                      "Located adjacent to epithelial cell nests and may appear to merge with them",
                      "It can be difficult to distinguish neoplastic spindle cells from reactive fibroblasts forming desmoplastic stroma",
                      "Stromal myofibroblasts around tumor cells nests can be strongly positive for muscle markers (lamellar pattern)"
                    ]
                  },
                  {
                    "text": "Foci of bone &/or cartilage formation are rarely present"
                  },
                  {
                    "text": "Differential diagnosis includes HGASC, syringomatous tumor (SyT) of the nipple, and benign sclerosing lesions"
                  }
                ],
                "High-Grade Adenosquamous Carcinoma (HGASC)": [
                  {
                    "text": "HGASC is similar to LGASC except that higher grade features are present"
                  },
                  {
                    "text": "There may be a more extensive SpCC component composed of cells with high-grade nuclei and mitotic activity"
                  },
                  {
                    "text": "The non-SpCC component may also show less tubule formation (e.g., infiltration of ragged nests of tumor cells), high-grade nuclei, and mitotic activity"
                  }
                ],
                "Mixed MBC (~ 30%)": [
                  {
                    "text": "Many MBCs show multiple patterns"
                  },
                  {
                    "text": "Having 3 or more patterns may be a poor prognostic feature"
                  }
                ],
                "Ductal Carcinoma In Situ (DCIS)": [
                  {
                    "text": "DCIS is generally scant or absent in cases of MBC"
                  },
                  {
                    "text": "When present, this finding supports classification as MBC, even if definite epithelial differentiation is not seen in the invasive carcinoma"
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "A definitive diagnosis of MBC can be challenging on limited core needle biopsy"
                  },
                  {
                    "text": "MBC should always be considered in the differential diagnosis of an atypical spindle cell lesion"
                  },
                  {
                    "text": "Overdiagnosis of small lesions as LGASC should be avoided and diagnosis deferred to excisional specimenA diagnosis of \"low-grade sclerosing lesion\" and providing the differential diagnosis is usually preferable in this setting",
                    "sub_points": [
                      "A diagnosis of \"low-grade sclerosing lesion\" and providing the differential diagnosis is usually preferable in this setting"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry for MBC": [
                  {
                    "text": "Hormone receptorsMajority (> 90%) of MBCs are negative for ER and PR",
                    "sub_points": [
                      "Majority (> 90%) of MBCs are negative for ER and PR"
                    ]
                  },
                  {
                    "text": "HER2HER2 overexpression is rare (< 5%)",
                    "sub_points": [
                      "HER2 overexpression is rare (< 5%)"
                    ]
                  },
                  {
                    "text": "Cytokeratins (CKs)Keratin expression is the most helpful marker to establish a diagnosis of MBC in difficult casesMay be very focal &/or weakMay require the use of multiple CK markers of both HMW and LMWHMW CKs are 1-6 and 9-17LMW CKs are 7, 8, 18-20Many MBCs only express HMW CKs typical for myoepithelial, basal, squamous, or possible progenitor (stem) cells (CKs 5, 6, 14, or 17)The broad-spectrum AE1/AE3 CK cocktail does not contain CKs 14 and 17 and is less likely to be positive in MBCsAE1 detects CKs 10, 15, 16, and 19AE3 detects CKs 1-8The broad-spectrum MNF 116 CK cocktail includes CKs 5, 6, 8, 17, and 18 and is more likely to be positive in MBC than AE1/AE3The 34βE12 (903) cocktail includes HMW CKs 1, 5, 10, and 14 and is more likely to be positive in MBC than AE1/AE3Individual antibodies for CKs 14 and 17 also available",
                    "sub_points": [
                      "Keratin expression is the most helpful marker to establish a diagnosis of MBC in difficult casesMay be very focal &/or weakMay require the use of multiple CK markers of both HMW and LMWHMW CKs are 1-6 and 9-17LMW CKs are 7, 8, 18-20",
                      "May be very focal &/or weak",
                      "May require the use of multiple CK markers of both HMW and LMW",
                      "HMW CKs are 1-6 and 9-17",
                      "LMW CKs are 7, 8, 18-20",
                      "Many MBCs only express HMW CKs typical for myoepithelial, basal, squamous, or possible progenitor (stem) cells (CKs 5, 6, 14, or 17)",
                      "The broad-spectrum AE1/AE3 CK cocktail does not contain CKs 14 and 17 and is less likely to be positive in MBCsAE1 detects CKs 10, 15, 16, and 19AE3 detects CKs 1-8",
                      "AE1 detects CKs 10, 15, 16, and 19",
                      "AE3 detects CKs 1-8",
                      "The broad-spectrum MNF 116 CK cocktail includes CKs 5, 6, 8, 17, and 18 and is more likely to be positive in MBC than AE1/AE3",
                      "The 34βE12 (903) cocktail includes HMW CKs 1, 5, 10, and 14 and is more likely to be positive in MBC than AE1/AE3",
                      "Individual antibodies for CKs 14 and 17 also available"
                    ]
                  },
                  {
                    "text": "p63 and p40p63 expression is seen in > 90% of MBCsBoth myoepithelial cells and squamous cells show nuclear positivity for p63p63 can be very useful for evaluation of SpCCs and SqCCsStromal cells (fibroblasts and myofibroblasts) and PTs are usually negative for p63Malignant PTs can occasionally be positive for p63For the evaluation of MBCs, p63 is a better marker than p40 to detect epithelial differentiationp40 is a truncated form of p63 and is more specific for squamous differentiationPositive in a subset of p63(+) cells",
                    "sub_points": [
                      "p63 expression is seen in > 90% of MBCs",
                      "Both myoepithelial cells and squamous cells show nuclear positivity for p63",
                      "p63 can be very useful for evaluation of SpCCs and SqCCs",
                      "Stromal cells (fibroblasts and myofibroblasts) and PTs are usually negative for p63Malignant PTs can occasionally be positive for p63",
                      "Malignant PTs can occasionally be positive for p63",
                      "For the evaluation of MBCs, p63 is a better marker than p40 to detect epithelial differentiationp40 is a truncated form of p63 and is more specific for squamous differentiationPositive in a subset of p63(+) cells",
                      "p40 is a truncated form of p63 and is more specific for squamous differentiation",
                      "Positive in a subset of p63(+) cells"
                    ]
                  },
                  {
                    "text": "Other myoepithelial markersMany MBCs are positive for 1 or more myoepithelial markersIncludes smooth muscle actin, P-cadherin, and CD102 distinct luminal-like and myoepithelial-like cell populations are not typically presentIf they are, classification as an epithelial/myoepithelial carcinoma [e.g., adenoid cystic carcinoma (AdCC) or adenomyoepithelial carcinoma] may be more appropriate",
                    "sub_points": [
                      "Many MBCs are positive for 1 or more myoepithelial markersIncludes smooth muscle actin, P-cadherin, and CD10",
                      "Includes smooth muscle actin, P-cadherin, and CD10",
                      "2 distinct luminal-like and myoepithelial-like cell populations are not typically presentIf they are, classification as an epithelial/myoepithelial carcinoma [e.g., adenoid cystic carcinoma (AdCC) or adenomyoepithelial carcinoma] may be more appropriate",
                      "If they are, classification as an epithelial/myoepithelial carcinoma [e.g., adenoid cystic carcinoma (AdCC) or adenomyoepithelial carcinoma] may be more appropriate"
                    ]
                  },
                  {
                    "text": "SOX10Positive in ~ 45% of MBCMay be helpful to distinguish metaplastic SqCC of the breast from SqCCs of other sitesSqCCs of lung, skin, cervix, oral mucosa, and esophagus are SOX10(-)",
                    "sub_points": [
                      "Positive in ~ 45% of MBC",
                      "May be helpful to distinguish metaplastic SqCC of the breast from SqCCs of other sitesSqCCs of lung, skin, cervix, oral mucosa, and esophagus are SOX10(-)",
                      "SqCCs of lung, skin, cervix, oral mucosa, and esophagus are SOX10(-)"
                    ]
                  },
                  {
                    "text": "CD34Negative in MBCOther spindle cell lesions of the breast are generally positive, except for fibromatosis and nodular fasciitis",
                    "sub_points": [
                      "Negative in MBC",
                      "Other spindle cell lesions of the breast are generally positive, except for fibromatosis and nodular fasciitis"
                    ]
                  },
                  {
                    "text": "TRPS1Positive in ~ 95% of MBCAlso positive in the majority of malignant PTs (95%) and some types of sarcomasChondrosarcoma, osteosarcoma, angiosarcoma, and synovial sarcoma",
                    "sub_points": [
                      "Positive in ~ 95% of MBC",
                      "Also positive in the majority of malignant PTs (95%) and some types of sarcomasChondrosarcoma, osteosarcoma, angiosarcoma, and synovial sarcoma",
                      "Chondrosarcoma, osteosarcoma, angiosarcoma, and synovial sarcoma"
                    ]
                  },
                  {
                    "text": "GATA3Positive in ~ 33-50% of MBC but also positive in SqCCs of other sitesSkin (~ 80%), lung (~ 5-15%), cervix (~ 20%)",
                    "sub_points": [
                      "Positive in ~ 33-50% of MBC but also positive in SqCCs of other sitesSkin (~ 80%), lung (~ 5-15%), cervix (~ 20%)",
                      "Skin (~ 80%), lung (~ 5-15%), cervix (~ 20%)"
                    ]
                  },
                  {
                    "text": "β-catenin: NuclearReported in ~ 23% of MBCsNot reported in FLMC, but few cases have been tested",
                    "sub_points": [
                      "Reported in ~ 23% of MBCs",
                      "Not reported in FLMC, but few cases have been tested"
                    ]
                  },
                  {
                    "text": "Markers indicating basal phenotypeMajority of MBCs are negative for ER and PR, positive for EGFR &/or CK5/6, and positive for CK14 and p63This combination of markers is frequently seen in basal-like BCs, as defined by gene expression profilingClassification of basal-like BC by IHC does not currently have implications for prognosis or response to chemotherapy",
                    "sub_points": [
                      "Majority of MBCs are negative for ER and PR, positive for EGFR &/or CK5/6, and positive for CK14 and p63",
                      "This combination of markers is frequently seen in basal-like BCs, as defined by gene expression profiling",
                      "Classification of basal-like BC by IHC does not currently have implications for prognosis or response to chemotherapy"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Squamous Cell Carcinoma (SqCC) of the Skin": [
                  {
                    "text": "Can arise from mammary skin or cutaneous appendages"
                  },
                  {
                    "text": "May secondarily involve underlying breast parenchymaCareful examination for in situ carcinoma associated with skin or cutaneous appendages is helpful",
                    "sub_points": [
                      "Careful examination for in situ carcinoma associated with skin or cutaneous appendages is helpful"
                    ]
                  },
                  {
                    "text": "Clinical history may be helpful to determine if the carcinoma first presented as a skin mass or as a breast mass with secondary skin involvement"
                  },
                  {
                    "text": "SOX10 can help distinguish SqCC of the breast (~ 45% positive) from SqCC of the skin (< 5% positive)"
                  },
                  {
                    "text": "GATA3 is not helpful, as SqCCs of the skin and the breast are both positive"
                  }
                ],
                "Phyllodes Tumor (PT)": [
                  {
                    "text": "PT with prominent stromal overgrowth can closely resemble SpCC"
                  },
                  {
                    "text": "May consist of a pure spindle cell proliferation or show heterologous differentiation, including chondrosarcoma or osteosarcomaAssociation with liposarcoma or rhabdomyosarcoma is more common in PT than in MBC",
                    "sub_points": [
                      "Association with liposarcoma or rhabdomyosarcoma is more common in PT than in MBC"
                    ]
                  },
                  {
                    "text": "Extensive sampling to identify the benign epithelial component of PT is the most helpful diagnostic feature"
                  },
                  {
                    "text": "Malignant PTs can show focal CK and p63 expression, TRPS1 positivity, and are also usually CD34(-)"
                  }
                ],
                "Sarcoma": [
                  {
                    "text": "Primary sarcomas of the breast are exceedingly rare"
                  },
                  {
                    "text": "Angiosarcoma is the most common and can be primary or secondary to radiation or chronic lymphedemaRare acantholytic/angiomatoid SqCCs can mimic angiosarcoma",
                    "sub_points": [
                      "Rare acantholytic/angiomatoid SqCCs can mimic angiosarcoma"
                    ]
                  },
                  {
                    "text": "Heterologous differentiation in PTs and MBCs is more common than in primary sarcoma"
                  },
                  {
                    "text": "Important to rule out MBC or PT before diagnosing sarcoma"
                  }
                ],
                "Epithelial/Myoepithelial Tumors": [
                  {
                    "text": "Unusual breast neoplasms composed of 2 populations of cells with distinct luminal and myoepithelial characteristics"
                  },
                  {
                    "text": "Myoepithelial component can appear spindled &/or produce matrixThese features are morphologically similar to a metaplastic or mesenchymal component",
                    "sub_points": [
                      "These features are morphologically similar to a metaplastic or mesenchymal component"
                    ]
                  },
                  {
                    "text": "Carcinomas with epithelial/myoepithelial cell populations (e.g., adenomyoepithelial carcinomas) may overlap with MBC if the spindle cell component is prominent &/or matrix is present"
                  },
                  {
                    "text": "Adenoid cystic carcinoma (AdCC) is most commonImportant to recognize AdCC, as this carcinoma has very favorable prognosis",
                    "sub_points": [
                      "Important to recognize AdCC, as this carcinoma has very favorable prognosis"
                    ]
                  },
                  {
                    "text": "Pleomorphic adenoma (mixed tumor) is rarely seen in the breast but is important to recognize as a benign tumorMatrix is the dominant component compared to the epithelium",
                    "sub_points": [
                      "Matrix is the dominant component compared to the epithelium"
                    ]
                  },
                  {
                    "text": "Epithelial component lacks atypia, mitoses, and necrosis"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Nuclear pleomorphism is minimal, and mitoses are rare"
                  },
                  {
                    "text": "Aberrant nuclear β-catenin is present in majority of cases of fibromatosis but also present in ~ 1/3 of SpCCsBoth are negative for CD34Nuclear β-catenin has not been reported in FLMC, but very few cases have been tested",
                    "sub_points": [
                      "Both are negative for CD34",
                      "Nuclear β-catenin has not been reported in FLMC, but very few cases have been tested"
                    ]
                  },
                  {
                    "text": "Fibromatosis is negative for cytokeratins and p63"
                  }
                ],
                "Syringomatous Tumor (SyT) of the Nipple": [
                  {
                    "text": "SyT is very similar in morphology to LGASC"
                  },
                  {
                    "text": "SyT is limited to the dermis of the nipple-areola complex with very focal, if any, involvement of deeper tissue"
                  },
                  {
                    "text": "A neoplastic spindle cell component should not be present"
                  },
                  {
                    "text": "A superficially located LGASC invading into the skin could be difficult to distinguish from SyT in a small superficial biopsy"
                  }
                ],
                "Benign Sclerosing Lesions": [
                  {
                    "text": "Small areas (1-2 mm) within sclerosing lesions can have an appearance very similar to LGASC"
                  },
                  {
                    "text": "These have been termed \"adenosquamous proliferations\" (ASPs)"
                  },
                  {
                    "text": "If these areas extend beyond the benign lesion into adjacent stroma, LGASC arising in a benign lesion can be in the differential diagnosis"
                  }
                ],
                "Tubular Carcinoma": [
                  {
                    "text": "Tubular carcinoma could resemble the small glands present in LGASC"
                  },
                  {
                    "text": "The positivity for ER and the lack of squamous features and p63 positivity would identify tubular carcinoma and exclude LGASC"
                  }
                ],
                "Metastases": [
                  {
                    "text": "A metastasis to the breast can be a possibility in cases of MBC, as DCIS is often absent, and MBCs are almost always negative for hormone receptors and HER2"
                  },
                  {
                    "text": "The types of metastatic tumors that might mimic MBC are usually well known and unlikely to be occult at the primary site"
                  },
                  {
                    "text": "Morphologic comparison of the primary lesion and the breast lesion is generally the most helpful for diagnosis"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "MBC encompasses a heterogeneous group of carcinomas demonstrating features that overlap with malignant PTs and sarcomas"
                  },
                  {
                    "text": "The prognosis for some types of MBC is significantly worse than for other TNBCs"
                  },
                  {
                    "text": "MBCs with a more favorable prognosis, FLMC and LGASC, are important to recognize"
                  },
                  {
                    "text": "Some benign lesions have morphologic similarity to MBCs and need to be distinguished from them (e.g., SyT, sclerosing lesions, pleomorphic adenoma, fibromatosis)"
                  }
                ]
              },
              "REPORTING": {
                "MBC Guidelines": [
                  {
                    "text": "MBCs are graded using the Nottingham Grading System and reported according to the College of American Pathologists Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Low-Grade Adenosquamous Carcinoma": {
            "name": "Low-Grade Adenosquamous Carcinoma",
            "url": "https://app.pathprimer.com/document/ec7b9b06-50d3-4f2d-84ed-e4dbf9b91da8/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Subtype of metaplastic carcinoma consisting of well-formed tubules and nests of squamous cells in background of spindle cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Very rare: < 1% of all carcinomas"
                  },
                  {
                    "text": "Often associated with sclerosing lesions or adenomyoepithelioma"
                  },
                  {
                    "text": "Example of triple negative carcinoma with good prognosisVery low incidence of lymph node metastasesVery rare cases metastasize",
                    "sub_points": [
                      "Very low incidence of lymph node metastases",
                      "Very rare cases metastasize"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Consist of tubules and squamous nestsSome tumors also have neoplastic spindle cell component",
                    "sub_points": [
                      "Some tumors also have neoplastic spindle cell component"
                    ]
                  },
                  {
                    "text": "Cell types include myoepithelial-like cells, luminal-like cells, and squamous cellsMixture of cell types and heterogeneity in protein expression aid in recognition of this tumor",
                    "sub_points": [
                      "Mixture of cell types and heterogeneity in protein expression aid in recognition of this tumor"
                    ]
                  },
                  {
                    "text": "Nuclei are low grade, and mitoses are generally not seen"
                  },
                  {
                    "text": "Extent of tumor may be difficult to define due to low-grade appearance of tumor cells in periphery"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Estrogen, progesterone, and androgen receptors: Negative"
                  },
                  {
                    "text": "HER2: Negative"
                  },
                  {
                    "text": "Keratins, p63, and myoepithelial markers show variable patterns in multiple cell types"
                  },
                  {
                    "text": "EGFR (HER1): Positive (~ 50%)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Syringomatous tumor of nipple"
                  },
                  {
                    "text": "Metaplastic breast carcinoma"
                  },
                  {
                    "text": "Squamous cell carcinoma"
                  },
                  {
                    "text": "Sclerosing adenosis and radial sclerosing lesions"
                  },
                  {
                    "text": "Tubular carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Low-grade adenosquamous carcinoma (LGASC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Type of metaplastic carcinoma consisting of well-formed tubules and nests of squamous cells in background of spindle cells, associated with relatively good prognosis"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Biology": [
                  {
                    "text": "LGASC is frequently associated with benign proliferative lesionsSclerosing papillomas, complex sclerosing lesions, radial sclerosing lesions, and adenomyoepitheliomas",
                    "sub_points": [
                      "Sclerosing papillomas, complex sclerosing lesions, radial sclerosing lesions, and adenomyoepitheliomas"
                    ]
                  },
                  {
                    "text": "Small foci (typically 1-2 mm) adjacent to benign lesions have histologic and immunophenotypic similarity to LGASC (termed adenosquamous proliferation or ASP)These may be precursor lesions for LGASC",
                    "sub_points": [
                      "These may be precursor lesions for LGASC"
                    ]
                  },
                  {
                    "text": "Activating mutations inPIK3CAandAKT1are common in numerous lesions, including proliferative lesionsUsual ductal hyperplasia, columnar cell change, papillomas, adenomyoepitheliomas as well as in normal breast tissue and carcinomasIn one study, the same mutation occurred in the myoepithelial and epithelial cells of papillomas, supporting that the mutation occurred in a precursor cell",
                    "sub_points": [
                      "Usual ductal hyperplasia, columnar cell change, papillomas, adenomyoepitheliomas as well as in normal breast tissue and carcinomas",
                      "In one study, the same mutation occurred in the myoepithelial and epithelial cells of papillomas, supporting that the mutation occurred in a precursor cell"
                    ]
                  },
                  {
                    "text": "These are important genes in the phosphatidylinositol 3-kinase/AKT pathway related to cell proliferation, survival, angiogenesis, and motilitySomatic mutations likely occur early in development and predispose to the development of multiple proliferative lesions but are not specific to the type of lesion",
                    "sub_points": [
                      "Somatic mutations likely occur early in development and predispose to the development of multiple proliferative lesions but are not specific to the type of lesion"
                    ]
                  },
                  {
                    "text": "PIK3CAmutations are found in ~ 50% of LGASCIn one reported case, infiltrating epitheliosis, ductal carcinoma in situ (DCIS), and LGASC all shared the samePIK3CAmutationThis could either mean that the lesions are directly related to each other or that they all arose separately in an area of breast tissue with this mutation",
                    "sub_points": [
                      "In one reported case, infiltrating epitheliosis, ductal carcinoma in situ (DCIS), and LGASC all shared the samePIK3CAmutation",
                      "This could either mean that the lesions are directly related to each other or that they all arose separately in an area of breast tissue with this mutation"
                    ]
                  },
                  {
                    "text": "LGASC belongs to a group of breast neoplasms that are composed of multiple types of tumor cellsAdenomyoepitheliomas, pleomorphic adenomas, and adenoid cystic carcinoma show dual luminal and myoepithelial cell populationsLGASC shows a more complex pattern that also includes squamous cells and cells that appear to have mixed features of luminal and myoepithelial cellsSyringomatous tumor of the nipple (ST) has a very similar pattern as LGASCMultiple cell types and variable immunoreactivity can make diagnosis of these tumors challengingHowever, these features are also very characteristic of LGASC and aid in its recognitionAlthough carcinomas in this group are generally \"triple negative breast cancers\" (TNBCs), they tend to have very favorable clinical outcomes, as is observed for LGASCThe capacity of tumor cells to display different lines of differentiation may be a sign of low malignant potential",
                    "sub_points": [
                      "Adenomyoepitheliomas, pleomorphic adenomas, and adenoid cystic carcinoma show dual luminal and myoepithelial cell populations",
                      "LGASC shows a more complex pattern that also includes squamous cells and cells that appear to have mixed features of luminal and myoepithelial cellsSyringomatous tumor of the nipple (ST) has a very similar pattern as LGASCMultiple cell types and variable immunoreactivity can make diagnosis of these tumors challengingHowever, these features are also very characteristic of LGASC and aid in its recognition",
                      "Syringomatous tumor of the nipple (ST) has a very similar pattern as LGASC",
                      "Multiple cell types and variable immunoreactivity can make diagnosis of these tumors challengingHowever, these features are also very characteristic of LGASC and aid in its recognition",
                      "However, these features are also very characteristic of LGASC and aid in its recognition",
                      "Although carcinomas in this group are generally \"triple negative breast cancers\" (TNBCs), they tend to have very favorable clinical outcomes, as is observed for LGASCThe capacity of tumor cells to display different lines of differentiation may be a sign of low malignant potential",
                      "The capacity of tumor cells to display different lines of differentiation may be a sign of low malignant potential"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare: < 1% of invasive breast carcinomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Mean: 55-70 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most present as palpable masses"
                  },
                  {
                    "text": "Some detected as masses or calcifications on screening mammography"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "LGASC is example of a TNBC with a relatively good prognosisLow incidence of lymph node metastases2 cases, each with 1 node involved1 carcinoma was 3.5 cm; size of other carcinoma was not providedVery rare cases recur locally &/or metastasize to distant sites1 reported death from local chest wall involvement1 reported death after recurrence as a higher grade carcinomaIn a recent study of 41 patients with at least 8-year follow-up, no metastases were observed",
                    "sub_points": [
                      "Low incidence of lymph node metastases2 cases, each with 1 node involved1 carcinoma was 3.5 cm; size of other carcinoma was not provided",
                      "2 cases, each with 1 node involved1 carcinoma was 3.5 cm; size of other carcinoma was not provided",
                      "1 carcinoma was 3.5 cm; size of other carcinoma was not provided",
                      "Very rare cases recur locally &/or metastasize to distant sites1 reported death from local chest wall involvement1 reported death after recurrence as a higher grade carcinoma",
                      "1 reported death from local chest wall involvement",
                      "1 reported death after recurrence as a higher grade carcinoma",
                      "In a recent study of 41 patients with at least 8-year follow-up, no metastases were observed"
                    ]
                  },
                  {
                    "text": "Majority of patients have not received chemotherapy"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Generally form masses with lobulated or irregular margins"
                  },
                  {
                    "text": "Calcifications may be present; either in stroma or in associated sclerosing lesions"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Generally forms irregular massesLGASC may be ill-defined due to diffusely infiltrative pattern into adipose tissue",
                    "sub_points": [
                      "LGASC may be ill-defined due to diffusely infiltrative pattern into adipose tissue"
                    ]
                  },
                  {
                    "text": "Size ranges from 0.5-8 cm with typical size of 2 cm"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "MutationsPIK3CAmutations in ~ 50%Kinase (H1047L and H1047R) and helical (E542K) domain missense mutations reportedNoTP53mutations",
                    "sub_points": [
                      "PIK3CAmutations in ~ 50%Kinase (H1047L and H1047R) and helical (E542K) domain missense mutations reported",
                      "Kinase (H1047L and H1047R) and helical (E542K) domain missense mutations reported",
                      "NoTP53mutations"
                    ]
                  },
                  {
                    "text": "Copy number alterations2 LGASCs analyzed showed complex copy number changes, including amplificationsEGFRamplification reported in a single case",
                    "sub_points": [
                      "2 LGASCs analyzed showed complex copy number changes, including amplifications",
                      "EGFRamplification reported in a single case"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "4 types of cells are typically present(1)Luminal-like cells: p63(-) and low molecular weight keratin (+): Generally located in the center of cell nestsThese cells have features of luminal cellsForming small, rounded, and compressed glandular structures(2)Squamous cells: p63 and cytokeratin 10(+): Typically found forming solid nests or in center of tubulesMay produce keratin and form cysts(3)Myoepithelial-like cells: p63 and cytokeratin 5/14(+): Generally located at periphery of cell nestsThese cells variably express other proteins found in myoepithelial cellsIt has been proposed that these are progenitor cells that give rise to other cell types(4)Spindle cells: Variably positive for p63 &/or keratins: Located adjacent to epithelial nestsDifficult to distinguish from reactive fibroblasts associated with tumorTypically adjacent to tubules and appear to merge with themA study has shown the same gene amplification found in epithelial cells and spindle cells, showing that some spindle cells are neoplasticKeratin MNF116 can show positivity in ~ 10-20% of stromal cells in benign sclerosing lesionsp63 and other keratins are more reliable to identify tumor cells",
                    "sub_points": [
                      "(1)Luminal-like cells: p63(-) and low molecular weight keratin (+): Generally located in the center of cell nestsThese cells have features of luminal cellsForming small, rounded, and compressed glandular structures",
                      "These cells have features of luminal cells",
                      "Forming small, rounded, and compressed glandular structures",
                      "(2)Squamous cells: p63 and cytokeratin 10(+): Typically found forming solid nests or in center of tubulesMay produce keratin and form cysts",
                      "May produce keratin and form cysts",
                      "(3)Myoepithelial-like cells: p63 and cytokeratin 5/14(+): Generally located at periphery of cell nestsThese cells variably express other proteins found in myoepithelial cellsIt has been proposed that these are progenitor cells that give rise to other cell types",
                      "These cells variably express other proteins found in myoepithelial cells",
                      "It has been proposed that these are progenitor cells that give rise to other cell types",
                      "(4)Spindle cells: Variably positive for p63 &/or keratins: Located adjacent to epithelial nestsDifficult to distinguish from reactive fibroblasts associated with tumorTypically adjacent to tubules and appear to merge with themA study has shown the same gene amplification found in epithelial cells and spindle cells, showing that some spindle cells are neoplasticKeratin MNF116 can show positivity in ~ 10-20% of stromal cells in benign sclerosing lesionsp63 and other keratins are more reliable to identify tumor cells",
                      "Difficult to distinguish from reactive fibroblasts associated with tumorTypically adjacent to tubules and appear to merge with them",
                      "Typically adjacent to tubules and appear to merge with them",
                      "A study has shown the same gene amplification found in epithelial cells and spindle cells, showing that some spindle cells are neoplasticKeratin MNF116 can show positivity in ~ 10-20% of stromal cells in benign sclerosing lesionsp63 and other keratins are more reliable to identify tumor cells",
                      "Keratin MNF116 can show positivity in ~ 10-20% of stromal cells in benign sclerosing lesions",
                      "p63 and other keratins are more reliable to identify tumor cells"
                    ]
                  },
                  {
                    "text": "The tumor is composed of both glandular structures and squamous cell nestsGlandular structuresare well formed and consist of multiple cell layersShape of glands is rounded rather than angulatedOuter cell layer is typically p63(+) but usually lacks other myoepithelial markersInner layer of cells may be either luminal-like or squamousSome inner cells show more intense immunoreactivity for keratin than outer cells (core pattern)This pattern may vary from tubule to tubule and vary for different keratinsPresent in ~ 3/4 of tumorsSolid nestsusually consist of p63(+) squamous cellsOften have characteristic comma or tadpole shapesKeratin-filled cysts &/or keratin pearls may be present",
                    "sub_points": [
                      "Glandular structuresare well formed and consist of multiple cell layersShape of glands is rounded rather than angulatedOuter cell layer is typically p63(+) but usually lacks other myoepithelial markersInner layer of cells may be either luminal-like or squamousSome inner cells show more intense immunoreactivity for keratin than outer cells (core pattern)This pattern may vary from tubule to tubule and vary for different keratinsPresent in ~ 3/4 of tumors",
                      "Shape of glands is rounded rather than angulated",
                      "Outer cell layer is typically p63(+) but usually lacks other myoepithelial markers",
                      "Inner layer of cells may be either luminal-like or squamous",
                      "Some inner cells show more intense immunoreactivity for keratin than outer cells (core pattern)This pattern may vary from tubule to tubule and vary for different keratinsPresent in ~ 3/4 of tumors",
                      "This pattern may vary from tubule to tubule and vary for different keratins",
                      "Present in ~ 3/4 of tumors",
                      "Solid nestsusually consist of p63(+) squamous cellsOften have characteristic comma or tadpole shapesKeratin-filled cysts &/or keratin pearls may be present",
                      "Often have characteristic comma or tadpole shapes",
                      "Keratin-filled cysts &/or keratin pearls may be present"
                    ]
                  },
                  {
                    "text": "Nuclear pleomorphism is minimal, and mitoses are usually absentLow-grade cytology and paucity of mitotic figures are histologic correlates of LGASC's indolent behaviorNecrosis would be highly unusualLymphovascular invasion not seen",
                    "sub_points": [
                      "Low-grade cytology and paucity of mitotic figures are histologic correlates of LGASC's indolent behavior",
                      "Necrosis would be highly unusual",
                      "Lymphovascular invasion not seen"
                    ]
                  },
                  {
                    "text": "Stromal reaction is variable~ 1/2 associated with reactive cellular stromaMarked immunoreactivity for muscle markers can be seen in myofibroblasts surrounding epithelial nests (lamellar pattern) in ~ 1/2 of casesStromal reaction may be absent around cell nests at periphery of tumor, making extent of tumor difficult to assess~ 1/2 associated with paucicellular elastotic and hyalinized stroma",
                    "sub_points": [
                      "~ 1/2 associated with reactive cellular stromaMarked immunoreactivity for muscle markers can be seen in myofibroblasts surrounding epithelial nests (lamellar pattern) in ~ 1/2 of casesStromal reaction may be absent around cell nests at periphery of tumor, making extent of tumor difficult to assess",
                      "Marked immunoreactivity for muscle markers can be seen in myofibroblasts surrounding epithelial nests (lamellar pattern) in ~ 1/2 of cases",
                      "Stromal reaction may be absent around cell nests at periphery of tumor, making extent of tumor difficult to assess",
                      "~ 1/2 associated with paucicellular elastotic and hyalinized stroma"
                    ]
                  },
                  {
                    "text": "Carcinoma infiltrates around normal breast epithelium and into adipose tissueOften extends beyond gross or radiologic massPeripheral extent of tumor may blend imperceptibly with surrounding normal breast parenchymaExtent, size, and margins may be difficult to define because tubules can mimic benign structuresThis growth pattern is associated with risk of positive margins and local recurrence",
                    "sub_points": [
                      "Often extends beyond gross or radiologic mass",
                      "Peripheral extent of tumor may blend imperceptibly with surrounding normal breast parenchyma",
                      "Extent, size, and margins may be difficult to define because tubules can mimic benign structures",
                      "This growth pattern is associated with risk of positive margins and local recurrence"
                    ]
                  },
                  {
                    "text": "Lymphocytic aggregates are often present at peripheryLarge aggregates are described as resembling cannonballsThe presence of peripheral lymphoid aggregates may be helpful in delineating the general boundaries and extent of the lesion",
                    "sub_points": [
                      "Large aggregates are described as resembling cannonballs",
                      "The presence of peripheral lymphoid aggregates may be helpful in delineating the general boundaries and extent of the lesion"
                    ]
                  },
                  {
                    "text": "Foci of bone or cartilage formation can be present"
                  },
                  {
                    "text": "Often associated with sclerosing or papillary lesions or with adenomyoepithelioma"
                  },
                  {
                    "text": "LGASC can be associated with higher grade carcinomaMalignant spindle cell component with high-grade nuclei and mitoses may be present",
                    "sub_points": [
                      "Malignant spindle cell component with high-grade nuclei and mitoses may be present"
                    ]
                  },
                  {
                    "text": "DCIS is rarely present in adjacent breast tissueIt can be difficult to distinguish DCIS from areas of invasionDCIS should have normal myoepithelial cell layer as demonstrated by expression of multiple markers",
                    "sub_points": [
                      "It can be difficult to distinguish DCIS from areas of invasion",
                      "DCIS should have normal myoepithelial cell layer as demonstrated by expression of multiple markers"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis can be difficult on core needle biopsyAll of the histologic features of LGASC may not be present in core biopsy sampleCarcinoma can resemble radial sclerosing lesion",
                    "sub_points": [
                      "All of the histologic features of LGASC may not be present in core biopsy sample",
                      "Carcinoma can resemble radial sclerosing lesion"
                    ]
                  },
                  {
                    "text": "Squamous nests in stroma are uncommon findings in benign lesions"
                  },
                  {
                    "text": "Overdiagnosis of small lesions as LGASC should be avoided and diagnosis deferred to excisional specimen"
                  },
                  {
                    "text": "A diagnosis of \"low-grade sclerosing lesion\" with a comment about the relevant differential, recommending excision may be warranted"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Estrogen, progesterone, and androgen receptors: Negative"
                  },
                  {
                    "text": "HER2: Negative"
                  },
                  {
                    "text": "High molecular weight cytokeratins (5/6 and 14): Positive in subset of cellsGenerally positive in peripheral cells, cells with squamous appearance, and some spindle cells in some cases",
                    "sub_points": [
                      "Generally positive in peripheral cells, cells with squamous appearance, and some spindle cells in some cases"
                    ]
                  },
                  {
                    "text": "Low molecular weight cytokeratins (e.g., 8/18): Positive in subset of cellsGenerally positive in centrally located cells with luminal appearance",
                    "sub_points": [
                      "Generally positive in centrally located cells with luminal appearance"
                    ]
                  },
                  {
                    "text": "p63: Positive in subset of cellsGenerally positive in peripheral cells and cells with squamous appearanceSome spindle cells may be positive",
                    "sub_points": [
                      "Generally positive in peripheral cells and cells with squamous appearance",
                      "Some spindle cells may be positive"
                    ]
                  },
                  {
                    "text": "Muscle markers (actin, myosin, calponin): Variably positiveOften negative in p63(+) tumor cellsWhen negative, helpful to demonstrate these cells are not normal myoepithelial cellsStromal fibroblasts can be strongly positive around tumor cells nests (lamellar pattern)",
                    "sub_points": [
                      "Often negative in p63(+) tumor cellsWhen negative, helpful to demonstrate these cells are not normal myoepithelial cells",
                      "When negative, helpful to demonstrate these cells are not normal myoepithelial cells",
                      "Stromal fibroblasts can be strongly positive around tumor cells nests (lamellar pattern)"
                    ]
                  },
                  {
                    "text": "EGFR (HER1): Positive (~ 50%)"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Syringomatous Tumor of Nipple (ST)": [
                  {
                    "text": "Usually presents as subcutaneous palpable mass in nipple/areolar dermisOften associated with benign sclerosing lesions of nipple",
                    "sub_points": [
                      "Often associated with benign sclerosing lesions of nipple"
                    ]
                  },
                  {
                    "text": "Histologic appearance is very similar to LGASCCell nests and tubules infiltrate in dermis and smooth muscle of dermisTumor cells show mixed myoepithelial, luminal, and squamous types, as are seen in LGASCTumor spindle cells are not seenPerineural invasion may be present",
                    "sub_points": [
                      "Cell nests and tubules infiltrate in dermis and smooth muscle of dermisTumor cells show mixed myoepithelial, luminal, and squamous types, as are seen in LGASC",
                      "Tumor cells show mixed myoepithelial, luminal, and squamous types, as are seen in LGASC",
                      "Tumor spindle cells are not seen",
                      "Perineural invasion may be present"
                    ]
                  },
                  {
                    "text": "ST is limited to dermis of nipple-areola complex with very focal, if any, involvement of deeper tissueLGASC arises in breast parenchymaHowever, some arise in retroareolar regionIt may be difficult or impossible to distinguish these lesions on superficial biopsies or if LGASC invades into skin",
                    "sub_points": [
                      "LGASC arises in breast parenchymaHowever, some arise in retroareolar region",
                      "However, some arise in retroareolar region",
                      "It may be difficult or impossible to distinguish these lesions on superficial biopsies or if LGASC invades into skin"
                    ]
                  },
                  {
                    "text": "Local recurrence is possible if not completely excisedDoes not metastasize",
                    "sub_points": [
                      "Does not metastasize"
                    ]
                  }
                ],
                "Metaplastic Breast Carcinoma": [
                  {
                    "text": "Metaplastic carcinomas can have areas of squamous metaplasia and spindle cellsCan arise in association with sclerosing lesions &/or cysts",
                    "sub_points": [
                      "Can arise in association with sclerosing lesions &/or cysts"
                    ]
                  },
                  {
                    "text": "Nuclear pleomorphism, mitoses, necrosis, and prominent, malignant-appearing spindle cell component support classification as metaplastic spindle cell &/or squamous carcinoma rather than LGASC"
                  }
                ],
                "Squamous Cell Carcinoma": [
                  {
                    "text": "Generally forms large, centrally located massCenter of carcinoma may be cystic, or carcinomas may arise in the wall of a cyst",
                    "sub_points": [
                      "Center of carcinoma may be cystic, or carcinomas may arise in the wall of a cyst"
                    ]
                  },
                  {
                    "text": "Nuclear pleomorphism and necrosis are typically present"
                  },
                  {
                    "text": "Glandular areas are not present"
                  }
                ],
                "Sclerosing Adenosis and Radial Sclerosing Lesions": [
                  {
                    "text": "These lesions consist of epithelial elements in collagenous stromaProminent layer of normal myoepithelial cells is presentCells are positive for p63 as well as other myoepithelial markersAlthough some myoepithelial markers may be lost in some benign lesions, smooth muscle actin, as well as others, are generally present",
                    "sub_points": [
                      "Prominent layer of normal myoepithelial cells is presentCells are positive for p63 as well as other myoepithelial markersAlthough some myoepithelial markers may be lost in some benign lesions, smooth muscle actin, as well as others, are generally present",
                      "Cells are positive for p63 as well as other myoepithelial markersAlthough some myoepithelial markers may be lost in some benign lesions, smooth muscle actin, as well as others, are generally present",
                      "Although some myoepithelial markers may be lost in some benign lesions, smooth muscle actin, as well as others, are generally present"
                    ]
                  },
                  {
                    "text": "Small areas (1-2 mm) may have appearance very similar to LGASC (termed adenosquamous proliferation or ASP)Diagnosis of LGASC should not be made when these areas are limited to benign lesionIf these areas extend beyond benign lesion, and infiltrate around normal ducts and lobules, LGASC could be considered",
                    "sub_points": [
                      "Diagnosis of LGASC should not be made when these areas are limited to benign lesion",
                      "If these areas extend beyond benign lesion, and infiltrate around normal ducts and lobules, LGASC could be considered"
                    ]
                  }
                ],
                "Tubular Carcinoma": [
                  {
                    "text": "Consist of small, well-formed angulated glands in desmoplastic stromaSolid &/or squamoid nests are not presentSpindle cell component is not presentTumor cells are negative for p63",
                    "sub_points": [
                      "Solid &/or squamoid nests are not presentSpindle cell component is not present",
                      "Spindle cell component is not present",
                      "Tumor cells are negative for p63"
                    ]
                  },
                  {
                    "text": "Often associated with flat epithelial atypia, atypical ductal hyperplasia, &/or low-grade DCIS"
                  },
                  {
                    "text": "All are positive for ERIf negative, other diagnoses (e.g., microglandular adenosis) or problems with assay should be considered",
                    "sub_points": [
                      "If negative, other diagnoses (e.g., microglandular adenosis) or problems with assay should be considered"
                    ]
                  },
                  {
                    "text": "The presence of adjacent low-grade DCIS is more in keeping with a diagnosis of tubular carcinoma"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "LGASC is important example of triple negative or basal carcinoma with relatively good prognosisUnique histologic appearance and immunophenotype have been sources of diagnostic challenges and speculation over its histogenesisBecause of the favorable prognosis, LGASC must be differentiated from other higher grade metaplastic carcinomas",
                    "sub_points": [
                      "Unique histologic appearance and immunophenotype have been sources of diagnostic challenges and speculation over its histogenesis",
                      "Because of the favorable prognosis, LGASC must be differentiated from other higher grade metaplastic carcinomas"
                    ]
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Some benign lesions can show significant overlap and must be distinguished from LGASC (e.g., ST, radial sclerosing lesions)"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Adenoid Cystic Carcinoma": {
            "name": "Adenoid Cystic Carcinoma",
            "url": "https://app.pathprimer.com/document/1d4fab9c-b80e-4a80-b41b-bb2fc3d173dd/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Adenoid cystic carcinoma (AdCC) is an invasive carcinoma composed of luminal and myoepithelial cellsRare: < 5% of breast cancers",
                    "sub_points": [
                      "Rare: < 5% of breast cancers"
                    ]
                  },
                  {
                    "text": "Associated with overexpression of MYB due to anMYB::NFIBgene rearrangement; other types of rearrangements or gene amplification occur but are rare"
                  },
                  {
                    "text": "Classic AdCC (C-AdCC)has 2 well-defined cell populations and is usually grade 1 or 2~ 70-90% have theMYB::NFIBgene rearrangement",
                    "sub_points": [
                      "~ 70-90% have theMYB::NFIBgene rearrangement"
                    ]
                  },
                  {
                    "text": "Solid-basaloid AdCC (SB-AdCC)consists predominantly of the myoepithelial cell component and is frequently grade 3~ 10-20%MYB::NFIBgene rearrangement, and ~ 30-60% have NOTCH mutations",
                    "sub_points": [
                      "~ 10-20%MYB::NFIBgene rearrangement, and ~ 30-60% have NOTCH mutations"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "C-AdCChas excellent prognosis: 90-100% survival at 10 yearsCan be successfully treated with local therapy",
                    "sub_points": [
                      "Can be successfully treated with local therapy"
                    ]
                  },
                  {
                    "text": "SB-AdCChas a higher likelihood of distant metastasis and deathMay be treated with chemotherapy",
                    "sub_points": [
                      "May be treated with chemotherapy"
                    ]
                  },
                  {
                    "text": "Overdiagnosis of AdCC must be avoided~ 20% of AdCCs on review do not fulfill criteria",
                    "sub_points": [
                      "~ 20% of AdCCs on review do not fulfill criteria"
                    ]
                  },
                  {
                    "text": "These cancers may not be treated with appropriate chemotherapy, which can lead to poor outcomes"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "C-AdCC has 3 histologic patterns: Cribriform, reticular-tubular, and solid"
                  },
                  {
                    "text": "SB-AdCC has a predominant solid pattern"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Triple negative breast carcinoma with basaloid features"
                  },
                  {
                    "text": "Adenomyoepithelioma, pleomorphic adenoma, cylindroma"
                  },
                  {
                    "text": "Cribriform pattern of ductal carcinoma in situ or invasive carcinoma"
                  },
                  {
                    "text": "Collagenous spherulosis"
                  },
                  {
                    "text": "Solid papillary carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Classic adenoid cystic carcinoma (C-AdCC)"
                  },
                  {
                    "text": "Solid-basaloid adenoid cystic carcinoma (SB-AdCC)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Adenoid Cystic Carcinoma (AdCC)": [
                  {
                    "text": "AdCC is characterized by having 2 neoplastic cell populations (luminal and myoepithelial) associated with the frequent gene translocation,MYB::NFIB< 5% of all breast carcinomas",
                    "sub_points": [
                      "< 5% of all breast carcinomas"
                    ]
                  },
                  {
                    "text": "3 subtypes are recognized by the World Health Organization"
                  },
                  {
                    "text": "Although the subtypes have phenotypic similarities, the genomic differences, biologic behavior, and prognosis make it imperative that pathologists specify the subtype of AdCC when making this diagnosis"
                  }
                ],
                "Classic Adenoid Cystic Carcinoma (C-AdCC)": [
                  {
                    "text": "Distinct neoplastic populations of luminal and myoepithelial cells are readily identifiableThe myoepithelial population is almost always associated with the production of basement membrane-like material (creating pseudolumina) and p63 positivityThe luminal population forms true lumina and is positive for low molecular weight keratins",
                    "sub_points": [
                      "The myoepithelial population is almost always associated with the production of basement membrane-like material (creating pseudolumina) and p63 positivity",
                      "The luminal population forms true lumina and is positive for low molecular weight keratins"
                    ]
                  },
                  {
                    "text": "The most common genomic finding is a chromosomal translocation resulting in anMYB::NFIBfusion gene (present in ~ 70-90% of cases)MYB protein is expressed strongly and diffusely in tumor cellsCD117 (c-KIT) is under control of MYB and is also often overexpressed in the luminal tumor cells",
                    "sub_points": [
                      "MYB protein is expressed strongly and diffusely in tumor cells",
                      "CD117 (c-KIT) is under control of MYB and is also often overexpressed in the luminal tumor cells"
                    ]
                  },
                  {
                    "text": "Has an excellent prognosis with low local recurrence and metastatic rates and very few deaths due to disease"
                  }
                ],
                "Solid-Basaloid Adenoid Cystic Carcinoma (SB-AdCC)": [
                  {
                    "text": "~ 30-40% of breast AdCCs are classified as SB-AdCC"
                  },
                  {
                    "text": "Although 2 neoplastic cell populations are present, the myoepithelial population predominates, and the luminal cell population may be difficult to identifyThe myoepithelial cells are less likely to express p63 and are rarely associated with basement membrane-like material",
                    "sub_points": [
                      "The myoepithelial cells are less likely to express p63 and are rarely associated with basement membrane-like material"
                    ]
                  },
                  {
                    "text": "Only ~ 10-20% have the characteristicMYB::NFIBfusion geneMutations not commonly observed in C-AdCC are present, such as in NOTCH genes (~ 30-60%)",
                    "sub_points": [
                      "Mutations not commonly observed in C-AdCC are present, such as in NOTCH genes (~ 30-60%)"
                    ]
                  },
                  {
                    "text": "MYB is expressed in ~ 65-95%, including in carcinomas without the fusion gene"
                  },
                  {
                    "text": "~ 70-80% are grade 3 compared to < 5% of C-AdCC"
                  },
                  {
                    "text": "Has a higher local recurrence and metastatic rates with a ~ 40% death rate"
                  }
                ],
                "Adenoid Cystic Carcinoma With High-Grade Transformation": [
                  {
                    "text": "Very rare finding of C-AdCC in continuity with a poorly differentiated carcinoma"
                  },
                  {
                    "text": "In the cases studied, both components shared the common translocation, but the poorly differentiated component had acquired additional genetic alterationsIncludeNOTCH1,EP300, andFGFR1",
                    "sub_points": [
                      "IncludeNOTCH1,EP300, andFGFR1"
                    ]
                  },
                  {
                    "text": "These carcinomas have a poor prognosis"
                  }
                ],
                "Precursor Lesions": [
                  {
                    "text": "It is difficult to identify an in situ component in the majority of cases due to the presence of the neoplastic myoepithelial cell component of the tumorIn some cases, cells at the periphery of tumor cell nests are positive for a myoepithelial cell marker that is absent in the remainder of this populationThese may be benign myoepithelial cells identifying these areas as carcinoma in situ",
                    "sub_points": [
                      "In some cases, cells at the periphery of tumor cell nests are positive for a myoepithelial cell marker that is absent in the remainder of this population",
                      "These may be benign myoepithelial cells identifying these areas as carcinoma in situ"
                    ]
                  },
                  {
                    "text": "A few cases of AdCC are associated with microglandular adenosis or adenomyoepithelioma (AME)Although these lesions may act as precursors in rare cases, the majority of AdCC are not associated with identifiable precursor lesions",
                    "sub_points": [
                      "Although these lesions may act as precursors in rare cases, the majority of AdCC are not associated with identifiable precursor lesions"
                    ]
                  }
                ],
                "Relationship to Salivary Gland Adenoid Cystic Carcinoma": [
                  {
                    "text": "Morphologically similar carcinomas are seen in salivary glands and other body sites"
                  },
                  {
                    "text": "Both C-AdCC and salivary gland AdCC are strongly associated with translocations ofMYBresulting in increased expression of MYB protein"
                  },
                  {
                    "text": "Salivary gland AdCC has a higher local recurrence rate (~ 60%) and more frequent distant metastasis (~ 20-40%), resulting in a poorer prognosisSolid areas of growth within salivary gland AdCCs are used for grading and are a poor prognostic factor",
                    "sub_points": [
                      "Solid areas of growth within salivary gland AdCCs are used for grading and are a poor prognostic factor"
                    ]
                  },
                  {
                    "text": "Differing microRNA profiles of AdCCs from different sites may assist in identifying biologic differences"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare: < 0.1-3% of all breast carcinomas"
                  }
                ],
                "Age": [
                  {
                    "text": "Average: 50-65 years; range: 30-97 yearsMedian age slightly younger for C-AdCC (~ 55 years) compared to SB-AdCC (~ 65 years)",
                    "sub_points": [
                      "Median age slightly younger for C-AdCC (~ 55 years) compared to SB-AdCC (~ 65 years)"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Majority of patients are female; ~ 1% of AdCC cases reported in male patients"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "African American women have lower incidence compared to women of European descent"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most frequently presents as palpable, circumscribed, or lobulated mass below nippleSome are tenderMay have been present for several years",
                    "sub_points": [
                      "Some are tender",
                      "May have been present for several years"
                    ]
                  },
                  {
                    "text": "Rarely presents as mammographic mass; may be lobulated or irregular"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete excision with negative margins recommendedMargins can be difficult to evaluate, as tumor cells can invade as small nests in stroma without marked stromal response",
                    "sub_points": [
                      "Margins can be difficult to evaluate, as tumor cells can invade as small nests in stroma without marked stromal response"
                    ]
                  },
                  {
                    "text": "Lymph nodes are sometimes sampledIncidence of lymph node metastasis is very low for C-AdCC (< 5%) but higher for SB-AdCC (~ 15-30%)",
                    "sub_points": [
                      "Incidence of lymph node metastasis is very low for C-AdCC (< 5%) but higher for SB-AdCC (~ 15-30%)"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Local recurrence rates are lowRadiation may decrease local recurrence",
                    "sub_points": [
                      "Radiation may decrease local recurrence"
                    ]
                  },
                  {
                    "text": "Systemic therapyChemotherapy generally not recommended for C-AdCC (reportedly used in ~ 15%)Chemotherapy is more commonly used for SB-AdCC (reportedly used in ~ 70%)However, efficacy of chemotherapy for SB-AdCC is uncertain due to the small number of casesVariability in response to neoadjuvant chemotherapy has ranged from no response to a marked response in case reports",
                    "sub_points": [
                      "Chemotherapy generally not recommended for C-AdCC (reportedly used in ~ 15%)",
                      "Chemotherapy is more commonly used for SB-AdCC (reportedly used in ~ 70%)However, efficacy of chemotherapy for SB-AdCC is uncertain due to the small number of casesVariability in response to neoadjuvant chemotherapy has ranged from no response to a marked response in case reports",
                      "However, efficacy of chemotherapy for SB-AdCC is uncertain due to the small number of cases",
                      "Variability in response to neoadjuvant chemotherapy has ranged from no response to a marked response in case reports"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "C-AdCC has an excellent prognosisGenerally cured by complete excisionDistant metastasis is rare (3-8%)May recur after long periods of time and can have a prolonged clinical course90-100% survival at 10 years",
                    "sub_points": [
                      "Generally cured by complete excision",
                      "Distant metastasis is rare (3-8%)May recur after long periods of time and can have a prolonged clinical course",
                      "May recur after long periods of time and can have a prolonged clinical course",
                      "90-100% survival at 10 years"
                    ]
                  },
                  {
                    "text": "SB-AdCC has a poorer prognosisTumors with > 50% basaloid component are more likely to show poorer prognostic featuresAxillary lymph node metastasis (~ 15-30%) and distant metastasis (~ 45-65%) are frequentShorter time to distant metastasis (median: 22 months) compared to C-AdCC (84 months)~ 40% death rate",
                    "sub_points": [
                      "Tumors with > 50% basaloid component are more likely to show poorer prognostic features",
                      "Axillary lymph node metastasis (~ 15-30%) and distant metastasis (~ 45-65%) are frequent",
                      "Shorter time to distant metastasis (median: 22 months) compared to C-AdCC (84 months)",
                      "~ 40% death rate"
                    ]
                  },
                  {
                    "text": "Most common metastatic site is lung; also reported to bone, liver, brain, and kidney"
                  },
                  {
                    "text": "Both C-AdCC and SB-AdCC will score as having a poor prognosis using current commercial proprietary prognostic testsTherefore, histologic type is more important than gene expression profiling in predicting outcome for AdCC",
                    "sub_points": [
                      "Therefore, histologic type is more important than gene expression profiling in predicting outcome for AdCC"
                    ]
                  }
                ],
                "Misdiagnosis of Triple Negative Breast Carcinoma (TNBC) as Adenoid Cystic Carcinoma": [
                  {
                    "text": "Misclassification of poorly differentiated TNBC as AdCC reported in ~ 20% of casesThese cancers may not be treated with appropriate chemotherapy, which can lead to poor outcomes",
                    "sub_points": [
                      "These cancers may not be treated with appropriate chemotherapy, which can lead to poor outcomes"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Form circumscribed or lobulated massesExtent may be greater than that apparent on imaging",
                    "sub_points": [
                      "Extent may be greater than that apparent on imaging"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Firm, white, circumscribed, or ill-defined massMicroscopic extent of tumor may be greater than appreciated grossly due to minimal stromal response associated with peripheral infiltrating tumor nestsOccasionally, pink, tan, or gray microcysts may be evident",
                    "sub_points": [
                      "Microscopic extent of tumor may be greater than appreciated grossly due to minimal stromal response associated with peripheral infiltrating tumor nests",
                      "Occasionally, pink, tan, or gray microcysts may be evident"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "Majority 1-4 cm (average: 3 cm)Can range from 0.5-12.0 cm in size",
                    "sub_points": [
                      "Can range from 0.5-12.0 cm in size"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Overall changesMajority have diploid DNA content with a low frequency of genomic changes compared to other types of TNBCsLoss of 16q and gain of 1q infrequentIn contrast, these changes are frequently found in grade 1 invasive ductal carcinomasSB-AdCC has more rearrangements than C-AdCC but fewer than TNBC",
                    "sub_points": [
                      "Majority have diploid DNA content with a low frequency of genomic changes compared to other types of TNBCsLoss of 16q and gain of 1q infrequentIn contrast, these changes are frequently found in grade 1 invasive ductal carcinomas",
                      "Loss of 16q and gain of 1q infrequentIn contrast, these changes are frequently found in grade 1 invasive ductal carcinomas",
                      "In contrast, these changes are frequently found in grade 1 invasive ductal carcinomas",
                      "SB-AdCC has more rearrangements than C-AdCC but fewer than TNBC"
                    ]
                  },
                  {
                    "text": "MYB::NFIBtranslocationThe most common finding is a chromosomal translocation resulting in anMYB::NFIBgene fusion: t(6;9)(q22-23;p23-24)Present in the majority of C-AdCC (~ 70-90%) and in the minority of SB-AdCC (~ 10-20%)The loss of the 3' miRNA binding sites that regulateMYBmay result in increased transcriptionBoth genes are transcription factorsMYB plays a key role in regulating stem and progenitor cellsNFIBrole unclearNFIBis also involved in fusion withHMGA2in pleomorphic adenomas (PAs) of salivary glandThese benign tumors also consist of both myoepithelial and luminal cellsSome tumors have fusions ofNFIBwith an unidentified gene partner",
                    "sub_points": [
                      "The most common finding is a chromosomal translocation resulting in anMYB::NFIBgene fusion: t(6;9)(q22-23;p23-24)Present in the majority of C-AdCC (~ 70-90%) and in the minority of SB-AdCC (~ 10-20%)The loss of the 3' miRNA binding sites that regulateMYBmay result in increased transcription",
                      "Present in the majority of C-AdCC (~ 70-90%) and in the minority of SB-AdCC (~ 10-20%)",
                      "The loss of the 3' miRNA binding sites that regulateMYBmay result in increased transcription",
                      "Both genes are transcription factors",
                      "MYB plays a key role in regulating stem and progenitor cells",
                      "NFIBrole unclearNFIBis also involved in fusion withHMGA2in pleomorphic adenomas (PAs) of salivary glandThese benign tumors also consist of both myoepithelial and luminal cellsSome tumors have fusions ofNFIBwith an unidentified gene partner",
                      "NFIBis also involved in fusion withHMGA2in pleomorphic adenomas (PAs) of salivary glandThese benign tumors also consist of both myoepithelial and luminal cells",
                      "These benign tumors also consist of both myoepithelial and luminal cells",
                      "Some tumors have fusions ofNFIBwith an unidentified gene partner"
                    ]
                  },
                  {
                    "text": "Other rearrangements involvingMYBorMYBL1Much less common than theMYB::NFIBfusion geneMYBL1::NFIBorMYBL1::ACTN1gene fusions are detected in a few casesMYBL1encodes A-MYB, which is structurally related to c-MYB and activates similar pathwaysBoth proteins activate similar pathwaysSome tumors may have intrachromosomal rearrangements involvingMYBthat are not detected by standard techniquesRN7SKP203::EIF4G2fusions may be present in AdCC ±MYBrearrangements",
                    "sub_points": [
                      "Much less common than theMYB::NFIBfusion gene",
                      "MYBL1::NFIBorMYBL1::ACTN1gene fusions are detected in a few casesMYBL1encodes A-MYB, which is structurally related to c-MYB and activates similar pathwaysBoth proteins activate similar pathways",
                      "MYBL1encodes A-MYB, which is structurally related to c-MYB and activates similar pathways",
                      "Both proteins activate similar pathways",
                      "Some tumors may have intrachromosomal rearrangements involvingMYBthat are not detected by standard techniques",
                      "RN7SKP203::EIF4G2fusions may be present in AdCC ±MYBrearrangements"
                    ]
                  },
                  {
                    "text": "MYBamplification or mutationMYBamplification occurs in rare cancers and results in protein overexpressionMYBcan also be mutated in some cases",
                    "sub_points": [
                      "MYBamplification occurs in rare cancers and results in protein overexpression",
                      "MYBcan also be mutated in some cases"
                    ]
                  },
                  {
                    "text": "MutationsMutations in NOTCH genes are found in 30-60% of SB-AdCC compared to < 5% of C-AdCCNOTCH activation downregulates p63, which could correlate with loss of p63 immunoreactivityNOTCH expression may be associated with more aggressive outcomesCREBBPmutations reported in SB-AdCCActivating mutations inCD117(c-KIT) absent or rareTP53mutations are rare, whereas mutations are common in other types of TNBC (~ 80%)PIK3CAmutations are usually absent",
                    "sub_points": [
                      "Mutations in NOTCH genes are found in 30-60% of SB-AdCC compared to < 5% of C-AdCCNOTCH activation downregulates p63, which could correlate with loss of p63 immunoreactivityNOTCH expression may be associated with more aggressive outcomes",
                      "NOTCH activation downregulates p63, which could correlate with loss of p63 immunoreactivity",
                      "NOTCH expression may be associated with more aggressive outcomes",
                      "CREBBPmutations reported in SB-AdCC",
                      "Activating mutations inCD117(c-KIT) absent or rare",
                      "TP53mutations are rare, whereas mutations are common in other types of TNBC (~ 80%)",
                      "PIK3CAmutations are usually absent"
                    ]
                  }
                ],
                "mRNA": [
                  {
                    "text": "Gene expression profiling classifies AdCC as a basal-like carcinoma"
                  },
                  {
                    "text": "MYBmRNA is overexpressedPresent in AdCC ± gene fusionMay be other activating mechanisms in some carcinomas",
                    "sub_points": [
                      "Present in AdCC ± gene fusion",
                      "May be other activating mechanisms in some carcinomas"
                    ]
                  },
                  {
                    "text": "NormalBRCA1mRNA levelsIn contrast, basal-like carcinomas frequently haveBRCA1gene promoter methylation resulting in dysfunctional signaling pathway",
                    "sub_points": [
                      "In contrast, basal-like carcinomas frequently haveBRCA1gene promoter methylation resulting in dysfunctional signaling pathway"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "MYB protein is expressed by the majority of AdCC"
                  },
                  {
                    "text": "Protein expression patterns for luminal and myoepithelial cells identify 2 distinct tumor cell populationsMost proteins are expressed by only 1 population",
                    "sub_points": [
                      "Most proteins are expressed by only 1 population"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "C-AdCC3 architectural patternsCribriform: Most common pattern due to lumina and pseudoluminaReticular-tubular: Tumor cells are surrounded by predominant component of stromaSolid: Myoepithelial cells predominate with few luminal cellsPseudolumina(stromal invaginations)Rounded spaces are surrounded by myoepithelial cellsSpaces are filled with basement membrane-type material that can be collagenous, myxoid, or mucinousConsist of duplicated basal lamina and glycosaminoglycansTrue luminaLuminal cells form small tubules, which may be empty or filled flocculent secretionsCells are generally small with scant cytoplasmNuclei have dense chromatin without prominent nucleoliNo marked nuclear pleomorphismMitoses are absent or rareRare cases show squamous or sebaceous differentiationThe Nottingham system of grading can be usedThe majority are grade 1 or 2 with only rare tumors reported as grade 3 (< 5%)Other grading systems have been suggested but have not been shown to be superior for prognosticationAlthough the central portion of the tumor forms a mass due to closely apposed nests of tumor cells, tumor cell nests also have an infiltrative pattern into surrounding breast tissueA desmoplastic response is often absent, making the periphery of the carcinoma difficult to detect by imaging or during surgery",
                    "sub_points": [
                      "3 architectural patternsCribriform: Most common pattern due to lumina and pseudoluminaReticular-tubular: Tumor cells are surrounded by predominant component of stromaSolid: Myoepithelial cells predominate with few luminal cells",
                      "Cribriform: Most common pattern due to lumina and pseudolumina",
                      "Reticular-tubular: Tumor cells are surrounded by predominant component of stroma",
                      "Solid: Myoepithelial cells predominate with few luminal cells",
                      "Pseudolumina(stromal invaginations)Rounded spaces are surrounded by myoepithelial cellsSpaces are filled with basement membrane-type material that can be collagenous, myxoid, or mucinousConsist of duplicated basal lamina and glycosaminoglycans",
                      "Rounded spaces are surrounded by myoepithelial cells",
                      "Spaces are filled with basement membrane-type material that can be collagenous, myxoid, or mucinousConsist of duplicated basal lamina and glycosaminoglycans",
                      "Consist of duplicated basal lamina and glycosaminoglycans",
                      "True luminaLuminal cells form small tubules, which may be empty or filled flocculent secretions",
                      "Luminal cells form small tubules, which may be empty or filled flocculent secretions",
                      "Cells are generally small with scant cytoplasmNuclei have dense chromatin without prominent nucleoliNo marked nuclear pleomorphismMitoses are absent or rareRare cases show squamous or sebaceous differentiation",
                      "Nuclei have dense chromatin without prominent nucleoli",
                      "No marked nuclear pleomorphism",
                      "Mitoses are absent or rare",
                      "Rare cases show squamous or sebaceous differentiation",
                      "The Nottingham system of grading can be usedThe majority are grade 1 or 2 with only rare tumors reported as grade 3 (< 5%)Other grading systems have been suggested but have not been shown to be superior for prognostication",
                      "The majority are grade 1 or 2 with only rare tumors reported as grade 3 (< 5%)",
                      "Other grading systems have been suggested but have not been shown to be superior for prognostication",
                      "Although the central portion of the tumor forms a mass due to closely apposed nests of tumor cells, tumor cell nests also have an infiltrative pattern into surrounding breast tissueA desmoplastic response is often absent, making the periphery of the carcinoma difficult to detect by imaging or during surgery",
                      "A desmoplastic response is often absent, making the periphery of the carcinoma difficult to detect by imaging or during surgery"
                    ]
                  },
                  {
                    "text": "SB-AdCCConsists almost entirely of myoepithelial cells with a minor luminal cell populationIHC for low molecular weight keratins (e.g., CK7) can help identify lumina when sparseMyoepithelial cells have scant cytoplasm (high nuclear:cytoplasmic ratio) conferring the basaloid appearanceNuclei are hyperchromatic with greater pleomorphismMitoses often present and may be numerousMyoepithelial cells may not express p63 (only ~ 40-50% of tumors show positivity)Architectural patternsMajority have a solid patternCribriform pattern is less common, as true lumina are absent or scarce, and basement membrane-like material is often absentMay invade as ragged nests of cells rather than as circumscribed nestsA myxohyaline stroma is characteristicNeovascularization (dense capillary vessels in peritumoral or intratumoral stroma away from the biopsy site) was a poor prognostic factor in one study50% of patients with this feature had nodal involvement and 50% had distant metastasis",
                    "sub_points": [
                      "Consists almost entirely of myoepithelial cells with a minor luminal cell populationIHC for low molecular weight keratins (e.g., CK7) can help identify lumina when sparse",
                      "IHC for low molecular weight keratins (e.g., CK7) can help identify lumina when sparse",
                      "Myoepithelial cells have scant cytoplasm (high nuclear:cytoplasmic ratio) conferring the basaloid appearanceNuclei are hyperchromatic with greater pleomorphismMitoses often present and may be numerousMyoepithelial cells may not express p63 (only ~ 40-50% of tumors show positivity)",
                      "Nuclei are hyperchromatic with greater pleomorphism",
                      "Mitoses often present and may be numerous",
                      "Myoepithelial cells may not express p63 (only ~ 40-50% of tumors show positivity)",
                      "Architectural patternsMajority have a solid patternCribriform pattern is less common, as true lumina are absent or scarce, and basement membrane-like material is often absent",
                      "Majority have a solid patternCribriform pattern is less common, as true lumina are absent or scarce, and basement membrane-like material is often absent",
                      "Cribriform pattern is less common, as true lumina are absent or scarce, and basement membrane-like material is often absent",
                      "May invade as ragged nests of cells rather than as circumscribed nestsA myxohyaline stroma is characteristic",
                      "A myxohyaline stroma is characteristic",
                      "Neovascularization (dense capillary vessels in peritumoral or intratumoral stroma away from the biopsy site) was a poor prognostic factor in one study50% of patients with this feature had nodal involvement and 50% had distant metastasis",
                      "50% of patients with this feature had nodal involvement and 50% had distant metastasis"
                    ]
                  },
                  {
                    "text": "AdCC with high-grade transformationVery rare cases of AdCC are associated with a poorly differentiated component that lacks features of AdCCHistologic types have included malignant adenomyoepithelioma (AME), small cell carcinoma, as well as carcinomas of no special type",
                    "sub_points": [
                      "Very rare cases of AdCC are associated with a poorly differentiated component that lacks features of AdCCHistologic types have included malignant adenomyoepithelioma (AME), small cell carcinoma, as well as carcinomas of no special type",
                      "Histologic types have included malignant adenomyoepithelioma (AME), small cell carcinoma, as well as carcinomas of no special type"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "May be difficult to diagnose if reticular-tubular pattern or solid pattern is predominantFinal classification is best made after excision",
                    "sub_points": [
                      "Final classification is best made after excision"
                    ]
                  },
                  {
                    "text": "Collagenous spherulosis (CS) may be in the differential diagnosisCS generally involves single lobular unitGenerally an incidental finding or occasionally associated with calcificationsCS forming a mass detected by imaging would be unusual",
                    "sub_points": [
                      "CS generally involves single lobular unit",
                      "Generally an incidental finding or occasionally associated with calcifications",
                      "CS forming a mass detected by imaging would be unusual"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "IHC studies demonstrate 2 distinct cell populations"
                  },
                  {
                    "text": "Luminal cellsUsually positive for low molecular weight keratins (cytokeratin 7 or CAM5.2), epithelial membrane antigen, and carcinoembryonic antigenTypically highlights formation of luminaIn some cases, luminal cells reported to be positive for cytokeratins 5/6CD117 positivity is only specific for AdCC if only the luminal cells are positivePositivity can be seen in other breast carcinomas and is not diagnostic of AdCCReactivity for CD117 varies with antibody usedNegative for myoepithelial markers, especially p63",
                    "sub_points": [
                      "Usually positive for low molecular weight keratins (cytokeratin 7 or CAM5.2), epithelial membrane antigen, and carcinoembryonic antigenTypically highlights formation of luminaIn some cases, luminal cells reported to be positive for cytokeratins 5/6",
                      "Typically highlights formation of lumina",
                      "In some cases, luminal cells reported to be positive for cytokeratins 5/6",
                      "CD117 positivity is only specific for AdCC if only the luminal cells are positivePositivity can be seen in other breast carcinomas and is not diagnostic of AdCCReactivity for CD117 varies with antibody used",
                      "Positivity can be seen in other breast carcinomas and is not diagnostic of AdCC",
                      "Reactivity for CD117 varies with antibody used",
                      "Negative for myoepithelial markers, especially p63"
                    ]
                  },
                  {
                    "text": "Myoepithelial cellsUsually positive for p63, smooth muscle actin, calponin, maspin, laminin, and cytokeratins 14 and 17However, positivity for all myoepithelial markers will not be seen in all tumorsOf note, p63 is positive in > 95% of C-AdCC but only ~ 40-60% of SB-AdCCNegative for luminal markers",
                    "sub_points": [
                      "Usually positive for p63, smooth muscle actin, calponin, maspin, laminin, and cytokeratins 14 and 17However, positivity for all myoepithelial markers will not be seen in all tumors",
                      "However, positivity for all myoepithelial markers will not be seen in all tumors",
                      "Of note, p63 is positive in > 95% of C-AdCC but only ~ 40-60% of SB-AdCC",
                      "Negative for luminal markers"
                    ]
                  },
                  {
                    "text": "Hormone receptors: Predominantly negativeRare carcinomas may show focal positivityAndrogen receptor reported to be positive in some tumors",
                    "sub_points": [
                      "Rare carcinomas may show focal positivity",
                      "Androgen receptor reported to be positive in some tumors"
                    ]
                  },
                  {
                    "text": "MYB: Strong and diffuse positivity in the majority of C-AdCC (> 95%) and SB-AdCC (~ 65-95% of tumor cells)Positive in tumors with knownMYBtranslocations as well as tumors that lack anMYBrearrangement by conventional analysisMyoepithelial cells show stronger stainingStrong diffuse MYB staining has a high specificity for the diagnosis of C-AdCC and SB-AdCCHowever, results may vary with different antibodies",
                    "sub_points": [
                      "Positive in tumors with knownMYBtranslocations as well as tumors that lack anMYBrearrangement by conventional analysis",
                      "Myoepithelial cells show stronger staining",
                      "Strong diffuse MYB staining has a high specificity for the diagnosis of C-AdCC and SB-AdCC",
                      "However, results may vary with different antibodies"
                    ]
                  },
                  {
                    "text": "HER2: Negative"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Detection ofMYB::NFIBtranslocation can be used to support diagnosisMay be detected with FISH break-apart probesNot necessary for C-AdCCAbsence does not preclude the diagnosisUnknown if this translocation is specific for AdCC or might be seen in other epithelial/myoepithelial carcinomasPresent in some cylindromas",
                    "sub_points": [
                      "May be detected with FISH break-apart probes",
                      "Not necessary for C-AdCCAbsence does not preclude the diagnosis",
                      "Absence does not preclude the diagnosis",
                      "Unknown if this translocation is specific for AdCC or might be seen in other epithelial/myoepithelial carcinomasPresent in some cylindromas",
                      "Present in some cylindromas"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Triple Negative Breast Carcinoma (TNBC) With Basaloid Features": [
                  {
                    "text": "TNBCs can have a basaloid appearance with scant cytoplasm and hyperchromatic nuclei, which resemble the myoepithelial component of AdCC"
                  },
                  {
                    "text": "However, 2 distinct cell populations are not presentImmunoperoxidase studies may show heterogeneous overlapping immunoreactivity for markers that should show separate populations of cells in AdCC",
                    "sub_points": [
                      "Immunoperoxidase studies may show heterogeneous overlapping immunoreactivity for markers that should show separate populations of cells in AdCC"
                    ]
                  },
                  {
                    "text": "Immunoreactivity for MYB &/or CD117 (c-KIT), particularly if weak and heterogeneous, should not be used as the sole criteria to classify a carcinoma as AdCCMYB is positive in ~ 40-65% of TNBCs but is usually weak and heterogeneousCD117 is positive in ~ 50% of cases of TNBCsCD117 positivity is only specific for AdCC if it is only positive in a tubule-forming luminal population and not in a p63-positive myoepithelial population",
                    "sub_points": [
                      "MYB is positive in ~ 40-65% of TNBCs but is usually weak and heterogeneous",
                      "CD117 is positive in ~ 50% of cases of TNBCsCD117 positivity is only specific for AdCC if it is only positive in a tubule-forming luminal population and not in a p63-positive myoepithelial population",
                      "CD117 positivity is only specific for AdCC if it is only positive in a tubule-forming luminal population and not in a p63-positive myoepithelial population"
                    ]
                  },
                  {
                    "text": "TP53mutations are common, whereas they are rare in AdCC"
                  }
                ],
                "Collagenous Spherulosis (CS)": [
                  {
                    "text": "Typically seen as a small incidental finding (< 1 cm) or associated with calcifications by imaging"
                  },
                  {
                    "text": "Unlikely to be confused with AdCC, which presents as a mass"
                  },
                  {
                    "text": "A possible difficulty in diagnosis would only arise in very small core needle biopsies"
                  },
                  {
                    "text": "Both CS and AdCC are composed of 2 cell populationsBoth associated with formation of basement membrane material by myoepithelial cell populationCS resembles cribriform pattern of AdCC",
                    "sub_points": [
                      "Both associated with formation of basement membrane material by myoepithelial cell population",
                      "CS resembles cribriform pattern of AdCC"
                    ]
                  },
                  {
                    "text": "Myoepithelial cells of CS are more often positive for multiple IHC markers than those in AdCCLikely due to neoplastic cells in AdCC showing aberrant loss of expression in some cases",
                    "sub_points": [
                      "Likely due to neoplastic cells in AdCC showing aberrant loss of expression in some cases"
                    ]
                  },
                  {
                    "text": "Luminal cells in CS are less likely to form lumina and less likely to be positive for CD117 (c-KIT)However, immunoreactivity for CD117 can also be variable in AdCC and may depend on antibody usedLuminal cells in CS are frequently positive for ER and PR, whereas this is uncommon in AdCC",
                    "sub_points": [
                      "However, immunoreactivity for CD117 can also be variable in AdCC and may depend on antibody used",
                      "Luminal cells in CS are frequently positive for ER and PR, whereas this is uncommon in AdCC"
                    ]
                  }
                ],
                "Cylindroma": [
                  {
                    "text": "Most commonly occurs as a benign eccrine skin tumor found in dermisRarely arise deeper in breast, usually near the nippleNuclear atypia and mitoses are absent~ 60% of dermal tumors have theMYB::NFIBgene fusion found in AdCCPositive for MYB by immunohistochemistryIn 2 breast tumors studied, the translocation was not detectedSome cylindromas, including breast tumors, are associated with Brooke-Spiegler or familial cylindromatosis syndromeDue to germline mutations in the tumor suppressor geneCYLDat 16q12.1CYLDmutation and loss of normal allele occur in ~ 75% of sporadic dermal cylindromasDocumented in 2 cases of breast sporadic cylindromasAlterations inCYLDhave not been found in AdCC with the exception of one unusual case that lacked theMYB::NFIBfusion geneThe possibility that this single case may have been a cylindroma has been suggested",
                    "sub_points": [
                      "Rarely arise deeper in breast, usually near the nipple",
                      "Nuclear atypia and mitoses are absent",
                      "~ 60% of dermal tumors have theMYB::NFIBgene fusion found in AdCCPositive for MYB by immunohistochemistryIn 2 breast tumors studied, the translocation was not detected",
                      "Positive for MYB by immunohistochemistry",
                      "In 2 breast tumors studied, the translocation was not detected",
                      "Some cylindromas, including breast tumors, are associated with Brooke-Spiegler or familial cylindromatosis syndromeDue to germline mutations in the tumor suppressor geneCYLDat 16q12.1CYLDmutation and loss of normal allele occur in ~ 75% of sporadic dermal cylindromasDocumented in 2 cases of breast sporadic cylindromasAlterations inCYLDhave not been found in AdCC with the exception of one unusual case that lacked theMYB::NFIBfusion geneThe possibility that this single case may have been a cylindroma has been suggested",
                      "Due to germline mutations in the tumor suppressor geneCYLDat 16q12.1",
                      "CYLDmutation and loss of normal allele occur in ~ 75% of sporadic dermal cylindromasDocumented in 2 cases of breast sporadic cylindromas",
                      "Documented in 2 cases of breast sporadic cylindromas",
                      "Alterations inCYLDhave not been found in AdCC with the exception of one unusual case that lacked theMYB::NFIBfusion geneThe possibility that this single case may have been a cylindroma has been suggested",
                      "The possibility that this single case may have been a cylindroma has been suggested"
                    ]
                  },
                  {
                    "text": "Forms well-circumscribed massTumor cell nests fit together in jigsaw-like patternNests of cells are surrounded by a thick basement membrane",
                    "sub_points": [
                      "Tumor cell nests fit together in jigsaw-like pattern",
                      "Nests of cells are surrounded by a thick basement membrane"
                    ]
                  },
                  {
                    "text": "Composed of distinct populations of myoepithelial and luminal cellsLuminal cells cluster in the center of tumor cell nests and are surrounded by myoepithelial cellsBasement membrane production is seen in tumor cell nestsSmall lumina can be present",
                    "sub_points": [
                      "Luminal cells cluster in the center of tumor cell nests and are surrounded by myoepithelial cellsBasement membrane production is seen in tumor cell nestsSmall lumina can be present",
                      "Basement membrane production is seen in tumor cell nests",
                      "Small lumina can be present"
                    ]
                  }
                ],
                "Adenomyoepithelioma (AME)": [
                  {
                    "text": "Majority are benign lesions consisting of luminal and myoepithelial cellsDo not have theMYBgene rearrangements characteristic of AdCC",
                    "sub_points": [
                      "Do not have theMYBgene rearrangements characteristic of AdCC"
                    ]
                  },
                  {
                    "text": "Form expansile, well-circumscribed massesDo not have infiltrative pattern except for the tubular variantBasement membrane-like material formation is absent or minimal",
                    "sub_points": [
                      "Do not have infiltrative pattern except for the tubular variant",
                      "Basement membrane-like material formation is absent or minimal"
                    ]
                  },
                  {
                    "text": "Luminal cells can appear apocrine, squamous, or have sebaceous appearance"
                  },
                  {
                    "text": "Myoepithelial cells can be spindled, plasmacytoid, or myoid in appearanceIn contrast, the myoepithelial cells in AdCC have a basaloid appearance",
                    "sub_points": [
                      "In contrast, the myoepithelial cells in AdCC have a basaloid appearance"
                    ]
                  },
                  {
                    "text": "Malignant AME has features of malignancy (high nuclear grade, increased mitotic rate, necrosis) and can metastasize"
                  }
                ],
                "Pleomorphic Adenoma (PA)": [
                  {
                    "text": "Very rare breast tumor that resembles PA of the salivary gland"
                  },
                  {
                    "text": "Consist of luminal and myoepithelial cells in a very prominent stromal matrixChondroid, myxoid, or osseous",
                    "sub_points": [
                      "Chondroid, myxoid, or osseous"
                    ]
                  },
                  {
                    "text": "Grow as circumscribed or lobulated masses and do not invade into adjacent stroma"
                  }
                ],
                "Ductal Carcinoma In Situ, Cribriform Pattern": [
                  {
                    "text": "Cribriform spaces are empty or filled with secretions"
                  },
                  {
                    "text": "Almost all are positive for ER and PR"
                  },
                  {
                    "text": "Normal myoepithelial cells are limited to periphery"
                  }
                ],
                "Invasive Cribriform Carcinoma": [
                  {
                    "text": "Cribriform spaces are empty or filled with secretionsDoes not produce basement membrane-like material",
                    "sub_points": [
                      "Does not produce basement membrane-like material"
                    ]
                  },
                  {
                    "text": "Almost all are positive for ER and PR"
                  },
                  {
                    "text": "Cells positive for myoepithelial markers are not present"
                  }
                ],
                "Solid Papillary Carcinoma (SPC)": [
                  {
                    "text": "SPC is typically diffusely positive for hormone receptors, and up to 2/3 express neuroendocrine markersAdCC is typically negative for ER, PR, and neuroendocrine markers",
                    "sub_points": [
                      "AdCC is typically negative for ER, PR, and neuroendocrine markers"
                    ]
                  },
                  {
                    "text": "SB-AdCC rarely can show morphologic overlap with SPC"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "The subtype of AdCC (C-AdCC or SB-AdCC) should be specified, as the prognosis and treatment varies"
                  },
                  {
                    "text": "Reporting of IHC results should include identification of 2 discrete cell populations"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Reported using College of American Pathologists checklist for invasive carcinomas"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Secretory Carcinoma": {
            "name": "Secretory Carcinoma",
            "url": "https://app.pathprimer.com/document/083cc122-ec45-43b1-9036-60f4de69267f/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Very rare type of invasive breast carcinoma (< 0.2% of breast carcinomas)"
                  },
                  {
                    "text": "Only breast carcinoma with a balanced translocation, t(12;15)(p13;q25), resulting inETV6::NTRK3gene fusion tyrosine kinase productSame translocation occurs in pediatric mesenchymal cancers (congenital fibrosarcoma and congenital cellular mesoblastic nephroma) and mammary analogue secretory carcinoma of the salivary gland, thyroid, and skin",
                    "sub_points": [
                      "Same translocation occurs in pediatric mesenchymal cancers (congenital fibrosarcoma and congenital cellular mesoblastic nephroma) and mammary analogue secretory carcinoma of the salivary gland, thyroid, and skin"
                    ]
                  },
                  {
                    "text": "Member of the \"low-grade triple negative neoplasia family\""
                  },
                  {
                    "text": "Occurs over wide age range: < 5 years to > 80 yearsOccurs in both females and malesMost common breast carcinoma in pediatric patients (~ 80%)",
                    "sub_points": [
                      "Occurs in both females and males",
                      "Most common breast carcinoma in pediatric patients (~ 80%)"
                    ]
                  },
                  {
                    "text": "Majority of patients are treated successfully with only surgeryRecurrences and distant metastases are rareDisease-specific survival is 94% at 5 years and 91% at 10 years",
                    "sub_points": [
                      "Recurrences and distant metastases are rare",
                      "Disease-specific survival is 94% at 5 years and 91% at 10 years"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Intracellular and extracellular eosinophilic bubbly secretory material is characteristic"
                  },
                  {
                    "text": "Cells have low to moderate nuclear grade and low proliferative rate"
                  },
                  {
                    "text": "Majority are negative for ER, PR, and HER2 and strongly positive for S100"
                  },
                  {
                    "text": "Positivity for PAN-TRK is helpful to confirm diagnosis"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Acinic cell carcinoma"
                  },
                  {
                    "text": "Invasive carcinoma with apocrine differentiation"
                  },
                  {
                    "text": "Cystic hypersecretory carcinoma"
                  },
                  {
                    "text": "Granular cell tumor"
                  },
                  {
                    "text": "Microglandular adenosis"
                  },
                  {
                    "text": "Lactational change in normal breast tissue"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Juvenile breast carcinoma (not recommended by WHO)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare type of breast cancer characterized by theETV6::NTRK3gene translocation"
                  },
                  {
                    "text": "Not all cases have been confirmed with molecular studiesLimits analysis of large series, as some nonsecretory cancers may be included",
                    "sub_points": [
                      "Limits analysis of large series, as some nonsecretory cancers may be included"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Secretory carcinoma has a pathognomonic balanced translocation, t(12;15) (p13:q25), resulting in anETV6::NTRK3gene fusion productThe fusion protein is a chimeric tyrosine kinase with transforming activityPresent in secretory ductal carcinoma in situ (DCIS) and secretory invasive carcinoma",
                    "sub_points": [
                      "The fusion protein is a chimeric tyrosine kinase with transforming activity",
                      "Present in secretory ductal carcinoma in situ (DCIS) and secretory invasive carcinoma"
                    ]
                  },
                  {
                    "text": "The same translocation also occurs in some nonbreast tumors at a high frequency (> 90% of cases)Mammary analogue secretory carcinoma arising in the salivary gland, thyroid, and skinPediatric mesenchymal tumorsCongenital fibrosarcoma and congenital cellular mesoblastic nephroma",
                    "sub_points": [
                      "Mammary analogue secretory carcinoma arising in the salivary gland, thyroid, and skin",
                      "Pediatric mesenchymal tumorsCongenital fibrosarcoma and congenital cellular mesoblastic nephroma",
                      "Congenital fibrosarcoma and congenital cellular mesoblastic nephroma"
                    ]
                  },
                  {
                    "text": "Similar translocations involving NTRK gene (NTRK1,NTRK2, andNTRK3) fusions occur at lower frequencies in many types of cancers (~ 5-25%)Papillary thyroid carcinoma, pediatric glioma, acute myeloid leukemia, others",
                    "sub_points": [
                      "Papillary thyroid carcinoma, pediatric glioma, acute myeloid leukemia, others"
                    ]
                  },
                  {
                    "text": "Tumors with these translocations have relatively few other genomic changes"
                  },
                  {
                    "text": "Fusion genes derived from NTRK are oncogenic driversThe oncogenic chimeric protein activates signaling involved in proliferation, survival, and angiogenesisFusion gene activates RAS-MAPK and PI3K pathways to drive oncologic processesLarotrectinib, a selective TRK inhibitor, has marked and durable antitumor activity in TRK-fusion-positive cancers",
                    "sub_points": [
                      "The oncogenic chimeric protein activates signaling involved in proliferation, survival, and angiogenesis",
                      "Fusion gene activates RAS-MAPK and PI3K pathways to drive oncologic processes",
                      "Larotrectinib, a selective TRK inhibitor, has marked and durable antitumor activity in TRK-fusion-positive cancers"
                    ]
                  }
                ],
                "Low-Grade Triple Negative Breast Carcinoma (TNBC) Family Member": [
                  {
                    "text": "Secretory carcinoma is a type of TNBC due to the absence of expression of hormone receptors and HER2 in the majority of cases"
                  },
                  {
                    "text": "\"Low-grade\" members of this family have a relatively good prognosis compared to TNBC in general"
                  },
                  {
                    "text": "Multiomic studies indicate that secretory carcinoma has substantially different genomic and proteomic profiles compared with basal-like TNBC"
                  },
                  {
                    "text": "Some of the other members of this family are also characterized by specific genomic changesAdenoid cystic carcinoma (MYB::NFIBfusion gene), solid papillary carcinoma with reverse polarity (IDH2R172 hotspot mutations), others",
                    "sub_points": [
                      "Adenoid cystic carcinoma (MYB::NFIBfusion gene), solid papillary carcinoma with reverse polarity (IDH2R172 hotspot mutations), others"
                    ]
                  }
                ],
                "Hormonal": [
                  {
                    "text": "Secretory carcinoma is not associated with pregnancy or lactationAppearance only mimics lactating breast tissue",
                    "sub_points": [
                      "Appearance only mimics lactating breast tissue"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare type of invasive breast carcinoma (< 0.2% of breast carcinomas)"
                  }
                ],
                "Age": [
                  {
                    "text": "Occurs over wide range: < 5 years to > 80 years (median age: 53 years)Most common type of pediatric breast cancer (~ 80% of cases)",
                    "sub_points": [
                      "Most common type of pediatric breast cancer (~ 80% of cases)"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Occurs in both females and males2/3 of female cases occur < 30 years of age3/4 of male cases occur < 30 years of age",
                    "sub_points": [
                      "2/3 of female cases occur < 30 years of age",
                      "3/4 of male cases occur < 30 years of age"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Slow-growing mass with generally circumscribed margins detected by palpation or imagingMay be present for several years",
                    "sub_points": [
                      "May be present for several years"
                    ]
                  },
                  {
                    "text": "Occurs at any location in breastGenerally subareolar in prepubertal patients and men (where majority of breast tissue is located)",
                    "sub_points": [
                      "Generally subareolar in prepubertal patients and men (where majority of breast tissue is located)"
                    ]
                  },
                  {
                    "text": "Nipple discharge is not a typical featureNot associated with prior or current pregnancy or lactation",
                    "sub_points": [
                      "Not associated with prior or current pregnancy or lactation"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Majority of patients have been treated surgically with excision of the carcinoma and axillary lymph nodes"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "There are insufficient numbers of patients to determine possible benefit of chemotherapy &/or radiationSome patients with metastatic secretory carcinoma who received chemotherapy progressed during treatment",
                    "sub_points": [
                      "Some patients with metastatic secretory carcinoma who received chemotherapy progressed during treatment"
                    ]
                  },
                  {
                    "text": "TRK inhibitors have shown antitumor activity in TRK fusion-positive cancers, regardless of age or tumor type"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Indolent biologic behavior; majority of patients remain free of disease after surgical excision~ 30% of patients have axillary lymph node metastasesRare in cancers < 2 cmUsually < 3 nodes involvedNodal metastases do not predict poor outcome",
                    "sub_points": [
                      "~ 30% of patients have axillary lymph node metastasesRare in cancers < 2 cmUsually < 3 nodes involvedNodal metastases do not predict poor outcome",
                      "Rare in cancers < 2 cm",
                      "Usually < 3 nodes involved",
                      "Nodal metastases do not predict poor outcome"
                    ]
                  },
                  {
                    "text": "Recurrences may occur many years after initial treatment (> 10 years)Most are local and occur in residual breast tissue, surgical scars, or nodes",
                    "sub_points": [
                      "Most are local and occur in residual breast tissue, surgical scars, or nodes"
                    ]
                  },
                  {
                    "text": "Systemic metastases are rareOnly 6 cases with distant metastases reportedMajority reported prior to identification of translocationOnly 1 case documented to have translocationIt is possible some other cases were mimics of secretory carcinoma",
                    "sub_points": [
                      "Only 6 cases with distant metastases reported",
                      "Majority reported prior to identification of translocationOnly 1 case documented to have translocationIt is possible some other cases were mimics of secretory carcinoma",
                      "Only 1 case documented to have translocation",
                      "It is possible some other cases were mimics of secretory carcinoma"
                    ]
                  },
                  {
                    "text": "Only rare deaths reported (< 5% of patients)Young patients tend to have better prognosis than older patientsPoorer prognosis may be associated with very large carcinomas and multiple nodal metastases (> 3)",
                    "sub_points": [
                      "Young patients tend to have better prognosis than older patients",
                      "Poorer prognosis may be associated with very large carcinomas and multiple nodal metastases (> 3)"
                    ]
                  },
                  {
                    "text": "Disease-specific survival is 94% at 5 years and 91% at 10 years"
                  },
                  {
                    "text": "Commercial prognostic assaysWould likely be predicted to have poor prognosis due to lack of hormone receptorsThese assays have not been validated for rare tumorsHistologic appearance currently more important than proprietary assays",
                    "sub_points": [
                      "Would likely be predicted to have poor prognosis due to lack of hormone receptors",
                      "These assays have not been validated for rare tumors",
                      "Histologic appearance currently more important than proprietary assays"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Usually form circumscribed or microlobulated densitiesCan be irregular and may have calcificationsCalcifications may be present",
                    "sub_points": [
                      "Can be irregular and may have calcifications",
                      "Calcifications may be present"
                    ]
                  },
                  {
                    "text": "Imaging features are not specific"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Gross tumors are firm and typically lobulated or circumscribedNo features are specific for secretory carcinoma",
                    "sub_points": [
                      "No features are specific for secretory carcinoma"
                    ]
                  },
                  {
                    "text": "Size ranges from < 1 cm to > 10 cm (typically 1.5-3.0 cm)"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Rearrangements and mutationsBalanced translocation t(12;15)(p13;q25) results inETV6::NTRK3gene fusion productETV6(TEL) encodes E26 transformation-specific transcription factor active in hematopoiesis and angiogenesisNTRK3encodes neurotrophic tyrosine receptor kinase 3; predominantly expressed in CNSFusion protein is a chimeric tyrosine kinase with transforming activitySequencing studies show a very low mutational burden",
                    "sub_points": [
                      "Balanced translocation t(12;15)(p13;q25) results inETV6::NTRK3gene fusion productETV6(TEL) encodes E26 transformation-specific transcription factor active in hematopoiesis and angiogenesisNTRK3encodes neurotrophic tyrosine receptor kinase 3; predominantly expressed in CNSFusion protein is a chimeric tyrosine kinase with transforming activity",
                      "ETV6(TEL) encodes E26 transformation-specific transcription factor active in hematopoiesis and angiogenesis",
                      "NTRK3encodes neurotrophic tyrosine receptor kinase 3; predominantly expressed in CNS",
                      "Fusion protein is a chimeric tyrosine kinase with transforming activity",
                      "Sequencing studies show a very low mutational burden"
                    ]
                  },
                  {
                    "text": "Copy number changesComparative genomic hybridization shows small number of alterations per carcinoma: 2.0Typically gains of 8q or 1q and losses of 22qNo loss of heterozygosity (LOH) at 17p13 (TP53gene)LOH is present at this site in 47% of breast carcinomas of no special type",
                    "sub_points": [
                      "Comparative genomic hybridization shows small number of alterations per carcinoma: 2.0Typically gains of 8q or 1q and losses of 22q",
                      "Typically gains of 8q or 1q and losses of 22q",
                      "No loss of heterozygosity (LOH) at 17p13 (TP53gene)LOH is present at this site in 47% of breast carcinomas of no special type",
                      "LOH is present at this site in 47% of breast carcinomas of no special type"
                    ]
                  }
                ],
                "mRNA": [
                  {
                    "text": "Gene expression profiling results have not been reported"
                  }
                ],
                "Protein": [
                  {
                    "text": "Classified as basal-like carcinoma by IHC surrogate studies for molecular subtypesNegative for ER, PR, and HER2Positive for high molecular weight keratins (e.g., cytokeratin 5/6) and EGFR",
                    "sub_points": [
                      "Negative for ER, PR, and HER2",
                      "Positive for high molecular weight keratins (e.g., cytokeratin 5/6) and EGFR"
                    ]
                  },
                  {
                    "text": "Epithelial membrane antigen, α-lactalbumin, and S100 protein are frequently expressed"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "3 main growth patterns are recognizedSolid, microcystic (honeycomb), and tubular",
                    "sub_points": [
                      "Solid, microcystic (honeycomb), and tubular"
                    ]
                  },
                  {
                    "text": "Large nests of cells with solid or microcystic patterns can be circumscribed or irregularSeparated by thick fibrous bands giving a lobulated appearanceMicrocysts contain eosinophilic secretions and can mimic thyroid follicles",
                    "sub_points": [
                      "Separated by thick fibrous bands giving a lobulated appearance",
                      "Microcysts contain eosinophilic secretions and can mimic thyroid follicles"
                    ]
                  },
                  {
                    "text": "In the tubular pattern, the carcinoma invades as smaller foci of tumor cells in desmoplastic stroma"
                  },
                  {
                    "text": "Cells typically have uniform, round nuclei with minimal pleomorphism and small nucleoli"
                  },
                  {
                    "text": "Mitoses are absent or infrequent"
                  },
                  {
                    "text": "Cytoplasm has typical bubbly (vacuolated) or granular cytoplasm due to secretory materialCells are positive for periodic acid-Schiff (PAS) and Alcian blueSignet-ring cells may be presentSome carcinomas have an apocrine appearance",
                    "sub_points": [
                      "Cells are positive for periodic acid-Schiff (PAS) and Alcian blue",
                      "Signet-ring cells may be present",
                      "Some carcinomas have an apocrine appearance"
                    ]
                  },
                  {
                    "text": "Dense eosinophilic secretory material is present in intracytoplasmic vacuoles, lumina, and as extracellular depositsPositive for PAS (diastase resistant), Alcian blue, and mucicarmine",
                    "sub_points": [
                      "Positive for PAS (diastase resistant), Alcian blue, and mucicarmine"
                    ]
                  },
                  {
                    "text": "May be associated with DCISDCIS has a secretory appearance similar to the invasive carcinomaIHC for myoepithelial cells may be necessary to distinguish circumscribed nests of invasive carcinoma from DCISPapillary and cribriform patterns of DCIS are most commonCentral comedo-like necrosis is uncommonSecretory DCIS without invasion is very rareThe same gene translocation is present in DCIS",
                    "sub_points": [
                      "DCIS has a secretory appearance similar to the invasive carcinomaIHC for myoepithelial cells may be necessary to distinguish circumscribed nests of invasive carcinoma from DCIS",
                      "IHC for myoepithelial cells may be necessary to distinguish circumscribed nests of invasive carcinoma from DCIS",
                      "Papillary and cribriform patterns of DCIS are most common",
                      "Central comedo-like necrosis is uncommon",
                      "Secretory DCIS without invasion is very rare",
                      "The same gene translocation is present in DCIS"
                    ]
                  },
                  {
                    "text": "Grade (Nottingham grading system)Nuclei usually well or moderate grade; rarely high gradeProliferation low by mitotic count or Ki-67",
                    "sub_points": [
                      "Nuclei usually well or moderate grade; rarely high grade",
                      "Proliferation low by mitotic count or Ki-67"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Absence of hormone receptors in a carcinoma forming acini is a clue to the correct diagnosis"
                  },
                  {
                    "text": "S100 and PAN-TRK expression are helpful for diagnosis"
                  },
                  {
                    "text": "Can be mistaken for DCIS or invasive cribriform carcinoma in small specimens"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Periodic acid-Schiff (PAS) with diastase, Alcian blue, mucicarmine: Positive in secretory material"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptors: Majority negative (~ 90%)Can show low level of positivity in subset; more frequently in adults",
                    "sub_points": [
                      "Can show low level of positivity in subset; more frequently in adults"
                    ]
                  },
                  {
                    "text": "Androgen receptor: Majority negative"
                  },
                  {
                    "text": "HER2: Negative (only 1 case reported to be positive)"
                  },
                  {
                    "text": "S100: Majority positive (nuclear and cytoplasmic)"
                  },
                  {
                    "text": "Pan-TRK: Majority positive (> 95%)Pan-TRK antibody identifies NTRK fusion proteinsDiffuse &/or focal strong nuclear positivity is a sensitive and specific marker for secretory carcinomaCytoplasmic staining can also be seen",
                    "sub_points": [
                      "Pan-TRK antibody identifies NTRK fusion proteins",
                      "Diffuse &/or focal strong nuclear positivity is a sensitive and specific marker for secretory carcinomaCytoplasmic staining can also be seen",
                      "Cytoplasmic staining can also be seen"
                    ]
                  },
                  {
                    "text": "GATA3: ~ 80% positive; TRPS1: > 80% positive"
                  },
                  {
                    "text": "CytokeratinCytokeratin 8/18 positive ~ 100% (may be weak or focal)Basal cytokeratin 5/6 positive in ~ 80%Basal cytokeratins 14 and 17 positive in ~ 30%",
                    "sub_points": [
                      "Cytokeratin 8/18 positive ~ 100% (may be weak or focal)",
                      "Basal cytokeratin 5/6 positive in ~ 80%",
                      "Basal cytokeratins 14 and 17 positive in ~ 30%"
                    ]
                  },
                  {
                    "text": "p63: Majority negative for nuclear positivityCytoplasmic immunoreactivity may be present (also may be seen in any cell with a secretory appearance)",
                    "sub_points": [
                      "Cytoplasmic immunoreactivity may be present (also may be seen in any cell with a secretory appearance)"
                    ]
                  },
                  {
                    "text": "E-cadherin: Positive (100%)"
                  },
                  {
                    "text": "CD117 (C-Kit): Positive (~ 70%, can be weak and focal)"
                  },
                  {
                    "text": "EGFR (HER1): Many positive (~ 50%)"
                  },
                  {
                    "text": "GCDFP-15 (BRST-2): Majority negative"
                  },
                  {
                    "text": "SOX10: Positive in secretory carcinoma of salivary gland (~ 60%)"
                  },
                  {
                    "text": "MUC4: Positive in secretory carcinoma of salivary gland (~ 80%)"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Translocation t(12;15)(p13;q25) confirms diagnosisFISH using break-apart probes can document abnormalities in geneETV62 probes labeled with different colors detect 3' and 5' ends ofETV6geneIf gene is normal, both probes are located togetherIf translocation has occurred, the 2 ends of the gene are located far apart",
                    "sub_points": [
                      "FISH using break-apart probes can document abnormalities in geneETV62 probes labeled with different colors detect 3' and 5' ends ofETV6geneIf gene is normal, both probes are located togetherIf translocation has occurred, the 2 ends of the gene are located far apart",
                      "2 probes labeled with different colors detect 3' and 5' ends ofETV6gene",
                      "If gene is normal, both probes are located together",
                      "If translocation has occurred, the 2 ends of the gene are located far apart"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acinic Cell Carcinoma (ACC)": [
                  {
                    "text": "Very rare; less common than secretory carcinoma"
                  },
                  {
                    "text": "Commonly infiltrates breast tissue as small round tubulesCells with PAS(+) basophilic granules may be present",
                    "sub_points": [
                      "Cells with PAS(+) basophilic granules may be present"
                    ]
                  },
                  {
                    "text": "Coarse cytoplasmic eosinophilic granules characteristic"
                  },
                  {
                    "text": "Some ACCs closely resemble secretory carcinomaLike secretory carcinomas, hormone receptors and HER2 are negative, and S100 is usually positiveLacks translocation found in secretory carcinoma",
                    "sub_points": [
                      "Like secretory carcinomas, hormone receptors and HER2 are negative, and S100 is usually positive",
                      "Lacks translocation found in secretory carcinoma"
                    ]
                  },
                  {
                    "text": "Lysozyme, amylase, and α-1-antichymotrypsin are usually positive in ACC"
                  }
                ],
                "Invasive Carcinoma With Apocrine Differentiation": [
                  {
                    "text": "Usually solid pattern rather than glandular with secretions"
                  },
                  {
                    "text": "Most are grade 2 or 3"
                  },
                  {
                    "text": "Hormone receptor positivity (~ 50%), HER2 positivity (~ 50%), and GCDFP-15 positivity (~ 70%) would not be seen in secretory carcinoma"
                  }
                ],
                "Invasive Cribriform Carcinoma": [
                  {
                    "text": "Cytoplasm usually lacks foamy eosinophilic quality"
                  },
                  {
                    "text": "Secretions often present but are not darkly eosinophilic"
                  },
                  {
                    "text": "Almost all are strongly positive for hormone receptors"
                  }
                ],
                "Cystic Hypersecretory Carcinoma": [
                  {
                    "text": "Consists of grossly evident cystic spaces filled with densely eosinophilic secretory material (resembling thyroid colloid)Negative for ER, PR, and HER2 and positive for S100",
                    "sub_points": [
                      "Negative for ER, PR, and HER2 and positive for S100"
                    ]
                  },
                  {
                    "text": "Cells have pleomorphic hyperchromatic nuclei, and cytoplasm is generally scantNuclei may be centrally clear (similar to papillary thyroid carcinoma)Secretory carcinomas have bland nuclei",
                    "sub_points": [
                      "Nuclei may be centrally clear (similar to papillary thyroid carcinoma)",
                      "Secretory carcinomas have bland nuclei"
                    ]
                  },
                  {
                    "text": "Cytoplasm is generally scantSecretory carcinomas have abundant foamy cytoplasm",
                    "sub_points": [
                      "Secretory carcinomas have abundant foamy cytoplasm"
                    ]
                  },
                  {
                    "text": "Majority of cases are DCISRare, associated invasive carcinomas are poorly differentiated and have a solid growth patternLacks histologic features of secretory carcinoma",
                    "sub_points": [
                      "Rare, associated invasive carcinomas are poorly differentiated and have a solid growth patternLacks histologic features of secretory carcinoma",
                      "Lacks histologic features of secretory carcinoma"
                    ]
                  }
                ],
                "Microglandular Adenosis (MGA)": [
                  {
                    "text": "MGA is characterized by small, uniform tubules scattered in breast tissue containing dense eosinophilic materialSecretory carcinoma has tubules of variable size and also has solid and cribriform growth patterns",
                    "sub_points": [
                      "Secretory carcinoma has tubules of variable size and also has solid and cribriform growth patterns"
                    ]
                  },
                  {
                    "text": "MGA and secretory carcinoma are both typically negative for ER, PR, and HER2 and strongly positive for S100Both have invasive pattern but do not (MGA) or rarely (secretory carcinoma) metastasize or cause death of patient",
                    "sub_points": [
                      "Both have invasive pattern but do not (MGA) or rarely (secretory carcinoma) metastasize or cause death of patient"
                    ]
                  }
                ],
                "Granular Cell Tumor": [
                  {
                    "text": "Benign tumor with abundant granular cytoplasm and small, uniform nucleiThe solid variant of secretory carcinoma can resemble granular cell tumorIn most cases, tubule formation with secretions in secretory carcinoma exclude granular cell tumor",
                    "sub_points": [
                      "The solid variant of secretory carcinoma can resemble granular cell tumor",
                      "In most cases, tubule formation with secretions in secretory carcinoma exclude granular cell tumor"
                    ]
                  },
                  {
                    "text": "Both granular cell tumors and secretory carcinomas are strongly positive for S100Secretory carcinomas are positive for keratins",
                    "sub_points": [
                      "Secretory carcinomas are positive for keratins"
                    ]
                  }
                ],
                "Lactational Changes in Normal Breast Tissue": [
                  {
                    "text": "Occur in breast tissue with normal underlying architectureOccasionally, these changes are pronounced and form circumscribed masses (lactational adenomas)",
                    "sub_points": [
                      "Occasionally, these changes are pronounced and form circumscribed masses (lactational adenomas)"
                    ]
                  },
                  {
                    "text": "Solid, cribriform, and infiltrative patterns are not present"
                  },
                  {
                    "text": "During pregnancy and lactation, lumina appear empty, as secretory products are water soluble and dissolve during processingLuminal eosinophilic secretions seen in secretory carcinoma are not present",
                    "sub_points": [
                      "Luminal eosinophilic secretions seen in secretory carcinoma are not present"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Secretory carcinoma is a member of the low-grade TNBC family because it generally has an indolent course and good prognosis"
                  },
                  {
                    "text": "Overdiagnosis of secretory carcinoma must be avoided, as patients may not receive appropriate treatment"
                  },
                  {
                    "text": "Molecular studies to identifyETV6translocation are often helpful to confirm diagnosis"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Reported according to College of American Pathologists invasive breast cancer protocol"
                  },
                  {
                    "text": "Graded using standard criteria (Nottingham Grading System)If carcinoma is poorly differentiated, other possible diagnoses should be considered",
                    "sub_points": [
                      "If carcinoma is poorly differentiated, other possible diagnoses should be considered"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "HER2-Positive Breast Carcinoma": {
            "name": "HER2-Positive Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/836069bb-cd93-4bb2-9cdb-bf592728b133/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Classification": [
                  {
                    "text": "HER2(+) breast carcinomas (BCs) are characterized by HER2 gene amplification and HER2 protein overexpression"
                  },
                  {
                    "text": "15-25% of BCsHER2 BC[estrogen receptor (ER)(-)]: ~ 50%Tend to have high levels of uniform HER2 expressionLuminal HER2 BC[ER(+)]: ~ 50%Tend to have lower levels of HER2 expression and greater heterogeneity in expression",
                    "sub_points": [
                      "HER2 BC[estrogen receptor (ER)(-)]: ~ 50%Tend to have high levels of uniform HER2 expression",
                      "Tend to have high levels of uniform HER2 expression",
                      "Luminal HER2 BC[ER(+)]: ~ 50%Tend to have lower levels of HER2 expression and greater heterogeneity in expression",
                      "Tend to have lower levels of HER2 expression and greater heterogeneity in expression"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "PresentationUsually present with larger tumor size and positive lymph nodes, resulting in higher AJCC stageAssociated with poor histologic prognostic factors (high grade, necrosis, lymphovascular invasion)",
                    "sub_points": [
                      "Usually present with larger tumor size and positive lymph nodes, resulting in higher AJCC stage",
                      "Associated with poor histologic prognostic factors (high grade, necrosis, lymphovascular invasion)"
                    ]
                  },
                  {
                    "text": "Treatment and response to treatmentMany forms of targeted treatment for HER2 are availableHER2(+)BCs have the highest rates of pathologic complete response to neoadjuvant therapy (~ 40-70%)Luminal HER2 BCs are also treated with endocrine therapy",
                    "sub_points": [
                      "Many forms of targeted treatment for HER2 are available",
                      "HER2(+)BCs have the highest rates of pathologic complete response to neoadjuvant therapy (~ 40-70%)",
                      "Luminal HER2 BCs are also treated with endocrine therapy"
                    ]
                  },
                  {
                    "text": "Time to recurrenceHER2 BC: Bimodal pattern with high early and lower late peaksLuminal HER2 BC: Lower early peak with later events for > 10 years",
                    "sub_points": [
                      "HER2 BC: Bimodal pattern with high early and lower late peaks",
                      "Luminal HER2 BC: Lower early peak with later events for > 10 years"
                    ]
                  },
                  {
                    "text": "Metastatic patternHER2 BC: Visceral and brain sites (55%) are more common than bone (45%)Luminal HER2 BC: Bone (50%) vs. other sites (50%)",
                    "sub_points": [
                      "HER2 BC: Visceral and brain sites (55%) are more common than bone (45%)",
                      "Luminal HER2 BC: Bone (50%) vs. other sites (50%)"
                    ]
                  },
                  {
                    "text": "PrognosisFavorable when HER2-targeted therapy is available",
                    "sub_points": [
                      "Favorable when HER2-targeted therapy is available"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Majority are grades 2-3 and have apocrine features"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Human epidermal growth factor receptor 2 (HER2)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "HER-2/neu, c-erbB2, NEU, NGL, TKR1, CD340, ERBB2"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Luminal breast carcinoma (BC): Estrogen receptor (ER)(+) and HER2(-)"
                  },
                  {
                    "text": "HER2(+)BC: All HER2(+)BCs, including ER(+) and ER(-) BCsLuminal HER2 BC: ER(+) and HER2(+)HER2 BC: ER(-) and HER2(+)",
                    "sub_points": [
                      "Luminal HER2 BC: ER(+) and HER2(+)",
                      "HER2 BC: ER(-) and HER2(+)"
                    ]
                  },
                  {
                    "text": "Triple negative BC (TNBC): ER(-), progesterone receptor (PR)(-), and HER2(-)"
                  },
                  {
                    "text": "Note: The molecular groups of BC are defined in different ways in different contexts"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Molecular Types of Breast Carcinoma": [
                  {
                    "text": "Gene expression profiling (GEP) demonstrates that BCs can be sorted into molecular groups based on the mRNA expression pattern of thousands of genes"
                  },
                  {
                    "text": "4 major groups identified by GEP are closely related to 4 groups of BCs classified based on expression of ER and HER2; there is ~ 80% overlap between the groups identified by these 2 methodsIf the classification is different using the 2 methods, it is unclear when or in what circumstances classification by GEP provides additional information for clinical management",
                    "sub_points": [
                      "If the classification is different using the 2 methods, it is unclear when or in what circumstances classification by GEP provides additional information for clinical management"
                    ]
                  },
                  {
                    "text": "HER2 BC, as defined by being ER(-) and HER2(+), closely corresponds to the \"HER2-enriched\" group defined by mRNA\"HER2-enriched\" BCs are also ER(-)However, not all \"HER2-enriched\" BCs are HER2(+), as determined by standard clinical assays",
                    "sub_points": [
                      "\"HER2-enriched\" BCs are also ER(-)",
                      "However, not all \"HER2-enriched\" BCs are HER2(+), as determined by standard clinical assays"
                    ]
                  },
                  {
                    "text": "Luminal HER2 BC, as defined by being ER(+) and HER2(+), corresponds to a subset of the \"luminal B\" group defined by mRNAOnly ~ 50% of the \"luminal B\" group is HER2(+)",
                    "sub_points": [
                      "Only ~ 50% of the \"luminal B\" group is HER2(+)"
                    ]
                  },
                  {
                    "text": "HER2(+)BCs have important biological, clinical, epidemiologic, and prognostic differences when compared to each other and to the other molecular types of BC"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "ERBB2(HER2) Amplification and Mutation": [
                  {
                    "text": "ERBB2,located on chromosome 17q12, encodes HER2, a 185 kDa membrane tyrosine kinase growth factor receptorMember of family of genes that includes epidermal growth factor receptor (EGFR or HER1)Receptor family regulates signaling involved in cell growth, differentiation, and cell survivalImportant role in carcinogenesisStable genetic change: Majority of cancers continue to express HER2 with recurrenceHowever, HER2 may be absent in recurrences, especially after targeted therapyLikely due to heterogeneity of expression and selection of HER2(-) subclones",
                    "sub_points": [
                      "Member of family of genes that includes epidermal growth factor receptor (EGFR or HER1)",
                      "Receptor family regulates signaling involved in cell growth, differentiation, and cell survival",
                      "Important role in carcinogenesisStable genetic change: Majority of cancers continue to express HER2 with recurrenceHowever, HER2 may be absent in recurrences, especially after targeted therapyLikely due to heterogeneity of expression and selection of HER2(-) subclones",
                      "Stable genetic change: Majority of cancers continue to express HER2 with recurrence",
                      "However, HER2 may be absent in recurrences, especially after targeted therapyLikely due to heterogeneity of expression and selection of HER2(-) subclones",
                      "Likely due to heterogeneity of expression and selection of HER2(-) subclones"
                    ]
                  },
                  {
                    "text": "AmplificationofERBB2is the mechanism of mRNA and HER2 protein overexpressionAn alternative mechanism of protein overexpression has not been reportedOverexpression increases receptor activation and HER receptor family signaling; signaling promotes angiogenesis, proliferation, cell survival, invasion, and metastasis, resulting in an aggressive courseAdjacent genes are coamplified withERBB2(HER2) (HER2 amplicon)Number of genes amplified is variable; minimum of 6 genes (and possibly several dozen) are coamplifiedVariations in number of coamplified genes may explain some differences in response to HER2-targeted therapyOnly a subset of these genes show overexpression of protein products70% also amplify ≥ 1 other DNA segmentChromosome 17 centromere enumeration probe (CEP17) sequences are amplified in 10-20%True chromosome 17 polysomy (duplication of entire chromosome) is rare: Only 1-2% of cancers",
                    "sub_points": [
                      "An alternative mechanism of protein overexpression has not been reported",
                      "Overexpression increases receptor activation and HER receptor family signaling; signaling promotes angiogenesis, proliferation, cell survival, invasion, and metastasis, resulting in an aggressive course",
                      "Adjacent genes are coamplified withERBB2(HER2) (HER2 amplicon)Number of genes amplified is variable; minimum of 6 genes (and possibly several dozen) are coamplifiedVariations in number of coamplified genes may explain some differences in response to HER2-targeted therapyOnly a subset of these genes show overexpression of protein products",
                      "Number of genes amplified is variable; minimum of 6 genes (and possibly several dozen) are coamplified",
                      "Variations in number of coamplified genes may explain some differences in response to HER2-targeted therapy",
                      "Only a subset of these genes show overexpression of protein products",
                      "70% also amplify ≥ 1 other DNA segmentChromosome 17 centromere enumeration probe (CEP17) sequences are amplified in 10-20%True chromosome 17 polysomy (duplication of entire chromosome) is rare: Only 1-2% of cancers",
                      "Chromosome 17 centromere enumeration probe (CEP17) sequences are amplified in 10-20%",
                      "True chromosome 17 polysomy (duplication of entire chromosome) is rare: Only 1-2% of cancers"
                    ]
                  },
                  {
                    "text": "MutationofERBB2occurs in ~ 2-8% of BCsNot detected by routine testing because mutations have not been reported to increase protein levelsMutations must be identified by DNA sequencingMajority are activating mutations in the kinase domainERBB2(HER2) andERBB3(HER3) mutations are more frequently seen in recurrent (~ 18%) compared to primary (~ 9%) carcinomas and are more common in cancers of lobular morphologyResponse to tyrosine kinase inhibitors (TKIs) (e.g., neratimib) is observed, but resistance can developAdditionalERBB2(HER2) mutations or amplification can arise",
                    "sub_points": [
                      "Not detected by routine testing because mutations have not been reported to increase protein levels",
                      "Mutations must be identified by DNA sequencing",
                      "Majority are activating mutations in the kinase domainERBB2(HER2) andERBB3(HER3) mutations are more frequently seen in recurrent (~ 18%) compared to primary (~ 9%) carcinomas and are more common in cancers of lobular morphologyResponse to tyrosine kinase inhibitors (TKIs) (e.g., neratimib) is observed, but resistance can developAdditionalERBB2(HER2) mutations or amplification can arise",
                      "ERBB2(HER2) andERBB3(HER3) mutations are more frequently seen in recurrent (~ 18%) compared to primary (~ 9%) carcinomas and are more common in cancers of lobular morphology",
                      "Response to tyrosine kinase inhibitors (TKIs) (e.g., neratimib) is observed, but resistance can developAdditionalERBB2(HER2) mutations or amplification can arise",
                      "AdditionalERBB2(HER2) mutations or amplification can arise"
                    ]
                  }
                ],
                "HER2 Overexpressing Breast Carcinomas": [
                  {
                    "text": "15-25% of invasive BCs overexpress HER2 protein"
                  },
                  {
                    "text": "~ 1/2 are ER(+) and 1/2 are ER(-)"
                  },
                  {
                    "text": "In some studies, \"HER2(+) carcinoma\" includes both types, and in some studies, only ER(-)BCs are included"
                  },
                  {
                    "text": "HER2 BCHER2 expression is typically stronger with greaterERBB2(HER2) amplification, and expression is more homogeneous compared to luminal HER2 BCThese BCs share gene expression patterns with basal-like BCs and also share some clinical characteristics",
                    "sub_points": [
                      "HER2 expression is typically stronger with greaterERBB2(HER2) amplification, and expression is more homogeneous compared to luminal HER2 BC",
                      "These BCs share gene expression patterns with basal-like BCs and also share some clinical characteristics"
                    ]
                  },
                  {
                    "text": "Luminal HER2 BCMultiple terms have been used to refer to these carcinomas, including luminal B, HER2(+), triple positive, and double positiveLuminal B: In some studies, all luminal B carcinomas are HER2(+); in other studies, this group also includes HER2(-)BCsTriple-positive BC: This term includes the PR(+)BCs in this group but excludes PR(-)BCsDouble-positive BC: This term has been used for BCs that are positive for ER and PR or BCs that are positive for ER and HER2Carcinomas are typically high grade with a high proliferative indexCompared to other luminal BCs, ER is often expressed at lower levels; active HER2 pathway downregulates PR, and many luminal HER2 BCs are PR(-)Compared to HER2 BC, HER2 expression may be heterogeneous; number of HER2 (ERBB2) genes relatively low",
                    "sub_points": [
                      "Multiple terms have been used to refer to these carcinomas, including luminal B, HER2(+), triple positive, and double positiveLuminal B: In some studies, all luminal B carcinomas are HER2(+); in other studies, this group also includes HER2(-)BCsTriple-positive BC: This term includes the PR(+)BCs in this group but excludes PR(-)BCsDouble-positive BC: This term has been used for BCs that are positive for ER and PR or BCs that are positive for ER and HER2",
                      "Luminal B: In some studies, all luminal B carcinomas are HER2(+); in other studies, this group also includes HER2(-)BCs",
                      "Triple-positive BC: This term includes the PR(+)BCs in this group but excludes PR(-)BCs",
                      "Double-positive BC: This term has been used for BCs that are positive for ER and PR or BCs that are positive for ER and HER2",
                      "Carcinomas are typically high grade with a high proliferative index",
                      "Compared to other luminal BCs, ER is often expressed at lower levels; active HER2 pathway downregulates PR, and many luminal HER2 BCs are PR(-)",
                      "Compared to HER2 BC, HER2 expression may be heterogeneous; number of HER2 (ERBB2) genes relatively low"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Incidence: ~ 15-25% of BCsDifferences likely due to differences in demographics of patient populations and assay methodology used for evaluationThe number of HER2(+)BCs may be higher when only metastases are testedIncidence is relatively constant with age; the marked increase in luminal BCs with age results in the other 3 molecular types accounting for a smaller proportion of BCs occurring at older ages",
                    "sub_points": [
                      "Differences likely due to differences in demographics of patient populations and assay methodology used for evaluation",
                      "The number of HER2(+)BCs may be higher when only metastases are tested",
                      "Incidence is relatively constant with age; the marked increase in luminal BCs with age results in the other 3 molecular types accounting for a smaller proportion of BCs occurring at older ages"
                    ]
                  },
                  {
                    "text": "Age: Patients are typically younger (~ 53 years) than average women with BC (~ 61 years)"
                  },
                  {
                    "text": "Sex: Less common in males than in femalesHER2-targeted therapy is effective in male patients",
                    "sub_points": [
                      "HER2-targeted therapy is effective in male patients"
                    ]
                  },
                  {
                    "text": "Ethnicity: No significant differences in rates of luminal and nonluminal HER2 BCs in different ethnic populations have been reportedHowever, because luminal BCs are less frequent in African American women and Hispanic American women, HER2(+)BCs comprise a relatively larger proportion of BCs in these populations",
                    "sub_points": [
                      "However, because luminal BCs are less frequent in African American women and Hispanic American women, HER2(+)BCs comprise a relatively larger proportion of BCs in these populations"
                    ]
                  },
                  {
                    "text": "Association with germline mutationsLi-Fraumeni syndrome (TP53mutations): 55-65% of cancers overexpress HER2~ 40-50% are luminal HER2 BC~ 15% are HER2 BC~ 25-45% are HER2(-)BRCA1andBRCA2HER2 overexpression is very rare",
                    "sub_points": [
                      "Li-Fraumeni syndrome (TP53mutations): 55-65% of cancers overexpress HER2~ 40-50% are luminal HER2 BC~ 15% are HER2 BC~ 25-45% are HER2(-)",
                      "~ 40-50% are luminal HER2 BC",
                      "~ 15% are HER2 BC",
                      "~ 25-45% are HER2(-)",
                      "BRCA1andBRCA2HER2 overexpression is very rare",
                      "HER2 overexpression is very rare"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "HER2(+)BCs typically present with larger tumor sizes and with more positive nodes (resulting in higher stage) compared to luminal BCs"
                  },
                  {
                    "text": "BCs presenting as ductal carcinoma in situ (DCIS) involving the nipple epidermis (Paget disease of the nipple) are predominantly HER2(+)"
                  },
                  {
                    "text": "30-40% of inflammatory carcinomas are HER2(+)"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Overview of HER2-targeted therapyTypically used in combination with a variety of different chemotherapy regimensRemarkable efficacy in adjuvant, neoadjuvant, and metastatic settingsPatients with HER2(+)BC are candidates for HER2-targeted therapyHER2-targeted therapy can be continued for years after completion of primary therapy",
                    "sub_points": [
                      "Typically used in combination with a variety of different chemotherapy regimensRemarkable efficacy in adjuvant, neoadjuvant, and metastatic settingsPatients with HER2(+)BC are candidates for HER2-targeted therapyHER2-targeted therapy can be continued for years after completion of primary therapy",
                      "Remarkable efficacy in adjuvant, neoadjuvant, and metastatic settings",
                      "Patients with HER2(+)BC are candidates for HER2-targeted therapy",
                      "HER2-targeted therapy can be continued for years after completion of primary therapy"
                    ]
                  },
                  {
                    "text": "Humanized monoclonal antibodies to HER2Trastuzumab(Herceptin)Binds to the extracellular epitope (domain IV) of HER2Combines mouse recognition sequence of monoclonal antibody (4D5) with human IgG1Has high affinity and specificity for HER2 receptorInhibits growth of HER2-overexpressing cells in preclinical studiesMay stimulate immune-mediated tumor cell cytotoxicityMay act synergistically with chemotherapy to induce tumor cell apoptosisImproves response, delays time to progression, and improves survival when used alone or with chemotherapy in metastatic BCAdjuvant trastuzumab given during &/or after chemotherapy results in significant improvement in disease-free and overall survivalCan reduce relative risk of recurrence by 40% and risk of death by 34%Benefit is independent of tumor size, lymph node status, hormone receptor status, and patient ageClinical trials have shown that patients with HER2-low-expressing [protein expression 1+ or 2+ but in situ hybridization (ISH)(-)] BCs do not benefitSafety considerationsCardiac dysfunction occurs in 2-4% of patients treated with trastuzumab and anthracycline-based chemotherapyPertuzumab(Perjeta)Binds extracellular dimerization domain (subdomain II) of HER2 proteinThis is a different epitope than the one bound by trastuzumabIn contrast to trastuzumab, pertuzumab blocks ligand-dependent heterodimerization of HER2 with other HER family membersAlso blocks ligand-activated signaling from HER2/EGFR and HER2/HER3 heterodimersTrastuzumab combined with pertuzumab and chemotherapyThis dual-targeting combination shows significant improvement in progression-free survivalApproved for adjuvant therapy for high-risk BCs, neoadjuvant therapy (NAT), and treatment of metastatic BCOther approachesPertuzumab in combination with trastuzumab and docetaxel has been approved for neoadjuvant treatmentPertuzumab, trastuzumab, and standard adjuvant chemotherapy have been approved for adjuvant treatment of patients with high-risk cancersCDK4/6 inhibitors may increase sensitivity of cancers to targeted HER2 therapyVaccines against HER2 are under investigation",
                    "sub_points": [
                      "Trastuzumab(Herceptin)Binds to the extracellular epitope (domain IV) of HER2Combines mouse recognition sequence of monoclonal antibody (4D5) with human IgG1Has high affinity and specificity for HER2 receptorInhibits growth of HER2-overexpressing cells in preclinical studiesMay stimulate immune-mediated tumor cell cytotoxicityMay act synergistically with chemotherapy to induce tumor cell apoptosisImproves response, delays time to progression, and improves survival when used alone or with chemotherapy in metastatic BCAdjuvant trastuzumab given during &/or after chemotherapy results in significant improvement in disease-free and overall survivalCan reduce relative risk of recurrence by 40% and risk of death by 34%Benefit is independent of tumor size, lymph node status, hormone receptor status, and patient ageClinical trials have shown that patients with HER2-low-expressing [protein expression 1+ or 2+ but in situ hybridization (ISH)(-)] BCs do not benefitSafety considerationsCardiac dysfunction occurs in 2-4% of patients treated with trastuzumab and anthracycline-based chemotherapy",
                      "Binds to the extracellular epitope (domain IV) of HER2Combines mouse recognition sequence of monoclonal antibody (4D5) with human IgG1Has high affinity and specificity for HER2 receptorInhibits growth of HER2-overexpressing cells in preclinical studiesMay stimulate immune-mediated tumor cell cytotoxicityMay act synergistically with chemotherapy to induce tumor cell apoptosis",
                      "Combines mouse recognition sequence of monoclonal antibody (4D5) with human IgG1",
                      "Has high affinity and specificity for HER2 receptor",
                      "Inhibits growth of HER2-overexpressing cells in preclinical studies",
                      "May stimulate immune-mediated tumor cell cytotoxicity",
                      "May act synergistically with chemotherapy to induce tumor cell apoptosis",
                      "Improves response, delays time to progression, and improves survival when used alone or with chemotherapy in metastatic BC",
                      "Adjuvant trastuzumab given during &/or after chemotherapy results in significant improvement in disease-free and overall survivalCan reduce relative risk of recurrence by 40% and risk of death by 34%Benefit is independent of tumor size, lymph node status, hormone receptor status, and patient age",
                      "Can reduce relative risk of recurrence by 40% and risk of death by 34%",
                      "Benefit is independent of tumor size, lymph node status, hormone receptor status, and patient age",
                      "Clinical trials have shown that patients with HER2-low-expressing [protein expression 1+ or 2+ but in situ hybridization (ISH)(-)] BCs do not benefit",
                      "Safety considerationsCardiac dysfunction occurs in 2-4% of patients treated with trastuzumab and anthracycline-based chemotherapy",
                      "Cardiac dysfunction occurs in 2-4% of patients treated with trastuzumab and anthracycline-based chemotherapy",
                      "Pertuzumab(Perjeta)Binds extracellular dimerization domain (subdomain II) of HER2 proteinThis is a different epitope than the one bound by trastuzumabIn contrast to trastuzumab, pertuzumab blocks ligand-dependent heterodimerization of HER2 with other HER family membersAlso blocks ligand-activated signaling from HER2/EGFR and HER2/HER3 heterodimers",
                      "Binds extracellular dimerization domain (subdomain II) of HER2 proteinThis is a different epitope than the one bound by trastuzumabIn contrast to trastuzumab, pertuzumab blocks ligand-dependent heterodimerization of HER2 with other HER family membersAlso blocks ligand-activated signaling from HER2/EGFR and HER2/HER3 heterodimers",
                      "This is a different epitope than the one bound by trastuzumab",
                      "In contrast to trastuzumab, pertuzumab blocks ligand-dependent heterodimerization of HER2 with other HER family members",
                      "Also blocks ligand-activated signaling from HER2/EGFR and HER2/HER3 heterodimers",
                      "Trastuzumab combined with pertuzumab and chemotherapyThis dual-targeting combination shows significant improvement in progression-free survivalApproved for adjuvant therapy for high-risk BCs, neoadjuvant therapy (NAT), and treatment of metastatic BC",
                      "This dual-targeting combination shows significant improvement in progression-free survival",
                      "Approved for adjuvant therapy for high-risk BCs, neoadjuvant therapy (NAT), and treatment of metastatic BC",
                      "Other approachesPertuzumab in combination with trastuzumab and docetaxel has been approved for neoadjuvant treatmentPertuzumab, trastuzumab, and standard adjuvant chemotherapy have been approved for adjuvant treatment of patients with high-risk cancersCDK4/6 inhibitors may increase sensitivity of cancers to targeted HER2 therapyVaccines against HER2 are under investigation",
                      "Pertuzumab in combination with trastuzumab and docetaxel has been approved for neoadjuvant treatment",
                      "Pertuzumab, trastuzumab, and standard adjuvant chemotherapy have been approved for adjuvant treatment of patients with high-risk cancers",
                      "CDK4/6 inhibitors may increase sensitivity of cancers to targeted HER2 therapy",
                      "Vaccines against HER2 are under investigation"
                    ]
                  },
                  {
                    "text": "Antibody-drug conjugates (ADCs) targeting HER2ADCs deliver potent cytotoxic agents into tumor cells by selective HER2 antibody bindingThe antibody targets HER2(+) tumor cells, resulting in the cytotoxic agent being released into the tumor microenvironmentT-DM1(ado-trastuzumab-emtansine: Kadcyla)Emtansine (a microtubule cytotoxin), which kills cells by binding to tubulin, is conjugated to trastuzumabAfter the ADC is internalized into HER2-expressing tumor cells, emtansine is released and causes cell deathApproved for treatment of metastatic disease and patients with residual invasive disease after completion of NATRisk of recurrence of invasive disease or death is 50% lower with adjuvant T-DM1 than trastuzumab alone for these patientsTDX-d (trastuzumab-deruxtecan)Deruxtecan (a topoisomerase I inhibitor) is conjugated to trastuzumabDelivers a highly membrane-permeable cytotoxic payloadTDX-d induces a potent \"bystander killing\" effect on cells in close proximity regardless of HER2 statusApproved for treatment of recurrent metastatic HER2-overexpressing BCs after prior HER2-directed therapyAlso FDA approved for treatment of metastatic BC with low-level HER2 expressionHER2 1+ (\"low\"), HER2 2+ [ISH(-)], or HER2 0 but \"ultralow\" (weak, barely perceptible membrane staining in ≤ 10% of tumor cells)",
                    "sub_points": [
                      "ADCs deliver potent cytotoxic agents into tumor cells by selective HER2 antibody bindingThe antibody targets HER2(+) tumor cells, resulting in the cytotoxic agent being released into the tumor microenvironment",
                      "The antibody targets HER2(+) tumor cells, resulting in the cytotoxic agent being released into the tumor microenvironment",
                      "T-DM1(ado-trastuzumab-emtansine: Kadcyla)Emtansine (a microtubule cytotoxin), which kills cells by binding to tubulin, is conjugated to trastuzumabAfter the ADC is internalized into HER2-expressing tumor cells, emtansine is released and causes cell deathApproved for treatment of metastatic disease and patients with residual invasive disease after completion of NATRisk of recurrence of invasive disease or death is 50% lower with adjuvant T-DM1 than trastuzumab alone for these patients",
                      "Emtansine (a microtubule cytotoxin), which kills cells by binding to tubulin, is conjugated to trastuzumab",
                      "After the ADC is internalized into HER2-expressing tumor cells, emtansine is released and causes cell death",
                      "Approved for treatment of metastatic disease and patients with residual invasive disease after completion of NAT",
                      "Risk of recurrence of invasive disease or death is 50% lower with adjuvant T-DM1 than trastuzumab alone for these patients",
                      "TDX-d (trastuzumab-deruxtecan)Deruxtecan (a topoisomerase I inhibitor) is conjugated to trastuzumabDelivers a highly membrane-permeable cytotoxic payloadTDX-d induces a potent \"bystander killing\" effect on cells in close proximity regardless of HER2 statusApproved for treatment of recurrent metastatic HER2-overexpressing BCs after prior HER2-directed therapyAlso FDA approved for treatment of metastatic BC with low-level HER2 expressionHER2 1+ (\"low\"), HER2 2+ [ISH(-)], or HER2 0 but \"ultralow\" (weak, barely perceptible membrane staining in ≤ 10% of tumor cells)",
                      "Deruxtecan (a topoisomerase I inhibitor) is conjugated to trastuzumab",
                      "Delivers a highly membrane-permeable cytotoxic payload",
                      "TDX-d induces a potent \"bystander killing\" effect on cells in close proximity regardless of HER2 status",
                      "Approved for treatment of recurrent metastatic HER2-overexpressing BCs after prior HER2-directed therapy",
                      "Also FDA approved for treatment of metastatic BC with low-level HER2 expressionHER2 1+ (\"low\"), HER2 2+ [ISH(-)], or HER2 0 but \"ultralow\" (weak, barely perceptible membrane staining in ≤ 10% of tumor cells)",
                      "HER2 1+ (\"low\"), HER2 2+ [ISH(-)], or HER2 0 but \"ultralow\" (weak, barely perceptible membrane staining in ≤ 10% of tumor cells)"
                    ]
                  },
                  {
                    "text": "TKIs targeting mutated HER2Lapatinib(Tykerb)Oral dual TKI that reversibly binds and inhibits kinase activity of both HER2 and HER1Improves outcome in patients with advanced disease in combination with chemotherapyNeratinib(Nerlynx)Oral TKI that irreversibly binds to HER1, HER2, and HER4Has shown activity in HER2-overexpressing metastatic BC, including CNS response12 months of neratinib treatment following completion of trastuzumab in HER2-overexpressing BC significantly reduces disease recurrence and deathMay be more effective for ER(+) cancersTucatinib(Tukysa)Selective for kinase domain of HER2, sparing other HER2 family membersSignificant benefit in HER2-overexpressing metastatic BC, including CNS responseDoubled the intracranial objective response and reduced risk of intracranial progression by 2/3",
                    "sub_points": [
                      "Lapatinib(Tykerb)Oral dual TKI that reversibly binds and inhibits kinase activity of both HER2 and HER1Improves outcome in patients with advanced disease in combination with chemotherapy",
                      "Oral dual TKI that reversibly binds and inhibits kinase activity of both HER2 and HER1",
                      "Improves outcome in patients with advanced disease in combination with chemotherapy",
                      "Neratinib(Nerlynx)Oral TKI that irreversibly binds to HER1, HER2, and HER4Has shown activity in HER2-overexpressing metastatic BC, including CNS response12 months of neratinib treatment following completion of trastuzumab in HER2-overexpressing BC significantly reduces disease recurrence and deathMay be more effective for ER(+) cancers",
                      "Oral TKI that irreversibly binds to HER1, HER2, and HER4",
                      "Has shown activity in HER2-overexpressing metastatic BC, including CNS response",
                      "12 months of neratinib treatment following completion of trastuzumab in HER2-overexpressing BC significantly reduces disease recurrence and death",
                      "May be more effective for ER(+) cancers",
                      "Tucatinib(Tukysa)Selective for kinase domain of HER2, sparing other HER2 family membersSignificant benefit in HER2-overexpressing metastatic BC, including CNS responseDoubled the intracranial objective response and reduced risk of intracranial progression by 2/3",
                      "Selective for kinase domain of HER2, sparing other HER2 family members",
                      "Significant benefit in HER2-overexpressing metastatic BC, including CNS responseDoubled the intracranial objective response and reduced risk of intracranial progression by 2/3",
                      "Doubled the intracranial objective response and reduced risk of intracranial progression by 2/3"
                    ]
                  },
                  {
                    "text": "Chemotherapy (not HER2 targeted)HER2 status may be predictive for either resistance or sensitivity to different types of chemotherapiesIndicator of greater response to anthracycline therapyMay be secondary to coamplification of HER2 with topoisomerase II α (TOP2A)TOP2Aamplification occurs in ~ 1/3 of HER2-overexpressing BCs and is more common in luminal HER2 BCsHER2 may predict for response and benefit from paclitaxel in either metastatic or adjuvant settingsRelative, but not absolute, lower benefit from nonanthracycline, nontaxane-containing chemotherapy regimens",
                    "sub_points": [
                      "HER2 status may be predictive for either resistance or sensitivity to different types of chemotherapies",
                      "Indicator of greater response to anthracycline therapyMay be secondary to coamplification of HER2 with topoisomerase II α (TOP2A)TOP2Aamplification occurs in ~ 1/3 of HER2-overexpressing BCs and is more common in luminal HER2 BCs",
                      "May be secondary to coamplification of HER2 with topoisomerase II α (TOP2A)",
                      "TOP2Aamplification occurs in ~ 1/3 of HER2-overexpressing BCs and is more common in luminal HER2 BCs",
                      "HER2 may predict for response and benefit from paclitaxel in either metastatic or adjuvant settings",
                      "Relative, but not absolute, lower benefit from nonanthracycline, nontaxane-containing chemotherapy regimens"
                    ]
                  },
                  {
                    "text": "Endocrine therapyUsed to treat luminal HER2 BC in addition to other therapyHER2 positivity may be associated with relative, but not absolute, resistance to endocrine therapyEffect may be specific to selective ER modulator therapy, such as tamoxifen",
                    "sub_points": [
                      "Used to treat luminal HER2 BC in addition to other therapy",
                      "HER2 positivity may be associated with relative, but not absolute, resistance to endocrine therapyEffect may be specific to selective ER modulator therapy, such as tamoxifen",
                      "Effect may be specific to selective ER modulator therapy, such as tamoxifen"
                    ]
                  }
                ],
                "Response to Neoadjuvant Therapy (NAT)": [
                  {
                    "text": "Luminal and nonluminal HER2(+)BCs have the highest pathologic complete response (pCR) rate to HER2-targeted NAT compared to luminal BCs and TNBC"
                  },
                  {
                    "text": "Predictors of pCR include HER2 (3+) status [compared to HER2 (2+) and HER2-amplified status], high nuclear grade, and absence of ER"
                  },
                  {
                    "text": "~ 20% of previously HER2(+)BCs are HER2(-) after HER2-targeted therapy but with a wide range in different studies (~ 15-40%)Both amplification and protein expression are lostLikely due to heterogeneity of HER2 expression and selection of preexisting HER2(-) clonesMay depend on the type of HER2-targeted therapyMay vary with the number of HER2 (ERBB2) genes before NAT [BCs with lower numbers of HER2 genes and equivocal (2+) protein expression are more likely to be heterogeneous for expression]Loss of expression is a poor prognostic factor",
                    "sub_points": [
                      "Both amplification and protein expression are lostLikely due to heterogeneity of HER2 expression and selection of preexisting HER2(-) clones",
                      "Likely due to heterogeneity of HER2 expression and selection of preexisting HER2(-) clones",
                      "May depend on the type of HER2-targeted therapy",
                      "May vary with the number of HER2 (ERBB2) genes before NAT [BCs with lower numbers of HER2 genes and equivocal (2+) protein expression are more likely to be heterogeneous for expression]",
                      "Loss of expression is a poor prognostic factor"
                    ]
                  },
                  {
                    "text": "De novo and acquired resistance to HER2-targeted therapy is a significant clinical problemBCs with little or no response to NAT can retain high expression of HER2Mechanisms of resistance to targeted therapy are poorly understoodProteolysis of the extracellular domain in some BCs can prevent binding by monoclonal antibodies; however, response to TKIs should not be alteredA better understanding of predictors of response/resistance and strategies to treat tumors that are refractory to HER2-targeted therapy is crucialMay provide a framework for developing new therapeutic strategies to overcome resistanceMay help to prolong duration of response and decrease treatment-related toxicityPatients with resistant disease are candidates for ADCs (e.g., TDX-d)",
                    "sub_points": [
                      "BCs with little or no response to NAT can retain high expression of HER2",
                      "Mechanisms of resistance to targeted therapy are poorly understoodProteolysis of the extracellular domain in some BCs can prevent binding by monoclonal antibodies; however, response to TKIs should not be altered",
                      "Proteolysis of the extracellular domain in some BCs can prevent binding by monoclonal antibodies; however, response to TKIs should not be altered",
                      "A better understanding of predictors of response/resistance and strategies to treat tumors that are refractory to HER2-targeted therapy is crucialMay provide a framework for developing new therapeutic strategies to overcome resistanceMay help to prolong duration of response and decrease treatment-related toxicity",
                      "May provide a framework for developing new therapeutic strategies to overcome resistance",
                      "May help to prolong duration of response and decrease treatment-related toxicity",
                      "Patients with resistant disease are candidates for ADCs (e.g., TDX-d)"
                    ]
                  },
                  {
                    "text": "HER2 BC: ~ 70% pCRPatients who achieve a pCR have a significantly better 5-year survival (~ 90%) compared to patients who do not (~ 60%)May indicate that residual disease is resistant to continued HER2-targeted therapyPatients with residual disease are candidates for ADCs (e.g., T-DM1)",
                    "sub_points": [
                      "Patients who achieve a pCR have a significantly better 5-year survival (~ 90%) compared to patients who do not (~ 60%)",
                      "May indicate that residual disease is resistant to continued HER2-targeted therapy",
                      "Patients with residual disease are candidates for ADCs (e.g., T-DM1)"
                    ]
                  },
                  {
                    "text": "Luminal HER2 BC: ~ 40% pCRLower pCR rate may be due to generally lower levels of HER2 expression and HER2 heterogeneityHowever, patients without achievement of pCR have a favorable survival at 5 yearsMay be due to effectiveness of adjuvant endocrine therapy, particularly in this timeframeSimilar to other luminal BCs, late recurrence and death occurs after 8 years",
                    "sub_points": [
                      "Lower pCR rate may be due to generally lower levels of HER2 expression and HER2 heterogeneity",
                      "However, patients without achievement of pCR have a favorable survival at 5 years",
                      "May be due to effectiveness of adjuvant endocrine therapy, particularly in this timeframe",
                      "Similar to other luminal BCs, late recurrence and death occurs after 8 years"
                    ]
                  }
                ],
                "Time to Recurrence": [
                  {
                    "text": "HER2 BC: This is the only molecular type reported to have a bimodal recurrence pattern high early peak at ~ 4-5 years followed by a lower peak at ~ 8 yearsHigh early peak at ~ 2 years followed by a 2nd lower peak at ~ 8 years",
                    "sub_points": [
                      "High early peak at ~ 2 years followed by a 2nd lower peak at ~ 8 years"
                    ]
                  },
                  {
                    "text": "Luminal HER2 BC: Low early peak ~ 4-5 years followed by a low rate of recurrences for > 10 years"
                  }
                ],
                "Metastatic Pattern": [
                  {
                    "text": "Metastatic sites are more similar to TNBCs than luminal BCs"
                  },
                  {
                    "text": "HER2 BC: Bone (~ 40%), liver (~ 20%), lung (~ 20%), brain (~ 20%)"
                  },
                  {
                    "text": "Luminal HER2 BC: Bone (~ 45%), liver (~ 20%), lung (~ 15%), brain (~ 20%)"
                  },
                  {
                    "text": "Brain metastases are more common after treatment with HER2-targeted therapy; may be related to inability of trastuzumab to cross blood-brain barrier"
                  },
                  {
                    "text": "The 2013 HER2 testing guideline update emphasizes the importance of repeat testing of metastases for HER2Change from negative to positive: ~ 9-16% of cancersPossibly due to a de novo amplification event or to outgrowth of a previously undetected subpopulationChange from positive to negative: ~ 15% of cancersLikely due to heterogeneity of expression in primary carcinoma with possible selection of subclones after treatment",
                    "sub_points": [
                      "Change from negative to positive: ~ 9-16% of cancersPossibly due to a de novo amplification event or to outgrowth of a previously undetected subpopulation",
                      "Possibly due to a de novo amplification event or to outgrowth of a previously undetected subpopulation",
                      "Change from positive to negative: ~ 15% of cancersLikely due to heterogeneity of expression in primary carcinoma with possible selection of subclones after treatment",
                      "Likely due to heterogeneity of expression in primary carcinoma with possible selection of subclones after treatment"
                    ]
                  }
                ],
                "AJCC (8th Edition) Anatomic Stage": [
                  {
                    "text": "Luminal HER2 BCs are more likely to be stage I (~ 40%) compared to HER2 BCs (~ 30%), but less likely than luminal BCs (≥ 50%)"
                  },
                  {
                    "text": "In general, for each anatomic stage, patients with HER2(+)BCs have lower survival than patients with luminal BCs but better survival than patients with TNBCsHowever, the improved survival over TNBCs is highly dependent on the use of HER2-targeted therapy",
                    "sub_points": [
                      "However, the improved survival over TNBCs is highly dependent on the use of HER2-targeted therapy"
                    ]
                  }
                ],
                "AJCC (8th Edition) Prognostic Stage": [
                  {
                    "text": "In the AJCC (8th edition), prognostic stage groups include anatomic stage as well as ER, PR, HER2, grade, and the result of a multigene prognostic test (if available)"
                  },
                  {
                    "text": "Although HER2(+)BCs often have unfavorable anatomic (size and lymph node positivity) and biologic (high histologic grade) features, due to the availability of HER2-targeted therapy, the prognosis is favorable for many patients"
                  },
                  {
                    "text": "In many cases, HER2(+)BCs are moved to a lower prognostic stage due to the effectiveness of treatment"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Histologic typesInvasive BC of no special type (\"ductal\")> 90% of HER2(+) carcinomas are not of a special typeThe most frequent histologic feature is the presence of an apocrine appearance~ 20-50% of luminal HER2 BCs~ 80% of HER2 BCsThis appearance correlates with the majority of these BCs expressing androgen receptorInvasive micropapillary carcinomaOnly special type that shows greater than average HER2 overexpression~ 20-30% are HER2(+)Majority are ER(+)A basolateral HER2 staining pattern is often seenOften present in clusters of cells with the inverted tubule morphologyThe outward-facing apical aspect of the cells does not stain for HER2The pattern of immunoreactivity can be weak and heterogeneousComplicates interpretation, as the incomplete staining pattern would be interpreted as 1+In this setting, the basolateral pattern can be interpreted as equivocal (2+)ISH is helpful to identify amplification when there is an unusual staining patternInvasive lobular carcinomaLikelihood of HER2 positivity is dependent on gradeEdge enhancement can mimic HER2 positivityGrade 1 and grade 2: < 5%Grade 3: 10-30%Many of these carcinomas have apocrine featuresThese carcinomas may also be negative for hormone receptorsDue to the dyscohesive pattern of infiltration, edge enhancement around cells can mimic true membrane positivityISH is helpful to identify gene amplificationOther special histologic typesRarely overexpress HER2 (< 5%)",
                    "sub_points": [
                      "Invasive BC of no special type (\"ductal\")> 90% of HER2(+) carcinomas are not of a special typeThe most frequent histologic feature is the presence of an apocrine appearance~ 20-50% of luminal HER2 BCs~ 80% of HER2 BCsThis appearance correlates with the majority of these BCs expressing androgen receptor",
                      "> 90% of HER2(+) carcinomas are not of a special type",
                      "The most frequent histologic feature is the presence of an apocrine appearance~ 20-50% of luminal HER2 BCs~ 80% of HER2 BCs",
                      "~ 20-50% of luminal HER2 BCs",
                      "~ 80% of HER2 BCs",
                      "This appearance correlates with the majority of these BCs expressing androgen receptor",
                      "Invasive micropapillary carcinomaOnly special type that shows greater than average HER2 overexpression~ 20-30% are HER2(+)Majority are ER(+)A basolateral HER2 staining pattern is often seenOften present in clusters of cells with the inverted tubule morphologyThe outward-facing apical aspect of the cells does not stain for HER2The pattern of immunoreactivity can be weak and heterogeneousComplicates interpretation, as the incomplete staining pattern would be interpreted as 1+In this setting, the basolateral pattern can be interpreted as equivocal (2+)ISH is helpful to identify amplification when there is an unusual staining pattern",
                      "Only special type that shows greater than average HER2 overexpression",
                      "~ 20-30% are HER2(+)Majority are ER(+)",
                      "Majority are ER(+)",
                      "A basolateral HER2 staining pattern is often seenOften present in clusters of cells with the inverted tubule morphologyThe outward-facing apical aspect of the cells does not stain for HER2The pattern of immunoreactivity can be weak and heterogeneousComplicates interpretation, as the incomplete staining pattern would be interpreted as 1+",
                      "Often present in clusters of cells with the inverted tubule morphology",
                      "The outward-facing apical aspect of the cells does not stain for HER2",
                      "The pattern of immunoreactivity can be weak and heterogeneous",
                      "Complicates interpretation, as the incomplete staining pattern would be interpreted as 1+",
                      "In this setting, the basolateral pattern can be interpreted as equivocal (2+)",
                      "ISH is helpful to identify amplification when there is an unusual staining pattern",
                      "Invasive lobular carcinomaLikelihood of HER2 positivity is dependent on gradeEdge enhancement can mimic HER2 positivityGrade 1 and grade 2: < 5%Grade 3: 10-30%Many of these carcinomas have apocrine featuresThese carcinomas may also be negative for hormone receptorsDue to the dyscohesive pattern of infiltration, edge enhancement around cells can mimic true membrane positivityISH is helpful to identify gene amplification",
                      "Likelihood of HER2 positivity is dependent on gradeEdge enhancement can mimic HER2 positivity",
                      "Edge enhancement can mimic HER2 positivity",
                      "Grade 1 and grade 2: < 5%",
                      "Grade 3: 10-30%Many of these carcinomas have apocrine featuresThese carcinomas may also be negative for hormone receptors",
                      "Many of these carcinomas have apocrine features",
                      "These carcinomas may also be negative for hormone receptors",
                      "Due to the dyscohesive pattern of infiltration, edge enhancement around cells can mimic true membrane positivity",
                      "ISH is helpful to identify gene amplification",
                      "Other special histologic typesRarely overexpress HER2 (< 5%)",
                      "Rarely overexpress HER2 (< 5%)"
                    ]
                  }
                ],
                "Histologic Grade": [
                  {
                    "text": "The majority are either grade 2 or 3"
                  },
                  {
                    "text": "Necrosis is present in ~ 40%"
                  },
                  {
                    "text": "HER2 overexpression is uncommon in grade 1 tumors (< 5%)"
                  }
                ],
                "Lymphovascular Invasion (LVI) and Lymph Node Metastases": [
                  {
                    "text": "LVI and lymph node metastases are more common compared to luminal BC and TNBC"
                  }
                ],
                "Ductal Carcinoma In Situ (DCIS)": [
                  {
                    "text": "DCIS associated with invasive carcinoma"
                  },
                  {
                    "text": "HER2(+)BC is associated with more extensive DCIS compared to luminal BC and TNBCMultiple foci of invasion may be presentAssociated invasive BC is usually also HER2(+)In rare cases, the associated invasive BC is HER2(-)May yield incorrect results for some assays unless only invasive component is analyzedCan be problematic for RT-PCR tests for HER2 mRNASome assay methods may require microdissection",
                    "sub_points": [
                      "Multiple foci of invasion may be present",
                      "Associated invasive BC is usually also HER2(+)",
                      "In rare cases, the associated invasive BC is HER2(-)May yield incorrect results for some assays unless only invasive component is analyzedCan be problematic for RT-PCR tests for HER2 mRNASome assay methods may require microdissection",
                      "May yield incorrect results for some assays unless only invasive component is analyzed",
                      "Can be problematic for RT-PCR tests for HER2 mRNA",
                      "Some assay methods may require microdissection"
                    ]
                  },
                  {
                    "text": "DCIS in the absence of invasive carcinomaCompared to the molecular types of invasive BCs, luminal-type DCIS is less common (~ 45% vs. 70%), and HER2(+) DCIS is more common (~ 45% vs. ~ 20%)~ 50% of HER2(+) DCIS is ER(+) and 50% is ER(-)There is no recommendation to perform HER2 on cases of DCIS if invasive carcinoma is absentHER2-targeted therapy is not standard treatment outside of a clinical trialHER2 positivity is associated with high nuclear grade, central necrosis, higher rates of invasive BC on excision, and higher rates of local recurrence",
                    "sub_points": [
                      "Compared to the molecular types of invasive BCs, luminal-type DCIS is less common (~ 45% vs. 70%), and HER2(+) DCIS is more common (~ 45% vs. ~ 20%)~ 50% of HER2(+) DCIS is ER(+) and 50% is ER(-)",
                      "~ 50% of HER2(+) DCIS is ER(+) and 50% is ER(-)",
                      "There is no recommendation to perform HER2 on cases of DCIS if invasive carcinoma is absentHER2-targeted therapy is not standard treatment outside of a clinical trial",
                      "HER2-targeted therapy is not standard treatment outside of a clinical trial",
                      "HER2 positivity is associated with high nuclear grade, central necrosis, higher rates of invasive BC on excision, and higher rates of local recurrence"
                    ]
                  },
                  {
                    "text": "DCIS involving nipple skin (Paget disease of nipple)DCIS presenting as Paget disease of the nipple is HER2(+) in > 80% of cases~ 50% are associated with HER2(+) BC deeper in the breastToker cells, which can be mistaken for Paget disease, are usually HER2(-)Rare cases of atypical Toker cell hyperplasia can show weak HER2 positivity",
                    "sub_points": [
                      "DCIS presenting as Paget disease of the nipple is HER2(+) in > 80% of cases",
                      "~ 50% are associated with HER2(+) BC deeper in the breast",
                      "Toker cells, which can be mistaken for Paget disease, are usually HER2(-)",
                      "Rare cases of atypical Toker cell hyperplasia can show weak HER2 positivity"
                    ]
                  }
                ],
                "Lobular Carcinoma In Situ (LCIS)": [
                  {
                    "text": "LCIS, classic type is HER2(-)"
                  },
                  {
                    "text": "Pleomorphic and florid types of LCIS may be HER2(+)"
                  }
                ],
                "Core Needle Biopsy (CNB)": [
                  {
                    "text": "It is important to perform HER2 testing on invasive BCs on CNB, as many patients will be considered for NATExcellent concordance in most studies comparing matched CNB and excision results",
                    "sub_points": [
                      "Excellent concordance in most studies comparing matched CNB and excision results"
                    ]
                  },
                  {
                    "text": "However, CNBs only sample a small portion of large &/or locally advanced invasive carcinomasHeterogeneous HER2 overexpression can be missed",
                    "sub_points": [
                      "Heterogeneous HER2 overexpression can be missed"
                    ]
                  },
                  {
                    "text": "If the CNB result is negative, consider repeating study on the excision in the following casesThe amount of invasive BC is small relative to the entire BCBC is high grade, especially if the amount of invasive tumor is limitedResection specimen contains high-grade BC that is morphologically distinct from that in CNBThere is residual invasive BC after NAT",
                    "sub_points": [
                      "The amount of invasive BC is small relative to the entire BC",
                      "BC is high grade, especially if the amount of invasive tumor is limited",
                      "Resection specimen contains high-grade BC that is morphologically distinct from that in CNB",
                      "There is residual invasive BC after NAT"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Methods": [
                  {
                    "text": "HER2 overexpression can be documented by evaluation of DNA (ISH), mRNA, and protein (IHC) assays"
                  },
                  {
                    "text": "IHC, FISH, and CISH methods have received FDA approval for assessing HER2 status in clinical practiceBoth IHC and FISH have been clinically validated to predict benefit from HER2-directed therapy in prospective randomized clinical trialsConsidered \"gold standard\" for HER2 evaluation",
                    "sub_points": [
                      "Both IHC and FISH have been clinically validated to predict benefit from HER2-directed therapy in prospective randomized clinical trials",
                      "Considered \"gold standard\" for HER2 evaluation"
                    ]
                  },
                  {
                    "text": "Studies should be repeated on recurrent or metastatic disease, as HER2 status can changeHeterogeneity for expression may have been missed if testing was performed on small biopsySelection of subclones can occur after targeted therapyA new primary carcinoma with different HER2 status may have developedIf a discordant result is obtained, both assays should be reviewed to determine if there may be technical problems and should be repeated",
                    "sub_points": [
                      "Heterogeneity for expression may have been missed if testing was performed on small biopsy",
                      "Selection of subclones can occur after targeted therapy",
                      "A new primary carcinoma with different HER2 status may have developed",
                      "If a discordant result is obtained, both assays should be reviewed to determine if there may be technical problems and should be repeated"
                    ]
                  }
                ],
                "DNA (ISH)": [
                  {
                    "text": "Analysis for gene amplification is usually evaluated by ISHProbes can be detected by fluorescence (FISH) or by chromogens (CISH)ASCO/CAP HER2 testing guidelines and FDA-approved methods available",
                    "sub_points": [
                      "Probes can be detected by fluorescence (FISH) or by chromogens (CISH)ASCO/CAP HER2 testing guidelines and FDA-approved methods available",
                      "ASCO/CAP HER2 testing guidelines and FDA-approved methods available"
                    ]
                  }
                ],
                "Protein (IHC)": [
                  {
                    "text": "Protein overexpression is evaluated by IHC"
                  },
                  {
                    "text": "HER2 BCs usually strongly express the protein in a homogeneous and contiguous cell population comprising > 95% of tumor cellsISH typically shows high levels of HER2 (ERBB2) gene amplification and high ratiosIf ISH does not show amplification, the possibility of overstaining &/or overinterpretation of IHC slide should be consideredAn IHC 3+ result in the absence of gene amplification and due to a different mechanism has not been reportedOverexpression of HER2 protein in the absence of amplification has not been documentedIn discordant cases (i.e., a 3+ result on IHC in the absence of amplification), IHC should be repeated to exclude the possibility of overstainingCancers that strongly overexpress HER2 (a 3+ result) in a smaller subclone of tumor cells are exceedingly rareISH is helpful to document amplification in these cases and avoid misclassification",
                    "sub_points": [
                      "ISH typically shows high levels of HER2 (ERBB2) gene amplification and high ratiosIf ISH does not show amplification, the possibility of overstaining &/or overinterpretation of IHC slide should be consideredAn IHC 3+ result in the absence of gene amplification and due to a different mechanism has not been reported",
                      "If ISH does not show amplification, the possibility of overstaining &/or overinterpretation of IHC slide should be considered",
                      "An IHC 3+ result in the absence of gene amplification and due to a different mechanism has not been reported",
                      "Overexpression of HER2 protein in the absence of amplification has not been documentedIn discordant cases (i.e., a 3+ result on IHC in the absence of amplification), IHC should be repeated to exclude the possibility of overstaining",
                      "In discordant cases (i.e., a 3+ result on IHC in the absence of amplification), IHC should be repeated to exclude the possibility of overstaining",
                      "Cancers that strongly overexpress HER2 (a 3+ result) in a smaller subclone of tumor cells are exceedingly rareISH is helpful to document amplification in these cases and avoid misclassification",
                      "ISH is helpful to document amplification in these cases and avoid misclassification"
                    ]
                  },
                  {
                    "text": "Luminal HER2 BCs often show lower levels of protein expression and are more likely to show heterogeneous expressionIHC can be used to target areas for ISH analysis in cases that show heterogeneity",
                    "sub_points": [
                      "IHC can be used to target areas for ISH analysis in cases that show heterogeneity"
                    ]
                  }
                ],
                "mRNA": [
                  {
                    "text": "HER2 mRNA level is evaluated and reported as part of the Oncotype DX assay (Genomic Health)Should not be used for treatment decisions or to select patients for targeted therapyMany cancers considered HER2(+) by ISH &/or IHC are classified as negative (up to 50%)If the single-gene HER2 score is equivocal or positive for a cancer considered HER2(-) by conventional testing, reassessment of the IHC &/or ISH testing should be considered",
                    "sub_points": [
                      "Should not be used for treatment decisions or to select patients for targeted therapyMany cancers considered HER2(+) by ISH &/or IHC are classified as negative (up to 50%)If the single-gene HER2 score is equivocal or positive for a cancer considered HER2(-) by conventional testing, reassessment of the IHC &/or ISH testing should be considered",
                      "Many cancers considered HER2(+) by ISH &/or IHC are classified as negative (up to 50%)",
                      "If the single-gene HER2 score is equivocal or positive for a cancer considered HER2(-) by conventional testing, reassessment of the IHC &/or ISH testing should be considered"
                    ]
                  },
                  {
                    "text": "mRNA methods for clinical assessment of HER2 are not recommended in ASCO/CAP guidelines"
                  },
                  {
                    "text": "Proprietary assays are available to determine molecular types of BC~ 35% of molecular HER2 carcinomas by these assays are HER2(-)~ 15% of basal-like carcinomas by these assays are HER2(+)These assays should not be used to determine eligibility for targeted therapy",
                    "sub_points": [
                      "~ 35% of molecular HER2 carcinomas by these assays are HER2(-)",
                      "~ 15% of basal-like carcinomas by these assays are HER2(+)",
                      "These assays should not be used to determine eligibility for targeted therapy"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Invasive carcinomas can be reported according to CAP Invasive Breast Cancer Protocol"
                  },
                  {
                    "text": "HER2 testing results should be reported according to ASCO/CAP guidelines"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Inflammatory Carcinoma": {
            "name": "Inflammatory Carcinoma",
            "url": "https://app.pathprimer.com/document/6737cb27-3d8c-4e54-bee4-2d49ceeda9f0/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Inflammatory breast carcinoma (IFBC)Defined by the clinical presentation of edema and erythema of ≥ 1/3 of breast skin (T4d)",
                    "sub_points": [
                      "Defined by the clinical presentation of edema and erythema of ≥ 1/3 of breast skin (T4d)"
                    ]
                  },
                  {
                    "text": "Clinical appearance results from tumor emboli within dermal lymphatic spaces"
                  },
                  {
                    "text": "Not associated with true inflammation or tumor-infiltrating lymphocytes"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "1-5% of all breast cancers"
                  },
                  {
                    "text": "May be initially misdiagnosed as mastitis or cellulitis and treated with antibiotics"
                  },
                  {
                    "text": "Neoadjuvant chemotherapy is the standard of care, followed by mastectomy and radiationResponse to therapy provides prognostic informationHowever, ~ 1/2 of cancers undergoing pathologic complete response recur",
                    "sub_points": [
                      "Response to therapy provides prognostic information",
                      "However, ~ 1/2 of cancers undergoing pathologic complete response recur"
                    ]
                  },
                  {
                    "text": "Poor prognosis: Median overall survival is ~ 3-4 years"
                  }
                ],
                "Molecular": [
                  {
                    "text": "No genomic hallmark has been discovered that is common to all cases of IFBC"
                  },
                  {
                    "text": "Gene expression profiling has demonstrated marked transcriptional heterogeneity among IFBCs"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "The majority are of no special type (\"ductal\")"
                  },
                  {
                    "text": "Associated with prominent dermal lymphovascular invasion that obstructs lymphatic outflow, causing clinical symptoms"
                  },
                  {
                    "text": "Diffusely infiltrative pattern without formation of discrete mass by palpation or imaging"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Less likely to be hormone receptor (+) and more likely to be HER2(+) than non-IFBC"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Mimics of dermal lymphovascular invasion"
                  },
                  {
                    "text": "Metastasis to breast"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Inflammatory breast carcinoma (IFBC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "IFBC is defined by the clinical presentation of diffuse erythema and edema involving ≥ 1/3 of breast skin in a patient with documented invasive breast carcinoma (BC)"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Primary Inflammatory Breast Carcinoma (IFBC)": [
                  {
                    "text": "IFBC is the most aggressive type of breast carcinoma (BC)Distinct clinical subtype with unique clinical presentationRapid onset of symptoms often over just a few weeks~ 25-30% of patients present with distant metastases, compared with < 10% of all BC patients",
                    "sub_points": [
                      "Distinct clinical subtype with unique clinical presentation",
                      "Rapid onset of symptoms often over just a few weeks",
                      "~ 25-30% of patients present with distant metastases, compared with < 10% of all BC patients"
                    ]
                  },
                  {
                    "text": "The defining features of IFBC are the clinical symptoms of diffuse erythema and edema involving ≥ 1/3 of the breastThe pathologic correlate is extensive dermal lymphovascular invasion (LVI) causing blockage by tumor emboli",
                    "sub_points": [
                      "The pathologic correlate is extensive dermal lymphovascular invasion (LVI) causing blockage by tumor emboli"
                    ]
                  },
                  {
                    "text": "IFBCs have a diffusely infiltrative pattern such that a discrete identifiable tumor mass cannot be identified"
                  },
                  {
                    "text": "Although some IFBCs respond well to treatment, there is a high rate of recurrence even after a pathologic complete response (pCR)"
                  },
                  {
                    "text": "Overall prognosis is poor across all molecular subtypes"
                  },
                  {
                    "text": "Assigned a separate category in TNM classification (T4d)"
                  }
                ],
                "Secondary IFBC": [
                  {
                    "text": "Secondary IFBC is the rare instance of a non-IFBC recurring as IFBC"
                  },
                  {
                    "text": "The etiology is unknown but could possibly be related to vascular involvement due to posttraumatic healing and angiogenesis"
                  }
                ],
                "Biology of IFBC": [
                  {
                    "text": "Despite sharing a diffuse growth pattern, massive dermal LVI, and rapid metastasis, IFBCs show a remarkable degree of morphologic and biologic heterogeneity"
                  },
                  {
                    "text": "No specific alteration in DNA, mRNA, or protein has been found in common, nor has the biologic basis of the clinical manifestations been fully explained"
                  },
                  {
                    "text": "Distribution of immune cell subtypes and an immunosuppressive tumor microenvironment may contribute to poor prognosis"
                  }
                ],
                "Clinical Mimics of IFBC": [
                  {
                    "text": "Infectious mastitisCan cause the same type of skin and breast changesMastitis is exceedingly rare outside of the lactational periodTreatment is delayed in some patients because patients are treated with antibiotics",
                    "sub_points": [
                      "Can cause the same type of skin and breast changes",
                      "Mastitis is exceedingly rare outside of the lactational period",
                      "Treatment is delayed in some patients because patients are treated with antibiotics"
                    ]
                  },
                  {
                    "text": "Lymph node obstructionTumors of multiple types (e.g., melanoma and lymphoma) can massively involve axillary lymph nodes causing lymphatic obstruction and edema of the breast",
                    "sub_points": [
                      "Tumors of multiple types (e.g., melanoma and lymphoma) can massively involve axillary lymph nodes causing lymphatic obstruction and edema of the breast"
                    ]
                  },
                  {
                    "text": "Locally advanced BCLarge BCs can invade into dermis and ulcerate the skin causing erythema and edemaThe clinical skin signs are predominantly due to the skin involvement and not to dermal LVIThese BCs are not classified as IFBC",
                    "sub_points": [
                      "Large BCs can invade into dermis and ulcerate the skin causing erythema and edema",
                      "The clinical skin signs are predominantly due to the skin involvement and not to dermal LVI",
                      "These BCs are not classified as IFBC"
                    ]
                  },
                  {
                    "text": "Radiation recallCan occur weeks, months, or years after radiation treatmentCauses skin erythema, edema, blistering, and ulceration in the prior radiation fieldMay be triggered by drug treatment or vaccination",
                    "sub_points": [
                      "Can occur weeks, months, or years after radiation treatment",
                      "Causes skin erythema, edema, blistering, and ulceration in the prior radiation field",
                      "May be triggered by drug treatment or vaccination"
                    ]
                  },
                  {
                    "text": "Skin diseasesMany types of skin diseases can involve breast skin causing erythema",
                    "sub_points": [
                      "Many types of skin diseases can involve breast skin causing erythema"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "A high body mass index is independent risk factor of IFBC"
                  }
                ],
                "Incidence": [
                  {
                    "text": "1-5% of all breast cancer cases~ 2.5 per 100,000 women per yearTime-trended data from SEER database suggest incidence may be increasingFactors causing this rise in diagnosis are unclear",
                    "sub_points": [
                      "~ 2.5 per 100,000 women per year",
                      "Time-trended data from SEER database suggest incidence may be increasingFactors causing this rise in diagnosis are unclear",
                      "Factors causing this rise in diagnosis are unclear"
                    ]
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Slightly more common in Black American women"
                  },
                  {
                    "text": "Lowest frequency in Asian American women and Pacific Islander American women"
                  }
                ],
                "Presentation": [
                  {
                    "text": "The diagnosis of IFBC relies on the initial clinical presentation of patientDiffuse erythema and edema involving ≥ 1/3 or more of breast skinGives rise to peau d'orange appearance (resembles skin of orange/orange peel)Cooper ligaments tether skin to deeper breast tissues creating dimpling of the edematous skin",
                    "sub_points": [
                      "Diffuse erythema and edema involving ≥ 1/3 or more of breast skinGives rise to peau d'orange appearance (resembles skin of orange/orange peel)Cooper ligaments tether skin to deeper breast tissues creating dimpling of the edematous skin",
                      "Gives rise to peau d'orange appearance (resembles skin of orange/orange peel)Cooper ligaments tether skin to deeper breast tissues creating dimpling of the edematous skin",
                      "Cooper ligaments tether skin to deeper breast tissues creating dimpling of the edematous skin"
                    ]
                  },
                  {
                    "text": "The breast may enlarge rapidly over a period of weeks"
                  },
                  {
                    "text": "Up to 15% of patients present with bilateral involvementThis is likely due to cancer metastasizing to the contralateral breast",
                    "sub_points": [
                      "This is likely due to cancer metastasizing to the contralateral breast"
                    ]
                  },
                  {
                    "text": "A palpable mass is usually not present, making the diagnosis more difficult~ 30% of patients will not have a palpable massWhen present, the mass is often ill defined and can be difficult to palpate due to edema",
                    "sub_points": [
                      "~ 30% of patients will not have a palpable massWhen present, the mass is often ill defined and can be difficult to palpate due to edema",
                      "When present, the mass is often ill defined and can be difficult to palpate due to edema"
                    ]
                  },
                  {
                    "text": "Some patients have palpable axillary nodesHowever, this finding is also common in true inflammatory conditions",
                    "sub_points": [
                      "However, this finding is also common in true inflammatory conditions"
                    ]
                  },
                  {
                    "text": "May be initially diagnosed as mastitis or cellulitis and treated with antibioticsBreast infections rare outside lactational periodCarcinoma should be considered in the differential diagnosis in nonlactating womenBut, IFBC can rarely occur during lactation",
                    "sub_points": [
                      "Breast infections rare outside lactational periodCarcinoma should be considered in the differential diagnosis in nonlactating womenBut, IFBC can rarely occur during lactation",
                      "Carcinoma should be considered in the differential diagnosis in nonlactating women",
                      "But, IFBC can rarely occur during lactation"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Surgery prior to neoadjuvant therapy (NAT)Surgery as a 1st treatment is generally contraindicated due to a high risk of locoregional and distant recurrenceThere is a high likelihood of positive margins due to diffuse skin involvement",
                    "sub_points": [
                      "Surgery as a 1st treatment is generally contraindicated due to a high risk of locoregional and distant recurrence",
                      "There is a high likelihood of positive margins due to diffuse skin involvement"
                    ]
                  },
                  {
                    "text": "NAT (presurgical therapy)The standard of care is NAT prior to surgeryThe goal is to eliminate micrometastatic disease, reduce tumor burden, and identify BCs that will respond to treatmentPatients whose BCS respond well may also benefit from subsequent surgery and radiationResponse to NAT provides information on prognosisA pathologic complete response (pCR) is a predictor for a more favorable outcomeHowever, 1/2 of patients with a pCR will subsequently recur",
                    "sub_points": [
                      "The standard of care is NAT prior to surgery",
                      "The goal is to eliminate micrometastatic disease, reduce tumor burden, and identify BCs that will respond to treatment",
                      "Patients whose BCS respond well may also benefit from subsequent surgery and radiationResponse to NAT provides information on prognosisA pathologic complete response (pCR) is a predictor for a more favorable outcomeHowever, 1/2 of patients with a pCR will subsequently recur",
                      "Response to NAT provides information on prognosis",
                      "A pathologic complete response (pCR) is a predictor for a more favorable outcomeHowever, 1/2 of patients with a pCR will subsequently recur",
                      "However, 1/2 of patients with a pCR will subsequently recur"
                    ]
                  },
                  {
                    "text": "Surgery after NATMastectomy is generally performed if there has been a response to treatmentSentinel node biopsy may not be accurate due to aberrant lymphatic drainageAxillary dissection is often performed",
                    "sub_points": [
                      "Mastectomy is generally performed if there has been a response to treatment",
                      "Sentinel node biopsy may not be accurate due to aberrant lymphatic drainage",
                      "Axillary dissection is often performed"
                    ]
                  },
                  {
                    "text": "Radiation therapyAfter mastectomy, radiation therapy to the chest wall and regional lymph nodes is recommended",
                    "sub_points": [
                      "After mastectomy, radiation therapy to the chest wall and regional lymph nodes is recommended"
                    ]
                  },
                  {
                    "text": "Adjuvant therapyEndocrine therapy for ER(+) BCsHER2-targeted therapy for HER2(+) BCs",
                    "sub_points": [
                      "Endocrine therapy for ER(+) BCs",
                      "HER2-targeted therapy for HER2(+) BCs"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Median overall survival for IFBC patients is ~ 3-4 years (compared to ~ 6-7 years for locally advanced BC and > 10 years for non-T4 BC)5-year survival rate: ~ 30%Accounts for 7-10% of BC-associated deathsLower survival rates are observed among Black American women and those with ER(-) BCs",
                    "sub_points": [
                      "5-year survival rate: ~ 30%",
                      "Accounts for 7-10% of BC-associated deaths",
                      "Lower survival rates are observed among Black American women and those with ER(-) BCs"
                    ]
                  },
                  {
                    "text": "Current targeted therapy (e.g., HER2-directed treatment) has resulted in improved survival in some patientsOutcome for IFBC remains worse than that for patients with non-IFBC locally advanced BCs",
                    "sub_points": [
                      "Outcome for IFBC remains worse than that for patients with non-IFBC locally advanced BCs"
                    ]
                  },
                  {
                    "text": "Non-IFBC with dermal lymphovascular invasion (LVI) has a poorer prognosis than BCs without dermal LVI but not as poor as IFBCSometimes referred to as \"occult IFBC\"Extent of dermal LVI may be too limited to cause the clinical skin changes or the patient may have presented early in the course of the diseasePathologists cannot make a diagnosis of IFBC in the absence of the clinical signsBCs that are associated with skin changes involving < 1/3 of the breast would be classified as T4b due to the skin edema",
                    "sub_points": [
                      "Sometimes referred to as \"occult IFBC\"Extent of dermal LVI may be too limited to cause the clinical skin changes or the patient may have presented early in the course of the disease",
                      "Extent of dermal LVI may be too limited to cause the clinical skin changes or the patient may have presented early in the course of the disease",
                      "Pathologists cannot make a diagnosis of IFBC in the absence of the clinical signs",
                      "BCs that are associated with skin changes involving < 1/3 of the breast would be classified as T4b due to the skin edema"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Skin thickening"
                  },
                  {
                    "text": "Diffuse increase in breast density compared with contralateral breastTrabecular thickening",
                    "sub_points": [
                      "Trabecular thickening"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Skin thickening"
                  },
                  {
                    "text": "Diffuse, increased echogenicity and dilated lymphatics due to edema"
                  },
                  {
                    "text": "Very useful modality to determine best area for diagnostic biopsy"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Patients will generally have undergone NAT before surgery"
                  },
                  {
                    "text": "Information about the pretreatment BC is essential for optimal evaluationLocation and extent of BCLocation and number of clips placed at site(s) of BCLocation of skin biopsies showing BCResponse to NATSkin changes usually resolveIncrease in breast size may or may not resolve",
                    "sub_points": [
                      "Location and extent of BC",
                      "Location and number of clips placed at site(s) of BC",
                      "Location of skin biopsies showing BC",
                      "Response to NATSkin changes usually resolveIncrease in breast size may or may not resolve",
                      "Skin changes usually resolve",
                      "Increase in breast size may or may not resolve"
                    ]
                  },
                  {
                    "text": "Gross appearance of mastectomy can be highly variableSkin typically looks normalThickening, erythema, and induration usually resolve after NATScar may be present if skin biopsy was performed for diagnosisThe tumor bed may be indistinct clinically, radiologically, and by gross inspectionIt is essential to identify any clips marking prior location of BC radiologically &/or grosslyRadiographing the specimen prior to processing to identify clips is highly recommendedIf clips are dislodged or lost during sectioning, it may be impossible to identify the tumor bed and to document a pCR",
                    "sub_points": [
                      "Skin typically looks normalThickening, erythema, and induration usually resolve after NATScar may be present if skin biopsy was performed for diagnosis",
                      "Thickening, erythema, and induration usually resolve after NAT",
                      "Scar may be present if skin biopsy was performed for diagnosis",
                      "The tumor bed may be indistinct clinically, radiologically, and by gross inspectionIt is essential to identify any clips marking prior location of BC radiologically &/or grossly",
                      "It is essential to identify any clips marking prior location of BC radiologically &/or grossly",
                      "Radiographing the specimen prior to processing to identify clips is highly recommendedIf clips are dislodged or lost during sectioning, it may be impossible to identify the tumor bed and to document a pCR",
                      "If clips are dislodged or lost during sectioning, it may be impossible to identify the tumor bed and to document a pCR"
                    ]
                  },
                  {
                    "text": "If response was poor, grossly evident BC may be presentMajority are centrally located in breast",
                    "sub_points": [
                      "Majority are centrally located in breast"
                    ]
                  },
                  {
                    "text": "Extensive residual BC may be present in absence of gross lesions"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "No genomic hallmark has been discovered that is common to all cases of IFBCHER2,MYC,PIK3CA, andFGFR1amplifications andTP53,BRCA2, andPTENmutations are commonMYC transcriptional activity may contribute to poor prognosis in ER(+) IFBC",
                    "sub_points": [
                      "HER2,MYC,PIK3CA, andFGFR1amplifications andTP53,BRCA2, andPTENmutations are common",
                      "MYC transcriptional activity may contribute to poor prognosis in ER(+) IFBC"
                    ]
                  },
                  {
                    "text": "Tumor mutation burden higher in IFBC than in non-IFBC"
                  },
                  {
                    "text": "Genomic instability is part of IFBC biologyHigh frequency of copy number alteration and complex patterns of chromosomal imbalances",
                    "sub_points": [
                      "High frequency of copy number alteration and complex patterns of chromosomal imbalances"
                    ]
                  },
                  {
                    "text": "ALK pathwayRecent data suggest specific and unknown alterations in activation of ALK pathway are found in IFBCActivation related toALKgene amplification at 2p23IfALKamplification confirmed, ALK-targeted therapy may be warranted",
                    "sub_points": [
                      "Recent data suggest specific and unknown alterations in activation of ALK pathway are found in IFBCActivation related toALKgene amplification at 2p23IfALKamplification confirmed, ALK-targeted therapy may be warranted",
                      "Activation related toALKgene amplification at 2p23",
                      "IfALKamplification confirmed, ALK-targeted therapy may be warranted"
                    ]
                  }
                ],
                "mRNA": [
                  {
                    "text": "Gene expression profiling has demonstrated marked transcriptional heterogeneity among IFBCs"
                  },
                  {
                    "text": "Studies have been limited bySmall numbers of BCs due to rarity of diseaseDiffering definitions of IFBCDiffuse pattern of infiltration leading to large stroma:tumor cell ratio in samples",
                    "sub_points": [
                      "Small numbers of BCs due to rarity of disease",
                      "Differing definitions of IFBC",
                      "Diffuse pattern of infiltration leading to large stroma:tumor cell ratio in samples"
                    ]
                  },
                  {
                    "text": "IFBC includes basal (20-40%), HER2 (20-40%), and luminal A and B subtypesThe proportion of molecular subtypes in IFBC differs compared with non-IFBCLuminal BCs are less common compared to non-IFBCOverrepresentation of basal-like and HER2(+) BCsThe expected aggressive clinical features associated with these BC subtypes are not alone sufficient to explain poor prognosisBCs of the luminal subtype also have poor prognosisSuggests that independent gene sets are responsible for molecular subtype and specific characteristics of IFBC",
                    "sub_points": [
                      "The proportion of molecular subtypes in IFBC differs compared with non-IFBCLuminal BCs are less common compared to non-IFBCOverrepresentation of basal-like and HER2(+) BCs",
                      "Luminal BCs are less common compared to non-IFBC",
                      "Overrepresentation of basal-like and HER2(+) BCs",
                      "The expected aggressive clinical features associated with these BC subtypes are not alone sufficient to explain poor prognosisBCs of the luminal subtype also have poor prognosis",
                      "BCs of the luminal subtype also have poor prognosis",
                      "Suggests that independent gene sets are responsible for molecular subtype and specific characteristics of IFBC"
                    ]
                  },
                  {
                    "text": "One group has reported nuclear factor-κB hyperactivation and augmented insulin-like growth factor signalingAssociated with increased tumor cell invasion, angiogenesis, and metastatic potentialIt is unclear if this expression pattern is related to absence of ER expression or specifically to IFBC",
                    "sub_points": [
                      "Associated with increased tumor cell invasion, angiogenesis, and metastatic potential",
                      "It is unclear if this expression pattern is related to absence of ER expression or specifically to IFBC"
                    ]
                  },
                  {
                    "text": "Another group has reported pattern of RhoC GTPase positivity and WISP-3 negativity in 90% of IFBCThis pattern is rare in non-IFBC",
                    "sub_points": [
                      "This pattern is rare in non-IFBC"
                    ]
                  },
                  {
                    "text": "Activation of angiogenesis pathways has been described by microarray studies"
                  },
                  {
                    "text": "Recent studies have demonstrated high levels of translation initiation factorEIF4G1Regulates p120 catenin, which anchors E-cadherin",
                    "sub_points": [
                      "Regulates p120 catenin, which anchors E-cadherin"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "The term inflammatory refers to the clinical appearance of skin, which mimics inflammationA significant inflammatory infiltrate is not feature of this type of BCExtensive tumor-infiltrating lymphocytes are uncommon and are not a defining feature",
                    "sub_points": [
                      "A significant inflammatory infiltrate is not feature of this type of BC",
                      "Extensive tumor-infiltrating lymphocytes are uncommon and are not a defining feature"
                    ]
                  },
                  {
                    "text": "IFBC cannot be diagnosed only by pathologic features"
                  },
                  {
                    "text": "Histologic type and gradeNo special type (\"ductal\") most common< 10% lobular in type~ 2/3 poorly differentiated, 1/3 moderately differentiated",
                    "sub_points": [
                      "No special type (\"ductal\") most common< 10% lobular in type",
                      "< 10% lobular in type",
                      "~ 2/3 poorly differentiated, 1/3 moderately differentiated"
                    ]
                  },
                  {
                    "text": "Typically have diffusely infiltrative pattern, often without a prominent desmoplastic responseCorrelates with frequent absence of discrete mass by palpation or imaging",
                    "sub_points": [
                      "Correlates with frequent absence of discrete mass by palpation or imaging"
                    ]
                  },
                  {
                    "text": "Mammary skin changesUsually absent after treatmentDilated lymphatic spaces and small capillaries may be present",
                    "sub_points": [
                      "Usually absent after treatment",
                      "Dilated lymphatic spaces and small capillaries may be present"
                    ]
                  },
                  {
                    "text": "Prominent LVI is rarely seen in IFBC that has responded to NATIf present, LVI may be present throughout the breast in addition to the dermis",
                    "sub_points": [
                      "If present, LVI may be present throughout the breast in addition to the dermis"
                    ]
                  },
                  {
                    "text": "Ductal carcinoma in situ is usually minimal or absent"
                  }
                ],
                "Skin Punch Biopsy": [
                  {
                    "text": "Often used to investigate the possibility of IFBCAt least 2 skin punch biopsies (2-8 mm) recommendedDeeper levels may be helpful to look for small foci of LVI",
                    "sub_points": [
                      "At least 2 skin punch biopsies (2-8 mm) recommended",
                      "Deeper levels may be helpful to look for small foci of LVI"
                    ]
                  },
                  {
                    "text": "If dermal LVI is seen, this confirms the diagnosis of IFBC in the appropriate clinical setting of diagnostic skin changesConfirmed in ~ 75% of cases",
                    "sub_points": [
                      "Confirmed in ~ 75% of cases"
                    ]
                  },
                  {
                    "text": "If dermal LVI is not seen, this does not necessarily preclude the clinical diagnosis of IFBCDermal LVI may be scattered and missed in a small biopsy",
                    "sub_points": [
                      "Dermal LVI may be scattered and missed in a small biopsy"
                    ]
                  },
                  {
                    "text": "If the biopsy shows true acute or chronic inflammation (e.g. cellulitis), the patient likely has a disease other than IFBC"
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Biopsy may be performed if a mass can be identified by palpation or imaging"
                  },
                  {
                    "text": "LVI in the breast supports a diagnosis of IFBC but is not sufficient without clinical skin changes"
                  },
                  {
                    "text": "Finding of an inflammatory process would be evidence against IFBC"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptors: 40% ER(+), 20% PR(+)More likely to be negative compared with non-IFBC (~ 70-80% positive)",
                    "sub_points": [
                      "More likely to be negative compared with non-IFBC (~ 70-80% positive)"
                    ]
                  },
                  {
                    "text": "HER2: 40-50% positiveMore likely to be positive compared with non-IFBC (15-20% positive)HER2FISH ratio has prognostic value for HER2(+) non-IFBC, but not for HER2(+) IFBC treated with NATThis disparity may be due to underlying aggressive nature of IFBC",
                    "sub_points": [
                      "More likely to be positive compared with non-IFBC (15-20% positive)",
                      "HER2FISH ratio has prognostic value for HER2(+) non-IFBC, but not for HER2(+) IFBC treated with NATThis disparity may be due to underlying aggressive nature of IFBC",
                      "This disparity may be due to underlying aggressive nature of IFBC"
                    ]
                  },
                  {
                    "text": "p53: 60-80% positiveThese cancers have a poorer prognosis compared with IFBC without p53 overexpression",
                    "sub_points": [
                      "These cancers have a poorer prognosis compared with IFBC without p53 overexpression"
                    ]
                  },
                  {
                    "text": "AngiogenesisHigh microvessel density seen with CD31 stainingOverexpression of angiogenic factors, such as VEGF",
                    "sub_points": [
                      "High microvessel density seen with CD31 staining",
                      "Overexpression of angiogenic factors, such as VEGF"
                    ]
                  },
                  {
                    "text": "P-cadherin: ~ 75% positiveMore likely to be positive compared with non-IFBC (~ 50%)Marker of myoepithelial cells and associated with basal-like BCOverexpression has proinvasive activity and may contribute to aggressive tumor biology",
                    "sub_points": [
                      "More likely to be positive compared with non-IFBC (~ 50%)",
                      "Marker of myoepithelial cells and associated with basal-like BC",
                      "Overexpression has proinvasive activity and may contribute to aggressive tumor biology"
                    ]
                  },
                  {
                    "text": "E-cadherin: May be overexpressedMay facilitate and sustain cohesion of tumor cell clumps invading and forming emboli",
                    "sub_points": [
                      "May facilitate and sustain cohesion of tumor cell clumps invading and forming emboli"
                    ]
                  },
                  {
                    "text": "MUC1 (sialomucin): May be positive"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Mimics of Dermal LVI": [
                  {
                    "text": "Rarely, histiocytes or other inflammatory cells or giant cells after surgery can mimic LVI"
                  },
                  {
                    "text": "A portion of a skin appendage when cut tangentially and with retraction artifact can also resemble LVI"
                  },
                  {
                    "text": "BCs invading into the dermis with retraction artifact can appear to be in lymphaticsSuch a case would be more likely to be a locally advanced BC rather than IFBC",
                    "sub_points": [
                      "Such a case would be more likely to be a locally advanced BC rather than IFBC"
                    ]
                  }
                ],
                "Metastasis to Breast": [
                  {
                    "text": "Metastases to the breast very rarely present with skin changes resembling IFBC"
                  },
                  {
                    "text": "The majority of patients have a history of prior malignancy"
                  },
                  {
                    "text": "Morphologic features suggestive of a nonbreast primary should prompt additional studiesFor example, ovarian carcinoma often has a papillary architecture and is associated with psammoma-body calcifications",
                    "sub_points": [
                      "For example, ovarian carcinoma often has a papillary architecture and is associated with psammoma-body calcifications"
                    ]
                  }
                ]
              },
              "STAGING": {
                "AJCC Classification": [
                  {
                    "text": "IFBC, defined as diffuse erythema and edema (peau d'orange) involving ≥ 1/3 of skin, is classified as T4dInvasive BC must be confirmed by biopsyDermal LVI need not be confirmed pathologically but is present in > 80% of cases with an adequate biopsy",
                    "sub_points": [
                      "Invasive BC must be confirmed by biopsy",
                      "Dermal LVI need not be confirmed pathologically but is present in > 80% of cases with an adequate biopsy"
                    ]
                  },
                  {
                    "text": "BCs with dermal LVI, but without clinical skin involvement, are assigned a T category according to tumor size"
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "IFBCs are reported according to the College of American Pathology Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Apocrine Carcinoma": {
            "name": "Invasive Apocrine Carcinoma",
            "url": "https://app.pathprimer.com/document/4f256e5f-d9b8-4cbd-96fe-3993b2a85d5b/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Invasive apocrine carcinoma (IAC) is defined by prominent apocrine features"
                  }
                ],
                "Classification": [
                  {
                    "text": "The majority of IACs are positive for androgen receptor (AR) and GCDFP-15 and negative for estrogen receptor (ER)~ 1/2 are HER2(+)",
                    "sub_points": [
                      "~ 1/2 are HER2(+)"
                    ]
                  },
                  {
                    "text": "Characterized by a gene expression pattern largely driven by expression of AR"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Incidence varies from < 1% up to 4% depending on diagnostic criteria"
                  },
                  {
                    "text": "IAC does not have specific epidemiologic, clinical, or imaging features"
                  },
                  {
                    "text": "Apocrine triple negative breast carcinomas (TNBCs) are more likely to be grade 1 or 2 and have a more favorable prognosis compared to other TNBCs"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Histologic criteria for IAC must be present in > 90% of the cancerAbundant eosinophilic granular or vacuolated cytoplasm with distinct cell bordersLarge round to oval nuclei with moderate to marked atypia and prominent nucleoli",
                    "sub_points": [
                      "Abundant eosinophilic granular or vacuolated cytoplasm with distinct cell borders",
                      "Large round to oval nuclei with moderate to marked atypia and prominent nucleoli"
                    ]
                  },
                  {
                    "text": "DCIS with apocrine features is recognized by abnormal architecture and nuclear atypia"
                  },
                  {
                    "text": "Pleomorphic apocrine LCIS can be ER(-) and HER2(+)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Benign apocrine lesions"
                  },
                  {
                    "text": "Sclerosing adenosis involved by apocrine change"
                  },
                  {
                    "text": "Granular cell tumor"
                  },
                  {
                    "text": "Invasive carcinomas with abundant cytoplasm"
                  },
                  {
                    "text": "Cutaneous apocrine carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive apocrine carcinoma (IAC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Carcinoma with apocrine differentiation or apocrine carcinoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Characterized by cells with large nuclei with prominent nucleoli and abundant eosinophilic granular or vacuolated cytoplasmMorphologic appearance resembles apocrine sweat glands",
                    "sub_points": [
                      "Morphologic appearance resembles apocrine sweat glands"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Invasive apocrine carcinomas (IACs) are recognized by pathologists due to the characteristic cytologic and nuclear features"
                  },
                  {
                    "text": "Various definitions for defining \"apocrine carcinoma\" include morphology, immunoreactivity for certain proteins, and gene expression profiling, as well as combinations of these features"
                  },
                  {
                    "text": "The combinations of these different features identify similar and overlapping, but not identical, groups of carcinomas"
                  }
                ],
                "Biologic Types of Apocrine Carcinoma": [
                  {
                    "text": "Based on the expression of estrogen receptor (ER), androgen receptor (AR), and HER2, IACs can be divided into distinct groups"
                  },
                  {
                    "text": "ER(-)/AR(+)/HER2(-): ~ 55% of IACsThese are triple negative breast carcinomas (TNBCs) that are not basal-like carcinomas (BLCs) by gene expression profiling due to AR expressionThese carcinomas cluster with ER(+) carcinomas and are sometimes referred to as luminal AR(+) carcinoma~ 75% of TNBCs with apocrine morphology are AR(+)~ 20-30% of all TNBCs are AR(+)> 95% are GCDFP-15(+) and ~ 75% GATA3(+)Only ~ 10% of nonapocrine AR(-) TNBC is GATA3(+) and < 5% are GCDFP-15(+)In 1 study, 6 apocrine TNBCs were positive for claudin-1 and 3 and were negative for claudin-4Compared to AR(-) TNBCs, these IACs are more likely to be grade 1 (~ 10-15% vs. < 2%) or grade 2 (~ 35-55% vs. 15%), and less likely to be grade 3 (~ 30-55% vs. 85%)Compared to nonapocrine TNBCs in the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program, apocrine TNBCs occurred in older women, were smaller, were more likely to be grade 1 or 2, and patients had significantly improved survival (82% vs. 74% at 5 years)",
                    "sub_points": [
                      "These are triple negative breast carcinomas (TNBCs) that are not basal-like carcinomas (BLCs) by gene expression profiling due to AR expressionThese carcinomas cluster with ER(+) carcinomas and are sometimes referred to as luminal AR(+) carcinoma~ 75% of TNBCs with apocrine morphology are AR(+)~ 20-30% of all TNBCs are AR(+)",
                      "These carcinomas cluster with ER(+) carcinomas and are sometimes referred to as luminal AR(+) carcinoma",
                      "~ 75% of TNBCs with apocrine morphology are AR(+)~ 20-30% of all TNBCs are AR(+)",
                      "~ 20-30% of all TNBCs are AR(+)",
                      "> 95% are GCDFP-15(+) and ~ 75% GATA3(+)Only ~ 10% of nonapocrine AR(-) TNBC is GATA3(+) and < 5% are GCDFP-15(+)",
                      "Only ~ 10% of nonapocrine AR(-) TNBC is GATA3(+) and < 5% are GCDFP-15(+)",
                      "In 1 study, 6 apocrine TNBCs were positive for claudin-1 and 3 and were negative for claudin-4",
                      "Compared to AR(-) TNBCs, these IACs are more likely to be grade 1 (~ 10-15% vs. < 2%) or grade 2 (~ 35-55% vs. 15%), and less likely to be grade 3 (~ 30-55% vs. 85%)",
                      "Compared to nonapocrine TNBCs in the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program, apocrine TNBCs occurred in older women, were smaller, were more likely to be grade 1 or 2, and patients had significantly improved survival (82% vs. 74% at 5 years)"
                    ]
                  },
                  {
                    "text": "ER(-)/AR(+)/HER2(+): ~ 20-55% of IACsThese carcinomas often express HER2 at very high levels~ 80% of cancers that are ER(-) and HER2(+) show apocrine morphology",
                    "sub_points": [
                      "These carcinomas often express HER2 at very high levels",
                      "~ 80% of cancers that are ER(-) and HER2(+) show apocrine morphology"
                    ]
                  },
                  {
                    "text": "ER(+): ~ 24-40% of IACs~ 10-50% of these carcinomas are AR(-) and ~ 1/2 are HER2(+)~ 55% of carcinomas that are ER(+) and HER2(+) show apocrine morphologyThese carcinomas may be excluded from studies of IAC if absence of ER is a criterion for diagnosis",
                    "sub_points": [
                      "~ 10-50% of these carcinomas are AR(-) and ~ 1/2 are HER2(+)",
                      "~ 55% of carcinomas that are ER(+) and HER2(+) show apocrine morphology",
                      "These carcinomas may be excluded from studies of IAC if absence of ER is a criterion for diagnosis"
                    ]
                  },
                  {
                    "text": "ER(-)/AR(-)/HER2(-): < 5% of IACsThis small group is a rare type of apocrine TNBC that does not express AR",
                    "sub_points": [
                      "This small group is a rare type of apocrine TNBC that does not express AR"
                    ]
                  }
                ],
                "Criteria for Apocrine Carcinoma": [
                  {
                    "text": "A definition of pure apocrine carcinoma (PAC) has been proposed> 90% of tumor cells show apocrine morphology (this is an essential WHO diagnostic criterion)ER(-) and AR(+) (this is a desirable WHO diagnostic criterion)",
                    "sub_points": [
                      "> 90% of tumor cells show apocrine morphology (this is an essential WHO diagnostic criterion)",
                      "ER(-) and AR(+) (this is a desirable WHO diagnostic criterion)"
                    ]
                  },
                  {
                    "text": "IACs not meeting these criteria have been termed apocrine like carcinoma (ALC)"
                  },
                  {
                    "text": "Of all IACs, > 1/2 are PAC and the remainder ALC according to this definition"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Benign Apocrine Breast Lesions": [
                  {
                    "text": "Apocrine glands normally occur in skinBreasts evolved from skin appendages and, thus, have many features in common with themGrowth of cutaneous apocrine glands is stimulated by androgens",
                    "sub_points": [
                      "Breasts evolved from skin appendages and, thus, have many features in common with them",
                      "Growth of cutaneous apocrine glands is stimulated by androgens"
                    ]
                  },
                  {
                    "text": "Apocrine change is commonly seen in cysts in adult breast tissue as metaplasiaCells with functional apocrine characteristics have been described in fetal breast tissue",
                    "sub_points": [
                      "Cells with functional apocrine characteristics have been described in fetal breast tissue"
                    ]
                  },
                  {
                    "text": "Benign apocrine lesions usually express AR and are negative for ER and PRAlthough these lesions do not showHER2gene amplification, moderate cytoplasmic and basal/lateral membrane immunoreactivity is often seen",
                    "sub_points": [
                      "Although these lesions do not showHER2gene amplification, moderate cytoplasmic and basal/lateral membrane immunoreactivity is often seen"
                    ]
                  },
                  {
                    "text": "Some apocrine lesions show loss of heterozygosity and genetic changes, supporting that some are clonal lesions and may be nonobligate precursors of apocrine carcinomasAtypical apocrine proliferations are found more commonly in breasts with apocrine carcinomas",
                    "sub_points": [
                      "Atypical apocrine proliferations are found more commonly in breasts with apocrine carcinomas"
                    ]
                  }
                ],
                "Androgen Metabolism in Breast Cancer": [
                  {
                    "text": "The majority of breast cancers (70-80%) express ARER/PR(+), HER2(+): ~ 80%ER/PR(+), HER2(-): ~ 60%ER/PR(-), HER2(+): ~ 50%HER2 may induce AR transactivation through MAP kinase pathwayER/PR(-), HER2(-): ~ 20-30%",
                    "sub_points": [
                      "ER/PR(+), HER2(+): ~ 80%",
                      "ER/PR(+), HER2(-): ~ 60%",
                      "ER/PR(-), HER2(+): ~ 50%HER2 may induce AR transactivation through MAP kinase pathway",
                      "HER2 may induce AR transactivation through MAP kinase pathway",
                      "ER/PR(-), HER2(-): ~ 20-30%"
                    ]
                  },
                  {
                    "text": "IAC is AR(+) in 50-80% of casesEnhanced metabolism of testosterone precursors has been reported in IACAltered androgen metabolism may play a role in pathogenesis and tumor progressionAR is inhibitory and counteracts the oncogenic activity of ER-α in ER(+) breast cancerAR expression is prognostic in ER(+) breast cancer and is correlated with better outcomesOngoing clinical trials are investigating efficacy of antiandrogen drugs in AR(+) breast cancerTherapies that inhibit androgen signaling (e.g., antiandrogen bicalutamide, CYP17 inhibitor abiraterone acetate) are used in prostate cancer",
                    "sub_points": [
                      "Enhanced metabolism of testosterone precursors has been reported in IAC",
                      "Altered androgen metabolism may play a role in pathogenesis and tumor progression",
                      "AR is inhibitory and counteracts the oncogenic activity of ER-α in ER(+) breast cancerAR expression is prognostic in ER(+) breast cancer and is correlated with better outcomes",
                      "AR expression is prognostic in ER(+) breast cancer and is correlated with better outcomes",
                      "Ongoing clinical trials are investigating efficacy of antiandrogen drugs in AR(+) breast cancerTherapies that inhibit androgen signaling (e.g., antiandrogen bicalutamide, CYP17 inhibitor abiraterone acetate) are used in prostate cancer",
                      "Therapies that inhibit androgen signaling (e.g., antiandrogen bicalutamide, CYP17 inhibitor abiraterone acetate) are used in prostate cancer"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "< 1% up to 4% depending on diagnostic criteria"
                  }
                ],
                "Presentation": [
                  {
                    "text": "There are no characteristic clinical or radiographic features specific to IAC"
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "Currently no specific treatment based on classification as IAC"
                  },
                  {
                    "text": "Altered androgen metabolism may be a therapeutically useful targetResponses to anti-androgen therapy in AR(+) TNBC have been reported",
                    "sub_points": [
                      "Responses to anti-androgen therapy in AR(+) TNBC have been reported"
                    ]
                  },
                  {
                    "text": "Magnitude of benefit from chemotherapy for IAC is unclear, mixed results from retrospective registries"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Some NCDB- and SEER-based studies have shown better overall survival for AR(+) apocrine TNBC compared to AR(-) nonapocrine TNBC"
                  },
                  {
                    "text": "Studies of survival need to control for the different biologic types of IAC"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "There are no imaging features specific to IAC"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "There are no gross features specific to IAC"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "MutationsMost common mutations arePIK3CA(~ 70-100%),PTEN(~ 33%), andTP53(~ 30%) in ER(-)/AR(+)/HER2(-) IACSome carcinomas in patients with Cowden syndrome (germlinePTENmutation) show apocrine morphology",
                    "sub_points": [
                      "Most common mutations arePIK3CA(~ 70-100%),PTEN(~ 33%), andTP53(~ 30%) in ER(-)/AR(+)/HER2(-) IAC",
                      "Some carcinomas in patients with Cowden syndrome (germlinePTENmutation) show apocrine morphology"
                    ]
                  },
                  {
                    "text": "Copy number changesChromosomal gains of 1p, 1q, and 2q as well as losses of 1p, 12q, 16q, 17q, and 22qAlso common in other types of breast carcinoma",
                    "sub_points": [
                      "Chromosomal gains of 1p, 1q, and 2q as well as losses of 1p, 12q, 16q, 17q, and 22qAlso common in other types of breast carcinoma",
                      "Also common in other types of breast carcinoma"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "IACs fall into multiple groups defined by gene expression profilingLargely driven by expression of ER, AR, and HER2 in subsets of these cancers",
                    "sub_points": [
                      "Largely driven by expression of ER, AR, and HER2 in subsets of these cancers"
                    ]
                  },
                  {
                    "text": "Molecular apocrine tumors (MATs)This group shows high expression of AR (~ 60%) and ~ 50% overexpress HER2The signature also includes increased expression of numerous genes with roles in metabolism and expression of luminal rather than basal keratinsSome MATs do not have apocrine morphology~ 93% overlap with ER(-)/AR(+)/HER2(-) IAC~ 67% overlap with ER(-)/AR(+)/HER2(+) IAC",
                    "sub_points": [
                      "This group shows high expression of AR (~ 60%) and ~ 50% overexpress HER2",
                      "The signature also includes increased expression of numerous genes with roles in metabolism and expression of luminal rather than basal keratinsSome MATs do not have apocrine morphology",
                      "Some MATs do not have apocrine morphology",
                      "~ 93% overlap with ER(-)/AR(+)/HER2(-) IAC",
                      "~ 67% overlap with ER(-)/AR(+)/HER2(+) IAC"
                    ]
                  },
                  {
                    "text": "Luminal AR groupGroup includes some IACs that are TNBCs but are AR(+)This group shows low response to neoadjuvant chemotherapy (~ 10%) compared to other molecular basal-like groups (> 50%)However, survival is not diminished, possibly due to lower proliferation",
                    "sub_points": [
                      "Group includes some IACs that are TNBCs but are AR(+)",
                      "This group shows low response to neoadjuvant chemotherapy (~ 10%) compared to other molecular basal-like groups (> 50%)However, survival is not diminished, possibly due to lower proliferation",
                      "However, survival is not diminished, possibly due to lower proliferation"
                    ]
                  },
                  {
                    "text": "HER2-enriched groupSome IACs are in this groupIncludes most pleomorphic lobular carcinomas with apocrine features",
                    "sub_points": [
                      "Some IACs are in this group",
                      "Includes most pleomorphic lobular carcinomas with apocrine features"
                    ]
                  },
                  {
                    "text": "Luminal groupSome IACs cluster with other ER(+) carcinomas",
                    "sub_points": [
                      "Some IACs cluster with other ER(+) carcinomas"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "IAC has characteristic nuclear and cytoplasmic features that should be present in > 90% of tumor cellsNuclei (most commonly nuclear grade 2 or 3)Round &/or pleomorphic, large vesicular nucleiProminent, often multiple, nucleoliHowever, some carcinomas have low nuclear gradeCytoplasmAbundant, nuclear:cytoplasmic ratio 1:2 or greaterEosinophilic and finely granular most common; some may have foamy or clear cytoplasmSharply defined cell bordersCarcinomas with focal apocrine appearance are common (~ 30% of carcinomas of no special type) and should not be classified as IAC",
                    "sub_points": [
                      "Nuclei (most commonly nuclear grade 2 or 3)Round &/or pleomorphic, large vesicular nucleiProminent, often multiple, nucleoliHowever, some carcinomas have low nuclear grade",
                      "Round &/or pleomorphic, large vesicular nuclei",
                      "Prominent, often multiple, nucleoli",
                      "However, some carcinomas have low nuclear grade",
                      "CytoplasmAbundant, nuclear:cytoplasmic ratio 1:2 or greaterEosinophilic and finely granular most common; some may have foamy or clear cytoplasmSharply defined cell borders",
                      "Abundant, nuclear:cytoplasmic ratio 1:2 or greater",
                      "Eosinophilic and finely granular most common; some may have foamy or clear cytoplasm",
                      "Sharply defined cell borders",
                      "Carcinomas with focal apocrine appearance are common (~ 30% of carcinomas of no special type) and should not be classified as IAC"
                    ]
                  },
                  {
                    "text": "Growth patternsSolid/sheet-like without tubule formation: Majority of IACSingle cell \"lobular\": Minority of IAC (E-cadherin negative)Usually poorly differentiatedIncludes some lobular carcinomas described as histiocytoidWell-formed tubules: RareMay be classified as grade 1 due to lack of nuclear pleomorphism and low mitotic rateThis is an unusual type of grade 1 carcinoma that can be TNBC or HER2(+)",
                    "sub_points": [
                      "Solid/sheet-like without tubule formation: Majority of IAC",
                      "Single cell \"lobular\": Minority of IAC (E-cadherin negative)Usually poorly differentiatedIncludes some lobular carcinomas described as histiocytoid",
                      "Usually poorly differentiated",
                      "Includes some lobular carcinomas described as histiocytoid",
                      "Well-formed tubules: RareMay be classified as grade 1 due to lack of nuclear pleomorphism and low mitotic rateThis is an unusual type of grade 1 carcinoma that can be TNBC or HER2(+)",
                      "May be classified as grade 1 due to lack of nuclear pleomorphism and low mitotic rate",
                      "This is an unusual type of grade 1 carcinoma that can be TNBC or HER2(+)"
                    ]
                  },
                  {
                    "text": "Apocrine DCISCan be difficult to recognize in isolation as it can be difficult to distinguish benign metaplasia from a clonal neoplastic proliferationHigh nuclear grade, necrosis, and atypical architectural patterns (e.g., cribriform spaces or micropapillae) are useful diagnostic featuresAll architectural patterns can be seenComedo, solid, cribriform, papillary, and micropapillary",
                    "sub_points": [
                      "Can be difficult to recognize in isolation as it can be difficult to distinguish benign metaplasia from a clonal neoplastic proliferationHigh nuclear grade, necrosis, and atypical architectural patterns (e.g., cribriform spaces or micropapillae) are useful diagnostic featuresAll architectural patterns can be seenComedo, solid, cribriform, papillary, and micropapillary",
                      "High nuclear grade, necrosis, and atypical architectural patterns (e.g., cribriform spaces or micropapillae) are useful diagnostic features",
                      "All architectural patterns can be seenComedo, solid, cribriform, papillary, and micropapillary",
                      "Comedo, solid, cribriform, papillary, and micropapillary"
                    ]
                  },
                  {
                    "text": "Apocrine LCISPleomorphic apocrine LCIS (PALCIS) has high nuclear grade and often has central necrosis~ 60% are ER(-) and > 40% are HER2(+)",
                    "sub_points": [
                      "Pleomorphic apocrine LCIS (PALCIS) has high nuclear grade and often has central necrosis~ 60% are ER(-) and > 40% are HER2(+)",
                      "~ 60% are ER(-) and > 40% are HER2(+)"
                    ]
                  },
                  {
                    "text": "Apocrine encapsulated papillary carcinoma (A-EPC)This is a rare, well-circumscribed tumor that usually presents as a palpable subareolar mass in older womenNo myoepithelial cells are present at the periphery or in fibrovascular cores using multiple IHC markersOf the cases tested, the carcinomas have been ER(-), AR(+), HER2(-), GCDP-15(+)Only 1 has been associated with frankly invasive carcinomaThese cases are distinct from high-grade EPC, which shows marked nuclear pleomorphism and increased mitosesApocrine features have not been described in this group~ 1/2 are ER(-)",
                    "sub_points": [
                      "This is a rare, well-circumscribed tumor that usually presents as a palpable subareolar mass in older women",
                      "No myoepithelial cells are present at the periphery or in fibrovascular cores using multiple IHC markers",
                      "Of the cases tested, the carcinomas have been ER(-), AR(+), HER2(-), GCDP-15(+)",
                      "Only 1 has been associated with frankly invasive carcinoma",
                      "These cases are distinct from high-grade EPC, which shows marked nuclear pleomorphism and increased mitosesApocrine features have not been described in this group~ 1/2 are ER(-)",
                      "Apocrine features have not been described in this group",
                      "~ 1/2 are ER(-)"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Apocrine lesions may be challenging on limited needle biopsy samples"
                  },
                  {
                    "text": "Apocrine metaplasia or apocrine atypical hyperplasia or carcinoma in situ in sclerosing adenosis can mimic IACRounded or lobulated border by imaging or histology suggests sclerosing adenosis rather than invasive carcinomaBack-to-back involved spaces with little intervening stroma also suggests sclerosing adenosis rather than invasive carcinoma",
                    "sub_points": [
                      "Rounded or lobulated border by imaging or histology suggests sclerosing adenosis rather than invasive carcinoma",
                      "Back-to-back involved spaces with little intervening stroma also suggests sclerosing adenosis rather than invasive carcinoma"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "PAS diastaseReactivity: PositiveStaining pattern: Cytoplasmic (granular pattern)",
                    "sub_points": [
                      "Reactivity: Positive",
                      "Staining pattern: Cytoplasmic (granular pattern)"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "ER and PR: > 50% are negativeMay be positive for ER-β but negative for ER-α",
                    "sub_points": [
                      "May be positive for ER-β but negative for ER-α"
                    ]
                  },
                  {
                    "text": "HER2: ~ 50% are positive"
                  },
                  {
                    "text": "AR: 50-80% are positiveTypically strong diffuse expression is seen",
                    "sub_points": [
                      "Typically strong diffuse expression is seen"
                    ]
                  },
                  {
                    "text": "Gross cystic disease fluid protein-15 (GCDFP-15): > 75% are positiveTypically, > 50% of cells show reactivity for GCDFP-15GCDFP-15 is regulated by AR and is a diagnostic marker for mammary differentiationExpression of both GCDFP-15 and AR are correlated~ 23% of nonapocrine breast carcinomas are also positive for GCDFP-15, including most lobular carcinomasTherefore, GCDFP-15 expression is not specific for apocrine differentiation",
                    "sub_points": [
                      "Typically, > 50% of cells show reactivity for GCDFP-15",
                      "GCDFP-15 is regulated by AR and is a diagnostic marker for mammary differentiationExpression of both GCDFP-15 and AR are correlated",
                      "Expression of both GCDFP-15 and AR are correlated",
                      "~ 23% of nonapocrine breast carcinomas are also positive for GCDFP-15, including most lobular carcinomasTherefore, GCDFP-15 expression is not specific for apocrine differentiation",
                      "Therefore, GCDFP-15 expression is not specific for apocrine differentiation"
                    ]
                  },
                  {
                    "text": "p53: 46-50% positive"
                  },
                  {
                    "text": "Carcinoembryonic antigen (CEA-P): ~ 47% positive"
                  },
                  {
                    "text": "Programmed death-ligand 1 (PD-L1)IAC are often PD-L1 negative",
                    "sub_points": [
                      "IAC are often PD-L1 negative"
                    ]
                  },
                  {
                    "text": "TRPS1: ~ 64% positiveLower (15-35%) for apocrine TNBCs that are AR(+)",
                    "sub_points": [
                      "Lower (15-35%) for apocrine TNBCs that are AR(+)"
                    ]
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Cells from benign and malignant apocrine lesions have numerous mitochondriaSome show incomplete cristaeVarying numbers of osmiophilic secretory granules",
                    "sub_points": [
                      "Some show incomplete cristae",
                      "Varying numbers of osmiophilic secretory granules"
                    ]
                  },
                  {
                    "text": "Secretory granules, empty vesicles, and other intracytoplasmic organelles typically present"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Benign Apocrine Lesions": [
                  {
                    "text": "Apocrine metaplasia is a frequent finding in breast tissueOften associated with calcifications (calcium phosphate and calcium oxalate)Partial involvement of lesions (e.g., papillomas) is an indication of polyclonality supporting a benign diagnosis",
                    "sub_points": [
                      "Often associated with calcifications (calcium phosphate and calcium oxalate)",
                      "Partial involvement of lesions (e.g., papillomas) is an indication of polyclonality supporting a benign diagnosis"
                    ]
                  },
                  {
                    "text": "Rare benign apocrine lesions can lack myoepithelial cellsThe absence of myoepithelial cells alone is not sufficient for classification as invasive carcinoma",
                    "sub_points": [
                      "The absence of myoepithelial cells alone is not sufficient for classification as invasive carcinoma"
                    ]
                  }
                ],
                "Sclerosing Adenosis (SA)": [
                  {
                    "text": "AS involved by apocrine metaplasia or apocrine DCIS can closely mimic IAC"
                  },
                  {
                    "text": "Usually has circumscribed borders, a back-to-back swirling pattern, and associated dense stroma"
                  },
                  {
                    "text": "Immunoperoxidase studies to demonstrate myoepithelial cells are helpful in problematic casesMany tumor cells in IAC are p63(+) but will not have the basal location and morphology of myoepithelial cells",
                    "sub_points": [
                      "Many tumor cells in IAC are p63(+) but will not have the basal location and morphology of myoepithelial cells"
                    ]
                  }
                ],
                "Granular Cell Tumor": [
                  {
                    "text": "Benign tumor that can form masses with circumscribed or irregular borders"
                  },
                  {
                    "text": "Has small uniform round nuclei and abundant granular eosinophilic cytoplasmIAC typically has large pleomorphic nuclei with nucleoli",
                    "sub_points": [
                      "IAC typically has large pleomorphic nuclei with nucleoli"
                    ]
                  },
                  {
                    "text": "Cytokeratin(-) and S100(+)IAC is strongly cytokeratin(+) and may or may not be S100(+)",
                    "sub_points": [
                      "IAC is strongly cytokeratin(+) and may or may not be S100(+)"
                    ]
                  },
                  {
                    "text": "CD68(+) (> 95%)"
                  }
                ],
                "Breast Carcinomas With Abundant Cytoplasm": [
                  {
                    "text": "Several types of carcinomas are characterized by abundant cytoplasm"
                  },
                  {
                    "text": "Histologic features may overlap with apocrine carcinoma"
                  },
                  {
                    "text": "Lipid-rich carcinoma: Abundant microvacuolated, foamy, or clear cytoplasm due to lipidsER and AR (-), HER2 and S100 may be (+)",
                    "sub_points": [
                      "ER and AR (-), HER2 and S100 may be (+)"
                    ]
                  },
                  {
                    "text": "Sebaceous carcinoma: Finely vacuolated cytoplasm due to lipidsER, AR, and HER2 may be (+), GCDFP-15(-), S100 (-)",
                    "sub_points": [
                      "ER, AR, and HER2 may be (+), GCDFP-15(-), S100 (-)"
                    ]
                  },
                  {
                    "text": "Oncocytic carcinoma: Abundant granular eosinophilic cytoplasm due to numerous mitochondriaAntimitochondrial antibodies are positiveER majority (+), AR ~ 1/4 (+), HER2 ~ 1/4 (+), GCDFP-15 ~ 1/3 (+)",
                    "sub_points": [
                      "Antimitochondrial antibodies are positive",
                      "ER majority (+), AR ~ 1/4 (+), HER2 ~ 1/4 (+), GCDFP-15 ~ 1/3 (+)"
                    ]
                  },
                  {
                    "text": "Glycogen-rich carcinoma: Clear or finely vacuolated cytoplasm due to glycogenER and HER2 may be (+), GCDFP-15(-)",
                    "sub_points": [
                      "ER and HER2 may be (+), GCDFP-15(-)"
                    ]
                  },
                  {
                    "text": "Secretory carcinoma: Eosinophilic cytoplasm and extracellular eosinophilic secretionsER and HER2 (-), S100 strongly (+)",
                    "sub_points": [
                      "ER and HER2 (-), S100 strongly (+)"
                    ]
                  },
                  {
                    "text": "Acinic cell carcinoma: Amphophilic coarsely granular cytoplasm due to zymogen-like granulesER, AR, and HER2 (-), GCDFP-15 can be focally (+), S100(+), lysozyme(+), α1-antichymostrypsin(+)",
                    "sub_points": [
                      "ER, AR, and HER2 (-), GCDFP-15 can be focally (+), S100(+), lysozyme(+), α1-antichymostrypsin(+)"
                    ]
                  },
                  {
                    "text": "Histiocytoid (lobular) carcinoma: Foamy, clear cytoplasm due to secretory vacuoles &/or mucinER and HER2 can be positive or negative, the majority are AR and GCDFP-15 (+)",
                    "sub_points": [
                      "ER and HER2 can be positive or negative, the majority are AR and GCDFP-15 (+)"
                    ]
                  },
                  {
                    "text": "Prognosis and therapy for these types are based on standard prognostic and predictive markersThese histologic variants need to be distinguished from benign cells and nonbreast tumorsIt is not necessary to perform special tests to attempt to distinguish these special types of carcinoma",
                    "sub_points": [
                      "These histologic variants need to be distinguished from benign cells and nonbreast tumors",
                      "It is not necessary to perform special tests to attempt to distinguish these special types of carcinoma"
                    ]
                  }
                ],
                "Cutaneous Apocrine Carcinoma (Sweat Gland Carcinoma of Skin)": [
                  {
                    "text": "The breast evolved as a modified skin appendageBreast and skin appendage tumors can be very similar in appearance",
                    "sub_points": [
                      "Breast and skin appendage tumors can be very similar in appearance"
                    ]
                  },
                  {
                    "text": "Sweat gland carcinomas of skin can have the same appearance and immunoprofile as IAC"
                  },
                  {
                    "text": "Important distinguishing features are the location of the carcinoma (i.e., dermis vs. deep in breast tissue) and the presence or absence of DCISSweat gland carcinomas are much less common than IAC of breast",
                    "sub_points": [
                      "Sweat gland carcinomas are much less common than IAC of breast"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "IAC is recognized morphologically by the characteristic histologic appearance"
                  },
                  {
                    "text": "At this time, there is no need to perform additional studies for classification (e.g., GCDFP-15 or AR)"
                  },
                  {
                    "text": "Many TNBC that are IAC express ARClinicians may request AR testing to enroll patients on clinical trials",
                    "sub_points": [
                      "Clinicians may request AR testing to enroll patients on clinical trials"
                    ]
                  },
                  {
                    "text": "Apocrine change in benign sclerosing lesions is a close mimic of IACMyoepithelial markers should be performed in difficult cases",
                    "sub_points": [
                      "Myoepithelial markers should be performed in difficult cases"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Invasive carcinomas are reported according to the College of American Pathology Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Neuroendocrine Carcinoma": {
            "name": "Invasive Neuroendocrine Carcinoma",
            "url": "https://app.pathprimer.com/document/1715e728-bf6f-40ae-8246-b24f0101149c/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Neuroendocrine neoplasia (NEN) includes breast-invasive carcinomas with predominant neuroendocrine (NE) histologic features (> 90%) and extensive expression of chromogranin &/or synaptophysin"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "NENs of the breast may have a different biology than NENs occurring at other anatomic sitesNo known normal NE-type cell in breastNo counterpart to carcinoid tumors of other sites",
                    "sub_points": [
                      "No known normal NE-type cell in breast",
                      "No counterpart to carcinoid tumors of other sites"
                    ]
                  },
                  {
                    "text": "May result from early divergent differentiation of precursor cells into NE and epithelial lines"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "< 1% by 5th edition (2019) WHO criteriaHowever, 10-30% of breast carcinomas have some degree of expression of NE markers",
                    "sub_points": [
                      "However, 10-30% of breast carcinomas have some degree of expression of NE markers"
                    ]
                  },
                  {
                    "text": "Prognosis and treatment are as for other breast carcinomas of similar grade, biologic type, and stage"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "2 types of breast NEN recognized by WHONeuroendocrine tumor (NET): Grades 1 and 2All invasive carcinomasHave some morphologic resemblance to carcinoid tumors arising at other sitesNeuroendocrine carcinoma (NEC): Grade 3Can have similar morphology to small cell carcinoma of lung or consist of large cells",
                    "sub_points": [
                      "Neuroendocrine tumor (NET): Grades 1 and 2All invasive carcinomasHave some morphologic resemblance to carcinoid tumors arising at other sites",
                      "All invasive carcinomas",
                      "Have some morphologic resemblance to carcinoid tumors arising at other sites",
                      "Neuroendocrine carcinoma (NEC): Grade 3Can have similar morphology to small cell carcinoma of lung or consist of large cells",
                      "Can have similar morphology to small cell carcinoma of lung or consist of large cells"
                    ]
                  },
                  {
                    "text": "Solid papillary carcinoma and mucinous carcinoma type B are no longer considered NENs"
                  },
                  {
                    "text": "Invasive breast carcinoma of no special type with NE marker expression is no longer considered NEN"
                  },
                  {
                    "text": "Metastatic breast carcinoma should always be suspected for any metastasis with NE features"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Chromogranin A and synaptophysin most specific"
                  },
                  {
                    "text": "ER expression; > 90% NET; 50-60% NEC"
                  },
                  {
                    "text": "HER2: Negative"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Invasive carcinoma with NE features"
                  },
                  {
                    "text": "Metastatic carcinoid tumor to breast"
                  },
                  {
                    "text": "Metastatic small cell carcinoma to breast"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Neuroendocrine (NE)"
                  },
                  {
                    "text": "Neuroendocrine neoplasm (NEN)"
                  },
                  {
                    "text": "Neuroendocrine tumor (NET)"
                  },
                  {
                    "text": "Neuroendocrine carcinoma (NEC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Endocrine carcinoma and carcinoid tumor are not recommended"
                  }
                ],
                "Definitions": [
                  {
                    "text": "NEN includes breast-invasive carcinomas with predominant NE architecture and cytologic features (> 90%)Requires \"extensive\" expression of chromogranin &/or synaptophysinNET: Grade 1 or 2NEC: Grade 3",
                    "sub_points": [
                      "Requires \"extensive\" expression of chromogranin &/or synaptophysin",
                      "NET: Grade 1 or 2",
                      "NEC: Grade 3"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "The International Agency for Research on Cancer (IARC) and the World Health Organization (WHO) applied a uniform classification for neuroendocrine neoplasms (NENs) for lesions arising across all anatomic sites to breast tumors in the WHO 5th edition"
                  },
                  {
                    "text": "All breast NENs are invasive carcinomas and are classified as 2 types based on the histologic appearance and the expression of chromogranin &/or synaptophysinNeuroendocrine tumor (NET): Grades 1 and 2NET may not be recognized as an invasive carcinoma by clinicians and patients if this is the only diagnostic term usedNeuroendocrine carcinoma (NEC): Grade 3",
                    "sub_points": [
                      "Neuroendocrine tumor (NET): Grades 1 and 2NET may not be recognized as an invasive carcinoma by clinicians and patients if this is the only diagnostic term used",
                      "NET may not be recognized as an invasive carcinoma by clinicians and patients if this is the only diagnostic term used",
                      "Neuroendocrine carcinoma (NEC): Grade 3"
                    ]
                  },
                  {
                    "text": "Carcinomas that express NE markers but lack NE histologic features are not included as NENsTherefore, solid papillary carcinoma and mucinous carcinoma are not NENs, although they commonly express NE markers",
                    "sub_points": [
                      "Therefore, solid papillary carcinoma and mucinous carcinoma are not NENs, although they commonly express NE markers"
                    ]
                  },
                  {
                    "text": "The biologic origins of breast NENs may be different than those arising at other sites from NE type cellsUnlike other sites, such as lung and gastrointestinal tract, a NE cell of the normal breast has not been identifiedThere is only a single report of benign-appearing NE cells observed in the same breasts as 3 NECsPositive for chromogranin &/or synaptophysinCells were isolated, clustered, or circumferentialSome located between basally located and luminal epithelial cellsNot limited in distribution to tissue surrounding carcinomaHowever, these cells have not been reported by others and have not been reported in the absence of a NECA counterpart to a \"carcinoid\" tumor at other sites is not seen in the breastSyndromes related to systemic production of neuropeptides are not associated with breast NENsPrognostic factors for NENs in other organ systems are not used in the breastThese include necrosis and expression of peptide hormones",
                    "sub_points": [
                      "Unlike other sites, such as lung and gastrointestinal tract, a NE cell of the normal breast has not been identifiedThere is only a single report of benign-appearing NE cells observed in the same breasts as 3 NECsPositive for chromogranin &/or synaptophysinCells were isolated, clustered, or circumferentialSome located between basally located and luminal epithelial cellsNot limited in distribution to tissue surrounding carcinomaHowever, these cells have not been reported by others and have not been reported in the absence of a NEC",
                      "There is only a single report of benign-appearing NE cells observed in the same breasts as 3 NECsPositive for chromogranin &/or synaptophysinCells were isolated, clustered, or circumferentialSome located between basally located and luminal epithelial cellsNot limited in distribution to tissue surrounding carcinoma",
                      "Positive for chromogranin &/or synaptophysin",
                      "Cells were isolated, clustered, or circumferential",
                      "Some located between basally located and luminal epithelial cells",
                      "Not limited in distribution to tissue surrounding carcinoma",
                      "However, these cells have not been reported by others and have not been reported in the absence of a NEC",
                      "A counterpart to a \"carcinoid\" tumor at other sites is not seen in the breastSyndromes related to systemic production of neuropeptides are not associated with breast NENs",
                      "Syndromes related to systemic production of neuropeptides are not associated with breast NENs",
                      "Prognostic factors for NENs in other organ systems are not used in the breastThese include necrosis and expression of peptide hormones",
                      "These include necrosis and expression of peptide hormones"
                    ]
                  },
                  {
                    "text": "More likely, in breast carcinomas, the expression of NE proteins is an aberrant pattern that is seen due to genetic changes during carcinogenesis rather than origin from a specific cell typeMay result from early divergent differentiation of cells into NE marker expressing cellsSome breast carcinomas show heterogeneity in NE features and NE marker expressionIn one study, ~ 15% of carcinomas with biallelicRB1genetic alterations showed NE morphology and expression of NE markersIn some cases, these features were not seen in the primary carcinoma but occurred after prolonged adjuvant hormonal therapy",
                    "sub_points": [
                      "May result from early divergent differentiation of cells into NE marker expressing cellsSome breast carcinomas show heterogeneity in NE features and NE marker expression",
                      "Some breast carcinomas show heterogeneity in NE features and NE marker expression",
                      "In one study, ~ 15% of carcinomas with biallelicRB1genetic alterations showed NE morphology and expression of NE markersIn some cases, these features were not seen in the primary carcinoma but occurred after prolonged adjuvant hormonal therapy",
                      "In some cases, these features were not seen in the primary carcinoma but occurred after prolonged adjuvant hormonal therapy"
                    ]
                  },
                  {
                    "text": "Prominent NE differentiation can be seen with in situ and invasive breast carcinomas of other histologic typesSuggests that NENs of the breast likely have a similar etiology compared with other ER-matched breast cancers",
                    "sub_points": [
                      "Suggests that NENs of the breast likely have a similar etiology compared with other ER-matched breast cancers"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "< 1% of breast carcinomas using WHO (5th edition) criteria"
                  },
                  {
                    "text": "~ 10-30% of breast carcinomas have \"NE features\" if chromogranin and synaptophysin are performed on all carcinomas~ 1/3 have histologic features of NETNEC is very rare~ 2/3 lack histologic features of NEN~ 75% no special type, ~ 15% solid papillary, ~ 5% mucinous, and ~ 4% lobularIncidence is higher if other NE markers are used",
                    "sub_points": [
                      "~ 1/3 have histologic features of NETNEC is very rare",
                      "NEC is very rare",
                      "~ 2/3 lack histologic features of NEN~ 75% no special type, ~ 15% solid papillary, ~ 5% mucinous, and ~ 4% lobular",
                      "~ 75% no special type, ~ 15% solid papillary, ~ 5% mucinous, and ~ 4% lobular",
                      "Incidence is higher if other NE markers are used"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Same age distribution as carcinomas of no special type; median at diagnosis: 61 years"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Similar clinical presentation compared with other breast carcinomas; postmenopausal women more likely affected"
                  },
                  {
                    "text": "Palpable mass or mammographic densityCalcifications have not been associated with these tumors",
                    "sub_points": [
                      "Calcifications have not been associated with these tumors"
                    ]
                  },
                  {
                    "text": "Extremely rare breast carcinomas produce ectopic hormonesHuman chorionic gonadotropin, calcitonin, adrenocorticotrophic hormone, parathormone, and epinephrine have been reportedClinical symptoms from these hormones are very rare",
                    "sub_points": [
                      "Human chorionic gonadotropin, calcitonin, adrenocorticotrophic hormone, parathormone, and epinephrine have been reported",
                      "Clinical symptoms from these hormones are very rare"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Typically managed as invasive carcinomas of similar grade, biologic type, and stageManagement is not altered by presence of NE markers",
                    "sub_points": [
                      "Management is not altered by presence of NE markers"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Information is limited due to small numbers of patients and varying definitions of NE breast carcinoma"
                  },
                  {
                    "text": "The presence of NE features has not been shown to alter cancer-specific survival for carcinomas matched by stage and grade"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "Usually present as mass-forming lesions"
                  },
                  {
                    "text": "No specific imaging features"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "No specific gross features"
                  }
                ]
              },
              "MOLECULAR": {
                "Overview": [
                  {
                    "text": "Few breast NENs as defined by WHO have been studied"
                  },
                  {
                    "text": "Almost equal distribution of luminal A (52%) and luminal B (48%) tumors by expression profiling"
                  },
                  {
                    "text": "The observed biologic differences between NET and NEC suggest that these groups may not be closely related"
                  }
                ],
                "Neuroendocrine Tumor Mutations": [
                  {
                    "text": "ARID1AandATRXmutations (chromatin-remodeling genes)Higher frequency compared to other ER(+) carcinomasMutations in chromatin remodeling genes are also observed in NENs of other sites",
                    "sub_points": [
                      "Higher frequency compared to other ER(+) carcinomas",
                      "Mutations in chromatin remodeling genes are also observed in NENs of other sites"
                    ]
                  },
                  {
                    "text": "FOXA1,TP53,GATA3mutationsMost commonly mutated genes afterARID1A",
                    "sub_points": [
                      "Most commonly mutated genes afterARID1A"
                    ]
                  },
                  {
                    "text": "PIK3CAandTP53mutationsLower frequency compared to other ER(+) carcinomas",
                    "sub_points": [
                      "Lower frequency compared to other ER(+) carcinomas"
                    ]
                  }
                ],
                "Neuroendocrine Carcinoma Mutations": [
                  {
                    "text": "TP53(75%) mutations andRB1(19%) lossAlso seen in small cell lung carcinoma",
                    "sub_points": [
                      "Also seen in small cell lung carcinoma"
                    ]
                  },
                  {
                    "text": "PIK3CAmutations (~ 1/3)Not present in pulmonary NEC",
                    "sub_points": [
                      "Not present in pulmonary NEC"
                    ]
                  }
                ],
                "Copy Number Changes": [
                  {
                    "text": "Trisomy 7 present in 2 of 7 breast NECs (defined as > 50% cells positive for chromogranin or synaptophysin)Trisomy 7 also present in 5 of 6 lung NETsSignificance not clear",
                    "sub_points": [
                      "Trisomy 7 also present in 5 of 6 lung NETs",
                      "Significance not clear"
                    ]
                  },
                  {
                    "text": "Low frequency of 1q gains and 16q lossesFrequently present in ER(+) breast carcinomas",
                    "sub_points": [
                      "Frequently present in ER(+) breast carcinomas"
                    ]
                  }
                ],
                "Gene Expression Profiling": [
                  {
                    "text": "~ 2/3 are classified as luminal A and 1/3 as luminal B"
                  }
                ],
                "RB1Alterations": [
                  {
                    "text": "~ 1% of ER(+) breast carcinomas have pathogenic/inactivating alterations in RB1"
                  },
                  {
                    "text": "Of these, ~ 15% have NE morphology and express NE markers"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "NETGrade 1 or 2Most common histologic pattern of breast NETHave some similarities to carcinoid tumors arising at other sitesSolid nests, cords, and trabecular patternsSeparated by thin fibrovascular stromaSmall lumen-like spaces may be presentSpindle, plasmacytoid, or large clear cellsFine chromatin with small inconspicuous nucleoliMay have eosinophilic cytoplasmic granulesLower grade tumors tend to have higher expression of NE markersAssociated ductal carcinoma in situ (DCIS) has same cytologic features",
                    "sub_points": [
                      "Grade 1 or 2",
                      "Most common histologic pattern of breast NETHave some similarities to carcinoid tumors arising at other sites",
                      "Have some similarities to carcinoid tumors arising at other sites",
                      "Solid nests, cords, and trabecular patternsSeparated by thin fibrovascular stromaSmall lumen-like spaces may be present",
                      "Separated by thin fibrovascular stroma",
                      "Small lumen-like spaces may be present",
                      "Spindle, plasmacytoid, or large clear cellsFine chromatin with small inconspicuous nucleoliMay have eosinophilic cytoplasmic granules",
                      "Fine chromatin with small inconspicuous nucleoli",
                      "May have eosinophilic cytoplasmic granules",
                      "Lower grade tumors tend to have higher expression of NE markers",
                      "Associated ductal carcinoma in situ (DCIS) has same cytologic features"
                    ]
                  },
                  {
                    "text": "NECGrade 3Densely packed cells in a solid infiltrative patternMitoses and necrosis frequentLymphovascular invasion frequentSmall cell typeSimilar morphology to small cell carcinoma of lungVery rare (< 1% of all carcinomas)Some tumors show mixed histology with NEC intermingled with carcinoma of non-small cell typeNuclei are small and hyperchromaticScant cytoplasm results in densely cellular patternCrush artifact commonAssociated DCIS has same cytologic featuresLarge cell typeLarge pleomorphic nuclei with coarse chromatinModerate amounts of cytoplasmAssociated DCIS has same cytologic features",
                    "sub_points": [
                      "Grade 3",
                      "Densely packed cells in a solid infiltrative pattern",
                      "Mitoses and necrosis frequent",
                      "Lymphovascular invasion frequent",
                      "Small cell typeSimilar morphology to small cell carcinoma of lungVery rare (< 1% of all carcinomas)Some tumors show mixed histology with NEC intermingled with carcinoma of non-small cell typeNuclei are small and hyperchromaticScant cytoplasm results in densely cellular patternCrush artifact commonAssociated DCIS has same cytologic features",
                      "Similar morphology to small cell carcinoma of lungVery rare (< 1% of all carcinomas)Some tumors show mixed histology with NEC intermingled with carcinoma of non-small cell type",
                      "Very rare (< 1% of all carcinomas)",
                      "Some tumors show mixed histology with NEC intermingled with carcinoma of non-small cell type",
                      "Nuclei are small and hyperchromatic",
                      "Scant cytoplasm results in densely cellular pattern",
                      "Crush artifact common",
                      "Associated DCIS has same cytologic features",
                      "Large cell typeLarge pleomorphic nuclei with coarse chromatinModerate amounts of cytoplasmAssociated DCIS has same cytologic features",
                      "Large pleomorphic nuclei with coarse chromatin",
                      "Moderate amounts of cytoplasm",
                      "Associated DCIS has same cytologic features"
                    ]
                  },
                  {
                    "text": "DCIS with NE featuresSolid papillary or organoid growth patterns are typicalUnusual are cribriform or comedo patternsIdentification useful to exclude metastasis from another site for associated invasive carcinoma",
                    "sub_points": [
                      "Solid papillary or organoid growth patterns are typical",
                      "Unusual are cribriform or comedo patterns",
                      "Identification useful to exclude metastasis from another site for associated invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Metastatic breast carcinoma with NE featuresMetastatic carcinomas with NE features can easily be mistaken for other types of carcinomaThe observation that many breast cancers strongly express NE markers is underappreciatedMetastatic breast carcinoma should always be considered in women with metastatic diseaseMany have a history of breast cancer, but this may not be provided to the pathologistSome women have occult breast cancers, such as lobular carcinoma, which can have an NE histologic appearanceMetastatic breast carcinoma should always be considered when NET at another site is diagnosedCan closely mimic carcinoid tumors in lung and liverCan closely mimic metastatic small cell carcinomaComparison of the primary carcinoma and metastasis, as well as IHC studies for NE makers on the primary carcinoma, can be helpful for correct classificationIt is especially important to correctly identify ER(+) breast carcinoma as long-term palliation with endocrine therapy is possibleHowever, metastatic carcinoma can also acquire NE morphology, which was not present in the primary carcinomaCommon markers for all breast carcinomas are typically expressed in breast carcinomas with NE features but not in NETs from other sitesER, PR, GCDFP-15, mammaglobin, GATA3Misdiagnosis frequently results in inappropriate surgery and chemotherapyPatients often fail to receive highly effective endocrine treatment",
                    "sub_points": [
                      "Metastatic carcinomas with NE features can easily be mistaken for other types of carcinoma",
                      "The observation that many breast cancers strongly express NE markers is underappreciated",
                      "Metastatic breast carcinoma should always be considered in women with metastatic diseaseMany have a history of breast cancer, but this may not be provided to the pathologistSome women have occult breast cancers, such as lobular carcinoma, which can have an NE histologic appearance",
                      "Many have a history of breast cancer, but this may not be provided to the pathologist",
                      "Some women have occult breast cancers, such as lobular carcinoma, which can have an NE histologic appearance",
                      "Metastatic breast carcinoma should always be considered when NET at another site is diagnosedCan closely mimic carcinoid tumors in lung and liverCan closely mimic metastatic small cell carcinoma",
                      "Can closely mimic carcinoid tumors in lung and liver",
                      "Can closely mimic metastatic small cell carcinoma",
                      "Comparison of the primary carcinoma and metastasis, as well as IHC studies for NE makers on the primary carcinoma, can be helpful for correct classificationIt is especially important to correctly identify ER(+) breast carcinoma as long-term palliation with endocrine therapy is possible",
                      "It is especially important to correctly identify ER(+) breast carcinoma as long-term palliation with endocrine therapy is possible",
                      "However, metastatic carcinoma can also acquire NE morphology, which was not present in the primary carcinoma",
                      "Common markers for all breast carcinomas are typically expressed in breast carcinomas with NE features but not in NETs from other sitesER, PR, GCDFP-15, mammaglobin, GATA3",
                      "ER, PR, GCDFP-15, mammaglobin, GATA3",
                      "Misdiagnosis frequently results in inappropriate surgery and chemotherapyPatients often fail to receive highly effective endocrine treatment",
                      "Patients often fail to receive highly effective endocrine treatment"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Carcinomas with NE features may raise the possibility of metastasis from another site"
                  },
                  {
                    "text": "Identification of carcinoma in situ is the best evidence of a breast primary, if present"
                  },
                  {
                    "text": "Comparison with prior histology and a panel of IHC markers are helpful to support breast primary or to confirm likely metastatic disease"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Grimelius (silver stain)Argyrophilia: Fine black granules in cytoplasmCorrelates with neurosecretory granules, as seen by electron microscopyCarcinomas are positive for chromogranin by IHCHowever, may also be positive in secretory products",
                    "sub_points": [
                      "Argyrophilia: Fine black granules in cytoplasm",
                      "Correlates with neurosecretory granules, as seen by electron microscopyCarcinomas are positive for chromogranin by IHCHowever, may also be positive in secretory products",
                      "Carcinomas are positive for chromogranin by IHC",
                      "However, may also be positive in secretory products"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "NE markers: Gold standard in NEN diagnosis; criteria for positivityPositive results have been defined as 1-2% of cells to > 50% to > 90% of cellsWHO (3rd edition, 2003): > 50% positive cellsWHO (4th edition, 2012): No threshold specifiedWHO (5th edition, 2019): \"Extensive expression\" or \"diffuse uniform immunoreactivity\"Criteria for a positive result cannot be defined, as expression has not been linked to an objective association or outcome (e.g., prognosis)Carcinomas typically express 1 or more, but not all, NE markersTherefore, the number of carcinomas considered NE in type varies with the number of markers testedWHO does not recommend the routine use of NE markers when histologic features are absent",
                    "sub_points": [
                      "Positive results have been defined as 1-2% of cells to > 50% to > 90% of cellsWHO (3rd edition, 2003): > 50% positive cellsWHO (4th edition, 2012): No threshold specifiedWHO (5th edition, 2019): \"Extensive expression\" or \"diffuse uniform immunoreactivity\"",
                      "WHO (3rd edition, 2003): > 50% positive cells",
                      "WHO (4th edition, 2012): No threshold specified",
                      "WHO (5th edition, 2019): \"Extensive expression\" or \"diffuse uniform immunoreactivity\"",
                      "Criteria for a positive result cannot be defined, as expression has not been linked to an objective association or outcome (e.g., prognosis)",
                      "Carcinomas typically express 1 or more, but not all, NE markersTherefore, the number of carcinomas considered NE in type varies with the number of markers tested",
                      "Therefore, the number of carcinomas considered NE in type varies with the number of markers tested",
                      "WHO does not recommend the routine use of NE markers when histologic features are absent"
                    ]
                  },
                  {
                    "text": "Chromogranin AGranins are components of neurosecretory granulesBreast NENs: ~ 50% positiveTumors from other sitesCarcinoid: ~ 90% positiveSmall cell carcinoma: ~ 45% positive",
                    "sub_points": [
                      "Granins are components of neurosecretory granules",
                      "Breast NENs: ~ 50% positive",
                      "Tumors from other sitesCarcinoid: ~ 90% positiveSmall cell carcinoma: ~ 45% positive",
                      "Carcinoid: ~ 90% positive",
                      "Small cell carcinoma: ~ 45% positive"
                    ]
                  },
                  {
                    "text": "SynaptophysinGlycoprotein found in presynaptic vesiclesBreast NETs: ~ 16% positiveBreast NECs: ~ 50% positiveTumors from other sitesCarcinoid: ~ 95% positiveSmall cell carcinoma: ~ 55% positive",
                    "sub_points": [
                      "Glycoprotein found in presynaptic vesicles",
                      "Breast NETs: ~ 16% positive",
                      "Breast NECs: ~ 50% positive",
                      "Tumors from other sitesCarcinoid: ~ 95% positiveSmall cell carcinoma: ~ 55% positive",
                      "Carcinoid: ~ 95% positive",
                      "Small cell carcinoma: ~ 55% positive"
                    ]
                  },
                  {
                    "text": "Neuron specific enolaseGlycolytic enzyme found preferentially in neurons and NE cellsNot very specific for NE differentiationBreast NECs: ~ 100% positiveTumors from other sitesCarcinoid: ~ 80% positiveSmall cell carcinoma: ~ 70% positive",
                    "sub_points": [
                      "Glycolytic enzyme found preferentially in neurons and NE cellsNot very specific for NE differentiation",
                      "Not very specific for NE differentiation",
                      "Breast NECs: ~ 100% positive",
                      "Tumors from other sitesCarcinoid: ~ 80% positiveSmall cell carcinoma: ~ 70% positive",
                      "Carcinoid: ~ 80% positive",
                      "Small cell carcinoma: ~ 70% positive"
                    ]
                  },
                  {
                    "text": "CD56N-cellular adhesion moleculeMay be positive in breast NENsTumors from other sitesCarcinoid: ~ 75% positiveSmall cell carcinoma: ~ 90% positive",
                    "sub_points": [
                      "N-cellular adhesion molecule",
                      "May be positive in breast NENs",
                      "Tumors from other sitesCarcinoid: ~ 75% positiveSmall cell carcinoma: ~ 90% positive",
                      "Carcinoid: ~ 75% positive",
                      "Small cell carcinoma: ~ 90% positive"
                    ]
                  },
                  {
                    "text": "Other NE markersLess well studied; significance unclearLeu-7/CD57, bombesin, neurofilament triplet protein, insulinoma associated protein 1 (INSM1)",
                    "sub_points": [
                      "Less well studied; significance unclear",
                      "Leu-7/CD57, bombesin, neurofilament triplet protein, insulinoma associated protein 1 (INSM1)"
                    ]
                  },
                  {
                    "text": "ER and PRBreast NETs: > 90% positiveBreast NECs: ~ 50-60% positiveTumors from other sitesCarcinoid: < 5% positiveSmall cell carcinoma: < 5% positive",
                    "sub_points": [
                      "Breast NETs: > 90% positive",
                      "Breast NECs: ~ 50-60% positive",
                      "Tumors from other sitesCarcinoid: < 5% positiveSmall cell carcinoma: < 5% positive",
                      "Carcinoid: < 5% positive",
                      "Small cell carcinoma: < 5% positive"
                    ]
                  },
                  {
                    "text": "HER2: Negative"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Ultrastructural features of NE differentiation can be demonstrated in cytoplasm of some breast carcinomasHowever, nonendocrine breast cells and cells during pregnancy and lactation can have secretory granules",
                    "sub_points": [
                      "However, nonendocrine breast cells and cells during pregnancy and lactation can have secretory granules"
                    ]
                  },
                  {
                    "text": "Neurosecretory (dense core) granulesRound, membrane-bound vesicles with dense central coreMultiple typesChromogranin and Leu-7/CD57 are found in matrix of granules",
                    "sub_points": [
                      "Round, membrane-bound vesicles with dense central coreMultiple types",
                      "Multiple types",
                      "Chromogranin and Leu-7/CD57 are found in matrix of granules"
                    ]
                  },
                  {
                    "text": "Clear vesicles of presynaptic typeCorrelates with synaptophysin expression",
                    "sub_points": [
                      "Correlates with synaptophysin expression"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Invasive Carcinoma With Neuroendocrine Features": [
                  {
                    "text": "~ 10-30% of breast carcinomas are positive for NE markersPercentage depends on types and number of markers used and cut-off criteria for positivityWHO recommends only using chromogranin and synaptophysin for defining NET and NEC",
                    "sub_points": [
                      "Percentage depends on types and number of markers used and cut-off criteria for positivity",
                      "WHO recommends only using chromogranin and synaptophysin for defining NET and NEC"
                    ]
                  },
                  {
                    "text": "NE expression is commonly present in some special typesSolid papillary carcinoma: ~ 70% positive by IHCMucinous carcinoma, hypercellular variant (type B) ~ 20% positive by IHC",
                    "sub_points": [
                      "Solid papillary carcinoma: ~ 70% positive by IHC",
                      "Mucinous carcinoma, hypercellular variant (type B) ~ 20% positive by IHC"
                    ]
                  },
                  {
                    "text": "Expression of NE markers has not been clearly linked to clinical, prognostic, or pathologic featuresWHO does not recommend the routine use of NE markers for the evaluation of breast carcinomas",
                    "sub_points": [
                      "WHO does not recommend the routine use of NE markers for the evaluation of breast carcinomas"
                    ]
                  },
                  {
                    "text": "Some carcinomas can have a NE histologic appearance but do not express NE markersAlveolar lobular carcinomaCribriform carcinoma",
                    "sub_points": [
                      "Alveolar lobular carcinoma",
                      "Cribriform carcinoma"
                    ]
                  },
                  {
                    "text": "Current WHO definition of NENs requires both morphologic and IHC criteriaSolid papillary and mucinous carcinoma no longer includedInvasive breast carcinomas of no special type with expression of NE markers by IHC no longer included",
                    "sub_points": [
                      "Solid papillary and mucinous carcinoma no longer included",
                      "Invasive breast carcinomas of no special type with expression of NE markers by IHC no longer included"
                    ]
                  }
                ],
                "Metastatic Carcinoid Tumor": [
                  {
                    "text": "In ~ 50% of cases, a breast mass is the presenting symptom of an occult carcinoid tumor"
                  },
                  {
                    "text": "Majority of patients have symptoms of carcinoid syndrome"
                  },
                  {
                    "text": "Carcinoid tumors can closely mimic LCIS, low-grade DCIS, and well-differentiated invasive carcinomasCarcinoid should be suspected when low-grade malignancy is ER(-)",
                    "sub_points": [
                      "Carcinoid should be suspected when low-grade malignancy is ER(-)"
                    ]
                  },
                  {
                    "text": "Carcinoid tumor is more likely to be strongly positive for chromogranin than breast NET"
                  },
                  {
                    "text": "Identification of in situ component is helpful to demonstrate that NET has arisen in the breast"
                  },
                  {
                    "text": "A primary carcinoid tumor of the breast is not recognized by WHOCarcinoid syndrome due to ectopic hormone production has not been reportedAlthough an alternative primary site was not found in all reported cases of breast carcinoid tumors, extent of work-up has not been clearly reported in all casesPrimary carcinoid tumors at other sites can be quite small and difficult to detect",
                    "sub_points": [
                      "Carcinoid syndrome due to ectopic hormone production has not been reportedAlthough an alternative primary site was not found in all reported cases of breast carcinoid tumors, extent of work-up has not been clearly reported in all casesPrimary carcinoid tumors at other sites can be quite small and difficult to detect",
                      "Although an alternative primary site was not found in all reported cases of breast carcinoid tumors, extent of work-up has not been clearly reported in all cases",
                      "Primary carcinoid tumors at other sites can be quite small and difficult to detect"
                    ]
                  }
                ],
                "Metastatic Small Cell Carcinoma": [
                  {
                    "text": "The 1st evidence of lung carcinoma as a breast metastasis with this morphology are rareTypically, patients have known lung primaryLung carcinomas usually metastasize to the ipsilateral breast (~ 2/3 of cases)",
                    "sub_points": [
                      "Typically, patients have known lung primary",
                      "Lung carcinomas usually metastasize to the ipsilateral breast (~ 2/3 of cases)"
                    ]
                  },
                  {
                    "text": "Majority of lung small cell carcinomas are TTF-1(+)Rare breast carcinomas are also TTF-1(+)",
                    "sub_points": [
                      "Rare breast carcinomas are also TTF-1(+)"
                    ]
                  },
                  {
                    "text": "Other markers for breast and lung are helpful in this setting"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "All NENs of the breast are invasive carcinomas"
                  },
                  {
                    "text": "NET might not be recognized as invasive carcinoma by clinicians and patients if this is only diagnostic term usedIt is important for pathologists to specify that NET is an invasive carcinomaImportant to rule out metastasis from other primary sites",
                    "sub_points": [
                      "It is important for pathologists to specify that NET is an invasive carcinoma",
                      "Important to rule out metastasis from other primary sites"
                    ]
                  },
                  {
                    "text": "There is currently no value in performing NE markers on carcinomas without NE histologic features"
                  },
                  {
                    "text": "Classification of a breast carcinoma as a NEN currently does not have prognostic or treatment implications"
                  },
                  {
                    "text": "Breast carcinoma must always be considered in the differential diagnosis of metastatic carcinoma in women"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Locally Recurrent Carcinoma": {
            "name": "Locally Recurrent Carcinoma",
            "url": "https://app.pathprimer.com/document/f84a89b1-6c6a-4e34-9ee3-42f56265e068/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "True recurrence (TR): Invasive breast carcinoma (BC) survives initial treatment and recurs"
                  },
                  {
                    "text": "New primary (NP): After a diagnosis of invasive BC, the patient develops a 2nd BC not related to the 1st BC"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "~ 10% of patients undergoing breast conservation for BC develop a 2nd BC within 10 years< 10 years: Majority TR10 years: 50% TR, 50% NP> 10 years: Majority NP",
                    "sub_points": [
                      "< 10 years: Majority TR",
                      "10 years: 50% TR, 50% NP",
                      "> 10 years: Majority NP"
                    ]
                  },
                  {
                    "text": "~ 5% of patients undergoing mastectomy for BC have a chest wall recurrence80% in skin and 20% in pectoralis muscleMajority are TRIn rare cases, NP arises in residual breast tissue",
                    "sub_points": [
                      "80% in skin and 20% in pectoralis muscle",
                      "Majority are TR",
                      "In rare cases, NP arises in residual breast tissue"
                    ]
                  },
                  {
                    "text": "TR has poor prognosisBC is resistant to treatment",
                    "sub_points": [
                      "BC is resistant to treatment"
                    ]
                  },
                  {
                    "text": "NP has better prognosisBC may be sensitive to therapy",
                    "sub_points": [
                      "BC may be sensitive to therapy"
                    ]
                  },
                  {
                    "text": "Likelihood of recurrence varies with BC typeLowest for luminal BC (ER positive, HER2 negative)Highest for triple negative BCs",
                    "sub_points": [
                      "Lowest for luminal BC (ER positive, HER2 negative)",
                      "Highest for triple negative BCs"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Classification as TR or NP can be assessed using clinical, pathologic, and molecular features in varying combinations"
                  },
                  {
                    "text": "All methods used consistently show that NPs have a better prognosis than TRs and that NPs become more common compared with TRs over time"
                  },
                  {
                    "text": "When classification based on clinical and pathologic features is compared to classification based on molecular features, there is ~ 2/3 agreement on the correct classification"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Angiosarcoma"
                  },
                  {
                    "text": "Scar tissue"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "A subsequent breast carcinoma (BC) after breast-conserving therapy (BCT) or in chest wall after mastectomy, following prior diagnosis of BC"
                  },
                  {
                    "text": "True recurrences (TRs) are due to failure to eradicate BC by initial treatment"
                  },
                  {
                    "text": "New primaries (NPs) are not clonally related to the 1st BC"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Background": [
                  {
                    "text": "Several phase III trials in early invasive BC have demonstrated noninferiority of BCT followed by radiation, compared with mastectomyRequires complete surgical excision of the primary BCAcceptable margins defined as \"no tumor on ink\"",
                    "sub_points": [
                      "Requires complete surgical excision of the primary BC",
                      "Acceptable margins defined as \"no tumor on ink\""
                    ]
                  },
                  {
                    "text": "~ 10% of women undergoing BCT for invasive BC are diagnosed with ipsilateral BC within 10 yearsLikelihood depends on type of BCLuminal breast carcinoma [estrogen receptor (ER) positive, HER2 negative]: ~ 4% riskTriple negative BC (TNBC) (negative for hormone receptors and HER2): ~ 11% riskHER2 BC (positive for HER2): ~ 16% risk",
                    "sub_points": [
                      "Likelihood depends on type of BCLuminal breast carcinoma [estrogen receptor (ER) positive, HER2 negative]: ~ 4% riskTriple negative BC (TNBC) (negative for hormone receptors and HER2): ~ 11% riskHER2 BC (positive for HER2): ~ 16% risk",
                      "Luminal breast carcinoma [estrogen receptor (ER) positive, HER2 negative]: ~ 4% risk",
                      "Triple negative BC (TNBC) (negative for hormone receptors and HER2): ~ 11% risk",
                      "HER2 BC (positive for HER2): ~ 16% risk"
                    ]
                  },
                  {
                    "text": "< 5% of patients undergoing mastectomy develop local chest wall recurrenceMajority are TR in skin and muscle80% in skin or subcutaneous tissue20% in pectoralis muscleIn rare cases, NP can develop in residual normal breast tissue not removed by initial surgery",
                    "sub_points": [
                      "Majority are TR in skin and muscle80% in skin or subcutaneous tissue20% in pectoralis muscle",
                      "80% in skin or subcutaneous tissue",
                      "20% in pectoralis muscle",
                      "In rare cases, NP can develop in residual normal breast tissue not removed by initial surgery"
                    ]
                  },
                  {
                    "text": "Time from 1st to 2nd BC diagnosis is important1-5 years: ~ 80-90% of recurrences are TR5-10 years: ~ 50-60% TR and ~ 40% NP10 years: 50% TR and 50% NP10-15 years: ~ 30% TR and ~ 70% NP",
                    "sub_points": [
                      "1-5 years: ~ 80-90% of recurrences are TR",
                      "5-10 years: ~ 50-60% TR and ~ 40% NP",
                      "10 years: 50% TR and 50% NP",
                      "10-15 years: ~ 30% TR and ~ 70% NP"
                    ]
                  },
                  {
                    "text": "It is important to try and distinguish TR from NP"
                  },
                  {
                    "text": "True recurrence (TR)Identifies treatment-resistant BCSubsequent treatment with same agents may not be effectivePoor prognostic factorIndication of failure of prior treatmentCould be due to inadequate surgery, inadequate margin evaluation, failure to deliver systemic therapy, &/or radiation therapyIn some cases, initial treatment may be considered to have been optimal, but BC has recurred due to uncontrollable factors (e.g., treatment-resistant cancer in lymphatics)This is important information for clinical trials evaluating efficacy of treatment",
                    "sub_points": [
                      "Identifies treatment-resistant BCSubsequent treatment with same agents may not be effectivePoor prognostic factor",
                      "Subsequent treatment with same agents may not be effective",
                      "Poor prognostic factor",
                      "Indication of failure of prior treatmentCould be due to inadequate surgery, inadequate margin evaluation, failure to deliver systemic therapy, &/or radiation therapyIn some cases, initial treatment may be considered to have been optimal, but BC has recurred due to uncontrollable factors (e.g., treatment-resistant cancer in lymphatics)This is important information for clinical trials evaluating efficacy of treatment",
                      "Could be due to inadequate surgery, inadequate margin evaluation, failure to deliver systemic therapy, &/or radiation therapy",
                      "In some cases, initial treatment may be considered to have been optimal, but BC has recurred due to uncontrollable factors (e.g., treatment-resistant cancer in lymphatics)",
                      "This is important information for clinical trials evaluating efficacy of treatment"
                    ]
                  },
                  {
                    "text": "New primary (NP)NPs are not more likely to be resistant to treatment than BCs in generalNot an indication of failure of the initial therapyPatients with multiple biologically different BCs may be at high risk for NPs due to a germline mutation or environmental exposure (e.g., chest radiation)",
                    "sub_points": [
                      "NPs are not more likely to be resistant to treatment than BCs in general",
                      "Not an indication of failure of the initial therapy",
                      "Patients with multiple biologically different BCs may be at high risk for NPs due to a germline mutation or environmental exposure (e.g., chest radiation)"
                    ]
                  }
                ],
                "Recurrent Carcinoma After Breast-Conserving Therapy or Mastectomy": [
                  {
                    "text": "AfterBCTMay be ductal carcinoma in situ (DCIS) or invasive BC~ 1/3 of cases will be NPLocation, histologic type, and tumor markers can help determine if BC is more likely TR or NPRecurrent DCIS has favorable prognosis~ 1/2 of recurrent cases after diagnosis of DCIS will again be DCIS, and 1/2 will be invasive BCRecurrent invasive BC after initial diagnosis of invasive BC has a less favorable prognosisIf TR, then BC is resistant to therapy given to patient and prognosis is generally poorIf NP, prognosis is more favorable, as BC may be sensitive to treatmentIf patient has developed a new invasive BC due to residual DCIS, effect on prognosis is less clearThis finding suggests original DCIS was resistant to treatmentUnknown if this would predict resistance to treatment of subsequent invasive BC",
                    "sub_points": [
                      "May be ductal carcinoma in situ (DCIS) or invasive BC",
                      "~ 1/3 of cases will be NP",
                      "Location, histologic type, and tumor markers can help determine if BC is more likely TR or NP",
                      "Recurrent DCIS has favorable prognosis~ 1/2 of recurrent cases after diagnosis of DCIS will again be DCIS, and 1/2 will be invasive BC",
                      "~ 1/2 of recurrent cases after diagnosis of DCIS will again be DCIS, and 1/2 will be invasive BC",
                      "Recurrent invasive BC after initial diagnosis of invasive BC has a less favorable prognosisIf TR, then BC is resistant to therapy given to patient and prognosis is generally poorIf NP, prognosis is more favorable, as BC may be sensitive to treatmentIf patient has developed a new invasive BC due to residual DCIS, effect on prognosis is less clearThis finding suggests original DCIS was resistant to treatmentUnknown if this would predict resistance to treatment of subsequent invasive BC",
                      "If TR, then BC is resistant to therapy given to patient and prognosis is generally poor",
                      "If NP, prognosis is more favorable, as BC may be sensitive to treatment",
                      "If patient has developed a new invasive BC due to residual DCIS, effect on prognosis is less clearThis finding suggests original DCIS was resistant to treatmentUnknown if this would predict resistance to treatment of subsequent invasive BC",
                      "This finding suggests original DCIS was resistant to treatment",
                      "Unknown if this would predict resistance to treatment of subsequent invasive BC"
                    ]
                  },
                  {
                    "text": "After mastectomyMajority of cases are TRs and occur in chest wall, skeletal muscle, or skinPrognosis generally poor because majority of patients eventually develop distant metastasesRecurrent BC likely arose from foci of lymphovascular invasionBC in skin can have multiple types of originsScar recurrences could be due to displacement of tumor cells during surgeryCore needle biopsy site recurrences are likely due to displacement of tumor cells during biopsyLikely underreported because skin puncture site of core needle biopsy is not routinely recorded> 20 cases reported; majority did not receive postoperative radiationMajority are invasive BCs recurring as invasive carcinoma in skin and subcutaneous tissue3 reported cases of DCIS with microinvasion recurring as DCIS involving breast epidermis (Paget disease) at puncture site and not involving the nipple/areolaRecurrences in skin near original site of BC could be due to BC remaining in skin flap or in adjacent lymphaticsThe majority of chest wall recurrences after nipple-sparing mastectomy (NSM) are near the site of the primary BCSuperficially located BCs may be less likely to be completely removedRecurrences in skin away from scars and the primary BC are likely due to dermal lymphovascular invasionIt is unknown if the origin of the TR has prognostic importanceSkin recurrences can closely resemble DCIS or papillomasOften have a circumscribed appearance, possibly due to origin in lymphatic spacesMyoepithelial cells are absentThe BC is present in dermis where breast ducts would not be present and is not close to the nippleIn rare cases, NP may occur due to residual normal breast tissue remaining after mastectomyIt is impossible to remove all breast tissue in all patients; breast tissue can be present in subcutaneous tissue in the skin flap and can extend into axillaIn NSM, ducts and lobules above the smooth muscle of the areola are not removedIt is important to evaluate chest wall excisions for residual normal breast tissue &/or DCISNP occurring in residual breast tissue likely has a better prognosis than TR",
                    "sub_points": [
                      "Majority of cases are TRs and occur in chest wall, skeletal muscle, or skinPrognosis generally poor because majority of patients eventually develop distant metastasesRecurrent BC likely arose from foci of lymphovascular invasion",
                      "Prognosis generally poor because majority of patients eventually develop distant metastases",
                      "Recurrent BC likely arose from foci of lymphovascular invasion",
                      "BC in skin can have multiple types of originsScar recurrences could be due to displacement of tumor cells during surgeryCore needle biopsy site recurrences are likely due to displacement of tumor cells during biopsyLikely underreported because skin puncture site of core needle biopsy is not routinely recorded> 20 cases reported; majority did not receive postoperative radiationMajority are invasive BCs recurring as invasive carcinoma in skin and subcutaneous tissue3 reported cases of DCIS with microinvasion recurring as DCIS involving breast epidermis (Paget disease) at puncture site and not involving the nipple/areolaRecurrences in skin near original site of BC could be due to BC remaining in skin flap or in adjacent lymphaticsThe majority of chest wall recurrences after nipple-sparing mastectomy (NSM) are near the site of the primary BCSuperficially located BCs may be less likely to be completely removedRecurrences in skin away from scars and the primary BC are likely due to dermal lymphovascular invasionIt is unknown if the origin of the TR has prognostic importance",
                      "Scar recurrences could be due to displacement of tumor cells during surgery",
                      "Core needle biopsy site recurrences are likely due to displacement of tumor cells during biopsyLikely underreported because skin puncture site of core needle biopsy is not routinely recorded> 20 cases reported; majority did not receive postoperative radiationMajority are invasive BCs recurring as invasive carcinoma in skin and subcutaneous tissue3 reported cases of DCIS with microinvasion recurring as DCIS involving breast epidermis (Paget disease) at puncture site and not involving the nipple/areola",
                      "Likely underreported because skin puncture site of core needle biopsy is not routinely recorded",
                      "> 20 cases reported; majority did not receive postoperative radiation",
                      "Majority are invasive BCs recurring as invasive carcinoma in skin and subcutaneous tissue",
                      "3 reported cases of DCIS with microinvasion recurring as DCIS involving breast epidermis (Paget disease) at puncture site and not involving the nipple/areola",
                      "Recurrences in skin near original site of BC could be due to BC remaining in skin flap or in adjacent lymphaticsThe majority of chest wall recurrences after nipple-sparing mastectomy (NSM) are near the site of the primary BCSuperficially located BCs may be less likely to be completely removed",
                      "The majority of chest wall recurrences after nipple-sparing mastectomy (NSM) are near the site of the primary BC",
                      "Superficially located BCs may be less likely to be completely removed",
                      "Recurrences in skin away from scars and the primary BC are likely due to dermal lymphovascular invasion",
                      "It is unknown if the origin of the TR has prognostic importance",
                      "Skin recurrences can closely resemble DCIS or papillomasOften have a circumscribed appearance, possibly due to origin in lymphatic spacesMyoepithelial cells are absentThe BC is present in dermis where breast ducts would not be present and is not close to the nipple",
                      "Often have a circumscribed appearance, possibly due to origin in lymphatic spaces",
                      "Myoepithelial cells are absent",
                      "The BC is present in dermis where breast ducts would not be present and is not close to the nipple",
                      "In rare cases, NP may occur due to residual normal breast tissue remaining after mastectomyIt is impossible to remove all breast tissue in all patients; breast tissue can be present in subcutaneous tissue in the skin flap and can extend into axillaIn NSM, ducts and lobules above the smooth muscle of the areola are not removedIt is important to evaluate chest wall excisions for residual normal breast tissue &/or DCISNP occurring in residual breast tissue likely has a better prognosis than TR",
                      "It is impossible to remove all breast tissue in all patients; breast tissue can be present in subcutaneous tissue in the skin flap and can extend into axilla",
                      "In NSM, ducts and lobules above the smooth muscle of the areola are not removed",
                      "It is important to evaluate chest wall excisions for residual normal breast tissue &/or DCIS",
                      "NP occurring in residual breast tissue likely has a better prognosis than TR"
                    ]
                  },
                  {
                    "text": "Recurrence in nippleCan occur after BCT or NSMRecurrences as DCIS in nipple epidermis (Paget disease of nipple) are usually due to HER2 BC (~ 80%)Recurrences as invasive BC can be difficult to detect clinically and by imagingNipple may be subtly firmer on palpationImaging may not show a lesion or only show slight thickening or enhancement on MRBCs can be masked by the smooth muscle of the areola",
                    "sub_points": [
                      "Can occur after BCT or NSM",
                      "Recurrences as DCIS in nipple epidermis (Paget disease of nipple) are usually due to HER2 BC (~ 80%)",
                      "Recurrences as invasive BC can be difficult to detect clinically and by imagingNipple may be subtly firmer on palpationImaging may not show a lesion or only show slight thickening or enhancement on MRBCs can be masked by the smooth muscle of the areola",
                      "Nipple may be subtly firmer on palpation",
                      "Imaging may not show a lesion or only show slight thickening or enhancement on MR",
                      "BCs can be masked by the smooth muscle of the areola"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "TR in the breast after BCT often presents in the same manner as original BCBCs presenting as mammographic calcifications often recur as calcificationsBCs presenting as palpable masses or mammographic densities usually recur as masses",
                    "sub_points": [
                      "BCs presenting as mammographic calcifications often recur as calcifications",
                      "BCs presenting as palpable masses or mammographic densities usually recur as masses"
                    ]
                  },
                  {
                    "text": "Recurrences after mastectomy often present as subcutaneous skin nodulesNodules are commonly associated with prior surgical scar",
                    "sub_points": [
                      "Nodules are commonly associated with prior surgical scar"
                    ]
                  },
                  {
                    "text": "TR more likely to be diagnosed at shorter intervals than NP"
                  },
                  {
                    "text": "In rare cases, BC that did not present as inflammatory carcinoma recurs as \"secondary inflammatory\" BC"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Highly dependent upon type of recurrence"
                  },
                  {
                    "text": "Recurrence as DCIS can be treated with surgery and radiationUnlikely to have impact on prognosis",
                    "sub_points": [
                      "Unlikely to have impact on prognosis"
                    ]
                  },
                  {
                    "text": "Recurrence as invasive BC varies in prognosisTR has poor prognosis (indicator of treatment-resistant cancer)The shorter the interval to recurrence (which is a measure of growth rate of BC), the worse the prognosisThe majority of patients with TR will develop distant metastases; risk is 3-4x higher than patients without local recurrenceNP has more favorable prognosis depending on stage and grade of BCPatients with NP are at higher risk for contralateral BC",
                    "sub_points": [
                      "TR has poor prognosis (indicator of treatment-resistant cancer)",
                      "The shorter the interval to recurrence (which is a measure of growth rate of BC), the worse the prognosis",
                      "The majority of patients with TR will develop distant metastases; risk is 3-4x higher than patients without local recurrence",
                      "NP has more favorable prognosis depending on stage and grade of BC",
                      "Patients with NP are at higher risk for contralateral BC"
                    ]
                  }
                ],
                "Risk Factors for True Recurrence (TR)": [
                  {
                    "text": "Young ageMore likely to have TNBCs and HER2 BC",
                    "sub_points": [
                      "More likely to have TNBCs and HER2 BC"
                    ]
                  },
                  {
                    "text": "Molecular subtypes of BC have different risks of local recurrence at 10 yearsLuminal BC has the lowest risk: ~ 5% for low-grade BC and ~ 10% for high-grade BCHER2 BC has low risk if treated with HER2-targeted therapyTNBC has highest risk (~ 20%)Not reduced by wide negative margins or mastectomyMay be due to tumor in lymphatic spaces and lack of treatment modalities that can be administered over long periods of timeEffective systemic therapy may decrease likelihood of TR",
                    "sub_points": [
                      "Luminal BC has the lowest risk: ~ 5% for low-grade BC and ~ 10% for high-grade BC",
                      "HER2 BC has low risk if treated with HER2-targeted therapy",
                      "TNBC has highest risk (~ 20%)Not reduced by wide negative margins or mastectomyMay be due to tumor in lymphatic spaces and lack of treatment modalities that can be administered over long periods of time",
                      "Not reduced by wide negative margins or mastectomy",
                      "May be due to tumor in lymphatic spaces and lack of treatment modalities that can be administered over long periods of time",
                      "Effective systemic therapy may decrease likelihood of TR"
                    ]
                  },
                  {
                    "text": "The 21-gene recurrence score assay (Oncotype DX) is predictive for local recurrence in patients with luminal BC10-year locoregional recurrence ~ 3-4% for low score, ~ 3-7% for intermediate score, and ~ 10-16% for high score",
                    "sub_points": [
                      "10-year locoregional recurrence ~ 3-4% for low score, ~ 3-7% for intermediate score, and ~ 10-16% for high score"
                    ]
                  },
                  {
                    "text": "Extensive intraductal componentMost common in HER2 BC",
                    "sub_points": [
                      "Most common in HER2 BC"
                    ]
                  },
                  {
                    "text": "Skin involvement by BCMore likely to be associated with lymphovascular invasion and lymph node metastases",
                    "sub_points": [
                      "More likely to be associated with lymphovascular invasion and lymph node metastases"
                    ]
                  },
                  {
                    "text": "Multiple BCsMore likely to be associated with extensive carcinoma in situ &/or lymphovascular invasion",
                    "sub_points": [
                      "More likely to be associated with extensive carcinoma in situ &/or lymphovascular invasion"
                    ]
                  },
                  {
                    "text": "Margins positive for DCIS or invasive BCMajority of patients with positive margins will undergo additional surgeryTR can occur in patients with initial negative marginsLymphovascular invasion can be source of TR",
                    "sub_points": [
                      "Majority of patients with positive margins will undergo additional surgery",
                      "TR can occur in patients with initial negative marginsLymphovascular invasion can be source of TR",
                      "Lymphovascular invasion can be source of TR"
                    ]
                  },
                  {
                    "text": "Omission of radiation therapy for women undergoing breast conservation"
                  },
                  {
                    "text": "Extensive lymphovascular invasion"
                  },
                  {
                    "text": "Extensive nodal involvementMore likely to be associated with extensive lymphovascular invasion",
                    "sub_points": [
                      "More likely to be associated with extensive lymphovascular invasion"
                    ]
                  }
                ],
                "Risk Factors for New Primary (NP)": [
                  {
                    "text": "Young ageMore likely to have germline mutations, putting these women at higher risk for multiple BCsAlso at higher risk for contralateral BCs",
                    "sub_points": [
                      "More likely to have germline mutations, putting these women at higher risk for multiple BCs",
                      "Also at higher risk for contralateral BCs"
                    ]
                  },
                  {
                    "text": "Omission of whole-breast radiationRadiation may also treat precursor lesions elsewhere in breastNot yet known if partial breast irradiation will result in relative increase in NP at other sites in breast",
                    "sub_points": [
                      "Radiation may also treat precursor lesions elsewhere in breast",
                      "Not yet known if partial breast irradiation will result in relative increase in NP at other sites in breast"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Methods to Distinguish True Recurrence (TR) From New Primary (NP)": [
                  {
                    "text": "OverviewA TR is not expected to be identical to prior BCBCs are genetically unstable and consist of multiple clonesClones present may change over time and can be selected by treatmentRecurrence due to an invasive BC related to residual DCIS is a special type of recurrence that has not been well studiedInvasive BCs typically consist of a subset of clones present in DCISA 2nd invasive BC may share some, but not all, of the changes that were present in the 1st invasive BCNP may share some characteristics with a prior biologically separate BCThe majority of breast BCs are of no special type (ductal) and are ER positiveBCs arising in patients with germline mutations share that mutation and often have similar characteristicsFor example, BCs associated withBRCA1mutations are usually high-grade TNBCs with dense lymphocytic infiltratesMolecular tests (DNA or mRNA) could give an estimate of the likelihood of TR or NPNo commercial assays to specifically distinguish between TR and NP are currently availableMultiple methods have been developed using clinical features, pathologic features, and molecular features in various combinationsAll methods used consistently show that NPs have a better prognosis than TRs and that NPs become more common compared with TRs over timeWhen classification based on clinical and pathologic features is compared to classification based on molecular features, there is ~ 2/3 agreement on the correct classification",
                    "sub_points": [
                      "A TR is not expected to be identical to prior BCBCs are genetically unstable and consist of multiple clonesClones present may change over time and can be selected by treatmentRecurrence due to an invasive BC related to residual DCIS is a special type of recurrence that has not been well studiedInvasive BCs typically consist of a subset of clones present in DCISA 2nd invasive BC may share some, but not all, of the changes that were present in the 1st invasive BC",
                      "BCs are genetically unstable and consist of multiple clonesClones present may change over time and can be selected by treatment",
                      "Clones present may change over time and can be selected by treatment",
                      "Recurrence due to an invasive BC related to residual DCIS is a special type of recurrence that has not been well studiedInvasive BCs typically consist of a subset of clones present in DCISA 2nd invasive BC may share some, but not all, of the changes that were present in the 1st invasive BC",
                      "Invasive BCs typically consist of a subset of clones present in DCIS",
                      "A 2nd invasive BC may share some, but not all, of the changes that were present in the 1st invasive BC",
                      "NP may share some characteristics with a prior biologically separate BCThe majority of breast BCs are of no special type (ductal) and are ER positiveBCs arising in patients with germline mutations share that mutation and often have similar characteristicsFor example, BCs associated withBRCA1mutations are usually high-grade TNBCs with dense lymphocytic infiltrates",
                      "The majority of breast BCs are of no special type (ductal) and are ER positive",
                      "BCs arising in patients with germline mutations share that mutation and often have similar characteristicsFor example, BCs associated withBRCA1mutations are usually high-grade TNBCs with dense lymphocytic infiltrates",
                      "For example, BCs associated withBRCA1mutations are usually high-grade TNBCs with dense lymphocytic infiltrates",
                      "Molecular tests (DNA or mRNA) could give an estimate of the likelihood of TR or NPNo commercial assays to specifically distinguish between TR and NP are currently available",
                      "No commercial assays to specifically distinguish between TR and NP are currently available",
                      "Multiple methods have been developed using clinical features, pathologic features, and molecular features in various combinations",
                      "All methods used consistently show that NPs have a better prognosis than TRs and that NPs become more common compared with TRs over time",
                      "When classification based on clinical and pathologic features is compared to classification based on molecular features, there is ~ 2/3 agreement on the correct classification"
                    ]
                  },
                  {
                    "text": "Morphologic featuresLocation in breast70-90% of recurrences occur in same area of breastHowever, relative locations of 1st and 2nd BCs are often difficult to defineBreast imaging can be helpful if prior surgical site can be identifiedNP can also occur in same general location as prior BCAssociation with prior surgical siteHyalinized scar tissue may be present at prior siteIt may be difficult to distinguish scar tissue from dense breast tissueIn some cases, granulomas may persistSuture material may be presentHowever, in majority of cases, suture material will have been resorbedMetal clips may be presentChanges associated with prior surgical site must be distinguished from more recent diagnostic biopsyRecent biopsies will have fat necrosis, hemorrhage, and stromal reactionIf it is a core needle biopsy, there may be biodegradable carrier material placed at sitePrior biopsy clip may be presentHistologic type of BCTR generally has same appearance as original BCIf 2nd BC has different morphology, it is more likely to be NPHowever, majority of BCs are of no special type, and it may not be possible to make this distinction on morphologyPresence of DCISRecurrent invasive BCs associated with DCIS have a better prognosis than recurrent BCs without DCISLikely a combination of NPs and recurrences due to residual DCIS associated with the 1st BC",
                    "sub_points": [
                      "Location in breast70-90% of recurrences occur in same area of breastHowever, relative locations of 1st and 2nd BCs are often difficult to defineBreast imaging can be helpful if prior surgical site can be identifiedNP can also occur in same general location as prior BC",
                      "70-90% of recurrences occur in same area of breastHowever, relative locations of 1st and 2nd BCs are often difficult to defineBreast imaging can be helpful if prior surgical site can be identifiedNP can also occur in same general location as prior BC",
                      "However, relative locations of 1st and 2nd BCs are often difficult to define",
                      "Breast imaging can be helpful if prior surgical site can be identified",
                      "NP can also occur in same general location as prior BC",
                      "Association with prior surgical siteHyalinized scar tissue may be present at prior siteIt may be difficult to distinguish scar tissue from dense breast tissueIn some cases, granulomas may persistSuture material may be presentHowever, in majority of cases, suture material will have been resorbedMetal clips may be presentChanges associated with prior surgical site must be distinguished from more recent diagnostic biopsyRecent biopsies will have fat necrosis, hemorrhage, and stromal reactionIf it is a core needle biopsy, there may be biodegradable carrier material placed at sitePrior biopsy clip may be present",
                      "Hyalinized scar tissue may be present at prior siteIt may be difficult to distinguish scar tissue from dense breast tissueIn some cases, granulomas may persist",
                      "It may be difficult to distinguish scar tissue from dense breast tissue",
                      "In some cases, granulomas may persist",
                      "Suture material may be presentHowever, in majority of cases, suture material will have been resorbedMetal clips may be present",
                      "However, in majority of cases, suture material will have been resorbed",
                      "Metal clips may be present",
                      "Changes associated with prior surgical site must be distinguished from more recent diagnostic biopsyRecent biopsies will have fat necrosis, hemorrhage, and stromal reactionIf it is a core needle biopsy, there may be biodegradable carrier material placed at sitePrior biopsy clip may be present",
                      "Recent biopsies will have fat necrosis, hemorrhage, and stromal reaction",
                      "If it is a core needle biopsy, there may be biodegradable carrier material placed at site",
                      "Prior biopsy clip may be present",
                      "Histologic type of BCTR generally has same appearance as original BCIf 2nd BC has different morphology, it is more likely to be NPHowever, majority of BCs are of no special type, and it may not be possible to make this distinction on morphology",
                      "TR generally has same appearance as original BC",
                      "If 2nd BC has different morphology, it is more likely to be NP",
                      "However, majority of BCs are of no special type, and it may not be possible to make this distinction on morphology",
                      "Presence of DCISRecurrent invasive BCs associated with DCIS have a better prognosis than recurrent BCs without DCISLikely a combination of NPs and recurrences due to residual DCIS associated with the 1st BC",
                      "Recurrent invasive BCs associated with DCIS have a better prognosis than recurrent BCs without DCISLikely a combination of NPs and recurrences due to residual DCIS associated with the 1st BC",
                      "Likely a combination of NPs and recurrences due to residual DCIS associated with the 1st BC"
                    ]
                  },
                  {
                    "text": "IHC markersER, PR, and HER2 are generally the same in TRHowever, majority of BCs are ER/PR positive and HER2 negativeTherefore, the same common marker pattern does not necessarily indicate a TRIn addition, a different pattern does not necessarily indicate NPPR loss (or selection for PR-negative cells) can occur if patient has been treated with aromatase inhibitorHER2 loss (or selection for HER2-negative cells) can occur after HER2-targeted treatmentIf there is a major change in markers (e.g., TNBC to luminal BC), then recurrence is more likely to be NPOther markers can be used to compare 1st and 2nd BCs for similarities or differences in expression",
                    "sub_points": [
                      "ER, PR, and HER2 are generally the same in TRHowever, majority of BCs are ER/PR positive and HER2 negativeTherefore, the same common marker pattern does not necessarily indicate a TRIn addition, a different pattern does not necessarily indicate NPPR loss (or selection for PR-negative cells) can occur if patient has been treated with aromatase inhibitorHER2 loss (or selection for HER2-negative cells) can occur after HER2-targeted treatmentIf there is a major change in markers (e.g., TNBC to luminal BC), then recurrence is more likely to be NP",
                      "However, majority of BCs are ER/PR positive and HER2 negativeTherefore, the same common marker pattern does not necessarily indicate a TRIn addition, a different pattern does not necessarily indicate NPPR loss (or selection for PR-negative cells) can occur if patient has been treated with aromatase inhibitorHER2 loss (or selection for HER2-negative cells) can occur after HER2-targeted treatment",
                      "Therefore, the same common marker pattern does not necessarily indicate a TR",
                      "In addition, a different pattern does not necessarily indicate NP",
                      "PR loss (or selection for PR-negative cells) can occur if patient has been treated with aromatase inhibitor",
                      "HER2 loss (or selection for HER2-negative cells) can occur after HER2-targeted treatment",
                      "If there is a major change in markers (e.g., TNBC to luminal BC), then recurrence is more likely to be NP",
                      "Other markers can be used to compare 1st and 2nd BCs for similarities or differences in expression"
                    ]
                  },
                  {
                    "text": "Genomic changesMutational analysisDNA mutationsIf both BCs have the same mutation, and a germline mutation is excluded, this is good evidence for a TRHowever, BCs can gain or lose clones with mutations during tumor progression and after treatmentDNA breakpoint and DNA copy number alterationsAssumes genetic changes in BCs are relatively stable over timeLess specific than identifying specific mutationsLoss of heterozygosity (LOH)PCR-based LOH (allelic imbalance) assay has been used in research studies of TR and NPCan be performed on formalin-fixed, paraffin-embedded tissueMicrosatellite alleles in tumor suppressor genes are frequently lost in BCsEach BC has a characteristic pattern of lossThis can be a sensitive assay to identify BCs arising from same clone of malignant cellsLess specific than identifying specific mutations",
                    "sub_points": [
                      "Mutational analysisDNA mutationsIf both BCs have the same mutation, and a germline mutation is excluded, this is good evidence for a TRHowever, BCs can gain or lose clones with mutations during tumor progression and after treatment",
                      "DNA mutationsIf both BCs have the same mutation, and a germline mutation is excluded, this is good evidence for a TRHowever, BCs can gain or lose clones with mutations during tumor progression and after treatment",
                      "If both BCs have the same mutation, and a germline mutation is excluded, this is good evidence for a TR",
                      "However, BCs can gain or lose clones with mutations during tumor progression and after treatment",
                      "DNA breakpoint and DNA copy number alterationsAssumes genetic changes in BCs are relatively stable over timeLess specific than identifying specific mutations",
                      "Assumes genetic changes in BCs are relatively stable over time",
                      "Less specific than identifying specific mutations",
                      "Loss of heterozygosity (LOH)PCR-based LOH (allelic imbalance) assay has been used in research studies of TR and NPCan be performed on formalin-fixed, paraffin-embedded tissueMicrosatellite alleles in tumor suppressor genes are frequently lost in BCsEach BC has a characteristic pattern of lossThis can be a sensitive assay to identify BCs arising from same clone of malignant cellsLess specific than identifying specific mutations",
                      "PCR-based LOH (allelic imbalance) assay has been used in research studies of TR and NPCan be performed on formalin-fixed, paraffin-embedded tissueMicrosatellite alleles in tumor suppressor genes are frequently lost in BCsEach BC has a characteristic pattern of lossThis can be a sensitive assay to identify BCs arising from same clone of malignant cells",
                      "Can be performed on formalin-fixed, paraffin-embedded tissue",
                      "Microsatellite alleles in tumor suppressor genes are frequently lost in BCs",
                      "Each BC has a characteristic pattern of loss",
                      "This can be a sensitive assay to identify BCs arising from same clone of malignant cells",
                      "Less specific than identifying specific mutations"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Angiosarcoma": [
                  {
                    "text": "Patients receiving radiation therapy for BC are at increased risk for angiosarcomaIncidence of angiosarcoma is very low",
                    "sub_points": [
                      "Incidence of angiosarcoma is very low"
                    ]
                  },
                  {
                    "text": "Radiation-associated angiosarcomas usually arise in radiated skinPresent as erythematous plaques and nodulesThis would be an unusual appearance for BC",
                    "sub_points": [
                      "Present as erythematous plaques and nodules",
                      "This would be an unusual appearance for BC"
                    ]
                  },
                  {
                    "text": "Angiosarcomas can appear epithelioid and resemble poorly differentiated BCAn IHC panel may be necessary to distinguish angiosarcoma from recurrent BCAngiosarcomas may be keratin positive; some poorly differentiated BCs may only be positive for basal keratinsSome poorly differentiated BCs are negative for commonly used keratins and may only be positive for high molecular weight (basal) keratinsAngiosarcomas and some breast BCs are positive for podoplanin (D2-40)More specific endothelial markers should be used",
                    "sub_points": [
                      "An IHC panel may be necessary to distinguish angiosarcoma from recurrent BCAngiosarcomas may be keratin positive; some poorly differentiated BCs may only be positive for basal keratinsSome poorly differentiated BCs are negative for commonly used keratins and may only be positive for high molecular weight (basal) keratinsAngiosarcomas and some breast BCs are positive for podoplanin (D2-40)More specific endothelial markers should be used",
                      "Angiosarcomas may be keratin positive; some poorly differentiated BCs may only be positive for basal keratinsSome poorly differentiated BCs are negative for commonly used keratins and may only be positive for high molecular weight (basal) keratins",
                      "Some poorly differentiated BCs are negative for commonly used keratins and may only be positive for high molecular weight (basal) keratins",
                      "Angiosarcomas and some breast BCs are positive for podoplanin (D2-40)",
                      "More specific endothelial markers should be used"
                    ]
                  }
                ],
                "Scar Tissue": [
                  {
                    "text": "Occasionally, scar tissue at a prior surgical site will appear to increase in size after long period of timeHowever, recurrent invasive BCs can also be masked by scar tissue and are only detected when they become larger than prior scar",
                    "sub_points": [
                      "However, recurrent invasive BCs can also be masked by scar tissue and are only detected when they become larger than prior scar"
                    ]
                  },
                  {
                    "text": "Traumatic neuromas can form small masses in breast or in subcutaneous tissue"
                  },
                  {
                    "text": "Degenerating/regenerating muscle fibers injured by prior surgery can mimic pleomorphic malignant cells"
                  },
                  {
                    "text": "Excision may be necessary to exclude recurrent carcinoma"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Distinction between TR and NP has clinical, prognostic, and biologic importance"
                  },
                  {
                    "text": "Pathologist can play important role in assessing likelihood of origin of 2nd BC"
                  }
                ]
              },
              "REPORTING": {
                "Key Elements to Report": [
                  {
                    "text": "When possible, prior BC should be compared to current BC morphologically and by expression of ER, PR, and HER2Statement should be made on likelihood of BC being TR or NP",
                    "sub_points": [
                      "Statement should be made on likelihood of BC being TR or NP"
                    ]
                  },
                  {
                    "text": "Relationship to identified prior surgical site should be reported when possible"
                  },
                  {
                    "text": "If recurrence is after mastectomyReport residual normal breast tissue and DCIS, if present, as this supports NP",
                    "sub_points": [
                      "Report residual normal breast tissue and DCIS, if present, as this supports NP"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Checklist for the Reporting of Invasive Breast Carcinoma": {
            "name": "Checklist for the Reporting of Invasive Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/e7c746e0-7294-4615-aa15-a4c29f811bb6/lesson/bd0936b2-3c99-468e-a30f-861e32fd253e",
            "content": {}
          }
        }
      },
      "Prognostic and Predictive Factors": {
        "name": "Prognostic and Predictive Factors",
        "url": "https://app.pathprimer.com/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
        "topics": {
          "Overview of Prognostic and Predictive Factors": {
            "name": "Overview of Prognostic and Predictive Factors",
            "url": "https://app.pathprimer.com/document/bcb92d03-82a4-46e9-a5af-e1f70272e265/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "Overview": {
                "Introduction": [
                  {
                    "text": "The ability to predict the benefit from treatment and prognosis for patients with breast carcinoma (BC) is critically important for individual patients, clinical care, clinical trials, and basic researchPatients diagnosed with BC understandably want to know what treatment will be beneficial and if they will survive",
                    "sub_points": [
                      "Patients diagnosed with BC understandably want to know what treatment will be beneficial and if they will survive"
                    ]
                  },
                  {
                    "text": "There is a very wide range of outcomes for patients with BCSome patients have the same survival as patients without BC even in the absence of treatmentOther patients have a < 20% chance of being alive in 5 years, even with maximum treatment",
                    "sub_points": [
                      "Some patients have the same survival as patients without BC even in the absence of treatment",
                      "Other patients have a < 20% chance of being alive in 5 years, even with maximum treatment"
                    ]
                  },
                  {
                    "text": "The important determinants of response to treatment and likely survival are provided in pathology reports from breast and axillary node biopsies and excisions"
                  },
                  {
                    "text": "For patients who present with distant metastases, imaging demonstration of disease, with biopsy confirmation in some cases, is their most important prognostic factor"
                  }
                ],
                "Prognostic Factors": [
                  {
                    "text": "Prognostic factors predict the patient's clinical course in terms of risk of disease recurrence and deathPatient-related factors: Age, menopausal status, performance status, comorbiditiesAnatomic factors: Distant metastases (location of metastases), lymph node metastasis, tumor sizeHistologic factors: Tumor grade, histologic type, tumor-infiltrating lymphocytes (TILs)Molecular type of BC: Luminal BC [ER(+)/HER2(-)], luminal HER2 BC [ER(+)/HER2(+), HER2 BC (ER(-)/HER2(+)], triple negative BC (TNBC) [ER(-)/HER2(-)]Expression of proteins that can be targeted by treatment (e.g., ER and HER2)Multigene assays have prognostic value for distant recurrence and survivalOncotype DX recurrence score (RS), MammaPrint, Prosigna risk of recurrence (ROR), EndoPredict",
                    "sub_points": [
                      "Patient-related factors: Age, menopausal status, performance status, comorbidities",
                      "Anatomic factors: Distant metastases (location of metastases), lymph node metastasis, tumor size",
                      "Histologic factors: Tumor grade, histologic type, tumor-infiltrating lymphocytes (TILs)",
                      "Molecular type of BC: Luminal BC [ER(+)/HER2(-)], luminal HER2 BC [ER(+)/HER2(+), HER2 BC (ER(-)/HER2(+)], triple negative BC (TNBC) [ER(-)/HER2(-)]",
                      "Expression of proteins that can be targeted by treatment (e.g., ER and HER2)",
                      "Multigene assays have prognostic value for distant recurrence and survivalOncotype DX recurrence score (RS), MammaPrint, Prosigna risk of recurrence (ROR), EndoPredict",
                      "Oncotype DX recurrence score (RS), MammaPrint, Prosigna risk of recurrence (ROR), EndoPredict"
                    ]
                  },
                  {
                    "text": "Prognostic factors are important whether evaluated prior to therapy or after neoadjuvant therapyAfter treatment, response to treatment is an important additional prognostic factor for high-grade luminal BC, luminal HER2 BC, HER2 BC, and TNBCLow-grade ER(+) cancers rarely show pathologic complete responses, and response is not a strong prognostic factor for this group",
                    "sub_points": [
                      "After treatment, response to treatment is an important additional prognostic factor for high-grade luminal BC, luminal HER2 BC, HER2 BC, and TNBCLow-grade ER(+) cancers rarely show pathologic complete responses, and response is not a strong prognostic factor for this group",
                      "Low-grade ER(+) cancers rarely show pathologic complete responses, and response is not a strong prognostic factor for this group"
                    ]
                  },
                  {
                    "text": "Major prognostic factors have been extensively clinically validated as useful in determining probability of local &/or distant disease recurrencePrognostic factors are robust in terms of their ability to predict disease recurrenceBasis for clinical risk assessment and decisions on need for adjuvant systemic therapy",
                    "sub_points": [
                      "Prognostic factors are robust in terms of their ability to predict disease recurrence",
                      "Basis for clinical risk assessment and decisions on need for adjuvant systemic therapy"
                    ]
                  },
                  {
                    "text": "Clinically useful for individual patients, clinical trials, and basic researchIndividual patientsHelp guide treatment for current BCIdentifies patients who may not require systemic therapy [i.e., ductal carcinoma in situ (DCIS) or small invasive BCs]Identifies patients with higher risk of recurrence (ROR) who will likely benefit from systemic therapyCan help guide decisions about additional medical treatment (e.g., benefit from prophylactic surgery)Clinical trialsPatients of similar prognosis are identified for each clinical trialAllows meaningful comparison of trialsAllows meaningful comparison of survival to historical dataBasic researchIdentifies groups of similar patientsChanges over time can be studiedPatients in different geographic locations can be compared",
                    "sub_points": [
                      "Individual patientsHelp guide treatment for current BCIdentifies patients who may not require systemic therapy [i.e., ductal carcinoma in situ (DCIS) or small invasive BCs]Identifies patients with higher risk of recurrence (ROR) who will likely benefit from systemic therapyCan help guide decisions about additional medical treatment (e.g., benefit from prophylactic surgery)",
                      "Help guide treatment for current BCIdentifies patients who may not require systemic therapy [i.e., ductal carcinoma in situ (DCIS) or small invasive BCs]Identifies patients with higher risk of recurrence (ROR) who will likely benefit from systemic therapy",
                      "Identifies patients who may not require systemic therapy [i.e., ductal carcinoma in situ (DCIS) or small invasive BCs]",
                      "Identifies patients with higher risk of recurrence (ROR) who will likely benefit from systemic therapy",
                      "Can help guide decisions about additional medical treatment (e.g., benefit from prophylactic surgery)",
                      "Clinical trialsPatients of similar prognosis are identified for each clinical trialAllows meaningful comparison of trialsAllows meaningful comparison of survival to historical data",
                      "Patients of similar prognosis are identified for each clinical trialAllows meaningful comparison of trialsAllows meaningful comparison of survival to historical data",
                      "Allows meaningful comparison of trials",
                      "Allows meaningful comparison of survival to historical data",
                      "Basic researchIdentifies groups of similar patientsChanges over time can be studiedPatients in different geographic locations can be compared",
                      "Identifies groups of similar patientsChanges over time can be studiedPatients in different geographic locations can be compared",
                      "Changes over time can be studied",
                      "Patients in different geographic locations can be compared"
                    ]
                  }
                ],
                "Predictive Factors": [
                  {
                    "text": "Predictive factors predict the likelihood that a patient will benefit from a specific type of treatmentEndocrine therapyBCs that express ER and PR at high levels are more likely to respond to endocrine therapyBCs that do not express hormone receptors are very unlikely to benefit from endocrine therapyChemotherapyBCs with high proliferative rates and tumor necrosis are more likely to show pathologic complete response to neoadjuvant treatmentBiologic and targeted therapiesBCs that overexpress HER2 are more likely to respond to HER2-targeted therapyMany other therapeutic agents under investigation are paired with companion diagnostic test designed to identify BCs most likely to respond to treatmentExpression of PD-L1 is being used to identify BCs that may be susceptible to immune modulating treatmentMutations in phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) are detected by DNA sequencing to identify BCs to be treated with PI3K inhibitorsMutations inBRCA1andBRCA2are detected by DNA sequencing to identify patients who may benefit from inhibition of alternative DNA repair pathway [poly-ADP ribose polymerase (PARP) inhibitor]Mutations inESR1(ESR) andERBB2(HER2) in recurrent BC are detected by DNA sequencing to identify patients who could benefit from treatments targeting these alterations",
                    "sub_points": [
                      "Endocrine therapyBCs that express ER and PR at high levels are more likely to respond to endocrine therapyBCs that do not express hormone receptors are very unlikely to benefit from endocrine therapy",
                      "BCs that express ER and PR at high levels are more likely to respond to endocrine therapy",
                      "BCs that do not express hormone receptors are very unlikely to benefit from endocrine therapy",
                      "ChemotherapyBCs with high proliferative rates and tumor necrosis are more likely to show pathologic complete response to neoadjuvant treatment",
                      "BCs with high proliferative rates and tumor necrosis are more likely to show pathologic complete response to neoadjuvant treatment",
                      "Biologic and targeted therapiesBCs that overexpress HER2 are more likely to respond to HER2-targeted therapyMany other therapeutic agents under investigation are paired with companion diagnostic test designed to identify BCs most likely to respond to treatmentExpression of PD-L1 is being used to identify BCs that may be susceptible to immune modulating treatmentMutations in phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) are detected by DNA sequencing to identify BCs to be treated with PI3K inhibitorsMutations inBRCA1andBRCA2are detected by DNA sequencing to identify patients who may benefit from inhibition of alternative DNA repair pathway [poly-ADP ribose polymerase (PARP) inhibitor]Mutations inESR1(ESR) andERBB2(HER2) in recurrent BC are detected by DNA sequencing to identify patients who could benefit from treatments targeting these alterations",
                      "BCs that overexpress HER2 are more likely to respond to HER2-targeted therapy",
                      "Many other therapeutic agents under investigation are paired with companion diagnostic test designed to identify BCs most likely to respond to treatmentExpression of PD-L1 is being used to identify BCs that may be susceptible to immune modulating treatmentMutations in phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) are detected by DNA sequencing to identify BCs to be treated with PI3K inhibitorsMutations inBRCA1andBRCA2are detected by DNA sequencing to identify patients who may benefit from inhibition of alternative DNA repair pathway [poly-ADP ribose polymerase (PARP) inhibitor]Mutations inESR1(ESR) andERBB2(HER2) in recurrent BC are detected by DNA sequencing to identify patients who could benefit from treatments targeting these alterations",
                      "Expression of PD-L1 is being used to identify BCs that may be susceptible to immune modulating treatment",
                      "Mutations in phosphatidylinositol-4,5-biphosphate 3-kinase (PIK3CA) are detected by DNA sequencing to identify BCs to be treated with PI3K inhibitors",
                      "Mutations inBRCA1andBRCA2are detected by DNA sequencing to identify patients who may benefit from inhibition of alternative DNA repair pathway [poly-ADP ribose polymerase (PARP) inhibitor]",
                      "Mutations inESR1(ESR) andERBB2(HER2) in recurrent BC are detected by DNA sequencing to identify patients who could benefit from treatments targeting these alterations"
                    ]
                  }
                ],
                "Factors That Are Both Prognostic and Predictive": [
                  {
                    "text": "Some factors are both prognostic and predictiveHormone receptor and HER2 expressionSome multigene expression assays designed as prognostic assays are also predictive of benefit of treatmente.g., Oncotype DX recurrence score (RS) provides prognostic and predictive information for ER(+)BCsA low RS identifies patients who do not have additional benefit from adding chemotherapy to endocrine therapy; survival is the same for both groupsA high RS identifies patients who benefit from chemotherapy and endocrine therapy; survival is improved for the group receiving chemotherapy",
                    "sub_points": [
                      "Hormone receptor and HER2 expression",
                      "Some multigene expression assays designed as prognostic assays are also predictive of benefit of treatmente.g., Oncotype DX recurrence score (RS) provides prognostic and predictive information for ER(+)BCsA low RS identifies patients who do not have additional benefit from adding chemotherapy to endocrine therapy; survival is the same for both groupsA high RS identifies patients who benefit from chemotherapy and endocrine therapy; survival is improved for the group receiving chemotherapy",
                      "e.g., Oncotype DX recurrence score (RS) provides prognostic and predictive information for ER(+)BCsA low RS identifies patients who do not have additional benefit from adding chemotherapy to endocrine therapy; survival is the same for both groupsA high RS identifies patients who benefit from chemotherapy and endocrine therapy; survival is improved for the group receiving chemotherapy",
                      "A low RS identifies patients who do not have additional benefit from adding chemotherapy to endocrine therapy; survival is the same for both groups",
                      "A high RS identifies patients who benefit from chemotherapy and endocrine therapy; survival is improved for the group receiving chemotherapy"
                    ]
                  },
                  {
                    "text": "Development of new treatment regimens and novel targeted agents has led to a shift from risk assessment (prognosis) to treatment responsiveness (prediction)Provides better patient selection for specific treatmentsResults in improved patient response ratesReduces toxicity from therapies that are unlikely to be of benefit",
                    "sub_points": [
                      "Provides better patient selection for specific treatments",
                      "Results in improved patient response rates",
                      "Reduces toxicity from therapies that are unlikely to be of benefit"
                    ]
                  },
                  {
                    "text": "The size of BCs has a relationship to treatment responseLarger BCs are more likely to consist of genetically heterogeneous clones of tumor cells and, therefore, may be more resistant to treatmentSmaller BCs more often undergo a pathologic complete response to neoadjuvant chemotherapyThe centrally located cells of larger BCs usually have a lower mitotic rate (possibly due to ischemia) and may be more resistant the chemotherapy",
                    "sub_points": [
                      "Larger BCs are more likely to consist of genetically heterogeneous clones of tumor cells and, therefore, may be more resistant to treatmentSmaller BCs more often undergo a pathologic complete response to neoadjuvant chemotherapy",
                      "Smaller BCs more often undergo a pathologic complete response to neoadjuvant chemotherapy",
                      "The centrally located cells of larger BCs usually have a lower mitotic rate (possibly due to ischemia) and may be more resistant the chemotherapy"
                    ]
                  }
                ],
                "Combining Prognostic and Predictive Factors": [
                  {
                    "text": "More information is gained by combining multiple factors"
                  },
                  {
                    "text": "There are many systems that combine pathologic, molecular, &/or clinical factors into overall prognostic scores"
                  }
                ]
              },
              "American Joint Commission on Cancer (AJCC) Stage": {
                "Overview": [
                  {
                    "text": "The most important prognostic and predictive factors are used for AJCC staging (8th edition, in effect Jan 1, 2018)"
                  },
                  {
                    "text": "Anatomic stage includes local extent of tumor (T), regional lymph node metastasis (N), and distant metastasis (M)"
                  },
                  {
                    "text": "In the 8th edition, biologic factors are also included to determine the clinical prognostic stage (CPS) and pathologic prognostic stage (PPS)Grade, ER, PR, and HER2 are used to determine stages I, II, and IIIIn a subset of patients, a multigene assay result can also be includedBiologic factors are not used for stages 0 and IVUnion for International Cancer Control (UICC) did not adopt this system and continues to use anatomic stageAnatomic stage continues to be used for populations in which ER, PR, &/or HER2 may not be availableStages I, II, and III consist of combinations of different anatomic stages and cancers of different biologic types predicted to have the same survival at 5 yearsExpected survival is based on patients receiving optimal therapy",
                    "sub_points": [
                      "Grade, ER, PR, and HER2 are used to determine stages I, II, and IIIIn a subset of patients, a multigene assay result can also be included",
                      "In a subset of patients, a multigene assay result can also be included",
                      "Biologic factors are not used for stages 0 and IV",
                      "Union for International Cancer Control (UICC) did not adopt this system and continues to use anatomic stage",
                      "Anatomic stage continues to be used for populations in which ER, PR, &/or HER2 may not be available",
                      "Stages I, II, and III consist of combinations of different anatomic stages and cancers of different biologic types predicted to have the same survival at 5 yearsExpected survival is based on patients receiving optimal therapy",
                      "Expected survival is based on patients receiving optimal therapy"
                    ]
                  }
                ],
                "Anatomic Stage": [
                  {
                    "text": "T classificationBased on features of the primary BCT1, T2, and T3invasive BCs are classified based on size, which is an independent prognostic factorPalpable invasive BCs have a worse prognosis compared with nonpalpable BCs (detected by screening) of same sizeTumor size also directly correlates with the number of involved lymph nodes and increased RORPatients with BCs ≤ 1 cm have an excellent prognosis, and selected patients have little benefit from systemic therapyT4invasive BCs are defined by features other than sizeOriginally defined as BCs not amenable to surgery due to rapid local recurrenceCurrent prognosis is improved with better surgical and adjuvant treatmentIncludes chest wall invasion (into intercostal muscles), skin ulceration, satellite skin nodules, and clinical symptoms of inflammatory carcinoma",
                    "sub_points": [
                      "Based on features of the primary BC",
                      "T1, T2, and T3invasive BCs are classified based on size, which is an independent prognostic factorPalpable invasive BCs have a worse prognosis compared with nonpalpable BCs (detected by screening) of same size",
                      "Palpable invasive BCs have a worse prognosis compared with nonpalpable BCs (detected by screening) of same size",
                      "Tumor size also directly correlates with the number of involved lymph nodes and increased RORPatients with BCs ≤ 1 cm have an excellent prognosis, and selected patients have little benefit from systemic therapy",
                      "Patients with BCs ≤ 1 cm have an excellent prognosis, and selected patients have little benefit from systemic therapy",
                      "T4invasive BCs are defined by features other than sizeOriginally defined as BCs not amenable to surgery due to rapid local recurrenceCurrent prognosis is improved with better surgical and adjuvant treatmentIncludes chest wall invasion (into intercostal muscles), skin ulceration, satellite skin nodules, and clinical symptoms of inflammatory carcinoma",
                      "Originally defined as BCs not amenable to surgery due to rapid local recurrenceCurrent prognosis is improved with better surgical and adjuvant treatment",
                      "Current prognosis is improved with better surgical and adjuvant treatment",
                      "Includes chest wall invasion (into intercostal muscles), skin ulceration, satellite skin nodules, and clinical symptoms of inflammatory carcinoma"
                    ]
                  },
                  {
                    "text": "N classificationPrognosis is dependent on the size of the largest metastasis and the number of metastasesMacrometastases measure > 2 mm and have prognostic significanceIsolated tumor cells and micrometastases have minimal prognostic significanceSurvival is similar to patients with negative nodesPrognosis diminishes with each additional lymph node metastasisA subset (10-30%) of node (-) patients eventually develop distant metastasesSome of these BCs may metastasize to nodal basins that are generally not sampled (e.g., internal mammary nodes)Other BCs may metastasize primarily via blood vessels (e.g., spindle cell carcinomas)Lymph nodes are removed or sampled primarily for prognostication and to control extensive axillary disease (i.e., multiple palpable nodes)Removal of positive lymph nodes has little or no effect on survival",
                    "sub_points": [
                      "Prognosis is dependent on the size of the largest metastasis and the number of metastasesMacrometastases measure > 2 mm and have prognostic significanceIsolated tumor cells and micrometastases have minimal prognostic significanceSurvival is similar to patients with negative nodes",
                      "Macrometastases measure > 2 mm and have prognostic significance",
                      "Isolated tumor cells and micrometastases have minimal prognostic significanceSurvival is similar to patients with negative nodes",
                      "Survival is similar to patients with negative nodes",
                      "Prognosis diminishes with each additional lymph node metastasis",
                      "A subset (10-30%) of node (-) patients eventually develop distant metastasesSome of these BCs may metastasize to nodal basins that are generally not sampled (e.g., internal mammary nodes)Other BCs may metastasize primarily via blood vessels (e.g., spindle cell carcinomas)",
                      "Some of these BCs may metastasize to nodal basins that are generally not sampled (e.g., internal mammary nodes)",
                      "Other BCs may metastasize primarily via blood vessels (e.g., spindle cell carcinomas)",
                      "Lymph nodes are removed or sampled primarily for prognostication and to control extensive axillary disease (i.e., multiple palpable nodes)Removal of positive lymph nodes has little or no effect on survival",
                      "Removal of positive lymph nodes has little or no effect on survival"
                    ]
                  },
                  {
                    "text": "M classificationPatients with M1 (stage IV) disease have a poor prognosis, < 10% survival at 10 yearsSurvival varies with the molecular type of BCPatients with luminal HER2 BC have the best survival compared to other typesPatients with TNBCs have the worst survivalPatients who develop distant metastases many years after diagnosis have a better prognosis than patients who have distant metastases at initial diagnosis or shortly after diagnosisIndicative of BCs with a slower growth rate and likely response to initial therapyGenerally detected clinically or radiologicallySites of distant metastatic spread varies according to the molecular type of BCLuminal BCs primarily metastasize to bone with fewer metastasis to visceral sites and brainLong survival is possible with palliative treatment for bone-only metastasesLuminal HER2 BC, HER2 BC, and TNBC are relatively more likely to metastasize to visceral sites and brain",
                    "sub_points": [
                      "Patients with M1 (stage IV) disease have a poor prognosis, < 10% survival at 10 yearsSurvival varies with the molecular type of BCPatients with luminal HER2 BC have the best survival compared to other typesPatients with TNBCs have the worst survivalPatients who develop distant metastases many years after diagnosis have a better prognosis than patients who have distant metastases at initial diagnosis or shortly after diagnosisIndicative of BCs with a slower growth rate and likely response to initial therapy",
                      "Survival varies with the molecular type of BCPatients with luminal HER2 BC have the best survival compared to other typesPatients with TNBCs have the worst survival",
                      "Patients with luminal HER2 BC have the best survival compared to other types",
                      "Patients with TNBCs have the worst survival",
                      "Patients who develop distant metastases many years after diagnosis have a better prognosis than patients who have distant metastases at initial diagnosis or shortly after diagnosisIndicative of BCs with a slower growth rate and likely response to initial therapy",
                      "Indicative of BCs with a slower growth rate and likely response to initial therapy",
                      "Generally detected clinically or radiologically",
                      "Sites of distant metastatic spread varies according to the molecular type of BCLuminal BCs primarily metastasize to bone with fewer metastasis to visceral sites and brainLong survival is possible with palliative treatment for bone-only metastasesLuminal HER2 BC, HER2 BC, and TNBC are relatively more likely to metastasize to visceral sites and brain",
                      "Luminal BCs primarily metastasize to bone with fewer metastasis to visceral sites and brainLong survival is possible with palliative treatment for bone-only metastases",
                      "Long survival is possible with palliative treatment for bone-only metastases",
                      "Luminal HER2 BC, HER2 BC, and TNBC are relatively more likely to metastasize to visceral sites and brain"
                    ]
                  }
                ],
                "Pathologic Prognostic Stage (PPS)": [
                  {
                    "text": "Only used for patients with surgery as the 1st treatment with available pT and pN"
                  },
                  {
                    "text": "For selected patients, a low multigene assay score can be used to assign a PPS IA"
                  }
                ],
                "Clinical Prognostic Stage (CPS)": [
                  {
                    "text": "Used for all patients using a combination of clinical, imaging, and pathologic information"
                  },
                  {
                    "text": "CPS can be a higher stage than PPS because the patient population used to calculate survival for different groups included patients with a poorer prognosisPatients who are not surgical candidates due to advanced disease, comorbid conditions, or agePatients undergoing neoadjuvant therapy tend to have more advanced cancers of unfavorable molecular types",
                    "sub_points": [
                      "Patients who are not surgical candidates due to advanced disease, comorbid conditions, or age",
                      "Patients undergoing neoadjuvant therapy tend to have more advanced cancers of unfavorable molecular types"
                    ]
                  },
                  {
                    "text": "A multigene assay is not used to assign CPS because pT and pN may not be known"
                  }
                ]
              },
              "Pathologic Prognostic Factors": {
                "HistologicGrade": [
                  {
                    "text": "All invasive BCs are graded using the Nottingham Grading System (NGS)Recommended by the National Comprehensive Cancer Network, American Society of Clinical Oncology, College of American Pathologists, AJCC, the European Working Group on Breast Screening Pathology, and others",
                    "sub_points": [
                      "Recommended by the National Comprehensive Cancer Network, American Society of Clinical Oncology, College of American Pathologists, AJCC, the European Working Group on Breast Screening Pathology, and others"
                    ]
                  },
                  {
                    "text": "NGS grade is based on glandular (acinar)/tubular differentiation, nuclear score, and mitotic score"
                  },
                  {
                    "text": "Adherence to strict morphologic criteria is needed for reproducibility so that grade is reliably useful as significant prognostic factor"
                  },
                  {
                    "text": "Histologic grade is prognosticGrade 1 cancers (well differentiated) have favorable prognosis (low risk); almost all are ER(+)Grade 2 cancers (moderately differentiated) have intermediate prognosis (intermediate risk)Grade 3 cancers (poorly differentiated) have less favorable prognosis (high risk)",
                    "sub_points": [
                      "Grade 1 cancers (well differentiated) have favorable prognosis (low risk); almost all are ER(+)",
                      "Grade 2 cancers (moderately differentiated) have intermediate prognosis (intermediate risk)",
                      "Grade 3 cancers (poorly differentiated) have less favorable prognosis (high risk)"
                    ]
                  },
                  {
                    "text": "Extensive necrosis (> 1 HPF) identifies grade 3 BCs with a particularly poor prognosisHowever, necrosis is also predictive of good response to chemotherapy",
                    "sub_points": [
                      "However, necrosis is also predictive of good response to chemotherapy"
                    ]
                  }
                ],
                "Lymphovascular Invasion (LVI)": [
                  {
                    "text": "Peritumoral LVI has prognostic significance for risk of local and distant recurrenceRecurrence for stage I disease with LVI is ~ 38% compared with 22% in its absence",
                    "sub_points": [
                      "Recurrence for stage I disease with LVI is ~ 38% compared with 22% in its absence"
                    ]
                  },
                  {
                    "text": "Closely associated with lymph node metastases but is an independent factorPrognosis is diminished if both LVI and nodal metastases are present",
                    "sub_points": [
                      "Prognosis is diminished if both LVI and nodal metastases are present"
                    ]
                  },
                  {
                    "text": "Currently, unnecessary to distinguish small capillaries from lymphatics using IHC markers, as both have prognostic significance"
                  }
                ],
                "SpecialHistologic Types of Invasive Carcinoma": [
                  {
                    "text": "Strict criteria for the diagnosis of these special types of BC are important to maintain prognostic significanceShould fulfill criteria in > 90% of BC",
                    "sub_points": [
                      "Should fulfill criteria in > 90% of BC"
                    ]
                  },
                  {
                    "text": "Histologic types with better prognosis are associated with grade 1 or 2, expression of ER/PR, and absence of HER2 overexpressionTubular, tubulolobular, mucinous (colloid), papillary, cribriform, and majority of lobular carcinomas",
                    "sub_points": [
                      "Tubular, tubulolobular, mucinous (colloid), papillary, cribriform, and majority of lobular carcinomas"
                    ]
                  },
                  {
                    "text": "Some TNBCs have a relatively good prognosisAdenoid cystic, low-grade adenosquamous, and secretory carcinomaBCs with a medullary pattern have a relatively better prognosis compared to poorly differentiated BCs of similar size and stage in the absence of a lymphoplasmacytic infiltrate",
                    "sub_points": [
                      "Adenoid cystic, low-grade adenosquamous, and secretory carcinoma",
                      "BCs with a medullary pattern have a relatively better prognosis compared to poorly differentiated BCs of similar size and stage in the absence of a lymphoplasmacytic infiltrate"
                    ]
                  },
                  {
                    "text": "Some histologic types of BC have an unfavorable prognosisMetaplastic, invasive micropapillary carcinoma",
                    "sub_points": [
                      "Metaplastic, invasive micropapillary carcinoma"
                    ]
                  }
                ],
                "Tumor-Infiltrating Lymphocytes (TILs)": [
                  {
                    "text": "Assessment of TILs can provide valuable information about host immune response to tumor"
                  },
                  {
                    "text": "Higher levels of TILs are associated with better response to systemic therapy and longer progression-free and overall survival (OS)"
                  }
                ],
                "ER and PRExpression": [
                  {
                    "text": "PrognosisDependent on stage of the BC and length of follow-upLittle to no prognostic effect for stage 0 and stage I BCs, as majority are cured by local treatment (surgery and radiation)Moderate effect for stage II BCs and marked effect for stages III and IV BCs for up to 10 yearsOver time, BCs may eventually develop resistance to endocrine therapyAlmost no increase in survival compared to ER(-)BCs at 20 yearsFor ER(+)BCs, recurrence occurs at a low rate over a long period of timePatients can survive for long periods of time with metastases, which are most commonly to boneDisease-free survival (DFS) may be substantially different from overall survival (OS)For TNBCs, recurrence almost always occurs within the first 10 yearsPatients who do not recur in the first 8-10 years are likely curedDFS is very similar to OS",
                    "sub_points": [
                      "Dependent on stage of the BC and length of follow-up",
                      "Little to no prognostic effect for stage 0 and stage I BCs, as majority are cured by local treatment (surgery and radiation)",
                      "Moderate effect for stage II BCs and marked effect for stages III and IV BCs for up to 10 yearsOver time, BCs may eventually develop resistance to endocrine therapy",
                      "Over time, BCs may eventually develop resistance to endocrine therapy",
                      "Almost no increase in survival compared to ER(-)BCs at 20 years",
                      "For ER(+)BCs, recurrence occurs at a low rate over a long period of timePatients can survive for long periods of time with metastases, which are most commonly to boneDisease-free survival (DFS) may be substantially different from overall survival (OS)",
                      "Patients can survive for long periods of time with metastases, which are most commonly to bone",
                      "Disease-free survival (DFS) may be substantially different from overall survival (OS)",
                      "For TNBCs, recurrence almost always occurs within the first 10 yearsPatients who do not recur in the first 8-10 years are likely curedDFS is very similar to OS",
                      "Patients who do not recur in the first 8-10 years are likely cured",
                      "DFS is very similar to OS"
                    ]
                  },
                  {
                    "text": "Prediction of benefit from endocrine therapyER and PR expression are powerful predictive factors for patients likely to benefit from endocrine therapyThere is no survival benefit for patients with ER(-)BCs treated with tamoxifenHigher levels of ER expression with PR expression may predict for greater response to endocrine therapyLower limit of expression that correlates with treatment benefit is not yet well definedASCO/CAP guidelines recommend classifying any carcinoma with ≥ 1% immunoreactive cells by IHC studies as positive",
                    "sub_points": [
                      "ER and PR expression are powerful predictive factors for patients likely to benefit from endocrine therapyThere is no survival benefit for patients with ER(-)BCs treated with tamoxifen",
                      "There is no survival benefit for patients with ER(-)BCs treated with tamoxifen",
                      "Higher levels of ER expression with PR expression may predict for greater response to endocrine therapyLower limit of expression that correlates with treatment benefit is not yet well definedASCO/CAP guidelines recommend classifying any carcinoma with ≥ 1% immunoreactive cells by IHC studies as positive",
                      "Lower limit of expression that correlates with treatment benefit is not yet well defined",
                      "ASCO/CAP guidelines recommend classifying any carcinoma with ≥ 1% immunoreactive cells by IHC studies as positive"
                    ]
                  }
                ],
                "HER2 Expression": [
                  {
                    "text": "Overexpression is associated with more aggressive diseaseWithout HER2-targeted therapy, which blocks HER2 function, patients with HER2(+)BC have a poor prognosisHowever, with HER2-targeted therapy, the majority of these patients have a very favorable prognosis",
                    "sub_points": [
                      "Without HER2-targeted therapy, which blocks HER2 function, patients with HER2(+)BC have a poor prognosis",
                      "However, with HER2-targeted therapy, the majority of these patients have a very favorable prognosis"
                    ]
                  },
                  {
                    "text": "Multiple types of HER2-targeted therapy are availableAntibodies that block HER2 functionAntibodies that deliver chemotherapeutic agents (antibody-drug conjugates or ADCs)Tyrosine kinase inhibitorsVaccines to HER2 protein",
                    "sub_points": [
                      "Antibodies that block HER2 function",
                      "Antibodies that deliver chemotherapeutic agents (antibody-drug conjugates or ADCs)",
                      "Tyrosine kinase inhibitors",
                      "Vaccines to HER2 protein"
                    ]
                  },
                  {
                    "text": "HER2 overexpression by IHC or FISH is a predictive factor for benefit from HER2-targeted therapy"
                  },
                  {
                    "text": "BCs with low levels of HER2 expression (e.g., 1+ or ultralow) may respond to antibody-drug conjugates (ADCs), which direct chemotherapeutic agents to tumor cells using the HER2 receptor"
                  },
                  {
                    "text": "HER2 may also have a predictive role for response to anthracycline-based chemotherapy"
                  },
                  {
                    "text": "NSABP B47 trial randomized node (+) or high-risk node (-) women with HER2 IHC 1 or 2+ with FISH ratio < 2 to Trastuzumab + chemo vs. chemo + placeboTrial showed no significant difference in DFS and no trend for efficacy with adding Trastuzumab for HER2-low expressors",
                    "sub_points": [
                      "Trial showed no significant difference in DFS and no trend for efficacy with adding Trastuzumab for HER2-low expressors"
                    ]
                  }
                ],
                "Proliferation": [
                  {
                    "text": "The proliferative rate of BC is associated with OS and disease-free survival (DFS)"
                  },
                  {
                    "text": "Highly proliferative BCs are associated with better response to chemotherapy"
                  },
                  {
                    "text": "Proliferation can be measured in a variety of waysMitotic count: Included as part of histologic gradeIHC markers, including Ki-67 (MIB-1), cyclin-D, cyclin-E, p27, p21S-phase fraction by flow cytometryGene expression profilingmRNA levels of proliferation-related genes are included in a number of commercially available multigene assays",
                    "sub_points": [
                      "Mitotic count: Included as part of histologic grade",
                      "IHC markers, including Ki-67 (MIB-1), cyclin-D, cyclin-E, p27, p21",
                      "S-phase fraction by flow cytometry",
                      "Gene expression profilingmRNA levels of proliferation-related genes are included in a number of commercially available multigene assays",
                      "mRNA levels of proliferation-related genes are included in a number of commercially available multigene assays"
                    ]
                  },
                  {
                    "text": "Good correlation between different methods~ 50% of BCs have low proliferation by any measure, and ~ 50% have higher rates of proliferation",
                    "sub_points": [
                      "~ 50% of BCs have low proliferation by any measure, and ~ 50% have higher rates of proliferation"
                    ]
                  },
                  {
                    "text": "Proliferative rates are a continuum and are not bimodalCut-off point for low and high rates may be difficult to define",
                    "sub_points": [
                      "Cut-off point for low and high rates may be difficult to define"
                    ]
                  }
                ]
              },
              "Molecular Assays": {
                "Gene Expression Profiling": [
                  {
                    "text": "There are multiple assays that are correlated with prognosis (risk of distant recurrence)Oncotype DX RS (Genomic Health) and MammaPrint (Agendia) are based on mRNA levelsProsigna ROR (Prosigna; NanoString Technologies) and EndoPredict (Myriad Genetics) are based on mRNA levels and anatomic factors",
                    "sub_points": [
                      "Oncotype DX RS (Genomic Health) and MammaPrint (Agendia) are based on mRNA levels",
                      "Prosigna ROR (Prosigna; NanoString Technologies) and EndoPredict (Myriad Genetics) are based on mRNA levels and anatomic factors"
                    ]
                  },
                  {
                    "text": "Most useful for luminal BCsThe majority of luminal HER2 BC, HER2 BC, and TNBC would be classified as high risk",
                    "sub_points": [
                      "The majority of luminal HER2 BC, HER2 BC, and TNBC would be classified as high risk"
                    ]
                  },
                  {
                    "text": "All gene expression profiles include proliferation genes as an important part of the profiles' prognostic powerEmphasizes need for some measure of proliferation in any risk classificationProliferation appears to be strongest prognostic factor for luminal BCs",
                    "sub_points": [
                      "Emphasizes need for some measure of proliferation in any risk classification",
                      "Proliferation appears to be strongest prognostic factor for luminal BCs"
                    ]
                  },
                  {
                    "text": "The greatest clinical value of these assays has been to identify patients who do not benefit from the addition of chemotherapy to endocrine therapyPatients whose BCs are determined to be at low risk for recurrence when treated with endocrine therapy alone are unlikely to benefit from chemotherapyPatients whose BCs are determined to be at high risk for recurrence when treated with endocrine therapy alone fall into 3 groupsHigh genomic risk and high clinical risk (based on tumor size and nodal status); this group is most likely to benefit from chemotherapyHigh genomic risk and low clinical risk; this group may not benefit from chemotherapy, as local treatment may be curativeLow genomic risk and high clinical risk; this group may not benefit from chemotherapy, as BC may not be responsive to chemotherapy",
                    "sub_points": [
                      "Patients whose BCs are determined to be at low risk for recurrence when treated with endocrine therapy alone are unlikely to benefit from chemotherapy",
                      "Patients whose BCs are determined to be at high risk for recurrence when treated with endocrine therapy alone fall into 3 groupsHigh genomic risk and high clinical risk (based on tumor size and nodal status); this group is most likely to benefit from chemotherapyHigh genomic risk and low clinical risk; this group may not benefit from chemotherapy, as local treatment may be curativeLow genomic risk and high clinical risk; this group may not benefit from chemotherapy, as BC may not be responsive to chemotherapy",
                      "High genomic risk and high clinical risk (based on tumor size and nodal status); this group is most likely to benefit from chemotherapy",
                      "High genomic risk and low clinical risk; this group may not benefit from chemotherapy, as local treatment may be curative",
                      "Low genomic risk and high clinical risk; this group may not benefit from chemotherapy, as BC may not be responsive to chemotherapy"
                    ]
                  },
                  {
                    "text": "Assays that combine genomic risk with anatomic factors make it difficult to determine source of risk"
                  },
                  {
                    "text": "Considering genomic risk and clinical risk separately provides more information to help guide patient management"
                  },
                  {
                    "text": "A future goal is to develop gene expression signatures that will predict response to specific therapeutic agents"
                  }
                ]
              },
              "Other Methods of Combining Factors": {
                "Calculated Risk Scores": [
                  {
                    "text": "Use combinations of anatomic factors and biologic factors to create a weighted scoreNottingham Prognostic Index (NPI) Plus: Tumor size, nodal ratio, stage, T, N, M, ER, PR, HER2, HER1, HER3, HER4, cytokeratin 5/6, cytokeratin 7/8, p53, MUC1IHC4 score: Includes ER, PR, HER2, and Ki-67Magee equations: Use different combinations of grade, ER (H-score), PR (H-score), HER2, tumor size (cm), and Ki-67 indexFlanagan Prognostic Index: Uses nuclear grade, mitotic count, ER (H-score), PR (H-score), HER2Breast Cancer Prognostic score (BCPS): Uses ER, PR, HER2, T, N, and MTang Prognostic Index: Uses T, mitotic rate, PR, HER2, luminal A ER(+) HER2(-), and luminal B ER(+) HER2(+)Orucevic Nomogram: Uses grade, PR, histologic type, LVI, and patient ageEden Prognostic Index: Uses grade, tumor size, LVI, lymphocytic infiltrate, ER, PR, and patient age",
                    "sub_points": [
                      "Nottingham Prognostic Index (NPI) Plus: Tumor size, nodal ratio, stage, T, N, M, ER, PR, HER2, HER1, HER3, HER4, cytokeratin 5/6, cytokeratin 7/8, p53, MUC1",
                      "IHC4 score: Includes ER, PR, HER2, and Ki-67",
                      "Magee equations: Use different combinations of grade, ER (H-score), PR (H-score), HER2, tumor size (cm), and Ki-67 index",
                      "Flanagan Prognostic Index: Uses nuclear grade, mitotic count, ER (H-score), PR (H-score), HER2",
                      "Breast Cancer Prognostic score (BCPS): Uses ER, PR, HER2, T, N, and M",
                      "Tang Prognostic Index: Uses T, mitotic rate, PR, HER2, luminal A ER(+) HER2(-), and luminal B ER(+) HER2(+)",
                      "Orucevic Nomogram: Uses grade, PR, histologic type, LVI, and patient age",
                      "Eden Prognostic Index: Uses grade, tumor size, LVI, lymphocytic infiltrate, ER, PR, and patient age"
                    ]
                  }
                ]
              },
              "Calculated Risk Scores": {
                "Overview": [
                  {
                    "text": "There have been multiple attempts to reproduce risk scores obtained by gene expression profiling by using multiple pathologic variables weighted according to importance"
                  },
                  {
                    "text": "These scores are most commonly compared to Oncotype DX RSIn general, calculated scores are concordant with actual RS in ~ 2/3 of casesCancers with low calculated scores are unlikely to have high RSCancers with high calculated scores are unlikely to have low RSCancers with intermediate scores could have high or low RS",
                    "sub_points": [
                      "In general, calculated scores are concordant with actual RS in ~ 2/3 of casesCancers with low calculated scores are unlikely to have high RSCancers with high calculated scores are unlikely to have low RSCancers with intermediate scores could have high or low RS",
                      "Cancers with low calculated scores are unlikely to have high RS",
                      "Cancers with high calculated scores are unlikely to have low RS",
                      "Cancers with intermediate scores could have high or low RS"
                    ]
                  },
                  {
                    "text": "Calculated scores that include tumor size or lymph node status may be better at prognosis but not as useful for prediction of benefit from chemotherapy"
                  }
                ],
                "IHC4 Score (Cuzick)": [
                  {
                    "text": "Includes ER, PR, HER2, and Ki-67Combining IHC4 score with clinical/pathologic variables (pN, pT, grade, age) improves prognostic accuracy",
                    "sub_points": [
                      "Combining IHC4 score with clinical/pathologic variables (pN, pT, grade, age) improves prognostic accuracy"
                    ]
                  }
                ],
                "Magee Equations": [
                  {
                    "text": "Equations use different combinations of grade, ER (H-score), PR (H-score), HER2, tumor size (cm), and Ki-67 index"
                  },
                  {
                    "text": "Calculated score is concordant with actual RS in ~ 2/3 of cancers (R²=0.62 to 0.59)"
                  },
                  {
                    "text": "If predicted RS and actual RS are different, it is unknown which one is more predictive of outcome"
                  },
                  {
                    "text": "These equations may be of value in identifying cancers highly likely to have low RSCancers with ER H-score ≥ 200, PR H-score ≥ 150, and mitotic score 1 are likely to have RS < 25",
                    "sub_points": [
                      "Cancers with ER H-score ≥ 200, PR H-score ≥ 150, and mitotic score 1 are likely to have RS < 25"
                    ]
                  }
                ],
                "Flanagan Prognostic Index": [
                  {
                    "text": "Uses nuclear grade, mitotic count, ER (H-score), PR (H-score), HER2"
                  },
                  {
                    "text": "RS=13.424 + 5.420 (nuclear grade) + 5.538 (mitotic count) - 0.045 (ER H-score) - 0.030 (PR H-score) + 9.486 (HER2)"
                  },
                  {
                    "text": "Predicts Oncotype DX RS with R²=0.66"
                  }
                ],
                "Geradts Prognostic Index [Breast Cancer Prognostic Score(BCPS)]": [
                  {
                    "text": "Includes ER (Allred score), PR (Allred score), HER2, and 3 components of tumor grade"
                  },
                  {
                    "text": "BCPS = 40.0 - 5.3 (ER Allred score) - 2.7 (PR Allred score) + 13.0 (HER2 score) + 2.3 (tubule score) + 2.4 (nuclear score) + 6.5 (mitotic score)"
                  },
                  {
                    "text": "HER2 score (for either IHC or FISH): 1 = negative; 2 = equivocal; 3 = overexpressed"
                  },
                  {
                    "text": "Correlates with Oncotype DX RS (R² = 0.42)56% of cases had the same low-/intermediate-/or high-risk classification",
                    "sub_points": [
                      "56% of cases had the same low-/intermediate-/or high-risk classification"
                    ]
                  }
                ],
                "Tang Prognostic Index": [
                  {
                    "text": "Uses T, mitotic rate, PR (Allred score), HER2, luminal A [ER(+)/HER2(-)], and luminal B [ER(+)/HER2(+)]"
                  },
                  {
                    "text": "Correlates with Oncotype DX RS"
                  }
                ],
                "Orucevic Nomogram": [
                  {
                    "text": "Uses grade, PR, tumor size, histologic type, LVI, and patient age"
                  },
                  {
                    "text": "Developed with SEER data to predict low and high Oncotype DX RS"
                  }
                ],
                "Eden Prognostic Index": [
                  {
                    "text": "Includes grade, tumor size, patient age, angioinvasion, ER (percentage of cells), PR (percentage of cells), and lymphocytic infiltrate"
                  },
                  {
                    "text": "Index was developed using a group of node (-) patients; therefore, node status could not be included"
                  },
                  {
                    "text": "F = 1 (grade) + 0.51 (size in cm) -0.14 (age in years) + 1.2 (angioinvasion status) - 0.011 (ER) - 0.00026 (PR) - 0.34 (lymphocytic infiltrate) + 3.0"
                  },
                  {
                    "text": "F > 0 identifies node (-) patients with a poor prognosis"
                  },
                  {
                    "text": "Index is not predictive for ER(-) cancers"
                  },
                  {
                    "text": "Provides similar results to MammaPrint"
                  }
                ]
              },
              "Nottingham Prognostic Index (NPI)": {
                "Overview": [
                  {
                    "text": "Includes lymph node status, tumor size, and gradeNPI = 0.2 x tumor size (cm) + lymph node status + grade (1, 2, or 3)Lymph node status: 1 = node (-); 2 = 1-3 (+) nodes; 3 = 4 or more (+) nodes",
                    "sub_points": [
                      "NPI = 0.2 x tumor size (cm) + lymph node status + grade (1, 2, or 3)",
                      "Lymph node status: 1 = node (-); 2 = 1-3 (+) nodes; 3 = 4 or more (+) nodes"
                    ]
                  },
                  {
                    "text": "5 prognostic groups can be identified using scores with different 5-, 10-, and 15-year survivalsExcellent (scores < 2.41): 97%, 91%, 84%Good (2.41-3.41): 93%, 82%, 74%Moderate I (3.41-4.4): 85%, 73%, 63%Moderate II (4.41-5.4): 75%, 55%, 46%Poor (> 5.4): 42%, 26%, 18%",
                    "sub_points": [
                      "Excellent (scores < 2.41): 97%, 91%, 84%",
                      "Good (2.41-3.41): 93%, 82%, 74%",
                      "Moderate I (3.41-4.4): 85%, 73%, 63%",
                      "Moderate II (4.41-5.4): 75%, 55%, 46%",
                      "Poor (> 5.4): 42%, 26%, 18%"
                    ]
                  },
                  {
                    "text": "Has been validated as prognostically significant across multiple studies"
                  }
                ],
                "Nottingham Prognostic Index Plus": [
                  {
                    "text": "Includes tumor size, tubule score, nuclear score, mitosis score, nodal ratio (number of positive nodes/total number of nodes), stage, and 10 immunoperoxidase markersER, PR, HER2, cytokeratin 5/6, cytokeratin 7/8 (CAM5.2), EGFR (HER1), c-erbB3 (HER3), c-erbB4 (HER4), p53, mucin 1 (MUC1)Levels of immunoreactivity were evaluated by H-score (values from 0 to 300)",
                    "sub_points": [
                      "ER, PR, HER2, cytokeratin 5/6, cytokeratin 7/8 (CAM5.2), EGFR (HER1), c-erbB3 (HER3), c-erbB4 (HER4), p53, mucin 1 (MUC1)",
                      "Levels of immunoreactivity were evaluated by H-score (values from 0 to 300)"
                    ]
                  },
                  {
                    "text": "7 biologic classes of breast cancer are identified based on IHC panelLuminal A: ER(+), PR(+), CK7/8(+), HER3(+), HER4(+)Luminal B: ER(+), PR(-), CK7/8(+), HER3(+), HER4(+)Luminal N: ER(+), PR(+), CK7/8(+), HER3(-), HER4(-)HER2(+)/ER(+): ER(+), HER2(+)HER2(+)/ER(-): ER(-), HER2(+)Basal p53 altered: ER(-), CK5/6(+), p53(+)Basal p53 normal: ER(-), CK5/6(+), p53(-)",
                    "sub_points": [
                      "Luminal A: ER(+), PR(+), CK7/8(+), HER3(+), HER4(+)",
                      "Luminal B: ER(+), PR(-), CK7/8(+), HER3(+), HER4(+)",
                      "Luminal N: ER(+), PR(+), CK7/8(+), HER3(-), HER4(-)",
                      "HER2(+)/ER(+): ER(+), HER2(+)",
                      "HER2(+)/ER(-): ER(-), HER2(+)",
                      "Basal p53 altered: ER(-), CK5/6(+), p53(+)",
                      "Basal p53 normal: ER(-), CK5/6(+), p53(-)"
                    ]
                  },
                  {
                    "text": "Each biologic class has specific formula for determining NPI+"
                  }
                ]
              },
              "Clinical Calculators": {
                "Adjuvant! Online": [
                  {
                    "text": "Web-based prognostic tool is available at www.adjuvantonline.comIncludes patient age, menopausal status, comorbidities, tumor size (cm), grade, number of positive nodes, ER (positive or negative)Based on SEER data and randomized trial overviews",
                    "sub_points": [
                      "Includes patient age, menopausal status, comorbidities, tumor size (cm), grade, number of positive nodes, ER (positive or negative)",
                      "Based on SEER data and randomized trial overviews"
                    ]
                  },
                  {
                    "text": "Predicts 10-year breast cancer survival and efficacy of adjuvant therapy"
                  },
                  {
                    "text": "Should not be used for tubular carcinoma, papillary carcinoma, medullary carcinoma, or inflammatory carcinoma"
                  },
                  {
                    "text": "Underestimates survival in women younger than age 40 and overestimates survival for women with LVI"
                  }
                ],
                "PREDICT-Plus": [
                  {
                    "text": "Web-based prognostic tool is available at www.predict.nhs.uk/predict.htmlPredicts survival based on patient age, tumor size, grade, number of positive nodes, ER (positive or negative), HER2, mode of detection, type of treatment (chemotherapy or endocrine therapy)Based on population-based registry",
                    "sub_points": [
                      "Predicts survival based on patient age, tumor size, grade, number of positive nodes, ER (positive or negative), HER2, mode of detection, type of treatment (chemotherapy or endocrine therapy)",
                      "Based on population-based registry"
                    ]
                  }
                ]
              },
              "Bio-Score": {
                "Overview": [
                  {
                    "text": "Bio-Score is system that combines AJCC anatomic stage with biologic factors"
                  },
                  {
                    "text": "Each factor is assigned from 0 to 4 pointsAnatomic stage: I = 0, IIA = 1, IIB = 2, IIIA = 3, IIIC = 4There were insufficient cases of stage IIIB to be analyzedNuclear grade: I or II = 0, III = 1ER: Positive = 0, negative = 1HER2: Positive = 0, negative = 1",
                    "sub_points": [
                      "Anatomic stage: I = 0, IIA = 1, IIB = 2, IIIA = 3, IIIC = 4There were insufficient cases of stage IIIB to be analyzed",
                      "There were insufficient cases of stage IIIB to be analyzed",
                      "Nuclear grade: I or II = 0, III = 1",
                      "ER: Positive = 0, negative = 1",
                      "HER2: Positive = 0, negative = 1"
                    ]
                  },
                  {
                    "text": "Scores range from 0 to 7"
                  },
                  {
                    "text": "Survival diminishes with increased scoreEach score is combination of different anatomic stages and biologic type of cancer",
                    "sub_points": [
                      "Each score is combination of different anatomic stages and biologic type of cancer"
                    ]
                  }
                ]
              },
              "Neoadjuvant Therapy": {
                "Systems to Evaluate Cancer Response": [
                  {
                    "text": "In addition to all prognostic factors in absence of presurgical therapy, response to therapy is also prognostic factorHas greatest prognostic impact for ER(-) and HER2(+) cancersMany systems for evaluating response to therapy have been developed",
                    "sub_points": [
                      "Has greatest prognostic impact for ER(-) and HER2(+) cancers",
                      "Many systems for evaluating response to therapy have been developed"
                    ]
                  },
                  {
                    "text": "AJCC stage before and after treatment has prognostic importanceNeo-Bioscoreincludes pretreatment stage, posttreatment stage, ER, HER2, and grade, which are combined in point system (0 to 7 points)Increasing score is associated with decreased survival",
                    "sub_points": [
                      "Neo-Bioscoreincludes pretreatment stage, posttreatment stage, ER, HER2, and grade, which are combined in point system (0 to 7 points)Increasing score is associated with decreased survival",
                      "Increasing score is associated with decreased survival"
                    ]
                  },
                  {
                    "text": "Residual cancer burden (RCB)quantifies amount of invasive carcinoma in breast and lymph nodes after treatmentWeb-based calculator is available at www.mdanderson.org/breastcancer_RCBSurvival is diminished with increasing RCB classThis method was recommended by international working group",
                    "sub_points": [
                      "Web-based calculator is available at www.mdanderson.org/breastcancer_RCB",
                      "Survival is diminished with increasing RCB class",
                      "This method was recommended by international working group"
                    ]
                  },
                  {
                    "text": "Preoperative Endocrine Prognostic Index (PEPI)score is used to evaluate response to endocrine therapyEvaluates Ki-67, ER (Allred score), tumor size, and nodal status after endocrine therapyPredictive of relapse-free survival",
                    "sub_points": [
                      "Evaluates Ki-67, ER (Allred score), tumor size, and nodal status after endocrine therapy",
                      "Predictive of relapse-free survival"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Size and Multiple Foci": {
            "name": "Size and Multiple Foci",
            "url": "https://app.pathprimer.com/document/b63a3b52-db91-4d3e-96f2-ff42af9c9edd/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "Multiple Invasive Cancers": {
                "Overview": [
                  {
                    "text": "10-25% of patients have > 1 focus of invasive breast carcinoma (IBC) in the same breast at time of diagnosisIncidence increases with more extensive imaging work-up (including MR) &/or detailed pathologic evaluationMR finds additional foci of cancer in 10-30% of patients",
                    "sub_points": [
                      "Incidence increases with more extensive imaging work-up (including MR) &/or detailed pathologic evaluationMR finds additional foci of cancer in 10-30% of patients",
                      "MR finds additional foci of cancer in 10-30% of patients"
                    ]
                  },
                  {
                    "text": "Patients with multiple IBCs are more likely to have a family history of IBC (± a germline mutation), have lobular carcinomas, and present with bilateral IBCs"
                  },
                  {
                    "text": "The terms multifocal and multicentric have been used to describe cases of multiple carcinomas but have been defined in different waysDo not always specify whether carcinoma in situ is included as a \"carcinoma\"Some definitions only include grossly identified IBCs, whereas others also include IBCs only seen microscopically",
                    "sub_points": [
                      "Do not always specify whether carcinoma in situ is included as a \"carcinoma\"",
                      "Some definitions only include grossly identified IBCs, whereas others also include IBCs only seen microscopically"
                    ]
                  },
                  {
                    "text": "Multifocal is generally defined as > 1 focus of IBC within 1 quadrantMay refer to IBCs in close proximityHas also been used for any case with ≥ 2 foci",
                    "sub_points": [
                      "May refer to IBCs in close proximity",
                      "Has also been used for any case with ≥ 2 foci"
                    ]
                  },
                  {
                    "text": "Multicentric has multiple definitions≥ 2 foci in different quadrants of breast≥ 2 foci a certain distance apart, which can be from 2-5 cmFoci involving different ductal systems≥ 2 biologically independent IBCs",
                    "sub_points": [
                      "≥ 2 foci in different quadrants of breast",
                      "≥ 2 foci a certain distance apart, which can be from 2-5 cm",
                      "Foci involving different ductal systems",
                      "≥ 2 biologically independent IBCs"
                    ]
                  },
                  {
                    "text": "Multicentric and multifocal are not useful terms unless specifically definedDifficult to apply to most pathology specimensDo not address underlying biology responsible for multiple foci of invasion",
                    "sub_points": [
                      "Difficult to apply to most pathology specimens",
                      "Do not address underlying biology responsible for multiple foci of invasion"
                    ]
                  },
                  {
                    "text": "Multiple IBCs are associated with a greater incidence of lymphovascular invasion (LVI) and lymph node metastasesEach IBC has an independent risk of metastasis; thus, overall risk is increasedIf multiple IBCs have different tumor markers, metastases may also vary with regard to tumor markersMultiple foci of IBC do not diminish survival as compared to a single IBC, if adjusted for the number of lymph node metastases",
                    "sub_points": [
                      "Each IBC has an independent risk of metastasis; thus, overall risk is increased",
                      "If multiple IBCs have different tumor markers, metastases may also vary with regard to tumor markers",
                      "Multiple foci of IBC do not diminish survival as compared to a single IBC, if adjusted for the number of lymph node metastases"
                    ]
                  }
                ],
                "Etiology": [
                  {
                    "text": "There are 3 etiologies for multiple IBCs"
                  },
                  {
                    "text": "(1) Invasive carcinomas associated with extensive ductal carcinoma in situ (DCIS)Most common setting in which multiple IBCs ariseResponsible for at least 2/3 of casesIBCs are usually very similar to each other with respect to grade, histologic type, and tumor markersEach IBC is typically associated with DCISIn unusual cases, marked heterogeneity in underlying DCIS can lead to heterogeneity in associated IBCsHER2(+) IBCs are more commonly associated with extensive DCIS with multiple foci of invasionHormone receptor and HER2(-) (triple negative) IBCs are rarely associated with extensive DCIS and are less likely to occur as multiple foci",
                    "sub_points": [
                      "Most common setting in which multiple IBCs ariseResponsible for at least 2/3 of cases",
                      "Responsible for at least 2/3 of cases",
                      "IBCs are usually very similar to each other with respect to grade, histologic type, and tumor markers",
                      "Each IBC is typically associated with DCIS",
                      "In unusual cases, marked heterogeneity in underlying DCIS can lead to heterogeneity in associated IBCs",
                      "HER2(+) IBCs are more commonly associated with extensive DCIS with multiple foci of invasionHormone receptor and HER2(-) (triple negative) IBCs are rarely associated with extensive DCIS and are less likely to occur as multiple foci",
                      "Hormone receptor and HER2(-) (triple negative) IBCs are rarely associated with extensive DCIS and are less likely to occur as multiple foci"
                    ]
                  },
                  {
                    "text": "(2) Invasive carcinoma with extensive lymphovascular invasion (LVI) and intramammary metastasesThese cases usually consist of a single large IBC associated with multiple smaller IBCs arising from LVIIBCs arise from the same malignant clone of cells and are usually identical in grade, histologic type, and tumor markersIn these cases, the smaller IBCs are not associated with DCIS",
                    "sub_points": [
                      "These cases usually consist of a single large IBC associated with multiple smaller IBCs arising from LVI",
                      "IBCs arise from the same malignant clone of cells and are usually identical in grade, histologic type, and tumor markers",
                      "In these cases, the smaller IBCs are not associated with DCIS"
                    ]
                  },
                  {
                    "text": "(3) Biologically separate invasive carcinomasRare occurrenceIBCs are usually widely separated and not associated with the same area of DCISIBCs may differ in grade, histologic type, and tumor markersPatients with germline mutations may have multiple synchronous IBCsIBCs may be similar, as they share the same germline mutationMore common withBRCA2mutations (~ 37%) compared toBRCA1mutations (~ 15%)Cancers associated withBRCA2are usually ER(+) and more likely to be associated with DCIS",
                    "sub_points": [
                      "Rare occurrence",
                      "IBCs are usually widely separated and not associated with the same area of DCIS",
                      "IBCs may differ in grade, histologic type, and tumor markers",
                      "Patients with germline mutations may have multiple synchronous IBCsIBCs may be similar, as they share the same germline mutationMore common withBRCA2mutations (~ 37%) compared toBRCA1mutations (~ 15%)Cancers associated withBRCA2are usually ER(+) and more likely to be associated with DCIS",
                      "IBCs may be similar, as they share the same germline mutation",
                      "More common withBRCA2mutations (~ 37%) compared toBRCA1mutations (~ 15%)Cancers associated withBRCA2are usually ER(+) and more likely to be associated with DCIS",
                      "Cancers associated withBRCA2are usually ER(+) and more likely to be associated with DCIS"
                    ]
                  },
                  {
                    "text": "There are 3 reasons for a unifocal invasive carcinoma appearing to be multiple foci"
                  },
                  {
                    "text": "(1) Invasive carcinoma with adjacentsatellite fociMost commonly seen with invasive lobular carcinomasUsually detected as a large central carcinoma surrounded by multiple smaller satellite carcinomas within few a mmLikely due to infiltration of the carcinoma along fibrovascular septa, resulting in a false impression of separate carcinomas in 2 dimensions",
                    "sub_points": [
                      "Most commonly seen with invasive lobular carcinomas",
                      "Usually detected as a large central carcinoma surrounded by multiple smaller satellite carcinomas within few a mm",
                      "Likely due to infiltration of the carcinoma along fibrovascular septa, resulting in a false impression of separate carcinomas in 2 dimensions"
                    ]
                  },
                  {
                    "text": "(2) Invasive carcinoma after neoadjuvant chemotherapy (NAT)After a marked response, residual IBC is often present as multiple foci scattered over a fibrotic tumor bedExtent of invasive IBC can be difficult to quantify by sizeSize of largest contiguous focus is used for AJCC T classificationCellularity of carcinoma averaged over the tumor bed is used for the residual cancer burden (RCB) system",
                    "sub_points": [
                      "After a marked response, residual IBC is often present as multiple foci scattered over a fibrotic tumor bed",
                      "Extent of invasive IBC can be difficult to quantify by size",
                      "Size of largest contiguous focus is used for AJCC T classification",
                      "Cellularity of carcinoma averaged over the tumor bed is used for the residual cancer burden (RCB) system"
                    ]
                  },
                  {
                    "text": "(3) Transection of an invasive carcinoma and removal in multiple specimensSmall or difficult to palpate IBCs may be transected during surgeryIBCs in 2 different specimens may be misinterpreted as 2 different IBCsThe presence of both IBCs extensively at margins is an important clueAdding sizes of a transected IBC in 2 specimens may overestimate actual sizeCorrelation with imaging studies may be helpful to determine most likely actual sizeMinimal and maximal tumor sizes can be estimated based on 2 sections of cancer",
                    "sub_points": [
                      "Small or difficult to palpate IBCs may be transected during surgery",
                      "IBCs in 2 different specimens may be misinterpreted as 2 different IBCsThe presence of both IBCs extensively at margins is an important clue",
                      "The presence of both IBCs extensively at margins is an important clue",
                      "Adding sizes of a transected IBC in 2 specimens may overestimate actual sizeCorrelation with imaging studies may be helpful to determine most likely actual sizeMinimal and maximal tumor sizes can be estimated based on 2 sections of cancer",
                      "Correlation with imaging studies may be helpful to determine most likely actual size",
                      "Minimal and maximal tumor sizes can be estimated based on 2 sections of cancer"
                    ]
                  }
                ],
                "Selection of Carcinoma for Ancillary Testing": [
                  {
                    "text": "The largest IBC should always undergo testing for ER, PR, and HER2"
                  },
                  {
                    "text": "Smaller foci can also be considered for testing in some settingsComparable in size to largest IBCDifferent histologic typeDifferent histologic grade",
                    "sub_points": [
                      "Comparable in size to largest IBC",
                      "Different histologic type",
                      "Different histologic grade"
                    ]
                  },
                  {
                    "text": "If an IBC is sent for multigene testing, the IBC most likely to have the highest score should be chosenHigher gradeLow or absent hormone receptor expressionHER2(+) cancers are not usually sent for testing, as patients are usually treated with chemotherapy",
                    "sub_points": [
                      "Higher grade",
                      "Low or absent hormone receptor expression",
                      "HER2(+) cancers are not usually sent for testing, as patients are usually treated with chemotherapy"
                    ]
                  },
                  {
                    "text": "IBCs with a core needle biopsy site should be avoided, as this can lead to a higher score due to intermingling of tumor with inflammatory and reactive stromal cells"
                  }
                ]
              },
              "Size of Invasive Cancer": {
                "Prognosis": [
                  {
                    "text": "Size is an important independent prognostic factor for both node (-) and node (+) patientsSize is defined as the greatest linear dimension of IBCAdjacent carcinoma in situ is not included",
                    "sub_points": [
                      "Size is defined as the greatest linear dimension of IBC",
                      "Adjacent carcinoma in situ is not included"
                    ]
                  },
                  {
                    "text": "IBCs grow at very different ratesSome IBCs grow very slowly or appear stable in size for many yearsTypically well-differentiated ER(+) IBCsOther IBCs grow rapidlyMost common in young womenIn older women, may be detected as interval IBCs defined as IBCs detected by palpation in time between mammographic screeningsTypically poorly differentiated ER(-) IBCs",
                    "sub_points": [
                      "Some IBCs grow very slowly or appear stable in size for many yearsTypically well-differentiated ER(+) IBCs",
                      "Typically well-differentiated ER(+) IBCs",
                      "Other IBCs grow rapidlyMost common in young womenIn older women, may be detected as interval IBCs defined as IBCs detected by palpation in time between mammographic screeningsTypically poorly differentiated ER(-) IBCs",
                      "Most common in young women",
                      "In older women, may be detected as interval IBCs defined as IBCs detected by palpation in time between mammographic screenings",
                      "Typically poorly differentiated ER(-) IBCs"
                    ]
                  },
                  {
                    "text": "IBCs ≤ 1 cm in size and node (-) are an important groupPatients have an excellent prognosis and may not require systemic therapyMajority of patients with IBCs > 1 cm will be offered systemic therapyDetermining the best size for AJCC T classification often requires correlation of size on imaging, size in core needle biopsy, as well as gross and microscopic examination of the excisional specimen",
                    "sub_points": [
                      "Patients have an excellent prognosis and may not require systemic therapyMajority of patients with IBCs > 1 cm will be offered systemic therapy",
                      "Majority of patients with IBCs > 1 cm will be offered systemic therapy",
                      "Determining the best size for AJCC T classification often requires correlation of size on imaging, size in core needle biopsy, as well as gross and microscopic examination of the excisional specimen"
                    ]
                  },
                  {
                    "text": "Lymph node metastases are closely correlated with sizeLikelihood of nodal metastases increases rapidly from IBC size 0-4 cm and then levels off at ~ 70-90% for IBCs > 5 cmSome very large IBCs do not metastasize to axillary lymph nodesMay metastasize using blood vessels or via lymphatics to internal mammary nodesMay be of a biologic type that rarely metastasizes to lymph nodes (e.g., spindle cell carcinoma)May lack metastatic potential",
                    "sub_points": [
                      "Likelihood of nodal metastases increases rapidly from IBC size 0-4 cm and then levels off at ~ 70-90% for IBCs > 5 cm",
                      "Some very large IBCs do not metastasize to axillary lymph nodesMay metastasize using blood vessels or via lymphatics to internal mammary nodesMay be of a biologic type that rarely metastasizes to lymph nodes (e.g., spindle cell carcinoma)May lack metastatic potential",
                      "May metastasize using blood vessels or via lymphatics to internal mammary nodes",
                      "May be of a biologic type that rarely metastasizes to lymph nodes (e.g., spindle cell carcinoma)",
                      "May lack metastatic potential"
                    ]
                  }
                ],
                "Detection": [
                  {
                    "text": "Typical size of IBCs detected by palpation is 2-3 cmScreening by patient breast self-examination does not decrease number of breast cancer deathsSuggests that by the time an IBC is palpable, IBCs capable of metastasizing will have already done so",
                    "sub_points": [
                      "Screening by patient breast self-examination does not decrease number of breast cancer deaths",
                      "Suggests that by the time an IBC is palpable, IBCs capable of metastasizing will have already done so"
                    ]
                  },
                  {
                    "text": "Nonpalpable IBCs detected by screening are much smaller in sizeAverage size of IBCs associated with mammographic density is ~ 1 cmAverage size of IBCs detected as mammographic calcifications (without evident mass) is 0.6 cmMore often well differentiated, tubular type, and ER(+)Screen-detected IBCs have a better prognosis than palpable IBCs of same size",
                    "sub_points": [
                      "Average size of IBCs associated with mammographic density is ~ 1 cm",
                      "Average size of IBCs detected as mammographic calcifications (without evident mass) is 0.6 cm",
                      "More often well differentiated, tubular type, and ER(+)",
                      "Screen-detected IBCs have a better prognosis than palpable IBCs of same size"
                    ]
                  }
                ]
              },
              "Methods of Evaluation": {
                "Breast Imaging: Number of Foci": [
                  {
                    "text": "Imaging is an effective method of identifying multiple separate masses correlating with multiple IBCs"
                  },
                  {
                    "text": "Size and distance between IBCs can sometimes be determined best by imaging"
                  }
                ],
                "Breast Imaging: Size": [
                  {
                    "text": "Imaging can be very helpful in determining size of IBCs in some situationsSmall IBCs that have previously undergone needle biopsy can be difficult to evaluateOverestimates can occur if biopsy sites are includedUnderestimates can occur if a substantial portion of IBC has been removed",
                    "sub_points": [
                      "Small IBCs that have previously undergone needle biopsy can be difficult to evaluateOverestimates can occur if biopsy sites are includedUnderestimates can occur if a substantial portion of IBC has been removed",
                      "Overestimates can occur if biopsy sites are included",
                      "Underestimates can occur if a substantial portion of IBC has been removed"
                    ]
                  },
                  {
                    "text": "Size prior to core needle biopsy may be more accurate than residual size in excisional specimen"
                  },
                  {
                    "text": "Ultrasound, in general, provides measurement closest to size by gross examination"
                  },
                  {
                    "text": "MR may overestimate size by including adjacent DCIS or benign enhancing tissue"
                  }
                ],
                "Gross Examination: Number of Foci": [
                  {
                    "text": "Helpful to determine number and spatial relationship of masses by imaging prior to processing specimen"
                  },
                  {
                    "text": "Size of each gross mass and its relationship to (distance from) other masses, as well as from margins, should be recorded"
                  },
                  {
                    "text": "Tissue between separate masses should be submitted to evaluate whether or not they represent portions of a single large IBC"
                  }
                ],
                "Gross Examination: Size": [
                  {
                    "text": "Majority of IBCs are associated with a desmoplastic response and are hard to palpationMost IBCs are white or tan and blend in with normal fibrous breast stromaVisual appearances can be misleading and result in overestimating sizeSize by palpation is more accurateMost IBCs have a distinct edge or shelf at the junction with adjacent breast stromaEdges of IBC can be pinched between 2 fingers to determine extent of invasive component",
                    "sub_points": [
                      "Most IBCs are white or tan and blend in with normal fibrous breast stromaVisual appearances can be misleading and result in overestimating size",
                      "Visual appearances can be misleading and result in overestimating size",
                      "Size by palpation is more accurateMost IBCs have a distinct edge or shelf at the junction with adjacent breast stromaEdges of IBC can be pinched between 2 fingers to determine extent of invasive component",
                      "Most IBCs have a distinct edge or shelf at the junction with adjacent breast stroma",
                      "Edges of IBC can be pinched between 2 fingers to determine extent of invasive component"
                    ]
                  },
                  {
                    "text": "Minority of IBCs diffusely invade in fibroadipose tissue, and it may be difficult to determine extent grosslySubmitting cassettes in organized fashion (e.g., 1 every cm) allows microscopic mapping of the extent of the IBC",
                    "sub_points": [
                      "Submitting cassettes in organized fashion (e.g., 1 every cm) allows microscopic mapping of the extent of the IBC"
                    ]
                  }
                ],
                "Microscopic Examination: Number of Foci": [
                  {
                    "text": "Microscopic examination of tissue between 2 grossly apparent IBCs is useful to determine if 1 or 2 separate IBCs are present"
                  },
                  {
                    "text": "Foci of invasion identified microscopically can only be identified as separate areas of invasion if tissue is designated as being away from grossly apparent IBCs"
                  }
                ],
                "Microscopic Examination: Size": [
                  {
                    "text": "Gross size should always be confirmed microscopicallySome IBCs, particularly lobular carcinomas, have a diffusely invasive pattern and may be larger than apparent on gross examinationSome patients have dense stroma, and borders of IBC may be difficult to determinePrior core needle biopsy sites can result in stromal fibrosis and inflammation that can make tumor size difficult to measureSize can only be determined by measuring from a glass slide when the IBC is small (generally < 1 cm)",
                    "sub_points": [
                      "Some IBCs, particularly lobular carcinomas, have a diffusely invasive pattern and may be larger than apparent on gross examination",
                      "Some patients have dense stroma, and borders of IBC may be difficult to determine",
                      "Prior core needle biopsy sites can result in stromal fibrosis and inflammation that can make tumor size difficult to measure",
                      "Size can only be determined by measuring from a glass slide when the IBC is small (generally < 1 cm)"
                    ]
                  }
                ]
              },
              "Difficult Specimens": {
                "Core Needle Biopsy Followed by Excision": [
                  {
                    "text": "Size of IBC on core needle biopsy gives lower limit of size of carcinomaIn the majority of cases, size of IBC in excision will be largerHowever, if size in excision is smaller, size on core should be used for T classificationSize on core can be helpful to evaluate reliability of negative results on core for ER, PR, or HER2If size on core is very small compared to entire IBC, repeat studies on excision may be helpful",
                    "sub_points": [
                      "In the majority of cases, size of IBC in excision will be larger",
                      "However, if size in excision is smaller, size on core should be used for T classification",
                      "Size on core can be helpful to evaluate reliability of negative results on core for ER, PR, or HER2If size on core is very small compared to entire IBC, repeat studies on excision may be helpful",
                      "If size on core is very small compared to entire IBC, repeat studies on excision may be helpful"
                    ]
                  },
                  {
                    "text": "Size of IBC in core should not be added to size in excisionIdeally, core site will pierce center of IBC and size can be determined grossly &/or microscopicallyIf residual IBC is only present at 1 side of a biopsy cavity, pre-core needle biopsy size will be difficult to determineIn some cases, pre-core needle biopsy size by imaging may be best determination of size",
                    "sub_points": [
                      "Ideally, core site will pierce center of IBC and size can be determined grossly &/or microscopically",
                      "If residual IBC is only present at 1 side of a biopsy cavity, pre-core needle biopsy size will be difficult to determine",
                      "In some cases, pre-core needle biopsy size by imaging may be best determination of size"
                    ]
                  }
                ],
                "Diffusely Invasive Carcinomas": [
                  {
                    "text": "Some IBCs have a diffusely invasive pattern and either do not form a palpable mass or form an ill-defined massA subset of invasive lobular carcinomas can have the appearance of innumerable small invasive foci throughout a specimenIBCs associated with a clinical presentation of inflammatory carcinoma are often difficult to define grossly",
                    "sub_points": [
                      "A subset of invasive lobular carcinomas can have the appearance of innumerable small invasive foci throughout a specimen",
                      "IBCs associated with a clinical presentation of inflammatory carcinoma are often difficult to define grossly"
                    ]
                  },
                  {
                    "text": "Size may not be easily determined by imaging or gross examination"
                  },
                  {
                    "text": "Estimates of size may be provided when an exact size is not possibleNumber of blocks with IBCNumber of fociMinimal size estimate based on size of largest contiguous focusSize based on involvement of opposing margins",
                    "sub_points": [
                      "Number of blocks with IBC",
                      "Number of fociMinimal size estimate based on size of largest contiguous focus",
                      "Minimal size estimate based on size of largest contiguous focus",
                      "Size based on involvement of opposing margins"
                    ]
                  }
                ]
              },
              "Reporting Criteria": {
                "Multiple Cancers": [
                  {
                    "text": "Report the presence, number, and size of multiple IBCsModifier \"m\" is used to signify that multiple foci of IBC are present and evident by either imaging or gross evaluationIn the absence of NAT, \"m\" is not used if additional small foci are only seen microscopicallyAfter NAT, \"m\" can be used to signify multiple foci of IBC in a tumor bed",
                    "sub_points": [
                      "Modifier \"m\" is used to signify that multiple foci of IBC are present and evident by either imaging or gross evaluation",
                      "In the absence of NAT, \"m\" is not used if additional small foci are only seen microscopically",
                      "After NAT, \"m\" can be used to signify multiple foci of IBC in a tumor bed"
                    ]
                  },
                  {
                    "text": "Grade and histologic type should be reported for each focus if different"
                  },
                  {
                    "text": "Distance between foci should be reported"
                  },
                  {
                    "text": "Report findings that could be etiology of multiple cancersExtensive carcinoma in situ, LVI, satellite foci, or biologically separate IBC",
                    "sub_points": [
                      "Extensive carcinoma in situ, LVI, satellite foci, or biologically separate IBC"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "Size for AJCC T classification is largest focus of IBCSizes of multiple IBCs should not be added together",
                    "sub_points": [
                      "Sizes of multiple IBCs should not be added together"
                    ]
                  },
                  {
                    "text": "When it is not possible to provide specific size, a note explaining the reason for uncertainty is helpfulEstimate of smallest &/or largest possible size is often helpful",
                    "sub_points": [
                      "Estimate of smallest &/or largest possible size is often helpful"
                    ]
                  },
                  {
                    "text": "Correlation with imaging may be suggested if studies are not available to pathologist"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "AJCC Breast Cancer Staging": {
            "name": "AJCC Breast Cancer Staging",
            "url": "https://app.pathprimer.com/document/f8c0c7e1-3c54-4696-b287-617aef220edb/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "American Joint Committee on Cancer (AJCC) staging is the standard method to classify patients into groups according to prognosis"
                  }
                ]
              },
              "Anatomic Stage": {
                "Overview": [
                  {
                    "text": "Identifying groups of cancer patients with similar prognosis is useful for multiple purposesIndividual patient care, clinical trials, epidemiologic studies, and research",
                    "sub_points": [
                      "Individual patient care, clinical trials, epidemiologic studies, and research"
                    ]
                  },
                  {
                    "text": "The results of these studies can then be applied to similar patients"
                  },
                  {
                    "text": "Pierre Denoix, MD of L'Institut Gustave Roussy developed theTumorNodesMetastasis (TNM) systemAdopted by the Union for International Cancer Control (UICC) in 1958 (1st edition of staging manual)Adopted by the AJCC in 1977 (1st edition of staging manual)",
                    "sub_points": [
                      "Adopted by the Union for International Cancer Control (UICC) in 1958 (1st edition of staging manual)",
                      "Adopted by the AJCC in 1977 (1st edition of staging manual)"
                    ]
                  },
                  {
                    "text": "Although there were refinements, the breast cancer staging system stayed substantially the same for 60 years"
                  },
                  {
                    "text": "In the 1st-7th editions, staging was based on anatomic factors"
                  },
                  {
                    "text": "In the AJCC 8th edition, biologic factors were addedGrade, ER, PR, and HER2Multigene prognostic assay result (for some carcinomas)The UICC did not adopt the AJCC system of adding biologic factors",
                    "sub_points": [
                      "Grade, ER, PR, and HER2",
                      "Multigene prognostic assay result (for some carcinomas)",
                      "The UICC did not adopt the AJCC system of adding biologic factors"
                    ]
                  }
                ],
                "Advantages of Anatomic Stages": [
                  {
                    "text": "Determined by readily available standard techniques that can be applied in varying settings"
                  },
                  {
                    "text": "Can be compared across time and in diverse locations"
                  },
                  {
                    "text": "Can be applied to all carcinomas when not all ancillary special studies are available"
                  },
                  {
                    "text": "Reproducible, facilitating comparison across different sites"
                  }
                ],
                "Anatomic Stages": [
                  {
                    "text": "Patients are divided into 5 stages with different survival rates at 10 yearsStage 0: > 95% survival at 10 yearsDuctal carcinoma in situ (DCIS)Excellent survival maintained out to 20 years (~ 97%)< 5% of breast carcinomas in nonscreened populations20-30% of breast carcinomas in screened populationsStage I: > 90% survival at 10 yearsInvasive carcinoma < 2 cm with negative lymph nodes or only micrometastases~ 50% of invasive carcinomasIncidence has increased with screeningStage IA: Node (-) or isolated tumor cellsStage IB: MicrometastasesFirst created for 7th editionRecognized that prognosis for women with small metastases is similar to node (-) womenStage II: ~ 60% survival at 10 yearsInvasive carcinoma > 2 cm with negative lymph nodesInvasive carcinoma < 5 cm with 1-3 positive lymph nodes~ 30% of invasive carcinomasIncidence has decreased with screeningStage III: Locally advanced disease: ~ 40% survival at 10 yearsInvasive carcinoma > 5 cm with 1-3 positive lymph nodesAny size carcinoma with > 4 positive lymph nodesT4 carcinoma (skin or chest wall invasion or inflammatory carcinoma)Only 5-10% of patientsIncidence has decreased due to greater awareness and earlier detectionStage IV: < 10% survival at 10 yearsDistant metastasis at the time of diagnosisOnly 5-10% of patientsIncidence has not changed substantially over timeLikely a subset of carcinomas that metastasize early, prior to possible detection by screening",
                    "sub_points": [
                      "Stage 0: > 95% survival at 10 yearsDuctal carcinoma in situ (DCIS)Excellent survival maintained out to 20 years (~ 97%)< 5% of breast carcinomas in nonscreened populations20-30% of breast carcinomas in screened populations",
                      "Ductal carcinoma in situ (DCIS)",
                      "Excellent survival maintained out to 20 years (~ 97%)",
                      "< 5% of breast carcinomas in nonscreened populations",
                      "20-30% of breast carcinomas in screened populations",
                      "Stage I: > 90% survival at 10 yearsInvasive carcinoma < 2 cm with negative lymph nodes or only micrometastases~ 50% of invasive carcinomasIncidence has increased with screeningStage IA: Node (-) or isolated tumor cellsStage IB: MicrometastasesFirst created for 7th editionRecognized that prognosis for women with small metastases is similar to node (-) women",
                      "Invasive carcinoma < 2 cm with negative lymph nodes or only micrometastases",
                      "~ 50% of invasive carcinomas",
                      "Incidence has increased with screening",
                      "Stage IA: Node (-) or isolated tumor cells",
                      "Stage IB: MicrometastasesFirst created for 7th editionRecognized that prognosis for women with small metastases is similar to node (-) women",
                      "First created for 7th edition",
                      "Recognized that prognosis for women with small metastases is similar to node (-) women",
                      "Stage II: ~ 60% survival at 10 yearsInvasive carcinoma > 2 cm with negative lymph nodesInvasive carcinoma < 5 cm with 1-3 positive lymph nodes~ 30% of invasive carcinomasIncidence has decreased with screening",
                      "Invasive carcinoma > 2 cm with negative lymph nodes",
                      "Invasive carcinoma < 5 cm with 1-3 positive lymph nodes",
                      "~ 30% of invasive carcinomas",
                      "Incidence has decreased with screening",
                      "Stage III: Locally advanced disease: ~ 40% survival at 10 yearsInvasive carcinoma > 5 cm with 1-3 positive lymph nodesAny size carcinoma with > 4 positive lymph nodesT4 carcinoma (skin or chest wall invasion or inflammatory carcinoma)Only 5-10% of patientsIncidence has decreased due to greater awareness and earlier detection",
                      "Invasive carcinoma > 5 cm with 1-3 positive lymph nodes",
                      "Any size carcinoma with > 4 positive lymph nodes",
                      "T4 carcinoma (skin or chest wall invasion or inflammatory carcinoma)",
                      "Only 5-10% of patients",
                      "Incidence has decreased due to greater awareness and earlier detection",
                      "Stage IV: < 10% survival at 10 yearsDistant metastasis at the time of diagnosisOnly 5-10% of patientsIncidence has not changed substantially over timeLikely a subset of carcinomas that metastasize early, prior to possible detection by screening",
                      "Distant metastasis at the time of diagnosis",
                      "Only 5-10% of patients",
                      "Incidence has not changed substantially over time",
                      "Likely a subset of carcinomas that metastasize early, prior to possible detection by screening"
                    ]
                  }
                ],
                "T: Staging Issues": [
                  {
                    "text": "DCISDCIS is classified as TisTis (Paget) is used for rare cases in which tumor cells are only present in the epidermisTis (DCIS) is used when ducts and lobules in the breast are involvedIn the AJCC 8th edition, lobular carcinoma in situ (LCIS) is no longer included in this categoryThe reason given is that LCIS is not treated similar to carcinoma (e.g., surgery or radiation) but rather with increased surveillance and possible chemoprevention with endocrine agentsHowever, clinical trials are underway to determine if some women with DCIS can also forgo surgery and radiationcTis is used when the diagnosis is based on a core needle biopsy or an incisional biopsypTis is used after complete excisionIf no residual DCIS is present (i.e., the DCIS was completely removed by the core needle biopsy), the designation of the core needle biopsy as cTis is changed to pTis",
                    "sub_points": [
                      "DCIS is classified as TisTis (Paget) is used for rare cases in which tumor cells are only present in the epidermisTis (DCIS) is used when ducts and lobules in the breast are involved",
                      "Tis (Paget) is used for rare cases in which tumor cells are only present in the epidermis",
                      "Tis (DCIS) is used when ducts and lobules in the breast are involved",
                      "In the AJCC 8th edition, lobular carcinoma in situ (LCIS) is no longer included in this categoryThe reason given is that LCIS is not treated similar to carcinoma (e.g., surgery or radiation) but rather with increased surveillance and possible chemoprevention with endocrine agentsHowever, clinical trials are underway to determine if some women with DCIS can also forgo surgery and radiation",
                      "The reason given is that LCIS is not treated similar to carcinoma (e.g., surgery or radiation) but rather with increased surveillance and possible chemoprevention with endocrine agents",
                      "However, clinical trials are underway to determine if some women with DCIS can also forgo surgery and radiation",
                      "cTis is used when the diagnosis is based on a core needle biopsy or an incisional biopsy",
                      "pTis is used after complete excisionIf no residual DCIS is present (i.e., the DCIS was completely removed by the core needle biopsy), the designation of the core needle biopsy as cTis is changed to pTis",
                      "If no residual DCIS is present (i.e., the DCIS was completely removed by the core needle biopsy), the designation of the core needle biopsy as cTis is changed to pTis"
                    ]
                  },
                  {
                    "text": "Size of invasive carcinomaThe size of an invasive carcinoma is used for the T classification of most breast carcinomasDoes not include associated carcinoma in situClinical, radiologic, gross, and microscopic information should be used to determine best size for T classificationIt is helpful to include the largest contiguous size when reporting core needle biopsies, as the size in the excision may be smallerHowever, the size in the core needle biopsy cannot be added to the size in the excisionSize can be difficult to determine if the carcinoma has been removed in multiple specimensThe size in multiple specimens cannot be simply added together, as this can result in a size larger than the true sizeThe best T classification often requires correlation of clinical, radiologic, gross, and microscopic information",
                    "sub_points": [
                      "The size of an invasive carcinoma is used for the T classification of most breast carcinomasDoes not include associated carcinoma in situClinical, radiologic, gross, and microscopic information should be used to determine best size for T classification",
                      "Does not include associated carcinoma in situ",
                      "Clinical, radiologic, gross, and microscopic information should be used to determine best size for T classification",
                      "It is helpful to include the largest contiguous size when reporting core needle biopsies, as the size in the excision may be smallerHowever, the size in the core needle biopsy cannot be added to the size in the excision",
                      "However, the size in the core needle biopsy cannot be added to the size in the excision",
                      "Size can be difficult to determine if the carcinoma has been removed in multiple specimensThe size in multiple specimens cannot be simply added together, as this can result in a size larger than the true size",
                      "The size in multiple specimens cannot be simply added together, as this can result in a size larger than the true size",
                      "The best T classification often requires correlation of clinical, radiologic, gross, and microscopic information"
                    ]
                  },
                  {
                    "text": "Multiple invasive carcinomasThe T category is based on the largest carcinomaThe \"m\" modifier is used when multiple carcinomas are evident clinically, by imaging, or grosslyIf the patient has not received neoadjuvant therapy, \"m\" is not used for multiple foci only evident on microscopic evaluation",
                    "sub_points": [
                      "The T category is based on the largest carcinoma",
                      "The \"m\" modifier is used when multiple carcinomas are evident clinically, by imaging, or grossly",
                      "If the patient has not received neoadjuvant therapy, \"m\" is not used for multiple foci only evident on microscopic evaluation"
                    ]
                  },
                  {
                    "text": "T4 categoryOriginally defined as carcinomas not amenable to surgery due to rapid local recurrenceCurrent prognosis is improved with better surgical and adjuvant treatmentMany of these patients are now surgical candidatesNeoadjuvant treatment is useful to identify subsets of patients whose disease is responsive to treatment",
                    "sub_points": [
                      "Originally defined as carcinomas not amenable to surgery due to rapid local recurrenceCurrent prognosis is improved with better surgical and adjuvant treatmentMany of these patients are now surgical candidatesNeoadjuvant treatment is useful to identify subsets of patients whose disease is responsive to treatment",
                      "Current prognosis is improved with better surgical and adjuvant treatment",
                      "Many of these patients are now surgical candidates",
                      "Neoadjuvant treatment is useful to identify subsets of patients whose disease is responsive to treatment"
                    ]
                  },
                  {
                    "text": "T4a: Extension to chest wallInvasion must be into intercostal (serratus) muscles ± bone invasionThese carcinomas cannot be completely resected without removing ribsDoes not include adherence to or invasion of pectoralis muscles",
                    "sub_points": [
                      "Invasion must be into intercostal (serratus) muscles ± bone invasionThese carcinomas cannot be completely resected without removing ribs",
                      "These carcinomas cannot be completely resected without removing ribs",
                      "Does not include adherence to or invasion of pectoralis muscles"
                    ]
                  },
                  {
                    "text": "T4b: Skin involvementUlceration of skinMust be due to direct invasion by the carcinomaThese are usually very large, bulky, locally advanced carcinomasDoes not include ulceration due to a prior procedure or DCIS involving nipple epidermis (Paget disease)Small, superficial carcinomas with ulceration are unlikely to have the same poor prognosis associated with large ulcerating carcinomasCarcinomas that invade into the skin but do not cause ulceration are assigned a T category based on sizeSkin invasion increases the likelihood of lymph node metastasisSatellite skin nodulesThe invasive carcinoma in the dermis must be separate from the main carcinomaThese are usually intramammary metastases due to dermal lymphovascular invasionThe skin nodule should be evident clinically, radiologically, or grosslyIf the dermal invasive carcinoma is only found on microscopic evaluation, the carcinoma should not be classified as T4bEdemaPeau d'orange (skin of orange) appearance is due to tethering of skin by Cooper ligaments causing pitting of skin swollen by edemaThis includes skin edema with insufficient clinical finding for classification as inflammatory carcinomaThis finding cannot be determined in surgical excisions and is rarely used for staging",
                    "sub_points": [
                      "Ulceration of skinMust be due to direct invasion by the carcinomaThese are usually very large, bulky, locally advanced carcinomasDoes not include ulceration due to a prior procedure or DCIS involving nipple epidermis (Paget disease)Small, superficial carcinomas with ulceration are unlikely to have the same poor prognosis associated with large ulcerating carcinomasCarcinomas that invade into the skin but do not cause ulceration are assigned a T category based on sizeSkin invasion increases the likelihood of lymph node metastasis",
                      "Must be due to direct invasion by the carcinomaThese are usually very large, bulky, locally advanced carcinomas",
                      "These are usually very large, bulky, locally advanced carcinomas",
                      "Does not include ulceration due to a prior procedure or DCIS involving nipple epidermis (Paget disease)",
                      "Small, superficial carcinomas with ulceration are unlikely to have the same poor prognosis associated with large ulcerating carcinomas",
                      "Carcinomas that invade into the skin but do not cause ulceration are assigned a T category based on sizeSkin invasion increases the likelihood of lymph node metastasis",
                      "Skin invasion increases the likelihood of lymph node metastasis",
                      "Satellite skin nodulesThe invasive carcinoma in the dermis must be separate from the main carcinomaThese are usually intramammary metastases due to dermal lymphovascular invasionThe skin nodule should be evident clinically, radiologically, or grosslyIf the dermal invasive carcinoma is only found on microscopic evaluation, the carcinoma should not be classified as T4b",
                      "The invasive carcinoma in the dermis must be separate from the main carcinomaThese are usually intramammary metastases due to dermal lymphovascular invasion",
                      "These are usually intramammary metastases due to dermal lymphovascular invasion",
                      "The skin nodule should be evident clinically, radiologically, or grosslyIf the dermal invasive carcinoma is only found on microscopic evaluation, the carcinoma should not be classified as T4b",
                      "If the dermal invasive carcinoma is only found on microscopic evaluation, the carcinoma should not be classified as T4b",
                      "EdemaPeau d'orange (skin of orange) appearance is due to tethering of skin by Cooper ligaments causing pitting of skin swollen by edemaThis includes skin edema with insufficient clinical finding for classification as inflammatory carcinomaThis finding cannot be determined in surgical excisions and is rarely used for staging",
                      "Peau d'orange (skin of orange) appearance is due to tethering of skin by Cooper ligaments causing pitting of skin swollen by edema",
                      "This includes skin edema with insufficient clinical finding for classification as inflammatory carcinoma",
                      "This finding cannot be determined in surgical excisions and is rarely used for staging"
                    ]
                  },
                  {
                    "text": "T4d: Inflammatory carcinomaDefined by clinical signs of diffuse erythema and edema (peau d'orange) involving 1/3 or more of the skin of breastThis is the only component of anatomic staging based on clinical findingsCorrelates with carcinomas with extensive dermal lymphovascular invasionThe carcinoma blocks lymphatics causing the swelling and erythemaNo actual inflammation is presentIf true inflammation is present, it is unlikely that the carcinoma is truly \"inflammatory\"A secondary infection or other inflammatory process may be presentDermal lymphovascular invasion in the absence of clinical signs is not diagnostic of inflammatory carcinomaHowever, this is a poor prognostic finding",
                    "sub_points": [
                      "Defined by clinical signs of diffuse erythema and edema (peau d'orange) involving 1/3 or more of the skin of breastThis is the only component of anatomic staging based on clinical findings",
                      "This is the only component of anatomic staging based on clinical findings",
                      "Correlates with carcinomas with extensive dermal lymphovascular invasionThe carcinoma blocks lymphatics causing the swelling and erythemaNo actual inflammation is presentIf true inflammation is present, it is unlikely that the carcinoma is truly \"inflammatory\"A secondary infection or other inflammatory process may be present",
                      "The carcinoma blocks lymphatics causing the swelling and erythema",
                      "No actual inflammation is presentIf true inflammation is present, it is unlikely that the carcinoma is truly \"inflammatory\"A secondary infection or other inflammatory process may be present",
                      "If true inflammation is present, it is unlikely that the carcinoma is truly \"inflammatory\"",
                      "A secondary infection or other inflammatory process may be present",
                      "Dermal lymphovascular invasion in the absence of clinical signs is not diagnostic of inflammatory carcinomaHowever, this is a poor prognostic finding",
                      "However, this is a poor prognostic finding"
                    ]
                  },
                  {
                    "text": "T categories after neoadjuvant therapyThe same general rules applyThe largest contiguous focus of invasive carcinoma in a tumor bed, measured from histologic sections, is used for the T categoryThis can be difficult to determine when there are scattered tumor cells in between areas of denser clusters of tumor cellsAlso providing the size of the tumor bed and the overall cellularity is useful to communicate the amount of tumor presentCellularity can be compared with the prior core needle biopsyThis is used for the determination of the residual cancer burden (RCB) scoreThe \"m\" category is applied for multiple foci of invasive carcinoma over a tumor bed if evident grossly or microscopicallyIn rare cases in which only lymphovascular invasion is present, there is no AJCC T categoryHowever, this finding precludes classification as a pathologic complete response",
                    "sub_points": [
                      "The same general rules apply",
                      "The largest contiguous focus of invasive carcinoma in a tumor bed, measured from histologic sections, is used for the T categoryThis can be difficult to determine when there are scattered tumor cells in between areas of denser clusters of tumor cellsAlso providing the size of the tumor bed and the overall cellularity is useful to communicate the amount of tumor presentCellularity can be compared with the prior core needle biopsyThis is used for the determination of the residual cancer burden (RCB) score",
                      "This can be difficult to determine when there are scattered tumor cells in between areas of denser clusters of tumor cells",
                      "Also providing the size of the tumor bed and the overall cellularity is useful to communicate the amount of tumor presentCellularity can be compared with the prior core needle biopsyThis is used for the determination of the residual cancer burden (RCB) score",
                      "Cellularity can be compared with the prior core needle biopsy",
                      "This is used for the determination of the residual cancer burden (RCB) score",
                      "The \"m\" category is applied for multiple foci of invasive carcinoma over a tumor bed if evident grossly or microscopically",
                      "In rare cases in which only lymphovascular invasion is present, there is no AJCC T categoryHowever, this finding precludes classification as a pathologic complete response",
                      "However, this finding precludes classification as a pathologic complete response"
                    ]
                  }
                ],
                "N: Staging Issues": [
                  {
                    "text": "NumberPrognosis diminishes with each additional lymph node metastasisN0: Negative nodes, ~ 83% 5-year survivalN1a: 1-3 positive nodes, ~ 73% 5-year survivalN2a: 4-9 positive nodes, ~ 46% 5-year survivalN3a: 10 or more positive nodes, ~ 28% 5-year survivalThe total number of positive nodes includes macrometastases and micrometastases but not isolated tumor cellsSeparate nodules of invasive carcinoma without residual nodal architecture are classified as an additional lymph node metastasis",
                    "sub_points": [
                      "Prognosis diminishes with each additional lymph node metastasisN0: Negative nodes, ~ 83% 5-year survivalN1a: 1-3 positive nodes, ~ 73% 5-year survivalN2a: 4-9 positive nodes, ~ 46% 5-year survivalN3a: 10 or more positive nodes, ~ 28% 5-year survival",
                      "N0: Negative nodes, ~ 83% 5-year survival",
                      "N1a: 1-3 positive nodes, ~ 73% 5-year survival",
                      "N2a: 4-9 positive nodes, ~ 46% 5-year survival",
                      "N3a: 10 or more positive nodes, ~ 28% 5-year survival",
                      "The total number of positive nodes includes macrometastases and micrometastases but not isolated tumor cells",
                      "Separate nodules of invasive carcinoma without residual nodal architecture are classified as an additional lymph node metastasis"
                    ]
                  },
                  {
                    "text": "Size of metastasesIsolated tumor cells (< 0.2 cm or < 200 cells) are classified as N0 (i+)These are often seen when IHC studies for keratin are routinely performedThere is no requirement to perform keratin studiesMicrometastases are ≤ 2 mm and have very little impact on prognosisPatients with only micrometastases are stage I because their prognosis is similar to patients with negative nodesMacrometastases measure > 2 mm and have prognostic significanceIf extranodal extension is present, it is included in the size of the lymph node metastasisTumor in lymphatics is not considered extranodal extensionIf a lymph node metastasis is associated with desmoplasia, the entire area of the carcinoma with the desmoplasia is measured",
                    "sub_points": [
                      "Isolated tumor cells (< 0.2 cm or < 200 cells) are classified as N0 (i+)These are often seen when IHC studies for keratin are routinely performedThere is no requirement to perform keratin studies",
                      "These are often seen when IHC studies for keratin are routinely performed",
                      "There is no requirement to perform keratin studies",
                      "Micrometastases are ≤ 2 mm and have very little impact on prognosisPatients with only micrometastases are stage I because their prognosis is similar to patients with negative nodes",
                      "Patients with only micrometastases are stage I because their prognosis is similar to patients with negative nodes",
                      "Macrometastases measure > 2 mm and have prognostic significance",
                      "If extranodal extension is present, it is included in the size of the lymph node metastasisTumor in lymphatics is not considered extranodal extension",
                      "Tumor in lymphatics is not considered extranodal extension",
                      "If a lymph node metastasis is associated with desmoplasia, the entire area of the carcinoma with the desmoplasia is measured"
                    ]
                  },
                  {
                    "text": "N categories after neoadjuvant therapyThe same general rules applyThe largest contiguous focus in a tumor bed is used for the sizeThe size does not include the fibrosis of the tumor bedNodes with fibrosis consistent with treated tumor are reported but are not used for stagingIsolated tumor cells are classified as N0 (i+) but preclude classification as a pathologic complete response",
                    "sub_points": [
                      "The same general rules apply",
                      "The largest contiguous focus in a tumor bed is used for the sizeThe size does not include the fibrosis of the tumor bed",
                      "The size does not include the fibrosis of the tumor bed",
                      "Nodes with fibrosis consistent with treated tumor are reported but are not used for staging",
                      "Isolated tumor cells are classified as N0 (i+) but preclude classification as a pathologic complete response"
                    ]
                  }
                ],
                "Metastasis: Staging Issues": [
                  {
                    "text": "M0 can only be assigned by a clinician based on clinical examination, laboratory tests, &/or by imaging"
                  },
                  {
                    "text": "M1 can be assigned by a pathologist if a biopsy of a metastatic site is performed"
                  },
                  {
                    "text": "MX was eliminated in the AJCC 7th edition and should not be usedTumor registrars use pT instead of cT and pN instead of cN, when availableHowever, they should use cM0 or cM1 instead of pMX, when availableThus, using MX can lead to confusion and the inability to stage carcinomas",
                    "sub_points": [
                      "Tumor registrars use pT instead of cT and pN instead of cN, when availableHowever, they should use cM0 or cM1 instead of pMX, when availableThus, using MX can lead to confusion and the inability to stage carcinomas",
                      "However, they should use cM0 or cM1 instead of pMX, when available",
                      "Thus, using MX can lead to confusion and the inability to stage carcinomas"
                    ]
                  }
                ],
                "Disadvantages of Anatomic Stages": [
                  {
                    "text": "The biologic type of breast carcinomas is also very important for prognosis"
                  },
                  {
                    "text": "Within each stage, survival varies according to biologic type at 5 yearsStage I: 93% to > 99%Stage II: 80-97%Stage III: 50-89%Stage IV: 20-55%",
                    "sub_points": [
                      "Stage I: 93% to > 99%",
                      "Stage II: 80-97%",
                      "Stage III: 50-89%",
                      "Stage IV: 20-55%"
                    ]
                  },
                  {
                    "text": "In the AJCC 8th edition, biologic type was combined with anatomic stage for the first time"
                  }
                ]
              },
              "AJCC 8th Edition (2019)": {
                "Biologic Types of Carcinomas": [
                  {
                    "text": "The biologic factors of grade, ER expression, PR expression, and HER2 positivity are included"
                  },
                  {
                    "text": "There are 24 possible combinations of these factors9 combinations make up 92% of all carcinomas",
                    "sub_points": [
                      "9 combinations make up 92% of all carcinomas"
                    ]
                  },
                  {
                    "text": "The biologic factors alter stages I, II, and III but not 0 or IV"
                  },
                  {
                    "text": "National Cancer Data Base (NCDB) was used to determine 5-year survival for each of these groups at 5 yearsWomen diagnosed with invasive carcinoma from 2010-2012 were includedSurvival assumes the patient received appropriate treatmentIf the survival at 3 years of a group (defined by grade, ER, PR, and HER2) for an anatomic stage was above or below the 95% confidence interval of the survival for all patients at that anatomic stage, this group was moved to a lower or higher stageIn general, carcinomas of favorable biology [e.g., grade 1 and ER(+)] may be moved to a lower stage and carcinomas of unfavorable biology may be moved to a higher stage [e.g., grade 3 and ER(-)]Each prognostic stage group consists of a mixture of anatomic stages and biologic types of carcinoma predicted to have the same survival at 5 years~ 25-40% of patients are assigned to a different prognostic stage group compared to the anatomic stage~ 70% of ER(-)/PR(-)/HER2(-) (triple negative) carcinomas are moved to a higher stage~ 60% of ER(+)/PR(+) carcinomas are moved to a lower stage",
                    "sub_points": [
                      "Women diagnosed with invasive carcinoma from 2010-2012 were included",
                      "Survival assumes the patient received appropriate treatment",
                      "If the survival at 3 years of a group (defined by grade, ER, PR, and HER2) for an anatomic stage was above or below the 95% confidence interval of the survival for all patients at that anatomic stage, this group was moved to a lower or higher stage",
                      "In general, carcinomas of favorable biology [e.g., grade 1 and ER(+)] may be moved to a lower stage and carcinomas of unfavorable biology may be moved to a higher stage [e.g., grade 3 and ER(-)]",
                      "Each prognostic stage group consists of a mixture of anatomic stages and biologic types of carcinoma predicted to have the same survival at 5 years",
                      "~ 25-40% of patients are assigned to a different prognostic stage group compared to the anatomic stage~ 70% of ER(-)/PR(-)/HER2(-) (triple negative) carcinomas are moved to a higher stage~ 60% of ER(+)/PR(+) carcinomas are moved to a lower stage",
                      "~ 70% of ER(-)/PR(-)/HER2(-) (triple negative) carcinomas are moved to a higher stage",
                      "~ 60% of ER(+)/PR(+) carcinomas are moved to a lower stage"
                    ]
                  }
                ],
                "Pathologic Prognostic Stage (PPS)": [
                  {
                    "text": "This system is only used for patients with carcinomas that have not been treated and for which a pathologic T and N category can be assigned"
                  },
                  {
                    "text": "This group includes > 90% of the patients in the NCDB"
                  },
                  {
                    "text": "A multigene panel result can be included in staging in this groupApplicable to carcinomas that are pT1 or pT2, pN0, cM0, ER(+), and HER2(-)If the Oncotype DX recurrence score is < 11, the PPS is IAOther multigene panels may be incorporated into staging in the futureA multigene assay is not required in order to provide a stage",
                    "sub_points": [
                      "Applicable to carcinomas that are pT1 or pT2, pN0, cM0, ER(+), and HER2(-)",
                      "If the Oncotype DX recurrence score is < 11, the PPS is IA",
                      "Other multigene panels may be incorporated into staging in the future",
                      "A multigene assay is not required in order to provide a stage"
                    ]
                  }
                ],
                "Clinical Prognostic Stage (CPS)": [
                  {
                    "text": "This stage can be assigned to all patients based on combinations of clinical, imaging, &/or pathologic information"
                  },
                  {
                    "text": "The survival for CPS included all of the patients in the NCDB"
                  },
                  {
                    "text": "When compared to PPS, the stage is the same in ~ 2/3 of cases and higher in ~ 1/3 of casesThe additional patients include those with a poorer prognosisPatients who are not surgical candidates due to advanced carcinoma, comorbid conditions, or agePatients who received neoadjuvant therapy who tend to have more advanced carcinomas of less favorable biologic types",
                    "sub_points": [
                      "The additional patients include those with a poorer prognosisPatients who are not surgical candidates due to advanced carcinoma, comorbid conditions, or agePatients who received neoadjuvant therapy who tend to have more advanced carcinomas of less favorable biologic types",
                      "Patients who are not surgical candidates due to advanced carcinoma, comorbid conditions, or age",
                      "Patients who received neoadjuvant therapy who tend to have more advanced carcinomas of less favorable biologic types"
                    ]
                  },
                  {
                    "text": "A multigene panel result cannot be used because the pT and pN may not be known"
                  },
                  {
                    "text": "It is important to note that CPS is different than the previous editions' clinical stageThe clinical stage was the best approximation of anatomic stage based on clinical and imaging findingsCPS is a stage assignment based on the survival of a larger group of patients than PPS",
                    "sub_points": [
                      "The clinical stage was the best approximation of anatomic stage based on clinical and imaging findings",
                      "CPS is a stage assignment based on the survival of a larger group of patients than PPS"
                    ]
                  }
                ],
                "Advantages of the 8th Edition Staging System": [
                  {
                    "text": "Multiple studies have shown that PPS and CPS are better predictors of survival at 5 years"
                  }
                ],
                "Limitations of the 8th Edition PPS and CPS Staging System": [
                  {
                    "text": "Patients can only be staged if all required information is availableThis can limit applicability in some settingsAnatomic stage can be used when PPS and CPS cannot be assigned",
                    "sub_points": [
                      "This can limit applicability in some settings",
                      "Anatomic stage can be used when PPS and CPS cannot be assigned"
                    ]
                  },
                  {
                    "text": "Information about PPS and CPS cannot be compared to prior studies using anatomic stageHowever, because anatomic stage information is collected, this information can be generated",
                    "sub_points": [
                      "However, because anatomic stage information is collected, this information can be generated"
                    ]
                  },
                  {
                    "text": "The survival for different biologic types of carcinoma is greatest at 5 years but changes over timeDeaths due to ER(+) carcinomas are lower than other types in the first 10 years but continue to occur over a long period of time (decades)Deaths due to ER(-) carcinomas usually occur in the first 8 years and are rare after that timeTherefore, the ability of PPS and CPS to predict survival for groups of mixed biologic types of carcinomas may be diminished at longer time periods",
                    "sub_points": [
                      "Deaths due to ER(+) carcinomas are lower than other types in the first 10 years but continue to occur over a long period of time (decades)",
                      "Deaths due to ER(-) carcinomas usually occur in the first 8 years and are rare after that time",
                      "Therefore, the ability of PPS and CPS to predict survival for groups of mixed biologic types of carcinomas may be diminished at longer time periods"
                    ]
                  },
                  {
                    "text": "Biologic factors are not used for stage IV carcinomasSurvival for these patients is also dependent on the biologic type of carcinoma",
                    "sub_points": [
                      "Survival for these patients is also dependent on the biologic type of carcinoma"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lymph Node Metastases": {
            "name": "Lymph Node Metastases",
            "url": "https://app.pathprimer.com/document/4c1ee627-5a05-4a26-b5e1-b2d7382e7559/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "CLINICAL IMPLICATIONS": {
                "Breast Cancer Metastasis to Regional Lymph Nodes": [
                  {
                    "text": "The 1st site of metastasis for the majority of breast cancer patients is to regional lymph nodes (LNs)The majority of women with palpable cancers (60-80%) and ~ 15% of women with mammographically detected cancers present with LN metastasis",
                    "sub_points": [
                      "The majority of women with palpable cancers (60-80%) and ~ 15% of women with mammographically detected cancers present with LN metastasis"
                    ]
                  },
                  {
                    "text": "In the absence of distant metastasis, the number of positive LNs is the most important anatomic prognostic factorDemonstrates not just potential for metastasis but actual metastasis and ability for tumor growth at another site",
                    "sub_points": [
                      "Demonstrates not just potential for metastasis but actual metastasis and ability for tumor growth at another site"
                    ]
                  },
                  {
                    "text": "20-year survival~ 88% of women with small cancers and negative LNs (stage I)The ~ 12% of women who do poorly may have cancers that metastasize via blood vessels or to nodal basins that are not sampledCarcinomas negative for hormone receptors and HER2 (especially spindle cell carcinomas) are less likely to metastasize to LNs~ 74% of women with 1-3 positive LNsTherefore, either distant metastases are not present, or they are controlled by treatment in majority of patients~ 47% of women with > 3 positive LNsThe majority of these women eventually develop distant metastases",
                    "sub_points": [
                      "~ 88% of women with small cancers and negative LNs (stage I)The ~ 12% of women who do poorly may have cancers that metastasize via blood vessels or to nodal basins that are not sampledCarcinomas negative for hormone receptors and HER2 (especially spindle cell carcinomas) are less likely to metastasize to LNs",
                      "The ~ 12% of women who do poorly may have cancers that metastasize via blood vessels or to nodal basins that are not sampled",
                      "Carcinomas negative for hormone receptors and HER2 (especially spindle cell carcinomas) are less likely to metastasize to LNs",
                      "~ 74% of women with 1-3 positive LNsTherefore, either distant metastases are not present, or they are controlled by treatment in majority of patients",
                      "Therefore, either distant metastases are not present, or they are controlled by treatment in majority of patients",
                      "~ 47% of women with > 3 positive LNsThe majority of these women eventually develop distant metastases",
                      "The majority of these women eventually develop distant metastases"
                    ]
                  },
                  {
                    "text": "LN metastases are a harbinger of distant disease but are not the sole site from which distant metastases ariseLNs are biopsied to gain information, but removal of LNs does not improve survivalIf information about metastasis is not needed for treatment decisions, axillary radiation is effective at controlling local disease if limited in extentThere is a low risk of axillary recurrence if nodes are not palpablePatients with bulky axillary disease may benefit from surgical debulking to control local symptoms",
                    "sub_points": [
                      "LNs are biopsied to gain information, but removal of LNs does not improve survival",
                      "If information about metastasis is not needed for treatment decisions, axillary radiation is effective at controlling local disease if limited in extent",
                      "There is a low risk of axillary recurrence if nodes are not palpable",
                      "Patients with bulky axillary disease may benefit from surgical debulking to control local symptoms"
                    ]
                  },
                  {
                    "text": "Axillary LNsThe major outflow of lymphatic fluid from the breast is to 1 or 2 sentinel LNs (SLNs) in the axillaRare breast cancers metastasize via lymphatics draining to other nodal basinsInternal mammary nodes (IMNs), supraclavicular LNs, very rarely contralateral axillary LNsIntramammary LNs may be involved by carcinoma but are rarely, if ever, the SLNsNegative SLNs indicate a low risk of additional axillary LN involvementAccurate determination of axillary LN status is critical for staging, surgical decision making, and prognosis",
                    "sub_points": [
                      "The major outflow of lymphatic fluid from the breast is to 1 or 2 sentinel LNs (SLNs) in the axillaRare breast cancers metastasize via lymphatics draining to other nodal basinsInternal mammary nodes (IMNs), supraclavicular LNs, very rarely contralateral axillary LNsIntramammary LNs may be involved by carcinoma but are rarely, if ever, the SLNsNegative SLNs indicate a low risk of additional axillary LN involvement",
                      "Rare breast cancers metastasize via lymphatics draining to other nodal basinsInternal mammary nodes (IMNs), supraclavicular LNs, very rarely contralateral axillary LNs",
                      "Internal mammary nodes (IMNs), supraclavicular LNs, very rarely contralateral axillary LNs",
                      "Intramammary LNs may be involved by carcinoma but are rarely, if ever, the SLNs",
                      "Negative SLNs indicate a low risk of additional axillary LN involvement",
                      "Accurate determination of axillary LN status is critical for staging, surgical decision making, and prognosis"
                    ]
                  },
                  {
                    "text": "IMNsSome cancers metastasize to IMNsMore common for medially located rather than laterally located cancersMajority of carcinomas that metastasize to IMNs also metastasize to axillary LNsIf radiologic findings are inconclusive as to whether IMNs are involved, fine-needle aspiration (FNA) to establish positivity may be attemptedLower survival if metastases are present in both axillary and IMNsMorbidity from biopsy is high due to locationThese LNs lie below ribs and sternum and are difficult to approach surgicallySometimes removed as part of breast reconstruction when mobilizing the internal mammary artery",
                    "sub_points": [
                      "Some cancers metastasize to IMNsMore common for medially located rather than laterally located cancersMajority of carcinomas that metastasize to IMNs also metastasize to axillary LNsIf radiologic findings are inconclusive as to whether IMNs are involved, fine-needle aspiration (FNA) to establish positivity may be attemptedLower survival if metastases are present in both axillary and IMNsMorbidity from biopsy is high due to locationThese LNs lie below ribs and sternum and are difficult to approach surgicallySometimes removed as part of breast reconstruction when mobilizing the internal mammary artery",
                      "More common for medially located rather than laterally located cancersMajority of carcinomas that metastasize to IMNs also metastasize to axillary LNsIf radiologic findings are inconclusive as to whether IMNs are involved, fine-needle aspiration (FNA) to establish positivity may be attempted",
                      "Majority of carcinomas that metastasize to IMNs also metastasize to axillary LNs",
                      "If radiologic findings are inconclusive as to whether IMNs are involved, fine-needle aspiration (FNA) to establish positivity may be attempted",
                      "Lower survival if metastases are present in both axillary and IMNs",
                      "Morbidity from biopsy is high due to locationThese LNs lie below ribs and sternum and are difficult to approach surgicallySometimes removed as part of breast reconstruction when mobilizing the internal mammary artery",
                      "These LNs lie below ribs and sternum and are difficult to approach surgically",
                      "Sometimes removed as part of breast reconstruction when mobilizing the internal mammary artery"
                    ]
                  },
                  {
                    "text": "Contralateral axillary lymph nodes2nd breast primary must be excludedClassified as M1 (distant metastasis)Carcinomas are usually medially located, involve skin, and are locally advanced",
                    "sub_points": [
                      "2nd breast primary must be excluded",
                      "Classified as M1 (distant metastasis)",
                      "Carcinomas are usually medially located, involve skin, and are locally advanced"
                    ]
                  }
                ],
                "Size of Lymph Node Metastases and Prognostic Significance": [
                  {
                    "text": "Macrometastases (≥ 0.2 cm) are prognostically significant for overall and disease-free survival0.2 cm was originally chosen as size that could be measured with ruler and did not require special measuring devices0.2 cm is also size that can be reliably detected by thinly slicing nodes and examining all slices with 1 H&E section",
                    "sub_points": [
                      "0.2 cm was originally chosen as size that could be measured with ruler and did not require special measuring devices",
                      "0.2 cm is also size that can be reliably detected by thinly slicing nodes and examining all slices with 1 H&E section"
                    ]
                  },
                  {
                    "text": "Smaller metastases [micrometastases and isolated tumor cells (ITCs)] have a very small effect on prognosis in the absence of neoadjuvant therapy (NAT)Survival is diminished by < 3% at 5-10 years as compared with LN(-) womenNo practical technique can detect all small metastases; hundreds of slides per LN would need to be examinedClinical impact is too small to uniformly recommend studies to detect a subset of these metastasesNo currently used clinically feasible protocols detect all ITCs and all micrometastases that may be present in LNsEffect on prognosis is so small that treatment recommendations should be based on their presence with cautionCancers associated with small metastases often have other adverse prognostic factors that would be indications for systemic treatment",
                    "sub_points": [
                      "Survival is diminished by < 3% at 5-10 years as compared with LN(-) women",
                      "No practical technique can detect all small metastases; hundreds of slides per LN would need to be examined",
                      "Clinical impact is too small to uniformly recommend studies to detect a subset of these metastasesNo currently used clinically feasible protocols detect all ITCs and all micrometastases that may be present in LNs",
                      "No currently used clinically feasible protocols detect all ITCs and all micrometastases that may be present in LNs",
                      "Effect on prognosis is so small that treatment recommendations should be based on their presence with caution",
                      "Cancers associated with small metastases often have other adverse prognostic factors that would be indications for systemic treatment"
                    ]
                  },
                  {
                    "text": "Prognosis is diminished with each additional LN macrometastasisDifference in survival between 0 positive nodes and 1 positive node is similar to difference for each additional node; no sharp drop-off in survivalNumber of uninvolved nodes and ratio of positive:negative nodes also have prognostic significanceVery important to always identify as many separate nodes as possibleWhen 1 SLN is involved, the number of additional negative nodes may be used to determine the need for additional node dissection",
                    "sub_points": [
                      "Difference in survival between 0 positive nodes and 1 positive node is similar to difference for each additional node; no sharp drop-off in survival",
                      "Number of uninvolved nodes and ratio of positive:negative nodes also have prognostic significanceVery important to always identify as many separate nodes as possibleWhen 1 SLN is involved, the number of additional negative nodes may be used to determine the need for additional node dissection",
                      "Very important to always identify as many separate nodes as possible",
                      "When 1 SLN is involved, the number of additional negative nodes may be used to determine the need for additional node dissection"
                    ]
                  },
                  {
                    "text": "Extracapsular extension (ECE) is more likely when multiple LNs are involved and, when extensive, correlates with the clinical finding of matted LNsMay be used in decisions on benefit of axillary radiation",
                    "sub_points": [
                      "May be used in decisions on benefit of axillary radiation"
                    ]
                  }
                ],
                "Sentinel Lymph Node Biopsy": [
                  {
                    "text": "Major outflow of lymph from the breast is to 1 or 2 SLNs in axilla"
                  },
                  {
                    "text": "May be identified by blue dye, radioactive tracer (Tc-99m colloid), or both"
                  },
                  {
                    "text": "Majority of SLNs will be both blue and hot (i.e., radioactive)~ 5% of SLNs are blue but not hot; these are likely true SLNs~ 10-40% of nodes are hot but not blueSmaller dye particles reach higher nodes more easily when injected in the same location as radiotracerDifferent location of injection can affect nodes reached",
                    "sub_points": [
                      "~ 5% of SLNs are blue but not hot; these are likely true SLNs",
                      "~ 10-40% of nodes are hot but not blue",
                      "Smaller dye particles reach higher nodes more easily when injected in the same location as radiotracer",
                      "Different location of injection can affect nodes reached"
                    ]
                  },
                  {
                    "text": "Likelihood of non-SLN positivity is very low when the SLN is negative< 1-2% risk of axillary recurrence",
                    "sub_points": [
                      "< 1-2% risk of axillary recurrence"
                    ]
                  },
                  {
                    "text": "Models to predict likelihood of non-SLN positivity when SLN is positive have been developedMajority use number of positive SLNs, size of largest metastasis, presence of extranodal invasion, number of negative SLNs, tumor size, tumor grade",
                    "sub_points": [
                      "Majority use number of positive SLNs, size of largest metastasis, presence of extranodal invasion, number of negative SLNs, tumor size, tumor grade"
                    ]
                  },
                  {
                    "text": "Avoidance of full axillary dissection reduces the frequency of subsequent lymphedema, pain, &/or numbness"
                  }
                ],
                "Lymph Nodes After Neoadjuvant Therapy": [
                  {
                    "text": "Documenting metastatic disease to LNs prior to NAT is necessary to accurately classify patients for trials and to derive information about treatment responsePalpable LNs may be sampled by FNA or core needle biopsyNonpalpable, but enlarged, LNs can be identified by ultrasound and sampled by needle biopsyIf no enlarged LNs are identified, SLN biopsy can be used to document a negative LN; no additional nodal sampling is then necessary after treatment",
                    "sub_points": [
                      "Palpable LNs may be sampled by FNA or core needle biopsy",
                      "Nonpalpable, but enlarged, LNs can be identified by ultrasound and sampled by needle biopsy",
                      "If no enlarged LNs are identified, SLN biopsy can be used to document a negative LN; no additional nodal sampling is then necessary after treatment"
                    ]
                  },
                  {
                    "text": "LN metastases remaining after NAT are an adverse prognostic findingResponse in LN metastases has more prognostic significance than response of cancer in breastIndication of incomplete response to therapySmall, residual metastases are as prognostically important as larger metastasesAlthough ITCs are classified as pN0 (i+), this finding is not considered a pathologic complete response (pCR)Degree of response of metastases to treatment should be reported (e.g., presence and extent of fibrosis)",
                    "sub_points": [
                      "Response in LN metastases has more prognostic significance than response of cancer in breastIndication of incomplete response to therapy",
                      "Indication of incomplete response to therapy",
                      "Small, residual metastases are as prognostically important as larger metastasesAlthough ITCs are classified as pN0 (i+), this finding is not considered a pathologic complete response (pCR)",
                      "Although ITCs are classified as pN0 (i+), this finding is not considered a pathologic complete response (pCR)",
                      "Degree of response of metastases to treatment should be reported (e.g., presence and extent of fibrosis)"
                    ]
                  },
                  {
                    "text": "LNs with fibrous scars but without residual carcinoma should be reported"
                  },
                  {
                    "text": "However, some metastases (~ 25%) resolve completely after NAT without leaving a fibrous scarTherefore, it is not always possible to determine the extent of axillary LN involvement prior to NAT",
                    "sub_points": [
                      "Therefore, it is not always possible to determine the extent of axillary LN involvement prior to NAT"
                    ]
                  },
                  {
                    "text": "The number of LNs likely involved by metastases prior to NAT may be used to make decisions about axillary radiation"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Large metastases efface the surface of the LN and appear as firm, white nodule(s)Gross size of metastases should be notedSampling may be limited to 1 section most likely to show extranodal invasion",
                    "sub_points": [
                      "Gross size of metastases should be noted",
                      "Sampling may be limited to 1 section most likely to show extranodal invasion"
                    ]
                  },
                  {
                    "text": "Metastases < 1 cm may not be grossly evidentGrossly negative LNs should be completely examined microscopically",
                    "sub_points": [
                      "Grossly negative LNs should be completely examined microscopically"
                    ]
                  },
                  {
                    "text": "The number of LNs examined and the number of positive LNs must be determined as accurately as possibleEach LN should be separately identifiedLNs should be inked with different colors if slices from > 1 LN will be placed in the same cassetteSize &/or shape of an LN is not reliable to identify different LNs when submitted together",
                    "sub_points": [
                      "Each LN should be separately identified",
                      "LNs should be inked with different colors if slices from > 1 LN will be placed in the same cassetteSize &/or shape of an LN is not reliable to identify different LNs when submitted together",
                      "Size &/or shape of an LN is not reliable to identify different LNs when submitted together"
                    ]
                  },
                  {
                    "text": "If extensive ECE is present, it may be difficult to determine the number of positive LNs (i.e., the LNs are matted)Attempt must be made to identify as many separate LNs as possible",
                    "sub_points": [
                      "Attempt must be made to identify as many separate LNs as possible"
                    ]
                  },
                  {
                    "text": "LNs may be stained blue due to the dye used to identify the SLN or black due to carbon injected at the time of needle biopsy"
                  },
                  {
                    "text": "LN marked by clip or radioactive seedPrior to NAT, an LN undergoing core needle biopsy may be marked by clip &/or localizer device (e.g., Savi Scout, magseed, radioactive seed)Specimen radiography should be used to find clip &/or localizer device",
                    "sub_points": [
                      "Prior to NAT, an LN undergoing core needle biopsy may be marked by clip &/or localizer device (e.g., Savi Scout, magseed, radioactive seed)",
                      "Specimen radiography should be used to find clip &/or localizer device"
                    ]
                  },
                  {
                    "text": "LN marked by carbon injectionAt some institutions, a carbon solution is injected into an LN and the surrounding tissue at the time of needle biopsyThe LN and surrounding tissue will be stained blackOf note, LNs can also appear black due to uptake of tattoo pigment from dermal tattoos in the area",
                    "sub_points": [
                      "At some institutions, a carbon solution is injected into an LN and the surrounding tissue at the time of needle biopsy",
                      "The LN and surrounding tissue will be stained black",
                      "Of note, LNs can also appear black due to uptake of tattoo pigment from dermal tattoos in the area"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Evaluation of Lymph Nodes for Staging": [
                  {
                    "text": "The main prognostic value of LN staging is to report the number of LNs with macrometastases"
                  },
                  {
                    "text": "Additional micrometastases and ITCs may or may not be detected depending on the methods used to evaluate LNs and by chance"
                  },
                  {
                    "text": "No method currently used will detect all metastases smaller than macrometastases"
                  },
                  {
                    "text": "In general, the largest contiguous focus is used to determine size"
                  },
                  {
                    "text": "However, size can be difficult to determine if there are multiple scattered foci or the metastatic cells have a dispersed single cell patternIn these cases, the pathologist must exercise their judgment as to the best N category based on the overall volume of disease in the LN",
                    "sub_points": [
                      "In these cases, the pathologist must exercise their judgment as to the best N category based on the overall volume of disease in the LN"
                    ]
                  }
                ],
                "Macrometastases": [
                  {
                    "text": "Report size of largest dimension of largest metastatic deposit, > 0.2 cm"
                  },
                  {
                    "text": "If ECE is present, it is included in the total size of the metastasis"
                  },
                  {
                    "text": "If desmoplastic stroma is present between tumor nests, the entire area is considered a contiguous metastatic focus"
                  }
                ],
                "Micrometastases": [
                  {
                    "text": "Defined as > 0.02 cm to ≤ 0.2 cm, or > 200 cellsA specific number of cells was included as a criterion to prevent metastases in a dispersed pattern (e.g., lobular carcinomas) being classified as ITCs even when 100s to 1,000s of cells are presentIf 200 cells are present on 1 slide, it is likely there are > 1,000 cells in the entire LN (approximately the number of cells in the smallest micrometastasis)As a pragmatic decision, 200 cells was chosen as they can be counted in a short period of timeThe majority of cases of ITCs consist of < 200 cells",
                    "sub_points": [
                      "A specific number of cells was included as a criterion to prevent metastases in a dispersed pattern (e.g., lobular carcinomas) being classified as ITCs even when 100s to 1,000s of cells are present",
                      "If 200 cells are present on 1 slide, it is likely there are > 1,000 cells in the entire LN (approximately the number of cells in the smallest micrometastasis)",
                      "As a pragmatic decision, 200 cells was chosen as they can be counted in a short period of time",
                      "The majority of cases of ITCs consist of < 200 cells"
                    ]
                  }
                ],
                "Isolated Tumor Cells": [
                  {
                    "text": "Defined as ≤ 0.02 cm and < 200 cells in 1 slice of the LNCells in multiple slices are not added together",
                    "sub_points": [
                      "Cells in multiple slices are not added together"
                    ]
                  },
                  {
                    "text": "The size of a 0.02-cm focus is ~ 20 cells in a linear array"
                  }
                ],
                "Extracapsular Extension": [
                  {
                    "text": "Different methods of measuring have been suggestedSpan of the carcinoma in perpendicular direction outside LN capsuleWidest dimension of invasive frontBoth are usually similar in size",
                    "sub_points": [
                      "Span of the carcinoma in perpendicular direction outside LN capsule",
                      "Widest dimension of invasive front",
                      "Both are usually similar in size"
                    ]
                  },
                  {
                    "text": "In some cases, it can be difficult to distinguish ECE from involvement of the center of fatty LNDo not report unless it is clear the tumor cells are outside of the LN",
                    "sub_points": [
                      "Do not report unless it is clear the tumor cells are outside of the LN"
                    ]
                  },
                  {
                    "text": "Invasion into adipose tissue at the hilum is considered ECE if outside the LN"
                  },
                  {
                    "text": "Tumor in lymphatics in axillary tissue is not classified as ECE"
                  },
                  {
                    "text": "ECE is predictive of additional LN metastases"
                  }
                ],
                "Lymphovascular Invasion (LVI)": [
                  {
                    "text": "LVI adjacent to positive LNs is common and need not be reported"
                  },
                  {
                    "text": "If only LVI is present in the absence of LN metastases, deeper levels may reveal tumor within LNIf not, presence of axillary LVI should be reported",
                    "sub_points": [
                      "If not, presence of axillary LVI should be reported"
                    ]
                  }
                ],
                "Invasive Carcinoma in Axillary Adipose Tissue": [
                  {
                    "text": "Invasive carcinoma without evidence of nodal tissue in the axilla is counted as an LN metastasis"
                  }
                ],
                "Lobular Carcinoma": [
                  {
                    "text": "Often metastasizes as single cells in dispersed pattern"
                  },
                  {
                    "text": "Can be difficult to classify: Pathologist must use best judgmentIHC studies for keratin may be helpful to demonstrate the number of cells present",
                    "sub_points": [
                      "IHC studies for keratin may be helpful to demonstrate the number of cells present"
                    ]
                  }
                ],
                "Lymph Nodes After Neoadjuvant Therapy": [
                  {
                    "text": "There are 3 types of LNs after NAT: LNs with residual disease, with a fibrous tumor bed, and those normal in appearance"
                  },
                  {
                    "text": "LNs with residual diseaseReport size of metastasis and the presence or absence of treatment responseThe size of the largest contiguous focus of tumor cells (not including tumor bed) is used for American Joint Committee on Cancer (AJCC) N classificationThe largest extent of tumor cells over the tumor bed (including the tumor bed) is used for calculating residual cancer burden (RCB)",
                    "sub_points": [
                      "Report size of metastasis and the presence or absence of treatment response",
                      "The size of the largest contiguous focus of tumor cells (not including tumor bed) is used for American Joint Committee on Cancer (AJCC) N classification",
                      "The largest extent of tumor cells over the tumor bed (including the tumor bed) is used for calculating residual cancer burden (RCB)"
                    ]
                  },
                  {
                    "text": "LNs with tumor bedsLNs with areas of fibrosis (generally > 0.2 cm) were likely involved by carcinoma prior to NATReporting the number of LNs with fibrosis is helpful in judging the extent of axillary involvement prior to NAT and informing decisions about axillary radiation",
                    "sub_points": [
                      "LNs with areas of fibrosis (generally > 0.2 cm) were likely involved by carcinoma prior to NAT",
                      "Reporting the number of LNs with fibrosis is helpful in judging the extent of axillary involvement prior to NAT and informing decisions about axillary radiation"
                    ]
                  },
                  {
                    "text": "LNs normal in appearance~ 25% of metastases completely resolve without evidence of prior tumor involvementThus, the extent of axillary involvement prior to NAT can only be estimated but cannot be known with certainty",
                    "sub_points": [
                      "~ 25% of metastases completely resolve without evidence of prior tumor involvement",
                      "Thus, the extent of axillary involvement prior to NAT can only be estimated but cannot be known with certainty"
                    ]
                  }
                ]
              },
              "Reporting Criteria": {
                "AJCC/UICC N Classification": [
                  {
                    "text": "N classification is based solely on axillary and intramammary LNs in the majority of breast cancersIntramammary nodes are included in total countAt least 1 metastasis must be a macrometastasis for classification as pN1a or higherNodes with ITCs are not included in the total count of positive nodes",
                    "sub_points": [
                      "Intramammary nodes are included in total count",
                      "At least 1 metastasis must be a macrometastasis for classification as pN1a or higher",
                      "Nodes with ITCs are not included in the total count of positive nodes"
                    ]
                  },
                  {
                    "text": "In rare cases in which other nodal groups are involved at presentation, additional N categories applyIMNs, infraclavicular nodes, or level III nodes",
                    "sub_points": [
                      "IMNs, infraclavicular nodes, or level III nodes"
                    ]
                  },
                  {
                    "text": "pN0: No metastases are detected in nodes"
                  },
                  {
                    "text": "pN0(i+): ITCs are presentLargest cohesive cluster measures ≤ 0.02 cmNo more than 200 cells are present on any single complete cross section of nodepN0(i-) is undefined term, as no technique completely eliminates possibility of ITCs",
                    "sub_points": [
                      "Largest cohesive cluster measures ≤ 0.02 cm",
                      "No more than 200 cells are present on any single complete cross section of node",
                      "pN0(i-) is undefined term, as no technique completely eliminates possibility of ITCs"
                    ]
                  },
                  {
                    "text": "pN0(mol+): Molecular test (generally RT-PCR) is positive, but no metastases are seen on H&ESize of metastasis cannot be determined with certaintyMacrometastases can be missed depending on amount of tissue apportioned for assayFalse-positive results occur with RT-PCR in 5% or more of patients",
                    "sub_points": [
                      "Size of metastasis cannot be determined with certainty",
                      "Macrometastases can be missed depending on amount of tissue apportioned for assay",
                      "False-positive results occur with RT-PCR in 5% or more of patients"
                    ]
                  },
                  {
                    "text": "pN1mi: A micrometastasis is presentDefined as > 0.02 cm or > 200 cells but ≤ 0.2 cm",
                    "sub_points": [
                      "Defined as > 0.02 cm or > 200 cells but ≤ 0.2 cm"
                    ]
                  },
                  {
                    "text": "PN1a: Metastases in 1-3 axillary LNs"
                  },
                  {
                    "text": "PN2a: Metastases in 4-10 axillary LNs"
                  },
                  {
                    "text": "PN3a: Metastases in > 10 axillary LNs"
                  },
                  {
                    "text": "(sn) modifierUsed if ≤ 5 SLNs and non-SLNs are removedIntroduced in AJCC 6th edition to indicate cases in which nodal classification was based only on SLNsIn these cases, only 1 or 2 nodes may be examined, and actual nodal classification could be different if all axillary nodes were examinedIn some cases, however, several SLNs are removed such that the number is similar to low axillary dissection",
                    "sub_points": [
                      "Used if ≤ 5 SLNs and non-SLNs are removed",
                      "Introduced in AJCC 6th edition to indicate cases in which nodal classification was based only on SLNs",
                      "In these cases, only 1 or 2 nodes may be examined, and actual nodal classification could be different if all axillary nodes were examinedIn some cases, however, several SLNs are removed such that the number is similar to low axillary dissection",
                      "In some cases, however, several SLNs are removed such that the number is similar to low axillary dissection"
                    ]
                  }
                ]
              },
              "Ancillary Studies": {
                "Immunohistochemistry (IHC)": [
                  {
                    "text": "Additional studies on LNs, including multiple levels &/or IHC, are not required or recommended to be performed routinely on histologically negative LNs by multiple groupsCollege of American Pathologists (CAP), American Joint Committee on Cancer (AJCC), International Collaboration on Cancer Reporting (ICCR), American Association of Directors of Anatomic and Surgical Pathology (ADASP)",
                    "sub_points": [
                      "College of American Pathologists (CAP), American Joint Committee on Cancer (AJCC), International Collaboration on Cancer Reporting (ICCR), American Association of Directors of Anatomic and Surgical Pathology (ADASP)"
                    ]
                  },
                  {
                    "text": "If IHC is performed on nodes negative by H&E, usually only ITCs are detectedSlide used for IHC is also a level, and sometimes metastases are detected due to deeper level rather than IHC",
                    "sub_points": [
                      "Slide used for IHC is also a level, and sometimes metastases are detected due to deeper level rather than IHC"
                    ]
                  },
                  {
                    "text": "However, IHC for keratin can be helpful to determine presence and extent of metastasis from invasive lobular carcinomas or to identify atypical cells seen on H&ECells of lobular carcinoma can closely resemble lymphocytes or histiocytes",
                    "sub_points": [
                      "Cells of lobular carcinoma can closely resemble lymphocytes or histiocytes"
                    ]
                  },
                  {
                    "text": "Cells should have the morphology of breast carcinoma before classifying them as cancer cellsPlasma cells may be positive for many IHC markersReticulin cells can be positive for keratin CAM5.2Reticulin cells have spindly processes, encircle germinal centers, and do not have epithelial cell morphologyKeratin (+) cells (e.g., squames) can be artifactually transferred to slides but are usually out of plane of sectionBenign epithelial inclusions in LNs are keratin (+) but may also be associated with myoepithelial cells or markers (+) in endosalpingiosis",
                    "sub_points": [
                      "Plasma cells may be positive for many IHC markers",
                      "Reticulin cells can be positive for keratin CAM5.2Reticulin cells have spindly processes, encircle germinal centers, and do not have epithelial cell morphology",
                      "Reticulin cells have spindly processes, encircle germinal centers, and do not have epithelial cell morphology",
                      "Keratin (+) cells (e.g., squames) can be artifactually transferred to slides but are usually out of plane of section",
                      "Benign epithelial inclusions in LNs are keratin (+) but may also be associated with myoepithelial cells or markers (+) in endosalpingiosis"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Non-Breast Cancer Metastases": [
                  {
                    "text": "The majority of malignancies in axillary LNs are carcinomas55% carcinoma, 35% lymphoma, 10% melanomaOther types of metastasis are very rare and are usually from patients with well-known primaries",
                    "sub_points": [
                      "55% carcinoma, 35% lymphoma, 10% melanoma",
                      "Other types of metastasis are very rare and are usually from patients with well-known primaries"
                    ]
                  },
                  {
                    "text": "For women, the most common metastatic carcinoma is from the breastBreast: ~ 80%Lung: 10% (~ 2/3 ipsilateral lung, ~ 1/3 contralateral lung)Skin primary of the ipsilateral trunk and arm ~ 10%Metastatic squamous cell of skin can mimic metaplastic breast carcinomaA history of prior skin carcinomas should be considered",
                    "sub_points": [
                      "Breast: ~ 80%",
                      "Lung: 10% (~ 2/3 ipsilateral lung, ~ 1/3 contralateral lung)",
                      "Skin primary of the ipsilateral trunk and arm ~ 10%Metastatic squamous cell of skin can mimic metaplastic breast carcinomaA history of prior skin carcinomas should be considered",
                      "Metastatic squamous cell of skin can mimic metaplastic breast carcinoma",
                      "A history of prior skin carcinomas should be considered"
                    ]
                  },
                  {
                    "text": "Carcinomas first identified as an axillary metastasis in the absence of a known primary carcinoma are eventually identified as breast carcinoma in ~ 65% of casesImaging studies identify the primary site in most womenHowever, in some cases, a primary breast carcinoma cannot be identifiedDifferential diagnosisCarcinoma is very small and not detected by imagingThe \"metastasis\" may be a primary carcinoma arising in the high upper outer quadrant with a dense lymphocytic responseThe carcinoma may have regressed: Theoretically possible but this occurrence has not been well documentedA benign inclusion in an LN gave rise to a carcinomaThe failure to identify the primary site in the breast is not a poor prognostic factorPrognosis is similar to women with the same number of positive LNs",
                    "sub_points": [
                      "Imaging studies identify the primary site in most women",
                      "However, in some cases, a primary breast carcinoma cannot be identified",
                      "Differential diagnosisCarcinoma is very small and not detected by imagingThe \"metastasis\" may be a primary carcinoma arising in the high upper outer quadrant with a dense lymphocytic responseThe carcinoma may have regressed: Theoretically possible but this occurrence has not been well documentedA benign inclusion in an LN gave rise to a carcinoma",
                      "Carcinoma is very small and not detected by imaging",
                      "The \"metastasis\" may be a primary carcinoma arising in the high upper outer quadrant with a dense lymphocytic response",
                      "The carcinoma may have regressed: Theoretically possible but this occurrence has not been well documented",
                      "A benign inclusion in an LN gave rise to a carcinoma",
                      "The failure to identify the primary site in the breast is not a poor prognostic factor",
                      "Prognosis is similar to women with the same number of positive LNs"
                    ]
                  }
                ],
                "Lymphoma": [
                  {
                    "text": "Multiple types of lymphomas occur in axillary LNs"
                  },
                  {
                    "text": "Obstruction of LNs can cause swelling and erythema of the breast and mimic inflammatory carcinoma"
                  },
                  {
                    "text": "High-grade lymphomas can have an epithelioid appearance and may be mistaken for carcinoma in this setting"
                  },
                  {
                    "text": "IHC for lymphocyte and epithelial markers will identify cell typeSome lymphomas can be positive for epithelial membrane antigen (EMA)Thus, the preferred marker to identify malignancies as carcinoma is keratin",
                    "sub_points": [
                      "Some lymphomas can be positive for epithelial membrane antigen (EMA)",
                      "Thus, the preferred marker to identify malignancies as carcinoma is keratin"
                    ]
                  }
                ],
                "Invasive Carcinoma With Medullary Features": [
                  {
                    "text": "Some carcinomas are well circumscribed and associated with a prominent lymphocytic infiltrateGerminal centers can be present in areas of tumor-infiltrating lymphocytes and are not evidence of nodal tissue",
                    "sub_points": [
                      "Germinal centers can be present in areas of tumor-infiltrating lymphocytes and are not evidence of nodal tissue"
                    ]
                  },
                  {
                    "text": "If located in the high upper outer quadrant, it may be difficult to distinguish this type of carcinoma from metastasis to an LNA definite LN will have an outer capsule with a peripheral sinus",
                    "sub_points": [
                      "A definite LN will have an outer capsule with a peripheral sinus"
                    ]
                  },
                  {
                    "text": "The presence of carcinoma in situ &/or normal breast tissue can help establish a diagnosis of primary breast carcinoma"
                  }
                ],
                "Primary Skin Carcinomas": [
                  {
                    "text": "Adnexal tumors of skin can arise in axillary dermisPresentation as a palpable dermal mass can clinically mimic metastasis to an LNIf a specimen is designated axillary mass or LN, the possibility of a skin primary carcinoma may not be considered",
                    "sub_points": [
                      "Presentation as a palpable dermal mass can clinically mimic metastasis to an LN",
                      "If a specimen is designated axillary mass or LN, the possibility of a skin primary carcinoma may not be considered"
                    ]
                  },
                  {
                    "text": "These carcinomas can closely resemble breast carcinomasProtein expression can also be similar",
                    "sub_points": [
                      "Protein expression can also be similar"
                    ]
                  },
                  {
                    "text": "Carcinomas limited to dermis should be clearly distinguished from metastatic carcinoma in LN"
                  },
                  {
                    "text": "If the patient has a known breast carcinoma, the carcinomas should be compared"
                  }
                ],
                "Ectopic Breast Tissue in Lymph Nodes": [
                  {
                    "text": "In rare cases, normal ducts with luminal and myoepithelial cell layers are present in axillary LNsThought to be a developmental anomaly",
                    "sub_points": [
                      "Thought to be a developmental anomaly"
                    ]
                  },
                  {
                    "text": "Benign inclusions are often located in the outer sinus or capsule of LNs"
                  },
                  {
                    "text": "Consist of combinations of glandular elements, benign proliferative lesions, cysts, and squamous cell areas"
                  },
                  {
                    "text": "Some have a myoepithelial cell layer and may be associated with stromaIHC is helpful to document true myoepithelial cell layerOthers lack myoepithelial cells or are too small for IHC studies",
                    "sub_points": [
                      "IHC is helpful to document true myoepithelial cell layer",
                      "Others lack myoepithelial cells or are too small for IHC studies"
                    ]
                  },
                  {
                    "text": "Some cause lymphadenopathySquamous cysts can rupture and cause adjacent inflammatory response with giant cellsPapillomas can become quite large",
                    "sub_points": [
                      "Squamous cysts can rupture and cause adjacent inflammatory response with giant cells",
                      "Papillomas can become quite large"
                    ]
                  },
                  {
                    "text": "In rare cases, ectopic tissue gives rise to ductal carcinoma in situ (DCIS) or invasive carcinoma"
                  },
                  {
                    "text": "Important to compare morphology of cells in LN to primary carcinoma in breastDistinction between benign inclusions and true metastases is not possible with molecular (RT-PCR) tests",
                    "sub_points": [
                      "Distinction between benign inclusions and true metastases is not possible with molecular (RT-PCR) tests"
                    ]
                  }
                ],
                "Displaced Epithelium": [
                  {
                    "text": "Epithelial cells may be iatrogenically pushed into vascular spaces and transported to LNs after biopsyCan be benign or malignantMost commonly seen in patients with intraductal papillomas and multiple core needle biopsiesMay be increased after breast massage prior to SLN biopsy",
                    "sub_points": [
                      "Can be benign or malignant",
                      "Most commonly seen in patients with intraductal papillomas and multiple core needle biopsies",
                      "May be increased after breast massage prior to SLN biopsy"
                    ]
                  },
                  {
                    "text": "Most are small and would be classified as ITCs"
                  },
                  {
                    "text": "Cells are present as detached fragments, sometimes with papillary configurationDisplaced epithelium is usually located only in subcapsular sinus of nodeCells should be compared with patient's breast cancer",
                    "sub_points": [
                      "Displaced epithelium is usually located only in subcapsular sinus of node",
                      "Cells should be compared with patient's breast cancer"
                    ]
                  },
                  {
                    "text": "Presence of giant cells, histiocytes, and degenerating blood cells has been suggested as evidence of artifactual displacementHas been termed \"benign mechanical transport\"Reliability of these criteria to distinguish true metastases from artifact is uncertainClinical significance of displaced malignant cells vs. true metastasis is unknown",
                    "sub_points": [
                      "Has been termed \"benign mechanical transport\"",
                      "Reliability of these criteria to distinguish true metastases from artifact is uncertain",
                      "Clinical significance of displaced malignant cells vs. true metastasis is unknown"
                    ]
                  },
                  {
                    "text": "Benign cells may not morphologically resemble breast cancerImportant to compare morphology of cells in LN to histology of primary breast cancerMorphologic difference (e.g., low-grade cells in papillary fragments in patient with high-grade tumor) supports classification as artifactual displacement",
                    "sub_points": [
                      "Important to compare morphology of cells in LN to histology of primary breast cancer",
                      "Morphologic difference (e.g., low-grade cells in papillary fragments in patient with high-grade tumor) supports classification as artifactual displacement"
                    ]
                  },
                  {
                    "text": "IHC can be helpful in some casesDemonstration of both luminal and myoepithelial cells supports artifactual displacement of benign cellsDifferences in ER, PR, and HER2 results for cells in node and patient's breast cancer support that cells are benign",
                    "sub_points": [
                      "Demonstration of both luminal and myoepithelial cells supports artifactual displacement of benign cells",
                      "Differences in ER, PR, and HER2 results for cells in node and patient's breast cancer support that cells are benign"
                    ]
                  }
                ],
                "Nevus Cell Nests": [
                  {
                    "text": "Nevus cells are melanocytic-type cells that may be present in the capsule of LNsOccasionally, they involve interlobar septa and can appear to be within LN",
                    "sub_points": [
                      "Occasionally, they involve interlobar septa and can appear to be within LN"
                    ]
                  },
                  {
                    "text": "Cells are spindle-shaped with low- to intermediate-grade nuclei and usually do not resemble breast carcinoma"
                  },
                  {
                    "text": "IHC can be used to show that cells are negative for keratin and positive for S100 and other melanocytic markers"
                  }
                ],
                "Normal Nodal Components": [
                  {
                    "text": "Histiocytic infiltrates can be prominent and cluster in focal areasSome carcinomas also have histiocytic appearanceImmunoperoxidase study for keratin may be helpful in difficult cases",
                    "sub_points": [
                      "Some carcinomas also have histiocytic appearanceImmunoperoxidase study for keratin may be helpful in difficult cases",
                      "Immunoperoxidase study for keratin may be helpful in difficult cases"
                    ]
                  },
                  {
                    "text": "Signet-ring cell sinus histiocytosis closely resembles lobular carcinoma"
                  },
                  {
                    "text": "Prominent germinal centers close to the periphery of an LN can mimic carcinoma"
                  },
                  {
                    "text": "High endothelial venules can mimic tubules of well-differentiated carcinomas"
                  }
                ],
                "Endosalpingiosis": [
                  {
                    "text": "Forms small glandular structures with low columnar cellsUsually present in capsule or periphery of nodeCan be associated with calcifications",
                    "sub_points": [
                      "Usually present in capsule or periphery of node",
                      "Can be associated with calcifications"
                    ]
                  },
                  {
                    "text": "Histologic features of endosalpingiosis are characteristicCiliated columnar cellsIntercalated (peg) cells with clear cytoplasmSecretory cells",
                    "sub_points": [
                      "Ciliated columnar cells",
                      "Intercalated (peg) cells with clear cytoplasm",
                      "Secretory cells"
                    ]
                  },
                  {
                    "text": "Cells are positive for PAX8 and WT1 (nuclear)Primary carcinoma is negative for both",
                    "sub_points": [
                      "Primary carcinoma is negative for both"
                    ]
                  },
                  {
                    "text": "Can be positive for ER"
                  },
                  {
                    "text": "No myoepithelial cells are present"
                  }
                ],
                "Foreign/Extracellular Material": [
                  {
                    "text": "GoldGold (from rheumatoid arthritis treatment) forms black granular deposits in histiocytesRadiopaque and can look like calcifications on mammography",
                    "sub_points": [
                      "Gold (from rheumatoid arthritis treatment) forms black granular deposits in histiocytes",
                      "Radiopaque and can look like calcifications on mammography"
                    ]
                  },
                  {
                    "text": "Tattoo pigmentSimilar appearance to gold but other colors may be presentPresent in histiocytes or extracellularlySome pigments are radiopaque and can mimic calcifications on mammographyReactive LNs can be enlargedNode can grossly appear pigmented blue or blackCan mimic blue dye marking SLN",
                    "sub_points": [
                      "Similar appearance to gold but other colors may be presentPresent in histiocytes or extracellularly",
                      "Present in histiocytes or extracellularly",
                      "Some pigments are radiopaque and can mimic calcifications on mammography",
                      "Reactive LNs can be enlarged",
                      "Node can grossly appear pigmented blue or blackCan mimic blue dye marking SLN",
                      "Can mimic blue dye marking SLN"
                    ]
                  },
                  {
                    "text": "SiliconeSilicone from implants can drain to regional LNsCan cause lymphadenopathyMetastatic carcinoma and silicone can be present in same nodeGiant cells can mimic tumor cells at low power",
                    "sub_points": [
                      "Silicone from implants can drain to regional LNsCan cause lymphadenopathy",
                      "Can cause lymphadenopathy",
                      "Metastatic carcinoma and silicone can be present in same node",
                      "Giant cells can mimic tumor cells at low power"
                    ]
                  },
                  {
                    "text": "AmyloidCan cause lymphadenopathyMay be localized or part of a systemic diseasePlasmacytoma or low-grade B-cell lymphomaAmyloid due to insulin injections has rarely been identified in LNs",
                    "sub_points": [
                      "Can cause lymphadenopathy",
                      "May be localized or part of a systemic diseasePlasmacytoma or low-grade B-cell lymphoma",
                      "Plasmacytoma or low-grade B-cell lymphoma",
                      "Amyloid due to insulin injections has rarely been identified in LNs"
                    ]
                  }
                ],
                "Extramedullary Hematopoiesis": [
                  {
                    "text": "Bone marrow elements in nodes can mimic carcinomaMyeloid, erythroid, and megakaryocytes can be present",
                    "sub_points": [
                      "Myeloid, erythroid, and megakaryocytes can be present"
                    ]
                  },
                  {
                    "text": "May be more common in women after neoadjuvant chemotherapy"
                  },
                  {
                    "text": "Megakaryocytes can resemble tumor cells after treatmentUsually present as scattered large cells with large, multilobated nuclei and smudged chromatinNegative for keratin and positive for factor VIII and CD42b",
                    "sub_points": [
                      "Usually present as scattered large cells with large, multilobated nuclei and smudged chromatin",
                      "Negative for keratin and positive for factor VIII and CD42b"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Histologic Grade": {
            "name": "Histologic Grade",
            "url": "https://app.pathprimer.com/document/564493c8-26cd-4113-b31e-6b43cf9cdd73/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Basal-like carcinoma (BLC)"
                  },
                  {
                    "text": "Triple negative breast carcinoma (TNBC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Nottingham grading system (NGS)"
                  },
                  {
                    "text": "Elston and Ellis grading"
                  },
                  {
                    "text": "Modified Bloom-Richardson grade"
                  }
                ]
              },
              "Introduction": {
                "Classification of Breast Cancer": [
                  {
                    "text": "Breast carcinomas (BCs) are very heterogeneous in clinical behaviorAt one extreme, BCs very closely resemble benign breast tissue morphologicallySome would never result in clinical symptoms during a patient's lifetimeAt the other extreme, BCs do not have any resemblance to normal tissueSome cause death in a short interval of time",
                    "sub_points": [
                      "At one extreme, BCs very closely resemble benign breast tissue morphologicallySome would never result in clinical symptoms during a patient's lifetime",
                      "Some would never result in clinical symptoms during a patient's lifetime",
                      "At the other extreme, BCs do not have any resemblance to normal tissueSome cause death in a short interval of time",
                      "Some cause death in a short interval of time"
                    ]
                  },
                  {
                    "text": "Grading of BCs was developed in order to identify groups with similar clinical outcomesThe phenotype of a BC is correlated with changes in the genome, transcriptome, and proteome, which determine response to treatment, time to recurrence, pattern of metastasis, and survival",
                    "sub_points": [
                      "The phenotype of a BC is correlated with changes in the genome, transcriptome, and proteome, which determine response to treatment, time to recurrence, pattern of metastasis, and survival"
                    ]
                  },
                  {
                    "text": "Histologic grade is an independent prognostic indicator and correlates with molecular alterations"
                  },
                  {
                    "text": "Histologic grade also adds important information when combined with tumor size, nodal status, and expression of hormone receptors and HER2"
                  }
                ]
              },
              "Nottingham Grading System": {
                "Overview": [
                  {
                    "text": "Most widely used system for BC grading"
                  },
                  {
                    "text": "Recommended by the College of American Pathologists (CAP), American Joint Committee on Cancer (AJCC), and European Commission Working Group on Breast Screening Pathology"
                  },
                  {
                    "text": "Required for the assignment of grade in the AJCC 8th edition staging manual"
                  },
                  {
                    "text": "All types of BC are graded"
                  },
                  {
                    "text": "The 3 components of grade are evaluated separately and given scores of 1 to 3"
                  }
                ],
                "Glandular (Acinar)/Tubule Formation (G/TF)": [
                  {
                    "text": "Normal luminal cells line ducts and lobules and form tubules or glandular structures"
                  },
                  {
                    "text": "The ability of tumor cells to continue to form tubules in the absence of supporting cells and structures is most common in estrogen receptor (ER)(+) or luminal BCsSome ER(-)BCs that form tubules express androgen receptor (AR) (may be classified as luminal AR by gene expression profiling)< 10% of HER2(+), triple negative BCs (TNBC; negative for hormone receptors and HER2)/basal-like carcinomas (BLC) form tubules",
                    "sub_points": [
                      "Some ER(-)BCs that form tubules express androgen receptor (AR) (may be classified as luminal AR by gene expression profiling)",
                      "< 10% of HER2(+), triple negative BCs (TNBC; negative for hormone receptors and HER2)/basal-like carcinomas (BLC) form tubules"
                    ]
                  },
                  {
                    "text": "BCs that do not form tubules may arise from cells that lack this capacity (possibly progenitor cells or myoepithelial-like cells) or may have lost this capacityMajority of ER(-)BCs are in this group",
                    "sub_points": [
                      "Majority of ER(-)BCs are in this group"
                    ]
                  },
                  {
                    "text": "Tubule formation is more closely linked to gene expression (mRNA) rather than genetic changes (DNA)Not closely related to proliferation",
                    "sub_points": [
                      "Not closely related to proliferation"
                    ]
                  },
                  {
                    "text": "A recent study demonstrated that concordance in classifying G/TF was poor amongst breast pathologists when classifying unusual patterns"
                  },
                  {
                    "text": "An expanded description of GT/F improved concordance for both breast and general practice pathologists as well as trainees"
                  },
                  {
                    "text": "Expanded description of GT/FGT/F is present when tumor cells form/create a \"luminal space\" surrounded by polarized cellsThe normal luminal cells of the breast have an apical-basal polarity with the apical portion facing the lumen (sometimes with apical blebs) and the basal portion lying on the basement membraneIn some tumors, very well-formed tubules and cribriform spaces also show similar orientationHowever, very well-developed polarization is not required to include a space as G/TFSome luminal spaces may be tubular in 3 dimensions, whereas others may be enclosed spaces that may have round, oval, or sinuous contoursThe space can appear empty, filled with secretory material or mucin, or contain necrotic debrisComplex architecture, such as multiple luminal spaces within a tumor cell island, is considered G/TFThis is often seen in cribriform and mucinous BCs and may be seen in micropapillary carcinomasMicropapillary BC consists of clusters of cells with the apical portion oriented outward toward an empty stromal spaceIf the cells form an inner empty space (the inverted tubule pattern), this is included as G/TFIntracytoplasmic lumen formation (signet-ring cells with intracytoplasmic vacuoles) is not included as G/TFG/TF is not present if a space is present due to dyscohesive cells or focal necrosisPapillary structures are not included as G/TFArtifactual spaces due to suboptimal fixation, tissue processing, tissue shrinkage, or freezing should not be mistaken for G/TFAll types of BCs are evaluated for G/TFThese include mucinous, cribriform, and micropapillary carcinomas as well as all other typesThe other components of grading (i.e., nuclear pleomorphism and mitotic score) do not alter the evaluation of G/TFSpecifically, high nuclear grade or frequent mitoses do not exclude the presence of G/TF",
                    "sub_points": [
                      "GT/F is present when tumor cells form/create a \"luminal space\" surrounded by polarized cellsThe normal luminal cells of the breast have an apical-basal polarity with the apical portion facing the lumen (sometimes with apical blebs) and the basal portion lying on the basement membraneIn some tumors, very well-formed tubules and cribriform spaces also show similar orientationHowever, very well-developed polarization is not required to include a space as G/TF",
                      "The normal luminal cells of the breast have an apical-basal polarity with the apical portion facing the lumen (sometimes with apical blebs) and the basal portion lying on the basement membrane",
                      "In some tumors, very well-formed tubules and cribriform spaces also show similar orientation",
                      "However, very well-developed polarization is not required to include a space as G/TF",
                      "Some luminal spaces may be tubular in 3 dimensions, whereas others may be enclosed spaces that may have round, oval, or sinuous contours",
                      "The space can appear empty, filled with secretory material or mucin, or contain necrotic debris",
                      "Complex architecture, such as multiple luminal spaces within a tumor cell island, is considered G/TFThis is often seen in cribriform and mucinous BCs and may be seen in micropapillary carcinomas",
                      "This is often seen in cribriform and mucinous BCs and may be seen in micropapillary carcinomas",
                      "Micropapillary BC consists of clusters of cells with the apical portion oriented outward toward an empty stromal spaceIf the cells form an inner empty space (the inverted tubule pattern), this is included as G/TF",
                      "If the cells form an inner empty space (the inverted tubule pattern), this is included as G/TF",
                      "Intracytoplasmic lumen formation (signet-ring cells with intracytoplasmic vacuoles) is not included as G/TF",
                      "G/TF is not present if a space is present due to dyscohesive cells or focal necrosis",
                      "Papillary structures are not included as G/TF",
                      "Artifactual spaces due to suboptimal fixation, tissue processing, tissue shrinkage, or freezing should not be mistaken for G/TF",
                      "All types of BCs are evaluated for G/TFThese include mucinous, cribriform, and micropapillary carcinomas as well as all other types",
                      "These include mucinous, cribriform, and micropapillary carcinomas as well as all other types",
                      "The other components of grading (i.e., nuclear pleomorphism and mitotic score) do not alter the evaluation of G/TFSpecifically, high nuclear grade or frequent mitoses do not exclude the presence of G/TF",
                      "Specifically, high nuclear grade or frequent mitoses do not exclude the presence of G/TF"
                    ]
                  }
                ],
                "Nuclear Pleomorphism": [
                  {
                    "text": "Size, shape, and chromatin pattern are altered by the DNA content and genomic alterations of the nucleusSize and appearance of the nucleolus is determined by transcriptional activity",
                    "sub_points": [
                      "Size and appearance of the nucleolus is determined by transcriptional activity"
                    ]
                  },
                  {
                    "text": "Low nuclear grade scores are almost exclusively found in ER(+) or luminal A BCsVery rarely found in HER2(+) or TNBC/BLCs, which are typically higher grade",
                    "sub_points": [
                      "Very rarely found in HER2(+) or TNBC/BLCs, which are typically higher grade"
                    ]
                  },
                  {
                    "text": "In contrast, high nuclear pleomorphism scores are found in the majority of HER2(+), TNBCs, and BLCs and in ~ 1/4 of ER(+) or luminal A BCs"
                  }
                ],
                "Mitoses": [
                  {
                    "text": "BC cells undergo repeated rounds of proliferation during each menstrual cycle during reproductive lifeIn normal cells, proliferation is strongly governed and regulated by estrogen stimulation",
                    "sub_points": [
                      "In normal cells, proliferation is strongly governed and regulated by estrogen stimulation"
                    ]
                  },
                  {
                    "text": "Rapidly proliferating BCs increase the tumor burden that results in morbidity, and eventually mortality, from BCMany genes involved in BC development are associated with maintaining genomic integrityEach mitotic event creates opportunities for additional genetic damage and DNA changesMultiple genetically distinct clones develop in high-grade BCsProliferation is also the target of many chemotherapeutic agentsA subset of highly proliferative cancers is highly sensitive to treatment~ 3/4 of TNBC/BLCs have high proliferation scores compared to < 10% of ER(+) or luminal A BCs",
                    "sub_points": [
                      "Many genes involved in BC development are associated with maintaining genomic integrity",
                      "Each mitotic event creates opportunities for additional genetic damage and DNA changes",
                      "Multiple genetically distinct clones develop in high-grade BCs",
                      "Proliferation is also the target of many chemotherapeutic agentsA subset of highly proliferative cancers is highly sensitive to treatment~ 3/4 of TNBC/BLCs have high proliferation scores compared to < 10% of ER(+) or luminal A BCs",
                      "A subset of highly proliferative cancers is highly sensitive to treatment",
                      "~ 3/4 of TNBC/BLCs have high proliferation scores compared to < 10% of ER(+) or luminal A BCs"
                    ]
                  },
                  {
                    "text": "Slowly proliferating BCs may not cause clinical symptoms for long periods of timeThese BCs are relatively resistant to chemotherapeutic agentsMore likely to be ER(+)~ 2/3 of ER(+) or luminal A BCs have low proliferation compared to < 10% of TNBC/BLCs",
                    "sub_points": [
                      "These BCs are relatively resistant to chemotherapeutic agents",
                      "More likely to be ER(+)",
                      "~ 2/3 of ER(+) or luminal A BCs have low proliferation compared to < 10% of TNBC/BLCs"
                    ]
                  },
                  {
                    "text": "Major gene expression profiles developed for prognosis are dominated by genes involved in and governing proliferation"
                  }
                ],
                "Scoring": [
                  {
                    "text": "Each component is assessed independently, and the sum of the 3 scores determines the final grade"
                  },
                  {
                    "text": "Glandular/tubule formation (G/TF) scoreProportion of tumor with G/TF is assessedIncludes simple tubules, cell nests with lumina, cribriform patterns, and micropapillary clusters with central spaces (\"inverted tubules\")Score 1: > 75%Score 2: 10-75%Score 3: < 10%The architectural pattern is assessed over the entire area of the BC",
                    "sub_points": [
                      "Proportion of tumor with G/TF is assessed",
                      "Includes simple tubules, cell nests with lumina, cribriform patterns, and micropapillary clusters with central spaces (\"inverted tubules\")Score 1: > 75%Score 2: 10-75%Score 3: < 10%",
                      "Score 1: > 75%",
                      "Score 2: 10-75%",
                      "Score 3: < 10%",
                      "The architectural pattern is assessed over the entire area of the BC"
                    ]
                  },
                  {
                    "text": "Nuclear pleomorphism scoreThe size, shape, and nucleoli of nuclei are assessed in the area showing the highest degree of pleomorphism compared to normal epithelial cellsScore 1: Nuclei small (2-3x size of RBCs; < 1.5x the size of normal nuclei) with regular outlines, uniform nuclear chromatin with small or absent nucleoliSimilar in size to normal breast epithelial cellsLittle variation in sizeScore 2: Cells larger than normal with open vesicular nuclei (1.5-2x) and visible nucleoli (small and inconspicuous)Mild to moderate variability in both size and shape of nucleiOccasional enlarged or markedly pleomorphic nucleus may be presentScore 3: Cells are larger, have vesicular nuclei (> 2x the size of normal nuclei), often with prominent nucleoliMarked variation in size and shapeLarge and bizarre forms may be presentNuclei are scored at the periphery or in area of carcinoma with highest nuclear grade in cases with variability",
                    "sub_points": [
                      "The size, shape, and nucleoli of nuclei are assessed in the area showing the highest degree of pleomorphism compared to normal epithelial cellsScore 1: Nuclei small (2-3x size of RBCs; < 1.5x the size of normal nuclei) with regular outlines, uniform nuclear chromatin with small or absent nucleoliSimilar in size to normal breast epithelial cellsLittle variation in sizeScore 2: Cells larger than normal with open vesicular nuclei (1.5-2x) and visible nucleoli (small and inconspicuous)Mild to moderate variability in both size and shape of nucleiOccasional enlarged or markedly pleomorphic nucleus may be presentScore 3: Cells are larger, have vesicular nuclei (> 2x the size of normal nuclei), often with prominent nucleoliMarked variation in size and shapeLarge and bizarre forms may be present",
                      "Score 1: Nuclei small (2-3x size of RBCs; < 1.5x the size of normal nuclei) with regular outlines, uniform nuclear chromatin with small or absent nucleoliSimilar in size to normal breast epithelial cellsLittle variation in size",
                      "Similar in size to normal breast epithelial cells",
                      "Little variation in size",
                      "Score 2: Cells larger than normal with open vesicular nuclei (1.5-2x) and visible nucleoli (small and inconspicuous)Mild to moderate variability in both size and shape of nucleiOccasional enlarged or markedly pleomorphic nucleus may be present",
                      "Mild to moderate variability in both size and shape of nuclei",
                      "Occasional enlarged or markedly pleomorphic nucleus may be present",
                      "Score 3: Cells are larger, have vesicular nuclei (> 2x the size of normal nuclei), often with prominent nucleoliMarked variation in size and shapeLarge and bizarre forms may be present",
                      "Marked variation in size and shape",
                      "Large and bizarre forms may be present",
                      "Nuclei are scored at the periphery or in area of carcinoma with highest nuclear grade in cases with variability"
                    ]
                  },
                  {
                    "text": "Mitotic scoreThe size of a high-power (40x) microscope field must be known in order to determine the correct scoreSizes of microscope fields can vary > 6xTables correlating mitotic counts with field sizes and scores for grading are available (e.g., CAP Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of the Breast) at www.cap.org; accessed November 16, 2024Includes methods for determining field sizeMitotic figures in 10 HPF (40x objective) in the most mitotically active part of BC are assessedField diameter 0.40 mm: Score 1: ≤ 4; score 2: 5-9; score 3: ≥ 10Field diameter 0.50 mm: Score 1: ≤ 7; score 2: 8-14; score 3: ≥ 15Field diameter 0.60 mm: Score 1: ≤ 10; score 2: 11-20; score 3: ≥ 21If score is close to cut-off point, additional fields should be counted before determining final scoreOnly fields that are representative of the cellularity of the BC should be chosenMitotic counts are usually highest at peripheryOnly clearly identifiable mitotic figures should be included in the mitotic scoreHyperchromatic, karyorrhectic, or apoptotic nuclei should not be countedCounting mitoses per area instead of per cell has greater prognostic significanceMore cellular BCs typically will be more mitotically activeThe combination of both features has more prognostic value than using the percentage of positive cells",
                    "sub_points": [
                      "The size of a high-power (40x) microscope field must be known in order to determine the correct scoreSizes of microscope fields can vary > 6xTables correlating mitotic counts with field sizes and scores for grading are available (e.g., CAP Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of the Breast) at www.cap.org; accessed November 16, 2024Includes methods for determining field size",
                      "Sizes of microscope fields can vary > 6x",
                      "Tables correlating mitotic counts with field sizes and scores for grading are available (e.g., CAP Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of the Breast) at www.cap.org; accessed November 16, 2024Includes methods for determining field size",
                      "Includes methods for determining field size",
                      "Mitotic figures in 10 HPF (40x objective) in the most mitotically active part of BC are assessedField diameter 0.40 mm: Score 1: ≤ 4; score 2: 5-9; score 3: ≥ 10Field diameter 0.50 mm: Score 1: ≤ 7; score 2: 8-14; score 3: ≥ 15Field diameter 0.60 mm: Score 1: ≤ 10; score 2: 11-20; score 3: ≥ 21",
                      "Field diameter 0.40 mm: Score 1: ≤ 4; score 2: 5-9; score 3: ≥ 10",
                      "Field diameter 0.50 mm: Score 1: ≤ 7; score 2: 8-14; score 3: ≥ 15",
                      "Field diameter 0.60 mm: Score 1: ≤ 10; score 2: 11-20; score 3: ≥ 21",
                      "If score is close to cut-off point, additional fields should be counted before determining final score",
                      "Only fields that are representative of the cellularity of the BC should be chosen",
                      "Mitotic counts are usually highest at periphery",
                      "Only clearly identifiable mitotic figures should be included in the mitotic scoreHyperchromatic, karyorrhectic, or apoptotic nuclei should not be counted",
                      "Hyperchromatic, karyorrhectic, or apoptotic nuclei should not be counted",
                      "Counting mitoses per area instead of per cell has greater prognostic significanceMore cellular BCs typically will be more mitotically activeThe combination of both features has more prognostic value than using the percentage of positive cells",
                      "More cellular BCs typically will be more mitotically active",
                      "The combination of both features has more prognostic value than using the percentage of positive cells"
                    ]
                  },
                  {
                    "text": "Final grade (sum of scores)Grade 1 (sum of scores = 3-5)Well-differentiated BCGrade 2 (sum of scores = 6-7)Moderately differentiated BCGrade 3 (sum of scores = 8-9)Poorly differentiated BCIt is recommended that the 3 components of the score, as well as the final grade, be reported",
                    "sub_points": [
                      "Grade 1 (sum of scores = 3-5)Well-differentiated BC",
                      "Well-differentiated BC",
                      "Grade 2 (sum of scores = 6-7)Moderately differentiated BC",
                      "Moderately differentiated BC",
                      "Grade 3 (sum of scores = 8-9)Poorly differentiated BC",
                      "Poorly differentiated BC",
                      "It is recommended that the 3 components of the score, as well as the final grade, be reported"
                    ]
                  }
                ],
                "AJCC 8th Edition Breast Carcinoma Staging": [
                  {
                    "text": "In the 8th edition, anatomic factors were combined with biologic factorsAnatomic factors: T (tumor size and extent), N (node status), M (metastases)Biologic factors: Grade, ER, PR, HER2, and a prognostic score from gene expression profiling (if available)",
                    "sub_points": [
                      "Anatomic factors: T (tumor size and extent), N (node status), M (metastases)",
                      "Biologic factors: Grade, ER, PR, HER2, and a prognostic score from gene expression profiling (if available)"
                    ]
                  },
                  {
                    "text": "There are 2 prognostic stage categories (pathologic prognostic stage and clinical prognostic stage)Groups of patients with BCs with similar survival at 5 years are placed into the same groupSome patients with biologically favorable BCs (e.g., luminal BCs) are moved to lower prognostic stagesSome patients with biologically adverse BCs (e.g., TNBC/BLC) are moved to higher prognostic stages",
                    "sub_points": [
                      "Groups of patients with BCs with similar survival at 5 years are placed into the same groupSome patients with biologically favorable BCs (e.g., luminal BCs) are moved to lower prognostic stagesSome patients with biologically adverse BCs (e.g., TNBC/BLC) are moved to higher prognostic stages",
                      "Some patients with biologically favorable BCs (e.g., luminal BCs) are moved to lower prognostic stages",
                      "Some patients with biologically adverse BCs (e.g., TNBC/BLC) are moved to higher prognostic stages"
                    ]
                  },
                  {
                    "text": "More accurately predicts clinical outcomes of BC patients than traditional anatomic staging at 5 years"
                  },
                  {
                    "text": "Represents a significant change in the codification of BC stagingReflects advances in our understanding of the biology of BC",
                    "sub_points": [
                      "Reflects advances in our understanding of the biology of BC"
                    ]
                  }
                ],
                "Tissue Handling and Grade": [
                  {
                    "text": "Tissue handling, fixation, and specimen preparation should be optimizedCautery and crushing during surgery can preclude evaluationCrushing must be avoided during processingDelayed fixation can reduce mitotic count",
                    "sub_points": [
                      "Cautery and crushing during surgery can preclude evaluation",
                      "Crushing must be avoided during processing",
                      "Delayed fixation can reduce mitotic count"
                    ]
                  },
                  {
                    "text": "High-quality tissue sections are necessary for morphologic assessment of histologic gradeMay have significant influence on accuracy and observer agreementThickly cut sections, shatter artifact, and suboptimal staining can all interfere with assessment",
                    "sub_points": [
                      "May have significant influence on accuracy and observer agreement",
                      "Thickly cut sections, shatter artifact, and suboptimal staining can all interfere with assessment"
                    ]
                  }
                ],
                "Grade onCore Needle Biopsies": [
                  {
                    "text": "Accuracy of histologic grading in core needle biopsies is variable compared with excised BCDependent on quality of core needle biopsy sampleCrush artifact may preclude gradingDependent on degree of heterogeneity in BCSmall sample may not be representative of entire BC",
                    "sub_points": [
                      "Dependent on quality of core needle biopsy sampleCrush artifact may preclude grading",
                      "Crush artifact may preclude grading",
                      "Dependent on degree of heterogeneity in BCSmall sample may not be representative of entire BC",
                      "Small sample may not be representative of entire BC"
                    ]
                  },
                  {
                    "text": "Reported concordance rates between biopsy and excision range from 60-75%"
                  },
                  {
                    "text": "Grading of BCs on core needle biopsy should be considered provisionalGrade on cores tends to be lower than grade on excisionLikely related to sampling and morphologic variabilityRarely changes from grade 1 to 3 or from 3 to 1Important consideration for patients who are candidates for neoadjuvant chemotherapy",
                    "sub_points": [
                      "Grade on cores tends to be lower than grade on excisionLikely related to sampling and morphologic variabilityRarely changes from grade 1 to 3 or from 3 to 1",
                      "Likely related to sampling and morphologic variability",
                      "Rarely changes from grade 1 to 3 or from 3 to 1",
                      "Important consideration for patients who are candidates for neoadjuvant chemotherapy"
                    ]
                  }
                ],
                "Interobserver Agreement and Grade": [
                  {
                    "text": "Accuracy and interobserver agreement are dependent on experience and application of strict criteriaKappa values for G/TF indicate substantial level of agreementLower levels of agreement reported for mitotic count and nuclear scoreAccurate grading is important for ensuring prognostic significanceFeasibility of digital image analysis for improving scoring reproducibility under investigation",
                    "sub_points": [
                      "Kappa values for G/TF indicate substantial level of agreement",
                      "Lower levels of agreement reported for mitotic count and nuclear score",
                      "Accurate grading is important for ensuring prognostic significance",
                      "Feasibility of digital image analysis for improving scoring reproducibility under investigation"
                    ]
                  },
                  {
                    "text": "However, BCs with discordant grade assignments by 2 observers can truly be of intermediate grade (e.g., grade 1 to 2 or 2 to 3)The survival of patients with these cancers is intermediate between patients with BCs with the lower and higher gradeFor example, if 1 observer assigns grade 1, and a 2nd observer assigns grade 2, the patient's survival is worse than having a grade 1 BC but better than having a grade 2 BC",
                    "sub_points": [
                      "The survival of patients with these cancers is intermediate between patients with BCs with the lower and higher grade",
                      "For example, if 1 observer assigns grade 1, and a 2nd observer assigns grade 2, the patient's survival is worse than having a grade 1 BC but better than having a grade 2 BC"
                    ]
                  }
                ]
              },
              "Special Histologic Types and Grade": {
                "General Considerations": [
                  {
                    "text": "All invasive BCs are graded except for microinvasion (< 0.1 cm)"
                  },
                  {
                    "text": "For reporting, the grade of the largest focus of BC is the most importantIf smaller foci of different histologic grade are present, this should be noted in a comment",
                    "sub_points": [
                      "If smaller foci of different histologic grade are present, this should be noted in a comment"
                    ]
                  },
                  {
                    "text": "Some special histologic types of BC are always associated with a specific grade, and others can be of any grade"
                  }
                ],
                "Lobular Carcinoma": [
                  {
                    "text": "Invasive lobular carcinomas (ILCs) are graded using the same criteria as for BCs of no special type (ductal carcinomas)Grade 1 (15% of ILCs): 3 G/TF score + 1 nuclear score + 1 mitotic scoreOften resemble lymphocytesGrade 2 (75% of ILCs): 3 G/TF score + 2 nuclear score + 1 mitotic scoreOften resemble histiocytesGrade 3 (10% of ILCs): 3 G/TF score + 2 or 3 nuclear score + 2 or 3 mitotic score",
                    "sub_points": [
                      "Grade 1 (15% of ILCs): 3 G/TF score + 1 nuclear score + 1 mitotic scoreOften resemble lymphocytes",
                      "Often resemble lymphocytes",
                      "Grade 2 (75% of ILCs): 3 G/TF score + 2 nuclear score + 1 mitotic scoreOften resemble histiocytes",
                      "Often resemble histiocytes",
                      "Grade 3 (10% of ILCs): 3 G/TF score + 2 or 3 nuclear score + 2 or 3 mitotic score"
                    ]
                  },
                  {
                    "text": "Identifies 3 groups of differing prognosis"
                  },
                  {
                    "text": "Grade provides more information than descriptive termsClassic ILC is used for grades 1 and 2 ILCsPleomorphic ILC is used for grades 2 and 3 ILCs",
                    "sub_points": [
                      "Classic ILC is used for grades 1 and 2 ILCs",
                      "Pleomorphic ILC is used for grades 2 and 3 ILCs"
                    ]
                  }
                ],
                "Tubular Carcinoma": [
                  {
                    "text": "All are grade 1"
                  },
                  {
                    "text": "Diagnostic criteria require G/TF score of 1 and exclude nuclear score of 3"
                  }
                ],
                "ER(-) Carcinoma": [
                  {
                    "text": "Almost all grade 3"
                  },
                  {
                    "text": "Some special subgroups can be of lower grade due to low mitotic ratesLow-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, AR(+) TNBC",
                    "sub_points": [
                      "Low-grade adenosquamous carcinoma, fibromatosis-like metaplastic carcinoma, AR(+) TNBC"
                    ]
                  }
                ],
                "Carcinomas With Medullary Pattern": [
                  {
                    "text": "All are grade 3"
                  },
                  {
                    "text": "Prognosis is more favorable than other grade 3 carcinomas of similar sizeMay be due to association with a lymphoplasmacytic infiltrate, which is correlated with response to chemotherapy and prognosis",
                    "sub_points": [
                      "May be due to association with a lymphoplasmacytic infiltrate, which is correlated with response to chemotherapy and prognosis"
                    ]
                  }
                ],
                "Invasive Micropapillary Carcinoma": [
                  {
                    "text": "Usually grade 2 or 3"
                  },
                  {
                    "text": "These BCs show anchorage-independent growth and form spheroids that resemble inverted tubules or micropapillae on cross section"
                  },
                  {
                    "text": "The relationship of formation of spheroids to lumen formation has not yet been elucidated"
                  },
                  {
                    "text": "The inverted tubule pattern is included as G/TF"
                  }
                ],
                "Mucinous Carcinoma": [
                  {
                    "text": "Usually grade 1, can be grade 2, or, rarely, grade 3"
                  },
                  {
                    "text": "Lumina formed by cells within tumor cell clusters is included as G/TF"
                  },
                  {
                    "text": "Some have micropapillary pattern of growth in mucinThis pattern is associated with less favorable prognosis than when micropapillary pattern is absentHowever, prognosis is better than micropapillary",
                    "sub_points": [
                      "This pattern is associated with less favorable prognosis than when micropapillary pattern is absent",
                      "However, prognosis is better than micropapillary"
                    ]
                  }
                ],
                "Adenoid Cystic Carcinoma (AdCC)": [
                  {
                    "text": "> 95% of patients with classic-type AdCC do well without treatment"
                  },
                  {
                    "text": "Specific grading systems developed to identify the small number of classic AdCCs that metastasize have not been successful"
                  },
                  {
                    "text": "More important than grade is to specify an AdCC as being classic or solid-basaloid in type"
                  },
                  {
                    "text": "Solid-basaloid AdCC is important to recognize, as these carcinomas usually have marked nuclear atypia and a high mitotic rate"
                  }
                ]
              },
              "Clinical/Pathologic Correlates and Grade": {
                "Histologic Grade1Carcinomas": [
                  {
                    "text": "Well differentiated: 20% of BCs"
                  },
                  {
                    "text": "More common in older women"
                  },
                  {
                    "text": "Frequently found by mammographic screeningAccount for majority of excess invasive BCs detected in screened populations",
                    "sub_points": [
                      "Account for majority of excess invasive BCs detected in screened populations"
                    ]
                  },
                  {
                    "text": "Almost all ER &/or PR (+)"
                  },
                  {
                    "text": "Very rarely HER2(+)"
                  },
                  {
                    "text": "Typically show a low Ki-67 proliferative index correlating with low mitotic score"
                  },
                  {
                    "text": "Less likely to demonstrate axillary lymph node metastases at presentationWhen present, metastases are usually small and few in number",
                    "sub_points": [
                      "When present, metastases are usually small and few in number"
                    ]
                  },
                  {
                    "text": "Generally slow growing with recurrence occurring late in course (> 10 years after diagnosis)Metastases are typically to bonePatients can survive for long time periods (decades) after distant recurrence with hormonal therapy",
                    "sub_points": [
                      "Metastases are typically to bone",
                      "Patients can survive for long time periods (decades) after distant recurrence with hormonal therapy"
                    ]
                  },
                  {
                    "text": "Less likely to benefit from chemotherapy"
                  },
                  {
                    "text": "Most likely to receive significant benefit from hormonal therapy"
                  }
                ],
                "Histologic Grade 2 Carcinomas": [
                  {
                    "text": "Moderately differentiated: 30-35% of BCs"
                  },
                  {
                    "text": "Features of these tumors are intermediate between grades 1 and 2 BCsMay be due to intermingling of BCs that are actually grade 1 or grade 2",
                    "sub_points": [
                      "May be due to intermingling of BCs that are actually grade 1 or grade 2"
                    ]
                  },
                  {
                    "text": "Genomic grading and separation by other measures of proliferation indicate that this may not be a true biologic categoryMolecular findings challenge clinical relevance of intermediate-grade BC",
                    "sub_points": [
                      "Molecular findings challenge clinical relevance of intermediate-grade BC"
                    ]
                  }
                ],
                "Histologic Grade3Carcinomas": [
                  {
                    "text": "Poorly differentiated: 45-50% of BCs"
                  },
                  {
                    "text": "Relatively higher incidence in younger individuals and African American women or Hispanic American women"
                  },
                  {
                    "text": "Most commonly present as a palpable mass in younger women or as an interval carcinoma in older women undergoing screening"
                  },
                  {
                    "text": "~ 1/2 ER &/or PR (-)"
                  },
                  {
                    "text": "~ 1/3-1/2 HER2(+)"
                  },
                  {
                    "text": "Typically show high Ki-67 proliferative index correlating with high mitotic score"
                  },
                  {
                    "text": "More likely to demonstrate axillary lymph node metastases at presentationMetastases may be large and multiple",
                    "sub_points": [
                      "Metastases may be large and multiple"
                    ]
                  },
                  {
                    "text": "Recurrences usually early in course of the disease (3-5 years after diagnosis)Metastases typically to brain and visceral organsLong survival after distant recurrence is unusual",
                    "sub_points": [
                      "Metastases typically to brain and visceral organs",
                      "Long survival after distant recurrence is unusual"
                    ]
                  },
                  {
                    "text": "Subset (~ 15-30%) have pathologic complete response to chemotherapyMany of these patients have long-term survival and may be cured",
                    "sub_points": [
                      "Many of these patients have long-term survival and may be cured"
                    ]
                  },
                  {
                    "text": "Molecular differences when compared to grade 1 BCs support that these are 2 distinct types of BCDifferences in grade are present at in situ stageGrade 3 BC is not thought to be due to dedifferentiation of grade 1 BC",
                    "sub_points": [
                      "Differences in grade are present at in situ stage",
                      "Grade 3 BC is not thought to be due to dedifferentiation of grade 1 BC"
                    ]
                  }
                ],
                "Prognosis andGrade": [
                  {
                    "text": "Many clinical studies have validated and confirmed important prognostic significance of tumor grade for breast cancer-specific survival and disease-free survival"
                  },
                  {
                    "text": "Significant association between grade and survival holds true for different tumor subgroupsGrade is correlated with overall survival independent of tumor size and number of positive lymph nodesGrade is correlated with overall survival regardless of clinical stage",
                    "sub_points": [
                      "Grade is correlated with overall survival independent of tumor size and number of positive lymph nodes",
                      "Grade is correlated with overall survival regardless of clinical stage"
                    ]
                  },
                  {
                    "text": "Grade remains an independent prognostic factor for ER(+)BCs in multivariate analyses that include molecular signatures that primarily evaluate proliferationMolecular signatures that underlie grade are currently under investigation",
                    "sub_points": [
                      "Molecular signatures that underlie grade are currently under investigation"
                    ]
                  },
                  {
                    "text": "Tumor-infiltrating lymphocyte scores have been shown to significantly correlate with histologic grade"
                  }
                ]
              },
              "Grade and Genomic Changes": {
                "Genomic Grade Index (GGI)": [
                  {
                    "text": "GGI was developed using gene expression profiling"
                  },
                  {
                    "text": "97 genes were found to be differentially expressed between low and high histologic grade BCsMajority of genes are associated with cell cycle regulation and proliferationLow and high GGI strongly associated with disease-free and overall survival in ER(+)BCsLow GGI found in luminal A BCsHigh GGI found in luminal B, HER2, and BLCsLow and high GGI associated with histologic gradeHistologic grade 1: ~ 85% low GGIHistologic grade 3: ~ 90% high GGI",
                    "sub_points": [
                      "Majority of genes are associated with cell cycle regulation and proliferation",
                      "Low and high GGI strongly associated with disease-free and overall survival in ER(+)BCsLow GGI found in luminal A BCsHigh GGI found in luminal B, HER2, and BLCs",
                      "Low GGI found in luminal A BCs",
                      "High GGI found in luminal B, HER2, and BLCs",
                      "Low and high GGI associated with histologic gradeHistologic grade 1: ~ 85% low GGIHistologic grade 3: ~ 90% high GGI",
                      "Histologic grade 1: ~ 85% low GGI",
                      "Histologic grade 3: ~ 90% high GGI"
                    ]
                  },
                  {
                    "text": "GGI reclassified histologic grade 2 BCs into 2 groups~ 2/3 were low GGI and had outcomes similar to other low-grade BCs~ 1/3 were high GGI and had outcomes similar to other high-grade BCsGGI has challenged the clinical relevance of grade 2",
                    "sub_points": [
                      "~ 2/3 were low GGI and had outcomes similar to other low-grade BCs",
                      "~ 1/3 were high GGI and had outcomes similar to other high-grade BCs",
                      "GGI has challenged the clinical relevance of grade 2"
                    ]
                  },
                  {
                    "text": "GGI has helped validate histologic grade as important prognostic factorProvides molecular basis underlying different grades of BC",
                    "sub_points": [
                      "Provides molecular basis underlying different grades of BC"
                    ]
                  },
                  {
                    "text": "Simplified index using 4 genes associated with cell cycle progression and proliferation is determined using qRT-PCR (PCR-GGI) and can be used to analyze formalin-fixed tissueGenes used areMYBL2[also used in Oncotype DX (Genomic Health; Redwood City, CA)],KPNA2[also used in MammaPrint (Agendia; Irvine, CA)],CDK1, andCDC20Results are similar to 97-gene assay",
                    "sub_points": [
                      "Genes used areMYBL2[also used in Oncotype DX (Genomic Health; Redwood City, CA)],KPNA2[also used in MammaPrint (Agendia; Irvine, CA)],CDK1, andCDC20",
                      "Results are similar to 97-gene assay"
                    ]
                  },
                  {
                    "text": "Histologic grade 2 BCs can also be subdivided by other measures of proliferationKi-67 (MIB-1) is positive in all cycling cells (i.e., all cells not in G0)Histologic grade 1: 1-15% positive cells (mean: ~ 10%)Histologic grade 2: 3-40% positive cells (mean: ~ 10%)Histologic grade 3: 8-85% positive cells (mean: ~ 20%)Grade 2 BCs can be divided into 2 groups based on Ki-67 scores; generally, cut-off point of 15% is used",
                    "sub_points": [
                      "Ki-67 (MIB-1) is positive in all cycling cells (i.e., all cells not in G0)Histologic grade 1: 1-15% positive cells (mean: ~ 10%)Histologic grade 2: 3-40% positive cells (mean: ~ 10%)Histologic grade 3: 8-85% positive cells (mean: ~ 20%)",
                      "Histologic grade 1: 1-15% positive cells (mean: ~ 10%)",
                      "Histologic grade 2: 3-40% positive cells (mean: ~ 10%)",
                      "Histologic grade 3: 8-85% positive cells (mean: ~ 20%)",
                      "Grade 2 BCs can be divided into 2 groups based on Ki-67 scores; generally, cut-off point of 15% is used"
                    ]
                  }
                ],
                "Grade andChanges in DNA": [
                  {
                    "text": "The number and pattern of genomic copy number alterations differ significantly when stratified by gradeThe average number of chromosomal changes increases with increasing gradeIn high-grade tumors: 5p, 8q, 10p, 17q12, and 19 gains, and 3p, 4, 5q proximal, 9p, 11p, 18q, and 21 lossesLow-grade carcinomas have fewer genomic alterations",
                    "sub_points": [
                      "The average number of chromosomal changes increases with increasing gradeIn high-grade tumors: 5p, 8q, 10p, 17q12, and 19 gains, and 3p, 4, 5q proximal, 9p, 11p, 18q, and 21 lossesLow-grade carcinomas have fewer genomic alterations",
                      "In high-grade tumors: 5p, 8q, 10p, 17q12, and 19 gains, and 3p, 4, 5q proximal, 9p, 11p, 18q, and 21 losses",
                      "Low-grade carcinomas have fewer genomic alterations"
                    ]
                  },
                  {
                    "text": "Close correlation between DNA copy number and mRNA expression levels has been reported"
                  },
                  {
                    "text": "Gene amplification may be common mechanism for increased gene expression in breast tumorsMay help explain GGI",
                    "sub_points": [
                      "May help explain GGI"
                    ]
                  },
                  {
                    "text": "Evolving data is shedding light on molecular underpinnings of grade and its relevance to prognosis in BC"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lymphovascular Invasion": {
            "name": "Lymphovascular Invasion",
            "url": "https://app.pathprimer.com/document/030e0d3f-17ea-4ac2-abb1-0b1603342dc4/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Lymphovascular invasion (LVI)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Lymphatic/vascular invasion or angiolymphatic invasion"
                  },
                  {
                    "text": "Vascular invasion"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Tumor emboli within peritumoral vascular channels (lymphatics and capillaries) outside the main tumor massLVI is an early event in the development of metastasisAssociated with large tumor size, positive lymph nodes, and high histologic gradeAssociated with a higher potential for local recurrence and distant metastasis",
                    "sub_points": [
                      "LVI is an early event in the development of metastasis",
                      "Associated with large tumor size, positive lymph nodes, and high histologic grade",
                      "Associated with a higher potential for local recurrence and distant metastasis"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "Present in 10-90% of invasive breast carcinomas"
                  },
                  {
                    "text": "Incidence varies with patient population, tumor type, and diagnostic criteria used to define LVIRisk of LVI is higher in younger patients",
                    "sub_points": [
                      "Risk of LVI is higher in younger patients"
                    ]
                  },
                  {
                    "text": "Molecular mechanisms of LVI and associated genes that may represent therapeutic targets are under investigationExpression of cell proliferation-related and extracellular pathway genes are increasedLVI does not correlate with gene expression markers for lymphangiogenesis or immune response",
                    "sub_points": [
                      "Expression of cell proliferation-related and extracellular pathway genes are increased",
                      "LVI does not correlate with gene expression markers for lymphangiogenesis or immune response"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Risk Factors": [
                  {
                    "text": "Blood vessel invasion and riskIn a small subset of breast carcinomas, metastasis is via blood vesselsNot associated with lymph node metastasisFewer vessels are involved, and tumor emboli are smaller than those in lymphatics~ 20-30% of axillary node (-) patients develop distant metastasesSome due to lymph node metastasis via internal mammary lymph nodesSome likely due to blood vessel invasionSpindle cell carcinomas, phyllodes tumors, and angiosarcomas are examples of tumors that rarely involve lymph nodesDifficult to distinguish lymphatics from small capillariesImmunoperoxidase markers cannot always identify the type of vessel with confidenceMajority of patients with blood vessel involvement also have LVIFor practical purposes, there is no need to distinguish lymphatic from capillary to diagnose LVI",
                    "sub_points": [
                      "In a small subset of breast carcinomas, metastasis is via blood vesselsNot associated with lymph node metastasisFewer vessels are involved, and tumor emboli are smaller than those in lymphatics~ 20-30% of axillary node (-) patients develop distant metastasesSome due to lymph node metastasis via internal mammary lymph nodesSome likely due to blood vessel invasionSpindle cell carcinomas, phyllodes tumors, and angiosarcomas are examples of tumors that rarely involve lymph nodes",
                      "Not associated with lymph node metastasis",
                      "Fewer vessels are involved, and tumor emboli are smaller than those in lymphatics",
                      "~ 20-30% of axillary node (-) patients develop distant metastasesSome due to lymph node metastasis via internal mammary lymph nodesSome likely due to blood vessel invasion",
                      "Some due to lymph node metastasis via internal mammary lymph nodes",
                      "Some likely due to blood vessel invasion",
                      "Spindle cell carcinomas, phyllodes tumors, and angiosarcomas are examples of tumors that rarely involve lymph nodes",
                      "Difficult to distinguish lymphatics from small capillariesImmunoperoxidase markers cannot always identify the type of vessel with confidenceMajority of patients with blood vessel involvement also have LVIFor practical purposes, there is no need to distinguish lymphatic from capillary to diagnose LVI",
                      "Immunoperoxidase markers cannot always identify the type of vessel with confidence",
                      "Majority of patients with blood vessel involvement also have LVI",
                      "For practical purposes, there is no need to distinguish lymphatic from capillary to diagnose LVI"
                    ]
                  },
                  {
                    "text": "Perineural invasion (PNI) and riskMost patients with PNI also have LVIIt would be very difficult to establish PNI as separate prognostic factor due to its rarityPNI is usually seen within carcinomas and is rarely seen in the surrounding tissueOther lesions can mimic PNIBenign sclerosing lesions can involve nerves and should not be mistaken for malignancyThe smooth muscle of the areola can be mistaken for nerves when involved by carcinoma",
                    "sub_points": [
                      "Most patients with PNI also have LVIIt would be very difficult to establish PNI as separate prognostic factor due to its rarity",
                      "It would be very difficult to establish PNI as separate prognostic factor due to its rarity",
                      "PNI is usually seen within carcinomas and is rarely seen in the surrounding tissue",
                      "Other lesions can mimic PNIBenign sclerosing lesions can involve nerves and should not be mistaken for malignancyThe smooth muscle of the areola can be mistaken for nerves when involved by carcinoma",
                      "Benign sclerosing lesions can involve nerves and should not be mistaken for malignancy",
                      "The smooth muscle of the areola can be mistaken for nerves when involved by carcinoma"
                    ]
                  }
                ],
                "LVI and risk": [
                  {
                    "text": "Lymphatic channels are the main route for metastasisLVI is associated with nodal metastasesBlood vessel invasion in the absence of LVI is very rare (< 5% of cancers)",
                    "sub_points": [
                      "LVI is associated with nodal metastases",
                      "Blood vessel invasion in the absence of LVI is very rare (< 5% of cancers)"
                    ]
                  },
                  {
                    "text": "Peritumoral LVI has independent prognostic significanceAssociated with an increased risk of axillary lymph node metastasis as well as local and distant recurrence",
                    "sub_points": [
                      "Associated with an increased risk of axillary lymph node metastasis as well as local and distant recurrence"
                    ]
                  },
                  {
                    "text": "Intratumoral LVI is difficult to detectLymphatics are fewer in number and usually compressedIt is very difficult to distinguish intratumoral LVI from retraction artifact of stromaPrognostic significance of intratumoral LVI alone is uncertain",
                    "sub_points": [
                      "Lymphatics are fewer in number and usually compressed",
                      "It is very difficult to distinguish intratumoral LVI from retraction artifact of stroma",
                      "Prognostic significance of intratumoral LVI alone is uncertain"
                    ]
                  },
                  {
                    "text": "LVI is more frequently associated with breast cancers demonstrating other aggressive featuresHigh histologic grade and proliferationAbsence of hormone receptor expressionInvasive micropapillary features",
                    "sub_points": [
                      "High histologic grade and proliferation",
                      "Absence of hormone receptor expression",
                      "Invasive micropapillary features"
                    ]
                  },
                  {
                    "text": "LVI is associated with significantly increased risk for recurrence or death independent of nodal statusRecurrence for stage I [node (-)] invasive cancer increases from 22-38% with LVIPresence of LVI increases risk for metastases in additional nodes if the sentinel node is positiveLVI may be associated with resistance to chemotherapyIn some cases, only residual carcinoma is in LVI; may be a protected niche",
                    "sub_points": [
                      "Recurrence for stage I [node (-)] invasive cancer increases from 22-38% with LVI",
                      "Presence of LVI increases risk for metastases in additional nodes if the sentinel node is positive",
                      "LVI may be associated with resistance to chemotherapyIn some cases, only residual carcinoma is in LVI; may be a protected niche",
                      "In some cases, only residual carcinoma is in LVI; may be a protected niche"
                    ]
                  },
                  {
                    "text": "Vascular space involvement may serve as a reservoir for tumor cells in skin and chest wallThis tissue cannot be entirely removed by conventional tumor surgery",
                    "sub_points": [
                      "This tissue cannot be entirely removed by conventional tumor surgery"
                    ]
                  },
                  {
                    "text": "Presence of both LVI and lymph node metastasis confers worse prognosis than either alone"
                  },
                  {
                    "text": "Quantification of LVIAttempts to associate the number of foci of LVI with risk have not provided consistent results",
                    "sub_points": [
                      "Attempts to associate the number of foci of LVI with risk have not provided consistent results"
                    ]
                  },
                  {
                    "text": "LVI in dermis of overlying breast skin is a particularly poor prognostic factorExtensive dermal LVI causes skin erythema and edema that are characteristic of inflammatory carcinoma",
                    "sub_points": [
                      "Extensive dermal LVI causes skin erythema and edema that are characteristic of inflammatory carcinoma"
                    ]
                  }
                ],
                "Therapeutic Implications": [
                  {
                    "text": "LVI is useful in therapeutic decision making, particularly for node (-) patients with small cancersLVI is present in 5-10% of patients with node (-) tumors and is an important prognostic factor in this group",
                    "sub_points": [
                      "LVI is present in 5-10% of patients with node (-) tumors and is an important prognostic factor in this group"
                    ]
                  },
                  {
                    "text": "LVI may be taken into consideration in decisions about postmastectomy radiation"
                  },
                  {
                    "text": "Comprehensive regional nodal irradiation is recommended for patients with LVI"
                  }
                ]
              },
              "MICROSCOPIC": {
                "General Features": [
                  {
                    "text": "Use of LVI as prognostic factor is hampered by lack of consensus on how to define its presenceStrict criteria for LVI aid in making correct diagnosis and ensuring the significance of the finding",
                    "sub_points": [
                      "Strict criteria for LVI aid in making correct diagnosis and ensuring the significance of the finding"
                    ]
                  },
                  {
                    "text": "LVI should be assessed at the periphery, beyond the advancing border of invasive carcinomas (peritumoral)World Health Organization (WHO) recommends only reporting peritumoral LVIMost LVIs will be within 1-2 mm of the edge of an invasive carcinomaIf foci are only seen at a greater distance, they are more likely to be artifactualIntratumoral LVI need not be reported",
                    "sub_points": [
                      "World Health Organization (WHO) recommends only reporting peritumoral LVI",
                      "Most LVIs will be within 1-2 mm of the edge of an invasive carcinoma",
                      "If foci are only seen at a greater distance, they are more likely to be artifactual",
                      "Intratumoral LVI need not be reported"
                    ]
                  },
                  {
                    "text": "Tumor emboli should be within vascular channels lined by a single layer of endothelial cellsNuclei of endothelial cells are not always apparentLymphatics and small capillaries are not surrounded by muscular layer or elasticaRed blood cells may be present in either structureLarge arteries or veins with muscular walls are rarely involvedLarger vessels can be identified with elastic stainsElastin fibers are also present surrounding ducts and should not be mistaken for blood vesselsIHC for smooth muscle markers is also helpful for identifying larger vessels",
                    "sub_points": [
                      "Nuclei of endothelial cells are not always apparent",
                      "Lymphatics and small capillaries are not surrounded by muscular layer or elasticaRed blood cells may be present in either structure",
                      "Red blood cells may be present in either structure",
                      "Large arteries or veins with muscular walls are rarely involvedLarger vessels can be identified with elastic stainsElastin fibers are also present surrounding ducts and should not be mistaken for blood vesselsIHC for smooth muscle markers is also helpful for identifying larger vessels",
                      "Larger vessels can be identified with elastic stains",
                      "Elastin fibers are also present surrounding ducts and should not be mistaken for blood vessels",
                      "IHC for smooth muscle markers is also helpful for identifying larger vessels"
                    ]
                  },
                  {
                    "text": "Tumor emboli usually do not completely conform to the shape of the spaceIf a space is completely filled by tumor cells, it is difficult to recognize as LVIOften mimics ductal carcinoma in situ (DCIS)Tumor cells in a larger space of a different shape favor LVIIn retraction artifact, the shape of the tumor and space are usually identicalSpaces may be elongated and sinusoidal as a lymphatic passes in and out of the plane of sectionBranch points (Y-shaped focus) are more likely to be due to LVI than DCIS",
                    "sub_points": [
                      "If a space is completely filled by tumor cells, it is difficult to recognize as LVIOften mimics ductal carcinoma in situ (DCIS)",
                      "Often mimics ductal carcinoma in situ (DCIS)",
                      "Tumor cells in a larger space of a different shape favor LVIIn retraction artifact, the shape of the tumor and space are usually identical",
                      "In retraction artifact, the shape of the tumor and space are usually identical",
                      "Spaces may be elongated and sinusoidal as a lymphatic passes in and out of the plane of section",
                      "Branch points (Y-shaped focus) are more likely to be due to LVI than DCIS"
                    ]
                  },
                  {
                    "text": "Recognizing the anatomic distribution aids in the identification of lymphaticsOften are found adjacent to small blood vessels and run between lobules in interlobular septaOften seen adjacent to a small arteriole and veinMay cup around arteriole in a C shape",
                    "sub_points": [
                      "Often are found adjacent to small blood vessels and run between lobules in interlobular septa",
                      "Often seen adjacent to a small arteriole and vein",
                      "May cup around arteriole in a C shape"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Endothelial cell markersUsed to confirm tumor cells are in space lined by endothelial cellsNot all lining cells are reactive for available markersPrognostic significance of LVI detected only by IHC and not seen after careful review of H&E sections is unclear",
                    "sub_points": [
                      "Used to confirm tumor cells are in space lined by endothelial cells",
                      "Not all lining cells are reactive for available markers",
                      "Prognostic significance of LVI detected only by IHC and not seen after careful review of H&E sections is unclear"
                    ]
                  },
                  {
                    "text": "CD34Positive in blood vessels and also in some lymphaticsAlso positive in stromal cellsLimits its usefulness for distinguishing LVI from retraction artifact",
                    "sub_points": [
                      "Positive in blood vessels and also in some lymphatics",
                      "Also positive in stromal cellsLimits its usefulness for distinguishing LVI from retraction artifact",
                      "Limits its usefulness for distinguishing LVI from retraction artifact"
                    ]
                  },
                  {
                    "text": "CD31Predominantly positive in blood vessels",
                    "sub_points": [
                      "Predominantly positive in blood vessels"
                    ]
                  },
                  {
                    "text": "Podoplanin (D2-40, monoclonal antibody)Mucin-type transmembrane glycoprotein first described in lymphatic endothelial cellsPodoplanin selectively detects lymphatic endothelial cells over blood vessel endothelial cellsMost sensitive and specific marker for lymphatic endothelial cellsIncreases number of foci of LVI detected by 20% over H&E sections alonePattern should be strong and linearEndothelial cells of arteries, veins, and capillaries should not be positiveMyoepithelial cells can be positive for podoplaninPattern in myoepithelial cells is often weak, granular, and membranousNot a very useful marker to distinguish LVI from DCISPodoplanin may also be positive in basal-like carcinomas, squamous cell carcinomas, and angiosarcomasUse of this marker to evaluate LVI in these tumor types may be more difficult",
                    "sub_points": [
                      "Mucin-type transmembrane glycoprotein first described in lymphatic endothelial cells",
                      "Podoplanin selectively detects lymphatic endothelial cells over blood vessel endothelial cellsMost sensitive and specific marker for lymphatic endothelial cellsIncreases number of foci of LVI detected by 20% over H&E sections alonePattern should be strong and linearEndothelial cells of arteries, veins, and capillaries should not be positive",
                      "Most sensitive and specific marker for lymphatic endothelial cellsIncreases number of foci of LVI detected by 20% over H&E sections alone",
                      "Increases number of foci of LVI detected by 20% over H&E sections alone",
                      "Pattern should be strong and linear",
                      "Endothelial cells of arteries, veins, and capillaries should not be positive",
                      "Myoepithelial cells can be positive for podoplaninPattern in myoepithelial cells is often weak, granular, and membranousNot a very useful marker to distinguish LVI from DCIS",
                      "Pattern in myoepithelial cells is often weak, granular, and membranous",
                      "Not a very useful marker to distinguish LVI from DCIS",
                      "Podoplanin may also be positive in basal-like carcinomas, squamous cell carcinomas, and angiosarcomasUse of this marker to evaluate LVI in these tumor types may be more difficult",
                      "Use of this marker to evaluate LVI in these tumor types may be more difficult"
                    ]
                  },
                  {
                    "text": "Integrin beta-4Beta-4 concurrently stains lymphatic and vascular endothelia and peripheral nerves as well as the majority of tumor cellsBeta-4 staining increases the diagnostic accuracy and interobserves concordance for LVI and PNI",
                    "sub_points": [
                      "Beta-4 concurrently stains lymphatic and vascular endothelia and peripheral nerves as well as the majority of tumor cells",
                      "Beta-4 staining increases the diagnostic accuracy and interobserves concordance for LVI and PNI"
                    ]
                  }
                ],
                "Positive Axillary Lymph Node in the Absence of Lymphovascular Invasion": [
                  {
                    "text": "Usually occurs when there is 1 or only few positive lymph nodes"
                  },
                  {
                    "text": "Frequently occurs with dyscohesive (e.g., lobular) carcinomasCohesive carcinomas grow as contiguous plugs of tumor within lymphatics with adhesion to vessel wallDyscohesive carcinomas are present as dispersed cells in lymphatics, not adherent to wall, and may only be present transiently",
                    "sub_points": [
                      "Cohesive carcinomas grow as contiguous plugs of tumor within lymphatics with adhesion to vessel wall",
                      "Dyscohesive carcinomas are present as dispersed cells in lymphatics, not adherent to wall, and may only be present transiently"
                    ]
                  },
                  {
                    "text": "LVI may be present but not recognizedTumor cells filling lymphatics completely can be mistaken for DCIS or for invasive carcinomaAbsence of a stromal reaction and an anatomic distribution not typical for DCIS are important cluesWhen few foci are present, they may not be seen on all levels of a block or may not have been sampled in submitted tissue",
                    "sub_points": [
                      "Tumor cells filling lymphatics completely can be mistaken for DCIS or for invasive carcinomaAbsence of a stromal reaction and an anatomic distribution not typical for DCIS are important clues",
                      "Absence of a stromal reaction and an anatomic distribution not typical for DCIS are important clues",
                      "When few foci are present, they may not be seen on all levels of a block or may not have been sampled in submitted tissue"
                    ]
                  },
                  {
                    "text": "Diagnosis of LVI should not be made based only due to the presence of lymph node metastases"
                  }
                ],
                "Negative Lymph Nodes in the Presence of Lymphovascular Invasion": [
                  {
                    "text": "LVI may be present, although no metastases are present in lymph nodesReported in 5-10% of node (-) carcinomas",
                    "sub_points": [
                      "Reported in 5-10% of node (-) carcinomas"
                    ]
                  },
                  {
                    "text": "Lymphatic drainage may be toward internal mammary nodes, particularly for medially located carcinomas, or to supraclavicular nodes"
                  },
                  {
                    "text": "Metastatic foci may not have reached axillary nodes or may not be able to establish viable growth in nodes"
                  },
                  {
                    "text": "The sentinel node may not have been removedThe technique used may have failed for a number of technical or biologic reasonse.g., lymph nodes filled with tumor may not take up dye or radiotracer",
                    "sub_points": [
                      "The technique used may have failed for a number of technical or biologic reasonse.g., lymph nodes filled with tumor may not take up dye or radiotracer",
                      "e.g., lymph nodes filled with tumor may not take up dye or radiotracer"
                    ]
                  }
                ],
                "Extent of Lymphovascular Invasion": [
                  {
                    "text": "The number of foci of LVI can range from 1 or 2 in a single block to numerous foci in multiple blocks, adjacent to and away from the invasive carcinoma"
                  },
                  {
                    "text": "The College of American Pathologists \"Protocol for the Examination of Resection Specimens from Patients with Invasive Carcinoma of the Breast\" provides 2 optional choices for reporting extent (version 4.10.0.0, protocol posting date June 2024)Focal (LVI in 1 block only)Extensive (LVI in 2 or more blocks)The pathologist can also choose to report the number of blocks with LVI to communicate the extent",
                    "sub_points": [
                      "Focal (LVI in 1 block only)",
                      "Extensive (LVI in 2 or more blocks)",
                      "The pathologist can also choose to report the number of blocks with LVI to communicate the extent"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Ductal Carcinoma In Situ": [
                  {
                    "text": "Both LVI and DCIS form circumscribed nests of tumor cellsCentral necrosis with calcifications may be present in either LVI or DCISStromal reaction is usually absent surrounding LVI and may be absent or minimal surrounding DCISStromal reaction (e.g., lymphocytic infiltrate) favors DCIS over LVI",
                    "sub_points": [
                      "Central necrosis with calcifications may be present in either LVI or DCIS",
                      "Stromal reaction is usually absent surrounding LVI and may be absent or minimal surrounding DCISStromal reaction (e.g., lymphocytic infiltrate) favors DCIS over LVI",
                      "Stromal reaction (e.g., lymphocytic infiltrate) favors DCIS over LVI"
                    ]
                  },
                  {
                    "text": "DCIS has a typical distribution of ducts and lobules in breast tissueLVI is more typically present in sinusoidal-shaped spaces associated with blood vessels running between lobules that are often not involved by DCISDCIS is typically present in the terminal duct lobular unit and involves multiple adjacent spaces",
                    "sub_points": [
                      "LVI is more typically present in sinusoidal-shaped spaces associated with blood vessels running between lobules that are often not involved by DCIS",
                      "DCIS is typically present in the terminal duct lobular unit and involves multiple adjacent spaces"
                    ]
                  },
                  {
                    "text": "DCIS has a myoepithelial cell layer, which can be identified by IHCCompressed cells at the edges of LVI can mimic the appearance of myoepithelial cellsBoth myoepithelial cells and lymphatic lining cells can be positive for podoplanin (D2-40)p63 is more specific than muscle-type markers to identify myoepithelial cells in this situation",
                    "sub_points": [
                      "Compressed cells at the edges of LVI can mimic the appearance of myoepithelial cells",
                      "Both myoepithelial cells and lymphatic lining cells can be positive for podoplanin (D2-40)",
                      "p63 is more specific than muscle-type markers to identify myoepithelial cells in this situation"
                    ]
                  },
                  {
                    "text": "DCIS generally completely fills spaces, whereas LVI often only partially fills spaces"
                  },
                  {
                    "text": "Careful attention to the anatomic distribution and patterns can be helpful in making the distinction between DCIS and LVI"
                  }
                ],
                "Invasive Carcinoma": [
                  {
                    "text": "Retraction artifact is most commonly seen around foci of invasive carcinoma in the main tumor massLVI should only be assessed outside the borders of invasive carcinoma",
                    "sub_points": [
                      "LVI should only be assessed outside the borders of invasive carcinoma"
                    ]
                  },
                  {
                    "text": "In retraction artifact, tumor cells are usually the same shape as the surrounding spaceIn LVI, tumor cells may not completely conform to space, or space may be larger than cell cluster",
                    "sub_points": [
                      "In LVI, tumor cells may not completely conform to space, or space may be larger than cell cluster"
                    ]
                  },
                  {
                    "text": "Invasive carcinomas with retraction artifact are typically associated with a prominent stromal responseLVI typically not associated with stromal response",
                    "sub_points": [
                      "LVI typically not associated with stromal response"
                    ]
                  },
                  {
                    "text": "Spaces forming retraction artifacts should not be lined by endothelial cellsTrue endothelial cells can be identified by vascular markers (CD31 or podoplanin)Fibroblasts and myofibroblasts can mimic lining endothelial cells in retraction artifact",
                    "sub_points": [
                      "True endothelial cells can be identified by vascular markers (CD31 or podoplanin)",
                      "Fibroblasts and myofibroblasts can mimic lining endothelial cells in retraction artifact"
                    ]
                  },
                  {
                    "text": "Some invasive carcinomas typically show clear spaces around infiltrating tumor cellsInvasive micropapillary carcinoma has an invasive pattern of clusters of cells in cleared-out spacesAlso associated with extensive LVI and increased incidence of lymph node metastases at presentationIt may be difficult to distinguish between LVI and invasive micropapillary morphologyRetraction or clear spaces around tumor cells in other cancer types have been associated with increased risk of lymph node metastasesStromal clefts may be prelymphatic spacesThis pattern is most commonly seen with poorly differentiated carcinomasThese cancers are frequently associated with true LVI",
                    "sub_points": [
                      "Invasive micropapillary carcinoma has an invasive pattern of clusters of cells in cleared-out spacesAlso associated with extensive LVI and increased incidence of lymph node metastases at presentationIt may be difficult to distinguish between LVI and invasive micropapillary morphology",
                      "Also associated with extensive LVI and increased incidence of lymph node metastases at presentation",
                      "It may be difficult to distinguish between LVI and invasive micropapillary morphology",
                      "Retraction or clear spaces around tumor cells in other cancer types have been associated with increased risk of lymph node metastasesStromal clefts may be prelymphatic spacesThis pattern is most commonly seen with poorly differentiated carcinomasThese cancers are frequently associated with true LVI",
                      "Stromal clefts may be prelymphatic spaces",
                      "This pattern is most commonly seen with poorly differentiated carcinomas",
                      "These cancers are frequently associated with true LVI"
                    ]
                  }
                ],
                "Artifactual Displacement of Epithelial Cells": [
                  {
                    "text": "Both benign and malignant cells can be pushed into lymphatic spaces or artifactual cleftsGenerally seen after biopsy and near prior biopsy siteCan occur during core needle biopsy, surgical excision, or during specimen handling",
                    "sub_points": [
                      "Generally seen after biopsy and near prior biopsy site",
                      "Can occur during core needle biopsy, surgical excision, or during specimen handling"
                    ]
                  },
                  {
                    "text": "If cells appear benign and do not resemble carcinoma, LVI should not be diagnosed"
                  },
                  {
                    "text": "LVI should not be diagnosed if tumor cells within spaces are only seen within the biopsy site and are not present elsewhere"
                  }
                ]
              },
              "Molecular": {
                "Gene Expression Profiling": [
                  {
                    "text": "A 99-gene signature was developed by comparing LVI-positive and LVI-negative cancers and identified 2 subtypes"
                  },
                  {
                    "text": "The signature was an independent predictor of poor prognosis"
                  },
                  {
                    "text": "The subtype with a poorer prognosis was associated with larger tumors, higher grade, absence of hormone receptors, overexpression of HER2, and the intrinsic HER2-enriched, basal-like, and luminal B types"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hormone Receptors (ER/PR/AR)": {
            "name": "Hormone Receptors (ER/PR/AR)",
            "url": "https://app.pathprimer.com/document/35d1351a-b31d-49cf-a09e-399e33b431ab/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), breast carcinoma (BC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "ER-α"
                  }
                ]
              },
              "Breast Hormone Receptors": {
                "ER, PR, and AR": [
                  {
                    "text": "Breast development, differentiation, milk production, and milk ejection are influenced by many hormones, including ER, PR, prolactin, oxytocin, and human placental lactogenAR has antiestrogenic effect that inhibits growth",
                    "sub_points": [
                      "AR has antiestrogenic effect that inhibits growth"
                    ]
                  },
                  {
                    "text": "All likely play roles in BC development, but only ER and PR are evaluated in routine pathology practiceAR is being explored as a potential therapeutic target in ER(-)BCs",
                    "sub_points": [
                      "AR is being explored as a potential therapeutic target in ER(-)BCs"
                    ]
                  },
                  {
                    "text": "ER, PR, and AR belong to the nuclear receptor superfamilyAct as transcriptional factors regulated by ligand bindingAfter binding, the ligand receptor complex is relocated to the nucleusThe complex binds to specific DNA response elements in the receptor's target genesResults in hormone-stimulated transcriptionER(+)BCs are dependent on the activated ER pathway for proliferation, survival, and progression",
                    "sub_points": [
                      "Act as transcriptional factors regulated by ligand binding",
                      "After binding, the ligand receptor complex is relocated to the nucleus",
                      "The complex binds to specific DNA response elements in the receptor's target genesResults in hormone-stimulated transcription",
                      "Results in hormone-stimulated transcription",
                      "ER(+)BCs are dependent on the activated ER pathway for proliferation, survival, and progression"
                    ]
                  },
                  {
                    "text": "2 different forms of ER exist: ER-α and ER-βEach ER is encoded by a separate gene:ESR1(ER-α; chromosome 6) andESR2(ER-β; chromosome 14)These 2 proteins have significant sequence homologyDNA-binding regions very similar; likely bind the same target genesLigand-binding regions are less similar; likely have different repertoires of ligands",
                    "sub_points": [
                      "Each ER is encoded by a separate gene:ESR1(ER-α; chromosome 6) andESR2(ER-β; chromosome 14)",
                      "These 2 proteins have significant sequence homologyDNA-binding regions very similar; likely bind the same target genesLigand-binding regions are less similar; likely have different repertoires of ligands",
                      "DNA-binding regions very similar; likely bind the same target genes",
                      "Ligand-binding regions are less similar; likely have different repertoires of ligands"
                    ]
                  }
                ],
                "ER-α": [
                  {
                    "text": "ER-α is the most important hormone receptor in BC"
                  },
                  {
                    "text": "Expressed in luminal cells but not myoepithelial cellsBinding to estrogen stimulates growth of normal cells and BCs that express ERIn normal cells, expression can be turned on and off and is lower in cells during mitosisNot all normal cells are positive for ER at all timesAlso present in some stromal cells (e.g., myofibroblasts), smooth muscle of areola, and some lymphocytes",
                    "sub_points": [
                      "Binding to estrogen stimulates growth of normal cells and BCs that express ERIn normal cells, expression can be turned on and off and is lower in cells during mitosisNot all normal cells are positive for ER at all times",
                      "In normal cells, expression can be turned on and off and is lower in cells during mitosis",
                      "Not all normal cells are positive for ER at all times",
                      "Also present in some stromal cells (e.g., myofibroblasts), smooth muscle of areola, and some lymphocytes"
                    ]
                  },
                  {
                    "text": "ER-α is activated by binding to 17-β-estradiol (estrogen)Regulates expression of numerous genes responsible for the mRNA gene signature of luminal BCs",
                    "sub_points": [
                      "Regulates expression of numerous genes responsible for the mRNA gene signature of luminal BCs"
                    ]
                  },
                  {
                    "text": "ER-α is functionally regulated by phosphorylation through various kinase signaling pathwaysFunctions include chromatin interaction, coregulator recruitment, and gene expressionSite-specific ER-α phosphorylation in BC cells elicits unique gene expression profilesAberrant phosphorylation culminates in significant effects on BC growth, morphology, migration, and invasion",
                    "sub_points": [
                      "Functions include chromatin interaction, coregulator recruitment, and gene expression",
                      "Site-specific ER-α phosphorylation in BC cells elicits unique gene expression profilesAberrant phosphorylation culminates in significant effects on BC growth, morphology, migration, and invasion",
                      "Aberrant phosphorylation culminates in significant effects on BC growth, morphology, migration, and invasion"
                    ]
                  },
                  {
                    "text": "In untreated BC, mutational changes in ER-α are uncommonER-α mutations and splice variants may be present when carcinomas become resistant to endocrine therapy (ET)These changes do not alter protein levels or detection of ER-α by IHC",
                    "sub_points": [
                      "ER-α mutations and splice variants may be present when carcinomas become resistant to endocrine therapy (ET)These changes do not alter protein levels or detection of ER-α by IHC",
                      "These changes do not alter protein levels or detection of ER-α by IHC"
                    ]
                  }
                ],
                "ER-β": [
                  {
                    "text": "ER-β is more widely distributed than ER-α and can be found in luminal cells, myoepithelial cells, stromal cells, lymphocytes, and endothelial cellsAt least 5 isoforms are found in BC",
                    "sub_points": [
                      "At least 5 isoforms are found in BC"
                    ]
                  },
                  {
                    "text": "ER-β is activated by binding to 17-β-estradiol (estrogen), estriol, or related ligands and forms homodimers or heterodimers with ER-α to interact with DNA sequences and activate transcriptionRegulates genes involved with proliferation and apoptosisHas antiproliferative effects to oppose function of ER-α",
                    "sub_points": [
                      "Regulates genes involved with proliferation and apoptosis",
                      "Has antiproliferative effects to oppose function of ER-α"
                    ]
                  },
                  {
                    "text": "ER-β is found at different frequencies in molecular types of BC~ 70% of ER-α(+) carcinomasHigher expression in lobular, tubular, and mucinous carcinomasTypically smaller tumor size, low grade, HER2(-), and have negative lymph nodes~ 55% of HER2(+), ER-α(-) carcinomas~ 60% of HER2(-), ER-α(-) carcinomas",
                    "sub_points": [
                      "~ 70% of ER-α(+) carcinomasHigher expression in lobular, tubular, and mucinous carcinomasTypically smaller tumor size, low grade, HER2(-), and have negative lymph nodes",
                      "Higher expression in lobular, tubular, and mucinous carcinomas",
                      "Typically smaller tumor size, low grade, HER2(-), and have negative lymph nodes",
                      "~ 55% of HER2(+), ER-α(-) carcinomas",
                      "~ 60% of HER2(-), ER-α(-) carcinomas"
                    ]
                  },
                  {
                    "text": "Investigation has been hindered by the number of ER-β types and differences in antibody immunoreactivity patternsCurrent interest in investigating ER-β as target for therapy in ER-α(-) carcinomas",
                    "sub_points": [
                      "Current interest in investigating ER-β as target for therapy in ER-α(-) carcinomas"
                    ]
                  },
                  {
                    "text": "ER-β has not been consistently shown to have utility as a prognostic factor or predictor of response to treatment"
                  }
                ],
                "PR": [
                  {
                    "text": "PR is expressed by luminal cells, some stromal cells, and rare lymphocytes"
                  },
                  {
                    "text": "PR expression is regulated by ER-αER-α(-) and PR(+) carcinomas are exceedingly rareMany are due to assay failure, resulting in a false-negative result for ER-α or a false-positive result for PRRare carcinomas appear to express PR in the absence of ER; this pattern has been associated with other poor prognostic factorsMechanism not well understood",
                    "sub_points": [
                      "ER-α(-) and PR(+) carcinomas are exceedingly rare",
                      "Many are due to assay failure, resulting in a false-negative result for ER-α or a false-positive result for PR",
                      "Rare carcinomas appear to express PR in the absence of ER; this pattern has been associated with other poor prognostic factorsMechanism not well understood",
                      "Mechanism not well understood"
                    ]
                  },
                  {
                    "text": "PR is activated by binding to progesteroneComplex moves to nucleus where it binds to DNA and activates transcriptionPR also interacts with ER-α to direct chromatin remodelingMay result in antiproliferative effects",
                    "sub_points": [
                      "Complex moves to nucleus where it binds to DNA and activates transcription",
                      "PR also interacts with ER-α to direct chromatin remodelingMay result in antiproliferative effects",
                      "May result in antiproliferative effects"
                    ]
                  },
                  {
                    "text": "PR is expressed in ~ 65% of ER-α(+)BCs"
                  },
                  {
                    "text": "Multiple mechanisms for loss or diminished PR expression are recognizedAbnormal ER-α signaling pathwayHetero- or homozygous loss ofPRG(PR) gene in 21% of ER-α(+) carcinomasDownregulation by HER2Aromatase inhibitor treatment resulting in decreased circulating estrogen",
                    "sub_points": [
                      "Abnormal ER-α signaling pathway",
                      "Hetero- or homozygous loss ofPRG(PR) gene in 21% of ER-α(+) carcinomas",
                      "Downregulation by HER2",
                      "Aromatase inhibitor treatment resulting in decreased circulating estrogen"
                    ]
                  },
                  {
                    "text": "PR absence is observed in higher grade carcinomas and is associated with a worse prognosis"
                  }
                ],
                "AR": [
                  {
                    "text": "AR is expressed by luminal cells, stromal cells, and adipocytes"
                  },
                  {
                    "text": "Activated by binding to testosterone or 5α-dihydrotestosterone (DHT)"
                  },
                  {
                    "text": "Inhibitor of of ER-α stimulated breast growth and proliferation"
                  },
                  {
                    "text": "AR is present in the majority of BCs (dependent on subtype)~ 80% of ER-α(+) carcinomasMore common in lower grade carcinomasAR(+) confers improved DFS and OS in ER(+)BC~ 20% of ER-α(-) carcinomasSome are in the group of luminal AR carcinomas (molecular apocrine)Many have an apocrine appearanceSome form tubules and are classified as grade 1May have lower responses to chemotherapy but slower growth rate and better survival compared to other ER-α(-) carcinomasAR may bind to ER response elements and stimulate proliferationNormal apocrine glands and cells with apocrine metaplasia are also ER-α(-)/AR(+)Role of AR in BC is likely dependent on context (BC subtype, circulating hormones, tumor microenvironment)AR can stimulate proliferation in the absence of ER-αAR is emerging as a potential therapeutic target in BCAR testing may be required for entrance into targeted AR therapy trials",
                    "sub_points": [
                      "~ 80% of ER-α(+) carcinomasMore common in lower grade carcinomasAR(+) confers improved DFS and OS in ER(+)BC",
                      "More common in lower grade carcinomas",
                      "AR(+) confers improved DFS and OS in ER(+)BC",
                      "~ 20% of ER-α(-) carcinomasSome are in the group of luminal AR carcinomas (molecular apocrine)Many have an apocrine appearanceSome form tubules and are classified as grade 1May have lower responses to chemotherapy but slower growth rate and better survival compared to other ER-α(-) carcinomasAR may bind to ER response elements and stimulate proliferation",
                      "Some are in the group of luminal AR carcinomas (molecular apocrine)Many have an apocrine appearanceSome form tubules and are classified as grade 1May have lower responses to chemotherapy but slower growth rate and better survival compared to other ER-α(-) carcinomas",
                      "Many have an apocrine appearance",
                      "Some form tubules and are classified as grade 1",
                      "May have lower responses to chemotherapy but slower growth rate and better survival compared to other ER-α(-) carcinomas",
                      "AR may bind to ER response elements and stimulate proliferation",
                      "Normal apocrine glands and cells with apocrine metaplasia are also ER-α(-)/AR(+)",
                      "Role of AR in BC is likely dependent on context (BC subtype, circulating hormones, tumor microenvironment)",
                      "AR can stimulate proliferation in the absence of ER-α",
                      "AR is emerging as a potential therapeutic target in BCAR testing may be required for entrance into targeted AR therapy trials",
                      "AR testing may be required for entrance into targeted AR therapy trials"
                    ]
                  }
                ]
              },
              "Hormone Receptors and Breast Carcinoma": {
                "Risk Factors for Developing ER(+) Carcinomas": [
                  {
                    "text": "70-80% of BCs express ERER(+)BCs show marked increase with ageAt age 30, ER(+) and (-) carcinomas are approximately equal in frequencyAt age 70, ~ 80% of carcinomas are ER(+)Increase with age is most pronounced in women of European ancestry and is lower in women of African, Asian, or Hispanic ancestryThus, the relative proportion of ER(-)BCs is higher in these populations",
                    "sub_points": [
                      "ER(+)BCs show marked increase with ageAt age 30, ER(+) and (-) carcinomas are approximately equal in frequencyAt age 70, ~ 80% of carcinomas are ER(+)",
                      "At age 30, ER(+) and (-) carcinomas are approximately equal in frequency",
                      "At age 70, ~ 80% of carcinomas are ER(+)",
                      "Increase with age is most pronounced in women of European ancestry and is lower in women of African, Asian, or Hispanic ancestryThus, the relative proportion of ER(-)BCs is higher in these populations",
                      "Thus, the relative proportion of ER(-)BCs is higher in these populations"
                    ]
                  },
                  {
                    "text": "Factors associated with prolonged increased exposure to estrogen are associated with an elevated lifetime risk for developing ER(+)BCFemale sexEarly menarcheLate menopauseObesity after menopause (adipose tissue can be converted into estrogens)NulliparityHormone replacement therapyExcessive alcohol consumption can increase estrogen exposureDecreased liver function increases estrogen levels",
                    "sub_points": [
                      "Female sex",
                      "Early menarche",
                      "Late menopause",
                      "Obesity after menopause (adipose tissue can be converted into estrogens)",
                      "Nulliparity",
                      "Hormone replacement therapy",
                      "Excessive alcohol consumption can increase estrogen exposureDecreased liver function increases estrogen levels",
                      "Decreased liver function increases estrogen levels"
                    ]
                  },
                  {
                    "text": "Factors associated with lower estrogen exposure are associated with a decreased lifetime risk for developing ER(+)BCLate menarcheEarly menopauseObesity prior to menopause (menstrual cycles may be reduced or absent)Child bearing (especially beginning at early age)BreastfeedingOophorectomyCruciferous vegetables (e.g., broccoli, Brussels sprouts) can decrease estrogen exposureIndole-3-carbinol causes estrogen to be changed to inactive metaboliteChemoprevention with tamoxifen or other ETs",
                    "sub_points": [
                      "Late menarche",
                      "Early menopause",
                      "Obesity prior to menopause (menstrual cycles may be reduced or absent)",
                      "Child bearing (especially beginning at early age)",
                      "Breastfeeding",
                      "Oophorectomy",
                      "Cruciferous vegetables (e.g., broccoli, Brussels sprouts) can decrease estrogen exposureIndole-3-carbinol causes estrogen to be changed to inactive metabolite",
                      "Indole-3-carbinol causes estrogen to be changed to inactive metabolite",
                      "Chemoprevention with tamoxifen or other ETs"
                    ]
                  }
                ],
                "Pathogenesis of ER(+) Carcinomas": [
                  {
                    "text": "Inappropriate, abnormal, &/or prolonged estrogen exposure stimulates proliferation of ER(+) breast cellsIncreases number of epithelial cells and predisposes cells to mutations and abnormal growthIncreases likelihood of ER-dependent BCs",
                    "sub_points": [
                      "Increases number of epithelial cells and predisposes cells to mutations and abnormal growthIncreases likelihood of ER-dependent BCs",
                      "Increases likelihood of ER-dependent BCs"
                    ]
                  },
                  {
                    "text": "Estrogen can also act as a direct mutagen for breast cells by forming estrogen-DNA adducts"
                  }
                ],
                "Breast Carcinoma Subtypes: Classification by Protein Expression": [
                  {
                    "text": "The most important feature separating BCs into different groups is the presence or absence of ER expression"
                  },
                  {
                    "text": "ER(+)/PR(+)~ 65%: Usually well- or moderately differentiated carcinomasIncludes almost all carcinomas with tubule or cribriform patterns, tubular carcinomas, grade 1 and 2 lobular carcinomas, and mucinous carcinomas",
                    "sub_points": [
                      "Includes almost all carcinomas with tubule or cribriform patterns, tubular carcinomas, grade 1 and 2 lobular carcinomas, and mucinous carcinomas"
                    ]
                  },
                  {
                    "text": "ER(+)/PR(-)~ 15%: Usually grade 2 or 3; rarely grade 1PR is downregulated by HER2; 30-50% of ER(+)/PR(-) carcinomas show HER2 amplificationMore aggressive clinical courseMore frequent in older women with larger carcinomas with higher rate of proliferation [when compared to ER(+)/PR(+) carcinomas]These BCs may be intrinsically resistant to ETClinical trial data are unclear as to whether these patients should be treated differently compared to patients with ER(+)/PR(+)BCsSome medical oncologists are more likely to include chemotherapy in addition to hormonal therapy",
                    "sub_points": [
                      "PR is downregulated by HER2; 30-50% of ER(+)/PR(-) carcinomas show HER2 amplification",
                      "More aggressive clinical course",
                      "More frequent in older women with larger carcinomas with higher rate of proliferation [when compared to ER(+)/PR(+) carcinomas]",
                      "These BCs may be intrinsically resistant to ETClinical trial data are unclear as to whether these patients should be treated differently compared to patients with ER(+)/PR(+)BCsSome medical oncologists are more likely to include chemotherapy in addition to hormonal therapy",
                      "Clinical trial data are unclear as to whether these patients should be treated differently compared to patients with ER(+)/PR(+)BCs",
                      "Some medical oncologists are more likely to include chemotherapy in addition to hormonal therapy"
                    ]
                  },
                  {
                    "text": "ER(-)/PR(+)< 10%: Usually grade 3Some cases are due to technical problems with either ER or PR assayAssay should be repeated on same or different tissue block before reporting this resultSome cases are due to a true unusual pattern of hormone receptor expressionBiologic basis of PR expression in absence of ER expression is not well understoodPossibly due to changes in ER, resulting in loss of antigenicity (e.g., mutations or splice variants)Possibly due to ER-independent pathways, regulating PR expressionThese carcinomas tend to be larger and occur in younger womenPatients are eligible for ET2017 St. Galen and National Comprehensive Cancer Network guidelines consider these to be hormone receptor (+) BCsAmerican Joint Committee on Cancer (AJCC) 8th edition staging system may assign these BCs to lower prognostic stages compared to ER(-)/PR(-)BCs",
                    "sub_points": [
                      "Some cases are due to technical problems with either ER or PR assayAssay should be repeated on same or different tissue block before reporting this result",
                      "Assay should be repeated on same or different tissue block before reporting this result",
                      "Some cases are due to a true unusual pattern of hormone receptor expressionBiologic basis of PR expression in absence of ER expression is not well understoodPossibly due to changes in ER, resulting in loss of antigenicity (e.g., mutations or splice variants)Possibly due to ER-independent pathways, regulating PR expression",
                      "Biologic basis of PR expression in absence of ER expression is not well understoodPossibly due to changes in ER, resulting in loss of antigenicity (e.g., mutations or splice variants)Possibly due to ER-independent pathways, regulating PR expression",
                      "Possibly due to changes in ER, resulting in loss of antigenicity (e.g., mutations or splice variants)",
                      "Possibly due to ER-independent pathways, regulating PR expression",
                      "These carcinomas tend to be larger and occur in younger women",
                      "Patients are eligible for ET2017 St. Galen and National Comprehensive Cancer Network guidelines consider these to be hormone receptor (+) BCsAmerican Joint Committee on Cancer (AJCC) 8th edition staging system may assign these BCs to lower prognostic stages compared to ER(-)/PR(-)BCs",
                      "2017 St. Galen and National Comprehensive Cancer Network guidelines consider these to be hormone receptor (+) BCs",
                      "American Joint Committee on Cancer (AJCC) 8th edition staging system may assign these BCs to lower prognostic stages compared to ER(-)/PR(-)BCs"
                    ]
                  },
                  {
                    "text": "ER(-)/PR(-)~ 15%: Usually grade 3~ 1/3 of these carcinomas show HER2 amplificationThese carcinomas are relatively more common in young women and women of African or Hispanic ancestry",
                    "sub_points": [
                      "~ 1/3 of these carcinomas show HER2 amplification",
                      "These carcinomas are relatively more common in young women and women of African or Hispanic ancestry"
                    ]
                  }
                ],
                "Breast Carcinoma Subtypes: Classification by mRNA": [
                  {
                    "text": "Gene expression profiling confirmed the major importance in ER status controlling gene signatures of BCs"
                  },
                  {
                    "text": "2 major subtypes of ER(+)BCThese types represent 2 ends of a spectrum of BCs with ER expression and proliferation ranging from very low to very high",
                    "sub_points": [
                      "These types represent 2 ends of a spectrum of BCs with ER expression and proliferation ranging from very low to very high"
                    ]
                  },
                  {
                    "text": "Luminal A typeTypically show high levels of ER expression, usually also positive for PRMajority are grade 1 or 2 with low proliferationInvade as well-formed tubules, cribriform nests, or papillaeVast majority are HER2(-)Usually highly responsive to ET",
                    "sub_points": [
                      "Typically show high levels of ER expression, usually also positive for PR",
                      "Majority are grade 1 or 2 with low proliferation",
                      "Invade as well-formed tubules, cribriform nests, or papillae",
                      "Vast majority are HER2(-)",
                      "Usually highly responsive to ET"
                    ]
                  },
                  {
                    "text": "Luminal B typeLower levels of ER expression, may be PR(-)Majority are grade 2 or 3 with high proliferationTubules may be present but less well formed; may invade as nests and sheets of tumor cells~ 50% HER2(+) (luminal HER2 subtype)May be less responsive to ET",
                    "sub_points": [
                      "Lower levels of ER expression, may be PR(-)",
                      "Majority are grade 2 or 3 with high proliferation",
                      "Tubules may be present but less well formed; may invade as nests and sheets of tumor cells",
                      "~ 50% HER2(+) (luminal HER2 subtype)",
                      "May be less responsive to ET"
                    ]
                  }
                ]
              },
              "Clinical Implications": {
                "Prognostic Implications": [
                  {
                    "text": "Prognosis based on ER expression is related to stage and time of follow-upStage 0 [ductal carcinoma in situ (DCIS)] and stage 1 BCs have a good prognosis (> 85% survival) at 20 years, regardless of ER statusStage 2, 3, and 4 ER(+)BCs have a better prognosis compared to ER(-)BCs up to 10 years of follow-upBetween 10-20 years, improved prognosis diminishesSurvival for ER(+) and ER(-) BCs is similar at 20 yearsLikely due to eventual mortality from slow-growing BCs and acquisition of endocrine resistance",
                    "sub_points": [
                      "Stage 0 [ductal carcinoma in situ (DCIS)] and stage 1 BCs have a good prognosis (> 85% survival) at 20 years, regardless of ER status",
                      "Stage 2, 3, and 4 ER(+)BCs have a better prognosis compared to ER(-)BCs up to 10 years of follow-upBetween 10-20 years, improved prognosis diminishesSurvival for ER(+) and ER(-) BCs is similar at 20 yearsLikely due to eventual mortality from slow-growing BCs and acquisition of endocrine resistance",
                      "Between 10-20 years, improved prognosis diminishesSurvival for ER(+) and ER(-) BCs is similar at 20 yearsLikely due to eventual mortality from slow-growing BCs and acquisition of endocrine resistance",
                      "Survival for ER(+) and ER(-) BCs is similar at 20 years",
                      "Likely due to eventual mortality from slow-growing BCs and acquisition of endocrine resistance"
                    ]
                  },
                  {
                    "text": "PRGgene is regulated by ER, and PR is usually detected in tumor cells with activated ER pathwayPR status is independently associated with outcomeER(+)/PR(+)BCs confer a better prognosis than ER(+)/PR(-)BCsThis may be related to different tumor biology for the ER(+)/PR(-) subset of BCsLow PR expression is significantly correlated with postmenopausal status, larger tumor size, low ER expression, and worse distant relapse-free survival",
                    "sub_points": [
                      "PR status is independently associated with outcome",
                      "ER(+)/PR(+)BCs confer a better prognosis than ER(+)/PR(-)BCsThis may be related to different tumor biology for the ER(+)/PR(-) subset of BCsLow PR expression is significantly correlated with postmenopausal status, larger tumor size, low ER expression, and worse distant relapse-free survival",
                      "This may be related to different tumor biology for the ER(+)/PR(-) subset of BCs",
                      "Low PR expression is significantly correlated with postmenopausal status, larger tumor size, low ER expression, and worse distant relapse-free survival"
                    ]
                  },
                  {
                    "text": "BCs negative for ER and PR have a worse prognosis compared to hormone receptor (+) BCsPatients who develop distant metastases after treatment rarely have prolonged survivalHowever, ER(-)BCs with a pathologic complete response after neoadjuvant chemotherapy have a very favorable prognosis",
                    "sub_points": [
                      "Patients who develop distant metastases after treatment rarely have prolonged survival",
                      "However, ER(-)BCs with a pathologic complete response after neoadjuvant chemotherapy have a very favorable prognosis"
                    ]
                  }
                ],
                "Predictive Implications": [
                  {
                    "text": "ER expression in BC is highly predictive for clinical benefit from ETsIn general, ER(+)/HER2(-)BCs do not respond well to chemotherapySome patients with distant metastases survive for many years with hormonal treatment",
                    "sub_points": [
                      "In general, ER(+)/HER2(-)BCs do not respond well to chemotherapy",
                      "Some patients with distant metastases survive for many years with hormonal treatment"
                    ]
                  },
                  {
                    "text": "Clinical benefit from ET is only seen in BCs that test positive for ER &/or PR"
                  },
                  {
                    "text": "American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines recommend performing clinically validated assays for ER and PR on every newly diagnosed invasive BC and ER on newly diagnosed DCIS"
                  }
                ],
                "AJCC Staging (8th Edition)": [
                  {
                    "text": "In the 8th edition of AJCC staging (effective 1/1/2018), ER and PR status is included in determining prognostic stageAnatomic T, N, and M, HER2 status, grade, and (if available) a low multigene assay score are also included",
                    "sub_points": [
                      "Anatomic T, N, and M, HER2 status, grade, and (if available) a low multigene assay score are also included"
                    ]
                  },
                  {
                    "text": "This system recognizes the importance of ER and PR expression in determining prognosis"
                  }
                ],
                "Treatment Strategies: Invasive Carcinoma": [
                  {
                    "text": "Endocrine therapy (ET)Most commonly administered 1st-line therapy for ER(+)BCCan be achieved using pharmaceuticals or surgeryClinical benefit of ET is limited by ET drug resistance",
                    "sub_points": [
                      "Most commonly administered 1st-line therapy for ER(+)BC",
                      "Can be achieved using pharmaceuticals or surgery",
                      "Clinical benefit of ET is limited by ET drug resistance"
                    ]
                  },
                  {
                    "text": "SurgeryOophorectomy is effective at reducing hormone levelsIn patients withBRCA1orBRCA2mutations, surgery also reduces risk of ovarian or tubal carcinomas",
                    "sub_points": [
                      "Oophorectomy is effective at reducing hormone levels",
                      "In patients withBRCA1orBRCA2mutations, surgery also reduces risk of ovarian or tubal carcinomas"
                    ]
                  },
                  {
                    "text": "DrugsSelective ER modulators (SERMs) act as ER antagonists in breast tissue (e.g., tamoxifen)Tamoxifen acts as an antagonist to ER in breast tissueHowever, tamoxifen is an ER agonist in bone (acting against osteoporosis) and a partial agonist in endometrium (acting to increase risk of carcinoma)Aromatase inhibitorsblock conversion of precursors to estrogen in peripheral tissue (e.g., anastrozole, letrozole, exemestane)Antagonists or refractory agonistsblock gonadotropin-releasing hormone[GnRH, a.k.a. luteinizing hormone-releasing hormone (LH-RH)] (e.g., leuprolide, goserelin)Results in ovarian function suppression, may benefit some high-risk ER(+)BCs in premenopausal patientsSelective ER degraders (SERDs) bind to ER and inhibit dimerization (e.g., fulvestrant, elacestrant)Accelerate hormone receptor degradationCan result in a false-negative hormone receptor result by IHC in patients being treatedReduce translocation of ER to nucleusDirect antiestrogenic effect2nd-generation SERDs are more potent with improved oral bioavailability and pharmacokineticsCyclin-dependent kinase 4/6 inhibitors(CDK4/6i) combined with ET improve outcomes for advanced or high-risk early-stage ER(+)BC (e.g., palbociclib)CDK4/6i target cell cycle control machinery to help overcome aspects of endocrine resistanceDevelopment of intrinsic or acquired resistance can limit efficacy of CDK4/6iPhosphoinositide 3-kinase (PI3K) inhibitors(e.g., buparlisib, pictilisib)The PI3K/AKT/mTOR pathway is implicated in some cases of endocrine-resistant ER(+)BC with PI3K/AKT/mTOR pathway alterationsA number of inhibitors are under development and testing for endocrine-resistant ER(+)BC with pathway alterationsMultiple new targeted agents are in clinical development or have been approved for advanced ER(+)BC",
                    "sub_points": [
                      "Selective ER modulators (SERMs) act as ER antagonists in breast tissue (e.g., tamoxifen)Tamoxifen acts as an antagonist to ER in breast tissueHowever, tamoxifen is an ER agonist in bone (acting against osteoporosis) and a partial agonist in endometrium (acting to increase risk of carcinoma)",
                      "Tamoxifen acts as an antagonist to ER in breast tissueHowever, tamoxifen is an ER agonist in bone (acting against osteoporosis) and a partial agonist in endometrium (acting to increase risk of carcinoma)",
                      "However, tamoxifen is an ER agonist in bone (acting against osteoporosis) and a partial agonist in endometrium (acting to increase risk of carcinoma)",
                      "Aromatase inhibitorsblock conversion of precursors to estrogen in peripheral tissue (e.g., anastrozole, letrozole, exemestane)",
                      "Antagonists or refractory agonistsblock gonadotropin-releasing hormone[GnRH, a.k.a. luteinizing hormone-releasing hormone (LH-RH)] (e.g., leuprolide, goserelin)Results in ovarian function suppression, may benefit some high-risk ER(+)BCs in premenopausal patients",
                      "Results in ovarian function suppression, may benefit some high-risk ER(+)BCs in premenopausal patients",
                      "Selective ER degraders (SERDs) bind to ER and inhibit dimerization (e.g., fulvestrant, elacestrant)Accelerate hormone receptor degradationCan result in a false-negative hormone receptor result by IHC in patients being treatedReduce translocation of ER to nucleusDirect antiestrogenic effect2nd-generation SERDs are more potent with improved oral bioavailability and pharmacokinetics",
                      "Accelerate hormone receptor degradationCan result in a false-negative hormone receptor result by IHC in patients being treated",
                      "Can result in a false-negative hormone receptor result by IHC in patients being treated",
                      "Reduce translocation of ER to nucleus",
                      "Direct antiestrogenic effect",
                      "2nd-generation SERDs are more potent with improved oral bioavailability and pharmacokinetics",
                      "Cyclin-dependent kinase 4/6 inhibitors(CDK4/6i) combined with ET improve outcomes for advanced or high-risk early-stage ER(+)BC (e.g., palbociclib)CDK4/6i target cell cycle control machinery to help overcome aspects of endocrine resistanceDevelopment of intrinsic or acquired resistance can limit efficacy of CDK4/6i",
                      "CDK4/6i target cell cycle control machinery to help overcome aspects of endocrine resistance",
                      "Development of intrinsic or acquired resistance can limit efficacy of CDK4/6i",
                      "Phosphoinositide 3-kinase (PI3K) inhibitors(e.g., buparlisib, pictilisib)The PI3K/AKT/mTOR pathway is implicated in some cases of endocrine-resistant ER(+)BC with PI3K/AKT/mTOR pathway alterationsA number of inhibitors are under development and testing for endocrine-resistant ER(+)BC with pathway alterations",
                      "The PI3K/AKT/mTOR pathway is implicated in some cases of endocrine-resistant ER(+)BC with PI3K/AKT/mTOR pathway alterationsA number of inhibitors are under development and testing for endocrine-resistant ER(+)BC with pathway alterations",
                      "A number of inhibitors are under development and testing for endocrine-resistant ER(+)BC with pathway alterations",
                      "Multiple new targeted agents are in clinical development or have been approved for advanced ER(+)BC"
                    ]
                  }
                ],
                "Treatment Strategies: Ductal Carcinoma In Situ": [
                  {
                    "text": "The NSABP B-24 DCIS trial demonstrated that tamoxifen reduced the likelihood of local recurrence if DCIS was positive for ER or PRPatients were randomized to treatment ± tamoxifenRetrospective analysis determined ER and PR expression in a subset of patients on studyTamoxifen reduced likelihood of local recurrence if DCIS was ER(+) or PR(+)Benefit was not seen for ER(-)/PR(-) DCISHowever, too few cases of ER(-)/PR(-) DCIS were included to exclude possibility of small effect",
                    "sub_points": [
                      "Patients were randomized to treatment ± tamoxifen",
                      "Retrospective analysis determined ER and PR expression in a subset of patients on studyTamoxifen reduced likelihood of local recurrence if DCIS was ER(+) or PR(+)Benefit was not seen for ER(-)/PR(-) DCISHowever, too few cases of ER(-)/PR(-) DCIS were included to exclude possibility of small effect",
                      "Tamoxifen reduced likelihood of local recurrence if DCIS was ER(+) or PR(+)",
                      "Benefit was not seen for ER(-)/PR(-) DCISHowever, too few cases of ER(-)/PR(-) DCIS were included to exclude possibility of small effect",
                      "However, too few cases of ER(-)/PR(-) DCIS were included to exclude possibility of small effect"
                    ]
                  },
                  {
                    "text": "Tamoxifen treatment does not have survival benefit for DCIS"
                  },
                  {
                    "text": "ASCO/CAP guidelines recommend ER testing of DCIS"
                  }
                ],
                "Resistance to Endocrine Therapy": [
                  {
                    "text": "Primary resistance to ET is defined as disease recurrence within 2 years of adjuvant ET or progression in first 6 months of ET for metastatic BC"
                  },
                  {
                    "text": "Acquired resistance to ET is frequently observed after an interval of treatmentMost common in recurrent or metastatic disease after long-term ET, including aromatase inhibitors (10-40% of cases)In the majority of cases, these carcinomas continue to express ER as detected by IHCMajor clinical challenge, limiting the success of ET",
                    "sub_points": [
                      "Most common in recurrent or metastatic disease after long-term ET, including aromatase inhibitors (10-40% of cases)",
                      "In the majority of cases, these carcinomas continue to express ER as detected by IHC",
                      "Major clinical challenge, limiting the success of ET"
                    ]
                  },
                  {
                    "text": "There are multiple possible resistance mechanismsGain of function mutations inESR1(ER1) gene(~ 20-40% of metastatic disease)Results in ligand-independent constitutive activationESR1mutations are rare in primary carcinomas (< 1%)Most common in recurrent lobular carcinomasSERDs have activity against mutantESR1BCAlteration in upstream growth factor signaling pathwaysMutations in genes causing increase in MAPK, PI3K/Akt/MTOR signalingIncreased expression of EGFR, HER2, or IGF-1RCross-talk between ER and other signaling pathwaysMay activate ER via phosphorylation or ER-coactivator phosphorylation, abrogating the need for activation by estrogenChanges in other signaling pathwaysMutations in genes resulting in alterations in ER transcriptional regulation",
                    "sub_points": [
                      "Gain of function mutations inESR1(ER1) gene(~ 20-40% of metastatic disease)Results in ligand-independent constitutive activationESR1mutations are rare in primary carcinomas (< 1%)Most common in recurrent lobular carcinomasSERDs have activity against mutantESR1BC",
                      "Results in ligand-independent constitutive activation",
                      "ESR1mutations are rare in primary carcinomas (< 1%)",
                      "Most common in recurrent lobular carcinomas",
                      "SERDs have activity against mutantESR1BC",
                      "Alteration in upstream growth factor signaling pathwaysMutations in genes causing increase in MAPK, PI3K/Akt/MTOR signalingIncreased expression of EGFR, HER2, or IGF-1RCross-talk between ER and other signaling pathwaysMay activate ER via phosphorylation or ER-coactivator phosphorylation, abrogating the need for activation by estrogen",
                      "Mutations in genes causing increase in MAPK, PI3K/Akt/MTOR signaling",
                      "Increased expression of EGFR, HER2, or IGF-1RCross-talk between ER and other signaling pathwaysMay activate ER via phosphorylation or ER-coactivator phosphorylation, abrogating the need for activation by estrogen",
                      "Cross-talk between ER and other signaling pathways",
                      "May activate ER via phosphorylation or ER-coactivator phosphorylation, abrogating the need for activation by estrogen",
                      "Changes in other signaling pathwaysMutations in genes resulting in alterations in ER transcriptional regulation",
                      "Mutations in genes resulting in alterations in ER transcriptional regulation"
                    ]
                  },
                  {
                    "text": "Current therapeutic strategies to improve outcome in endocrine-resistant BC include targeted approachesMultiple new targeted agents are in clinical development or have been approved for advanced or high-risk early-stage ER(+)BCInhibitors against CDK4/6 (palbociclib, ribociclib, abemaciclib)Inhibitors against mechanistic target of rapamycin (mTOR) (everolimus)Inhibitors against PI3K (alpelisib) and AKT (capivasertib)Proteolysis targeting chimeras (PROTACs)Next-generation SERDs (elacestrant), antibody drug conjugates, histone deacetylase (HDAC) inhibitorsOptimal combination and sequencing of new therapies to overcome resistance remains challenging",
                    "sub_points": [
                      "Multiple new targeted agents are in clinical development or have been approved for advanced or high-risk early-stage ER(+)BCInhibitors against CDK4/6 (palbociclib, ribociclib, abemaciclib)Inhibitors against mechanistic target of rapamycin (mTOR) (everolimus)Inhibitors against PI3K (alpelisib) and AKT (capivasertib)Proteolysis targeting chimeras (PROTACs)Next-generation SERDs (elacestrant), antibody drug conjugates, histone deacetylase (HDAC) inhibitors",
                      "Inhibitors against CDK4/6 (palbociclib, ribociclib, abemaciclib)",
                      "Inhibitors against mechanistic target of rapamycin (mTOR) (everolimus)",
                      "Inhibitors against PI3K (alpelisib) and AKT (capivasertib)",
                      "Proteolysis targeting chimeras (PROTACs)",
                      "Next-generation SERDs (elacestrant), antibody drug conjugates, histone deacetylase (HDAC) inhibitors",
                      "Optimal combination and sequencing of new therapies to overcome resistance remains challenging"
                    ]
                  }
                ],
                "Testing Multiple Ipsilateral Synchronous Primary Breast Carcinomas": [
                  {
                    "text": "~ 10% of patients have > 1 invasive carcinoma due to multiple etiologiesDCIS giving rise to > 1 focus of invasionIntramammary metastasis via lymphovascular invasionBiologically separate BCs",
                    "sub_points": [
                      "DCIS giving rise to > 1 focus of invasion",
                      "Intramammary metastasis via lymphovascular invasion",
                      "Biologically separate BCs"
                    ]
                  },
                  {
                    "text": "Standard of care is to perform biomarker testing on the largest focus of invasion"
                  },
                  {
                    "text": "CAP guidelines also recommend performing studies on smaller carcinoma(s) if they are discordant in grade or histology with the largest BC"
                  }
                ],
                "Testing After Neoadjuvant Therapy": [
                  {
                    "text": "~ 5-25% of carcinomas show a change in ER &/or PR status after neoadjuvant therapyLoss of expressionMay be due to heterogeneous expression in pretreatment BC with expression not seen in minimal residual diseaseMay be due to changes due to treatment (e.g., selection of resistant clones, particularly after targeted therapy)Poor prognostic factorGain of expressionMay be due to heterogeneous expression in pretreatment BC with expression seen in larger area of residual diseaseChemotherapy may preferentially select against ER(-) clones/BCs, resulting in increased relative number of ER(+) clones/BCs after treatmentLess likely to be a direct alteration in expression due to treatmentChange from ER(-) to ER(+) is observed in ~ 10-15% of patientsPatients are eligible for ETPatients have improved survival compared to patients whose BCs remain ER(-) after treatmentRepeat testing for ER in carcinomas that were ER(-) prior to treatment can have clinical significance for these patients",
                    "sub_points": [
                      "Loss of expressionMay be due to heterogeneous expression in pretreatment BC with expression not seen in minimal residual diseaseMay be due to changes due to treatment (e.g., selection of resistant clones, particularly after targeted therapy)Poor prognostic factor",
                      "May be due to heterogeneous expression in pretreatment BC with expression not seen in minimal residual disease",
                      "May be due to changes due to treatment (e.g., selection of resistant clones, particularly after targeted therapy)",
                      "Poor prognostic factor",
                      "Gain of expressionMay be due to heterogeneous expression in pretreatment BC with expression seen in larger area of residual diseaseChemotherapy may preferentially select against ER(-) clones/BCs, resulting in increased relative number of ER(+) clones/BCs after treatmentLess likely to be a direct alteration in expression due to treatmentChange from ER(-) to ER(+) is observed in ~ 10-15% of patientsPatients are eligible for ETPatients have improved survival compared to patients whose BCs remain ER(-) after treatmentRepeat testing for ER in carcinomas that were ER(-) prior to treatment can have clinical significance for these patients",
                      "May be due to heterogeneous expression in pretreatment BC with expression seen in larger area of residual diseaseChemotherapy may preferentially select against ER(-) clones/BCs, resulting in increased relative number of ER(+) clones/BCs after treatment",
                      "Chemotherapy may preferentially select against ER(-) clones/BCs, resulting in increased relative number of ER(+) clones/BCs after treatment",
                      "Less likely to be a direct alteration in expression due to treatment",
                      "Change from ER(-) to ER(+) is observed in ~ 10-15% of patientsPatients are eligible for ETPatients have improved survival compared to patients whose BCs remain ER(-) after treatment",
                      "Patients are eligible for ET",
                      "Patients have improved survival compared to patients whose BCs remain ER(-) after treatment",
                      "Repeat testing for ER in carcinomas that were ER(-) prior to treatment can have clinical significance for these patients"
                    ]
                  }
                ],
                "Testing of Distant Metastases": [
                  {
                    "text": "Testing metastatic sites for ER and PR is often requested to help guide therapy"
                  },
                  {
                    "text": "If morphology and immunoprofile are concordant with the primary BC, results are reassuring"
                  },
                  {
                    "text": "However, ~ 20-25% of metastases have discordant findings compared to primary BCLosses are more common than gains and associated with poorer prognosis",
                    "sub_points": [
                      "Losses are more common than gains and associated with poorer prognosis"
                    ]
                  },
                  {
                    "text": "If results are discordant, additional studies may be appropriate"
                  },
                  {
                    "text": "Gain of ER &/or PR can occur in multiple settingsHeterogeneity of expression may not have been detected in the primary BCThe original result may have been a false-negativeThe metastasis may be from a different primary BC (e.g., subsequent BC)",
                    "sub_points": [
                      "Heterogeneity of expression may not have been detected in the primary BC",
                      "The original result may have been a false-negative",
                      "The metastasis may be from a different primary BC (e.g., subsequent BC)"
                    ]
                  },
                  {
                    "text": "Loss of ER &/or PR can occur due to multiple factorsTechnical issues with assayProblems with tissue (prolonged cold ischemic time, cautery)Problems during processing (suboptimal fixation time, fixative other than formalin, decalcification)Only a small number of tumor cells are available for evaluationTreatment with a SERD resulting in degradation of protein and loss of immunoreactivityThe metastasis is from a different primary BC or is another type of tumor",
                    "sub_points": [
                      "Technical issues with assay",
                      "Problems with tissue (prolonged cold ischemic time, cautery)",
                      "Problems during processing (suboptimal fixation time, fixative other than formalin, decalcification)",
                      "Only a small number of tumor cells are available for evaluation",
                      "Treatment with a SERD resulting in degradation of protein and loss of immunoreactivity",
                      "The metastasis is from a different primary BC or is another type of tumor"
                    ]
                  }
                ]
              },
              "Immunohistochemical Testing for Hormone Receptors": {
                "Introduction": [
                  {
                    "text": "ASCO/CAP guidelines recommend hormone receptor testing by IHCER and PR testing is performed on newly diagnosed invasive BCER testing is performed on newly diagnosed DCIS",
                    "sub_points": [
                      "ER and PR testing is performed on newly diagnosed invasive BC",
                      "ER testing is performed on newly diagnosed DCIS"
                    ]
                  },
                  {
                    "text": "IHC has a number of advantages over ligand-binding assay methodologiesLower costMorphologic confirmation of evaluation of tumor cells and not normal breast elementsIHC detects nuclear hormone receptor proteins and excludes cases with cytoplasmic positivityRapid turnaround timeAbility to assay smaller tissue samples, such as core needle biopsies",
                    "sub_points": [
                      "Lower cost",
                      "Morphologic confirmation of evaluation of tumor cells and not normal breast elementsIHC detects nuclear hormone receptor proteins and excludes cases with cytoplasmic positivity",
                      "IHC detects nuclear hormone receptor proteins and excludes cases with cytoplasmic positivity",
                      "Rapid turnaround time",
                      "Ability to assay smaller tissue samples, such as core needle biopsies"
                    ]
                  }
                ],
                "Specimen Handling": [
                  {
                    "text": "Ideally, breast specimens should be sectioned and placed in an adequate volume of fixative within 1 hour of removalCore needle biopsies are often the specimens with the best preservation of biomolecules compared to excisions or mastectomiesNeedle biopsy techniques that use heat or freezing should be avoided, as these treatments have adverse effects on biomolecules and morphologyDue to the relatively small size of BCs on core needle biopsy compared to excisions in some cases, repeat studies when negative results are obtained can be considered",
                    "sub_points": [
                      "Core needle biopsies are often the specimens with the best preservation of biomolecules compared to excisions or mastectomiesNeedle biopsy techniques that use heat or freezing should be avoided, as these treatments have adverse effects on biomolecules and morphologyDue to the relatively small size of BCs on core needle biopsy compared to excisions in some cases, repeat studies when negative results are obtained can be considered",
                      "Needle biopsy techniques that use heat or freezing should be avoided, as these treatments have adverse effects on biomolecules and morphology",
                      "Due to the relatively small size of BCs on core needle biopsy compared to excisions in some cases, repeat studies when negative results are obtained can be considered"
                    ]
                  },
                  {
                    "text": "For larger specimens, the invasive carcinoma should be identified grosslyA sample of BC and fibrous normal tissue can be placed together in the same cassette and immediately placed in formalinEnsures good fixation of BC as well as normal breast tissue to function as an internal control for ER and PRA section from the periphery of the BC is preferred over a section from the centerCenters of BCs are often fibrotic or necrotic",
                    "sub_points": [
                      "A sample of BC and fibrous normal tissue can be placed together in the same cassette and immediately placed in formalinEnsures good fixation of BC as well as normal breast tissue to function as an internal control for ER and PR",
                      "Ensures good fixation of BC as well as normal breast tissue to function as an internal control for ER and PR",
                      "A section from the periphery of the BC is preferred over a section from the centerCenters of BCs are often fibrotic or necrotic",
                      "Centers of BCs are often fibrotic or necrotic"
                    ]
                  }
                ],
                "Breast Tissue Fixation": [
                  {
                    "text": "Breast tissue samples must be fixed in 10% neutral buffered formalinFixation time: Recommended to be at least 6 hours and no more than 72 hours before processingFormalin fixation occurs over time (12-24 hours)Cross-linking of proteins occurs, which stabilizes the tissue and also alters antigenic epitopes in some casesUnder- or overfixation can lead to technical problems with the assay and may give false-negative resultsSmall biopsy samples require the same amount of fixation time as larger resection samples",
                    "sub_points": [
                      "Fixation time: Recommended to be at least 6 hours and no more than 72 hours before processingFormalin fixation occurs over time (12-24 hours)Cross-linking of proteins occurs, which stabilizes the tissue and also alters antigenic epitopes in some casesUnder- or overfixation can lead to technical problems with the assay and may give false-negative resultsSmall biopsy samples require the same amount of fixation time as larger resection samples",
                      "Formalin fixation occurs over time (12-24 hours)Cross-linking of proteins occurs, which stabilizes the tissue and also alters antigenic epitopes in some cases",
                      "Cross-linking of proteins occurs, which stabilizes the tissue and also alters antigenic epitopes in some cases",
                      "Under- or overfixation can lead to technical problems with the assay and may give false-negative results",
                      "Small biopsy samples require the same amount of fixation time as larger resection samples"
                    ]
                  },
                  {
                    "text": "Other types of fixatives can diminish immunoreactivity and must be specifically validated before using"
                  },
                  {
                    "text": "Decalcification can result in decreased antigenicityCommon solutions used for decalcification include nitric acid, hydrochloric acid, formic acidAcid solutions allow for rapid decalcification but tend to degrade DNA, RNA, and proteinsIf a specimen must be decalcified, treatment time should be minimizedIf possible, soft tissue areas should be separated and not decalcifiedNegative results must be interpreted with caution, especially if patient's breast BC was ER(+) &/or PR(+)False-negative result could lead to inappropriate treatment of patientsUsing chelating agents, such as ethylenediaminetetraacetic acid (EDTA), can circumvent the negative effects of acid decalcification on DNA and proteinThe time of decalcification should be minimized, when possible",
                    "sub_points": [
                      "Common solutions used for decalcification include nitric acid, hydrochloric acid, formic acidAcid solutions allow for rapid decalcification but tend to degrade DNA, RNA, and proteins",
                      "Acid solutions allow for rapid decalcification but tend to degrade DNA, RNA, and proteins",
                      "If a specimen must be decalcified, treatment time should be minimizedIf possible, soft tissue areas should be separated and not decalcified",
                      "If possible, soft tissue areas should be separated and not decalcified",
                      "Negative results must be interpreted with caution, especially if patient's breast BC was ER(+) &/or PR(+)False-negative result could lead to inappropriate treatment of patients",
                      "False-negative result could lead to inappropriate treatment of patients",
                      "Using chelating agents, such as ethylenediaminetetraacetic acid (EDTA), can circumvent the negative effects of acid decalcification on DNA and protein",
                      "The time of decalcification should be minimized, when possible"
                    ]
                  }
                ],
                "Unstained Slides": [
                  {
                    "text": "Slides used for IHC studies should be freshly cut"
                  },
                  {
                    "text": "Antigenicity diminishes over time for ER and PR on cut slides stored at room temperature"
                  },
                  {
                    "text": "In contrast, antigenicity can be maintained in tissue stored as paraffin blocks or as tissue on slides stored at -80 °C"
                  }
                ],
                "Antibodies": [
                  {
                    "text": "ER/PR IHC assays should be performed following standardized methods using validated assays"
                  },
                  {
                    "text": "Antibodies for ER and PR IHC should have well-established specificity and sensitivityAssays should be clinically validated, showing good correlation with patient outcomes in published reportsAntibodies for ER meeting these criteria are 1D5, 6F11, and SP1Antibodies for PR meeting these criteria are 1294, 1A6, and 312Each of these antibodies is equivalent or superior to ligand-binding assays in correlation with outcome and benefit from ET",
                    "sub_points": [
                      "Assays should be clinically validated, showing good correlation with patient outcomes in published reports",
                      "Antibodies for ER meeting these criteria are 1D5, 6F11, and SP1",
                      "Antibodies for PR meeting these criteria are 1294, 1A6, and 312Each of these antibodies is equivalent or superior to ligand-binding assays in correlation with outcome and benefit from ET",
                      "Each of these antibodies is equivalent or superior to ligand-binding assays in correlation with outcome and benefit from ET"
                    ]
                  }
                ],
                "Interpretation": [
                  {
                    "text": "The goal for ER/PR analysis is to identify patients most likely to benefit from ET"
                  },
                  {
                    "text": "Interpretation includes percentage of positive tumor cell nuclei and average intensity of staining reactionAR is interpreted using the same criteria",
                    "sub_points": [
                      "AR is interpreted using the same criteria"
                    ]
                  },
                  {
                    "text": "Positive: ≥ 1% immunoreactive cellsThe percentage of positive cells is providedPatients are eligible for ET",
                    "sub_points": [
                      "The percentage of positive cells is provided",
                      "Patients are eligible for ET"
                    ]
                  },
                  {
                    "text": "Low positive: 1-10% immunoreactive cellsThere is limited data on the benefit of ET for patients with low levels of ER/PR expressionBCs with low results are heterogeneous in biology and behaviorThese BCs often have gene expression profiles more similar to ER(-) carcinomasSteps to confirm/adjudicate results per lab-specific protocols (status of controls, correlation with morphology, proper assay performed) should be takenAccording to the CAP reporting protocol, this category is only suggested for ER results for invasive BCs",
                    "sub_points": [
                      "There is limited data on the benefit of ET for patients with low levels of ER/PR expressionBCs with low results are heterogeneous in biology and behaviorThese BCs often have gene expression profiles more similar to ER(-) carcinomas",
                      "BCs with low results are heterogeneous in biology and behavior",
                      "These BCs often have gene expression profiles more similar to ER(-) carcinomas",
                      "Steps to confirm/adjudicate results per lab-specific protocols (status of controls, correlation with morphology, proper assay performed) should be taken",
                      "According to the CAP reporting protocol, this category is only suggested for ER results for invasive BCs"
                    ]
                  },
                  {
                    "text": "Negative: 0 or < 1% immunoreactive cellsInternal control (when present, such as luminal cells) should be documented as being positiveIf negative, reasons for a false-negative result should be considered",
                    "sub_points": [
                      "Internal control (when present, such as luminal cells) should be documented as being positiveIf negative, reasons for a false-negative result should be considered",
                      "If negative, reasons for a false-negative result should be considered"
                    ]
                  },
                  {
                    "text": "Levels of expression of ER in BCs demonstrates a broad dynamic range that can vary by several hundred foldER expression levels may provide valuable information that could influence decision-making for specific types of adjuvant therapyIHC assay for ER and PR should be optimized so that staining captures the broad dynamic range of expression in terms of both distribution and intensity of stainingHowever, highly sensitive assays show primarily bimodal distribution with few BCs in midrange",
                    "sub_points": [
                      "ER expression levels may provide valuable information that could influence decision-making for specific types of adjuvant therapy",
                      "IHC assay for ER and PR should be optimized so that staining captures the broad dynamic range of expression in terms of both distribution and intensity of stainingHowever, highly sensitive assays show primarily bimodal distribution with few BCs in midrange",
                      "However, highly sensitive assays show primarily bimodal distribution with few BCs in midrange"
                    ]
                  },
                  {
                    "text": "Threshold cut-off point for defining ER positivity should be clinically validated against patient outcomeClinical studies have shown that patients with as few as 1% ER(+) cells derived benefit from ET with tamoxifenMagnitude of benefit appears to vary with different levels of ER expressionGreatest benefit from tamoxifen seen for those patients with high levels of ER expression",
                    "sub_points": [
                      "Clinical studies have shown that patients with as few as 1% ER(+) cells derived benefit from ET with tamoxifen",
                      "Magnitude of benefit appears to vary with different levels of ER expressionGreatest benefit from tamoxifen seen for those patients with high levels of ER expression",
                      "Greatest benefit from tamoxifen seen for those patients with high levels of ER expression"
                    ]
                  }
                ],
                "Interpretation for Ductal Carcinoma In Situ": [
                  {
                    "text": "ER testing for newly diagnosed DCIS is recommended by ASCO/CAP guidelinesPR testing is optional",
                    "sub_points": [
                      "PR testing is optional"
                    ]
                  },
                  {
                    "text": "Helps determine potential benefit of ET to reduce risk of local recurrence and of subsequent bilateral ER(+)BCs"
                  },
                  {
                    "text": "Evaluation criteria are the same for invasive BC and DCIS"
                  },
                  {
                    "text": "The majority of DCIS is positive for ER and PRER(+)/PR(+) ~ 85%; ER(-)/PR(-) ~ 15%; other combinations < 5%Immunoreactivity can be markedly heterogeneous with both positive and negative areasMay be difficult to distinguish rare tumor cell positivity from residual normal epithelial cellsIn the majority of cases, ER and PR expression is the same for invasive BC and its associated DCISIn rare cases, expression is discordant [typically DCIS(+) and invasive carcinoma (-)]This can lead to inaccurate results for methods that do not distinguish in situ from invasive BC (e.g., some gene profiling assays or automated image analysis)",
                    "sub_points": [
                      "ER(+)/PR(+) ~ 85%; ER(-)/PR(-) ~ 15%; other combinations < 5%",
                      "Immunoreactivity can be markedly heterogeneous with both positive and negative areas",
                      "May be difficult to distinguish rare tumor cell positivity from residual normal epithelial cells",
                      "In the majority of cases, ER and PR expression is the same for invasive BC and its associated DCISIn rare cases, expression is discordant [typically DCIS(+) and invasive carcinoma (-)]",
                      "In rare cases, expression is discordant [typically DCIS(+) and invasive carcinoma (-)]",
                      "This can lead to inaccurate results for methods that do not distinguish in situ from invasive BC (e.g., some gene profiling assays or automated image analysis)"
                    ]
                  }
                ],
                "Interpretation for Core Needle Biopsy": [
                  {
                    "text": "ER and PR testing can be performed on core needle biopsy samples"
                  },
                  {
                    "text": "Core needle biopsy specimens are more likely to be placed rapidly into fixative with negligible cold ischemic time70-80% of all invasive BCs are ER(+) &/or PR(+)Results allow planning for appropriate adjuvant or neoadjuvant ETNegative result on core needle biopsy must be carefully correlated with other pathologic features> 95% of grade 1 invasive BCs are strongly ER(+)Negative result in grade 1 BC should be questionedConsideration should be given to having test repeated or repeating ER/PR testing on surgical excisionShould also consider other diagnoses, such as microglandular adenosis, lymphoma, or metastasisNormal breast elements (intrinsic controls for ER and PR) should be checked for appropriate stainingIf normal breast elements are negative, this suggests technical problem or issue with tissueIf preanalytic variables are suboptimal (e.g., prolonged cold ischemic time, inadequate formalin fixation, use of different fixative), there may be loss of tissue antigenicity resulting in false-negative resultIf normal breast elements are negative, this should be noted in comment, and consideration should be given to repeat testingNormal breast elements may not be present in limited core needle biopsy sampleThis should be noted in comment, and consideration should be given to repeat testing if carcinoma is ER(-) and PR(-)",
                    "sub_points": [
                      "70-80% of all invasive BCs are ER(+) &/or PR(+)Results allow planning for appropriate adjuvant or neoadjuvant ET",
                      "Results allow planning for appropriate adjuvant or neoadjuvant ET",
                      "Negative result on core needle biopsy must be carefully correlated with other pathologic features> 95% of grade 1 invasive BCs are strongly ER(+)Negative result in grade 1 BC should be questionedConsideration should be given to having test repeated or repeating ER/PR testing on surgical excisionShould also consider other diagnoses, such as microglandular adenosis, lymphoma, or metastasisNormal breast elements (intrinsic controls for ER and PR) should be checked for appropriate stainingIf normal breast elements are negative, this suggests technical problem or issue with tissueIf preanalytic variables are suboptimal (e.g., prolonged cold ischemic time, inadequate formalin fixation, use of different fixative), there may be loss of tissue antigenicity resulting in false-negative resultIf normal breast elements are negative, this should be noted in comment, and consideration should be given to repeat testing",
                      "> 95% of grade 1 invasive BCs are strongly ER(+)Negative result in grade 1 BC should be questionedConsideration should be given to having test repeated or repeating ER/PR testing on surgical excisionShould also consider other diagnoses, such as microglandular adenosis, lymphoma, or metastasis",
                      "Negative result in grade 1 BC should be questioned",
                      "Consideration should be given to having test repeated or repeating ER/PR testing on surgical excision",
                      "Should also consider other diagnoses, such as microglandular adenosis, lymphoma, or metastasis",
                      "Normal breast elements (intrinsic controls for ER and PR) should be checked for appropriate stainingIf normal breast elements are negative, this suggests technical problem or issue with tissueIf preanalytic variables are suboptimal (e.g., prolonged cold ischemic time, inadequate formalin fixation, use of different fixative), there may be loss of tissue antigenicity resulting in false-negative resultIf normal breast elements are negative, this should be noted in comment, and consideration should be given to repeat testing",
                      "If normal breast elements are negative, this suggests technical problem or issue with tissue",
                      "If preanalytic variables are suboptimal (e.g., prolonged cold ischemic time, inadequate formalin fixation, use of different fixative), there may be loss of tissue antigenicity resulting in false-negative result",
                      "If normal breast elements are negative, this should be noted in comment, and consideration should be given to repeat testing",
                      "Normal breast elements may not be present in limited core needle biopsy sampleThis should be noted in comment, and consideration should be given to repeat testing if carcinoma is ER(-) and PR(-)",
                      "This should be noted in comment, and consideration should be given to repeat testing if carcinoma is ER(-) and PR(-)"
                    ]
                  }
                ]
              },
              "Quality Control": {
                "Routine Use of Control Materials": [
                  {
                    "text": "Positive and negative controls should be included with every ER and PR assay"
                  },
                  {
                    "text": "Batch controls can be used to monitor assay performance and to detect loss of sensitivity or assay analytical drift"
                  },
                  {
                    "text": "On-slide controls can be used to help ensure that all reagents were properly dispensed onto slideControls should be clearly identified to avoid confusion with the diagnostic tissue",
                    "sub_points": [
                      "Controls should be clearly identified to avoid confusion with the diagnostic tissue"
                    ]
                  },
                  {
                    "text": "Different tissues and cell types, including internal and external controls, can be used as well"
                  },
                  {
                    "text": "Best on-slide (+) controls are normal breast elements from patient's breast tissueNormal breast elements usually show ER expression in ~ 5-10% of luminal epithelial cellsNonepithelial cells can also be ER(+): Myofibroblasts, smooth muscle of areola, rare lymphocytes",
                    "sub_points": [
                      "Normal breast elements usually show ER expression in ~ 5-10% of luminal epithelial cellsNonepithelial cells can also be ER(+): Myofibroblasts, smooth muscle of areola, rare lymphocytes",
                      "Nonepithelial cells can also be ER(+): Myofibroblasts, smooth muscle of areola, rare lymphocytes"
                    ]
                  },
                  {
                    "text": "Internal controlsThe best control is the patient's own normal breast epithelium, which has undergone the same conditions as the BCThe tissue block selected for ER/PR testing should contain, if possible, adjacent normal breast elementsThe status of normal breast epithelium should always be reportedIf negative, the assay should be reevaluated and possibly repeated",
                    "sub_points": [
                      "The best control is the patient's own normal breast epithelium, which has undergone the same conditions as the BC",
                      "The tissue block selected for ER/PR testing should contain, if possible, adjacent normal breast elements",
                      "The status of normal breast epithelium should always be reportedIf negative, the assay should be reevaluated and possibly repeated",
                      "If negative, the assay should be reevaluated and possibly repeated"
                    ]
                  }
                ],
                "False-Positive Results": [
                  {
                    "text": "Very rare"
                  },
                  {
                    "text": "Possible causesEntrapped normal breast tissue within carcinomaMisinterpretation of ER(+) normal cells (myofibroblasts, lymphocytes, hepatocytes in liver biopsies)Cytoplasmic positivityMistaking control tissue on same slide for carcinomaTranscription errorImage analysis systems overinterpreting faintly staining nuclei",
                    "sub_points": [
                      "Entrapped normal breast tissue within carcinoma",
                      "Misinterpretation of ER(+) normal cells (myofibroblasts, lymphocytes, hepatocytes in liver biopsies)",
                      "Cytoplasmic positivity",
                      "Mistaking control tissue on same slide for carcinoma",
                      "Transcription error",
                      "Image analysis systems overinterpreting faintly staining nuclei"
                    ]
                  }
                ],
                "False-Negative Results": [
                  {
                    "text": "There are many reasons for false-negative resultsMajority can be detected by noting absence of immunoreactivity in normal luminal cells",
                    "sub_points": [
                      "Majority can be detected by noting absence of immunoreactivity in normal luminal cells"
                    ]
                  },
                  {
                    "text": "Possible causesProlonged cold ischemic timeVery short fixation time (< 6 hours)Protein cross linking must occur for optimal antigenicityVery long fixation time (weeks to months)Exposure to heat, such as intraoperative cauteryDecalcificationIf BC is ER(+), and metastasis is negative in bone specimen, possibility of false-negative result must be notedNonformalin fixation (e.g., Bouin)Assay problems (antibody expired, dilution too high, etc.)",
                    "sub_points": [
                      "Prolonged cold ischemic time",
                      "Very short fixation time (< 6 hours)Protein cross linking must occur for optimal antigenicity",
                      "Protein cross linking must occur for optimal antigenicity",
                      "Very long fixation time (weeks to months)",
                      "Exposure to heat, such as intraoperative cautery",
                      "DecalcificationIf BC is ER(+), and metastasis is negative in bone specimen, possibility of false-negative result must be noted",
                      "If BC is ER(+), and metastasis is negative in bone specimen, possibility of false-negative result must be noted",
                      "Nonformalin fixation (e.g., Bouin)",
                      "Assay problems (antibody expired, dilution too high, etc.)"
                    ]
                  }
                ],
                "Analytical Validation": [
                  {
                    "text": "Helps ensure accuracy, sensitivity, and specificity for assay"
                  },
                  {
                    "text": "Assay validation should be against clinically validated method"
                  }
                ],
                "Monitor Daily Testing Results": [
                  {
                    "text": "Review of batch controls and on-slide controls to document accurate assay performanceEvaluate for analytical drift and loss of sensitivity",
                    "sub_points": [
                      "Evaluate for analytical drift and loss of sensitivity"
                    ]
                  },
                  {
                    "text": "Some carcinoma types should almost always be ER(+)Grade 1 BC, carcinomas with tubule formation, and tubular, mucinous, and lobular carcinomas",
                    "sub_points": [
                      "Grade 1 BC, carcinomas with tubule formation, and tubular, mucinous, and lobular carcinomas"
                    ]
                  },
                  {
                    "text": "If a special histologic type of carcinoma is ER(-), as is normal tissue, the assay has likely failedIf assay is shown to be correct, alternative diagnoses for low-grade ER(-) lesion should be consideredLuminal AR carcinoma (molecular apocrine), microglandular adenosis, lymphoma, metastasis to breast",
                    "sub_points": [
                      "If assay is shown to be correct, alternative diagnoses for low-grade ER(-) lesion should be consideredLuminal AR carcinoma (molecular apocrine), microglandular adenosis, lymphoma, metastasis to breast",
                      "Luminal AR carcinoma (molecular apocrine), microglandular adenosis, lymphoma, metastasis to breast"
                    ]
                  }
                ],
                "Concordance With Previous Results": [
                  {
                    "text": "Multiple studies on a carcinoma are often performed, which may include the diagnostic biopsy, excision, local recurrence, &/or distant metastasis"
                  },
                  {
                    "text": "In the majority of cases, the receptor results are concordant"
                  },
                  {
                    "text": "When not concordant, this could be due to a true change in the carcinoma, an alteration due to treatment, assay failure, or the tumor may not be the same primary carcinoma"
                  },
                  {
                    "text": "Additional quality-assurance measures to determine the likely reason for the change in expression may be of value"
                  }
                ],
                "Perform Periodic Trend Analysis": [
                  {
                    "text": "The percentage of ER and PR (+) and (-) cases should be within the expected norm for BC in a similar population"
                  }
                ],
                "Participate in ER and PRIHC Proficiency Program": [
                  {
                    "text": "Must be high concordance between central laboratory analysis and individual laboratory results"
                  },
                  {
                    "text": "CAP provides testing opportunities"
                  }
                ]
              },
              "Hormone Receptor Testing by mRNA": {
                "Gene Expression Profiling": [
                  {
                    "text": "Commercially available tests provide information about hormone receptors (e.g., Oncotype DX from GenomicHealth, TargetPrint from Agendia)"
                  },
                  {
                    "text": "Expression levels are determined using RT-PCR to quantify"
                  },
                  {
                    "text": "Results are highly correlated (> 90%) with results from IHCIf there is a discrepancy between results, the reason for the discrepancy should be investigatedThe positive result is, in general, the correct resultIHC study is usually correct",
                    "sub_points": [
                      "If there is a discrepancy between results, the reason for the discrepancy should be investigated",
                      "The positive result is, in general, the correct result",
                      "IHC study is usually correct"
                    ]
                  },
                  {
                    "text": "There are many reasons for false-negative results by gene expression profilingmRNA is averaged over stroma, inflammatory cells, biopsy sites, and carcinomaIf the BC is small, the majority of the sample may consist of a prior biopsy siteSome carcinomas are of low cellularity (e.g., lobular BC) or there may be few cells present after biopsymRNA is highly labile compared to protein and may be more poorly preserved after prolonged ischemic time",
                    "sub_points": [
                      "mRNA is averaged over stroma, inflammatory cells, biopsy sites, and carcinomaIf the BC is small, the majority of the sample may consist of a prior biopsy site",
                      "If the BC is small, the majority of the sample may consist of a prior biopsy site",
                      "Some carcinomas are of low cellularity (e.g., lobular BC) or there may be few cells present after biopsy",
                      "mRNA is highly labile compared to protein and may be more poorly preserved after prolonged ischemic time"
                    ]
                  },
                  {
                    "text": "A false-negative result for ER or PR will also result in an overall inaccurate result for the assay"
                  },
                  {
                    "text": "Current ASCO/CAP guidelines only recommend using IHC studies for determining ER and PR status"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "HER2": {
            "name": "HER2",
            "url": "https://app.pathprimer.com/document/e254cfd1-37a2-41af-bc95-8a6099f92fa5/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Human epidermal growth factor receptor-2 (HER2)"
                  },
                  {
                    "text": "HER2(+) breast carcinoma (BC) [HER2(+)BC]"
                  },
                  {
                    "text": "Chromosome 17 centromere enumeration probe (CEP17)"
                  },
                  {
                    "text": "Immunohistochemistry (IHC)"
                  },
                  {
                    "text": "In situ hybridization (ISH), fluorescence ISH (FISH), chromogenic ISH (CISH), silver-enhanced ISH (SISH)"
                  },
                  {
                    "text": "Genetic heterogeneity (GH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "HER2: HER2/neu, NEU, NGL, TKR1, c-erbB2, CD340, ERBB2"
                  },
                  {
                    "text": "Centromere 17 enumeration probes: CEP17, CN17, D17Z1"
                  }
                ]
              },
              "HER2": {
                "Introduction": [
                  {
                    "text": "HER2 (ERBB2gene) is a member of the epidermal growth factor receptor familyIncludes HER1 (epidermal growth factor receptor 1 or EGFR), HER2 (also EGFR-2 or erbB-2), HER3 (also erbB-3), and HER4 (also erbB-4)These tyrosine kinases promote cell proliferation and oppose apoptosisReceptor dimerization leads to activation of the intracellular tyrosine kinase portion of moleculeTyrosine kinase activation initiates receptor signaling through phosphorylationRegulates intracellular signaling through MAP-kinase and PI3-kinase pathwaysBinding of high-affinity ligands to HER receptors leads to conformational change in moleculesConformational change promotes receptor activation through dimerizationHER family members form homo- and heterodimers",
                    "sub_points": [
                      "Includes HER1 (epidermal growth factor receptor 1 or EGFR), HER2 (also EGFR-2 or erbB-2), HER3 (also erbB-3), and HER4 (also erbB-4)",
                      "These tyrosine kinases promote cell proliferation and oppose apoptosis",
                      "Receptor dimerization leads to activation of the intracellular tyrosine kinase portion of moleculeTyrosine kinase activation initiates receptor signaling through phosphorylationRegulates intracellular signaling through MAP-kinase and PI3-kinase pathways",
                      "Tyrosine kinase activation initiates receptor signaling through phosphorylation",
                      "Regulates intracellular signaling through MAP-kinase and PI3-kinase pathways",
                      "Binding of high-affinity ligands to HER receptors leads to conformational change in moleculesConformational change promotes receptor activation through dimerizationHER family members form homo- and heterodimers",
                      "Conformational change promotes receptor activation through dimerizationHER family members form homo- and heterodimers",
                      "HER family members form homo- and heterodimers"
                    ]
                  },
                  {
                    "text": "HER2 (ERBB2) gene: Located on chromosome 17q12Translated into 185 kDa transmembrane protein",
                    "sub_points": [
                      "Translated into 185 kDa transmembrane protein"
                    ]
                  },
                  {
                    "text": "HER2 is normally expressed by breast epithelial cellsLow levels of protein expression are not usually detected by clinical assays",
                    "sub_points": [
                      "Low levels of protein expression are not usually detected by clinical assays"
                    ]
                  },
                  {
                    "text": "Abnormalities in HER2 are likely important early events in oncogenesis and contribute to tumor growth and disseminationLike HER2, other members of this receptor family have been implicated in the development of cancerHER1 implicated in cancers of lung, colon, and head and neckHER2 overexpression occurs in other carcinomas (gastric, bladder, lung, esophagus)",
                    "sub_points": [
                      "Like HER2, other members of this receptor family have been implicated in the development of cancerHER1 implicated in cancers of lung, colon, and head and neckHER2 overexpression occurs in other carcinomas (gastric, bladder, lung, esophagus)",
                      "HER1 implicated in cancers of lung, colon, and head and neck",
                      "HER2 overexpression occurs in other carcinomas (gastric, bladder, lung, esophagus)"
                    ]
                  },
                  {
                    "text": "HER2(+)BCs present at higher stages (larger tumor size and frequent positive lymph nodes), have high proliferative rates, and often metastasize to visceral sites and brain~ 15-20% of BCs overexpress HER2",
                    "sub_points": [
                      "~ 15-20% of BCs overexpress HER2"
                    ]
                  },
                  {
                    "text": "The mechanism of overexpression is amplification ofERBB2resulting in increased expression of mRNA and receptor protein; other mechanisms leading to protein overexpression have not been described"
                  },
                  {
                    "text": "Mutations inERBB2are rare (~ 2-8% of BCs) and have not been associated with increased protein expressionOnly detected by DNA sequencingMore commonly found as a secondary event after treatmentMany are activating mutations in the kinase domainTreatment with tyrosine kinase inhibitors (e.g., neratinib) show benefit, but resistance often developsAdditional mutations or amplification ofERBB2have been reported",
                    "sub_points": [
                      "Only detected by DNA sequencing",
                      "More commonly found as a secondary event after treatment",
                      "Many are activating mutations in the kinase domain",
                      "Treatment with tyrosine kinase inhibitors (e.g., neratinib) show benefit, but resistance often developsAdditional mutations or amplification ofERBB2have been reported",
                      "Additional mutations or amplification ofERBB2have been reported"
                    ]
                  },
                  {
                    "text": "It is clinically important to identify the level of HER2 expression in BCs, as very effective HER2-targeted therapy is availableHER2(+)BC can be treated with all types of HER2-targeted therapyDefined as IHC 3+ or IHC 2+ and positive ISH resultsHER2(low)BC can be treated with antibody-drug conjugates (ADCs)Defined as IHC 1+ or IHC 2+ with negative ISH resultsHER2(0)BC has shown response to ADCs in early clinical trialsDefined as IHC 0+Ongoing studies will clarify if it is important to distinguish IHC 0+ from IHC 1+ results",
                    "sub_points": [
                      "HER2(+)BC can be treated with all types of HER2-targeted therapyDefined as IHC 3+ or IHC 2+ and positive ISH results",
                      "Defined as IHC 3+ or IHC 2+ and positive ISH results",
                      "HER2(low)BC can be treated with antibody-drug conjugates (ADCs)Defined as IHC 1+ or IHC 2+ with negative ISH results",
                      "Defined as IHC 1+ or IHC 2+ with negative ISH results",
                      "HER2(0)BC has shown response to ADCs in early clinical trialsDefined as IHC 0+Ongoing studies will clarify if it is important to distinguish IHC 0+ from IHC 1+ results",
                      "Defined as IHC 0+",
                      "Ongoing studies will clarify if it is important to distinguish IHC 0+ from IHC 1+ results"
                    ]
                  },
                  {
                    "text": "Due to high response rates to targeted therapy, many patients with these cancers now have a favorable prognosis"
                  },
                  {
                    "text": "Treatment guidelines from American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) and National Comprehensive Cancer Network (NCCN) recommend HER2 testing for all invasive BCs"
                  }
                ]
              },
              "HER2 in Carcinogenesis": {
                "HER2Gene Amplification": [
                  {
                    "text": "HER2gene amplification is thought to be an early event in pathogenesis and carcinogenesis of HER2(+)BCHER2(+) ductal carcinoma in situ (DCIS) is more common than HER2(+) invasive carcinoma",
                    "sub_points": [
                      "HER2(+) ductal carcinoma in situ (DCIS) is more common than HER2(+) invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Amplification drives gene expression resulting in increased protein expressionHER2 assays can evaluate DNA (ISH), mRNA, &/or protein (IHC)Majority of carcinomas with gene amplification also show increased protein levels",
                    "sub_points": [
                      "HER2 assays can evaluate DNA (ISH), mRNA, &/or protein (IHC)",
                      "Majority of carcinomas with gene amplification also show increased protein levels"
                    ]
                  },
                  {
                    "text": "Overexpression of HER2 protein increases likelihood of receptor activation and signalingPromotes angiogenesis, proliferation, cell motilityDrives proliferationProtects cells against apoptosisIncreases tumor cell motility and invasionContributes to more aggressive biologic behavior and malignant phenotype",
                    "sub_points": [
                      "Promotes angiogenesis, proliferation, cell motility",
                      "Drives proliferation",
                      "Protects cells against apoptosis",
                      "Increases tumor cell motility and invasion",
                      "Contributes to more aggressive biologic behavior and malignant phenotype"
                    ]
                  },
                  {
                    "text": "ERBB2amplification is a stable genetic changeHER2 overexpression is seen in primary carcinomas as well as metastasesHowever, in some cases, HER2 overexpression is lost in residual carcinoma after treatment or in metastasesMost likely due to initial tumor heterogeneity and selective effects of targeted therapy",
                    "sub_points": [
                      "HER2 overexpression is seen in primary carcinomas as well as metastases",
                      "However, in some cases, HER2 overexpression is lost in residual carcinoma after treatment or in metastasesMost likely due to initial tumor heterogeneity and selective effects of targeted therapy",
                      "Most likely due to initial tumor heterogeneity and selective effects of targeted therapy"
                    ]
                  }
                ],
                "HER2Gene Mutation": [
                  {
                    "text": "Less common than amplification (~ 2-8% of carcinomas)Higher frequency in primary lobular carcinomas (~ 9%) and recurrent lobular carcinomas (~ 18%)DNA sequencing to identify mutations may be performed for patients eligible for clinical protocols",
                    "sub_points": [
                      "Higher frequency in primary lobular carcinomas (~ 9%) and recurrent lobular carcinomas (~ 18%)",
                      "DNA sequencing to identify mutations may be performed for patients eligible for clinical protocols"
                    ]
                  },
                  {
                    "text": "Majority are activating mutationsTreatment with tyrosine kinase inhibitors (e.g., neratinib) show benefit, but resistance often developsAdditional mutations or amplification ofERBB2have been reported",
                    "sub_points": [
                      "Treatment with tyrosine kinase inhibitors (e.g., neratinib) show benefit, but resistance often developsAdditional mutations or amplification ofERBB2have been reported",
                      "Additional mutations or amplification ofERBB2have been reported"
                    ]
                  },
                  {
                    "text": "No mutation increasing protein expression has been reported"
                  }
                ]
              },
              "HER2: Prognosis": {
                "HER2Gene Amplification": [
                  {
                    "text": "ERBB2gene amplification/overexpression plays pivotal role in driving tumor biologyContributes to aggressive clinical course for HER2(+)BCDecreased disease-free and overall survivalHigher incidence of local recurrence compared to luminal carcinomasIncreased incidence of lymph node metastasesMore frequent metastases to brain, liver, and lung compared to luminal carcinomas40-50% of patients with brain metastases have HER2(+)BC",
                    "sub_points": [
                      "Contributes to aggressive clinical course for HER2(+)BCDecreased disease-free and overall survivalHigher incidence of local recurrence compared to luminal carcinomasIncreased incidence of lymph node metastasesMore frequent metastases to brain, liver, and lung compared to luminal carcinomas40-50% of patients with brain metastases have HER2(+)BC",
                      "Decreased disease-free and overall survival",
                      "Higher incidence of local recurrence compared to luminal carcinomas",
                      "Increased incidence of lymph node metastases",
                      "More frequent metastases to brain, liver, and lung compared to luminal carcinomas",
                      "40-50% of patients with brain metastases have HER2(+)BC"
                    ]
                  },
                  {
                    "text": "HER2 overexpression significantly correlates with a number of unfavorable tumor characteristicsHigher proliferative indexLarger tumor sizeHigher tumor gradeLymph node metastases (often multiple)More commonly associated with some histologic types: Apocrine, micropapillary, grade III lobular, clinical inflammatory carcinomaMore extensive DCIS",
                    "sub_points": [
                      "Higher proliferative index",
                      "Larger tumor size",
                      "Higher tumor grade",
                      "Lymph node metastases (often multiple)",
                      "More commonly associated with some histologic types: Apocrine, micropapillary, grade III lobular, clinical inflammatory carcinoma",
                      "More extensive DCIS"
                    ]
                  },
                  {
                    "text": "HER2-targeted therapy has markedly improved the prognosis for patients with HER2(+) carcinomasIn the AJCC (8th edition) staging system, the prognostic stage may be lower for HER2(+) vs. HER2(-) carcinomas due to improved survival",
                    "sub_points": [
                      "In the AJCC (8th edition) staging system, the prognostic stage may be lower for HER2(+) vs. HER2(-) carcinomas due to improved survival"
                    ]
                  }
                ]
              },
              "HER2: Specimen Handling": {
                "Breast Tissue Fixation": [
                  {
                    "text": "Breast specimens should be sectioned and placed in fixative, ideally within 1 hour from removalTissue must be fixed in 10% neutral-buffered formalinFormalin fixation is part of FDA approval for test kits that evaluate HER2 by IHC and FISHThe total fixation time should be recordedIf the specimen is not carefully sectioned into thin slices (~ 5 mm), fixation of the carcinoma may not begin for hours",
                    "sub_points": [
                      "Tissue must be fixed in 10% neutral-buffered formalinFormalin fixation is part of FDA approval for test kits that evaluate HER2 by IHC and FISH",
                      "Formalin fixation is part of FDA approval for test kits that evaluate HER2 by IHC and FISH",
                      "The total fixation time should be recordedIf the specimen is not carefully sectioned into thin slices (~ 5 mm), fixation of the carcinoma may not begin for hours",
                      "If the specimen is not carefully sectioned into thin slices (~ 5 mm), fixation of the carcinoma may not begin for hours"
                    ]
                  },
                  {
                    "text": "It is helpful to include sections of carcinoma and adjacent normal fibrous tissue (either in the same tissue fragment or separate tissue fragment) in blocksHelps to ensure normal breast tissue is available as an internal control for breast biomarker testing",
                    "sub_points": [
                      "Helps to ensure normal breast tissue is available as an internal control for breast biomarker testing"
                    ]
                  },
                  {
                    "text": "Fixation time recommended to be no less than 6-8 hours and no more than 72 hours before processingUnderfixation can lead to technical problems with IHCVery long fixation times (weeks) can result in excessive cross linking of proteins by formalin and can alter resultsSmall biopsies require the same amount of fixation time as larger resection samples",
                    "sub_points": [
                      "Underfixation can lead to technical problems with IHC",
                      "Very long fixation times (weeks) can result in excessive cross linking of proteins by formalin and can alter results",
                      "Small biopsies require the same amount of fixation time as larger resection samples"
                    ]
                  },
                  {
                    "text": "Acid decalcification can interfere with evaluation of specimens by ISH due to DNA degradationSpecimens treated with very careful EDTA decalcification and daily monitoring by specimen radiography can be used for ISH and IHCNegative results using other methods of decalcification should be interpreted with caution",
                    "sub_points": [
                      "Specimens treated with very careful EDTA decalcification and daily monitoring by specimen radiography can be used for ISH and IHC",
                      "Negative results using other methods of decalcification should be interpreted with caution"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "IHC and ISH can be performed on core needle biopsies (CNBs)"
                  },
                  {
                    "text": "Concordance between CNBs and subsequent excisions is 85-90%"
                  },
                  {
                    "text": "Discordant results can be due to tumor heterogeneity (i.e., only small portion of large carcinoma may be sampled in a CNB) or differences in fixation"
                  },
                  {
                    "text": "If results on CNB are negative, consider repeat studies on the subsequent excision in the following situationsAmount of carcinoma in CNB is small (< 0.5 cm), especially if primary carcinoma is large (i.e., T2)Carcinoma is poorly differentiatedMultiple foci of invasion are presentBoth IHC and ISH showed results close to threshold for reaching a positive result (e.g., equivocal IHC and ISH with 4-5 HER2 gene copies)The resection specimen contains high-grade carcinoma that is morphologically distinct from the CNB sampleThere is doubt about specimen handling of CNB (i.e., long cold ischemic time, nonstandard fixation)Residual carcinoma is present after neoadjuvant therapy (NAT)The likelihood of HER2(+) results in this setting is low (< 10%) unless only a small portion of the carcinoma on CNB was sampled prior to treatmentIn turn, a change from HER2(+) to HER2(-) after NAT is an adverse prognostic factor",
                    "sub_points": [
                      "Amount of carcinoma in CNB is small (< 0.5 cm), especially if primary carcinoma is large (i.e., T2)",
                      "Carcinoma is poorly differentiated",
                      "Multiple foci of invasion are present",
                      "Both IHC and ISH showed results close to threshold for reaching a positive result (e.g., equivocal IHC and ISH with 4-5 HER2 gene copies)",
                      "The resection specimen contains high-grade carcinoma that is morphologically distinct from the CNB sample",
                      "There is doubt about specimen handling of CNB (i.e., long cold ischemic time, nonstandard fixation)",
                      "Residual carcinoma is present after neoadjuvant therapy (NAT)The likelihood of HER2(+) results in this setting is low (< 10%) unless only a small portion of the carcinoma on CNB was sampled prior to treatmentIn turn, a change from HER2(+) to HER2(-) after NAT is an adverse prognostic factor",
                      "The likelihood of HER2(+) results in this setting is low (< 10%) unless only a small portion of the carcinoma on CNB was sampled prior to treatment",
                      "In turn, a change from HER2(+) to HER2(-) after NAT is an adverse prognostic factor"
                    ]
                  }
                ]
              },
              "HER2: Assays": {
                "Introduction": [
                  {
                    "text": "HER2 status is determined clinically by IHC or ISH or bothIHC detects HER2 protein overexpression on membranes of tumor cellsISH (FISH, CISH, and SISH) detectsERBB2gene amplification in nuclei of tumor cellsBoth IHC and FISH have been clinically validated to help predict response to HER2-targeted therapy",
                    "sub_points": [
                      "IHC detects HER2 protein overexpression on membranes of tumor cells",
                      "ISH (FISH, CISH, and SISH) detectsERBB2gene amplification in nuclei of tumor cellsBoth IHC and FISH have been clinically validated to help predict response to HER2-targeted therapy",
                      "Both IHC and FISH have been clinically validated to help predict response to HER2-targeted therapy"
                    ]
                  },
                  {
                    "text": "RT-PCR evaluates HER2 mRNA levels and is used to determine Oncotype DX recurrence score (Genomic Health; Redwood City, CA) and by other proprietary tests to determine molecular typeNot currently used to make treatment decisionsMany HER2(+)BC by IHC and FISH assays are negative by Oncotype DX assayRequires tissue microdissection if DCIS shows stronger HER2 positivity or if little carcinoma in relation to stroma is presentWill not detect heterogeneity of overexpression",
                    "sub_points": [
                      "Not currently used to make treatment decisionsMany HER2(+)BC by IHC and FISH assays are negative by Oncotype DX assay",
                      "Many HER2(+)BC by IHC and FISH assays are negative by Oncotype DX assay",
                      "Requires tissue microdissection if DCIS shows stronger HER2 positivity or if little carcinoma in relation to stroma is present",
                      "Will not detect heterogeneity of overexpression"
                    ]
                  },
                  {
                    "text": "HER2 testing has become an essential part of the clinical evaluation of invasive carcinomaHER2 testing is not required for DCIS except as part of a clinical trial",
                    "sub_points": [
                      "HER2 testing is not required for DCIS except as part of a clinical trial"
                    ]
                  },
                  {
                    "text": "Decisions about HER2-targeted therapy include concerns about cost and potential toxicitiesHER2-targeted therapy should only be used for patients whose carcinomas have been evaluated by a validated test",
                    "sub_points": [
                      "HER2-targeted therapy should only be used for patients whose carcinomas have been evaluated by a validated test"
                    ]
                  },
                  {
                    "text": "HER2 testing guidelines from ASCO/CAP define algorithms and test interpretation criteriaThe 2018 focused guideline update provided more rigorous interpretation criteria for uncommon HER2 results using dual-probe ISH testing",
                    "sub_points": [
                      "The 2018 focused guideline update provided more rigorous interpretation criteria for uncommon HER2 results using dual-probe ISH testing"
                    ]
                  }
                ],
                "IHC: Antibodies": [
                  {
                    "text": "Multiple antibodies are available for evaluation of HER2 expression in formalin-fixed, paraffin-embedded samples"
                  },
                  {
                    "text": "Antibody clones have varying sensitivities and specificities and sites of bindingIntracellular domain (ICD) antibodies3B5 (mouse, monoclonal), predominantly used in older studies: C-terminus, preferentially recognizes unphosphorylated formAO485 (rabbit, polyclonal), part of FDA-approved kit (HercepTestTM, Dako, Denmark AIS; Glostrup, Denmark)Approved for testing breast and gastric carcinomasDetects an 11-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by CB11 and 4B5Polyclonal antibodies can be associated with increased background staining in cytoplasm and in normal cellsCB11 (mouse, monoclonal), part of FDA-approved kits (OracleR HER2, Leica Biosystems for use on the BONDTM MAXTM automated staining instrument; InSiteTM Her-2/neu kit, BioGenex Laboratories)Approved for testing BCsDetects a 7-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and 4B54B5 (rabbit, monoclonal), part of FDA-approved kit (PATHWAY anti-HER-2/neu (4B5) for use with Ventana automated IHC devices, Ventana Medical Systems, Inc)Approved for testing BCsThis kit was originally FDA approved using antibody CB11 but was revised in 2019 for the use of antibody 4B5Detects a 10-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and CB114B5 recently approved for detection of HER2(low)BC for ADC treatmentExtracellular domain (ECD) antibodiesSP3 (rabbit, monoclonal)D8F12 (rabbit, monoclonal)These antibodies have shown high concordance with each other as well as with ISH results (> 90-95%)ECD of HER2 may be truncated, resulting in loss of the epitope detected by some antibodiesThis phenomenon could lead to discordant results between laboratories using different antibodies in rare carcinomas and discordance with ISH resultsCan be a mechanism of resistance to treatment with monoclonal antibodies that recognize the ECDIn contrast, tyrosine kinase inhibitors target ICD",
                    "sub_points": [
                      "Intracellular domain (ICD) antibodies3B5 (mouse, monoclonal), predominantly used in older studies: C-terminus, preferentially recognizes unphosphorylated formAO485 (rabbit, polyclonal), part of FDA-approved kit (HercepTestTM, Dako, Denmark AIS; Glostrup, Denmark)Approved for testing breast and gastric carcinomasDetects an 11-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by CB11 and 4B5Polyclonal antibodies can be associated with increased background staining in cytoplasm and in normal cellsCB11 (mouse, monoclonal), part of FDA-approved kits (OracleR HER2, Leica Biosystems for use on the BONDTM MAXTM automated staining instrument; InSiteTM Her-2/neu kit, BioGenex Laboratories)Approved for testing BCsDetects a 7-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and 4B54B5 (rabbit, monoclonal), part of FDA-approved kit (PATHWAY anti-HER-2/neu (4B5) for use with Ventana automated IHC devices, Ventana Medical Systems, Inc)Approved for testing BCsThis kit was originally FDA approved using antibody CB11 but was revised in 2019 for the use of antibody 4B5Detects a 10-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and CB114B5 recently approved for detection of HER2(low)BC for ADC treatment",
                      "3B5 (mouse, monoclonal), predominantly used in older studies: C-terminus, preferentially recognizes unphosphorylated form",
                      "AO485 (rabbit, polyclonal), part of FDA-approved kit (HercepTestTM, Dako, Denmark AIS; Glostrup, Denmark)Approved for testing breast and gastric carcinomasDetects an 11-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by CB11 and 4B5Polyclonal antibodies can be associated with increased background staining in cytoplasm and in normal cells",
                      "Approved for testing breast and gastric carcinomas",
                      "Detects an 11-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by CB11 and 4B5",
                      "Polyclonal antibodies can be associated with increased background staining in cytoplasm and in normal cells",
                      "CB11 (mouse, monoclonal), part of FDA-approved kits (OracleR HER2, Leica Biosystems for use on the BONDTM MAXTM automated staining instrument; InSiteTM Her-2/neu kit, BioGenex Laboratories)Approved for testing BCsDetects a 7-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and 4B5",
                      "Approved for testing BCs",
                      "Detects a 7-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and 4B5",
                      "4B5 (rabbit, monoclonal), part of FDA-approved kit (PATHWAY anti-HER-2/neu (4B5) for use with Ventana automated IHC devices, Ventana Medical Systems, Inc)Approved for testing BCsThis kit was originally FDA approved using antibody CB11 but was revised in 2019 for the use of antibody 4B5Detects a 10-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and CB114B5 recently approved for detection of HER2(low)BC for ADC treatment",
                      "Approved for testing BCs",
                      "This kit was originally FDA approved using antibody CB11 but was revised in 2019 for the use of antibody 4B5",
                      "Detects a 10-amino-acid epitope on HER2 that overlaps by 6 amino acids with the epitopes detected by A0485 and CB11",
                      "4B5 recently approved for detection of HER2(low)BC for ADC treatment",
                      "Extracellular domain (ECD) antibodiesSP3 (rabbit, monoclonal)D8F12 (rabbit, monoclonal)",
                      "SP3 (rabbit, monoclonal)",
                      "D8F12 (rabbit, monoclonal)",
                      "These antibodies have shown high concordance with each other as well as with ISH results (> 90-95%)ECD of HER2 may be truncated, resulting in loss of the epitope detected by some antibodiesThis phenomenon could lead to discordant results between laboratories using different antibodies in rare carcinomas and discordance with ISH resultsCan be a mechanism of resistance to treatment with monoclonal antibodies that recognize the ECDIn contrast, tyrosine kinase inhibitors target ICD",
                      "ECD of HER2 may be truncated, resulting in loss of the epitope detected by some antibodiesThis phenomenon could lead to discordant results between laboratories using different antibodies in rare carcinomas and discordance with ISH resultsCan be a mechanism of resistance to treatment with monoclonal antibodies that recognize the ECDIn contrast, tyrosine kinase inhibitors target ICD",
                      "This phenomenon could lead to discordant results between laboratories using different antibodies in rare carcinomas and discordance with ISH results",
                      "Can be a mechanism of resistance to treatment with monoclonal antibodies that recognize the ECD",
                      "In contrast, tyrosine kinase inhibitors target ICD"
                    ]
                  },
                  {
                    "text": "Original report of HER2 alterations in BC used IHC on frozen sectionsShowed excellent correlation withHER2gene amplification assessed by Southern blotsHowever, current clinical assays for HER2 utilize formalin-fixed tissue",
                    "sub_points": [
                      "Showed excellent correlation withHER2gene amplification assessed by Southern blots",
                      "However, current clinical assays for HER2 utilize formalin-fixed tissue"
                    ]
                  }
                ],
                "IHC: Interpretation": [
                  {
                    "text": "Scoring of HER2 results by IHC is semiquantitatively evaluatedOnly areas of invasive carcinoma are scoredThe pattern and intensity of membrane immunoreactivity are evaluatedThe percentage of cells with immunoreactivity in a contiguous area is evaluated",
                    "sub_points": [
                      "Only areas of invasive carcinoma are scoredThe pattern and intensity of membrane immunoreactivity are evaluatedThe percentage of cells with immunoreactivity in a contiguous area is evaluated",
                      "The pattern and intensity of membrane immunoreactivity are evaluated",
                      "The percentage of cells with immunoreactivity in a contiguous area is evaluated"
                    ]
                  },
                  {
                    "text": "HER2 IHC positive (3+): ~ 10-15% of cancersIntense circumferential membrane chicken-wire staining pattern in > 10% of invasive carcinoma (homogeneous and contiguous population of tumor cells)In > 95% of cases, invasive carcinoma is diffusely positive [> 90% cells (+) for circumferential membrane staining]The majority of these cancers will show amplification by ISH (> 95%)HER2gene number and ratio are usually highIn < 5% of cases, only a subpopulation of cells shows strong positivity (intratumoral heterogeneity)Proportion of tumor with strong expression is reported as a percentageSome carcinomas may be negative by ISH; additional testing may be warrantedIf the number of positive cells is > 10%, carcinoma is classified as HER2(+)BC with heterogeneityPositivity must be in a clustered, contiguous population of invasive tumor cells (i.e., not scattered throughout carcinoma)Requirement previously was > 30%, but this was lowered to > 10%In rare cases, associated DCIS overexpresses HER2, but invasive carcinoma is HER2(-)Should be documented to ensure this is taken into account during evaluation of other assaysPositive (3+) protein expression in the absence of gene amplification has not been conclusively demonstratedA repeat IHC study should be performed to determine if the original result was correct",
                    "sub_points": [
                      "Intense circumferential membrane chicken-wire staining pattern in > 10% of invasive carcinoma (homogeneous and contiguous population of tumor cells)In > 95% of cases, invasive carcinoma is diffusely positive [> 90% cells (+) for circumferential membrane staining]The majority of these cancers will show amplification by ISH (> 95%)HER2gene number and ratio are usually highIn < 5% of cases, only a subpopulation of cells shows strong positivity (intratumoral heterogeneity)Proportion of tumor with strong expression is reported as a percentageSome carcinomas may be negative by ISH; additional testing may be warrantedIf the number of positive cells is > 10%, carcinoma is classified as HER2(+)BC with heterogeneityPositivity must be in a clustered, contiguous population of invasive tumor cells (i.e., not scattered throughout carcinoma)Requirement previously was > 30%, but this was lowered to > 10%",
                      "In > 95% of cases, invasive carcinoma is diffusely positive [> 90% cells (+) for circumferential membrane staining]The majority of these cancers will show amplification by ISH (> 95%)HER2gene number and ratio are usually high",
                      "The majority of these cancers will show amplification by ISH (> 95%)",
                      "HER2gene number and ratio are usually high",
                      "In < 5% of cases, only a subpopulation of cells shows strong positivity (intratumoral heterogeneity)Proportion of tumor with strong expression is reported as a percentageSome carcinomas may be negative by ISH; additional testing may be warranted",
                      "Proportion of tumor with strong expression is reported as a percentage",
                      "Some carcinomas may be negative by ISH; additional testing may be warranted",
                      "If the number of positive cells is > 10%, carcinoma is classified as HER2(+)BC with heterogeneityPositivity must be in a clustered, contiguous population of invasive tumor cells (i.e., not scattered throughout carcinoma)Requirement previously was > 30%, but this was lowered to > 10%",
                      "Positivity must be in a clustered, contiguous population of invasive tumor cells (i.e., not scattered throughout carcinoma)",
                      "Requirement previously was > 30%, but this was lowered to > 10%",
                      "In rare cases, associated DCIS overexpresses HER2, but invasive carcinoma is HER2(-)Should be documented to ensure this is taken into account during evaluation of other assays",
                      "Should be documented to ensure this is taken into account during evaluation of other assays",
                      "Positive (3+) protein expression in the absence of gene amplification has not been conclusively demonstratedA repeat IHC study should be performed to determine if the original result was correct",
                      "A repeat IHC study should be performed to determine if the original result was correct"
                    ]
                  },
                  {
                    "text": "HER2 IHC equivocal (2+): ~ 15-25% of cancersThe updated ASCO/CAP HER2 guideline IHC equivocal definition includesWeak to moderate complete membrane staining observed in > 10% of tumor cellsUnusual staining patterns of HER2 by IHC can be encountered that are not covered by this definitionRare BCs show IHC staining that is moderate but incomplete (e.g., basolateral staining in micropapillary BC)This pattern should be classified as equivocal and ISH performed~ 20-25% of cancers with IHC 2+ scores showERBB2gene amplificationISH should be performed on all equivocal casesThese cancers are more likely to have lower numbers of gene copies compared to cancers with positive results (3+)",
                    "sub_points": [
                      "The updated ASCO/CAP HER2 guideline IHC equivocal definition includesWeak to moderate complete membrane staining observed in > 10% of tumor cellsUnusual staining patterns of HER2 by IHC can be encountered that are not covered by this definitionRare BCs show IHC staining that is moderate but incomplete (e.g., basolateral staining in micropapillary BC)This pattern should be classified as equivocal and ISH performed",
                      "Weak to moderate complete membrane staining observed in > 10% of tumor cellsUnusual staining patterns of HER2 by IHC can be encountered that are not covered by this definitionRare BCs show IHC staining that is moderate but incomplete (e.g., basolateral staining in micropapillary BC)This pattern should be classified as equivocal and ISH performed",
                      "Unusual staining patterns of HER2 by IHC can be encountered that are not covered by this definition",
                      "Rare BCs show IHC staining that is moderate but incomplete (e.g., basolateral staining in micropapillary BC)",
                      "This pattern should be classified as equivocal and ISH performed",
                      "~ 20-25% of cancers with IHC 2+ scores showERBB2gene amplificationISH should be performed on all equivocal casesThese cancers are more likely to have lower numbers of gene copies compared to cancers with positive results (3+)",
                      "ISH should be performed on all equivocal cases",
                      "These cancers are more likely to have lower numbers of gene copies compared to cancers with positive results (3+)"
                    ]
                  },
                  {
                    "text": "HER2 IHC negative (0 or 1+): ~ 70-75% of cancers0: No staining or membrane staining that is incomplete and is faint/barely perceptible in ≤ 10% of tumor cells1+: Incomplete membrane staining that is faint/barely perceptible in > 10% of tumor cellsCarcinomas with 0 or 1+ scores show good concordance with absence of amplification by ISH (> 95%)However, a 1+ score can be difficult to distinguish from a 2+ score in some casesAdditional ISH studies can be considered in \"borderline\" cases",
                    "sub_points": [
                      "0: No staining or membrane staining that is incomplete and is faint/barely perceptible in ≤ 10% of tumor cells",
                      "1+: Incomplete membrane staining that is faint/barely perceptible in > 10% of tumor cells",
                      "Carcinomas with 0 or 1+ scores show good concordance with absence of amplification by ISH (> 95%)However, a 1+ score can be difficult to distinguish from a 2+ score in some casesAdditional ISH studies can be considered in \"borderline\" cases",
                      "However, a 1+ score can be difficult to distinguish from a 2+ score in some casesAdditional ISH studies can be considered in \"borderline\" cases",
                      "Additional ISH studies can be considered in \"borderline\" cases"
                    ]
                  },
                  {
                    "text": "HER2(low)BC (IHC 1+ or IHC 2+ and ISH-)~ 45-55% of cancersIn 2022, the FDA approved ADC (TDX-d) for treatment of advanced HER2(low)BCEarly studies have also shown benefit of ADCs in the treatment of HER2(0)BCThe distinction between IHC 0+ and IHC 1+ is currently clinically relevant but could change in the future",
                    "sub_points": [
                      "In 2022, the FDA approved ADC (TDX-d) for treatment of advanced HER2(low)BC",
                      "Early studies have also shown benefit of ADCs in the treatment of HER2(0)BC",
                      "The distinction between IHC 0+ and IHC 1+ is currently clinically relevant but could change in the future"
                    ]
                  },
                  {
                    "text": "HER2 indeterminateIn some cases, technical issues prevent the assay from being conclusiveBiopsies with significant crush or edge artifacts are indeterminateStaining should not be overinterpreted as positiveLobular carcinomas often show edge enhancement rather than true positivityAdjacent (nonneoplastic) breast tissue should not show stainingImmunoreactivity of normal epithelial cells suggests that the assay is too sensitive and should not be interpretedHowever, cells with apocrine metaplasia often show positivity and are not indicative of overstainingSpecimens without normal breast epithelium present can be difficult to evaluate in the absence of this control for intensity of stainingISH should be considered for such studies to confirm a possible positive resultCytoplasmic positivity can preclude accurate evaluation of membrane positivityProlonged ischemia prior to fixation (> 1-2 hours), particularly at room temperature, can damage tissueMay lead to false-negative resultsSamples fixed for < 6 hours or > 72 hours in 10% neutral-buffered formalin can lead to technical problems in performing the assayMay result in false-negative or false-positive resultsSamples fixed in fixatives other than formalin may not give accurate resultsAlternative fixative must be rigorously validated by laboratory before being used for HER2 testingIndeterminate results require a repetition of the assay before HER2 status can be determined",
                    "sub_points": [
                      "In some cases, technical issues prevent the assay from being conclusiveBiopsies with significant crush or edge artifacts are indeterminateStaining should not be overinterpreted as positiveLobular carcinomas often show edge enhancement rather than true positivityAdjacent (nonneoplastic) breast tissue should not show stainingImmunoreactivity of normal epithelial cells suggests that the assay is too sensitive and should not be interpretedHowever, cells with apocrine metaplasia often show positivity and are not indicative of overstainingSpecimens without normal breast epithelium present can be difficult to evaluate in the absence of this control for intensity of stainingISH should be considered for such studies to confirm a possible positive resultCytoplasmic positivity can preclude accurate evaluation of membrane positivityProlonged ischemia prior to fixation (> 1-2 hours), particularly at room temperature, can damage tissueMay lead to false-negative resultsSamples fixed for < 6 hours or > 72 hours in 10% neutral-buffered formalin can lead to technical problems in performing the assayMay result in false-negative or false-positive resultsSamples fixed in fixatives other than formalin may not give accurate resultsAlternative fixative must be rigorously validated by laboratory before being used for HER2 testing",
                      "Biopsies with significant crush or edge artifacts are indeterminateStaining should not be overinterpreted as positiveLobular carcinomas often show edge enhancement rather than true positivity",
                      "Staining should not be overinterpreted as positive",
                      "Lobular carcinomas often show edge enhancement rather than true positivity",
                      "Adjacent (nonneoplastic) breast tissue should not show stainingImmunoreactivity of normal epithelial cells suggests that the assay is too sensitive and should not be interpretedHowever, cells with apocrine metaplasia often show positivity and are not indicative of overstainingSpecimens without normal breast epithelium present can be difficult to evaluate in the absence of this control for intensity of stainingISH should be considered for such studies to confirm a possible positive result",
                      "Immunoreactivity of normal epithelial cells suggests that the assay is too sensitive and should not be interpreted",
                      "However, cells with apocrine metaplasia often show positivity and are not indicative of overstaining",
                      "Specimens without normal breast epithelium present can be difficult to evaluate in the absence of this control for intensity of staining",
                      "ISH should be considered for such studies to confirm a possible positive result",
                      "Cytoplasmic positivity can preclude accurate evaluation of membrane positivity",
                      "Prolonged ischemia prior to fixation (> 1-2 hours), particularly at room temperature, can damage tissueMay lead to false-negative results",
                      "May lead to false-negative results",
                      "Samples fixed for < 6 hours or > 72 hours in 10% neutral-buffered formalin can lead to technical problems in performing the assayMay result in false-negative or false-positive results",
                      "May result in false-negative or false-positive results",
                      "Samples fixed in fixatives other than formalin may not give accurate resultsAlternative fixative must be rigorously validated by laboratory before being used for HER2 testing",
                      "Alternative fixative must be rigorously validated by laboratory before being used for HER2 testing",
                      "Indeterminate results require a repetition of the assay before HER2 status can be determined"
                    ]
                  }
                ],
                "ISH: Types of Assays": [
                  {
                    "text": "ISH is a morphology-based assay used to evaluate gene copy numberSingle-probe methods evaluate the number ofERBB2genesDual-probe methods evaluate the number ofERBB2genes and a chromosome 17 reference probe (e.g., CEP17)Results are reported as the number ofERBB2genes and CEP17 signals and the ratio HER2:CEP17",
                    "sub_points": [
                      "Single-probe methods evaluate the number ofERBB2genes",
                      "Dual-probe methods evaluate the number ofERBB2genes and a chromosome 17 reference probe (e.g., CEP17)Results are reported as the number ofERBB2genes and CEP17 signals and the ratio HER2:CEP17",
                      "Results are reported as the number ofERBB2genes and CEP17 signals and the ratio HER2:CEP17"
                    ]
                  },
                  {
                    "text": "Multiple methods for ISH are availableFISH utilizes fluorescent-labeled probes and fluorescence microscopy for detectionChromogenic/bright-field ISH (CISH, Duo-CISH) and silver-enhanced ISH (SISH) use light microscopyChromogen dye or silver deposition replaces fluorescent label for detection of gene copy numberLight microscopy facilitates correlation with morphologyCISH correlates well with FISH in most studiesFDA-approved CISH is recognized by ASCO/CAP guideline update for HER2 evaluation",
                    "sub_points": [
                      "FISH utilizes fluorescent-labeled probes and fluorescence microscopy for detection",
                      "Chromogenic/bright-field ISH (CISH, Duo-CISH) and silver-enhanced ISH (SISH) use light microscopyChromogen dye or silver deposition replaces fluorescent label for detection of gene copy numberLight microscopy facilitates correlation with morphologyCISH correlates well with FISH in most studiesFDA-approved CISH is recognized by ASCO/CAP guideline update for HER2 evaluation",
                      "Chromogen dye or silver deposition replaces fluorescent label for detection of gene copy number",
                      "Light microscopy facilitates correlation with morphology",
                      "CISH correlates well with FISH in most studies",
                      "FDA-approved CISH is recognized by ASCO/CAP guideline update for HER2 evaluation"
                    ]
                  },
                  {
                    "text": "With FISH and CISH, quantitative interpretation of results is more straightforward than with IHCConcordance rates between observers are higher with FISH than with IHC in some studiesHowever, heterogeneity of expression is easier to detect with IHC",
                    "sub_points": [
                      "Concordance rates between observers are higher with FISH than with IHC in some studies",
                      "However, heterogeneity of expression is easier to detect with IHC"
                    ]
                  },
                  {
                    "text": "Chromosome 17 centromere sequences (CEP17)A probe to the centromeric region of chromosome 17 is utilized in dual-probe methods as chromosome reference probeNormal (2 copies of CEP17)Tissue sections are thinner than nuclei; therefore, on average, only 1.6 CEP17 signals are seen per cellThe ratio of HER2:CEP17 normalizesERBB2gene number for tissue thicknessCEP17 is also helpful to identify cells that have duplicated DNA prior to division and areas of overlapping nucleiHowever, if CEP17 has undergone separate amplification or deletion events, the ratio may not be useful for these purposesPolysomy (increase in CEP17)Polysomy is defined as ≥ 3 CEP17 signals per nucleus10-50% of HER2(+)BC have increased CEP17 sequencesHowever, true polysomy (duplication of entire chromosome) is only present in ~ 1% of cancersIn the majority of cases, increased CEP17 is due to a separate duplication of centromeric DNA (i.e., not 1 large amplified segment, including bothERBB2and CEP17)Carcinomas with 3-5 copies ofERBB2gene and increased CEP17 generally do not show increased protein expression (group 4)In rare cases withERBB2≥ 6, the ratio is < 2.0 due to increased CEP17 numbers (group 3)Leads to discordance between single-probe (ERBB2gene number) and dual-probe (ratio) criteria for amplificationIf not previously done, IHC should be performedCarcinomas that are IHC 2+ or 3+ are classified as HER2(+)BC according to HER2 guidelinesHowever, the majority of these cancers show heterogeneous 2+ immunoreactivityASCO/CAP guidelines recommend scoring these cancers as HER2(+) byERBB2copy numberIt is not yet clear if carcinomas with 2+ scores by IHC, ≥ 6 gene copies, but ratios < 2.0 will benefit from targeted therapyMonosomy< 2% of cancers show only a single CEP17 signalRatio will be ≥ 2, but < 4 copies of HER2 may be present (group 2)Updated ASCO/CAP guidelines recommend classifying HER2 results for these cases based on IHC resultsIf IHC result is not 3+, it is now recommended to consider the cancer HER2(-) due to low HER2 copy numberIt is not clear if ratios ≥ 2.0 in presence of monosomy will predict benefit from targeted therapy",
                    "sub_points": [
                      "A probe to the centromeric region of chromosome 17 is utilized in dual-probe methods as chromosome reference probe",
                      "Normal (2 copies of CEP17)Tissue sections are thinner than nuclei; therefore, on average, only 1.6 CEP17 signals are seen per cellThe ratio of HER2:CEP17 normalizesERBB2gene number for tissue thicknessCEP17 is also helpful to identify cells that have duplicated DNA prior to division and areas of overlapping nucleiHowever, if CEP17 has undergone separate amplification or deletion events, the ratio may not be useful for these purposes",
                      "Tissue sections are thinner than nuclei; therefore, on average, only 1.6 CEP17 signals are seen per cell",
                      "The ratio of HER2:CEP17 normalizesERBB2gene number for tissue thickness",
                      "CEP17 is also helpful to identify cells that have duplicated DNA prior to division and areas of overlapping nuclei",
                      "However, if CEP17 has undergone separate amplification or deletion events, the ratio may not be useful for these purposes",
                      "Polysomy (increase in CEP17)Polysomy is defined as ≥ 3 CEP17 signals per nucleus10-50% of HER2(+)BC have increased CEP17 sequencesHowever, true polysomy (duplication of entire chromosome) is only present in ~ 1% of cancersIn the majority of cases, increased CEP17 is due to a separate duplication of centromeric DNA (i.e., not 1 large amplified segment, including bothERBB2and CEP17)Carcinomas with 3-5 copies ofERBB2gene and increased CEP17 generally do not show increased protein expression (group 4)In rare cases withERBB2≥ 6, the ratio is < 2.0 due to increased CEP17 numbers (group 3)Leads to discordance between single-probe (ERBB2gene number) and dual-probe (ratio) criteria for amplificationIf not previously done, IHC should be performedCarcinomas that are IHC 2+ or 3+ are classified as HER2(+)BC according to HER2 guidelinesHowever, the majority of these cancers show heterogeneous 2+ immunoreactivityASCO/CAP guidelines recommend scoring these cancers as HER2(+) byERBB2copy numberIt is not yet clear if carcinomas with 2+ scores by IHC, ≥ 6 gene copies, but ratios < 2.0 will benefit from targeted therapy",
                      "Polysomy is defined as ≥ 3 CEP17 signals per nucleus10-50% of HER2(+)BC have increased CEP17 sequencesHowever, true polysomy (duplication of entire chromosome) is only present in ~ 1% of cancers",
                      "10-50% of HER2(+)BC have increased CEP17 sequences",
                      "However, true polysomy (duplication of entire chromosome) is only present in ~ 1% of cancers",
                      "In the majority of cases, increased CEP17 is due to a separate duplication of centromeric DNA (i.e., not 1 large amplified segment, including bothERBB2and CEP17)",
                      "Carcinomas with 3-5 copies ofERBB2gene and increased CEP17 generally do not show increased protein expression (group 4)",
                      "In rare cases withERBB2≥ 6, the ratio is < 2.0 due to increased CEP17 numbers (group 3)Leads to discordance between single-probe (ERBB2gene number) and dual-probe (ratio) criteria for amplificationIf not previously done, IHC should be performedCarcinomas that are IHC 2+ or 3+ are classified as HER2(+)BC according to HER2 guidelinesHowever, the majority of these cancers show heterogeneous 2+ immunoreactivityASCO/CAP guidelines recommend scoring these cancers as HER2(+) byERBB2copy numberIt is not yet clear if carcinomas with 2+ scores by IHC, ≥ 6 gene copies, but ratios < 2.0 will benefit from targeted therapy",
                      "Leads to discordance between single-probe (ERBB2gene number) and dual-probe (ratio) criteria for amplification",
                      "If not previously done, IHC should be performed",
                      "Carcinomas that are IHC 2+ or 3+ are classified as HER2(+)BC according to HER2 guidelines",
                      "However, the majority of these cancers show heterogeneous 2+ immunoreactivity",
                      "ASCO/CAP guidelines recommend scoring these cancers as HER2(+) byERBB2copy number",
                      "It is not yet clear if carcinomas with 2+ scores by IHC, ≥ 6 gene copies, but ratios < 2.0 will benefit from targeted therapy",
                      "Monosomy< 2% of cancers show only a single CEP17 signalRatio will be ≥ 2, but < 4 copies of HER2 may be present (group 2)Updated ASCO/CAP guidelines recommend classifying HER2 results for these cases based on IHC resultsIf IHC result is not 3+, it is now recommended to consider the cancer HER2(-) due to low HER2 copy numberIt is not clear if ratios ≥ 2.0 in presence of monosomy will predict benefit from targeted therapy",
                      "< 2% of cancers show only a single CEP17 signal",
                      "Ratio will be ≥ 2, but < 4 copies of HER2 may be present (group 2)",
                      "Updated ASCO/CAP guidelines recommend classifying HER2 results for these cases based on IHC resultsIf IHC result is not 3+, it is now recommended to consider the cancer HER2(-) due to low HER2 copy numberIt is not clear if ratios ≥ 2.0 in presence of monosomy will predict benefit from targeted therapy",
                      "If IHC result is not 3+, it is now recommended to consider the cancer HER2(-) due to low HER2 copy number",
                      "It is not clear if ratios ≥ 2.0 in presence of monosomy will predict benefit from targeted therapy"
                    ]
                  }
                ],
                "ISH: 2018 ASCO/CAP Focused Update": [
                  {
                    "text": "H&E slide corresponding to block used for ISH should be carefully examinedAreas of invasive carcinoma are identified and markedAreas of DCIS should be noted in order to exclude them from evaluationIn rare cases, DCIS will show amplification but not associated invasive carcinoma",
                    "sub_points": [
                      "Areas of invasive carcinoma are identified and marked",
                      "Areas of DCIS should be noted in order to exclude them from evaluationIn rare cases, DCIS will show amplification but not associated invasive carcinoma",
                      "In rare cases, DCIS will show amplification but not associated invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Update recommends that ISH and IHC slides should be reviewed together for uncommon HER2 ISH resultsIncludes cases of monosomy, polysomy (amplification of CEP17), and equivocal ISH resultsReview of HER2 IHC slide is helpful to identify areas of heterogeneous protein expression that should be correlated with ISH resultsHeterogeneity in HER2 protein overexpression can be used to target areas forERBB2ISH analysisIHC results should be used to resolve final HER2 status for such cases",
                    "sub_points": [
                      "Includes cases of monosomy, polysomy (amplification of CEP17), and equivocal ISH results",
                      "Review of HER2 IHC slide is helpful to identify areas of heterogeneous protein expression that should be correlated with ISH resultsHeterogeneity in HER2 protein overexpression can be used to target areas forERBB2ISH analysisIHC results should be used to resolve final HER2 status for such cases",
                      "Heterogeneity in HER2 protein overexpression can be used to target areas forERBB2ISH analysis",
                      "IHC results should be used to resolve final HER2 status for such cases"
                    ]
                  },
                  {
                    "text": "The entire ISH slide is scanned to select the best areas for analysis and to evaluate for GHAt least 2-4 representative fields are analyzedFluorescent counterstains allow identification of areas of invasive carcinomaNumber of signals from randomly selected invasive tumor cell nuclei are countedGood gene signals should be present in > 75% of tumor cells to ensure adequate hybridizationCells should be nonoverlapping, have distinct nuclear membranes, and have at least 1 signal per cellIf 2 different probes are used, at least 1 signal from each probe should be seen in each cell countedSufficient numbers of nuclei are counted to ensure that ratio is representative of entire cancerAt least 40 cells, 20 in each of 2 fields, should be countedIn dual-probe systems, bothERBB2count and CEP17 count are determined in the same set of cellsAverage number of signals for each probe are used to calculate HER2:CEP17 ratioIf result is classified as equivocal, additional cells should be counted &/or assay should be repeated",
                    "sub_points": [
                      "At least 2-4 representative fields are analyzed",
                      "Fluorescent counterstains allow identification of areas of invasive carcinoma",
                      "Number of signals from randomly selected invasive tumor cell nuclei are countedGood gene signals should be present in > 75% of tumor cells to ensure adequate hybridizationCells should be nonoverlapping, have distinct nuclear membranes, and have at least 1 signal per cellIf 2 different probes are used, at least 1 signal from each probe should be seen in each cell countedSufficient numbers of nuclei are counted to ensure that ratio is representative of entire cancerAt least 40 cells, 20 in each of 2 fields, should be countedIn dual-probe systems, bothERBB2count and CEP17 count are determined in the same set of cellsAverage number of signals for each probe are used to calculate HER2:CEP17 ratioIf result is classified as equivocal, additional cells should be counted &/or assay should be repeated",
                      "Good gene signals should be present in > 75% of tumor cells to ensure adequate hybridization",
                      "Cells should be nonoverlapping, have distinct nuclear membranes, and have at least 1 signal per cell",
                      "If 2 different probes are used, at least 1 signal from each probe should be seen in each cell counted",
                      "Sufficient numbers of nuclei are counted to ensure that ratio is representative of entire cancer",
                      "At least 40 cells, 20 in each of 2 fields, should be counted",
                      "In dual-probe systems, bothERBB2count and CEP17 count are determined in the same set of cellsAverage number of signals for each probe are used to calculate HER2:CEP17 ratio",
                      "Average number of signals for each probe are used to calculate HER2:CEP17 ratio",
                      "If result is classified as equivocal, additional cells should be counted &/or assay should be repeated"
                    ]
                  },
                  {
                    "text": "ISH: PositiveGroup 1 (~ 15-20% of cancers): Ratio ≥ 2.0, average HER2 copy number ≥ 4 signals per cell> 90% of tumors with this result show HER2 protein overexpression by IHC (scored as 3+ or 2+)IHC and ISH methods of evaluating HER2 are concordant in majority of cases",
                    "sub_points": [
                      "Group 1 (~ 15-20% of cancers): Ratio ≥ 2.0, average HER2 copy number ≥ 4 signals per cell> 90% of tumors with this result show HER2 protein overexpression by IHC (scored as 3+ or 2+)IHC and ISH methods of evaluating HER2 are concordant in majority of cases",
                      "> 90% of tumors with this result show HER2 protein overexpression by IHC (scored as 3+ or 2+)",
                      "IHC and ISH methods of evaluating HER2 are concordant in majority of cases"
                    ]
                  },
                  {
                    "text": "ISH: Additional work-up necessaryGroup 2 (~ 0.4% of cancers): Ratio ≥ 2, average HER2 copy number < 4 signals per cellThis occurs when the CEP17 number is lower than normal (e.g., average result of 1)The IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive; this would be a highly unusual result; it would be prudent to confirm the IHC resultGroup 3 (~ 0.6% of cancers): Ratio < 2, average HER2 copy number ≥ 6 (i.e., amplification of CEP17)This occurs when CEP17 is amplifiedThe IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is positive; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positiveGroup 4 (~ 4.5% of cancers): Ratio < 2, average HER2 copy number ≥ 4.0 and < 6.0This occurs in cancers with low level of HER2 amplificationThe IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive; this would be an unusual result; it would be prudent to confirm the IHC result",
                    "sub_points": [
                      "Group 2 (~ 0.4% of cancers): Ratio ≥ 2, average HER2 copy number < 4 signals per cellThis occurs when the CEP17 number is lower than normal (e.g., average result of 1)The IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive; this would be a highly unusual result; it would be prudent to confirm the IHC result",
                      "This occurs when the CEP17 number is lower than normal (e.g., average result of 1)",
                      "The IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive; this would be a highly unusual result; it would be prudent to confirm the IHC result",
                      "0-1+: Final HER2 status negative",
                      "2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status",
                      "3+: Final HER2 status positive; this would be a highly unusual result; it would be prudent to confirm the IHC result",
                      "Group 3 (~ 0.6% of cancers): Ratio < 2, average HER2 copy number ≥ 6 (i.e., amplification of CEP17)This occurs when CEP17 is amplifiedThe IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is positive; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive",
                      "This occurs when CEP17 is amplified",
                      "The IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is positive; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive",
                      "0-1+: Final HER2 status negative",
                      "2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is positive; if not confirmed, laboratory adjudicates final status",
                      "3+: Final HER2 status positive",
                      "Group 4 (~ 4.5% of cancers): Ratio < 2, average HER2 copy number ≥ 4.0 and < 6.0This occurs in cancers with low level of HER2 amplificationThe IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive; this would be an unusual result; it would be prudent to confirm the IHC result",
                      "This occurs in cancers with low level of HER2 amplification",
                      "The IHC result is required for interpretation0-1+: Final HER2 status negative2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status3+: Final HER2 status positive; this would be an unusual result; it would be prudent to confirm the IHC result",
                      "0-1+: Final HER2 status negative",
                      "2+: ISH repeated by a person blinded to original result counting at least 20 cells; if original result is confirmed, the result is negative; if not confirmed, laboratory adjudicates final status",
                      "3+: Final HER2 status positive; this would be an unusual result; it would be prudent to confirm the IHC result"
                    ]
                  },
                  {
                    "text": "ISH: NegativeGroup 5 (~ 75-80% of cancers): Ratio < 2 and average HER2 copy number < 4.0> 95% of tumors without gene amplification do not show HER2 protein overexpression (0/1+)",
                    "sub_points": [
                      "Group 5 (~ 75-80% of cancers): Ratio < 2 and average HER2 copy number < 4.0> 95% of tumors without gene amplification do not show HER2 protein overexpression (0/1+)",
                      "> 95% of tumors without gene amplification do not show HER2 protein overexpression (0/1+)"
                    ]
                  },
                  {
                    "text": "ISH equivocalIn 2013 ASCO/CAP guidelines update, it was possible to have equivocal results by both IHC and ISHThis created problems in classifying some cancers for HER2 status2018 guidelines eliminate equivocal results by correlating ISH results with IHC and recommending counting additional cells by ISH in some cases (groups 2, 3, and 4)In \"borderline\" cases, additional testing on other specimens may be of value (e.g., excisional specimen after core needle biopsy, biopsy of metastasis)Carcinomas with heterogeneous expression may have subclones with higher levels of expressionSome carcinomas biologically have true borderline expression after repeat testing; reflects that expression is continuous and not bimodalAdditional testing using alternative chromosome 17 probes should not be used routinely for resolving HER2 statusRARAis adjacent to HER2 on long arm of chromosome 17;SMSandTP53are on short arm of chromosome 17All of these genes can undergo separate amplification or deletion events",
                    "sub_points": [
                      "In 2013 ASCO/CAP guidelines update, it was possible to have equivocal results by both IHC and ISHThis created problems in classifying some cancers for HER2 status",
                      "This created problems in classifying some cancers for HER2 status",
                      "2018 guidelines eliminate equivocal results by correlating ISH results with IHC and recommending counting additional cells by ISH in some cases (groups 2, 3, and 4)",
                      "In \"borderline\" cases, additional testing on other specimens may be of value (e.g., excisional specimen after core needle biopsy, biopsy of metastasis)Carcinomas with heterogeneous expression may have subclones with higher levels of expressionSome carcinomas biologically have true borderline expression after repeat testing; reflects that expression is continuous and not bimodal",
                      "Carcinomas with heterogeneous expression may have subclones with higher levels of expression",
                      "Some carcinomas biologically have true borderline expression after repeat testing; reflects that expression is continuous and not bimodal",
                      "Additional testing using alternative chromosome 17 probes should not be used routinely for resolving HER2 statusRARAis adjacent to HER2 on long arm of chromosome 17;SMSandTP53are on short arm of chromosome 17All of these genes can undergo separate amplification or deletion events",
                      "RARAis adjacent to HER2 on long arm of chromosome 17;SMSandTP53are on short arm of chromosome 17",
                      "All of these genes can undergo separate amplification or deletion events"
                    ]
                  },
                  {
                    "text": "ISH inadequate for interpretationSome assay results are inadequate for interpretation and must be repeated in the following situationsA total of at least 40 nonoverlapping, intact tumor nuclei cannot be identifiedEither positive or negative control results fall outside expected valuesHybridization signals are not uniform throughout areas of invasive tumor (> 75% of cells)Background is too high or obscures gene signalsEnzymatic digestion is not optimized to produce scorable signalsNuclear borders are indistinct or lost (overdigestion)Persistence of green autofluorescence obscures the signal (underdigestion)",
                    "sub_points": [
                      "Some assay results are inadequate for interpretation and must be repeated in the following situationsA total of at least 40 nonoverlapping, intact tumor nuclei cannot be identifiedEither positive or negative control results fall outside expected valuesHybridization signals are not uniform throughout areas of invasive tumor (> 75% of cells)Background is too high or obscures gene signalsEnzymatic digestion is not optimized to produce scorable signalsNuclear borders are indistinct or lost (overdigestion)Persistence of green autofluorescence obscures the signal (underdigestion)",
                      "A total of at least 40 nonoverlapping, intact tumor nuclei cannot be identified",
                      "Either positive or negative control results fall outside expected values",
                      "Hybridization signals are not uniform throughout areas of invasive tumor (> 75% of cells)",
                      "Background is too high or obscures gene signals",
                      "Enzymatic digestion is not optimized to produce scorable signals",
                      "Nuclear borders are indistinct or lost (overdigestion)",
                      "Persistence of green autofluorescence obscures the signal (underdigestion)"
                    ]
                  }
                ],
                "HER2 Genetic Heterogeneity": [
                  {
                    "text": "~ 50% of HER2(+)BC demonstrate high levels ofHER2amplification/protein overexpression diffusely through all areas of invasive tumor"
                  },
                  {
                    "text": "~ 50% of HER2(+)BC show lesser degrees ofHER2amplification/protein expression, which may indicate GH"
                  },
                  {
                    "text": "In one proposed definition, GH is present when > 5% but < 50% of tumor cells show amplification (ratio ≥ 2.0 or ≥ 6 genes)If > 50% of cells show amplification, carcinoma is reported as HER2(+) without GH",
                    "sub_points": [
                      "If > 50% of cells show amplification, carcinoma is reported as HER2(+) without GH"
                    ]
                  },
                  {
                    "text": "When present, GH occurs in 3 separate patternsDiscrete clustered populations (clones) of amplified and nonamplified tumor cellsDiffuse intermingling of amplified and nonamplified cells across tumorIsolated amplified cells in a nonamplified tumor",
                    "sub_points": [
                      "Discrete clustered populations (clones) of amplified and nonamplified tumor cells",
                      "Diffuse intermingling of amplified and nonamplified cells across tumor",
                      "Isolated amplified cells in a nonamplified tumor"
                    ]
                  },
                  {
                    "text": "The only pattern of GH that is currently utilized for determining if a cancer is HER2(+) is discrete, aggregated, or clustered amplified cells"
                  },
                  {
                    "text": "Classification is based on average results over the entire carcinomaIf > 10% of invasive tumor cells show gene amplification (ratio ≥ 2.0 and HER2 count is ≥ 4) in cluster/contiguous population, result is reported as HER2(+) with GHAny aggregate population of amplified cells comprising > 10% of total invasive tumor must be counted and reported separatelyHER2:CEP17 ratio should then be calculated and reported for each population of cells separatelyReported as HER2(+)BC with HER2 GH with comment describing findingsReport the percentage of invasive carcinoma showingHER2amplificationIf amplified population of tumor has histologically distinct appearance, this should be commented onISH should not be evaluated by only counting dispersed (nonclustered) cells with the highest level of gene amplification",
                    "sub_points": [
                      "If > 10% of invasive tumor cells show gene amplification (ratio ≥ 2.0 and HER2 count is ≥ 4) in cluster/contiguous population, result is reported as HER2(+) with GHAny aggregate population of amplified cells comprising > 10% of total invasive tumor must be counted and reported separatelyHER2:CEP17 ratio should then be calculated and reported for each population of cells separately",
                      "Any aggregate population of amplified cells comprising > 10% of total invasive tumor must be counted and reported separately",
                      "HER2:CEP17 ratio should then be calculated and reported for each population of cells separately",
                      "Reported as HER2(+)BC with HER2 GH with comment describing findingsReport the percentage of invasive carcinoma showingHER2amplificationIf amplified population of tumor has histologically distinct appearance, this should be commented on",
                      "Report the percentage of invasive carcinoma showingHER2amplification",
                      "If amplified population of tumor has histologically distinct appearance, this should be commented on",
                      "ISH should not be evaluated by only counting dispersed (nonclustered) cells with the highest level of gene amplification"
                    ]
                  },
                  {
                    "text": "Significance of GH for determining benefit from HER2-targeted therapy is unclearRetrospective analysis from 9831 adjuvant trial showed that HER2(+)BC with IHC 3+ in at least 10-30% of invasive carcinoma benefited from trastuzumab",
                    "sub_points": [
                      "Retrospective analysis from 9831 adjuvant trial showed that HER2(+)BC with IHC 3+ in at least 10-30% of invasive carcinoma benefited from trastuzumab"
                    ]
                  },
                  {
                    "text": "If GH is detected on CNBReport should state that findings might not be representative of entire carcinomaAdditional testing on excision may be of value",
                    "sub_points": [
                      "Report should state that findings might not be representative of entire carcinoma",
                      "Additional testing on excision may be of value"
                    ]
                  }
                ],
                "HER2 Testing Algorithms": [
                  {
                    "text": "ISH and IHC assays are best viewed as complementary methodologiesThese tests examine different aspects of HER2 biologyMajority of carcinomas have concordant results for bothSubset of BCs are positive by one assay but negative by other assayIHC and ISH aid in understanding of underlying biology of these cancers",
                    "sub_points": [
                      "These tests examine different aspects of HER2 biology",
                      "Majority of carcinomas have concordant results for both",
                      "Subset of BCs are positive by one assay but negative by other assayIHC and ISH aid in understanding of underlying biology of these cancers",
                      "IHC and ISH aid in understanding of underlying biology of these cancers"
                    ]
                  },
                  {
                    "text": "Initial testing by IHCISH testing is reflexively performed on equivocal and discordant casesTesting algorithm assumes that IHC assays are validated, highly standardized, accurate, and reproducibleLaboratories must exercise rigorous quality control and follow published guidelinesAssay must be validated to show high degree of concordance with ISH resultsFacilitates recognition of GH or unusual patterns of HER2 expressionCancers with low protein expression but positive results by ISH (e.g., with low numbers of HER2) may not be detected",
                    "sub_points": [
                      "ISH testing is reflexively performed on equivocal and discordant cases",
                      "Testing algorithm assumes that IHC assays are validated, highly standardized, accurate, and reproducibleLaboratories must exercise rigorous quality control and follow published guidelinesAssay must be validated to show high degree of concordance with ISH results",
                      "Laboratories must exercise rigorous quality control and follow published guidelines",
                      "Assay must be validated to show high degree of concordance with ISH results",
                      "Facilitates recognition of GH or unusual patterns of HER2 expression",
                      "Cancers with low protein expression but positive results by ISH (e.g., with low numbers of HER2) may not be detected"
                    ]
                  },
                  {
                    "text": "Initial testing by ISHIHC testing also must be performed on group ISH 2, 3, 4 casesAdditional cells are also counted by ISH for IHC equivocal casesMore difficult to identify cancers with heterogeneous expression or unusual patterns",
                    "sub_points": [
                      "IHC testing also must be performed on group ISH 2, 3, 4 casesAdditional cells are also counted by ISH for IHC equivocal cases",
                      "Additional cells are also counted by ISH for IHC equivocal cases",
                      "More difficult to identify cancers with heterogeneous expression or unusual patterns"
                    ]
                  },
                  {
                    "text": "Initial testing by both IHC and ISHConcordance can be determined for all casesMost likely algorithm to identify all HER2(+)BCsHowever, unnecessary testing is performed on clearly positive and clearly negative cancers",
                    "sub_points": [
                      "Concordance can be determined for all cases",
                      "Most likely algorithm to identify all HER2(+)BCsHowever, unnecessary testing is performed on clearly positive and clearly negative cancers",
                      "However, unnecessary testing is performed on clearly positive and clearly negative cancers"
                    ]
                  },
                  {
                    "text": "With any algorithm, if HER2 results are discordant with pathology findings, additional HER2 testing should be considered on same or different specimen"
                  }
                ]
              },
              "HER2 Assays: Quality Assurance": {
                "Routine Use of Control Materials": [
                  {
                    "text": "Positive and negative controls should be run with every assay to help ensure proper assay performanceBatch control using HER2(+) cell lines helps ensure appropriate assay sensitivityBatch controls can be used to monitor assay performance and detect loss of sensitivity or assay analytical driftKnown HER2(+) sample on same slide as test sample helps to ensure that all reagents were dispensed appropriately",
                    "sub_points": [
                      "Batch control using HER2(+) cell lines helps ensure appropriate assay sensitivity",
                      "Batch controls can be used to monitor assay performance and detect loss of sensitivity or assay analytical drift",
                      "Known HER2(+) sample on same slide as test sample helps to ensure that all reagents were dispensed appropriately"
                    ]
                  }
                ],
                "Monitor Daily Testing Results": [
                  {
                    "text": "Review of batch controls and on slide controls to ensure accurate assay performanceEvaluate results for analytical drift and sensitivity",
                    "sub_points": [
                      "Evaluate results for analytical drift and sensitivity"
                    ]
                  }
                ],
                "Perform Periodic Trend Analysis": [
                  {
                    "text": "Helps ensure that percentage of HER2(+) cases are within expected benchmark norm for BC population"
                  }
                ],
                "Participate in HER2 Testing Proficiency Program": [
                  {
                    "text": "Helps ensure high concordance and accuracy of individual laboratory results"
                  }
                ],
                "Discordant IHC and ISH Assays": [
                  {
                    "text": "IHC and ISH results are concordant in > 90% of cases"
                  },
                  {
                    "text": "If discordance is found, each assay should be reviewed to determine if there is a technical problem"
                  },
                  {
                    "text": "Rare cancers can have unusual expression patterns"
                  },
                  {
                    "text": "The most common discordance is an IHC 3+ result that is not associated with gene amplificationIn the majority of cases, a 2nd review of the IHC shows an equivocal result and repeat IHC is negativeA mechanism for HER2 protein overexpression in the absence of amplification has not been reported",
                    "sub_points": [
                      "In the majority of cases, a 2nd review of the IHC shows an equivocal result and repeat IHC is negative",
                      "A mechanism for HER2 protein overexpression in the absence of amplification has not been reported"
                    ]
                  }
                ],
                "Critical Evaluation of HER2 Assays": [
                  {
                    "text": "Tissue handling and fixation parameters must comply with guidelines"
                  },
                  {
                    "text": "Controls must demonstrate expected results"
                  },
                  {
                    "text": "HER2 test status should be concordant with the histologic appearance and clinical history"
                  },
                  {
                    "text": "Continuous monitoring of QA/QC and assay performance is essential"
                  },
                  {
                    "text": "Concordance of HER2 results on different specimens for QAIt is always helpful to correlate HER2 results when available on multiple specimensThere are multiple reasons why results could be discordantTechnical problems with one or both assaysSpecimen handling problems with one or both assaysHeterogeneity of HER2 expression and limited biopsy (e.g., CNB)Selection of subclones, particularly after targeted treatmentEmergence of new primary BCWhat is thought to be a \"metastasis\" is a different primary carcinoma",
                    "sub_points": [
                      "It is always helpful to correlate HER2 results when available on multiple specimens",
                      "There are multiple reasons why results could be discordantTechnical problems with one or both assaysSpecimen handling problems with one or both assaysHeterogeneity of HER2 expression and limited biopsy (e.g., CNB)Selection of subclones, particularly after targeted treatmentEmergence of new primary BCWhat is thought to be a \"metastasis\" is a different primary carcinoma",
                      "Technical problems with one or both assays",
                      "Specimen handling problems with one or both assays",
                      "Heterogeneity of HER2 expression and limited biopsy (e.g., CNB)",
                      "Selection of subclones, particularly after targeted treatment",
                      "Emergence of new primary BC",
                      "What is thought to be a \"metastasis\" is a different primary carcinoma"
                    ]
                  }
                ],
                "AnalyticalValidation Requirements": [
                  {
                    "text": "Laboratories are responsible for ensuring reliability and accuracy of their testing resultsRigorous quality control includes compliance with accreditation and proficiency testing requirements of HER2 test assaysInterobserver agreement for all pathologists interpreting HER2 results should be documented",
                    "sub_points": [
                      "Rigorous quality control includes compliance with accreditation and proficiency testing requirements of HER2 test assays",
                      "Interobserver agreement for all pathologists interpreting HER2 results should be documented"
                    ]
                  },
                  {
                    "text": "2013 ASCO/CAP guidelines update changed initial test validation requirementsInitial validation for HER2 should include 20 negative and 20 positive cases for FDA-approved assays (IHC and ISH)40 negative and 40 positive cases are required for laboratory-developed testsValidation is ASCO/CAP guideline requirement before HER2 test can be offered clinicallySamples are tested in parallel by alternative validated method (ISH if validating IHC)Tests can be performed using validated method in either same or another laboratorySpecific concordance requirements are not specified in 2013 guideline for initial testing validationIdeally, concordance between IHC and ISH methodologies should be > 90%Laboratories should monitor ongoing concordance between 2 methods as part of their QA/QCValidation requirement does not apply to assays previously validated following 2007 testing guideline",
                    "sub_points": [
                      "Initial validation for HER2 should include 20 negative and 20 positive cases for FDA-approved assays (IHC and ISH)40 negative and 40 positive cases are required for laboratory-developed tests",
                      "40 negative and 40 positive cases are required for laboratory-developed tests",
                      "Validation is ASCO/CAP guideline requirement before HER2 test can be offered clinically",
                      "Samples are tested in parallel by alternative validated method (ISH if validating IHC)Tests can be performed using validated method in either same or another laboratory",
                      "Tests can be performed using validated method in either same or another laboratory",
                      "Specific concordance requirements are not specified in 2013 guideline for initial testing validationIdeally, concordance between IHC and ISH methodologies should be > 90%Laboratories should monitor ongoing concordance between 2 methods as part of their QA/QC",
                      "Ideally, concordance between IHC and ISH methodologies should be > 90%",
                      "Laboratories should monitor ongoing concordance between 2 methods as part of their QA/QC",
                      "Validation requirement does not apply to assays previously validated following 2007 testing guideline"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Carcinoma With Extensive Intraductal Component": {
            "name": "Carcinoma With Extensive Intraductal Component",
            "url": "https://app.pathprimer.com/document/4db4e37c-5c3e-4a62-870b-e90de4e3a877/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Extensive intraductal component (EIC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Classification of extent of ductal carcinoma in situ (DCIS) associated with invasive breast carcinomas (BCs)"
                  }
                ],
                "Overview": [
                  {
                    "text": "Invasive BCs are associated with variable amounts of DCISSome invasive BCs have minimal to no DCISOther invasive BCs are associated with DCIS involving several cm or up to all 4 quadrants of the breast",
                    "sub_points": [
                      "Some invasive BCs have minimal to no DCIS",
                      "Other invasive BCs are associated with DCIS involving several cm or up to all 4 quadrants of the breast"
                    ]
                  },
                  {
                    "text": "There are 2 groups of invasive BCs defined as having an EICType 1 EIC(+)Both of the following features are presentDCIS comprises ≥ 25% of the area within the invasive BCandDCIS is present outside the border of the invasive BCType 2 EIC(+)Extensive DCIS is present outside the border of a small invasive BC (not specifically defined but generally ~ ≤ 1 cm)Multiple foci of invasion are present in some casesBecause of the small size, these invasive BCs cannot fulfill the criteria of having ≥ 25% DCIS within the area of invasion",
                    "sub_points": [
                      "Type 1 EIC(+)Both of the following features are presentDCIS comprises ≥ 25% of the area within the invasive BCandDCIS is present outside the border of the invasive BC",
                      "Both of the following features are presentDCIS comprises ≥ 25% of the area within the invasive BCandDCIS is present outside the border of the invasive BC",
                      "DCIS comprises ≥ 25% of the area within the invasive BCand",
                      "DCIS is present outside the border of the invasive BC",
                      "Type 2 EIC(+)Extensive DCIS is present outside the border of a small invasive BC (not specifically defined but generally ~ ≤ 1 cm)Multiple foci of invasion are present in some casesBecause of the small size, these invasive BCs cannot fulfill the criteria of having ≥ 25% DCIS within the area of invasion",
                      "Extensive DCIS is present outside the border of a small invasive BC (not specifically defined but generally ~ ≤ 1 cm)",
                      "Multiple foci of invasion are present in some cases",
                      "Because of the small size, these invasive BCs cannot fulfill the criteria of having ≥ 25% DCIS within the area of invasion"
                    ]
                  },
                  {
                    "text": "The majority of invasive BCs are EIC(-)EIC(+): 25-40%EIC(-): 60-75%",
                    "sub_points": [
                      "EIC(+): 25-40%",
                      "EIC(-): 60-75%"
                    ]
                  },
                  {
                    "text": "The extent of DCIS is correlated with the biologic type of invasive BCLuminal BC [ER(+)/HER2(-)]: ~ 15% EIC(+)HER2(+) BC: ~ 30% EIC(+)Also likely to have multiple foci of invasionTriple negative BC [ER(-)/PR(-)/HER2(-)]: ~ 10% EIC(+)Associated DCIS is usually focal; may be present as cancerization of lobules at edge of the invasive BCSome subtypes are only very rarely associated with DCIS (e.g., spindle cell metaplastic carcinoma)",
                    "sub_points": [
                      "Luminal BC [ER(+)/HER2(-)]: ~ 15% EIC(+)",
                      "HER2(+) BC: ~ 30% EIC(+)Also likely to have multiple foci of invasion",
                      "Also likely to have multiple foci of invasion",
                      "Triple negative BC [ER(-)/PR(-)/HER2(-)]: ~ 10% EIC(+)Associated DCIS is usually focal; may be present as cancerization of lobules at edge of the invasive BCSome subtypes are only very rarely associated with DCIS (e.g., spindle cell metaplastic carcinoma)",
                      "Associated DCIS is usually focal; may be present as cancerization of lobules at edge of the invasive BC",
                      "Some subtypes are only very rarely associated with DCIS (e.g., spindle cell metaplastic carcinoma)"
                    ]
                  },
                  {
                    "text": "Invasive BCs that are EIC(+) are more likely to have multiple foci of invasionEIC(+): 17% of cases have multiple foci of invasionEIC(-): 5% of cases have multiple foci of invasionThe multiple invasive foci are usually similar in histologic appearance and marker expressionIn rare cases, the associated DCIS is biologically heterogeneous, and the multiple foci of invasion have different histologic appearances and marker expression profiles",
                    "sub_points": [
                      "EIC(+): 17% of cases have multiple foci of invasion",
                      "EIC(-): 5% of cases have multiple foci of invasion",
                      "The multiple invasive foci are usually similar in histologic appearance and marker expressionIn rare cases, the associated DCIS is biologically heterogeneous, and the multiple foci of invasion have different histologic appearances and marker expression profiles",
                      "In rare cases, the associated DCIS is biologically heterogeneous, and the multiple foci of invasion have different histologic appearances and marker expression profiles"
                    ]
                  },
                  {
                    "text": "EIC is not predictive for overall survival, recurrence-free survival, or distant metastasisEIC is an independent risk factor for local recurrence after breast-conserving surgery",
                    "sub_points": [
                      "EIC is an independent risk factor for local recurrence after breast-conserving surgery"
                    ]
                  },
                  {
                    "text": "Local recurrences of BC are often due to residual DCIS, as it is usually possible to remove the invasive BC with negative marginsDCIS is more difficult to completely remove at surgery, as the extent cannot be determined with certainty by imaging or grossly intraoperativelyEIC(+) BCs are surgically challenging due to the volume of breast tissue involvedAccurate pathologic assessment of all margins is important",
                    "sub_points": [
                      "DCIS is more difficult to completely remove at surgery, as the extent cannot be determined with certainty by imaging or grossly intraoperatively",
                      "EIC(+) BCs are surgically challenging due to the volume of breast tissue involved",
                      "Accurate pathologic assessment of all margins is important"
                    ]
                  },
                  {
                    "text": "The Society of Surgical Oncology (SSO)-American Society for Radiation Oncology (ASTRO) issued consensus guidelines for margin evaluation of invasive BCMargins with no ink on invasive BC or DCIS are considered negative and do not require reexcisionThis recommendation is not changed for EIC(+) BCsGuideline applies to early-stage invasive BC treated with breast-conserving therapy (BCT) followed by whole-breast irradiationNot applicable for patients with only DCISNot applicable for patients with invasive BC undergoing partial breast irradiation or no radiationNot applicable for patients undergoing neoadjuvant chemotherapyThe multidisciplinary consensus panel used metaanalysis of margin width and ipsilateral breast tumor recurrence (IBTR) based on 33 studiesPositive marginsInk on invasive BC or DCIS is associated with 2x increased risk of IBTR compared with BCs with negative marginsPositive margins after breast-conserving surgery signify significant possibility of residual disease around resection cavityIncreased risk is not mitigated by favorable biology, endocrine therapy, or radiation boostWider marginsDo not significantly decrease rate of IBTR compared with no ink on BCNo evidence that wider margins reduce IBTR for younger patients, unfavorable biology, lobular BCs, or BCs with EICEIC and IBTREIC identifies patients who may have a large residual DCIS burden after BCTPatients with EIC(+) BCs, but not EIC(-) BCs, are frequently found to have considerable residual DCIS on reexcision5-year IBTR approaches 0% for EIC(+) BCs when no tumor cells are at inked margin or when margins were reported as close5-year IBTR reported as 50% for EIC(+) BC with greater than focal margin positivityObtaining a postoperative mammogram to identify residual calcifications in patients with EIC(+) BC after excision may be warrantedPanel conclusionsStudies support there is no increased risk of IBTR when margins are negativeBased on this data, use of margins wider than \"no ink on tumor\" is not supportedUse of \"no ink on tumor\" as a standard for an adequate margin was recommended in the current era of multidisciplinary care and multimodality treatmentAssociated with low rates of IBTRPotential to decrease reexcision rates, improve cosmetic outcomes, and reduce costPanel emphasized that guidelines are not a substitute for clinical judgmentIn some situations, wider margins may be of benefitExample provided is a young patient with EIC(+) BC and a tumor < 1 mm from margin over broad frontImplications for pathologistsPathologists should continue to report positive margins and distance to all negative margins according to College of American Pathologists reporting guidelinesInterpretations of margin width (such as \"close\") should not be used",
                    "sub_points": [
                      "Margins with no ink on invasive BC or DCIS are considered negative and do not require reexcision",
                      "This recommendation is not changed for EIC(+) BCs",
                      "Guideline applies to early-stage invasive BC treated with breast-conserving therapy (BCT) followed by whole-breast irradiationNot applicable for patients with only DCISNot applicable for patients with invasive BC undergoing partial breast irradiation or no radiationNot applicable for patients undergoing neoadjuvant chemotherapy",
                      "Not applicable for patients with only DCIS",
                      "Not applicable for patients with invasive BC undergoing partial breast irradiation or no radiation",
                      "Not applicable for patients undergoing neoadjuvant chemotherapy",
                      "The multidisciplinary consensus panel used metaanalysis of margin width and ipsilateral breast tumor recurrence (IBTR) based on 33 studies",
                      "Positive marginsInk on invasive BC or DCIS is associated with 2x increased risk of IBTR compared with BCs with negative marginsPositive margins after breast-conserving surgery signify significant possibility of residual disease around resection cavityIncreased risk is not mitigated by favorable biology, endocrine therapy, or radiation boost",
                      "Ink on invasive BC or DCIS is associated with 2x increased risk of IBTR compared with BCs with negative margins",
                      "Positive margins after breast-conserving surgery signify significant possibility of residual disease around resection cavity",
                      "Increased risk is not mitigated by favorable biology, endocrine therapy, or radiation boost",
                      "Wider marginsDo not significantly decrease rate of IBTR compared with no ink on BCNo evidence that wider margins reduce IBTR for younger patients, unfavorable biology, lobular BCs, or BCs with EIC",
                      "Do not significantly decrease rate of IBTR compared with no ink on BC",
                      "No evidence that wider margins reduce IBTR for younger patients, unfavorable biology, lobular BCs, or BCs with EIC",
                      "EIC and IBTREIC identifies patients who may have a large residual DCIS burden after BCTPatients with EIC(+) BCs, but not EIC(-) BCs, are frequently found to have considerable residual DCIS on reexcision5-year IBTR approaches 0% for EIC(+) BCs when no tumor cells are at inked margin or when margins were reported as close5-year IBTR reported as 50% for EIC(+) BC with greater than focal margin positivityObtaining a postoperative mammogram to identify residual calcifications in patients with EIC(+) BC after excision may be warranted",
                      "EIC identifies patients who may have a large residual DCIS burden after BCT",
                      "Patients with EIC(+) BCs, but not EIC(-) BCs, are frequently found to have considerable residual DCIS on reexcision",
                      "5-year IBTR approaches 0% for EIC(+) BCs when no tumor cells are at inked margin or when margins were reported as close",
                      "5-year IBTR reported as 50% for EIC(+) BC with greater than focal margin positivity",
                      "Obtaining a postoperative mammogram to identify residual calcifications in patients with EIC(+) BC after excision may be warranted",
                      "Panel conclusionsStudies support there is no increased risk of IBTR when margins are negativeBased on this data, use of margins wider than \"no ink on tumor\" is not supportedUse of \"no ink on tumor\" as a standard for an adequate margin was recommended in the current era of multidisciplinary care and multimodality treatmentAssociated with low rates of IBTRPotential to decrease reexcision rates, improve cosmetic outcomes, and reduce cost",
                      "Studies support there is no increased risk of IBTR when margins are negative",
                      "Based on this data, use of margins wider than \"no ink on tumor\" is not supported",
                      "Use of \"no ink on tumor\" as a standard for an adequate margin was recommended in the current era of multidisciplinary care and multimodality treatmentAssociated with low rates of IBTRPotential to decrease reexcision rates, improve cosmetic outcomes, and reduce cost",
                      "Associated with low rates of IBTR",
                      "Potential to decrease reexcision rates, improve cosmetic outcomes, and reduce cost",
                      "Panel emphasized that guidelines are not a substitute for clinical judgmentIn some situations, wider margins may be of benefitExample provided is a young patient with EIC(+) BC and a tumor < 1 mm from margin over broad front",
                      "In some situations, wider margins may be of benefitExample provided is a young patient with EIC(+) BC and a tumor < 1 mm from margin over broad front",
                      "Example provided is a young patient with EIC(+) BC and a tumor < 1 mm from margin over broad front",
                      "Implications for pathologistsPathologists should continue to report positive margins and distance to all negative margins according to College of American Pathologists reporting guidelinesInterpretations of margin width (such as \"close\") should not be used",
                      "Pathologists should continue to report positive margins and distance to all negative margins according to College of American Pathologists reporting guidelinesInterpretations of margin width (such as \"close\") should not be used",
                      "Interpretations of margin width (such as \"close\") should not be used"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Age Range": [
                  {
                    "text": "Women with EIC(+) BCs tend to be younger (40s) and premenopausal"
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Clinical Utility": [
                  {
                    "text": "EIC is used to estimate the likelihood of residual BC in the breast after excision of invasive BC"
                  },
                  {
                    "text": "The criteria for EIC was developed for specimens in which invasive BC was excised with a narrow rim of surrounding tissue"
                  },
                  {
                    "text": "Some BCs do not fit well into the classification system for EICSome BCs have < 25% DCIS within the invasive BC but are associated with extensive DCIS in surrounding tissueThis type of BC should not be classified as EIC(-)In these cases, an estimate of the amount of surrounding DCIS is helpful by estimating the size &/or extente.g., the number of blocks with DCIS outside the invasive BC gives an estimate of the extent of DCIS",
                    "sub_points": [
                      "Some BCs have < 25% DCIS within the invasive BC but are associated with extensive DCIS in surrounding tissueThis type of BC should not be classified as EIC(-)",
                      "This type of BC should not be classified as EIC(-)",
                      "In these cases, an estimate of the amount of surrounding DCIS is helpful by estimating the size &/or extente.g., the number of blocks with DCIS outside the invasive BC gives an estimate of the extent of DCIS",
                      "e.g., the number of blocks with DCIS outside the invasive BC gives an estimate of the extent of DCIS"
                    ]
                  },
                  {
                    "text": "When invasive BCs are excised with wide margins, the status of the margins is more important for determining the likelihood of residual disease than EIC"
                  }
                ],
                "Core Needle Biopsies": [
                  {
                    "text": "Attempts have been made to evaluate EIC on core needle biopsies"
                  },
                  {
                    "text": "Absence of DCIS in association with invasive BC increases likelihood carcinoma will be EIC(-)"
                  },
                  {
                    "text": "If DCIS is present, ~ 1/3 of carcinomas will be EIC(+)"
                  },
                  {
                    "text": "Mammographic calcifications, if associated with BC, are a better indication of the extent of DCIS"
                  }
                ]
              },
              "Imaging Correlations": {
                "General Considerations": [
                  {
                    "text": "With the use of improved preoperative breast imaging, it has become more common to detect BCs with extensive associated DCIS as well as to detect multiple foci of invasive BC"
                  }
                ],
                "Mammography": [
                  {
                    "text": "DCIS is frequently associated with calcificationsExtent of high-grade DCIS with necrosis usually correlates well with area of mammographic calcificationsLow-grade DCIS is associated with fewer, and more sporadic, calcifications, and extent is often underestimated by the area of mammographic calcificationsMammography of invasive BCs with calcifications provides most accurate extent of EIC",
                    "sub_points": [
                      "Extent of high-grade DCIS with necrosis usually correlates well with area of mammographic calcifications",
                      "Low-grade DCIS is associated with fewer, and more sporadic, calcifications, and extent is often underestimated by the area of mammographic calcifications",
                      "Mammography of invasive BCs with calcifications provides most accurate extent of EIC"
                    ]
                  }
                ],
                "Magnetic Resonance Imaging": [
                  {
                    "text": "Majority of cases of DCIS are associated with increased periductal angiogenesis, resulting in enhancement on MR"
                  },
                  {
                    "text": "Can detect areas of enhancement surrounding invasive BCs that correlate with extent of DCIS"
                  },
                  {
                    "text": "In such cases, MR is more accurate than mammography in predicting extent of DCISAccuracy is better for high-grade DCIS than for low-grade DCIS, probably due to greater degree of angiogenesis associated with high-grade DCIS",
                    "sub_points": [
                      "Accuracy is better for high-grade DCIS than for low-grade DCIS, probably due to greater degree of angiogenesis associated with high-grade DCIS"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "DNA Analysis and Gene Copy Number Alterations": {
            "name": "DNA Analysis and Gene Copy Number Alterations",
            "url": "https://app.pathprimer.com/document/c7b95d00-25b5-4247-a738-a111bdc49c93/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Studies of changes in DNA in breast cancer"
                  }
                ]
              },
              "DNA Alterations in Breast Cancer": {
                "Introduction": [
                  {
                    "text": "Completion of the Human Genome Project greatly expanded our knowledge of human DNA sequences"
                  },
                  {
                    "text": "High throughput technologies can quantify gene expression, copy number alteration (CNA), and mutations at the whole genome levelThese technologies are robust and have been successfully applied in cancer researchProvide more comprehensive assessment of biologic characteristics from each individual tumorIdentify therapeutic targets in subsets of patients that could benefit from specific targeted therapyMajor challenge: Biologic interpretation of these vast data sets",
                    "sub_points": [
                      "These technologies are robust and have been successfully applied in cancer researchProvide more comprehensive assessment of biologic characteristics from each individual tumorIdentify therapeutic targets in subsets of patients that could benefit from specific targeted therapy",
                      "Provide more comprehensive assessment of biologic characteristics from each individual tumor",
                      "Identify therapeutic targets in subsets of patients that could benefit from specific targeted therapy",
                      "Major challenge: Biologic interpretation of these vast data sets"
                    ]
                  },
                  {
                    "text": "Chromosomal instability (CIN) is part of the genetic variability inherent in cancerResults in CNA in whole or parts of chromosomes in cancer cellsCIN is part of the genomic landscape of cancerObserved in differing degrees in most cancersAggressive subtypes of breast cancer demonstrate a higher incidence of CIN and CNATumor suppressors, such asTP53andRB1(pRB), are commonly mutated &/or disabled in cancerThese genes play a role in protection against CINTheir dysfunction contributes to establishing CIN",
                    "sub_points": [
                      "Results in CNA in whole or parts of chromosomes in cancer cellsCIN is part of the genomic landscape of cancerObserved in differing degrees in most cancersAggressive subtypes of breast cancer demonstrate a higher incidence of CIN and CNA",
                      "CIN is part of the genomic landscape of cancer",
                      "Observed in differing degrees in most cancers",
                      "Aggressive subtypes of breast cancer demonstrate a higher incidence of CIN and CNA",
                      "Tumor suppressors, such asTP53andRB1(pRB), are commonly mutated &/or disabled in cancerThese genes play a role in protection against CINTheir dysfunction contributes to establishing CIN",
                      "These genes play a role in protection against CIN",
                      "Their dysfunction contributes to establishing CIN"
                    ]
                  }
                ],
                "Techniques": [
                  {
                    "text": "Development of new genomic technologies provide new tools to study breast cancerConventional cytogenetics: Visualizes all chromosomes, detects large translocations and chromosomal duplication or lossCytogenetic analysis has demonstrated that patterns of genetic alterations may have prognostic significance in breast cancerComplex karyotypes or presence of homologous-staining regions are correlated with poor outcomeDetection of t(1;16) unbalanced translocation or 16q losses are associated with improved survivalComparative genomic hybridization (CGH): Detects gains or losses of short DNA segments throughout genome; numerous alterations have been describedRecurrent gains at 1q31-q32, 8p12, 8q12 and 8q24, 11q13, 17q12, 17q23-q24, and 20q13Recurrent losses are observed at 1p, 6q, 8p, 11q23-qter, 13q, 16q, 17p, and 22qMany gains and losses occur in regions that harbor known protooncogenes and tumor suppressor genesMay cause gene overexpression or loss of functionClose correlation between DNA CNA and mRNA expression levelSuggests gene amplification is a common mechanism for increased gene expressionIn situ hybridization (ISH): Uses probes to visualize CNA or specific gene translocationsLoss of heterozygosity (LOH): Detects loss of 1 of 2 alleles of specific genesLOH can help identify recessive mutations in critical genes in genomic regionsNext-generation sequencing (NGS): Deletions and duplications (CNA), insertions, inversions, translocations can be detected by NGSThese changes are diagnostically relevant, contributing to a large fraction of all genetic alterations in cancerWith the expanding clinical role for NGS, information on CNA is readily availableEnables ability to test large number of genes for CNA",
                    "sub_points": [
                      "Conventional cytogenetics: Visualizes all chromosomes, detects large translocations and chromosomal duplication or lossCytogenetic analysis has demonstrated that patterns of genetic alterations may have prognostic significance in breast cancerComplex karyotypes or presence of homologous-staining regions are correlated with poor outcomeDetection of t(1;16) unbalanced translocation or 16q losses are associated with improved survival",
                      "Cytogenetic analysis has demonstrated that patterns of genetic alterations may have prognostic significance in breast cancer",
                      "Complex karyotypes or presence of homologous-staining regions are correlated with poor outcome",
                      "Detection of t(1;16) unbalanced translocation or 16q losses are associated with improved survival",
                      "Comparative genomic hybridization (CGH): Detects gains or losses of short DNA segments throughout genome; numerous alterations have been describedRecurrent gains at 1q31-q32, 8p12, 8q12 and 8q24, 11q13, 17q12, 17q23-q24, and 20q13Recurrent losses are observed at 1p, 6q, 8p, 11q23-qter, 13q, 16q, 17p, and 22qMany gains and losses occur in regions that harbor known protooncogenes and tumor suppressor genesMay cause gene overexpression or loss of functionClose correlation between DNA CNA and mRNA expression levelSuggests gene amplification is a common mechanism for increased gene expression",
                      "Recurrent gains at 1q31-q32, 8p12, 8q12 and 8q24, 11q13, 17q12, 17q23-q24, and 20q13",
                      "Recurrent losses are observed at 1p, 6q, 8p, 11q23-qter, 13q, 16q, 17p, and 22q",
                      "Many gains and losses occur in regions that harbor known protooncogenes and tumor suppressor genesMay cause gene overexpression or loss of function",
                      "May cause gene overexpression or loss of function",
                      "Close correlation between DNA CNA and mRNA expression levelSuggests gene amplification is a common mechanism for increased gene expression",
                      "Suggests gene amplification is a common mechanism for increased gene expression",
                      "In situ hybridization (ISH): Uses probes to visualize CNA or specific gene translocations",
                      "Loss of heterozygosity (LOH): Detects loss of 1 of 2 alleles of specific genesLOH can help identify recessive mutations in critical genes in genomic regions",
                      "LOH can help identify recessive mutations in critical genes in genomic regions",
                      "Next-generation sequencing (NGS): Deletions and duplications (CNA), insertions, inversions, translocations can be detected by NGSThese changes are diagnostically relevant, contributing to a large fraction of all genetic alterations in cancerWith the expanding clinical role for NGS, information on CNA is readily availableEnables ability to test large number of genes for CNA",
                      "These changes are diagnostically relevant, contributing to a large fraction of all genetic alterations in cancer",
                      "With the expanding clinical role for NGS, information on CNA is readily available",
                      "Enables ability to test large number of genes for CNA"
                    ]
                  }
                ],
                "Clinical Applications": [
                  {
                    "text": "Genomic technologies are being applied to clinical breast cancer samplesCGH allows genome-wide investigation of CNAHas resulted in major advances in the understanding of breast carcinogenesis and tumor progression",
                    "sub_points": [
                      "CGH allows genome-wide investigation of CNA",
                      "Has resulted in major advances in the understanding of breast carcinogenesis and tumor progression"
                    ]
                  },
                  {
                    "text": "Molecular studies may be useful for breast cancer diagnosis, predicting benefit from therapy and prognosisSecretory carcinoma of the breast has a balanced translocation: t(12;15)(p13;q25)Results inETV6::NTRK3gene fusionAlso present in mammary analog secretory carcinoma of salivary gland, infantile fibrosarcoma, and cellular congenital mesoblastic nephromaAdenoid cystic carcinoma of the breast has a balanced translocation: t(6;9)(q22-23; p23-24)Results inMYB::NFIBgene fusionAlso present in adenoid cystic carcinoma of salivary glandERBB2(HER2) gene amplification: ~ 20% of breast carcinomasPredicts benefit from HER2-targeted therapiesFGFR1amplifications associated with poor prognosis in node (+), ER(+), HER2(-) breast carcinoma",
                    "sub_points": [
                      "Secretory carcinoma of the breast has a balanced translocation: t(12;15)(p13;q25)Results inETV6::NTRK3gene fusionAlso present in mammary analog secretory carcinoma of salivary gland, infantile fibrosarcoma, and cellular congenital mesoblastic nephroma",
                      "Results inETV6::NTRK3gene fusion",
                      "Also present in mammary analog secretory carcinoma of salivary gland, infantile fibrosarcoma, and cellular congenital mesoblastic nephroma",
                      "Adenoid cystic carcinoma of the breast has a balanced translocation: t(6;9)(q22-23; p23-24)Results inMYB::NFIBgene fusionAlso present in adenoid cystic carcinoma of salivary gland",
                      "Results inMYB::NFIBgene fusion",
                      "Also present in adenoid cystic carcinoma of salivary gland",
                      "ERBB2(HER2) gene amplification: ~ 20% of breast carcinomasPredicts benefit from HER2-targeted therapies",
                      "Predicts benefit from HER2-targeted therapies",
                      "FGFR1amplifications associated with poor prognosis in node (+), ER(+), HER2(-) breast carcinoma"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Molecular Pathogenesis": [
                  {
                    "text": "Cancer development and progression is due to the accumulation of recurrent genomic alterationsGenomic changes can alter gene expression, inducing growth advantage and clonal expansion",
                    "sub_points": [
                      "Genomic changes can alter gene expression, inducing growth advantage and clonal expansion"
                    ]
                  },
                  {
                    "text": "Major germline mutations increasing risk of breast carcinoma are involved in maintaining the integrity of the genomeBRCA1,BRCA2,TP53,CHEK2, and others",
                    "sub_points": [
                      "BRCA1,BRCA2,TP53,CHEK2, and others"
                    ]
                  },
                  {
                    "text": "Common somatic mutations, such as inTP53, are also related to genetic stability"
                  },
                  {
                    "text": "Breast carcinomas are characterized by complex genomic changes and CNA, which alter gene expression"
                  },
                  {
                    "text": "Genomic studies suggest separate molecular pathways lead to development of low- and high-grade breast carcinomasUnique patterns of DNA CNA and mutations are detected for low- and high-grade carcinomasGene expression profiling studies also show distinctive patterns of mRNA expressionDifferential changes found in low- and high-grade invasive carcinomas are also shared with low- and high-grade ductal carcinoma in situ (DCIS)Molecular heterogeneity of breast cancer already exists in in situ lesionsThus, genomic changes occur early in course of development of cancerLikely play role in disease pathogenesis, initiation of tumor formation, and tumor progression",
                    "sub_points": [
                      "Unique patterns of DNA CNA and mutations are detected for low- and high-grade carcinomasGene expression profiling studies also show distinctive patterns of mRNA expression",
                      "Gene expression profiling studies also show distinctive patterns of mRNA expression",
                      "Differential changes found in low- and high-grade invasive carcinomas are also shared with low- and high-grade ductal carcinoma in situ (DCIS)Molecular heterogeneity of breast cancer already exists in in situ lesionsThus, genomic changes occur early in course of development of cancerLikely play role in disease pathogenesis, initiation of tumor formation, and tumor progression",
                      "Molecular heterogeneity of breast cancer already exists in in situ lesions",
                      "Thus, genomic changes occur early in course of development of cancer",
                      "Likely play role in disease pathogenesis, initiation of tumor formation, and tumor progression"
                    ]
                  }
                ]
              },
              "CLINICAL IMPLICATIONS": {
                "Genomic Changes and Tumor Grade": [
                  {
                    "text": "Genomic aberrations and CNA are correlated with traditional clinicopathologic factors in breast cancerNumber and pattern of genomic aberrations differ most significantly when stratified by tumor gradeAverage number of chromosomal changes increases with increasing tumor gradePatterns of genomic alterations (genomic signatures) differ significantly when stratified by grade",
                    "sub_points": [
                      "Number and pattern of genomic aberrations differ most significantly when stratified by tumor gradeAverage number of chromosomal changes increases with increasing tumor gradePatterns of genomic alterations (genomic signatures) differ significantly when stratified by grade",
                      "Average number of chromosomal changes increases with increasing tumor grade",
                      "Patterns of genomic alterations (genomic signatures) differ significantly when stratified by grade"
                    ]
                  },
                  {
                    "text": "The prototype for DNA copy number change is amplification ofERBB2(HER2) gene on long arm of chromosome 17 (17q12)Increased number of genes leads to higher levels of mRNA and increase in protein expressionThis genomic change is significantly and independently correlated with high-grade carcinomas< 1% of low-grade carcinomas show evidence ofERBB2(HER2) gene amplification",
                    "sub_points": [
                      "Increased number of genes leads to higher levels of mRNA and increase in protein expression",
                      "This genomic change is significantly and independently correlated with high-grade carcinomas< 1% of low-grade carcinomas show evidence ofERBB2(HER2) gene amplification",
                      "< 1% of low-grade carcinomas show evidence ofERBB2(HER2) gene amplification"
                    ]
                  }
                ],
                "Low-Grade Invasive Carcinoma": [
                  {
                    "text": "Tend to have fewer chromosomal alterations compared with high-grade carcinomas and have a normal DNA contentERBB2(HER2) is not amplifiedLow proliferative index",
                    "sub_points": [
                      "ERBB2(HER2) is not amplified",
                      "Low proliferative index"
                    ]
                  },
                  {
                    "text": "Most frequent genomic changesLosses on chromosome 16q and gains on 1qOther reported changes include chromosomal gains on 8q, 11q, 16p, and 17q and losses on 16q, 1p, 8p, 11q, 13q, and 22qMutations inESR1(ER) gene may occur when carcinomas become resistant to endocrine therapySimilar changes are found in low-grade DCIS, lobular carcinoma in situ (LCIS), and invasive lobular carcinomaChanges likely occur early in course of disease and play role in pathogenesisLow-grade ductal and lobular carcinomas may share common biologic origin",
                    "sub_points": [
                      "Losses on chromosome 16q and gains on 1q",
                      "Other reported changes include chromosomal gains on 8q, 11q, 16p, and 17q and losses on 16q, 1p, 8p, 11q, 13q, and 22q",
                      "Mutations inESR1(ER) gene may occur when carcinomas become resistant to endocrine therapy",
                      "Similar changes are found in low-grade DCIS, lobular carcinoma in situ (LCIS), and invasive lobular carcinomaChanges likely occur early in course of disease and play role in pathogenesisLow-grade ductal and lobular carcinomas may share common biologic origin",
                      "Changes likely occur early in course of disease and play role in pathogenesis",
                      "Low-grade ductal and lobular carcinomas may share common biologic origin"
                    ]
                  }
                ],
                "High-Grade Invasive Carcinoma": [
                  {
                    "text": "Tend to have more frequent, extensive, and complex chromosomal alterations and have abnormal DNA contentOften overexpressMYC(c-MYC) andERBB2(HER2) by gene amplificationDemonstrate frequent loss of p53 functionHigh proliferative index",
                    "sub_points": [
                      "Often overexpressMYC(c-MYC) andERBB2(HER2) by gene amplification",
                      "Demonstrate frequent loss of p53 function",
                      "High proliferative index"
                    ]
                  },
                  {
                    "text": "Most frequent genomic changesLosses on chromosome 17p, 1p, 19p, and 19q; infrequent losses on 16qGenomic chromosomal gains on 8q, 17q, and 20q",
                    "sub_points": [
                      "Losses on chromosome 17p, 1p, 19p, and 19q; infrequent losses on 16q",
                      "Genomic chromosomal gains on 8q, 17q, and 20q"
                    ]
                  },
                  {
                    "text": "Similar changes are found in high-grade DCISChanges likely occur early in course of development of disease and likely play role in pathogenesis",
                    "sub_points": [
                      "Changes likely occur early in course of development of disease and likely play role in pathogenesis"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Expression Profiling, mRNA: Overview": {
            "name": "Expression Profiling, mRNA: Overview",
            "url": "https://app.pathprimer.com/document/03681738-6cf0-4344-b02b-86faf648ebb0/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "OVERVIEW": {
                "Precision Medicine for Cancer Therapy": [
                  {
                    "text": "Model for making medical decisions that are tailored to individual cancer patients and their disease biologyEmploys a combination of diagnostic testing and treatment optionsOffers potential for a more targeted therapeutic approach for treatment recommendationsRequires use of a pretherapeutic companion diagnostic, well-defined biomarker, or multigene panel testing, linked to prognosis and treatment responseTesting must indicate efficacy of specific drug regimen or targeted therapeutic agentIdeally, results of this testing should be integrated with traditional evaluation using clinical and histopathologic factors for final treatment planning",
                    "sub_points": [
                      "Employs a combination of diagnostic testing and treatment options",
                      "Offers potential for a more targeted therapeutic approach for treatment recommendations",
                      "Requires use of a pretherapeutic companion diagnostic, well-defined biomarker, or multigene panel testing, linked to prognosis and treatment responseTesting must indicate efficacy of specific drug regimen or targeted therapeutic agentIdeally, results of this testing should be integrated with traditional evaluation using clinical and histopathologic factors for final treatment planning",
                      "Testing must indicate efficacy of specific drug regimen or targeted therapeutic agent",
                      "Ideally, results of this testing should be integrated with traditional evaluation using clinical and histopathologic factors for final treatment planning"
                    ]
                  },
                  {
                    "text": "Multigene panels and biomarker testing have increased our understanding of tumor biology and clinical behavior"
                  },
                  {
                    "text": "Accurate evaluation of the risk of both early and late recurrences is important for treatment decisions"
                  },
                  {
                    "text": "Gene expression profiling (GEP) has proved clinically useful prognostic and predictive information for optimizing patient management"
                  }
                ]
              },
              "GENE EXPRESSION PROFILING": {
                "Introduction": [
                  {
                    "text": "GEP can provide value beyond traditional clinical/pathologic prognostic and predictive factors"
                  },
                  {
                    "text": "GEP uses cDNA microarrays or quantitative RT-PCR (qRT-PCR) on samples of tumor tissue to detect mRNA levelsAllows simultaneous examination of global changes in patterns of gene expressionHas the ability to molecularly profile breast tumors using mRNA levels from 20,000-25,000 genes",
                    "sub_points": [
                      "Allows simultaneous examination of global changes in patterns of gene expression",
                      "Has the ability to molecularly profile breast tumors using mRNA levels from 20,000-25,000 genes"
                    ]
                  },
                  {
                    "text": "GEP has added greatly to our understanding of the biologic diversity of breast cancer by providingImportant insights into breast tumor biologyClinically meaningful molecular tumor classificationIdentification of good and poor prognostic groups, beyond traditional pathologic factorsIdentification of cancers more susceptible to specific types of therapy, especially chemotherapy benefitPersonalized treatment strategies",
                    "sub_points": [
                      "Important insights into breast tumor biology",
                      "Clinically meaningful molecular tumor classification",
                      "Identification of good and poor prognostic groups, beyond traditional pathologic factors",
                      "Identification of cancers more susceptible to specific types of therapy, especially chemotherapy benefit",
                      "Personalized treatment strategies"
                    ]
                  }
                ],
                "Unsupervised Cluster Analysis": [
                  {
                    "text": "Requires fresh or snap-frozen tissue samples from cohorts of breast cancer patients with outcome dataRNA from the tumor is analyzed using cDNA microarraysDetermines the level of mRNA gene expression relative to reference RNAData on expression levels for thousands of genes are collected for analysisComputer and statistical analysis is needed to look for biologically meaningful patterns",
                    "sub_points": [
                      "RNA from the tumor is analyzed using cDNA microarraysDetermines the level of mRNA gene expression relative to reference RNAData on expression levels for thousands of genes are collected for analysisComputer and statistical analysis is needed to look for biologically meaningful patterns",
                      "Determines the level of mRNA gene expression relative to reference RNA",
                      "Data on expression levels for thousands of genes are collected for analysis",
                      "Computer and statistical analysis is needed to look for biologically meaningful patterns"
                    ]
                  },
                  {
                    "text": "Unsupervised cluster analysis (class discovery approach)Sorts tumors into related clusters based on similarities in gene expression profilesDendrograms used to illustrate degree of relatedness between different tumorsBiologically significant groups of tumors are identified",
                    "sub_points": [
                      "Sorts tumors into related clusters based on similarities in gene expression profiles",
                      "Dendrograms used to illustrate degree of relatedness between different tumors",
                      "Biologically significant groups of tumors are identified"
                    ]
                  },
                  {
                    "text": "This approach was used to develop the intrinsic molecular classification of breast cancers and Prosigna breast cancer prognostic gene signature; expression of ER, HER2, and proliferation genes help define molecular subtypes"
                  },
                  {
                    "text": "Has been adapted for use in formalin-fixed tissues"
                  }
                ],
                "Supervised Cluster Analysis": [
                  {
                    "text": "Supervised and unsupervised cluster analyses use similar tissue, extraction, and statistical analysis"
                  },
                  {
                    "text": "Supervised cluster analysis (class prediction approach) differs by organizing data according to known groupsInitial step: Separate tumors into groups based on clinical outcomes (e.g., relapsed vs. not)Compare gene signatures between distinct groupsDetermine genes identifying tumor as belonging to 1 of the 2 groups (e.g., relapsed vs. not)Multiple tests may lead to many false-positives (gene falling into 1 of the 2 groups by chance)Independent validation of predicted gene signature is necessary",
                    "sub_points": [
                      "Initial step: Separate tumors into groups based on clinical outcomes (e.g., relapsed vs. not)",
                      "Compare gene signatures between distinct groupsDetermine genes identifying tumor as belonging to 1 of the 2 groups (e.g., relapsed vs. not)Multiple tests may lead to many false-positives (gene falling into 1 of the 2 groups by chance)Independent validation of predicted gene signature is necessary",
                      "Determine genes identifying tumor as belonging to 1 of the 2 groups (e.g., relapsed vs. not)",
                      "Multiple tests may lead to many false-positives (gene falling into 1 of the 2 groups by chance)",
                      "Independent validation of predicted gene signature is necessary"
                    ]
                  },
                  {
                    "text": "This approach was used to develop the 70-gene prognostic signature assay (MammaPrint)Genes related to cellular pathways involving apoptosis, growth signals, tissue invasion, and angiogenesis define gene classifiers for predicting outcome",
                    "sub_points": [
                      "Genes related to cellular pathways involving apoptosis, growth signals, tissue invasion, and angiogenesis define gene classifiers for predicting outcome"
                    ]
                  }
                ]
              },
              "IDENTIFICATION OF MOLECULAR SUBTYPES": {
                "4Major Types of Breast Cancer by GEP": [
                  {
                    "text": "Microarrays and unsupervised analysis group breast cancers into distinctive subsets using patterns of mRNA expression"
                  },
                  {
                    "text": "Results of GEP support that groups of cancers defined by ER, PR, HER2, and proliferation also share a much broader range of gene expression patternsER(+) and ER(-) cancers show many differences and may arise from different cell types",
                    "sub_points": [
                      "ER(+) and ER(-) cancers show many differences and may arise from different cell types"
                    ]
                  },
                  {
                    "text": "Breast cancers can be divided into 4 or more groups in different waysA common way is to divide the largest luminal group into 2 different groups: Luminal A and luminal BIn this system, ER(+)/HER2(+) cancers are combined with ER(+)/HER2(-) luminal B cancersHowever, these 2 groups of cancers have important differencesAn alternative method is to separate all the luminal ER(+)/HER2(-) cancers into 1 group and to identify ER(+)/HER2(+) cancers as a separate group (luminal HER2)",
                    "sub_points": [
                      "A common way is to divide the largest luminal group into 2 different groups: Luminal A and luminal BIn this system, ER(+)/HER2(+) cancers are combined with ER(+)/HER2(-) luminal B cancersHowever, these 2 groups of cancers have important differences",
                      "In this system, ER(+)/HER2(+) cancers are combined with ER(+)/HER2(-) luminal B cancers",
                      "However, these 2 groups of cancers have important differences",
                      "An alternative method is to separate all the luminal ER(+)/HER2(-) cancers into 1 group and to identify ER(+)/HER2(+) cancers as a separate group (luminal HER2)"
                    ]
                  },
                  {
                    "text": "Molecular subtypes show many important differences inIncidence according to agePattern and frequency of DNA mutationsResponse to neoadjuvant therapyTime to recurrenceLocation of metastatic diseaseSurvival",
                    "sub_points": [
                      "Incidence according to age",
                      "Pattern and frequency of DNA mutations",
                      "Response to neoadjuvant therapy",
                      "Time to recurrence",
                      "Location of metastatic disease",
                      "Survival"
                    ]
                  }
                ],
                "Luminal Subtype A (~ 55% of Breast Cancers) by GEP": [
                  {
                    "text": "Gene expression patternER: High expressionGenes regulated by ER (including PR) and genes associated with ER activationHER2 or EGFR (HER1): Not overexpressedProliferation-related genes: Low expressionLuminal cytokeratins (e.g., low molecular weight cytokeratins 8/18): ExpressedUsually does not express high molecular weight keratins (basal keratins)Pattern similar to normal luminal cells",
                    "sub_points": [
                      "ER: High expressionGenes regulated by ER (including PR) and genes associated with ER activation",
                      "Genes regulated by ER (including PR) and genes associated with ER activation",
                      "HER2 or EGFR (HER1): Not overexpressed",
                      "Proliferation-related genes: Low expression",
                      "Luminal cytokeratins (e.g., low molecular weight cytokeratins 8/18): ExpressedUsually does not express high molecular weight keratins (basal keratins)",
                      "Usually does not express high molecular weight keratins (basal keratins)",
                      "Pattern similar to normal luminal cells"
                    ]
                  },
                  {
                    "text": "Histologic grade: Usually 1 or 2Includes majority of special histologic typesTubular carcinoma, mucinous carcinoma, papillary carcinoma, grades 1 and 2 lobular carcinomas",
                    "sub_points": [
                      "Includes majority of special histologic typesTubular carcinoma, mucinous carcinoma, papillary carcinoma, grades 1 and 2 lobular carcinomas",
                      "Tubular carcinoma, mucinous carcinoma, papillary carcinoma, grades 1 and 2 lobular carcinomas"
                    ]
                  },
                  {
                    "text": "Clinical featuresMarked increase in incidence with ageIndolent clinical course of diseaseBetter prognosis compared with other subtypesLow rate of recurrence but over long period of timeMetastatic pattern is most commonly to bone, often after long disease-free interval",
                    "sub_points": [
                      "Marked increase in incidence with age",
                      "Indolent clinical course of disease",
                      "Better prognosis compared with other subtypes",
                      "Low rate of recurrence but over long period of time",
                      "Metastatic pattern is most commonly to bone, often after long disease-free interval"
                    ]
                  },
                  {
                    "text": "Treatment implicationsResponds well to hormonal therapy (e.g., tamoxifen, aromatase inhibitors)May be adequately treated with hormonal therapy aloneUsually has little or no response to chemotherapy, resulting in lack of survival benefitMarked or pathologic complete response (pCR) to neoadjuvant chemotherapy is unusual (< 10%)",
                    "sub_points": [
                      "Responds well to hormonal therapy (e.g., tamoxifen, aromatase inhibitors)",
                      "May be adequately treated with hormonal therapy alone",
                      "Usually has little or no response to chemotherapy, resulting in lack of survival benefitMarked or pathologic complete response (pCR) to neoadjuvant chemotherapy is unusual (< 10%)",
                      "Marked or pathologic complete response (pCR) to neoadjuvant chemotherapy is unusual (< 10%)"
                    ]
                  }
                ],
                "Luminal Subtype B (~ 10-15% of Breast Cancers) by GEP": [
                  {
                    "text": "Of note, in some studies, \"luminal B\" is used to refer to both HER2(+) and HER2(-) cancers, in some to only ER(+)/HER2(+) cancers, and in other studies, \"luminal B\" is used to refer to only ER(+)/HER2(-) cancers"
                  },
                  {
                    "text": "\"Luminal HER2\" can be used to refer to just the HER2(+) subgroup"
                  },
                  {
                    "text": "Gene expression patternER and ER-related genes: Often at low levelsPR: May be negative or show low-level expressionHER2: Overexpressed in 30-50% of casesEGFR (HER1): May be overexpressedProliferation-related genes: Usually high expressionKi-67 proliferation index may be useful to help separate luminal B from luminal A tumorsLuminal cytokeratins (e.g., low molecular weight cytokeratins 8/18): ExpressedUsually does not express high molecular weight keratins (basal keratins)",
                    "sub_points": [
                      "ER and ER-related genes: Often at low levels",
                      "PR: May be negative or show low-level expression",
                      "HER2: Overexpressed in 30-50% of cases",
                      "EGFR (HER1): May be overexpressed",
                      "Proliferation-related genes: Usually high expressionKi-67 proliferation index may be useful to help separate luminal B from luminal A tumors",
                      "Ki-67 proliferation index may be useful to help separate luminal B from luminal A tumors",
                      "Luminal cytokeratins (e.g., low molecular weight cytokeratins 8/18): ExpressedUsually does not express high molecular weight keratins (basal keratins)",
                      "Usually does not express high molecular weight keratins (basal keratins)"
                    ]
                  },
                  {
                    "text": "Histologic grade: Usually 2 or 3"
                  },
                  {
                    "text": "Clinical featuresEarly peak of recurrence for HER2(-) cancers (~ 4-5 years)Early peak of recurrence for HER2(+) cancers (~ 3 years)Late recurrences are associated with both typesPoorer prognosis compared to luminal A cancerThe HER2(-) group is the most common subtype associated with germlineBRCA2mutationsThe HER2(+) group can be associated with germlineTP53mutations (Li-Fraumeni)",
                    "sub_points": [
                      "Early peak of recurrence for HER2(-) cancers (~ 4-5 years)",
                      "Early peak of recurrence for HER2(+) cancers (~ 3 years)",
                      "Late recurrences are associated with both types",
                      "Poorer prognosis compared to luminal A cancer",
                      "The HER2(-) group is the most common subtype associated with germlineBRCA2mutations",
                      "The HER2(+) group can be associated with germlineTP53mutations (Li-Fraumeni)"
                    ]
                  },
                  {
                    "text": "Treatment implicationsLess responsive to tamoxifen therapy; may have a better response to aromatase inhibitorsLuminal A cancers may be more likely to respond to chemotherapy compared to HER2(-) luminal B cancers, but only ~ 10% pCRHER2(+) luminal B tumors may be treated with HER2-directed therapy in addition to chemotherapy with ~ 40% pCR rate after neoadjuvant therapy",
                    "sub_points": [
                      "Less responsive to tamoxifen therapy; may have a better response to aromatase inhibitors",
                      "Luminal A cancers may be more likely to respond to chemotherapy compared to HER2(-) luminal B cancers, but only ~ 10% pCR",
                      "HER2(+) luminal B tumors may be treated with HER2-directed therapy in addition to chemotherapy with ~ 40% pCR rate after neoadjuvant therapy"
                    ]
                  }
                ],
                "HER2 Subtype (~ 5-10% of Breast Cancers) by GEP": [
                  {
                    "text": "Gene expression patternHER2: Usually overexpressed but can be HER2(-) according to conventional clinical assaysAlso overexpresses adjacent genes on HER2 amplicon; number of genes varies in different cancersMay includeTOP2A(associated with sensitivity to anthracyclines) andGRB7Identification of HER2 subtype by GEP confirmed that these cancers represent a clinically distinct subsetHER2-subtype tumors defined by GEP do not completely overlap with HER2(+) tumors defined clinically by IHC &/or FISHHER2-targeted therapy should be determined by conventional assays for protein and gene numberER or PR: Not expressedProliferation-related genes: Usually high expressionHigh molecular weight keratins (e.g., CK5/6): May be expressed in some casesEGFR (HER1): May be expressed",
                    "sub_points": [
                      "HER2: Usually overexpressed but can be HER2(-) according to conventional clinical assaysAlso overexpresses adjacent genes on HER2 amplicon; number of genes varies in different cancersMay includeTOP2A(associated with sensitivity to anthracyclines) andGRB7Identification of HER2 subtype by GEP confirmed that these cancers represent a clinically distinct subsetHER2-subtype tumors defined by GEP do not completely overlap with HER2(+) tumors defined clinically by IHC &/or FISHHER2-targeted therapy should be determined by conventional assays for protein and gene number",
                      "Also overexpresses adjacent genes on HER2 amplicon; number of genes varies in different cancers",
                      "May includeTOP2A(associated with sensitivity to anthracyclines) andGRB7",
                      "Identification of HER2 subtype by GEP confirmed that these cancers represent a clinically distinct subsetHER2-subtype tumors defined by GEP do not completely overlap with HER2(+) tumors defined clinically by IHC &/or FISHHER2-targeted therapy should be determined by conventional assays for protein and gene number",
                      "HER2-subtype tumors defined by GEP do not completely overlap with HER2(+) tumors defined clinically by IHC &/or FISH",
                      "HER2-targeted therapy should be determined by conventional assays for protein and gene number",
                      "ER or PR: Not expressed",
                      "Proliferation-related genes: Usually high expression",
                      "High molecular weight keratins (e.g., CK5/6): May be expressed in some cases",
                      "EGFR (HER1): May be expressed"
                    ]
                  },
                  {
                    "text": "Histologic grade: Usually 3Often multifocal, associated with extensive ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "Often multifocal, associated with extensive ductal carcinoma in situ (DCIS)"
                    ]
                  },
                  {
                    "text": "Clinical featuresIncidence does not increase markedly with ageRelatively more frequent in younger patientsMore likely to have multiple involved lymph nodesEarly peak of recurrence at ~ 4-5 years and lower late peak at ~ 8 yearsPrognosis is generally poor without HER2-targeted therapyCan be associated with germlineTP53mutations (Li-Fraumeni)",
                    "sub_points": [
                      "Incidence does not increase markedly with ageRelatively more frequent in younger patients",
                      "Relatively more frequent in younger patients",
                      "More likely to have multiple involved lymph nodes",
                      "Early peak of recurrence at ~ 4-5 years and lower late peak at ~ 8 years",
                      "Prognosis is generally poor without HER2-targeted therapy",
                      "Can be associated with germlineTP53mutations (Li-Fraumeni)"
                    ]
                  },
                  {
                    "text": "Treatment implicationsResponds to HER2-targeted treatment in combination with or following chemotherapy~ 70% of patients in some studies have a pCR",
                    "sub_points": [
                      "Responds to HER2-targeted treatment in combination with or following chemotherapy",
                      "~ 70% of patients in some studies have a pCR"
                    ]
                  },
                  {
                    "text": "Of note, in some studies, the \"HER2\" group includes both ER(+) and ER(-) cancers"
                  }
                ],
                "Basal-Like Subtype (~ 10% of Breast Cancers) by GEP": [
                  {
                    "text": "Gene expression patternER or PR: Usually not expressed~ 10% are ER(+)HER2: Usually not expressed~ 10% are HER2(+)Proliferation-related genes: High expressionHigh molecular weight \"basal\" CK 5/14/17: Often expressedEGFR (HER1): May be expressed",
                    "sub_points": [
                      "ER or PR: Usually not expressed~ 10% are ER(+)",
                      "~ 10% are ER(+)",
                      "HER2: Usually not expressed~ 10% are HER2(+)",
                      "~ 10% are HER2(+)",
                      "Proliferation-related genes: High expression",
                      "High molecular weight \"basal\" CK 5/14/17: Often expressed",
                      "EGFR (HER1): May be expressed"
                    ]
                  },
                  {
                    "text": "Histologic grade: Usually 3Well-demarcated tumor mass with pushing borderCells arranged in syncytial-like sheets; no evidence of tubule formationCentral fibrotic focus may be presentBrisk host lymphocytic stromal reaction to tumor",
                    "sub_points": [
                      "Well-demarcated tumor mass with pushing borderCells arranged in syncytial-like sheets; no evidence of tubule formation",
                      "Cells arranged in syncytial-like sheets; no evidence of tubule formation",
                      "Central fibrotic focus may be present",
                      "Brisk host lymphocytic stromal reaction to tumor"
                    ]
                  },
                  {
                    "text": "Most basal-like carcinomas are aggressive; however, this group shows morphologic and clinical heterogeneityDifferent morphologies associated with basal subtypeCarcinoma with medullary patternBetter prognosis than stage- and grade-matched carcinomas of no special typeMetaplastic carcinomaPrognosis grade dependent but generally poorAdenoid cystic carcinoma, secretory carcinoma, low-grade adenosquamous carcinomaGood to excellent prognosis",
                    "sub_points": [
                      "Different morphologies associated with basal subtypeCarcinoma with medullary patternBetter prognosis than stage- and grade-matched carcinomas of no special typeMetaplastic carcinomaPrognosis grade dependent but generally poorAdenoid cystic carcinoma, secretory carcinoma, low-grade adenosquamous carcinomaGood to excellent prognosis",
                      "Carcinoma with medullary patternBetter prognosis than stage- and grade-matched carcinomas of no special type",
                      "Better prognosis than stage- and grade-matched carcinomas of no special type",
                      "Metaplastic carcinomaPrognosis grade dependent but generally poor",
                      "Prognosis grade dependent but generally poor",
                      "Adenoid cystic carcinoma, secretory carcinoma, low-grade adenosquamous carcinomaGood to excellent prognosis",
                      "Good to excellent prognosis"
                    ]
                  },
                  {
                    "text": "Clinical featuresDoes not show marked increase in incidence with ageRelatively more common in younger patientsRelatively more common in women of non-European descent because luminal cancers are less common in these groupsMost common subtype associated withBRCA1mutationsMay have positive breast cancer family historySporadic basal-like subtype cancers and familialBRCA1cancers could share similar etiologyMay be related to loss of normalBRCA1function and abnormalities in DNA repair pathwaysPoor prognosis and aggressive clinical course for majority of basal cancersEarly peak of recurrence in 4-5 yearsRecurrences after 8 years are very unlikely except for unusual typesLess likely to have involved lymph nodes than in other subtypes",
                    "sub_points": [
                      "Does not show marked increase in incidence with ageRelatively more common in younger patientsRelatively more common in women of non-European descent because luminal cancers are less common in these groups",
                      "Relatively more common in younger patients",
                      "Relatively more common in women of non-European descent because luminal cancers are less common in these groups",
                      "Most common subtype associated withBRCA1mutationsMay have positive breast cancer family historySporadic basal-like subtype cancers and familialBRCA1cancers could share similar etiologyMay be related to loss of normalBRCA1function and abnormalities in DNA repair pathways",
                      "May have positive breast cancer family history",
                      "Sporadic basal-like subtype cancers and familialBRCA1cancers could share similar etiologyMay be related to loss of normalBRCA1function and abnormalities in DNA repair pathways",
                      "May be related to loss of normalBRCA1function and abnormalities in DNA repair pathways",
                      "Poor prognosis and aggressive clinical course for majority of basal cancers",
                      "Early peak of recurrence in 4-5 yearsRecurrences after 8 years are very unlikely except for unusual types",
                      "Recurrences after 8 years are very unlikely except for unusual types",
                      "Less likely to have involved lymph nodes than in other subtypes"
                    ]
                  },
                  {
                    "text": "Treatment implicationsGenerally treated with combination chemotherapyNo role for hormonal or HER2-targeted treatment if conventional assays confirm the absence of expressionTreatment strategies targeting defective DNA repair pathways have shown promiseCisplatin and mitomycin (DNA crosslinking agents) may be more effective than standard anthracycline-containing regimensBRCA1germline mutation carriers may be more likely to benefit from cisplatin-based therapyBRCA1/BRCA2germline mutation carriers may be more likely to respond to poly (ADP-ribose) polymerase inhibitors (PARP)PARP inhibitors may exploit homologous recombination deficiency in these tumors by synthetic lethal approachProvided significant benefit over standard chemotherapy with respect to progression-free survival in clinical trialMore likely to show pCR to neoadjuvant chemotherapy than ER(+) carcinomas (pCR in ~ 40%)Recent trials data have shown a role for immunotherapy in the metastatic and neoadjuvant settingBRCA1/2germline mutation carriers benefit from treatment with PARP inhibitors",
                    "sub_points": [
                      "Generally treated with combination chemotherapy",
                      "No role for hormonal or HER2-targeted treatment if conventional assays confirm the absence of expression",
                      "Treatment strategies targeting defective DNA repair pathways have shown promise",
                      "Cisplatin and mitomycin (DNA crosslinking agents) may be more effective than standard anthracycline-containing regimensBRCA1germline mutation carriers may be more likely to benefit from cisplatin-based therapyBRCA1/BRCA2germline mutation carriers may be more likely to respond to poly (ADP-ribose) polymerase inhibitors (PARP)PARP inhibitors may exploit homologous recombination deficiency in these tumors by synthetic lethal approachProvided significant benefit over standard chemotherapy with respect to progression-free survival in clinical trial",
                      "BRCA1germline mutation carriers may be more likely to benefit from cisplatin-based therapy",
                      "BRCA1/BRCA2germline mutation carriers may be more likely to respond to poly (ADP-ribose) polymerase inhibitors (PARP)PARP inhibitors may exploit homologous recombination deficiency in these tumors by synthetic lethal approachProvided significant benefit over standard chemotherapy with respect to progression-free survival in clinical trial",
                      "PARP inhibitors may exploit homologous recombination deficiency in these tumors by synthetic lethal approach",
                      "Provided significant benefit over standard chemotherapy with respect to progression-free survival in clinical trial",
                      "More likely to show pCR to neoadjuvant chemotherapy than ER(+) carcinomas (pCR in ~ 40%)",
                      "Recent trials data have shown a role for immunotherapy in the metastatic and neoadjuvant setting",
                      "BRCA1/2germline mutation carriers benefit from treatment with PARP inhibitors"
                    ]
                  },
                  {
                    "text": "Triple negative phenotype [ER, PR, HER2 (-)] commonly used as surrogate for basal-like subtypeTriple negative and basal subtype overlap by 70-80%Triple negative carcinomas that express AR (luminal androgen type) are not basal subtype",
                    "sub_points": [
                      "Triple negative and basal subtype overlap by 70-80%",
                      "Triple negative carcinomas that express AR (luminal androgen type) are not basal subtype"
                    ]
                  }
                ]
              },
              "Commercial Assays": {
                "Introduction": [
                  {
                    "text": "Multiple assays are marketed to aid in management of patients with breast cancer"
                  },
                  {
                    "text": "Current assays identify overlapping good and poor prognostic groupsChoice of different gene sets for each assay is likely due to basing selection on relatively small numbers of cancers expressing thousands of different genesAssignment by different assays to same molecular group is only modest for luminal A, B, and HER2 typesAssignment by different assays to same risk category is only modest",
                    "sub_points": [
                      "Choice of different gene sets for each assay is likely due to basing selection on relatively small numbers of cancers expressing thousands of different genes",
                      "Assignment by different assays to same molecular group is only modest for luminal A, B, and HER2 types",
                      "Assignment by different assays to same risk category is only modest"
                    ]
                  },
                  {
                    "text": "Results complement traditional prognostic factorsTumor size and lymph node status add important independent information for risk of recurrenceFew cancers < 1 cm in size are included in tumor banks used for development of assays",
                    "sub_points": [
                      "Tumor size and lymph node status add important independent information for risk of recurrence",
                      "Few cancers < 1 cm in size are included in tumor banks used for development of assays"
                    ]
                  },
                  {
                    "text": "Prediction is limited to ER(+) and HER2(-) cancersER(-) and HER2(+) cancers are generally placed in high-risk category; better predictors are neededPR(-) and cancers with high proliferative rates are also generally intermediate to high risk, and additional information may not be provided by GEP assay",
                    "sub_points": [
                      "ER(-) and HER2(+) cancers are generally placed in high-risk category; better predictors are needed",
                      "PR(-) and cancers with high proliferative rates are also generally intermediate to high risk, and additional information may not be provided by GEP assay"
                    ]
                  },
                  {
                    "text": "Predictive power is largely driven by genes related to differentiation, proliferation, and cell cycleOther measures of proliferation, such as mitotic count or Ki-67, might yield similar information if combined into a weighted score",
                    "sub_points": [
                      "Other measures of proliferation, such as mitotic count or Ki-67, might yield similar information if combined into a weighted score"
                    ]
                  },
                  {
                    "text": "Best for predicting short-term (< 10 years) distant recurrenceER(+) breast cancers have long natural history and can recur after > 10 years",
                    "sub_points": [
                      "ER(+) breast cancers have long natural history and can recur after > 10 years"
                    ]
                  },
                  {
                    "text": "ReproducibilityFor assays that can only be performed by single laboratory; reproducibility and accuracy cannot be independently evaluated",
                    "sub_points": [
                      "For assays that can only be performed by single laboratory; reproducibility and accuracy cannot be independently evaluated"
                    ]
                  },
                  {
                    "text": "High cost limits the use of these tests for patient care in some settingsReduced use of chemotherapy for low-risk patients may offset cost of testingHigh cost makes it difficult for independent researchers to study these assays",
                    "sub_points": [
                      "Reduced use of chemotherapy for low-risk patients may offset cost of testing",
                      "High cost makes it difficult for independent researchers to study these assays"
                    ]
                  }
                ],
                "Prognosis vs. Prediction of Benefit of Chemotherapy": [
                  {
                    "text": "The majority of these assays were designed as prognostic assays to determine risk of distant recurrenceBoth biologic type of cancer and anatomic stage (tumor size and lymph node status) are associated with the likelihood of distant metastasisSome assays only assess mRNA profile [e.g., Oncotype DX recurrence score (RS), MammaPrint], whereas others also include features of anatomic stage (e.g., Prosigna ROR, EPclin)",
                    "sub_points": [
                      "Both biologic type of cancer and anatomic stage (tumor size and lymph node status) are associated with the likelihood of distant metastasis",
                      "Some assays only assess mRNA profile [e.g., Oncotype DX recurrence score (RS), MammaPrint], whereas others also include features of anatomic stage (e.g., Prosigna ROR, EPclin)"
                    ]
                  },
                  {
                    "text": "Assays that predict benefit of specific types of therapy have immense clinical value, as they can ensure patients only receive appropriate treatmentThe greatest utility from multigene assays is the ability to identify patients who will receive little or no benefit from chemotherapyThese patients can be spared morbidity and cost of this treatmentLikelihood of response to chemotherapy is closely associated with biologic type (e.g., proliferation rate) rather than anatomic stage (tumor size and nodal status)",
                    "sub_points": [
                      "The greatest utility from multigene assays is the ability to identify patients who will receive little or no benefit from chemotherapyThese patients can be spared morbidity and cost of this treatment",
                      "These patients can be spared morbidity and cost of this treatment",
                      "Likelihood of response to chemotherapy is closely associated with biologic type (e.g., proliferation rate) rather than anatomic stage (tumor size and nodal status)"
                    ]
                  },
                  {
                    "text": "Multigene assays are capable of identifying groups of patients with very low recurrence risk when treated with only adjuvant endocrine therapyThese are typically cancers with high levels of expression of ER and PR and low expression of proliferation genesIt is unlikely that chemotherapy can improve excellent survival of these patients",
                    "sub_points": [
                      "These are typically cancers with high levels of expression of ER and PR and low expression of proliferation genes",
                      "It is unlikely that chemotherapy can improve excellent survival of these patients"
                    ]
                  },
                  {
                    "text": "Multigene assays also identify patients at high risk for distant recurrence, and cancers fall into 3 groupsGroup 1: High-risk biologic type and high-risk anatomic stage: This group will likely benefit from chemotherapyGroup 2: High-risk biologic type and low-risk anatomic stage [e.g., small tumor size and node (-)]: This group may not benefit from chemotherapy, as these patients may be cured by local therapyGroup 3: Low-risk biologic type and high-risk anatomic stage [e.g., large tumor size &/or node (+)]: This group may not benefit from chemotherapy due to biologic type and that anatomic extent of tumor is not well correlated with response to treatment",
                    "sub_points": [
                      "Group 1: High-risk biologic type and high-risk anatomic stage: This group will likely benefit from chemotherapy",
                      "Group 2: High-risk biologic type and low-risk anatomic stage [e.g., small tumor size and node (-)]: This group may not benefit from chemotherapy, as these patients may be cured by local therapy",
                      "Group 3: Low-risk biologic type and high-risk anatomic stage [e.g., large tumor size &/or node (+)]: This group may not benefit from chemotherapy due to biologic type and that anatomic extent of tumor is not well correlated with response to treatment"
                    ]
                  },
                  {
                    "text": "Assays that combine both tumor biologic features and anatomic stage into a single risk score make it difficult to determine the origin of the high-risk score"
                  },
                  {
                    "text": "Assessment of both biologic type and anatomic stage separately and together may provide the most useful information to guide patient management"
                  }
                ],
                "Role of Pathologist": [
                  {
                    "text": "Pathologists play an essential role in identifying the best block of the primary breast cancer to be used for ancillary testing from a specimen prior to treatment"
                  },
                  {
                    "text": "The block with the largest area of invasive cancer is generally chosenIncluding this block in the pathology report facilitates care of patientsIt is helpful to record size of cancer in block and percentage cellularityIf tissue on unstained slides is used for an assay, the slides must be freshly cutmRNA can degrade on cut slides in < 2 weeks",
                    "sub_points": [
                      "Including this block in the pathology report facilitates care of patientsIt is helpful to record size of cancer in block and percentage cellularity",
                      "It is helpful to record size of cancer in block and percentage cellularity",
                      "If tissue on unstained slides is used for an assay, the slides must be freshly cutmRNA can degrade on cut slides in < 2 weeks",
                      "mRNA can degrade on cut slides in < 2 weeks"
                    ]
                  },
                  {
                    "text": "Aberrant results can be obtained in some cases, and these features should be noted when present as mRNA is averaged over tumor cells and stromaVery low tumor cellularitySmaller cancers with relatively large biopsy sitesCancers associated with a dense lymphocytic infiltrateDuctal carcinoma in situ (DCIS) with discordant biomarker expressionIf DCIS has a different pattern of expression compared to invasive carcinoma, this should be notedMost common setting is HER2(+) DCIS associated with HER2(-) invasive carcinomaIf possible, a block without DCIS should be chosenIf this is not possible, the company should be notifiedExtra care can be taken to microdissect invasive cancer away from DCIS",
                    "sub_points": [
                      "Very low tumor cellularity",
                      "Smaller cancers with relatively large biopsy sites",
                      "Cancers associated with a dense lymphocytic infiltrate",
                      "Ductal carcinoma in situ (DCIS) with discordant biomarker expressionIf DCIS has a different pattern of expression compared to invasive carcinoma, this should be notedMost common setting is HER2(+) DCIS associated with HER2(-) invasive carcinomaIf possible, a block without DCIS should be chosenIf this is not possible, the company should be notifiedExtra care can be taken to microdissect invasive cancer away from DCIS",
                      "If DCIS has a different pattern of expression compared to invasive carcinoma, this should be notedMost common setting is HER2(+) DCIS associated with HER2(-) invasive carcinoma",
                      "Most common setting is HER2(+) DCIS associated with HER2(-) invasive carcinoma",
                      "If possible, a block without DCIS should be chosen",
                      "If this is not possible, the company should be notifiedExtra care can be taken to microdissect invasive cancer away from DCIS",
                      "Extra care can be taken to microdissect invasive cancer away from DCIS"
                    ]
                  },
                  {
                    "text": "Difficult areasMultiple synchronous ipsilateral invasive cancersIn general, the largest invasive cancer is sent for testingIf cancers are of different grade or known to have different patterns of ER, PR, and HER2 expression, usually the cancer most likely to have the highest score is sentIn some cases, oncologist may request that more than 1 cancer be sent for testingPrior treatmentCurrent assays are intended for evaluation of newly diagnosed cancers that have not been treatedTreatment can change gene expression patterns, which would invalidate the resultsIn such cases, it may be necessary to send a core needle biopsy obtained prior to treatmentMetastasisClinician may occasionally request to have metastasis sent for assayCurrent commercial assays have not been validated for metastasesPresence of numerous lymphocytes could result in invalid resultsBenign lesionsIt is important to remember that current assays are prognostic assays and not diagnostic assaysIf a benign lesion is inadvertently sent, it will likely be classified as intermediate to high risk of recurrence by some assays due to relatively low ER expression",
                    "sub_points": [
                      "Multiple synchronous ipsilateral invasive cancersIn general, the largest invasive cancer is sent for testingIf cancers are of different grade or known to have different patterns of ER, PR, and HER2 expression, usually the cancer most likely to have the highest score is sentIn some cases, oncologist may request that more than 1 cancer be sent for testing",
                      "In general, the largest invasive cancer is sent for testing",
                      "If cancers are of different grade or known to have different patterns of ER, PR, and HER2 expression, usually the cancer most likely to have the highest score is sent",
                      "In some cases, oncologist may request that more than 1 cancer be sent for testing",
                      "Prior treatmentCurrent assays are intended for evaluation of newly diagnosed cancers that have not been treatedTreatment can change gene expression patterns, which would invalidate the resultsIn such cases, it may be necessary to send a core needle biopsy obtained prior to treatment",
                      "Current assays are intended for evaluation of newly diagnosed cancers that have not been treatedTreatment can change gene expression patterns, which would invalidate the results",
                      "Treatment can change gene expression patterns, which would invalidate the results",
                      "In such cases, it may be necessary to send a core needle biopsy obtained prior to treatment",
                      "MetastasisClinician may occasionally request to have metastasis sent for assayCurrent commercial assays have not been validated for metastasesPresence of numerous lymphocytes could result in invalid results",
                      "Clinician may occasionally request to have metastasis sent for assay",
                      "Current commercial assays have not been validated for metastases",
                      "Presence of numerous lymphocytes could result in invalid results",
                      "Benign lesionsIt is important to remember that current assays are prognostic assays and not diagnostic assaysIf a benign lesion is inadvertently sent, it will likely be classified as intermediate to high risk of recurrence by some assays due to relatively low ER expression",
                      "It is important to remember that current assays are prognostic assays and not diagnostic assays",
                      "If a benign lesion is inadvertently sent, it will likely be classified as intermediate to high risk of recurrence by some assays due to relatively low ER expression"
                    ]
                  },
                  {
                    "text": "Quality assuranceIf the pathologist receives reports of multigene assays, an important QA measure is to compare the result to standard pathologic featuresIf risk score seems unlikely for cancer type, possible reasons should be consideredCancers of low cellularity or small size compared to stroma, lymphocytic infiltrate, or biopsy siteInappropriate block sentTechnical problem with assaySingle-gene scores provided by Oncotype DX RS can be compared to standard testingIf discordant, standard tests should be reviewedIf a single-gene score is incorrect, this will alter RSFor example, sparsely cellular, well-differentiated invasive lobular cancer might have low or negative ER or PR scoresCorrelation of single-gene scores and clinical testing recommendedOncologist should be aware of this possibility",
                    "sub_points": [
                      "If the pathologist receives reports of multigene assays, an important QA measure is to compare the result to standard pathologic features",
                      "If risk score seems unlikely for cancer type, possible reasons should be consideredCancers of low cellularity or small size compared to stroma, lymphocytic infiltrate, or biopsy siteInappropriate block sentTechnical problem with assay",
                      "Cancers of low cellularity or small size compared to stroma, lymphocytic infiltrate, or biopsy site",
                      "Inappropriate block sent",
                      "Technical problem with assay",
                      "Single-gene scores provided by Oncotype DX RS can be compared to standard testingIf discordant, standard tests should be reviewedIf a single-gene score is incorrect, this will alter RSFor example, sparsely cellular, well-differentiated invasive lobular cancer might have low or negative ER or PR scoresCorrelation of single-gene scores and clinical testing recommendedOncologist should be aware of this possibility",
                      "If discordant, standard tests should be reviewed",
                      "If a single-gene score is incorrect, this will alter RSFor example, sparsely cellular, well-differentiated invasive lobular cancer might have low or negative ER or PR scores",
                      "For example, sparsely cellular, well-differentiated invasive lobular cancer might have low or negative ER or PR scores",
                      "Correlation of single-gene scores and clinical testing recommended",
                      "Oncologist should be aware of this possibility"
                    ]
                  }
                ],
                "Oncotype DX RS (Prognostic and Predictive)": [
                  {
                    "text": "Marketed by Genomic Health, Inc."
                  },
                  {
                    "text": "21-gene RT-PCR assay (16 cancer-related genes, 5 reference genes)Includes ER, PR, and HER2; individual values provided for eachOnly applicable for ER(+) cancers",
                    "sub_points": [
                      "Includes ER, PR, and HER2; individual values provided for each",
                      "Only applicable for ER(+) cancers"
                    ]
                  },
                  {
                    "text": "Provides risk of distant recurrence at 10 years for patients with 0 to 3 positive nodes"
                  },
                  {
                    "text": "Correlated with magnitude of benefit of chemotherapyGreatest benefit for women with cancers of high riskNo benefit for women with cancers of low risk",
                    "sub_points": [
                      "Greatest benefit for women with cancers of high risk",
                      "No benefit for women with cancers of low risk"
                    ]
                  },
                  {
                    "text": "Benefit from chemotherapy depends on the patient's age (≤ 50 or > 50 years) and the RS"
                  }
                ],
                "MammaPrint (Prognostic and Predictive)": [
                  {
                    "text": "Marketed by Agendia BV"
                  },
                  {
                    "text": "Also referred to as the 70-gene microarray assay (Amsterdam signature)"
                  },
                  {
                    "text": "Test results provide 2 categories; good vs. poor prognosisCorrelation coefficient > 0.4: Good prognosisCorrelation coefficient ≤ 0.4: Poor prognosis",
                    "sub_points": [
                      "Correlation coefficient > 0.4: Good prognosis",
                      "Correlation coefficient ≤ 0.4: Poor prognosis"
                    ]
                  },
                  {
                    "text": "Prognosis score correlated with distant disease-free survival at 5 years for patients not receiving treatment"
                  },
                  {
                    "text": "Predictive of lack of benefit from chemotherapy in good prognosis groupBenefit from chemotherapy in poor prognosis group depends on clinical factors",
                    "sub_points": [
                      "Benefit from chemotherapy in poor prognosis group depends on clinical factors"
                    ]
                  },
                  {
                    "text": "Clinical trials showed that ER(+) breast carcinoma with high clinical risk but low genomic risk did not benefit from addition of chemotherapy"
                  },
                  {
                    "text": "Benefit from chemotherapy depends on the patient's age (≤ 50 or > 50 years) and the genomic risk score"
                  }
                ],
                "Breast Cancer Index (BCI) (Prognostic and Predictive)": [
                  {
                    "text": "Marketed by Biotheranostics"
                  },
                  {
                    "text": "BCI consists of 2 assaysHOXB13:IL17BR2-gene ratio (H:I)HighHOXB13mRNA levels and lowIL17BRmRNA levels are associated with recurrence for postmenopausal women with ER(+) cancer treated with tamoxifen for 5 yearsPrognostic for recurrencePredictive of tamoxifen benefit4 reference genes included to normalize mRNAACTB, HMBS, SDHA, UBCMolecular grade index (MGI)5-gene assay correlating with tumor grade that stratifies cancers into 2 groupsBUB1B, CENPA, NEK2, RACGAP1, RRM2",
                    "sub_points": [
                      "HOXB13:IL17BR2-gene ratio (H:I)HighHOXB13mRNA levels and lowIL17BRmRNA levels are associated with recurrence for postmenopausal women with ER(+) cancer treated with tamoxifen for 5 yearsPrognostic for recurrencePredictive of tamoxifen benefit4 reference genes included to normalize mRNAACTB, HMBS, SDHA, UBC",
                      "HighHOXB13mRNA levels and lowIL17BRmRNA levels are associated with recurrence for postmenopausal women with ER(+) cancer treated with tamoxifen for 5 yearsPrognostic for recurrencePredictive of tamoxifen benefit",
                      "Prognostic for recurrence",
                      "Predictive of tamoxifen benefit",
                      "4 reference genes included to normalize mRNAACTB, HMBS, SDHA, UBC",
                      "ACTB, HMBS, SDHA, UBC",
                      "Molecular grade index (MGI)5-gene assay correlating with tumor grade that stratifies cancers into 2 groupsBUB1B, CENPA, NEK2, RACGAP1, RRM2",
                      "5-gene assay correlating with tumor grade that stratifies cancers into 2 groupsBUB1B, CENPA, NEK2, RACGAP1, RRM2",
                      "BUB1B, CENPA, NEK2, RACGAP1, RRM2"
                    ]
                  },
                  {
                    "text": "The combination of H:I and MGI identifies 3 risk groupsLow risk: Low MGI and low or high H:IIntermediate risk: High MGI and low H:IHigh risk: High MGI and high H:I",
                    "sub_points": [
                      "Low risk: Low MGI and low or high H:I",
                      "Intermediate risk: High MGI and low H:I",
                      "High risk: High MGI and high H:I"
                    ]
                  },
                  {
                    "text": "Predicts risk of recurrence from 0-10 years for women with ER(+)/HER2(-) cancers treated with tamoxifenPrognostic for late distant recurrence (from 5-10 years) along with ROR and EPclinBCI has been shown to be predictive of benefit from letrozole after 5 years of tamoxifen",
                    "sub_points": [
                      "Prognostic for late distant recurrence (from 5-10 years) along with ROR and EPclinBCI has been shown to be predictive of benefit from letrozole after 5 years of tamoxifen",
                      "BCI has been shown to be predictive of benefit from letrozole after 5 years of tamoxifen"
                    ]
                  }
                ],
                "Prosigna Risk of Recurrence (Prognostic)": [
                  {
                    "text": "Marketed by Prosigna (Prosigna; NanoString Technologies)"
                  },
                  {
                    "text": "RT-PCR assay originally based on PAM50, measures expression levels of 50 genes4 genes were subsequently found to not provide sufficient additional information",
                    "sub_points": [
                      "4 genes were subsequently found to not provide sufficient additional information"
                    ]
                  },
                  {
                    "text": "ROR = molecular subtype (weighted coefficients for 4 subtypes) combined with proliferation score (based on 18-gene subset) and tumor size (≤ 2 cm or > 2 cm)Ranges from 0-1003 risk categories for node (-) patients2 risk categories for node (+) (1-3) patients (low and high)",
                    "sub_points": [
                      "Ranges from 0-100",
                      "3 risk categories for node (-) patients",
                      "2 risk categories for node (+) (1-3) patients (low and high)"
                    ]
                  },
                  {
                    "text": "Patients with cancers with low-risk scores may not benefit from chemotherapy"
                  },
                  {
                    "text": "Prognostic for late distant recurrence (from 5-10 years) along with BCI and EPclin"
                  }
                ],
                "EndoPredict (EP) (Prognostic)": [
                  {
                    "text": "Marketed by Myriad Genetics, Inc."
                  },
                  {
                    "text": "qRT-PCR test; 12 genes (8 cancer genes, 4 control genes)"
                  },
                  {
                    "text": "EP score ranges from 0-15 (threshold of 5 to discriminate low and high risk)"
                  },
                  {
                    "text": "EPclin risk score includes EP, tumor size, and node statusImproves prognostic power over EP scoreRanges from 1-6 (threshold of 3.3 to discriminate low and high risk)",
                    "sub_points": [
                      "Improves prognostic power over EP score",
                      "Ranges from 1-6 (threshold of 3.3 to discriminate low and high risk)"
                    ]
                  },
                  {
                    "text": "EPclin is prognostic for late distant recurrence (from 5-10 years) for women treated with endocrine therapy, along with BCI and ROR"
                  },
                  {
                    "text": "May be used to guide adjuvant treatment decisions in postmenopausal patients"
                  }
                ],
                "MapQuant Dx (Genomic Grade Index)": [
                  {
                    "text": "Marketed by Ipsogen SA"
                  },
                  {
                    "text": "97-gene microarray assayRequires fresh frozen tissue",
                    "sub_points": [
                      "Requires fresh frozen tissue"
                    ]
                  },
                  {
                    "text": "Modified quantitative RT-PCR assay using 4 genes has been developedMYBL2(also used in Oncotype DX),KPNA2(also used in MammaPrint),CDK1(CDC2), andCDC20Can be performed on formalin-fixed paraffin-embedded tissue",
                    "sub_points": [
                      "MYBL2(also used in Oncotype DX),KPNA2(also used in MammaPrint),CDK1(CDC2), andCDC20",
                      "Can be performed on formalin-fixed paraffin-embedded tissue"
                    ]
                  },
                  {
                    "text": "Appropriate patient populationPatients with ER(+) cancers",
                    "sub_points": [
                      "Patients with ER(+) cancers"
                    ]
                  },
                  {
                    "text": "Test resultsHigh or low genomic grade index (GGI)",
                    "sub_points": [
                      "High or low genomic grade index (GGI)"
                    ]
                  },
                  {
                    "text": "Correlates with disease-free and overall survival"
                  },
                  {
                    "text": "Associated with histologic gradeGrade 1: ~ 85% low GGIGrade 2: Cancers are split into low and high categoriesGrade 3: ~ 90% high GGI",
                    "sub_points": [
                      "Grade 1: ~ 85% low GGI",
                      "Grade 2: Cancers are split into low and high categories",
                      "Grade 3: ~ 90% high GGI"
                    ]
                  }
                ],
                "2nd-Generation Gene Expression Profiling Assays": [
                  {
                    "text": "Designed for defined subsets of cancers and to address specific clinical questions rather than overall prognosisPrediction of response to types of therapyFor example, response to anthracycline-based regimens or taxane-based regimensWound response indicator: May predict survivalInvasive gene signature: 186-gene profileCompares normal breast epithelial cells with CD44(+)/CD24(-) cells (breast cancer stem cells)May predict shorter overall survival and metastasis-free survival",
                    "sub_points": [
                      "Prediction of response to types of therapyFor example, response to anthracycline-based regimens or taxane-based regimens",
                      "For example, response to anthracycline-based regimens or taxane-based regimens",
                      "Wound response indicator: May predict survival",
                      "Invasive gene signature: 186-gene profileCompares normal breast epithelial cells with CD44(+)/CD24(-) cells (breast cancer stem cells)May predict shorter overall survival and metastasis-free survival",
                      "Compares normal breast epithelial cells with CD44(+)/CD24(-) cells (breast cancer stem cells)",
                      "May predict shorter overall survival and metastasis-free survival"
                    ]
                  }
                ]
              },
              "American Society of Clinical Oncology Clinical Practice Guidelines (2022)": {
                "Overview": [
                  {
                    "text": "American Society of Clinical Oncology (ASCO) makes recommendations on appropriate use of breast biomarker assay results to guide decision on adjuvant systemic therapy for early-stage invasive breast cancerEvidence-based guideline recommendations based on literature review and expert panel consensus",
                    "sub_points": [
                      "Evidence-based guideline recommendations based on literature review and expert panel consensus"
                    ]
                  },
                  {
                    "text": "No assay is recommended for treatment guidance for patients with HER2(+) or ER(-) cancers"
                  },
                  {
                    "text": "No assay has been validated for treatment decisions for patients with ≥ 4 positive lymph nodes"
                  },
                  {
                    "text": "No assay is recommended for premenopausal patients with positive lymph nodesCurrent data supports that these patients benefit from chemotherapyHowever, it is unclear if this is due to treatment effect on the cancer or that many of these patients become postmenopausal due to the treatment",
                    "sub_points": [
                      "Current data supports that these patients benefit from chemotherapyHowever, it is unclear if this is due to treatment effect on the cancer or that many of these patients become postmenopausal due to the treatment",
                      "However, it is unclear if this is due to treatment effect on the cancer or that many of these patients become postmenopausal due to the treatment"
                    ]
                  }
                ],
                "Oncotype DX RS": [
                  {
                    "text": "For ER(+)/HER2(-) cancerPostmenopausal women can have 0-3 positive lymph nodesPremenopausal women must have negative lymph nodes",
                    "sub_points": [
                      "Postmenopausal women can have 0-3 positive lymph nodes",
                      "Premenopausal women must have negative lymph nodes"
                    ]
                  },
                  {
                    "text": "This assay may be used to guide decisions for adjuvant endocrine and chemotherapy"
                  },
                  {
                    "text": "Not recommended to guide decisions about extended endocrine therapy"
                  }
                ],
                "MammaPrint": [
                  {
                    "text": "For ER(+)/HER2(-) cancerPatients over 50High clinical risk breast cancer with 0 to 3 positive lymph nodesShould not be used for low clinical risk breast cancer",
                    "sub_points": [
                      "Patients over 50",
                      "High clinical risk breast cancer with 0 to 3 positive lymph nodes",
                      "Should not be used for low clinical risk breast cancer"
                    ]
                  },
                  {
                    "text": "This assay may be used to guide decisions for adjuvant endocrine and chemotherapy"
                  },
                  {
                    "text": "Not recommended to guide decisions about extended endocrine therapy"
                  }
                ],
                "Prosigna (PAM50) Risk of Recurrence Score": [
                  {
                    "text": "For ER(+)/HER2(-) breast cancerPostmenopausal patientsNegative lymph nodes",
                    "sub_points": [
                      "Postmenopausal patients",
                      "Negative lymph nodes"
                    ]
                  },
                  {
                    "text": "This assay may be used to guide decisions on adjuvant systemic chemotherapy"
                  },
                  {
                    "text": "Not recommended to guide decisions about extended endocrine therapy"
                  }
                ],
                "EndoPredict": [
                  {
                    "text": "For ER(+)/HER2(-) breast cancerPostmenopausal patients with 0 to 3 positive lymph nodes",
                    "sub_points": [
                      "Postmenopausal patients with 0 to 3 positive lymph nodes"
                    ]
                  },
                  {
                    "text": "This assay may be used to guide decisions on adjuvant endocrine and chemotherapy"
                  },
                  {
                    "text": "Not recommended for decisions about extended endocrine therapy"
                  }
                ],
                "Breast Cancer Index": [
                  {
                    "text": "For ER(+)/HER2(-) breast cancerPatients postmenopausal or age > 50 years and with negative lymph nodesThis assay can be used to guide decisions for adjuvant endocrine and chemotherapyPatients with 0 to 3 positive lymph nodes treated with 5 years of endocrine therapy without recurrenceThis assay may be used to guide decisions on extended endocrine therapy",
                    "sub_points": [
                      "Patients postmenopausal or age > 50 years and with negative lymph nodesThis assay can be used to guide decisions for adjuvant endocrine and chemotherapy",
                      "This assay can be used to guide decisions for adjuvant endocrine and chemotherapy",
                      "Patients with 0 to 3 positive lymph nodes treated with 5 years of endocrine therapy without recurrenceThis assay may be used to guide decisions on extended endocrine therapy",
                      "This assay may be used to guide decisions on extended endocrine therapy"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Expression Profiling: Protein": {
            "name": "Expression Profiling: Protein",
            "url": "https://app.pathprimer.com/document/20927bc4-28a1-41b9-b0ce-1c168d3821f1/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Protein expression profiling refers to the identification of patterns of protein expression that identify clinically significant subtypes of breast carcinoma (BC)"
                  }
                ]
              },
              "Introduction": {
                "Clinically Relevant Tumor Classification": [
                  {
                    "text": "Prognosis: Classification should help distinguish different prognostic groups among patients with similar featuresThe ideal prognostic test would clearly separate patients with and without disease recurrence",
                    "sub_points": [
                      "The ideal prognostic test would clearly separate patients with and without disease recurrence"
                    ]
                  },
                  {
                    "text": "Prediction: Classification should help determine which patients will benefit from a specific type of therapyThe ideal predictive test would clearly separate patients into those whose carcinomas respond to treatment and those whose carcinomas will not",
                    "sub_points": [
                      "The ideal predictive test would clearly separate patients into those whose carcinomas respond to treatment and those whose carcinomas will not"
                    ]
                  },
                  {
                    "text": "Carcinomas can be separated into groups for prognosis or prediction using anatomic extent, morphology, DNA, mRNA, protein, or combinations of these features"
                  },
                  {
                    "text": "Protein expression profiling provides both prognostic and predictive information and can be used to identify important molecular types of BC"
                  }
                ],
                "Protein Expression Profiling": [
                  {
                    "text": "Both mRNA and protein provide information about gene expression"
                  },
                  {
                    "text": "There is a correlation between the level of mRNA and the corresponding protein, but it is not exact"
                  },
                  {
                    "text": "An advantage of gene expression profiling (GEP) is that dozens to thousands of mRNA transcripts can be assayed due to the structure of nucleic acids"
                  },
                  {
                    "text": "Determining the levels of numerous proteins is more challenging, as specific antibodies need to be created for each protein"
                  },
                  {
                    "text": "However, assays for proteins have multiple advantages over assays for mRNAProtein is a robust biomolecule compared to mRNALess susceptible to degradation from cold ischemic timeImmunohistochemical (IHC) assays are readily available in pathology laboratoriesAssays are relatively low cost with fast turnaround timeMorphologic confirmation of the tissue assayed is always availableCan distinguish expression in tumor cells vs. stromal cells vs. benign epithelial cellsThe subcellular location of the protein is determined: May be important to detect aberrant expression patterns [e.g., cytoplasmic location of estrogen receptor (ER)]In contrast, assays based on mRNA generally average amounts over all the tissue present, including benign and malignant cellsProteins are typically the direct target of therapye.g., therapeutic antibodies bind to membrane HER2 protein to disrupt signalingmRNA for HER2 may be present but may not be translated into functional molecules or may code for a truncated formTruncated HER2 may not serve as a target for therapeutic antibodies",
                    "sub_points": [
                      "Protein is a robust biomolecule compared to mRNALess susceptible to degradation from cold ischemic time",
                      "Less susceptible to degradation from cold ischemic time",
                      "Immunohistochemical (IHC) assays are readily available in pathology laboratoriesAssays are relatively low cost with fast turnaround time",
                      "Assays are relatively low cost with fast turnaround time",
                      "Morphologic confirmation of the tissue assayed is always availableCan distinguish expression in tumor cells vs. stromal cells vs. benign epithelial cellsThe subcellular location of the protein is determined: May be important to detect aberrant expression patterns [e.g., cytoplasmic location of estrogen receptor (ER)]In contrast, assays based on mRNA generally average amounts over all the tissue present, including benign and malignant cells",
                      "Can distinguish expression in tumor cells vs. stromal cells vs. benign epithelial cells",
                      "The subcellular location of the protein is determined: May be important to detect aberrant expression patterns [e.g., cytoplasmic location of estrogen receptor (ER)]",
                      "In contrast, assays based on mRNA generally average amounts over all the tissue present, including benign and malignant cells",
                      "Proteins are typically the direct target of therapye.g., therapeutic antibodies bind to membrane HER2 protein to disrupt signalingmRNA for HER2 may be present but may not be translated into functional molecules or may code for a truncated formTruncated HER2 may not serve as a target for therapeutic antibodies",
                      "e.g., therapeutic antibodies bind to membrane HER2 protein to disrupt signalingmRNA for HER2 may be present but may not be translated into functional molecules or may code for a truncated formTruncated HER2 may not serve as a target for therapeutic antibodies",
                      "mRNA for HER2 may be present but may not be translated into functional molecules or may code for a truncated form",
                      "Truncated HER2 may not serve as a target for therapeutic antibodies"
                    ]
                  },
                  {
                    "text": "Tests based on proteins have been validated for choosing endocrine or HER2-targeted therapyGEP assays may be discordant with standard assays for several reasonsExpression of protein may not be detected in cancers of low cellularity (e.g., lobular carcinomas) or with relatively large biopsy sitesmRNA may not be preserved in some suboptimally processed specimens",
                    "sub_points": [
                      "GEP assays may be discordant with standard assays for several reasonsExpression of protein may not be detected in cancers of low cellularity (e.g., lobular carcinomas) or with relatively large biopsy sitesmRNA may not be preserved in some suboptimally processed specimens",
                      "Expression of protein may not be detected in cancers of low cellularity (e.g., lobular carcinomas) or with relatively large biopsy sites",
                      "mRNA may not be preserved in some suboptimally processed specimens"
                    ]
                  },
                  {
                    "text": "Assays for ER, progesterone receptor (PR), and HER2 are standard practice for newly diagnosed invasive BCsCombining information into prognostic/predictive indices or identifying molecular types requires little or no additional cost",
                    "sub_points": [
                      "Combining information into prognostic/predictive indices or identifying molecular types requires little or no additional cost"
                    ]
                  }
                ],
                "Terminology": [
                  {
                    "text": "The terms \"luminal,\" \"luminal A,\" \"luminal B,\" \"HER2-enriched,\" and \"basal-like\" were originally developed for classification based on GEP"
                  },
                  {
                    "text": "These terms have also been used to describe similar groups of carcinomas as defined by protein expression profiling"
                  },
                  {
                    "text": "It is important to note that these groups are defined in different ways in different settings and when different assays are used"
                  },
                  {
                    "text": "In general, ~ 80% of carcinomas fall into the same molecular group using different methods"
                  }
                ]
              },
              "Protein Expression Profiling: Single Antibodies": {
                "ER, PR, HER2, Ki-67": [
                  {
                    "text": "Validated as useful for risk stratification and prediction of benefit from specific adjuvant therapiesER and PR: Response to tamoxifen, aromatase inhibitors, and other classes of endocrine therapyHER2: Response to trastuzumab, lapatinib, and other HER2-directed therapiesKi-67: High proliferative rate predicts increased benefit from chemotherapy",
                    "sub_points": [
                      "ER and PR: Response to tamoxifen, aromatase inhibitors, and other classes of endocrine therapy",
                      "HER2: Response to trastuzumab, lapatinib, and other HER2-directed therapies",
                      "Ki-67: High proliferative rate predicts increased benefit from chemotherapy"
                    ]
                  }
                ],
                "Cytokeratin Classification": [
                  {
                    "text": "BCs can be classified based on differential patterns of expression of cytokeratins by IHC"
                  },
                  {
                    "text": "Luminal subtypeExpress low molecular weight luminal cytokeratins, such as CK8 and CK18Usually do not express basal cytokeratins",
                    "sub_points": [
                      "Express low molecular weight luminal cytokeratins, such as CK8 and CK18",
                      "Usually do not express basal cytokeratins"
                    ]
                  },
                  {
                    "text": "Basal subtypeExpress high molecular weight basal cytokeratins, such as CK5/6, CK14, and CK17Also frequently express luminal cytokeratinsExpression of basal cytokeratins is correlated with other featuresHigh histologic and nuclear grade with pushing borders and marked increase in proliferationAbsence of ER expressionAggressive clinical course with poor prognosis and increased incidence of early recurrenceIncreased incidence of metastases to lungs and brainAssociated with germlineBRCA1mutations and familial BC",
                    "sub_points": [
                      "Express high molecular weight basal cytokeratins, such as CK5/6, CK14, and CK17",
                      "Also frequently express luminal cytokeratins",
                      "Expression of basal cytokeratins is correlated with other featuresHigh histologic and nuclear grade with pushing borders and marked increase in proliferationAbsence of ER expressionAggressive clinical course with poor prognosis and increased incidence of early recurrenceIncreased incidence of metastases to lungs and brainAssociated with germlineBRCA1mutations and familial BC",
                      "High histologic and nuclear grade with pushing borders and marked increase in proliferation",
                      "Absence of ER expression",
                      "Aggressive clinical course with poor prognosis and increased incidence of early recurrenceIncreased incidence of metastases to lungs and brain",
                      "Increased incidence of metastases to lungs and brain",
                      "Associated with germlineBRCA1mutations and familial BC"
                    ]
                  }
                ],
                "FOXA1 Expression": [
                  {
                    "text": "FOXA1: Forkhead family transcription factorProtein essential for optimum expression of many estrogen-responsive genesExpression segregates with genes that characterize luminal subtypes by expression analysisIndependent prognostic factor for ER(+)BC",
                    "sub_points": [
                      "Protein essential for optimum expression of many estrogen-responsive genes",
                      "Expression segregates with genes that characterize luminal subtypes by expression analysisIndependent prognostic factor for ER(+)BC",
                      "Independent prognostic factor for ER(+)BC"
                    ]
                  },
                  {
                    "text": "In large clinical cohorts, FOXA1 expression correlates with luminal subtype A BCExpression of FOXA1 was significant predictor of improved cancer-specific survival in patients with ER(+) tumorsPrognostic ability of FOXA1 in these low-risk BCs may prove to be useful in clinical treatment decisions",
                    "sub_points": [
                      "Expression of FOXA1 was significant predictor of improved cancer-specific survival in patients with ER(+) tumors",
                      "Prognostic ability of FOXA1 in these low-risk BCs may prove to be useful in clinical treatment decisions"
                    ]
                  }
                ],
                "Programmed Death Ligand 1 (PD-L1) Expression": [
                  {
                    "text": "PD-L1 expression in metastatic carcinomas negative for hormone receptors and HER2 [triple negative BC (TNBC)] helps identify patients who may be likely to respond to immune checkpoint blockade (ICB)"
                  },
                  {
                    "text": "ICB that disrupts PD1/PD-L1 interactions combined with chemotherapy has shown benefit for metastatic TNBC"
                  },
                  {
                    "text": "Pembrolizumab is approved as 1st-line treatment for metastatic TNBC with PD-L1 combined positive score > 10"
                  }
                ]
              },
              "Protein Expression Profiling: Multiple Antibody Panels": {
                "Panels": [
                  {
                    "text": "IHC panels using multiple antibodies have the potential to provide additional prognostic and predictive informationIdentifies BC subsets with differing outcomesMay help predict response to specific therapiesAnalytical techniques developed for evaluating GEP can be applied to IHCNumerous investigators have attempted to translate protein expression data into IHC panels",
                    "sub_points": [
                      "Identifies BC subsets with differing outcomes",
                      "May help predict response to specific therapies",
                      "Analytical techniques developed for evaluating GEP can be applied to IHCNumerous investigators have attempted to translate protein expression data into IHC panels",
                      "Numerous investigators have attempted to translate protein expression data into IHC panels"
                    ]
                  },
                  {
                    "text": "ChallengesIdentification of optimal panels correlated with patient outcome or response to treatmentStandardization of tissue handling and fixationStandardization of assay procedures, positive and negative controls, criteria for interpretation",
                    "sub_points": [
                      "Identification of optimal panels correlated with patient outcome or response to treatment",
                      "Standardization of tissue handling and fixation",
                      "Standardization of assay procedures, positive and negative controls, criteria for interpretation"
                    ]
                  }
                ],
                "Molecular Classification of Breast Carcinomas Using Protein Panels": [
                  {
                    "text": "BCs can be separated according to protein expression into molecular types similar to those identified by GEPThese groups have important biologic, clinical, epidemiologic, and prognostic differencesThe names applied to these groups vary in different studies and in different contexts",
                    "sub_points": [
                      "These groups have important biologic, clinical, epidemiologic, and prognostic differences",
                      "The names applied to these groups vary in different studies and in different contexts"
                    ]
                  },
                  {
                    "text": "Classification based on ER and HER24 groups are identified using expression of these 2 proteinsLuminal BC: ER(+) and HER2(-)Luminal HER2 BC: ER(+) and HER2(+)HER2 BC: ER(-) and HER2(+)TNBC: ER(-) and HER2(-)There is ~ 80% overlap with similar groups identified by GEP",
                    "sub_points": [
                      "4 groups are identified using expression of these 2 proteinsLuminal BC: ER(+) and HER2(-)Luminal HER2 BC: ER(+) and HER2(+)HER2 BC: ER(-) and HER2(+)TNBC: ER(-) and HER2(-)",
                      "Luminal BC: ER(+) and HER2(-)",
                      "Luminal HER2 BC: ER(+) and HER2(+)",
                      "HER2 BC: ER(-) and HER2(+)",
                      "TNBC: ER(-) and HER2(-)",
                      "There is ~ 80% overlap with similar groups identified by GEP"
                    ]
                  },
                  {
                    "text": "Classification based on ER, HER2, HER1 (EGFR), Ki-67, and basal cytokeratins (e.g., CK5/6)6 groups are identifiedLuminal A subtype: ER(+), HER2(-), Ki-67 low, basal cytokeratins (-)Usually PR(+)Luminal B subtype HER2(-): ER(+), HER2(-), Ki-67 highMay be PR(-)Luminal B subtype HER2(+): ER(+), HER2(+), Ki-67 highMay be PR(-)HER2 subtype: ER(-), HER2(+), Ki-67 highUsually PR(-)Basal subtype:ER(-), PR(-), HER2(-), HER1 (EGFR)(+), basal cytokeratins (+)Identifies basal-like carcinomas defined by GEP with 76% sensitivity, 100% specificityOther IHC panels have also been used to define this groupDoes not identify ~ 10% that are ER(+) or ~ 10% that are HER2(+)Includes some ER(-) carcinomas that are androgen receptor (AR)(+) (\"luminal AR triple negative carcinoma\") that are not basal-like by GEPNonbasal normal breast subtypeER(-), PR(-), HER2(-), HER1 (EGFR)(-), basal cytokeratins (-)The \"normal breast\" subtype of BCs is a rare subtype of unclear significance either by GEP or by IHC",
                    "sub_points": [
                      "6 groups are identifiedLuminal A subtype: ER(+), HER2(-), Ki-67 low, basal cytokeratins (-)Usually PR(+)Luminal B subtype HER2(-): ER(+), HER2(-), Ki-67 highMay be PR(-)Luminal B subtype HER2(+): ER(+), HER2(+), Ki-67 highMay be PR(-)HER2 subtype: ER(-), HER2(+), Ki-67 highUsually PR(-)Basal subtype:ER(-), PR(-), HER2(-), HER1 (EGFR)(+), basal cytokeratins (+)Identifies basal-like carcinomas defined by GEP with 76% sensitivity, 100% specificityOther IHC panels have also been used to define this groupDoes not identify ~ 10% that are ER(+) or ~ 10% that are HER2(+)Includes some ER(-) carcinomas that are androgen receptor (AR)(+) (\"luminal AR triple negative carcinoma\") that are not basal-like by GEPNonbasal normal breast subtypeER(-), PR(-), HER2(-), HER1 (EGFR)(-), basal cytokeratins (-)The \"normal breast\" subtype of BCs is a rare subtype of unclear significance either by GEP or by IHC",
                      "Luminal A subtype: ER(+), HER2(-), Ki-67 low, basal cytokeratins (-)Usually PR(+)",
                      "Usually PR(+)",
                      "Luminal B subtype HER2(-): ER(+), HER2(-), Ki-67 highMay be PR(-)",
                      "May be PR(-)",
                      "Luminal B subtype HER2(+): ER(+), HER2(+), Ki-67 highMay be PR(-)",
                      "May be PR(-)",
                      "HER2 subtype: ER(-), HER2(+), Ki-67 highUsually PR(-)",
                      "Usually PR(-)",
                      "Basal subtype:ER(-), PR(-), HER2(-), HER1 (EGFR)(+), basal cytokeratins (+)Identifies basal-like carcinomas defined by GEP with 76% sensitivity, 100% specificityOther IHC panels have also been used to define this groupDoes not identify ~ 10% that are ER(+) or ~ 10% that are HER2(+)Includes some ER(-) carcinomas that are androgen receptor (AR)(+) (\"luminal AR triple negative carcinoma\") that are not basal-like by GEP",
                      "Identifies basal-like carcinomas defined by GEP with 76% sensitivity, 100% specificity",
                      "Other IHC panels have also been used to define this group",
                      "Does not identify ~ 10% that are ER(+) or ~ 10% that are HER2(+)",
                      "Includes some ER(-) carcinomas that are androgen receptor (AR)(+) (\"luminal AR triple negative carcinoma\") that are not basal-like by GEP",
                      "Nonbasal normal breast subtypeER(-), PR(-), HER2(-), HER1 (EGFR)(-), basal cytokeratins (-)The \"normal breast\" subtype of BCs is a rare subtype of unclear significance either by GEP or by IHC",
                      "ER(-), PR(-), HER2(-), HER1 (EGFR)(-), basal cytokeratins (-)",
                      "The \"normal breast\" subtype of BCs is a rare subtype of unclear significance either by GEP or by IHC"
                    ]
                  }
                ],
                "Mammostrat Assay": [
                  {
                    "text": "Alternative approach to profiling BC patients for prognosis and treatment response utilizing IHCDeveloped by Applied Genomics, Inc. in collaboration with researchers at Stanford UniversityAttempted to translate diversity revealed by GEP into new IHC tests with potential clinical utilityUtilized gene expression data sets to select hundreds of novel targets for production of new antibodiesAntibodies screened across several thousand formalin-fixed, paraffin-embedded tumor samples to identify quality IHC reagentsMost robust IHC markers further investigated for their ability to identify clinically significant subsets of solid tumors",
                    "sub_points": [
                      "Developed by Applied Genomics, Inc. in collaboration with researchers at Stanford UniversityAttempted to translate diversity revealed by GEP into new IHC tests with potential clinical utility",
                      "Attempted to translate diversity revealed by GEP into new IHC tests with potential clinical utility",
                      "Utilized gene expression data sets to select hundreds of novel targets for production of new antibodiesAntibodies screened across several thousand formalin-fixed, paraffin-embedded tumor samples to identify quality IHC reagentsMost robust IHC markers further investigated for their ability to identify clinically significant subsets of solid tumors",
                      "Antibodies screened across several thousand formalin-fixed, paraffin-embedded tumor samples to identify quality IHC reagents",
                      "Most robust IHC markers further investigated for their ability to identify clinically significant subsets of solid tumors"
                    ]
                  },
                  {
                    "text": "Panel developed for determining prognosis of early-stage ER(+) and node (-) BCStep 1: Panel of antibodies was used to score well-characterized BC cohortStep 2: Identified antibodies with univariate association with BC recurrenceStep 3: Generated Cox Proportional Hazard models using stage I/II cohort data fit to predict recurrence",
                    "sub_points": [
                      "Step 1: Panel of antibodies was used to score well-characterized BC cohort",
                      "Step 2: Identified antibodies with univariate association with BC recurrence",
                      "Step 3: Generated Cox Proportional Hazard models using stage I/II cohort data fit to predict recurrence"
                    ]
                  },
                  {
                    "text": "5 antibodies identified as minimal panel for prediction of recurrenceSLC7A5: Amino acid transport (may help sustain tumor cell growth): 31.4% of scorePositive: > 10% membrane positivityTP53: Tumor suppressor gene (involved in cell cycle control): 22.9% of scorePositive: > 10% nuclear positivityNDRG1: Stress/hypoxia response protein: 20.9% of scorePositive: Confluent uniform cytoplasmic or membrane positivityTRMT2A(HTF9C): Methyl transferase gene family homology: 14.5% of scorePositive: > 10% cytoplasmic positivityCEACAM5: Embryonic expressed protein: 10.3% of scorePositive: > 10% cytoplasmic or membrane positivity",
                    "sub_points": [
                      "SLC7A5: Amino acid transport (may help sustain tumor cell growth): 31.4% of scorePositive: > 10% membrane positivity",
                      "Positive: > 10% membrane positivity",
                      "TP53: Tumor suppressor gene (involved in cell cycle control): 22.9% of scorePositive: > 10% nuclear positivity",
                      "Positive: > 10% nuclear positivity",
                      "NDRG1: Stress/hypoxia response protein: 20.9% of scorePositive: Confluent uniform cytoplasmic or membrane positivity",
                      "Positive: Confluent uniform cytoplasmic or membrane positivity",
                      "TRMT2A(HTF9C): Methyl transferase gene family homology: 14.5% of scorePositive: > 10% cytoplasmic positivity",
                      "Positive: > 10% cytoplasmic positivity",
                      "CEACAM5: Embryonic expressed protein: 10.3% of scorePositive: > 10% cytoplasmic or membrane positivity",
                      "Positive: > 10% cytoplasmic or membrane positivity"
                    ]
                  },
                  {
                    "text": "Biologic assessment independent of proliferation, HER2, and hormone receptors"
                  },
                  {
                    "text": "Results are scored as positive or negative and used in algorithm to calculate risk index (RI)Clinically validated on 3 independent institutional cohorts of patientsClinically validated on archival tissue samples from NSABP B14 and B20 clinical trialsResults similar to Oncotype DX on same patient samples",
                    "sub_points": [
                      "Clinically validated on 3 independent institutional cohorts of patients",
                      "Clinically validated on archival tissue samples from NSABP B14 and B20 clinical trials",
                      "Results similar to Oncotype DX on same patient samples"
                    ]
                  },
                  {
                    "text": "RI classifies ER(+) and node (-) patients into 3 groups with different percentage risk of recurrence at 10 yearsLow risk: 7.6%; moderate risk: 16.3%; high risk: 20.9%",
                    "sub_points": [
                      "Low risk: 7.6%; moderate risk: 16.3%; high risk: 20.9%"
                    ]
                  },
                  {
                    "text": "Patients with high RI appear to derive greatest benefit from adjuvant chemotherapy"
                  }
                ],
                "IHC4 Score": [
                  {
                    "text": "Panel developed using retrospective cohort of ER(+)BCs from Arimidex, tamoxifen, alone or in combination trial (ATAC) endocrine therapy trialIncorporates ER, PR, Ki-67, and HER2 IHC semiquantitative resultsResults used to calculate risk score using weighting factors and algorithmER₁₀ = H score/30PR₁₀ = percentage of positive cells/10HER2 = 0, 1+, 3+ (2+ cases scored as negative or positive based on FISH)Ki-67 = percentage of positive cellsIHC4 = 94.7 x [-0.1 ER₁₀ - 0.079 PR₁₀ + 0.586 HER2 + 0.24 ln (1 + Ki-67)]",
                    "sub_points": [
                      "Incorporates ER, PR, Ki-67, and HER2 IHC semiquantitative results",
                      "Results used to calculate risk score using weighting factors and algorithmER₁₀ = H score/30PR₁₀ = percentage of positive cells/10HER2 = 0, 1+, 3+ (2+ cases scored as negative or positive based on FISH)Ki-67 = percentage of positive cells",
                      "ER₁₀ = H score/30",
                      "PR₁₀ = percentage of positive cells/10",
                      "HER2 = 0, 1+, 3+ (2+ cases scored as negative or positive based on FISH)",
                      "Ki-67 = percentage of positive cells",
                      "IHC4 = 94.7 x [-0.1 ER₁₀ - 0.079 PR₁₀ + 0.586 HER2 + 0.24 ln (1 + Ki-67)]"
                    ]
                  },
                  {
                    "text": "Demonstrates prognostic utility similar to Oncotype DX recurrence scoreCombining IHC4 score with clinical and pathologic variables (pN and pT, histologic grade, and patient age) improves prognostic accuracy",
                    "sub_points": [
                      "Combining IHC4 score with clinical and pathologic variables (pN and pT, histologic grade, and patient age) improves prognostic accuracy"
                    ]
                  }
                ],
                "Magee Equations": [
                  {
                    "text": "Multiple scoring systems have been developed to predict the Oncotype DX recurrence score, including the Magee equations"
                  },
                  {
                    "text": "3 Magee equations have been developed"
                  },
                  {
                    "text": "These equations use ER, PR, HER2, Ki-67, and tumor size (see online calculator in \"Selected References\")ER = H scorePR = H scoreHER2 = negative, equivocal (2+ with HER2 gene copies 4 to < 6), positiveNottingham score = 3 to 9Ki-67 = percentage of cellsTumor size (in cm)",
                    "sub_points": [
                      "ER = H score",
                      "PR = H score",
                      "HER2 = negative, equivocal (2+ with HER2 gene copies 4 to < 6), positive",
                      "Nottingham score = 3 to 9",
                      "Ki-67 = percentage of cells",
                      "Tumor size (in cm)"
                    ]
                  },
                  {
                    "text": "e.g., Magee equation 2 = 18.8042 + (Nottingham score x 2.34123) + (ER x -0.03749) + (PR x -0.03065) + (HER2) + (tumor size x 0.04267)60% concordance with Oncotype DX recurrence score57% of results are in intermediate rangeThese cancers could have recurrence scores in low, intermediate, or high rangeWhen these 2 methods give discordant results, it is unknown which one is more predictive",
                    "sub_points": [
                      "60% concordance with Oncotype DX recurrence score57% of results are in intermediate rangeThese cancers could have recurrence scores in low, intermediate, or high rangeWhen these 2 methods give discordant results, it is unknown which one is more predictive",
                      "57% of results are in intermediate rangeThese cancers could have recurrence scores in low, intermediate, or high range",
                      "These cancers could have recurrence scores in low, intermediate, or high range",
                      "When these 2 methods give discordant results, it is unknown which one is more predictive"
                    ]
                  }
                ],
                "Ku-IHC4": [
                  {
                    "text": "Different scoring technique also using ER, PR, HER2, and Ki-67ER = percentage of positive cellsPR = percentage of positive cellsHER2 = 0, 1+, 2+, 3+Ki-67 = percentage of positive cells",
                    "sub_points": [
                      "ER = percentage of positive cells",
                      "PR = percentage of positive cells",
                      "HER2 = 0, 1+, 2+, 3+",
                      "Ki-67 = percentage of positive cells"
                    ]
                  },
                  {
                    "text": "KUIHC4 score = 0.9728 ER + 1.0012 PR + 0.5269 HER2 + 3.9844 Ki-67"
                  },
                  {
                    "text": "Provides prognostic information for relapse at 5 years"
                  }
                ]
              },
              "Special Techniques for Protein Evaluation: Quantitative Assessment": {
                "Image Analysis": [
                  {
                    "text": "IHC studies are analogous to ELISA tests performed in clinical laboratoriesProtein detection chemistry in ELISA test is similar to what is performed for IHCELISA tests are recognized as being quantitativeIHC-stained slides have potential to be quantifiedStrict standardization and quality assurance for all preanalytical and analytical variables are important for meaningful quantitationA number of studies have suggested that the quantitative level of protein expression might be more predictive of sensitivity for targeted therapies",
                    "sub_points": [
                      "Protein detection chemistry in ELISA test is similar to what is performed for IHCELISA tests are recognized as being quantitativeIHC-stained slides have potential to be quantifiedStrict standardization and quality assurance for all preanalytical and analytical variables are important for meaningful quantitation",
                      "ELISA tests are recognized as being quantitative",
                      "IHC-stained slides have potential to be quantified",
                      "Strict standardization and quality assurance for all preanalytical and analytical variables are important for meaningful quantitation",
                      "A number of studies have suggested that the quantitative level of protein expression might be more predictive of sensitivity for targeted therapies"
                    ]
                  },
                  {
                    "text": "Several computerized image analysis applications for IHC quantification have been developedImage analysis systems are commercially available for clinical and research applicationsSome commercially available systems have received clearance from FDA for quantitative assessment of ER, PR, and HER2Computer algorithms can measure IHC localized to nuclear, membrane, and cytoplasmic cellular compartmentsReporting tools integrate picture, graphics, and multiple assay results into clinical reports",
                    "sub_points": [
                      "Image analysis systems are commercially available for clinical and research applicationsSome commercially available systems have received clearance from FDA for quantitative assessment of ER, PR, and HER2",
                      "Some commercially available systems have received clearance from FDA for quantitative assessment of ER, PR, and HER2",
                      "Computer algorithms can measure IHC localized to nuclear, membrane, and cytoplasmic cellular compartmentsReporting tools integrate picture, graphics, and multiple assay results into clinical reports",
                      "Reporting tools integrate picture, graphics, and multiple assay results into clinical reports"
                    ]
                  },
                  {
                    "text": "Computerized image analysis has been shown to provide more accurate and objective ER, PR, and HER2 IHC interpretation relative to manual microscopyAssistance of digital microscopy improves interpathologist reproducibility in numerous reportsMay be helpful in defining clinically relevant thresholds that cannot be accurately detected by the eye",
                    "sub_points": [
                      "Assistance of digital microscopy improves interpathologist reproducibility in numerous reportsMay be helpful in defining clinically relevant thresholds that cannot be accurately detected by the eye",
                      "May be helpful in defining clinically relevant thresholds that cannot be accurately detected by the eye"
                    ]
                  },
                  {
                    "text": "Not yet shown to provide clinically relevant information beyond standard manual interpretation"
                  }
                ],
                "Use of Automated Quantitative Immunofluorescence Analysis (AQUA)": [
                  {
                    "text": "AQUA: Fluorescence-based method that provides objective and continuous protein expression scores in tissueUtilizes automated fluorescence microscopy and advanced image analysis algorithmsMolecular identification of compartments is used to quantify biomarker expression as a function of pixel intensity in specific tissues compartmentsMeasured AQUA scores are directly proportional to molecules per unit area or protein concentrationAssessment of HER2 by AQUA analysis has significant linear relationship with FISHHER2 expression as determined by AQUA analysis predicts response to trastuzumabMay help better define lower levels of HER2 expression required for response to new antibody drug conjugatesQuantitative assessment of ER as continuous variable may be clinically useful",
                    "sub_points": [
                      "Utilizes automated fluorescence microscopy and advanced image analysis algorithmsMolecular identification of compartments is used to quantify biomarker expression as a function of pixel intensity in specific tissues compartmentsMeasured AQUA scores are directly proportional to molecules per unit area or protein concentration",
                      "Molecular identification of compartments is used to quantify biomarker expression as a function of pixel intensity in specific tissues compartments",
                      "Measured AQUA scores are directly proportional to molecules per unit area or protein concentration",
                      "Assessment of HER2 by AQUA analysis has significant linear relationship with FISHHER2 expression as determined by AQUA analysis predicts response to trastuzumabMay help better define lower levels of HER2 expression required for response to new antibody drug conjugates",
                      "HER2 expression as determined by AQUA analysis predicts response to trastuzumab",
                      "May help better define lower levels of HER2 expression required for response to new antibody drug conjugates",
                      "Quantitative assessment of ER as continuous variable may be clinically useful"
                    ]
                  },
                  {
                    "text": "Clinical utility will require that additional information acquired by this technique is shown to be useful for patient management"
                  }
                ],
                "Fluorescent Nanoparticles": [
                  {
                    "text": "Streptavidin-coated phosphor-integrated dot fluorescent nanoparticles (PID) are brightly fluorescent particlesCan be used to quantitatively detect proteins in tissue section where the PID will bind via primary antibody and biotin-labeled secondary antibodyImage-processing method can be used to calculate the number of PID nanoparticlesReadout includes the average PID/cell (PID score/cells) and the average number of PID nanoparticles per unit area (100 μm²)",
                    "sub_points": [
                      "Can be used to quantitatively detect proteins in tissue section where the PID will bind via primary antibody and biotin-labeled secondary antibody",
                      "Image-processing method can be used to calculate the number of PID nanoparticlesReadout includes the average PID/cell (PID score/cells) and the average number of PID nanoparticles per unit area (100 μm²)",
                      "Readout includes the average PID/cell (PID score/cells) and the average number of PID nanoparticles per unit area (100 μm²)"
                    ]
                  },
                  {
                    "text": "PID HER2 quantitative measurements show a strong linear correlation with HER2 ELISA analysis in breast cell lines"
                  },
                  {
                    "text": "PID also showed strong correlations with conventional HER2 testing via IHC and ISH in routine clinical samples"
                  },
                  {
                    "text": "In a HER2 neoadjuvant study, patients with a pathologic complete response (pCR) had a significantly higher PID score compared with patients who did not achieve a pCRPID scores significantly correlated to residual cancer burden (RCB) class (P= 0.026, R2 = 0.9975)",
                    "sub_points": [
                      "PID scores significantly correlated to residual cancer burden (RCB) class (P= 0.026, R2 = 0.9975)"
                    ]
                  },
                  {
                    "text": "As with AQUA, clinical utility will require that additional information acquired by this technique is shown to be useful for patient management"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Expression Profiling: Oncotype DX Assay": {
            "name": "Expression Profiling: Oncotype DX Assay",
            "url": "https://app.pathprimer.com/document/5811dc8f-4d67-4dd9-8ec8-fe017093a9e7/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "ONCOTYPE DX ASSAY FOR INVASIVE CARCINOMA": {
                "Introduction": [
                  {
                    "text": "Oncotype DX recurrence score (RS) is a proprietary 21-gene RT-PCR mRNA-based multigene assayDeveloped through a collaboration between Genomic Health Incorporated and National Surgical Adjuvant Breast and Bowel Project (NSABP)Marketed by Exact Sciences Corporation (https://precisiononcology.exactsciences.com)Utilizes TaqMan (Invitrogen) QRT-PCRPredicts distant recurrence at 10 years and likelihood of benefit of chemotherapy for estrogen receptor (ER)(+) invasive cancersUseful to identify patients who would be offered chemotherapy based on conventional risk factors for recurrence, but a low RS supports that chemotherapy would not improve outcomeClinical risk factors used to favor chemotherapy include large tumor size, lymphovascular invasion, &/or positive lymph nodesSlowly growing, endocrine treatment-responsive cancers are less likely to respond to chemotherapyStudies have shown ~ 1/3 reduction in use of chemotherapy with testingResults in decreased morbidity and costMost widely used prognostic and predictive multigene assay for ER(+) breast carcinoma in USA",
                    "sub_points": [
                      "Developed through a collaboration between Genomic Health Incorporated and National Surgical Adjuvant Breast and Bowel Project (NSABP)Marketed by Exact Sciences Corporation (https://precisiononcology.exactsciences.com)Utilizes TaqMan (Invitrogen) QRT-PCR",
                      "Marketed by Exact Sciences Corporation (https://precisiononcology.exactsciences.com)",
                      "Utilizes TaqMan (Invitrogen) QRT-PCR",
                      "Predicts distant recurrence at 10 years and likelihood of benefit of chemotherapy for estrogen receptor (ER)(+) invasive cancersUseful to identify patients who would be offered chemotherapy based on conventional risk factors for recurrence, but a low RS supports that chemotherapy would not improve outcomeClinical risk factors used to favor chemotherapy include large tumor size, lymphovascular invasion, &/or positive lymph nodesSlowly growing, endocrine treatment-responsive cancers are less likely to respond to chemotherapyStudies have shown ~ 1/3 reduction in use of chemotherapy with testingResults in decreased morbidity and cost",
                      "Useful to identify patients who would be offered chemotherapy based on conventional risk factors for recurrence, but a low RS supports that chemotherapy would not improve outcomeClinical risk factors used to favor chemotherapy include large tumor size, lymphovascular invasion, &/or positive lymph nodesSlowly growing, endocrine treatment-responsive cancers are less likely to respond to chemotherapy",
                      "Clinical risk factors used to favor chemotherapy include large tumor size, lymphovascular invasion, &/or positive lymph nodes",
                      "Slowly growing, endocrine treatment-responsive cancers are less likely to respond to chemotherapy",
                      "Studies have shown ~ 1/3 reduction in use of chemotherapy with testingResults in decreased morbidity and cost",
                      "Results in decreased morbidity and cost",
                      "Most widely used prognostic and predictive multigene assay for ER(+) breast carcinoma in USA"
                    ]
                  },
                  {
                    "text": "Oncotype DX RS is not diagnostic testBenign lesions can have RSs in intermediate-risk rangeLow scores require higher levels of expression of hormone receptors, which are not typically seen in benign lesionsA diagnosis of carcinoma must be made by a pathologist and an appropriate block selected for assay",
                    "sub_points": [
                      "Benign lesions can have RSs in intermediate-risk rangeLow scores require higher levels of expression of hormone receptors, which are not typically seen in benign lesions",
                      "Low scores require higher levels of expression of hormone receptors, which are not typically seen in benign lesions",
                      "A diagnosis of carcinoma must be made by a pathologist and an appropriate block selected for assay"
                    ]
                  }
                ],
                "RS for Invasive Carcinoma": [
                  {
                    "text": "Assay evaluates mRNA from 21 genes16 cancer-related and 5 reference/housekeeping genesHeavily influenced by proliferation-related genes (~ 48% of score), hormone receptor-related genes (~ 16% of score), and HER2-related genes (~ 22% of score)5 reference genes are used to normalize level of expression of cancer-related genesHelps to control for RNA fragmentation, which occurs in formalin-fixed tissueRS ranges from 0-100",
                    "sub_points": [
                      "16 cancer-related and 5 reference/housekeeping genes",
                      "Heavily influenced by proliferation-related genes (~ 48% of score), hormone receptor-related genes (~ 16% of score), and HER2-related genes (~ 22% of score)",
                      "5 reference genes are used to normalize level of expression of cancer-related genesHelps to control for RNA fragmentation, which occurs in formalin-fixed tissue",
                      "Helps to control for RNA fragmentation, which occurs in formalin-fixed tissue",
                      "RS ranges from 0-100"
                    ]
                  },
                  {
                    "text": "Original RS categories3 categories were defined by 10-year risk of distant recurrence if treated with 5 years of tamoxifenLow risk (RS < 18): 7% group average [95% confidence interval (CI) 4-10%]Intermediate risk (RS 18-31): 14% group average (95% CI 8-20%)High risk (RS > 31): 31% group average (95% CI 24-37%)",
                    "sub_points": [
                      "3 categories were defined by 10-year risk of distant recurrence if treated with 5 years of tamoxifenLow risk (RS < 18): 7% group average [95% confidence interval (CI) 4-10%]Intermediate risk (RS 18-31): 14% group average (95% CI 8-20%)High risk (RS > 31): 31% group average (95% CI 24-37%)",
                      "Low risk (RS < 18): 7% group average [95% confidence interval (CI) 4-10%]",
                      "Intermediate risk (RS 18-31): 14% group average (95% CI 8-20%)",
                      "High risk (RS > 31): 31% group average (95% CI 24-37%)"
                    ]
                  },
                  {
                    "text": "Modified RS categoriesGroups have been modified based on TAILORx and NSABP B-20 trials\"Benefit\" is defined by superior distant recurrence-free survival comparing chemoendocrine therapy vs. endocrine therapy alonePatients ≤ 50 years of ageLow risk (RS 0-15): < 1% benefit from chemotherapyIntermediate risk (RS 16-20): ~ 1.6% benefit from chemotherapyPatients in this group at low clinical risk (defined as: ≤ 3 cm tumor size and grade 1; ≤ 2 cm tumor size and grade 2; ≤ 1 cm tumor size and grade 3) did not show benefit with addition of chemotherapyIntermediate risk (RS 21-25): ~ 6.5% benefit from chemotherapyHigh risk (RS 26-100): > 15% benefit from chemotherapyPatients > 50 years of ageLow risk (RS 0-25): < 1% benefit from chemotherapyHigh risk (RS 26-100): > 15% benefit from chemotherapyCut-off points and criteria for determining benefit from chemotherapy may be modified in the future based on results of additional trials",
                    "sub_points": [
                      "Groups have been modified based on TAILORx and NSABP B-20 trials\"Benefit\" is defined by superior distant recurrence-free survival comparing chemoendocrine therapy vs. endocrine therapy alone",
                      "\"Benefit\" is defined by superior distant recurrence-free survival comparing chemoendocrine therapy vs. endocrine therapy alone",
                      "Patients ≤ 50 years of ageLow risk (RS 0-15): < 1% benefit from chemotherapyIntermediate risk (RS 16-20): ~ 1.6% benefit from chemotherapyPatients in this group at low clinical risk (defined as: ≤ 3 cm tumor size and grade 1; ≤ 2 cm tumor size and grade 2; ≤ 1 cm tumor size and grade 3) did not show benefit with addition of chemotherapyIntermediate risk (RS 21-25): ~ 6.5% benefit from chemotherapyHigh risk (RS 26-100): > 15% benefit from chemotherapy",
                      "Low risk (RS 0-15): < 1% benefit from chemotherapy",
                      "Intermediate risk (RS 16-20): ~ 1.6% benefit from chemotherapyPatients in this group at low clinical risk (defined as: ≤ 3 cm tumor size and grade 1; ≤ 2 cm tumor size and grade 2; ≤ 1 cm tumor size and grade 3) did not show benefit with addition of chemotherapy",
                      "Patients in this group at low clinical risk (defined as: ≤ 3 cm tumor size and grade 1; ≤ 2 cm tumor size and grade 2; ≤ 1 cm tumor size and grade 3) did not show benefit with addition of chemotherapy",
                      "Intermediate risk (RS 21-25): ~ 6.5% benefit from chemotherapy",
                      "High risk (RS 26-100): > 15% benefit from chemotherapy",
                      "Patients > 50 years of ageLow risk (RS 0-25): < 1% benefit from chemotherapyHigh risk (RS 26-100): > 15% benefit from chemotherapy",
                      "Low risk (RS 0-25): < 1% benefit from chemotherapy",
                      "High risk (RS 26-100): > 15% benefit from chemotherapy",
                      "Cut-off points and criteria for determining benefit from chemotherapy may be modified in the future based on results of additional trials"
                    ]
                  }
                ],
                "Endorsements": [
                  {
                    "text": "Use of RS to guide management decisions for patients with ER(+)/HER2(-) cancers has been recommended byAmerican Society for Clinical Oncology (ASCO) clinical practice guidelineMay be used to guide decisions on adjuvant endocrine and chemotherapy in postmenopausal or age > 50 patients with 0-3 positive nodes or age ≤ 50 with negative nodeNot recommended for premenopausal women with 1-3 positive nodes; studies have shown a benefit from chemotherapy in this groupIt is unclear if the benefit is due to an effect on the cancer or if the benefit is due to patients becoming postmenopausal due to chemotherapyNot recommended to determining the benefit of extended endocrine therapyNational Comprehensive Cancer Network (NCCN) clinical practice guidelineSt. Gallen consensus panel guidelineEuropean Society for Medical Oncology (ESMO) clinical practice guidelineEuropean Group on Tumor Markers (EGTM) recommendations",
                    "sub_points": [
                      "American Society for Clinical Oncology (ASCO) clinical practice guidelineMay be used to guide decisions on adjuvant endocrine and chemotherapy in postmenopausal or age > 50 patients with 0-3 positive nodes or age ≤ 50 with negative nodeNot recommended for premenopausal women with 1-3 positive nodes; studies have shown a benefit from chemotherapy in this groupIt is unclear if the benefit is due to an effect on the cancer or if the benefit is due to patients becoming postmenopausal due to chemotherapyNot recommended to determining the benefit of extended endocrine therapy",
                      "May be used to guide decisions on adjuvant endocrine and chemotherapy in postmenopausal or age > 50 patients with 0-3 positive nodes or age ≤ 50 with negative node",
                      "Not recommended for premenopausal women with 1-3 positive nodes; studies have shown a benefit from chemotherapy in this groupIt is unclear if the benefit is due to an effect on the cancer or if the benefit is due to patients becoming postmenopausal due to chemotherapy",
                      "It is unclear if the benefit is due to an effect on the cancer or if the benefit is due to patients becoming postmenopausal due to chemotherapy",
                      "Not recommended to determining the benefit of extended endocrine therapy",
                      "National Comprehensive Cancer Network (NCCN) clinical practice guideline",
                      "St. Gallen consensus panel guideline",
                      "European Society for Medical Oncology (ESMO) clinical practice guideline",
                      "European Group on Tumor Markers (EGTM) recommendations"
                    ]
                  }
                ]
              },
              "CLINICAL STUDIES": {
                "Validation for Prognosis": [
                  {
                    "text": "NSABP B-14 clinical trial was used to validate RS for risk of distant recurrence for patients with ER(+) node (-) cancers treated with tamoxifenParaffin blocks from 668 patients from tamoxifen-treated arm from trial were assayedRS was an independent and highly significant predictor of 10-year recurrence-free survivalLow RS: 6.8% risk for recurrenceIntermediate RS: 14.3% risk for recurrenceHigh RS: 30.5% risk for recurrenceIn multivariate analysis, only tumor grade and RS were independent predictors of outcomeTumor grade showed higher hazard ratio than RS for predicting disease recurrence~ 50% of cancers had low RS",
                    "sub_points": [
                      "Paraffin blocks from 668 patients from tamoxifen-treated arm from trial were assayed",
                      "RS was an independent and highly significant predictor of 10-year recurrence-free survivalLow RS: 6.8% risk for recurrenceIntermediate RS: 14.3% risk for recurrenceHigh RS: 30.5% risk for recurrence",
                      "Low RS: 6.8% risk for recurrence",
                      "Intermediate RS: 14.3% risk for recurrence",
                      "High RS: 30.5% risk for recurrence",
                      "In multivariate analysis, only tumor grade and RS were independent predictors of outcomeTumor grade showed higher hazard ratio than RS for predicting disease recurrence",
                      "Tumor grade showed higher hazard ratio than RS for predicting disease recurrence",
                      "~ 50% of cancers had low RS"
                    ]
                  }
                ],
                "Validation for Prediction": [
                  {
                    "text": "NSABP B-20 clinical trial was used to validate RS for prediction of benefit of chemotherapyThis trial examined the benefit of adding chemotherapy to tamoxifen for ER(+) node (-) breast carcinoma patients",
                    "sub_points": [
                      "This trial examined the benefit of adding chemotherapy to tamoxifen for ER(+) node (-) breast carcinoma patients"
                    ]
                  },
                  {
                    "text": "Patients were randomized to receive tamoxifen alone or tamoxifen and chemotherapyCancers with high RS received the greatest benefit from addition of chemotherapyCancers with low RS did not receive any additional benefit from adding chemotherapy to their endocrine treatmentBenefit for chemotherapy for patients whose cancers had intermediate RS was less clear",
                    "sub_points": [
                      "Cancers with high RS received the greatest benefit from addition of chemotherapy",
                      "Cancers with low RS did not receive any additional benefit from adding chemotherapy to their endocrine treatment",
                      "Benefit for chemotherapy for patients whose cancers had intermediate RS was less clear"
                    ]
                  },
                  {
                    "text": "Access to paraffin blocks from this trial has been a major advantage for Oncotype DX assay compared to other multigene assaysProvided for direct evaluation of prediction of benefit of chemotherapy in a randomized study",
                    "sub_points": [
                      "Provided for direct evaluation of prediction of benefit of chemotherapy in a randomized study"
                    ]
                  }
                ],
                "Validation for Node (+) Patients": [
                  {
                    "text": "SWOG 8814 clinical trial was used to validate RS for postmenopausal women with ER(+) node (+) cancersBenefit from chemotherapy added to tamoxifen was not seen in low RS group; benefit also not seen in cancers with high ER (Allred score 7 or 8) and HER2(-)Benefit from chemotherapy added to tamoxifen was found in high RS group",
                    "sub_points": [
                      "Benefit from chemotherapy added to tamoxifen was not seen in low RS group; benefit also not seen in cancers with high ER (Allred score 7 or 8) and HER2(-)",
                      "Benefit from chemotherapy added to tamoxifen was found in high RS group"
                    ]
                  },
                  {
                    "text": "Arimidex, tamoxifen, alone or in combination (ATAC) clinical trial was used to validate RS for postmenopausal women with ER(+) node (+) or (-) cancersRS was predictive of distant recurrence for cancers treated with endocrine therapy in both node (+) and (-) groups",
                    "sub_points": [
                      "RS was predictive of distant recurrence for cancers treated with endocrine therapy in both node (+) and (-) groups"
                    ]
                  }
                ],
                "Prospective Trials": [
                  {
                    "text": "Trial assigning individualized options for treatment Rx (TAILORx)Women with ER(+)/HER2(-) node (-) cancers with RS between 11-25 were eligibleRandomized to chemotherapy and endocrine therapy or only endocrine therapyFor entire group, endocrine therapy was equivalent to chemotherapy and endocrine therapyFor women > 50 years of age, there was no benefit to chemotherapyThere was some benefit for women < 50 years of age whose cancers had scores between 16-25",
                    "sub_points": [
                      "Women with ER(+)/HER2(-) node (-) cancers with RS between 11-25 were eligible",
                      "Randomized to chemotherapy and endocrine therapy or only endocrine therapy",
                      "For entire group, endocrine therapy was equivalent to chemotherapy and endocrine therapyFor women > 50 years of age, there was no benefit to chemotherapyThere was some benefit for women < 50 years of age whose cancers had scores between 16-25",
                      "For women > 50 years of age, there was no benefit to chemotherapy",
                      "There was some benefit for women < 50 years of age whose cancers had scores between 16-25"
                    ]
                  },
                  {
                    "text": "Rx for positive node endocrine responsive trial (RxPONDER; SWOG S1007)Women with ER(+)/HER2(-) cancers with RS ≤ 25 and 1-3 positive nodes were eligible5,018 women enrolled (33.2% premenopausal, 66.8% postmenopausal)Randomized to chemotherapy and endocrine therapy or to only endocrine therapyPostmenopausal women, no additional benefit of adjuvant chemotherapy with RS 25 or lowerRegardless of 1 vs. 2-3 involved nodes or range of RS (0-13 vs. 14-25)Suggests chemotherapy can safely be omitted for postmenopausal women with 1-3 positive nodes, RS < 25Premenopausal women, improved disease-free survival with adjuvant chemotherapy, regardless of RS or nodal involvement (1 vs. 2-3)Remains unclear whether adjuvant chemotherapy adds benefit to that of optimal endocrine therapy with ovarian suppressionUpdated guidelines, RS should be offered to postmenopausal women with ER(+)/HER2(-), 1-3 positive nodes to guide decisions regarding adjuvant treatmentRS should not be offered or used to guide systemic therapy in premenopausal women at this timeInsufficient evidence for use of RS for treatment guidance among patients with 4 or more positive nodes",
                    "sub_points": [
                      "Women with ER(+)/HER2(-) cancers with RS ≤ 25 and 1-3 positive nodes were eligible5,018 women enrolled (33.2% premenopausal, 66.8% postmenopausal)",
                      "5,018 women enrolled (33.2% premenopausal, 66.8% postmenopausal)",
                      "Randomized to chemotherapy and endocrine therapy or to only endocrine therapy",
                      "Postmenopausal women, no additional benefit of adjuvant chemotherapy with RS 25 or lowerRegardless of 1 vs. 2-3 involved nodes or range of RS (0-13 vs. 14-25)Suggests chemotherapy can safely be omitted for postmenopausal women with 1-3 positive nodes, RS < 25",
                      "Regardless of 1 vs. 2-3 involved nodes or range of RS (0-13 vs. 14-25)",
                      "Suggests chemotherapy can safely be omitted for postmenopausal women with 1-3 positive nodes, RS < 25",
                      "Premenopausal women, improved disease-free survival with adjuvant chemotherapy, regardless of RS or nodal involvement (1 vs. 2-3)Remains unclear whether adjuvant chemotherapy adds benefit to that of optimal endocrine therapy with ovarian suppression",
                      "Remains unclear whether adjuvant chemotherapy adds benefit to that of optimal endocrine therapy with ovarian suppression",
                      "Updated guidelines, RS should be offered to postmenopausal women with ER(+)/HER2(-), 1-3 positive nodes to guide decisions regarding adjuvant treatmentRS should not be offered or used to guide systemic therapy in premenopausal women at this time",
                      "RS should not be offered or used to guide systemic therapy in premenopausal women at this time",
                      "Insufficient evidence for use of RS for treatment guidance among patients with 4 or more positive nodes"
                    ]
                  }
                ]
              },
              "ONCOTYPE DX SINGLE-GENE SCORES": {
                "Scores for ER, PR, and HER2": [
                  {
                    "text": "Single-gene scores (SGS) for ER, progesterone receptor (PR), and HER2 are provided as part of RS assayThese scores are not intended to supplant conventional testing (CT)Results from CT should be used for treatment-related decisions",
                    "sub_points": [
                      "These scores are not intended to supplant conventional testing (CT)",
                      "Results from CT should be used for treatment-related decisions"
                    ]
                  },
                  {
                    "text": "Discrepant results between SGS and CT are important to note and resolveIf SGS is incorrect and CT is correct, RS score may not reflect biology of tumorIf SGS is correct and CT is incorrect, the problem in testing should be investigated",
                    "sub_points": [
                      "If SGS is incorrect and CT is correct, RS score may not reflect biology of tumor",
                      "If SGS is correct and CT is incorrect, the problem in testing should be investigated"
                    ]
                  },
                  {
                    "text": "Discrepancies may occur because gene expression profiling results are averaged over an area that includes benign cells and ductal carcinoma in situ (DCIS)Low cellularity carcinomas (e.g., lobular carcinoma) may only constitute a small number of the total cells evaluatedA block with a small cancer with a large biopsy site can include more benign cells than tumor cellsCellular biopsy sites can contribute mitotically active stromal and inflammatory cells that are ER/PR(-)In rare cases, DCIS can express hormone receptors or HER2 but invasive carcinoma does not",
                    "sub_points": [
                      "Low cellularity carcinomas (e.g., lobular carcinoma) may only constitute a small number of the total cells evaluated",
                      "A block with a small cancer with a large biopsy site can include more benign cells than tumor cells",
                      "Cellular biopsy sites can contribute mitotically active stromal and inflammatory cells that are ER/PR(-)",
                      "In rare cases, DCIS can express hormone receptors or HER2 but invasive carcinoma does not"
                    ]
                  },
                  {
                    "text": "In contrast, CT evaluates only tumor cells and identifies subcellular locationStromal and inflammatory cells are excluded",
                    "sub_points": [
                      "Stromal and inflammatory cells are excluded"
                    ]
                  }
                ],
                "Estrogen Receptor": [
                  {
                    "text": "RS assay is only applicable for ER(+) cancers; therefore, ER score should always be positive"
                  },
                  {
                    "text": "~ 99% concordance with CT"
                  },
                  {
                    "text": "In rare discordant cases, immunohistochemical (IHC) assay is generally correct"
                  }
                ],
                "Progesterone Receptor": [
                  {
                    "text": "~ 94% concordance with CT"
                  },
                  {
                    "text": "In discordant cases, positive result by CT is generally correct result and shows low expression of PR"
                  }
                ],
                "HER2": [
                  {
                    "text": "HER2(+) cancers are rarely sent for RS, as chemotherapy is generally recommended"
                  },
                  {
                    "text": "Some cancers classified as HER2(+) by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are negative by SGSExact number has varied in different studies",
                    "sub_points": [
                      "Exact number has varied in different studies"
                    ]
                  },
                  {
                    "text": "Discrepant results may be due to multiple factorsTumor heterogeneity: Different blocks or areas of carcinoma may be testedIn ER(+) cancers, HER2 expression is often at low levels and can be heterogeneousCancer-specific variation in gene number, mRNA quantity, and protein expressionInclusion of nontumor elements in sample used for mRNA assayLow level of expression averaged over tumor and stromaDiscordant expression between DCIS and invasive carcinoma",
                    "sub_points": [
                      "Tumor heterogeneity: Different blocks or areas of carcinoma may be testedIn ER(+) cancers, HER2 expression is often at low levels and can be heterogeneous",
                      "In ER(+) cancers, HER2 expression is often at low levels and can be heterogeneous",
                      "Cancer-specific variation in gene number, mRNA quantity, and protein expression",
                      "Inclusion of nontumor elements in sample used for mRNA assay",
                      "Low level of expression averaged over tumor and stroma",
                      "Discordant expression between DCIS and invasive carcinoma"
                    ]
                  },
                  {
                    "text": "ASCO/CAP guidelines for HER2 testing recommend IHC and FISH but not mRNA-based assaysNegative SGS does not alter prior classification as HER2(+)",
                    "sub_points": [
                      "Negative SGS does not alter prior classification as HER2(+)"
                    ]
                  }
                ]
              },
              "RS: PATHOLOGY-CLINICAL (RSPC)": {
                "Combining RS With Clinical Factors": [
                  {
                    "text": "More accurate determination of risk of recurrence (ROR) can be obtained by combining RS with clinical factorsRSPC is based on reanalysis of trial data from NSABP B-14, B-20, and TransATACIncorporates RS, patient age, tumor size, and tumor grade to predict 10-year RORMay have more prognostic value than just RS",
                    "sub_points": [
                      "RSPC is based on reanalysis of trial data from NSABP B-14, B-20, and TransATAC",
                      "Incorporates RS, patient age, tumor size, and tumor grade to predict 10-year ROR",
                      "May have more prognostic value than just RS"
                    ]
                  },
                  {
                    "text": "Calculator is available on the Oncotype DX websiteCalculator is provided for educational purposes",
                    "sub_points": [
                      "Calculator is provided for educational purposes"
                    ]
                  },
                  {
                    "text": "RSPC vs. RSRSPC may be higher or lower than RSRSPC is not as predictive of benefit from chemotherapy compared to RSTherefore, if RSPC is higher than RS, this result has not been shown to predict benefit from chemotherapy",
                    "sub_points": [
                      "RSPC may be higher or lower than RS",
                      "RSPC is not as predictive of benefit from chemotherapy compared to RS",
                      "Therefore, if RSPC is higher than RS, this result has not been shown to predict benefit from chemotherapy"
                    ]
                  }
                ]
              },
              "COMPARISON TO OTHER ASSAYS": {
                "Genes Included in Assays": [
                  {
                    "text": "RS shares some genes in common with other assaysProsigna ROR (11 genes):ESR1(ER),PGR(PR),ERBB2(HER2),MKI67(Ki-67),BIRC5,CCNB1,MYBL2,MMP11,GRB7,BCL2,BAG1MammaPrint (1 gene):SCUBE2EndoPredict (EP) (1 gene):BIRC5",
                    "sub_points": [
                      "Prosigna ROR (11 genes):ESR1(ER),PGR(PR),ERBB2(HER2),MKI67(Ki-67),BIRC5,CCNB1,MYBL2,MMP11,GRB7,BCL2,BAG1",
                      "MammaPrint (1 gene):SCUBE2",
                      "EndoPredict (EP) (1 gene):BIRC5"
                    ]
                  }
                ],
                "Concordance of RS With Other Assays": [
                  {
                    "text": "Multigene assays evaluate similar sets of genes, but they do not provide equivalent results for all patientsIt is important to distinguish use of results for prognosis/recurrence (which may be improved by adding additional features, such as tumor size) vs. using results for prediction of benefit from chemotherapy (which may not be improved by adding additional features)",
                    "sub_points": [
                      "It is important to distinguish use of results for prognosis/recurrence (which may be improved by adding additional features, such as tumor size) vs. using results for prediction of benefit from chemotherapy (which may not be improved by adding additional features)"
                    ]
                  },
                  {
                    "text": "OPTIMA prelim trialDetermined Oncotype DX RS, Prosigna ROR, and MammaPrint on 313 ER(+)/HER2(-) on cancers that were either ≥ 3 cm or associated with 1-9 positive nodesRS and MammaPrint assigned 74% of patients to same risk category (low/intermediate vs. high)For patients with intermediate RS, other studies have shown that ~ 45% are low risk and ~ 55% are high risk by MammaPrintRS and Prosigna ROR assigned 77.5% of patients to same risk category (low/intermediate vs. high)",
                    "sub_points": [
                      "Determined Oncotype DX RS, Prosigna ROR, and MammaPrint on 313 ER(+)/HER2(-) on cancers that were either ≥ 3 cm or associated with 1-9 positive nodes",
                      "RS and MammaPrint assigned 74% of patients to same risk category (low/intermediate vs. high)For patients with intermediate RS, other studies have shown that ~ 45% are low risk and ~ 55% are high risk by MammaPrint",
                      "For patients with intermediate RS, other studies have shown that ~ 45% are low risk and ~ 55% are high risk by MammaPrint",
                      "RS and Prosigna ROR assigned 77.5% of patients to same risk category (low/intermediate vs. high)"
                    ]
                  },
                  {
                    "text": "RS vs. EndoPredict (EP) Clinical(EPclin) risk scoreCancers from 928 patients treated with anastrozole or tamoxifen for 5 years were evaluated by both assays~ 13% of cancers were EPclin low but RS intermediate/high~ 16% of cancers were EPclin high but RS lowEPclin provided more prognostic information than RSThis result was interpreted to be at least partly due to inclusion of tumor size and nodal status in EPclinBetter comparison may be RS vs. EP score or RSPC vs. EPclin",
                    "sub_points": [
                      "Cancers from 928 patients treated with anastrozole or tamoxifen for 5 years were evaluated by both assays~ 13% of cancers were EPclin low but RS intermediate/high~ 16% of cancers were EPclin high but RS low",
                      "~ 13% of cancers were EPclin low but RS intermediate/high",
                      "~ 16% of cancers were EPclin high but RS low",
                      "EPclin provided more prognostic information than RSThis result was interpreted to be at least partly due to inclusion of tumor size and nodal status in EPclinBetter comparison may be RS vs. EP score or RSPC vs. EPclin",
                      "This result was interpreted to be at least partly due to inclusion of tumor size and nodal status in EPclin",
                      "Better comparison may be RS vs. EP score or RSPC vs. EPclin"
                    ]
                  },
                  {
                    "text": "RS vs. Prosigna RORBoth assays performed on 52 ER(+)/HER2(-) node (-) cancersThere was 53.8% concordance (low, intermediate, or high risk)Of 7 cancers classified as high risk by ROR, 4 were classified as low risk by RSThese cancers had high ER levelsOf 3 cancers classified as high risk by RS, 1 was classified as low, 1 as intermediate, and 1 as high risk by Prosigna ROR2 cancers classified as low or intermediate risk had low ER levelsProsigna includes tumor sizeBetter comparison may be RSPC vs. Prosigna ROR",
                    "sub_points": [
                      "Both assays performed on 52 ER(+)/HER2(-) node (-) cancers",
                      "There was 53.8% concordance (low, intermediate, or high risk)Of 7 cancers classified as high risk by ROR, 4 were classified as low risk by RSThese cancers had high ER levelsOf 3 cancers classified as high risk by RS, 1 was classified as low, 1 as intermediate, and 1 as high risk by Prosigna ROR2 cancers classified as low or intermediate risk had low ER levels",
                      "Of 7 cancers classified as high risk by ROR, 4 were classified as low risk by RSThese cancers had high ER levels",
                      "These cancers had high ER levels",
                      "Of 3 cancers classified as high risk by RS, 1 was classified as low, 1 as intermediate, and 1 as high risk by Prosigna ROR2 cancers classified as low or intermediate risk had low ER levels",
                      "2 cancers classified as low or intermediate risk had low ER levels",
                      "Prosigna includes tumor sizeBetter comparison may be RSPC vs. Prosigna ROR",
                      "Better comparison may be RSPC vs. Prosigna ROR"
                    ]
                  },
                  {
                    "text": "Oncotype DX, Prosigna, EP, andBreast Cancer Index (BCI)These assays were compared in the TransATAC studyOncotype DX RS was found to be more influenced by estrogen-related genes, whereas Prosigna ROR, EP, and BCI were more influenced by proliferation-related genesIt is possible this could explain why RS shows a lower correlation with prognosis after 5 years as compared to the other assays",
                    "sub_points": [
                      "These assays were compared in the TransATAC study",
                      "Oncotype DX RS was found to be more influenced by estrogen-related genes, whereas Prosigna ROR, EP, and BCI were more influenced by proliferation-related genes",
                      "It is possible this could explain why RS shows a lower correlation with prognosis after 5 years as compared to the other assays"
                    ]
                  }
                ]
              },
              "REQUIREMENTS FOR TESTING": {
                "Patient Selection": [
                  {
                    "text": "Any case of DCIS treated with breast-conserving therapy is eligible for testingPatients undergoing mastectomy would not be eligibleCases with positive margins should not be eligible",
                    "sub_points": [
                      "Patients undergoing mastectomy would not be eligible",
                      "Cases with positive margins should not be eligible"
                    ]
                  },
                  {
                    "text": "However, reliability of score in cases of DCIS with features not well represented in validation cohorts is less certainDCIS > 2.5 cm: Not included in original validation study and likely underrepresented in Ontario cohortAverage extent of DCIS for all patients is ~ 3 cmFew cases of ER(-) DCIS includedFew cases of HER2(+) DCIS includedBecause test does not factor in a number of important predictive factors, it may not be valid for patients outside of enrollment criteria for the clinical trial",
                    "sub_points": [
                      "DCIS > 2.5 cm: Not included in original validation study and likely underrepresented in Ontario cohortAverage extent of DCIS for all patients is ~ 3 cm",
                      "Average extent of DCIS for all patients is ~ 3 cm",
                      "Few cases of ER(-) DCIS included",
                      "Few cases of HER2(+) DCIS included",
                      "Because test does not factor in a number of important predictive factors, it may not be valid for patients outside of enrollment criteria for the clinical trial"
                    ]
                  }
                ],
                "Specimen Selection and Tissue Requirements": [
                  {
                    "text": "Similar to specimens sent for Oncotype DX RS for invasive carcinoma"
                  }
                ]
              },
              "PREDICTION OF ONCOTYPE DX RS": {
                "Using Routinely Determined Information": [
                  {
                    "text": "Because RS incorporates ER, PR, HER2, and proliferation (which are also routinely determined for all invasive cancers), this information can be used to predict RS"
                  },
                  {
                    "text": "Cancers very likely to have low or high RS can be identifiedGrade 1 cancers ER and PR (+) and HER2(-) are very unlikely to have high RS (< 1%)Carcinomas of favorable histology are unlikely to have high RS (tubular, mucinous, cribriform, lobular)Grade 3, PR(-) cancers are likely to have high RSHER2(+) cancers are very likely to have high RS",
                    "sub_points": [
                      "Grade 1 cancers ER and PR (+) and HER2(-) are very unlikely to have high RS (< 1%)",
                      "Carcinomas of favorable histology are unlikely to have high RS (tubular, mucinous, cribriform, lobular)",
                      "Grade 3, PR(-) cancers are likely to have high RS",
                      "HER2(+) cancers are very likely to have high RS"
                    ]
                  },
                  {
                    "text": "It may not be necessary to obtain RS to make treatment decisions in some groups"
                  },
                  {
                    "text": "If RS appears discordant with the expected result based on pathologic features, possibility of error in some component of testing should be considered"
                  }
                ],
                "Weighted Equations to Predict RS": [
                  {
                    "text": "Equations have been developed to attempt to predict RSValues for ER, PR, HER2, proliferation (Ki-67 or mitotic score) are included in a weighted equationSome equations also include tumor size, components of grade, node status; these models may have greater prognostic power for ROR but less predictive power for the benefit of chemotherapy",
                    "sub_points": [
                      "Values for ER, PR, HER2, proliferation (Ki-67 or mitotic score) are included in a weighted equation",
                      "Some equations also include tumor size, components of grade, node status; these models may have greater prognostic power for ROR but less predictive power for the benefit of chemotherapy"
                    ]
                  },
                  {
                    "text": "Calculated score is in same category (low, intermediate, or high) as actual RS in ~ 2/3 of casesCancers with low calculated score are very unlikely to have actual high RSGrade 1, high PR, low proliferation; ~ 75% low score, none with high scoreCancers with high calculated score are very unlikely to have actual low RSGrade 3, low or absent PR, high proliferation; ~ 80% high score, none with low score",
                    "sub_points": [
                      "Cancers with low calculated score are very unlikely to have actual high RSGrade 1, high PR, low proliferation; ~ 75% low score, none with high score",
                      "Grade 1, high PR, low proliferation; ~ 75% low score, none with high score",
                      "Cancers with high calculated score are very unlikely to have actual low RSGrade 3, low or absent PR, high proliferation; ~ 80% high score, none with low score",
                      "Grade 3, low or absent PR, high proliferation; ~ 80% high score, none with low score"
                    ]
                  },
                  {
                    "text": "~ 1/3 of cancers have intermediate calculated scoreActual RS can be low or high",
                    "sub_points": [
                      "Actual RS can be low or high"
                    ]
                  },
                  {
                    "text": "When calculated score is different from actual RS, it is unknown which score is more predictive of ultimate outcome"
                  }
                ]
              },
              "AJCC 8TH EDITION CANCER STAGING": {
                "Multigene Assays and Breast Cancer Staging": [
                  {
                    "text": "Both anatomic stage and biologic type of cancer provide important prognostic informationAnatomic stage: Tumor (T), node (N), and metastasis (M)Biologic type: Grade, ER, PR, and HER2",
                    "sub_points": [
                      "Anatomic stage: Tumor (T), node (N), and metastasis (M)",
                      "Biologic type: Grade, ER, PR, and HER2"
                    ]
                  },
                  {
                    "text": "In the American Joint Committee on Cancer (AJCC), 8th edition (in effect on 1/1/2018), anatomic stage is combined with biologic type for 1st timeMultigene assay can also be incorporated for subset of patientsThe Union for International Cancer Control (UICC) did not adopt this system and continues to use anatomic stage",
                    "sub_points": [
                      "Multigene assay can also be incorporated for subset of patients",
                      "The Union for International Cancer Control (UICC) did not adopt this system and continues to use anatomic stage"
                    ]
                  },
                  {
                    "text": "There are 2 new systems of defining stagePathologic prognostic stage: Only applies to patients who have undergone surgery as their 1st treatmentpT, pN, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 & IVMultigene assay can be included, if availableAssay is not required for stagingOnly applicable to T1-T2, N0, cM0, ER(+), and HER2(-) cancersPathologic Prognostic Stage group IA is assigned if Oncotype DX RS is < 11AJCC panel suggests other multigene assays may be included in staging in futureClinical prognostic stage: Applicable to all patientsPatients who have undergone surgery as their 1st treatment, patients who have not undergone surgery, who are not eligible for surgery, and patients who have received neoadjuvant therapyT, N, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IVMultigene assay is not included because it may not be possible to determine T and N with certainty",
                    "sub_points": [
                      "Pathologic prognostic stage: Only applies to patients who have undergone surgery as their 1st treatmentpT, pN, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 & IVMultigene assay can be included, if availableAssay is not required for stagingOnly applicable to T1-T2, N0, cM0, ER(+), and HER2(-) cancersPathologic Prognostic Stage group IA is assigned if Oncotype DX RS is < 11AJCC panel suggests other multigene assays may be included in staging in future",
                      "pT, pN, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 & IV",
                      "Biologic type is not used to determine stages 0 & IV",
                      "Multigene assay can be included, if availableAssay is not required for stagingOnly applicable to T1-T2, N0, cM0, ER(+), and HER2(-) cancersPathologic Prognostic Stage group IA is assigned if Oncotype DX RS is < 11",
                      "Assay is not required for staging",
                      "Only applicable to T1-T2, N0, cM0, ER(+), and HER2(-) cancers",
                      "Pathologic Prognostic Stage group IA is assigned if Oncotype DX RS is < 11",
                      "AJCC panel suggests other multigene assays may be included in staging in future",
                      "Clinical prognostic stage: Applicable to all patientsPatients who have undergone surgery as their 1st treatment, patients who have not undergone surgery, who are not eligible for surgery, and patients who have received neoadjuvant therapyT, N, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IVMultigene assay is not included because it may not be possible to determine T and N with certainty",
                      "Patients who have undergone surgery as their 1st treatment, patients who have not undergone surgery, who are not eligible for surgery, and patients who have received neoadjuvant therapyT, N, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IV",
                      "T, N, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and III",
                      "Biologic type is not used to determine stages 0 and IV",
                      "Multigene assay is not included because it may not be possible to determine T and N with certainty"
                    ]
                  }
                ]
              },
              "ONCOTYPE DX FOR DCIS": {
                "Development of Score": [
                  {
                    "text": "Modification of Oncotype DX assay for invasive carcinoma"
                  },
                  {
                    "text": "Predicts likelihood of ipsilateral recurrence of DCIS after surgery without radiation therapy (XRT)Value is to identify patients who may not require XRTStudy showed that recommendations for XRT may change for ~ 30% of patients with overall reduction in XRT use",
                    "sub_points": [
                      "Value is to identify patients who may not require XRT",
                      "Study showed that recommendations for XRT may change for ~ 30% of patients with overall reduction in XRT use"
                    ]
                  },
                  {
                    "text": "12 of 21 genes used for invasive carcinoma assay are included (7 cancer-related and 5 reference genes)PGR,GSTM1,MKI67(Ki-67),AURKA(STK15),BIRC5,CCNB1,MYBL2ExcludesESR1group and invasion group",
                    "sub_points": [
                      "PGR,GSTM1,MKI67(Ki-67),AURKA(STK15),BIRC5,CCNB1,MYBL2ExcludesESR1group and invasion group",
                      "ExcludesESR1group and invasion group"
                    ]
                  },
                  {
                    "text": "Weighted values are used to determine DCIS scoreDCIS RS = + 0.31 proliferation group - 0.08 PR - 0.9 GSTM1",
                    "sub_points": [
                      "DCIS RS = + 0.31 proliferation group - 0.08 PR - 0.9 GSTM1"
                    ]
                  },
                  {
                    "text": "Results are grouped into low, intermediate, and high scores"
                  },
                  {
                    "text": "SGS are provided for ER and PR"
                  }
                ],
                "Clinical Studies": [
                  {
                    "text": "ECOG 5194 was used to validate assayTrial included patients with DCIS treated with surgical excision without XRT (could receive tamoxifen)Specimens had to be completely sequentially sampled to determine extent and marginsPatient and tumor characteristics79.8% ≥ 50 years of age, 33.9% high nuclear grade97.2% ER(+) [only 9 ER(-) cases]85.6% HER2(-) [only 25 HER2(+) cases]2 arms to study in this trialLow to intermediate grade: Extent ≤ 2.5 cmIpsilateral recurrence at 10 years: 14.6%High grade: Extent ≤ 1 cmIpsilateral recurrence at 10 years: 19.0%Margins had to be ≥ 0.3 cm50% had margins > 1 cm48.5% had negative reexcisionsAfter surgery, no residual mammographic calcifications could be present327 cases (49% of study cases) were used for Oncotype DX assay to correlate with 10-year risk of ipsilateral recurrenceLow risk (75% of cases), 10.6% risk of any recurrence, 3.7% risk of invasive recurrenceIntermediate risk (14% of cases), 26.7% risk of any recurrence, 12.3% risk of invasive recurrenceHigh risk (11% of cases), 25.9% risk of any recurrence, 19.2% risk of invasive recurrenceIn multivariate analysis, DCIS score, extent of DCIS (tumor size), and menopausal status were independently associated with recurrence riskGreater extent was associated with higher riskPremenopausal women had higher riskNuclear grade was not associated with increased riskDCIS score is not predictive of contralateral recurrence",
                    "sub_points": [
                      "Trial included patients with DCIS treated with surgical excision without XRT (could receive tamoxifen)",
                      "Specimens had to be completely sequentially sampled to determine extent and margins",
                      "Patient and tumor characteristics79.8% ≥ 50 years of age, 33.9% high nuclear grade97.2% ER(+) [only 9 ER(-) cases]85.6% HER2(-) [only 25 HER2(+) cases]",
                      "79.8% ≥ 50 years of age, 33.9% high nuclear grade",
                      "97.2% ER(+) [only 9 ER(-) cases]",
                      "85.6% HER2(-) [only 25 HER2(+) cases]",
                      "2 arms to study in this trialLow to intermediate grade: Extent ≤ 2.5 cmIpsilateral recurrence at 10 years: 14.6%High grade: Extent ≤ 1 cmIpsilateral recurrence at 10 years: 19.0%",
                      "Low to intermediate grade: Extent ≤ 2.5 cmIpsilateral recurrence at 10 years: 14.6%",
                      "Ipsilateral recurrence at 10 years: 14.6%",
                      "High grade: Extent ≤ 1 cmIpsilateral recurrence at 10 years: 19.0%",
                      "Ipsilateral recurrence at 10 years: 19.0%",
                      "Margins had to be ≥ 0.3 cm50% had margins > 1 cm48.5% had negative reexcisions",
                      "50% had margins > 1 cm",
                      "48.5% had negative reexcisions",
                      "After surgery, no residual mammographic calcifications could be present",
                      "327 cases (49% of study cases) were used for Oncotype DX assay to correlate with 10-year risk of ipsilateral recurrenceLow risk (75% of cases), 10.6% risk of any recurrence, 3.7% risk of invasive recurrenceIntermediate risk (14% of cases), 26.7% risk of any recurrence, 12.3% risk of invasive recurrenceHigh risk (11% of cases), 25.9% risk of any recurrence, 19.2% risk of invasive recurrence",
                      "Low risk (75% of cases), 10.6% risk of any recurrence, 3.7% risk of invasive recurrence",
                      "Intermediate risk (14% of cases), 26.7% risk of any recurrence, 12.3% risk of invasive recurrence",
                      "High risk (11% of cases), 25.9% risk of any recurrence, 19.2% risk of invasive recurrence",
                      "In multivariate analysis, DCIS score, extent of DCIS (tumor size), and menopausal status were independently associated with recurrence riskGreater extent was associated with higher riskPremenopausal women had higher riskNuclear grade was not associated with increased risk",
                      "Greater extent was associated with higher risk",
                      "Premenopausal women had higher risk",
                      "Nuclear grade was not associated with increased risk",
                      "DCIS score is not predictive of contralateral recurrence"
                    ]
                  },
                  {
                    "text": "Ontario Cohort was used to validate assay571 cases of DCIS treated with surgery alone with negative margins80.7% ≥ 50 years of age32.2% high nuclear grade94.7% ER(+)17.5% HER2(+)24.5% > 10 mm45% margins 1-3 mm17.5% had local recurrence during median follow-up of 9.6 years57% of recurrences were invasive carcinomaDCIS score was associated with ROR at 10 yearsLow risk (62.2% of patients)12.7% risk of any recurrence8.0% risk of invasive recurrenceIntermediate risk (16.6% of patients)33.0% risk of any recurrence20.9% risk of invasive recurrenceHigh risk (21.2% of patients)27.8% risk of any recurrence15.5% risk of invasive recurrence",
                    "sub_points": [
                      "571 cases of DCIS treated with surgery alone with negative margins80.7% ≥ 50 years of age32.2% high nuclear grade94.7% ER(+)17.5% HER2(+)24.5% > 10 mm45% margins 1-3 mm",
                      "80.7% ≥ 50 years of age",
                      "32.2% high nuclear grade",
                      "94.7% ER(+)",
                      "17.5% HER2(+)",
                      "24.5% > 10 mm",
                      "45% margins 1-3 mm",
                      "17.5% had local recurrence during median follow-up of 9.6 years57% of recurrences were invasive carcinoma",
                      "57% of recurrences were invasive carcinoma",
                      "DCIS score was associated with ROR at 10 yearsLow risk (62.2% of patients)12.7% risk of any recurrence8.0% risk of invasive recurrenceIntermediate risk (16.6% of patients)33.0% risk of any recurrence20.9% risk of invasive recurrenceHigh risk (21.2% of patients)27.8% risk of any recurrence15.5% risk of invasive recurrence",
                      "Low risk (62.2% of patients)12.7% risk of any recurrence8.0% risk of invasive recurrence",
                      "12.7% risk of any recurrence",
                      "8.0% risk of invasive recurrence",
                      "Intermediate risk (16.6% of patients)33.0% risk of any recurrence20.9% risk of invasive recurrence",
                      "33.0% risk of any recurrence",
                      "20.9% risk of invasive recurrence",
                      "High risk (21.2% of patients)27.8% risk of any recurrence15.5% risk of invasive recurrence",
                      "27.8% risk of any recurrence",
                      "15.5% risk of invasive recurrence"
                    ]
                  }
                ]
              },
              "PREDICTION OF ONCOTYPE DX DCIS RS": {
                "Calculated DCIS RS": [
                  {
                    "text": "PR and mitotic rate (both used in DCIS score) can be determined in routine pathologic practice"
                  },
                  {
                    "text": "In one study, these values and presence of associated lymphocytic infiltrate were correlated with DCIS scoreBlock sent for assay was assessed for these featuresNumber of mitotic figures was counted for all areas of DCIS present in slidePR ≥ 90% positive cells, ≤ 1 mitotic figure, absence of lymphocytic infiltrateAll 13 patients had low scoreAt least 2 of following: PR(-), > 1 mitotic figure, dense lymphocytic infiltrateAll 5 patients had intermediate or high DCIS score",
                    "sub_points": [
                      "Block sent for assay was assessed for these featuresNumber of mitotic figures was counted for all areas of DCIS present in slide",
                      "Number of mitotic figures was counted for all areas of DCIS present in slide",
                      "PR ≥ 90% positive cells, ≤ 1 mitotic figure, absence of lymphocytic infiltrateAll 13 patients had low score",
                      "All 13 patients had low score",
                      "At least 2 of following: PR(-), > 1 mitotic figure, dense lymphocytic infiltrateAll 5 patients had intermediate or high DCIS score",
                      "All 5 patients had intermediate or high DCIS score"
                    ]
                  },
                  {
                    "text": "Additional studies on larger groups of patients will be necessary to determine if these results are reproducible"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Expression Profiling: MammaPrint Assay": {
            "name": "Expression Profiling: MammaPrint Assay",
            "url": "https://app.pathprimer.com/document/98508baa-80f1-4132-9f13-f4f77d161f24/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "MammaPrint Assay": {
                "Introduction": [
                  {
                    "text": "MammaPrint (MP) is a proprietary 70-gene mRNA assayMarketed by Agendia, BVa.k.a. the \"Amsterdam signature\"",
                    "sub_points": [
                      "Marketed by Agendia, BV",
                      "a.k.a. the \"Amsterdam signature\""
                    ]
                  },
                  {
                    "text": "Prognostic for risk of distant recurrence at 5 yearsLow risk: 1.3% risk of distant recurrence at 5 yearsHigh risk: 11.7% risk of distant recurrence at 5 years",
                    "sub_points": [
                      "Low risk: 1.3% risk of distant recurrence at 5 years",
                      "High risk: 11.7% risk of distant recurrence at 5 years"
                    ]
                  },
                  {
                    "text": "Predictive for benefit of chemotherapy in high-risk group"
                  },
                  {
                    "text": "Other companion tests are offeredBluePrint: 80-gene classifier to identify luminal-like, HER2-like, and basal-like carcinomasTargetPrint: Quantifies mRNA for estrogen receptor (ER), progesterone receptor (PR), and HER2",
                    "sub_points": [
                      "BluePrint: 80-gene classifier to identify luminal-like, HER2-like, and basal-like carcinomas",
                      "TargetPrint: Quantifies mRNA for estrogen receptor (ER), progesterone receptor (PR), and HER2"
                    ]
                  }
                ],
                "Test Development": [
                  {
                    "text": "Developed at the Netherlands Cancer Institute1st cohort used frozen tumor tissue from 98 patients with node (-) invasive breast carcinomaRNA from cases was hybridized to 25,000-gene microarrayUnsupervised statistical clustering analysis was performedIdentified 5,000 genes with significant variation between different breast carcinoma casesTumor samples were separated into 2 general classes1 class correlated with mostly ER(+) tumors1 class correlated with mostly ER(-) tumorsStatistical methods that incorporated clinical outcome data were then appliedPatients separated into 2 groups based on outcomeRelapse within 5 years (34 patients) and disease-free at 5 years or more (44 patients)Identified 231 genes whose expression was correlated with outcomeFinal optimal 70-gene set for determining good and poor prognosis was identifiedIncluded genes involved in cell cycle and proliferation, invasion and metastasis, angiogenesis, signal transduction",
                    "sub_points": [
                      "1st cohort used frozen tumor tissue from 98 patients with node (-) invasive breast carcinoma",
                      "RNA from cases was hybridized to 25,000-gene microarray",
                      "Unsupervised statistical clustering analysis was performedIdentified 5,000 genes with significant variation between different breast carcinoma cases",
                      "Identified 5,000 genes with significant variation between different breast carcinoma cases",
                      "Tumor samples were separated into 2 general classes1 class correlated with mostly ER(+) tumors1 class correlated with mostly ER(-) tumors",
                      "1 class correlated with mostly ER(+) tumors",
                      "1 class correlated with mostly ER(-) tumors",
                      "Statistical methods that incorporated clinical outcome data were then appliedPatients separated into 2 groups based on outcomeRelapse within 5 years (34 patients) and disease-free at 5 years or more (44 patients)Identified 231 genes whose expression was correlated with outcome",
                      "Patients separated into 2 groups based on outcomeRelapse within 5 years (34 patients) and disease-free at 5 years or more (44 patients)",
                      "Relapse within 5 years (34 patients) and disease-free at 5 years or more (44 patients)",
                      "Identified 231 genes whose expression was correlated with outcome",
                      "Final optimal 70-gene set for determining good and poor prognosis was identifiedIncluded genes involved in cell cycle and proliferation, invasion and metastasis, angiogenesis, signal transduction",
                      "Included genes involved in cell cycle and proliferation, invasion and metastasis, angiogenesis, signal transduction"
                    ]
                  }
                ],
                "Test Validation, Prognosis, and Clinical Validity": [
                  {
                    "text": "Validation study included 295 consecutive breast carcinomas with available banked, fresh-frozen tissue from Netherlands Cancer InstituteCohort included node (-) and node (+) patients < 53 years of ageIncluded some ER(-) patients and some patients who had received chemotherapy",
                    "sub_points": [
                      "Cohort included node (-) and node (+) patients < 53 years of age",
                      "Included some ER(-) patients and some patients who had received chemotherapy"
                    ]
                  },
                  {
                    "text": "Study showed strikingly different outcomes for patients with good vs. poor signaturesGood prognosis genetic signature (115 patients or 39%)14.8% 10-year distant recurrence [confidence interval (CI) ± 4.3]Poor prognosis genetic signature (180 patients or 61%)50% 10-year distant recurrence (CI ± 4.5)Correlated with traditional high-risk pathologic factorsYounger patient ageIncreased tumor size, higher histologic grade, absence of ER expressionMultivariate analysis with MP assay, added substantial prognostic valueIndependent predictor of disease outcomeAdded to predictive power of pathologic factorsPrognostic power is independent of patient age and lymph node statusEstimated hazard ratio for distant metastases in poor prognosis vs. good prognosis signature: 5.1 (CI 2.9-9.0;P< 0.001)",
                    "sub_points": [
                      "Good prognosis genetic signature (115 patients or 39%)14.8% 10-year distant recurrence [confidence interval (CI) ± 4.3]",
                      "14.8% 10-year distant recurrence [confidence interval (CI) ± 4.3]",
                      "Poor prognosis genetic signature (180 patients or 61%)50% 10-year distant recurrence (CI ± 4.5)Correlated with traditional high-risk pathologic factorsYounger patient ageIncreased tumor size, higher histologic grade, absence of ER expression",
                      "50% 10-year distant recurrence (CI ± 4.5)",
                      "Correlated with traditional high-risk pathologic factorsYounger patient ageIncreased tumor size, higher histologic grade, absence of ER expression",
                      "Younger patient age",
                      "Increased tumor size, higher histologic grade, absence of ER expression",
                      "Multivariate analysis with MP assay, added substantial prognostic valueIndependent predictor of disease outcomeAdded to predictive power of pathologic factorsPrognostic power is independent of patient age and lymph node statusEstimated hazard ratio for distant metastases in poor prognosis vs. good prognosis signature: 5.1 (CI 2.9-9.0;P< 0.001)",
                      "Independent predictor of disease outcome",
                      "Added to predictive power of pathologic factorsPrognostic power is independent of patient age and lymph node status",
                      "Prognostic power is independent of patient age and lymph node status",
                      "Estimated hazard ratio for distant metastases in poor prognosis vs. good prognosis signature: 5.1 (CI 2.9-9.0;P< 0.001)"
                    ]
                  }
                ],
                "Predictive Value and Clinical Utility": [
                  {
                    "text": "MP validation studies showed that risk prediction is related primarily to early recurrencePatients at risk for early recurrence may be appropriately suited for adjuvant or neoadjuvant chemotherapyStudies suggest that poor prognostic signature is predictive for pathologic response to neoadjuvant chemotherapyMetaanalysis has shown that MP is also predictive for adjuvant chemotherapy benefit",
                    "sub_points": [
                      "Patients at risk for early recurrence may be appropriately suited for adjuvant or neoadjuvant chemotherapyStudies suggest that poor prognostic signature is predictive for pathologic response to neoadjuvant chemotherapyMetaanalysis has shown that MP is also predictive for adjuvant chemotherapy benefit",
                      "Studies suggest that poor prognostic signature is predictive for pathologic response to neoadjuvant chemotherapy",
                      "Metaanalysis has shown that MP is also predictive for adjuvant chemotherapy benefit"
                    ]
                  },
                  {
                    "text": "Utility of MP assay prospectively shown in MINDACT trial"
                  }
                ],
                "Endorsements": [
                  {
                    "text": "Use of MP to guide management decisions for patients with node (+) and node (-) cancers has been recommended by multiple groupsAmerican Society for Clinical Oncology (ASCO) clinical practice guidelineNational Comprehensive Cancer Network (NCCN) clinical practice guidelineSt. Gallen consensus panel guidelineEuropean Society for Medical Oncology (ESMO) clinical practice guideline",
                    "sub_points": [
                      "American Society for Clinical Oncology (ASCO) clinical practice guideline",
                      "National Comprehensive Cancer Network (NCCN) clinical practice guideline",
                      "St. Gallen consensus panel guideline",
                      "European Society for Medical Oncology (ESMO) clinical practice guideline"
                    ]
                  }
                ]
              },
              "Clinical Studies": {
                "MINDACT Trial": [
                  {
                    "text": "MINDACTtrial:Microarrayin node (-) and 0-3 positive lymph nodedisease mayavoidchemotherapy (EORTC-10041-BCG)Randomized phase III study, enrolled > 6,600 patients from 2006-2011 in EuropePatients had MP performed to determine genomic riskClinical risk was determined by using modified version of Adjuvant! Online (version 8.0 with HER2 status)Patients low risk by clinical criteria and low risk by MP received hormonal therapyPatients high risk by clinical criteria and high risk by MP received chemotherapy and hormonal therapyPatients with discordant risk by clinical criteria and MP were randomized to receive hormonal therapy alone vs. chemotherapy and hormonal therapy41% (2,745 patients) had tumors with low clinical and low genomic risk8.8% (592 patients) had tumors with low clinical risk and high genomic risk23.2% (1,550 patients) had tumors with high clinical risk and low genomic risk27% (1,806 patients) had tumor with high clinical risk and high genomic riskThe results provided level IA evidence for the clinical utility of MPThe study showed assay results must be used in addition to standard clinical-pathologic criteria, including age, for selecting patients for adjuvant chemotherapy",
                    "sub_points": [
                      "Randomized phase III study, enrolled > 6,600 patients from 2006-2011 in Europe",
                      "Patients had MP performed to determine genomic risk",
                      "Clinical risk was determined by using modified version of Adjuvant! Online (version 8.0 with HER2 status)",
                      "Patients low risk by clinical criteria and low risk by MP received hormonal therapy",
                      "Patients high risk by clinical criteria and high risk by MP received chemotherapy and hormonal therapy",
                      "Patients with discordant risk by clinical criteria and MP were randomized to receive hormonal therapy alone vs. chemotherapy and hormonal therapy41% (2,745 patients) had tumors with low clinical and low genomic risk8.8% (592 patients) had tumors with low clinical risk and high genomic risk23.2% (1,550 patients) had tumors with high clinical risk and low genomic risk27% (1,806 patients) had tumor with high clinical risk and high genomic risk",
                      "41% (2,745 patients) had tumors with low clinical and low genomic risk",
                      "8.8% (592 patients) had tumors with low clinical risk and high genomic risk",
                      "23.2% (1,550 patients) had tumors with high clinical risk and low genomic risk",
                      "27% (1,806 patients) had tumor with high clinical risk and high genomic risk",
                      "The results provided level IA evidence for the clinical utility of MP",
                      "The study showed assay results must be used in addition to standard clinical-pathologic criteria, including age, for selecting patients for adjuvant chemotherapy"
                    ]
                  },
                  {
                    "text": "MINDACT and ASCO clinical practice guideline recommendationsPatients > 50 years of age with 0-3 positive nodes [ER(+)/HER2(-)]Ifhighclinical risk, butlowgenomic risk, MP may be used to inform decision to withhold adjuvant chemotherapyMP identified a good prognostic group with potential limited chemotherapy benefitImplies that the extent (stage) of disease does not predict efficacy of chemotherapyPatients should be informed that benefit of chemotherapy cannot be completely excluded, particularly in patients with > 1 involved lymph nodeIflowclinical risk, buthighgenomic risk, MPshould notbe used to inform decisions about adjuvant chemotherapyPatients with low clinical risk had excellent outcomes and did not appear to benefit from chemotherapy, even with high genomic riskThese patients likely do not have systemic disease and, thus, do not benefit from systemic treatment",
                    "sub_points": [
                      "Patients > 50 years of age with 0-3 positive nodes [ER(+)/HER2(-)]Ifhighclinical risk, butlowgenomic risk, MP may be used to inform decision to withhold adjuvant chemotherapyMP identified a good prognostic group with potential limited chemotherapy benefitImplies that the extent (stage) of disease does not predict efficacy of chemotherapyPatients should be informed that benefit of chemotherapy cannot be completely excluded, particularly in patients with > 1 involved lymph node",
                      "Ifhighclinical risk, butlowgenomic risk, MP may be used to inform decision to withhold adjuvant chemotherapyMP identified a good prognostic group with potential limited chemotherapy benefitImplies that the extent (stage) of disease does not predict efficacy of chemotherapy",
                      "MP identified a good prognostic group with potential limited chemotherapy benefit",
                      "Implies that the extent (stage) of disease does not predict efficacy of chemotherapy",
                      "Patients should be informed that benefit of chemotherapy cannot be completely excluded, particularly in patients with > 1 involved lymph node",
                      "Iflowclinical risk, buthighgenomic risk, MPshould notbe used to inform decisions about adjuvant chemotherapyPatients with low clinical risk had excellent outcomes and did not appear to benefit from chemotherapy, even with high genomic riskThese patients likely do not have systemic disease and, thus, do not benefit from systemic treatment",
                      "Patients with low clinical risk had excellent outcomes and did not appear to benefit from chemotherapy, even with high genomic risk",
                      "These patients likely do not have systemic disease and, thus, do not benefit from systemic treatment"
                    ]
                  }
                ]
              },
              "BluePrint": {
                "Molecular Subtypes of Breast Carcinoma": [
                  {
                    "text": "BluePrint is an 80-gene panel for defining intrinsic molecular subtypesIncludes ER, PR, androgen receptor (AR), and HER2Only 4 genes are also included in MP:RUNDC1,SCUBE2,CDCA7,RTN4RL1",
                    "sub_points": [
                      "Includes ER, PR, androgen receptor (AR), and HER2",
                      "Only 4 genes are also included in MP:RUNDC1,SCUBE2,CDCA7,RTN4RL1"
                    ]
                  },
                  {
                    "text": "Divides breast carcinomas into following typesLuminal type (58 genes)Luminal type/MP low = luminal type ALuminal type/MP high = luminal type BBasal type (28 genes)HER2 type (4 genes)30% are HER2(-) according to conventional testsTreatment with HER2-targeted agents should be determined by conventional testing",
                    "sub_points": [
                      "Luminal type (58 genes)Luminal type/MP low = luminal type ALuminal type/MP high = luminal type B",
                      "Luminal type/MP low = luminal type A",
                      "Luminal type/MP high = luminal type B",
                      "Basal type (28 genes)",
                      "HER2 type (4 genes)30% are HER2(-) according to conventional testsTreatment with HER2-targeted agents should be determined by conventional testing",
                      "30% are HER2(-) according to conventional tests",
                      "Treatment with HER2-targeted agents should be determined by conventional testing"
                    ]
                  },
                  {
                    "text": "BluePrint can only be ordered in conjunction with MP"
                  },
                  {
                    "text": "Targeted therapy should be based on results of conventional tests and not on molecular assays"
                  }
                ]
              },
              "Comparison to Other Assays": {
                "Genes Included in Assays": [
                  {
                    "text": "MP shares only few genes in common with other assaysOncotype DX recurrence score (RS) (1 gene):SCUBE2Prosigna (PAM50) risk of recurrence (ROR) (3 genes):MELK, ORC6, NDC80(KNTC2)",
                    "sub_points": [
                      "Oncotype DX recurrence score (RS) (1 gene):SCUBE2",
                      "Prosigna (PAM50) risk of recurrence (ROR) (3 genes):MELK, ORC6, NDC80(KNTC2)"
                    ]
                  },
                  {
                    "text": "BluePrint shares some genes in common with other assaysProsigna (PAM50) ROR (9 genes):ESR1, PGR, ERBB2, BCL2, NAT1, FOXA1, FOXC1, MLPH, GRB7Oncotype DX RS (6 genes):ESR1, PGR, ERBB2, BCL2, GRB7, SCUBE2",
                    "sub_points": [
                      "Prosigna (PAM50) ROR (9 genes):ESR1, PGR, ERBB2, BCL2, NAT1, FOXA1, FOXC1, MLPH, GRB7",
                      "Oncotype DX RS (6 genes):ESR1, PGR, ERBB2, BCL2, GRB7, SCUBE2"
                    ]
                  }
                ],
                "Concordance of MP With Other Assays": [
                  {
                    "text": "OPTIMA Prelim Trial determined MP, Oncotype DX RS, and Prosigna ROR on 313 ER(+) HER2(-) cancers that were either ≥ 3 cm or associated with 1-9 positive nodesMP and Oncotype DX RS assigned 74% of patients to same risk category (low/intermediate vs. high)For patients with intermediate risk score, other studies have shown that ~ 45% are low risk and ~ 55% are high risk by MPMP and Prosigna ROR assigned 78% of patients to same risk category (low/intermediate vs. high)",
                    "sub_points": [
                      "MP and Oncotype DX RS assigned 74% of patients to same risk category (low/intermediate vs. high)For patients with intermediate risk score, other studies have shown that ~ 45% are low risk and ~ 55% are high risk by MP",
                      "For patients with intermediate risk score, other studies have shown that ~ 45% are low risk and ~ 55% are high risk by MP",
                      "MP and Prosigna ROR assigned 78% of patients to same risk category (low/intermediate vs. high)"
                    ]
                  },
                  {
                    "text": "Although multigene assays are similar, they do not provide equivalent results for all patients"
                  }
                ]
              },
              "TargetPrint": {
                "Single Gene Scores": [
                  {
                    "text": "A quantitative assessment of ER, PR, and HER2 mRNA levels is provided"
                  }
                ]
              },
              "Requirements for Testing": {
                "Patient Selection": [
                  {
                    "text": "This assay should only be performed in appropriate patient population with eligible cancersWomenPrimary invasive breast carcinoma",
                    "sub_points": [
                      "Women",
                      "Primary invasive breast carcinoma"
                    ]
                  },
                  {
                    "text": "ER(+) or (-)"
                  },
                  {
                    "text": "HER2(+) or (-)"
                  },
                  {
                    "text": "Node (-) or 1-3 positive nodesFDA approved in USA for node (-) cancers",
                    "sub_points": [
                      "FDA approved in USA for node (-) cancers"
                    ]
                  },
                  {
                    "text": "≤ 5 cm in size"
                  },
                  {
                    "text": "Stage I or II"
                  }
                ],
                "Specimen Selection": [
                  {
                    "text": "Can be performed on formalin-fixed paraffin-embedded tissue or fresh frozen tissue from invasive carcinomas"
                  },
                  {
                    "text": "Core needle biopsies or excisional specimens can be assayedTumor cellularity should be ≥ 30%",
                    "sub_points": [
                      "Tumor cellularity should be ≥ 30%"
                    ]
                  },
                  {
                    "text": "Blocks or slides can be sent10 unstained slides with 5-μn sections are requested",
                    "sub_points": [
                      "10 unstained slides with 5-μn sections are requested"
                    ]
                  }
                ]
              },
              "AJCC 8th Edition Cancer Staging": {
                "Multigene Assays and Breast Cancer Staging": [
                  {
                    "text": "Both anatomic stage and biologic type of cancer provide important prognostic informationAnatomic stage: Tumor (T), node (N), and metastasis (M)Biologic type: Grade, ER, PR, HER2",
                    "sub_points": [
                      "Anatomic stage: Tumor (T), node (N), and metastasis (M)",
                      "Biologic type: Grade, ER, PR, HER2"
                    ]
                  },
                  {
                    "text": "In the American Joint Committee on Cancer (AJCC) 8th edition (in effect 1/1/2018), anatomic stage and biologic type are combined for 1st timeA multigene assay can also be incorporated for patients with low scoresThe Union for International Cancer Control (UICC) did not adopt the new system and continues to use anatomic stage",
                    "sub_points": [
                      "A multigene assay can also be incorporated for patients with low scores",
                      "The Union for International Cancer Control (UICC) did not adopt the new system and continues to use anatomic stage"
                    ]
                  },
                  {
                    "text": "There are 2 new systems defining stagePathologic prognostic stage(only applies to patients who have undergone surgery as their 1st treatment)pT, pN, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IVMultigene assay can be included, if availableAssay is not required for stagingOnly applicable to T1-T2, N0 cM0, ER(+), HER2(-) cancersPathologic prognostic stage group IA is assigned if Oncotype DX RS is < 11AJCC panel suggests other multigene assays may be included in the future",
                    "sub_points": [
                      "Pathologic prognostic stage(only applies to patients who have undergone surgery as their 1st treatment)pT, pN, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IVMultigene assay can be included, if availableAssay is not required for stagingOnly applicable to T1-T2, N0 cM0, ER(+), HER2(-) cancersPathologic prognostic stage group IA is assigned if Oncotype DX RS is < 11AJCC panel suggests other multigene assays may be included in the future",
                      "pT, pN, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IV",
                      "Biologic type is not used to determine stages 0 and IV",
                      "Multigene assay can be included, if availableAssay is not required for stagingOnly applicable to T1-T2, N0 cM0, ER(+), HER2(-) cancersPathologic prognostic stage group IA is assigned if Oncotype DX RS is < 11AJCC panel suggests other multigene assays may be included in the future",
                      "Assay is not required for staging",
                      "Only applicable to T1-T2, N0 cM0, ER(+), HER2(-) cancers",
                      "Pathologic prognostic stage group IA is assigned if Oncotype DX RS is < 11",
                      "AJCC panel suggests other multigene assays may be included in the future"
                    ]
                  },
                  {
                    "text": "Clinical prognostic stage(applicable to all patients)Also includes patients who have not undergone surgery, patients not eligible for surgery, and patients who have received neoadjuvant therapyT, N, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IVMultigene assay is not included because it may not be possible to determine T and N with certainty",
                    "sub_points": [
                      "Also includes patients who have not undergone surgery, patients not eligible for surgery, and patients who have received neoadjuvant therapy",
                      "T, N, cM0, grade, ER, PR, and HER2 are used to determine stages I, II, and IIIBiologic type is not used to determine stages 0 and IV",
                      "Biologic type is not used to determine stages 0 and IV",
                      "Multigene assay is not included because it may not be possible to determine T and N with certainty"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Circulating Tumor Cells, Circulating Tumor DNA, and Next-Generation Sequencing": {
            "name": "Circulating Tumor Cells, Circulating Tumor DNA, and Next-Generation Sequencing",
            "url": "https://app.pathprimer.com/document/ea02f694-14da-445a-a1e8-63bb9456bf23/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "Terminology": {
                "Abbreviations": [
                  {
                    "text": "Circulating tumor cells (CTCs)"
                  },
                  {
                    "text": "Circulating tumor DNA (ctDNA)"
                  },
                  {
                    "text": "Cell-free DNA (cfDNA)"
                  }
                ]
              },
              "Circulating Tumor Cells and Cell-Free DNA": {
                "Introduction": [
                  {
                    "text": "Breast carcinoma (BC) is biologically heterogeneous diseaseIndividual cancer subtypes are characterized by different prognoses and sensitivities to drugsBCs show heterogeneity in molecular characteristics and cellular compositionClinical heterogeneity in terms of treatment response and outcome reflect diverse molecular heterogeneity",
                    "sub_points": [
                      "Individual cancer subtypes are characterized by different prognoses and sensitivities to drugs",
                      "BCs show heterogeneity in molecular characteristics and cellular composition",
                      "Clinical heterogeneity in terms of treatment response and outcome reflect diverse molecular heterogeneity"
                    ]
                  },
                  {
                    "text": "Pathologic staging of BC is clinically useful for determining the course of diseaseIdentification of tumor cells in lymph nodes and bone marrow indicates increased risk for local recurrence and additional distant metastasisPatients with known disease outside the breast are usually recommended to undergo systemic treatment",
                    "sub_points": [
                      "Identification of tumor cells in lymph nodes and bone marrow indicates increased risk for local recurrence and additional distant metastasisPatients with known disease outside the breast are usually recommended to undergo systemic treatment",
                      "Patients with known disease outside the breast are usually recommended to undergo systemic treatment"
                    ]
                  },
                  {
                    "text": "A significant number of early-stage BCs will recur at distant sites following surgical excision with intent to cure (i.e., to completely remove the cancer)Suggests that current clinical evaluation for the presence of distant disease is inadequate for some patientsMore sensitive methods for determining tumor cell dissemination and risk for metastasis are neededTumor cells spread to distant sites through venous and lymphatic circulation before development of clinically detectable disease",
                    "sub_points": [
                      "Suggests that current clinical evaluation for the presence of distant disease is inadequate for some patientsMore sensitive methods for determining tumor cell dissemination and risk for metastasis are neededTumor cells spread to distant sites through venous and lymphatic circulation before development of clinically detectable disease",
                      "More sensitive methods for determining tumor cell dissemination and risk for metastasis are needed",
                      "Tumor cells spread to distant sites through venous and lymphatic circulation before development of clinically detectable disease"
                    ]
                  },
                  {
                    "text": "The discovery of actionable biomarkers and improvements in diagnostic tools have led to an evolution of available targets for treatment and alternative methods for diagnosisWith a biomarker approach, BC has led the way to a new paradigm of precision medicine in solid tumorsBiomarker-guided treatment has increased treatment efficacy, focusing therapy on tumors harboring specific alterations and molecular drivers of progressionUp until recently, biomarker testing has relied on analyses conducted on tissue samples obtained by invasive proceduresCan be challenging due to tumor heterogeneity and sampling constraintsMetastatic sites may not be easily accessible, and sampling can result in morbidity to the patient",
                    "sub_points": [
                      "With a biomarker approach, BC has led the way to a new paradigm of precision medicine in solid tumors",
                      "Biomarker-guided treatment has increased treatment efficacy, focusing therapy on tumors harboring specific alterations and molecular drivers of progression",
                      "Up until recently, biomarker testing has relied on analyses conducted on tissue samples obtained by invasive proceduresCan be challenging due to tumor heterogeneity and sampling constraintsMetastatic sites may not be easily accessible, and sampling can result in morbidity to the patient",
                      "Can be challenging due to tumor heterogeneity and sampling constraints",
                      "Metastatic sites may not be easily accessible, and sampling can result in morbidity to the patient"
                    ]
                  },
                  {
                    "text": "Liquid biopsy is a rapidly developing procedure for patients with BC as well as other solid tumorsIncludes sampling of blood, urine, or other body fluidsEnables analysis of various components of biofluids (DNA, RNA, CTCs, extracellular vesicles)",
                    "sub_points": [
                      "Includes sampling of blood, urine, or other body fluids",
                      "Enables analysis of various components of biofluids (DNA, RNA, CTCs, extracellular vesicles)"
                    ]
                  },
                  {
                    "text": "The value of liquid biopsy for assessing the presence of CTCs and ctDNA is under investigation and being rapidly incorporated into clinical care with multiple applicationsEarly detection of disease and disease progressionAssessment of prognostic and predictive markersDetermination of risk stratificationMonitoring treatmentIdentification of resistance mechanismsIdentification of actionable biomarkers",
                    "sub_points": [
                      "Early detection of disease and disease progression",
                      "Assessment of prognostic and predictive markers",
                      "Determination of risk stratification",
                      "Monitoring treatment",
                      "Identification of resistance mechanisms",
                      "Identification of actionable biomarkers"
                    ]
                  },
                  {
                    "text": "Advantage: Liquid biopsy is a minimally invasive procedure to obtain diagnostic material for monitoring and treatment decision makingTherefore, serial sampling and testing over time is possible",
                    "sub_points": [
                      "Therefore, serial sampling and testing over time is possible"
                    ]
                  }
                ]
              },
              "Circulating Tumor Cells": {
                "Overview": [
                  {
                    "text": "CTC analysis offers opportunity for liquid biopsy to yield clinically useful resultsAllows assessment of disease response over timeMay enable real-time monitoring of disease statusPotential for individualization of therapy based on molecular characterization of CTCs",
                    "sub_points": [
                      "Allows assessment of disease response over timeMay enable real-time monitoring of disease status",
                      "May enable real-time monitoring of disease status",
                      "Potential for individualization of therapy based on molecular characterization of CTCs"
                    ]
                  },
                  {
                    "text": "Numerous studies have investigated detection of CTCs in peripheral blood as a surrogate for early disseminationCTCs represent a liquid component of solid tumors and indicate the presence of residual diseaseCTCs are detected in 10-30% of patients with nonmetastatic BC by conventional evaluationHowever, not all of these patients will develop clinically evident metastasesIn addition, some patients without CTCs will develop metastasesDetection of CTCs may represent a method for very early detection of micrometastasisMay be useful in identification of aggressive tumors, which shed cells into the bloodstreamCurrent data are unclear on how this information can be used in BC managementCTCs may have role as surrogate markers to monitor treatment response",
                    "sub_points": [
                      "CTCs represent a liquid component of solid tumors and indicate the presence of residual diseaseCTCs are detected in 10-30% of patients with nonmetastatic BC by conventional evaluationHowever, not all of these patients will develop clinically evident metastasesIn addition, some patients without CTCs will develop metastases",
                      "CTCs are detected in 10-30% of patients with nonmetastatic BC by conventional evaluation",
                      "However, not all of these patients will develop clinically evident metastases",
                      "In addition, some patients without CTCs will develop metastases",
                      "Detection of CTCs may represent a method for very early detection of micrometastasisMay be useful in identification of aggressive tumors, which shed cells into the bloodstreamCurrent data are unclear on how this information can be used in BC management",
                      "May be useful in identification of aggressive tumors, which shed cells into the bloodstream",
                      "Current data are unclear on how this information can be used in BC management",
                      "CTCs may have role as surrogate markers to monitor treatment response"
                    ]
                  },
                  {
                    "text": "There are clinical challenges in using BC CTCsAccurate enumeration of CTCs is difficult given their scarcity and heterogeneous morphologyCharacterization of heterogeneity of CTCs within an individual and interpreting its significance are complexA clinically relevant metastatic potential of detected CTCs may not be clear for an individual patientNot all patients with CTCs will develop clinically evident metastases",
                    "sub_points": [
                      "Accurate enumeration of CTCs is difficult given their scarcity and heterogeneous morphology",
                      "Characterization of heterogeneity of CTCs within an individual and interpreting its significance are complex",
                      "A clinically relevant metastatic potential of detected CTCs may not be clear for an individual patientNot all patients with CTCs will develop clinically evident metastases",
                      "Not all patients with CTCs will develop clinically evident metastases"
                    ]
                  }
                ],
                "Testing Strategies for Circulating Tumor Cells": [
                  {
                    "text": "Recent technical advances have made reliable detection of CTCs possible"
                  },
                  {
                    "text": "CTCs are rare findings within the bloodstream requiring specific and sensitive methodologies for detectionStrategies for detection have attempted to exploit differences between epithelial cells and blood or between benign and malignant cells",
                    "sub_points": [
                      "Strategies for detection have attempted to exploit differences between epithelial cells and blood or between benign and malignant cells"
                    ]
                  },
                  {
                    "text": "Most technical methods for detecting CTCs rely on combinations of cell enrichment and detection stepsAntibody-coated immunomagnetic beads can be used to tag and separate epithelial cells from whole bloodThese isolated cells are then characterized as CTCs based on detection of selected biologic markersIn BC, RT-PCR for genes coding for cytokeratins, MUC1, CEA, mammaglobin, and HER2 have been used to identify putative CTCs by DNA analysisImmunohistochemistry (IHC) and immunofluorescence for epithelial markers have also been used to identify CTCs by protein analysis",
                    "sub_points": [
                      "Antibody-coated immunomagnetic beads can be used to tag and separate epithelial cells from whole blood",
                      "These isolated cells are then characterized as CTCs based on detection of selected biologic markersIn BC, RT-PCR for genes coding for cytokeratins, MUC1, CEA, mammaglobin, and HER2 have been used to identify putative CTCs by DNA analysisImmunohistochemistry (IHC) and immunofluorescence for epithelial markers have also been used to identify CTCs by protein analysis",
                      "In BC, RT-PCR for genes coding for cytokeratins, MUC1, CEA, mammaglobin, and HER2 have been used to identify putative CTCs by DNA analysis",
                      "Immunohistochemistry (IHC) and immunofluorescence for epithelial markers have also been used to identify CTCs by protein analysis"
                    ]
                  },
                  {
                    "text": "CTCs are found in the peripheral blood in up to 40% of patients with newly diagnosed BCThe incidence of CTCs is higher for methods that use RT-PCR compared with immunologic methodsCTCs are found in 20-30% of stage I or II BC patients detected by RT-PCR forKRT19(CK19) mRNACTCs are found in 50-75% of patients with stage IV metastatic BC (MBC)CTCs can be isolated using these methods and used for further analysis",
                    "sub_points": [
                      "The incidence of CTCs is higher for methods that use RT-PCR compared with immunologic methods",
                      "CTCs are found in 20-30% of stage I or II BC patients detected by RT-PCR forKRT19(CK19) mRNA",
                      "CTCs are found in 50-75% of patients with stage IV metastatic BC (MBC)",
                      "CTCs can be isolated using these methods and used for further analysis"
                    ]
                  }
                ],
                "Types of Tests for Circulating Tumor Cells": [
                  {
                    "text": "Blood represents a convenient clinical sample, is easily obtained, and has been studied most extensively for CTCsSome studies suggest that assessment of bone marrow for tumor cells may be a better predictor of outcome",
                    "sub_points": [
                      "Some studies suggest that assessment of bone marrow for tumor cells may be a better predictor of outcome"
                    ]
                  },
                  {
                    "text": "Current methods are limited to the ability to accurately identify and count CTCs"
                  },
                  {
                    "text": "Sample type, volume, and collection can influence the results of CTC assaysRapid processing of samples to avoid detection of target degradation is recommendedRT-PCR-detected transcripts may decline or increase over time",
                    "sub_points": [
                      "Rapid processing of samples to avoid detection of target degradation is recommendedRT-PCR-detected transcripts may decline or increase over time",
                      "RT-PCR-detected transcripts may decline or increase over time"
                    ]
                  },
                  {
                    "text": "Newer methods under development are seeking to capture viable tumor cells from circulationIsolated viable CTCs may be grown in tissue cultureViable CTCs can undergo further molecular analysisMay provide clinically useful information",
                    "sub_points": [
                      "Isolated viable CTCs may be grown in tissue culture",
                      "Viable CTCs can undergo further molecular analysisMay provide clinically useful information",
                      "May provide clinically useful information"
                    ]
                  },
                  {
                    "text": "Commercial CTC detection methodology [CellSearch assay (Veridex)] is availableUtilizes immunomagnetic selection to enrich for CTCsImmunomagnetic selection is followed by immunofluorescent detection of CTCsNuclear staining with 4', 6-diamidino-2-phenylindole is used to help identify intact cellsEpithelial markers, such as cytokeratin and HER2, are used to identify tumor cellsFluorescent staining with CD45 highlights contaminating leukocytes that are eliminated from analysisThis assay is cleared by the FDA for use as a prognostic test in metastatic cancers of breast, prostate, and colon",
                    "sub_points": [
                      "Utilizes immunomagnetic selection to enrich for CTCsImmunomagnetic selection is followed by immunofluorescent detection of CTCsNuclear staining with 4', 6-diamidino-2-phenylindole is used to help identify intact cellsEpithelial markers, such as cytokeratin and HER2, are used to identify tumor cellsFluorescent staining with CD45 highlights contaminating leukocytes that are eliminated from analysis",
                      "Immunomagnetic selection is followed by immunofluorescent detection of CTCs",
                      "Nuclear staining with 4', 6-diamidino-2-phenylindole is used to help identify intact cells",
                      "Epithelial markers, such as cytokeratin and HER2, are used to identify tumor cells",
                      "Fluorescent staining with CD45 highlights contaminating leukocytes that are eliminated from analysis",
                      "This assay is cleared by the FDA for use as a prognostic test in metastatic cancers of breast, prostate, and colon"
                    ]
                  }
                ],
                "Circulating Tumor Cells and Clinical Significance": [
                  {
                    "text": "CTCs and MBCThe presence of CTCs is a strong indicator of poor survival in MBC patientsMBC patients with CTCs have a worse prognosis than those without elevated CTCsIn one study, patients who were negative for CTCs showed a median overall survival of 28.3 monthsPatients with elevated CTCs had a median overall survival of only 12.8 monthsEvaluation of CTCs has advantages over traditional methods of clinical surveillanceThe number of CTCs correlates with disease progression up to 7-9 weeks before imaging evidence of progressionElevated CTCs correlate with a higher number of metastatic sites and rapid progression compared with low CTC countsPatients with consistently high CTCs or an increase in CTCs during systemic therapy have reduced survivalChanges in CTCs from baseline and after 3 cycles of treatment correlate with radiologic response to chemotherapyThe number of CTCs in serial follow-up samples may be valuable for predicting outcome and treatment efficacyWhether CTC enumeration should guide specific treatment decisions or treatment changes remains unclear and is actively being investigated",
                    "sub_points": [
                      "The presence of CTCs is a strong indicator of poor survival in MBC patients",
                      "MBC patients with CTCs have a worse prognosis than those without elevated CTCsIn one study, patients who were negative for CTCs showed a median overall survival of 28.3 monthsPatients with elevated CTCs had a median overall survival of only 12.8 months",
                      "In one study, patients who were negative for CTCs showed a median overall survival of 28.3 months",
                      "Patients with elevated CTCs had a median overall survival of only 12.8 months",
                      "Evaluation of CTCs has advantages over traditional methods of clinical surveillanceThe number of CTCs correlates with disease progression up to 7-9 weeks before imaging evidence of progressionElevated CTCs correlate with a higher number of metastatic sites and rapid progression compared with low CTC countsPatients with consistently high CTCs or an increase in CTCs during systemic therapy have reduced survivalChanges in CTCs from baseline and after 3 cycles of treatment correlate with radiologic response to chemotherapy",
                      "The number of CTCs correlates with disease progression up to 7-9 weeks before imaging evidence of progression",
                      "Elevated CTCs correlate with a higher number of metastatic sites and rapid progression compared with low CTC counts",
                      "Patients with consistently high CTCs or an increase in CTCs during systemic therapy have reduced survival",
                      "Changes in CTCs from baseline and after 3 cycles of treatment correlate with radiologic response to chemotherapy",
                      "The number of CTCs in serial follow-up samples may be valuable for predicting outcome and treatment efficacy",
                      "Whether CTC enumeration should guide specific treatment decisions or treatment changes remains unclear and is actively being investigated"
                    ]
                  },
                  {
                    "text": "CTCs and early-stage BCNewly diagnosed BC patients may have CTCs in peripheral bloodCTC detection is associated with worse prognosis; it is an independent predictor of BC progression-free and overall survivalThe prognostic association of CTCs is independent of nodal status or whether the patient receives adjuvant chemotherapyStudies have defined > 5 CTCs per 7.5 mL of blood as a cutoff for CTC(+) is associated with unfavorable prognosisA positive CTC assay 5 years after diagnosis of estrogen receptor-positive [ER(+)] BC is independently prognostic for late clinical recurrenceCTCs may be useful to stratify risk of late recurrenceMay have implications for extended endocrine therapy",
                    "sub_points": [
                      "Newly diagnosed BC patients may have CTCs in peripheral blood",
                      "CTC detection is associated with worse prognosis; it is an independent predictor of BC progression-free and overall survivalThe prognostic association of CTCs is independent of nodal status or whether the patient receives adjuvant chemotherapyStudies have defined > 5 CTCs per 7.5 mL of blood as a cutoff for CTC(+) is associated with unfavorable prognosis",
                      "The prognostic association of CTCs is independent of nodal status or whether the patient receives adjuvant chemotherapy",
                      "Studies have defined > 5 CTCs per 7.5 mL of blood as a cutoff for CTC(+) is associated with unfavorable prognosis",
                      "A positive CTC assay 5 years after diagnosis of estrogen receptor-positive [ER(+)] BC is independently prognostic for late clinical recurrenceCTCs may be useful to stratify risk of late recurrenceMay have implications for extended endocrine therapy",
                      "CTCs may be useful to stratify risk of late recurrence",
                      "May have implications for extended endocrine therapy"
                    ]
                  },
                  {
                    "text": "CTCs and BC subtypesThe prognostic value of CTCs may depend on BC subtypeIn HER2(+)BC treated with HER2-targeted therapy, no association between CTCs at baseline and outcome is observedFor other types of BC, the prognostic value of CTCs at baseline is independent of disease site and subtypeResults of CTCs are likely context specific",
                    "sub_points": [
                      "The prognostic value of CTCs may depend on BC subtypeIn HER2(+)BC treated with HER2-targeted therapy, no association between CTCs at baseline and outcome is observedFor other types of BC, the prognostic value of CTCs at baseline is independent of disease site and subtypeResults of CTCs are likely context specific",
                      "In HER2(+)BC treated with HER2-targeted therapy, no association between CTCs at baseline and outcome is observed",
                      "For other types of BC, the prognostic value of CTCs at baseline is independent of disease site and subtype",
                      "Results of CTCs are likely context specific"
                    ]
                  }
                ],
                "Circulating Tumor Cells and Treatment Decisions": [
                  {
                    "text": "CTCs and adjuvant therapyKRT19(CK19) mRNA has been used to detect CTCs in clinical studies for adjuvant treatmentPeripheral blood samples are used to assess for CTCs before and after adjuvant chemotherapyDetection ofKRT19(CK19) mRNA(+) CTCs post chemotherapy demonstrates multiple clinical associationsInvolvement of > 3 axillary lymph nodesIncreased incidence of clinical relapseReduction in disease-free and overall disease-related survivalIn multivariate analysis, detection ofKRT19(CK19) mRNA(+) CTCs before and after adjuvant chemotherapy was an independent factor associated with reduced disease-free survivalChanges inKRT19(CK19) mRNA(+) CTCs in blood after adjuvant chemotherapy can provide clinical informationChanges in CTCs during therapy can serve as an early parameter to evaluate treatment responsivenessAn increase in CTCs is a predictor of early relapseA decline in CTCs after systemic therapy is associated with improved progression-free and overall survivalThe persistence of CTCs after systemic therapy is an independent risk factor indicating the presence of chemotherapy-resistant residual disease",
                    "sub_points": [
                      "KRT19(CK19) mRNA has been used to detect CTCs in clinical studies for adjuvant treatment",
                      "Peripheral blood samples are used to assess for CTCs before and after adjuvant chemotherapy",
                      "Detection ofKRT19(CK19) mRNA(+) CTCs post chemotherapy demonstrates multiple clinical associationsInvolvement of > 3 axillary lymph nodesIncreased incidence of clinical relapseReduction in disease-free and overall disease-related survival",
                      "Involvement of > 3 axillary lymph nodes",
                      "Increased incidence of clinical relapse",
                      "Reduction in disease-free and overall disease-related survival",
                      "In multivariate analysis, detection ofKRT19(CK19) mRNA(+) CTCs before and after adjuvant chemotherapy was an independent factor associated with reduced disease-free survival",
                      "Changes inKRT19(CK19) mRNA(+) CTCs in blood after adjuvant chemotherapy can provide clinical informationChanges in CTCs during therapy can serve as an early parameter to evaluate treatment responsivenessAn increase in CTCs is a predictor of early relapseA decline in CTCs after systemic therapy is associated with improved progression-free and overall survivalThe persistence of CTCs after systemic therapy is an independent risk factor indicating the presence of chemotherapy-resistant residual disease",
                      "Changes in CTCs during therapy can serve as an early parameter to evaluate treatment responsiveness",
                      "An increase in CTCs is a predictor of early relapse",
                      "A decline in CTCs after systemic therapy is associated with improved progression-free and overall survival",
                      "The persistence of CTCs after systemic therapy is an independent risk factor indicating the presence of chemotherapy-resistant residual disease"
                    ]
                  },
                  {
                    "text": "CTCs and neoadjuvant therapy (NAT)In a meta-analysis, detection of CTCs before NAT had a detrimental impact on overall survival but not on the likelihood of pathologic complete responseCTC count is an independent prognostic factor in early BC patients treated by NATPersistent CTCs after NAT are associated with an increased risk for relapseThe data on CTCs are complementary to current prognostic models based on tumor characteristics and response to NAT",
                    "sub_points": [
                      "In a meta-analysis, detection of CTCs before NAT had a detrimental impact on overall survival but not on the likelihood of pathologic complete responseCTC count is an independent prognostic factor in early BC patients treated by NATPersistent CTCs after NAT are associated with an increased risk for relapseThe data on CTCs are complementary to current prognostic models based on tumor characteristics and response to NAT",
                      "CTC count is an independent prognostic factor in early BC patients treated by NAT",
                      "Persistent CTCs after NAT are associated with an increased risk for relapse",
                      "The data on CTCs are complementary to current prognostic models based on tumor characteristics and response to NAT"
                    ]
                  },
                  {
                    "text": "CTCsand treatment of patients with MBCPatients with high-baseline CTCs gain minimal benefit from endocrine therapy and greater benefit from combination chemotherapyA prospective randomized clinical trial evaluated the significance of CTCsEligible patients had measurable metastatic disease and were started on a new therapeutic regimenElevated CTCs at any time point was associated with a high likelihood of a short time to disease progressionAt 1st follow-up visit, patients with elevated CTCs had a worse prognosis than those withoutElevated CTCs at a later time were also associated with rapid subsequent disease progressionIt is unclear whether changing therapy when elevated CTCs are found will impact the ultimate clinical outcomeProspective clinical trials are currently underway to try to address this question",
                    "sub_points": [
                      "Patients with high-baseline CTCs gain minimal benefit from endocrine therapy and greater benefit from combination chemotherapy",
                      "A prospective randomized clinical trial evaluated the significance of CTCsEligible patients had measurable metastatic disease and were started on a new therapeutic regimenElevated CTCs at any time point was associated with a high likelihood of a short time to disease progressionAt 1st follow-up visit, patients with elevated CTCs had a worse prognosis than those withoutElevated CTCs at a later time were also associated with rapid subsequent disease progression",
                      "Eligible patients had measurable metastatic disease and were started on a new therapeutic regimen",
                      "Elevated CTCs at any time point was associated with a high likelihood of a short time to disease progression",
                      "At 1st follow-up visit, patients with elevated CTCs had a worse prognosis than those without",
                      "Elevated CTCs at a later time were also associated with rapid subsequent disease progression",
                      "It is unclear whether changing therapy when elevated CTCs are found will impact the ultimate clinical outcome",
                      "Prospective clinical trials are currently underway to try to address this question"
                    ]
                  },
                  {
                    "text": "CTCs and radiotherapyPatients with detectable CTCs who received radiotherapy after surgery had longer disease-free survival and overall survival compared with no radiotherapyPatients without CTCs did not experience longer survival outcome after radiotherapyCTC status may be an important predictive marker for benefit from radiotherapy in early-stage BC",
                    "sub_points": [
                      "Patients with detectable CTCs who received radiotherapy after surgery had longer disease-free survival and overall survival compared with no radiotherapyPatients without CTCs did not experience longer survival outcome after radiotherapy",
                      "Patients without CTCs did not experience longer survival outcome after radiotherapy",
                      "CTC status may be an important predictive marker for benefit from radiotherapy in early-stage BC"
                    ]
                  }
                ],
                "Genomic Analysis and Assessment of Biomarkers in Circulating Tumor Cells": [
                  {
                    "text": "Despite demonstrated clinical significance of CTCs, little is known about the molecular nature of these cells"
                  },
                  {
                    "text": "Studies of secondary phenotyping and genotyping of immunomagnetically detected CTCs have been reportedRecent studies have demonstrated the feasibility of high-content molecular analysis of CTCsMicroarrays and next-generation sequencing (NGS) analysis have been used to analyze CTCsAllows analysis for global gene expression, mutation detection, and copy number aberrations in CTCsTranscriptome analysis of CTCs has confirmed overexpression of genes associated with aggressive BC phenotypesGenomic DNA analysis of CTCs has revealed copy number aberrations that are frequently seen in BCConfirms clonal relationship of CTCs with matched primary tumorsThese studies provide cogent evidence of the malignant origin of CTCs",
                    "sub_points": [
                      "Recent studies have demonstrated the feasibility of high-content molecular analysis of CTCs",
                      "Microarrays and next-generation sequencing (NGS) analysis have been used to analyze CTCsAllows analysis for global gene expression, mutation detection, and copy number aberrations in CTCs",
                      "Allows analysis for global gene expression, mutation detection, and copy number aberrations in CTCs",
                      "Transcriptome analysis of CTCs has confirmed overexpression of genes associated with aggressive BC phenotypes",
                      "Genomic DNA analysis of CTCs has revealed copy number aberrations that are frequently seen in BCConfirms clonal relationship of CTCs with matched primary tumorsThese studies provide cogent evidence of the malignant origin of CTCs",
                      "Confirms clonal relationship of CTCs with matched primary tumors",
                      "These studies provide cogent evidence of the malignant origin of CTCs"
                    ]
                  },
                  {
                    "text": "Nucleic acid and protein-based assays have been developed to evaluate ER, progesterone receptor (PR), and HER2 status in CTCsThresholds for positive signals have typically been defined based on benchmarking expression levels in cancer cell linesConventional FISH and comparative genomic hybridization have been used to assess forHER2gene amplificationCurrently, there is no consensus on methods to use for biomarkers in CTCs, and criteria for positivity have yet to be standardizedClinical validation of therapeutic predictiveness of these approaches is needed",
                    "sub_points": [
                      "Thresholds for positive signals have typically been defined based on benchmarking expression levels in cancer cell lines",
                      "Conventional FISH and comparative genomic hybridization have been used to assess forHER2gene amplification",
                      "Currently, there is no consensus on methods to use for biomarkers in CTCs, and criteria for positivity have yet to be standardized",
                      "Clinical validation of therapeutic predictiveness of these approaches is needed"
                    ]
                  },
                  {
                    "text": "Hormone receptor and HER2 evaluationSeveral studies have compared hormone receptor status between CTCs and matched primary tumorsThis comparative analysis showed a wide range of agreement for hormone receptors (40-70%)Similar to hormone receptors, studies have shown discordance in HER2 status between CTCs and matched primary tumorsThe clinical significance of these findings is unclearThe use of CTC-based biomarkers to guide therapy has not been incorporated into clinical practiceThis is due to the need for further technical validation and studies demonstrating clinical utility and efficacyMethodologies for assessment of hormone receptors and HER2 in CTCs have not been standardizedReliable testing of these markers can be extremely challenging due to technical difficulties and scarcity of CTCs available for analysisRigorous optimization experiments and clinical studies required to validate these methods are neededIntratumoral heterogeneity occurring in CTCs as well as tumor tissue further complicate biomarker assessment",
                    "sub_points": [
                      "Several studies have compared hormone receptor status between CTCs and matched primary tumorsThis comparative analysis showed a wide range of agreement for hormone receptors (40-70%)",
                      "This comparative analysis showed a wide range of agreement for hormone receptors (40-70%)",
                      "Similar to hormone receptors, studies have shown discordance in HER2 status between CTCs and matched primary tumorsThe clinical significance of these findings is unclear",
                      "The clinical significance of these findings is unclear",
                      "The use of CTC-based biomarkers to guide therapy has not been incorporated into clinical practiceThis is due to the need for further technical validation and studies demonstrating clinical utility and efficacyMethodologies for assessment of hormone receptors and HER2 in CTCs have not been standardizedReliable testing of these markers can be extremely challenging due to technical difficulties and scarcity of CTCs available for analysisRigorous optimization experiments and clinical studies required to validate these methods are neededIntratumoral heterogeneity occurring in CTCs as well as tumor tissue further complicate biomarker assessment",
                      "This is due to the need for further technical validation and studies demonstrating clinical utility and efficacy",
                      "Methodologies for assessment of hormone receptors and HER2 in CTCs have not been standardized",
                      "Reliable testing of these markers can be extremely challenging due to technical difficulties and scarcity of CTCs available for analysis",
                      "Rigorous optimization experiments and clinical studies required to validate these methods are needed",
                      "Intratumoral heterogeneity occurring in CTCs as well as tumor tissue further complicate biomarker assessment"
                    ]
                  }
                ],
                "Future Directions for Circulating Tumor Cells": [
                  {
                    "text": "Genomic analysis and assessment of biomarkers in CTCs may provide additional information on tumor biologyTechnologies for molecular profiling of CTCs have begun to elucidate the molecular nature of these cellsNumerous clinical studies have unequivocally shown strong association between elevated CTCs and unfavorable clinical outcomesCTCs may prove useful for serial tumor evaluation, disease monitoring, and clinical decision makingThere is a need for optimized assay standardization, accepted criteria for interpretation, and rigorous clinical validationThe incorporation of CTC assays into well-designed clinical trials will help define the clinical utility of this technology",
                    "sub_points": [
                      "Technologies for molecular profiling of CTCs have begun to elucidate the molecular nature of these cells",
                      "Numerous clinical studies have unequivocally shown strong association between elevated CTCs and unfavorable clinical outcomes",
                      "CTCs may prove useful for serial tumor evaluation, disease monitoring, and clinical decision makingThere is a need for optimized assay standardization, accepted criteria for interpretation, and rigorous clinical validation",
                      "There is a need for optimized assay standardization, accepted criteria for interpretation, and rigorous clinical validation",
                      "The incorporation of CTC assays into well-designed clinical trials will help define the clinical utility of this technology"
                    ]
                  }
                ]
              },
              "Circulating Tumor DNA (ctDNA)": {
                "Circulating Tumor DNA and Liquid Biopsy": [
                  {
                    "text": "Liquid biopsy allows the detection of fragments of ctDNA primarily from apoptotic and necrotic tumor cellsctDNA reflects real-time tumor burdenctDNA has been studied as a prognostic biomarker, a tool for detection of minimal residual disease, and a monitor for treatment response",
                    "sub_points": [
                      "ctDNA reflects real-time tumor burden",
                      "ctDNA has been studied as a prognostic biomarker, a tool for detection of minimal residual disease, and a monitor for treatment response"
                    ]
                  },
                  {
                    "text": "A promising area of clinical application of new molecular technologies includes genomic characterization of ctDNAProvides an additional tool to personalize treatment decisions in a dynamic and noninvasive wayProvides clinical utility for identification of actionable mutations and serial monitoring for additional changes",
                    "sub_points": [
                      "Provides an additional tool to personalize treatment decisions in a dynamic and noninvasive way",
                      "Provides clinical utility for identification of actionable mutations and serial monitoring for additional changes"
                    ]
                  },
                  {
                    "text": "ctDNA is released from tumor tissue and CTCs into the circulation following apoptosis and necrosis of tumor cellsRepresents a tiny fraction of ctDNA found in the bloodstreamctDNA can be captured for molecular analysisctDNA is able to detect the majority of actionable alterations found in tumor tissue (~ 60%)The extent of ctDNA and the number of patients with increased levels is greater in women with advanced diseaseIt is a promising complementary tool in precision oncology for BC and other solid tumors",
                    "sub_points": [
                      "Represents a tiny fraction of ctDNA found in the bloodstream",
                      "ctDNA can be captured for molecular analysis",
                      "ctDNA is able to detect the majority of actionable alterations found in tumor tissue (~ 60%)",
                      "The extent of ctDNA and the number of patients with increased levels is greater in women with advanced disease",
                      "It is a promising complementary tool in precision oncology for BC and other solid tumors"
                    ]
                  },
                  {
                    "text": "Characterization of ctDNA has several potential clinically relevant applicationsNoninvasive tumor genotypingMonitoring of treatment responseIdentifying mechanisms of resistanceThe gene for ER,ESR1,is mutated in almost 1/2 of patients with metastatic ER(+) diseaseMutations are uncommon in primary tumors and enriched in metastatic ER(+) diseaseThe majority ofESR1mutations are detected in cancers of women receiving aromatase inhibitors (AI) for ER(+) metastatic diseaseMutations arise under the selective pressure from AI treatmentMutations in ligand-binding domains of ER can lead to constitutive activation in absence of estradiol, which leads to resistance to AI, and decreased sensitivity to tamoxifenDetection ofESR1mutations in ctDNA is associated with shorter progression-free survival for patients treated with AI compared with wildtypeESR1Patients withESR1mutations and advanced ER(+)BC show improved progression-free survival with fulvestrant treatment compared with AIIn the PADA-1 trial, patients with ER(+) advanced BC were randomized to switch from AI to fulvestrant upon early detection of anESR1mutation by ctDNAFulvestrant is a selective ER degrader (SERD)ESR1mutations were detected through serial monitoring of ctDNAPatients who switched to fulvestrant experienced doubling of progression-free survivalPatients withESR1-wildtype cancer had similar progression-free survival irrespective of the type of endocrine therapy administeredThis trial further emphasized the role of liquid biopsy and ctDNA in patient treatment monitoringIn the EMERALD trial, patients with ER(+) advanced BC were randomized to elacestrant or standard of careElacestrant is a selective ER modulator (SERM) and a SERDPatients withESR1-mutated BC had improved progression-free survival when treated with elacestrant, and the benefit was greater than that observed for patients withESR1-wildtype cancersThe PADA-1 and EMERALD trials established liquid biopsy as the test of choice to identify secondaryESR1mutationsAnESR1mutation is an actionable mechanism of acquired resistance to endocrine therapyIn the setting of advanced cancer with a mutated constitutively activated ER, therapy that causes degradation of ER has been shown to be more effective than agents that reduce estradiol levels or block estradiol bindingSurveillance and identification of residual diseasectDNA analysis across the disease course offers a number of potential clinical applicationsMay allow for meaningful discrimination between patients highly likely to be cured from those with a high risk for recurrenceStrong evidence suggests that ctDNA detection correlates with ongoing residual disease, increased recurrence risk, and poor overall survivalEarly identification of residual disease would allow for closer monitoring &/or additional therapyIdeally, ctDNA levels would precede radiologic progression, thus allowing for the identification and escalation of treatment in patients with residual diseaseSurveillance could also help to identify patients at low risk for whom deescalated treatment would be appropriate",
                    "sub_points": [
                      "Noninvasive tumor genotyping",
                      "Monitoring of treatment response",
                      "Identifying mechanisms of resistanceThe gene for ER,ESR1,is mutated in almost 1/2 of patients with metastatic ER(+) diseaseMutations are uncommon in primary tumors and enriched in metastatic ER(+) diseaseThe majority ofESR1mutations are detected in cancers of women receiving aromatase inhibitors (AI) for ER(+) metastatic diseaseMutations arise under the selective pressure from AI treatmentMutations in ligand-binding domains of ER can lead to constitutive activation in absence of estradiol, which leads to resistance to AI, and decreased sensitivity to tamoxifenDetection ofESR1mutations in ctDNA is associated with shorter progression-free survival for patients treated with AI compared with wildtypeESR1Patients withESR1mutations and advanced ER(+)BC show improved progression-free survival with fulvestrant treatment compared with AIIn the PADA-1 trial, patients with ER(+) advanced BC were randomized to switch from AI to fulvestrant upon early detection of anESR1mutation by ctDNAFulvestrant is a selective ER degrader (SERD)ESR1mutations were detected through serial monitoring of ctDNAPatients who switched to fulvestrant experienced doubling of progression-free survivalPatients withESR1-wildtype cancer had similar progression-free survival irrespective of the type of endocrine therapy administeredThis trial further emphasized the role of liquid biopsy and ctDNA in patient treatment monitoringIn the EMERALD trial, patients with ER(+) advanced BC were randomized to elacestrant or standard of careElacestrant is a selective ER modulator (SERM) and a SERDPatients withESR1-mutated BC had improved progression-free survival when treated with elacestrant, and the benefit was greater than that observed for patients withESR1-wildtype cancersThe PADA-1 and EMERALD trials established liquid biopsy as the test of choice to identify secondaryESR1mutationsAnESR1mutation is an actionable mechanism of acquired resistance to endocrine therapyIn the setting of advanced cancer with a mutated constitutively activated ER, therapy that causes degradation of ER has been shown to be more effective than agents that reduce estradiol levels or block estradiol binding",
                      "The gene for ER,ESR1,is mutated in almost 1/2 of patients with metastatic ER(+) diseaseMutations are uncommon in primary tumors and enriched in metastatic ER(+) disease",
                      "Mutations are uncommon in primary tumors and enriched in metastatic ER(+) disease",
                      "The majority ofESR1mutations are detected in cancers of women receiving aromatase inhibitors (AI) for ER(+) metastatic diseaseMutations arise under the selective pressure from AI treatment",
                      "Mutations arise under the selective pressure from AI treatment",
                      "Mutations in ligand-binding domains of ER can lead to constitutive activation in absence of estradiol, which leads to resistance to AI, and decreased sensitivity to tamoxifen",
                      "Detection ofESR1mutations in ctDNA is associated with shorter progression-free survival for patients treated with AI compared with wildtypeESR1",
                      "Patients withESR1mutations and advanced ER(+)BC show improved progression-free survival with fulvestrant treatment compared with AI",
                      "In the PADA-1 trial, patients with ER(+) advanced BC were randomized to switch from AI to fulvestrant upon early detection of anESR1mutation by ctDNAFulvestrant is a selective ER degrader (SERD)ESR1mutations were detected through serial monitoring of ctDNAPatients who switched to fulvestrant experienced doubling of progression-free survivalPatients withESR1-wildtype cancer had similar progression-free survival irrespective of the type of endocrine therapy administeredThis trial further emphasized the role of liquid biopsy and ctDNA in patient treatment monitoring",
                      "Fulvestrant is a selective ER degrader (SERD)",
                      "ESR1mutations were detected through serial monitoring of ctDNA",
                      "Patients who switched to fulvestrant experienced doubling of progression-free survival",
                      "Patients withESR1-wildtype cancer had similar progression-free survival irrespective of the type of endocrine therapy administered",
                      "This trial further emphasized the role of liquid biopsy and ctDNA in patient treatment monitoring",
                      "In the EMERALD trial, patients with ER(+) advanced BC were randomized to elacestrant or standard of careElacestrant is a selective ER modulator (SERM) and a SERDPatients withESR1-mutated BC had improved progression-free survival when treated with elacestrant, and the benefit was greater than that observed for patients withESR1-wildtype cancers",
                      "Elacestrant is a selective ER modulator (SERM) and a SERD",
                      "Patients withESR1-mutated BC had improved progression-free survival when treated with elacestrant, and the benefit was greater than that observed for patients withESR1-wildtype cancers",
                      "The PADA-1 and EMERALD trials established liquid biopsy as the test of choice to identify secondaryESR1mutationsAnESR1mutation is an actionable mechanism of acquired resistance to endocrine therapyIn the setting of advanced cancer with a mutated constitutively activated ER, therapy that causes degradation of ER has been shown to be more effective than agents that reduce estradiol levels or block estradiol binding",
                      "AnESR1mutation is an actionable mechanism of acquired resistance to endocrine therapy",
                      "In the setting of advanced cancer with a mutated constitutively activated ER, therapy that causes degradation of ER has been shown to be more effective than agents that reduce estradiol levels or block estradiol binding",
                      "Surveillance and identification of residual diseasectDNA analysis across the disease course offers a number of potential clinical applicationsMay allow for meaningful discrimination between patients highly likely to be cured from those with a high risk for recurrenceStrong evidence suggests that ctDNA detection correlates with ongoing residual disease, increased recurrence risk, and poor overall survivalEarly identification of residual disease would allow for closer monitoring &/or additional therapyIdeally, ctDNA levels would precede radiologic progression, thus allowing for the identification and escalation of treatment in patients with residual diseaseSurveillance could also help to identify patients at low risk for whom deescalated treatment would be appropriate",
                      "ctDNA analysis across the disease course offers a number of potential clinical applicationsMay allow for meaningful discrimination between patients highly likely to be cured from those with a high risk for recurrence",
                      "May allow for meaningful discrimination between patients highly likely to be cured from those with a high risk for recurrence",
                      "Strong evidence suggests that ctDNA detection correlates with ongoing residual disease, increased recurrence risk, and poor overall survival",
                      "Early identification of residual disease would allow for closer monitoring &/or additional therapy",
                      "Ideally, ctDNA levels would precede radiologic progression, thus allowing for the identification and escalation of treatment in patients with residual disease",
                      "Surveillance could also help to identify patients at low risk for whom deescalated treatment would be appropriate"
                    ]
                  },
                  {
                    "text": "Limitations of ctDNA use in the clinical settingThere is heterogeneity in ctDNA methodologies used, and the results obtained by different studies differThe short half-life of ctDNA and the variable shedding of tumor DNA make testing at a single time point likely to be insufficientThe imperfect sensitivity of ctDNA is such that a negative result can be misleading and falsely reassuringCurrently, there is an incomplete understanding of how to respond clinically to a positive ctDNA result",
                    "sub_points": [
                      "There is heterogeneity in ctDNA methodologies used, and the results obtained by different studies differ",
                      "The short half-life of ctDNA and the variable shedding of tumor DNA make testing at a single time point likely to be insufficient",
                      "The imperfect sensitivity of ctDNA is such that a negative result can be misleading and falsely reassuring",
                      "Currently, there is an incomplete understanding of how to respond clinically to a positive ctDNA result"
                    ]
                  },
                  {
                    "text": "Further trials are needed to help guide management following detection of ctDNA"
                  }
                ]
              },
              "Next-Generation Sequencing (NGS)": {
                "Massive Parallel Sequencing of DNA Molecules": [
                  {
                    "text": "NGS is a diagnostic assay, interrogating DNA or RNA to decipher tumor biomarker profilesTumor DNA to be analyzed can be extracted from formalin-fixed or frozen tissue or from blood (ctDNA)Allows the identification of multiple mechanisms involved in tumor development and progressionNGS profiling is rapidly being implemented in the clinicMost often used for identifying targetable alterations in the setting of advanced or metastatic diseaseA limited panel of a few dozen genes is suitable for analyzing known targetable oncogenes in a cost-effective way across a number of solid tumorsLarger scale sequencing allows for estimating tumor mutation burden and microsatellite instability (MSI) using bioinformatics toolsThis can be used clinically as a biomarker for immunotherapy",
                    "sub_points": [
                      "Tumor DNA to be analyzed can be extracted from formalin-fixed or frozen tissue or from blood (ctDNA)",
                      "Allows the identification of multiple mechanisms involved in tumor development and progression",
                      "NGS profiling is rapidly being implemented in the clinic",
                      "Most often used for identifying targetable alterations in the setting of advanced or metastatic disease",
                      "A limited panel of a few dozen genes is suitable for analyzing known targetable oncogenes in a cost-effective way across a number of solid tumors",
                      "Larger scale sequencing allows for estimating tumor mutation burden and microsatellite instability (MSI) using bioinformatics toolsThis can be used clinically as a biomarker for immunotherapy",
                      "This can be used clinically as a biomarker for immunotherapy"
                    ]
                  },
                  {
                    "text": "NGS can be performed on both tissue and blood samplesProvides testing for specific gene alterations with predictive and prognostic potentialThe ability to analyze multiple genes simultaneouslyThe ability to identify alterations in nucleotide sequencesPoint mutations, deletions, insertionsGene rearrangements, fusions, copy number variationsThe feasibility for NGS screening of MBC and the clinical utility of targeted therapy has been assessed in a number of clinical trialsStudies show that a subset of patients benefit from high-throughput genomics and targeted therapyNGS screening for targetable alterations must be integrated with clinical and pathologic data to accurately determine best therapeutic options",
                    "sub_points": [
                      "Provides testing for specific gene alterations with predictive and prognostic potentialThe ability to analyze multiple genes simultaneouslyThe ability to identify alterations in nucleotide sequencesPoint mutations, deletions, insertionsGene rearrangements, fusions, copy number variationsThe feasibility for NGS screening of MBC and the clinical utility of targeted therapy has been assessed in a number of clinical trialsStudies show that a subset of patients benefit from high-throughput genomics and targeted therapy",
                      "The ability to analyze multiple genes simultaneously",
                      "The ability to identify alterations in nucleotide sequencesPoint mutations, deletions, insertionsGene rearrangements, fusions, copy number variations",
                      "Point mutations, deletions, insertions",
                      "Gene rearrangements, fusions, copy number variations",
                      "The feasibility for NGS screening of MBC and the clinical utility of targeted therapy has been assessed in a number of clinical trialsStudies show that a subset of patients benefit from high-throughput genomics and targeted therapy",
                      "Studies show that a subset of patients benefit from high-throughput genomics and targeted therapy",
                      "NGS screening for targetable alterations must be integrated with clinical and pathologic data to accurately determine best therapeutic options"
                    ]
                  },
                  {
                    "text": "Germline testing for BC by tissue testing and ctDNAA germline mutation is any DNA variant within germ cells that can be passed along to offspring; the mutation is present in every somatic cell of offspring developing from a fertilized egg with the mutationInherited germline mutations are involved in ~ 5-10% of BCsRecommendations for germline testing vary depending on the recommending organizationNCCN recommends testing for high-penetrance BC susceptibility genes in all male patients and certain female patients who are at increased risk for BCGenes to be tested includeBRCA1,BRCA2,CDH1,PALB2,PTEN,STK11,andTP53ASCO suggests performing germline testing for genetic alterations linked to approved therapies in patients with metastatic solid tumors who are considered to be candidates for such treatmentsBRCA1/BRCA2deleterious variants are the main biomarkers for treatment with poly(ADP)ribose polymerase (PARP) inhibitorsOlympiAD and EMBRCA trials showed benefit from PARP inhibitors in patients with germlineBRCA1/BRCA2mutationsScreening for these mutations is carried out in the locally advanced cancer or metastatic settingGermline and somaticBRCA1/BRCA2mutations confer sensitivity to platinum-based chemotherapy and PARP inhibitors in BC and other solid tumors with homologous recombination deficienciesTesting provides crucial information for clinical and therapeutic management",
                    "sub_points": [
                      "A germline mutation is any DNA variant within germ cells that can be passed along to offspring; the mutation is present in every somatic cell of offspring developing from a fertilized egg with the mutation",
                      "Inherited germline mutations are involved in ~ 5-10% of BCs",
                      "Recommendations for germline testing vary depending on the recommending organization",
                      "NCCN recommends testing for high-penetrance BC susceptibility genes in all male patients and certain female patients who are at increased risk for BCGenes to be tested includeBRCA1,BRCA2,CDH1,PALB2,PTEN,STK11,andTP53",
                      "Genes to be tested includeBRCA1,BRCA2,CDH1,PALB2,PTEN,STK11,andTP53",
                      "BRCA1,BRCA2,CDH1,PALB2,PTEN,STK11,andTP53",
                      "ASCO suggests performing germline testing for genetic alterations linked to approved therapies in patients with metastatic solid tumors who are considered to be candidates for such treatmentsBRCA1/BRCA2deleterious variants are the main biomarkers for treatment with poly(ADP)ribose polymerase (PARP) inhibitorsOlympiAD and EMBRCA trials showed benefit from PARP inhibitors in patients with germlineBRCA1/BRCA2mutationsScreening for these mutations is carried out in the locally advanced cancer or metastatic settingGermline and somaticBRCA1/BRCA2mutations confer sensitivity to platinum-based chemotherapy and PARP inhibitors in BC and other solid tumors with homologous recombination deficienciesTesting provides crucial information for clinical and therapeutic management",
                      "BRCA1/BRCA2deleterious variants are the main biomarkers for treatment with poly(ADP)ribose polymerase (PARP) inhibitorsOlympiAD and EMBRCA trials showed benefit from PARP inhibitors in patients with germlineBRCA1/BRCA2mutations",
                      "OlympiAD and EMBRCA trials showed benefit from PARP inhibitors in patients with germlineBRCA1/BRCA2mutations",
                      "Screening for these mutations is carried out in the locally advanced cancer or metastatic setting",
                      "Germline and somaticBRCA1/BRCA2mutations confer sensitivity to platinum-based chemotherapy and PARP inhibitors in BC and other solid tumors with homologous recombination deficiencies",
                      "Testing provides crucial information for clinical and therapeutic management"
                    ]
                  },
                  {
                    "text": "Somatic testing for BC by ctDNACan provide early detection of disease recurrence &/or disease progressionDetection of preclinical metastasesPrediction of recurrence after surgery &/or NAT by detecting tumor-specific hotspot mutations, rearrangements, &/or amplificationsThe most common driver mutations in BC areTP53(37%),PIK3CA(21%),AKT1(7%),EGFR(5%), andKRAS(5%)The frequency of mutations detected by ctDNA increases with metastatic recurrence, nodal involvement, and distant metastasesNot all BC patients will have hotspot mutationsctDNA is a surrogate marker for minimal residual disease after treatmentPersonalized monitoring of ctDNA may aid in assessment of treatment response and help fine-tune NATPatients who remain ctDNA(+) after the start of NAT are significantly more likely to experience residual diseaseFor patients who have residual disease, ctDNA(+) significantly increases their risk of recurrenceIn contrast, patients who have residual disease and who are ctDNA(-) have an excellent outcome, similar to complete respondersctDNA persistence during NAT and after primary treatment is associated with poor prognosisctDNA is a prognostic and predictive factor for therapy effectiveness and treatment resistancePatients with ctDNATP53mutations have shorter progression-free survival in response to HER2-directed therapy than those withoutctDNATP53mutations predict lower efficacy to HER2 tyrosine kinase inhibitorsctDNAESR1mutations in advanced BC are associated with worse progression-free survival compared with wildtypeESR1Monitoring ofESR1mutations serves as a predictive biomarker of endocrine resistanceESR1mutations are predictive of benefit from fulvestrant, everolimus, or elacestrant vs. AIsAlterations of the PI3K/AKT/PTEN pathway can predict endocrine treatment resistance to endocrine therapyThe PI3K/AKT/PTEN signaling pathway is involved in cell metabolism, proliferation, and survivalUp to 50% of patients with ER(+)BC have hyperactivation of the PI3K/AKT1/PTEN pathwayHyperactivation of this pathway can drive disease progressionAKT is a serine threonine kinase that is a central regulatory protein in this pathwayAKT signaling may also be activated in the absence of genetic alterations in endocrine resistanceFor ER(+)BC,PI3KorAKT1mutations have been correlated with endocrine treatment resistanceInhibition of this pathway in patients who are harboring alterations has shown benefit in pretreated ER(+) advanced BCThe PI3K alpha-selective inhibitor (alpelisib) has been approved in combination with endocrine therapyThe mTOR inhibitor (everolimus) has been approved in combination with endocrine therapyThe AKT inhibitor (capivasertib) has demonstrated greater efficacy than endocrine therapyPI3Khotspot mutations have been classified as level IA mutations in clinical practice according to the ESMODetection of MSI by NGS has been approved as a predictive marker for immune checkpoint inhibitor therapyIdentification of neurotrophic tyrosine receptor kinaseSLITRK1fusion has been approved as a predictive marker for tyrosine kinase inhibitorsHowever, the prevalence of MSI andSLITRK1fusions in BC is low (< 5%)",
                    "sub_points": [
                      "Can provide early detection of disease recurrence &/or disease progressionDetection of preclinical metastasesPrediction of recurrence after surgery &/or NAT by detecting tumor-specific hotspot mutations, rearrangements, &/or amplificationsThe most common driver mutations in BC areTP53(37%),PIK3CA(21%),AKT1(7%),EGFR(5%), andKRAS(5%)The frequency of mutations detected by ctDNA increases with metastatic recurrence, nodal involvement, and distant metastasesNot all BC patients will have hotspot mutations",
                      "Detection of preclinical metastases",
                      "Prediction of recurrence after surgery &/or NAT by detecting tumor-specific hotspot mutations, rearrangements, &/or amplifications",
                      "The most common driver mutations in BC areTP53(37%),PIK3CA(21%),AKT1(7%),EGFR(5%), andKRAS(5%)",
                      "TP53(37%),PIK3CA(21%),AKT1(7%),EGFR(5%), andKRAS(5%)",
                      "The frequency of mutations detected by ctDNA increases with metastatic recurrence, nodal involvement, and distant metastases",
                      "Not all BC patients will have hotspot mutations",
                      "ctDNA is a surrogate marker for minimal residual disease after treatmentPersonalized monitoring of ctDNA may aid in assessment of treatment response and help fine-tune NATPatients who remain ctDNA(+) after the start of NAT are significantly more likely to experience residual diseaseFor patients who have residual disease, ctDNA(+) significantly increases their risk of recurrenceIn contrast, patients who have residual disease and who are ctDNA(-) have an excellent outcome, similar to complete respondersctDNA persistence during NAT and after primary treatment is associated with poor prognosis",
                      "Personalized monitoring of ctDNA may aid in assessment of treatment response and help fine-tune NAT",
                      "Patients who remain ctDNA(+) after the start of NAT are significantly more likely to experience residual disease",
                      "For patients who have residual disease, ctDNA(+) significantly increases their risk of recurrence",
                      "In contrast, patients who have residual disease and who are ctDNA(-) have an excellent outcome, similar to complete responders",
                      "ctDNA persistence during NAT and after primary treatment is associated with poor prognosis",
                      "ctDNA is a prognostic and predictive factor for therapy effectiveness and treatment resistancePatients with ctDNATP53mutations have shorter progression-free survival in response to HER2-directed therapy than those withoutctDNATP53mutations predict lower efficacy to HER2 tyrosine kinase inhibitorsctDNAESR1mutations in advanced BC are associated with worse progression-free survival compared with wildtypeESR1Monitoring ofESR1mutations serves as a predictive biomarker of endocrine resistanceESR1mutations are predictive of benefit from fulvestrant, everolimus, or elacestrant vs. AIs",
                      "Patients with ctDNATP53mutations have shorter progression-free survival in response to HER2-directed therapy than those without",
                      "ctDNATP53mutations predict lower efficacy to HER2 tyrosine kinase inhibitors",
                      "ctDNAESR1mutations in advanced BC are associated with worse progression-free survival compared with wildtypeESR1",
                      "Monitoring ofESR1mutations serves as a predictive biomarker of endocrine resistance",
                      "ESR1mutations are predictive of benefit from fulvestrant, everolimus, or elacestrant vs. AIs",
                      "Alterations of the PI3K/AKT/PTEN pathway can predict endocrine treatment resistance to endocrine therapyThe PI3K/AKT/PTEN signaling pathway is involved in cell metabolism, proliferation, and survivalUp to 50% of patients with ER(+)BC have hyperactivation of the PI3K/AKT1/PTEN pathwayHyperactivation of this pathway can drive disease progressionAKT is a serine threonine kinase that is a central regulatory protein in this pathwayAKT signaling may also be activated in the absence of genetic alterations in endocrine resistanceFor ER(+)BC,PI3KorAKT1mutations have been correlated with endocrine treatment resistanceInhibition of this pathway in patients who are harboring alterations has shown benefit in pretreated ER(+) advanced BCThe PI3K alpha-selective inhibitor (alpelisib) has been approved in combination with endocrine therapyThe mTOR inhibitor (everolimus) has been approved in combination with endocrine therapyThe AKT inhibitor (capivasertib) has demonstrated greater efficacy than endocrine therapyPI3Khotspot mutations have been classified as level IA mutations in clinical practice according to the ESMO",
                      "The PI3K/AKT/PTEN signaling pathway is involved in cell metabolism, proliferation, and survivalUp to 50% of patients with ER(+)BC have hyperactivation of the PI3K/AKT1/PTEN pathwayHyperactivation of this pathway can drive disease progressionAKT is a serine threonine kinase that is a central regulatory protein in this pathwayAKT signaling may also be activated in the absence of genetic alterations in endocrine resistanceFor ER(+)BC,PI3KorAKT1mutations have been correlated with endocrine treatment resistance",
                      "Up to 50% of patients with ER(+)BC have hyperactivation of the PI3K/AKT1/PTEN pathway",
                      "Hyperactivation of this pathway can drive disease progression",
                      "AKT is a serine threonine kinase that is a central regulatory protein in this pathway",
                      "AKT signaling may also be activated in the absence of genetic alterations in endocrine resistance",
                      "For ER(+)BC,PI3KorAKT1mutations have been correlated with endocrine treatment resistance",
                      "Inhibition of this pathway in patients who are harboring alterations has shown benefit in pretreated ER(+) advanced BCThe PI3K alpha-selective inhibitor (alpelisib) has been approved in combination with endocrine therapyThe mTOR inhibitor (everolimus) has been approved in combination with endocrine therapyThe AKT inhibitor (capivasertib) has demonstrated greater efficacy than endocrine therapy",
                      "The PI3K alpha-selective inhibitor (alpelisib) has been approved in combination with endocrine therapy",
                      "The mTOR inhibitor (everolimus) has been approved in combination with endocrine therapy",
                      "The AKT inhibitor (capivasertib) has demonstrated greater efficacy than endocrine therapy",
                      "PI3Khotspot mutations have been classified as level IA mutations in clinical practice according to the ESMO",
                      "Detection of MSI by NGS has been approved as a predictive marker for immune checkpoint inhibitor therapy",
                      "Identification of neurotrophic tyrosine receptor kinaseSLITRK1fusion has been approved as a predictive marker for tyrosine kinase inhibitorsHowever, the prevalence of MSI andSLITRK1fusions in BC is low (< 5%)",
                      "However, the prevalence of MSI andSLITRK1fusions in BC is low (< 5%)"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Response to Neoadjuvant Therapy": {
            "name": "Response to Neoadjuvant Therapy",
            "url": "https://app.pathprimer.com/document/1eda9d95-34bf-4cb1-91f5-461cb810fa9f/lesson/91a8bcb4-b8c1-4551-8d97-0b9b9273da6d",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Neoadjuvant therapy (NAT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Preoperative therapy"
                  },
                  {
                    "text": "Presurgical therapy"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Patients are treated with chemotherapy, targeted therapy, &/or hormonal therapy prior to surgical removal of invasive breast carcinoma (IBC)"
                  }
                ]
              },
              "NEOADJUVANT THERAPY FOR INVASIVE BREAST CARCINOMA": {
                "Adjuvant vs. Neoadjuvant Therapy (NAT)": [
                  {
                    "text": "Patients who receive adjuvant therapy undergo surgical removal of their invasive breast carcinoma (IBC) and any positive lymph nodes and then may be treated systemically with therapeutic agentsSpecific response to treatment cannot be determinedSome patients may do well due to surgery and radiation rather than systemic treatmentCancer may or may not have responded to chemotherapySome patients may have extended survival due to response to systemic treatment of cancer but eventually succumbThis group may not be identified if only survival is consideredThe endpoint for clinical trials of adjuvant therapy is recurrence or death that may not occur for many years or possibly decades",
                    "sub_points": [
                      "Specific response to treatment cannot be determinedSome patients may do well due to surgery and radiation rather than systemic treatmentCancer may or may not have responded to chemotherapySome patients may have extended survival due to response to systemic treatment of cancer but eventually succumbThis group may not be identified if only survival is considered",
                      "Some patients may do well due to surgery and radiation rather than systemic treatmentCancer may or may not have responded to chemotherapy",
                      "Cancer may or may not have responded to chemotherapy",
                      "Some patients may have extended survival due to response to systemic treatment of cancer but eventually succumbThis group may not be identified if only survival is considered",
                      "This group may not be identified if only survival is considered",
                      "The endpoint for clinical trials of adjuvant therapy is recurrence or death that may not occur for many years or possibly decades"
                    ]
                  },
                  {
                    "text": "Patients who receive NAT have their diagnosis of IBC made by needle biopsy and are then treated systemically with therapeutic agentsNAT can include chemotherapy, immunotherapy, targeted therapy, &/or endocrine therapyResponse to treatment is monitored by physical examination and imagingThere is the opportunity to change treatment if there is no response or progression occursAt completion of treatment, the patient undergoes surgery1st endpoint for clinical trials is the pathologic response of the IBC to treatmentThis information is available immediately after treatment for individual patients and within months to a few years for trials2nd endpoint for clinical trials is survival, recurrence, or deathThis is the most important endpoint but is typically evaluated after many years of follow-up",
                    "sub_points": [
                      "NAT can include chemotherapy, immunotherapy, targeted therapy, &/or endocrine therapy",
                      "Response to treatment is monitored by physical examination and imagingThere is the opportunity to change treatment if there is no response or progression occurs",
                      "There is the opportunity to change treatment if there is no response or progression occurs",
                      "At completion of treatment, the patient undergoes surgery",
                      "1st endpoint for clinical trials is the pathologic response of the IBC to treatmentThis information is available immediately after treatment for individual patients and within months to a few years for trials",
                      "This information is available immediately after treatment for individual patients and within months to a few years for trials",
                      "2nd endpoint for clinical trials is survival, recurrence, or deathThis is the most important endpoint but is typically evaluated after many years of follow-up",
                      "This is the most important endpoint but is typically evaluated after many years of follow-up"
                    ]
                  },
                  {
                    "text": "The timing of systemic therapy before or after surgery does not alter survival"
                  },
                  {
                    "text": "However, information about treatment response can be used to deescalate treatment (when there is a good response) or escalate treatment (when there is a poor response)"
                  }
                ],
                "Value of Neoadjuvant Therapy: 3 Main Benefits": [
                  {
                    "text": "Surgical eligibilityPatients who present with nonoperable, locally advanced IBC may become eligible for surgery if there is a good responseNAT identifies patients with IBCs that can be controlled locallySome patients who would require mastectomy can become eligible for breast conservation",
                    "sub_points": [
                      "Patients who present with nonoperable, locally advanced IBC may become eligible for surgery if there is a good responseNAT identifies patients with IBCs that can be controlled locally",
                      "NAT identifies patients with IBCs that can be controlled locally",
                      "Some patients who would require mastectomy can become eligible for breast conservation"
                    ]
                  },
                  {
                    "text": "PrognosisPathologic complete response (pCR = no residual IBC in breast or nodes) to NAT is a strong prognostic factor for some molecular subtypes of breast IBC\"Luminal A IBC\" ER(+)/HER2(-), grade 1 or 2: < 10% pCRPatients who would not benefit from chemotherapy can be identified by gene expression profiling and generally do not undergo NATPatients with or without a pCR have similar survival for at least 8 years, > 80-90%\"Luminal B IBC\" ER(+)/HER2(-), grade 3: ~ 10% pCR, ~ > 90% survival with pCR, ~ 40% survival without pCR\"Luminal HER2 IBC\" ER(+)/HER2(+): ~ 40% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR\"HER2 IBC\" ER(-)/HER2(+): ~ 70% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR\"Triple negative BC (TNBC)\" ER(-)/HER2(-): ~ 40% pCR, ~ 90% survival with pCR, ~ 40% survival without pCRInformation about response to NAT can be used to guide therapy for patients and to evaluate trialsIndividual patients: Prognostic information can be used to guide further treatment and help determine the benefit of prophylactic surgeryClinical trials: Response to NAT is a short-term endpoint (months to a few years) that can be used to compare different treatments using fewer patients over a shorter period of time",
                    "sub_points": [
                      "Pathologic complete response (pCR = no residual IBC in breast or nodes) to NAT is a strong prognostic factor for some molecular subtypes of breast IBC\"Luminal A IBC\" ER(+)/HER2(-), grade 1 or 2: < 10% pCRPatients who would not benefit from chemotherapy can be identified by gene expression profiling and generally do not undergo NATPatients with or without a pCR have similar survival for at least 8 years, > 80-90%\"Luminal B IBC\" ER(+)/HER2(-), grade 3: ~ 10% pCR, ~ > 90% survival with pCR, ~ 40% survival without pCR\"Luminal HER2 IBC\" ER(+)/HER2(+): ~ 40% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR\"HER2 IBC\" ER(-)/HER2(+): ~ 70% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR\"Triple negative BC (TNBC)\" ER(-)/HER2(-): ~ 40% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR",
                      "\"Luminal A IBC\" ER(+)/HER2(-), grade 1 or 2: < 10% pCRPatients who would not benefit from chemotherapy can be identified by gene expression profiling and generally do not undergo NATPatients with or without a pCR have similar survival for at least 8 years, > 80-90%",
                      "Patients who would not benefit from chemotherapy can be identified by gene expression profiling and generally do not undergo NAT",
                      "Patients with or without a pCR have similar survival for at least 8 years, > 80-90%",
                      "\"Luminal B IBC\" ER(+)/HER2(-), grade 3: ~ 10% pCR, ~ > 90% survival with pCR, ~ 40% survival without pCR",
                      "\"Luminal HER2 IBC\" ER(+)/HER2(+): ~ 40% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR",
                      "\"HER2 IBC\" ER(-)/HER2(+): ~ 70% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR",
                      "\"Triple negative BC (TNBC)\" ER(-)/HER2(-): ~ 40% pCR, ~ 90% survival with pCR, ~ 40% survival without pCR",
                      "Information about response to NAT can be used to guide therapy for patients and to evaluate trialsIndividual patients: Prognostic information can be used to guide further treatment and help determine the benefit of prophylactic surgeryClinical trials: Response to NAT is a short-term endpoint (months to a few years) that can be used to compare different treatments using fewer patients over a shorter period of time",
                      "Individual patients: Prognostic information can be used to guide further treatment and help determine the benefit of prophylactic surgery",
                      "Clinical trials: Response to NAT is a short-term endpoint (months to a few years) that can be used to compare different treatments using fewer patients over a shorter period of time"
                    ]
                  },
                  {
                    "text": "Research toolsPaired pre- and posttreatment samples of IBCs are valuable resource for researchCan be used to investigate how IBCs respond and how to predict which carcinomas will respondMultigene assays are being developed to attempt to predict which IBCs will respond to specific types of therapy",
                    "sub_points": [
                      "Paired pre- and posttreatment samples of IBCs are valuable resource for researchCan be used to investigate how IBCs respond and how to predict which carcinomas will respond",
                      "Can be used to investigate how IBCs respond and how to predict which carcinomas will respond",
                      "Multigene assays are being developed to attempt to predict which IBCs will respond to specific types of therapy"
                    ]
                  }
                ],
                "Definition of Pathologic Complete Response (pCR)": [
                  {
                    "text": "Multiple definitions of pCR have been used in clinical trialsNear absence of IBC in breastComplete absence of IBC in breastAbsence of IBC and ductal carcinoma in situ (DCIS) in breastAbsence of IBC in breast and nodes",
                    "sub_points": [
                      "Near absence of IBC in breast",
                      "Complete absence of IBC in breast",
                      "Absence of IBC and ductal carcinoma in situ (DCIS) in breast",
                      "Absence of IBC in breast and nodes"
                    ]
                  },
                  {
                    "text": "Response in lymph nodes has more prognostic value than response in breastMetastatic carcinoma in nodes may be more representative of distant metastases than IBC in breastResidual metastatic carcinoma in nodes is a predictive factor for recurrence after NAT",
                    "sub_points": [
                      "Metastatic carcinoma in nodes may be more representative of distant metastases than IBC in breast",
                      "Residual metastatic carcinoma in nodes is a predictive factor for recurrence after NAT"
                    ]
                  },
                  {
                    "text": "Residual ductal carcinoma in situ (DCIS) predicts local recurrence but not overall survival"
                  },
                  {
                    "text": "Recommended definition of pCR is absence of IBC in breast and no metastatic carcinoma in nodes; DCIS can be presentUSA FDA endorses this definition for evaluation of clinical trials",
                    "sub_points": [
                      "USA FDA endorses this definition for evaluation of clinical trials"
                    ]
                  },
                  {
                    "text": "Differential diagnosis of pCR includes failure to identify the tumor bed in the specimenPlacing a clip before treatment and finding and evaluating the adjacent tissue post treatment is essential for accurate assessment of response",
                    "sub_points": [
                      "Placing a clip before treatment and finding and evaluating the adjacent tissue post treatment is essential for accurate assessment of response"
                    ]
                  }
                ],
                "Clinical vs. Pathologic Response to Neoadjuvant Therapy": [
                  {
                    "text": "Clinical/radiologic evaluation of response can only estimate likelihood of residual cancer20% of patients thought clinically to have residual disease have had a pCRTumor bed may continue to form a palpable mass and appear as a radiologic density but lack viable tumor cells30-50% of patients thought clinically to have had a pCR have residual diseaseConsiderable residual IBC can be present even if no palpable mass remains and imaging findings resolve after treatmentIBCs typically become less cellular and have diminished blood flow, resulting in a softer mass that is difficult to palpateEnhancement by MR is typically decreased",
                    "sub_points": [
                      "20% of patients thought clinically to have residual disease have had a pCRTumor bed may continue to form a palpable mass and appear as a radiologic density but lack viable tumor cells",
                      "Tumor bed may continue to form a palpable mass and appear as a radiologic density but lack viable tumor cells",
                      "30-50% of patients thought clinically to have had a pCR have residual diseaseConsiderable residual IBC can be present even if no palpable mass remains and imaging findings resolve after treatmentIBCs typically become less cellular and have diminished blood flow, resulting in a softer mass that is difficult to palpateEnhancement by MR is typically decreased",
                      "Considerable residual IBC can be present even if no palpable mass remains and imaging findings resolve after treatment",
                      "IBCs typically become less cellular and have diminished blood flow, resulting in a softer mass that is difficult to palpate",
                      "Enhancement by MR is typically decreased"
                    ]
                  },
                  {
                    "text": "Pathologic evaluation is the gold standard for response to NAT"
                  },
                  {
                    "text": "An international working group has recommended reporting American Joint Committee on Cancer (AJCC) stage (\"y\") and residual cancer burden (RCB) for patients on clinical trialsMany other methods of evaluating response have also been developed",
                    "sub_points": [
                      "Many other methods of evaluating response have also been developed"
                    ]
                  }
                ],
                "Pretreatment Evaluation": [
                  {
                    "text": "BreastCore needle biopsy must show definitive invasive IBCA clip must be placed to mark the site of the IBCIf there is complete or near-complete response, there may not be an alternative method to identify site of the IBCCalcifications associated with IBC and DCIS generally remain after NATNot all carcinomas are associated with calcifications, and this finding should not be relied upon to identify tumor siteHistologic type and grade are reportedReporting cellularity is helpful because some systems of evaluating response require this information (e.g., Miller-Payne, Sataloff, Pinder)ER, PR, and HER2 studies must be completed prior to treatmentIf uncertain or equivocal, additional biopsies should be consideredIf amount of IBC is very small in the needle biopsy (i.e., < 0.5 cm), and markers are negative, a 2nd biopsy that might be more representative could be consideredFactors associated with response to NAT can be reportedIBCs more likely to respond to NAT are ER(-), HER2(+), grade 3, highly proliferative, necrotic, and have a dense lymphocytic infiltrateIBCs less likely to respond to NAT are ER(+) and lobular in typePredictors of response to endocrine therapy are high levels of ER(+) and PR(+)Predictor of response to HER2-targeted therapy is HER2(+) at higher levels (e.g., HER2 3+ with high amplification vs. HER2 2+ with low amplification)",
                    "sub_points": [
                      "Core needle biopsy must show definitive invasive IBCA clip must be placed to mark the site of the IBCIf there is complete or near-complete response, there may not be an alternative method to identify site of the IBCCalcifications associated with IBC and DCIS generally remain after NATNot all carcinomas are associated with calcifications, and this finding should not be relied upon to identify tumor site",
                      "A clip must be placed to mark the site of the IBC",
                      "If there is complete or near-complete response, there may not be an alternative method to identify site of the IBC",
                      "Calcifications associated with IBC and DCIS generally remain after NATNot all carcinomas are associated with calcifications, and this finding should not be relied upon to identify tumor site",
                      "Not all carcinomas are associated with calcifications, and this finding should not be relied upon to identify tumor site",
                      "Histologic type and grade are reportedReporting cellularity is helpful because some systems of evaluating response require this information (e.g., Miller-Payne, Sataloff, Pinder)",
                      "Reporting cellularity is helpful because some systems of evaluating response require this information (e.g., Miller-Payne, Sataloff, Pinder)",
                      "ER, PR, and HER2 studies must be completed prior to treatmentIf uncertain or equivocal, additional biopsies should be consideredIf amount of IBC is very small in the needle biopsy (i.e., < 0.5 cm), and markers are negative, a 2nd biopsy that might be more representative could be considered",
                      "If uncertain or equivocal, additional biopsies should be considered",
                      "If amount of IBC is very small in the needle biopsy (i.e., < 0.5 cm), and markers are negative, a 2nd biopsy that might be more representative could be considered",
                      "Factors associated with response to NAT can be reportedIBCs more likely to respond to NAT are ER(-), HER2(+), grade 3, highly proliferative, necrotic, and have a dense lymphocytic infiltrateIBCs less likely to respond to NAT are ER(+) and lobular in type",
                      "IBCs more likely to respond to NAT are ER(-), HER2(+), grade 3, highly proliferative, necrotic, and have a dense lymphocytic infiltrate",
                      "IBCs less likely to respond to NAT are ER(+) and lobular in type",
                      "Predictors of response to endocrine therapy are high levels of ER(+) and PR(+)",
                      "Predictor of response to HER2-targeted therapy is HER2(+) at higher levels (e.g., HER2 3+ with high amplification vs. HER2 2+ with low amplification)"
                    ]
                  },
                  {
                    "text": "Lymph nodesThe best method to evaluate nodes is either fine-needle aspiration (FNA) or core needle biopsyThis leaves the metastasis in place so that it can be evaluated for response to NATIf a positive node is completely removed, any response cannot be evaluatedPalpable nodes can be sampled by needle biopsyEnlarged nonpalpable nodes can be identified by ultrasound and biopsiedA biopsied node may or may not be marked by a clip &/or localization device for later identification and removalPractice varies among institutionsIf there are no nodes large enough for biopsy, sentinel node biopsy may be performedSentinel node biopsy prior to treatment is more accurate than after treatmentIf node is free of carcinoma, no additional nodal sampling is necessary after treatment",
                    "sub_points": [
                      "The best method to evaluate nodes is either fine-needle aspiration (FNA) or core needle biopsyThis leaves the metastasis in place so that it can be evaluated for response to NATIf a positive node is completely removed, any response cannot be evaluated",
                      "This leaves the metastasis in place so that it can be evaluated for response to NAT",
                      "If a positive node is completely removed, any response cannot be evaluated",
                      "Palpable nodes can be sampled by needle biopsy",
                      "Enlarged nonpalpable nodes can be identified by ultrasound and biopsied",
                      "A biopsied node may or may not be marked by a clip &/or localization device for later identification and removalPractice varies among institutions",
                      "Practice varies among institutions",
                      "If there are no nodes large enough for biopsy, sentinel node biopsy may be performedSentinel node biopsy prior to treatment is more accurate than after treatmentIf node is free of carcinoma, no additional nodal sampling is necessary after treatment",
                      "Sentinel node biopsy prior to treatment is more accurate than after treatment",
                      "If node is free of carcinoma, no additional nodal sampling is necessary after treatment"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "If an IBC remains palpable clinically, the prosector will be able to identify it grossly"
                  },
                  {
                    "text": "If an IBC is no longer palpable after NAT, or is difficult to palpate, the specimen should be radiographed to identify clips, calcifications, and any other findings that were associated with the pretreatment IBC"
                  }
                ],
                "Specimen Handling": [
                  {
                    "text": "It is very important for the prosector to know characteristics of the IBC prior to NATSize, number, and location of carcinoma(s)Results of core needle biopsy and tumor markersSkin &/or chest wall invasionInflammatory IBC presentation with skin changes (involvement of dermal lymphatics)Presence of clips or calcifications marking site or sites of IBC &/or DCISSize and number of enlarged lymph nodesType of biopsy and resultsAnticipated response to NAT by clinical examination or imaging",
                    "sub_points": [
                      "Size, number, and location of carcinoma(s)Results of core needle biopsy and tumor markers",
                      "Results of core needle biopsy and tumor markers",
                      "Skin &/or chest wall invasion",
                      "Inflammatory IBC presentation with skin changes (involvement of dermal lymphatics)",
                      "Presence of clips or calcifications marking site or sites of IBC &/or DCIS",
                      "Size and number of enlarged lymph nodesType of biopsy and results",
                      "Type of biopsy and results",
                      "Anticipated response to NAT by clinical examination or imaging"
                    ]
                  },
                  {
                    "text": "If grossly evident IBC is present, the size, number of IBCs, and relationship of IBCs to each other should be describedTypical partial response to treatment is seen as multiple foci of invasion scattered over the tumor bed",
                    "sub_points": [
                      "Typical partial response to treatment is seen as multiple foci of invasion scattered over the tumor bed"
                    ]
                  },
                  {
                    "text": "If there is not a grossly evident IBC, the tumor bed must be identified using pretreatment location and size of tumor, imaging findings, &/or gross core needle biopsy siteUse of radiographs and diagrams to show location of tumor bed and areas sampled can be usefulRadiographs to show area of clips and potential residual calcifications reduce the number of sections required to adequately evaluate the specimen",
                    "sub_points": [
                      "Use of radiographs and diagrams to show location of tumor bed and areas sampled can be useful",
                      "Radiographs to show area of clips and potential residual calcifications reduce the number of sections required to adequately evaluate the specimen"
                    ]
                  },
                  {
                    "text": "Extent of sampling adjacent to clip(s) depends on extent of carcinoma prior to treatmentIf practical, the entire tumor bed should be sampled if patient may have had pCRMultiple blocks to represent a complete cross section of the tumor bed are helpful to estimate residual cellularityIf the tumor bed is quite large, at least 1 block of tissue per centimeter of tumor bed is suggestedThe value of additional tissue sampling can be determined after examination of the initial slidesIf grossly evident IBC is present, it is not necessary to sample the entire IBC",
                    "sub_points": [
                      "If practical, the entire tumor bed should be sampled if patient may have had pCRMultiple blocks to represent a complete cross section of the tumor bed are helpful to estimate residual cellularity",
                      "Multiple blocks to represent a complete cross section of the tumor bed are helpful to estimate residual cellularity",
                      "If the tumor bed is quite large, at least 1 block of tissue per centimeter of tumor bed is suggestedThe value of additional tissue sampling can be determined after examination of the initial slides",
                      "The value of additional tissue sampling can be determined after examination of the initial slides",
                      "If grossly evident IBC is present, it is not necessary to sample the entire IBC"
                    ]
                  },
                  {
                    "text": "Gross presence of tumor bed at margins should be notedAll margins should be sampled with perpendicular sections",
                    "sub_points": [
                      "All margins should be sampled with perpendicular sections"
                    ]
                  },
                  {
                    "text": "If skin was involved before NAT, or dermal lymphovascular invasion was present, additional sections of skin should be takenErythema and edema of skin seen prior to treatment usually resolve after NATThese features cannot be evaluated grossly in specimens in the absence of blood flow",
                    "sub_points": [
                      "Erythema and edema of skin seen prior to treatment usually resolve after NAT",
                      "These features cannot be evaluated grossly in specimens in the absence of blood flow"
                    ]
                  },
                  {
                    "text": "If chest wall was involved prior to NAT, the area closest to tumor/tumor bed should be sampled"
                  },
                  {
                    "text": "Lymph nodes should be carefully searched for and completely submitted for microscopic examinationNodes may be smaller and fewer in number after treatmentHowever, ~ 85% of patients should have > 10 nodes in a full axillary dissectionIf a lymph node was marked with clip, axillary tissue should be radiographed to identify the clipSentinel lymph node biopsy is less successful after NATIdentification rate lower (80-90%; goal is > 90%)False-negative rate higher (12-14%; goal is < 10%)",
                    "sub_points": [
                      "Nodes may be smaller and fewer in number after treatmentHowever, ~ 85% of patients should have > 10 nodes in a full axillary dissection",
                      "However, ~ 85% of patients should have > 10 nodes in a full axillary dissection",
                      "If a lymph node was marked with clip, axillary tissue should be radiographed to identify the clip",
                      "Sentinel lymph node biopsy is less successful after NATIdentification rate lower (80-90%; goal is > 90%)False-negative rate higher (12-14%; goal is < 10%)",
                      "Identification rate lower (80-90%; goal is > 90%)",
                      "False-negative rate higher (12-14%; goal is < 10%)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "General Features": [
                  {
                    "text": "Tumor bedThe tumor bed must be identified microscopicallyDense fibrosis, histiocytes, lymphocytes, occasional giant cells, and hemosiderin-laden macrophages are typicalBiodegradable carrier material from prior core needle biopsies may still be identifiableTumor bed does not have the same appearance as normal breast tissueIf only normal breast tissue is present, additional gross sampling is indicatedIf no residual IBC is present, additional sampling of tumor bed should be consideredImmunoperoxidase studies for keratin are of questionable value in the absence of identifiable tumor cells on routine histologyIt may be difficult to distinguish keratin debris from rare residual tumor cellsThe size of the tumor bed is important for determining the RCB",
                    "sub_points": [
                      "The tumor bed must be identified microscopicallyDense fibrosis, histiocytes, lymphocytes, occasional giant cells, and hemosiderin-laden macrophages are typicalBiodegradable carrier material from prior core needle biopsies may still be identifiableTumor bed does not have the same appearance as normal breast tissueIf only normal breast tissue is present, additional gross sampling is indicated",
                      "Dense fibrosis, histiocytes, lymphocytes, occasional giant cells, and hemosiderin-laden macrophages are typicalBiodegradable carrier material from prior core needle biopsies may still be identifiable",
                      "Biodegradable carrier material from prior core needle biopsies may still be identifiable",
                      "Tumor bed does not have the same appearance as normal breast tissueIf only normal breast tissue is present, additional gross sampling is indicated",
                      "If only normal breast tissue is present, additional gross sampling is indicated",
                      "If no residual IBC is present, additional sampling of tumor bed should be consideredImmunoperoxidase studies for keratin are of questionable value in the absence of identifiable tumor cells on routine histologyIt may be difficult to distinguish keratin debris from rare residual tumor cells",
                      "Immunoperoxidase studies for keratin are of questionable value in the absence of identifiable tumor cells on routine histologyIt may be difficult to distinguish keratin debris from rare residual tumor cells",
                      "It may be difficult to distinguish keratin debris from rare residual tumor cells",
                      "The size of the tumor bed is important for determining the RCB"
                    ]
                  },
                  {
                    "text": "Invasive carcinomaWhen there is minimal response, the IBC may show a 2- to 3-mm fibrotic zone around the peripheryThe cells at the periphery usually have the highest mitotic rate and are the most likely to respond to NATThe IBC is typically of similar appearance and cellularity to pretreatment IBCCentral necrosis within an IBC is typically intrinsic to the tumor and not the result of IBCCentral necrosis is frequently seen in IBCs in the absence of NATWhen there is marked response, residual IBC is usually present as scattered foci over fibrotic tumor bedResidual IBC usually resembles the pretreatment IBC but is often less cellularLobular carcinomas are often very paucicellular both with and without NAT: Scattered cells can be difficult to identifyThe grade of IBCs after treatment is prognostically significantIn rare cases, IBC may appear to be more poorly differentiated or, very rarely, more well differentiatedThe size of the largest contiguous focus of IBC (measured from tissue sections) is used for AJCC T classificationThe percentage cellularity of IBC over the tumor bed is used for RCBIBCs after endocrine NAT typically show minimal changesA central fibrotic area is described in some cases, but it is unclear if this is due to the treatmentLymphovascular invasion can be present in the absence of stromal invasionWhen calculating residual cellularity, IBC and lymphovascular invasion (but not DCIS) are included",
                    "sub_points": [
                      "When there is minimal response, the IBC may show a 2- to 3-mm fibrotic zone around the peripheryThe cells at the periphery usually have the highest mitotic rate and are the most likely to respond to NATThe IBC is typically of similar appearance and cellularity to pretreatment IBCCentral necrosis within an IBC is typically intrinsic to the tumor and not the result of IBCCentral necrosis is frequently seen in IBCs in the absence of NAT",
                      "The cells at the periphery usually have the highest mitotic rate and are the most likely to respond to NAT",
                      "The IBC is typically of similar appearance and cellularity to pretreatment IBC",
                      "Central necrosis within an IBC is typically intrinsic to the tumor and not the result of IBCCentral necrosis is frequently seen in IBCs in the absence of NAT",
                      "Central necrosis is frequently seen in IBCs in the absence of NAT",
                      "When there is marked response, residual IBC is usually present as scattered foci over fibrotic tumor bedResidual IBC usually resembles the pretreatment IBC but is often less cellularLobular carcinomas are often very paucicellular both with and without NAT: Scattered cells can be difficult to identifyThe grade of IBCs after treatment is prognostically significantIn rare cases, IBC may appear to be more poorly differentiated or, very rarely, more well differentiatedThe size of the largest contiguous focus of IBC (measured from tissue sections) is used for AJCC T classificationThe percentage cellularity of IBC over the tumor bed is used for RCB",
                      "Residual IBC usually resembles the pretreatment IBC but is often less cellularLobular carcinomas are often very paucicellular both with and without NAT: Scattered cells can be difficult to identify",
                      "Lobular carcinomas are often very paucicellular both with and without NAT: Scattered cells can be difficult to identify",
                      "The grade of IBCs after treatment is prognostically significantIn rare cases, IBC may appear to be more poorly differentiated or, very rarely, more well differentiated",
                      "In rare cases, IBC may appear to be more poorly differentiated or, very rarely, more well differentiated",
                      "The size of the largest contiguous focus of IBC (measured from tissue sections) is used for AJCC T classification",
                      "The percentage cellularity of IBC over the tumor bed is used for RCB",
                      "IBCs after endocrine NAT typically show minimal changesA central fibrotic area is described in some cases, but it is unclear if this is due to the treatment",
                      "A central fibrotic area is described in some cases, but it is unclear if this is due to the treatment",
                      "Lymphovascular invasion can be present in the absence of stromal invasionWhen calculating residual cellularity, IBC and lymphovascular invasion (but not DCIS) are included",
                      "When calculating residual cellularity, IBC and lymphovascular invasion (but not DCIS) are included"
                    ]
                  },
                  {
                    "text": "DCIS: Residual DCIS may be present within &/or away from the tumor bed (site of previous IBC)In some cases, there is no residual IBC but only DCISIt is important to distinguish DCIS from IBCResidual DCIS in the absence of IBC or lymphovascular invasion is classified as pCRImmunoperoxidase studies for myoepithelial markers should be used when necessaryPresence of DCIS can be helpful in identifying location of tumor bedDCIS may be similar in appearance or may have higher nuclear gradeDCIS may have a distinctive appearance after NATTumor cells can be located in center of ducts and lobules with several layers of normal cells at periphery",
                    "sub_points": [
                      "In some cases, there is no residual IBC but only DCISIt is important to distinguish DCIS from IBCResidual DCIS in the absence of IBC or lymphovascular invasion is classified as pCRImmunoperoxidase studies for myoepithelial markers should be used when necessary",
                      "It is important to distinguish DCIS from IBCResidual DCIS in the absence of IBC or lymphovascular invasion is classified as pCR",
                      "Residual DCIS in the absence of IBC or lymphovascular invasion is classified as pCR",
                      "Immunoperoxidase studies for myoepithelial markers should be used when necessary",
                      "Presence of DCIS can be helpful in identifying location of tumor bed",
                      "DCIS may be similar in appearance or may have higher nuclear grade",
                      "DCIS may have a distinctive appearance after NATTumor cells can be located in center of ducts and lobules with several layers of normal cells at periphery",
                      "Tumor cells can be located in center of ducts and lobules with several layers of normal cells at periphery"
                    ]
                  },
                  {
                    "text": "Normal breastNormal breast tissue may undergo treatment-related changesDucts and lobules may appear atrophic with thickened basement membranesScattered cells with nuclear pleomorphism may be seen; however, ductal architecture is normalIn some cases, it may be difficult to distinguish treatment-related changes from residual DCIS",
                    "sub_points": [
                      "Normal breast tissue may undergo treatment-related changesDucts and lobules may appear atrophic with thickened basement membranesScattered cells with nuclear pleomorphism may be seen; however, ductal architecture is normalIn some cases, it may be difficult to distinguish treatment-related changes from residual DCIS",
                      "Ducts and lobules may appear atrophic with thickened basement membranes",
                      "Scattered cells with nuclear pleomorphism may be seen; however, ductal architecture is normal",
                      "In some cases, it may be difficult to distinguish treatment-related changes from residual DCIS"
                    ]
                  },
                  {
                    "text": "Lymph nodesLymph nodes should be evaluated for residual carcinoma and for evidence of prior tumor involvementLymph nodes with documented metastases prior to treatment show variable degrees of response~ 55% show some degree of fibrous scarring~ 10% have a residual histiocytic infiltrate~ 35% completely resolve without evidence of the prior metastasisSentinel node is not as predictive of response in nonsentinel nodes after NATResponse to NAT may vary in different nodesResidual metastatic carcinoma may be scattered over a fibrous tumor bedThe size of the largest contiguous focus of carcinoma (not including tumor bed changes) is used for N classificationThe largest distance between foci of carcinoma (including tumor bed changes) is used for RCBMicrometastases have same prognostic significance as macrometastases after treatmentPrognostic significance of isolated tumor cells has not been well studiedCurrently not considered pCRValue of performing keratin on nodes (-) by H&E has not been demonstratedNumber of nodes with evidence of prior tumor involvement, but without residual tumor, should be reportedThis includes large areas of fibrosis, prominent histiocytic infiltrates, or mucin poolsIn the absence of NAT, lymph nodes occasionally show small areas of fibrosisIn some cases, it may be impossible to determine with certainty whether or not a node was previously involved by carcinomaThe number of nodes likely involved by metastasis prior to NAT may be used to decide whether to radiate the axillaIf a positive node was documented by needle biopsy prior to treatment, and no evidence of prior tumor is seen in any node after treatment, the possibility that the previously positive node was not excised should be considered2nd examination of specimen and additional tissue submission should be consideredHowever, it is possible for metastases to completely resolve, leaving a normal-appearing nodePlacement of a clip in a positive node prior to treatment ensures the node will be excised after treatmentExtramedullary hematopoiesis can occur in nodes after treatmentMegakaryocytes should be distinguished from residual carcinomaKeratin studies can be helpful to identify atypical cells",
                    "sub_points": [
                      "Lymph nodes should be evaluated for residual carcinoma and for evidence of prior tumor involvement",
                      "Lymph nodes with documented metastases prior to treatment show variable degrees of response~ 55% show some degree of fibrous scarring~ 10% have a residual histiocytic infiltrate~ 35% completely resolve without evidence of the prior metastasis",
                      "~ 55% show some degree of fibrous scarring",
                      "~ 10% have a residual histiocytic infiltrate",
                      "~ 35% completely resolve without evidence of the prior metastasis",
                      "Sentinel node is not as predictive of response in nonsentinel nodes after NATResponse to NAT may vary in different nodes",
                      "Response to NAT may vary in different nodes",
                      "Residual metastatic carcinoma may be scattered over a fibrous tumor bedThe size of the largest contiguous focus of carcinoma (not including tumor bed changes) is used for N classificationThe largest distance between foci of carcinoma (including tumor bed changes) is used for RCB",
                      "The size of the largest contiguous focus of carcinoma (not including tumor bed changes) is used for N classification",
                      "The largest distance between foci of carcinoma (including tumor bed changes) is used for RCB",
                      "Micrometastases have same prognostic significance as macrometastases after treatment",
                      "Prognostic significance of isolated tumor cells has not been well studiedCurrently not considered pCRValue of performing keratin on nodes (-) by H&E has not been demonstrated",
                      "Currently not considered pCR",
                      "Value of performing keratin on nodes (-) by H&E has not been demonstrated",
                      "Number of nodes with evidence of prior tumor involvement, but without residual tumor, should be reportedThis includes large areas of fibrosis, prominent histiocytic infiltrates, or mucin poolsIn the absence of NAT, lymph nodes occasionally show small areas of fibrosisIn some cases, it may be impossible to determine with certainty whether or not a node was previously involved by carcinomaThe number of nodes likely involved by metastasis prior to NAT may be used to decide whether to radiate the axillaIf a positive node was documented by needle biopsy prior to treatment, and no evidence of prior tumor is seen in any node after treatment, the possibility that the previously positive node was not excised should be considered2nd examination of specimen and additional tissue submission should be consideredHowever, it is possible for metastases to completely resolve, leaving a normal-appearing nodePlacement of a clip in a positive node prior to treatment ensures the node will be excised after treatment",
                      "This includes large areas of fibrosis, prominent histiocytic infiltrates, or mucin pools",
                      "In the absence of NAT, lymph nodes occasionally show small areas of fibrosisIn some cases, it may be impossible to determine with certainty whether or not a node was previously involved by carcinoma",
                      "In some cases, it may be impossible to determine with certainty whether or not a node was previously involved by carcinoma",
                      "The number of nodes likely involved by metastasis prior to NAT may be used to decide whether to radiate the axilla",
                      "If a positive node was documented by needle biopsy prior to treatment, and no evidence of prior tumor is seen in any node after treatment, the possibility that the previously positive node was not excised should be considered2nd examination of specimen and additional tissue submission should be consideredHowever, it is possible for metastases to completely resolve, leaving a normal-appearing nodePlacement of a clip in a positive node prior to treatment ensures the node will be excised after treatment",
                      "2nd examination of specimen and additional tissue submission should be considered",
                      "However, it is possible for metastases to completely resolve, leaving a normal-appearing node",
                      "Placement of a clip in a positive node prior to treatment ensures the node will be excised after treatment",
                      "Extramedullary hematopoiesis can occur in nodes after treatmentMegakaryocytes should be distinguished from residual carcinomaKeratin studies can be helpful to identify atypical cells",
                      "Megakaryocytes should be distinguished from residual carcinoma",
                      "Keratin studies can be helpful to identify atypical cells"
                    ]
                  }
                ],
                "Ancillary Studies": [
                  {
                    "text": "ER, PR, and HER2Determined on pretreatment core needle biopsyMay be repeated on residual disease after NAT",
                    "sub_points": [
                      "Determined on pretreatment core needle biopsy",
                      "May be repeated on residual disease after NAT"
                    ]
                  },
                  {
                    "text": "Results are concordant after NAT in the majority of casesResults are more likely to be discordant for receptor targeted by therapy",
                    "sub_points": [
                      "Results are more likely to be discordant for receptor targeted by therapy"
                    ]
                  },
                  {
                    "text": "Change from positive to negativePatient will continue to be treated with targeted therapy after treatmentIf ER &/or PR become negative, it is unknown if this is permanent alteration in IBCLoss of ER in 20% after endocrine therapy and 12% after chemotherapyLoss of PR in 85% after aromatase inhibitor therapy (decreased estrogen) and 7% after tamoxifenAbsence of hormone receptors after NAT is a poor prognostic factorHER2(+) IBCs are HER2(-) in ~ 30% of cases after HER2-targeted therapy but in only 13% after nontargeted chemotherapyIBCs lack protein expression and gene amplificationLikely due to selection of HER2(-) clone but may be related to sampling issue of a heterogeneously expressing IBC with needle biopsyUnknown if this is predictive for carcinoma at metastatic sitesLoss of HER2 expression after NAT is a poor prognostic factor; more common with ER(+) cancers",
                    "sub_points": [
                      "Patient will continue to be treated with targeted therapy after treatmentIf ER &/or PR become negative, it is unknown if this is permanent alteration in IBCLoss of ER in 20% after endocrine therapy and 12% after chemotherapyLoss of PR in 85% after aromatase inhibitor therapy (decreased estrogen) and 7% after tamoxifenAbsence of hormone receptors after NAT is a poor prognostic factorHER2(+) IBCs are HER2(-) in ~ 30% of cases after HER2-targeted therapy but in only 13% after nontargeted chemotherapyIBCs lack protein expression and gene amplificationLikely due to selection of HER2(-) clone but may be related to sampling issue of a heterogeneously expressing IBC with needle biopsyUnknown if this is predictive for carcinoma at metastatic sitesLoss of HER2 expression after NAT is a poor prognostic factor; more common with ER(+) cancers",
                      "If ER &/or PR become negative, it is unknown if this is permanent alteration in IBCLoss of ER in 20% after endocrine therapy and 12% after chemotherapyLoss of PR in 85% after aromatase inhibitor therapy (decreased estrogen) and 7% after tamoxifenAbsence of hormone receptors after NAT is a poor prognostic factor",
                      "Loss of ER in 20% after endocrine therapy and 12% after chemotherapy",
                      "Loss of PR in 85% after aromatase inhibitor therapy (decreased estrogen) and 7% after tamoxifen",
                      "Absence of hormone receptors after NAT is a poor prognostic factor",
                      "HER2(+) IBCs are HER2(-) in ~ 30% of cases after HER2-targeted therapy but in only 13% after nontargeted chemotherapyIBCs lack protein expression and gene amplificationLikely due to selection of HER2(-) clone but may be related to sampling issue of a heterogeneously expressing IBC with needle biopsyUnknown if this is predictive for carcinoma at metastatic sitesLoss of HER2 expression after NAT is a poor prognostic factor; more common with ER(+) cancers",
                      "IBCs lack protein expression and gene amplification",
                      "Likely due to selection of HER2(-) clone but may be related to sampling issue of a heterogeneously expressing IBC with needle biopsy",
                      "Unknown if this is predictive for carcinoma at metastatic sites",
                      "Loss of HER2 expression after NAT is a poor prognostic factor; more common with ER(+) cancers"
                    ]
                  },
                  {
                    "text": "Change from negative to positiveThis may identify additional treatment that could benefit patientLikely due to subpopulation of cells missed by core needle biopsy and possible selection by treatmentGain of ER &/or PR in ~ 10% after chemotherapyBetter prognosis when treated with endocrine therapyGain of HER2 in 5% after chemotherapyRetesting of original specimen could be considered to determine if original result was correct",
                    "sub_points": [
                      "This may identify additional treatment that could benefit patient",
                      "Likely due to subpopulation of cells missed by core needle biopsy and possible selection by treatmentGain of ER &/or PR in ~ 10% after chemotherapyBetter prognosis when treated with endocrine therapyGain of HER2 in 5% after chemotherapy",
                      "Gain of ER &/or PR in ~ 10% after chemotherapyBetter prognosis when treated with endocrine therapy",
                      "Better prognosis when treated with endocrine therapy",
                      "Gain of HER2 in 5% after chemotherapy",
                      "Retesting of original specimen could be considered to determine if original result was correct"
                    ]
                  },
                  {
                    "text": "Ki-67Changes in Ki-67 score are used to assess response in some trials of neoadjuvant endocrine therapyTesting should be performed and evaluated according to design of study",
                    "sub_points": [
                      "Changes in Ki-67 score are used to assess response in some trials of neoadjuvant endocrine therapy",
                      "Testing should be performed and evaluated according to design of study"
                    ]
                  },
                  {
                    "text": "Multigene assaysGenerally not validated for IBCs after NAT",
                    "sub_points": [
                      "Generally not validated for IBCs after NAT"
                    ]
                  }
                ]
              },
              "Reporting After Neoadjuvant Therapy": {
                "Reporting Residual Invasive Carcinoma": [
                  {
                    "text": "All prognostic factors prior to treatment are also prognostic after NAT"
                  },
                  {
                    "text": "Additional prognostic factors after NAT have been used in systems for evaluating responseChange in IBC sizeChange in tumor cellularity: Most IBCs become less cellularResponse in lymph nodes: Response of metastatic carcinoma has greater prognostic value than response in breast",
                    "sub_points": [
                      "Change in IBC size",
                      "Change in tumor cellularity: Most IBCs become less cellular",
                      "Response in lymph nodes: Response of metastatic carcinoma has greater prognostic value than response in breast"
                    ]
                  },
                  {
                    "text": "Histologic type, grade, lymphovascular invasion, and size should be reportedSize may be difficult to determine if there are multiple scattered foci over tumor bedReporting options are size of largest contiguous focus, number of foci, and number of blocks",
                    "sub_points": [
                      "Size may be difficult to determine if there are multiple scattered foci over tumor bedReporting options are size of largest contiguous focus, number of foci, and number of blocks",
                      "Reporting options are size of largest contiguous focus, number of foci, and number of blocks"
                    ]
                  },
                  {
                    "text": "Tumor cellularity and change in cellularity are prognostic factors and are used in some systems of reporting response to NATFor very paucicellular IBCs, cytokeratin studies may be helpful to identify location and extent of residual IBC",
                    "sub_points": [
                      "For very paucicellular IBCs, cytokeratin studies may be helpful to identify location and extent of residual IBC"
                    ]
                  },
                  {
                    "text": "ER, PR, and HER2 should be repeated if residual IBC is present, particularly if the original studies were negativeMarkers negative before treatment may be positive post treatment due to limited pretreatment sampling, selection of tumor subclones by treatment, or treatment effect on tumor cells",
                    "sub_points": [
                      "Markers negative before treatment may be positive post treatment due to limited pretreatment sampling, selection of tumor subclones by treatment, or treatment effect on tumor cells"
                    ]
                  }
                ],
                "Reporting Residual Ductal Carcinoma In Situ": [
                  {
                    "text": "Report type and extent"
                  },
                  {
                    "text": "If only DCIS is present, this is considered pCR"
                  },
                  {
                    "text": "IHC should be used, if necessary, to distinguish DCIS from residual IBC or lymphatic invasion"
                  }
                ],
                "Reporting Margins": [
                  {
                    "text": "Margins should be evaluated for presence of IBC and DCIS"
                  },
                  {
                    "text": "In general, the size of the tumor bed is approximately the size of IBC prior to treatmentIBC can be present as multiple foci throughout tumor bed if there has been a partial responseIf tumor bed is present at margin, there may be an increased likelihood of residual carcinoma in breast",
                    "sub_points": [
                      "IBC can be present as multiple foci throughout tumor bed if there has been a partial response",
                      "If tumor bed is present at margin, there may be an increased likelihood of residual carcinoma in breast"
                    ]
                  },
                  {
                    "text": "An international working group has recommended reporting tumor bed at margin for patients on clinical trialsIn the absence of a clinical trial, institutions can determine whether or not these changes are reportedThe benefit of resecting patients due to tumor bed changes at the margin is not yet clear",
                    "sub_points": [
                      "In the absence of a clinical trial, institutions can determine whether or not these changes are reported",
                      "The benefit of resecting patients due to tumor bed changes at the margin is not yet clear"
                    ]
                  }
                ],
                "Reporting Lymph Node Status": [
                  {
                    "text": "Lymph nodes should be evaluated for metastatic carcinoma and response to treatmentIf metastatic carcinoma is present, associated features suggesting treatment response (e.g., scarring fibrosis) should be notedIn selected cases with fibrosis and scattered atypical cells, cytokeratin studies may be helpful to document presence of residual carcinomaSmall lymph node metastases (< 2 mm) have the same prognostic significance as larger metastases in the absence of NATSmall metastases after NAT are indicative of partial responseAny tumor cells in nodes, including isolated tumor cells (ITCs), excludes pCRNodes with ITCs are not counted as positive nodes for AJCC N classificationNodes with ITCs are counted as positive nodes for RCBIn nodes without carcinoma, presence of features suggesting prior involvement (e.g., scarring fibrosis) should be notedHowever, metastatic carcinoma in nodes can undergo pCR without leaving histologic evidence in nodePathologic evaluation of nodes only after NAT is not reliable to determine nodal status prior to NAT when nodes are negative",
                    "sub_points": [
                      "If metastatic carcinoma is present, associated features suggesting treatment response (e.g., scarring fibrosis) should be notedIn selected cases with fibrosis and scattered atypical cells, cytokeratin studies may be helpful to document presence of residual carcinoma",
                      "In selected cases with fibrosis and scattered atypical cells, cytokeratin studies may be helpful to document presence of residual carcinoma",
                      "Small lymph node metastases (< 2 mm) have the same prognostic significance as larger metastases in the absence of NATSmall metastases after NAT are indicative of partial responseAny tumor cells in nodes, including isolated tumor cells (ITCs), excludes pCRNodes with ITCs are not counted as positive nodes for AJCC N classificationNodes with ITCs are counted as positive nodes for RCB",
                      "Small metastases after NAT are indicative of partial response",
                      "Any tumor cells in nodes, including isolated tumor cells (ITCs), excludes pCR",
                      "Nodes with ITCs are not counted as positive nodes for AJCC N classification",
                      "Nodes with ITCs are counted as positive nodes for RCB",
                      "In nodes without carcinoma, presence of features suggesting prior involvement (e.g., scarring fibrosis) should be notedHowever, metastatic carcinoma in nodes can undergo pCR without leaving histologic evidence in node",
                      "However, metastatic carcinoma in nodes can undergo pCR without leaving histologic evidence in node",
                      "Pathologic evaluation of nodes only after NAT is not reliable to determine nodal status prior to NAT when nodes are negative"
                    ]
                  }
                ],
                "Reporting Response to Neoadjuvant Therapy": [
                  {
                    "text": "> 8 systems have been developed to classify response of breast carcinomas to treatment"
                  },
                  {
                    "text": "The extent of tumor prior to treatment is also an important prognostic factorFor example, > 90% of all patients with pCR will not recur; however, 50% of patients with pretreatment inflammatory carcinoma and pCR do recur",
                    "sub_points": [
                      "For example, > 90% of all patients with pCR will not recur; however, 50% of patients with pretreatment inflammatory carcinoma and pCR do recur"
                    ]
                  },
                  {
                    "text": "2 systems are recommended for reportingAJCC stage before NAT, post NAT, and change in stage are all prognostically significantA clinical prognostic stage is assigned when patients have received NATRCB is used post treatment and is prognostically significantCalculator is available at www.mdanderson.org/breastcancer_RCB",
                    "sub_points": [
                      "AJCC stage before NAT, post NAT, and change in stage are all prognostically significantA clinical prognostic stage is assigned when patients have received NAT",
                      "A clinical prognostic stage is assigned when patients have received NAT",
                      "RCB is used post treatment and is prognostically significantCalculator is available at www.mdanderson.org/breastcancer_RCB",
                      "Calculator is available at www.mdanderson.org/breastcancer_RCB"
                    ]
                  }
                ],
                "American Joint Committee on Cancer (AJCC) \"y\" Stage": [
                  {
                    "text": "T classification is based on the largest contiguous focus of IBCCan be difficult to determine when there are scattered small foci over the tumor bedMeasuring the entire tumor bed overestimates residual IBCMeasuring the single largest contiguous focus of cancer may underestimate residual IBC\"m\" is used to denote multiple foci of IBC after NAT",
                    "sub_points": [
                      "Can be difficult to determine when there are scattered small foci over the tumor bedMeasuring the entire tumor bed overestimates residual IBCMeasuring the single largest contiguous focus of cancer may underestimate residual IBC",
                      "Measuring the entire tumor bed overestimates residual IBC",
                      "Measuring the single largest contiguous focus of cancer may underestimate residual IBC",
                      "\"m\" is used to denote multiple foci of IBC after NAT"
                    ]
                  },
                  {
                    "text": "N classification is based on the largest contiguous focus of metastatic carcinoma in a node, not including tumor bed changesIsolated tumor cells are classified as N0 (i+), but this finding precludes a pCR",
                    "sub_points": [
                      "Isolated tumor cells are classified as N0 (i+), but this finding precludes a pCR"
                    ]
                  }
                ],
                "Residual Cancer Burden": [
                  {
                    "text": "Quantifies amount of residual IBC after treatment in breast and nodesIncludes percentage cellularity over tumor bed (stromal invasion and lymphovascular invasion), number of lymph node metastases, and size of largest lymph node metastasisCellularity contributed by DCIS is estimated only to exclude DCIS from overall cellularityA node with isolated tumor cells is considered a positive node for calculating RCB",
                    "sub_points": [
                      "Includes percentage cellularity over tumor bed (stromal invasion and lymphovascular invasion), number of lymph node metastases, and size of largest lymph node metastasisCellularity contributed by DCIS is estimated only to exclude DCIS from overall cellularity",
                      "Cellularity contributed by DCIS is estimated only to exclude DCIS from overall cellularity",
                      "A node with isolated tumor cells is considered a positive node for calculating RCB"
                    ]
                  },
                  {
                    "text": "Online calculator and information about how to evaluate specimens are available (www.mdanderson.org/breastcancer_RCB)"
                  },
                  {
                    "text": "Determined as continuous value, which is divided into 4 groups: RCB 0 (pCR), RCB I, RCB II, RCB III"
                  },
                  {
                    "text": "Residual proliferative cancer burden (RPCB) combines RCB with posttreatment Ki-67 scoreIdentifies group without pCR with similar good prognosis",
                    "sub_points": [
                      "Identifies group without pCR with similar good prognosis"
                    ]
                  }
                ],
                "Residual Disease in Breast and Nodes": [
                  {
                    "text": "Modification of Nottingham prognostic index"
                  },
                  {
                    "text": "Residual disease in breast and nodes (RDBN): 0.2 x tumor size (cm) + lymph node stage (0-3) + histologic grade (1-3)Lymph node stage: 0 = negative nodes; 1 = 1-4 positive nodes; 2 = 5-7 positive nodes; 3 ≥ 8 positive nodesGrade is determined after treatmentDoes not require online calculator",
                    "sub_points": [
                      "Lymph node stage: 0 = negative nodes; 1 = 1-4 positive nodes; 2 = 5-7 positive nodes; 3 ≥ 8 positive nodes",
                      "Grade is determined after treatment",
                      "Does not require online calculator"
                    ]
                  },
                  {
                    "text": "Divided into 4 groupsLevel 1 = 0 (pCR); level 2 = 0.1-2.9; level 3 = 3.0-4.3; level 4 ≥ 4.4",
                    "sub_points": [
                      "Level 1 = 0 (pCR); level 2 = 0.1-2.9; level 3 = 3.0-4.3; level 4 ≥ 4.4"
                    ]
                  }
                ],
                "Sataloff": [
                  {
                    "text": "Tumor and nodes are evaluated separately2 categories of partial response",
                    "sub_points": [
                      "2 categories of partial response"
                    ]
                  },
                  {
                    "text": "Lowest category includes patients without pCR"
                  },
                  {
                    "text": "TumorT-A: Total or near-total therapeutic effectT-B: > 50% therapeutic effect but less than total or near totalT-C: < 50% therapeutic effect, but effect evidentT-D: No therapeutic effect",
                    "sub_points": [
                      "T-A: Total or near-total therapeutic effect",
                      "T-B: > 50% therapeutic effect but less than total or near total",
                      "T-C: < 50% therapeutic effect, but effect evident",
                      "T-D: No therapeutic effect"
                    ]
                  },
                  {
                    "text": "NodesN-A: Evidence of therapeutic effect, no metastatic diseaseN-B: No nodal metastasis or therapeutic effectN-C: Evidence of therapeutic effect, but nodal metastasis presentN-D: Viable metastatic disease, no therapeutic effect",
                    "sub_points": [
                      "N-A: Evidence of therapeutic effect, no metastatic disease",
                      "N-B: No nodal metastasis or therapeutic effect",
                      "N-C: Evidence of therapeutic effect, but nodal metastasis present",
                      "N-D: Viable metastatic disease, no therapeutic effect"
                    ]
                  }
                ],
                "Chevalier": [
                  {
                    "text": "Grades 1 and 2 are considered pCROnly 1 category of partial response",
                    "sub_points": [
                      "Only 1 category of partial response"
                    ]
                  },
                  {
                    "text": "Grade 1: Disappearance of all tumor either on macroscopic or microscopic assessment (pCR)"
                  },
                  {
                    "text": "Grade 2: Presence of in situ carcinoma in breast, no invasive carcinoma and negative lymph nodes (pCR)"
                  },
                  {
                    "text": "Grade 3: Presence of invasive carcinoma with stromal alteration, such as sclerosis or fibrosis"
                  },
                  {
                    "text": "Grade 4: No or few modifications of tumoral appearance"
                  }
                ],
                "Pinder": [
                  {
                    "text": "Evaluates breast and lymph nodes separately"
                  },
                  {
                    "text": "Breast(1) pCR, either (i) no residual carcinoma or, (ii) no residual invasive carcinoma but DCIS present(2) Partial response to therapy, either (i) minimal residual disease/near-total effect (e.g., < 10% of tumor remaining), or (ii) evidence of response to therapy but 10-50% of tumor remaining, or (iii) > 50% of tumor cellularity remains evident when compared to the previous core needle biopsy, although some features of response to therapy present(3) No evidence of response to therapy",
                    "sub_points": [
                      "(1) pCR, either (i) no residual carcinoma or, (ii) no residual invasive carcinoma but DCIS present",
                      "(2) Partial response to therapy, either (i) minimal residual disease/near-total effect (e.g., < 10% of tumor remaining), or (ii) evidence of response to therapy but 10-50% of tumor remaining, or (iii) > 50% of tumor cellularity remains evident when compared to the previous core needle biopsy, although some features of response to therapy present",
                      "(3) No evidence of response to therapy"
                    ]
                  },
                  {
                    "text": "Lymph Nodes(1) No evidence of metastatic disease and no evidence of changes in lymph nodes(2) Metastatic tumor not detected but evidence of response/downstaging, e.g., fibrosis(3) Metastatic disease present but also evidence of response, such as nodal fibrosis(4) Metastatic disease present with no evidence of response to therapy",
                    "sub_points": [
                      "(1) No evidence of metastatic disease and no evidence of changes in lymph nodes",
                      "(2) Metastatic tumor not detected but evidence of response/downstaging, e.g., fibrosis",
                      "(3) Metastatic disease present but also evidence of response, such as nodal fibrosis",
                      "(4) Metastatic disease present with no evidence of response to therapy"
                    ]
                  }
                ],
                "Preoperative Endocrine Prognostic Index": [
                  {
                    "text": "Used to evaluate prognosis after endocrine therapy"
                  },
                  {
                    "text": "Assigns points to 4 posttreatment features to predict breast cancer-specific survival (values are slightly different for relapse-free survival)Tumor size: T1/2 = 0 points; T3/4 = 3 pointsNode status: Negative = 0; positive = 3ER status: Negative (Allred 0 or 2) = 3; positive (Allred 3-8) = 0Ki-67 score: 0-2.7% = 0; > 2.7-7.3% = 1; > 7.3-19.7% = 2; > 19.7-53.1% = 3; > 53.1% = 3",
                    "sub_points": [
                      "Tumor size: T1/2 = 0 points; T3/4 = 3 points",
                      "Node status: Negative = 0; positive = 3",
                      "ER status: Negative (Allred 0 or 2) = 3; positive (Allred 3-8) = 0",
                      "Ki-67 score: 0-2.7% = 0; > 2.7-7.3% = 1; > 7.3-19.7% = 2; > 19.7-53.1% = 3; > 53.1% = 3"
                    ]
                  },
                  {
                    "text": "Scores are divided into 3 groups"
                  },
                  {
                    "text": "Group 1 = 0 points; group 2 = 1-3 points; group 3 = ≥ 4 points"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Stromal Lesions": {
        "name": "Stromal Lesions",
        "url": "https://app.pathprimer.com/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
        "topics": {
          "Fibroadenoma": {
            "name": "Fibroadenoma",
            "url": "https://app.pathprimer.com/document/ac2c730d-8099-43ad-b37e-4330dc9c780b/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "The fibroepithelial lesion (FEL) family includes fibroadenomatoid changes, fibroadenoma (FA), and phyllodes tumors"
                  },
                  {
                    "text": "FAs range from hyperplasias (tumor cells are polyclonal) to benign neoplasias (tumor cells are monoclonal)Arise from intralobular stromal cells",
                    "sub_points": [
                      "Arise from intralobular stromal cells"
                    ]
                  },
                  {
                    "text": "~ 45-60% of FAs haveMED12(mediator complex subunit) mutationsMutations occur in the stromal cells and not the accompanying polyclonal epithelial cells",
                    "sub_points": [
                      "Mutations occur in the stromal cells and not the accompanying polyclonal epithelial cells"
                    ]
                  },
                  {
                    "text": "Mutations and hormonal influences are important in etiology"
                  },
                  {
                    "text": "Some are iatrogenic and develop after treatment with cyclosporine"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Detected as mobile, circumscribed palpable masses in younger women between 20-35 years of ageCan enlarge in size and sometimes infarct during pregnancy",
                    "sub_points": [
                      "Can enlarge in size and sometimes infarct during pregnancy"
                    ]
                  },
                  {
                    "text": "In older women, typically present as mammographic circumscribed masses or clusters of calcifications"
                  },
                  {
                    "text": "Very rare in men"
                  },
                  {
                    "text": "Most FAs can be diagnosed by core needle biopsy and followed radiographically"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Circumscribed or lobulated mass"
                  },
                  {
                    "text": "Calcifications may be present, particularly in older women"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Phyllodes tumor"
                  },
                  {
                    "text": "Fibroadenomatoid changes"
                  },
                  {
                    "text": "Hamartoma"
                  },
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia (PASH)"
                  },
                  {
                    "text": "Tubular adenoma"
                  },
                  {
                    "text": "Periductal stromal hyperplasia or tumor"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fibroadenoma (FA)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Adenofibroma (not recommended by WHO)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Biphasic fibroepithelial tumor consisting of a proliferation of intralobular stromal cells and associated epithelial cells"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Introduction": [
                  {
                    "text": "During embryologic development, stroma differentiates 1st and induces downgrowth of cells from epidermis to form the ductal system"
                  },
                  {
                    "text": "This synergistic relationship between epithelial and stromal cells persists in duct/lobular units"
                  },
                  {
                    "text": "Fibroepithelial lesions (FELs) occur when the intralobular stroma expands in volume relative to the associated epithelial cells"
                  },
                  {
                    "text": "The FEL family includes fibroadenomatoid changes, fibroadenomas (FAs), and phyllodes tumors (PTs)"
                  },
                  {
                    "text": "This group includes benign hyperplasias, benign monoclonal tumors, and malignant tumors with the capacity to metastasize"
                  },
                  {
                    "text": "~ 97% are FAs and < 3% are PTs"
                  }
                ],
                "Genomic Changes": [
                  {
                    "text": "FAs range from hyperplasias (polyclonal) to benign neoplasias (monoclonal)"
                  },
                  {
                    "text": "Tumor-related mutations occur in the stromal cells and not the accompanying polyclonal epithelial cells"
                  },
                  {
                    "text": "~ 45-60% of FAs haveMED12(mediator complex subunit) mutationsThe same spectrum of mutations are also found in uterine leiomyomasResults in dysregulated estrogen signaling and extracellular matrix organizationLikely involved in the pathogenesis of both tumor typesMutations found in FAs have not been linked to the likelihood of recurrence",
                    "sub_points": [
                      "The same spectrum of mutations are also found in uterine leiomyomas",
                      "Results in dysregulated estrogen signaling and extracellular matrix organizationLikely involved in the pathogenesis of both tumor types",
                      "Likely involved in the pathogenesis of both tumor types",
                      "Mutations found in FAs have not been linked to the likelihood of recurrence"
                    ]
                  },
                  {
                    "text": "The co-occurrence of FAs and PTs with the sameMED12mutation in rare patients supports a common origin for some tumorsPTs may arise when the tumor acquires additional mutations, such as in theTERTpromoterHowever, pathways leading to PT independent of FAs andMED12mutations are also proposed",
                    "sub_points": [
                      "PTs may arise when the tumor acquires additional mutations, such as in theTERTpromoter",
                      "However, pathways leading to PT independent of FAs andMED12mutations are also proposed"
                    ]
                  }
                ],
                "Hormonal Influences": [
                  {
                    "text": "Multiple lines of evidence suggest role for hormonesSome stromal cells express estrogen receptor β &/or progesterone receptorFAs are common in young premenopausal womenFAs in postmenopausal women may decrease in size and become hyalinizedWhen present in men, they are often associated with gynecomastiaTransgender women can develop FAs when treated with hormonal therapyFAs can grow rapidly during pregnancy",
                    "sub_points": [
                      "Some stromal cells express estrogen receptor β &/or progesterone receptor",
                      "FAs are common in young premenopausal womenFAs in postmenopausal women may decrease in size and become hyalinized",
                      "FAs in postmenopausal women may decrease in size and become hyalinized",
                      "When present in men, they are often associated with gynecomastia",
                      "Transgender women can develop FAs when treated with hormonal therapy",
                      "FAs can grow rapidly during pregnancy"
                    ]
                  }
                ],
                "Hereditary": [
                  {
                    "text": "Myxoid FAs and breast myxomas are part of Carney complex (CNC)/syndromeBreast lesions occur in 20% of female patients and may be bilateralAdditional associated lesions include cardiac and cutaneous myxomas, primary pigmented nodular adrenocortical disease, large cell calcifying Sertoli cell tumors, multiple thyroid lesions, growth hormone-producing pituitary adenoma, and othersTypically have pigmented skin lesions (lentigos, blue nevi, café au lait spots), characteristically involving vermilion border of lip and intercanthal portion of eyeType 1 (CNC1):PRKAR1A(17q23-24)Type 2 (CNC2): Locus at 2p1630% of patients do not have an identified germline mutation",
                    "sub_points": [
                      "Breast lesions occur in 20% of female patients and may be bilateral",
                      "Additional associated lesions include cardiac and cutaneous myxomas, primary pigmented nodular adrenocortical disease, large cell calcifying Sertoli cell tumors, multiple thyroid lesions, growth hormone-producing pituitary adenoma, and others",
                      "Typically have pigmented skin lesions (lentigos, blue nevi, café au lait spots), characteristically involving vermilion border of lip and intercanthal portion of eye",
                      "Type 1 (CNC1):PRKAR1A(17q23-24)",
                      "Type 2 (CNC2): Locus at 2p16",
                      "30% of patients do not have an identified germline mutation"
                    ]
                  },
                  {
                    "text": "FAs are more common in African American womenReason unknown",
                    "sub_points": [
                      "Reason unknown"
                    ]
                  }
                ],
                "Iatrogenic": [
                  {
                    "text": "Cyclosporine treatment of kidney transplant recipients is associated with an increase in FAsMechanism unknown but postulated to be a direct effect on fibroblasts or interaction with the prolactin receptor",
                    "sub_points": [
                      "Mechanism unknown but postulated to be a direct effect on fibroblasts or interaction with the prolactin receptor"
                    ]
                  },
                  {
                    "text": "Affects men and women: FAs can be multiple and bilateral"
                  },
                  {
                    "text": "May regress when treated with a different medication"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Most common solid benign breast lesion"
                  }
                ],
                "Age": [
                  {
                    "text": "Typically occur in younger women (20-35 years)"
                  },
                  {
                    "text": "In older women, associated with continued elevated hormone levels either due to replacement therapy or obesity"
                  }
                ],
                "Sex": [
                  {
                    "text": "Very rare in male patientsMay be older adults and associated with gynecomastiaMay be associated with exogenous hormone treatmentPTs more common than FAs",
                    "sub_points": [
                      "May be older adults and associated with gynecomastia",
                      "May be associated with exogenous hormone treatment",
                      "PTs more common than FAs"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "~ 75% present as painless, slowly growing, mobile, well-defined, palpable nodules in young women"
                  },
                  {
                    "text": "~ 25% present as mammographic masses with circumscribed marginsMay present as mammographic calcifications in older womenMay regress in size with ageStroma typically undergoes hyalinization, which can serve as a substrate for calcifications",
                    "sub_points": [
                      "May present as mammographic calcifications in older womenMay regress in size with ageStroma typically undergoes hyalinization, which can serve as a substrate for calcifications",
                      "May regress in size with age",
                      "Stroma typically undergoes hyalinization, which can serve as a substrate for calcifications"
                    ]
                  },
                  {
                    "text": "Majority do not increase in size with prolonged follow-up"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Most FAs can be diagnosed by core needle biopsy and followed by imaging"
                  },
                  {
                    "text": "Surgical removal may be indicated for large &/or symptomatic lesions, at patient request, or for rare lesions that continue to grow in size"
                  },
                  {
                    "text": "Ultrasound-guided cryoablation has been explored as an alternative to surgery"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "No indication for additional radiation treatment or systemic therapy"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "FAs are benignThe only clinical importance is in distinguishing FAs from malignanciesThe majority of FAs diagnosed by core needle biopsy remain stable in size and do not require excisionFor the minority that increase in size, benign PTs are found in ~ 1-5%",
                    "sub_points": [
                      "The only clinical importance is in distinguishing FAs from malignancies",
                      "The majority of FAs diagnosed by core needle biopsy remain stable in size and do not require excisionFor the minority that increase in size, benign PTs are found in ~ 1-5%",
                      "For the minority that increase in size, benign PTs are found in ~ 1-5%"
                    ]
                  },
                  {
                    "text": "FAs confer a similar risk of subsequent breast cancer as proliferative breast disease without atypia (PDWA)The risk is most likely related to the greater likelihood of finding other types of PDWA in women with FAs rather than to the FA itselfComplex FAs are more commonly associated with PDWA and atypical hyperplasia (AH) than simple FAsIn one study, the relative risk for simple FAs was 1.49 (95% CI: 1.26-1.74) and for complex FAs 2.27 (95% CI: 1.63-3.10)However, the presence of PDWA and AH either within or adjacent to FAs was concluded to be the predominant determinant of risk",
                    "sub_points": [
                      "The risk is most likely related to the greater likelihood of finding other types of PDWA in women with FAs rather than to the FA itselfComplex FAs are more commonly associated with PDWA and atypical hyperplasia (AH) than simple FAsIn one study, the relative risk for simple FAs was 1.49 (95% CI: 1.26-1.74) and for complex FAs 2.27 (95% CI: 1.63-3.10)However, the presence of PDWA and AH either within or adjacent to FAs was concluded to be the predominant determinant of risk",
                      "Complex FAs are more commonly associated with PDWA and atypical hyperplasia (AH) than simple FAs",
                      "In one study, the relative risk for simple FAs was 1.49 (95% CI: 1.26-1.74) and for complex FAs 2.27 (95% CI: 1.63-3.10)However, the presence of PDWA and AH either within or adjacent to FAs was concluded to be the predominant determinant of risk",
                      "However, the presence of PDWA and AH either within or adjacent to FAs was concluded to be the predominant determinant of risk"
                    ]
                  },
                  {
                    "text": "FAs with atypical hyperplasia (AH) confined to the FA have not been shown to increase risk above PDWA"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Circumscribed or smoothly lobulated massMay be ill-defined if obscured by dense stroma or if fibroadenomatoid changes are present",
                    "sub_points": [
                      "May be ill-defined if obscured by dense stroma or if fibroadenomatoid changes are present"
                    ]
                  },
                  {
                    "text": "Calcifications may be present and appear as a clusterMore common in older womenCalcifications may be coarse (large popcorn calcifications) or numerous and smallMay mimic calcifications seen in ductal carcinoma in situ (DCIS) due to clustering",
                    "sub_points": [
                      "More common in older women",
                      "Calcifications may be coarse (large popcorn calcifications) or numerous and small",
                      "May mimic calcifications seen in ductal carcinoma in situ (DCIS) due to clustering"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Circumscribed or smoothly lobulated mass"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Smooth bordered mass; may have nonenhancing internal septations"
                  },
                  {
                    "text": "Enhancement is generally slower than that seen with carcinomas"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "White, firm (rubbery), palpable mass with circumscribed margins"
                  },
                  {
                    "text": "Mass usually bulges above normal breast tissue; slit-like spaces may be presentCarcinomas typically have flat surface",
                    "sub_points": [
                      "Carcinomas typically have flat surface"
                    ]
                  },
                  {
                    "text": "Large FAs may have a leaf-like appearance due to areas of stromal growth separated by epithelial-lined clefts"
                  },
                  {
                    "text": "Multiple synchronous FAs can be present"
                  }
                ],
                "Size": [
                  {
                    "text": "Majority < 3 cm but can be very large"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "MutationsFAs have fewer somatic mutations (median 5) compared to PTs and carcinomasMediator complex subunit 12 (MED12), retinoic acid receptor alpha (RARA), and lysine (K)-specific methyltransferase 2D (KMT2D) may interact with the estrogen receptorMED12mutations are the most common: Occur in ~ 45-60%Majority in codon 44 of exon 2 on Xq13Occur primarily in intracanalicular FAs and not in myxoid FAsAlso found in PTs but rare in other breast lesionsRARAmutations occur in ~ 14% of casesKMT2Dmutations occur in ~ 14% of casesMany of the mutations found in PTs are not found in FAsSuggests additional mutations are necessary for more aggressive behavior",
                    "sub_points": [
                      "FAs have fewer somatic mutations (median 5) compared to PTs and carcinomasMediator complex subunit 12 (MED12), retinoic acid receptor alpha (RARA), and lysine (K)-specific methyltransferase 2D (KMT2D) may interact with the estrogen receptor",
                      "Mediator complex subunit 12 (MED12), retinoic acid receptor alpha (RARA), and lysine (K)-specific methyltransferase 2D (KMT2D) may interact with the estrogen receptor",
                      "MED12mutations are the most common: Occur in ~ 45-60%Majority in codon 44 of exon 2 on Xq13Occur primarily in intracanalicular FAs and not in myxoid FAsAlso found in PTs but rare in other breast lesions",
                      "Majority in codon 44 of exon 2 on Xq13",
                      "Occur primarily in intracanalicular FAs and not in myxoid FAs",
                      "Also found in PTs but rare in other breast lesions",
                      "RARAmutations occur in ~ 14% of cases",
                      "KMT2Dmutations occur in ~ 14% of cases",
                      "Many of the mutations found in PTs are not found in FAsSuggests additional mutations are necessary for more aggressive behavior",
                      "Suggests additional mutations are necessary for more aggressive behavior"
                    ]
                  },
                  {
                    "text": "Copy number aberrationsLoss of heterozygosity (LOH) is very uncommonCommon in PTsGain of 1q present in some FAs as well as in some PTs",
                    "sub_points": [
                      "Loss of heterozygosity (LOH) is very uncommonCommon in PTs",
                      "Common in PTs",
                      "Gain of 1q present in some FAs as well as in some PTs"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Biphasic growth patternAdmixed glandular and stromal elementsVariable morphologic appearance; depends on relative amount and configuration of each elementRegular and symmetric distribution of epithelial and stromal elements should be presentFAs have well-circumscribed pushing borders and do not infiltrate adjacent parenchymaCan be difficult to distinguish infiltration of stroma from fibroadenomatoid changes in adjacent stroma",
                    "sub_points": [
                      "Admixed glandular and stromal elementsVariable morphologic appearance; depends on relative amount and configuration of each elementRegular and symmetric distribution of epithelial and stromal elements should be present",
                      "Variable morphologic appearance; depends on relative amount and configuration of each element",
                      "Regular and symmetric distribution of epithelial and stromal elements should be present",
                      "FAs have well-circumscribed pushing borders and do not infiltrate adjacent parenchymaCan be difficult to distinguish infiltration of stroma from fibroadenomatoid changes in adjacent stroma",
                      "Can be difficult to distinguish infiltration of stroma from fibroadenomatoid changes in adjacent stroma"
                    ]
                  },
                  {
                    "text": "Stromal componentTypically loose and may have myxoid appearanceMyxoid stroma is more typical in younger individualsDensely fibrotic and hyalinized stroma is more common in older womenStroma typically shows low cellularity, lacks mitotic activity, and cells are cytologically blandStromal cells concentrically cuff glandular structures or are arrayed perpendicular to basement membranePredominantly CD34(+) specialized fibroblastsCD34(+) spindle cells are in perilobular and, to lesser extent, interlobular stroma of normal breastsPseudoangiomatous stromal hyperplasia (PASH) can be present but is more common in PTBenign heterologous elements, including adipose tissue, smooth muscle, or bone, are rare findingsIf fat is present, evaluation for possible stromal invasion or liposarcomatous differentiation in a PT is importantIn rare cases, atypical bizarre multinucleated stromal giant cells are presentLikely degenerative in natureThese should not be used to classify tumor as PT",
                    "sub_points": [
                      "Typically loose and may have myxoid appearanceMyxoid stroma is more typical in younger individualsDensely fibrotic and hyalinized stroma is more common in older women",
                      "Myxoid stroma is more typical in younger individuals",
                      "Densely fibrotic and hyalinized stroma is more common in older women",
                      "Stroma typically shows low cellularity, lacks mitotic activity, and cells are cytologically blandStromal cells concentrically cuff glandular structures or are arrayed perpendicular to basement membranePredominantly CD34(+) specialized fibroblastsCD34(+) spindle cells are in perilobular and, to lesser extent, interlobular stroma of normal breasts",
                      "Stromal cells concentrically cuff glandular structures or are arrayed perpendicular to basement membrane",
                      "Predominantly CD34(+) specialized fibroblastsCD34(+) spindle cells are in perilobular and, to lesser extent, interlobular stroma of normal breasts",
                      "CD34(+) spindle cells are in perilobular and, to lesser extent, interlobular stroma of normal breasts",
                      "Pseudoangiomatous stromal hyperplasia (PASH) can be present but is more common in PT",
                      "Benign heterologous elements, including adipose tissue, smooth muscle, or bone, are rare findingsIf fat is present, evaluation for possible stromal invasion or liposarcomatous differentiation in a PT is important",
                      "If fat is present, evaluation for possible stromal invasion or liposarcomatous differentiation in a PT is important",
                      "In rare cases, atypical bizarre multinucleated stromal giant cells are presentLikely degenerative in natureThese should not be used to classify tumor as PT",
                      "Likely degenerative in nature",
                      "These should not be used to classify tumor as PT"
                    ]
                  },
                  {
                    "text": "Glandular componentThe epithelial component is composed of cuboidal or columnar cells with uniform nucleiGlandular structures are surrounded by a supportive myoepithelial layerThere are 2 main patternsIntracanalicular: Stroma causes elongation, distortion, and compression of glandular elements, resulting in clefting and frond-like architecturePericanalicular: Stroma surrounds glandular elements without distorting them, resulting in a solid patternMany FAs have both patternsSclerosing adenosis, apocrine cysts, and epithelial hyperplasia may be presentSome tumors are hybrid lesions with areas of both epithelial predominance and stromal predominanceDuring pregnancy, the epithelium can undergo lactational changesSquamous metaplasia may be present",
                    "sub_points": [
                      "The epithelial component is composed of cuboidal or columnar cells with uniform nucleiGlandular structures are surrounded by a supportive myoepithelial layer",
                      "Glandular structures are surrounded by a supportive myoepithelial layer",
                      "There are 2 main patternsIntracanalicular: Stroma causes elongation, distortion, and compression of glandular elements, resulting in clefting and frond-like architecturePericanalicular: Stroma surrounds glandular elements without distorting them, resulting in a solid patternMany FAs have both patterns",
                      "Intracanalicular: Stroma causes elongation, distortion, and compression of glandular elements, resulting in clefting and frond-like architecture",
                      "Pericanalicular: Stroma surrounds glandular elements without distorting them, resulting in a solid pattern",
                      "Many FAs have both patterns",
                      "Sclerosing adenosis, apocrine cysts, and epithelial hyperplasia may be presentSome tumors are hybrid lesions with areas of both epithelial predominance and stromal predominance",
                      "Some tumors are hybrid lesions with areas of both epithelial predominance and stromal predominance",
                      "During pregnancy, the epithelium can undergo lactational changes",
                      "Squamous metaplasia may be present"
                    ]
                  },
                  {
                    "text": "FA with epithelial atypiaAlthough rare, atypical ductal or lobular hyperplasia and ductal (DCIS) or lobular (LCIS) carcinoma in situ may involve FAsClassification can be difficult due to distortion of duct spaces by stromaLCIS and DCIS can be diagnosed with confidence if the surrounding breast tissue is also involvedDiagnosis can be difficult if only present in FAIf surrounding tissue has not been excised, additional surgery to determine diagnosis and margins may be warrantedIf atypia is confined to the FA on core needle biopsy, the likelihood of a diagnosis of carcinoma on excision is low (< 5%)Atypia confined to a FA on excision does not increase the subsequent risk of carcinomaInvasive carcinomas involve < 0.5% of FAsRare carcinomas are detected incidentally adjacent to FA",
                    "sub_points": [
                      "Although rare, atypical ductal or lobular hyperplasia and ductal (DCIS) or lobular (LCIS) carcinoma in situ may involve FAs",
                      "Classification can be difficult due to distortion of duct spaces by stromaLCIS and DCIS can be diagnosed with confidence if the surrounding breast tissue is also involvedDiagnosis can be difficult if only present in FAIf surrounding tissue has not been excised, additional surgery to determine diagnosis and margins may be warranted",
                      "LCIS and DCIS can be diagnosed with confidence if the surrounding breast tissue is also involved",
                      "Diagnosis can be difficult if only present in FA",
                      "If surrounding tissue has not been excised, additional surgery to determine diagnosis and margins may be warranted",
                      "If atypia is confined to the FA on core needle biopsy, the likelihood of a diagnosis of carcinoma on excision is low (< 5%)",
                      "Atypia confined to a FA on excision does not increase the subsequent risk of carcinoma",
                      "Invasive carcinomas involve < 0.5% of FAsRare carcinomas are detected incidentally adjacent to FA",
                      "Rare carcinomas are detected incidentally adjacent to FA"
                    ]
                  },
                  {
                    "text": "CalcificationsSome are associated with epithelial component; probably forming on glandular secretionsCalcifications also form directly on regularly repeating collagenized stromaThis is the only type of breast stroma that frequently calcifiesSmall calcifications can appear as minute blue bubbles in dense collagen",
                    "sub_points": [
                      "Some are associated with epithelial component; probably forming on glandular secretions",
                      "Calcifications also form directly on regularly repeating collagenized stromaThis is the only type of breast stroma that frequently calcifiesSmall calcifications can appear as minute blue bubbles in dense collagen",
                      "This is the only type of breast stroma that frequently calcifies",
                      "Small calcifications can appear as minute blue bubbles in dense collagen"
                    ]
                  },
                  {
                    "text": "VariantsComplex FA: FAs with at least 1 of the following: Cysts > 3 mm, sclerosing adenosis, epithelial calcifications, &/or papillary apocrine metaplasiaAny slight increase in risk for subsequent carcinoma is more likely to be due to associated PDWACellular FA: Mildly to moderately increased stromal cellularity, often with a pericanalicular growth pattern, and < 1 stromal mitosis/mm² (< 2 mitoses per 10 HPF)However, some definitions allow for a greater number of mitoses in younger patientsJuvenile FA: Stromal cellularity is mild to moderate, with fascicular arrangement, no substantial nuclear atypia, and usually < 1 stromal mitosis/mm² (< 2 mitoses per 10 HPF)However, some definitions allow for a greater number of mitoses in younger patientsThis term has been used for several different types of lesions and, therefore, should only be used if the type of lesion is definedFA with atypical ductal hyperplasia in women of any ageFA in young woman: May show greater stromal cellularity and epithelial hyperplasiaFA with cellular stromaLarge rapidly growing FA, usually in young womenGiant FA: FA of large size; can have leaf-like (phyllodes) architectureMyxoid FA: FA with prominent myxoid changes in stromal componentStromal changes can resemble mucin",
                    "sub_points": [
                      "Complex FA: FAs with at least 1 of the following: Cysts > 3 mm, sclerosing adenosis, epithelial calcifications, &/or papillary apocrine metaplasiaAny slight increase in risk for subsequent carcinoma is more likely to be due to associated PDWA",
                      "Any slight increase in risk for subsequent carcinoma is more likely to be due to associated PDWA",
                      "Cellular FA: Mildly to moderately increased stromal cellularity, often with a pericanalicular growth pattern, and < 1 stromal mitosis/mm² (< 2 mitoses per 10 HPF)However, some definitions allow for a greater number of mitoses in younger patients",
                      "However, some definitions allow for a greater number of mitoses in younger patients",
                      "Juvenile FA: Stromal cellularity is mild to moderate, with fascicular arrangement, no substantial nuclear atypia, and usually < 1 stromal mitosis/mm² (< 2 mitoses per 10 HPF)However, some definitions allow for a greater number of mitoses in younger patientsThis term has been used for several different types of lesions and, therefore, should only be used if the type of lesion is definedFA with atypical ductal hyperplasia in women of any ageFA in young woman: May show greater stromal cellularity and epithelial hyperplasiaFA with cellular stromaLarge rapidly growing FA, usually in young women",
                      "However, some definitions allow for a greater number of mitoses in younger patients",
                      "This term has been used for several different types of lesions and, therefore, should only be used if the type of lesion is definedFA with atypical ductal hyperplasia in women of any ageFA in young woman: May show greater stromal cellularity and epithelial hyperplasiaFA with cellular stromaLarge rapidly growing FA, usually in young women",
                      "FA with atypical ductal hyperplasia in women of any age",
                      "FA in young woman: May show greater stromal cellularity and epithelial hyperplasia",
                      "FA with cellular stroma",
                      "Large rapidly growing FA, usually in young women",
                      "Giant FA: FA of large size; can have leaf-like (phyllodes) architecture",
                      "Myxoid FA: FA with prominent myxoid changes in stromal componentStromal changes can resemble mucin",
                      "Stromal changes can resemble mucin"
                    ]
                  },
                  {
                    "text": "FAs in pediatric populationFA is the most common breast mass in patients < 19 years of ageMay have increased cellularity, moderate nuclear atypia, and mitoses (~ 6 per 10 HPF)MED12mutations occur in ~ 35-55%NoTERTmutations identifiedFAs behave in a benign fashion in young patients and should not be overdiagnosed as PT",
                    "sub_points": [
                      "FA is the most common breast mass in patients < 19 years of age",
                      "May have increased cellularity, moderate nuclear atypia, and mitoses (~ 6 per 10 HPF)MED12mutations occur in ~ 35-55%NoTERTmutations identified",
                      "MED12mutations occur in ~ 35-55%",
                      "NoTERTmutations identified",
                      "FAs behave in a benign fashion in young patients and should not be overdiagnosed as PT"
                    ]
                  },
                  {
                    "text": "NecrosisNecrosis would be highly unusual in FAHowever, FAs can grow rapidly during pregnancy and undergo infarction; this should not be mistaken for a sign of malignancy",
                    "sub_points": [
                      "Necrosis would be highly unusual in FA",
                      "However, FAs can grow rapidly during pregnancy and undergo infarction; this should not be mistaken for a sign of malignancy"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis of FA can usually be made on core needle biopsyTargeted lesion is usually a mass with circumscribed margins or a cluster of calcificationsDiagnosis of FA does not correlate well with a mass with spiculated margins",
                    "sub_points": [
                      "Targeted lesion is usually a mass with circumscribed margins or a cluster of calcifications",
                      "Diagnosis of FA does not correlate well with a mass with spiculated margins"
                    ]
                  },
                  {
                    "text": "Some FELs on core needle biopsy are difficult to classify as FA or PTIf a definitive diagnosis is not possible, a diagnosis of FEL can be made with final classification on the excisional specimenHowever, the term \"FEL\" should not be used to describe a lesion unless PT is in the differential diagnosisClinicians may assume there is a risk for PT when this term is usedFor example, a lesion with overlapping features of a tubular adenoma and an FA might be described as an FEL, but excision would not be indicated in this setting",
                    "sub_points": [
                      "If a definitive diagnosis is not possible, a diagnosis of FEL can be made with final classification on the excisional specimen",
                      "However, the term \"FEL\" should not be used to describe a lesion unless PT is in the differential diagnosisClinicians may assume there is a risk for PT when this term is usedFor example, a lesion with overlapping features of a tubular adenoma and an FA might be described as an FEL, but excision would not be indicated in this setting",
                      "Clinicians may assume there is a risk for PT when this term is used",
                      "For example, a lesion with overlapping features of a tubular adenoma and an FA might be described as an FEL, but excision would not be indicated in this setting"
                    ]
                  },
                  {
                    "text": "Features favoring FA over PT include the followingSmall size (< 3 cm) by imaging, no history of recent increase in sizeIf there has been an increase in size, the likelihood of a PT is increasedStroma only mildly cellular and lacking appearance of PASHMitoses are absent or rareMitoses > 2 per 10 HPF or Ki-67 > 5% favors PTHowever, up to 7 mitoses per 10 HPF (3.57 mitoses/mm²) may be acceptable for a cellular FA, especially in a young patientBoth FA and PT can have low proliferative ratesBalance of stroma and epithelium (i.e., no stromal overgrowth)Cores are not fragmentedFragmentation is more likely when stromal overgrowth is presentNo stromal infiltration is seenAdipose tissue is not present in lesion",
                    "sub_points": [
                      "Small size (< 3 cm) by imaging, no history of recent increase in sizeIf there has been an increase in size, the likelihood of a PT is increased",
                      "If there has been an increase in size, the likelihood of a PT is increased",
                      "Stroma only mildly cellular and lacking appearance of PASH",
                      "Mitoses are absent or rareMitoses > 2 per 10 HPF or Ki-67 > 5% favors PTHowever, up to 7 mitoses per 10 HPF (3.57 mitoses/mm²) may be acceptable for a cellular FA, especially in a young patientBoth FA and PT can have low proliferative rates",
                      "Mitoses > 2 per 10 HPF or Ki-67 > 5% favors PT",
                      "However, up to 7 mitoses per 10 HPF (3.57 mitoses/mm²) may be acceptable for a cellular FA, especially in a young patient",
                      "Both FA and PT can have low proliferative rates",
                      "Balance of stroma and epithelium (i.e., no stromal overgrowth)",
                      "Cores are not fragmentedFragmentation is more likely when stromal overgrowth is present",
                      "Fragmentation is more likely when stromal overgrowth is present",
                      "No stromal infiltration is seen",
                      "Adipose tissue is not present in lesion"
                    ]
                  },
                  {
                    "text": "AH is rarely present in an FAIf limited to the FA, the upgrade to carcinoma on excision is low (< 5%)",
                    "sub_points": [
                      "If limited to the FA, the upgrade to carcinoma on excision is low (< 5%)"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "In general, IHC is not required unless another type of spindle cell lesion is in the differential diagnosis"
                  },
                  {
                    "text": "CD34: Positive"
                  },
                  {
                    "text": "Estrogen and progesterone receptors: May be positive"
                  },
                  {
                    "text": "β-catenin: 60-90% show aberrant nuclear positivity"
                  },
                  {
                    "text": "Ki-67: Typically very low (< 5%)Some PTs also have low Ki-67 scoresNot typically used for diagnosis",
                    "sub_points": [
                      "Some PTs also have low Ki-67 scores",
                      "Not typically used for diagnosis"
                    ]
                  },
                  {
                    "text": "Muscle markers: May be positive or negativeMore likely to be positive in lesions with myoid-appearing stroma due to myofibroblast prominence",
                    "sub_points": [
                      "More likely to be positive in lesions with myoid-appearing stroma due to myofibroblast prominence"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Phyllodes Tumor": [
                  {
                    "text": "Uncommon neoplasm accounting for < 1% of primary mammary tumorsTypically occurs in older patients compared with FA (median age at diagnosis: 45 years)",
                    "sub_points": [
                      "Typically occurs in older patients compared with FA (median age at diagnosis: 45 years)"
                    ]
                  },
                  {
                    "text": "FAs and benign PTs overlap in histologic appearance and genomic changesBoth have a low risk of local recurrence and essentially no risk of distant metastases",
                    "sub_points": [
                      "Both have a low risk of local recurrence and essentially no risk of distant metastases"
                    ]
                  },
                  {
                    "text": "Features favoring benign PT over FA: Marked increased stromal cellularity, nuclear atypia, stromal mitoses, stromal overgrowth, &/or infiltration into adjacent tissue"
                  }
                ],
                "Fibroadenomatoid Changes": [
                  {
                    "text": "Same features as FA but do not form a discrete massMost likely represents hyperplastic stromal changes and not a neoplastic proliferation",
                    "sub_points": [
                      "Most likely represents hyperplastic stromal changes and not a neoplastic proliferation"
                    ]
                  },
                  {
                    "text": "Typically present as ill-defined palpable mass, mammographic density &/or calcifications"
                  },
                  {
                    "text": "In rare cases, stromal invasion by a PT can be mistaken for fibroadenomatoid changes"
                  }
                ],
                "Hamartoma (Fibroadenolipoma)": [
                  {
                    "text": "Like FAs, hamartomas form masses with circumscribed borders and are composed of both epithelial and stromal cells"
                  },
                  {
                    "text": "Hamartomas and FAs can be distinguished by several featuresThe epithelial component includes both ducts and lobules, and the ducts are not typically distorted by the stroma (intracanalicular pattern)Stromal predominance is not characteristicAdipose tissue is usually found in hamartomas but very unusual for FAsRadiologic imaging usually suggests hamartoma because of adipose tissue",
                    "sub_points": [
                      "The epithelial component includes both ducts and lobules, and the ducts are not typically distorted by the stroma (intracanalicular pattern)",
                      "Stromal predominance is not characteristic",
                      "Adipose tissue is usually found in hamartomas but very unusual for FAsRadiologic imaging usually suggests hamartoma because of adipose tissue",
                      "Radiologic imaging usually suggests hamartoma because of adipose tissue"
                    ]
                  },
                  {
                    "text": "In both hamartomas and FAs, the stroma can show smooth muscle differentiation (\"myoid hamartoma\") or PASH"
                  }
                ],
                "Tubular Adenoma": [
                  {
                    "text": "Circumscribed lesion consisting of small, round, acinar spaces surrounded by scant loosely cellular stroma"
                  },
                  {
                    "text": "Less common than FAAlso occurs in young women",
                    "sub_points": [
                      "Also occurs in young women"
                    ]
                  },
                  {
                    "text": "May be brown on gross examinationFAs are usually white",
                    "sub_points": [
                      "FAs are usually white"
                    ]
                  },
                  {
                    "text": "Some lesions consist of both tubular adenoma and FAProbably hyperplasias with differing relative predominance of stromal and epithelial elementsTubular adenoma is sometimes classified as FA variant",
                    "sub_points": [
                      "Probably hyperplasias with differing relative predominance of stromal and epithelial elements",
                      "Tubular adenoma is sometimes classified as FA variant"
                    ]
                  }
                ],
                "Pseudoangiomatous Stromal Hyperplasia (PASH)": [
                  {
                    "text": "Proliferation of myofibroblasts that surround rather than distort ducts and lobulesAssociated with characteristic clefting of stromaFascicular PASH is more cellular and often lacks clefting",
                    "sub_points": [
                      "Associated with characteristic clefting of stroma",
                      "Fascicular PASH is more cellular and often lacks clefting"
                    ]
                  },
                  {
                    "text": "Can form circumscribed or ill-defined mass but is most frequently an incidental finding"
                  },
                  {
                    "text": "Can be present within stroma of FA or PT"
                  },
                  {
                    "text": "Similar lesions but without stromal clefting can be termed \"fibrous tumors\"Likely proliferating fibroblasts instead of myofibroblasts",
                    "sub_points": [
                      "Likely proliferating fibroblasts instead of myofibroblasts"
                    ]
                  }
                ],
                "Periductal Stromal Hyperplasia or Tumor": [
                  {
                    "text": "This is a rare lesion in which there is increased stromal cellularity cuffing ducts"
                  },
                  {
                    "text": "Instead of forming a contiguous mass, the lesion follows along ducts"
                  },
                  {
                    "text": "Periductal stromal tumors are classified as PTs"
                  }
                ],
                "Myxoma and Angiomyxoma": [
                  {
                    "text": "Myxomas and angiomyxomas rarely occur in the breast"
                  },
                  {
                    "text": "They consist of hypocellular myxoid stroma with a delicate vasculature that often infiltrates into adjacent stromaStromal neutrophils are commonMitoses are rare",
                    "sub_points": [
                      "Stromal neutrophils are common",
                      "Mitoses are rare"
                    ]
                  },
                  {
                    "text": "In lesions occurring deep in the breast, entrapment of lobules can mimic myxoid FA"
                  },
                  {
                    "text": "~ 2/3 lack expression of PRKAR1A by IHC, which can be helpful for classification"
                  },
                  {
                    "text": "These lesions, as well as myxoid FAs, can be associated with Carney complex/syndrome~ 7% of breast angiomyxomas occur in patients with Carney complex/syndrome",
                    "sub_points": [
                      "~ 7% of breast angiomyxomas occur in patients with Carney complex/syndrome"
                    ]
                  }
                ],
                "Myofibroepithelial Nodule (MFN)": [
                  {
                    "text": "MFNs form masses consisting of a myofibroblastic cellular stroma with admixed dense collagenNo adipose tissue is present in the mass",
                    "sub_points": [
                      "No adipose tissue is present in the mass"
                    ]
                  },
                  {
                    "text": "The cells are strongly and diffusely positive for smooth muscle actinFAs generally show more focal and weaker staining",
                    "sub_points": [
                      "FAs generally show more focal and weaker staining"
                    ]
                  },
                  {
                    "text": "The margins may be circumscribed or focally irregular"
                  },
                  {
                    "text": "The stromal cells surround epithelium, but an intracanalicular pattern is not present"
                  },
                  {
                    "text": "The differential diagnosis includes cellular FA, myoid hamartoma, and PASH"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Only important differential diagnosis is PTCellular FA and benign PT are on morphologic and biologic continuumIf tumor is not clearly PT, it is preferable to classify as FA but discuss differential in note",
                    "sub_points": [
                      "Cellular FA and benign PT are on morphologic and biologic continuum",
                      "If tumor is not clearly PT, it is preferable to classify as FA but discuss differential in note"
                    ]
                  },
                  {
                    "text": "Enlargement and infarction during pregnancy can raise concern for malignancyIf such a lesion is sent for intraoperative evaluation, necrosis must not be overinterpreted as malignancy",
                    "sub_points": [
                      "If such a lesion is sent for intraoperative evaluation, necrosis must not be overinterpreted as malignancy"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Correlate clinical (palpable mass) or imaging (mass &/or calcifications) with FA"
                  },
                  {
                    "text": "List unusual features, such as stromal mitoses or stromal overgrowthMay be appropriate to include differential diagnosis of benign PT",
                    "sub_points": [
                      "May be appropriate to include differential diagnosis of benign PT"
                    ]
                  },
                  {
                    "text": "Incidental clinically occult FAs in patients with carcinoma have no significance and need not be reported"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Phyllodes Tumor": {
            "name": "Phyllodes Tumor",
            "url": "https://app.pathprimer.com/document/c65924d6-45f9-46e3-83be-dcff47074374/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Biphasic tumor consisting of neoplastic stromal cells surrounding nonneoplastic epithelial-lined clefts, creating leaf-like fronds"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Uncommon: < 1% of all breast tumors"
                  },
                  {
                    "text": "Peak age range: 35-55 years"
                  },
                  {
                    "text": "More common in Asian populations (~ 7% of breast tumors)"
                  },
                  {
                    "text": "> 90% of phyllodes tumors (PTs) follow benign clinical course and are adequately treated by surgical resection"
                  },
                  {
                    "text": "In rare cases (~ 2% of PTs), distant metastases occur and usually result in death of patient"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Diagnosis of PT requires presence of both spindle stromal cells and benign epithelium (biphasic)"
                  },
                  {
                    "text": "If a benign epithelial component is absent, the differential includes sarcoma"
                  },
                  {
                    "text": "Characteristics of stromal cells are used to distinguish PT from fibroadenoma and for classification"
                  },
                  {
                    "text": "Evaluation of stroma is used to classify PT into 3 groupsGroups correlate with likelihood of local recurrence and metastasis",
                    "sub_points": [
                      "Groups correlate with likelihood of local recurrence and metastasis"
                    ]
                  },
                  {
                    "text": "Margins can be difficult to evaluate, particularly in reexcision specimens"
                  },
                  {
                    "text": "Recurrent PT can acquire more advanced morphologic features as well as additional genetic changes"
                  },
                  {
                    "text": "Metastases consist only of stromal componentBone and lung are most common sites",
                    "sub_points": [
                      "Bone and lung are most common sites"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Fibroadenoma with cellular stroma"
                  },
                  {
                    "text": "Fibromatosis"
                  },
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia (PASH)"
                  },
                  {
                    "text": "Spindle cell carcinoma"
                  },
                  {
                    "text": "Primary sarcoma of breast"
                  },
                  {
                    "text": "Metastatic spindle cell tumors"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Phyllodes tumor (PT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Cystosarcoma phyllodes (not recommended)"
                  },
                  {
                    "text": "Phylloides tumor (not recommended)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Biphasic tumor consisting of neoplastic clonal intralobular-type stromal cells and benign nonclonal epithelial cells"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Phyllodes Tumors (PTs)": [
                  {
                    "text": "During embryonic development, breast stromal cells are the first to differentiateThe stroma induces downgrowth of overlying epithelium to form primitive ductsThis molecular crosstalk continues throughout life",
                    "sub_points": [
                      "The stroma induces downgrowth of overlying epithelium to form primitive ducts",
                      "This molecular crosstalk continues throughout life"
                    ]
                  },
                  {
                    "text": "Fibroepithelial lesions (FELs) arise from the intralobular stroma that supports the acini in lobulesThis group includes polyclonal hyperplasias, benign monoclonal tumors, and malignant tumors with the capacity to metastasizeThe associated epithelium is polyclonal and is stimulated to proliferate by the stromal cells",
                    "sub_points": [
                      "This group includes polyclonal hyperplasias, benign monoclonal tumors, and malignant tumors with the capacity to metastasize",
                      "The associated epithelium is polyclonal and is stimulated to proliferate by the stromal cells"
                    ]
                  },
                  {
                    "text": "Fibroadenomas (FAs) are the most common type of FEL (~ 97%), followed by PTs (< 3%)"
                  },
                  {
                    "text": "Although there is a morphologic continuum from FAs to PTs, it is not clear if some or all PTs arise from FAsThe presence of identical mutations in FAs and PTs in the same patient supports that some PTs arise from FAsHowever, some PTs may arise along an independent pathway",
                    "sub_points": [
                      "The presence of identical mutations in FAs and PTs in the same patient supports that some PTs arise from FAs",
                      "However, some PTs may arise along an independent pathway"
                    ]
                  },
                  {
                    "text": "PTs acquire additional mutations that are not found in FAs"
                  },
                  {
                    "text": "From benign, to borderline, to malignant PTs (MPTs), these lesions show increasing autonomous growth of stromal cellsIn more advanced lesions, stromal cells outgrow epithelial cells (stromal overgrowth)MPT may consist almost entirely of stromaMPTs possess many characteristics of mesenchymal stem cellsTumors are enriched in aldehyde dehydrogenase 1 (ALDH) and ALDH/disialoganglioside (GD2) (+) subpopulationsCells expressing ALDH &/or GD2 had higher capacity for tumor formation in xenograft experiments",
                    "sub_points": [
                      "In more advanced lesions, stromal cells outgrow epithelial cells (stromal overgrowth)",
                      "MPT may consist almost entirely of stromaMPTs possess many characteristics of mesenchymal stem cellsTumors are enriched in aldehyde dehydrogenase 1 (ALDH) and ALDH/disialoganglioside (GD2) (+) subpopulationsCells expressing ALDH &/or GD2 had higher capacity for tumor formation in xenograft experiments",
                      "MPTs possess many characteristics of mesenchymal stem cellsTumors are enriched in aldehyde dehydrogenase 1 (ALDH) and ALDH/disialoganglioside (GD2) (+) subpopulationsCells expressing ALDH &/or GD2 had higher capacity for tumor formation in xenograft experiments",
                      "Tumors are enriched in aldehyde dehydrogenase 1 (ALDH) and ALDH/disialoganglioside (GD2) (+) subpopulations",
                      "Cells expressing ALDH &/or GD2 had higher capacity for tumor formation in xenograft experiments"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Germline mutations~ 8% of women with PT have germline mutations (e.g.,CHEK2,ATM,RAD51D)Increased risk for women with Li-Fraumeni syndrome (germlineTP53mutations), but their risk for breast carcinoma is much higher",
                    "sub_points": [
                      "~ 8% of women with PT have germline mutations (e.g.,CHEK2,ATM,RAD51D)",
                      "Increased risk for women with Li-Fraumeni syndrome (germlineTP53mutations), but their risk for breast carcinoma is much higher"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "Uncommon: 0.3-1% of all breast tumors and ~ 2.5% of FELs"
                  }
                ],
                "Age": [
                  {
                    "text": "Peak range: 35-55 yearsCan occur at any age",
                    "sub_points": [
                      "Can occur at any age"
                    ]
                  },
                  {
                    "text": "Typical age for FA is 10 years younger than age for PT"
                  }
                ],
                "Sex": [
                  {
                    "text": "Very rare in men but can occur"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "More common in Asian populations (~ 7% of breast tumors)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Most common presentation is as a palpable painless mass"
                  },
                  {
                    "text": "Less commonly detected as a mass on mammographic screening"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete excision of all PTs recommendedIncomplete excision increases risk for local recurrenceRecurrence rates increase from benign to MPTMost recurrences occur in first 2 yearsVery wide margins are not shown to decrease local recurrence",
                    "sub_points": [
                      "Incomplete excision increases risk for local recurrence",
                      "Recurrence rates increase from benign to MPTMost recurrences occur in first 2 yearsVery wide margins are not shown to decrease local recurrence",
                      "Most recurrences occur in first 2 years",
                      "Very wide margins are not shown to decrease local recurrence"
                    ]
                  },
                  {
                    "text": "Benign and borderline PTs have a low rate of recurrence with close or negative marginsThe presence and extent of a positive margin are not good predictors of recurrenceClose clinical follow-up is an alternative in this group",
                    "sub_points": [
                      "The presence and extent of a positive margin are not good predictors of recurrence",
                      "Close clinical follow-up is an alternative in this group"
                    ]
                  },
                  {
                    "text": "Lower rates of recurrence after mastectomy"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Chemotherapy has not been shown to be effectiveHowever, it is not possible to perform randomized trials due to rarity of PT and adverse events",
                    "sub_points": [
                      "However, it is not possible to perform randomized trials due to rarity of PT and adverse events"
                    ]
                  },
                  {
                    "text": "Metastatic PT is usually fatal regardless of treatment"
                  }
                ],
                "Radiation": [
                  {
                    "text": "Benefit of radiation therapy is unclear"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "The rarity of PTs and adverse events associated with them make prognosis difficult to studyLarge series from referral centers may not be representative of prognosis in generalTreatment is not standardized",
                    "sub_points": [
                      "Large series from referral centers may not be representative of prognosis in general",
                      "Treatment is not standardized"
                    ]
                  },
                  {
                    "text": "Outcome can be predicted to some extent by type of PTBenign PT: ~ 60-75% of cases~ 10-17% risk of local recurrence< 1% risk of distant metastasis; only reported to occur in large seriesSuch a case has never been described in detailMay be locally recurrent PT that progressed to higher gradeMay be cases that were undersampled, and higher grade area was missedBorderline PT: ~ 15-20% of cases~ 14-25% risk of local recurrence~ 2% risk of distant metastasisMalignant PT: ~ 10-20% of cases~ 23-30% risk of local recurrence~ 17% risk of distant metastasisPredictors include age > 50 years, stromal overgrowth, marked stromal cellularity, diffuse marked nuclear atypia, necrosis, high mitotic rate ≥ 10/10 HPFs, large size (> 9 cm), and malignant heterologous elements",
                    "sub_points": [
                      "Benign PT: ~ 60-75% of cases~ 10-17% risk of local recurrence< 1% risk of distant metastasis; only reported to occur in large seriesSuch a case has never been described in detailMay be locally recurrent PT that progressed to higher gradeMay be cases that were undersampled, and higher grade area was missed",
                      "~ 10-17% risk of local recurrence",
                      "< 1% risk of distant metastasis; only reported to occur in large seriesSuch a case has never been described in detailMay be locally recurrent PT that progressed to higher gradeMay be cases that were undersampled, and higher grade area was missed",
                      "Such a case has never been described in detail",
                      "May be locally recurrent PT that progressed to higher grade",
                      "May be cases that were undersampled, and higher grade area was missed",
                      "Borderline PT: ~ 15-20% of cases~ 14-25% risk of local recurrence~ 2% risk of distant metastasis",
                      "~ 14-25% risk of local recurrence",
                      "~ 2% risk of distant metastasis",
                      "Malignant PT: ~ 10-20% of cases~ 23-30% risk of local recurrence~ 17% risk of distant metastasisPredictors include age > 50 years, stromal overgrowth, marked stromal cellularity, diffuse marked nuclear atypia, necrosis, high mitotic rate ≥ 10/10 HPFs, large size (> 9 cm), and malignant heterologous elements",
                      "~ 23-30% risk of local recurrence",
                      "~ 17% risk of distant metastasis",
                      "Predictors include age > 50 years, stromal overgrowth, marked stromal cellularity, diffuse marked nuclear atypia, necrosis, high mitotic rate ≥ 10/10 HPFs, large size (> 9 cm), and malignant heterologous elements"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Mass with circumscribed margins most commonCalcifications very uncommon",
                    "sub_points": [
                      "Calcifications very uncommon"
                    ]
                  },
                  {
                    "text": "Partially indistinct margins may indicate infiltration into adjacent stroma"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Can have the appearance of a complex cyst due to the leaf-like growth pattern in large lesionsInternal hyperechoic striations correlate with cleftsMay have intramural cystic spaces",
                    "sub_points": [
                      "Internal hyperechoic striations correlate with clefts",
                      "May have intramural cystic spaces"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Typically well-defined, lobulated/bosselated massesPT with stromal infiltration may have an irregular border with tumor protruding into adjacent breast parenchyma",
                    "sub_points": [
                      "PT with stromal infiltration may have an irregular border with tumor protruding into adjacent breast parenchyma"
                    ]
                  },
                  {
                    "text": "Often show cleft-like cystic spaces"
                  }
                ],
                "Size": [
                  {
                    "text": "Most often 4-8 cm (range: 1-40 cm)"
                  }
                ],
                "Sections to Be Submitted": [
                  {
                    "text": "Because PT can be very heterogeneous morphologically, areas throughout the tumor should be sampled~ 1/3 have areas that could be classified as FAHigher grade features or malignant heterologous elements may be focalEpithelial component may be very focal in MPT",
                    "sub_points": [
                      "~ 1/3 have areas that could be classified as FA",
                      "Higher grade features or malignant heterologous elements may be focal",
                      "Epithelial component may be very focal in MPT"
                    ]
                  },
                  {
                    "text": "Tumor sampling should include at least 1 section per cm of greatest sizePreferable to completely sample PTs when possible",
                    "sub_points": [
                      "Preferable to completely sample PTs when possible"
                    ]
                  },
                  {
                    "text": "Margins of MPT should be extensively sampled if undergoing breast-conserving therapy"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Changes are very variable from tumor to tumor and also variable within tumorsSuggests that many subclones with different genetic changes arise during progression",
                    "sub_points": [
                      "Suggests that many subclones with different genetic changes arise during progression"
                    ]
                  },
                  {
                    "text": "Copy number changesMost common are gain of 1q and loss of 13, 7p12, 3p24, 10p12, and 9p21Number of chromosomal changes increases with PT classificationBenign: 3 changes; borderline: 4 changes; malignant: 9 changesLoss of heterozygosity (LOH) increases with PT classificationExtent of LOH is correlated with mitotic rateFAs show fewer changesSome show gain of 1q similar to PTLOH is very low in FAs",
                    "sub_points": [
                      "Most common are gain of 1q and loss of 13, 7p12, 3p24, 10p12, and 9p21",
                      "Number of chromosomal changes increases with PT classificationBenign: 3 changes; borderline: 4 changes; malignant: 9 changes",
                      "Benign: 3 changes; borderline: 4 changes; malignant: 9 changes",
                      "Loss of heterozygosity (LOH) increases with PT classificationExtent of LOH is correlated with mitotic rate",
                      "Extent of LOH is correlated with mitotic rate",
                      "FAs show fewer changesSome show gain of 1q similar to PTLOH is very low in FAs",
                      "Some show gain of 1q similar to PT",
                      "LOH is very low in FAs"
                    ]
                  },
                  {
                    "text": "MutationsMED12exon 2 mutations occur in both FAs and PTsFA (~ 45-60%), benign PT (~ 60%), borderline PT (~ 50%), MPT (~ 40%)PTs with FA-like areas are more likely to haveMED12mutations (~ 70% vs. ~ 10%)TERTpromoter mutations are much more common in PTFA (~ 6%), benign PT (~ 30%), borderline PT (~ 60%), MPT (~ 45%)Mutations involvingRARA,FLNA,SETD2,KMT2D,BCOR, andMAP3K1occur in both but more common in PTMutations inNF1,RB1,TP53,PIK3CA,ERBB4, andEGFRare more common in borderline/malignant than benign PT",
                    "sub_points": [
                      "MED12exon 2 mutations occur in both FAs and PTsFA (~ 45-60%), benign PT (~ 60%), borderline PT (~ 50%), MPT (~ 40%)PTs with FA-like areas are more likely to haveMED12mutations (~ 70% vs. ~ 10%)",
                      "FA (~ 45-60%), benign PT (~ 60%), borderline PT (~ 50%), MPT (~ 40%)",
                      "PTs with FA-like areas are more likely to haveMED12mutations (~ 70% vs. ~ 10%)",
                      "TERTpromoter mutations are much more common in PTFA (~ 6%), benign PT (~ 30%), borderline PT (~ 60%), MPT (~ 45%)",
                      "FA (~ 6%), benign PT (~ 30%), borderline PT (~ 60%), MPT (~ 45%)",
                      "Mutations involvingRARA,FLNA,SETD2,KMT2D,BCOR, andMAP3K1occur in both but more common in PT",
                      "Mutations inNF1,RB1,TP53,PIK3CA,ERBB4, andEGFRare more common in borderline/malignant than benign PT"
                    ]
                  },
                  {
                    "text": "Recurrent tumorsMay acquire additional genomic changes, which correlates with increase in more advanced morphologic features in ~ 1/3 of cases",
                    "sub_points": [
                      "May acquire additional genomic changes, which correlates with increase in more advanced morphologic features in ~ 1/3 of cases"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "Majority of changes are in genes related to proliferation and stromal/epithelial interactionsPAX3andSIX1are most overexpressed genes",
                    "sub_points": [
                      "PAX3andSIX1are most overexpressed genes"
                    ]
                  },
                  {
                    "text": "Patterns of expression vary by PT classificationSupports separation into 3 groups",
                    "sub_points": [
                      "Supports separation into 3 groups"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "Tumors express proteins typical of intralobular stromal cells"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Requires presence of both stromal cells and benign epitheliumEpithelium often shows heterogeneous or nonuniform distribution in PT compared with FAIf a benign epithelial component is absent, the differential includes sarcoma",
                    "sub_points": [
                      "Epithelium often shows heterogeneous or nonuniform distribution in PT compared with FA",
                      "If a benign epithelial component is absent, the differential includes sarcoma"
                    ]
                  },
                  {
                    "text": "Growth patternIntracanalicular growth pattern: Stromal cells push and distort epithelium; create cleft-like spaces lined by epitheliumThis pattern gives rise to the \"phyllodes\" (phyllon means leaf in Greek) pattern of leaf-like frondsHowever, this type of architecture is also seen in FAs and is neither sufficient nor required to classify a lesion as a PTThis pattern is also not used to subclassify PTsThe leaf-like fronds in FAs tend to fit together, creating narrow slit-like clefts, whereas the fronds of PTs may be more irregularPericanalicular growth pattern: Stromal cells surround epithelium; result in a solid pattern without leaf-like structuresPTs often have both growth patterns",
                    "sub_points": [
                      "Intracanalicular growth pattern: Stromal cells push and distort epithelium; create cleft-like spaces lined by epitheliumThis pattern gives rise to the \"phyllodes\" (phyllon means leaf in Greek) pattern of leaf-like frondsHowever, this type of architecture is also seen in FAs and is neither sufficient nor required to classify a lesion as a PTThis pattern is also not used to subclassify PTsThe leaf-like fronds in FAs tend to fit together, creating narrow slit-like clefts, whereas the fronds of PTs may be more irregular",
                      "This pattern gives rise to the \"phyllodes\" (phyllon means leaf in Greek) pattern of leaf-like fronds",
                      "However, this type of architecture is also seen in FAs and is neither sufficient nor required to classify a lesion as a PT",
                      "This pattern is also not used to subclassify PTs",
                      "The leaf-like fronds in FAs tend to fit together, creating narrow slit-like clefts, whereas the fronds of PTs may be more irregular",
                      "Pericanalicular growth pattern: Stromal cells surround epithelium; result in a solid pattern without leaf-like structures",
                      "PTs often have both growth patterns"
                    ]
                  },
                  {
                    "text": "An epithelial component must be present but is not used for classificationUsually shows little or no nuclear atypiaEpithelial hyperplasia may be presentMost common in lower grade PT; usually absent in higher grade PTNormal myoepithelial layer is presentIn rare cases, atypical lobular hyperplasia, atypical ductal hyperplasia, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive carcinoma involve PT",
                    "sub_points": [
                      "Usually shows little or no nuclear atypia",
                      "Epithelial hyperplasia may be presentMost common in lower grade PT; usually absent in higher grade PT",
                      "Most common in lower grade PT; usually absent in higher grade PT",
                      "Normal myoepithelial layer is present",
                      "In rare cases, atypical lobular hyperplasia, atypical ductal hyperplasia, lobular carcinoma in situ (LCIS), ductal carcinoma in situ (DCIS), or invasive carcinoma involve PT"
                    ]
                  },
                  {
                    "text": "Necrosis is present in ~ 10% of MPTsCan be infarct-like or tumor necrosis",
                    "sub_points": [
                      "Can be infarct-like or tumor necrosis"
                    ]
                  },
                  {
                    "text": "6 features are used to distinguish PT from FA and for classification of PT by WHO(1) Stromal cellularityCan be uniform in FAs and MPTs and more likely variable and nonuniform in benign and borderline PTsVaries from paucicellular to mild, moderate, or marked cellularityIn very cellular areas, cells are organized in parallel arrays (fascicles)Condensation (increased cellularity) is often found adjacent to epithelium (\"cambium\" layer)Cells may overlap in very highly cellular stroma(2) Stromal overgrowthDefined as an area of cellular stroma that lacks any epithelial component in a circle with a diameter of 5.4 mmEquivalent to 1 low-power field (4x objective and 10x eyepiece) with an area of 22.9 mm² when the field diameter is 0.50 mm, as recommended by WHODoes not include paucicellular hyalinized areas(3) Stromal atypiaNuclear atypia varies from none to mild, moderate, or markedMarkedly pleomorphic nuclei are only seen in MPTDoes not include scattered multinucleated cells that may be degenerative in nature(4) Mitotic activityThe mitotic rate generally increases in each category from FAs to MPTsThe majority of PTs will have at least some mitosesOften located close to the epitheliumMitoses in the epithelial component are not used for classificationThe number of mitoses per 10 HPF used for classification must be adjusted for the field size of the microscope used for counting(5) Tumor borderFA and benign PT have pushing circumscribed bordersFAs and benign PTs should have a well-defined, noninfiltrative borderMust be distinguished from fibroadenomatoid changes in adjacent tissueAdipose tissue within PT is usually an indication of invasion; liposarcoma must also be consideredFat necrosis, possibly due to a core needle biopsy, can mimic nuclear atypia due to reactive changes(6) Malignant heterologous elementsLiposarcoma, chondrosarcoma, osteosarcoma, and rhabdomyosarcoma can occur in PTBenign metaplastic components can occur in PTMore common as part of MPT than as a sarcoma or metaplastic carcinomaExtensive sampling may be necessary to identify a benign epithelial component diagnostic of MPTIf well-differentiated liposarcoma is present, this is not sufficient for classification as MPTThese tumors lack theMDM2andCDK4amplifications present in liposarcomas outside of PTsSupports that this is a different type of liposarcomaPatients with this type of PT have a favorable outcome; therefore, PT should not be classified as malignant based only on this finding by WHO criteriaIf any other malignant heterologous element is present, the PT is classified as malignant",
                    "sub_points": [
                      "(1) Stromal cellularityCan be uniform in FAs and MPTs and more likely variable and nonuniform in benign and borderline PTsVaries from paucicellular to mild, moderate, or marked cellularityIn very cellular areas, cells are organized in parallel arrays (fascicles)Condensation (increased cellularity) is often found adjacent to epithelium (\"cambium\" layer)Cells may overlap in very highly cellular stroma",
                      "Can be uniform in FAs and MPTs and more likely variable and nonuniform in benign and borderline PTs",
                      "Varies from paucicellular to mild, moderate, or marked cellularity",
                      "In very cellular areas, cells are organized in parallel arrays (fascicles)",
                      "Condensation (increased cellularity) is often found adjacent to epithelium (\"cambium\" layer)",
                      "Cells may overlap in very highly cellular stroma",
                      "(2) Stromal overgrowthDefined as an area of cellular stroma that lacks any epithelial component in a circle with a diameter of 5.4 mmEquivalent to 1 low-power field (4x objective and 10x eyepiece) with an area of 22.9 mm² when the field diameter is 0.50 mm, as recommended by WHODoes not include paucicellular hyalinized areas",
                      "Defined as an area of cellular stroma that lacks any epithelial component in a circle with a diameter of 5.4 mmEquivalent to 1 low-power field (4x objective and 10x eyepiece) with an area of 22.9 mm² when the field diameter is 0.50 mm, as recommended by WHO",
                      "Equivalent to 1 low-power field (4x objective and 10x eyepiece) with an area of 22.9 mm² when the field diameter is 0.50 mm, as recommended by WHO",
                      "Does not include paucicellular hyalinized areas",
                      "(3) Stromal atypiaNuclear atypia varies from none to mild, moderate, or markedMarkedly pleomorphic nuclei are only seen in MPTDoes not include scattered multinucleated cells that may be degenerative in nature",
                      "Nuclear atypia varies from none to mild, moderate, or marked",
                      "Markedly pleomorphic nuclei are only seen in MPT",
                      "Does not include scattered multinucleated cells that may be degenerative in nature",
                      "(4) Mitotic activityThe mitotic rate generally increases in each category from FAs to MPTsThe majority of PTs will have at least some mitosesOften located close to the epitheliumMitoses in the epithelial component are not used for classificationThe number of mitoses per 10 HPF used for classification must be adjusted for the field size of the microscope used for counting",
                      "The mitotic rate generally increases in each category from FAs to MPTs",
                      "The majority of PTs will have at least some mitosesOften located close to the epithelium",
                      "Often located close to the epithelium",
                      "Mitoses in the epithelial component are not used for classification",
                      "The number of mitoses per 10 HPF used for classification must be adjusted for the field size of the microscope used for counting",
                      "(5) Tumor borderFA and benign PT have pushing circumscribed bordersFAs and benign PTs should have a well-defined, noninfiltrative borderMust be distinguished from fibroadenomatoid changes in adjacent tissueAdipose tissue within PT is usually an indication of invasion; liposarcoma must also be consideredFat necrosis, possibly due to a core needle biopsy, can mimic nuclear atypia due to reactive changes",
                      "FA and benign PT have pushing circumscribed borders",
                      "FAs and benign PTs should have a well-defined, noninfiltrative border",
                      "Must be distinguished from fibroadenomatoid changes in adjacent tissue",
                      "Adipose tissue within PT is usually an indication of invasion; liposarcoma must also be consideredFat necrosis, possibly due to a core needle biopsy, can mimic nuclear atypia due to reactive changes",
                      "Fat necrosis, possibly due to a core needle biopsy, can mimic nuclear atypia due to reactive changes",
                      "(6) Malignant heterologous elementsLiposarcoma, chondrosarcoma, osteosarcoma, and rhabdomyosarcoma can occur in PTBenign metaplastic components can occur in PTMore common as part of MPT than as a sarcoma or metaplastic carcinomaExtensive sampling may be necessary to identify a benign epithelial component diagnostic of MPTIf well-differentiated liposarcoma is present, this is not sufficient for classification as MPTThese tumors lack theMDM2andCDK4amplifications present in liposarcomas outside of PTsSupports that this is a different type of liposarcomaPatients with this type of PT have a favorable outcome; therefore, PT should not be classified as malignant based only on this finding by WHO criteriaIf any other malignant heterologous element is present, the PT is classified as malignant",
                      "Liposarcoma, chondrosarcoma, osteosarcoma, and rhabdomyosarcoma can occur in PTBenign metaplastic components can occur in PT",
                      "Benign metaplastic components can occur in PT",
                      "More common as part of MPT than as a sarcoma or metaplastic carcinoma",
                      "Extensive sampling may be necessary to identify a benign epithelial component diagnostic of MPT",
                      "If well-differentiated liposarcoma is present, this is not sufficient for classification as MPTThese tumors lack theMDM2andCDK4amplifications present in liposarcomas outside of PTsSupports that this is a different type of liposarcomaPatients with this type of PT have a favorable outcome; therefore, PT should not be classified as malignant based only on this finding by WHO criteria",
                      "These tumors lack theMDM2andCDK4amplifications present in liposarcomas outside of PTs",
                      "Supports that this is a different type of liposarcoma",
                      "Patients with this type of PT have a favorable outcome; therefore, PT should not be classified as malignant based only on this finding by WHO criteria",
                      "If any other malignant heterologous element is present, the PT is classified as malignant"
                    ]
                  },
                  {
                    "text": "Classification of PTsPTs are classified into benign, borderline, and malignant categoriesWHO definition of MPT includes 2 possibilities(1) Tumors with all the first 5 features(2) Any PT with a malignant heterologous element except for well-differentiated liposarcomaRefined diagnostic criteria definition of MPT includes 2 possibilities(1) Stromal overgrowth and at least 1 other feature (marked stromal cellularity, marked stromal cytologic atypia, ≥ 10 mitoses per 10 HPF)(2) In the absence of stromal overgrowth, marked cellularity and at least 1 other feature (permeative borders, marked stromal cytologic atypia, ≥ 10 mitoses per 10 HPF)Compared to WHO criteria in a validation study, more lesions were classified as MPT and fewer lesions classified as borderline PT metastasized (0% vs. 9.6%)Because there are different classification systems and criteria may change with additional studies, it is imperative that pathologists routinely report all of these features",
                    "sub_points": [
                      "PTs are classified into benign, borderline, and malignant categories",
                      "WHO definition of MPT includes 2 possibilities(1) Tumors with all the first 5 features(2) Any PT with a malignant heterologous element except for well-differentiated liposarcoma",
                      "(1) Tumors with all the first 5 features",
                      "(2) Any PT with a malignant heterologous element except for well-differentiated liposarcoma",
                      "Refined diagnostic criteria definition of MPT includes 2 possibilities(1) Stromal overgrowth and at least 1 other feature (marked stromal cellularity, marked stromal cytologic atypia, ≥ 10 mitoses per 10 HPF)(2) In the absence of stromal overgrowth, marked cellularity and at least 1 other feature (permeative borders, marked stromal cytologic atypia, ≥ 10 mitoses per 10 HPF)Compared to WHO criteria in a validation study, more lesions were classified as MPT and fewer lesions classified as borderline PT metastasized (0% vs. 9.6%)",
                      "(1) Stromal overgrowth and at least 1 other feature (marked stromal cellularity, marked stromal cytologic atypia, ≥ 10 mitoses per 10 HPF)",
                      "(2) In the absence of stromal overgrowth, marked cellularity and at least 1 other feature (permeative borders, marked stromal cytologic atypia, ≥ 10 mitoses per 10 HPF)",
                      "Compared to WHO criteria in a validation study, more lesions were classified as MPT and fewer lesions classified as borderline PT metastasized (0% vs. 9.6%)",
                      "Because there are different classification systems and criteria may change with additional studies, it is imperative that pathologists routinely report all of these features"
                    ]
                  },
                  {
                    "text": "Margin evaluationResidual PT at a margin is predictor of higher likelihood of recurrenceMargins can be difficult to evaluate for lower grade PT if stroma is not very cellularMargin reexcisions are very difficult to evaluate if biopsy site changes are present at the marginReactive fibroblasts present due to surgery may be impossible to distinguish from tumor cells",
                    "sub_points": [
                      "Residual PT at a margin is predictor of higher likelihood of recurrence",
                      "Margins can be difficult to evaluate for lower grade PT if stroma is not very cellular",
                      "Margin reexcisions are very difficult to evaluate if biopsy site changes are present at the marginReactive fibroblasts present due to surgery may be impossible to distinguish from tumor cells",
                      "Reactive fibroblasts present due to surgery may be impossible to distinguish from tumor cells"
                    ]
                  },
                  {
                    "text": "Recurrent PTMay recur as multiple nodules within and surrounding tumor bed~ 25% recur at a higher classification than the original PTAdditional genetic changes are often acquired",
                    "sub_points": [
                      "May recur as multiple nodules within and surrounding tumor bed",
                      "~ 25% recur at a higher classification than the original PTAdditional genetic changes are often acquired",
                      "Additional genetic changes are often acquired"
                    ]
                  },
                  {
                    "text": "Metastatic PTOnly stromal component metastasizesLymph node metastases are very rareDistant metastases are most common to lung and bone",
                    "sub_points": [
                      "Only stromal component metastasizes",
                      "Lymph node metastases are very rare",
                      "Distant metastases are most common to lung and bone"
                    ]
                  },
                  {
                    "text": "Periductal stromal tumor (PST)PT with a pericanalicular pattern of growth along ducts distributed in normal breast tissueThis is considered a subtype of PT by WHODoes not form a contiguous massLesions with features of both PST and PT occur, and PST may recur as PT\"Periductal stromal sarcoma\" refers to tumors with the malignant features of PTPeriductal stromal hyperplasia is a similar lesion but without features of PT",
                    "sub_points": [
                      "PT with a pericanalicular pattern of growth along ducts distributed in normal breast tissueThis is considered a subtype of PT by WHO",
                      "This is considered a subtype of PT by WHO",
                      "Does not form a contiguous mass",
                      "Lesions with features of both PST and PT occur, and PST may recur as PT",
                      "\"Periductal stromal sarcoma\" refers to tumors with the malignant features of PT",
                      "Periductal stromal hyperplasia is a similar lesion but without features of PT"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "PT vs. cellular FAPT can be heterogeneous with some areas having the appearance of FAIf diagnosis is uncertain, best to diagnose FEL and suggest classification after excisionCorrelation with imaging studies and clinical history may be helpful in challenging cases\"FEL\" should not be used unless PT is in the differential diagnosis, as this is the context in which this term is typically usedFeatures favoring PT on core needle biopsyMarkedly cellular stromaInvasive/infiltrating borderStromal overgrowthMitotic rate > 2 per 10 HPFIf 0 or 1, not helpful for distinctionKi-67 > 5%If < 5%, not helpful for distinctionRecent increase in size favors PT unless patient is pregnant",
                    "sub_points": [
                      "PT can be heterogeneous with some areas having the appearance of FA",
                      "If diagnosis is uncertain, best to diagnose FEL and suggest classification after excisionCorrelation with imaging studies and clinical history may be helpful in challenging cases\"FEL\" should not be used unless PT is in the differential diagnosis, as this is the context in which this term is typically used",
                      "Correlation with imaging studies and clinical history may be helpful in challenging cases",
                      "\"FEL\" should not be used unless PT is in the differential diagnosis, as this is the context in which this term is typically used",
                      "Features favoring PT on core needle biopsyMarkedly cellular stromaInvasive/infiltrating borderStromal overgrowthMitotic rate > 2 per 10 HPFIf 0 or 1, not helpful for distinctionKi-67 > 5%If < 5%, not helpful for distinctionRecent increase in size favors PT unless patient is pregnant",
                      "Markedly cellular stroma",
                      "Invasive/infiltrating border",
                      "Stromal overgrowth",
                      "Mitotic rate > 2 per 10 HPFIf 0 or 1, not helpful for distinction",
                      "If 0 or 1, not helpful for distinction",
                      "Ki-67 > 5%If < 5%, not helpful for distinction",
                      "If < 5%, not helpful for distinction",
                      "Recent increase in size favors PT unless patient is pregnant"
                    ]
                  },
                  {
                    "text": "PT vs. other spindle cell lesionsThe stroma can resemble pseudoangiomatous stromal hyperplasia (PASH), fibromatosis, or spindle cell carcinomaIHC can be helpful to identify fibromatosis or carcinomaThere are no specific markers to identify a lesion as PTPT can occasionally be positive for nuclear β-catenin, cytokeratin, and p63, which can make the distinction from other lesions difficultLower grade PT is positive for CD34 and fibromatosis and carcinoma are negative; does not exclude other stromal lesions, such as PASH",
                    "sub_points": [
                      "The stroma can resemble pseudoangiomatous stromal hyperplasia (PASH), fibromatosis, or spindle cell carcinoma",
                      "IHC can be helpful to identify fibromatosis or carcinomaThere are no specific markers to identify a lesion as PTPT can occasionally be positive for nuclear β-catenin, cytokeratin, and p63, which can make the distinction from other lesions difficultLower grade PT is positive for CD34 and fibromatosis and carcinoma are negative; does not exclude other stromal lesions, such as PASH",
                      "There are no specific markers to identify a lesion as PTPT can occasionally be positive for nuclear β-catenin, cytokeratin, and p63, which can make the distinction from other lesions difficultLower grade PT is positive for CD34 and fibromatosis and carcinoma are negative; does not exclude other stromal lesions, such as PASH",
                      "PT can occasionally be positive for nuclear β-catenin, cytokeratin, and p63, which can make the distinction from other lesions difficult",
                      "Lower grade PT is positive for CD34 and fibromatosis and carcinoma are negative; does not exclude other stromal lesions, such as PASH"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Ki-67More Ki-67(+) cells are found in PT compared to FABenign PT: ~ 1-5%, borderline PT: ~ 6-25%, MPT: ~10-50%Absent or very low Ki-67 does not distinguish between FA and PT on core needle biopsyKi-67 > 5% on core needle biopsy is a high predictor of PT",
                    "sub_points": [
                      "More Ki-67(+) cells are found in PT compared to FABenign PT: ~ 1-5%, borderline PT: ~ 6-25%, MPT: ~10-50%",
                      "Benign PT: ~ 1-5%, borderline PT: ~ 6-25%, MPT: ~10-50%",
                      "Absent or very low Ki-67 does not distinguish between FA and PT on core needle biopsyKi-67 > 5% on core needle biopsy is a high predictor of PT",
                      "Ki-67 > 5% on core needle biopsy is a high predictor of PT"
                    ]
                  },
                  {
                    "text": "p63, cytokeratin, and p40Focal p63, p40, and cytokeratin positivity can be seen in MPT but not in other typesFocal expression of these markers does not definitively distinguish PT from spindle cell carcinomaDefinitive diagnosis may not be possible when sampling is limited, such as with core needle biopsy",
                    "sub_points": [
                      "Focal p63, p40, and cytokeratin positivity can be seen in MPT but not in other typesFocal expression of these markers does not definitively distinguish PT from spindle cell carcinomaDefinitive diagnosis may not be possible when sampling is limited, such as with core needle biopsy",
                      "Focal expression of these markers does not definitively distinguish PT from spindle cell carcinoma",
                      "Definitive diagnosis may not be possible when sampling is limited, such as with core needle biopsy"
                    ]
                  },
                  {
                    "text": "CD34Majority of PTs are CD34(+), as are most breast stromal cellsDegree of positivity for CD34 decreases with higher classification and may be absent in MPTIn combination with absence of immunoreactivity for keratin can support diagnosis of PT over carcinoma or fibromatosis",
                    "sub_points": [
                      "Majority of PTs are CD34(+), as are most breast stromal cells",
                      "Degree of positivity for CD34 decreases with higher classification and may be absent in MPT",
                      "In combination with absence of immunoreactivity for keratin can support diagnosis of PT over carcinoma or fibromatosis"
                    ]
                  },
                  {
                    "text": "TRPS1Positive in the stromal cells of all types of PT and in heterologous elementsTRPS1 is also positive in carcinomas and sarcomas",
                    "sub_points": [
                      "Positive in the stromal cells of all types of PT and in heterologous elements",
                      "TRPS1 is also positive in carcinomas and sarcomas"
                    ]
                  },
                  {
                    "text": "C-kit (CD117)Stromal cells can be positive10% of PTs expressed CD117 in one large seriesCD117 protein expression was associated with unfavorable pathologic parameters and poorer prognosisOverexpression was not associated with mutations inKITgene",
                    "sub_points": [
                      "Stromal cells can be positive10% of PTs expressed CD117 in one large seriesCD117 protein expression was associated with unfavorable pathologic parameters and poorer prognosisOverexpression was not associated with mutations inKITgene",
                      "10% of PTs expressed CD117 in one large seriesCD117 protein expression was associated with unfavorable pathologic parameters and poorer prognosisOverexpression was not associated with mutations inKITgene",
                      "CD117 protein expression was associated with unfavorable pathologic parameters and poorer prognosis",
                      "Overexpression was not associated with mutations inKITgene"
                    ]
                  },
                  {
                    "text": "p53More common in MPT; rare or absent in FA and benign and borderline PTNot correlated with recurrence or death",
                    "sub_points": [
                      "More common in MPT; rare or absent in FA and benign and borderline PT",
                      "Not correlated with recurrence or death"
                    ]
                  },
                  {
                    "text": "β-cateninNuclear positivity is often present in PTMore common in benign and borderline PT and FA and in zone adjacent to epitheliumAlso occurs in fibromatosis and invasive carcinomaNot useful for diagnosis",
                    "sub_points": [
                      "Nuclear positivity is often present in PTMore common in benign and borderline PT and FA and in zone adjacent to epithelium",
                      "More common in benign and borderline PT and FA and in zone adjacent to epithelium",
                      "Also occurs in fibromatosis and invasive carcinomaNot useful for diagnosis",
                      "Not useful for diagnosis"
                    ]
                  }
                ],
                "16-Gene Panel": [
                  {
                    "text": "A 16-gene panel has been developed to help diagnose FELsFA: 0 mutations (34%), 1 mutation (40%), ≥ 2 mutations (26%)Benign PT: 0 mutations (17%), 1 mutation (29%), ≥ 2 mutations (54%)Borderline PT: 0 mutations (15%), 1 mutation (18%), ≥ 2 mutations (68%)MPT: 0 mutations (19%), 1 mutation (19%), ≥ 2 mutations (63%)",
                    "sub_points": [
                      "FA: 0 mutations (34%), 1 mutation (40%), ≥ 2 mutations (26%)",
                      "Benign PT: 0 mutations (17%), 1 mutation (29%), ≥ 2 mutations (54%)",
                      "Borderline PT: 0 mutations (15%), 1 mutation (18%), ≥ 2 mutations (68%)",
                      "MPT: 0 mutations (19%), 1 mutation (19%), ≥ 2 mutations (63%)"
                    ]
                  },
                  {
                    "text": "The results support that FELs form a biologic continuum and that there is heterogeneity in each group"
                  }
                ],
                "Singapore Nomogram": [
                  {
                    "text": "A nomogram using 4 features (\"AMOS\") is used to generate a numerical valueAtypia in stroma: Mild, moderate, markedMitoses per 10 HPF in stroma: Continuous variableOvergrowth of stroma: Absent or presentSurgical margin: Negative or positive",
                    "sub_points": [
                      "Atypia in stroma: Mild, moderate, marked",
                      "Mitoses per 10 HPF in stroma: Continuous variable",
                      "Overgrowth of stroma: Absent or present",
                      "Surgical margin: Negative or positive"
                    ]
                  },
                  {
                    "text": "The total number of points is used to predict recurrence at 3 time intervals"
                  },
                  {
                    "text": "An online calculator is not currently available"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Fibroadenoma With Cellular Stroma": [
                  {
                    "text": "FAs are typically smaller than PTs, but there is a broad overlap in size"
                  },
                  {
                    "text": "FA has uniform distribution of glandular and stromal elements with no stromal overgrowthAreas of low cellularity and hyalinization are not considered stromal overgrowth",
                    "sub_points": [
                      "Areas of low cellularity and hyalinization are not considered stromal overgrowth"
                    ]
                  },
                  {
                    "text": "Cytologic atypia is minimal, and mitotic figures are rareFA can grow during pregnancy and could possibly have more mitoses in this setting",
                    "sub_points": [
                      "FA can grow during pregnancy and could possibly have more mitoses in this setting"
                    ]
                  },
                  {
                    "text": "Histologic features may overlap with benign PT"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Fibromatosis consists of stromal cells infiltrating around normal ducts and lobulesThe benign epithelial component in PT distinguishes it from fibromatosis",
                    "sub_points": [
                      "The benign epithelial component in PT distinguishes it from fibromatosis"
                    ]
                  },
                  {
                    "text": "CD34 is negative in fibromatosis and positive in PT but may be negative in MPT"
                  },
                  {
                    "text": "Both fibromatosis and PT commonly express nuclear β-catenin; therefore, this marker is not useful to distinguish these entities"
                  }
                ],
                "Pseudoangiomatous Stromal Hyperplasia (PASH)": [
                  {
                    "text": "PASH rarely forms masses < 2 cm, whereas PT is usually larger"
                  },
                  {
                    "text": "PASH surrounds but does not distort breast epithelium"
                  },
                  {
                    "text": "The stroma of PT can have the appearance of PASHCan be difficult to distinguish on limited core needle biopsy",
                    "sub_points": [
                      "Can be difficult to distinguish on limited core needle biopsy"
                    ]
                  }
                ],
                "Spindle Cell Carcinoma": [
                  {
                    "text": "Can be difficult to distinguish from sarcomas and MPT"
                  },
                  {
                    "text": "Features favoring carcinoma include epithelioid areas and associated DCIS"
                  },
                  {
                    "text": "Immunoperoxidase studies are often necessaryStrong diffuse positivity for cytokeratins (especially high molecular weight keratins) and p63 as well as the absence of CD34 favor carcinomaHowever, PTs can have focal positivity",
                    "sub_points": [
                      "Strong diffuse positivity for cytokeratins (especially high molecular weight keratins) and p63 as well as the absence of CD34 favor carcinoma",
                      "However, PTs can have focal positivity"
                    ]
                  }
                ],
                "Primary Sarcoma": [
                  {
                    "text": "Extremely rare breast malignancyMore common to see malignant heterologous elements in PT or metaplastic carcinoma",
                    "sub_points": [
                      "More common to see malignant heterologous elements in PT or metaplastic carcinoma"
                    ]
                  },
                  {
                    "text": "Diagnosis requires thorough sampling of lesionNeed to exclude MPT with prominent stromal overgrowth",
                    "sub_points": [
                      "Need to exclude MPT with prominent stromal overgrowth"
                    ]
                  }
                ],
                "Metastatic Spindle Cell Tumors": [
                  {
                    "text": "It is very rare for a spindle cell tumor to metastasize to the breast"
                  },
                  {
                    "text": "Usually, there is a well-known prior history of a malignancy"
                  },
                  {
                    "text": "Metastatic melanoma would be most likely in the absence of a known primary"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Cellular FA and benign PT are part of a biologic spectrum of stromal proliferationsBoth have a small risk of local recurrence and essentially no risk of distant metastasisDifficult-to-classify lesions may be best diagnosed as FA with more aggressive treatment only for recurrent lesions",
                    "sub_points": [
                      "Both have a small risk of local recurrence and essentially no risk of distant metastasis",
                      "Difficult-to-classify lesions may be best diagnosed as FA with more aggressive treatment only for recurrent lesions"
                    ]
                  },
                  {
                    "text": "MPT may be very difficult to distinguish from sarcoma and spindle cell carcinomaSpindle cell carcinoma is the most important diagnosis to exclude, as treatment will be differentMPT can be focally keratin and p63 (+)",
                    "sub_points": [
                      "Spindle cell carcinoma is the most important diagnosis to exclude, as treatment will be different",
                      "MPT can be focally keratin and p63 (+)"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "College of American Pathologists Protocol for the Examination of Resection Specimens From Patients With Phyllodes Tumor of the Breast": [
                  {
                    "text": "Provides format for reporting the features used for PT classification"
                  },
                  {
                    "text": "Applicable for benign, borderline, and MPTs"
                  },
                  {
                    "text": "Of note, the reporting elements do not include necrosis or well-differentiated liposarcoma, which should be reported if present"
                  }
                ],
                "Staging": [
                  {
                    "text": "AJCC 8th edition recommends staging MPT as a \"soft tissue sarcoma of the extremity and trunk\"T1 = ≤ 5 cm; T2 = > 5 cm but ≤ 10 cm; T3 = > 10 cm but ≤ 15 cm; T4 = > 15 cmN1 = any nodal metastasisM1 = distant metastasis",
                    "sub_points": [
                      "T1 = ≤ 5 cm; T2 = > 5 cm but ≤ 10 cm; T3 = > 10 cm but ≤ 15 cm; T4 = > 15 cm",
                      "N1 = any nodal metastasis",
                      "M1 = distant metastasis"
                    ]
                  },
                  {
                    "text": "UICC 8th edition recommends staging MPT as a sarcoma"
                  },
                  {
                    "text": "Studies evaluating the relationship of stage to survival are lacking for PT"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Pseudoangiomatous Stromal Hyperplasia": {
            "name": "Pseudoangiomatous Stromal Hyperplasia",
            "url": "https://app.pathprimer.com/document/e37f15a6-e663-49d7-858f-3a65bc02eb41/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia (PASH) is a very common stromal finding that can be seen, at least focally, in the majority of breast biopsies"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Occurs most frequently in women of childbearing age and postmenopausal women receiving hormonal therapy"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Can form palpable masses or radiographic densities with circumscribed or ill-defined margins"
                  },
                  {
                    "text": "Growth is likely stimulated by endogenous or exogenous hormones"
                  },
                  {
                    "text": "PASH is present in settings of breast enlargement, e.g., juvenile hypertrophy, rapid growth of breasts during pregnancy, gynecomastia, and breast enlargement in men and women during certain types of HIV therapy"
                  },
                  {
                    "text": "Biopsy of masses is indicated to exclude malignancyBecause PASH is a common incidental finding, radiologic correlation is important to ensure the targeted lesion has been sampled",
                    "sub_points": [
                      "Because PASH is a common incidental finding, radiologic correlation is important to ensure the targeted lesion has been sampled"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Prominent, slit-like stromal clefts lined by bland stromal myofibroblasts"
                  },
                  {
                    "text": "Clefts can involve both inter- and intralobular stroma and appear to invade into lobules"
                  },
                  {
                    "text": "Fascicular PASH has greater cellularity and lacks clefting"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Angiosarcoma"
                  },
                  {
                    "text": "Myofibroblastoma"
                  },
                  {
                    "text": "Fibrous tumors/myofibroblastic stromal hyperplasia"
                  },
                  {
                    "text": "Fibromatosis"
                  },
                  {
                    "text": "Fibroadenoma and phyllodes tumor"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia (PASH)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Pseudoangiomatous hyperplasia of mammary stroma"
                  },
                  {
                    "text": "Nodular myofibroblastic stromal hyperplasia"
                  },
                  {
                    "text": "Fascicular, nodular, mass-forming, or tumorous PASH"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Very common stromal finding that can be seen, at least focally, in the majority of breast biopsies"
                  },
                  {
                    "text": "Stromal myofibroblasts form clefts that resemble anastomosing, slit-like vascular spaces"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hormonal Influences": [
                  {
                    "text": "There are multiple lines of evidence that PASH is a hyperplasia of stromal myofibroblasts due to either endogenous or exogenous hormonal stimulationOccurs most frequently in women of childbearing ageCan increase in size during pregnancySeen in postmenopausal women receiving hormonal therapyCan result in bilateral breast enlargement and also involve bilateral axillary tissue\"Juvenile hypertrophy\" consists of the changes of gynecomastia and PASHPASH is seen in the stroma of early gynecomastia in menGynecomastia is also thought to arise due to hormonal imbalanceMen and women receiving some forms of highly active antiretroviral therapy (HAART) develop breast enlargement due to gynecomastia or PASHThese agents may interact with estrogenThe breast enlargement can regress when treatment is withdrawnMyofibroblasts in normal breast stroma, as well as in PASH and myofibroblastomas, are often positive for ER and PR",
                    "sub_points": [
                      "Occurs most frequently in women of childbearing ageCan increase in size during pregnancy",
                      "Can increase in size during pregnancy",
                      "Seen in postmenopausal women receiving hormonal therapy",
                      "Can result in bilateral breast enlargement and also involve bilateral axillary tissue\"Juvenile hypertrophy\" consists of the changes of gynecomastia and PASH",
                      "\"Juvenile hypertrophy\" consists of the changes of gynecomastia and PASH",
                      "PASH is seen in the stroma of early gynecomastia in menGynecomastia is also thought to arise due to hormonal imbalance",
                      "Gynecomastia is also thought to arise due to hormonal imbalance",
                      "Men and women receiving some forms of highly active antiretroviral therapy (HAART) develop breast enlargement due to gynecomastia or PASHThese agents may interact with estrogenThe breast enlargement can regress when treatment is withdrawn",
                      "These agents may interact with estrogen",
                      "The breast enlargement can regress when treatment is withdrawn",
                      "Myofibroblasts in normal breast stroma, as well as in PASH and myofibroblastomas, are often positive for ER and PR"
                    ]
                  },
                  {
                    "text": "It has been suggested that clefts are prelymphatic channels that drain into true lymphaticsSome carcinomas invade in a pattern suggesting that they involve clefts seen in PASH",
                    "sub_points": [
                      "Some carcinomas invade in a pattern suggesting that they involve clefts seen in PASH"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Most commonly seen as an incidental finding in breast biopsies"
                  },
                  {
                    "text": "Rarely presents as a palpable mass or a density on imaging studies"
                  },
                  {
                    "text": "May grow in sizeRapid growth can occur during pregnancy and can be associated with peau d'orange and skin necrosisRarely, PASH presents as rapid enlargement of a mass or diffusely in both breasts",
                    "sub_points": [
                      "Rapid growth can occur during pregnancy and can be associated with peau d'orange and skin necrosis",
                      "Rarely, PASH presents as rapid enlargement of a mass or diffusely in both breasts"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Mass-forming PASH should be biopsied to exclude malignancy"
                  },
                  {
                    "text": "After malignancy is excluded, no other treatment is necessary"
                  },
                  {
                    "text": "Symptomatic mass-forming PASH may be surgically excised"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign lesionRarely, mass-forming PASH may recur after surgical excisionRecurrent lesions are more likely in younger patients",
                    "sub_points": [
                      "Rarely, mass-forming PASH may recur after surgical excision",
                      "Recurrent lesions are more likely in younger patients"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "A mass with circumscribed or ill-defined margins or focal asymmetry"
                  },
                  {
                    "text": "Calcifications are not characteristic"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Smooth-bordered mass with slow enhancement is characteristicMore unusual findings are clumped enhancement or irregular mass",
                    "sub_points": [
                      "More unusual findings are clumped enhancement or irregular mass"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Mass-forming PASH can appear as a firm, rubbery, circumscribed, white nodule (size ranges from 1-10 cm)"
                  },
                  {
                    "text": "Large clefts seen grossly in some fibroadenomas are not present"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Prominent, slit-like stromal clefts are presentClefts are lined by bland stromal myofibroblastsNuclear pleomorphism and mitoses are not seenClefts can involve both inter- and intralobular stroma and can appear to dissect into lobules",
                    "sub_points": [
                      "Clefts are lined by bland stromal myofibroblastsNuclear pleomorphism and mitoses are not seen",
                      "Nuclear pleomorphism and mitoses are not seen",
                      "Clefts can involve both inter- and intralobular stroma and can appear to dissect into lobules"
                    ]
                  },
                  {
                    "text": "Spaces are empty or contain only rare red blood cellsBlood may be present if there has been a prior biopsy",
                    "sub_points": [
                      "Blood may be present if there has been a prior biopsy"
                    ]
                  },
                  {
                    "text": "Stroma is paucicellular in most casesCellular variant, \"fascicular PASH,\" is characterized by short, poorly formed fascicles of spindle cellsClefting may be absent or only present focally",
                    "sub_points": [
                      "Cellular variant, \"fascicular PASH,\" is characterized by short, poorly formed fascicles of spindle cellsClefting may be absent or only present focally",
                      "Clefting may be absent or only present focally"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Histologic findings are not specific for a mass because the stromal changes can also be an incidental findingPASH is seen in > 25% of biopsies as incidental finding",
                    "sub_points": [
                      "PASH is seen in > 25% of biopsies as incidental finding"
                    ]
                  },
                  {
                    "text": "In the limited sampling of a needle biopsy, it can be difficult to distinguish PASH from the stroma of some fibroadenomas and phyllodes tumors"
                  },
                  {
                    "text": "Radiologic correlation is necessary to ensure the targeted lesion was biopsied before concluding that PASH is the underlying lesionImaging follow-up is also helpful to detect lesions that increase in size",
                    "sub_points": [
                      "Imaging follow-up is also helpful to detect lesions that increase in size"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Myofibroblast markers: PositiveCD34, actin, smooth muscle myosin heavy chain",
                    "sub_points": [
                      "CD34, actin, smooth muscle myosin heavy chain"
                    ]
                  },
                  {
                    "text": "Vascular markers: NegativeCD31, factor VIII, and others",
                    "sub_points": [
                      "CD31, factor VIII, and others"
                    ]
                  },
                  {
                    "text": "Hormone receptors; majority positive for ER &/or PR"
                  },
                  {
                    "text": "Bcl-2: Positive"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Angiosarcoma": [
                  {
                    "text": "Infiltrates in breast tissue as abnormal anastomosing blood vesselsThe involvement of inter- and intralobular stroma by PASH mimics this infiltrative pattern",
                    "sub_points": [
                      "The involvement of inter- and intralobular stroma by PASH mimics this infiltrative pattern"
                    ]
                  },
                  {
                    "text": "The vascular spaces of angiosarcoma are filled with blood, whereas the pseudovascular spaces of PASH are empty"
                  },
                  {
                    "text": "Angiosarcomas have nuclear pleomorphism, mitoses, and solid areas or tufting, which are not seen in PASH"
                  },
                  {
                    "text": "Angiosarcomas usually form large, irregular masses; unlikely to present as a circumscribed mass"
                  },
                  {
                    "text": "Immunoperoxidase studies distinguish endothelial cells of vascular lesions from myofibroblasts of PASH"
                  }
                ],
                "Myofibroblastoma": [
                  {
                    "text": "Both myofibroblastoma and PASH are proliferations of myofibroblasts"
                  },
                  {
                    "text": "Myofibroblastomas are neoplastic clonal tumors with characteristic genetic changes"
                  },
                  {
                    "text": "Myofibroblastoma has features not seen in PASHHigher cellularity organized in short fascicles without stromal cleftingForms a solid mass with absent or minimal involvement of epitheliumHas discrete circumscribed borders",
                    "sub_points": [
                      "Higher cellularity organized in short fascicles without stromal clefting",
                      "Forms a solid mass with absent or minimal involvement of epithelium",
                      "Has discrete circumscribed borders"
                    ]
                  },
                  {
                    "text": "Myofibroblastoma and PASH are both positive for the same markers seen in normal myofibroblasts"
                  }
                ],
                "Fibrous Tumor/Myofibroblastic Stromal Hyperplasia": [
                  {
                    "text": "Benign stromal proliferations that are not associated with stromal clefting"
                  },
                  {
                    "text": "Consist of fibroblasts or myofibroblasts in interlobular and intralobular stroma"
                  },
                  {
                    "text": "Very similar to PASH in clinical and imaging presentations"
                  }
                ],
                "Gynecomastia": [
                  {
                    "text": "Often has PASH in stroma"
                  },
                  {
                    "text": "Clinical setting and characteristic epithelial changes identify lesion as gynecomastia in males"
                  }
                ],
                "Juvenile Hypertrophy": [
                  {
                    "text": "Occurs in setting of marked bilateral breast enlargement in young women at pubertyPASH is generally focal finding",
                    "sub_points": [
                      "PASH is generally focal finding"
                    ]
                  },
                  {
                    "text": "Stroma often shows the changes of PASH"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Lesions are more cellular than PASH, and cells are arranged into long, sweeping fasciclesOften have an infiltrative pattern and irregular borders",
                    "sub_points": [
                      "Often have an infiltrative pattern and irregular borders"
                    ]
                  },
                  {
                    "text": "CD34(-) and may show aberrant β-catenin nuclear positivity"
                  }
                ],
                "Fibroadenoma and Phyllodes Tumor": [
                  {
                    "text": "The stroma of fibroepithelial lesions can have the appearance of PASH"
                  },
                  {
                    "text": "The normal epithelial component may not be seen on core needle biopsies"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Myofibroblastoma": {
            "name": "Myofibroblastoma",
            "url": "https://app.pathprimer.com/document/595d62c5-7cf0-4e2e-b3b9-124b3f62705b/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Benign spindle cell neoplasm arising from myofibroblasts"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Deletions at 13q14 and 16q are likely important in pathogenesisAbsence ofRB1gene by deletion and 2nd event resulting in loss of Rb protein common",
                    "sub_points": [
                      "Absence ofRB1gene by deletion and 2nd event resulting in loss of Rb protein common"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Only breast lesion arising in comparable frequency in male and female patients"
                  },
                  {
                    "text": "Typically seen in older patient population"
                  },
                  {
                    "text": "Presents as a circumscribed mass"
                  },
                  {
                    "text": "No recurrences have been reported to date"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Uniform spindle cell proliferation arranged in discrete, intersecting bundles with varying component of adipose tissue"
                  },
                  {
                    "text": "Hyalinized bands of collagen separate cells into groups or clusters"
                  },
                  {
                    "text": "Numerous different patterns can resemble other spindle cell lesions of the breast"
                  },
                  {
                    "text": "Positive for hormone receptors, CD34, and muscle markers, and the majority are negative for Rb"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Spindle cell lipoma"
                  },
                  {
                    "text": "Solitary fibrous tumor"
                  },
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia"
                  },
                  {
                    "text": "Leiomyoma"
                  },
                  {
                    "text": "Fibromatosis"
                  },
                  {
                    "text": "Nodular fasciitis"
                  },
                  {
                    "text": "Spindle cell sarcoma"
                  },
                  {
                    "text": "Spindle cell metaplastic carcinoma"
                  },
                  {
                    "text": "Invasive lobular carcinoma"
                  },
                  {
                    "text": "Dermatofibrosarcoma protuberans"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Myofibroblastoma (MFB)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign spindle cell tumor of mammary stroma arising from breast myofibroblasts"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Loss ofRB1": [
                  {
                    "text": "Chromosome 13 rearrangements associated with loss of 13q14 characterize a family of morphologically similar tumors (\"13q/Rb family of tumors\")Includes the majority of mammary MFB and nonmammary MFBNonmammary locations for MFB include chest wall, axilla, inguinal region, trunk, extremities, intraabdominal, retroperitoneum, scrotumSpindle cell/pleomorphic lipomaCellular angiofibroma",
                    "sub_points": [
                      "Includes the majority of mammary MFB and nonmammary MFBNonmammary locations for MFB include chest wall, axilla, inguinal region, trunk, extremities, intraabdominal, retroperitoneum, scrotum",
                      "Nonmammary locations for MFB include chest wall, axilla, inguinal region, trunk, extremities, intraabdominal, retroperitoneum, scrotum",
                      "Spindle cell/pleomorphic lipoma",
                      "Cellular angiofibroma"
                    ]
                  },
                  {
                    "text": "The retinoblastoma transcriptional corepressor 1 gene (RB1) is located in the deleted regionThe protein gene product, Rb (or pRB), has roles in cell cycle progression and adipocytic differentiation and acts as a tumor suppressor",
                    "sub_points": [
                      "The protein gene product, Rb (or pRB), has roles in cell cycle progression and adipocytic differentiation and acts as a tumor suppressor"
                    ]
                  },
                  {
                    "text": "Members of the 13qRb family frequently do not express RbAbsence of protein may have a direct role in tumorigenesis",
                    "sub_points": [
                      "Absence of protein may have a direct role in tumorigenesis"
                    ]
                  }
                ],
                "Hormonal": [
                  {
                    "text": "MFB expresses estrogen (ER), progesterone (PR), and androgen (AR) receptors"
                  },
                  {
                    "text": "Possible role for sex hormones in pathogenesis"
                  },
                  {
                    "text": "Associated with other lesions thought to share hormonal etiologyPseudoangiomatous stromal hyperplasia (PASH)Gynecomastia",
                    "sub_points": [
                      "Pseudoangiomatous stromal hyperplasia (PASH)",
                      "Gynecomastia"
                    ]
                  },
                  {
                    "text": "However, no strong association with exogenous hormone use has been reported"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Uncommon mammary neoplasm; < 1% of mammary tumors"
                  }
                ],
                "Age": [
                  {
                    "text": "Typically seen in older patient population; peak incidence: 50-75 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "MFB occurs in women and men"
                  },
                  {
                    "text": "Only breast tumor with slight male predominanceOccasionally seen in association with gynecomastia",
                    "sub_points": [
                      "Occasionally seen in association with gynecomastia"
                    ]
                  }
                ],
                "Presentation": [
                  {
                    "text": "Often presents clinically as a palpable mobile, painless, circumscribed massSlow growingMost solitaryRarely multicentric or bilateral",
                    "sub_points": [
                      "Slow growing",
                      "Most solitaryRarely multicentric or bilateral",
                      "Rarely multicentric or bilateral"
                    ]
                  },
                  {
                    "text": "Some MFBs are detected as a lobulated mass with circumscribed margins that lack calcifications by screening mammography"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete surgical excision is recommended for lesions diagnosed on core needle biopsy"
                  },
                  {
                    "text": "However, recurrence or malignant transformation have not been reported"
                  },
                  {
                    "text": "Observation may be a reasonable alternative"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "No hormonal or radiation therapy recommended"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign mammary stromal tumor"
                  },
                  {
                    "text": "No recurrences in breast have been reported to date in follow-up studies2 possibly locally recurrent tumors after long intervals (17 years and 20 years) reportedAnatomic location was not provided",
                    "sub_points": [
                      "2 possibly locally recurrent tumors after long intervals (17 years and 20 years) reportedAnatomic location was not provided",
                      "Anatomic location was not provided"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Solid, circumscribed or smoothly lobulated massSome tumors have prominent component of adipose tissue as part of the lesion",
                    "sub_points": [
                      "Some tumors have prominent component of adipose tissue as part of the lesion"
                    ]
                  },
                  {
                    "text": "Not associated with calcifications"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Solid, circumscribed or smoothly lobulated massSome lesions are hyperechoic, depending on extent of adipose tissue in tumorSolid areas of tumor cells intermingled with adipose tissue can give rise to increased echogenicity",
                    "sub_points": [
                      "Some lesions are hyperechoic, depending on extent of adipose tissue in tumorSolid areas of tumor cells intermingled with adipose tissue can give rise to increased echogenicity",
                      "Solid areas of tumor cells intermingled with adipose tissue can give rise to increased echogenicity"
                    ]
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Mass with uniform enhancementHyperintense signal in T2-weighted imagesInternal septation reported",
                    "sub_points": [
                      "Hyperintense signal in T2-weighted images",
                      "Internal septation reported"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Well-circumscribed, lobulated mass with firm or rubbery consistency"
                  },
                  {
                    "text": "Cut surface has pink-tan, homogeneous whorled or nodular appearance"
                  }
                ],
                "Size": [
                  {
                    "text": "Typical lesion is ~ 2 cm; most are < 4 cmMFB up to 10 cm in size have been reported",
                    "sub_points": [
                      "MFB up to 10 cm in size have been reported"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA: Copy Number Alterations": [
                  {
                    "text": "Majority have deletion of 13q14 as documented by fluorescence in situ hybridization (FISH)Results in loss of theRB1geneThe protein product, Rb (or pRB), acts to regulate cell growth and proliferation and is a tumor suppressorLoss of Rb protein expression requires a 2nd eventTherefore, not all tumors with single allele loss ofRB1as shown by 13q14 deletion also show loss of Rb protein expressionLoss of both alleles found in some tumorsIn other tumors, loss of expression may be due to mutation or epigenetic alteration of the remaining alleleStudies of spindle cell lipoma (SCL) have shown 2 minimally deleted regions (MDR) at 13q14MDR1: 4 genes (including gene for retinoblastoma,RB1)MDR2: 34 genesDeletion of theFOXO1gene located at 13q14 has been used to support a diagnosis of MFBThis gene is not in the minimally deleted region (MDR) identified in some MFBs and, thus, is deleted in many, but not all cases, of MFB",
                    "sub_points": [
                      "Results in loss of theRB1geneThe protein product, Rb (or pRB), acts to regulate cell growth and proliferation and is a tumor suppressorLoss of Rb protein expression requires a 2nd eventTherefore, not all tumors with single allele loss ofRB1as shown by 13q14 deletion also show loss of Rb protein expressionLoss of both alleles found in some tumorsIn other tumors, loss of expression may be due to mutation or epigenetic alteration of the remaining allele",
                      "The protein product, Rb (or pRB), acts to regulate cell growth and proliferation and is a tumor suppressor",
                      "Loss of Rb protein expression requires a 2nd eventTherefore, not all tumors with single allele loss ofRB1as shown by 13q14 deletion also show loss of Rb protein expressionLoss of both alleles found in some tumorsIn other tumors, loss of expression may be due to mutation or epigenetic alteration of the remaining allele",
                      "Therefore, not all tumors with single allele loss ofRB1as shown by 13q14 deletion also show loss of Rb protein expression",
                      "Loss of both alleles found in some tumors",
                      "In other tumors, loss of expression may be due to mutation or epigenetic alteration of the remaining allele",
                      "Studies of spindle cell lipoma (SCL) have shown 2 minimally deleted regions (MDR) at 13q14MDR1: 4 genes (including gene for retinoblastoma,RB1)MDR2: 34 genes",
                      "MDR1: 4 genes (including gene for retinoblastoma,RB1)",
                      "MDR2: 34 genes",
                      "Deletion of theFOXO1gene located at 13q14 has been used to support a diagnosis of MFBThis gene is not in the minimally deleted region (MDR) identified in some MFBs and, thus, is deleted in many, but not all cases, of MFB",
                      "This gene is not in the minimally deleted region (MDR) identified in some MFBs and, thus, is deleted in many, but not all cases, of MFB"
                    ]
                  },
                  {
                    "text": "16q is also commonly deletedImportant genes in this region have not yet been identified",
                    "sub_points": [
                      "Important genes in this region have not yet been identified"
                    ]
                  }
                ],
                "Protein": [
                  {
                    "text": "Loss of Rb protein in majority of cases (90%)Suggests role in etiology of tumor, as biallelic deletion or inactivation is required for absence of protein",
                    "sub_points": [
                      "Suggests role in etiology of tumor, as biallelic deletion or inactivation is required for absence of protein"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "MFB encompasses a wide morphologic spectrumMost cases contain a variably prominent component of adipose tissueSpindle cell lipoma (SCL) is either the same tumor as MFB or very closely related",
                    "sub_points": [
                      "Most cases contain a variably prominent component of adipose tissueSpindle cell lipoma (SCL) is either the same tumor as MFB or very closely related",
                      "Spindle cell lipoma (SCL) is either the same tumor as MFB or very closely related"
                    ]
                  },
                  {
                    "text": "Well-circumscribed bordersPushing borders tend to compress normal breast parenchyma at peripheryCircumscribed with no true capsuleNo entrapment of ducts &/or lobules within the tumor in the majority of casesFocal involvement of adjacent ducts at the periphery is rarely seen",
                    "sub_points": [
                      "Pushing borders tend to compress normal breast parenchyma at periphery",
                      "Circumscribed with no true capsule",
                      "No entrapment of ducts &/or lobules within the tumor in the majority of casesFocal involvement of adjacent ducts at the periphery is rarely seen",
                      "Focal involvement of adjacent ducts at the periphery is rarely seen"
                    ]
                  },
                  {
                    "text": "Uniform spindle cell proliferationSlender, bipolar, or fusiform-shaped spindle cells with scant pale cytoplasmOvoid, uniform nuclei with inconspicuous/absent nucleoliNuclear pleomorphism is unusual and of unclear clinical significanceFloret-like multinucleated giant cells can be presentMitotic figures absent or rareSpindle cells closely apposed and arranged in discrete, intersecting bundles and clustersHaphazardly arranged intersecting fascicles of spindle cells are interrupted by thick bands of brightly eosinophilic collagen",
                    "sub_points": [
                      "Slender, bipolar, or fusiform-shaped spindle cells with scant pale cytoplasm",
                      "Ovoid, uniform nuclei with inconspicuous/absent nucleoliNuclear pleomorphism is unusual and of unclear clinical significanceFloret-like multinucleated giant cells can be present",
                      "Nuclear pleomorphism is unusual and of unclear clinical significance",
                      "Floret-like multinucleated giant cells can be present",
                      "Mitotic figures absent or rare",
                      "Spindle cells closely apposed and arranged in discrete, intersecting bundles and clustersHaphazardly arranged intersecting fascicles of spindle cells are interrupted by thick bands of brightly eosinophilic collagen",
                      "Haphazardly arranged intersecting fascicles of spindle cells are interrupted by thick bands of brightly eosinophilic collagen"
                    ]
                  },
                  {
                    "text": "Hyalinized bands of collagenDistributed throughout lesionCollagen bands separate spindle cells into groups or clusters",
                    "sub_points": [
                      "Distributed throughout lesion",
                      "Collagen bands separate spindle cells into groups or clusters"
                    ]
                  },
                  {
                    "text": "Heterologous foci of myoid (smooth muscle), cartilaginous, or osseous differentiation may be presentSome lesions overlap in appearance with leiomyoma",
                    "sub_points": [
                      "Some lesions overlap in appearance with leiomyoma"
                    ]
                  },
                  {
                    "text": "Mast cells are often intermingled with tumor cells"
                  },
                  {
                    "text": "Necrosis not presentMust be distinguished from prior core needle biopsy site",
                    "sub_points": [
                      "Must be distinguished from prior core needle biopsy site"
                    ]
                  },
                  {
                    "text": "5 major morphologic patterns and 4 rare patterns of MFB have been describedMore than 1 variant pattern can be seen in single lesionLipomatous pattern (lipomatous MFB)Varying degrees of adipose tissue are presentSome have a prominent component of cartilage (\"chondrolipoma\")The presence of spindle cells in adipose tissue can be misinterpreted as an infiltrative pattern, particularly in small biopsiesInfiltration around ducts and lobules is not presentCorrelation with the imaging appearance of a mass with circumscribed borders is helpful in order to not overdiagnose this finding as invasionEpithelioid/deciduoidMajority of cells are rounded rather than spindle in shapeSome tumors have a deciduoid pattern, as the cells have abundant eosinophilic cytoplasmThese tumors can mimic apocrine carcinoma, melanoma, or rhabdomyosarcomaCells form clusters (alveolar pattern) or appear to infiltrate stroma in a single fileMild to moderate nuclear pleomorphism may be presentBinucleated or multinucleated cells may be presentRounded cells and single cell pattern can closely mimic invasive lobular carcinomaHormone receptor positivity is present in both MFB and lobular carcinomaMFB is negative for keratinsFibrous/collagenizedPaucicellular lesion with dense stromaMay be difficult to distinguish from scar tissue or fascicular PASHMyxoidStroma is hypocellular and myxoid in appearanceKeloidal collagen fibers are present in myxoid stromaPalisading/schwannoma-likeResembles schwannomaNuclear palisading with formation of numerous Verocay-like bodiesUnlike true schwannomas, this variant is negative for S100InfiltratingIn very rare cases, true infiltration of tumor cells around normal epithelium occursUsually present at periphery of tumor and is minimal in extentCellular variantClosely packed tumor cells have a storiform or herringbone patternLeiomyomatous variantTumor cells have a smooth muscle appearance with cigar-shaped nucleiCan express caldesmonMay be negative for CD34",
                    "sub_points": [
                      "More than 1 variant pattern can be seen in single lesion",
                      "Lipomatous pattern (lipomatous MFB)Varying degrees of adipose tissue are presentSome have a prominent component of cartilage (\"chondrolipoma\")The presence of spindle cells in adipose tissue can be misinterpreted as an infiltrative pattern, particularly in small biopsiesInfiltration around ducts and lobules is not presentCorrelation with the imaging appearance of a mass with circumscribed borders is helpful in order to not overdiagnose this finding as invasion",
                      "Varying degrees of adipose tissue are present",
                      "Some have a prominent component of cartilage (\"chondrolipoma\")",
                      "The presence of spindle cells in adipose tissue can be misinterpreted as an infiltrative pattern, particularly in small biopsiesInfiltration around ducts and lobules is not presentCorrelation with the imaging appearance of a mass with circumscribed borders is helpful in order to not overdiagnose this finding as invasion",
                      "Infiltration around ducts and lobules is not present",
                      "Correlation with the imaging appearance of a mass with circumscribed borders is helpful in order to not overdiagnose this finding as invasion",
                      "Epithelioid/deciduoidMajority of cells are rounded rather than spindle in shapeSome tumors have a deciduoid pattern, as the cells have abundant eosinophilic cytoplasmThese tumors can mimic apocrine carcinoma, melanoma, or rhabdomyosarcomaCells form clusters (alveolar pattern) or appear to infiltrate stroma in a single fileMild to moderate nuclear pleomorphism may be presentBinucleated or multinucleated cells may be presentRounded cells and single cell pattern can closely mimic invasive lobular carcinomaHormone receptor positivity is present in both MFB and lobular carcinomaMFB is negative for keratins",
                      "Majority of cells are rounded rather than spindle in shapeSome tumors have a deciduoid pattern, as the cells have abundant eosinophilic cytoplasmThese tumors can mimic apocrine carcinoma, melanoma, or rhabdomyosarcoma",
                      "Some tumors have a deciduoid pattern, as the cells have abundant eosinophilic cytoplasm",
                      "These tumors can mimic apocrine carcinoma, melanoma, or rhabdomyosarcoma",
                      "Cells form clusters (alveolar pattern) or appear to infiltrate stroma in a single file",
                      "Mild to moderate nuclear pleomorphism may be presentBinucleated or multinucleated cells may be present",
                      "Binucleated or multinucleated cells may be present",
                      "Rounded cells and single cell pattern can closely mimic invasive lobular carcinomaHormone receptor positivity is present in both MFB and lobular carcinomaMFB is negative for keratins",
                      "Hormone receptor positivity is present in both MFB and lobular carcinoma",
                      "MFB is negative for keratins",
                      "Fibrous/collagenizedPaucicellular lesion with dense stromaMay be difficult to distinguish from scar tissue or fascicular PASH",
                      "Paucicellular lesion with dense stroma",
                      "May be difficult to distinguish from scar tissue or fascicular PASH",
                      "MyxoidStroma is hypocellular and myxoid in appearanceKeloidal collagen fibers are present in myxoid stroma",
                      "Stroma is hypocellular and myxoid in appearance",
                      "Keloidal collagen fibers are present in myxoid stroma",
                      "Palisading/schwannoma-likeResembles schwannomaNuclear palisading with formation of numerous Verocay-like bodiesUnlike true schwannomas, this variant is negative for S100",
                      "Resembles schwannomaNuclear palisading with formation of numerous Verocay-like bodies",
                      "Nuclear palisading with formation of numerous Verocay-like bodies",
                      "Unlike true schwannomas, this variant is negative for S100",
                      "InfiltratingIn very rare cases, true infiltration of tumor cells around normal epithelium occursUsually present at periphery of tumor and is minimal in extent",
                      "In very rare cases, true infiltration of tumor cells around normal epithelium occursUsually present at periphery of tumor and is minimal in extent",
                      "Usually present at periphery of tumor and is minimal in extent",
                      "Cellular variantClosely packed tumor cells have a storiform or herringbone pattern",
                      "Closely packed tumor cells have a storiform or herringbone pattern",
                      "Leiomyomatous variantTumor cells have a smooth muscle appearance with cigar-shaped nucleiCan express caldesmonMay be negative for CD34",
                      "Tumor cells have a smooth muscle appearance with cigar-shaped nuclei",
                      "Can express caldesmon",
                      "May be negative for CD34"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Differential diagnosis may be difficult when sampling is limited"
                  },
                  {
                    "text": "Variants, especially epithelioid MFB, can closely mimic other tumor typesIHC may be helpful for challenging cases",
                    "sub_points": [
                      "IHC may be helpful for challenging cases"
                    ]
                  },
                  {
                    "text": "Excision generally warranted for definitive diagnosis"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD34: Positive (90-95%)Majority of breast stromal cells are positiveOnly breast stromal lesions typically negative are fibromatosis and nodular fasciitis~ 5% of MFB are CD34(-) or only weakly (+)These cases have the typical morphologic appearance of MFBDiagnosis can be established using a combination of other IHC markers",
                    "sub_points": [
                      "Majority of breast stromal cells are positive",
                      "Only breast stromal lesions typically negative are fibromatosis and nodular fasciitis",
                      "~ 5% of MFB are CD34(-) or only weakly (+)These cases have the typical morphologic appearance of MFBDiagnosis can be established using a combination of other IHC markers",
                      "These cases have the typical morphologic appearance of MFB",
                      "Diagnosis can be established using a combination of other IHC markers"
                    ]
                  },
                  {
                    "text": "Hormone receptors: Majority positiveER, PR, and AR",
                    "sub_points": [
                      "ER, PR, and AR"
                    ]
                  },
                  {
                    "text": "Muscle markersSmooth muscle actin: Positive (70%)Desmin: Positive (70-90%)H-caldesmon: Positive in 50% (but only in < 10% of cells)May be used to distinguish MFB from leiomyoma (which is diffusely positive)Distinction not clinically important because both are benign lesions",
                    "sub_points": [
                      "Smooth muscle actin: Positive (70%)",
                      "Desmin: Positive (70-90%)",
                      "H-caldesmon: Positive in 50% (but only in < 10% of cells)May be used to distinguish MFB from leiomyoma (which is diffusely positive)Distinction not clinically important because both are benign lesions",
                      "May be used to distinguish MFB from leiomyoma (which is diffusely positive)",
                      "Distinction not clinically important because both are benign lesions"
                    ]
                  },
                  {
                    "text": "S100: Negative (~ 90%)"
                  },
                  {
                    "text": "Bcl-2: Positive (~ 80%)Other tumors in the differential diagnosis are also usually positive",
                    "sub_points": [
                      "Other tumors in the differential diagnosis are also usually positive"
                    ]
                  },
                  {
                    "text": "Rb: Negative (~ 90%)"
                  },
                  {
                    "text": "CD99 and CD10: Variably positive"
                  },
                  {
                    "text": "STAT6: NegativeUseful for distinguishing MFB from solitary fibrous tumor (SFT)SFT is the only tumor commonly positive for STAT6Positivity must be nuclear and not cytoplasmic",
                    "sub_points": [
                      "Useful for distinguishing MFB from solitary fibrous tumor (SFT)SFT is the only tumor commonly positive for STAT6Positivity must be nuclear and not cytoplasmic",
                      "SFT is the only tumor commonly positive for STAT6Positivity must be nuclear and not cytoplasmic",
                      "Positivity must be nuclear and not cytoplasmic"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "In situ hybridization can be used to demonstrate loss of 13q14 using 2 probes flankingFOX01(located at 13q14.11)In normal cells, 2 fusion signals are presentIn cells with deletion of 13q14, only 1 fusion signal is present70-80% of MFB have the deletion using this methodDemonstrating the presence of the deletion is not required for diagnosis",
                    "sub_points": [
                      "In normal cells, 2 fusion signals are present",
                      "In cells with deletion of 13q14, only 1 fusion signal is present",
                      "70-80% of MFB have the deletion using this methodDemonstrating the presence of the deletion is not required for diagnosis",
                      "Demonstrating the presence of the deletion is not required for diagnosis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Spindle Cell Lipoma (SCL)": [
                  {
                    "text": "Usually occur on neck, shoulder, and upper back of middle-aged men"
                  },
                  {
                    "text": "Shares loss of same region at 13q14 with loss of expression of RbLikely to be variants of the same tumor",
                    "sub_points": [
                      "Likely to be variants of the same tumor"
                    ]
                  },
                  {
                    "text": "The main differences include the followingMore abundant adipose tissue with thick ropey collagen in SCLSCL is negative for desmin, whereas the majority of MFBs are positive",
                    "sub_points": [
                      "More abundant adipose tissue with thick ropey collagen in SCL",
                      "SCL is negative for desmin, whereas the majority of MFBs are positive"
                    ]
                  }
                ],
                "Solitary Fibrous Tumor": [
                  {
                    "text": "Clinical and morphologic overlap with MFBTypically presents as a palpable mass with circumscribed marginsMuch less common than MFB in breastCan occur in males",
                    "sub_points": [
                      "Typically presents as a palpable mass with circumscribed margins",
                      "Much less common than MFB in breast",
                      "Can occur in males"
                    ]
                  },
                  {
                    "text": "Has a characteristicNAB2::STAT6gene fusion (12q13)Results in overexpression of C-terminal part of STAT6 in nucleusSTAT6 strongly expressed in majority of SFT by IHCSTAT6 not expressed in MFB or in other spindle cell lesions of the breast",
                    "sub_points": [
                      "Results in overexpression of C-terminal part of STAT6 in nucleusSTAT6 strongly expressed in majority of SFT by IHCSTAT6 not expressed in MFB or in other spindle cell lesions of the breast",
                      "STAT6 strongly expressed in majority of SFT by IHC",
                      "STAT6 not expressed in MFB or in other spindle cell lesions of the breast"
                    ]
                  },
                  {
                    "text": "GRIA2 is overexpressed in majority of SFTEncodes for AMPA-selective ionotropic glutamate receptor subunitMajority of SFT show cytoplasmic positivityAlso present in dermatofibrosarcoma protuberans (DFSP), leiomyosarcoma, synovial sarcoma, meningiomas, and myoepitheliomasNot present in SCL and fibromatosis",
                    "sub_points": [
                      "Encodes for AMPA-selective ionotropic glutamate receptor subunit",
                      "Majority of SFT show cytoplasmic positivityAlso present in dermatofibrosarcoma protuberans (DFSP), leiomyosarcoma, synovial sarcoma, meningiomas, and myoepitheliomasNot present in SCL and fibromatosis",
                      "Also present in dermatofibrosarcoma protuberans (DFSP), leiomyosarcoma, synovial sarcoma, meningiomas, and myoepitheliomas",
                      "Not present in SCL and fibromatosis"
                    ]
                  },
                  {
                    "text": "Rare SFTs have losses on 13qHowever, SFT does not show loss ofRB1by FISH, and Rb protein is expressed",
                    "sub_points": [
                      "However, SFT does not show loss ofRB1by FISH, and Rb protein is expressed"
                    ]
                  },
                  {
                    "text": "SFT and MFB have some pathologic features in commonBland spindle cells separated by bands of thick collagenMast cells frequently presentBoth CD34(+) (~ 90%), Bcl-2(+) (~ 80-85%)",
                    "sub_points": [
                      "Bland spindle cells separated by bands of thick collagen",
                      "Mast cells frequently present",
                      "Both CD34(+) (~ 90%), Bcl-2(+) (~ 80-85%)"
                    ]
                  },
                  {
                    "text": "Other features distinguish SFT from MFBPatternless pattern of short spindle cells rather than fasciclesProminent branching (staghorn) blood vessels with perivascular sclerosisNegative for muscle markers (< 10%), whereas MFB is positive (> 75%)Negative for hormone receptors (< 15%), whereas MFB is positive (> 60%)Positive for STAT6, whereas MFB is negativePositive for Rb (~ 90%), whereas MFB is negative for Rb (~ 90%)",
                    "sub_points": [
                      "Patternless pattern of short spindle cells rather than fascicles",
                      "Prominent branching (staghorn) blood vessels with perivascular sclerosis",
                      "Negative for muscle markers (< 10%), whereas MFB is positive (> 75%)",
                      "Negative for hormone receptors (< 15%), whereas MFB is positive (> 60%)",
                      "Positive for STAT6, whereas MFB is negative",
                      "Positive for Rb (~ 90%), whereas MFB is negative for Rb (~ 90%)"
                    ]
                  },
                  {
                    "text": "Rare nonmammary SFTs have metastasized and caused the death of patients~ 10% of reported SFTs of the breast have shown malignant features: Nuclear pleomorphism, increased mitoses, and necrosis1 case of distant metastasis to lung and bones has been reported, but no cases of death",
                    "sub_points": [
                      "~ 10% of reported SFTs of the breast have shown malignant features: Nuclear pleomorphism, increased mitoses, and necrosis1 case of distant metastasis to lung and bones has been reported, but no cases of death",
                      "1 case of distant metastasis to lung and bones has been reported, but no cases of death"
                    ]
                  }
                ],
                "Pseudoangiomatous Stromal Hyperplasia (PASH)": [
                  {
                    "text": "PASH is a hyperplastic myofibroblastic proliferationPASH and MFB have similar patterns of IHC reactivity, as both consist of myofibroblastsDeletion of 13q14 is not identified in PASH",
                    "sub_points": [
                      "PASH and MFB have similar patterns of IHC reactivity, as both consist of myofibroblastsDeletion of 13q14 is not identified in PASH",
                      "Deletion of 13q14 is not identified in PASH"
                    ]
                  },
                  {
                    "text": "PASH may form masses with well-defined margins, but many have ill-defined borders"
                  },
                  {
                    "text": "The slit-like clefts seen in PASH are not seen in MFBHowever, the fascicular variant is highly cellular, lacks clefts, and can resemble MFB",
                    "sub_points": [
                      "However, the fascicular variant is highly cellular, lacks clefts, and can resemble MFB"
                    ]
                  },
                  {
                    "text": "PASH involves the interlobular and intralobular stroma of ducts and lobulesMFB forms a solid mass without entrapping breast epithelium",
                    "sub_points": [
                      "MFB forms a solid mass without entrapping breast epithelium"
                    ]
                  }
                ],
                "Leiomyoma": [
                  {
                    "text": "May arise from smooth muscle of the areola or from blood vessels"
                  },
                  {
                    "text": "Cells are arranged in long, intersecting fascicles with little or no intervening stromaMFB more commonly grows as short fascicles divided by dense collagen",
                    "sub_points": [
                      "MFB more commonly grows as short fascicles divided by dense collagen"
                    ]
                  },
                  {
                    "text": "Presence of H-caldesmon (marker of smooth muscle) is used to distinguish leiomyoma from MFBLeiomyomas show strong, diffuse positivity in majority of cellsMFB shows only focal positivity",
                    "sub_points": [
                      "Leiomyomas show strong, diffuse positivity in majority of cells",
                      "MFB shows only focal positivity"
                    ]
                  },
                  {
                    "text": "CD34 is generally negative in leiomyoma and positive in MFB"
                  },
                  {
                    "text": "Some lesions have overlapping features of MFB and leiomyomaDistinction is not clinically importantLeiomyoma not reported to occur in male patients",
                    "sub_points": [
                      "Distinction is not clinically important",
                      "Leiomyoma not reported to occur in male patients"
                    ]
                  },
                  {
                    "text": "Rare cases of leiomyosarcoma of breast reportedTumors are generally large (> 3 cm) with a high mitotic rate",
                    "sub_points": [
                      "Tumors are generally large (> 3 cm) with a high mitotic rate"
                    ]
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Highly infiltrative lesion into adjacent breast parenchymaCells surround normal ducts and lobulesBorders may be irregular",
                    "sub_points": [
                      "Cells surround normal ducts and lobules",
                      "Borders may be irregular"
                    ]
                  },
                  {
                    "text": "Spindle cells are arranged in broad, sweeping fascicles"
                  },
                  {
                    "text": "Abundant collagenous matrix"
                  },
                  {
                    "text": "Patchy lymphocytic infiltrate often present at border of lesion"
                  },
                  {
                    "text": "IHC is helpful to distinguish from MFBCD34: NegativeHormone receptors: Usually negativeNuclear β-catenin is supportive but not specific for fibromatosisRb expression is intact",
                    "sub_points": [
                      "CD34: Negative",
                      "Hormone receptors: Usually negative",
                      "Nuclear β-catenin is supportive but not specific for fibromatosis",
                      "Rb expression is intact"
                    ]
                  }
                ],
                "Nodular Fasciitis": [
                  {
                    "text": "Very rare in breastOften in superficial adipose tissue rather than in breast proper",
                    "sub_points": [
                      "Often in superficial adipose tissue rather than in breast proper"
                    ]
                  },
                  {
                    "text": "May be associated with mitoses and rapid growth"
                  },
                  {
                    "text": "Infiltrative borders"
                  },
                  {
                    "text": "Stellate and plump myofibroblastic cells arranged in a tissue-culture patternGiant cells can be present",
                    "sub_points": [
                      "Giant cells can be present"
                    ]
                  },
                  {
                    "text": "Extravasated red blood cells and lymphocytic inflammatory reaction common"
                  },
                  {
                    "text": "Like fibromatosis, nodular fasciitis is negative for CD34"
                  },
                  {
                    "text": "Should be a diagnosis of exclusion after other spindle cell lesions have been excluded"
                  }
                ],
                "Spindle Cell Sarcoma": [
                  {
                    "text": "Sarcomas of the breast are very rare"
                  },
                  {
                    "text": "Usually a high-grade invasive tumor with infiltrating borders"
                  },
                  {
                    "text": "Typically very cellular with marked cytologic atypia"
                  },
                  {
                    "text": "Frequent mitotic figures and necrosis are common features"
                  }
                ],
                "Spindle Cell Metaplastic Carcinoma": [
                  {
                    "text": "Invasive carcinomas can consist entirely of spindle cells"
                  },
                  {
                    "text": "The grade can range from low (fibromatosis-like metaplastic carcinoma) to high"
                  },
                  {
                    "text": "It is important to consider carcinoma when evaluating spindle cell lesions on core needle biopsy, as the subsequent treatment will be different"
                  },
                  {
                    "text": "A panel of IHC studies is helpfulSpindle cell carcinomas are positive for keratins (high molecular weight more often than low molecular weight), and ~ 1/3 are positive for p63Positivity can be weak and focalThese carcinomas are negative for hormone receptors and CD34, whereas the majority of MFBs are positive for these markers",
                    "sub_points": [
                      "Spindle cell carcinomas are positive for keratins (high molecular weight more often than low molecular weight), and ~ 1/3 are positive for p63Positivity can be weak and focal",
                      "Positivity can be weak and focal",
                      "These carcinomas are negative for hormone receptors and CD34, whereas the majority of MFBs are positive for these markers"
                    ]
                  }
                ],
                "Invasive Lobular Carcinoma": [
                  {
                    "text": "The epithelioid pattern of MFB can closely mimic invasive lobular carcinoma"
                  },
                  {
                    "text": "Positivity for ER and PR is found in both lesions"
                  },
                  {
                    "text": "The following features should raise the possibility of MFBCircumscribed bordersLobular carcinomas are usually detected as irregular masses or areas of architectural distortionSpindle tumor cells: May be focal and best seen on IHCSpindle cells would be quite unusual for lobular carcinomaAbsence of lobular carcinoma in situ (LCIS)Tumor cells do not invade around normal structures",
                    "sub_points": [
                      "Circumscribed bordersLobular carcinomas are usually detected as irregular masses or areas of architectural distortion",
                      "Lobular carcinomas are usually detected as irregular masses or areas of architectural distortion",
                      "Spindle tumor cells: May be focal and best seen on IHCSpindle cells would be quite unusual for lobular carcinoma",
                      "Spindle cells would be quite unusual for lobular carcinoma",
                      "Absence of lobular carcinoma in situ (LCIS)",
                      "Tumor cells do not invade around normal structures"
                    ]
                  }
                ],
                "Dermatofibrosarcoma Protuberans (DFSP)": [
                  {
                    "text": "DFSP is a locally aggressive, low-grade tumor that occurs in the dermisCan progress to a higher grade neoplasm",
                    "sub_points": [
                      "Can progress to a higher grade neoplasm"
                    ]
                  },
                  {
                    "text": "The majority of breast cases involve the subcutaneous tissue with only a few focally involving the underlying breast tissue< 10% are centered within breast tissue",
                    "sub_points": [
                      "< 10% are centered within breast tissue"
                    ]
                  },
                  {
                    "text": "DFSP is characterized by a t(17;22)(q22;q13), resulting in aCOL1A1::PDGFBfusion product in ~ 85-95% of tumorsThe majority of breast DFSPs have the typical fusion, but a subset have aCOL6A3::PDGFDfusionDFSPs with theCOL6A3::PDGFDfusion predominantly occur in the torso of women (> 85%)",
                    "sub_points": [
                      "The majority of breast DFSPs have the typical fusion, but a subset have aCOL6A3::PDGFDfusionDFSPs with theCOL6A3::PDGFDfusion predominantly occur in the torso of women (> 85%)",
                      "DFSPs with theCOL6A3::PDGFDfusion predominantly occur in the torso of women (> 85%)"
                    ]
                  },
                  {
                    "text": "The tumors have ill-defined margins and infiltrate into the surrounding breast tissueThe cells surround epithelium and adipocytes (honeycomb pattern) but do not have a destructive pattern",
                    "sub_points": [
                      "The cells surround epithelium and adipocytes (honeycomb pattern) but do not have a destructive pattern"
                    ]
                  },
                  {
                    "text": "The tumor cells are uniform in appearance and form storiform and whorled patterns"
                  },
                  {
                    "text": "The tumor cells are slender and may be curvedNuclear atypia is minimal, and mitoses are rare",
                    "sub_points": [
                      "Nuclear atypia is minimal, and mitoses are rare"
                    ]
                  },
                  {
                    "text": "Collagen can be present between tumor cell bundles"
                  },
                  {
                    "text": "Positive for CD34 but negative for desmin and smooth muscle actin"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "A bland spindle cell proliferation forming a mass with circumscribed margins that often contains adipose tissue"
                  },
                  {
                    "text": "An absence of normal breast epithelium distinguishes MFB from most other benign stromal lesions"
                  },
                  {
                    "text": "The epithelioid variant can closely resemble hormone receptor-positive invasive lobular carcinomaA circumscribed border and the absence of cytokeratin expression is helpful to identify MFB",
                    "sub_points": [
                      "A circumscribed border and the absence of cytokeratin expression is helpful to identify MFB"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Important Features": [
                  {
                    "text": "Core needle biopsy: Definitive diagnosis may not be possible; excision is generally recommended"
                  },
                  {
                    "text": "Excision: Margins are not essential to document as tumors do not recur"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lipoma and Angiolipoma": {
            "name": "Lipoma and Angiolipoma",
            "url": "https://app.pathprimer.com/document/d0954712-6c7b-4920-962d-4e505f5e86f2/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Benign neoplasms consisting of mature adipose cells and blood vessels"
                  },
                  {
                    "text": "Distinct genomic changes support that these are 2 different neoplasms"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Lipomas and angiolipomas form soft, palpable, circumscribed masses"
                  },
                  {
                    "text": "Lesions are benign, and no treatment is necessary"
                  },
                  {
                    "text": "Palpable or clinically apparent masses may be excised for cosmetic reasons or due to patient preference"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Lipomas consist entirely of adipose tissue and are radiolucent with a thin capsuleIsoechoic on ultrasound compared to subcutaneous adipose tissue",
                    "sub_points": [
                      "Isoechoic on ultrasound compared to subcutaneous adipose tissue"
                    ]
                  },
                  {
                    "text": "Angiolipomas form dense massesMany are hyperechoic due to multiple components of differing echogenicity",
                    "sub_points": [
                      "Many are hyperechoic due to multiple components of differing echogenicity"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Mature adipose tissue without epithelial elements"
                  },
                  {
                    "text": "Well circumscribed and encapsulated with pushing borders"
                  },
                  {
                    "text": "Adipocytes are uniform in size throughout lesion"
                  },
                  {
                    "text": "Rare lesions have the appearance of a hibernoma (brown fat)"
                  },
                  {
                    "text": "After trauma, may show varying degrees of fibrosis, myxoid change, and calcification"
                  },
                  {
                    "text": "Angiolipomas consist of an additional component of small, round blood vessels with fibrin thrombi"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Myofibroblastoma/spindle cell lipoma"
                  },
                  {
                    "text": "Hamartoma"
                  },
                  {
                    "text": "Atypical lipomatous tumor/well-differentiated liposarcoma"
                  },
                  {
                    "text": "Angiosarcoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Benign neoplasms consisting of mature adipose cells and blood vessels"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Age: The majority occur in women and men between 40-60 years old"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Form soft, palpable, circumscribed masses detected clinically or on mammographyTypically present as slowly growing, solitary lesionsAngiolipomas of the breast are usually not painful in contrast to subcutaneous lesions",
                    "sub_points": [
                      "Typically present as slowly growing, solitary lesions",
                      "Angiolipomas of the breast are usually not painful in contrast to subcutaneous lesions"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Lesions are benign, and no treatment is necessary"
                  },
                  {
                    "text": "Palpable or clinically apparent masses may be excised for cosmetic reasons or due to patient preference"
                  },
                  {
                    "text": "Superficial or subcutaneous lesions are more likely to be clinically apparent and undergo excision"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign lesions without risk of local recurrence"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Lipomas and angiolipomas form oval or lobulated masses"
                  },
                  {
                    "text": "Lipomas consist entirely of adipose tissue and are radiolucent with a thin capsuleMasses with a typical appearance need not be biopsied",
                    "sub_points": [
                      "Masses with a typical appearance need not be biopsied"
                    ]
                  },
                  {
                    "text": "Angiolipomas form dense massesBiopsies are often performed for definitive diagnosis",
                    "sub_points": [
                      "Biopsies are often performed for definitive diagnosis"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Lipomas and angiolipomas form oval or lobulated masses"
                  },
                  {
                    "text": "Lipomas are isoechoic compared to subcutaneous adipose tissue"
                  },
                  {
                    "text": "Angiolipomas are often hyperechoicComposed of components of differing echogenicity (adipose tissue, vessel walls, and blood)",
                    "sub_points": [
                      "Composed of components of differing echogenicity (adipose tissue, vessel walls, and blood)"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Often fragmented without surrounding tissue"
                  },
                  {
                    "text": "Complete excisions show ovoid masses separated from surrounding tissue by a thin capsule"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Studies have been performed on lipomas and angiolipomas but not specifically on breast lesionsThe occurrence of different genomic changes supports that they are biologically distinct lesions",
                    "sub_points": [
                      "The occurrence of different genomic changes supports that they are biologically distinct lesions"
                    ]
                  },
                  {
                    "text": "High mobility group protein A2 (HMGA2) rearrangementsFound in 2/3 of lipomasRearrangement results in overexpressionThe DNA binding protein may have a role in adipogenesis",
                    "sub_points": [
                      "Found in 2/3 of lipomas",
                      "Rearrangement results in overexpression",
                      "The DNA binding protein may have a role in adipogenesis"
                    ]
                  },
                  {
                    "text": "Protein kinase D2 (PRKD2) mutations80% of angiolipomas have mutations in a subset of tumor cellsResults in protein overexpression, which is found in both adipocytes and vascular cellsIt is suggested that the mutation in a small number of tumor cells stimulates the growth of surrounding cells",
                    "sub_points": [
                      "80% of angiolipomas have mutations in a subset of tumor cells",
                      "Results in protein overexpression, which is found in both adipocytes and vascular cells",
                      "It is suggested that the mutation in a small number of tumor cells stimulates the growth of surrounding cells"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lipoma and angiolipoma consist of mature adipose tissue without epitheliumLesions are well circumscribed and encapsulated with pushing bordersNuclei of adipocytes are small, uniform, and located at periphery of cell",
                    "sub_points": [
                      "Lesions are well circumscribed and encapsulated with pushing borders",
                      "Nuclei of adipocytes are small, uniform, and located at periphery of cell"
                    ]
                  },
                  {
                    "text": "Appearance of lipoma may be altered secondary to trauma or impaired blood supplyAfter trauma, may show varying degrees of fibrosis, myxoid change, lipogranulomas, calcification",
                    "sub_points": [
                      "After trauma, may show varying degrees of fibrosis, myxoid change, lipogranulomas, calcification"
                    ]
                  },
                  {
                    "text": "Very rare lesions have the appearance of a hibernoma composed of brown fatCells with numerous minute vacuoles and a centrally located nucleus are intermingled with typical adipocytesMyxoid and spindle variants have been described",
                    "sub_points": [
                      "Cells with numerous minute vacuoles and a centrally located nucleus are intermingled with typical adipocytes",
                      "Myxoid and spindle variants have been described"
                    ]
                  },
                  {
                    "text": "Angiolipomas have an additional component of small, round blood vesselsBranching networks of small vessels are typically more prevalent in subcapsular regionTheir vessels are lined by a single layer of cells with bland nucleiThe vascular component can be the predominate componentFibrin thrombi are typically present within vesselsNuclear atypia, layering, and papillary tufting are not present",
                    "sub_points": [
                      "Branching networks of small vessels are typically more prevalent in subcapsular region",
                      "Their vessels are lined by a single layer of cells with bland nuclei",
                      "The vascular component can be the predominate component",
                      "Fibrin thrombi are typically present within vessels",
                      "Nuclear atypia, layering, and papillary tufting are not present"
                    ]
                  }
                ],
                "Core Needle Biopsies": [
                  {
                    "text": "Lipomas are rarely biopsied, as imaging findings are usually diagnosticHistologic features of lipoma on biopsy are nondiagnosticRadiologic correlation is necessary for final diagnosis",
                    "sub_points": [
                      "Histologic features of lipoma on biopsy are nondiagnostic",
                      "Radiologic correlation is necessary for final diagnosis"
                    ]
                  },
                  {
                    "text": "Angiolipomas may be biopsied because imaging findings are not specificFindings on needle biopsy can be diagnostic",
                    "sub_points": [
                      "Findings on needle biopsy can be diagnostic"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Myofibroblastoma/Spindle Cell Lipoma": [
                  {
                    "text": "Myofibroblastoma and spindle cell lipoma are very similar, if not identical, tumors"
                  },
                  {
                    "text": "Consist of admixtures of mature fat, myofibroblasts/fibroblasts, and varying degrees of myxoid changes"
                  },
                  {
                    "text": "Although adipose tissue can be very prominent, these lesions are distinguished from lipomas and angiolipomas by the myofibroblastic/fibroblastic component"
                  },
                  {
                    "text": "Myofibroblastoma and spindle cell lipoma both have rearrangements of 13q and loss of expression of the gene for retinoblastoma (RB1)"
                  }
                ],
                "Hamartoma": [
                  {
                    "text": "Usually presents as a mammographic mass with circumscribed borders containing adipose tissue"
                  },
                  {
                    "text": "Consist of normal-appearing ducts and lobules in addition to a minor component of fat"
                  }
                ],
                "Atypical Lipomatous Tumor/Well-Differentiated Liposarcoma": [
                  {
                    "text": "Extremely rare as a primary tumor in the breast"
                  },
                  {
                    "text": "Usually present as a large, palpable mass with irregular or ill-defined borders"
                  },
                  {
                    "text": "Variation in size of adipocytes, atypia, lipoblasts, and fibrous septa are good diagnostic clues for malignancy"
                  },
                  {
                    "text": "Immunohistochemical studies for MDM2 and CDK4 expression and in situ hybridization forMDM2amplification are helpful for classification"
                  },
                  {
                    "text": "Similar lesions may be seen as a heterologous component of a phyllodes tumor but lack MDM2 and CDK4 expression and amplification"
                  }
                ],
                "Angiosarcoma": [
                  {
                    "text": "The most common sarcoma of the breast"
                  },
                  {
                    "text": "Primary tumors present as large, palpable masses with irregular or ill-defined borders"
                  },
                  {
                    "text": "Features are present that would not be seen in an angiolipoma, including infiltrating malignant blood vessels, nuclear atypia, mitoses, and blood lakes"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Lymphocytic Lobulitis/Mastopathy": {
            "name": "Lymphocytic Lobulitis/Mastopathy",
            "url": "https://app.pathprimer.com/document/1367d1ec-6ace-444a-a177-cd0cb49acad6/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Lymphocytic lobulitis (LL): Lymphocytic infiltrate with a circumscribed border centered on lobules"
                  },
                  {
                    "text": "Sclerosing LL (SCLL): Associated with dense hyalinized stroma and atrophic lobules"
                  },
                  {
                    "text": "Nonsclerosing LL (NSCLL): Stroma and lobules are normal in appearance"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "SCLL:~ 40% of patients have a history of diabetes mellitus or other autoimmune diseaseDense stromal changes may be due to abnormal glucose deposition on collagen",
                    "sub_points": [
                      "Dense stromal changes may be due to abnormal glucose deposition on collagen"
                    ]
                  },
                  {
                    "text": "NSCLL:Majority have a strong family history of breast cancer (~ 50% withBRCA1orBRCA2mutations)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "SCLL: Majority form very hard palpable masses"
                  },
                  {
                    "text": "NSCLL: ~ 70% present as MR enhancement, ~ 30% as a mass, or it can be an incidental finding"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "SCLL: Dense lymphocytic infiltrates surround atrophic lobules and blood vesselsStroma is dense, paucicellular, often glassy in appearanceLymphocytes are predominantly B cells",
                    "sub_points": [
                      "Stroma is dense, paucicellular, often glassy in appearance",
                      "Lymphocytes are predominantly B cells"
                    ]
                  },
                  {
                    "text": "NSCLL: Dense lymphocytic infiltrates surround normal lobulesStroma is normal in appearanceLymphocytes are predominantly T cells",
                    "sub_points": [
                      "Stroma is normal in appearance",
                      "Lymphocytes are predominantly T cells"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Ductal carcinoma in situ with a T-cell infiltrate"
                  },
                  {
                    "text": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)"
                  },
                  {
                    "text": "IgG4-related sclerosing mastitis"
                  },
                  {
                    "text": "Postpregnancy regression"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Lymphocytic lobulitis (LL): Lesions composed of a lymphocytic infiltrate with a relatively circumscribed border centered on lobulesRare finding in core needle biopsies (~ 0.15%)~ 90% SCLL and ~ 10% NSCLL",
                    "sub_points": [
                      "Rare finding in core needle biopsies (~ 0.15%)",
                      "~ 90% SCLL and ~ 10% NSCLL"
                    ]
                  },
                  {
                    "text": "Sclerosing LL (SCLL): Very dense collagenized stromaa.k.a. diabetic mastopathyOccurs primarily in women with diabetes mellitus or other autoimmune diseasesThe lymphocytic infiltrate is predominantly B cells",
                    "sub_points": [
                      "a.k.a. diabetic mastopathy",
                      "Occurs primarily in women with diabetes mellitus or other autoimmune diseasesThe lymphocytic infiltrate is predominantly B cells",
                      "The lymphocytic infiltrate is predominantly B cells"
                    ]
                  },
                  {
                    "text": "Nonsclerosing LL (NSCLL):Not associated with stromal changesOccurs primarily in women with a strong family history, including women with germlineBRCA1andBRCA2mutationsThe lymphocytic infiltrate is predominantly T cells",
                    "sub_points": [
                      "Occurs primarily in women with a strong family history, including women with germlineBRCA1andBRCA2mutations",
                      "The lymphocytic infiltrate is predominantly T cells"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "SCLL~ 40% of patients have a history of diabetes mellitusMajority are insulin dependentStromal changes may be due to abnormal glucose deposition on collagen~ 10% of patients have autoimmune thyroid disease~ 50% of patients do not have an identifiable risk factorIt is unknown if SCLL is risk factor for developing these diseases",
                    "sub_points": [
                      "~ 40% of patients have a history of diabetes mellitusMajority are insulin dependentStromal changes may be due to abnormal glucose deposition on collagen",
                      "Majority are insulin dependent",
                      "Stromal changes may be due to abnormal glucose deposition on collagen",
                      "~ 10% of patients have autoimmune thyroid disease",
                      "~ 50% of patients do not have an identifiable risk factorIt is unknown if SCLL is risk factor for developing these diseases",
                      "It is unknown if SCLL is risk factor for developing these diseases"
                    ]
                  },
                  {
                    "text": "NSCLLFirst noted as an incidental finding in prophylactic mastectomies for women with a strong family history of breast cancerThe majority of women with clinically detected NSCLL also have a strong family history of breast cancer, often due toBRCA1orBRCA2mutations",
                    "sub_points": [
                      "First noted as an incidental finding in prophylactic mastectomies for women with a strong family history of breast cancer",
                      "The majority of women with clinically detected NSCLL also have a strong family history of breast cancer, often due toBRCA1orBRCA2mutations"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "SCLL: ~ 80% present with a very hard, palpable mass, well circumscribed or ill definedCan be multiple and bilateralDenser than breast carcinomasMay make needle biopsy difficult",
                    "sub_points": [
                      "Can be multiple and bilateral",
                      "Denser than breast carcinomas",
                      "May make needle biopsy difficult"
                    ]
                  },
                  {
                    "text": "NSCLL: ~ 70% detected as MR enhancement and ~ 30% as a massUsually solitary and unilateralMasses are rarely palpableAlso seen as an incidental finding in prophylactic mastectomies",
                    "sub_points": [
                      "Usually solitary and unilateral",
                      "Masses are rarely palpable",
                      "Also seen as an incidental finding in prophylactic mastectomies"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "These are benign lesions and treatment is unnecessary after carcinoma is excluded"
                  }
                ]
              },
              "IMAGING": {
                "Radiographic Findings": [
                  {
                    "text": "SCLL: Usually forms a circumscribed or ill-defined massMay be difficult to detect because surrounding stroma is also very dense",
                    "sub_points": [
                      "May be difficult to detect because surrounding stroma is also very dense"
                    ]
                  },
                  {
                    "text": "NSCLL: Majority present as enhancement on MR"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Gross Appearance": [
                  {
                    "text": "SCLL: Dense, white mass, circumscribed or ill defined (1 to > 6 cm)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "LLcan often be suspected by 1x inspection of glass slidesSmall, blue spots correspond to the lymphocytic infiltratesIn SCLL, the blue spots are present in a background of very pink stroma",
                    "sub_points": [
                      "Small, blue spots correspond to the lymphocytic infiltrates",
                      "In SCLL, the blue spots are present in a background of very pink stroma"
                    ]
                  },
                  {
                    "text": "SCLLis characterized by dense hyalinized paucicellular stroma, often glassy in appearanceIn some cases, fibroblasts have enlarged nuclei and appear epithelioid in shapeCan raise concern for carcinomaThe epithelioid stromal fibroblasts are positive for fibroblast and myofibroblast markers (CD34, smooth muscle actin, desmin, CD10)Dense lymphocytic infiltrates surround lobules, ducts, and blood vesselsLymphocytes are predominantly B cells intermingled with a smaller population of T cellsLobules are generally small in size and sparse in numberBasement membranes of ducts and lobules may be markedly thickened",
                    "sub_points": [
                      "In some cases, fibroblasts have enlarged nuclei and appear epithelioid in shapeCan raise concern for carcinoma",
                      "Can raise concern for carcinoma",
                      "The epithelioid stromal fibroblasts are positive for fibroblast and myofibroblast markers (CD34, smooth muscle actin, desmin, CD10)",
                      "Dense lymphocytic infiltrates surround lobules, ducts, and blood vessels",
                      "Lymphocytes are predominantly B cells intermingled with a smaller population of T cells",
                      "Lobules are generally small in size and sparse in numberBasement membranes of ducts and lobules may be markedly thickened",
                      "Basement membranes of ducts and lobules may be markedly thickened"
                    ]
                  },
                  {
                    "text": "NSCLLis characterized by normal-appearing lobules surrounded by dense lymphocytic infiltratesThe stroma is normal in appearanceBlood vessels are not usually involvedLymphocytes are predominantly T cells intermingled with a smaller population of B cells",
                    "sub_points": [
                      "The stroma is normal in appearance",
                      "Blood vessels are not usually involved",
                      "Lymphocytes are predominantly T cells intermingled with a smaller population of B cells"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "SCLL: Biopsies may be difficult to perform due to the hardness of the stromaCharacteristic stromal features are often present, allowing diagnosis to be made even in a limited specimen",
                    "sub_points": [
                      "Characteristic stromal features are often present, allowing diagnosis to be made even in a limited specimen"
                    ]
                  },
                  {
                    "text": "NSCLL: If the imaging lesion is a mass, excision may be advisable to evaluate the possibility of an adjacent carcinoma"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ductal Carcinoma In Situ (DCIS)": [
                  {
                    "text": "High-grade DCIS is often associated with a periductal lymphocytic infiltrate consisting predominantly of T cells"
                  },
                  {
                    "text": "If present in a clinging pattern, the appearance can closely mimic NSCLL"
                  },
                  {
                    "text": "The tumor cells have high-grade nuclei and are typically estrogen receptor (ER) negative"
                  }
                ],
                "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)": [
                  {
                    "text": "Lymphomas of the breast usually form solid masses composed of malignant cells"
                  },
                  {
                    "text": "CLL/SLL can be an incidental finding in breast tissue and closely mimic lymphocytic mastopathy (LM)"
                  },
                  {
                    "text": "The lymphocytic infiltrate may surround epithelium and vessels but is not limited to these areas and also involves intervening tissueThe stroma has a normal appearance",
                    "sub_points": [
                      "The stroma has a normal appearance"
                    ]
                  }
                ],
                "IgG4-Related Sclerosing Mastitis": [
                  {
                    "text": "Patients present with palpable masses that may be multiple &/or bilateral"
                  },
                  {
                    "text": "Not associated with diabetes or connective tissue disease"
                  },
                  {
                    "text": "The mass is composed of a dense lymphoplasmacytic infiltrate with germinal centers"
                  },
                  {
                    "text": "Unlike LM, lymphocytes are not centered around ducts, lobules, or blood vessels"
                  },
                  {
                    "text": "Ducts and lobules may be absent or only at periphery"
                  },
                  {
                    "text": "Stroma is scleroticUnlike SCLL, stroma is minor component of lesion",
                    "sub_points": [
                      "Unlike SCLL, stroma is minor component of lesion"
                    ]
                  },
                  {
                    "text": "Lymphocytes consist of a mixture of B cells and T cells"
                  },
                  {
                    "text": "Plasma cells are predominantly IgG4(+) [40-85% of all IgG(+) cells]"
                  }
                ],
                "Normal Breast Tissue": [
                  {
                    "text": "Mild perilobular lymphocytic infiltrates are commonly seen in normal breast tissue"
                  },
                  {
                    "text": "Often pronounced after cessation of pregnancy and breastfeeding"
                  },
                  {
                    "text": "Ducts and lobules are not atrophicDo not have thickened basement membranes",
                    "sub_points": [
                      "Do not have thickened basement membranes"
                    ]
                  },
                  {
                    "text": "Not associated with very dense interlobular stroma"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Granular Cell Tumor": {
            "name": "Granular Cell Tumor",
            "url": "https://app.pathprimer.com/document/693ff7f8-0a79-41d7-9f30-a46dedd8c409/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Uncommon breast tumor thought to arise from Schwann cells"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare; only 1 case per 100-200 cases of carcinoma"
                  },
                  {
                    "text": "Presents as firm to hard, palpable mass or as density on screening mammographyMargins can be circumscribed or spiculatedCan retract skin or be adherent to chest wall",
                    "sub_points": [
                      "Margins can be circumscribed or spiculated",
                      "Can retract skin or be adherent to chest wall"
                    ]
                  },
                  {
                    "text": "Most common in upper inner breast near supraclavicular nerveCarcinomas are most common in upper outer breast",
                    "sub_points": [
                      "Carcinomas are most common in upper outer breast"
                    ]
                  },
                  {
                    "text": "Majority are benign and cured by surgical excision"
                  },
                  {
                    "text": "Rare reports of local recurrence"
                  },
                  {
                    "text": "Very rare reports of malignant tumors with metastases to lymph nodes or lung"
                  }
                ],
                "Molecular": [
                  {
                    "text": "ATP6AP1-orATP6AP2-inactivating mutations in ~ 60-70%"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "\"Granular cell\" refers to the finely granular appearance of abundant cytoplasm"
                  },
                  {
                    "text": "Contains minute eosinophilic granules corresponding to numerous lysosomes"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Immunohistochemical studies are useful to distinguish granular cells from other types of cells"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Benign inflammatory lesions containing histiocytes"
                  },
                  {
                    "text": "Invasive carcinoma (histiocytoid, apocrine, secretory)"
                  },
                  {
                    "text": "Metastatic tumors (melanoma, renal cell carcinoma)"
                  },
                  {
                    "text": "Alveolar soft part sarcoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Granular cell tumor (GCT)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Granular cell myoblastoma (not recommended)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare neuroectodermal soft tissue neoplasm of Schwann cell originOccurs throughout body: Head and neck, skin or subcutaneous tissues of trunk, upper extremities, breasts, and female genital regionBreast GCTs mirror their histologic counterparts in other anatomic sites",
                    "sub_points": [
                      "Occurs throughout body: Head and neck, skin or subcutaneous tissues of trunk, upper extremities, breasts, and female genital region",
                      "Breast GCTs mirror their histologic counterparts in other anatomic sites"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genetics": [
                  {
                    "text": "The majority of GCTs of the breast and other sites have loss-of-function mutations in regulators of endosomal pHResults in accumulation of intracytoplasmic granules correlating with the histologic appearanceOncogenic, although the exact cause of tumorigenesis is not yet known",
                    "sub_points": [
                      "Results in accumulation of intracytoplasmic granules correlating with the histologic appearance",
                      "Oncogenic, although the exact cause of tumorigenesis is not yet known"
                    ]
                  },
                  {
                    "text": "Rare cases are associated with several syndromesBannayan-Riley-Ruvalcaba syndrome, neurofibromatosis type 1, Noonan syndrome, LEOPARD syndromePTPN11gene mutations have been reported in association with LEOPARD and Noonan syndromes",
                    "sub_points": [
                      "Bannayan-Riley-Ruvalcaba syndrome, neurofibromatosis type 1, Noonan syndrome, LEOPARD syndrome",
                      "PTPN11gene mutations have been reported in association with LEOPARD and Noonan syndromes"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare breast lesion: Only 1 GCT occurs for every 100-200 cases of carcinoma~ 1/1,000 of all breast tumors",
                    "sub_points": [
                      "~ 1/1,000 of all breast tumors"
                    ]
                  },
                  {
                    "text": "5-15% of all GCTs occur in breast"
                  }
                ],
                "Age": [
                  {
                    "text": "Mean: 45-55 years; occurs over a wide range (17-74 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Similar to other breast lesions, the majority occur in women with only 10% in men"
                  }
                ],
                "Ethnicity": [
                  {
                    "text": "Women of African heritage are affected more commonly than women of European heritage and are ~ 10 years younger"
                  }
                ],
                "Presentation": [
                  {
                    "text": "The majority of patients (~ 70%) present with a solitary palpable mass that may be firm or hard, usually asymptomaticMost common in upper inner breast (carcinomas are most common in upper outer breast)Location of GCT corresponds to area of innervation of supraclavicular nerveMass may retract skin or be adherent to chest wall",
                    "sub_points": [
                      "Most common in upper inner breast (carcinomas are most common in upper outer breast)Location of GCT corresponds to area of innervation of supraclavicular nerve",
                      "Location of GCT corresponds to area of innervation of supraclavicular nerve",
                      "Mass may retract skin or be adherent to chest wall"
                    ]
                  },
                  {
                    "text": "~ 25% are detected as a density on mammographic screening"
                  },
                  {
                    "text": "Most commonly present as a solitary massRarely, multiple masses are present (5-10%) in breast or elsewhere",
                    "sub_points": [
                      "Rarely, multiple masses are present (5-10%) in breast or elsewhere"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Most tumors are completely excised by surgery with negative marginsSubtotal excision may lead to local recurrence in lesions with infiltrating borders",
                    "sub_points": [
                      "Subtotal excision may lead to local recurrence in lesions with infiltrating borders"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "GCTs are almost always benign (~ 99% of cases)Slow growth rate",
                    "sub_points": [
                      "Slow growth rate"
                    ]
                  },
                  {
                    "text": "Rare reports of local recurrence"
                  },
                  {
                    "text": "Very rare reports of malignant GCT with metastases to lymph nodes or lung (~ 2% of cases)Features that favor malignancy include necrosis, spindle cell morphology, nuclear pleomorphism, increased mitotic activityHowever, malignant behavior cannot be accurately predicted based on appearance of tumor alone",
                    "sub_points": [
                      "Features that favor malignancy include necrosis, spindle cell morphology, nuclear pleomorphism, increased mitotic activity",
                      "However, malignant behavior cannot be accurately predicted based on appearance of tumor alone"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Mass with spiculated, circumscribed, or lobulated borders, typically < 3 cm in diameterLesions with spiculated borders have the same appearance as invasive carcinoma",
                    "sub_points": [
                      "Lesions with spiculated borders have the same appearance as invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Multiple masses are present in 5-10% of cases"
                  },
                  {
                    "text": "Calcifications are usually not present"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Hypoechoic solid mass with angulated margins"
                  },
                  {
                    "text": "Marked posterior shadowing may be present"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Low-intermediate signal intensity on T1-weighted images"
                  },
                  {
                    "text": "Often inconspicuous on T2-weighted images"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Palpable, white to yellow, firm to hard massClosely resembles invasive carcinoma",
                    "sub_points": [
                      "Closely resembles invasive carcinoma"
                    ]
                  },
                  {
                    "text": "Borders may be circumscribed, ill defined, or irregular"
                  },
                  {
                    "text": "Usually 1-3 cm; rare reports of tumors up to 6 cm"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA Mutations": [
                  {
                    "text": "~ 60-70% of GCTs (including breast tumors) have either anATP6AP1-or anATP6AP2-inactivating mutationThe mutations are mutually exclusiveRarely found in other neoplasms",
                    "sub_points": [
                      "The mutations are mutually exclusiveRarely found in other neoplasms",
                      "Rarely found in other neoplasms"
                    ]
                  },
                  {
                    "text": "These X chromosome genes code for vacuolar H+-ATPase components that regulate endosomal pHLoss-of-function mutations result in massive accumulation of intracytoplasmic granules, correlating with the histologic appearanceAlso oncogenic, but the exact mechanism is not yet completely understood",
                    "sub_points": [
                      "Loss-of-function mutations result in massive accumulation of intracytoplasmic granules, correlating with the histologic appearance",
                      "Also oncogenic, but the exact mechanism is not yet completely understood"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Solid proliferation of tumor cellsLesion is usually well demarcated and not encapsulatedCells infiltrate as cohesive sheets or small nestsInfiltration into adjacent connective tissue creates spiculated marginsClosely resembles invasive carcinoma on imagingSingle cell infiltration is less common",
                    "sub_points": [
                      "Lesion is usually well demarcated and not encapsulated",
                      "Cells infiltrate as cohesive sheets or small nestsInfiltration into adjacent connective tissue creates spiculated marginsClosely resembles invasive carcinoma on imagingSingle cell infiltration is less common",
                      "Infiltration into adjacent connective tissue creates spiculated marginsClosely resembles invasive carcinoma on imaging",
                      "Closely resembles invasive carcinoma on imaging",
                      "Single cell infiltration is less common"
                    ]
                  },
                  {
                    "text": "Cells are rounded or spindle-shaped"
                  },
                  {
                    "text": "\"Granular cell\" refers to the appearance of cytoplasmCytoplasm is abundant and contains eosinophilic granulesGranules are PAS(+) and diastase resistantIn some tumors, cytoplasm appears clearAppearance due to abundant lysosomesSmaller lysosomes are eosinophilicLarger lysosomes have surrounding halo",
                    "sub_points": [
                      "Cytoplasm is abundant and contains eosinophilic granulesGranules are PAS(+) and diastase resistantIn some tumors, cytoplasm appears clear",
                      "Granules are PAS(+) and diastase resistant",
                      "In some tumors, cytoplasm appears clear",
                      "Appearance due to abundant lysosomesSmaller lysosomes are eosinophilicLarger lysosomes have surrounding halo",
                      "Smaller lysosomes are eosinophilic",
                      "Larger lysosomes have surrounding halo"
                    ]
                  },
                  {
                    "text": "Nuclei are uniform in size and shape, small and oval with minimal pleomorphismNucleoli may be inconspicuous or prominentFocal areas of nuclear pleomorphism or occasional mitoses should not be interpreted as evidence of malignancy",
                    "sub_points": [
                      "Nucleoli may be inconspicuous or prominent",
                      "Focal areas of nuclear pleomorphism or occasional mitoses should not be interpreted as evidence of malignancy"
                    ]
                  },
                  {
                    "text": "Majority are benign; however, ~ 2% of lesions are malignantProposed histologic criteria for distinction between benign and malignant GCTNecrosisSpindle cell morphologyVesicular nuclei with prominent nucleoliIncreased mitotic activity (> 2 mitoses per 10 HPF at 200x magnification)High nuclear:cytoplasmic ratioSignificant nuclear pleomorphismThese criteria classify GCT histologically into atypical (2 of these 6 criteria are present) and malignant (3 or more criteria are present)Large size (> 5 cm) is also of concern for malignancyGCT with only focal pleomorphism and no other criteria should be classified as benignHowever, only a documented metastasis is clear evidence of malignancyMost common sites for distant metastases include bone, lung, and peritoneal cavity",
                    "sub_points": [
                      "Proposed histologic criteria for distinction between benign and malignant GCTNecrosisSpindle cell morphologyVesicular nuclei with prominent nucleoliIncreased mitotic activity (> 2 mitoses per 10 HPF at 200x magnification)High nuclear:cytoplasmic ratioSignificant nuclear pleomorphism",
                      "Necrosis",
                      "Spindle cell morphology",
                      "Vesicular nuclei with prominent nucleoli",
                      "Increased mitotic activity (> 2 mitoses per 10 HPF at 200x magnification)",
                      "High nuclear:cytoplasmic ratio",
                      "Significant nuclear pleomorphism",
                      "These criteria classify GCT histologically into atypical (2 of these 6 criteria are present) and malignant (3 or more criteria are present)Large size (> 5 cm) is also of concern for malignancyGCT with only focal pleomorphism and no other criteria should be classified as benign",
                      "Large size (> 5 cm) is also of concern for malignancy",
                      "GCT with only focal pleomorphism and no other criteria should be classified as benign",
                      "However, only a documented metastasis is clear evidence of malignancy",
                      "Most common sites for distant metastases include bone, lung, and peritoneal cavity"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis can be difficult if there is limited sampling"
                  },
                  {
                    "text": "GCT should always be considered for neoplasms with abundant foamy, clear, or granular cytoplasm"
                  },
                  {
                    "text": "Excision is generally recommendedThe natural history of GCT that is not excised is unknown",
                    "sub_points": [
                      "The natural history of GCT that is not excised is unknown"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Periodic acid-Schiff with diastase positive in a coarse granular pattern"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "S100(+) (> 95%)Strong immunoreactivity in nucleus and cytoplasmSupports peripheral nerve sheath originBreast carcinomas can also be positive",
                    "sub_points": [
                      "Strong immunoreactivity in nucleus and cytoplasm",
                      "Supports peripheral nerve sheath origin",
                      "Breast carcinomas can also be positive"
                    ]
                  },
                  {
                    "text": "SOX10(+) (> 90%)Breast carcinomas can also be positive",
                    "sub_points": [
                      "Breast carcinomas can also be positive"
                    ]
                  },
                  {
                    "text": "Calretinin (+) (~ 80%)Calretinin is primarily neuronal protein and further supports neuronal derivation",
                    "sub_points": [
                      "Calretinin is primarily neuronal protein and further supports neuronal derivation"
                    ]
                  },
                  {
                    "text": "CD68(+) (> 95%)Intracytoplasmic phagolysosomes are immunoreactiveDoes not reflect histocytic origin of this tumor",
                    "sub_points": [
                      "Intracytoplasmic phagolysosomes are immunoreactiveDoes not reflect histocytic origin of this tumor",
                      "Does not reflect histocytic origin of this tumor"
                    ]
                  },
                  {
                    "text": "Inhibin-α (+) (~ 50%)"
                  },
                  {
                    "text": "Neuron-specific enolase (+) (~ 90%)"
                  },
                  {
                    "text": "β-catenin (+) (majority)Normal membrane patternBreast cancers are also positive",
                    "sub_points": [
                      "Normal membrane pattern",
                      "Breast cancers are also positive"
                    ]
                  },
                  {
                    "text": "Cytokeratin (-) (100%)"
                  },
                  {
                    "text": "Hormone receptors (-) (0%)"
                  },
                  {
                    "text": "Muscle markers, majority (-)"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Granules seen by light microscopy correspond to numerous lysosomes"
                  },
                  {
                    "text": "Myelin figures are present, supporting neural origin"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Benign Inflammatory Lesions": [
                  {
                    "text": "Histiocytes and granular cells can be similar in appearance"
                  },
                  {
                    "text": "Cause of histiocytic infiltrate is usually apparent: Most commonly ruptured cysts, fat necrosis, or response to ruptured breast implants and siliconeInflammatory cells, hemosiderin-laden macrophages, and fibrosis favor a reactive process",
                    "sub_points": [
                      "Inflammatory cells, hemosiderin-laden macrophages, and fibrosis favor a reactive process"
                    ]
                  }
                ],
                "Invasive Carcinoma": [
                  {
                    "text": "Carcinomas with apocrine or histiocytoid features can resemble GCT"
                  },
                  {
                    "text": "Nuclear pleomorphism and mitotic figures are usually present"
                  },
                  {
                    "text": "Ductal carcinoma in situ (DCIS) is usually present"
                  },
                  {
                    "text": "Cytokeratin can be used to identify carcinomaS100 is positive in up to 1/3 of breast carcinomas",
                    "sub_points": [
                      "S100 is positive in up to 1/3 of breast carcinomas"
                    ]
                  }
                ],
                "Metastatic Tumors": [
                  {
                    "text": "Melanomas are the most common type of metastasis to breastS100 is positive in melanoma and in GCTOther melanoma markers (e.g., HMB-45) is usually negative in GCT",
                    "sub_points": [
                      "S100 is positive in melanoma and in GCT",
                      "Other melanoma markers (e.g., HMB-45) is usually negative in GCT"
                    ]
                  },
                  {
                    "text": "Renal cell carcinoma may also have granular cytoplasmBlood lakes are common due to delicate vasculatureRenal cell carcinoma is positive for cytokeratinMetastasis to breast would be very unusual",
                    "sub_points": [
                      "Blood lakes are common due to delicate vasculature",
                      "Renal cell carcinoma is positive for cytokeratin",
                      "Metastasis to breast would be very unusual"
                    ]
                  },
                  {
                    "text": "GCT from another site could metastasize to the breastIt would be difficult to determine if the breast lesion was a metastasis or if the patient had multiple tumors",
                    "sub_points": [
                      "It would be difficult to determine if the breast lesion was a metastasis or if the patient had multiple tumors"
                    ]
                  }
                ],
                "Alveolar Soft Part Sarcoma (ASPS)": [
                  {
                    "text": "Originally named malignant granular cell myoblastoma, as it was thought to be the malignant counterpart to GCTThese tumors have a specific translocation: der(17)t(X;17)(p11;q25)Translocation fuses transcription factor 3 (TFE3) gene to novel gene named ASPL, creating ASPL::TFE3fusion proteinNuclear immunoreactivity forTFE3product is present in ASPS, pediatric renal carcinomas withTFE3fusion proteins, and some GCTs (25-70%)However, the specific translocation andTFE3fusion proteins have not been reported in GCT",
                    "sub_points": [
                      "These tumors have a specific translocation: der(17)t(X;17)(p11;q25)",
                      "Translocation fuses transcription factor 3 (TFE3) gene to novel gene named ASPL, creating ASPL::TFE3fusion protein",
                      "Nuclear immunoreactivity forTFE3product is present in ASPS, pediatric renal carcinomas withTFE3fusion proteins, and some GCTs (25-70%)However, the specific translocation andTFE3fusion proteins have not been reported in GCT",
                      "However, the specific translocation andTFE3fusion proteins have not been reported in GCT"
                    ]
                  },
                  {
                    "text": "This rare type of sarcoma would be highly unusual in breast"
                  },
                  {
                    "text": "Dyscohesive cells form a clustered pseudoalveolar pattern and have distinct PAS(+) crystalline structures in the cytoplasmIn contrast, the cytoplasm of GCT is diffusely positive for PAS",
                    "sub_points": [
                      "In contrast, the cytoplasm of GCT is diffusely positive for PAS"
                    ]
                  },
                  {
                    "text": "ASPS is negative for cytokeratin, HMB-45, and S100 in the majority of cases"
                  },
                  {
                    "text": "Desmin and other skeletal muscle markers are positive in ~ 1/2 of cases"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "GCT can closely mimic invasive carcinoma by imaging and on gross examination"
                  },
                  {
                    "text": "GCT should always be considered for any lesion composed of cells with abundant granular cytoplasm"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nodular Fasciitis": {
            "name": "Nodular Fasciitis",
            "url": "https://app.pathprimer.com/document/8ce7bae6-6fe7-4b40-9e06-36987684eb78/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Nodular fasciitis (NF): Benign, self-limited proliferation of fibroblasts and myofibroblasts"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Majority (> 90%) of NF overexpress USP6 protein"
                  },
                  {
                    "text": "Most common partner in NF isMYH9"
                  },
                  {
                    "text": "Example of a clonal neoplasm that consistently undergoes spontaneous regression (transient neoplasia)"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Presents as a rapidly growing painful or tender mass"
                  },
                  {
                    "text": "Location may be in subcutaneous tissue, muscle fascia, or within breast parenchyma"
                  },
                  {
                    "text": "Without treatment, tumors spontaneously regress within a few months"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Many lesions have irregular margins and can closely resemble invasive carcinoma"
                  },
                  {
                    "text": "Location in subcutaneous tissue or near muscle fascia are important clues"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Appearance varies with age of lesion"
                  },
                  {
                    "text": "Composed of short, spindle-shaped cells"
                  },
                  {
                    "text": "Cells are loosely organized and do not have a specific patternDescribed as tissue culture appearance",
                    "sub_points": [
                      "Described as tissue culture appearance"
                    ]
                  },
                  {
                    "text": "Mitoses are typically frequent"
                  },
                  {
                    "text": "Large, myoid-type cells or multinucleated cells may be present"
                  },
                  {
                    "text": "Typically do not infiltrate into surrounding tissue"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Proliferative fasciitis and proliferative myositis"
                  },
                  {
                    "text": "Fibromatosis"
                  },
                  {
                    "text": "Myofibroblastoma"
                  },
                  {
                    "text": "Sarcoma"
                  },
                  {
                    "text": "Spindle cell carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Nodular fasciitis (NF)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Pseudosarcomatous fasciitis (not recommended)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign, self-limited mesenchymal neoplastic proliferation of fibroblasts/myofibroblasts"
                  },
                  {
                    "text": "May be triggered by local trauma or injury"
                  },
                  {
                    "text": "Arises spontaneously; similar to its counterpart occurring more frequently in soft tissues"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "USP6-Associated Neoplasms": [
                  {
                    "text": "A family of neoplasms is associated with translocations involvingUSP6, resulting in overexpression of the proteinNF, aneurysmal bone cyst (ABC), myositis ossificans, fibroosseous pseudotumor of digits, and a subgroup of fibromas of tendon sheath",
                    "sub_points": [
                      "NF, aneurysmal bone cyst (ABC), myositis ossificans, fibroosseous pseudotumor of digits, and a subgroup of fibromas of tendon sheath"
                    ]
                  },
                  {
                    "text": "Usually arise in young adults in superficial to deep soft tissue and bone"
                  },
                  {
                    "text": "All are lesions of fibroblasts/myofibroblasts with similarities in morphologic appearanceSolid to pseudocystic growth patternMixed cell population, including myofibroblasts, osteoclast-like giant cells, and lymphocytes, associated with increased vascularity (extravasated blood cells common)Myofibroblasts are positive for smooth muscle actinVariable degrees of bone formation",
                    "sub_points": [
                      "Solid to pseudocystic growth pattern",
                      "Mixed cell population, including myofibroblasts, osteoclast-like giant cells, and lymphocytes, associated with increased vascularity (extravasated blood cells common)Myofibroblasts are positive for smooth muscle actin",
                      "Myofibroblasts are positive for smooth muscle actin",
                      "Variable degrees of bone formation"
                    ]
                  },
                  {
                    "text": "Characterized by rapid growth followed by stability or regression in some casesThe mechanism resulting in regression is unknownVery rare cases of metastatic behavior have been associated with ABC and NF at sites other than breast",
                    "sub_points": [
                      "The mechanism resulting in regression is unknown",
                      "Very rare cases of metastatic behavior have been associated with ABC and NF at sites other than breast"
                    ]
                  },
                  {
                    "text": "The mechanism of overexpression is translocation of theUSP6gene to a promoter from another gene"
                  },
                  {
                    "text": "These lesions are rare examples of clonal neoplasms that can undergo spontaneous regression (transient neoplasia)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Presents as a rapidly growing, painful or tender mass that appears over 2-3 weeks"
                  },
                  {
                    "text": "May develop in response to injury, although history of trauma is often not documented"
                  },
                  {
                    "text": "Occurrence within breast is very rareLocation may be in subcutaneous tissue, muscle fascia, or within breast parenchyma",
                    "sub_points": [
                      "Location may be in subcutaneous tissue, muscle fascia, or within breast parenchyma"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "No treatment is necessary due to the self-limited clinical courseIn most cases, the lesion will be excised to exclude other neoplasms",
                    "sub_points": [
                      "In most cases, the lesion will be excised to exclude other neoplasms"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Tumors spontaneously regress within a few months"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "NF forms a mass that often has irregular margins"
                  },
                  {
                    "text": "Often indistinguishable from invasive carcinoma"
                  },
                  {
                    "text": "Location in subcutaneous tissue or near muscle fascia is helpful in determining likelihood of diagnosis of NF"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Generally small: 1-3 cmLesions > 5 cm would be highly unusual",
                    "sub_points": [
                      "Lesions > 5 cm would be highly unusual"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "MYH9::USP6Gene Fusion": [
                  {
                    "text": "Majority (> 90%) of NF at all sites overexpress USP6 protein (located on 17p13)USP6 (ubiquitin-specific protease 6; a.k.a. TRE17) is a member of the subfamily of deubiquitinating enzymes involved in inflammatory signaling, protein turnover, and intracellular trafficking as well as other functionsOverexpression not reported for proliferative fasciitis or proliferative myositis",
                    "sub_points": [
                      "USP6 (ubiquitin-specific protease 6; a.k.a. TRE17) is a member of the subfamily of deubiquitinating enzymes involved in inflammatory signaling, protein turnover, and intracellular trafficking as well as other functions",
                      "Overexpression not reported for proliferative fasciitis or proliferative myositis"
                    ]
                  },
                  {
                    "text": "Protein is overexpressed due to balanced translocation with another geneMost common partner in NF isMYH9(located on 22q12.3-q13) (~ 60% of tumors)MYH9is member of nonmuscle myosin class II family and is involved in cytokinesis, cell motility, maintenance of cell shape, and actin network disassemblyHighly expressed in subcutaneous fibroblastsNumerous other translocation partners occur in NF and other tumors",
                    "sub_points": [
                      "Most common partner in NF isMYH9(located on 22q12.3-q13) (~ 60% of tumors)MYH9is member of nonmuscle myosin class II family and is involved in cytokinesis, cell motility, maintenance of cell shape, and actin network disassemblyHighly expressed in subcutaneous fibroblastsNumerous other translocation partners occur in NF and other tumors",
                      "MYH9is member of nonmuscle myosin class II family and is involved in cytokinesis, cell motility, maintenance of cell shape, and actin network disassembly",
                      "Highly expressed in subcutaneous fibroblasts",
                      "Numerous other translocation partners occur in NF and other tumors"
                    ]
                  },
                  {
                    "text": "The translocation has been demonstrated in multiple cases of NF in the breast"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Borders are generally circumscribedCells form solid masses and do not infiltrate around ducts and lobulesHowever, focal infiltration into surrounding stroma may be present",
                    "sub_points": [
                      "Cells form solid masses and do not infiltrate around ducts and lobules",
                      "However, focal infiltration into surrounding stroma may be present"
                    ]
                  },
                  {
                    "text": "Features vary according to age of lesionEarly: Cellular with intervening myxoid stromaMid: More cellular without myxoid stromaLate: Less cellular with fibrous and hyalinized stroma",
                    "sub_points": [
                      "Early: Cellular with intervening myxoid stroma",
                      "Mid: More cellular without myxoid stroma",
                      "Late: Less cellular with fibrous and hyalinized stroma"
                    ]
                  },
                  {
                    "text": "Many lesions show mixed features of all stages"
                  },
                  {
                    "text": "Tumors consist of short, spindle to stellate cells with features of myofibroblastsCells loosely arranged, not organized in specific patternsTumor has disorganized tissue culture appearanceShort fascicles or small whorls may be presentMicrocysts typical",
                    "sub_points": [
                      "Cells loosely arranged, not organized in specific patternsTumor has disorganized tissue culture appearance",
                      "Tumor has disorganized tissue culture appearance",
                      "Short fascicles or small whorls may be present",
                      "Microcysts typical"
                    ]
                  },
                  {
                    "text": "Nuclei are small and uniformProminent nucleoli may be presentMild nuclear atypia may be seen",
                    "sub_points": [
                      "Prominent nucleoli may be present",
                      "Mild nuclear atypia may be seen"
                    ]
                  },
                  {
                    "text": "Mitoses are typically frequent, may be abundantAtypical mitotic figures should not be present",
                    "sub_points": [
                      "Atypical mitotic figures should not be present"
                    ]
                  },
                  {
                    "text": "Stroma is loose and myxoid in appearanceThick bands of collagen are typical in regressing lesions",
                    "sub_points": [
                      "Thick bands of collagen are typical in regressing lesions"
                    ]
                  },
                  {
                    "text": "Chronic inflammation is typical and consists predominantly of scattered lymphocytesInflammatory cells are distributed throughout and not restricted to periphery",
                    "sub_points": [
                      "Inflammatory cells are distributed throughout and not restricted to periphery"
                    ]
                  },
                  {
                    "text": "Red cell extravasation is commonSmall areas of hemorrhage may occur",
                    "sub_points": [
                      "Small areas of hemorrhage may occur"
                    ]
                  },
                  {
                    "text": "Large, myoid-type cells or multinucleated cells may be presentThis type of cell can be frequent in the related lesion proliferative fasciitisThese cells must not be mistaken for epithelial cells in spindle cell carcinoma",
                    "sub_points": [
                      "This type of cell can be frequent in the related lesion proliferative fasciitis",
                      "These cells must not be mistaken for epithelial cells in spindle cell carcinoma"
                    ]
                  },
                  {
                    "text": "Metaplastic bone formation is associated with some tumors"
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis can be difficult due to limited sampling"
                  },
                  {
                    "text": "Spindle cell carcinoma should be considered and excluded by appropriate immunohistochemical studies"
                  },
                  {
                    "text": "If a confident diagnosis can be made, the patient can be spared surgery, as the mass will regress"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "In general, immunohistochemical studies are not helpful for the diagnosis of NFMay be helpful in excluding other diagnoses, particularly when sampling is limited",
                    "sub_points": [
                      "May be helpful in excluding other diagnoses, particularly when sampling is limited"
                    ]
                  },
                  {
                    "text": "CD34: NegativeOnly other breast stromal lesion commonly negative for CD34 is fibromatosis",
                    "sub_points": [
                      "Only other breast stromal lesion commonly negative for CD34 is fibromatosis"
                    ]
                  },
                  {
                    "text": "Muscle markers: May be positive (may be focal)Smooth muscle α-actin, calponin, desmin",
                    "sub_points": [
                      "Smooth muscle α-actin, calponin, desmin"
                    ]
                  },
                  {
                    "text": "Cytokeratin and p63: NegativeImportant to exclude spindle cell carcinoma, especially in limited biopsies, such as core needle biopsiesHigh molecular weight keratins should be used, as these are more commonly positive in spindle cell carcinomas",
                    "sub_points": [
                      "Important to exclude spindle cell carcinoma, especially in limited biopsies, such as core needle biopsies",
                      "High molecular weight keratins should be used, as these are more commonly positive in spindle cell carcinomas"
                    ]
                  },
                  {
                    "text": "Nuclear β-catenin: NegativeCytoplasmic β-catenin may be presentAberrant expression of nuclear β-catenin favors fibromatosis, although this finding may also be seen in other lesions",
                    "sub_points": [
                      "Cytoplasmic β-catenin may be present",
                      "Aberrant expression of nuclear β-catenin favors fibromatosis, although this finding may also be seen in other lesions"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "Fluorescence in situ hybridization:USP6rearrangement"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Proliferative Fasciitis and Proliferative Myositis": [
                  {
                    "text": "Do not usually occur in breastInvolvement of anterior chest wall can be mistaken for breast lesions clinically",
                    "sub_points": [
                      "Involvement of anterior chest wall can be mistaken for breast lesions clinically"
                    ]
                  },
                  {
                    "text": "Lesions usually grow rapidly within few weeks, similar to NF"
                  },
                  {
                    "text": "Histologic appearance is similar to NFCells can entrap adipose tissue and skeletal muscleGanglion-like cells with abundant cytoplasm and 1 to several nuclei with prominent nucleoli may be frequentThese cells can be mistaken for epithelioid cells in spindle cell carcinomaCells may be positive for muscle-specific actin, smooth muscle-specific actin, and CD68Cells are negative for cytokeratins",
                    "sub_points": [
                      "Cells can entrap adipose tissue and skeletal muscle",
                      "Ganglion-like cells with abundant cytoplasm and 1 to several nuclei with prominent nucleoli may be frequentThese cells can be mistaken for epithelioid cells in spindle cell carcinomaCells may be positive for muscle-specific actin, smooth muscle-specific actin, and CD68Cells are negative for cytokeratins",
                      "These cells can be mistaken for epithelioid cells in spindle cell carcinoma",
                      "Cells may be positive for muscle-specific actin, smooth muscle-specific actin, and CD68",
                      "Cells are negative for cytokeratins"
                    ]
                  },
                  {
                    "text": "USP6translocation not reported in these lesions"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "Locally aggressive neoplasm of fibroblast/myofibroblasts"
                  },
                  {
                    "text": "Tumor cells are arranged in long fascicles that infiltrate into adjacent breast tissue and possibly into muscle"
                  },
                  {
                    "text": "Mitoses are infrequent"
                  },
                  {
                    "text": "Chronic inflammatory cells are characteristically located at periphery"
                  },
                  {
                    "text": "Both NF and fibromatosis are CD34(-) and show positivity for muscle markers present in myofibroblasts"
                  },
                  {
                    "text": "Majority of cases of fibromatosis have nuclear positivity for β-catenin, and this is not seen in NFHowever, some lack positivity",
                    "sub_points": [
                      "However, some lack positivity"
                    ]
                  },
                  {
                    "text": "NF is is distinguished from fibromatosis primarily on the basis of histologic features"
                  }
                ],
                "Myofibroblastoma": [
                  {
                    "text": "Benign neoplasm of myofibroblasts"
                  },
                  {
                    "text": "Cells are organized into short fascicles with interspersed thick collagen bands"
                  },
                  {
                    "text": "Chronic inflammation and extravasated blood cells within lesion are not typical"
                  },
                  {
                    "text": "Tumor cells are CD34(+) and hormone receptor (+)"
                  }
                ],
                "Sarcoma": [
                  {
                    "text": "NF can mimic sarcoma due to high cellularity, focal infiltrative pattern, and numerous mitoses"
                  },
                  {
                    "text": "Most sarcomas are larger in size (> 4 cm), have greater nuclear pleomorphism, and may have abnormal mitoses"
                  },
                  {
                    "text": "Some sarcomas are CD34(+) or other markers specific for type of sarcomaIn the majority of cases, immunohistochemical studies are not helpful to distinguish NF from sarcomasDistinction generally must be made on morphology",
                    "sub_points": [
                      "In the majority of cases, immunohistochemical studies are not helpful to distinguish NF from sarcomas",
                      "Distinction generally must be made on morphology"
                    ]
                  },
                  {
                    "text": "Angiosarcomas can have a predominant spindle cell pattern with poor formation of recognizable blood vesselsExtravasation of red blood cells and hemorrhage occur in both angiosarcoma and NFImmunohistochemical studies identify endothelial origin of cells of angiosarcoma",
                    "sub_points": [
                      "Extravasation of red blood cells and hemorrhage occur in both angiosarcoma and NF",
                      "Immunohistochemical studies identify endothelial origin of cells of angiosarcoma"
                    ]
                  }
                ],
                "Spindle Cell Carcinoma": [
                  {
                    "text": "Histologic appearance can range from clearly malignant to deceptively bland (fibromatosis-like metaplastic carcinoma)Frequent mitoses in NF can raise concern for malignancy",
                    "sub_points": [
                      "Frequent mitoses in NF can raise concern for malignancy"
                    ]
                  },
                  {
                    "text": "Broad spectrum cytokeratins, including high molecular weight (basal) keratins, may be necessary to demonstrate keratin immunoreactivityp63(+) in ~ 1/3 of spindle cell carcinomas",
                    "sub_points": [
                      "p63(+) in ~ 1/3 of spindle cell carcinomas"
                    ]
                  },
                  {
                    "text": "Nuclear pleomorphism and prominent nucleoli usually present"
                  },
                  {
                    "text": "Carcinomas typically invade in and around normal ducts and lobules and have irregular borders"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Proliferation of mitotically active spindle cells embedded in a myxoid to fibrous stromaTissue culture-like appearance with extravasated red blood cells and scattered lymphoid cells",
                    "sub_points": [
                      "Tissue culture-like appearance with extravasated red blood cells and scattered lymphoid cells"
                    ]
                  },
                  {
                    "text": "NF is commonly mistaken for sarcoma clinically and microscopically"
                  },
                  {
                    "text": "Majority of lesions are small relative to sarcomas that are typically very large"
                  },
                  {
                    "text": "High mitotic rate is not evidence of malignancy in the absence of other features"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fibromatosis": {
            "name": "Fibromatosis",
            "url": "https://app.pathprimer.com/document/17616f93-c0a7-4584-a549-03800dbb4e1a/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Neoplastic proliferation of fibroblasts/myofibroblasts that is locally infiltrative but does not metastasize"
                  },
                  {
                    "text": "Can occur within breast parenchyma but frequently arises from pectoralis fascia and extends into breast"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Some cases are associated with familial adenomatous polyposis (including Gardner and Turcot syndromes) and germline mutations inAPCgene"
                  },
                  {
                    "text": "Sporadic cases are also associated with mutations inAPCgene (10-20%) orCTNBB1(β-catenin) gene (50-80%)"
                  },
                  {
                    "text": "Many associated with prior trauma or surgery"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare; only 0.2% of breast tumors"
                  },
                  {
                    "text": "Most patients present with palpable mass or radiologic findings that closely mimic invasive carcinoma"
                  },
                  {
                    "text": "~ 1/2 have an indolent course with stable disease or resolution, and ~ 1/2 progress with local recurrence"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Long fascicles of spindle cells that infiltrate around normal ducts and lobules and may infiltrate into muscle"
                  },
                  {
                    "text": "Cells are bland, and mitoses are absent or rare"
                  },
                  {
                    "text": "Lymphocytic aggregates at periphery of tumor"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Aberrant nuclear β-catenin positivity and absence of CD34 in majority"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Gardner fibroma"
                  },
                  {
                    "text": "Fibromatosis-like metaplastic carcinoma"
                  },
                  {
                    "text": "Nodular fasciitis"
                  },
                  {
                    "text": "Myofibroblastoma"
                  },
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia"
                  },
                  {
                    "text": "Sarcoma"
                  },
                  {
                    "text": "Phyllodes tumor"
                  },
                  {
                    "text": "Reactive changes due to prior surgery or trauma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Mammary fibromatosis, aggressive fibromatosis"
                  },
                  {
                    "text": "Desmoid tumor, desmoid-type fibromatosis, extraabdominal desmoid tumor"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Neoplastic proliferation of fibroblasts and myofibroblasts that is locally infiltrative but does not metastasizeOccurs within breast parenchyma or arises from pectoralis fascia and extends into the breast",
                    "sub_points": [
                      "Occurs within breast parenchyma or arises from pectoralis fascia and extends into the breast"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Genomic Causes": [
                  {
                    "text": "Fibromatosis is a clonal neoplasm associated with activating mutations inCTNNB1(β-catenin gene) (somatic) or inactivating mutations in adenomatosis polyposis gene (APC) (somatic or germline)These mutations result in increased β-catenin protein, increased transcriptional signaling via the WN/β-catenin gene pathway, and an increase in proliferationThe abnormal regulation and increase in β-catenin protein results in accumulation in the nucleus, which is detected by immunohistochemistry (IHC) in 60-90% of tumors",
                    "sub_points": [
                      "These mutations result in increased β-catenin protein, increased transcriptional signaling via the WN/β-catenin gene pathway, and an increase in proliferation",
                      "The abnormal regulation and increase in β-catenin protein results in accumulation in the nucleus, which is detected by immunohistochemistry (IHC) in 60-90% of tumors"
                    ]
                  },
                  {
                    "text": "Germline mutationFamilial adenomatous polyposis (FAP) (includes Gardner syndrome and Turcot syndrome) is due to germline mutations inAPCFibromatosis occurs in the breast in ~ 10-15% of patients with FAP but is more common at other body sitesOnly 1-2% of breast fibromatosis occurs in persons with a germlineAPCmutationTherefore, ~ 10-20% of people with anAPCmutation detected in breast fibromatosis may have a germline mutation; additional testing can be considered for these patients",
                    "sub_points": [
                      "Familial adenomatous polyposis (FAP) (includes Gardner syndrome and Turcot syndrome) is due to germline mutations inAPC",
                      "Fibromatosis occurs in the breast in ~ 10-15% of patients with FAP but is more common at other body sites",
                      "Only 1-2% of breast fibromatosis occurs in persons with a germlineAPCmutationTherefore, ~ 10-20% of people with anAPCmutation detected in breast fibromatosis may have a germline mutation; additional testing can be considered for these patients",
                      "Therefore, ~ 10-20% of people with anAPCmutation detected in breast fibromatosis may have a germline mutation; additional testing can be considered for these patients"
                    ]
                  },
                  {
                    "text": "Somatic mutation2 major types of somatic mutations are found in breast fibromatosisCTNNB1Activating mutations are found in ~ 80% of breast fibromatosisAPCInactivating mutations are found in 10-20% of breast fibromatosisLoss of APC protein subsequently causes stabilization of β-catenin, which results in its accumulation~ 10% of breast fibromatosis do not have an identifiableCTNNB1orAPCmutation~ 40% of these tumors are positive for nuclear β-cateninMay have a different etiology that has not been identified",
                    "sub_points": [
                      "2 major types of somatic mutations are found in breast fibromatosis",
                      "CTNNB1Activating mutations are found in ~ 80% of breast fibromatosis",
                      "Activating mutations are found in ~ 80% of breast fibromatosis",
                      "APCInactivating mutations are found in 10-20% of breast fibromatosisLoss of APC protein subsequently causes stabilization of β-catenin, which results in its accumulation",
                      "Inactivating mutations are found in 10-20% of breast fibromatosis",
                      "Loss of APC protein subsequently causes stabilization of β-catenin, which results in its accumulation",
                      "~ 10% of breast fibromatosis do not have an identifiableCTNNB1orAPCmutation~ 40% of these tumors are positive for nuclear β-cateninMay have a different etiology that has not been identified",
                      "~ 40% of these tumors are positive for nuclear β-catenin",
                      "May have a different etiology that has not been identified"
                    ]
                  }
                ],
                "Prior Breast Trauma or Surgery": [
                  {
                    "text": "In some cases, fibromatosis occurs in an area of prior trauma, surgery (e.g., within capsule of breast implant), or radiationHas been referred to as secondary fibromatosisPrimary fibromatosis includes cases without this historyTumors may be more circumscribed rather than infiltrative",
                    "sub_points": [
                      "Has been referred to as secondary fibromatosisPrimary fibromatosis includes cases without this history",
                      "Primary fibromatosis includes cases without this history",
                      "Tumors may be more circumscribed rather than infiltrative"
                    ]
                  }
                ],
                "Hormone Stimulation": [
                  {
                    "text": "Some tumors may respond to endocrine treatmentTamoxifen has been used for some patientsEstrogen receptor (ER) and progesterone receptor (PR) expression are rare (< 5%)",
                    "sub_points": [
                      "Tamoxifen has been used for some patients",
                      "Estrogen receptor (ER) and progesterone receptor (PR) expression are rare (< 5%)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare; only 0.2% of breast tumors"
                  },
                  {
                    "text": "< 10% of all cases of fibromatosis"
                  }
                ],
                "Age": [
                  {
                    "text": "Most patients are in their 40s; however, any age can be affected"
                  },
                  {
                    "text": "~ 5% of breast cases occur in men"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Majority present with palpable mass or radiologic findings that closely mimic invasive carcinomaUsually painlessMay be fixed to pectoralis muscle or retract skin, which can be associated with painIrregular in shape",
                    "sub_points": [
                      "Usually painless",
                      "May be fixed to pectoralis muscle or retract skin, which can be associated with pain",
                      "Irregular in shape"
                    ]
                  },
                  {
                    "text": "Almost 50% of patients have prior history of trauma, particularly breast surgery, including implants"
                  }
                ],
                "Treatment": [
                  {
                    "text": "~ 50% of cases have an indolent course with either stable disease or regressionA \"watch and wait\" approach with active surveillance has been suggested with surgery reserved for tumors increasing in size",
                    "sub_points": [
                      "A \"watch and wait\" approach with active surveillance has been suggested with surgery reserved for tumors increasing in size"
                    ]
                  },
                  {
                    "text": "~ 50% of cases show progressive disease with infiltration of adjacent structuresThe tumor should be completely excised with attempt at uninvolved marginsResection of the chest wall with pectoralis muscle and ribs is necessary in some casesLocal recurrence is common within first 3 years (20-30%), even when margins are free of tumorYounger patients with larger tumors are at an increased risk for local recurrenceOther modalities have been used but with unclear benefit due to small numbers of patients with breast tumors treatedEndocrine therapyRadiation treatmentDefinitive radiotherapy may be utilized in unresectable diseaseSurgery + radiation may have better local controlImatinib (Gleevec)Cytotoxic chemotherapyTargeted therapies with other receptor tyrosine kinase inhibitors are under investigationNo predictors of response to systemic therapy or radiation have been reported",
                    "sub_points": [
                      "The tumor should be completely excised with attempt at uninvolved marginsResection of the chest wall with pectoralis muscle and ribs is necessary in some cases",
                      "Resection of the chest wall with pectoralis muscle and ribs is necessary in some cases",
                      "Local recurrence is common within first 3 years (20-30%), even when margins are free of tumorYounger patients with larger tumors are at an increased risk for local recurrence",
                      "Younger patients with larger tumors are at an increased risk for local recurrence",
                      "Other modalities have been used but with unclear benefit due to small numbers of patients with breast tumors treatedEndocrine therapyRadiation treatmentDefinitive radiotherapy may be utilized in unresectable diseaseSurgery + radiation may have better local controlImatinib (Gleevec)Cytotoxic chemotherapyTargeted therapies with other receptor tyrosine kinase inhibitors are under investigation",
                      "Endocrine therapy",
                      "Radiation treatmentDefinitive radiotherapy may be utilized in unresectable diseaseSurgery + radiation may have better local control",
                      "Definitive radiotherapy may be utilized in unresectable disease",
                      "Surgery + radiation may have better local control",
                      "Imatinib (Gleevec)",
                      "Cytotoxic chemotherapy",
                      "Targeted therapies with other receptor tyrosine kinase inhibitors are under investigation",
                      "No predictors of response to systemic therapy or radiation have been reported"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "The majority of patients have a very favorable prognosis with recurrences controlled by local treatment"
                  },
                  {
                    "text": "Fibromatosis does not metastasize: Very rare fatalities are due to local uncontrollable diseaseDeaths due to fibromatosis are rare overall and would be very unlikely for breast tumors",
                    "sub_points": [
                      "Deaths due to fibromatosis are rare overall and would be very unlikely for breast tumors"
                    ]
                  },
                  {
                    "text": "Very rare cases of radiation-associated sarcomas have arisen after treatment of fibromatosisIn one study, 3 of the sarcomas arose from the fibromatosis and had the sameCTNNB1mutation and 3 arose from stromal cells not related to the fibromatosis",
                    "sub_points": [
                      "In one study, 3 of the sarcomas arose from the fibromatosis and had the sameCTNNB1mutation and 3 arose from stromal cells not related to the fibromatosis"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Dense mass with irregular margins most commonLess common is a mass with circumscribed margins",
                    "sub_points": [
                      "Less common is a mass with circumscribed margins"
                    ]
                  },
                  {
                    "text": "If a lesion is very large, the breast can appear retracted and reduced in size"
                  },
                  {
                    "text": "Most typical location is close to, or arising from, pectoralis muscle fascia"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Irregular mass with thick echogenic rim"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Mass-forming lesion with irregular marginsMass is typically irregular and isointense to muscle on T1WI",
                    "sub_points": [
                      "Mass is typically irregular and isointense to muscle on T1WI"
                    ]
                  },
                  {
                    "text": "Variable enhancement kineticsSome reports of benign gradual enhancement patternOther enhancement patterns mimic malignancy",
                    "sub_points": [
                      "Some reports of benign gradual enhancement pattern",
                      "Other enhancement patterns mimic malignancy"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Firm to rubbery white mass"
                  },
                  {
                    "text": "Borders can be circumscribed, irregular, or ill defined"
                  },
                  {
                    "text": "Size can range from 1 cm to > 10 cm"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "MutationsCTNNB150-80% have mutations in exon 3, the majority in codons 41 and 45The serine to phenylalanine substitution at codon 45 (S45F mutation) has been associated with more aggressive behavior at other sites and was found at a lower rate in breast tumors (6% vs. 22%)Not found in nodular fasciitis, reactive stromal lesions, or low-grade sarcomasAPCMore common in breast fibromatosis as compared to all cases of fibromatosis (~ 10-20% vs. 2.6%)~ 10-20% of these patients may have a germlineAPCmutationMutations and deletions usually result in truncationThe 2nd allele is silenced by a 2nd mutation or loss of heterozygosityInactivating mutations inAPCinhibits the degradation of β-catenin and the accumulation in the nucleusCTNNB1andAPCmutations are mutually exclusive: Tumors do not have both mutationsNo other mutations were identified using a 151-gene panel in an analysis of 134 tumorsBreast metaplastic carcinomas can haveCNNB1mutations (~ 25-30% but at different locations) andAPCmutations (~ 5-10%)",
                    "sub_points": [
                      "CTNNB150-80% have mutations in exon 3, the majority in codons 41 and 45The serine to phenylalanine substitution at codon 45 (S45F mutation) has been associated with more aggressive behavior at other sites and was found at a lower rate in breast tumors (6% vs. 22%)Not found in nodular fasciitis, reactive stromal lesions, or low-grade sarcomas",
                      "50-80% have mutations in exon 3, the majority in codons 41 and 45The serine to phenylalanine substitution at codon 45 (S45F mutation) has been associated with more aggressive behavior at other sites and was found at a lower rate in breast tumors (6% vs. 22%)",
                      "The serine to phenylalanine substitution at codon 45 (S45F mutation) has been associated with more aggressive behavior at other sites and was found at a lower rate in breast tumors (6% vs. 22%)",
                      "Not found in nodular fasciitis, reactive stromal lesions, or low-grade sarcomas",
                      "APCMore common in breast fibromatosis as compared to all cases of fibromatosis (~ 10-20% vs. 2.6%)~ 10-20% of these patients may have a germlineAPCmutationMutations and deletions usually result in truncationThe 2nd allele is silenced by a 2nd mutation or loss of heterozygosityInactivating mutations inAPCinhibits the degradation of β-catenin and the accumulation in the nucleus",
                      "More common in breast fibromatosis as compared to all cases of fibromatosis (~ 10-20% vs. 2.6%)~ 10-20% of these patients may have a germlineAPCmutation",
                      "~ 10-20% of these patients may have a germlineAPCmutation",
                      "Mutations and deletions usually result in truncation",
                      "The 2nd allele is silenced by a 2nd mutation or loss of heterozygosity",
                      "Inactivating mutations inAPCinhibits the degradation of β-catenin and the accumulation in the nucleus",
                      "CTNNB1andAPCmutations are mutually exclusive: Tumors do not have both mutations",
                      "No other mutations were identified using a 151-gene panel in an analysis of 134 tumors",
                      "Breast metaplastic carcinomas can haveCNNB1mutations (~ 25-30% but at different locations) andAPCmutations (~ 5-10%)"
                    ]
                  },
                  {
                    "text": "Copy number changesLoss of heterozygosity observed at 6q and 5qGain of 20q and chromosome 8",
                    "sub_points": [
                      "Loss of heterozygosity observed at 6q and 5q",
                      "Gain of 20q and chromosome 8"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Resembles fibromatosis arising in other sites"
                  },
                  {
                    "text": "Long, sweeping fascicles of spindle cells infiltrate around normal ducts and lobulesCellularity may be variableMay infiltrate into or surrounding mammary ducts, muscle, nervesInvolvement of dermis or skin is unusualMay infiltrate around nerves",
                    "sub_points": [
                      "Cellularity may be variable",
                      "May infiltrate into or surrounding mammary ducts, muscle, nervesInvolvement of dermis or skin is unusual",
                      "Involvement of dermis or skin is unusual",
                      "May infiltrate around nerves"
                    ]
                  },
                  {
                    "text": "Spindle cells consist of fibroblasts and myofibroblastsCells are bland with minimal nuclear pleomorphismMitoses are rare",
                    "sub_points": [
                      "Cells are bland with minimal nuclear pleomorphism",
                      "Mitoses are rare"
                    ]
                  },
                  {
                    "text": "Lymphoid aggregates typically seen at periphery of tumorLymphoid follicles are occasionally present",
                    "sub_points": [
                      "Lymphoid follicles are occasionally present"
                    ]
                  },
                  {
                    "text": "Variable stromal collagen bundles; may be prominent"
                  },
                  {
                    "text": "Borders of lesion are usually irregularLesion easily distinguishable from normal stroma",
                    "sub_points": [
                      "Lesion easily distinguishable from normal stroma"
                    ]
                  },
                  {
                    "text": "Evaluation of margins for fibromatosis after excision may be difficult or impossibleReactive stromal fibroblasts due to surgery can be indistinguishable from primary tumor",
                    "sub_points": [
                      "Reactive stromal fibroblasts due to surgery can be indistinguishable from primary tumor"
                    ]
                  },
                  {
                    "text": "In addition to the conventional appearance, other patterns can be focally presentWhen these patterns are present in a core needle biopsy, the lesion may be difficult to recognize as fibromatosisHyalinized/hypocellular, staghorn vessel, myxoid, keloidal, nodular fasciitis-like, hypercellular",
                    "sub_points": [
                      "When these patterns are present in a core needle biopsy, the lesion may be difficult to recognize as fibromatosisHyalinized/hypocellular, staghorn vessel, myxoid, keloidal, nodular fasciitis-like, hypercellular",
                      "Hyalinized/hypocellular, staghorn vessel, myxoid, keloidal, nodular fasciitis-like, hypercellular"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis is often difficult to make on core needle biopsy with limited lesional tissue"
                  },
                  {
                    "text": "It is important to exclude other diagnoses, such as fibromatosis-like metaplastic carcinoma (FLMC) or phyllodes tumors, because if the diagnosis is fibromatosis, an excision may not be performed"
                  },
                  {
                    "text": "A panel of immunoperoxidase studies can be usedFibromatosis: CD34(-), nuclear β-catenin (+)(60-90%), keratin (-), p63(-)Carcinoma: Keratin (+), 1/3 p63(+), CD34(-), β-catenin (+) (~ 25%)Phyllodes tumor: CD34(+), may show positivity for nuclear β-catenin, keratin, and p63",
                    "sub_points": [
                      "Fibromatosis: CD34(-), nuclear β-catenin (+)(60-90%), keratin (-), p63(-)",
                      "Carcinoma: Keratin (+), 1/3 p63(+), CD34(-), β-catenin (+) (~ 25%)",
                      "Phyllodes tumor: CD34(+), may show positivity for nuclear β-catenin, keratin, and p63"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Nuclear β-catenin (+) in 60-90%Cytoplasmic positivity also present in ~ 10-15%Not specific for fibromatosis and may be seen in other benign and malignant tumors",
                    "sub_points": [
                      "Cytoplasmic positivity also present in ~ 10-15%",
                      "Not specific for fibromatosis and may be seen in other benign and malignant tumors"
                    ]
                  },
                  {
                    "text": "Muscle markers (desmin, actin, calponin), 40-80% show some degree of positivity"
                  },
                  {
                    "text": "CD34(-)Other stromal lesions of breast are generally CD34(+)Only other breast stromal tumor CD34(-) is nodular fasciitis",
                    "sub_points": [
                      "Other stromal lesions of breast are generally CD34(+)",
                      "Only other breast stromal tumor CD34(-) is nodular fasciitis"
                    ]
                  },
                  {
                    "text": "Cytokeratins (-)Spindle cell carcinoma should be excluded by use of broad-spectrum keratins, including basal-like keratins",
                    "sub_points": [
                      "Spindle cell carcinoma should be excluded by use of broad-spectrum keratins, including basal-like keratins"
                    ]
                  },
                  {
                    "text": "p63(-)Spindle cell carcinoma should be excluded using multiple markers, including p63",
                    "sub_points": [
                      "Spindle cell carcinoma should be excluded using multiple markers, including p63"
                    ]
                  },
                  {
                    "text": "Hormone receptors, majority negativeER-β expression in fibromatosis at sites other than breast was found in ~ 11% of tumors and correlated with proliferation and recurrence if expressed at high levels",
                    "sub_points": [
                      "ER-β expression in fibromatosis at sites other than breast was found in ~ 11% of tumors and correlated with proliferation and recurrence if expressed at high levels"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Gardner Fibroma": [
                  {
                    "text": "These benign fibrocollagenous tumors usually occur in children and young adults and typically present as painless, subcutaneous masses"
                  },
                  {
                    "text": "The majority (~ 70%) are associated with germline mutations inAPC(familial polyposis syndrome)The majority of lesions are positive for nuclear β-cateninCan be CD34(+)",
                    "sub_points": [
                      "The majority of lesions are positive for nuclear β-catenin",
                      "Can be CD34(+)"
                    ]
                  },
                  {
                    "text": "Compared to fibromatosis, the lesions are paucicellular with abundant collagenThe lesions are infiltrative and entrap adjacent tissue",
                    "sub_points": [
                      "The lesions are infiltrative and entrap adjacent tissue"
                    ]
                  },
                  {
                    "text": "Gardner fibroma-like areas can be seen in association with fibromatosis, and ~ 20-45% of patients develop fibromatosis"
                  }
                ],
                "Fibromatosis-Like Metaplastic Carcinoma (FLMC)": [
                  {
                    "text": "FLMC closely resembles fibromatosisCarcinomas generally have greater degree of cellular pleomorphism and more frequent mitosesHowever, they can be hypocellular and consist of very bland-appearing spindle cellsEpithelioid areas may be present",
                    "sub_points": [
                      "Carcinomas generally have greater degree of cellular pleomorphism and more frequent mitoses",
                      "However, they can be hypocellular and consist of very bland-appearing spindle cells",
                      "Epithelioid areas may be present"
                    ]
                  },
                  {
                    "text": "Carcinomas are positive for cytokeratins and 1/3 for p63It is important to use a broad spectrum of cytokeratin, including high molecular weight keratins, such as 14, 17",
                    "sub_points": [
                      "It is important to use a broad spectrum of cytokeratin, including high molecular weight keratins, such as 14, 17"
                    ]
                  },
                  {
                    "text": "Like fibromatosis, FLMC is negative for CD34 and can be positive for nuclear β-catenin"
                  }
                ],
                "Myofibroblastoma (MYB)": [
                  {
                    "text": "Like fibromatosis, MYB is a benign neoplasm of breast stromal cells"
                  },
                  {
                    "text": "MYB forms mass with circumscribed margins and does not surround normal ducts and lobulesFibromatosis can infiltrate around ducts and lobules",
                    "sub_points": [
                      "Fibromatosis can infiltrate around ducts and lobules"
                    ]
                  },
                  {
                    "text": "Fascicles are short, whereas fibromatosis has long fascicles"
                  },
                  {
                    "text": "MYB is positive for CD34, ER, and PR, distinguishing it from fibromatosis"
                  }
                ],
                "Nodular Fasciitis": [
                  {
                    "text": "Clinical history should be of a rapidly growing painful massTumors regress spontaneously within weeks to months",
                    "sub_points": [
                      "Tumors regress spontaneously within weeks to months"
                    ]
                  },
                  {
                    "text": "Typically located in subcutaneous tissueMargins are usually more circumscribed and less infiltrative than fibromatosisGenerally do not surround normal ducts and lobules",
                    "sub_points": [
                      "Margins are usually more circumscribed and less infiltrative than fibromatosis",
                      "Generally do not surround normal ducts and lobules"
                    ]
                  },
                  {
                    "text": "Stroma is generally looser (myxoid) and less cellular than fibromatosis"
                  },
                  {
                    "text": "Cells are usually haphazardly arranged and not in long fascicles"
                  },
                  {
                    "text": "Mitoses are usually present and are often frequent"
                  },
                  {
                    "text": "Red cell extravasation is characteristic"
                  },
                  {
                    "text": "Inflammatory cells are usually intermingled within tumor rather than predominantly at periphery as in fibromatosis"
                  },
                  {
                    "text": "Like fibromatosis, cells are CD34(-) and can be positive for muscle markers"
                  },
                  {
                    "text": "Unlike fibromatosis, cells are negative for nuclear β-catenin"
                  }
                ],
                "Pseudoangiomatous Stromal Hyperplasia (PASH)": [
                  {
                    "text": "Hyperplastic lesion of myofibroblasts with increased cellularity and stromal clefting"
                  },
                  {
                    "text": "May be detected as masses with circumscribed or ill-defined marginsAlso a common incidental finding",
                    "sub_points": [
                      "Also a common incidental finding"
                    ]
                  },
                  {
                    "text": "Cells surround ducts and lobules and preserve normal architecture"
                  },
                  {
                    "text": "Cells are short and rarely form well-defined fascicles"
                  },
                  {
                    "text": "CD34(+) and does not show nuclear β-catenin positivity"
                  }
                ],
                "Sarcoma": [
                  {
                    "text": "Most sarcomas are highly cellular, have markedly pleomorphic nuclei, and mitoses may be atypical"
                  },
                  {
                    "text": "Histologic features of specific sarcoma types may be present (e.g., liposarcoma, rhabdomyosarcoma, osteosarcoma)"
                  },
                  {
                    "text": "In some cases, IHC can be helpful to identify proteins associated with specific sarcomas"
                  },
                  {
                    "text": "Some sarcomas show nuclear β-catenin positivity but are often CD34(+)"
                  }
                ],
                "Phyllodes Tumor": [
                  {
                    "text": "Tumors with stromal overgrowth and infiltration into surrounding breast tissue can closely resemble fibromatosis"
                  },
                  {
                    "text": "Nuclear pleomorphism and mitoses are usually present"
                  },
                  {
                    "text": "CD34(+) and can be positive for nuclear β-catenin"
                  }
                ],
                "Reactive Changes Due to Prior Surgery or Trauma": [
                  {
                    "text": "Prior history of surgery or trauma is helpful"
                  },
                  {
                    "text": "Inflammatory cells within mass, hemosiderin-laden macrophages, giant cells, and foreign material all favor a reactive process to trauma or surgery"
                  },
                  {
                    "text": "Evaluation of prior excisions of fibromatosis for residual tumor may be difficult"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "When cases of fibromatosis are reviewed, ~ 30% are reclassified as another tumorThe most important of these are FLMC (~ 30%) and phyllodes tumor (~ 15%)",
                    "sub_points": [
                      "The most important of these are FLMC (~ 30%) and phyllodes tumor (~ 15%)"
                    ]
                  },
                  {
                    "text": "A panel of IHC markers can aid in supporting a diagnosis of fibromatosis and excluding other diagnoses"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hemangiomas": {
            "name": "Hemangiomas",
            "url": "https://app.pathprimer.com/document/29264aa4-c6a2-45d8-8b55-0f80d1863832/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Hemangiomas are benign vascular lesions that occur in breast parenchyma and skin"
                  },
                  {
                    "text": "May be detected as palpable masses, masses with circumscribed margins on imaging, or as incidental findings"
                  },
                  {
                    "text": "Uncommon breast lesions~ 1% of mastectomies or ~ 5% of breast biopsies",
                    "sub_points": [
                      "~ 1% of mastectomies or ~ 5% of breast biopsies"
                    ]
                  },
                  {
                    "text": "The majority of benign lesions can be accurately diagnosed on core needle biopsyCorrelation with imaging findings is important to avoid over- or underdiagnosisExcision can be reserved for lesions with atypical features, large lesions (> 2 cm), or when there is radiologic/pathologic discordance",
                    "sub_points": [
                      "Correlation with imaging findings is important to avoid over- or underdiagnosis",
                      "Excision can be reserved for lesions with atypical features, large lesions (> 2 cm), or when there is radiologic/pathologic discordance"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Multiple types of hemangiomas occur in breast parenchymaPerilobular hemangioma, most common vascular lesionTypically small incidental findingCavernous hemangiomaCapillary hemangiomaComplex hemangiomaVenous hemangiomaAtypical hemangioma",
                    "sub_points": [
                      "Perilobular hemangioma, most common vascular lesionTypically small incidental finding",
                      "Typically small incidental finding",
                      "Cavernous hemangioma",
                      "Capillary hemangioma",
                      "Complex hemangioma",
                      "Venous hemangioma",
                      "Atypical hemangioma"
                    ]
                  },
                  {
                    "text": "Hemangiomas also occur in dermis of breast skinCutaneous lesions are usually benign capillary hemangiomasMust be distinguished from atypical vascular lesions occurring in skin after radiation treatment",
                    "sub_points": [
                      "Cutaneous lesions are usually benign capillary hemangiomas",
                      "Must be distinguished from atypical vascular lesions occurring in skin after radiation treatment"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Angiosarcoma"
                  },
                  {
                    "text": "Atypical postradiation vascular proliferation"
                  },
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia (PASH)"
                  },
                  {
                    "text": "Angiolipoma"
                  },
                  {
                    "text": "Papillary endothelial hyperplasia"
                  },
                  {
                    "text": "Angiomatosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Benign lesions of vascular origin occurring in or near breast parenchyma"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Estrogen": [
                  {
                    "text": "May play role in development of hemangiomasMore common in women than in menHemangiomas at sites other than breast have been reported toOccur after exogenous estrogen treatmentIncrease in size during pregnancyIn single case, subcutaneous hemangioma of breast was diagnosed after initiation of hormone replacement therapyPartial involution was observed after discontinuation of hormone replacementExpression of estrogen and progesterone receptors has been reported in some vascular lesionsAndrogen receptor expression is present in > 50% of benign vascular neoplasms",
                    "sub_points": [
                      "More common in women than in men",
                      "Hemangiomas at sites other than breast have been reported toOccur after exogenous estrogen treatmentIncrease in size during pregnancy",
                      "Occur after exogenous estrogen treatment",
                      "Increase in size during pregnancy",
                      "In single case, subcutaneous hemangioma of breast was diagnosed after initiation of hormone replacement therapyPartial involution was observed after discontinuation of hormone replacement",
                      "Partial involution was observed after discontinuation of hormone replacement",
                      "Expression of estrogen and progesterone receptors has been reported in some vascular lesionsAndrogen receptor expression is present in > 50% of benign vascular neoplasms",
                      "Androgen receptor expression is present in > 50% of benign vascular neoplasms"
                    ]
                  }
                ],
                "Hereditary Causes": [
                  {
                    "text": "Kasabach-Merritt syndromeHemangiomas present in infancyMost common in extremities but can involve any anatomic site, including breastBreast hemangiomas and angiosarcoma have been reported",
                    "sub_points": [
                      "Hemangiomas present in infancy",
                      "Most common in extremities but can involve any anatomic site, including breast",
                      "Breast hemangiomas and angiosarcoma have been reported"
                    ]
                  },
                  {
                    "text": "Poland syndromeUnilateral defect of pectoral muscle and ipsilateral syndactylyBreast may be absent or hypoplasticSingle case report of hemangioma of skin in infant",
                    "sub_points": [
                      "Unilateral defect of pectoral muscle and ipsilateral syndactyly",
                      "Breast may be absent or hypoplastic",
                      "Single case report of hemangioma of skin in infant"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Uncommon: ~ 1% of mastectomies or ~ 5% of breast biopsies"
                  }
                ],
                "Age": [
                  {
                    "text": "Median: 50-60 years but wide range (18 months to 82 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "More common in females (~ 95% of cases) than males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Majority (~ 50-60%) are incidental findings in biopsies for other lesions"
                  },
                  {
                    "text": "Of nonincidental lesions, 2/3 are detected by imaging and 1/3 as palpable masses"
                  },
                  {
                    "text": "Hemangiomas of the skin can present as red to purple discolored plaques"
                  }
                ],
                "Natural History": [
                  {
                    "text": "Some lesions undergo involution or resolve spontaneously"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Hemangiomas are benignRecurrence after incomplete excision has not been reported",
                    "sub_points": [
                      "Recurrence after incomplete excision has not been reported"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Oval or lobulated mass with circumscribed marginsDensity equal to breast parenchyma",
                    "sub_points": [
                      "Density equal to breast parenchyma"
                    ]
                  },
                  {
                    "text": "Punctate microcalcifications may be presentLikely related to thrombosis and phlebolith formation (coarse or eggshell-like calcifications)",
                    "sub_points": [
                      "Likely related to thrombosis and phlebolith formation (coarse or eggshell-like calcifications)"
                    ]
                  },
                  {
                    "text": "Many lesions are no longer seen after core needle biopsy"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Oval mass with circumscribed marginsDegree of echogenicity depends on dominant size of vascular channelsHypoechoic, isoechoic, or complex echotexturesCapillary hemangiomas may be hyperechoic; often present in adipose tissue",
                    "sub_points": [
                      "Degree of echogenicity depends on dominant size of vascular channels",
                      "Hypoechoic, isoechoic, or complex echotextures",
                      "Capillary hemangiomas may be hyperechoic; often present in adipose tissue"
                    ]
                  },
                  {
                    "text": "Hemangiomas are less conspicuous sonographically than they are clinically or mammographically"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Often detected as small area of enhancement due to increased blood flow"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Hemangiomas are well circumscribed, soft, spongy masses that are difficult to palpate"
                  },
                  {
                    "text": "Reddish brown color due to blood and hemosiderin"
                  }
                ],
                "Size": [
                  {
                    "text": "Typically small (0.5-2.0 cm)5-10% are > 2 cm",
                    "sub_points": [
                      "5-10% are > 2 cm"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Perilobular hemangiomaMost common vascular lesion (1-10% of breast biopsies)Typically a small (< 0.5 cm) incidental microscopic findingUsually form a well-circumscribed mass adjacent to a lobule and may involve intralobular stromaSome are ill defined and involve larger areas of breast parenchymaVascular spaces are lined by flattened endotheliumVessels are small and rounded with little or no muscular coatAtypical perilobular hemangiomas have hyperchromatic nuclei and may have anastomosing vascular channels",
                    "sub_points": [
                      "Most common vascular lesion (1-10% of breast biopsies)",
                      "Typically a small (< 0.5 cm) incidental microscopic finding",
                      "Usually form a well-circumscribed mass adjacent to a lobule and may involve intralobular stromaSome are ill defined and involve larger areas of breast parenchyma",
                      "Some are ill defined and involve larger areas of breast parenchyma",
                      "Vascular spaces are lined by flattened endothelium",
                      "Vessels are small and rounded with little or no muscular coat",
                      "Atypical perilobular hemangiomas have hyperchromatic nuclei and may have anastomosing vascular channels"
                    ]
                  },
                  {
                    "text": "Capillary hemangiomaMost common clinically evident vascular lesionComposed of capillary-sized, well-formed blood vesselsUsually form circumscribed or lobulated mass; however, some have ill-defined marginsUsually do not involve intralobular stromaCells may have hyperchromatic nucleiSome capillary hemangiomas occur in the dermisCherry angiomas occur in the skin of older adultsLobular capillary hemangioma (pyogenic granuloma) is typically exophytic and can be ulcerated",
                    "sub_points": [
                      "Most common clinically evident vascular lesion",
                      "Composed of capillary-sized, well-formed blood vessels",
                      "Usually form circumscribed or lobulated mass; however, some have ill-defined marginsUsually do not involve intralobular stroma",
                      "Usually do not involve intralobular stroma",
                      "Cells may have hyperchromatic nuclei",
                      "Some capillary hemangiomas occur in the dermisCherry angiomas occur in the skin of older adultsLobular capillary hemangioma (pyogenic granuloma) is typically exophytic and can be ulcerated",
                      "Cherry angiomas occur in the skin of older adults",
                      "Lobular capillary hemangioma (pyogenic granuloma) is typically exophytic and can be ulcerated"
                    ]
                  },
                  {
                    "text": "Cavernous hemangioma2nd most common clinically evident vascular lesionComposed of large, cavernous vascular channels congested with bloodThe dilated, thin-walled vessels are lined by flattened endotheliumVessels appear separate; anastomosing pattern would be unusualSmaller vessels may be present focally or at peripheryThrombosis may be present with papillary endothelial hyperplasia (Masson lesion)Dystrophic calcification may be found in organizing thrombiExtramedullary hematopoiesis may be presentSinusoidal hemangioma is a subtype that occurs in subcutaneous tissueConsists of closely packed thin-walled vesselsFocal nuclear atypia may be present",
                    "sub_points": [
                      "2nd most common clinically evident vascular lesion",
                      "Composed of large, cavernous vascular channels congested with blood",
                      "The dilated, thin-walled vessels are lined by flattened endothelium",
                      "Vessels appear separate; anastomosing pattern would be unusual",
                      "Smaller vessels may be present focally or at periphery",
                      "Thrombosis may be present with papillary endothelial hyperplasia (Masson lesion)",
                      "Dystrophic calcification may be found in organizing thrombi",
                      "Extramedullary hematopoiesis may be present",
                      "Sinusoidal hemangioma is a subtype that occurs in subcutaneous tissueConsists of closely packed thin-walled vesselsFocal nuclear atypia may be present",
                      "Consists of closely packed thin-walled vessels",
                      "Focal nuclear atypia may be present"
                    ]
                  },
                  {
                    "text": "Complex hemangiomaComposed of variably sized, small blood vessels, sometimes forming irregular anastomosing channelsNo nuclear pleomorphism or atypiaUsually small (< 1 cm) with circumscribed borders",
                    "sub_points": [
                      "Composed of variably sized, small blood vessels, sometimes forming irregular anastomosing channels",
                      "No nuclear pleomorphism or atypia",
                      "Usually small (< 1 cm) with circumscribed borders"
                    ]
                  },
                  {
                    "text": "Venous hemangiomaThought to be a type of vascular malformation occurring in subcutaneous tissueDisorderly venous proliferation with smooth muscle walls of varying thicknessVascular spaces may appear empty or filled with blood",
                    "sub_points": [
                      "Thought to be a type of vascular malformation occurring in subcutaneous tissue",
                      "Disorderly venous proliferation with smooth muscle walls of varying thickness",
                      "Vascular spaces may appear empty or filled with blood"
                    ]
                  },
                  {
                    "text": "Atypical hemangiomasLesions with features not typical for benign hemangiomas may be classified as atypical (~ 10% of total)Mild to moderate cytologic atypiaMitosesComplex anastomosing vesselsCentral infarctionThrombosis with papillary endothelial hyperplasia; can simulate more complex architectureIll-defined bordersBlood lakesInfiltrative pattern into normal parenchyma",
                    "sub_points": [
                      "Lesions with features not typical for benign hemangiomas may be classified as atypical (~ 10% of total)Mild to moderate cytologic atypiaMitosesComplex anastomosing vesselsCentral infarctionThrombosis with papillary endothelial hyperplasia; can simulate more complex architectureIll-defined bordersBlood lakesInfiltrative pattern into normal parenchyma",
                      "Mild to moderate cytologic atypia",
                      "Mitoses",
                      "Complex anastomosing vessels",
                      "Central infarction",
                      "Thrombosis with papillary endothelial hyperplasia; can simulate more complex architecture",
                      "Ill-defined borders",
                      "Blood lakes",
                      "Infiltrative pattern into normal parenchyma"
                    ]
                  },
                  {
                    "text": "Dermal hemangiomasCutaneous lesions are usually benign capillary hemangiomasMust be distinguished from atypical vascular lesions occurring in skin after radiation treatment",
                    "sub_points": [
                      "Cutaneous lesions are usually benign capillary hemangiomas",
                      "Must be distinguished from atypical vascular lesions occurring in skin after radiation treatment"
                    ]
                  },
                  {
                    "text": "Core needle biopsy changes after excisionChanges due to a core needle biopsy of a vascular lesion should not be mistaken for malignancy in excisionsHemorrhage simulating blood lakesThrombosis and papillary endothelial hyperplasia simulating anastomosing infiltrative vasculatureInfarction and necrosis",
                    "sub_points": [
                      "Changes due to a core needle biopsy of a vascular lesion should not be mistaken for malignancy in excisionsHemorrhage simulating blood lakesThrombosis and papillary endothelial hyperplasia simulating anastomosing infiltrative vasculatureInfarction and necrosis",
                      "Hemorrhage simulating blood lakes",
                      "Thrombosis and papillary endothelial hyperplasia simulating anastomosing infiltrative vasculature",
                      "Infarction and necrosis"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Lesions that are benign on core needle biopsy need not undergo excision if there is good radiologic/pathologic correlation"
                  },
                  {
                    "text": "Vascular lesions with atypical features, radiologic/pathologic discordance, or size > 2 cm are indications for excisionHowever, malignancy is rarely found",
                    "sub_points": [
                      "However, malignancy is rarely found"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Vascular markers (+)Endothelial cells express ERG, CD31, CD34, and factor VIII",
                    "sub_points": [
                      "Endothelial cells express ERG, CD31, CD34, and factor VIII"
                    ]
                  },
                  {
                    "text": "Supporting cell markers (+)Smooth muscle actin can be used to identify muscle coat",
                    "sub_points": [
                      "Smooth muscle actin can be used to identify muscle coat"
                    ]
                  },
                  {
                    "text": "Ki-67, absent or lowProliferation may be useful to help distinguish between benign and malignant vascular lesionsTypically 4-8% positive endothelial cells in hemangiomaMay be higher in areas of prior biopsy or thrombosisAngiosarcomas typically have 30-45% positive cellsThere is some overlap in proliferation between benign and malignant lesionsProliferation should not be used alone in making this distinction",
                    "sub_points": [
                      "Proliferation may be useful to help distinguish between benign and malignant vascular lesions",
                      "Typically 4-8% positive endothelial cells in hemangiomaMay be higher in areas of prior biopsy or thrombosis",
                      "May be higher in areas of prior biopsy or thrombosis",
                      "Angiosarcomas typically have 30-45% positive cells",
                      "There is some overlap in proliferation between benign and malignant lesionsProliferation should not be used alone in making this distinction",
                      "Proliferation should not be used alone in making this distinction"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Angiosarcoma": [
                  {
                    "text": "Usually present as a clinically apparent palpable mass with an irregular borderHas a diffuse infiltrative growth pattern invading into breast epitheliumHemangiomas are generally well circumscribedPostradiation angiosarcomas generally show extensive involvement of breast skin",
                    "sub_points": [
                      "Has a diffuse infiltrative growth pattern invading into breast epitheliumHemangiomas are generally well circumscribed",
                      "Hemangiomas are generally well circumscribed",
                      "Postradiation angiosarcomas generally show extensive involvement of breast skin"
                    ]
                  },
                  {
                    "text": "Majority > 2 cm and often > 5 cm in sizeHemangiomas are usually small (< 2 cm)",
                    "sub_points": [
                      "Hemangiomas are usually small (< 2 cm)"
                    ]
                  },
                  {
                    "text": "Has features that are not present in hemangiomasNuclear pleomorphism, mitoses, tufting, solid areas, blood lakes, and destructive invasion of breast tissue",
                    "sub_points": [
                      "Nuclear pleomorphism, mitoses, tufting, solid areas, blood lakes, and destructive invasion of breast tissue"
                    ]
                  },
                  {
                    "text": "Ki-67 positivity is higher on average in angiosarcoma compared with hemangiomas"
                  }
                ],
                "Pseudoangiomatous Stromal Hyperplasia (PASH)": [
                  {
                    "text": "May mimic vascular lesions due to anastomosing slit-like spaces formed by myofibroblastic stromal cells"
                  },
                  {
                    "text": "Empty pseudovascular spaces are not lined by true endothelial cellsLining cells are CD34(+) myofibroblasts and not endothelial cellsCD31 (endothelial marker) is negative in lining cells",
                    "sub_points": [
                      "Lining cells are CD34(+) myofibroblasts and not endothelial cells",
                      "CD31 (endothelial marker) is negative in lining cells"
                    ]
                  },
                  {
                    "text": "Can involve lobules in a pattern similar to angiosarcoma"
                  }
                ],
                "Atypical Postradiation Vascular Proliferation (APRVP)": [
                  {
                    "text": "Atypical vascular lesions arise in the skin of an irradiated breast"
                  },
                  {
                    "text": "Anastomosing, thin-walled vessels that may be empty or filled with blood are limited to the dermisIn contrast, hemangiomas consist of well-formed vessels",
                    "sub_points": [
                      "In contrast, hemangiomas consist of well-formed vessels"
                    ]
                  },
                  {
                    "text": "Significant nuclear atypia, mitoses, and tufting are absent"
                  }
                ],
                "Angiolipoma": [
                  {
                    "text": "Form masses with circumscribed borders and appear dense on mammographyPattern of vessels may mimic infiltration in small biopsies",
                    "sub_points": [
                      "Pattern of vessels may mimic infiltration in small biopsies"
                    ]
                  },
                  {
                    "text": "Consists of adipose tissue and small, round blood vessels"
                  },
                  {
                    "text": "Presence of hyaline thrombi within vessels is a clue to correct diagnosis"
                  }
                ],
                "Papillary Endothelial Hyperplasia": [
                  {
                    "text": "Organizing hemorrhage can closely resemble vascular lesionsSome patients may report prior history of trauma",
                    "sub_points": [
                      "Some patients may report prior history of trauma"
                    ]
                  },
                  {
                    "text": "May develop within a large vessel, within another vascular lesion (e.g., cavernous hemangioma), or in a prior surgical siteMargins are circumscribedMay be surrounded by smooth muscle or elastic fibers",
                    "sub_points": [
                      "Margins are circumscribed",
                      "May be surrounded by smooth muscle or elastic fibers"
                    ]
                  },
                  {
                    "text": "May cause difficulty in histologic interpretation due to its architectural complexityEndothelial cells line strands of fibrin and closely mimic irregular anastomosing blood vesselsCentral fibrin and hemorrhage can simulate necrosis and blood lakesLow mitotic activity with < 1 mitosis per 10 HPF",
                    "sub_points": [
                      "Endothelial cells line strands of fibrin and closely mimic irregular anastomosing blood vessels",
                      "Central fibrin and hemorrhage can simulate necrosis and blood lakes",
                      "Low mitotic activity with < 1 mitosis per 10 HPF"
                    ]
                  }
                ],
                "Angiomatosis": [
                  {
                    "text": "Very rare vascular lesion consisting of both blood and lymphatic vessels"
                  },
                  {
                    "text": "Presents as a large palpable mass, ~ 3 cm (range: 2-9 cm) with wide age range (infancy to adulthood)"
                  },
                  {
                    "text": "Large, thin-walled vessels are lined by bland endothelial cellsSome contain blood (\"hemangiomatous\"), and others appear empty (\"lymphangiomatous\")",
                    "sub_points": [
                      "Some contain blood (\"hemangiomatous\"), and others appear empty (\"lymphangiomatous\")"
                    ]
                  },
                  {
                    "text": "Normal breast epithelium, including lobular units, is surrounded, but not invaded, by vessels"
                  },
                  {
                    "text": "Can also arise in skin or be present in breast and involve skin"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Atypical Vascular Lesions: Post Radiation": {
            "name": "Atypical Vascular Lesions: Post Radiation",
            "url": "https://app.pathprimer.com/document/9c6354d7-e94b-4eca-a990-1477027a6f0d/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Atypical vascular lesions (AVLs) consist of complex anastomosing thin-walled vessels within the dermis of the skin several years after exposure to therapeutic radiation treatment"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "These lesions are only seen in clinical setting of prior radiation treatment for breast cancer"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Skin lesions arise within radiation field"
                  },
                  {
                    "text": "Typically occur 3-6 years after radiation treatment"
                  },
                  {
                    "text": "Lesions appear as soft fluid-filled vesicles, flesh-colored papules, or erythematous plaques or nodules of skin"
                  },
                  {
                    "text": "Complete excision of lesion is generally required for diagnosis and treatment"
                  },
                  {
                    "text": "Majority of cases do not recur or develop malignancy after complete excision"
                  },
                  {
                    "text": "Rare patients develop angiosarcomas"
                  },
                  {
                    "text": "Complete excision is generally required for diagnosis and treatment"
                  },
                  {
                    "text": "Majority of lesions do not recur or develop malignancy"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Lesions consist of complex anastomosing vascular channels in dermis"
                  },
                  {
                    "text": "Subcutaneous tissue or breast parenchyma is generally not involved"
                  },
                  {
                    "text": "2 typesLymphatic type (most common): Vessels are empty or filled with clear fluidVascular type (less common): Vessels are filled with blood",
                    "sub_points": [
                      "Lymphatic type (most common): Vessels are empty or filled with clear fluid",
                      "Vascular type (less common): Vessels are filled with blood"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "AVLs of the skin do not overexpress MYC"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Angiosarcoma"
                  },
                  {
                    "text": "Cutaneous hemangiomas"
                  },
                  {
                    "text": "Acquired progressive lymphangioma"
                  },
                  {
                    "text": "Reactive angioendotheliosis"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Atypical vascular lesion (AVL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Atypical postradiation vascular proliferation (APRVP)"
                  },
                  {
                    "text": "Note: The following synonyms are not recommended for useLymphangioma circumscriptum, benign lymphangiomatous papule (BLAP), benign lymphangioendothelioma, acquired progressive lymphangioma, acquired lymphangiectasis",
                    "sub_points": [
                      "Lymphangioma circumscriptum, benign lymphangiomatous papule (BLAP), benign lymphangioendothelioma, acquired progressive lymphangioma, acquired lymphangiectasis"
                    ]
                  }
                ],
                "Definitions": [
                  {
                    "text": "A proliferation of endothelial-like cells within the dermis of the skin several years after exposure to therapeutic radiation treatment"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "These lesions are only seen in the clinical setting of prior radiation treatment for carcinoma"
                  },
                  {
                    "text": "Radiation may predispose to the development of AVLs by 2 mechanismsEdemaCells lining lymphatics and small blood vessels could be damaged, leading to obstruction and edemaMay cause proliferation of blood vessels and lymphatics in dermisChronic edema increases the risk of angiosarcomaDNA damageIn one study, out of 4 AVLs, 2 hadTERT(hTERT) mutations, and 1 had anHRASmutationPostradiation angiosarcomas showed a higher frequency of multiple genetic alterations, including c-Myc amplification and mutations inTERT(hTERT),HRAS,TP53,EGFR,and other genesAlthough the majority of AVLs do not progress to angiosarcoma, rare cases of AVL in which this may have happened and the presence of mutations support that some lesions could act as nonobligate precursors",
                    "sub_points": [
                      "EdemaCells lining lymphatics and small blood vessels could be damaged, leading to obstruction and edemaMay cause proliferation of blood vessels and lymphatics in dermisChronic edema increases the risk of angiosarcoma",
                      "Cells lining lymphatics and small blood vessels could be damaged, leading to obstruction and edema",
                      "May cause proliferation of blood vessels and lymphatics in dermis",
                      "Chronic edema increases the risk of angiosarcoma",
                      "DNA damageIn one study, out of 4 AVLs, 2 hadTERT(hTERT) mutations, and 1 had anHRASmutationPostradiation angiosarcomas showed a higher frequency of multiple genetic alterations, including c-Myc amplification and mutations inTERT(hTERT),HRAS,TP53,EGFR,and other genesAlthough the majority of AVLs do not progress to angiosarcoma, rare cases of AVL in which this may have happened and the presence of mutations support that some lesions could act as nonobligate precursors",
                      "In one study, out of 4 AVLs, 2 hadTERT(hTERT) mutations, and 1 had anHRASmutationPostradiation angiosarcomas showed a higher frequency of multiple genetic alterations, including c-Myc amplification and mutations inTERT(hTERT),HRAS,TP53,EGFR,and other genes",
                      "Postradiation angiosarcomas showed a higher frequency of multiple genetic alterations, including c-Myc amplification and mutations inTERT(hTERT),HRAS,TP53,EGFR,and other genes",
                      "Although the majority of AVLs do not progress to angiosarcoma, rare cases of AVL in which this may have happened and the presence of mutations support that some lesions could act as nonobligate precursors"
                    ]
                  },
                  {
                    "text": "AVLs have not been reported following therapeutic mantle radiation for Hodgkin diseaseThe reason why Hodgkin disease patients are not affected is not knownMay be related to age at exposure and dosageYoung women treated with radiation therapy for Hodgkin disease are at increased risk for breast carcinoma",
                    "sub_points": [
                      "The reason why Hodgkin disease patients are not affected is not knownMay be related to age at exposure and dosageYoung women treated with radiation therapy for Hodgkin disease are at increased risk for breast carcinoma",
                      "May be related to age at exposure and dosage",
                      "Young women treated with radiation therapy for Hodgkin disease are at increased risk for breast carcinoma"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Usually > 60 years"
                  }
                ],
                "Sex": [
                  {
                    "text": "Only women have been reported to be affected"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Small skin lesions arise within the radiation field"
                  },
                  {
                    "text": "Lesions typically arise 3-6 years after radiation treatment but can develop within 1 yearAdditional lesions can occur over timePostradiation angiosarcomas generally occur 5-10 years after treatment",
                    "sub_points": [
                      "Additional lesions can occur over time",
                      "Postradiation angiosarcomas generally occur 5-10 years after treatment"
                    ]
                  },
                  {
                    "text": "May be solitary or numerous throughout the radiation field"
                  },
                  {
                    "text": "2 types of AVLsLymphatic type (~ 80%)Soft, flesh-colored (pink to brown) papules, fluid-filled vesicles, or plaquesVascular type (~ 20%)Erythematous plaques or nodulesClinical appearance can closely mimic angiosarcomaPatients may have lesions of both types",
                    "sub_points": [
                      "Lymphatic type (~ 80%)Soft, flesh-colored (pink to brown) papules, fluid-filled vesicles, or plaques",
                      "Soft, flesh-colored (pink to brown) papules, fluid-filled vesicles, or plaques",
                      "Vascular type (~ 20%)Erythematous plaques or nodulesClinical appearance can closely mimic angiosarcoma",
                      "Erythematous plaques or nodules",
                      "Clinical appearance can closely mimic angiosarcoma",
                      "Patients may have lesions of both types"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Complete excision is generally required for diagnosis and treatmentIn some cases, diagnostic features of angiosarcoma are apparent after complete excisionComplete excision may reduce subsequent risk of angiosarcoma",
                    "sub_points": [
                      "In some cases, diagnostic features of angiosarcoma are apparent after complete excision",
                      "Complete excision may reduce subsequent risk of angiosarcoma"
                    ]
                  },
                  {
                    "text": "Complete excision may not be possible in some patients with multiple lesions"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Majority of lesions do not recur or develop malignancy after complete excisionHowever, 10-20% of patients experience recurrence at the same site with AVL or develop new lesions",
                    "sub_points": [
                      "However, 10-20% of patients experience recurrence at the same site with AVL or develop new lesions"
                    ]
                  },
                  {
                    "text": "Rare patients progress to angiosarcomas arising in the dermisBenign-appearing lesions may progress to angiosarcoma over a period of yearsIt may be difficult to determine if angiosarcoma arose from AVL or if it is an independent lesionIdentification of mutated genes in common between AVL and postradiation angiosarcoma suggests that AVL could be a nonobligate precursor",
                    "sub_points": [
                      "Benign-appearing lesions may progress to angiosarcoma over a period of years",
                      "It may be difficult to determine if angiosarcoma arose from AVL or if it is an independent lesion",
                      "Identification of mutated genes in common between AVL and postradiation angiosarcoma suggests that AVL could be a nonobligate precursor"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Lesions are generally small (0.1-2 cm) as compared to the size of typical angiosarcoma (median: 7.5 cm)"
                  },
                  {
                    "text": "Lesions are generally solitary but may be multiple (2-4 or more)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lesions consist of large, dilated, thin-walled vesselsVessels infiltrate in the dermis in complex anastomosing patternsGenerally confined to a relatively small circumscribed area (< 2 cm)Wedge-shaped in relation to epidermis",
                    "sub_points": [
                      "Vessels infiltrate in the dermis in complex anastomosing patterns",
                      "Generally confined to a relatively small circumscribed area (< 2 cm)Wedge-shaped in relation to epidermis",
                      "Wedge-shaped in relation to epidermis"
                    ]
                  },
                  {
                    "text": "Single layer of lining cellsPapillary tufts or solid areas are not present",
                    "sub_points": [
                      "Papillary tufts or solid areas are not present"
                    ]
                  },
                  {
                    "text": "Nuclei can be plump but are bland and uniform in appearanceNuclei can protrude into lumen (hobnail appearance)Should not have prominent nucleoli",
                    "sub_points": [
                      "Nuclei can protrude into lumen (hobnail appearance)",
                      "Should not have prominent nucleoli"
                    ]
                  },
                  {
                    "text": "Mitoses should not be present"
                  },
                  {
                    "text": "In the vascular type, the spaces are filled with bloodIf there has been prior biopsy, there may be hemorrhage from prior procedureMay be difficult to distinguish from angiosarcoma in a small biopsy",
                    "sub_points": [
                      "If there has been prior biopsy, there may be hemorrhage from prior procedure",
                      "May be difficult to distinguish from angiosarcoma in a small biopsy"
                    ]
                  },
                  {
                    "text": "In the lymphatic type, the spaces appear empty or filled with clear fluid"
                  },
                  {
                    "text": "Lesion is restricted to dermisInvolvement of subcutaneous tissue is unusual; if present, it should be very focal",
                    "sub_points": [
                      "Involvement of subcutaneous tissue is unusual; if present, it should be very focal"
                    ]
                  },
                  {
                    "text": "Chronic inflammatory infiltrate is often present"
                  }
                ],
                "Skin Punch Biopsy": [
                  {
                    "text": "Diagnosis of AVL can only be made with confidence after complete excision"
                  },
                  {
                    "text": "If angiosarcoma is suspected, a strong positive result on IHC for MYC is supportiveHowever, a negative result does not exclude angiosarcomaA positive result (in the absence of other diagnostic features of angiosarcoma) should be confirmed by DNA analysis for amplificationAVL can show weak staining",
                    "sub_points": [
                      "However, a negative result does not exclude angiosarcoma",
                      "A positive result (in the absence of other diagnostic features of angiosarcoma) should be confirmed by DNA analysis for amplification",
                      "AVL can show weak staining"
                    ]
                  },
                  {
                    "text": "Often best to defer diagnosis to the excisional specimen"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "CD31 and CD34Usually positive in both lymphatic and vascular types",
                    "sub_points": [
                      "Usually positive in both lymphatic and vascular types"
                    ]
                  },
                  {
                    "text": "Podoplanin (D2-40) and PROX1Usually present in lymphatic type but not vascular type",
                    "sub_points": [
                      "Usually present in lymphatic type but not vascular type"
                    ]
                  },
                  {
                    "text": "Factor VIII, ERGUsually present in vascular type but not lymphatic type",
                    "sub_points": [
                      "Usually present in vascular type but not lymphatic type"
                    ]
                  },
                  {
                    "text": "Smooth muscle actinPositive in pericytes in vascular type; absent in lymphatic type",
                    "sub_points": [
                      "Positive in pericytes in vascular type; absent in lymphatic type"
                    ]
                  },
                  {
                    "text": "MYC: NegativeMajority of radiation-associated angiosarcomas showMYCamplification and overexpress MYC proteinISH can be used to confirmMYCamplificationOnly rare primary angiosarcomas overexpress MYCIf positive, can be helpful to identify angiosarcoma in small skin biopsies or in difficult casesIf negative, angiosarcoma is not excludedIf positive (in the absence of other features of angiosarcoma), amplification should be confirmed by DNA analysis",
                    "sub_points": [
                      "Majority of radiation-associated angiosarcomas showMYCamplification and overexpress MYC proteinISH can be used to confirmMYCamplificationOnly rare primary angiosarcomas overexpress MYC",
                      "ISH can be used to confirmMYCamplification",
                      "Only rare primary angiosarcomas overexpress MYC",
                      "If positive, can be helpful to identify angiosarcoma in small skin biopsies or in difficult casesIf negative, angiosarcoma is not excludedIf positive (in the absence of other features of angiosarcoma), amplification should be confirmed by DNA analysis",
                      "If negative, angiosarcoma is not excluded",
                      "If positive (in the absence of other features of angiosarcoma), amplification should be confirmed by DNA analysis"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Angiosarcoma": [
                  {
                    "text": "Most important lesion to distinguish from AVLClinical and histologic features of these 2 lesions may overlap, and it may not be possible to make a definitive diagnosis in a small biopsyBoth are immunoreactive for vascular markersComplete excision of AVLs is recommended to ensure areas diagnostic of angiosarcoma are not missed",
                    "sub_points": [
                      "Clinical and histologic features of these 2 lesions may overlap, and it may not be possible to make a definitive diagnosis in a small biopsyBoth are immunoreactive for vascular markers",
                      "Both are immunoreactive for vascular markers",
                      "Complete excision of AVLs is recommended to ensure areas diagnostic of angiosarcoma are not missed"
                    ]
                  },
                  {
                    "text": "Angiosarcomas are typically large, palpable masses (> 5 cm)AVLs are generally small lesions confined to the skin",
                    "sub_points": [
                      "AVLs are generally small lesions confined to the skin"
                    ]
                  },
                  {
                    "text": "Angiosarcomas can usually be distinguished from AVL based on histologic featuresMarked nuclear pleomorphism and mitotic activityRed blood cells within luminaExtravasated red blood cells and blood lakesTufting within lumina and solid areasInvolvement of subcutaneous tissue and breast tissue",
                    "sub_points": [
                      "Marked nuclear pleomorphism and mitotic activity",
                      "Red blood cells within lumina",
                      "Extravasated red blood cells and blood lakes",
                      "Tufting within lumina and solid areas",
                      "Involvement of subcutaneous tissue and breast tissue"
                    ]
                  },
                  {
                    "text": "IHC studies for MYC overexpression or ISH forMYCgene amplification are helpful to identify the majority of postradiation angiosarcomas"
                  }
                ],
                "Cutaneous Hemangiomas": [
                  {
                    "text": "Lesions consist of dilated blood vessels in skin"
                  },
                  {
                    "text": "Vessels have round contours; complex anastomosing channels should not be present"
                  },
                  {
                    "text": "Lumina are filled with blood"
                  },
                  {
                    "text": "Lesions occur primarily in patients without history of radiation therapy"
                  }
                ],
                "Acquired Lymphangioma/Lymphangiectasia": [
                  {
                    "text": "A lymphatic malformation of the skin occurring due to lymphatic obstruction causing chronic lymphedema after surgery or radiation therapy"
                  },
                  {
                    "text": "The lesions are flesh-colored vesicles and can be multiple"
                  },
                  {
                    "text": "Anastomosing dilated vessels lined by flattened endothelium may be empty or contain red blood cells"
                  },
                  {
                    "text": "Cytologic atypia and mitoses are absent"
                  },
                  {
                    "text": "Very similar to the lymphatic type of AVL but can occur in the absence of radiation treatment"
                  }
                ],
                "Diffuse Dermal Angiomatosis (DDA) of the Breast": [
                  {
                    "text": "Most often occurs in women between 20 and 60 years of age with pendulous breasts and a smoking historyMay also have a history of coronary artery disease, hypertension, surgery/trauma, diabetes, calciphylaxis, or antiphospholipid syndromeThe pathogenesis is thought to be a reaction in order to restore blood supply after occlusive vasculopathy has caused hypoxia",
                    "sub_points": [
                      "May also have a history of coronary artery disease, hypertension, surgery/trauma, diabetes, calciphylaxis, or antiphospholipid syndrome",
                      "The pathogenesis is thought to be a reaction in order to restore blood supply after occlusive vasculopathy has caused hypoxia"
                    ]
                  },
                  {
                    "text": "Patients develop large erythematous to violaceous plaques of the skin that can ulcerate and bleed, usually involving both breasts"
                  },
                  {
                    "text": "The lesions consist of small capillary-sized vessels and clusters of endothelial cells distributed through the reticular dermisThere is minimal intravascular proliferation (\"papillary endothelial hyperplasia\") as can be seen in reactive endotheliomatosis when intravascular thrombi are organizedExtravasated blood cells may be presentCellular atypia is absent and mitoses are rareMild chronic inflammation is present",
                    "sub_points": [
                      "There is minimal intravascular proliferation (\"papillary endothelial hyperplasia\") as can be seen in reactive endotheliomatosis when intravascular thrombi are organized",
                      "Extravasated blood cells may be present",
                      "Cellular atypia is absent and mitoses are rare",
                      "Mild chronic inflammation is present"
                    ]
                  },
                  {
                    "text": "DDA can be distinguished from AVL due to the small size of the vessels and the clinical setting"
                  },
                  {
                    "text": "Treatment is directed toward alleviating the hypoxiaCan be successfully treated with reduction mammoplasty, smoking cessation, and treatment of other underlying diseases",
                    "sub_points": [
                      "Can be successfully treated with reduction mammoplasty, smoking cessation, and treatment of other underlying diseases"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Angiosarcoma": {
            "name": "Angiosarcoma",
            "url": "https://app.pathprimer.com/document/5c70ed72-83af-479b-a45c-8ffe9129e013/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Angiosarcoma (AS): Malignant neoplasm arising from endothelial cells or their precursors"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Most common sarcoma arising in the breast (~ 40%)"
                  },
                  {
                    "text": "2 typesIdiopathic (primary) AS: Younger women (~ 50%)Presents as a rapidly growing, palpable breast massTreatment-related (secondary) AS: Older women (~ 50%)Presents with dark red or violaceous discoloration of the skin of the breast or an edematous ipsilateral armAssociated with radiation ± edema related to breast cancer treatmentMYCamplification in 55-65%",
                    "sub_points": [
                      "Idiopathic (primary) AS: Younger women (~ 50%)Presents as a rapidly growing, palpable breast mass",
                      "Presents as a rapidly growing, palpable breast mass",
                      "Treatment-related (secondary) AS: Older women (~ 50%)Presents with dark red or violaceous discoloration of the skin of the breast or an edematous ipsilateral armAssociated with radiation ± edema related to breast cancer treatmentMYCamplification in 55-65%",
                      "Presents with dark red or violaceous discoloration of the skin of the breast or an edematous ipsilateral arm",
                      "Associated with radiation ± edema related to breast cancer treatment",
                      "MYCamplification in 55-65%"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Most effective treatment is surgical removal of tumor with wide margins"
                  },
                  {
                    "text": "Median recurrence-free survival is ~ 3 years"
                  },
                  {
                    "text": "Most common metastatic sites are lung, liver, bone, and contralateral breast"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Abnormal, anastomosing vascular channels"
                  },
                  {
                    "text": "Borders are infiltrative and not well circumscribed"
                  },
                  {
                    "text": "In poorly differentiated tumors, solid spindle or epithelioid areas without evident vessel formation may be present"
                  },
                  {
                    "text": "A panel of markers for endothelial and epithelial antigens can help distinguish AS from poorly differentiated carcinoma"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Atypical vascular lesion"
                  },
                  {
                    "text": "Papillary endothelial hyperplasia"
                  },
                  {
                    "text": "Hemangioma"
                  },
                  {
                    "text": "Angiolipoma"
                  },
                  {
                    "text": "Pseudoangiomatous stromal hyperplasia"
                  },
                  {
                    "text": "Carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Angiosarcoma (AS)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant neoplasm arising from endothelial cells or their precursors"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "AS is the most common sarcoma arising in the breast (~ 40% of breast sarcomas)AS comprises < 0.1% of all breast malignancies",
                    "sub_points": [
                      "AS comprises < 0.1% of all breast malignancies"
                    ]
                  },
                  {
                    "text": "The incidence is increased in the breast due to breast cancer treatment-related AS"
                  }
                ],
                "Idiopathic (Primary) (~ 50%)": [
                  {
                    "text": "Occurs in younger women compared to treatment-related AS"
                  },
                  {
                    "text": "Tumors arise in breast parenchyma but may focally involve skin"
                  },
                  {
                    "text": "Risk factors have not been identified"
                  }
                ],
                "Treatment Related (Secondary) (~ 50%)": [
                  {
                    "text": "Risk factors include radiation therapy and postsurgical edema of the breast and ipsilateral arm> 90% of treatment-related (radiation and edema) AS show amplification ofMYCAlso found in other radiation-associated sarcomasMYCamplification is rare in idiopathic ASSurvival is diminished ifMYCis amplified and protein overexpressed",
                    "sub_points": [
                      "> 90% of treatment-related (radiation and edema) AS show amplification ofMYCAlso found in other radiation-associated sarcomas",
                      "Also found in other radiation-associated sarcomas",
                      "MYCamplification is rare in idiopathic AS",
                      "Survival is diminished ifMYCis amplified and protein overexpressed"
                    ]
                  },
                  {
                    "text": "RadiationRadiation treatment for breast cancer increases risk for AS by 9xChest wall radiation for Hodgkin disease increases risk for breast cancer but not ASReason for this is unknown; probably related to age when radiated &/or radiation dosesTumors arise in irradiated skin and present as erythematous and violaceous skin changesIn rare cases, tumors are present in deeper breast tissue without skin involvementAS may be preceded by postradiation atypical vascular lesions (AVLs) of the skinAVL may be a nonobligate precursor of AS in some casesPatients with radiation-associated sarcomas have poorer outcomes compared to nonradiation-associated sarcomasImproved outcome is observed if surgery removes all irradiated tissue by mastectomy and extensive excision of overlying skin",
                    "sub_points": [
                      "Radiation treatment for breast cancer increases risk for AS by 9xChest wall radiation for Hodgkin disease increases risk for breast cancer but not ASReason for this is unknown; probably related to age when radiated &/or radiation doses",
                      "Chest wall radiation for Hodgkin disease increases risk for breast cancer but not ASReason for this is unknown; probably related to age when radiated &/or radiation doses",
                      "Reason for this is unknown; probably related to age when radiated &/or radiation doses",
                      "Tumors arise in irradiated skin and present as erythematous and violaceous skin changesIn rare cases, tumors are present in deeper breast tissue without skin involvement",
                      "In rare cases, tumors are present in deeper breast tissue without skin involvement",
                      "AS may be preceded by postradiation atypical vascular lesions (AVLs) of the skinAVL may be a nonobligate precursor of AS in some cases",
                      "AVL may be a nonobligate precursor of AS in some cases",
                      "Patients with radiation-associated sarcomas have poorer outcomes compared to nonradiation-associated sarcomasImproved outcome is observed if surgery removes all irradiated tissue by mastectomy and extensive excision of overlying skin",
                      "Improved outcome is observed if surgery removes all irradiated tissue by mastectomy and extensive excision of overlying skin"
                    ]
                  },
                  {
                    "text": "EdemaAxillary dissection with removal of lymph nodes can increase edema in both the breast and ipsilateral armStewart-Treves syndrome describes AS arising in an area of longstanding lymphedemaFirst described for AS arising in the skin of an edematous arm after breast surgeryAS also occurs in edematous skin in other areas of the bodyWith more limited axillary surgery and better surgical techniques, this type of AS is now rare",
                    "sub_points": [
                      "Axillary dissection with removal of lymph nodes can increase edema in both the breast and ipsilateral armStewart-Treves syndrome describes AS arising in an area of longstanding lymphedemaFirst described for AS arising in the skin of an edematous arm after breast surgeryAS also occurs in edematous skin in other areas of the body",
                      "Stewart-Treves syndrome describes AS arising in an area of longstanding lymphedemaFirst described for AS arising in the skin of an edematous arm after breast surgeryAS also occurs in edematous skin in other areas of the body",
                      "First described for AS arising in the skin of an edematous arm after breast surgery",
                      "AS also occurs in edematous skin in other areas of the body",
                      "With more limited axillary surgery and better surgical techniques, this type of AS is now rare"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Idiopathic (primary)< 2% of sarcomas at all anatomical sites< 0.1% (~ 0.05%) of all breast malignanciesAS and malignant phyllodes tumor are about equal in incidence",
                    "sub_points": [
                      "< 2% of sarcomas at all anatomical sites",
                      "< 0.1% (~ 0.05%) of all breast malignancies",
                      "AS and malignant phyllodes tumor are about equal in incidence"
                    ]
                  },
                  {
                    "text": "Treatment related (secondary)Incidence peaks 5-10 years after treatment and is elevated out to 30 yearsCan occasionally occur within 2 yearsAbsolute number of affected women is small: ~ 3 in 1,000 women develop AS after treatment at 15 years",
                    "sub_points": [
                      "Incidence peaks 5-10 years after treatment and is elevated out to 30 yearsCan occasionally occur within 2 years",
                      "Can occasionally occur within 2 years",
                      "Absolute number of affected women is small: ~ 3 in 1,000 women develop AS after treatment at 15 years"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Idiopathic (primary): Median: 40 years (range: 15-75 years)~ 10% arise during or after pregnancy",
                    "sub_points": [
                      "~ 10% arise during or after pregnancy"
                    ]
                  },
                  {
                    "text": "Treatment related (secondary): Median: 70 years (range: 40-90 years)"
                  }
                ],
                "Sex": [
                  {
                    "text": "Almost all patients are female"
                  },
                  {
                    "text": "Idiopathic (primary) AS in males is very rareIf AS is considered in a male, alternative diagnoses, such as papillary endothelial hyperplasia, should be considered",
                    "sub_points": [
                      "If AS is considered in a male, alternative diagnoses, such as papillary endothelial hyperplasia, should be considered"
                    ]
                  },
                  {
                    "text": "Treatment-related AS can occur in males after breast cancer"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Idiopathic AS presents as an ill-defined, large, rapidly growing, palpable breast mass"
                  },
                  {
                    "text": "Treatment-related AS presents with dark red or violaceous discoloration of the skinMultiple skin lesions may be presentMay be mistaken for bruising by patientAn underlying palpable mass may be present",
                    "sub_points": [
                      "Multiple skin lesions may be present",
                      "May be mistaken for bruising by patient",
                      "An underlying palpable mass may be present"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Most effective treatment is surgical removal of tumor with wide marginsMost patients require mastectomy to achieve this goalRemoval of all irradiated skin in addition to mastectomy is associated with reduced local and distant recurrencesThese patients more commonly also undergo chemotherapy",
                    "sub_points": [
                      "Most patients require mastectomy to achieve this goal",
                      "Removal of all irradiated skin in addition to mastectomy is associated with reduced local and distant recurrencesThese patients more commonly also undergo chemotherapy",
                      "These patients more commonly also undergo chemotherapy"
                    ]
                  },
                  {
                    "text": "Chemotherapy and radiation therapy are also used but have less certain benefit"
                  },
                  {
                    "text": "Experimental therapies include inhibitors of vascular endothelial growth factor (VEGF), tyrosine kinase inhibitors, and immune-checkpoint inhibitors"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Many patients develop distant metastasesMost common sites are lung, liver, bone, and contralateral breastMetastasis to regional lymph nodes is rare",
                    "sub_points": [
                      "Most common sites are lung, liver, bone, and contralateral breast",
                      "Metastasis to regional lymph nodes is rare"
                    ]
                  },
                  {
                    "text": "Median recurrence-free survival is ~ 3 yearsMedian overall survival is < 6 years",
                    "sub_points": [
                      "Median overall survival is < 6 years"
                    ]
                  },
                  {
                    "text": "Larger tumors have poorer prognosisTumor grade has not been consistently linked to prognosisLow-grade AS can metastasize",
                    "sub_points": [
                      "Tumor grade has not been consistently linked to prognosisLow-grade AS can metastasize",
                      "Low-grade AS can metastasize"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Mass, ill-defined area of density, or asymmetry"
                  },
                  {
                    "text": "Tumors may be difficult to image, as desmoplastic response commonly associated with carcinomas is not presentMalignant vessels in adipose tissue can be similar to the density of normal breast tissue",
                    "sub_points": [
                      "Malignant vessels in adipose tissue can be similar to the density of normal breast tissue"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Tumors may appear lobulated, irregular, or ill defined"
                  },
                  {
                    "text": "Echogenicity may be variableMay have hyperechoic areas if AS invades into adipose tissue",
                    "sub_points": [
                      "May have hyperechoic areas if AS invades into adipose tissue"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Tumors range 1-20 cmMajority are > 2 cm; average size is 5 cmAlmost all vascular lesions of breast > 2 cm in size are malignantHowever, benign lesions, such as papillary endothelial hyperplasia, can be > 2 cm",
                    "sub_points": [
                      "Majority are > 2 cm; average size is 5 cmAlmost all vascular lesions of breast > 2 cm in size are malignantHowever, benign lesions, such as papillary endothelial hyperplasia, can be > 2 cm",
                      "Almost all vascular lesions of breast > 2 cm in size are malignant",
                      "However, benign lesions, such as papillary endothelial hyperplasia, can be > 2 cm"
                    ]
                  },
                  {
                    "text": "Size can be difficult to determine grossly both visually and by palpationCentral portion of tumor is usually hemorrhagic and firm to palpationInfiltrative periphery of tumor can blend into surrounding tissue and may not be visible",
                    "sub_points": [
                      "Central portion of tumor is usually hemorrhagic and firm to palpation",
                      "Infiltrative periphery of tumor can blend into surrounding tissue and may not be visible"
                    ]
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "Genomic changes are different for idiopathic and treatment-related AS"
                  },
                  {
                    "text": "Idiopathic (primary) ASKDR(kinase insert domain receptor)-activating mutations (60-70%)KDRcodes for VEGF receptor 2 (VEGFR2) (4q12), a tyrosine kinase receptorVEGFR induces endothelial proliferation, survival, migration, and tubular morphogenesisMajority in hotspot p.T771R in exon 16 (transmembrane region of VEGFR2)Loss of heterozygosity of the other allele is commonPIK3CA-/PIK3R1-activating mutations (40-70%)PIK2CAmutations are different than those frequently detected in other tumors (i.e., not Glu545 or His1047)Associated with poorer outcomesPTPRB-inactivating mutations (30%)Codes for a tyrosine phosphatase specific to endothelial cells that inhibits angiogenesisNot associated withKDRorPIK3CAmutationsPLCG1mutations (~ 20%)Codes for phospholipase C gamma 1Has an important role in the intracellular transduction of receptor-mediated tyrosine kinase activatorsAlterations inMYC,FLT4, andTP53are rare or not reported",
                    "sub_points": [
                      "KDR(kinase insert domain receptor)-activating mutations (60-70%)KDRcodes for VEGF receptor 2 (VEGFR2) (4q12), a tyrosine kinase receptorVEGFR induces endothelial proliferation, survival, migration, and tubular morphogenesisMajority in hotspot p.T771R in exon 16 (transmembrane region of VEGFR2)Loss of heterozygosity of the other allele is common",
                      "KDRcodes for VEGF receptor 2 (VEGFR2) (4q12), a tyrosine kinase receptorVEGFR induces endothelial proliferation, survival, migration, and tubular morphogenesis",
                      "VEGFR induces endothelial proliferation, survival, migration, and tubular morphogenesis",
                      "Majority in hotspot p.T771R in exon 16 (transmembrane region of VEGFR2)",
                      "Loss of heterozygosity of the other allele is common",
                      "PIK3CA-/PIK3R1-activating mutations (40-70%)PIK2CAmutations are different than those frequently detected in other tumors (i.e., not Glu545 or His1047)Associated with poorer outcomes",
                      "PIK2CAmutations are different than those frequently detected in other tumors (i.e., not Glu545 or His1047)",
                      "Associated with poorer outcomes",
                      "PTPRB-inactivating mutations (30%)Codes for a tyrosine phosphatase specific to endothelial cells that inhibits angiogenesisNot associated withKDRorPIK3CAmutations",
                      "Codes for a tyrosine phosphatase specific to endothelial cells that inhibits angiogenesis",
                      "Not associated withKDRorPIK3CAmutations",
                      "PLCG1mutations (~ 20%)Codes for phospholipase C gamma 1Has an important role in the intracellular transduction of receptor-mediated tyrosine kinase activators",
                      "Codes for phospholipase C gamma 1",
                      "Has an important role in the intracellular transduction of receptor-mediated tyrosine kinase activators",
                      "Alterations inMYC,FLT4, andTP53are rare or not reported"
                    ]
                  },
                  {
                    "text": "Treatment-related (secondary) ASMYCamplification (> 90%)MYC(8q21) is a protooncogene coding for a transcription factor involved in cellular proliferation, cell growth, apoptosis, and angiogenesisRare in idiopathic ASFLT4amplification (~ 20-25%)Codes for VEGF receptor 3 (VEGFR3 ) (5q35.3), which belongs to tyrosine kinase receptor familyRegulates endothelial cell growth and angiogenesisCoamplified withMYCNot reported in idiopathic ASAmplification associated with diffuse strong cytoplasmic immunoreactivity for protein in > 50% of cellsAVLs and other benign vascular lesions can occasionally show focal weak immunoreactivityPTPRB-inactivating mutations (45%)PLCG1mutations (9%)KDRmutations (~ 6%)TP53mutations (~ 10%)Incidence less common that that observed in other types of sarcomas (~ 60-90%)",
                    "sub_points": [
                      "MYCamplification (> 90%)MYC(8q21) is a protooncogene coding for a transcription factor involved in cellular proliferation, cell growth, apoptosis, and angiogenesisRare in idiopathic AS",
                      "MYC(8q21) is a protooncogene coding for a transcription factor involved in cellular proliferation, cell growth, apoptosis, and angiogenesis",
                      "Rare in idiopathic AS",
                      "FLT4amplification (~ 20-25%)Codes for VEGF receptor 3 (VEGFR3 ) (5q35.3), which belongs to tyrosine kinase receptor familyRegulates endothelial cell growth and angiogenesisCoamplified withMYCNot reported in idiopathic ASAmplification associated with diffuse strong cytoplasmic immunoreactivity for protein in > 50% of cellsAVLs and other benign vascular lesions can occasionally show focal weak immunoreactivity",
                      "Codes for VEGF receptor 3 (VEGFR3 ) (5q35.3), which belongs to tyrosine kinase receptor familyRegulates endothelial cell growth and angiogenesis",
                      "Regulates endothelial cell growth and angiogenesis",
                      "Coamplified withMYC",
                      "Not reported in idiopathic AS",
                      "Amplification associated with diffuse strong cytoplasmic immunoreactivity for protein in > 50% of cellsAVLs and other benign vascular lesions can occasionally show focal weak immunoreactivity",
                      "AVLs and other benign vascular lesions can occasionally show focal weak immunoreactivity",
                      "PTPRB-inactivating mutations (45%)",
                      "PLCG1mutations (9%)",
                      "KDRmutations (~ 6%)",
                      "TP53mutations (~ 10%)Incidence less common that that observed in other types of sarcomas (~ 60-90%)",
                      "Incidence less common that that observed in other types of sarcomas (~ 60-90%)"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Tumors consist of abnormal blood vessels in breast stroma and may involve the dermisBlood vessels are increased in number and form complex anastomosing channelsThe number of endothelial cells is typically increased and form papillary tufts within vessel lumina",
                    "sub_points": [
                      "Blood vessels are increased in number and form complex anastomosing channels",
                      "The number of endothelial cells is typically increased and form papillary tufts within vessel lumina"
                    ]
                  },
                  {
                    "text": "Nuclei may be enlarged, hyperchromatic, and pleomorphic"
                  },
                  {
                    "text": "Frequent mitotic figures may be seen and necrosis may be present"
                  },
                  {
                    "text": "Neoplastic vessels diffusely infiltrate into normal breast tissue (including lobules) and skinPericytes are often absent but can be present as shown by SMA",
                    "sub_points": [
                      "Pericytes are often absent but can be present as shown by SMA"
                    ]
                  },
                  {
                    "text": "Blood lakes due to massive extravasation from tumor vessels are a helpful diagnostic featureThese features need to be distinguished from possible effects of prior diagnostic biopsyPapillary endothelial hyperplasia (i.e., an organizing thrombus) can be present in areas of hemorrhage",
                    "sub_points": [
                      "These features need to be distinguished from possible effects of prior diagnostic biopsy",
                      "Papillary endothelial hyperplasia (i.e., an organizing thrombus) can be present in areas of hemorrhage"
                    ]
                  },
                  {
                    "text": "Epithelioid and spindle cell patternsHave a solid growth pattern, and vasoformative areas may be focal or absentCan closely resemble poorly differentiated carcinoma or another type of sarcomaMore common in treatment-related AS when recurrent carcinoma is an important considerationA panel of markers, including both endothelial and epithelial antigens, is often needed for definitive diagnosisAS can rarely be positive for cytokeratins and epithelial membrane antigen",
                    "sub_points": [
                      "Have a solid growth pattern, and vasoformative areas may be focal or absent",
                      "Can closely resemble poorly differentiated carcinoma or another type of sarcomaMore common in treatment-related AS when recurrent carcinoma is an important consideration",
                      "More common in treatment-related AS when recurrent carcinoma is an important consideration",
                      "A panel of markers, including both endothelial and epithelial antigens, is often needed for definitive diagnosisAS can rarely be positive for cytokeratins and epithelial membrane antigen",
                      "AS can rarely be positive for cytokeratins and epithelial membrane antigen"
                    ]
                  },
                  {
                    "text": "Capillary lobule pattern of treatment-related ASRare pattern that can mimic benign dermal vascular lesionsMultiple scattered dermal nodules are composed of tightly packed, well-formed, capillary-sized vesselsThe majority also have more conventional patterns of AS, but these may only be seen at the deep aspect of the lesion",
                    "sub_points": [
                      "Rare pattern that can mimic benign dermal vascular lesions",
                      "Multiple scattered dermal nodules are composed of tightly packed, well-formed, capillary-sized vessels",
                      "The majority also have more conventional patterns of AS, but these may only be seen at the deep aspect of the lesion"
                    ]
                  },
                  {
                    "text": "Grading of ASSome studies have shown that grade has prognostic significance, but other studies have notThe College of American Pathologists does not require reporting grade for ASProtocol for the Examination of Resection Specimens From Patients With Soft Tissue Tumors version 4.1.0.0 (June 2021)Reporting grade can be useful for descriptive purposes",
                    "sub_points": [
                      "Some studies have shown that grade has prognostic significance, but other studies have not",
                      "The College of American Pathologists does not require reporting grade for ASProtocol for the Examination of Resection Specimens From Patients With Soft Tissue Tumors version 4.1.0.0 (June 2021)",
                      "Protocol for the Examination of Resection Specimens From Patients With Soft Tissue Tumors version 4.1.0.0 (June 2021)",
                      "Reporting grade can be useful for descriptive purposes"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Vascular lesions may be difficult to classify on needle biopsies"
                  },
                  {
                    "text": "Correlation with imaging findings is helpful to avoid over- and underdiagnosis of ASLarge size and ill-defined or irregular margins by imaging increase likelihood of ASPortions of AS can appear deceptively benignMajority of such lesions should be classified after complete excisionSmall size and circumscribed margins would be highly unusual for ASBenign vascular lesions and papillary endothelial hyperplasia would be more common",
                    "sub_points": [
                      "Large size and ill-defined or irregular margins by imaging increase likelihood of ASPortions of AS can appear deceptively benignMajority of such lesions should be classified after complete excision",
                      "Portions of AS can appear deceptively benign",
                      "Majority of such lesions should be classified after complete excision",
                      "Small size and circumscribed margins would be highly unusual for ASBenign vascular lesions and papillary endothelial hyperplasia would be more common",
                      "Benign vascular lesions and papillary endothelial hyperplasia would be more common"
                    ]
                  },
                  {
                    "text": "A diagnosis of AS should be made with caution unless definitive features of malignancy are seen"
                  },
                  {
                    "text": "If the histologic appearance is concordant with a benign lesion, excision may not be necessary"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Panels to distinguish carcinoma from AS should include both epithelial and endothelial markers, as some are positive in both"
                  },
                  {
                    "text": "Endothelial markersCD34: Very sensitive but also positive in fibroblastic lesions and in other types of sarcomas; may be present in carcinomaCD31: Sensitive and specific marker; rarely present in carcinoma; may be positive in macrophagesERG: Sensitive and specific markerFLI-1: Sensitive; rarely present in carcinomaD2-40 (podoplanin): Positive in ~ 50-60%Also positive in myoepithelial cells and some breast carcinomasNot a good marker for distinguishing AS from carcinomaFVIII: Very specific but may not be positive in all AS; rarely present in carcinoma",
                    "sub_points": [
                      "CD34: Very sensitive but also positive in fibroblastic lesions and in other types of sarcomas; may be present in carcinoma",
                      "CD31: Sensitive and specific marker; rarely present in carcinoma; may be positive in macrophages",
                      "ERG: Sensitive and specific marker",
                      "FLI-1: Sensitive; rarely present in carcinoma",
                      "D2-40 (podoplanin): Positive in ~ 50-60%Also positive in myoepithelial cells and some breast carcinomasNot a good marker for distinguishing AS from carcinoma",
                      "Also positive in myoepithelial cells and some breast carcinomas",
                      "Not a good marker for distinguishing AS from carcinoma",
                      "FVIII: Very specific but may not be positive in all AS; rarely present in carcinoma"
                    ]
                  },
                  {
                    "text": "Epithelial markersCytokeratinsUsually focal or weak compared with carcinomas but present in ~ 20-30%Spindle cell carcinomas may only be positive for high molecular weight keratinsp63Usually negative but can be present in subset of ASEMACan be positive in both AS and carcinoma; not very useful for this differential",
                    "sub_points": [
                      "CytokeratinsUsually focal or weak compared with carcinomas but present in ~ 20-30%Spindle cell carcinomas may only be positive for high molecular weight keratins",
                      "Usually focal or weak compared with carcinomas but present in ~ 20-30%Spindle cell carcinomas may only be positive for high molecular weight keratins",
                      "Spindle cell carcinomas may only be positive for high molecular weight keratins",
                      "p63Usually negative but can be present in subset of AS",
                      "Usually negative but can be present in subset of AS",
                      "EMACan be positive in both AS and carcinoma; not very useful for this differential",
                      "Can be positive in both AS and carcinoma; not very useful for this differential"
                    ]
                  },
                  {
                    "text": "MYC (antibody for protein produced byMYC) positive in > 90% of treatment-related ASNot present in AVL; useful for this distinctionRarely present in idiopathic ASCommonly present in carcinomas",
                    "sub_points": [
                      "Not present in AVL; useful for this distinction",
                      "Rarely present in idiopathic AS",
                      "Commonly present in carcinomas"
                    ]
                  },
                  {
                    "text": "SMACan be used to identify abnormal vessels lacking SMA(+) pericytesHowever, SMA is positive in ~ 30% of AS",
                    "sub_points": [
                      "Can be used to identify abnormal vessels lacking SMA(+) pericytes",
                      "However, SMA is positive in ~ 30% of AS"
                    ]
                  }
                ],
                "In Situ Hybridization": [
                  {
                    "text": "MYCamplification can be helpful to distinguish AVL from treatment-related ASISH results for amplification are highly correlated with protein expression detected by IHC",
                    "sub_points": [
                      "ISH results for amplification are highly correlated with protein expression detected by IHC"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Atypical Vascular Lesion": [
                  {
                    "text": "Occur in skin after therapeutic radiation exposure"
                  },
                  {
                    "text": "Usually present clinically as small, often multiple, flesh-colored raised papules, fluid-filled vesicles, or erythematous plaques or nodules"
                  },
                  {
                    "text": "Ectatic thin-walled vessels form circumscribed (sometimes wedge-shaped) lesions confined to dermisVery focal extension into subcutaneous adipose tissue may be presentPlump nuclei with protrusion into lumina (hobnail appearance) may be present",
                    "sub_points": [
                      "Very focal extension into subcutaneous adipose tissue may be present",
                      "Plump nuclei with protrusion into lumina (hobnail appearance) may be present"
                    ]
                  },
                  {
                    "text": "LacksMYCamplification and protein overexpressionHowever, ~ 10% of AS are also negative for MYC",
                    "sub_points": [
                      "However, ~ 10% of AS are also negative for MYC"
                    ]
                  },
                  {
                    "text": "Complete excision is generally recommended for diagnosis and treatment"
                  },
                  {
                    "text": "In rare cases, may progress to AS"
                  }
                ],
                "Papillary Endothelial Hyperplasia (Masson Lesion or Tumor)": [
                  {
                    "text": "This is the most common benign lesion that is mistaken for breast AS59% of cases sent to the Armed Forces Institute of Pathology for consultation had a working diagnosis of AS",
                    "sub_points": [
                      "59% of cases sent to the Armed Forces Institute of Pathology for consultation had a working diagnosis of AS"
                    ]
                  },
                  {
                    "text": "Changes seen in an organizing thrombus can closely resemble the irregular anastomosing vessels of AS"
                  },
                  {
                    "text": "May be history of prior trauma or surgery"
                  },
                  {
                    "text": "Majority of lesions are much smaller than 2 cm in size and have circumscribed bordersLarger (> 2-cm) lesions can occur in surgical sitesLarge cases occurring in males and females have been misinterpreted as AS",
                    "sub_points": [
                      "Larger (> 2-cm) lesions can occur in surgical sites",
                      "Large cases occurring in males and females have been misinterpreted as AS"
                    ]
                  },
                  {
                    "text": "Areas of hemorrhage without ingrowth of endothelial cells or fibroblasts can be mistaken for a blood lake"
                  },
                  {
                    "text": "The pseudovascular spaces do not infiltrate into areas of normal stroma and around epitheliumIf a vascular lesion on core needle biopsy does not have an infiltrative pattern into breast tissue, papillary endothelial hyperplasia should be considered",
                    "sub_points": [
                      "If a vascular lesion on core needle biopsy does not have an infiltrative pattern into breast tissue, papillary endothelial hyperplasia should be considered"
                    ]
                  }
                ],
                "Hemangioma": [
                  {
                    "text": "Benign proliferations of blood vessels; most < 2 cm in sizeSmall (perilobular or capillary) hemangiomas are almost always small incidental findings (0.1-0.2 cm)Larger (cavernous or venous) hemangiomas may be palpable or present as mass on imagingVessels of different sizes, may have supporting cells",
                    "sub_points": [
                      "Small (perilobular or capillary) hemangiomas are almost always small incidental findings (0.1-0.2 cm)",
                      "Larger (cavernous or venous) hemangiomas may be palpable or present as mass on imagingVessels of different sizes, may have supporting cells",
                      "Vessels of different sizes, may have supporting cells"
                    ]
                  },
                  {
                    "text": "Borders are circumscribed or lobulated, but some vessels may extend into adjacent stroma"
                  },
                  {
                    "text": "Blood vessels are round in shape and lined by flattened endothelial cells, surrounded by supporting cells that express SMANo or minimal nuclear pleomorphism; mitoses are absent",
                    "sub_points": [
                      "No or minimal nuclear pleomorphism; mitoses are absent"
                    ]
                  },
                  {
                    "text": "Rare anastomosing hemangiomas consist of irregular interconnecting vesselsAlthough focal infiltration into breast tissue may be seen, the borders are predominantly circumscribed",
                    "sub_points": [
                      "Although focal infiltration into breast tissue may be seen, the borders are predominantly circumscribed"
                    ]
                  }
                ],
                "Pseudoangiomatous Stromal Hyperplasia": [
                  {
                    "text": "Presents as a palpable mass or radiologic density"
                  },
                  {
                    "text": "The proliferation of myofibroblasts with stromal clefting can mimic anastomosing blood vesselsThe spaces are empty without red blood cells, and hemorrhage is not present",
                    "sub_points": [
                      "The spaces are empty without red blood cells, and hemorrhage is not present"
                    ]
                  },
                  {
                    "text": "Stromal clefting can dissect into lobules, simulating invasive pattern of AS"
                  },
                  {
                    "text": "Nuclear pleomorphism, mitoses, and solid areas (or tufting) are absent"
                  }
                ],
                "Angiolipoma": [
                  {
                    "text": "Lesions are well circumscribed and usually small (< 2 cm)"
                  },
                  {
                    "text": "Benign lesions composed of adipose tissue and small, round, capillary-sized blood vesselsBlood vessels may have fibrin thrombi",
                    "sub_points": [
                      "Blood vessels may have fibrin thrombi"
                    ]
                  },
                  {
                    "text": "Cellular pleomorphism and mitoses are absent"
                  }
                ],
                "Diffuse Dermal Angiomatosis of the Breast": [
                  {
                    "text": "Most often occurs in women with pendulous breasts and a smoking historyUsually also have other diseases that can cause occlusive vasculopathy",
                    "sub_points": [
                      "Usually also have other diseases that can cause occlusive vasculopathy"
                    ]
                  },
                  {
                    "text": "Large erythematous to violaceous plaques of the skin can ulcerate and bleed"
                  },
                  {
                    "text": "Small capillary-sized vessels and clusters of endothelial cells are scattered in the reticular dermis"
                  },
                  {
                    "text": "Treatment modalities, such as reduction mammoplasty, smoking cessation, and treatment of underlying diseases, attempt to alleviate the hypoxic stimulus"
                  }
                ],
                "Poorly Differentiated Carcinoma": [
                  {
                    "text": "Women with history of breast cancer and radiation therapy are at risk for both recurrent carcinoma and treatment-related AS"
                  },
                  {
                    "text": "Poorly differentiated carcinoma and AS can be similar in histologic appearanceBoth can have spindled and epithelioid morphology",
                    "sub_points": [
                      "Both can have spindled and epithelioid morphology"
                    ]
                  },
                  {
                    "text": "Some carcinomas have a pseudovascular pattern"
                  },
                  {
                    "text": "IHC for both epithelial and endothelial markers may be necessary for diagnosis"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "AS should be suspected for any large vascular lesion"
                  },
                  {
                    "text": "Overdiagnosis can be avoided by recognizing common mimics"
                  },
                  {
                    "text": "Underdiagnosis can be avoided by excision after core needle biopsy of large lesions"
                  },
                  {
                    "text": "IHC panels must include multiple markers for endothelial and epithelial cells due to overlapping expression patterns"
                  }
                ]
              },
              "REPORTING": {
                "Synoptic Reporting": [
                  {
                    "text": "AS of the breast is reported using the College of American Pathologists Protocol for the Examination of Resection Specimens From Patients With Soft Tissue Tumors"
                  }
                ],
                "American Joint Committee on Cancer Classification": [
                  {
                    "text": "AS of the breast is classified using the AJCC (8th edition) staging system for soft tissue sarcomas of the trunk and extremities"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Sarcomas": {
            "name": "Sarcomas",
            "url": "https://app.pathprimer.com/document/7a415887-dccd-41d8-b539-c7acb7b4bcbb/lesson/9c7d1671-ed3c-4107-86fa-3633f8c9f256",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Malignant mesenchymal neoplasms derived from connective tissue elements of breast"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Mammary sarcoma can be primary, secondary to prior treatment for carcinoma, or metastatic from another site"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Primary sarcomas are exceedingly rare"
                  },
                  {
                    "text": "Most present as large palpable mass"
                  },
                  {
                    "text": "Prognosis depends on histologic type of tumor, grade, and stage at presentationMay show aggressive behavior with recurrenceMetastases to lymph nodes are rareMetastases to lungs, bone marrow, and liver most commonTumor size, grade, and negative margins are significantly associated with survival",
                    "sub_points": [
                      "May show aggressive behavior with recurrence",
                      "Metastases to lymph nodes are rare",
                      "Metastases to lungs, bone marrow, and liver most common",
                      "Tumor size, grade, and negative margins are significantly associated with survival"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Virtually any type of sarcoma described elsewhere may occur rarely as a primary lesion in breastAngiosarcoma, liposarcoma, leiomyosarcoma, osteosarcoma, and others",
                    "sub_points": [
                      "Angiosarcoma, liposarcoma, leiomyosarcoma, osteosarcoma, and others"
                    ]
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "Lineage-specific IHC markers helpful to identify specific type of sarcoma"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Metaplastic carcinoma"
                  },
                  {
                    "text": "Phyllodes tumor"
                  },
                  {
                    "text": "Fibromatosis"
                  },
                  {
                    "text": "Nodular fasciitis"
                  },
                  {
                    "text": "Myofibroblastoma"
                  },
                  {
                    "text": "Dermatofibrosarcoma protuberans"
                  },
                  {
                    "text": "Papillary endothelial hyperplasia"
                  },
                  {
                    "text": "Reactive spindle cell nodule at core needle biopsy site"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Malignant mesenchymal neoplasm derived from connective tissue elements of breast"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "Sarcomas of the breast are very rareMalignant neoplasms with a sarcomatous appearance or component are more likely to be carcinomas or a heterologous component of a phyllodes tumor",
                    "sub_points": [
                      "Malignant neoplasms with a sarcomatous appearance or component are more likely to be carcinomas or a heterologous component of a phyllodes tumor"
                    ]
                  },
                  {
                    "text": "Sarcomas can arise associated with a germline mutation, secondary to prior treatment for carcinoma, be metastatic to the breast, or have an unknown cause"
                  },
                  {
                    "text": "The etiology of most soft tissue sarcomas remains unknownThere are 2 classes of genetic alterations in sarcomasSimple-karyotype sarcomas associated with a recurrent mutation or translocationComplex-karyotype sarcomas with numerous chromosomal alterations",
                    "sub_points": [
                      "There are 2 classes of genetic alterations in sarcomasSimple-karyotype sarcomas associated with a recurrent mutation or translocationComplex-karyotype sarcomas with numerous chromosomal alterations",
                      "Simple-karyotype sarcomas associated with a recurrent mutation or translocation",
                      "Complex-karyotype sarcomas with numerous chromosomal alterations"
                    ]
                  },
                  {
                    "text": "Germline mutationsSome mutations increase the risk for breast sarcomasLi-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis type 1",
                    "sub_points": [
                      "Some mutations increase the risk for breast sarcomasLi-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis type 1",
                      "Li-Fraumeni syndrome, familial adenomatous polyposis, neurofibromatosis type 1"
                    ]
                  },
                  {
                    "text": "Radiation therapy55% of radiation-associated sarcomas overall occur in the breast after the treatment of cancer2/3 are angiosarcomas (ASs) that arise predominantly in the skin of the breast1/3 are of other types; the majority being undifferentiated pleomorphic spindle cell sarcomaGenerally occur in an older age group0.03-0.80% incidence with long-term follow-up (15 years)Criteria for defining postradiation sarcoma have been developedHistologic confirmation of sarcomaPrior history of radiation therapyLatency period after treatment of 5-6 years (range 2 to > 10 years) for breast sarcomas (median for other sites is 10 years)Sarcoma develops in previously radiated fieldMantle radiation for Hodgkin disease in young women increases the risk for breast carcinomas but has not been associated with sarcomas",
                    "sub_points": [
                      "55% of radiation-associated sarcomas overall occur in the breast after the treatment of cancer2/3 are angiosarcomas (ASs) that arise predominantly in the skin of the breast1/3 are of other types; the majority being undifferentiated pleomorphic spindle cell sarcomaGenerally occur in an older age group0.03-0.80% incidence with long-term follow-up (15 years)",
                      "2/3 are angiosarcomas (ASs) that arise predominantly in the skin of the breast",
                      "1/3 are of other types; the majority being undifferentiated pleomorphic spindle cell sarcoma",
                      "Generally occur in an older age group",
                      "0.03-0.80% incidence with long-term follow-up (15 years)",
                      "Criteria for defining postradiation sarcoma have been developedHistologic confirmation of sarcomaPrior history of radiation therapyLatency period after treatment of 5-6 years (range 2 to > 10 years) for breast sarcomas (median for other sites is 10 years)Sarcoma develops in previously radiated field",
                      "Histologic confirmation of sarcoma",
                      "Prior history of radiation therapyLatency period after treatment of 5-6 years (range 2 to > 10 years) for breast sarcomas (median for other sites is 10 years)Sarcoma develops in previously radiated field",
                      "Latency period after treatment of 5-6 years (range 2 to > 10 years) for breast sarcomas (median for other sites is 10 years)",
                      "Sarcoma develops in previously radiated field",
                      "Mantle radiation for Hodgkin disease in young women increases the risk for breast carcinomas but has not been associated with sarcomas"
                    ]
                  },
                  {
                    "text": "Chronic lymphedemaHistorically, complete lymph node dissection of the axilla sometimes resulted in edema of the breast and armStewart-Treves syndrome is AS resulting in the ipsilateral edematous arm or breast after surgery for breast carcinomaSome posttreatment ASs arising in the breast are likely related to edemaWith better surgical techniques and limited sampling of the axilla, the number of patients developing edema has diminished",
                    "sub_points": [
                      "Historically, complete lymph node dissection of the axilla sometimes resulted in edema of the breast and armStewart-Treves syndrome is AS resulting in the ipsilateral edematous arm or breast after surgery for breast carcinomaSome posttreatment ASs arising in the breast are likely related to edema",
                      "Stewart-Treves syndrome is AS resulting in the ipsilateral edematous arm or breast after surgery for breast carcinoma",
                      "Some posttreatment ASs arising in the breast are likely related to edema",
                      "With better surgical techniques and limited sampling of the axilla, the number of patients developing edema has diminished"
                    ]
                  },
                  {
                    "text": "Environmental exposuresSome compounds have been suggested, but not proven, as possible risk factors for breast sarcomaExposure to arsenic compounds, vinyl chloride, and alkylatorsTextured breast implants increase the risk of anaplastic large cell lymphomas but not sarcomas",
                    "sub_points": [
                      "Some compounds have been suggested, but not proven, as possible risk factors for breast sarcomaExposure to arsenic compounds, vinyl chloride, and alkylators",
                      "Exposure to arsenic compounds, vinyl chloride, and alkylators",
                      "Textured breast implants increase the risk of anaplastic large cell lymphomas but not sarcomas"
                    ]
                  },
                  {
                    "text": "No identified risk factor (idiopathic or de novo)Tend to occur in younger age groupMost common: AS followed by liposarcoma",
                    "sub_points": [
                      "Tend to occur in younger age group",
                      "Most common: AS followed by liposarcoma"
                    ]
                  },
                  {
                    "text": "MetastaticVery rare: Usually known history of sarcoma elsewhereSome types of sarcoma are more likely to be metastases than primary sarcomas of the breastRhabdomyosarcoma (10-40% of young females develop a breast metastasis), synovial sarcoma, alveolar soft part sarcoma, others",
                    "sub_points": [
                      "Very rare: Usually known history of sarcoma elsewhere",
                      "Some types of sarcoma are more likely to be metastases than primary sarcomas of the breastRhabdomyosarcoma (10-40% of young females develop a breast metastasis), synovial sarcoma, alveolar soft part sarcoma, others",
                      "Rhabdomyosarcoma (10-40% of young females develop a breast metastasis), synovial sarcoma, alveolar soft part sarcoma, others"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Sarcomas: < 0.1% of breast malignanciesPrimary sarcomas are exceedingly rareAnnual incidence of breast sarcomas: 4.6 cases per 1 million women",
                    "sub_points": [
                      "Primary sarcomas are exceedingly rare",
                      "Annual incidence of breast sarcomas: 4.6 cases per 1 million women"
                    ]
                  },
                  {
                    "text": "Primary breast sarcomas: < 5% of all soft tissue sarcomas"
                  },
                  {
                    "text": "Radiation-induced breast sarcomas: ~ 0.2% of patients with breast carcinoma treated with radiation"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Sarcomas arising in breast usually present as a palpable massOften rapidly enlarging",
                    "sub_points": [
                      "Often rapidly enlarging"
                    ]
                  },
                  {
                    "text": "Postradiation ASs present as violaceous skin lesionsOften preceded by atypical vascular lesions of the skin in the radiation field",
                    "sub_points": [
                      "Often preceded by atypical vascular lesions of the skin in the radiation field"
                    ]
                  }
                ],
                "Natural History": [
                  {
                    "text": "Based on histologic type of tumor, grade, and stage"
                  },
                  {
                    "text": "May show aggressive behavior with high likelihood for local/systemic recurrenceHematogenous disseminationMetastases to lungs, bone marrow, and liverMetastases to axillary lymph nodes are very rare",
                    "sub_points": [
                      "Hematogenous disseminationMetastases to lungs, bone marrow, and liverMetastases to axillary lymph nodes are very rare",
                      "Metastases to lungs, bone marrow, and liver",
                      "Metastases to axillary lymph nodes are very rare"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Surgical excision with clean marginsTotal mastectomy is most commonSmaller lesions may be treated with breast conservation",
                    "sub_points": [
                      "Total mastectomy is most common",
                      "Smaller lesions may be treated with breast conservation"
                    ]
                  },
                  {
                    "text": "Axillary dissection is not indicated, given rarity of lymph node involvement"
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Role of adjuvant chemotherapy &/or radiation therapy is unclear"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Primary mammary sarcomas have a prognosis similar to that of their soft tissue counterpartsBased on histologic type, grade, and stage of tumor",
                    "sub_points": [
                      "Based on histologic type, grade, and stage of tumor"
                    ]
                  },
                  {
                    "text": "Tumor size is significantly associated with overall survival (risk ratio: 1.3 per 1.0 cm increase)"
                  },
                  {
                    "text": "Tumor grade is prognostically significant in some studies"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Lobulated or ill-defined mass"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Circumscribed or mass with angulated marginsUltrasound is generally better for delineating size",
                    "sub_points": [
                      "Ultrasound is generally better for delineating size"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "Size": [
                  {
                    "text": "Superficial lesions tend to be smaller than those located deep in breastLarger lesions may show areas of hemorrhage and necrosis",
                    "sub_points": [
                      "Larger lesions may show areas of hemorrhage and necrosis"
                    ]
                  },
                  {
                    "text": "Most common: 3-5 cm (range: 1-20 cm)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Almost every type of sarcoma described elsewhere has occurred rarely as a primary lesion in the breast"
                  },
                  {
                    "text": "Angiosarcoma (AS)AS is the most common type of breast sarcoma (~ 40% of breast sarcomas)~ 1/2 are primary (idiopathic), and ~ 1/2 are secondary (treatment related)Both radiation and edema are risk factorsClinicopathologic features of the 2 types are differentPrimary AS occurs in younger patients; often presents as a mass lesion within the breastRadiation-associated AS occurs in older patients; almost always presents as tumor-related changes in previously irradiated skinPrimary AS of the breast is very uncommon in menLarge lesions (> 2 cm) of papillary endothelial hyperplasia (PEH) have been mistaken for ASGross lesions are ill-defined, hemorrhagic, firm massesThere is a wide range of appearancesDeceptively bland-appearing, well-formed vascular spaces but with complex anastomosing architectureSolid masses of spindle cellsSolid masses of epithelioid cellsThese ASs may be difficult to distinguish from recurrent carcinomaMust be distinguished from benign vascular or pseudovascular tumorsAtypical vascular lesions of skin after radiation treatmentHemangiomasPEHAngiolipomasPseudoangiomatous stroma hyperplasia (PASH)",
                    "sub_points": [
                      "AS is the most common type of breast sarcoma (~ 40% of breast sarcomas)~ 1/2 are primary (idiopathic), and ~ 1/2 are secondary (treatment related)Both radiation and edema are risk factorsClinicopathologic features of the 2 types are differentPrimary AS occurs in younger patients; often presents as a mass lesion within the breastRadiation-associated AS occurs in older patients; almost always presents as tumor-related changes in previously irradiated skin",
                      "~ 1/2 are primary (idiopathic), and ~ 1/2 are secondary (treatment related)Both radiation and edema are risk factors",
                      "Both radiation and edema are risk factors",
                      "Clinicopathologic features of the 2 types are differentPrimary AS occurs in younger patients; often presents as a mass lesion within the breastRadiation-associated AS occurs in older patients; almost always presents as tumor-related changes in previously irradiated skin",
                      "Primary AS occurs in younger patients; often presents as a mass lesion within the breast",
                      "Radiation-associated AS occurs in older patients; almost always presents as tumor-related changes in previously irradiated skin",
                      "Primary AS of the breast is very uncommon in menLarge lesions (> 2 cm) of papillary endothelial hyperplasia (PEH) have been mistaken for AS",
                      "Large lesions (> 2 cm) of papillary endothelial hyperplasia (PEH) have been mistaken for AS",
                      "Gross lesions are ill-defined, hemorrhagic, firm masses",
                      "There is a wide range of appearancesDeceptively bland-appearing, well-formed vascular spaces but with complex anastomosing architectureSolid masses of spindle cellsSolid masses of epithelioid cellsThese ASs may be difficult to distinguish from recurrent carcinoma",
                      "Deceptively bland-appearing, well-formed vascular spaces but with complex anastomosing architecture",
                      "Solid masses of spindle cells",
                      "Solid masses of epithelioid cellsThese ASs may be difficult to distinguish from recurrent carcinoma",
                      "These ASs may be difficult to distinguish from recurrent carcinoma",
                      "Must be distinguished from benign vascular or pseudovascular tumorsAtypical vascular lesions of skin after radiation treatmentHemangiomasPEHAngiolipomasPseudoangiomatous stroma hyperplasia (PASH)",
                      "Atypical vascular lesions of skin after radiation treatment",
                      "Hemangiomas",
                      "PEH",
                      "Angiolipomas",
                      "Pseudoangiomatous stroma hyperplasia (PASH)"
                    ]
                  },
                  {
                    "text": "LiposarcomaPrimary liposarcomas compose ~ 10% of breast sarcomasWell-differentiated liposarcoma: ~ 50%Pleomorphic liposarcoma: ~ 25%Myxoid liposarcoma: ~ 25%Dedifferentiated liposarcoma: < 10%Morphologic findings are similar to liposarcoma arising in other sitesTumor cells include lipoblasts and other atypical-appearing adipocytic cells with enlarged hyperchromatic nucleiLiposarcomatous heterologous differentiation in phyllodes tumor is more common than primary sarcomasThe majority are well-differentiated liposarcomaThese tumors lack the characteristicMDM2andCDK4amplification and, therefore, have a different biologic basisDiagnosis of primary liposarcoma of breast is one of exclusionMust be distinguished from lipomas",
                    "sub_points": [
                      "Primary liposarcomas compose ~ 10% of breast sarcomasWell-differentiated liposarcoma: ~ 50%Pleomorphic liposarcoma: ~ 25%Myxoid liposarcoma: ~ 25%Dedifferentiated liposarcoma: < 10%",
                      "Well-differentiated liposarcoma: ~ 50%",
                      "Pleomorphic liposarcoma: ~ 25%",
                      "Myxoid liposarcoma: ~ 25%",
                      "Dedifferentiated liposarcoma: < 10%",
                      "Morphologic findings are similar to liposarcoma arising in other sitesTumor cells include lipoblasts and other atypical-appearing adipocytic cells with enlarged hyperchromatic nuclei",
                      "Tumor cells include lipoblasts and other atypical-appearing adipocytic cells with enlarged hyperchromatic nuclei",
                      "Liposarcomatous heterologous differentiation in phyllodes tumor is more common than primary sarcomasThe majority are well-differentiated liposarcomaThese tumors lack the characteristicMDM2andCDK4amplification and, therefore, have a different biologic basisDiagnosis of primary liposarcoma of breast is one of exclusion",
                      "The majority are well-differentiated liposarcomaThese tumors lack the characteristicMDM2andCDK4amplification and, therefore, have a different biologic basis",
                      "These tumors lack the characteristicMDM2andCDK4amplification and, therefore, have a different biologic basis",
                      "Diagnosis of primary liposarcoma of breast is one of exclusion",
                      "Must be distinguished from lipomas"
                    ]
                  },
                  {
                    "text": "LeiomyosarcomaComposes ~ 10% of breast sarcomasMay arise from smooth muscle of nipple-areolar complex or in breast parenchymaLeiomyomas can also arise in the nipple or in breast parenchymaMorphologic and immunohistochemical findings are similar to leiomyosarcoma arising in other sitesIntersecting bundles of spindle cells with eosinophilic cytoplasmElongated nuclei with blunt ends and varying degrees of pleomorphism and mitotic activityMust be distinguished from tumors of myofibroblasts, such as myofibroblastoma and PASH",
                    "sub_points": [
                      "Composes ~ 10% of breast sarcomas",
                      "May arise from smooth muscle of nipple-areolar complex or in breast parenchymaLeiomyomas can also arise in the nipple or in breast parenchyma",
                      "Leiomyomas can also arise in the nipple or in breast parenchyma",
                      "Morphologic and immunohistochemical findings are similar to leiomyosarcoma arising in other sitesIntersecting bundles of spindle cells with eosinophilic cytoplasmElongated nuclei with blunt ends and varying degrees of pleomorphism and mitotic activity",
                      "Intersecting bundles of spindle cells with eosinophilic cytoplasm",
                      "Elongated nuclei with blunt ends and varying degrees of pleomorphism and mitotic activity",
                      "Must be distinguished from tumors of myofibroblasts, such as myofibroblastoma and PASH"
                    ]
                  },
                  {
                    "text": "Osteosarcoma (OS)Composes < 10% of breast sarcomasAll histologic variants, including fibroblastic, osteoblastic, chondroblastic, and telangiectatic, have been reportedHigh-grade, mitotically active tumors tend to have worse outcomeExtraskeletal OS of breast is a diagnosis of exclusionOsteogenic differentiation in metaplastic carcinoma and phyllodes tumor more common than primary OSExtensive sampling of lesion is helpful to detect other componentsCircumscribed margins and extensive calcification can be mistaken for a benign lesion by imagingMust be distinguished from heterotopic bone formation associated with inflammatory lesions",
                    "sub_points": [
                      "Composes < 10% of breast sarcomasAll histologic variants, including fibroblastic, osteoblastic, chondroblastic, and telangiectatic, have been reportedHigh-grade, mitotically active tumors tend to have worse outcome",
                      "All histologic variants, including fibroblastic, osteoblastic, chondroblastic, and telangiectatic, have been reported",
                      "High-grade, mitotically active tumors tend to have worse outcome",
                      "Extraskeletal OS of breast is a diagnosis of exclusionOsteogenic differentiation in metaplastic carcinoma and phyllodes tumor more common than primary OSExtensive sampling of lesion is helpful to detect other components",
                      "Osteogenic differentiation in metaplastic carcinoma and phyllodes tumor more common than primary OS",
                      "Extensive sampling of lesion is helpful to detect other components",
                      "Circumscribed margins and extensive calcification can be mistaken for a benign lesion by imaging",
                      "Must be distinguished from heterotopic bone formation associated with inflammatory lesions"
                    ]
                  },
                  {
                    "text": "Pleomorphic spindle cell sarcomaComposes < 10% of breast sarcomasSome tumors in this category have been classified as fibrosarcomas or malignant fibrous histiocytomasMalignant spindle cell proliferation arranged in herringbone or storiform patternsTumors tend to be high grade with frequent mitotic activity and areas of necrosisMay arise at site of prior breast radiationImportant to exclude metaplastic carcinoma and malignant phyllodes tumorThese are much more common than sarcomasFor carcinomas, multiple keratins should be used (including high molecular weight keratins) and p63For phyllodes tumors, extensive sampling may be necessary to identify the benign epithelial componentImportant to exclude benign stromal breast lesions, particularly nodular fasciitis, which can have a high number of mitoses and grow rapidlyDiagnosis of sarcoma without definite evidence of mesenchymal differentiation (e.g., vascular, adipocytic, muscle) should be made with extreme caution",
                    "sub_points": [
                      "Composes < 10% of breast sarcomas",
                      "Some tumors in this category have been classified as fibrosarcomas or malignant fibrous histiocytomasMalignant spindle cell proliferation arranged in herringbone or storiform patternsTumors tend to be high grade with frequent mitotic activity and areas of necrosisMay arise at site of prior breast radiation",
                      "Malignant spindle cell proliferation arranged in herringbone or storiform patterns",
                      "Tumors tend to be high grade with frequent mitotic activity and areas of necrosis",
                      "May arise at site of prior breast radiation",
                      "Important to exclude metaplastic carcinoma and malignant phyllodes tumorThese are much more common than sarcomasFor carcinomas, multiple keratins should be used (including high molecular weight keratins) and p63For phyllodes tumors, extensive sampling may be necessary to identify the benign epithelial component",
                      "These are much more common than sarcomas",
                      "For carcinomas, multiple keratins should be used (including high molecular weight keratins) and p63",
                      "For phyllodes tumors, extensive sampling may be necessary to identify the benign epithelial component",
                      "Important to exclude benign stromal breast lesions, particularly nodular fasciitis, which can have a high number of mitoses and grow rapidly",
                      "Diagnosis of sarcoma without definite evidence of mesenchymal differentiation (e.g., vascular, adipocytic, muscle) should be made with extreme caution"
                    ]
                  },
                  {
                    "text": "Malignant peripheral nerve sheath tumor (MPNST)Composes < 5% of breast sarcomas~ 16 cases reported in the breast25% associated with neurofibromatosisMust be distinguished from neurofibromas and traumatic neuromas",
                    "sub_points": [
                      "Composes < 5% of breast sarcomas~ 16 cases reported in the breast25% associated with neurofibromatosis",
                      "~ 16 cases reported in the breast",
                      "25% associated with neurofibromatosis",
                      "Must be distinguished from neurofibromas and traumatic neuromas"
                    ]
                  },
                  {
                    "text": "Sarcomas in adolescents and childrenRarely, rhabdomyosarcomas and synovial sarcomas can involve breast in younger patientsMay be primary or metastatic from another site~ 30% are primary rhabdomyosarcomas, and ~ 70% are metastases to the breast~ 50% of breast synovial sarcomas are primary, and ~ 50% are metastasesClinical evaluation and staging studies are helpful",
                    "sub_points": [
                      "Rarely, rhabdomyosarcomas and synovial sarcomas can involve breast in younger patients",
                      "May be primary or metastatic from another site~ 30% are primary rhabdomyosarcomas, and ~ 70% are metastases to the breast~ 50% of breast synovial sarcomas are primary, and ~ 50% are metastases",
                      "~ 30% are primary rhabdomyosarcomas, and ~ 70% are metastases to the breast",
                      "~ 50% of breast synovial sarcomas are primary, and ~ 50% are metastases",
                      "Clinical evaluation and staging studies are helpful"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "All malignant spindle cell lesions will undergo excision"
                  },
                  {
                    "text": "Carcinomas are important to identify, as nodal sampling would also be performed, &/or neoadjuvant chemotherapy may be used"
                  },
                  {
                    "text": "The specific type of sarcoma may not be possible to determine on core needle biopsyIn addition, it is not possible to exclude a phyllodes tumor until the entire lesion is evaluated",
                    "sub_points": [
                      "In addition, it is not possible to exclude a phyllodes tumor until the entire lesion is evaluated"
                    ]
                  },
                  {
                    "text": "If a vascular lesion is present but does not infiltrate around breast epithelium, a diagnosis of AS should be made with cautionPEH can closely mimic AS in limited sampling",
                    "sub_points": [
                      "PEH can closely mimic AS in limited sampling"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Lineage-specific markersHelpful to identify specific types of sarcomaAS: Vascular markers (ERG, FLI-1, others)D2-40 (podoplanin) can be positive in both AS and triple negative breast carcinomaLeiomyosarcoma: Smooth muscle markers (smooth muscle actin, desmin, caldesmon)Rhabdomyosarcoma: Skeletal muscle markers (desmin, myogenin, myoglobin)",
                    "sub_points": [
                      "Helpful to identify specific types of sarcomaAS: Vascular markers (ERG, FLI-1, others)D2-40 (podoplanin) can be positive in both AS and triple negative breast carcinomaLeiomyosarcoma: Smooth muscle markers (smooth muscle actin, desmin, caldesmon)Rhabdomyosarcoma: Skeletal muscle markers (desmin, myogenin, myoglobin)",
                      "AS: Vascular markers (ERG, FLI-1, others)D2-40 (podoplanin) can be positive in both AS and triple negative breast carcinoma",
                      "D2-40 (podoplanin) can be positive in both AS and triple negative breast carcinoma",
                      "Leiomyosarcoma: Smooth muscle markers (smooth muscle actin, desmin, caldesmon)",
                      "Rhabdomyosarcoma: Skeletal muscle markers (desmin, myogenin, myoglobin)"
                    ]
                  },
                  {
                    "text": "Markers to exclude carcinomaKeratins: Panel must include a wide variety of keratins, including high molecular weight keratinsMany spindle cell carcinomas are only positive for high molecular weight keratinsSome sarcomas can show positivity for keratin (e.g., synovial sarcoma, leiomyosarcoma)20-30% of ASs are positive for keratinOther sarcomas can show weak &/or focal positivityp63: Positive in ~ 1/3 of spindle cell breast carcinomasAlso positive in a small number of sarcomas",
                    "sub_points": [
                      "Keratins: Panel must include a wide variety of keratins, including high molecular weight keratinsMany spindle cell carcinomas are only positive for high molecular weight keratinsSome sarcomas can show positivity for keratin (e.g., synovial sarcoma, leiomyosarcoma)20-30% of ASs are positive for keratinOther sarcomas can show weak &/or focal positivity",
                      "Many spindle cell carcinomas are only positive for high molecular weight keratins",
                      "Some sarcomas can show positivity for keratin (e.g., synovial sarcoma, leiomyosarcoma)20-30% of ASs are positive for keratinOther sarcomas can show weak &/or focal positivity",
                      "20-30% of ASs are positive for keratin",
                      "Other sarcomas can show weak &/or focal positivity",
                      "p63: Positive in ~ 1/3 of spindle cell breast carcinomasAlso positive in a small number of sarcomas",
                      "Also positive in a small number of sarcomas"
                    ]
                  },
                  {
                    "text": "Vimentin: Positive but not specificAlso positive in many carcinomas and other tumorsAlmost never helpful in determining tumor type",
                    "sub_points": [
                      "Also positive in many carcinomas and other tumors",
                      "Almost never helpful in determining tumor type"
                    ]
                  },
                  {
                    "text": "TRPS1: Can be positive in carcinoma, sarcoma, and phyllodes tumor and is not helpful in this setting"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Cytogenetic analysis may be helpful in cases of suspected primary mammary sarcomaMany sarcomas have characteristic genetic changes",
                    "sub_points": [
                      "Many sarcomas have characteristic genetic changes"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Metaplastic Carcinoma": [
                  {
                    "text": "Subsets of these carcinomas show features characteristic of myoepithelial cellsSpindle cell morphology ± squamous differentiationMatrix (basement membrane) formation",
                    "sub_points": [
                      "Spindle cell morphology ± squamous differentiation",
                      "Matrix (basement membrane) formation"
                    ]
                  },
                  {
                    "text": "These features can mimic sarcomasPure spindle cell tumors can appear similar to sarcomaMatrix can resemble cartilage or osteoidTrue heterologous mesenchymal differentiation is very unusual",
                    "sub_points": [
                      "Pure spindle cell tumors can appear similar to sarcoma",
                      "Matrix can resemble cartilage or osteoid",
                      "True heterologous mesenchymal differentiation is very unusual"
                    ]
                  },
                  {
                    "text": "Use of term \"sarcomatoid carcinoma\" can create confusion with true sarcomas"
                  },
                  {
                    "text": "Extensive sampling to detect areas of epithelial differentiation &/or ductal carcinoma in situ can help exclude sarcomaA panel of immunostains for cytokeratin (particularly high molecular weight) and p63 are helpful to confirm diagnosis",
                    "sub_points": [
                      "A panel of immunostains for cytokeratin (particularly high molecular weight) and p63 are helpful to confirm diagnosis"
                    ]
                  },
                  {
                    "text": "Carcinomas are important to distinguish from sarcomasNodes are evaluated for carcinomasRadiation treatment and systemic chemotherapy are generally providedNeoadjuvant therapy can be considered after diagnosis on core needle biopsy",
                    "sub_points": [
                      "Nodes are evaluated for carcinomas",
                      "Radiation treatment and systemic chemotherapy are generally provided",
                      "Neoadjuvant therapy can be considered after diagnosis on core needle biopsy"
                    ]
                  }
                ],
                "Phyllodes Tumor With Heterologous Elements": [
                  {
                    "text": "High-grade phyllodes tumors can have areas of heterologous differentiationLiposarcoma, rhabdomyosarcoma, and OSMay be extensive or very focal",
                    "sub_points": [
                      "Liposarcoma, rhabdomyosarcoma, and OS",
                      "May be extensive or very focal"
                    ]
                  },
                  {
                    "text": "The most common heterologous element is well-differentiated liposarcomasThese tumors lack the characteristicMDM2andCDK4amplification and, therefore, have a different biologic basisAreas of liposarcoma may be mistaken for invasion of the phyllodes tumor into adipose tissue",
                    "sub_points": [
                      "These tumors lack the characteristicMDM2andCDK4amplification and, therefore, have a different biologic basis",
                      "Areas of liposarcoma may be mistaken for invasion of the phyllodes tumor into adipose tissue"
                    ]
                  },
                  {
                    "text": "\"Periductal stromal sarcoma\" is a subtype of phyllodes tumor in which tumor cells cuff ductal spaces that are distributed in breast tissue"
                  },
                  {
                    "text": "Extensive sampling to identify a benign epithelial component is necessary to identify phyllodes tumor"
                  }
                ],
                "Fibromatosis": [
                  {
                    "text": "More common in breast than sarcomas"
                  },
                  {
                    "text": "Can invade into normal tissue, into skeletal muscle, and around nervesInvasion into skin is very uncommon",
                    "sub_points": [
                      "Invasion into skin is very uncommon"
                    ]
                  },
                  {
                    "text": "Minimal nuclear pleomorphism and absence of mitoses distinguish fibromatosis from sarcoma"
                  }
                ],
                "Nodular Fasciitis": [
                  {
                    "text": "Usually in superficial location or in muscle fascia"
                  },
                  {
                    "text": "Majority are < 3 cm; tumors > 5 cm would be very unusual"
                  },
                  {
                    "text": "Rapid growth can raise concern for malignant tumor"
                  },
                  {
                    "text": "Cells have haphazard arrangement (similar to tissue culture)Malignant spindle cell tumors usually grow in organized fascicular patterns",
                    "sub_points": [
                      "Malignant spindle cell tumors usually grow in organized fascicular patterns"
                    ]
                  },
                  {
                    "text": "Mild to no nuclear atypia and fine chromatin pattern"
                  },
                  {
                    "text": "Frequent mitoses; atypical mitotic figures not seen"
                  },
                  {
                    "text": "Closely related lesion, proliferative fasciitis, may have ganglion-like cells that can be mistaken for rhabdomyoblasts"
                  }
                ],
                "Myofibroblastoma": [
                  {
                    "text": "Benign neoplastic proliferation of myofibroblasts"
                  },
                  {
                    "text": "Nuclear atypia is minimal, and mitoses are absent or rare"
                  },
                  {
                    "text": "Does not infiltrate around normal breast epitheliumPresence of adipose tissue in tumor could mimic infiltrative pattern on small biopsies",
                    "sub_points": [
                      "Presence of adipose tissue in tumor could mimic infiltrative pattern on small biopsies"
                    ]
                  }
                ],
                "Dermatofibrosarcoma Protuberans": [
                  {
                    "text": "Spindle cell neoplasm arising in dermis and infiltrating into subcutaneous tissueRare cases of tumor deeper in breast are reportedDermal-based lesions can invade into breast",
                    "sub_points": [
                      "Rare cases of tumor deeper in breast are reported",
                      "Dermal-based lesions can invade into breast"
                    ]
                  },
                  {
                    "text": "Spindle cells are arranged in storiform patternMinimal pleomorphism and rare mitoses typical",
                    "sub_points": [
                      "Minimal pleomorphism and rare mitoses typical"
                    ]
                  }
                ],
                "Stromal Giant Cells": [
                  {
                    "text": "Multinucleated giant cells with hyperchromatic nuclei are occasionally seen in normal breast stroma"
                  },
                  {
                    "text": "Thought to be due to degenerative changes and should not be mistaken as malignancy"
                  },
                  {
                    "text": "When present in another lesion, such as fibroadenoma or phyllodes tumor, they should not be misconstrued as evidence of malignancy or used to consider malignancy of higher grade"
                  }
                ],
                "Papillary Endothelial Hyperplasia (PEH)": [
                  {
                    "text": "PEH is organizing hemorrhage that can be associated with a blood vessel or prior surgical site"
                  },
                  {
                    "text": "It is the most common benign lesion misdiagnosed as AS"
                  },
                  {
                    "text": "PEH is generally small (< 1.5 cm) and often has circumscribed margins on imaging"
                  },
                  {
                    "text": "However, lesions can be quite large when associated with surgical sites (> 2 cm)"
                  }
                ],
                "Reactive Spindle Cell Nodule at Core Needle Biopsy Site": [
                  {
                    "text": "Reactive changes at a core needle biopsy site can rarely form a mass"
                  },
                  {
                    "text": "The cells can appear to infiltrate into adjacent stroma and can be mitotically active"
                  },
                  {
                    "text": "The stromal proliferation is only seen in the excision after the biopsy and is not present in the original biopsy"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Diagnosis of primary mammary sarcoma is one of exclusionDiagnosis can be established only after excluding metaplastic carcinoma and phyllodes tumorExtensive sampling of the lesion looking for epithelial or biphasic component should be undertakenIHC analysis using multiple antibodies for cytokeratins, as well as p63, is generally indicated",
                    "sub_points": [
                      "Diagnosis can be established only after excluding metaplastic carcinoma and phyllodes tumorExtensive sampling of the lesion looking for epithelial or biphasic component should be undertakenIHC analysis using multiple antibodies for cytokeratins, as well as p63, is generally indicated",
                      "Extensive sampling of the lesion looking for epithelial or biphasic component should be undertaken",
                      "IHC analysis using multiple antibodies for cytokeratins, as well as p63, is generally indicated"
                    ]
                  },
                  {
                    "text": "Carcinomas and sarcomas are treated differently; thus, distinction is clinically important"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Inflammatory Disorders": {
        "name": "Inflammatory Disorders",
        "url": "https://app.pathprimer.com/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
        "topics": {
          "Lactational Abscess": {
            "name": "Lactational Abscess",
            "url": "https://app.pathprimer.com/document/7cadcd2f-87d7-4741-a550-4295255d17ac/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Bacterial infection occurring during lactational period"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "There is a normal microbiota of the breast that is present prior to pregnancy and lactation"
                  },
                  {
                    "text": "During lactation, there is an active interchange of bacteria between the mother and childInfants ingest millions of bacteria from milk each dayBacteria are introduced into the breast due to retrograde flow",
                    "sub_points": [
                      "Infants ingest millions of bacteria from milk each day",
                      "Bacteria are introduced into the breast due to retrograde flow"
                    ]
                  },
                  {
                    "text": "Lactational abscesses likely arise from escape of bacteria and milk from the duct/lobular systemMost abscesses are due toStaphylococcus",
                    "sub_points": [
                      "Most abscesses are due toStaphylococcus"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Breast is focally swollen, painful, and erythematous"
                  },
                  {
                    "text": "Most abscesses resolve with treatment, and breastfeeding can continue"
                  },
                  {
                    "text": "Neonatal mastitisNeonates (both male and female) may transiently produce milk under the influence of maternal hormonesInfection and abscess formation are rare complications, typically diagnosed in 2nd-4th weeks of life",
                    "sub_points": [
                      "Neonates (both male and female) may transiently produce milk under the influence of maternal hormones",
                      "Infection and abscess formation are rare complications, typically diagnosed in 2nd-4th weeks of life"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Acute inflammatory infiltrate in breast tissue"
                  },
                  {
                    "text": "Gram stain often shows coccal forms in areas of neutrophils"
                  },
                  {
                    "text": "Later in breastfeeding, or after cessation of breastfeeding, galactoceles may form"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Inflammatory breast carcinoma"
                  },
                  {
                    "text": "Cystic neutrophilic granulomatous mastitis/granulomatous lobular mastitis"
                  },
                  {
                    "text": "Squamous metaplasia of lactiferous ducts"
                  },
                  {
                    "text": "Unusual infections"
                  },
                  {
                    "text": "Inflammation due to foreign bodies"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Bacterial infection occurring during the lactational period"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "There is a normal microbiota of the breast that is present prior to lactation and breastfeedingBacterial populations are related to those found in the skin and gut, but there are differences that are likely due to the anaerobic and lipid-rich environment of the duct/lobular system",
                    "sub_points": [
                      "Bacterial populations are related to those found in the skin and gut, but there are differences that are likely due to the anaerobic and lipid-rich environment of the duct/lobular system"
                    ]
                  },
                  {
                    "text": "During lactation, there is an active interchange of bacteria between the mother and childInfants ingest billions of bacteria from milk each dayThe predominant species isStaphylococcusIn turn, bacteria from the infant's oral flora are introduced into the breast via retrograde flow during suckling",
                    "sub_points": [
                      "Infants ingest billions of bacteria from milk each dayThe predominant species isStaphylococcus",
                      "The predominant species isStaphylococcus",
                      "In turn, bacteria from the infant's oral flora are introduced into the breast via retrograde flow during suckling"
                    ]
                  },
                  {
                    "text": "Lactational abscesses likely arise from escape of bacteria and milk from the duct/lobular systemThe abscesses occur deep in the breast and rarely involve the nipple and skin directly",
                    "sub_points": [
                      "The abscesses occur deep in the breast and rarely involve the nipple and skin directly"
                    ]
                  },
                  {
                    "text": "Most abscesses are due toStaphylococcusspecies﻿Streptococcal infections are less common",
                    "sub_points": [
                      "﻿Streptococcal infections are less common"
                    ]
                  },
                  {
                    "text": "Abscesses occurring outside the period of lactation and breastfeeding can have multiple etiologies and are often associated with mixed bacterial populationsNonlactational abscesses can be due to infections or inflammatory responses to noncellular substances",
                    "sub_points": [
                      "Nonlactational abscesses can be due to infections or inflammatory responses to noncellular substances"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "The breast is focally swollen, painful, and erythematous1-33% of breastfeeding women develop mastitis, but only 1-3% progress to abscess formation",
                    "sub_points": [
                      "1-33% of breastfeeding women develop mastitis, but only 1-3% progress to abscess formation"
                    ]
                  },
                  {
                    "text": "Usually occurs with 1st pregnancy and in first 6 weeks of breastfeeding"
                  },
                  {
                    "text": "Neonatal mastitisNeonates (both male and female) may transiently produce milk under influence of maternal hormones (termed \"witch's milk\" or galactorrhea of the newborn)Infection and abscess formation are rare, typically diagnosed in 2nd-4th weeks of life",
                    "sub_points": [
                      "Neonates (both male and female) may transiently produce milk under influence of maternal hormones (termed \"witch's milk\" or galactorrhea of the newborn)",
                      "Infection and abscess formation are rare, typically diagnosed in 2nd-4th weeks of life"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Breastfeeding or mechanical expression of milk should continue"
                  },
                  {
                    "text": "Antibiotics targetingStaphylococcusspecies are effective in most cases"
                  },
                  {
                    "text": "In rare cases, surgical incision and drainage may be necessaryMost specimens will be from an incision and drainage procedure and will consist of multiple small fragmentsSubmission of material for cultures should be performed",
                    "sub_points": [
                      "Most specimens will be from an incision and drainage procedure and will consist of multiple small fragments",
                      "Submission of material for cultures should be performed"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Most abscesses resolve with treatment, and breastfeeding can continue"
                  }
                ]
              },
              "MACROSCOPIC": {
                "Macroscopic Appearance": [
                  {
                    "text": "Most specimens will be from incision and drainage procedure and will consist of multiple small fragments"
                  },
                  {
                    "text": "Only ~ 15% of breast abscesses that require surgery occur during lactation"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Acute inflammatory infiltrate in breast tissue; tissue necrosis may be present"
                  },
                  {
                    "text": "Special stains for microorganisms may reveal bacterial forms associated with the neutrophilic infiltrate"
                  },
                  {
                    "text": "Later in breastfeeding, or after cessation of breastfeeding, galactoceles may formAssociated with chronic inflammation due to foreign material (lipids) in stromaMay be sterile unless there is a secondary infection",
                    "sub_points": [
                      "Associated with chronic inflammation due to foreign material (lipids) in stroma",
                      "May be sterile unless there is a secondary infection"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Gram stain: May reveal cocci, but many patients will have already received antibioticsMycobacterial and fungal infections are exceedingly rare in the breast; stains for these organisms have limited value unless histologic features suggest an unusual organism",
                    "sub_points": [
                      "Mycobacterial and fungal infections are exceedingly rare in the breast; stains for these organisms have limited value unless histologic features suggest an unusual organism"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Inflammatory Breast Carcinoma": [
                  {
                    "text": "The most important diagnosis to consider and exclude is inflammatory carcinoma arising during breastfeeding"
                  },
                  {
                    "text": "Symptoms of erythema and edema are caused by obstruction of dermal lymphatics by tumor cells"
                  },
                  {
                    "text": "If erythema and edema do not resolve promptly with antibiotic treatment, &/or a hard mass is present, this diagnosis should be considered"
                  }
                ],
                "Cystic Neutrophilic Granulomatous Mastitis (CNGM)/Granulomatous Lobular Mastitis (GLM)": [
                  {
                    "text": "Presents as a painful or tender, palpable mass in women with a past history of pregnancy or other reason for galactorrhea"
                  },
                  {
                    "text": "It would be very unusual for CNGM/GLM to present during pregnancy"
                  },
                  {
                    "text": "Biopsies show a mixed inflammatory infiltrate with scattered giant cells and lipid \"cysts\" or vacuolesGram-positive bacteria are present within lipid vacuoles and not within the neutrophilic infiltrateMost commonly identified asCorynebacteriumspecies by culture",
                    "sub_points": [
                      "Gram-positive bacteria are present within lipid vacuoles and not within the neutrophilic infiltrate",
                      "Most commonly identified asCorynebacteriumspecies by culture"
                    ]
                  }
                ],
                "Squamous Metaplasia of Lactiferous Ducts (SMOLD)": [
                  {
                    "text": "Presents as a painful erythematous subareolar mass"
                  },
                  {
                    "text": "Initial lesion is due to abnormal keratin production in lactiferous sinuses that incites an inflammatory response after rupture"
                  },
                  {
                    "text": "Almost all affected individuals have a history of smoking"
                  },
                  {
                    "text": "It would be highly unlikely for SMOLD to occur during breastfeeding"
                  }
                ],
                "Unusual Infections": [
                  {
                    "text": "Infections of the breast by mycobacteria, fungi, or parasites are very rare"
                  },
                  {
                    "text": "Candidiasis of nipple may occur during breastfeeding"
                  },
                  {
                    "text": "Rare cases of aspergillosis have been associated with breast implants"
                  }
                ],
                "Inflammation Due to Exogenous Foreign Material": [
                  {
                    "text": "Granulomatous inflammation can occur as response to foreign material, such as piercings or hair"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Fat Necrosis": {
            "name": "Fat Necrosis",
            "url": "https://app.pathprimer.com/document/44d08413-1bd6-4ce3-a7a5-690efdbc0694/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Benign inflammatory reaction secondary to injury of breast adipose tissueWide spectrum of clinical and radiologic appearancesMay be confused with carcinoma, both clinically and radiologically",
                    "sub_points": [
                      "Wide spectrum of clinical and radiologic appearances",
                      "May be confused with carcinoma, both clinically and radiologically"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "May be due to trauma, surgical procedures, pressure necrosis, radiation, other rare causes, or idiopathic"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Common findings are dystrophic calcifications, radiolucent oil cysts, and masses"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Early changesNecrosis of adipocytes; hemorrhage may be presentMixed inflammatory infiltrate of histiocytes, lymphocytes, and plasma cellsCalcifications frequently develop in cyst wall",
                    "sub_points": [
                      "Necrosis of adipocytes; hemorrhage may be present",
                      "Mixed inflammatory infiltrate of histiocytes, lymphocytes, and plasma cells",
                      "Calcifications frequently develop in cyst wall"
                    ]
                  },
                  {
                    "text": "Intermediate changesPhagocytosis of necrotic adipose cellsFoamy cytoplasm of histocytes and giant cells due to lipidsEarly fibrosis and calcification",
                    "sub_points": [
                      "Phagocytosis of necrotic adipose cells",
                      "Foamy cytoplasm of histocytes and giant cells due to lipids",
                      "Early fibrosis and calcification"
                    ]
                  },
                  {
                    "text": "Late changesNecrotic areas of adipose tissue are walled off by dense fibrosis (\"oil cysts\")Dense calcification occurs in walls of cysts (eggshell calcifications)",
                    "sub_points": [
                      "Necrotic areas of adipose tissue are walled off by dense fibrosis (\"oil cysts\")",
                      "Dense calcification occurs in walls of cysts (eggshell calcifications)"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Lupus mastitis"
                  },
                  {
                    "text": "Amyloidosis"
                  },
                  {
                    "text": "Granular cell tumor"
                  },
                  {
                    "text": "Invasive lobular carcinoma with histiocytoid appearance"
                  },
                  {
                    "text": "Rosai-Dorfman disease"
                  },
                  {
                    "text": "Erdheim-Chester disease"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Fat necrosis (FN)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign, nonsuppurative inflammatory reaction secondary to injury of breast connective tissue and adipose tissue"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Causes of Fat Necrosis": [
                  {
                    "text": "Breast lesionsRuptured cysts with inflammation secondary to spillage of contentsDuct ectasia with rupture",
                    "sub_points": [
                      "Ruptured cysts with inflammation secondary to spillage of contents",
                      "Duct ectasia with rupture"
                    ]
                  },
                  {
                    "text": "TraumaBlunt trauma to breast (e.g., seat belt injury after motor vehicle accident)Driver develops left breast upper outer injury and passenger develops right breast upper outer quadrant injury",
                    "sub_points": [
                      "Blunt trauma to breast (e.g., seat belt injury after motor vehicle accident)Driver develops left breast upper outer injury and passenger develops right breast upper outer quadrant injury",
                      "Driver develops left breast upper outer injury and passenger develops right breast upper outer quadrant injury"
                    ]
                  },
                  {
                    "text": "Pressure necrosisCan occur in lower portion of pendulous breasts",
                    "sub_points": [
                      "Can occur in lower portion of pendulous breasts"
                    ]
                  },
                  {
                    "text": "Surgery or needle biopsy (iatrogenic causes of trauma)Cyst aspiration or core needle biopsiesExcisions, reduction mammoplasty, implantsOncoplastic surgery results in a greater number of masses due to FN compared to simple excisionAutologous fat injectionCoronary artery bypass graftWhen the internal mammary artery is used for revascularization of the heart, in some cases, the ipsilateral breast becomes ischemic, resulting in FN",
                    "sub_points": [
                      "Cyst aspiration or core needle biopsies",
                      "Excisions, reduction mammoplasty, implantsOncoplastic surgery results in a greater number of masses due to FN compared to simple excision",
                      "Oncoplastic surgery results in a greater number of masses due to FN compared to simple excision",
                      "Autologous fat injection",
                      "Coronary artery bypass graftWhen the internal mammary artery is used for revascularization of the heart, in some cases, the ipsilateral breast becomes ischemic, resulting in FN",
                      "When the internal mammary artery is used for revascularization of the heart, in some cases, the ipsilateral breast becomes ischemic, resulting in FN"
                    ]
                  },
                  {
                    "text": "Radiation therapyPostradiation vascular damage (endarteritis obliterans) with subsequent hypoxia and ischemia damage",
                    "sub_points": [
                      "Postradiation vascular damage (endarteritis obliterans) with subsequent hypoxia and ischemia damage"
                    ]
                  },
                  {
                    "text": "Autoimmune diseasesLupus mastitisPolyarteritis nodosa, Weber-Christian disease, granulomatous angiopanniculitis",
                    "sub_points": [
                      "Lupus mastitis",
                      "Polyarteritis nodosa, Weber-Christian disease, granulomatous angiopanniculitis"
                    ]
                  },
                  {
                    "text": "AnticoagulationMost commonly occurs in obese middle-aged women treated with coumadin or warfarinOften manifests within 1st week of therapy",
                    "sub_points": [
                      "Most commonly occurs in obese middle-aged women treated with coumadin or warfarin",
                      "Often manifests within 1st week of therapy"
                    ]
                  },
                  {
                    "text": "IdiopathicIn ~ 50% of patients, the cause is unknown",
                    "sub_points": [
                      "In ~ 50% of patients, the cause is unknown"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Estimated to be 0.6% of breast excisions"
                  }
                ],
                "Age": [
                  {
                    "text": "Broad range: 37-68 years (mean: ~ 50 years)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "FN can mimic carcinoma by forming palpable or mammographic masses &/or mammographic calcifications"
                  },
                  {
                    "text": "Symptomatic FN typically presents as palpable massMay enlarge, remain unchanged, regress, or resolveFN is typically detected in the periareolar area and is often superficial in locationThese sites are most vulnerable to traumaCan be associated with skin changesBruising and tenderness (due to original trauma)Skin tethering or dimpling, nipple retraction (due to fibrosis associated with healing)",
                    "sub_points": [
                      "May enlarge, remain unchanged, regress, or resolve",
                      "FN is typically detected in the periareolar area and is often superficial in locationThese sites are most vulnerable to trauma",
                      "These sites are most vulnerable to trauma",
                      "Can be associated with skin changesBruising and tenderness (due to original trauma)Skin tethering or dimpling, nipple retraction (due to fibrosis associated with healing)",
                      "Bruising and tenderness (due to original trauma)",
                      "Skin tethering or dimpling, nipple retraction (due to fibrosis associated with healing)"
                    ]
                  },
                  {
                    "text": "Incidental lesions are detected by mammographyForms multiple types of lesionsOil (lipid) cysts, coarse calcifications, focal asymmetries, calcifications, or irregular masses\"Eggshell\" calcifications are characteristic around a central area of necrotic adipose tissueMany cases can be identified by the radiographic appearanceBiopsy is required if there are unusual imaging features",
                    "sub_points": [
                      "Forms multiple types of lesionsOil (lipid) cysts, coarse calcifications, focal asymmetries, calcifications, or irregular masses\"Eggshell\" calcifications are characteristic around a central area of necrotic adipose tissue",
                      "Oil (lipid) cysts, coarse calcifications, focal asymmetries, calcifications, or irregular masses",
                      "\"Eggshell\" calcifications are characteristic around a central area of necrotic adipose tissue",
                      "Many cases can be identified by the radiographic appearanceBiopsy is required if there are unusual imaging features",
                      "Biopsy is required if there are unusual imaging features"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign inflammatory process that should regress or resolve, although calcifications can become larger over time"
                  }
                ],
                "Management": [
                  {
                    "text": "FN must be distinguished from carcinomaPhysical examination and imaging findings can be similar",
                    "sub_points": [
                      "Physical examination and imaging findings can be similar"
                    ]
                  },
                  {
                    "text": "Even with a clear history of previous trauma, the possibility of malignancy should not be overlookedThe patient may first note a palpable mass due to an episode of trauma",
                    "sub_points": [
                      "The patient may first note a palpable mass due to an episode of trauma"
                    ]
                  },
                  {
                    "text": "Patients who have undergone breast-conserving surgery for breast cancer may develop FNFN related to treatment must be distinguished from cancer recurrence",
                    "sub_points": [
                      "FN related to treatment must be distinguished from cancer recurrence"
                    ]
                  },
                  {
                    "text": "Management may include short-term follow-up with imaging and physical examination in selected casesIn specific cases with worrisome clinical/radiographic features, biopsy is required to confirm diagnosis",
                    "sub_points": [
                      "In specific cases with worrisome clinical/radiographic features, biopsy is required to confirm diagnosis"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [],
                "Location": [
                  {
                    "text": "After trauma, mass typically occurs at site of injury"
                  },
                  {
                    "text": "In patients with no history of trauma, lesion is most often seen in the upper outer quadrant of breast"
                  },
                  {
                    "text": "Close correlation exists between the clinical age of lesion, the imaging findings, and the histologic appearance"
                  }
                ],
                "Mammographic Findings": [
                  {
                    "text": "Variable findings reflect histologic evolution of the inflammatory processEarly lesions can be ill-defined areas of densityRound or oval radiolucent oil cysts and dystrophic eggshell calcifications subsequently developProgressive thickening and deformity of skin and subcutaneous tissue can occur",
                    "sub_points": [
                      "Early lesions can be ill-defined areas of density",
                      "Round or oval radiolucent oil cysts and dystrophic eggshell calcifications subsequently develop",
                      "Progressive thickening and deformity of skin and subcutaneous tissue can occur"
                    ]
                  },
                  {
                    "text": "Can form irregular mass with ill-defined margins, asymmetry, or architectural distortion"
                  },
                  {
                    "text": "Often result in the development of pleomorphic calcifications, sometimes suspicious for malignancy"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Appearance ranges from solid nodules with posterior shadowing to complex intracystic massesCystic lesions may appear complex with mural nodules or with internal echogenic bandsOil cysts typically show posterior acoustic shadowing, corresponding to a round radiolucent lesion with curvilinear wall calcification on mammographyFat-fluid level that shifts in orientation with changes in patient position is considered diagnostic of oil cystsPresence of oil cyst within a mass with spiculated margins is reassuring for diagnosis of FNSolid masses may be well circumscribed or ill definedOften associated with distortion of surrounding breast parenchymaLesions may be hyperechoic due to adipose tissue intermingled with fibrosis",
                    "sub_points": [
                      "Cystic lesions may appear complex with mural nodules or with internal echogenic bandsOil cysts typically show posterior acoustic shadowing, corresponding to a round radiolucent lesion with curvilinear wall calcification on mammographyFat-fluid level that shifts in orientation with changes in patient position is considered diagnostic of oil cystsPresence of oil cyst within a mass with spiculated margins is reassuring for diagnosis of FN",
                      "Oil cysts typically show posterior acoustic shadowing, corresponding to a round radiolucent lesion with curvilinear wall calcification on mammography",
                      "Fat-fluid level that shifts in orientation with changes in patient position is considered diagnostic of oil cysts",
                      "Presence of oil cyst within a mass with spiculated margins is reassuring for diagnosis of FN",
                      "Solid masses may be well circumscribed or ill definedOften associated with distortion of surrounding breast parenchyma",
                      "Often associated with distortion of surrounding breast parenchyma",
                      "Lesions may be hyperechoic due to adipose tissue intermingled with fibrosis"
                    ]
                  },
                  {
                    "text": "Sensitivity of ultrasound higher than mammograms, especially in dense breasts"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "FN produces wide spectrum of findings on MRFibrosis may be seen as architectural distortion ± irregular marginsFibrosis may appear as high, intermediate, or low signal on T1-weighted MRNecrotic fat usually shows low signal intensity on T1-weighted MRMay be due to hemorrhage and inflammation",
                    "sub_points": [
                      "Fibrosis may be seen as architectural distortion ± irregular marginsFibrosis may appear as high, intermediate, or low signal on T1-weighted MR",
                      "Fibrosis may appear as high, intermediate, or low signal on T1-weighted MR",
                      "Necrotic fat usually shows low signal intensity on T1-weighted MRMay be due to hemorrhage and inflammation",
                      "May be due to hemorrhage and inflammation"
                    ]
                  },
                  {
                    "text": "FN can enhance after injection of contrast materialAmount of enhancement depends on intensity of inflammatory processEnhancement can be focal or diffuse, homogeneous or heterogeneousEnhancement patterns may vary from slow gradual enhancement to rapid enhancementMost avid enhancement usually occurs in early phase after initial injuryAs inflammatory changes resolve, degree of enhancement may decrease",
                    "sub_points": [
                      "Amount of enhancement depends on intensity of inflammatory processEnhancement can be focal or diffuse, homogeneous or heterogeneousEnhancement patterns may vary from slow gradual enhancement to rapid enhancementMost avid enhancement usually occurs in early phase after initial injuryAs inflammatory changes resolve, degree of enhancement may decrease",
                      "Enhancement can be focal or diffuse, homogeneous or heterogeneous",
                      "Enhancement patterns may vary from slow gradual enhancement to rapid enhancement",
                      "Most avid enhancement usually occurs in early phase after initial injury",
                      "As inflammatory changes resolve, degree of enhancement may decrease"
                    ]
                  },
                  {
                    "text": "FN may mimic malignancy on MR on basis of morphology or contrast kinetics"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "FN forms a demarcated mass with distinct yellow-gray and focally reddish colorOften retracts surrounding parenchyma",
                    "sub_points": [
                      "Often retracts surrounding parenchyma"
                    ]
                  },
                  {
                    "text": "Cystic degeneration may occur, resulting in a cavity that contains oily fluid secondary to necrotic fat"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Varies over time from initial injury to reaction to damaged tissue and, ultimately, to resolutionEarly-stage lesionsEarly changes include hemorrhage in fat, resulting in induration and firmness on gross examinationOver several weeks, the affected area becomes demarcated, forming distinct yellow-gray and focally reddish massCystic degeneration may result in a cavity that contains oily fluid secondary to necrotic fatCalcifications frequently develop in cyst wallsIntermediate-stage lesionsInfiltration of histiocytes, lymphocytes, plasma cells, and multinucleated giant cellsCytologic atypia should not be presentFoamy cytoplasm of histocytes and giant cells is due to phagocytosis of necrotic adipocytesHemosiderin depositionLate-stage lesionsCharacterized by development of varying degrees of fibrosis and calcificationReactive inflammatory components gradually replaced by fibrosis and scar formationLoculated degenerated fat may persist for months or years in cyst surrounded by fibrosisIn some cases, fibrosis and calcifications are only sequelae of FNReparative fibrotic process may replace areas of necrotic fat, resulting in a mass with spiculated margins that appears suspicious for malignancy on imaging",
                    "sub_points": [
                      "Early-stage lesionsEarly changes include hemorrhage in fat, resulting in induration and firmness on gross examinationOver several weeks, the affected area becomes demarcated, forming distinct yellow-gray and focally reddish massCystic degeneration may result in a cavity that contains oily fluid secondary to necrotic fatCalcifications frequently develop in cyst walls",
                      "Early changes include hemorrhage in fat, resulting in induration and firmness on gross examination",
                      "Over several weeks, the affected area becomes demarcated, forming distinct yellow-gray and focally reddish mass",
                      "Cystic degeneration may result in a cavity that contains oily fluid secondary to necrotic fat",
                      "Calcifications frequently develop in cyst walls",
                      "Intermediate-stage lesionsInfiltration of histiocytes, lymphocytes, plasma cells, and multinucleated giant cellsCytologic atypia should not be presentFoamy cytoplasm of histocytes and giant cells is due to phagocytosis of necrotic adipocytesHemosiderin deposition",
                      "Infiltration of histiocytes, lymphocytes, plasma cells, and multinucleated giant cellsCytologic atypia should not be present",
                      "Cytologic atypia should not be present",
                      "Foamy cytoplasm of histocytes and giant cells is due to phagocytosis of necrotic adipocytes",
                      "Hemosiderin deposition",
                      "Late-stage lesionsCharacterized by development of varying degrees of fibrosis and calcificationReactive inflammatory components gradually replaced by fibrosis and scar formationLoculated degenerated fat may persist for months or years in cyst surrounded by fibrosisIn some cases, fibrosis and calcifications are only sequelae of FNReparative fibrotic process may replace areas of necrotic fat, resulting in a mass with spiculated margins that appears suspicious for malignancy on imaging",
                      "Characterized by development of varying degrees of fibrosis and calcification",
                      "Reactive inflammatory components gradually replaced by fibrosis and scar formation",
                      "Loculated degenerated fat may persist for months or years in cyst surrounded by fibrosis",
                      "In some cases, fibrosis and calcifications are only sequelae of FN",
                      "Reparative fibrotic process may replace areas of necrotic fat, resulting in a mass with spiculated margins that appears suspicious for malignancy on imaging"
                    ]
                  },
                  {
                    "text": "Histiocytes adjacent to ruptured cysts are termed \"ochrocytes\" when they contain brown pigment (oxidized secretory lipids)"
                  },
                  {
                    "text": "Cellular spindled histiocytic pseudotumor (CSHPT)These are reactive inflammatory lesions associated with FNSpindle-shaped histiocytes infiltrate into breast tissueThere is a variable dense inflammatory infiltrate, including lymphocytes and plasma cells with occasional giant cellsMitoses may be present but are not atypicalThe appearance can mimic a histiocytoid carcinoma",
                    "sub_points": [
                      "These are reactive inflammatory lesions associated with FN",
                      "Spindle-shaped histiocytes infiltrate into breast tissue",
                      "There is a variable dense inflammatory infiltrate, including lymphocytes and plasma cells with occasional giant cells",
                      "Mitoses may be present but are not atypical",
                      "The appearance can mimic a histiocytoid carcinoma"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "FN is frequently seen in core needle biopsies for masses &/or calcifications"
                  },
                  {
                    "text": "Sufficient FN that could correlate with imaging lesion (i.e., generally involving majority of core) must be distinguished from incidental FN next to another lesion"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Lupus Mastitis": [
                  {
                    "text": "Rare manifestation of lupus (2-3% of patients)Can be presenting finding",
                    "sub_points": [
                      "Can be presenting finding"
                    ]
                  },
                  {
                    "text": "Average patient age: 40 years (range: 18-70 years)"
                  },
                  {
                    "text": "Single or multiple palpable massesSubcutaneous or deep",
                    "sub_points": [
                      "Subcutaneous or deep"
                    ]
                  },
                  {
                    "text": "Lymphocytic lobular panniculitis present with hyaline FNLymphocytic infiltration can be nodular or diffuse, periductal or perilobularGerminal centers may be presentMixed B- and T-cell populationMay include plasma cells",
                    "sub_points": [
                      "Lymphocytic infiltration can be nodular or diffuse, periductal or perilobular",
                      "Germinal centers may be present",
                      "Mixed B- and T-cell population",
                      "May include plasma cells"
                    ]
                  },
                  {
                    "text": "Lymphocytic vasculitis common"
                  }
                ],
                "Amyloidosis": [
                  {
                    "text": "Amyloid deposition can occur in patients with systemic amyloidosis or as an isolated mass in the breastCan present as a mass or calcifications",
                    "sub_points": [
                      "Can present as a mass or calcifications"
                    ]
                  },
                  {
                    "text": "In ~ 50% of patients with amyloid in breast, a hematologic disorder is also presentExtranodal marginal zone B-cell lymphoma, plasma cell proliferative disorder, plasmacytoma, chronic lymphoid leukemia, others",
                    "sub_points": [
                      "Extranodal marginal zone B-cell lymphoma, plasma cell proliferative disorder, plasmacytoma, chronic lymphoid leukemia, others"
                    ]
                  },
                  {
                    "text": "Amyloid is located in thickened basement membranes, within blood vessel walls, and as extracellular deposits"
                  },
                  {
                    "text": "Amyloid surrounding adipocytes in association with giant cells can mimic FNGenerally lacks lymphocytic infiltrate as seen in FN",
                    "sub_points": [
                      "Generally lacks lymphocytic infiltrate as seen in FN"
                    ]
                  },
                  {
                    "text": "Congo red staining and polarization can identify amyloid"
                  },
                  {
                    "text": "Sulfated Alcian blue also identifies amyloid"
                  },
                  {
                    "text": "Majority of cases are due to light chain (AL) deposition"
                  }
                ],
                "Granular Cell Tumor": [
                  {
                    "text": "Lipid-laden histocytes in FN and cells of granular cell tumor can be similar in appearanceHistiocytes should be strongly positive for CD68 and may be positive for S100Granular cells are S100(+), may be CD68(+)",
                    "sub_points": [
                      "Histiocytes should be strongly positive for CD68 and may be positive for S100",
                      "Granular cells are S100(+), may be CD68(+)"
                    ]
                  },
                  {
                    "text": "Granular cell tumor lacks other inflammatory cells and fat involvement characteristic of FN"
                  }
                ],
                "Invasive Lobular Carcinoma With Histiocytoid Pattern": [
                  {
                    "text": "Histiocytoid lobular carcinomas have abundant foamy cytoplasm and small bland nuclei"
                  },
                  {
                    "text": "Tumor cells can mimic histiocytes"
                  },
                  {
                    "text": "Other inflammatory changes associated with FN are absent unless there is also trauma"
                  },
                  {
                    "text": "Cells are identified as epithelial in type by IHC studies for cytokeratin"
                  }
                ],
                "Rosai-Dorfman Disease": [
                  {
                    "text": "This nonneoplastic inflammatory disease of unknown etiology that can involve skin and soft tissue of multiple sites also rarely involves the breast"
                  },
                  {
                    "text": "Presents as a mass detected by palpation or imaging"
                  },
                  {
                    "text": "Large, spindle-shaped and epithelioid histiocytes are intermingled in a chronic inflammatory infiltrate, including lymphocytes and plasma cellsHistiocytes are S100(+)Emperipolesis (engulfment of inflammatory cells by histiocytes) is characteristic",
                    "sub_points": [
                      "Histiocytes are S100(+)",
                      "Emperipolesis (engulfment of inflammatory cells by histiocytes) is characteristic"
                    ]
                  },
                  {
                    "text": "Inflammatory infiltrate is predominant component rather than adipose tissue, as is seen in FN"
                  }
                ],
                "Erdheim-Chester Disease": [
                  {
                    "text": "Very rare non-Langerhans cell histiocytosis (\"polyostotic sclerosing histiocytosis\") that may involve breast"
                  },
                  {
                    "text": "Characterized by infiltration of histiocytesHistiocytes: CD68(+), CD1a and S100 (-)Touton-type giant cells may be present",
                    "sub_points": [
                      "Histiocytes: CD68(+), CD1a and S100 (-)",
                      "Touton-type giant cells may be present"
                    ]
                  },
                  {
                    "text": "Mild lymphocytic infiltrate is present"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Duct Ectasia": {
            "name": "Duct Ectasia",
            "url": "https://app.pathprimer.com/document/f89428be-4f93-4eb8-9cf1-bc926d71b81c/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Constellation of findings, including ectasia (dilation) of large subareolar ducts, associated periductal inflammation, and periductal fibrosis"
                  },
                  {
                    "text": "Frequently associated with formation of subareolar mass &/or thick nipple discharge"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Walls of large ducts weaken with age; elastic fibers become attenuated"
                  },
                  {
                    "text": "Dilated ducts fill with secretory debris"
                  },
                  {
                    "text": "If rupture occurs, intense chronic inflammatory response results in response to extravasated lipids"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Patients present with palpable irregular subareolar mass that can be associated with skin retractionThick nipple discharge may be present",
                    "sub_points": [
                      "Thick nipple discharge may be present"
                    ]
                  }
                ],
                "Imaging": [
                  {
                    "text": "Dilated subareolar ducts, irregular subareolar mass, ± rod-shaped calcifications"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Subareolar ducts are ectatic and surrounded by chronic inflammation"
                  },
                  {
                    "text": "Hemosiderin and hemosiderin-laden macrophages may be present if there has been erosion of duct walls"
                  },
                  {
                    "text": "Lipids and lipid-laden macrophages (ochrocytes) are often present due to spillage of duct contents into stroma"
                  },
                  {
                    "text": "Luminal cells lining ducts may be infiltrated by lymphocytes and macrophages"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Cysts"
                  },
                  {
                    "text": "Squamous metaplasia of lactiferous ducts (SMOLD)"
                  },
                  {
                    "text": "Lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Duct ectasia (DE)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Nonproliferative inflammatory disorder of large ducts of breast affecting nipple and areola complex"
                  },
                  {
                    "text": "Constellation of findings, including ectasia (dilation) of large subareolar ducts, associated periductal inflammation, and periductal fibrosisFrequently associated with formation of subareolar mass &/or thick nipple discharge",
                    "sub_points": [
                      "Frequently associated with formation of subareolar mass &/or thick nipple discharge"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "Walls of large subareolar lactiferous sinuses weaken with age; does not explain cases reported in younger patientsElastic fibers thin and become attenuatedContractile properties of myoepithelial cells that normally expel secretions may diminish",
                    "sub_points": [
                      "Elastic fibers thin and become attenuated",
                      "Contractile properties of myoepithelial cells that normally expel secretions may diminish"
                    ]
                  },
                  {
                    "text": "Dilated ducts fill with secretory debrisInspissated secretions can result in thick nipple discharge of varying colors",
                    "sub_points": [
                      "Inspissated secretions can result in thick nipple discharge of varying colors"
                    ]
                  },
                  {
                    "text": "If rupture of duct wall occurs, intense chronic inflammatory response results in response to extravasated lipids"
                  },
                  {
                    "text": "Periductal fibrosis forms irregular massFibrosis can involve overlying skin causing retraction",
                    "sub_points": [
                      "Fibrosis can involve overlying skin causing retraction"
                    ]
                  },
                  {
                    "text": "\"Plasma cell mastitis\" and \"periductal mastitis\" have been used as terms for DEThese are poorly defined terms that are used to describe a variety of inflammatory diseases of the breast and should be avoided",
                    "sub_points": [
                      "These are poorly defined terms that are used to describe a variety of inflammatory diseases of the breast and should be avoided"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Perimenopausal or postmenopausal women"
                  },
                  {
                    "text": "Rare in children; may represent developmental anomaly"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Palpable, irregular subareolar mass that can be tethered to skin and nippleUsually not painful or erythematous",
                    "sub_points": [
                      "Usually not painful or erythematous"
                    ]
                  },
                  {
                    "text": "May be associated with thick nipple discharge"
                  },
                  {
                    "text": "Screening mammography may show irregular mass, dilated ducts, &/or calcifications"
                  }
                ],
                "Treatment": [
                  {
                    "text": "No treatment is necessary after biopsy demonstrates that clinical signs and symptoms are not due to carcinoma"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Benign finding in breast"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Dilated subareolar ducts typically present, which may be associated with an irregular mass"
                  },
                  {
                    "text": "Calcifications are often present in ductal distribution (linear and branching)Calcifications are large and rod-shaped (casting)",
                    "sub_points": [
                      "Calcifications are large and rod-shaped (casting)"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Subareolar, anechoic, fluid-filled dilated ducts"
                  },
                  {
                    "text": "Ducts also may be filled with debrisInspissated secretions are often visible and may be sufficiently echogenic to mimic intraductal tumor",
                    "sub_points": [
                      "Inspissated secretions are often visible and may be sufficiently echogenic to mimic intraductal tumor"
                    ]
                  },
                  {
                    "text": "Movement of particulate matter in secretions at real-time US is diagnostic feature of DE"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Tissue is usually dense, but discrete hard mass is not typically present"
                  },
                  {
                    "text": "In some cases, dilated ducts with inspissated debris may be seen grossly"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Subareolar ducts are dilated (ectatic)"
                  },
                  {
                    "text": "Chronic inflammation surrounds ductsLymphocytes and plasma cells are frequently seen; giant cells and well-formed granulomas are uncommonHemosiderin and hemosiderin-laden macrophages may be present if there has been erosion of duct wallsLipids and lipid-laden macrophages (ochrocytes) are often present due to spillage of duct contents into stroma",
                    "sub_points": [
                      "Lymphocytes and plasma cells are frequently seen; giant cells and well-formed granulomas are uncommon",
                      "Hemosiderin and hemosiderin-laden macrophages may be present if there has been erosion of duct walls",
                      "Lipids and lipid-laden macrophages (ochrocytes) are often present due to spillage of duct contents into stroma"
                    ]
                  },
                  {
                    "text": "Luminal cells lining ducts may be infiltrated by lymphocytes and histiocytes; histiocytes in duct walls can mimic atypical lobular hyperplasia"
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Needle biopsies of DE are rare, as location can be painful and uncomfortable for patient"
                  },
                  {
                    "text": "DE can be suggested, but dilated ducts and periductal chronic inflammation are also common incidental findings"
                  },
                  {
                    "text": "Excellent radiologic correlation is necessary to ensure biopsy is representative of the targeted lesion"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Cysts": [
                  {
                    "text": "\"Duct ectasia\" is often used as descriptive term for any enlarged epithelium-lined space in breast"
                  },
                  {
                    "text": "Enlarged spaces not associated with subareolar ducts are generally cysts resulting from unfolded lobules and terminal ducts"
                  },
                  {
                    "text": "This is usually an incidental finding seen in excisions for other lesionsNot associated with formation of subareolar mass or with nipple discharge",
                    "sub_points": [
                      "Not associated with formation of subareolar mass or with nipple discharge"
                    ]
                  },
                  {
                    "text": "DE should be reserved for lesions with the constellation of findings that correlate with clinical symptoms and imaging findings"
                  }
                ],
                "Squamous Metaplasia of Lactiferous Ducts (SMOLD)": [
                  {
                    "text": "Also termed recurrent subareolar abscess or Zuska disease"
                  },
                  {
                    "text": "Patients can be of any age, and both females and males are affectedDE usually occurs in older females",
                    "sub_points": [
                      "DE usually occurs in older females"
                    ]
                  },
                  {
                    "text": "Patients present with painful erythematous periareolar mass, usually thought to be infectionDE is generally painless, irregular mass, sometimes mimicking cancer",
                    "sub_points": [
                      "DE is generally painless, irregular mass, sometimes mimicking cancer"
                    ]
                  },
                  {
                    "text": "Inflammatory reaction results from escape of entrapped keratin from ruptured ductsSecondary bacterial infections can occur",
                    "sub_points": [
                      "Secondary bacterial infections can occur"
                    ]
                  },
                  {
                    "text": "Recurrences are common"
                  },
                  {
                    "text": "A periareolar fistula may develop after recurrencesFistulas do not occur with DE",
                    "sub_points": [
                      "Fistulas do not occur with DE"
                    ]
                  },
                  {
                    "text": "Strongly associated with history of tobacco useDE is not associated with tobacco use",
                    "sub_points": [
                      "DE is not associated with tobacco use"
                    ]
                  }
                ],
                "Lymphoma": [
                  {
                    "text": "Composed of solid masses of malignant lymphoid cellsLymphocytic infiltrate does not center around ducts, as in DEIn DE, there is generally mixed inflammatory infiltrate",
                    "sub_points": [
                      "Lymphocytic infiltrate does not center around ducts, as in DE",
                      "In DE, there is generally mixed inflammatory infiltrate"
                    ]
                  },
                  {
                    "text": "Lymphomas are generally not associated with nipple discharge"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Squamous Metaplasia of Lactiferous Ducts": {
            "name": "Squamous Metaplasia of Lactiferous Ducts",
            "url": "https://app.pathprimer.com/document/a2a0d999-7aa6-4293-a0e7-c82ba5bdabb2/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Squamous metaplasia of lactiferous ducts (SMOLD) is also known as recurrent subareolar abscess, periductal mastitis, and Zuska disease"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Keratin-producing cells extend to an abnormal depth into lactiferous sinuses"
                  },
                  {
                    "text": "When ruptured, an intense inflammatory response ensues"
                  },
                  {
                    "text": "> 90% of patients have a history of tobacco use"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Presents with an erythematous painful subareolar massTypically mistakenly treated as a lactational abscess",
                    "sub_points": [
                      "Typically mistakenly treated as a lactational abscess"
                    ]
                  },
                  {
                    "text": "Recurrences are common"
                  },
                  {
                    "text": "Secondary infections, often due to mixed anaerobes, may occur from incision and drainage (I&D)"
                  },
                  {
                    "text": "Surgery to excise the offending duct along with cessation of smoking reduce the likelihood of recurrence"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Findings from I&D specimens are often nonspecific, consisting of chronic active inflammation and scattered giant cellsKeratin in giant cells is a supporting findingPathologists can play an important role by suggesting SMOLD in the appropriate clinical setting",
                    "sub_points": [
                      "Keratin in giant cells is a supporting finding",
                      "Pathologists can play an important role by suggesting SMOLD in the appropriate clinical setting"
                    ]
                  },
                  {
                    "text": "Squamous metaplasia may only be seen in definitive excisions that remove the involved duct"
                  },
                  {
                    "text": "A specific etiology can be difficult to determine after multiple recurrences ± secondary infection"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Lactational abscess"
                  },
                  {
                    "text": "Nonlactational abscess"
                  },
                  {
                    "text": "Epidermal inclusion cyst of the nipple"
                  },
                  {
                    "text": "Duct ectasia"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Squamous metaplasia of lactiferous ducts (SMOLD)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Recurrent subareolar abscess"
                  },
                  {
                    "text": "Zuska disease"
                  },
                  {
                    "text": "Periductal mastitis"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Abnormal keratin formation and accumulation deep in lactiferous sinuses leads to rupture and an intense inflammatory response to keratin debris"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Etiology": [
                  {
                    "text": "The cause of subareolar abscesses outside of the lactational period is a subject of debate"
                  },
                  {
                    "text": "They present as painful erythematous masses, similar to other types of abscesses"
                  },
                  {
                    "text": "The initial treatment is often similar to that for lactational abscesses, which includes antibiotic treatment and incision and drainage (I&D)This often fails to resolve the symptoms, and recurrences are frequent (ergo the term recurrent subareolar abscess)",
                    "sub_points": [
                      "This often fails to resolve the symptoms, and recurrences are frequent (ergo the term recurrent subareolar abscess)"
                    ]
                  },
                  {
                    "text": "Some cases are associated with SMOLD, resulting in keratin-filled cysts, which can ruptureThe intense inflammatory reaction can be due to keratin debris aloneI&D may be ineffective because the offending duct and keratin debris are not adequately removedAntibiotics may be ineffective because the inflammation is not due to infection or, if a secondary infection is present, are not targeted to the causative bacteria",
                    "sub_points": [
                      "The intense inflammatory reaction can be due to keratin debris alone",
                      "I&D may be ineffective because the offending duct and keratin debris are not adequately removed",
                      "Antibiotics may be ineffective because the inflammation is not due to infection or, if a secondary infection is present, are not targeted to the causative bacteria"
                    ]
                  },
                  {
                    "text": "Proposed causes of SMOLDTobacco useAlmost all men and women affected by SMOLD have a history of tobacco useIt has been proposed that smoking leads to vitamin A deficiency, which results in abnormal squamous metaplasiaTobacco-related toxins in nipple secretions may play a role through direct damage to lactiferous ductsInverted nippleMany patients with SMOLD have inverted nipplesInversion of the nipple is more likely a result of recurrent episodes of retroareolar inflammation and fibrosis rather than the cause of the conditionNipple piercingsTissue damage and mechanical factors may have a pathogenetic role",
                    "sub_points": [
                      "Tobacco useAlmost all men and women affected by SMOLD have a history of tobacco useIt has been proposed that smoking leads to vitamin A deficiency, which results in abnormal squamous metaplasiaTobacco-related toxins in nipple secretions may play a role through direct damage to lactiferous ducts",
                      "Almost all men and women affected by SMOLD have a history of tobacco use",
                      "It has been proposed that smoking leads to vitamin A deficiency, which results in abnormal squamous metaplasia",
                      "Tobacco-related toxins in nipple secretions may play a role through direct damage to lactiferous ducts",
                      "Inverted nippleMany patients with SMOLD have inverted nipplesInversion of the nipple is more likely a result of recurrent episodes of retroareolar inflammation and fibrosis rather than the cause of the condition",
                      "Many patients with SMOLD have inverted nipples",
                      "Inversion of the nipple is more likely a result of recurrent episodes of retroareolar inflammation and fibrosis rather than the cause of the condition",
                      "Nipple piercingsTissue damage and mechanical factors may have a pathogenetic role",
                      "Tissue damage and mechanical factors may have a pathogenetic role"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [
                  {
                    "text": "Tobacco useAlmost all reported patients (> 90%) have a history of tobacco useTobacco leaves are also used to wrap other smoking products",
                    "sub_points": [
                      "Almost all reported patients (> 90%) have a history of tobacco use",
                      "Tobacco leaves are also used to wrap other smoking products"
                    ]
                  }
                ],
                "Incidence": [
                  {
                    "text": "Rare: < 1% of all breast biopsies"
                  }
                ],
                "Age": [
                  {
                    "text": "Occurs at any adult ageRare at ages < 20 due to association with tobacco use",
                    "sub_points": [
                      "Rare at ages < 20 due to association with tobacco use"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Occurs in both female and males"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Patients initially present with an erythematous, painful subareolar mass; purulent nipple discharge commonUsually mistaken for bacterial abscess due to presumedStaphylococcusspeciesThis is most common type of abscess in lactating women but rare outside of this settingInitial lesions of SMOLD are sterile; inflammatory response is to keratin debrisTypical treatment is I&D and antibiotics for a presumed staphylococcal infectionSurgeons usually avoid surgery involving the nipple due to cosmetic and functional concernsSymptoms may be relieved temporarilyHowever, treatment can exacerbate inflammation due to failure to remove keratin debris and keratin-producing epithelium",
                    "sub_points": [
                      "Usually mistaken for bacterial abscess due to presumedStaphylococcusspeciesThis is most common type of abscess in lactating women but rare outside of this settingInitial lesions of SMOLD are sterile; inflammatory response is to keratin debris",
                      "This is most common type of abscess in lactating women but rare outside of this setting",
                      "Initial lesions of SMOLD are sterile; inflammatory response is to keratin debris",
                      "Typical treatment is I&D and antibiotics for a presumed staphylococcal infectionSurgeons usually avoid surgery involving the nipple due to cosmetic and functional concerns",
                      "Surgeons usually avoid surgery involving the nipple due to cosmetic and functional concerns",
                      "Symptoms may be relieved temporarilyHowever, treatment can exacerbate inflammation due to failure to remove keratin debris and keratin-producing epithelium",
                      "However, treatment can exacerbate inflammation due to failure to remove keratin debris and keratin-producing epithelium"
                    ]
                  },
                  {
                    "text": "Recurrences are commonOften mystify patient and clinicians, as adequate treatment for the more common lactational abscesses has been providedPatients have been suspected of having Munchausen syndromeSubsequent treatment may again be I&D and antibioticsSecondary infections may occurOften due to mixed anaerobic species",
                    "sub_points": [
                      "Often mystify patient and clinicians, as adequate treatment for the more common lactational abscesses has been providedPatients have been suspected of having Munchausen syndrome",
                      "Patients have been suspected of having Munchausen syndrome",
                      "Subsequent treatment may again be I&D and antibiotics",
                      "Secondary infections may occurOften due to mixed anaerobic species",
                      "Often due to mixed anaerobic species"
                    ]
                  },
                  {
                    "text": "A fistula track may form after recurrencesThe path of least resistance is for the abscess to track below the smooth muscle of the areolaA single fistula track opening at the edge of the areola is very characteristicIn other types of nonlactational abscesses, there may be multiple fistula tracks located away from the nipple",
                    "sub_points": [
                      "The path of least resistance is for the abscess to track below the smooth muscle of the areola",
                      "A single fistula track opening at the edge of the areola is very characteristicIn other types of nonlactational abscesses, there may be multiple fistula tracks located away from the nipple",
                      "In other types of nonlactational abscesses, there may be multiple fistula tracks located away from the nipple"
                    ]
                  }
                ],
                "Treatment": [
                  {
                    "text": "Effective treatment requires surgical removal of the keratin-producing epitheliumA wedge resection of the nipple to remove the involved duct may be performedIf a fistula track is present, it should be removed in continuity with the involved duct",
                    "sub_points": [
                      "A wedge resection of the nipple to remove the involved duct may be performed",
                      "If a fistula track is present, it should be removed in continuity with the involved duct"
                    ]
                  },
                  {
                    "text": "Antibiotics may be required for recurrent lesions with secondary infectionsOften due to mixed anaerobic bacteriaCultures are often helpful to establish the type of bacteria and sensitivity to antibiotics",
                    "sub_points": [
                      "Often due to mixed anaerobic bacteria",
                      "Cultures are often helpful to establish the type of bacteria and sensitivity to antibiotics"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "After effective surgical management, recurrences are uncommon"
                  },
                  {
                    "text": "Termination of tobacco use may reduce the likelihood of recurrence"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Patient may not tolerate compression due to the painful mass"
                  },
                  {
                    "text": "The location of the lesion below the nipple also makes the mass difficult to visualize"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Examination may not be possible, as patient may not tolerate pressure from transducer"
                  },
                  {
                    "text": "Location below nipple makes use of ultrasound difficult"
                  },
                  {
                    "text": "In some patients, a mass with irregular margins is presentFistula tracts are generally not visible",
                    "sub_points": [
                      "Fistula tracts are generally not visible"
                    ]
                  }
                ],
                "MR Findings": [
                  {
                    "text": "MR may be better tolerated, as compression is not required"
                  },
                  {
                    "text": "In one study, MR was effective in imaging abscess cavity and associated fistula track"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "1st specimen is often an I&DThe specimen consists of multiple fragments of tissue that cannot be orientedIt can be difficult to distinguish skin from squamous metaplasia in ducts or a fistula tract",
                    "sub_points": [
                      "The specimen consists of multiple fragments of tissue that cannot be oriented",
                      "It can be difficult to distinguish skin from squamous metaplasia in ducts or a fistula tract"
                    ]
                  },
                  {
                    "text": "If a definitive resection is performed, there should be a small fragment of nipple skin and underlying abscess cavityIf possible, sections should be oriented perpendicular to nipple skin",
                    "sub_points": [
                      "If possible, sections should be oriented perpendicular to nipple skin"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "I&D specimens usually consist of tissue from the center of the abscessFindings may be nonspecific, consisting of chronic active inflammationThe presence of giant cells, especially if associated with keratin debris, is very suggestive of SMOLDWell-formed granulomas are unusualIn some cases, ducts partially replaced by squamous epithelium with entrapped keratin debris may be present",
                    "sub_points": [
                      "Findings may be nonspecific, consisting of chronic active inflammation",
                      "The presence of giant cells, especially if associated with keratin debris, is very suggestive of SMOLDWell-formed granulomas are unusual",
                      "Well-formed granulomas are unusual",
                      "In some cases, ducts partially replaced by squamous epithelium with entrapped keratin debris may be present"
                    ]
                  },
                  {
                    "text": "Definitive procedures should include nipple skin and orifice of involved ductIt is helpful to have the surgeon mark the skin surface and to ink and orient the tissue blocks perpendicular to this surfaceSquamous metaplasia of ductal epithelium with entrapped keratin deep to nipple is characteristicBecause patients often have had multiple prior procedures, squamous metaplasia due to surgery may be difficult to distinguish from a primary lesionThe fistula track is usually lined by squamous epithelium",
                    "sub_points": [
                      "It is helpful to have the surgeon mark the skin surface and to ink and orient the tissue blocks perpendicular to this surface",
                      "Squamous metaplasia of ductal epithelium with entrapped keratin deep to nipple is characteristic",
                      "Because patients often have had multiple prior procedures, squamous metaplasia due to surgery may be difficult to distinguish from a primary lesion",
                      "The fistula track is usually lined by squamous epithelium"
                    ]
                  },
                  {
                    "text": "If there is a secondary infection, acute inflammatory cells and bacteria may be present"
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Usually not performed due to pain and location near nipple"
                  },
                  {
                    "text": "A mixed inflammatory infiltrate with giant cells should suggest SMOLD or cystic neutrophilic granulomatous mastitis (CNGM)Location and clinical setting will help determine most likely diagnosis",
                    "sub_points": [
                      "Location and clinical setting will help determine most likely diagnosis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Bacterial Culture": [
                  {
                    "text": "If an abscess is suspected, tissue should be sent for both aerobic and anaerobic culture, including special cultures forCorynebacteriaspecies"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Lactational Abscess": [
                  {
                    "text": "The most common breast infections occur during lactation and breastfeeding"
                  },
                  {
                    "text": "The causative agent is usuallyStaphylococcusspecies or, less commonly,Streptococcusspecies"
                  },
                  {
                    "text": "I&D followed by antibiotics is an effective treatmentSpecimens usually consist of acute inflammatory cells",
                    "sub_points": [
                      "Specimens usually consist of acute inflammatory cells"
                    ]
                  },
                  {
                    "text": "These abscesses usually occur deeper in the breast and are not usually associated with the areola"
                  }
                ],
                "Nonlactational Abscess": [
                  {
                    "text": "Abscesses outside of lactation are rare and due to a wide variety of bacteria; cultures often show mixed anaerobesThe bacteria are likely derived from the normal microbiota of the breastInfections due to mycobacteria, fungi, or other organisms are exceedingly rare",
                    "sub_points": [
                      "The bacteria are likely derived from the normal microbiota of the breast",
                      "Infections due to mycobacteria, fungi, or other organisms are exceedingly rare"
                    ]
                  },
                  {
                    "text": "Most occur deeper in the breast and are not subareolar"
                  },
                  {
                    "text": "Majority are in women; men rarely affectedNot associated with tobacco use",
                    "sub_points": [
                      "Not associated with tobacco use"
                    ]
                  },
                  {
                    "text": "Often require prolonged antibiotic treatment, and recurrences are commonWith recurrences, multiple fistula tracts may open to the skin (i.e., they are not periareolar)",
                    "sub_points": [
                      "With recurrences, multiple fistula tracts may open to the skin (i.e., they are not periareolar)"
                    ]
                  },
                  {
                    "text": "CNGM is a specific subtype of abscess that is strongly associated with infections byCorynebacteriaspeciesCNGM has histologic features that overlap with granulomatous lobular mastitis (GLM), and these may be the same diseaseOnly occur in women with a history of childbearing or other reasons for galactorrheaThe specific histologic features of CNGM are not seen in SMOLD",
                    "sub_points": [
                      "CNGM has histologic features that overlap with granulomatous lobular mastitis (GLM), and these may be the same disease",
                      "Only occur in women with a history of childbearing or other reasons for galactorrhea",
                      "The specific histologic features of CNGM are not seen in SMOLD"
                    ]
                  }
                ],
                "Duct Ectasia": [
                  {
                    "text": "Usually occurs in older women and is not associated with tobacco use"
                  },
                  {
                    "text": "Typical presentation is as a painless, palpable, or radiographic mass or cheesy nipple dischargeUnlike SMOLD, duct ectasia is not usually painful and does not cause erythema",
                    "sub_points": [
                      "Unlike SMOLD, duct ectasia is not usually painful and does not cause erythema"
                    ]
                  },
                  {
                    "text": "Duct ectasia is associated with periductal chronic inflammationSquamous metaplasia and giant cell reaction to keratin are not typical features",
                    "sub_points": [
                      "Squamous metaplasia and giant cell reaction to keratin are not typical features"
                    ]
                  },
                  {
                    "text": "In many studies, duct ectasia is not clearly distinguished from SMOLD"
                  }
                ],
                "Epidermal Inclusion Cyst (EIC) of the Nipple": [
                  {
                    "text": "EICs form in follicles of the skin and dermis and can be found at any site, including breast"
                  },
                  {
                    "text": "The cyst is lined by keratin-producing epithelium and is expanded by keratin debris"
                  },
                  {
                    "text": "When ruptured, the keratin debris causes inflammation and pain"
                  },
                  {
                    "text": "Cases reported to be an EIC of the nipple/areola usually present clinically as a massThese could be cases of SMOLD detected before ruptureReported in both males and females, similar to SMOLDInformation about tobacco use is not providedComplete excision of the mass at 1st intervention is curative",
                    "sub_points": [
                      "These could be cases of SMOLD detected before rupture",
                      "Reported in both males and females, similar to SMOLD",
                      "Information about tobacco use is not provided",
                      "Complete excision of the mass at 1st intervention is curative"
                    ]
                  },
                  {
                    "text": "SMOLD differs from EIC of the nipple in that the squamous metaplasia could extend deeper into the breastDeeply involved ducts could possibly be more prone to rupture",
                    "sub_points": [
                      "Deeply involved ducts could possibly be more prone to rupture"
                    ]
                  }
                ],
                "Biopsy Site Changes": [
                  {
                    "text": "Breast biopsies are often associated with squamous metaplasia, chronic inflammation, and giant cells"
                  },
                  {
                    "text": "Because patients with SMOLD often undergo multiple surgical procedures, it can be difficult to distinguish biopsy site changes from the primary lesion"
                  },
                  {
                    "text": "Squamous metaplasia associated with surgery usually lines the excisional site rather than being present in ductsNot associated with extensive keratinaceous debrisGiant cell reaction is to foreign material and not to keratin",
                    "sub_points": [
                      "Not associated with extensive keratinaceous debris",
                      "Giant cell reaction is to foreign material and not to keratin"
                    ]
                  },
                  {
                    "text": "Squamous metaplasia due to biopsies does not present as a subareolar painful mass unless there is a perioperative infection"
                  },
                  {
                    "text": "Fragments of skin can be displaced into breast tissue after surgical proceduresThese fragments only rarely persist and form squamous cysts",
                    "sub_points": [
                      "These fragments only rarely persist and form squamous cysts"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Key Elements to Report": [
                  {
                    "text": "Findings from small incisional biopsies are often not diagnostic but may be very suggestive of SMOLD"
                  },
                  {
                    "text": "Pathologists can play important role in patient care by suggesting the diagnosis in the appropriate clinical settingSMOLD should be considered in patients with recurrent painful subareolar abscesses, especially if there is history of tobacco use",
                    "sub_points": [
                      "SMOLD should be considered in patients with recurrent painful subareolar abscesses, especially if there is history of tobacco use"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Nonlactational Abscess": {
            "name": "Nonlactational Abscess",
            "url": "https://app.pathprimer.com/document/75a44c71-ce1d-40d3-90b8-93ab65c87f98/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Inflammatory diseases of the breast characterized by clinical symptoms of pain and erythema associated with marked chronic/active inflammation"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Abscesses are the most common symptomatic disease of the breast after carcinoma\"Idiopathic granulomatous mastitis\" is a descriptive term denoting inflammation, including giant cells, and is not a specific disease",
                    "sub_points": [
                      "\"Idiopathic granulomatous mastitis\" is a descriptive term denoting inflammation, including giant cells, and is not a specific disease"
                    ]
                  },
                  {
                    "text": "Understanding the etiology of nonlactational abscesses, when possible, is important, as this can lead to effective treatment and resolution of symptoms"
                  },
                  {
                    "text": "Nonlactational abscesses have infectious and noninfectious etiologiesInfectious: Bacteria, fungi, parasitesNoninfectious: Reactions to keratin, hair, foreign material (surgical debris, piercings, implants)Autoimmune",
                    "sub_points": [
                      "Infectious: Bacteria, fungi, parasites",
                      "Noninfectious: Reactions to keratin, hair, foreign material (surgical debris, piercings, implants)",
                      "Autoimmune"
                    ]
                  },
                  {
                    "text": "The majority are bacterial infections that likely arise from the breast's normal microbiota"
                  },
                  {
                    "text": "These abscesses can cause considerable morbidity to patients due to persistence and recurrence"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Appropriate treatment requires recognition of the pathologic processCan include antibiotics, steroids, &/or surgery",
                    "sub_points": [
                      "Can include antibiotics, steroids, &/or surgery"
                    ]
                  },
                  {
                    "text": "Abscesses due to bacteria often require months of antibiotic treatment, and recurrences are common"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Sarcoidosis"
                  },
                  {
                    "text": "Duct ectasia"
                  },
                  {
                    "text": "Rosai-Dorfman disease"
                  },
                  {
                    "text": "Inflammatory breast carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Granulomatous lobular mastitis (GLM)"
                  },
                  {
                    "text": "Cystic neutrophilic granulomatous mastitis (CNGM)"
                  },
                  {
                    "text": "Squamous metaplasia of lactiferous ducts (SMOLD)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Abscesses of the breast occurring outside the period of pregnancy and lactation"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Introduction": [
                  {
                    "text": "Abscesses are the most common symptomatic disease of the breast after carcinomaPatients present with a tender, painful, palpable mass that is typically associated with skin erythema",
                    "sub_points": [
                      "Patients present with a tender, painful, palpable mass that is typically associated with skin erythema"
                    ]
                  },
                  {
                    "text": "There are many different etiologies, including infections, responses to endogenous and exogenous noncellular material, and autoimmune diseases"
                  },
                  {
                    "text": "Critical to identify underlying cause of the inflammation to ensure the patient receives optimal treatment"
                  },
                  {
                    "text": "Lactational abscesses are the most common, and the majority are due toStaphylococcusspecies"
                  },
                  {
                    "text": "Nonlactational abscesses have a wider range of causes, tend to be persistent, and frequently recur"
                  },
                  {
                    "text": "In the majority of cases, a mixed infiltrate of inflammatory cells and giant cells is present, which can be described as granulomatous mastitis (GM)\"Granulomatous\" is a descriptive term that signifies that giant cells are present; true granuloma formation is rare\"Idiopathic granulomatous mastitis\" (IGM) is a descriptive term meaning the cause of the GM is unknownUnfortunately, many studies refer to IGM as though it were a specific disease process and do not distinguish the many different possible causes",
                    "sub_points": [
                      "\"Granulomatous\" is a descriptive term that signifies that giant cells are present; true granuloma formation is rare",
                      "\"Idiopathic granulomatous mastitis\" (IGM) is a descriptive term meaning the cause of the GM is unknownUnfortunately, many studies refer to IGM as though it were a specific disease process and do not distinguish the many different possible causes",
                      "Unfortunately, many studies refer to IGM as though it were a specific disease process and do not distinguish the many different possible causes"
                    ]
                  },
                  {
                    "text": "They are often treated like lactational abscesses, and this treatment is typically ineffectiveThe mass persists and may progress to sinus tracts to the skinIf there is partial resolution, the pain and mass often recurs",
                    "sub_points": [
                      "The mass persists and may progress to sinus tracts to the skin",
                      "If there is partial resolution, the pain and mass often recurs"
                    ]
                  },
                  {
                    "text": "Affected patients have considerable morbidityThe refractory nature of these abscesses often leads to frustration for both patients and cliniciansSome patients have been accused of Munchausen syndrome",
                    "sub_points": [
                      "The refractory nature of these abscesses often leads to frustration for both patients and clinicians",
                      "Some patients have been accused of Munchausen syndrome"
                    ]
                  },
                  {
                    "text": "Understanding the etiology of these abscesses, when possible, is important, as this can lead to effective treatment and resolution of symptoms"
                  }
                ],
                "Infections": [
                  {
                    "text": "Infections can occur due to the breast's own normal microbiota or from exogenous infectious agents"
                  },
                  {
                    "text": "Normal breast microbiotaThe microbiota has similarities to the skin, oral cavity, and gut microbiotaDifferences in bacterial populations are likely due to the relative anoxic and lipid-rich environment of the duct/lobular systemBacteria are present in the normal breast prior to lactation and breastfeedingNumerous anaerobic bacteria are presentDuring breastfeeding, breast milk contains an abundance of multiple bacterial speciesAn exchange of bacteria occurs when the infant suckles milk and there is subsequent retrograde flow of milk back into the breast ductsThe most abundant species in milk are from staphylococci, streptococci, andPseudomonasIt is estimated that infants consume 7-8 billion bacteria per dayLactational abscesses occur when bacteria and milk escape from the ductal systemThese are generally readily resolved with antibiotic treatment and drainageSome nonlactational abscesses also likely occur due to lipids and bacteria outside of the ductal systemCNGM and GLM predominantly occur in women with a history of pregnancy or galactorrhea due to another causeThe most common identified type of bacteria,Corynebacteriumsp., is a member of the normal microbiota",
                    "sub_points": [
                      "The microbiota has similarities to the skin, oral cavity, and gut microbiotaDifferences in bacterial populations are likely due to the relative anoxic and lipid-rich environment of the duct/lobular system",
                      "Differences in bacterial populations are likely due to the relative anoxic and lipid-rich environment of the duct/lobular system",
                      "Bacteria are present in the normal breast prior to lactation and breastfeedingNumerous anaerobic bacteria are present",
                      "Numerous anaerobic bacteria are present",
                      "During breastfeeding, breast milk contains an abundance of multiple bacterial speciesAn exchange of bacteria occurs when the infant suckles milk and there is subsequent retrograde flow of milk back into the breast ductsThe most abundant species in milk are from staphylococci, streptococci, andPseudomonasIt is estimated that infants consume 7-8 billion bacteria per day",
                      "An exchange of bacteria occurs when the infant suckles milk and there is subsequent retrograde flow of milk back into the breast ducts",
                      "The most abundant species in milk are from staphylococci, streptococci, andPseudomonas",
                      "It is estimated that infants consume 7-8 billion bacteria per day",
                      "Lactational abscesses occur when bacteria and milk escape from the ductal systemThese are generally readily resolved with antibiotic treatment and drainage",
                      "These are generally readily resolved with antibiotic treatment and drainage",
                      "Some nonlactational abscesses also likely occur due to lipids and bacteria outside of the ductal systemCNGM and GLM predominantly occur in women with a history of pregnancy or galactorrhea due to another causeThe most common identified type of bacteria,Corynebacteriumsp., is a member of the normal microbiota",
                      "CNGM and GLM predominantly occur in women with a history of pregnancy or galactorrhea due to another causeThe most common identified type of bacteria,Corynebacteriumsp., is a member of the normal microbiota",
                      "The most common identified type of bacteria,Corynebacteriumsp., is a member of the normal microbiota"
                    ]
                  },
                  {
                    "text": "Exogenous infectious agentsMycobacteria, fungi, and parasites are extremely rare causes of nonlactational abscesses",
                    "sub_points": [
                      "Mycobacteria, fungi, and parasites are extremely rare causes of nonlactational abscesses"
                    ]
                  }
                ],
                "Endogenous Substances": [
                  {
                    "text": "Keratin debris from SMOLD or epidermal inclusion cysts (EICs) (of the skin or iatrogenic) or hairs (pilonidal sinuses) can invoke an intense inflammatory response"
                  },
                  {
                    "text": "Inflammatory responses to lipids from ruptured cysts, ducts, or to amyloid is usually milder and often does not produce symptoms"
                  }
                ],
                "Exogenous Foreign Material": [
                  {
                    "text": "Surgical debris, piercings, implants, and injections for breast augmentation can all result in inflammatory responses"
                  },
                  {
                    "text": "Pilonidal sinuses can result from either the patient's own hair or hair from other human or animal sources"
                  }
                ],
                "Autoimmune Disease": [
                  {
                    "text": "Autoimmune diseases are very rarely associated with GM"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Very rare: < 1% of breast biopsiesOf all breast abscesses undergoing surgical intervention, ~ 85% are nonlactational abscesses",
                    "sub_points": [
                      "Of all breast abscesses undergoing surgical intervention, ~ 85% are nonlactational abscesses"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Wide range"
                  }
                ],
                "Sex": [
                  {
                    "text": "Majority occur in women"
                  },
                  {
                    "text": "Some types occur only in women (CNGM/GLM)"
                  },
                  {
                    "text": "Some occur in both women and men (e.g., SMOLD, TB, pilonidal sinuses)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Patients present with an erythematous firm, discrete, painful, palpable breast mass ranging from 1-8 cm in size"
                  },
                  {
                    "text": "There may be skin retraction (due to the inflammation), and ~ 25% have enlarged regional lymph nodes"
                  },
                  {
                    "text": "With persistence/recurrence, sinus tracts may develop to the skin"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Appropriate treatment is dependent on identifying the cause of the abscess"
                  },
                  {
                    "text": "AntibioticsAppropriate when an infectious cause is identifiedOften, treatment is empirically directed toward staphylococcal sp., as the cause is assumed to be the same as lactational abscesses and is ineffectiveCultures are helpful to identify a specific organismWhen a bacterial infection is identified, the treatment should be targeted to the specific type of bacteriaTreatment may be required beyond the resolution of symptoms (weeks to many months)",
                    "sub_points": [
                      "Appropriate when an infectious cause is identified",
                      "Often, treatment is empirically directed toward staphylococcal sp., as the cause is assumed to be the same as lactational abscesses and is ineffective",
                      "Cultures are helpful to identify a specific organism",
                      "When a bacterial infection is identified, the treatment should be targeted to the specific type of bacteriaTreatment may be required beyond the resolution of symptoms (weeks to many months)",
                      "Treatment may be required beyond the resolution of symptoms (weeks to many months)"
                    ]
                  },
                  {
                    "text": "SurgerySurgery is appropriate to remove an inciting agent when present (e.g., duct excision for SMOLD, exogenous material)",
                    "sub_points": [
                      "Surgery is appropriate to remove an inciting agent when present (e.g., duct excision for SMOLD, exogenous material)"
                    ]
                  },
                  {
                    "text": "SteroidsSteroids may be therapeutic for some diseases and alleviate symptoms for others",
                    "sub_points": [
                      "Steroids may be therapeutic for some diseases and alleviate symptoms for others"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Many cases resolve when the etiology is identified and appropriate treatment is administered"
                  },
                  {
                    "text": "However, persistence and recurrence are common for many patients, as the cause is not determined and they receive inappropriate treatment"
                  }
                ]
              },
              "IMAGING": {
                "Ultrasonographic Findings": [
                  {
                    "text": "Abscesses typically form complex masses with both solid and fluid areas, tubular structures (debris-filled ducts), and ill-defined or angulated marginsOften have mixed echogenicity",
                    "sub_points": [
                      "Often have mixed echogenicity"
                    ]
                  },
                  {
                    "text": "Ultrasound is often used to drain abscesses and to obtain material for culture"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Some types of abscesses have characteristic histologic features"
                  },
                  {
                    "text": "However, in many cases, a specific etiology cannot be identified"
                  }
                ],
                "Cystic Neutrophilic Granulomatous Mastitis (CNGM)/Granulomatous Lobular Mastitis (GLM)": [
                  {
                    "text": "These lesions were originally described separately but likely represent the same disease"
                  },
                  {
                    "text": "Both only occur in women who have a history of secretory/lactational changes in the breastPrior pregnancy: Can be many years in the past (average: 2 years)Use of psychoactive drugs causing galactorrheaPituitary prolactinoma causing galactorrhea",
                    "sub_points": [
                      "Prior pregnancy: Can be many years in the past (average: 2 years)",
                      "Use of psychoactive drugs causing galactorrhea",
                      "Pituitary prolactinoma causing galactorrhea"
                    ]
                  },
                  {
                    "text": "There are rare reports of CNGM occurring after nipple piercing or core needle biopsy"
                  },
                  {
                    "text": "Present with a painful palpable mass: Usually located away from the nippleSkin erythema and edema can be presentFever, leukocytosis, nipple inversion, nipple discharge, and lymphadenopathy are less commonWith long duration/recurrences, 1 or more fistula tracts can open onto breast skin",
                    "sub_points": [
                      "Skin erythema and edema can be present",
                      "Fever, leukocytosis, nipple inversion, nipple discharge, and lymphadenopathy are less common",
                      "With long duration/recurrences, 1 or more fistula tracts can open onto breast skin"
                    ]
                  },
                  {
                    "text": "Core needle biopsies show a mixed inflammatory infiltrate with neutrophils and scattered giant cells; microscopic lipid cysts may be seen"
                  },
                  {
                    "text": "Large excisions show well-formed granulomas centered on ducts and lobulesEpithelium appears to be distorted or obscured by granulomasLocation suggests the reaction is due to seepage of lipids and bacteria from the duct/lobular systemCentral caseating necrosis is not present, but there may be microabscessesIf granulomas are scattered in breast stroma, other diagnoses, such as TB or sarcoid, should be considered",
                    "sub_points": [
                      "Epithelium appears to be distorted or obscured by granulomas",
                      "Location suggests the reaction is due to seepage of lipids and bacteria from the duct/lobular system",
                      "Central caseating necrosis is not present, but there may be microabscesses",
                      "If granulomas are scattered in breast stroma, other diagnoses, such as TB or sarcoid, should be considered"
                    ]
                  },
                  {
                    "text": "Langhans giant cells and chronic active inflammation are associated with granulomas"
                  },
                  {
                    "text": "Lipid \"cysts\" or vacuoles (\"lipogranulomas\") are a defining featureWithin an area of inflammation, rounded, clear spaces are rimmed by neutrophilsEpithelioid histiocytes and giant cells also surround the space",
                    "sub_points": [
                      "Within an area of inflammation, rounded, clear spaces are rimmed by neutrophils",
                      "Epithelioid histiocytes and giant cells also surround the space"
                    ]
                  },
                  {
                    "text": "Special stains for microorganisms should be performedIf present, bacteria are usually only seen within lipid vacuoles and not elsewhere in the inflammatory infiltrateBacteria found within lipid vacuoles are gram-positive bacilli and have features ofCorynebacteriumsp.Palisading, V shapes, and clubbingCorynebacteriumis derived from the Greek \"korune\" or club-shapedBacteria are easily missed if not sought for in this location &/or may be dismissed as an artifactBacteria are not present in all vacuoles and may be absent if the patient has been treated with antibioticsThese bacteria are lipophilic: The presence within an area of lipids may protect the bacteria from the immune response and antibiotics",
                    "sub_points": [
                      "If present, bacteria are usually only seen within lipid vacuoles and not elsewhere in the inflammatory infiltrate",
                      "Bacteria found within lipid vacuoles are gram-positive bacilli and have features ofCorynebacteriumsp.Palisading, V shapes, and clubbingCorynebacteriumis derived from the Greek \"korune\" or club-shapedBacteria are easily missed if not sought for in this location &/or may be dismissed as an artifactBacteria are not present in all vacuoles and may be absent if the patient has been treated with antibioticsThese bacteria are lipophilic: The presence within an area of lipids may protect the bacteria from the immune response and antibiotics",
                      "Palisading, V shapes, and clubbingCorynebacteriumis derived from the Greek \"korune\" or club-shaped",
                      "Corynebacteriumis derived from the Greek \"korune\" or club-shaped",
                      "Bacteria are easily missed if not sought for in this location &/or may be dismissed as an artifactBacteria are not present in all vacuoles and may be absent if the patient has been treated with antibiotics",
                      "Bacteria are not present in all vacuoles and may be absent if the patient has been treated with antibiotics",
                      "These bacteria are lipophilic: The presence within an area of lipids may protect the bacteria from the immune response and antibiotics"
                    ]
                  },
                  {
                    "text": "Treatment with antibiotics can require many months for resolution"
                  },
                  {
                    "text": "Experimental therapies include the use of lipophilic antibiotics and direct injection into the abscess"
                  },
                  {
                    "text": "If bacteria are not found in cases of GLM, it has been hypothesized that the granulomas may be an immune response to antigens associated with pregnancy or lactation"
                  }
                ],
                "Tuberculosis": [
                  {
                    "text": "TB of the breast is rare, even in locations where infection is endemic"
                  },
                  {
                    "text": "Most common in young women (often during lactation) but also occurs in older women and men"
                  },
                  {
                    "text": "Presents as a painful palpable massMore extensive disease can cause skin ulceration, draining sinuses, and be associated with lymphadenopathy",
                    "sub_points": [
                      "More extensive disease can cause skin ulceration, draining sinuses, and be associated with lymphadenopathy"
                    ]
                  },
                  {
                    "text": "Granulomas are scattered throughout breast tissue and not localized around epithelium, as is seen in CNGM/GLM"
                  },
                  {
                    "text": "Central caseating necrosis is present"
                  },
                  {
                    "text": "Mycobacteria are seen on special stains (e.g., Ziehl-Neelsen) in giant cells"
                  }
                ],
                "Other Bacterial Infections": [
                  {
                    "text": "In some patients, the clinical setting and histologic appearance are very suggestive of infection, but bacteria cannot be identified microscopically or by culture"
                  },
                  {
                    "text": "Bacteria typical of the breast microbiota may be difficult to culture because they are often anaerobic, fastidious (requiring special culture), or are few in numberPositive cultures may be dismissed as contaminated because a mixed flora or species common to skin are present",
                    "sub_points": [
                      "Positive cultures may be dismissed as contaminated because a mixed flora or species common to skin are present"
                    ]
                  },
                  {
                    "text": "Patients may have been treated empirically with antibiotics prior to biopsy, which can make identification more difficult"
                  },
                  {
                    "text": "Newer 16s rRNA or DNA sequencing techniques may prove helpful in identifying pathogens in these cases"
                  }
                ],
                "Fungal Infections": [
                  {
                    "text": "All fungal infections are very rare"
                  },
                  {
                    "text": "Candida: Can occur on nipple skin during breastfeeding but is unlikely to be biopsied"
                  },
                  {
                    "text": "Aspergillus: Rare cases associated with breast implants"
                  },
                  {
                    "text": "Histoplasma: Causes necrotizing granulomatous inflammationNarrow-based budding yeast forms",
                    "sub_points": [
                      "Narrow-based budding yeast forms"
                    ]
                  },
                  {
                    "text": "Blastomyces: Causes necrotizing granulomatous inflammationBroad-based budding yeast forms",
                    "sub_points": [
                      "Broad-based budding yeast forms"
                    ]
                  },
                  {
                    "text": "Cryptococcus: Yeast forms are found in infiltrates of foamy histiocytesMucicarmine and Fontana Masson stains are helpful to identify the polysaccharide capsule",
                    "sub_points": [
                      "Mucicarmine and Fontana Masson stains are helpful to identify the polysaccharide capsule"
                    ]
                  }
                ],
                "Parasitic Infections": [
                  {
                    "text": "All parasitic infections are very rare"
                  },
                  {
                    "text": "Inflammation forms a superficial, hard, nontender mass that can retract the skinRegional lymph nodes can be enlarged",
                    "sub_points": [
                      "Regional lymph nodes can be enlarged"
                    ]
                  },
                  {
                    "text": "Inflammatory reaction consists of a necrotic center and prominent infiltrate of eosinophilsPortions of viable and degenerating organisms may be seen in the area of necrosis",
                    "sub_points": [
                      "Portions of viable and degenerating organisms may be seen in the area of necrosis"
                    ]
                  },
                  {
                    "text": "Filariasis (round worms)Found worldwideDead worms in lymphatics may be seen as serpiginous calcificationsWuchereriabancrofti: South America, China, IndiaDirofilaria repens: North America, Europe, AsiaMore commonly infects dogs and cats but may also infect humansOnchocerca volvulus: Latin America, Sub-Saharan Africa",
                    "sub_points": [
                      "Found worldwide",
                      "Dead worms in lymphatics may be seen as serpiginous calcifications",
                      "Wuchereriabancrofti: South America, China, India",
                      "Dirofilaria repens: North America, Europe, AsiaMore commonly infects dogs and cats but may also infect humans",
                      "More commonly infects dogs and cats but may also infect humans",
                      "Onchocerca volvulus: Latin America, Sub-Saharan Africa"
                    ]
                  },
                  {
                    "text": "Sparganosis (tapeworm larva ofSpirometragenus)Southeast AsiaForms a palpable mass: Usually in subcutaneous tissue rather than deeper in breastCan be painful and pruriticDiagnosis can sometimes be made by ultrasound by imaging larval movementsAn eosinophilic tegument surrounds a myxoid matrix containing smooth muscle fibers and calcareous bodies",
                    "sub_points": [
                      "Southeast Asia",
                      "Forms a palpable mass: Usually in subcutaneous tissue rather than deeper in breastCan be painful and pruritic",
                      "Can be painful and pruritic",
                      "Diagnosis can sometimes be made by ultrasound by imaging larval movements",
                      "An eosinophilic tegument surrounds a myxoid matrix containing smooth muscle fibers and calcareous bodies"
                    ]
                  },
                  {
                    "text": "Schistosomiasis (parasitic fluke)Southeast Asia, South America, CaribbeanCalcified ova are present in ducts and lobules",
                    "sub_points": [
                      "Southeast Asia, South America, Caribbean",
                      "Calcified ova are present in ducts and lobules"
                    ]
                  },
                  {
                    "text": "Cysticercosis (larval form ofTaenia solium)Africa, Asia, Eastern Europe, Latin AmericaCysts can contain viable larva or calcified dead organismsLarva has a scolex and hooks",
                    "sub_points": [
                      "Africa, Asia, Eastern Europe, Latin America",
                      "Cysts can contain viable larva or calcified dead organismsLarva has a scolex and hooks",
                      "Larva has a scolex and hooks"
                    ]
                  }
                ],
                "Squamous Metaplasia of Lactiferous Ducts (SMOLD)": [
                  {
                    "text": "Presents as a painful subareolar mass with skin erythema"
                  },
                  {
                    "text": "Also termed Zuska disease and recurrent subareolar abscess"
                  },
                  {
                    "text": "Occurs in both females and malesThe majority of affected individuals have a history of smokingSmoking substances wrapped in tobacco leaves is also implicated",
                    "sub_points": [
                      "The majority of affected individuals have a history of smokingSmoking substances wrapped in tobacco leaves is also implicated",
                      "Smoking substances wrapped in tobacco leaves is also implicated"
                    ]
                  },
                  {
                    "text": "Squamous cells extend abnormally deep into lactiferous sinusesKeratin becomes trapped and distends the ductIf the duct ruptures, an intense inflammatory response ensues",
                    "sub_points": [
                      "Keratin becomes trapped and distends the duct",
                      "If the duct ruptures, an intense inflammatory response ensues"
                    ]
                  },
                  {
                    "text": "The initial lesion is usually thought to be an infection and often treated like a lactational abscessIncision and drainage can aggravate the inflammation by dispersing keratin in tissueAntibiotic treatment for staphylococcal species is typically ineffective, as the lesion can be sterileSecondary infections, usually after recurrence, are often due to mixed anaerobesThe name \"recurrent subareolar abscess\" arises due to frequent treatment that does not address the underlying disease",
                    "sub_points": [
                      "Incision and drainage can aggravate the inflammation by dispersing keratin in tissue",
                      "Antibiotic treatment for staphylococcal species is typically ineffective, as the lesion can be sterileSecondary infections, usually after recurrence, are often due to mixed anaerobes",
                      "Secondary infections, usually after recurrence, are often due to mixed anaerobes",
                      "The name \"recurrent subareolar abscess\" arises due to frequent treatment that does not address the underlying disease"
                    ]
                  },
                  {
                    "text": "With recurrence or persistence, a single fistula tract opening at the edge of the areola is characteristicThe inflammation burrows under the nipple and opens to the surface just beyond the smooth muscle of the areola",
                    "sub_points": [
                      "The inflammation burrows under the nipple and opens to the surface just beyond the smooth muscle of the areola"
                    ]
                  },
                  {
                    "text": "Appropriate treatment is excision of the involved duct, including the fistula tract (if present)Cessation of smoking can also be helpful",
                    "sub_points": [
                      "Cessation of smoking can also be helpful"
                    ]
                  }
                ],
                "Reactions to Endogenous Noncellular Material": [
                  {
                    "text": "Keratin debris and hair can incite an intense inflammatory reaction"
                  },
                  {
                    "text": "Reactions to secretions, milk (during lactation), calcifications, and amyloid are generally chronic, do not cause pain, and often resolve with timeThey can result in painless masses, which bring them to attentionDuct ectasia, ruptured cysts, and galactoceles are the most common types of lesions",
                    "sub_points": [
                      "They can result in painless masses, which bring them to attention",
                      "Duct ectasia, ruptured cysts, and galactoceles are the most common types of lesions"
                    ]
                  },
                  {
                    "text": "KeratinThe abscesses related to SMOLD are a reaction to keratin debris trapped deep in breast ducts (previously discussed)Epidermal inclusion cysts (EICs) can occur on breast skin or be deep in the breast due to iatrogenic displacement of skin during surgeryEICs occurring at the nipple can be difficult to distinguish from SMOLDRupture results in a painful inflammatory massReactions to keratin or hair are more intense and typically present as a painful mass with erythema",
                    "sub_points": [
                      "The abscesses related to SMOLD are a reaction to keratin debris trapped deep in breast ducts (previously discussed)",
                      "Epidermal inclusion cysts (EICs) can occur on breast skin or be deep in the breast due to iatrogenic displacement of skin during surgeryEICs occurring at the nipple can be difficult to distinguish from SMOLDRupture results in a painful inflammatory mass",
                      "EICs occurring at the nipple can be difficult to distinguish from SMOLD",
                      "Rupture results in a painful inflammatory mass",
                      "Reactions to keratin or hair are more intense and typically present as a painful mass with erythema"
                    ]
                  },
                  {
                    "text": "HairPilonidal sinuses result from hairs embedded in breast tissueThe hair can either be from the patient or from other humans or animalsBoth women and men are affectedReported to occur in sheep shearers, dog groomers, barbers, and beauticiansOften occur in the nipple/areolar region",
                    "sub_points": [
                      "Pilonidal sinuses result from hairs embedded in breast tissue",
                      "The hair can either be from the patient or from other humans or animals",
                      "Both women and men are affected",
                      "Reported to occur in sheep shearers, dog groomers, barbers, and beauticians",
                      "Often occur in the nipple/areolar region"
                    ]
                  }
                ],
                "Reactions to Exogenous Noncellular Material": [
                  {
                    "text": "Foreign material may be present in the breast due to biopsy, surgical procedures, cosmetic procedures, or trauma"
                  },
                  {
                    "text": "These materials generally do not cause pain or acute inflammation but do predispose to secondary infections"
                  },
                  {
                    "text": "Rare women report allergic-type symptoms to metalsNipple rings: Granulomas can form adjacent to the piercing siteClips marking core needle biopsy sites: Rare patients report symptoms that resolve when the clip is removed",
                    "sub_points": [
                      "Nipple rings: Granulomas can form adjacent to the piercing site",
                      "Clips marking core needle biopsy sites: Rare patients report symptoms that resolve when the clip is removed"
                    ]
                  }
                ],
                "Autoimmune Disease": [
                  {
                    "text": "Autoimmune diseases rarely present as breast masses"
                  },
                  {
                    "text": "Granulomatosis with polyangiitisFormerly known as Wegener granulomatosisCan involve breast primarily (rare) or as part of systemic involvement (lung and kidney)Chronic-active inflammation with fat necrosis and necrotizing vasculitis are typical findingsGranulomas may be present but are not a predominant feature",
                    "sub_points": [
                      "Formerly known as Wegener granulomatosis",
                      "Can involve breast primarily (rare) or as part of systemic involvement (lung and kidney)",
                      "Chronic-active inflammation with fat necrosis and necrotizing vasculitis are typical findingsGranulomas may be present but are not a predominant feature",
                      "Granulomas may be present but are not a predominant feature"
                    ]
                  },
                  {
                    "text": "IgG4-sclerosing mastitisIgG4-related mastitis is characterized by a dense lymphoplasmacytic infiltrate, stromal fibrosis, and obliterative phlebitisAn increased number of IgG4 plasma cells is characteristicGranulomas and giant cells are not typical featuresPresents as a breast mass in womenThe features of fibrosis and obliterative phlebitis are less common in the breastOnly ~ 25% of women have other organs in addition to breast involved by IgG4-related disease",
                    "sub_points": [
                      "IgG4-related mastitis is characterized by a dense lymphoplasmacytic infiltrate, stromal fibrosis, and obliterative phlebitisAn increased number of IgG4 plasma cells is characteristicGranulomas and giant cells are not typical features",
                      "An increased number of IgG4 plasma cells is characteristic",
                      "Granulomas and giant cells are not typical features",
                      "Presents as a breast mass in womenThe features of fibrosis and obliterative phlebitis are less common in the breast",
                      "The features of fibrosis and obliterative phlebitis are less common in the breast",
                      "Only ~ 25% of women have other organs in addition to breast involved by IgG4-related disease"
                    ]
                  }
                ],
                "Nonlactational Abscesses on Core Needle Biopsy": [
                  {
                    "text": "The initial specimen from the majority of cases of nonlactational abscesses is a core needle biopsy"
                  },
                  {
                    "text": "Diagnostic features may not be present with limited sampling"
                  },
                  {
                    "text": "It is important to recognize the lipid cysts of CNGM/GLM and the giant cell response to keratin of SMOLD when present"
                  },
                  {
                    "text": "The pathologist can often play an important clinical role in suggesting a differential diagnosis based on the clinical setting and the histologic features, even when a specific diagnosis cannot be provided"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "Gram stainThe majority of breast infections are caused by bacteria, and a Gram stain is the most likely stain to confirm organismsBacterial infections of the breast are often associated with GMAt other anatomic sites, giant cells are more commonly associated with mycobacteria or fungiMay be due to associated seepage of lipids and secretions, which stimulates a chronic inflammatory responseIn one study, thicker 6-μm sections showed more bacteria than 4-μm sections",
                    "sub_points": [
                      "The majority of breast infections are caused by bacteria, and a Gram stain is the most likely stain to confirm organismsBacterial infections of the breast are often associated with GMAt other anatomic sites, giant cells are more commonly associated with mycobacteria or fungiMay be due to associated seepage of lipids and secretions, which stimulates a chronic inflammatory response",
                      "Bacterial infections of the breast are often associated with GMAt other anatomic sites, giant cells are more commonly associated with mycobacteria or fungi",
                      "At other anatomic sites, giant cells are more commonly associated with mycobacteria or fungi",
                      "May be due to associated seepage of lipids and secretions, which stimulates a chronic inflammatory response",
                      "In one study, thicker 6-μm sections showed more bacteria than 4-μm sections"
                    ]
                  },
                  {
                    "text": "Acid fast and silver stainsExcept in unusual clinical settings or with morphologic findings, stains for mycobacteria or fungi are of limited value, as these organisms are very rarely seen in the breast",
                    "sub_points": [
                      "Except in unusual clinical settings or with morphologic findings, stains for mycobacteria or fungi are of limited value, as these organisms are very rarely seen in the breast"
                    ]
                  }
                ],
                "Bacterial Culture": [
                  {
                    "text": "Cultures should be sent when biopsies are performed of known or suspected abscessesShould include aerobic and anaerobic cultures and cultures specifically forCorynebacterium species and atypical mycobacteriaCultures may be negative in patients who have received prior antibiotic treatmentOften show multiple bacterial species and bacteria also present on skinResults may be dismissed as contaminants unless the clinical setting is knownCorynebacteria (especiallyCorynebacteriumkroppenstedtii) are commonly associated with CNGM/GLM but are difficult to cultureSpecial culture medium is required as well as prolonged incubation (> 72 hours)Identification and susceptibility testing may not be performed unless pathologic correlation confirms that the bacteria are pathogenicCultures can be negative, even in cases with histologically demonstrated bacteriaCorynebacteria are part of normal skin flora and may be classified by laboratories as contaminants",
                    "sub_points": [
                      "Should include aerobic and anaerobic cultures and cultures specifically forCorynebacterium species and atypical mycobacteria",
                      "Cultures may be negative in patients who have received prior antibiotic treatment",
                      "Often show multiple bacterial species and bacteria also present on skinResults may be dismissed as contaminants unless the clinical setting is known",
                      "Results may be dismissed as contaminants unless the clinical setting is known",
                      "Corynebacteria (especiallyCorynebacteriumkroppenstedtii) are commonly associated with CNGM/GLM but are difficult to cultureSpecial culture medium is required as well as prolonged incubation (> 72 hours)Identification and susceptibility testing may not be performed unless pathologic correlation confirms that the bacteria are pathogenicCultures can be negative, even in cases with histologically demonstrated bacteriaCorynebacteria are part of normal skin flora and may be classified by laboratories as contaminants",
                      "Special culture medium is required as well as prolonged incubation (> 72 hours)",
                      "Identification and susceptibility testing may not be performed unless pathologic correlation confirms that the bacteria are pathogenic",
                      "Cultures can be negative, even in cases with histologically demonstrated bacteriaCorynebacteria are part of normal skin flora and may be classified by laboratories as contaminants",
                      "Corynebacteria are part of normal skin flora and may be classified by laboratories as contaminants"
                    ]
                  }
                ],
                "16s rRNA Sequencing": [
                  {
                    "text": "16s rRNA polymerase chain reaction (PCR) amplification and sequencing can be used to identify difficult to culture bacteria"
                  },
                  {
                    "text": "This assay can be performed on formalin-fixed, paraffin-embedded tissue"
                  },
                  {
                    "text": "Appropriate controls are essential for reliable resultsResults can be falsely negative if insufficient microbial RNA is presentResults can be falsely positive due to contaminants in paraffin and water",
                    "sub_points": [
                      "Results can be falsely negative if insufficient microbial RNA is present",
                      "Results can be falsely positive due to contaminants in paraffin and water"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Sarcoidosis": [
                  {
                    "text": "Patients present with a painless breast mass"
                  },
                  {
                    "text": "Granulomas are well formed and scattered throughout breast tissueGranulomas are not specifically located adjacent to breast epitheliumSchaumann bodies (calcifications) and asteroid bodies can be present in histiocytes",
                    "sub_points": [
                      "Granulomas are not specifically located adjacent to breast epithelium",
                      "Schaumann bodies (calcifications) and asteroid bodies can be present in histiocytes"
                    ]
                  },
                  {
                    "text": "Necrosis and microabscesses would be very unusual"
                  }
                ],
                "Duct Ectasia": [
                  {
                    "text": "Presents as palpable nonpainful subareolar mass"
                  },
                  {
                    "text": "Thick nipple discharge may be present"
                  },
                  {
                    "text": "Large lactiferous ducts of nipple are ectatic and filled with inspissated lipid debrisEscape of lipids results in periductal chronic inflammation and fibrosis",
                    "sub_points": [
                      "Escape of lipids results in periductal chronic inflammation and fibrosis"
                    ]
                  }
                ],
                "Rosai-Dorfman Disease": [
                  {
                    "text": "This is a benign self-limited proliferation of S100(+) histiocytes and lymphocytes"
                  },
                  {
                    "text": "Rarely forms a painless breast mass"
                  },
                  {
                    "text": "Emperipolesis (macrophages engulfing neutrophils and other cells) is characteristic"
                  }
                ],
                "Inflammatory Breast Carcinoma": [
                  {
                    "text": "Inflammatory breast carcinoma should always be considered in women presenting with an erythematous breast"
                  },
                  {
                    "text": "The erythema and edema are due to lymphatic plugging by tumor cells and not to inflammation"
                  },
                  {
                    "text": "The skin changes are generally diffuse, involving much of the breast, and a palpable mass is usually absent"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Inflammation associated with giant cells (\"granulomatous inflammation\") in the breast is most commonly associated with bacterial infectionsA Gram stain is the most important for diagnosisInfections due to mycobacteria and fungi are vanishingly rare",
                    "sub_points": [
                      "A Gram stain is the most important for diagnosis",
                      "Infections due to mycobacteria and fungi are vanishingly rare"
                    ]
                  },
                  {
                    "text": "\"Idiopathic granulomatous mastitis\" and \"granulomatous mastitis\" are descriptive terms and not specific diseases"
                  },
                  {
                    "text": "Specific diagnoses should be considered and applied when appropriate"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Iatrogenic Changes": {
            "name": "Iatrogenic Changes",
            "url": "https://app.pathprimer.com/document/ef45d1fe-4bfe-4bda-9de4-97773d486588/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Pathologic changes occur in breast due to prior surgery, radiation therapy, and medical treatment and are important to recognizeThey are often important clues to critical patient history and can be the etiologic cause of symptoms, as well as benign and malignant tumorsIatrogenic changes can also be mistaken for malignancy",
                    "sub_points": [
                      "They are often important clues to critical patient history and can be the etiologic cause of symptoms, as well as benign and malignant tumors",
                      "Iatrogenic changes can also be mistaken for malignancy"
                    ]
                  },
                  {
                    "text": "Core needle biopsy site changes"
                  },
                  {
                    "text": "Surgical site changes"
                  },
                  {
                    "text": "Radiation changes"
                  },
                  {
                    "text": "Changes due to pharmaceuticalsNeoadjuvant chemotherapy/HER2-targeted therapyFulvestrantCyclosporineHighly active antiretroviral therapy (HAART)CoumadinAmyloid due to insulinGold",
                    "sub_points": [
                      "Neoadjuvant chemotherapy/HER2-targeted therapy",
                      "Fulvestrant",
                      "Cyclosporine",
                      "Highly active antiretroviral therapy (HAART)",
                      "Coumadin",
                      "Amyloid due to insulin",
                      "Gold"
                    ]
                  },
                  {
                    "text": "Tattoo pigment"
                  },
                  {
                    "text": "Breast implants"
                  },
                  {
                    "text": "Treatment-related tumorsPostradiation atypical vascular lesionRadiation-associated sarcomaRadiation-associated carcinomaHormone replacement treatment-related carcinomasBreast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and squamous cell carcinomaFibromatosis associated with surgery",
                    "sub_points": [
                      "Postradiation atypical vascular lesion",
                      "Radiation-associated sarcoma",
                      "Radiation-associated carcinoma",
                      "Hormone replacement treatment-related carcinomas",
                      "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and squamous cell carcinoma",
                      "Fibromatosis associated with surgery"
                    ]
                  },
                  {
                    "text": "Iatrogenic changes mimicking malignancyEpithelial displacementReactive spindle cell noduleInfarctionDegenerating or regenerating skeletal muscleAtypical cells in seroma fluid",
                    "sub_points": [
                      "Epithelial displacement",
                      "Reactive spindle cell nodule",
                      "Infarction",
                      "Degenerating or regenerating skeletal muscle",
                      "Atypical cells in seroma fluid"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Histologic changes in breast tissue due to prior treatment (surgery, radiation, or medical treatment)"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "It is important to recognize histologic changes related to prior medical treatment in the breastThey are often important clues to critical patient historyThey can be the etiologic cause of the patient's symptomsThey can cause benign and malignant tumorsThey can be mistaken for malignancy",
                    "sub_points": [
                      "They are often important clues to critical patient history",
                      "They can be the etiologic cause of the patient's symptoms",
                      "They can cause benign and malignant tumors",
                      "They can be mistaken for malignancy"
                    ]
                  }
                ],
                "Core Needle Biopsy Site Changes": [
                  {
                    "text": "Core needle biopsy sites are seen in the subsequent surgical excisionImportant to identify biopsy site changes histologicallyIf a clip was placed, it is important to identify the clip by specimen imaging and grossly",
                    "sub_points": [
                      "Important to identify biopsy site changes histologically",
                      "If a clip was placed, it is important to identify the clip by specimen imaging and grossly"
                    ]
                  },
                  {
                    "text": "The needle track is a linear area of fibrosis with increased cellularity and hemosiderin-laden macrophages adjacent to the biopsied lesion"
                  },
                  {
                    "text": "Grossly, the site usually has a small central area of hemorrhage (~ 0.5 cm) surrounded by an ill-defined firm area and fat necrosis"
                  },
                  {
                    "text": "The clip placed by the radiologist is very small (1-2 mm) but may be seen with careful examination"
                  },
                  {
                    "text": "Some clip deployment systems place biodegradable carrier material (BCM) within the biopsy cavityMay consist of collagen, polylactic acid, polyglycolic acid, starch pellets, or other materialThe material absorbs fluid and fills the empty biopsy cavityMay aid in holding clip in biopsy site and preventing migrationThe mass formed by BCM may be used for localization under ultrasound if excision is necessaryDoes not obscure surrounding breast tissue",
                    "sub_points": [
                      "May consist of collagen, polylactic acid, polyglycolic acid, starch pellets, or other material",
                      "The material absorbs fluid and fills the empty biopsy cavityMay aid in holding clip in biopsy site and preventing migrationThe mass formed by BCM may be used for localization under ultrasound if excision is necessary",
                      "May aid in holding clip in biopsy site and preventing migration",
                      "The mass formed by BCM may be used for localization under ultrasound if excision is necessary",
                      "Does not obscure surrounding breast tissue"
                    ]
                  },
                  {
                    "text": "BCM, pellet shape: Color and shape of grains of rice (0.5 x 0.15 cm, multiple)May be mistaken for calcifications or papillomaMay fall out of tissue during gross examinationMicroscopically, they have the appearance of a ring of ovoid white pelletsEventually, they are surrounded by chronic active inflammatory reaction with giant cells and resorbed",
                    "sub_points": [
                      "May be mistaken for calcifications or papilloma",
                      "May fall out of tissue during gross examination",
                      "Microscopically, they have the appearance of a ring of ovoid white pelletsEventually, they are surrounded by chronic active inflammatory reaction with giant cells and resorbed",
                      "Eventually, they are surrounded by chronic active inflammatory reaction with giant cells and resorbed"
                    ]
                  },
                  {
                    "text": "BCM, gel: Larger and rectangular-shaped (1 x 0.2 cm, solitary) or viscous fluidGross appearance depends on substance usedWhite and homogeneousPink and finely granularGray and translucentThe biopsy cavity is surrounded by a pseudosynovial lining with a minimal inflammatory responseCenter usually appears emptyCore site can be difficult to identify if BCM falls or seeps out and cavity collapsesBCM, collagen: Appears as dense paucicellular eosinophilic materialBlood vessels from source of collagen may be presentCollagen can calcify over time if not resorbed",
                    "sub_points": [
                      "Gross appearance depends on substance usedWhite and homogeneousPink and finely granularGray and translucent",
                      "White and homogeneous",
                      "Pink and finely granular",
                      "Gray and translucent",
                      "The biopsy cavity is surrounded by a pseudosynovial lining with a minimal inflammatory responseCenter usually appears emptyCore site can be difficult to identify if BCM falls or seeps out and cavity collapses",
                      "Center usually appears empty",
                      "Core site can be difficult to identify if BCM falls or seeps out and cavity collapses",
                      "BCM, collagen: Appears as dense paucicellular eosinophilic materialBlood vessels from source of collagen may be presentCollagen can calcify over time if not resorbed",
                      "Blood vessels from source of collagen may be present",
                      "Collagen can calcify over time if not resorbed"
                    ]
                  },
                  {
                    "text": "If a biopsy site is recognized, it is important to interpret the results of the excision in the context of the findings in the core biopsy"
                  },
                  {
                    "text": "If the site is transected at the margin, there may be clinical significanceClip may be lost into surgical fieldLoss of clip must be distinguished from failure of surgeon to excise the clip marking site of the lesion that was to be excisedTissue surrounding the clip site may not be adequately examined if carcinoma is present",
                    "sub_points": [
                      "Clip may be lost into surgical fieldLoss of clip must be distinguished from failure of surgeon to excise the clip marking site of the lesion that was to be excisedTissue surrounding the clip site may not be adequately examined if carcinoma is present",
                      "Loss of clip must be distinguished from failure of surgeon to excise the clip marking site of the lesion that was to be excised",
                      "Tissue surrounding the clip site may not be adequately examined if carcinoma is present"
                    ]
                  }
                ],
                "Surgical Site Changes": [
                  {
                    "text": "Early changesPresent when a subsequent reexcision of margins or a mastectomy is performedFat necrosis, chronic inflammation, blood- and hemosiderin-laden macrophages, and a giant cell reaction are typicalCautery artifact is often present due to common use of electrocautery (e.g., Bovie) to excise breast tissueElectric field is generated in tissueCells and nuclei become elongated due to electrical potential across cell membraneTissue with extensive cauterization loses recognizable histologic features and antigenicityER and PR results may be falsely negativeOther types of heat (e.g., ultrasonic coagulation or ablation) result in coagulative necrosisA seroma cavity can form and may be lined by cells with squamous metaplasiaSuture material is often presentBiodegradable suture(catgut suture) is a monofilament made of strands of collagenUsually ovoid in shape and brightly eosinophilic\"Catgut\" refers to the strings of a violin-like instrument: The sutures are made of bovine intestineSutures are resorbed by an exuberant chronic inflammatory infiltrate with foreign body giant cellsResorption can take place within 1-3 monthsCollagen can have jagged edges, and elongated nuclei may be presentMay be mistaken for heterotopic bone formationSuture material may be difficult to recognize in giant cells and may require polarizationPolyfilament and monofilament synthetic suturesMore common in skinRefractile and polarizableMetallic debris from surgery has the appearance of small, black deposits in histiocytes",
                    "sub_points": [
                      "Present when a subsequent reexcision of margins or a mastectomy is performed",
                      "Fat necrosis, chronic inflammation, blood- and hemosiderin-laden macrophages, and a giant cell reaction are typical",
                      "Cautery artifact is often present due to common use of electrocautery (e.g., Bovie) to excise breast tissueElectric field is generated in tissueCells and nuclei become elongated due to electrical potential across cell membraneTissue with extensive cauterization loses recognizable histologic features and antigenicityER and PR results may be falsely negativeOther types of heat (e.g., ultrasonic coagulation or ablation) result in coagulative necrosis",
                      "Electric field is generated in tissue",
                      "Cells and nuclei become elongated due to electrical potential across cell membrane",
                      "Tissue with extensive cauterization loses recognizable histologic features and antigenicityER and PR results may be falsely negative",
                      "ER and PR results may be falsely negative",
                      "Other types of heat (e.g., ultrasonic coagulation or ablation) result in coagulative necrosis",
                      "A seroma cavity can form and may be lined by cells with squamous metaplasia",
                      "Suture material is often present",
                      "Biodegradable suture(catgut suture) is a monofilament made of strands of collagenUsually ovoid in shape and brightly eosinophilic\"Catgut\" refers to the strings of a violin-like instrument: The sutures are made of bovine intestineSutures are resorbed by an exuberant chronic inflammatory infiltrate with foreign body giant cellsResorption can take place within 1-3 monthsCollagen can have jagged edges, and elongated nuclei may be presentMay be mistaken for heterotopic bone formationSuture material may be difficult to recognize in giant cells and may require polarization",
                      "Usually ovoid in shape and brightly eosinophilic\"Catgut\" refers to the strings of a violin-like instrument: The sutures are made of bovine intestine",
                      "\"Catgut\" refers to the strings of a violin-like instrument: The sutures are made of bovine intestine",
                      "Sutures are resorbed by an exuberant chronic inflammatory infiltrate with foreign body giant cellsResorption can take place within 1-3 months",
                      "Resorption can take place within 1-3 months",
                      "Collagen can have jagged edges, and elongated nuclei may be presentMay be mistaken for heterotopic bone formation",
                      "May be mistaken for heterotopic bone formation",
                      "Suture material may be difficult to recognize in giant cells and may require polarization",
                      "Polyfilament and monofilament synthetic suturesMore common in skinRefractile and polarizable",
                      "More common in skin",
                      "Refractile and polarizable",
                      "Metallic debris from surgery has the appearance of small, black deposits in histiocytes"
                    ]
                  },
                  {
                    "text": "Late changesHealed excision sites are seen as densely hyalinized areas of stroma, usually with an irregular shapeDystrophic calcifications can form over timeFat necrosis can undergo \"mummification\" with calcification around the periphery (eggshell calcifications)In a few patients, suture material and other types of foreign material may remain for many yearsSkeletal muscle can show degenerative/regenerative changes and look atypicalTraumatic neuromas may be presentIn rare cases, an old biopsy site increases in size after many years and raises concern for recurrent carcinomaRecurrence of carcinoma in association with a healed site is evidence that the carcinoma is a true recurrence and not a new primary carcinoma",
                    "sub_points": [
                      "Healed excision sites are seen as densely hyalinized areas of stroma, usually with an irregular shape",
                      "Dystrophic calcifications can form over time",
                      "Fat necrosis can undergo \"mummification\" with calcification around the periphery (eggshell calcifications)",
                      "In a few patients, suture material and other types of foreign material may remain for many years",
                      "Skeletal muscle can show degenerative/regenerative changes and look atypical",
                      "Traumatic neuromas may be present",
                      "In rare cases, an old biopsy site increases in size after many years and raises concern for recurrent carcinoma",
                      "Recurrence of carcinoma in association with a healed site is evidence that the carcinoma is a true recurrence and not a new primary carcinoma"
                    ]
                  }
                ],
                "Radiation Therapy": [
                  {
                    "text": "Results in sporadic nuclear atypia in normal breast tissueChanges may be most pronounced early after treatment and diminish over timeCan persist for at least 20 yearsSimilar changes can occur after chemotherapy",
                    "sub_points": [
                      "Changes may be most pronounced early after treatment and diminish over timeCan persist for at least 20 yearsSimilar changes can occur after chemotherapy",
                      "Can persist for at least 20 years",
                      "Similar changes can occur after chemotherapy"
                    ]
                  },
                  {
                    "text": "Cells should not be proliferative (i.e., should not have mitotic figures or form architecturally complex patterns)"
                  },
                  {
                    "text": "Basement membrane may be thickened and myoepithelial cells prominent"
                  },
                  {
                    "text": "Surrounding cells are usually normal in appearance"
                  },
                  {
                    "text": "Can closely resemble carcinoma in situThese changes could be mistaken for neoplasia if the pathologist is unaware of this historyPatient could undergo mastectomy if they are thought to have recurrent carcinomaTrue recurrent carcinoma generally has same appearance as carcinoma prior to treatmentComparison to previous carcinoma can be helpful in difficult cases",
                    "sub_points": [
                      "These changes could be mistaken for neoplasia if the pathologist is unaware of this history",
                      "Patient could undergo mastectomy if they are thought to have recurrent carcinomaTrue recurrent carcinoma generally has same appearance as carcinoma prior to treatmentComparison to previous carcinoma can be helpful in difficult cases",
                      "True recurrent carcinoma generally has same appearance as carcinoma prior to treatmentComparison to previous carcinoma can be helpful in difficult cases",
                      "Comparison to previous carcinoma can be helpful in difficult cases"
                    ]
                  },
                  {
                    "text": "Stromal fibroblasts can also have enlarged hyperchromatic (smudged) nucleiUsually scattered and limited in extent",
                    "sub_points": [
                      "Usually scattered and limited in extent"
                    ]
                  }
                ],
                "Pharmaceutical Changes": [
                  {
                    "text": "Neoadjuvant chemotherapyCarcinomas typically become less cellular and are seen as multiple scattered foci over a fibrotic tumor bedAn important clue is the presence of an out-of-proportion \"stromal reaction\" compared to the quantity of carcinomaSome cases of ductal carcinoma in situ (DCIS) have an appearance only seen after treatmentThe nuclei are markedly enlarged, and the cells are surrounded by a 2nd population of much smaller cellsThe tumor bed can be fibrotic and have scattered hemosiderin &/or a histiocytic reactionTumor bed changes are also seen in lymph node metastases that have responded to therapy",
                    "sub_points": [
                      "Carcinomas typically become less cellular and are seen as multiple scattered foci over a fibrotic tumor bedAn important clue is the presence of an out-of-proportion \"stromal reaction\" compared to the quantity of carcinoma",
                      "An important clue is the presence of an out-of-proportion \"stromal reaction\" compared to the quantity of carcinoma",
                      "Some cases of ductal carcinoma in situ (DCIS) have an appearance only seen after treatmentThe nuclei are markedly enlarged, and the cells are surrounded by a 2nd population of much smaller cells",
                      "The nuclei are markedly enlarged, and the cells are surrounded by a 2nd population of much smaller cells",
                      "The tumor bed can be fibrotic and have scattered hemosiderin &/or a histiocytic reaction",
                      "Tumor bed changes are also seen in lymph node metastases that have responded to therapy"
                    ]
                  },
                  {
                    "text": "FulvestrantThis endocrine treatment accelerates the degradation of hormone receptors and can diminish immunoreactivity for ER and PR",
                    "sub_points": [
                      "This endocrine treatment accelerates the degradation of hormone receptors and can diminish immunoreactivity for ER and PR"
                    ]
                  },
                  {
                    "text": "HER2-targeted therapyHER2-targeted therapy can select for HER2(-) tumor cells in carcinomas with heterogeneous expression",
                    "sub_points": [
                      "HER2-targeted therapy can select for HER2(-) tumor cells in carcinomas with heterogeneous expression"
                    ]
                  },
                  {
                    "text": "CyclosporineWomen and men treated with cyclosporine, usually due to renal transplants, can develop fibroadenomasThe fibroadenomas can be multiple and bilateralCyclosporine may have prolactin-like activityThe fibroadenomas can resolve after withdrawal of treatment",
                    "sub_points": [
                      "Women and men treated with cyclosporine, usually due to renal transplants, can develop fibroadenomasThe fibroadenomas can be multiple and bilateral",
                      "The fibroadenomas can be multiple and bilateral",
                      "Cyclosporine may have prolactin-like activity",
                      "The fibroadenomas can resolve after withdrawal of treatment"
                    ]
                  },
                  {
                    "text": "Highly active antiretroviral therapy (HAART)Women and men treated with HAART for HIV can develop breast enlargementThe pathologic findings are of gynecomastia (or gynecomastia-like hyperplasia) and pseudoangiomatous stromal hyperplasia (PASH)",
                    "sub_points": [
                      "Women and men treated with HAART for HIV can develop breast enlargement",
                      "The pathologic findings are of gynecomastia (or gynecomastia-like hyperplasia) and pseudoangiomatous stromal hyperplasia (PASH)"
                    ]
                  },
                  {
                    "text": "CoumadinA very rare complication of coumadin treatment is extensive tissue necrosis of the breastCan also cause skin necrosisAlso occurs at other body sites",
                    "sub_points": [
                      "A very rare complication of coumadin treatment is extensive tissue necrosis of the breastCan also cause skin necrosisAlso occurs at other body sites",
                      "Can also cause skin necrosis",
                      "Also occurs at other body sites"
                    ]
                  },
                  {
                    "text": "Amyloid due to insulinInsulin injected for the treatment of diabetes can form an amyloidoma if the same site is used repeatedlyOccasionally the amyloid migrates elsewhereInsulin-related amyloid has been reported in the breast and in axillary nodesOnly occurs with synthetic insulin and not to naturally occurring insulin",
                    "sub_points": [
                      "Insulin injected for the treatment of diabetes can form an amyloidoma if the same site is used repeatedly",
                      "Occasionally the amyloid migrates elsewhere",
                      "Insulin-related amyloid has been reported in the breast and in axillary nodes",
                      "Only occurs with synthetic insulin and not to naturally occurring insulin"
                    ]
                  },
                  {
                    "text": "GoldPatients treated with gold for rheumatoid arthritis can have gold accumulate as finely granular black material in macrophages in their axillary lymph nodesThe gold is radiodense and can be detected by mammographyA resulting \"mass\" (lymph node) in the axilla with \"calcifications\" (gold) can mimic carcinoma by imaging",
                    "sub_points": [
                      "Patients treated with gold for rheumatoid arthritis can have gold accumulate as finely granular black material in macrophages in their axillary lymph nodes",
                      "The gold is radiodense and can be detected by mammographyA resulting \"mass\" (lymph node) in the axilla with \"calcifications\" (gold) can mimic carcinoma by imaging",
                      "A resulting \"mass\" (lymph node) in the axilla with \"calcifications\" (gold) can mimic carcinoma by imaging"
                    ]
                  }
                ],
                "Tattoo Pigment": [
                  {
                    "text": "After mastectomy, tattoo pigment can be used to help create the appearance of a nipple and areolaThe pigment can be seen as dark, granular material in the dermis",
                    "sub_points": [
                      "The pigment can be seen as dark, granular material in the dermis"
                    ]
                  },
                  {
                    "text": "Tattoo pigment is sometimes injected into lymph nodes during needle biopsy prior to neoadjuvant therapyThe pathologist can use the presence of the pigment to identify the marked node",
                    "sub_points": [
                      "The pathologist can use the presence of the pigment to identify the marked node"
                    ]
                  },
                  {
                    "text": "Tattoo pigment can also be seen in lymph nodes in patients with tattoos of the torso or ipsilateral limbIt is typically black and resembles anthracotic pigment in mediastinal lymph nodesPigments of other colors can also be seen",
                    "sub_points": [
                      "It is typically black and resembles anthracotic pigment in mediastinal lymph nodes",
                      "Pigments of other colors can also be seen"
                    ]
                  },
                  {
                    "text": "Some pigments are radiodense and can mimic calcifications on imaging"
                  }
                ],
                "Breast Implants": [
                  {
                    "text": "Implants are placed for reconstruction or for cosmetic reasons"
                  },
                  {
                    "text": "A fibrotic capsule forms around the implant"
                  },
                  {
                    "text": "The outer shell is made of long-chain silicone and is filled with either saline or short-chain silicone"
                  },
                  {
                    "text": "Short-chain silicone can \"bleed\" through an intact shell into the surrounding tissue"
                  },
                  {
                    "text": "Silicone can also migrate to axillary lymph nodes"
                  },
                  {
                    "text": "Some implants are covered with a textured surface in an attempt to diminish the complication of capsular contracture or implant rotationPolyurethane has been used for this purpose and has a sponge-like structureOn histologic sections, the interstices of the sponge have a triangular shape",
                    "sub_points": [
                      "Polyurethane has been used for this purpose and has a sponge-like structure",
                      "On histologic sections, the interstices of the sponge have a triangular shape"
                    ]
                  }
                ],
                "Treatment-Associated Tumors": [
                  {
                    "text": "Postradiation atypical vascular lesionSingle or multiple skin papules can arise in the radiation field, consisting of anastomosing vascular channels in the dermisThe lesions can be lymphatic or vascular in type and do not overexpress MYCThe majority are benign, but there is concern that some could be precursors for angiosarcoma",
                    "sub_points": [
                      "Single or multiple skin papules can arise in the radiation field, consisting of anastomosing vascular channels in the dermis",
                      "The lesions can be lymphatic or vascular in type and do not overexpress MYC",
                      "The majority are benign, but there is concern that some could be precursors for angiosarcoma"
                    ]
                  },
                  {
                    "text": "Radiation-associated sarcomaAngiosarcoma after radiation therapy for breast carcinoma arises in the skinOther types of sarcoma are associated with radiation but are much less commonAngiosarcomas also arise in the skin of the upper extremity due to lymphedema after breast surgery (Stewart-Treves syndrome)Currently very rare due to better surgical techniques and limited axillary surgeryTreatment-related angiosarcoma overexpresses MYC, whereas this is only very rarely associated with primary angiosarcoma",
                    "sub_points": [
                      "Angiosarcoma after radiation therapy for breast carcinoma arises in the skinOther types of sarcoma are associated with radiation but are much less common",
                      "Other types of sarcoma are associated with radiation but are much less common",
                      "Angiosarcomas also arise in the skin of the upper extremity due to lymphedema after breast surgery (Stewart-Treves syndrome)Currently very rare due to better surgical techniques and limited axillary surgery",
                      "Currently very rare due to better surgical techniques and limited axillary surgery",
                      "Treatment-related angiosarcoma overexpresses MYC, whereas this is only very rarely associated with primary angiosarcoma"
                    ]
                  },
                  {
                    "text": "Radiation-associated carcinomaOccurs in females with radiation exposure of breasts during late teens and early 20sThe most common associated prior malignancy is Hodgkin disease treated with mantle radiationCarcinomas are not of a specific typeAn increased incidence of breast sarcomas has not been reported",
                    "sub_points": [
                      "Occurs in females with radiation exposure of breasts during late teens and early 20s",
                      "The most common associated prior malignancy is Hodgkin disease treated with mantle radiation",
                      "Carcinomas are not of a specific typeAn increased incidence of breast sarcomas has not been reported",
                      "An increased incidence of breast sarcomas has not been reported"
                    ]
                  },
                  {
                    "text": "Hormone replacement treatment-related carcinomasWomen taking hormonal therapy after menopause have an increased incidence of ER(+) cancersHormone use probably causes growth of small cancers to a size that is detectable by imagingEstrogen also acts as carcinogen and may cause cancer",
                    "sub_points": [
                      "Women taking hormonal therapy after menopause have an increased incidence of ER(+) cancers",
                      "Hormone use probably causes growth of small cancers to a size that is detectable by imagingEstrogen also acts as carcinogen and may cause cancer",
                      "Estrogen also acts as carcinogen and may cause cancer"
                    ]
                  },
                  {
                    "text": "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)Very rare form of T-cell lymphoma occurring in patients with implantsThe majority have been associated with breast implants, but cases are also associated with buttock implantsAlmost all implants have had a textured surface~ 75% present as a unilateral periimplant seroma and ~ 25% as a capsular massIn the majority of cases, lymphoma is only present in the seroma and the implant capsule, and the prognosis is very favorableIn a minority of cases, lymphoma extends beyond the capsule into the surrounding tissue and causes death in some patients",
                    "sub_points": [
                      "Very rare form of T-cell lymphoma occurring in patients with implantsThe majority have been associated with breast implants, but cases are also associated with buttock implants",
                      "The majority have been associated with breast implants, but cases are also associated with buttock implants",
                      "Almost all implants have had a textured surface",
                      "~ 75% present as a unilateral periimplant seroma and ~ 25% as a capsular mass",
                      "In the majority of cases, lymphoma is only present in the seroma and the implant capsule, and the prognosis is very favorable",
                      "In a minority of cases, lymphoma extends beyond the capsule into the surrounding tissue and causes death in some patients"
                    ]
                  },
                  {
                    "text": "Breast implant-associated squamous cell carcinomas and mesenchymal tumors~ 30 cases of squamous cell carcinomas have been reported, and some have caused patient deathVery rare mesenchymal tumors of diverse types have been reported",
                    "sub_points": [
                      "~ 30 cases of squamous cell carcinomas have been reported, and some have caused patient death",
                      "Very rare mesenchymal tumors of diverse types have been reported"
                    ]
                  },
                  {
                    "text": "Fibromatosis associated with surgery (or breast implant)May occur at the site of prior surgery in a subset of cases (\"secondary fibromatosis\")Majority of cases of fibromatosis are not associated with surgery",
                    "sub_points": [
                      "May occur at the site of prior surgery in a subset of cases (\"secondary fibromatosis\")Majority of cases of fibromatosis are not associated with surgery",
                      "Majority of cases of fibromatosis are not associated with surgery"
                    ]
                  }
                ],
                "Iatrogenic Changes Mimicking Malignancy": [
                  {
                    "text": "Epithelial displacementNormal or malignant cells can be pushed into stroma, vascular channels, or lymph nodes by palpation, biopsy, or pathology processingTrauma from manipulation can cause cells or groups of cells to be detached from normal milieu and be displacedIncreased number of isolated tumor cells are found after breast massage prior to sentinel node biopsyBenign epithelial cells with myoepithelial cells may be identified in lymph nodes after breast surgeryNormal epithelial cells can be found in granulation tissue of needle tracks or vascular spaces; most commonly seen related to papillary lesionsClinical significance of displacement of malignant cells is unknownFrequency of epithelial cells in needle tracks diminishes with length of time between needle biopsy and excisionSuggests that displaced cells may not surviveMay be due to absence of established vascular supply &/or detachment from other epithelial cellsDiagnosis of invasive carcinoma should be made with great caution if the only areas of invasion are in biopsy site changes and not in the surrounding parenchyma",
                    "sub_points": [
                      "Normal or malignant cells can be pushed into stroma, vascular channels, or lymph nodes by palpation, biopsy, or pathology processingTrauma from manipulation can cause cells or groups of cells to be detached from normal milieu and be displacedIncreased number of isolated tumor cells are found after breast massage prior to sentinel node biopsyBenign epithelial cells with myoepithelial cells may be identified in lymph nodes after breast surgeryNormal epithelial cells can be found in granulation tissue of needle tracks or vascular spaces; most commonly seen related to papillary lesions",
                      "Trauma from manipulation can cause cells or groups of cells to be detached from normal milieu and be displaced",
                      "Increased number of isolated tumor cells are found after breast massage prior to sentinel node biopsy",
                      "Benign epithelial cells with myoepithelial cells may be identified in lymph nodes after breast surgery",
                      "Normal epithelial cells can be found in granulation tissue of needle tracks or vascular spaces; most commonly seen related to papillary lesions",
                      "Clinical significance of displacement of malignant cells is unknownFrequency of epithelial cells in needle tracks diminishes with length of time between needle biopsy and excisionSuggests that displaced cells may not surviveMay be due to absence of established vascular supply &/or detachment from other epithelial cells",
                      "Frequency of epithelial cells in needle tracks diminishes with length of time between needle biopsy and excision",
                      "Suggests that displaced cells may not surviveMay be due to absence of established vascular supply &/or detachment from other epithelial cells",
                      "May be due to absence of established vascular supply &/or detachment from other epithelial cells",
                      "Diagnosis of invasive carcinoma should be made with great caution if the only areas of invasion are in biopsy site changes and not in the surrounding parenchyma"
                    ]
                  },
                  {
                    "text": "Reactive spindle cell noduleAn exuberant fibroblastic/myofibroblastic reaction can occur at core needle biopsy sitesPresence of hemorrhage, hemosiderin-laden macrophages, inflammatory cells, and giant cells helps to identify cells as reactive stromal cellsUsually observed when excision occurs 2-4 weeks after needle biopsyTargeted lesion is most often a papilloma or complex sclerosing lesion with reactive sclerotic stromaSize ranges from 0.1-1 cmPresence of moderate nuclear pleomorphism, occasional mitoses, and infiltrative pattern into surrounding stroma can raise concern for malignancyImmunoperoxidase studies can confirm identity of cells as fibroblasts or myofibroblasts and exclude the possibility of spindle cell carcinomaIf the cells represent an actual spindle cell lesion, the lesion also should be present on prior core needle biopsyIt would be highly unlikely for a spindle cell neoplasm to be detected as an incidental finding or to arise in the interval between needle biopsy and excision",
                    "sub_points": [
                      "An exuberant fibroblastic/myofibroblastic reaction can occur at core needle biopsy sitesPresence of hemorrhage, hemosiderin-laden macrophages, inflammatory cells, and giant cells helps to identify cells as reactive stromal cellsUsually observed when excision occurs 2-4 weeks after needle biopsyTargeted lesion is most often a papilloma or complex sclerosing lesion with reactive sclerotic stromaSize ranges from 0.1-1 cm",
                      "Presence of hemorrhage, hemosiderin-laden macrophages, inflammatory cells, and giant cells helps to identify cells as reactive stromal cells",
                      "Usually observed when excision occurs 2-4 weeks after needle biopsyTargeted lesion is most often a papilloma or complex sclerosing lesion with reactive sclerotic stroma",
                      "Targeted lesion is most often a papilloma or complex sclerosing lesion with reactive sclerotic stroma",
                      "Size ranges from 0.1-1 cm",
                      "Presence of moderate nuclear pleomorphism, occasional mitoses, and infiltrative pattern into surrounding stroma can raise concern for malignancy",
                      "Immunoperoxidase studies can confirm identity of cells as fibroblasts or myofibroblasts and exclude the possibility of spindle cell carcinoma",
                      "If the cells represent an actual spindle cell lesion, the lesion also should be present on prior core needle biopsyIt would be highly unlikely for a spindle cell neoplasm to be detected as an incidental finding or to arise in the interval between needle biopsy and excision",
                      "It would be highly unlikely for a spindle cell neoplasm to be detected as an incidental finding or to arise in the interval between needle biopsy and excision"
                    ]
                  },
                  {
                    "text": "InfarctionNeedle biopsy can cause infarction of a mass-forming lesionHistory of needle biopsy may not be provided if there was an attempted cyst aspiration that did not remove fluidIf a specimen was not obtained, the procedure may not be documentedBenign lesions can be mistaken for malignancy due to necrosis that can be complicated by squamous metaplasia and reactive stromal cellsMalignant lesions can be mistaken for benign lesions due to loss of cellularity and difficulty in interpreting necrotic cells",
                    "sub_points": [
                      "Needle biopsy can cause infarction of a mass-forming lesionHistory of needle biopsy may not be provided if there was an attempted cyst aspiration that did not remove fluidIf a specimen was not obtained, the procedure may not be documented",
                      "History of needle biopsy may not be provided if there was an attempted cyst aspiration that did not remove fluidIf a specimen was not obtained, the procedure may not be documented",
                      "If a specimen was not obtained, the procedure may not be documented",
                      "Benign lesions can be mistaken for malignancy due to necrosis that can be complicated by squamous metaplasia and reactive stromal cells",
                      "Malignant lesions can be mistaken for benign lesions due to loss of cellularity and difficulty in interpreting necrotic cells"
                    ]
                  },
                  {
                    "text": "Degenerating or regenerating skeletal muscleCells become rounded, and nuclei move to center of cellsNuclei are enlarged and hyperchromaticRarely resemble prior carcinomaMay be difficult to distinguish from high-grade phyllodes tumor located deep in breastMuscle cells are strongly positive for muscle markers by IHC",
                    "sub_points": [
                      "Cells become rounded, and nuclei move to center of cells",
                      "Nuclei are enlarged and hyperchromatic",
                      "Rarely resemble prior carcinoma",
                      "May be difficult to distinguish from high-grade phyllodes tumor located deep in breastMuscle cells are strongly positive for muscle markers by IHC",
                      "Muscle cells are strongly positive for muscle markers by IHC"
                    ]
                  },
                  {
                    "text": "Atypical cells in seroma fluidCells can have alarming nuclear atypia due to squamous metaplasia, radiation changes, &/or degenerative changesAtypical metaplastic cells must be distinguished from rare T-cell lymphomas arising in seromas associated with implants",
                    "sub_points": [
                      "Cells can have alarming nuclear atypia due to squamous metaplasia, radiation changes, &/or degenerative changes",
                      "Atypical metaplastic cells must be distinguished from rare T-cell lymphomas arising in seromas associated with implants"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Ruptured Cysts": [
                  {
                    "text": "Cysts can rupture spontaneously or due to trauma"
                  },
                  {
                    "text": "Secretory material dispersed into surrounding tissue can incite an intense chronic active inflammatory response"
                  },
                  {
                    "text": "Foreign material is not presentCalcium oxalate is refractile and polarizable and should be distinguished from foreign material",
                    "sub_points": [
                      "Calcium oxalate is refractile and polarizable and should be distinguished from foreign material"
                    ]
                  }
                ],
                "Fat Necrosis": [
                  {
                    "text": "Can occur with trauma or be present in the absence of traumaIn latter case, pressure necrosis may occur in dependent portions of pendulous breasts",
                    "sub_points": [
                      "In latter case, pressure necrosis may occur in dependent portions of pendulous breasts"
                    ]
                  },
                  {
                    "text": "Foreign material and cautery changes are absent"
                  }
                ],
                "Tumors": [
                  {
                    "text": "Some tumors mimic inflammatory cellsGranular cell tumors (histiocytes), invasive lobular carcinoma (lymphocytes, histiocytes, or hematopoietic cells in bone marrow), histiocytoid carcinoma (histiocytes), lymphomas (lymphocytes)",
                    "sub_points": [
                      "Granular cell tumors (histiocytes), invasive lobular carcinoma (lymphocytes, histiocytes, or hematopoietic cells in bone marrow), histiocytoid carcinoma (histiocytes), lymphomas (lymphocytes)"
                    ]
                  },
                  {
                    "text": "Generally lack a mixed inflammatory cell infiltrate typical of true inflammatory lesions"
                  },
                  {
                    "text": "IHC studies may be necessary to identify the type of cell"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Implant Pathology": {
            "name": "Implant Pathology",
            "url": "https://app.pathprimer.com/document/60a09f4b-16f5-491e-8598-446a1e4cc288/lesson/f231d890-916f-4da9-84ca-e92eca6d2716",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Implants are used for reconstruction after surgery or for augmentationConsist of a silicone shell filled with either silicone or salineTissue expanders are saline implants that are placed temporarily before tissue reconstruction",
                    "sub_points": [
                      "Consist of a silicone shell filled with either silicone or saline",
                      "Tissue expanders are saline implants that are placed temporarily before tissue reconstruction"
                    ]
                  },
                  {
                    "text": "Direct injection of foreign material has also been used for breast augmentationNot a medically approved procedureAssociated with a high rate of complications",
                    "sub_points": [
                      "Not a medically approved procedure",
                      "Associated with a high rate of complications"
                    ]
                  },
                  {
                    "text": "Estimated that 3-5 million women in USA currently have implants (~ 2-3% of women)~ 1/3 reconstruction, ~ 2/3 augmentation",
                    "sub_points": [
                      "~ 1/3 reconstruction, ~ 2/3 augmentation"
                    ]
                  },
                  {
                    "text": "ImagingPresence of implant complicates mammographic examinationFree silicone is highly echogenic on ultrasound and has snowstorm appearanceMR is the best imaging technique to detect rupture or a periimplant seroma",
                    "sub_points": [
                      "Presence of implant complicates mammographic examination",
                      "Free silicone is highly echogenic on ultrasound and has snowstorm appearance",
                      "MR is the best imaging technique to detect rupture or a periimplant seroma"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Malignancies most often present as a unilateral late occurrence of a seroma and, less commonly, as a capsular mass"
                  },
                  {
                    "text": "Implant-associated malignant complicationsBreast implant-associated anaplastic large cell lymphoma (BIA-ALCL)Breast implant-associated squamous cell carcinoma (BIA-SCC)",
                    "sub_points": [
                      "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)",
                      "Breast implant-associated squamous cell carcinoma (BIA-SCC)"
                    ]
                  },
                  {
                    "text": "Implant-associated benign complicationsCapsular contracture (most common)Capsular calcifications (complicates mammographic screening)Implant ruptureSilicone migration to lymph nodes and distant sitesInfection (usually during perioperative period)",
                    "sub_points": [
                      "Capsular contracture (most common)",
                      "Capsular calcifications (complicates mammographic screening)",
                      "Implant rupture",
                      "Silicone migration to lymph nodes and distant sites",
                      "Infection (usually during perioperative period)"
                    ]
                  }
                ]
              },
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "Silicone implant"
                  },
                  {
                    "text": "Saline implant"
                  },
                  {
                    "text": "Tissue expanders"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Foreign material placed within breast or chest wall to replace or augment breast tissue"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Introduction": [
                  {
                    "text": "The 1st silicone shell implant was placed in 1961"
                  },
                  {
                    "text": "In 1990s, concern was raised that implants might be associated with autoimmune-type diseasesThere were many well-publicized lawsuits based on these claims",
                    "sub_points": [
                      "There were many well-publicized lawsuits based on these claims"
                    ]
                  },
                  {
                    "text": "From 1992-2006, the use of silicone implants was restricted to FDA-approved research projects due to safety concerns"
                  },
                  {
                    "text": "In 1999, the National Institute of Medicine released a report stating that connective tissue disease was not more common in women with implants"
                  },
                  {
                    "text": "In 2006, the FDA lifted a moratorium on implants but did require follow-up studies of patients"
                  },
                  {
                    "text": "Estimated that 3-5 million women in the USA currently have breast implants (~ 2-3%)~ 1/3 of procedures are for reconstruction, ~ 2/3 for augmentation",
                    "sub_points": [
                      "~ 1/3 of procedures are for reconstruction, ~ 2/3 for augmentation"
                    ]
                  },
                  {
                    "text": "In 2018, the American Society of Plastic Surgeons reported that 313,735 women underwent breast augmentation and 29,236 underwent removal of implants"
                  },
                  {
                    "text": "The Federal Drug Association (FDA) requires reporting of implant-related complications"
                  }
                ],
                "Types of Breast Implants and Synthetic Materials": [
                  {
                    "text": "Saline implantsThin silicone outer shell filled with saline~ 10-15% of permanent implants in USAIf a saline implant ruptures, there is immediate deflation, and saline is quickly resorbed by surrounding tissueReplacement of the implant is required to restore cosmetic appearance",
                    "sub_points": [
                      "Thin silicone outer shell filled with saline",
                      "~ 10-15% of permanent implants in USA",
                      "If a saline implant ruptures, there is immediate deflation, and saline is quickly resorbed by surrounding tissueReplacement of the implant is required to restore cosmetic appearance",
                      "Replacement of the implant is required to restore cosmetic appearance"
                    ]
                  },
                  {
                    "text": "Silicone implantsThin silicone outer shell filled with silicone gel~ 85-90% of permanent implants in USAShort-chain liquid silicone can \"bleed\" through the long-chain silicone shell into surrounding capsule, even in absence of ruptureIf the implant ruptures, silicone is usually confined within the surrounding fibrotic capsuleImaging studies may be necessary to detect a ruptured implantSilicone can also be found in surrounding tissue, regional lymph nodes, and at distant sites",
                    "sub_points": [
                      "Thin silicone outer shell filled with silicone gel",
                      "~ 85-90% of permanent implants in USA",
                      "Short-chain liquid silicone can \"bleed\" through the long-chain silicone shell into surrounding capsule, even in absence of rupture",
                      "If the implant ruptures, silicone is usually confined within the surrounding fibrotic capsuleImaging studies may be necessary to detect a ruptured implant",
                      "Imaging studies may be necessary to detect a ruptured implant",
                      "Silicone can also be found in surrounding tissue, regional lymph nodes, and at distant sites"
                    ]
                  },
                  {
                    "text": "Textured implantsRough surfaced patches are used on some implants to reduce the fibrotic response resulting in capsular contracturePolyurethane in a sponge-like conformation has been used and has a specific histologic appearance in capsular tissueInterstices of the sponge have an angular or triangular shape in capsular tissue in 2 dimensionsBoth macrotextured and microtextured implants are marketedCan be filled with either saline or silicone",
                    "sub_points": [
                      "Rough surfaced patches are used on some implants to reduce the fibrotic response resulting in capsular contracture",
                      "Polyurethane in a sponge-like conformation has been used and has a specific histologic appearance in capsular tissueInterstices of the sponge have an angular or triangular shape in capsular tissue in 2 dimensions",
                      "Interstices of the sponge have an angular or triangular shape in capsular tissue in 2 dimensions",
                      "Both macrotextured and microtextured implants are marketed",
                      "Can be filled with either saline or silicone"
                    ]
                  },
                  {
                    "text": "Tissue expandersTemporary saline implants placed after surgeryUsually have a large port to allow additional saline to be added over timeEventually replaced with a permanent implant or tissue at time of final reconstructive surgery",
                    "sub_points": [
                      "Temporary saline implants placed after surgery",
                      "Usually have a large port to allow additional saline to be added over time",
                      "Eventually replaced with a permanent implant or tissue at time of final reconstructive surgery"
                    ]
                  },
                  {
                    "text": "Direct injection of foreign material for augmentationSubstances used include organic oils, silicone (industrial and medical), paraffin, and othersInjected blindly into breast tissue or pectoral musclesUsually migrate over time and result in a poor cosmetic appearanceCan disseminate to regional lymph nodes and more distantlyForeign material can closely mimic malignancy on examination and breast imagingMultiple breast massesSkin &/or nipple retractionLymphadenopathyNot an accepted medical procedurePatients may be reluctant to reveal this historyUsually do not know type of material injected",
                    "sub_points": [
                      "Substances used include organic oils, silicone (industrial and medical), paraffin, and others",
                      "Injected blindly into breast tissue or pectoral muscles",
                      "Usually migrate over time and result in a poor cosmetic appearanceCan disseminate to regional lymph nodes and more distantly",
                      "Can disseminate to regional lymph nodes and more distantly",
                      "Foreign material can closely mimic malignancy on examination and breast imagingMultiple breast massesSkin &/or nipple retractionLymphadenopathyNot an accepted medical procedure",
                      "Multiple breast masses",
                      "Skin &/or nipple retraction",
                      "Lymphadenopathy",
                      "Not an accepted medical procedure",
                      "Patients may be reluctant to reveal this historyUsually do not know type of material injected",
                      "Usually do not know type of material injected"
                    ]
                  },
                  {
                    "text": "Acellular dermal matrix for reconstructionProvides scaffold that may be permanent or later replaced by the patient's own tissuesKeeps implant and pectoralis muscle in appropriate locationsAids in ultimate shape and appearance of reconstructionCollagen is eventually replaced by vascular ingrowth and fibroblasts; mild chronic inflammation may be present",
                    "sub_points": [
                      "Provides scaffold that may be permanent or later replaced by the patient's own tissues",
                      "Keeps implant and pectoralis muscle in appropriate locations",
                      "Aids in ultimate shape and appearance of reconstruction",
                      "Collagen is eventually replaced by vascular ingrowth and fibroblasts; mild chronic inflammation may be present"
                    ]
                  }
                ],
                "Placement of Implants": [
                  {
                    "text": "Implants can be placed between breast tissue and pectoral muscle or between the pectoral muscle and chest wall (subpectoral)"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Complications and Treatment": [
                  {
                    "text": "Capsular contractureMost common complicationThick area of fibrosis forms around implantCauses deformation of implant shape, resulting in poor cosmetic appearanceAdditional surgery to remove implant &/or capsule may be necessary to achieve an acceptable cosmetic resultIn past, capsule was compressed to \"break\" capsuleThis technique is no longer used, as it can lead to migration of silicone to other sites",
                    "sub_points": [
                      "Most common complication",
                      "Thick area of fibrosis forms around implant",
                      "Causes deformation of implant shape, resulting in poor cosmetic appearance",
                      "Additional surgery to remove implant &/or capsule may be necessary to achieve an acceptable cosmetic result",
                      "In past, capsule was compressed to \"break\" capsuleThis technique is no longer used, as it can lead to migration of silicone to other sites",
                      "This technique is no longer used, as it can lead to migration of silicone to other sites"
                    ]
                  },
                  {
                    "text": "Rupture of silicone implantShort-chain silicone can \"bleed\" through an intact long-chain silicone implant shell into the surrounding capsuleSilicone is usually restricted to the capsule when the implant is intactHistologic evidence of silicone in capsule is not definitive evidence of ruptureSilicone granulomas can mimic cancers by palpation or imaging by forming masses adjacent to the implantSilicone shells thin over timeRupture more likely with older implantsSpecial mammographic techniques can be used to reduce likelihood of ruptureIf both implant and capsule are ruptured, silicone can migrate to distant sitesMost common site is regional lymph nodesSilicone can also migrate to distant subcutaneous tissue, lung, and other sites",
                    "sub_points": [
                      "Short-chain silicone can \"bleed\" through an intact long-chain silicone implant shell into the surrounding capsuleSilicone is usually restricted to the capsule when the implant is intactHistologic evidence of silicone in capsule is not definitive evidence of rupture",
                      "Silicone is usually restricted to the capsule when the implant is intact",
                      "Histologic evidence of silicone in capsule is not definitive evidence of rupture",
                      "Silicone granulomas can mimic cancers by palpation or imaging by forming masses adjacent to the implant",
                      "Silicone shells thin over timeRupture more likely with older implantsSpecial mammographic techniques can be used to reduce likelihood of rupture",
                      "Rupture more likely with older implants",
                      "Special mammographic techniques can be used to reduce likelihood of rupture",
                      "If both implant and capsule are ruptured, silicone can migrate to distant sitesMost common site is regional lymph nodesSilicone can also migrate to distant subcutaneous tissue, lung, and other sites",
                      "Most common site is regional lymph nodes",
                      "Silicone can also migrate to distant subcutaneous tissue, lung, and other sites"
                    ]
                  },
                  {
                    "text": "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)1,264 cases worldwide and 63 deaths as of 2023First reported in 1997The risk of developing BIA-ALCL varies widely and ranges from ~ 1 in 355 to 1 in 30,000 for women with textured implantsRisk factorsAlmost all cases are associated with textured implantsOnly 1 case reported by the FDA that may have only been associated with a smooth-surfaced implantBIA-ALCL can occur after having a textured implant replaced with a smooth-surfaced implantIn 2019, Allergan recalled all Biocell textured implants at the request of the FDA due to the association with BIA-ALCLAssociated with both saline and silicone implants and reconstructive and cosmetic surgeryOccurs with both saline (~ 60%) and silicone (~ 40%) implantsOccurs when implants are used for either augmentation (~ 60%) or reconstruction (~ 40%)Also reported in association with gluteal implants5 cases have occurred in women with germlineTP53mutations (Li-Fraumeni syndrome) and possible cases have occurred in women with germlineBRCA1andBRCA2mutations, raising concern that these groups may be at higher riskPresentationUsually presents 8-11 years after implant surgeryRange: < 1-44 years with a unilateral periimplant effusionIn ~ 75%, imaging reveals a seroma, and in ~ 25%, a capsular mass is presentHowever, > 90% of late-occurring seromas are not associated with malignancy5% of cases are bilateralEtiologyA specific etiology has not been established, although a chronic sustained T-cell response is proposedA possible role of bacteria in biofilms promoted by the irregular surface has been hypothesizedBacteria are found adjacent to implants in patients ± anaplastic large cell lymphoma (ALCL); a specific causative role has not been establishedReportingBIA-ALCL should be reported to the FDA MedWatch safety information and adverse event reporting programhttps://www.fda.gov/medical-devices/breast-implants/breast-implants-additional-resources (accessed October 25, 2024)BIA-ALCL should also be reported to the BIA-ALCL patient registry and outcomes for breast implants and lymphoma etiology and epidemiology (PROFILE) registryCollaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundationhttps://www.thepsf.org/research/registries/profile (accessed October 25, 2024)TreatmentWhen BIA-ALCL is diagnosed or suspected, en-bloc removal of the implant with the intact surrounding capsule is recommendedSystemic therapy is indicated in some casesPrognosisDependent on extent of tumorT1 (tumor in fluid or confined to the inner surface of the capsule)T2 (superficial infiltration of the capsule)T3 (deep infiltration of capsule)T1, T2, and T3 are ~ 70% of cases with 100% 5-year survivalT4 (extension beyond the limits of the capsule into soft tissue or breast parenchyma)T4 are ~ 30% of cases with 84% 5-year survivalRare cases with regional lymph node involvement have 75% 5-year survival",
                    "sub_points": [
                      "1,264 cases worldwide and 63 deaths as of 2023First reported in 1997",
                      "First reported in 1997",
                      "The risk of developing BIA-ALCL varies widely and ranges from ~ 1 in 355 to 1 in 30,000 for women with textured implants",
                      "Risk factorsAlmost all cases are associated with textured implantsOnly 1 case reported by the FDA that may have only been associated with a smooth-surfaced implantBIA-ALCL can occur after having a textured implant replaced with a smooth-surfaced implantIn 2019, Allergan recalled all Biocell textured implants at the request of the FDA due to the association with BIA-ALCLAssociated with both saline and silicone implants and reconstructive and cosmetic surgeryOccurs with both saline (~ 60%) and silicone (~ 40%) implantsOccurs when implants are used for either augmentation (~ 60%) or reconstruction (~ 40%)Also reported in association with gluteal implants5 cases have occurred in women with germlineTP53mutations (Li-Fraumeni syndrome) and possible cases have occurred in women with germlineBRCA1andBRCA2mutations, raising concern that these groups may be at higher risk",
                      "Almost all cases are associated with textured implantsOnly 1 case reported by the FDA that may have only been associated with a smooth-surfaced implantBIA-ALCL can occur after having a textured implant replaced with a smooth-surfaced implantIn 2019, Allergan recalled all Biocell textured implants at the request of the FDA due to the association with BIA-ALCL",
                      "Only 1 case reported by the FDA that may have only been associated with a smooth-surfaced implant",
                      "BIA-ALCL can occur after having a textured implant replaced with a smooth-surfaced implant",
                      "In 2019, Allergan recalled all Biocell textured implants at the request of the FDA due to the association with BIA-ALCL",
                      "Associated with both saline and silicone implants and reconstructive and cosmetic surgeryOccurs with both saline (~ 60%) and silicone (~ 40%) implantsOccurs when implants are used for either augmentation (~ 60%) or reconstruction (~ 40%)Also reported in association with gluteal implants",
                      "Occurs with both saline (~ 60%) and silicone (~ 40%) implants",
                      "Occurs when implants are used for either augmentation (~ 60%) or reconstruction (~ 40%)",
                      "Also reported in association with gluteal implants",
                      "5 cases have occurred in women with germlineTP53mutations (Li-Fraumeni syndrome) and possible cases have occurred in women with germlineBRCA1andBRCA2mutations, raising concern that these groups may be at higher risk",
                      "PresentationUsually presents 8-11 years after implant surgeryRange: < 1-44 years with a unilateral periimplant effusionIn ~ 75%, imaging reveals a seroma, and in ~ 25%, a capsular mass is presentHowever, > 90% of late-occurring seromas are not associated with malignancy5% of cases are bilateral",
                      "Usually presents 8-11 years after implant surgeryRange: < 1-44 years with a unilateral periimplant effusion",
                      "Range: < 1-44 years with a unilateral periimplant effusion",
                      "In ~ 75%, imaging reveals a seroma, and in ~ 25%, a capsular mass is presentHowever, > 90% of late-occurring seromas are not associated with malignancy",
                      "However, > 90% of late-occurring seromas are not associated with malignancy",
                      "5% of cases are bilateral",
                      "EtiologyA specific etiology has not been established, although a chronic sustained T-cell response is proposedA possible role of bacteria in biofilms promoted by the irregular surface has been hypothesizedBacteria are found adjacent to implants in patients ± anaplastic large cell lymphoma (ALCL); a specific causative role has not been established",
                      "A specific etiology has not been established, although a chronic sustained T-cell response is proposed",
                      "A possible role of bacteria in biofilms promoted by the irregular surface has been hypothesizedBacteria are found adjacent to implants in patients ± anaplastic large cell lymphoma (ALCL); a specific causative role has not been established",
                      "Bacteria are found adjacent to implants in patients ± anaplastic large cell lymphoma (ALCL); a specific causative role has not been established",
                      "ReportingBIA-ALCL should be reported to the FDA MedWatch safety information and adverse event reporting programhttps://www.fda.gov/medical-devices/breast-implants/breast-implants-additional-resources (accessed October 25, 2024)BIA-ALCL should also be reported to the BIA-ALCL patient registry and outcomes for breast implants and lymphoma etiology and epidemiology (PROFILE) registryCollaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundationhttps://www.thepsf.org/research/registries/profile (accessed October 25, 2024)",
                      "BIA-ALCL should be reported to the FDA MedWatch safety information and adverse event reporting programhttps://www.fda.gov/medical-devices/breast-implants/breast-implants-additional-resources (accessed October 25, 2024)",
                      "https://www.fda.gov/medical-devices/breast-implants/breast-implants-additional-resources (accessed October 25, 2024)",
                      "BIA-ALCL should also be reported to the BIA-ALCL patient registry and outcomes for breast implants and lymphoma etiology and epidemiology (PROFILE) registryCollaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundationhttps://www.thepsf.org/research/registries/profile (accessed October 25, 2024)",
                      "Collaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundation",
                      "https://www.thepsf.org/research/registries/profile (accessed October 25, 2024)",
                      "TreatmentWhen BIA-ALCL is diagnosed or suspected, en-bloc removal of the implant with the intact surrounding capsule is recommendedSystemic therapy is indicated in some cases",
                      "When BIA-ALCL is diagnosed or suspected, en-bloc removal of the implant with the intact surrounding capsule is recommended",
                      "Systemic therapy is indicated in some cases",
                      "PrognosisDependent on extent of tumorT1 (tumor in fluid or confined to the inner surface of the capsule)T2 (superficial infiltration of the capsule)T3 (deep infiltration of capsule)T1, T2, and T3 are ~ 70% of cases with 100% 5-year survivalT4 (extension beyond the limits of the capsule into soft tissue or breast parenchyma)T4 are ~ 30% of cases with 84% 5-year survivalRare cases with regional lymph node involvement have 75% 5-year survival",
                      "Dependent on extent of tumor",
                      "T1 (tumor in fluid or confined to the inner surface of the capsule)",
                      "T2 (superficial infiltration of the capsule)",
                      "T3 (deep infiltration of capsule)T1, T2, and T3 are ~ 70% of cases with 100% 5-year survival",
                      "T1, T2, and T3 are ~ 70% of cases with 100% 5-year survival",
                      "T4 (extension beyond the limits of the capsule into soft tissue or breast parenchyma)T4 are ~ 30% of cases with 84% 5-year survival",
                      "T4 are ~ 30% of cases with 84% 5-year survival",
                      "Rare cases with regional lymph node involvement have 75% 5-year survival"
                    ]
                  },
                  {
                    "text": "Breast implant-associated squamous cell carcinoma (BIA-SCC)~ 30 cases of BIA-SCC have been reported as of 2023 with ~ 20% mortalityLess common than SCC occurring elsewhere in the breastAssociated with both smooth and textured implants and reconstructive or cosmetic surgeryAlso commonly presents like BIA-ALCL with a late-onset seroma ± a palpable massCan occur 7-42 years after implantationAll diagnoses of BIA-SCC should be reported to the FDA MedWatch and PROFILE registries",
                    "sub_points": [
                      "~ 30 cases of BIA-SCC have been reported as of 2023 with ~ 20% mortalityLess common than SCC occurring elsewhere in the breast",
                      "Less common than SCC occurring elsewhere in the breast",
                      "Associated with both smooth and textured implants and reconstructive or cosmetic surgery",
                      "Also commonly presents like BIA-ALCL with a late-onset seroma ± a palpable mass",
                      "Can occur 7-42 years after implantation",
                      "All diagnoses of BIA-SCC should be reported to the FDA MedWatch and PROFILE registries"
                    ]
                  },
                  {
                    "text": "Breast implant-associated mesenchymal tumorsSarcomas occurring in women with implants are extremely rare and are of diverse typesOccurs with both saline and silicone implantsGenerally detected within 2-3 years of surgeryPresents as a mass-forming lesionIncludes fibromatosis and sarcomaFibromatosis is the most common type of tumorNot known to have mutations in adenomatosis polyposis coli gene or to have Gardner syndromeSpecific etiologic relationship between tumor formation and implants has not been established",
                    "sub_points": [
                      "Sarcomas occurring in women with implants are extremely rare and are of diverse types",
                      "Occurs with both saline and silicone implants",
                      "Generally detected within 2-3 years of surgeryPresents as a mass-forming lesion",
                      "Presents as a mass-forming lesion",
                      "Includes fibromatosis and sarcomaFibromatosis is the most common type of tumorNot known to have mutations in adenomatosis polyposis coli gene or to have Gardner syndrome",
                      "Fibromatosis is the most common type of tumorNot known to have mutations in adenomatosis polyposis coli gene or to have Gardner syndrome",
                      "Not known to have mutations in adenomatosis polyposis coli gene or to have Gardner syndrome",
                      "Specific etiologic relationship between tumor formation and implants has not been established"
                    ]
                  },
                  {
                    "text": "InfectionMost infections occur during perisurgical period and are due to common bacteria (Staphylococcusaureus) (< 5% of patients)In very rare cases, unusual organisms have been reported (i.e., fungi, actinomycetes, or mycobacteria)An acute inflammatory response to an implant would be unusual in the absence of infection",
                    "sub_points": [
                      "Most infections occur during perisurgical period and are due to common bacteria (Staphylococcusaureus) (< 5% of patients)",
                      "In very rare cases, unusual organisms have been reported (i.e., fungi, actinomycetes, or mycobacteria)",
                      "An acute inflammatory response to an implant would be unusual in the absence of infection"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "The presence of an implant complicates mammographic examinationSpecial views are available to visualize breast tissue around the implant",
                    "sub_points": [
                      "Special views are available to visualize breast tissue around the implant"
                    ]
                  },
                  {
                    "text": "Care must be taken to not rupture implant with compression"
                  },
                  {
                    "text": "Calcification of implant shell can obscure breast calcifications"
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Free silicone is highly echogenic and has snowstorm appearance"
                  }
                ],
                "MR Findings": [
                  {
                    "text": "Best imaging technique to detect ruptures of a silicone-filled implant and the presence of seromasIntracapsular and extracapsular rupture can be detectedSilicone in adjacent tissue and in axillary lymph nodes can be imaged",
                    "sub_points": [
                      "Intracapsular and extracapsular rupture can be detected",
                      "Silicone in adjacent tissue and in axillary lymph nodes can be imaged"
                    ]
                  },
                  {
                    "text": "In a case of rupture, the silicone shell can be seen floating within silicone gel (linguine sign)"
                  },
                  {
                    "text": "Seromas are seen as fluid surrounding an intact implant"
                  },
                  {
                    "text": "Masses within the implant capsule can also be detected"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Documentation of implantsGross description includes appearance and identifying marksIntact implants: May not be possible to distinguish saline from silicone implantRuptured implantsSaline implants will be empty and usually drySilicone implants will consist of portions of shell within viscous silicone gelRupture can occur during surgery for explantationPathologist cannot determine when rupture occurred",
                    "sub_points": [
                      "Gross description includes appearance and identifying marks",
                      "Intact implants: May not be possible to distinguish saline from silicone implant",
                      "Ruptured implantsSaline implants will be empty and usually drySilicone implants will consist of portions of shell within viscous silicone gelRupture can occur during surgery for explantationPathologist cannot determine when rupture occurred",
                      "Saline implants will be empty and usually dry",
                      "Silicone implants will consist of portions of shell within viscous silicone gel",
                      "Rupture can occur during surgery for explantationPathologist cannot determine when rupture occurred",
                      "Pathologist cannot determine when rupture occurred"
                    ]
                  },
                  {
                    "text": "Documentation of surrounding tissueCapsule is usually received in multiple fragmentsSilicone granulomas can have gross appearance of hard, irregular, gritty massesGross appearance can closely mimic invasive carcinomaCapsule should be sectioned perpendicular to capsule surface, if possibleAll grossly evident masses should be sampled",
                    "sub_points": [
                      "Capsule is usually received in multiple fragments",
                      "Silicone granulomas can have gross appearance of hard, irregular, gritty massesGross appearance can closely mimic invasive carcinoma",
                      "Gross appearance can closely mimic invasive carcinoma",
                      "Capsule should be sectioned perpendicular to capsule surface, if possible",
                      "All grossly evident masses should be sampled"
                    ]
                  },
                  {
                    "text": "Implants removed with known or suspected BIA-ALCLGuidelines have been issued for the pathologic evaluation of specimens when BIA-ALCL is suspectedThe same procedures can be used for BIA-SCCPhotographs should be taken to document the capsule with tissue and the implant before and during processingThe effusion fluid should be submitted for cytologic evaluation and flow cytometryFluid involved by ALCL is usually cloudy, viscous, and has membranous strandsThe specimen should be oriented (if possible) and margins inkedMargins should be reported when tumor cells infiltrate the capsuleThe capsule is pinned out and fixed in formalin overnightPerpendicular sections of the capsule are sampled from each margin (at least 2 sections per cassette in 6 cassettes)ALCL can be present in grossly normal-appearing capsulesAll mass-forming lesions and irregular areas of the capsule are sampled",
                    "sub_points": [
                      "Guidelines have been issued for the pathologic evaluation of specimens when BIA-ALCL is suspectedThe same procedures can be used for BIA-SCC",
                      "The same procedures can be used for BIA-SCC",
                      "Photographs should be taken to document the capsule with tissue and the implant before and during processing",
                      "The effusion fluid should be submitted for cytologic evaluation and flow cytometryFluid involved by ALCL is usually cloudy, viscous, and has membranous strands",
                      "Fluid involved by ALCL is usually cloudy, viscous, and has membranous strands",
                      "The specimen should be oriented (if possible) and margins inkedMargins should be reported when tumor cells infiltrate the capsule",
                      "Margins should be reported when tumor cells infiltrate the capsule",
                      "The capsule is pinned out and fixed in formalin overnight",
                      "Perpendicular sections of the capsule are sampled from each margin (at least 2 sections per cassette in 6 cassettes)ALCL can be present in grossly normal-appearing capsules",
                      "ALCL can be present in grossly normal-appearing capsules",
                      "All mass-forming lesions and irregular areas of the capsule are sampled"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "All implantsCapsule consists of dense fibrosis that is often calcifiedMetaplastic cartilage formation rarely occursChronic inflammatory cells may be presentAcute inflammation, eosinophils, or granulomas are unusual and suggest another pathologic processSecondary infections should be suspected and tissue sent for culture, if possibleInner surface of capsule is lined by pseudosynovium consisting of histiocytesCaused by chronic rubbing of implant against surfaceInner surface is smooth or polypoidHistiocytes are oriented perpendicular to surfaceSquamous metaplasiaAtypical squamous cells can be present lining seroma cavities after radiation treatmentHowever, not typically seen in implant capsules (~ 2% of cases)",
                    "sub_points": [
                      "Capsule consists of dense fibrosis that is often calcifiedMetaplastic cartilage formation rarely occurs",
                      "Metaplastic cartilage formation rarely occurs",
                      "Chronic inflammatory cells may be present",
                      "Acute inflammation, eosinophils, or granulomas are unusual and suggest another pathologic processSecondary infections should be suspected and tissue sent for culture, if possible",
                      "Secondary infections should be suspected and tissue sent for culture, if possible",
                      "Inner surface of capsule is lined by pseudosynovium consisting of histiocytesCaused by chronic rubbing of implant against surfaceInner surface is smooth or polypoidHistiocytes are oriented perpendicular to surface",
                      "Caused by chronic rubbing of implant against surface",
                      "Inner surface is smooth or polypoid",
                      "Histiocytes are oriented perpendicular to surface",
                      "Squamous metaplasiaAtypical squamous cells can be present lining seroma cavities after radiation treatmentHowever, not typically seen in implant capsules (~ 2% of cases)",
                      "Atypical squamous cells can be present lining seroma cavities after radiation treatment",
                      "However, not typically seen in implant capsules (~ 2% of cases)"
                    ]
                  },
                  {
                    "text": "Silicone implantsAll silicone implants \"bleed\" silicone gel through shellThis occurs in absence of frank ruptureSilicone has number of appearancesSilicone granulomas consist of numerous macrophages associated with intracellular and intercellular siliconeMay be refractile but is not polarizableRefractile substances have a refractive index different than that of normal tissue, appear brighter and shinier than tissueMore easily appreciated by lowering condenser or closing aperture of diaphragmIf polarizable material is present, it is probably not siliconeIntracellular silicone has appearance of multiple clear spheroidal shapes of varying sizes within histiocytesThe spheroidal shapes can cause notching of nuclei and mimic the appearance of lipoblastsExtracellular silicone has the appearance of clear spaces partially occupied by refractile material and surrounded by macrophages, giant cells, and lymphocytesOther organic oils can have the same histologic appearanceThe type of substance cannot be definitively identified based only on appearanceSpecial techniques (e.g., x-ray analysis or Raman spectroscopy) can be used to specifically identify foreign material as siliconeMuch of the silicone is dissolved during tissue processing",
                    "sub_points": [
                      "All silicone implants \"bleed\" silicone gel through shellThis occurs in absence of frank rupture",
                      "This occurs in absence of frank rupture",
                      "Silicone has number of appearancesSilicone granulomas consist of numerous macrophages associated with intracellular and intercellular siliconeMay be refractile but is not polarizableRefractile substances have a refractive index different than that of normal tissue, appear brighter and shinier than tissueMore easily appreciated by lowering condenser or closing aperture of diaphragmIf polarizable material is present, it is probably not siliconeIntracellular silicone has appearance of multiple clear spheroidal shapes of varying sizes within histiocytesThe spheroidal shapes can cause notching of nuclei and mimic the appearance of lipoblastsExtracellular silicone has the appearance of clear spaces partially occupied by refractile material and surrounded by macrophages, giant cells, and lymphocytesOther organic oils can have the same histologic appearanceThe type of substance cannot be definitively identified based only on appearanceSpecial techniques (e.g., x-ray analysis or Raman spectroscopy) can be used to specifically identify foreign material as siliconeMuch of the silicone is dissolved during tissue processing",
                      "Silicone granulomas consist of numerous macrophages associated with intracellular and intercellular silicone",
                      "May be refractile but is not polarizableRefractile substances have a refractive index different than that of normal tissue, appear brighter and shinier than tissueMore easily appreciated by lowering condenser or closing aperture of diaphragmIf polarizable material is present, it is probably not silicone",
                      "Refractile substances have a refractive index different than that of normal tissue, appear brighter and shinier than tissue",
                      "More easily appreciated by lowering condenser or closing aperture of diaphragm",
                      "If polarizable material is present, it is probably not silicone",
                      "Intracellular silicone has appearance of multiple clear spheroidal shapes of varying sizes within histiocytesThe spheroidal shapes can cause notching of nuclei and mimic the appearance of lipoblasts",
                      "The spheroidal shapes can cause notching of nuclei and mimic the appearance of lipoblasts",
                      "Extracellular silicone has the appearance of clear spaces partially occupied by refractile material and surrounded by macrophages, giant cells, and lymphocytesOther organic oils can have the same histologic appearanceThe type of substance cannot be definitively identified based only on appearance",
                      "Other organic oils can have the same histologic appearance",
                      "The type of substance cannot be definitively identified based only on appearance",
                      "Special techniques (e.g., x-ray analysis or Raman spectroscopy) can be used to specifically identify foreign material as silicone",
                      "Much of the silicone is dissolved during tissue processing"
                    ]
                  },
                  {
                    "text": "Implants with polyurethane patchesPolyurethane has the structure of a sponge and is found within the fibrotic capsuleIn cross section, interstices of sponge have triangular shape",
                    "sub_points": [
                      "Polyurethane has the structure of a sponge and is found within the fibrotic capsule",
                      "In cross section, interstices of sponge have triangular shape"
                    ]
                  },
                  {
                    "text": "Anaplastic large cell lymphoma (ALCL)Recognized as a specific type of T-cell lymphoma (BIA-ALCL) by the WHOOther types of lymphomas can be associated with implants but are very rareMost commonly present in seroma fluid and along surface of capsuleCan be a subtle finding with only a few cells present individually or as small clustersCells are large with pleomorphic, lobated (sometimes horseshoe-shaped) nuclei and 1 to multiple prominent nucleoliMitoses and necrosis are commonAlmost all CD30(+) and anaplastic lymphoma kinase (ALK)(-)~ 40-70% positive for EMA; may cause confusion with carcinoma unless other markers, such as keratins, are used for confirmationConstitutive activation of the JAK/STAT3 pathway is found in > 50% of casesExtension beyond the capsule is a poor prognostic factorExtent of involvement needs to be reported along with relationship to oriented margins",
                    "sub_points": [
                      "Recognized as a specific type of T-cell lymphoma (BIA-ALCL) by the WHOOther types of lymphomas can be associated with implants but are very rare",
                      "Other types of lymphomas can be associated with implants but are very rare",
                      "Most commonly present in seroma fluid and along surface of capsuleCan be a subtle finding with only a few cells present individually or as small clustersCells are large with pleomorphic, lobated (sometimes horseshoe-shaped) nuclei and 1 to multiple prominent nucleoliMitoses and necrosis are commonAlmost all CD30(+) and anaplastic lymphoma kinase (ALK)(-)~ 40-70% positive for EMA; may cause confusion with carcinoma unless other markers, such as keratins, are used for confirmationConstitutive activation of the JAK/STAT3 pathway is found in > 50% of cases",
                      "Can be a subtle finding with only a few cells present individually or as small clusters",
                      "Cells are large with pleomorphic, lobated (sometimes horseshoe-shaped) nuclei and 1 to multiple prominent nucleoli",
                      "Mitoses and necrosis are common",
                      "Almost all CD30(+) and anaplastic lymphoma kinase (ALK)(-)",
                      "~ 40-70% positive for EMA; may cause confusion with carcinoma unless other markers, such as keratins, are used for confirmation",
                      "Constitutive activation of the JAK/STAT3 pathway is found in > 50% of cases",
                      "Extension beyond the capsule is a poor prognostic factorExtent of involvement needs to be reported along with relationship to oriented margins",
                      "Extent of involvement needs to be reported along with relationship to oriented margins"
                    ]
                  },
                  {
                    "text": "Squamous cell carcinomaBIA-SCC are SCCs limited to, or predominantly within, the implant capsule",
                    "sub_points": [
                      "BIA-SCC are SCCs limited to, or predominantly within, the implant capsule"
                    ]
                  },
                  {
                    "text": "SarcomaVery rare with no specific type or featuresUsually forms a large, readily evident mass",
                    "sub_points": [
                      "Very rare with no specific type or features",
                      "Usually forms a large, readily evident mass"
                    ]
                  },
                  {
                    "text": "FibromatosisHas features of fibromatosis at other sitesForms a circumscribed or irregular mass that is firm but not hard",
                    "sub_points": [
                      "Has features of fibromatosis at other sites",
                      "Forms a circumscribed or irregular mass that is firm but not hard"
                    ]
                  },
                  {
                    "text": "Incidental nonsquamous cell carcinomaLikelihood of finding incidental carcinoma in capsule of implant is very low (~ 0.5%)Cancers are typically small and limited to capsuleMore likely in capsules placed for reconstructive purposes after diagnosis of breast cancer",
                    "sub_points": [
                      "Likelihood of finding incidental carcinoma in capsule of implant is very low (~ 0.5%)",
                      "Cancers are typically small and limited to capsule",
                      "More likely in capsules placed for reconstructive purposes after diagnosis of breast cancer"
                    ]
                  },
                  {
                    "text": "Directly injected materialsA wide variety of materials have been injected into breasts for augmentationHistologic appearance and tissue response depend on type of material",
                    "sub_points": [
                      "A wide variety of materials have been injected into breasts for augmentation",
                      "Histologic appearance and tissue response depend on type of material"
                    ]
                  },
                  {
                    "text": "Regional lymph nodesNumerous giant cells may be presentSilicone may be presentIn patients with carcinoma, metastatic carcinoma and silicone can be present in the same lymph node",
                    "sub_points": [
                      "Numerous giant cells may be present",
                      "Silicone may be present",
                      "In patients with carcinoma, metastatic carcinoma and silicone can be present in the same lymph node"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Hereditary Breast Cancer": {
        "name": "Hereditary Breast Cancer",
        "url": "https://app.pathprimer.com/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
        "topics": {
          "Overview of Hereditary Breast Cancer": {
            "name": "Overview of Hereditary Breast Cancer",
            "url": "https://app.pathprimer.com/document/165ead19-771e-4d6b-88fb-736f4f8f2817/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "KEY FACTS": {
                "Classification": [
                  {
                    "text": "It has been long recognized that many women with breast carcinoma (BC) also have affected relatives"
                  },
                  {
                    "text": "~ 10-25% of women with BC have a 1st-degree relative (parent, sister, daughter) with BC"
                  },
                  {
                    "text": "Increased risk is associated with families with premenopausal BC, multiple affected individuals, individuals with multiple BCs, and certain types of breast and other cancers"
                  },
                  {
                    "text": "BCs associated with germline mutationsAccount for 5-10% of all BCs15 major germline mutations contribute to BC riskHigh-risk genes(≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial riskModerate-risk genes(2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial riskLow-risk genes(differing results in studies):BARD1,BRIP1,NBN, RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial riskFeatures incommonAutosomal dominant inheritanceInherited via females and malesMajority of genes are associated with DNA repair pathwaysBCs occur at earlier ages compared to sporadic cancers and are often multiple and bilateralRisk of some nonbreast cancers is increased",
                    "sub_points": [
                      "Account for 5-10% of all BCs",
                      "15 major germline mutations contribute to BC riskHigh-risk genes(≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial riskModerate-risk genes(2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial riskLow-risk genes(differing results in studies):BARD1,BRIP1,NBN, RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial risk",
                      "High-risk genes(≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial risk",
                      "Together, these genes account for ~ 20% of familial risk",
                      "Moderate-risk genes(2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial risk",
                      "Together, these genes account for ~ 5% of familial risk",
                      "Low-risk genes(differing results in studies):BARD1,BRIP1,NBN, RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial risk",
                      "These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial risk",
                      "Features incommonAutosomal dominant inheritanceInherited via females and malesMajority of genes are associated with DNA repair pathwaysBCs occur at earlier ages compared to sporadic cancers and are often multiple and bilateralRisk of some nonbreast cancers is increased",
                      "Autosomal dominant inheritanceInherited via females and males",
                      "Inherited via females and males",
                      "Majority of genes are associated with DNA repair pathways",
                      "BCs occur at earlier ages compared to sporadic cancers and are often multiple and bilateral",
                      "Risk of some nonbreast cancers is increased"
                    ]
                  },
                  {
                    "text": "Familial cancersnotassociated with identified germline mutations5-10% of all BCsMay be due to polygenic risk from the combination of many genes, each conferring a low risk of BC",
                    "sub_points": [
                      "5-10% of all BCs",
                      "May be due to polygenic risk from the combination of many genes, each conferring a low risk of BC"
                    ]
                  }
                ]
              },
              "CLASSIFICATION": {
                "Hereditary Breast Cancer": [
                  {
                    "text": "Certain types of cancers clustering in families has been a well recognized observation for > 100 yearsIncludes breast, uterine, ovarian, colon, and gastric cancer, as well as others",
                    "sub_points": [
                      "Includes breast, uterine, ovarian, colon, and gastric cancer, as well as others"
                    ]
                  },
                  {
                    "text": "A family history of breast carcinoma (BC) is one of the most important risk factors for BC~ 10-25% of women with BC have a 1st-degree relative (parent, sister, daughter) with BCHaving an affected 1st-degree relative increases risk 2-3xIncreased risk is associated with families with premenopausal BC, multiple affected individuals, individuals with multiple BCs, and certain types of breast and other cancersHowever, the most common family history is a mother developing BC after menopauseSporadic breast BC in this age group is very commonThis history alone does not increase the risk of BC for daughters",
                    "sub_points": [
                      "~ 10-25% of women with BC have a 1st-degree relative (parent, sister, daughter) with BCHaving an affected 1st-degree relative increases risk 2-3x",
                      "Having an affected 1st-degree relative increases risk 2-3x",
                      "Increased risk is associated with families with premenopausal BC, multiple affected individuals, individuals with multiple BCs, and certain types of breast and other cancersHowever, the most common family history is a mother developing BC after menopauseSporadic breast BC in this age group is very commonThis history alone does not increase the risk of BC for daughters",
                      "However, the most common family history is a mother developing BC after menopauseSporadic breast BC in this age group is very commonThis history alone does not increase the risk of BC for daughters",
                      "Sporadic breast BC in this age group is very common",
                      "This history alone does not increase the risk of BC for daughters"
                    ]
                  },
                  {
                    "text": "Familial cancers associated with germline mutationsIncludes ~ 1/2 of familial cases of cancer and ~ 5-10% of all BCs15 major germline mutations contribute to BC riskHigh-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11These genes account for ~ 20% of familial riskModerate-risk genes (2-4x increased risk):ATM,CHEK2These genes account for ~ 5% of familial riskLow-risk genes (differing results in studies):BARD1,BRIP1,NBN,RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial riskMany of these genes are functionally related to each otherGenes functionally related toBRCA1andBRCA2:BARD1,CHEK2,NBN,RAD51DGenes in Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51B",
                    "sub_points": [
                      "Includes ~ 1/2 of familial cases of cancer and ~ 5-10% of all BCs",
                      "15 major germline mutations contribute to BC riskHigh-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11These genes account for ~ 20% of familial riskModerate-risk genes (2-4x increased risk):ATM,CHEK2These genes account for ~ 5% of familial riskLow-risk genes (differing results in studies):BARD1,BRIP1,NBN,RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial risk",
                      "High-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11These genes account for ~ 20% of familial risk",
                      "These genes account for ~ 20% of familial risk",
                      "Moderate-risk genes (2-4x increased risk):ATM,CHEK2These genes account for ~ 5% of familial risk",
                      "These genes account for ~ 5% of familial risk",
                      "Low-risk genes (differing results in studies):BARD1,BRIP1,NBN,RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial risk",
                      "These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial risk",
                      "Many of these genes are functionally related to each otherGenes functionally related toBRCA1andBRCA2:BARD1,CHEK2,NBN,RAD51DGenes in Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51B",
                      "Genes functionally related toBRCA1andBRCA2:BARD1,CHEK2,NBN,RAD51D",
                      "Genes in Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51B"
                    ]
                  },
                  {
                    "text": "Features common to all major germline mutationsAutosomal dominant inheritanceNormal protein function is lost when the remaining wildtype allele is rendered nonfunctional or abnormal; however, in some cases, the mutated protein interferes with function of normal protein (dominant negative mutations)Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutationsInherited via both females and males: Multiple individuals in family are usually affectedMajority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for BC has not been explainedBCs occur at younger ages compared to sporadic BCs and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutationsRisk of some nonbreast cancers is also increased",
                    "sub_points": [
                      "Autosomal dominant inheritanceNormal protein function is lost when the remaining wildtype allele is rendered nonfunctional or abnormal; however, in some cases, the mutated protein interferes with function of normal protein (dominant negative mutations)Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutationsInherited via both females and males: Multiple individuals in family are usually affected",
                      "Normal protein function is lost when the remaining wildtype allele is rendered nonfunctional or abnormal; however, in some cases, the mutated protein interferes with function of normal protein (dominant negative mutations)",
                      "Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutations",
                      "Inherited via both females and males: Multiple individuals in family are usually affected",
                      "Majority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for BC has not been explained",
                      "Act as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferation",
                      "Relative tissue specificity for BC has not been explained",
                      "BCs occur at younger ages compared to sporadic BCs and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutations",
                      "1st mutation present at birth",
                      "Destabilization of genome increases likelihood of additional mutations",
                      "Risk of some nonbreast cancers is also increased"
                    ]
                  },
                  {
                    "text": "Penetrance (percentage of carriers who develop BC)> 95% lifetime risk for some mutationsOther genes have lower penetrance (20% or lower lifetime risk)",
                    "sub_points": [
                      "> 95% lifetime risk for some mutations",
                      "Other genes have lower penetrance (20% or lower lifetime risk)"
                    ]
                  },
                  {
                    "text": "Risk of male BC15-20% of males with BC have a family history of breast or ovarian cancerIncreased risk for some mutations (BRCA2lifetime risk 7%;BRCA1lifetime risk 1.8%;PTENlifetime risk is unknown)",
                    "sub_points": [
                      "15-20% of males with BC have a family history of breast or ovarian cancer",
                      "Increased risk for some mutations (BRCA2lifetime risk 7%;BRCA1lifetime risk 1.8%;PTENlifetime risk is unknown)"
                    ]
                  },
                  {
                    "text": "HomozygosityHomozygosity for some mutations confers disease (e.g.,BRCA2andBRIP1: Fanconi anemia;ATM: Ataxia-telangiectasia)Homozygosity for other mutations is likely lethal (e.g.,BRCA1)",
                    "sub_points": [
                      "Homozygosity for some mutations confers disease (e.g.,BRCA2andBRIP1: Fanconi anemia;ATM: Ataxia-telangiectasia)",
                      "Homozygosity for other mutations is likely lethal (e.g.,BRCA1)"
                    ]
                  },
                  {
                    "text": "Founder mutations in ethnic populationsSome populations have very high incidences of specific mutations",
                    "sub_points": [
                      "Some populations have very high incidences of specific mutations"
                    ]
                  },
                  {
                    "text": "Spectrum of nonbreast cancersTypes of other cancers vary according to gene and sometimes are different for specific mutations",
                    "sub_points": [
                      "Types of other cancers vary according to gene and sometimes are different for specific mutations"
                    ]
                  },
                  {
                    "text": "Familial cancersnotassociated with identified germline mutations~ 1/2 of familial cases or 5-10% of all BCsSource of risk in these families has not yet been identified",
                    "sub_points": [
                      "~ 1/2 of familial cases or 5-10% of all BCs",
                      "Source of risk in these families has not yet been identified"
                    ]
                  },
                  {
                    "text": "Role of somatic mutations in genes responsible for hereditary BCTP53is frequently mutated in sporadic BCsBRCA1andBRCA2mutations are rare somatic mutationsGenes may be inactivated by other mechanisms, such as methylationCDH1is inactivated by somatic mutations in the majority of lobular BCs",
                    "sub_points": [
                      "TP53is frequently mutated in sporadic BCs",
                      "BRCA1andBRCA2mutations are rare somatic mutationsGenes may be inactivated by other mechanisms, such as methylation",
                      "Genes may be inactivated by other mechanisms, such as methylation",
                      "CDH1is inactivated by somatic mutations in the majority of lobular BCs"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "BRCA1(Hereditary Breast and Ovarian Cancer Syndrome)": [
                  {
                    "text": "Gene located on chromosome 17q21.31"
                  },
                  {
                    "text": "FunctionBreastcancer1(BRCA1) encodes for protein with central role in DNA repair, regulation of cell cycle checkpoints in response to DNA damage, and transcriptionRequired for error-free DNA double-strand break repairBRCA1function is required for transactivation of ER gene promoterMay explain why 90% ofBRCA1-associated carcinomas are negative for ER",
                    "sub_points": [
                      "Breastcancer1(BRCA1) encodes for protein with central role in DNA repair, regulation of cell cycle checkpoints in response to DNA damage, and transcriptionRequired for error-free DNA double-strand break repair",
                      "Required for error-free DNA double-strand break repair",
                      "BRCA1function is required for transactivation of ER gene promoterMay explain why 90% ofBRCA1-associated carcinomas are negative for ER",
                      "May explain why 90% ofBRCA1-associated carcinomas are negative for ER"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1-0.3%More common in some ethnic groups: Ashkenazi Jews, Finns, French CanadiansMean age of onset is 44 years, but age can vary with specific mutationsMutation can be suspected in young patients [35% risk for patients < 30 years of age with ER(-) poorly differentiated BC]",
                    "sub_points": [
                      "More common in some ethnic groups: Ashkenazi Jews, Finns, French Canadians",
                      "Mean age of onset is 44 years, but age can vary with specific mutations",
                      "Mutation can be suspected in young patients [35% risk for patients < 30 years of age with ER(-) poorly differentiated BC]"
                    ]
                  },
                  {
                    "text": "Lifetime risk of BC in women:40-90% (relative risk: 11.4)Magnitude of risk can vary for different mutations and for different types of BCResponsible for ~ 1/2 of BCs known to be due to germline mutation (~ 2% of all BCs)",
                    "sub_points": [
                      "Magnitude of risk can vary for different mutations and for different types of BC",
                      "Responsible for ~ 1/2 of BCs known to be due to germline mutation (~ 2% of all BCs)"
                    ]
                  },
                  {
                    "text": "Characteristics of BCs~ 70-80% ofBRCA1BCs share the same gene expression pattern with basal-type BCs defined by gene expression profilingBasal-type BCs overlap with triple negative BC (TNBC) (lack expression of hormone receptors and HER2) by ~ 80%10-25% of women < 50 years of age with TNBC have aBRCA1mutationMajority have somatic mutations inTP53Majority positive for basal markers, such as EGFR (HER1) and high molecular weight cytokeratins (e.g., CK5/6, CK14)Majority (~ 80%) of BCs have distinctive morphologyCircumscribed growth pattern with pushing borders, dense lymphocytic infiltrateHigh nuclear grade and high proliferative rate~ 20-30% ofBRCA1BCs are luminal B BC: ER(+)/HER2(-), higher gradeMore common in women developing BC at age > 50 years~ 85% show loss of wildtypeBRCA1allele, supporting that these are not sporadic BCs",
                    "sub_points": [
                      "~ 70-80% ofBRCA1BCs share the same gene expression pattern with basal-type BCs defined by gene expression profilingBasal-type BCs overlap with triple negative BC (TNBC) (lack expression of hormone receptors and HER2) by ~ 80%10-25% of women < 50 years of age with TNBC have aBRCA1mutationMajority have somatic mutations inTP53Majority positive for basal markers, such as EGFR (HER1) and high molecular weight cytokeratins (e.g., CK5/6, CK14)",
                      "Basal-type BCs overlap with triple negative BC (TNBC) (lack expression of hormone receptors and HER2) by ~ 80%",
                      "10-25% of women < 50 years of age with TNBC have aBRCA1mutation",
                      "Majority have somatic mutations inTP53",
                      "Majority positive for basal markers, such as EGFR (HER1) and high molecular weight cytokeratins (e.g., CK5/6, CK14)",
                      "Majority (~ 80%) of BCs have distinctive morphologyCircumscribed growth pattern with pushing borders, dense lymphocytic infiltrateHigh nuclear grade and high proliferative rate",
                      "Circumscribed growth pattern with pushing borders, dense lymphocytic infiltrate",
                      "High nuclear grade and high proliferative rate",
                      "~ 20-30% ofBRCA1BCs are luminal B BC: ER(+)/HER2(-), higher gradeMore common in women developing BC at age > 50 years~ 85% show loss of wildtypeBRCA1allele, supporting that these are not sporadic BCs",
                      "More common in women developing BC at age > 50 years",
                      "~ 85% show loss of wildtypeBRCA1allele, supporting that these are not sporadic BCs"
                    ]
                  },
                  {
                    "text": "Other associated cancersOvarian, fallopian tube, primary peritoneal (40-50% lifetime risk)Usually high-grade serous carcinomas~ 80% of women with both breast and ovarian cancer haveBRCAmutationAverage age of onset: 49-53 years (compared to 63 years in general population)Male breast cancer (1-5% lifetime risk, but ~ 1/2 risk ofBRCA2)Pancreatic cancer, colon cancer, and others",
                    "sub_points": [
                      "Ovarian, fallopian tube, primary peritoneal (40-50% lifetime risk)Usually high-grade serous carcinomas~ 80% of women with both breast and ovarian cancer haveBRCAmutationAverage age of onset: 49-53 years (compared to 63 years in general population)",
                      "Usually high-grade serous carcinomas",
                      "~ 80% of women with both breast and ovarian cancer haveBRCAmutation",
                      "Average age of onset: 49-53 years (compared to 63 years in general population)",
                      "Male breast cancer (1-5% lifetime risk, but ~ 1/2 risk ofBRCA2)",
                      "Pancreatic cancer, colon cancer, and others"
                    ]
                  }
                ],
                "BRCA2(Hereditary Breast and Ovarian Cancer Syndrome)": [
                  {
                    "text": "Gene located on chromosome 13q12.3"
                  },
                  {
                    "text": "FunctionBreastcancer2(BRCA2) is not structurally related toBRCA1, but both genes have very similar functions and regulatory roles",
                    "sub_points": [
                      "Breastcancer2(BRCA2) is not structurally related toBRCA1, but both genes have very similar functions and regulatory roles"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1-0.7%More common in some ethnic groups: Ashkenazi Jews, Icelandic populationsMean age of onset: 47 years; can vary with specific mutations",
                    "sub_points": [
                      "More common in some ethnic groups: Ashkenazi Jews, Icelandic populations",
                      "Mean age of onset: 47 years; can vary with specific mutations"
                    ]
                  },
                  {
                    "text": "Lifetime risk of female BC: 45-85% (relative risk: 11.7)Magnitude of risk can vary for different mutations and for different types of cancersResponsible for ~ 1/2 of cancers known to be due to germline mutation (~ 2% of all BCs)",
                    "sub_points": [
                      "Magnitude of risk can vary for different mutations and for different types of cancers",
                      "Responsible for ~ 1/2 of cancers known to be due to germline mutation (~ 2% of all BCs)"
                    ]
                  },
                  {
                    "text": "Characteristics of BCsPositive for hormone receptors and negative for HER2Luminal B BC is more common than luminal A BC by gene expression profiling or by receptor expression and gradeMajority are high grade",
                    "sub_points": [
                      "Positive for hormone receptors and negative for HER2",
                      "Luminal B BC is more common than luminal A BC by gene expression profiling or by receptor expression and grade",
                      "Majority are high grade"
                    ]
                  },
                  {
                    "text": "Other associated cancers and diseasesOvary, fallopian tube, primary peritoneal (10-20% lifetime risk)Usual age of onset is 55-58 years (compared to 63 years in general population)Male BC: 5-10% lifetime risk; ~ 5-15% of cases are associated withBRCA2Also increased risk of early-onset prostate cancerPancreatic cancer, prostate cancerHomozygousBRCA2mutations cause rare form of Fanconi anemia",
                    "sub_points": [
                      "Ovary, fallopian tube, primary peritoneal (10-20% lifetime risk)Usual age of onset is 55-58 years (compared to 63 years in general population)",
                      "Usual age of onset is 55-58 years (compared to 63 years in general population)",
                      "Male BC: 5-10% lifetime risk; ~ 5-15% of cases are associated withBRCA2Also increased risk of early-onset prostate cancer",
                      "Also increased risk of early-onset prostate cancer",
                      "Pancreatic cancer, prostate cancer",
                      "HomozygousBRCA2mutations cause rare form of Fanconi anemia"
                    ]
                  }
                ],
                "TP53(Li-Fraumeni Syndrome)": [
                  {
                    "text": "Gene located on chromosome 17p13.1"
                  },
                  {
                    "text": "FunctionTumorprotein53(TP53) encodes for protein with central role in cell cycle control, DNA replication, DNA repair, and apoptosisCrucial tumor suppressor gene, so called \"the guardian of the genome\"",
                    "sub_points": [
                      "Tumorprotein53(TP53) encodes for protein with central role in cell cycle control, DNA replication, DNA repair, and apoptosisCrucial tumor suppressor gene, so called \"the guardian of the genome\"",
                      "Crucial tumor suppressor gene, so called \"the guardian of the genome\""
                    ]
                  },
                  {
                    "text": "Incidence: 0.0025%A population in southeastern Brazil has 1/300 incidenceEarly onset: Average age at diagnosis is 33 years~ 55% of women develop BC by age 45~ 2-7% of women with BC diagnosed at < 30 years of ageRare for BC to be diagnosed after age 50",
                    "sub_points": [
                      "A population in southeastern Brazil has 1/300 incidenceEarly onset: Average age at diagnosis is 33 years~ 55% of women develop BC by age 45~ 2-7% of women with BC diagnosed at < 30 years of ageRare for BC to be diagnosed after age 50",
                      "Early onset: Average age at diagnosis is 33 years",
                      "~ 55% of women develop BC by age 45",
                      "~ 2-7% of women with BC diagnosed at < 30 years of age",
                      "Rare for BC to be diagnosed after age 50"
                    ]
                  },
                  {
                    "text": "Lifetime risk of female BC: >90% (relative risk: ~ 60-165)Penetrance varies for different mutations",
                    "sub_points": [
                      "Penetrance varies for different mutations"
                    ]
                  },
                  {
                    "text": "Characteristics of BCs1/3 of malignancies in affected families~ 40-50% luminal HER2: ER(+)/HER2(+)~ 40% luminal: ER(+)/HER2(-)~ 15% HER2: ER(-)/HER2(+)~ 5% TNBC: ER(-)/HER2(-)Male BC is rare",
                    "sub_points": [
                      "1/3 of malignancies in affected families",
                      "~ 40-50% luminal HER2: ER(+)/HER2(+)",
                      "~ 40% luminal: ER(+)/HER2(-)",
                      "~ 15% HER2: ER(-)/HER2(+)",
                      "~ 5% TNBC: ER(-)/HER2(-)",
                      "Male BC is rare"
                    ]
                  },
                  {
                    "text": "Other associated cancersSarcomas: Most occur in children < 10 years of ageAdrenal cortical carcinoma: Most occur in children ~ 3 years of ageBrain tumors: Occur in children or in 4th-5th decadesLeukemia",
                    "sub_points": [
                      "Sarcomas: Most occur in children < 10 years of age",
                      "Adrenal cortical carcinoma: Most occur in children ~ 3 years of age",
                      "Brain tumors: Occur in children or in 4th-5th decades",
                      "Leukemia"
                    ]
                  }
                ],
                "CDH1(Familial Gastric Cancer and Lobular Breast Cancer Syndrome)": [
                  {
                    "text": "Gene located on chromosome 16p22.1"
                  },
                  {
                    "text": "FunctionCadherin1(CDH1) encodes for epithelial cadherin (E-cadherin), which is a cell adhesion moleculeMutations interfere with function, increasing proliferation, invasion75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletionsLoss of protein results in cells rounding up and single cell infiltrative pattern due to lack of adhesion to adjacent cells",
                    "sub_points": [
                      "Cadherin1(CDH1) encodes for epithelial cadherin (E-cadherin), which is a cell adhesion molecule",
                      "Mutations interfere with function, increasing proliferation, invasion75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletionsLoss of protein results in cells rounding up and single cell infiltrative pattern due to lack of adhesion to adjacent cells",
                      "75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletions",
                      "Loss of protein results in cells rounding up and single cell infiltrative pattern due to lack of adhesion to adjacent cells"
                    ]
                  },
                  {
                    "text": "Incidence: 0.005%"
                  },
                  {
                    "text": "Lifetime risk of female BC: ~40-55% (relative risk: ~ 7)"
                  },
                  {
                    "text": "Characteristics of BCsWomen at increased risk for lobular BC: ER(+)/HER2(-)However, < 5% of women with lobular BCs do not haveCDH1germline mutations",
                    "sub_points": [
                      "Women at increased risk for lobular BC: ER(+)/HER2(-)However, < 5% of women with lobular BCs do not haveCDH1germline mutations",
                      "However, < 5% of women with lobular BCs do not haveCDH1germline mutations"
                    ]
                  },
                  {
                    "text": "Other associated cancers70-85% lifetime risk of developing gastric signet-ring cell carcinoma in majority of familiesGastric carcinomas are more common than BCs in most affected familiesFamilies developing only breast BCs have also been identifiedHowever, majority undergoing prophylactic gastrectomies have clinically occult gastric carcinomaGastric signet-ring cell carcinomas morphologically resemble lobular BCsBoth consist of dyscohesive cells, and cytoplasmic mucin creates the appearance of signet-ring cellsThey can be distinguished by protein expressionGastric carcinomas are typically ER(+), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)BCs are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)",
                    "sub_points": [
                      "70-85% lifetime risk of developing gastric signet-ring cell carcinoma in majority of familiesGastric carcinomas are more common than BCs in most affected familiesFamilies developing only breast BCs have also been identifiedHowever, majority undergoing prophylactic gastrectomies have clinically occult gastric carcinoma",
                      "Gastric carcinomas are more common than BCs in most affected families",
                      "Families developing only breast BCs have also been identifiedHowever, majority undergoing prophylactic gastrectomies have clinically occult gastric carcinoma",
                      "However, majority undergoing prophylactic gastrectomies have clinically occult gastric carcinoma",
                      "Gastric signet-ring cell carcinomas morphologically resemble lobular BCsBoth consist of dyscohesive cells, and cytoplasmic mucin creates the appearance of signet-ring cellsThey can be distinguished by protein expressionGastric carcinomas are typically ER(+), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)BCs are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)",
                      "Both consist of dyscohesive cells, and cytoplasmic mucin creates the appearance of signet-ring cells",
                      "They can be distinguished by protein expressionGastric carcinomas are typically ER(+), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)BCs are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)",
                      "Gastric carcinomas are typically ER(+), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)",
                      "BCs are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)"
                    ]
                  }
                ],
                "PTEN(Cowden Syndrome)": [
                  {
                    "text": "Tumor suppressor gene located on chromosome 10q23.31"
                  },
                  {
                    "text": "FunctionPhosphatase andTENsin homolog (PTEN) encodes for dual specificity phosphatase gene involved in control of proliferation signals and apoptosis",
                    "sub_points": [
                      "Phosphatase andTENsin homolog (PTEN) encodes for dual specificity phosphatase gene involved in control of proliferation signals and apoptosis"
                    ]
                  },
                  {
                    "text": "Incidence: 0.0005%Early onset; most women diagnosed between 38-46 years of age",
                    "sub_points": [
                      "Early onset; most women diagnosed between 38-46 years of age"
                    ]
                  },
                  {
                    "text": "Lifetime risk of female BC: 25-85%"
                  },
                  {
                    "text": "Characteristics of BCsMen also at increased risk for BC; magnitude of risk not yet determinedBCs have not been reported to have specific featuresOther breast lesions include fibroadenomas and hamartomas",
                    "sub_points": [
                      "Men also at increased risk for BC; magnitude of risk not yet determined",
                      "BCs have not been reported to have specific features",
                      "Other breast lesions include fibroadenomas and hamartomas"
                    ]
                  },
                  {
                    "text": "Other associated tumorsMultiple hamartomas (including trichilemmomas)Thyroid, renal, and endometrial cancer",
                    "sub_points": [
                      "Multiple hamartomas (including trichilemmomas)",
                      "Thyroid, renal, and endometrial cancer"
                    ]
                  }
                ],
                "STK11/LKB1 (Peutz-Jeghers Syndrome)": [
                  {
                    "text": "Gene located on chromosome 19p13.3"
                  },
                  {
                    "text": "FunctionSerine/threoninekinase11(a.k.a.liverkinase B1) encodes serine/threonine kinase involved in cell cycle regulation and mediation of apoptosis",
                    "sub_points": [
                      "Serine/threoninekinase11(a.k.a.liverkinase B1) encodes serine/threonine kinase involved in cell cycle regulation and mediation of apoptosis"
                    ]
                  },
                  {
                    "text": "Incidence: 0.001%Early onset: 8% by age 40 and 32% by age 60",
                    "sub_points": [
                      "Early onset: 8% by age 40 and 32% by age 60"
                    ]
                  },
                  {
                    "text": "Lifetime risk of female BC: ~40%"
                  },
                  {
                    "text": "Characteristics of BCsBCs have been reported to be ER(+)/HER2(-), but very few cases described",
                    "sub_points": [
                      "BCs have been reported to be ER(+)/HER2(-), but very few cases described"
                    ]
                  },
                  {
                    "text": "Other associated lesionsHamartomatous gastrointestinal polyps (including small intestine)Mucocutaneous pigmentation (lips and buccal mucosa)Ovarian cancer (sex cord-stromal tumors are most common): ~ 20% riskIncreased risk of cancer of colon, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix (adenoma malignum)",
                    "sub_points": [
                      "Hamartomatous gastrointestinal polyps (including small intestine)",
                      "Mucocutaneous pigmentation (lips and buccal mucosa)",
                      "Ovarian cancer (sex cord-stromal tumors are most common): ~ 20% risk",
                      "Increased risk of cancer of colon, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix (adenoma malignum)"
                    ]
                  }
                ],
                "PALB2": [
                  {
                    "text": "Gene located on chromosome.16p12.2"
                  },
                  {
                    "text": "3rd most prevalent BC gene afterBRCA1andBRCA2"
                  },
                  {
                    "text": "FunctionPartnerandlocalizer ofBRCA2(PALPB2) encodes for a protein that binds to BRCA2 protein and is part of a complex responsible for homologous recombination and double-strand DNA break repair",
                    "sub_points": [
                      "Partnerandlocalizer ofBRCA2(PALPB2) encodes for a protein that binds to BRCA2 protein and is part of a complex responsible for homologous recombination and double-strand DNA break repair"
                    ]
                  },
                  {
                    "text": "Incidence:0.1%"
                  },
                  {
                    "text": "Lifetime risk of female BC: 35-60% (relative risk: ~ 5)"
                  },
                  {
                    "text": "Characteristics of BCsReported to be ER(+) of higher grade or TNBC",
                    "sub_points": [
                      "Reported to be ER(+) of higher grade or TNBC"
                    ]
                  },
                  {
                    "text": "Other associated diseasesPancreatic cancer and ovarian cancerFanconi anemia when homozygous (PALB2is also termed FANCN)",
                    "sub_points": [
                      "Pancreatic cancer and ovarian cancer",
                      "Fanconi anemia when homozygous (PALB2is also termed FANCN)"
                    ]
                  }
                ],
                "ATM(Ataxia-Telangiectasia Carriers)": [
                  {
                    "text": "Gene located on chromosome 11q22-23"
                  },
                  {
                    "text": "FunctionAtaxia-telangiectasiamutated (ATM) codes for serine threonine kinase that phosphorylates p53 and BRCA1 in response to DNA double-strand breaks",
                    "sub_points": [
                      "Ataxia-telangiectasiamutated (ATM) codes for serine threonine kinase that phosphorylates p53 and BRCA1 in response to DNA double-strand breaks"
                    ]
                  },
                  {
                    "text": "Incidence: 0.5%"
                  },
                  {
                    "text": "Lifetime risk of female BC: 25-40% (relative risk: ~ 3)Varies with specific mutationEarlier onset than sporadic BC",
                    "sub_points": [
                      "Varies with specific mutation",
                      "Earlier onset than sporadic BC"
                    ]
                  },
                  {
                    "text": "Characteristics of BCsMajority intermediate to high grade~ 80% luminal: ER(+)/HER2(-)~ 15% luminal HER2: ER(+)/HER2(+)< 5% HER2: ER(-)/HER2(+)< 5% TNBC",
                    "sub_points": [
                      "Majority intermediate to high grade",
                      "~ 80% luminal: ER(+)/HER2(-)",
                      "~ 15% luminal HER2: ER(+)/HER2(+)",
                      "< 5% HER2: ER(-)/HER2(+)",
                      "< 5% TNBC"
                    ]
                  },
                  {
                    "text": "Other associated lesionsHeterozygotes may be more susceptible to DNA damage from radiationPossibly pancreatic cancerHomozygosity results in ataxia-telangiectasiaProgressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma",
                    "sub_points": [
                      "Heterozygotes may be more susceptible to DNA damage from radiation",
                      "Possibly pancreatic cancer",
                      "Homozygosity results in ataxia-telangiectasiaProgressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma",
                      "Progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma"
                    ]
                  }
                ],
                "CHEK2": [
                  {
                    "text": "Gene located on chromosome 22q12.1"
                  },
                  {
                    "text": "FunctionCheckpointkinase2(CHEK2) encodes for serine threonine kinase that phosphorylates p53 and BRCA1 to halt cell division in response to DNA damage",
                    "sub_points": [
                      "Checkpointkinase2(CHEK2) encodes for serine threonine kinase that phosphorylates p53 and BRCA1 to halt cell division in response to DNA damage"
                    ]
                  },
                  {
                    "text": "Incidence: 0.2-0.3%0.5-1% in eastern and northern European populationsLater onset of BC",
                    "sub_points": [
                      "0.5-1% in eastern and northern European populations",
                      "Later onset of BC"
                    ]
                  },
                  {
                    "text": "Lifetime risk of female BC: ~ 30% (relative risk ~ 2)Varies depending on specific mutation and whether or not there is family history of BCRisk can be increased after radiation exposure",
                    "sub_points": [
                      "Varies depending on specific mutation and whether or not there is family history of BC",
                      "Risk can be increased after radiation exposure"
                    ]
                  },
                  {
                    "text": "Characteristics of BCsIncreased risk for malesBCs are usually ER(+)",
                    "sub_points": [
                      "Increased risk for males",
                      "BCs are usually ER(+)"
                    ]
                  },
                  {
                    "text": "Other associated cancersMay be linked to prostate, lung, colon, kidney, and thyroid cancers, lymphoma, and sarcoma but degree of risk is unclear",
                    "sub_points": [
                      "May be linked to prostate, lung, colon, kidney, and thyroid cancers, lymphoma, and sarcoma but degree of risk is unclear"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Genetic Testing": [
                  {
                    "text": "Population to be testedNational Comprehensive Cancer Network (NCCN), US Preventative Services Task Force, National Institute for Health and Care Excellence, and other organizations recommend testing individuals at high risk for having a pathogenic mutation in a BC predisposition geneNCCN version 2.2025 (November 7, 2024) is available at www.nccn.org (accessed November 27, 2024)In general, high risk is defined as > 10% likelihood of having mutationHowever, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testingIn addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasonsCriteria based on cancer history to identify individuals at risk for high-penetrance BC genes generally include (but are not limited to)Personal history of BC at < 50 years, TNBC at < 60 years, multiple breast cancersTNBC at any ageMultiple primary BCs either synchronous or metachronous at any ageInvasive lobular BC with a personal or family history of diffuse gastric carcinoma at any ageMale BC at any age≥ 1st-degree relative with known germline mutation, BC at ≤ 50 years, male BC, ovarian cancer, pancreatic cancer, or prostate cancer with metastases or high-risk features≥ 3 diagnoses of BC &/or prostate cancer (any grade) on the same side of the family, including the person with BCFor a family, it is most useful to begin testing the individual with BCIf multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutationOnce a mutation is detected, other family members without cancer may choose testingCounseling should occur before testing to ensure patient is aware of possible implications for individual and familyA high level of expertise and synergistic cooperation between genetics and medical oncology is required",
                    "sub_points": [
                      "National Comprehensive Cancer Network (NCCN), US Preventative Services Task Force, National Institute for Health and Care Excellence, and other organizations recommend testing individuals at high risk for having a pathogenic mutation in a BC predisposition geneNCCN version 2.2025 (November 7, 2024) is available at www.nccn.org (accessed November 27, 2024)",
                      "NCCN version 2.2025 (November 7, 2024) is available at www.nccn.org (accessed November 27, 2024)",
                      "In general, high risk is defined as > 10% likelihood of having mutationHowever, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testingIn addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasons",
                      "However, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testing",
                      "In addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasons",
                      "Criteria based on cancer history to identify individuals at risk for high-penetrance BC genes generally include (but are not limited to)Personal history of BC at < 50 years, TNBC at < 60 years, multiple breast cancersTNBC at any ageMultiple primary BCs either synchronous or metachronous at any ageInvasive lobular BC with a personal or family history of diffuse gastric carcinoma at any ageMale BC at any age≥ 1st-degree relative with known germline mutation, BC at ≤ 50 years, male BC, ovarian cancer, pancreatic cancer, or prostate cancer with metastases or high-risk features≥ 3 diagnoses of BC &/or prostate cancer (any grade) on the same side of the family, including the person with BC",
                      "Personal history of BC at < 50 years, TNBC at < 60 years, multiple breast cancers",
                      "TNBC at any age",
                      "Multiple primary BCs either synchronous or metachronous at any age",
                      "Invasive lobular BC with a personal or family history of diffuse gastric carcinoma at any age",
                      "Male BC at any age",
                      "≥ 1st-degree relative with known germline mutation, BC at ≤ 50 years, male BC, ovarian cancer, pancreatic cancer, or prostate cancer with metastases or high-risk features",
                      "≥ 3 diagnoses of BC &/or prostate cancer (any grade) on the same side of the family, including the person with BC",
                      "For a family, it is most useful to begin testing the individual with BCIf multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutationOnce a mutation is detected, other family members without cancer may choose testing",
                      "If multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutation",
                      "Once a mutation is detected, other family members without cancer may choose testing",
                      "Counseling should occur before testing to ensure patient is aware of possible implications for individual and family",
                      "A high level of expertise and synergistic cooperation between genetics and medical oncology is required"
                    ]
                  },
                  {
                    "text": "Classification of resultsMutations are classified into 5 groupsBenign or likely benign: Both are considered a negative resultPathogenic or likely pathogenic: Both are considered a positive resultVariants of unknown significance (VUS): Should not be used for patient managementGenetic polymorphism that has not yet been associated with increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations because they are underrepresented in genetic databasesMust be identified in multiple individuals to determine clinical significance",
                    "sub_points": [
                      "Mutations are classified into 5 groupsBenign or likely benign: Both are considered a negative resultPathogenic or likely pathogenic: Both are considered a positive resultVariants of unknown significance (VUS): Should not be used for patient managementGenetic polymorphism that has not yet been associated with increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations because they are underrepresented in genetic databasesMust be identified in multiple individuals to determine clinical significance",
                      "Benign or likely benign: Both are considered a negative result",
                      "Pathogenic or likely pathogenic: Both are considered a positive result",
                      "Variants of unknown significance (VUS): Should not be used for patient managementGenetic polymorphism that has not yet been associated with increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations because they are underrepresented in genetic databasesMust be identified in multiple individuals to determine clinical significance",
                      "Genetic polymorphism that has not yet been associated with increased risk of cancer",
                      "Found in 3-7% of individuals tested forBRCA1andBRCA2",
                      "> 1,500 identified",
                      "More frequent in minority ethnic populations because they are underrepresented in genetic databases",
                      "Must be identified in multiple individuals to determine clinical significance"
                    ]
                  },
                  {
                    "text": "Extent of testingFull genome sequencing is required to detect all mutationsMay become feasible in near futureDoes not detect all genetic alterationsLimited sequence analysis can be used to detect most likely mutationCommon mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish populationHotspots for mutations within geneDetection of known mutation in familyDuplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis18% of genetic changes inBRCA1andBRCA2are not detected by standard testingAlso underlie pathogenic variants in other BC predisposition mutationsBRACAnalysis Large Rearrangement Test (BART) detects some rearrangementsAccount for 17% of deleterious mutations in individuals from Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean",
                    "sub_points": [
                      "Full genome sequencing is required to detect all mutationsMay become feasible in near futureDoes not detect all genetic alterations",
                      "May become feasible in near future",
                      "Does not detect all genetic alterations",
                      "Limited sequence analysis can be used to detect most likely mutationCommon mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish populationHotspots for mutations within geneDetection of known mutation in family",
                      "Common mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish population",
                      "Hotspots for mutations within gene",
                      "Detection of known mutation in family",
                      "Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis18% of genetic changes inBRCA1andBRCA2are not detected by standard testingAlso underlie pathogenic variants in other BC predisposition mutationsBRACAnalysis Large Rearrangement Test (BART) detects some rearrangementsAccount for 17% of deleterious mutations in individuals from Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean",
                      "18% of genetic changes inBRCA1andBRCA2are not detected by standard testing",
                      "Also underlie pathogenic variants in other BC predisposition mutations",
                      "BRACAnalysis Large Rearrangement Test (BART) detects some rearrangements",
                      "Account for 17% of deleterious mutations in individuals from Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean"
                    ]
                  },
                  {
                    "text": "Single gene testingUseful when relative has a known germline mutation, individual belongs to a group with a founder mutation of high frequency, or the family history is highly suggestive of a mutation in a specific geneHowever, mutations in other genes may be missedOf all individuals meeting recommended criteria for testing forBRCA1/BRCA1, ~ 10% will be found to have a germline mutationHowever, only in ~ 1/3 will mutation be inBRCA1/BRCA2In addition, ~ 6% of individuals who have aBRCA1/BRCA2germline mutation do not meet criteria for testing for these genesTherefore, multigene testing is required to detect the majority of germline mutations",
                    "sub_points": [
                      "Useful when relative has a known germline mutation, individual belongs to a group with a founder mutation of high frequency, or the family history is highly suggestive of a mutation in a specific geneHowever, mutations in other genes may be missed",
                      "However, mutations in other genes may be missed",
                      "Of all individuals meeting recommended criteria for testing forBRCA1/BRCA1, ~ 10% will be found to have a germline mutationHowever, only in ~ 1/3 will mutation be inBRCA1/BRCA2In addition, ~ 6% of individuals who have aBRCA1/BRCA2germline mutation do not meet criteria for testing for these genesTherefore, multigene testing is required to detect the majority of germline mutations",
                      "However, only in ~ 1/3 will mutation be inBRCA1/BRCA2",
                      "In addition, ~ 6% of individuals who have aBRCA1/BRCA2germline mutation do not meet criteria for testing for these genes",
                      "Therefore, multigene testing is required to detect the majority of germline mutations"
                    ]
                  },
                  {
                    "text": "Multigene panel testingCurrently, the most common method of testingCompanies offer different sets of panels and extent of testingCan offer results from 5-50 or more genesMay or may not offer evaluation of deletions and duplicationsIncreases number of VUSs detectedDetection of VUSs augments complexity of patient management",
                    "sub_points": [
                      "Currently, the most common method of testing",
                      "Companies offer different sets of panels and extent of testingCan offer results from 5-50 or more genesMay or may not offer evaluation of deletions and duplications",
                      "Can offer results from 5-50 or more genes",
                      "May or may not offer evaluation of deletions and duplications",
                      "Increases number of VUSs detectedDetection of VUSs augments complexity of patient management",
                      "Detection of VUSs augments complexity of patient management"
                    ]
                  },
                  {
                    "text": "Direct-to-consumer testingTypically only includes most common mutationsIf negative result is obtained, and there is strong likelihood of germline mutation due to personal or family history, more comprehensive testing by a certified laboratory should be pursuedIf a positive result is obtained, the result should be confirmed by a certified laboratoryIn one study, 40% of positive results obtained by direct-to-consumer testing could not be confirmed by a certified laboratory",
                    "sub_points": [
                      "Typically only includes most common mutationsIf negative result is obtained, and there is strong likelihood of germline mutation due to personal or family history, more comprehensive testing by a certified laboratory should be pursuedIf a positive result is obtained, the result should be confirmed by a certified laboratoryIn one study, 40% of positive results obtained by direct-to-consumer testing could not be confirmed by a certified laboratory",
                      "If negative result is obtained, and there is strong likelihood of germline mutation due to personal or family history, more comprehensive testing by a certified laboratory should be pursued",
                      "If a positive result is obtained, the result should be confirmed by a certified laboratoryIn one study, 40% of positive results obtained by direct-to-consumer testing could not be confirmed by a certified laboratory",
                      "In one study, 40% of positive results obtained by direct-to-consumer testing could not be confirmed by a certified laboratory"
                    ]
                  },
                  {
                    "text": "Polygenic risk scores (PRS)Common (> 1% incidence) single nucleotide polymorphisms can slightly increase risk of BC> 170 genes with mutations conferring low risk of BC have been identifiedAlthough of little significance alone, multiple polymorphisms can be combined into PRS to modify risk estimates for individuals ± germline mutationsIn combination, these low-risk genes may account for ~ 18% of familial risk of BC",
                    "sub_points": [
                      "Common (> 1% incidence) single nucleotide polymorphisms can slightly increase risk of BC> 170 genes with mutations conferring low risk of BC have been identified",
                      "> 170 genes with mutations conferring low risk of BC have been identified",
                      "Although of little significance alone, multiple polymorphisms can be combined into PRS to modify risk estimates for individuals ± germline mutations",
                      "In combination, these low-risk genes may account for ~ 18% of familial risk of BC"
                    ]
                  }
                ],
                "Medical Care of Individuals With Germline Mutations": [
                  {
                    "text": "OverviewThe longstanding approach for risk mitigation in affected individuals has centered around primary and secondary prevention strategiesIdentification of a pathogenic germline mutation may modify medical care in multiple areasNotification of relatives at possible riskChemopreventionProphylactic surgeryScreeningAlterations in cancer therapy targeted to mutation for patients who have BCAssisted reproduction to avoid passing mutation to next generationThe benefit of interventions is greatest for individuals with high-risk mutations and less certain for those with moderate-risk mutations",
                    "sub_points": [
                      "The longstanding approach for risk mitigation in affected individuals has centered around primary and secondary prevention strategies",
                      "Identification of a pathogenic germline mutation may modify medical care in multiple areasNotification of relatives at possible riskChemopreventionProphylactic surgeryScreeningAlterations in cancer therapy targeted to mutation for patients who have BCAssisted reproduction to avoid passing mutation to next generation",
                      "Notification of relatives at possible risk",
                      "Chemoprevention",
                      "Prophylactic surgery",
                      "Screening",
                      "Alterations in cancer therapy targeted to mutation for patients who have BC",
                      "Assisted reproduction to avoid passing mutation to next generation",
                      "The benefit of interventions is greatest for individuals with high-risk mutations and less certain for those with moderate-risk mutations"
                    ]
                  },
                  {
                    "text": "ChemopreventionTamoxifen reduces risk of ER(+)BC for women with a family history of BCHowever, risk of endometrial cancer and thrombosis is increasedThe benefit of chemoprevention for primary prevention of BC for individuals with germline mutations is not yet clearTreatment with tamoxifen for a 1st BC reduces the risk of a 2nd contralateral BC by ~ 44% inBRCA1/BRCA2carriers",
                    "sub_points": [
                      "Tamoxifen reduces risk of ER(+)BC for women with a family history of BCHowever, risk of endometrial cancer and thrombosis is increased",
                      "However, risk of endometrial cancer and thrombosis is increased",
                      "The benefit of chemoprevention for primary prevention of BC for individuals with germline mutations is not yet clear",
                      "Treatment with tamoxifen for a 1st BC reduces the risk of a 2nd contralateral BC by ~ 44% inBRCA1/BRCA2carriers"
                    ]
                  },
                  {
                    "text": "ScreeningClinical breast examination 2x yearly starting at age 25Patient self-breast awareness with periodic breast examinationsMammography at earlier age (10 years before age at which youngest relative with BC was diagnosed) or more frequentlyMR screening is more sensitive than mammography in young women with dense breastsHowever, lower specificity leads to greater numbers of biopsies for benign lesionsScreening by mammography and MR may be staggered every 6 months to decrease screening interval",
                    "sub_points": [
                      "Clinical breast examination 2x yearly starting at age 25Patient self-breast awareness with periodic breast examinations",
                      "Patient self-breast awareness with periodic breast examinations",
                      "Mammography at earlier age (10 years before age at which youngest relative with BC was diagnosed) or more frequently",
                      "MR screening is more sensitive than mammography in young women with dense breastsHowever, lower specificity leads to greater numbers of biopsies for benign lesions",
                      "However, lower specificity leads to greater numbers of biopsies for benign lesions",
                      "Screening by mammography and MR may be staggered every 6 months to decrease screening interval"
                    ]
                  },
                  {
                    "text": "Prophylactic surgeryBilateral mastectomy reduces risk of BC by 97%Not all breast tissue can be removed in all patients with acceptable cosmetic resultsMajor benefit is to women prior to development of BC; limited or no benefit after BC diagnosis with possible distant metastasesBilateral salpingo-oophorectomy reduces risk of ovarian and fallopian tube cancer by 70-95%Relevant for mutations that increase risk of both breast and ovarian cancerScreening for ovarian cancer has remained elusive, leading to a focus on primary preventionWomen remain at risk for primary peritoneal cancersReduces risk of BC by 50% in premenopausal women, presumably due to decrease in hormone productionReduces risk of ER(-)BCs forBRCA1patients to a lesser degree; mechanism is unknownInterval salpingectomy with delayed oophorectomy is undergoing study as a risk-reducing approach in high-risk womenMay help improve menopause-related quality of life while mitigating risk",
                    "sub_points": [
                      "Bilateral mastectomy reduces risk of BC by 97%Not all breast tissue can be removed in all patients with acceptable cosmetic resultsMajor benefit is to women prior to development of BC; limited or no benefit after BC diagnosis with possible distant metastases",
                      "Not all breast tissue can be removed in all patients with acceptable cosmetic results",
                      "Major benefit is to women prior to development of BC; limited or no benefit after BC diagnosis with possible distant metastases",
                      "Bilateral salpingo-oophorectomy reduces risk of ovarian and fallopian tube cancer by 70-95%Relevant for mutations that increase risk of both breast and ovarian cancerScreening for ovarian cancer has remained elusive, leading to a focus on primary preventionWomen remain at risk for primary peritoneal cancersReduces risk of BC by 50% in premenopausal women, presumably due to decrease in hormone productionReduces risk of ER(-)BCs forBRCA1patients to a lesser degree; mechanism is unknownInterval salpingectomy with delayed oophorectomy is undergoing study as a risk-reducing approach in high-risk womenMay help improve menopause-related quality of life while mitigating risk",
                      "Relevant for mutations that increase risk of both breast and ovarian cancer",
                      "Screening for ovarian cancer has remained elusive, leading to a focus on primary prevention",
                      "Women remain at risk for primary peritoneal cancers",
                      "Reduces risk of BC by 50% in premenopausal women, presumably due to decrease in hormone production",
                      "Reduces risk of ER(-)BCs forBRCA1patients to a lesser degree; mechanism is unknown",
                      "Interval salpingectomy with delayed oophorectomy is undergoing study as a risk-reducing approach in high-risk womenMay help improve menopause-related quality of life while mitigating risk",
                      "May help improve menopause-related quality of life while mitigating risk"
                    ]
                  },
                  {
                    "text": "Prophylactic radiation to reduce contralateral BC riskContralateral risk is ~ 40% for those withBRCA1and 26% for those withBRCA2mutationsA phase II trial has suggested that prophylactic contralateral irradiation can significantly reduce risk of contralateral BCsLong-term follow-up is ongoing",
                    "sub_points": [
                      "Contralateral risk is ~ 40% for those withBRCA1and 26% for those withBRCA2mutationsA phase II trial has suggested that prophylactic contralateral irradiation can significantly reduce risk of contralateral BCsLong-term follow-up is ongoing",
                      "A phase II trial has suggested that prophylactic contralateral irradiation can significantly reduce risk of contralateral BCs",
                      "Long-term follow-up is ongoing"
                    ]
                  },
                  {
                    "text": "Alterations in recommendations for systemic therapyFor patients with advanced BC, the presence of a germline mutation may alter the type of therapyBRCA1/BRCA1: Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors (olaparib or talazoparib)BRCA1/BRCA1-associated TNBC: Carboplatin",
                    "sub_points": [
                      "For patients with advanced BC, the presence of a germline mutation may alter the type of therapyBRCA1/BRCA1: Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors (olaparib or talazoparib)BRCA1/BRCA1-associated TNBC: Carboplatin",
                      "BRCA1/BRCA1: Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors (olaparib or talazoparib)",
                      "BRCA1/BRCA1-associated TNBC: Carboplatin"
                    ]
                  },
                  {
                    "text": "ChildbearingAssisted reproduction can be used to prevent a germline mutation being passed on to children",
                    "sub_points": [
                      "Assisted reproduction can be used to prevent a germline mutation being passed on to children"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Male Breast Carcinoma": {
            "name": "Male Breast Carcinoma",
            "url": "https://app.pathprimer.com/document/3e680be3-33c3-416d-941b-27d34806acff/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Male breast carcinoma (MBC) is histologically identical to female breast carcinoma (FBC)~ 1% of breast carcinoma (BC) casesLifetime risk for males without germline mutations is ~ 0.1%< 1% of all cancers in males are BC",
                    "sub_points": [
                      "~ 1% of breast carcinoma (BC) cases",
                      "Lifetime risk for males without germline mutations is ~ 0.1%< 1% of all cancers in males are BC",
                      "< 1% of all cancers in males are BC"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "~ 15-20% of MBC patients have a family history of breast or ovarian cancer"
                  },
                  {
                    "text": "Risk increased forBRCA1andBRCA2carriersBRCA1: Lifetime risk ~ 1-5%BRCA2: Lifetime risk ~ 5-10%60-75% chance ofBRCA2mutation in family",
                    "sub_points": [
                      "BRCA1: Lifetime risk ~ 1-5%",
                      "BRCA2: Lifetime risk ~ 5-10%60-75% chance ofBRCA2mutation in family",
                      "60-75% chance ofBRCA2mutation in family"
                    ]
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "MBC occurs in slightly older age group compared to FBC"
                  },
                  {
                    "text": "Typically presents with a painless firm palpable massSome males have nipple discharge due to involvement of large ducts",
                    "sub_points": [
                      "Some males have nipple discharge due to involvement of large ducts"
                    ]
                  },
                  {
                    "text": "Presents at higher stages compared to female patientsCancers are located close to skin and chest wall and can invade these structures early",
                    "sub_points": [
                      "Cancers are located close to skin and chest wall and can invade these structures early"
                    ]
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Similar to FBC"
                  },
                  {
                    "text": "Same prognostic factors are used in males and females"
                  },
                  {
                    "text": "Invasive BC of no special type (\"ductal\") is most common"
                  }
                ],
                "Ancillary Tests": [
                  {
                    "text": "ER(+) in 70-90%, PR(+) in 60-70% of MBCs"
                  },
                  {
                    "text": "HER2 overexpression and gene amplification are less frequent than in FBC"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Gynecomastia"
                  },
                  {
                    "text": "Myofibroblastoma"
                  },
                  {
                    "text": "Metastases to breast"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Male breast carcinoma (MBC)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Breast carcinoma (BC) occurring in male patients"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Male breast carcinoma (MBC) is rare (< 1% of cancers in males)"
                  },
                  {
                    "text": "In general, the histologic types of MBC are similar to those seen in women"
                  },
                  {
                    "text": "MBC tends to present at higher stages due to the predominant presentation as a palpable mass that can show early involvement of nearby skin and chest wall"
                  }
                ],
                "Molecular Subtypes": [
                  {
                    "text": "Breast carcinoma (BC) subtypes according to expression of ER, PR, and HER2 are different in MBC compared to female BC (FBC)Luminal subtype most common (90%)Less frequent HER2(+) (8%) and triple negative BC (TNBC) (2%) subtypes",
                    "sub_points": [
                      "Luminal subtype most common (90%)",
                      "Less frequent HER2(+) (8%) and triple negative BC (TNBC) (2%) subtypes"
                    ]
                  },
                  {
                    "text": "One study of gene expression profiling (mRNA) of MBC identified 2 typesLuminal M1: 70%Low expression of ER-associated genesLuminal M2: 30%Majority of MBC and FBC did not cluster into same groupsSuggests that MBC may have significant biologic differences compared to FBC",
                    "sub_points": [
                      "Luminal M1: 70%Low expression of ER-associated genes",
                      "Low expression of ER-associated genes",
                      "Luminal M2: 30%",
                      "Majority of MBC and FBC did not cluster into same groups",
                      "Suggests that MBC may have significant biologic differences compared to FBC"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hereditary Risk": [
                  {
                    "text": "Family history~ 15-20% of MBC patients have a family history of BC or ovarian carcinomaRisk increased in male patients with affected sister (RR 2.25) or mother and sister (RR 9.73)Genetic counseling and testing recommendedThe lifetime risk for male patients without germline mutations is ~ 0.1%",
                    "sub_points": [
                      "~ 15-20% of MBC patients have a family history of BC or ovarian carcinomaRisk increased in male patients with affected sister (RR 2.25) or mother and sister (RR 9.73)Genetic counseling and testing recommendedThe lifetime risk for male patients without germline mutations is ~ 0.1%",
                      "Risk increased in male patients with affected sister (RR 2.25) or mother and sister (RR 9.73)",
                      "Genetic counseling and testing recommended",
                      "The lifetime risk for male patients without germline mutations is ~ 0.1%"
                    ]
                  },
                  {
                    "text": "BRCA1(17q21)Estimated lifetime risk for MBC is ~ 1-5%< 4% of MBC isBRCA1associatedLower risk than forBRCA2mutation carriers",
                    "sub_points": [
                      "Estimated lifetime risk for MBC is ~ 1-5%< 4% of MBC isBRCA1associated",
                      "< 4% of MBC isBRCA1associated",
                      "Lower risk than forBRCA2mutation carriers"
                    ]
                  },
                  {
                    "text": "BRCA2(13q12.3)Estimated lifetime risk for MBC is ~ 5-10%~ 30% of men with MBC haveBRCA2mutationsBCs present at lower ageMay be associated with poor prognosisThere is 60-75% chance ofBRCA2mutation in family with MBC patientAlso associated with increased risk for prostate cancer, pancreatic cancer, and GI tract malignancies",
                    "sub_points": [
                      "Estimated lifetime risk for MBC is ~ 5-10%",
                      "~ 30% of men with MBC haveBRCA2mutationsBCs present at lower ageMay be associated with poor prognosis",
                      "BCs present at lower age",
                      "May be associated with poor prognosis",
                      "There is 60-75% chance ofBRCA2mutation in family with MBC patient",
                      "Also associated with increased risk for prostate cancer, pancreatic cancer, and GI tract malignancies"
                    ]
                  },
                  {
                    "text": "Other germline mutations associated with MBCCHEK2(22q12.1)PTEN(10q23.3) (Cowden syndrome)TP53(Li-Fraumeni syndrome)",
                    "sub_points": [
                      "CHEK2(22q12.1)",
                      "PTEN(10q23.3) (Cowden syndrome)",
                      "TP53(Li-Fraumeni syndrome)"
                    ]
                  }
                ],
                "Disorders With Hormonal Imbalance Conferring Risk": [
                  {
                    "text": "Estrogen-stimulated growth of breast tissue is normally antagonized by androgens in males"
                  },
                  {
                    "text": "A variety of disorders associated with hormonal imbalance have been linked to risk of MBCObesityPatients suffer hormonal imbalance (estrogen > testosterone)~ 3-8% of male patients with MBC have this syndromeRisk for breast cancer is ~ 2-5%Lobule formation may occurTesticular disorders associated with hypogonadismMumps orchitis, cryptorchidism, testicular injuryLiver diseaseDiabetesHyperthyroidismAlcohol abuseKlinefelter syndrome (47,XXY karyotype)",
                    "sub_points": [
                      "ObesityPatients suffer hormonal imbalance (estrogen > testosterone)~ 3-8% of male patients with MBC have this syndromeRisk for breast cancer is ~ 2-5%Lobule formation may occur",
                      "Patients suffer hormonal imbalance (estrogen > testosterone)~ 3-8% of male patients with MBC have this syndrome",
                      "~ 3-8% of male patients with MBC have this syndrome",
                      "Risk for breast cancer is ~ 2-5%Lobule formation may occur",
                      "Lobule formation may occur",
                      "Testicular disorders associated with hypogonadismMumps orchitis, cryptorchidism, testicular injury",
                      "Mumps orchitis, cryptorchidism, testicular injury",
                      "Liver disease",
                      "Diabetes",
                      "Hyperthyroidism",
                      "Alcohol abuse",
                      "Klinefelter syndrome (47,XXY karyotype)"
                    ]
                  }
                ],
                "Gynecomastia": [
                  {
                    "text": "Generally not considered to be MBC risk factorSome studies have suggested slight increased riskMay be attributed to the fact that both conditions share similar risk factors (hormonal imbalance)",
                    "sub_points": [
                      "Some studies have suggested slight increased riskMay be attributed to the fact that both conditions share similar risk factors (hormonal imbalance)",
                      "May be attributed to the fact that both conditions share similar risk factors (hormonal imbalance)"
                    ]
                  }
                ],
                "Environmental Causes": [
                  {
                    "text": "Radiation exposure increases risk of BC in both male and female patientsOccupational exposureTherapeutic chest wall radiation",
                    "sub_points": [
                      "Occupational exposure",
                      "Therapeutic chest wall radiation"
                    ]
                  },
                  {
                    "text": "Other risk factors have not been proven but are under investigationElectromagnetic field exposureOccupational exposure to gasoline and airline fuelsExposure to toxic waste material",
                    "sub_points": [
                      "Electromagnetic field exposure",
                      "Occupational exposure to gasoline and airline fuels",
                      "Exposure to toxic waste material"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "MBC accounts for < 1% of all BCs< 1% of all cancers in male patients0.13% of all cancer deaths in male patients annuallyIncidence has remained stable (2000-2005)",
                    "sub_points": [
                      "< 1% of all cancers in male patients",
                      "0.13% of all cancer deaths in male patients annually",
                      "Incidence has remained stable (2000-2005)"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "MBC occurs in slightly older age group compared to FBCMean age: 67 years (MBC) vs. 61 years (FBC)Younger male patients may also be affected",
                    "sub_points": [
                      "Mean age: 67 years (MBC) vs. 61 years (FBC)",
                      "Younger male patients may also be affected"
                    ]
                  },
                  {
                    "text": "Compared with sporadic MBC, median age of onset for familial MBC is typically younger"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Majority present with painless firm massLocated in subareolar regionTends to be located eccentrically in relationship to nippleFixation to skin &/or pectoralis muscle is commonPalpable lymph nodes in ~ 50%",
                    "sub_points": [
                      "Located in subareolar region",
                      "Tends to be located eccentrically in relationship to nipple",
                      "Fixation to skin &/or pectoralis muscle is common",
                      "Palpable lymph nodes in ~ 50%"
                    ]
                  },
                  {
                    "text": "Nipple discharge present in majorityTypically bloodyMay be associated with papillary ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "Typically bloody",
                      "May be associated with papillary ductal carcinoma in situ (DCIS)"
                    ]
                  },
                  {
                    "text": "Diagnosis may be delayedMBC is rare and is often not detected earlyAbsence of routine screening by examination or imaging contributes to delays in diagnosis",
                    "sub_points": [
                      "MBC is rare and is often not detected early",
                      "Absence of routine screening by examination or imaging contributes to delays in diagnosis"
                    ]
                  },
                  {
                    "text": "Minimal breast tissue in male patients results in BCs being closer to skin and chest wallInvasion of these structures occurs earlierIncreases likelihood of vascular invasion and nodal metastasis",
                    "sub_points": [
                      "Invasion of these structures occurs earlier",
                      "Increases likelihood of vascular invasion and nodal metastasis"
                    ]
                  },
                  {
                    "text": "BCs usually diagnosed at higher stages than FBC"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Majority of male patients undergo mastectomyBreast conservation may be considered a safe alternative in selected patients",
                    "sub_points": [
                      "Breast conservation may be considered a safe alternative in selected patients"
                    ]
                  },
                  {
                    "text": "Sentinel lymph node biopsy can be performedSame accuracy as for FBC reported",
                    "sub_points": [
                      "Same accuracy as for FBC reported"
                    ]
                  }
                ],
                "Adjuvant therapy": [
                  {
                    "text": "Chemotherapy: Generally the same for men and women with similar BCs"
                  },
                  {
                    "text": "Endocrine therapy: Generally has been tamoxifenOngoing trials are evaluating aromatase inhibitors, testosterone blockers, and CDK4/6 inhibitors for effectiveness and possible lower risk of side effects in males",
                    "sub_points": [
                      "Ongoing trials are evaluating aromatase inhibitors, testosterone blockers, and CDK4/6 inhibitors for effectiveness and possible lower risk of side effects in males"
                    ]
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Similar to that for FBC of similar stage and gradeMainly determined by AJCC stage, tumor grade, and receptor status",
                    "sub_points": [
                      "Mainly determined by AJCC stage, tumor grade, and receptor status"
                    ]
                  },
                  {
                    "text": "Often more advanced at diagnosis compared with FBC> 40% of MBCs present with stage III or IV disease at diagnosis, which adversely influences prognosisMost common metastatic site of MBC is bone (41%) followed by lung, liver, and brain",
                    "sub_points": [
                      "> 40% of MBCs present with stage III or IV disease at diagnosis, which adversely influences prognosis",
                      "Most common metastatic site of MBC is bone (41%) followed by lung, liver, and brain"
                    ]
                  },
                  {
                    "text": "Age, AJCC stage, and lymph node status are independent prognostic factors for survival"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "Imaging findings are similar to those seen in female patientsIrregular mass with spiculated marginsOften with coarse calcifications",
                    "sub_points": [
                      "Irregular mass with spiculated marginsOften with coarse calcifications",
                      "Often with coarse calcifications"
                    ]
                  },
                  {
                    "text": "Carcinomas tend to be eccentric in relationship to nippleIn contrast, gynecomastia has flame-shaped appearance extending symmetrically from nipple",
                    "sub_points": [
                      "In contrast, gynecomastia has flame-shaped appearance extending symmetrically from nipple"
                    ]
                  }
                ],
                "Ultrasonographic Findings": [
                  {
                    "text": "Distinguishes solid masses from cystsUseful in identifying solid masses that are more likely to be malignant",
                    "sub_points": [
                      "Useful in identifying solid masses that are more likely to be malignant"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "No specific features compared to FBC"
                  },
                  {
                    "text": "Majority are irregular, firm, gray to white massesIn situ component may appear grossly as partially cystic if large ducts of nipple are involved",
                    "sub_points": [
                      "In situ component may appear grossly as partially cystic if large ducts of nipple are involved"
                    ]
                  },
                  {
                    "text": "Fixation to skin or pectoralis muscle is common"
                  }
                ],
                "Size": [
                  {
                    "text": "1-5 cm (usually 2.0-2.5 cm)"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Invasive carcinomaInvasive BC of no special type (\"ductal\") is most common (85-90% of MBC)Identical in appearance to that occurring in FBCSpecial histologic types are unusual in MBCPapillary carcinomas are most common special typeUsually involve large duct system of nippleInvasive lobular carcinoma occurs rarelyOther special histologic types (medullary, mucinous, tubular) are also very rareGraded using same system as for FBCGrades 2 and 3 carcinoma reported in 80% of cases",
                    "sub_points": [
                      "Invasive BC of no special type (\"ductal\") is most common (85-90% of MBC)Identical in appearance to that occurring in FBC",
                      "Identical in appearance to that occurring in FBC",
                      "Special histologic types are unusual in MBCPapillary carcinomas are most common special typeUsually involve large duct system of nippleInvasive lobular carcinoma occurs rarelyOther special histologic types (medullary, mucinous, tubular) are also very rare",
                      "Papillary carcinomas are most common special typeUsually involve large duct system of nipple",
                      "Usually involve large duct system of nipple",
                      "Invasive lobular carcinoma occurs rarely",
                      "Other special histologic types (medullary, mucinous, tubular) are also very rare",
                      "Graded using same system as for FBCGrades 2 and 3 carcinoma reported in 80% of cases",
                      "Grades 2 and 3 carcinoma reported in 80% of cases"
                    ]
                  },
                  {
                    "text": "Carcinoma in situDCIS accounts for ~ 10% of all MBCsLobular carcinoma in situ (LCIS) is very rare in malesDCIS is microscopically similar to that seen in FBCAll architectural patterns have been reportedGreater incidence of papillary DCIS compared with FBCComedonecrosis in DCIS is less common in MBC compared with FBC",
                    "sub_points": [
                      "DCIS accounts for ~ 10% of all MBCsLobular carcinoma in situ (LCIS) is very rare in males",
                      "Lobular carcinoma in situ (LCIS) is very rare in males",
                      "DCIS is microscopically similar to that seen in FBCAll architectural patterns have been reportedGreater incidence of papillary DCIS compared with FBCComedonecrosis in DCIS is less common in MBC compared with FBC",
                      "All architectural patterns have been reported",
                      "Greater incidence of papillary DCIS compared with FBC",
                      "Comedonecrosis in DCIS is less common in MBC compared with FBC"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Hormone receptors (higher rates compared to FBC)ER: Positive in 70-90%, PR: Positive in 60-70%",
                    "sub_points": [
                      "ER: Positive in 70-90%, PR: Positive in 60-70%"
                    ]
                  },
                  {
                    "text": "HER2Overexpression occurs but less frequent than in FBC",
                    "sub_points": [
                      "Overexpression occurs but less frequent than in FBC"
                    ]
                  },
                  {
                    "text": "PSACan be positive in both MBC and FBC (~ 10-20%)Should not be used as only evidence for metastatic prostate to breastPAP reported to be more specific for prostate carcinoma",
                    "sub_points": [
                      "Can be positive in both MBC and FBC (~ 10-20%)",
                      "Should not be used as only evidence for metastatic prostate to breast",
                      "PAP reported to be more specific for prostate carcinoma"
                    ]
                  },
                  {
                    "text": "Other breast markersGATA3(+) (> 90%), GCDFP-15(+) (50-75%), mammaglobin (+) (40-70%)Usually CK7(+)/CK20(-)",
                    "sub_points": [
                      "GATA3(+) (> 90%), GCDFP-15(+) (50-75%), mammaglobin (+) (40-70%)",
                      "Usually CK7(+)/CK20(-)"
                    ]
                  }
                ],
                "Multigene Assays": [
                  {
                    "text": "Multigene assays (mRNA) are being utilized clinically for MBCRisk of recurrence scores are significantly associated with tumor grade and size but not nodal status in MBCFurther investigation is required due to the low number of cases tested",
                    "sub_points": [
                      "Risk of recurrence scores are significantly associated with tumor grade and size but not nodal status in MBC",
                      "Further investigation is required due to the low number of cases tested"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Gynecomastia": [
                  {
                    "text": "Nonneoplastic enlargement of male breast tissue due to hyperplasia of epithelium and stromaA variety of etiologies are linked to imbalance in ratio of free androgens and estrogensCan be seen in infants, during puberty, or in older adults",
                    "sub_points": [
                      "A variety of etiologies are linked to imbalance in ratio of free androgens and estrogens",
                      "Can be seen in infants, during puberty, or in older adults"
                    ]
                  },
                  {
                    "text": "Often bilateralIf unilateral or asymmetric, can raise concern for BC",
                    "sub_points": [
                      "If unilateral or asymmetric, can raise concern for BC"
                    ]
                  }
                ],
                "Myofibroblastoma": [
                  {
                    "text": "Clinical presentation (older adult male patients, palpable mass) may overlap with MBCUsually discrete mass with circumscribed bordersOnly breast lesion that occurs with approximately equal frequency in male and female patients",
                    "sub_points": [
                      "Usually discrete mass with circumscribed borders",
                      "Only breast lesion that occurs with approximately equal frequency in male and female patients"
                    ]
                  },
                  {
                    "text": "Uniform proliferation of spindle-shaped myofibroblasts forming a mass that does not include normal breast ducts and lobulesOval nuclei, pale cytoplasm, mitotic figures rareHyalinized bands of dense collagen separate spindle cells into groups or clustersVarying degree of adipose tissue seen in some lesions",
                    "sub_points": [
                      "Oval nuclei, pale cytoplasm, mitotic figures rare",
                      "Hyalinized bands of dense collagen separate spindle cells into groups or clusters",
                      "Varying degree of adipose tissue seen in some lesions"
                    ]
                  },
                  {
                    "text": "Epithelioid variant can mimic invasive lobular carcinomaA spindle cell component is generally present",
                    "sub_points": [
                      "A spindle cell component is generally present"
                    ]
                  },
                  {
                    "text": "Lesional cells ER(+), PR(+), cytokeratin (-)"
                  }
                ],
                "Metastasis to Breast": [
                  {
                    "text": "Metastatic tumors to male breast can mimic MBCNeed to integrate prior history, clinical and imaging findings, and compare with prior biopsy, if availableSuspect when cancer has unusual appearance, is negative for ER and PR, &/or lacks in situ carcinoma",
                    "sub_points": [
                      "Need to integrate prior history, clinical and imaging findings, and compare with prior biopsy, if available",
                      "Suspect when cancer has unusual appearance, is negative for ER and PR, &/or lacks in situ carcinoma"
                    ]
                  },
                  {
                    "text": "Immunohistochemical markers are helpful to distinguish metastases from primary BCProstate carcinomaTreatment for prostate carcinoma can increase risk for BC (orchiectomy, hormonal therapy)Hyperplasia associated with hormonal changes can be difficult to distinguish from carcinoma in situIf patient is receiving hormonal therapy, this treatment can alter appearance of metastatic prostate cancer or BCProstate carcinoma is usually CK7(-), PSA(+), PAP(+), ER(-)Some high-grade prostate carcinomas are ER(+)BC usually CK7(+), PSA(-), PAP(-), ER(+)However, some BCs are PSA(+)Both prostate carcinoma and BC can be strongly positive for chromogranin, synaptophysin, and other neuroendocrine markersLung adenocarcinomaUsually CK7(+)/CK20(-), TTF-1(+), &/or NAPSIN-A(+), GATA3(-)Very rare BCs are TTF-1(+)Some lung carcinomas are ER(+)",
                    "sub_points": [
                      "Prostate carcinomaTreatment for prostate carcinoma can increase risk for BC (orchiectomy, hormonal therapy)Hyperplasia associated with hormonal changes can be difficult to distinguish from carcinoma in situIf patient is receiving hormonal therapy, this treatment can alter appearance of metastatic prostate cancer or BCProstate carcinoma is usually CK7(-), PSA(+), PAP(+), ER(-)Some high-grade prostate carcinomas are ER(+)BC usually CK7(+), PSA(-), PAP(-), ER(+)However, some BCs are PSA(+)Both prostate carcinoma and BC can be strongly positive for chromogranin, synaptophysin, and other neuroendocrine markers",
                      "Treatment for prostate carcinoma can increase risk for BC (orchiectomy, hormonal therapy)",
                      "Hyperplasia associated with hormonal changes can be difficult to distinguish from carcinoma in situ",
                      "If patient is receiving hormonal therapy, this treatment can alter appearance of metastatic prostate cancer or BC",
                      "Prostate carcinoma is usually CK7(-), PSA(+), PAP(+), ER(-)Some high-grade prostate carcinomas are ER(+)",
                      "Some high-grade prostate carcinomas are ER(+)",
                      "BC usually CK7(+), PSA(-), PAP(-), ER(+)However, some BCs are PSA(+)",
                      "However, some BCs are PSA(+)",
                      "Both prostate carcinoma and BC can be strongly positive for chromogranin, synaptophysin, and other neuroendocrine markers",
                      "Lung adenocarcinomaUsually CK7(+)/CK20(-), TTF-1(+), &/or NAPSIN-A(+), GATA3(-)Very rare BCs are TTF-1(+)Some lung carcinomas are ER(+)",
                      "Usually CK7(+)/CK20(-), TTF-1(+), &/or NAPSIN-A(+), GATA3(-)",
                      "Very rare BCs are TTF-1(+)",
                      "Some lung carcinomas are ER(+)"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Same criteria used for FBC are used to diagnose and evaluate MBC"
                  },
                  {
                    "text": "Guidelines followed for diagnosis and treatment of MBC mostly based on FBC"
                  },
                  {
                    "text": "Genetic testing for germline mutations is indicated for patients with diagnosis of MBC"
                  }
                ]
              },
              "REPORTING": {
                "Staging": [
                  {
                    "text": "Same AJCC rules apply for MBC and FBC"
                  }
                ],
                "Reporting": [
                  {
                    "text": "MBC can be reported using College of American Pathologists checklist for reporting of BC"
                  },
                  {
                    "text": "MBC and FBC have different ICD-10 codes"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Breast Carcinoma, Female": {
            "name": "Breast Carcinoma, Female",
            "url": "https://app.pathprimer.com/document/569c7067-82ef-48ec-870b-4f56a2b1c9ab/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "Key Facts": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "~ 27% of breast cancer is thought to be due primarily to hereditary factors"
                  },
                  {
                    "text": "Only 5-10% due to highly penetrant germline mutations"
                  },
                  {
                    "text": "~ 10% of women diagnosed with breast cancer at < 45 years of age will have a germline mutation"
                  },
                  {
                    "text": "Familial risk not explainable by known mutations is likely due to additive effect of multiple genes"
                  },
                  {
                    "text": "Features incommon"
                  },
                  {
                    "text": "Autosomal dominant allelesInherited via females and males",
                    "sub_points": [
                      "Inherited via females and males"
                    ]
                  },
                  {
                    "text": "Majority of identified genes are associated with DNA repair pathways"
                  },
                  {
                    "text": "Breast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral"
                  },
                  {
                    "text": "Risk of nonbreast cancers increased"
                  }
                ],
                "Diagnostic Checklist": [
                  {
                    "text": "BRCA1(hereditary breast and ovarian cancer syndrome)"
                  },
                  {
                    "text": "BRCA2(hereditary breast and ovarian cancer syndrome)"
                  },
                  {
                    "text": "TP53(Li-Fraumeni syndrome)"
                  },
                  {
                    "text": "CDH1(familial gastric cancer and lobular breast cancer syndrome)"
                  },
                  {
                    "text": "PTEN(Cowden syndrome)"
                  },
                  {
                    "text": "CHEK2"
                  },
                  {
                    "text": "ATM(ataxia-telangiectasia carriers)"
                  },
                  {
                    "text": "STK11/LKB1(Peutz-Jeghers syndrome)"
                  },
                  {
                    "text": "BRIP1(FANCJorBACH1)"
                  }
                ]
              },
              "Etiology/Pathogenesis": {
                "Hereditary Breast Cancer": [
                  {
                    "text": "Long recognized that many women with breast cancer also have affected relatives~ 27% of breast cancer is thought to be due primarily to hereditary factorsOnly 5-10% due to highly penetrant germline mutations~ 10% of women diagnosed with breast cancer at < 45 years of age will have a germline mutation",
                    "sub_points": [
                      "~ 27% of breast cancer is thought to be due primarily to hereditary factorsOnly 5-10% due to highly penetrant germline mutations~ 10% of women diagnosed with breast cancer at < 45 years of age will have a germline mutation",
                      "Only 5-10% due to highly penetrant germline mutations",
                      "~ 10% of women diagnosed with breast cancer at < 45 years of age will have a germline mutation"
                    ]
                  },
                  {
                    "text": "Familial risk not explainable by known mutations is likely due to additive effect of multiple genesMultiple low penetrance genes may increase risk in familiesThese genes may also modify clinical features of high penetrance genesGenome-wide association studies are searching for this group of genesIt is unlikely that another highly penetrant gene such asBRCA1orBRCA2will be identified",
                    "sub_points": [
                      "Multiple low penetrance genes may increase risk in familiesThese genes may also modify clinical features of high penetrance genes",
                      "These genes may also modify clinical features of high penetrance genes",
                      "Genome-wide association studies are searching for this group of genes",
                      "It is unlikely that another highly penetrant gene such asBRCA1orBRCA2will be identified"
                    ]
                  },
                  {
                    "text": "Features common to all majorgermline mutationsAutosomal dominant allelesTumors occur when remaining wild-type allele is rendered nonfunctionalInherited via both females and malesMultiple individuals in a lineage are usually affectedMajority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for breast cancer has not been explainedCyclic proliferation throughout reproductive lifetime may predispose breast epithelium to errors in replicationUnlike gastrointestinal tract, skin, or bronchial airways, from which cells may be sloughed into the environment, cells with DNA damage may be able to survive within duct/lobular system of breastBreast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutationsRisk of nonbreast cancers increased",
                    "sub_points": [
                      "Autosomal dominant allelesTumors occur when remaining wild-type allele is rendered nonfunctionalInherited via both females and malesMultiple individuals in a lineage are usually affected",
                      "Tumors occur when remaining wild-type allele is rendered nonfunctional",
                      "Inherited via both females and males",
                      "Multiple individuals in a lineage are usually affected",
                      "Majority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for breast cancer has not been explainedCyclic proliferation throughout reproductive lifetime may predispose breast epithelium to errors in replicationUnlike gastrointestinal tract, skin, or bronchial airways, from which cells may be sloughed into the environment, cells with DNA damage may be able to survive within duct/lobular system of breast",
                      "Act as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferation",
                      "Relative tissue specificity for breast cancer has not been explained",
                      "Cyclic proliferation throughout reproductive lifetime may predispose breast epithelium to errors in replication",
                      "Unlike gastrointestinal tract, skin, or bronchial airways, from which cells may be sloughed into the environment, cells with DNA damage may be able to survive within duct/lobular system of breast",
                      "Breast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutations",
                      "1st mutation present at birth",
                      "Destabilization of genome increases likelihood of additional mutations",
                      "Risk of nonbreast cancers increased"
                    ]
                  },
                  {
                    "text": "Features specific to certaingermline mutationsType of breast carcinomaBRCA1:Negative for estrogen receptor [ER], progesterone receptor [PR], and HER2 with basal-like gene expression pattern (~90%)BRCA2:ER positive, HER2 negative, high grade, luminal B type gene expression patternTP53: ER positive, HER2 positive (~55%)CDH1: Lobular carcinomasSpecific tumor types have not been reported for other mutationsRisk of male breast cancerIncreased risk for some mutations (e.g.,BRCA1andBRCA2)Not reported for other mutations (e.g.,TP53)Penetrance> 95% lifetime risk for some mutationsOther genes have lower penetrance (20% or lower lifetime risk)Spectrum of nonbreast cancersTypes of other cancers vary according to gene and sometimes are different for specific mutationsFounder mutations in ethnic populationsSome populations have very high incidences of specific mutationsHomozygosityHomozygosity for some mutations confers disease (e.g.,BRCA2&BRIP1:  Fanconi anemia;ATM:  Ataxia-telangiectasia)Homozygosity for other mutations is likely lethal (e.g.,BRCA1)",
                    "sub_points": [
                      "Type of breast carcinomaBRCA1:Negative for estrogen receptor [ER], progesterone receptor [PR], and HER2 with basal-like gene expression pattern (~90%)BRCA2:ER positive, HER2 negative, high grade, luminal B type gene expression patternTP53: ER positive, HER2 positive (~55%)CDH1: Lobular carcinomasSpecific tumor types have not been reported for other mutations",
                      "BRCA1:Negative for estrogen receptor [ER], progesterone receptor [PR], and HER2 with basal-like gene expression pattern (~90%)",
                      "BRCA2:ER positive, HER2 negative, high grade, luminal B type gene expression pattern",
                      "TP53: ER positive, HER2 positive (~55%)",
                      "CDH1: Lobular carcinomas",
                      "Specific tumor types have not been reported for other mutations",
                      "Risk of male breast cancerIncreased risk for some mutations (e.g.,BRCA1andBRCA2)Not reported for other mutations (e.g.,TP53)",
                      "Increased risk for some mutations (e.g.,BRCA1andBRCA2)",
                      "Not reported for other mutations (e.g.,TP53)",
                      "Penetrance> 95% lifetime risk for some mutationsOther genes have lower penetrance (20% or lower lifetime risk)",
                      "> 95% lifetime risk for some mutations",
                      "Other genes have lower penetrance (20% or lower lifetime risk)",
                      "Spectrum of nonbreast cancersTypes of other cancers vary according to gene and sometimes are different for specific mutations",
                      "Types of other cancers vary according to gene and sometimes are different for specific mutations",
                      "Founder mutations in ethnic populationsSome populations have very high incidences of specific mutations",
                      "Some populations have very high incidences of specific mutations",
                      "HomozygosityHomozygosity for some mutations confers disease (e.g.,BRCA2&BRIP1:  Fanconi anemia;ATM:  Ataxia-telangiectasia)Homozygosity for other mutations is likely lethal (e.g.,BRCA1)",
                      "Homozygosity for some mutations confers disease (e.g.,BRCA2&BRIP1:  Fanconi anemia;ATM:  Ataxia-telangiectasia)",
                      "Homozygosity for other mutations is likely lethal (e.g.,BRCA1)"
                    ]
                  },
                  {
                    "text": "Role of somatic mutations in genes responsible for hereditary breast cancerTP53is frequently mutated in sporadic carcinomasBRCA1andBRCA2mutations are rareGenes may be inactivated by other mechanisms such as methylationCDH1is inactivated by somatic mutations in lobular cancers",
                    "sub_points": [
                      "TP53is frequently mutated in sporadic carcinomas",
                      "BRCA1andBRCA2mutations are rareGenes may be inactivated by other mechanisms such as methylation",
                      "Genes may be inactivated by other mechanisms such as methylation",
                      "CDH1is inactivated by somatic mutations in lobular cancers"
                    ]
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [
                  {
                    "text": "~ 10-25% of women with breast cancer have a 1st-degree relative (parent, sister, daughter) with breast cancerHaving an affected 1st-degree relative increases risk by 2-3x",
                    "sub_points": [
                      "Having an affected 1st-degree relative increases risk by 2-3x"
                    ]
                  },
                  {
                    "text": "Most common family history is a mother developing breast cancer after menopauseThis history does not increase risk of breast cancer for daughterSporadic breast cancer in this age group is very common",
                    "sub_points": [
                      "This history does not increase risk of breast cancer for daughter",
                      "Sporadic breast cancer in this age group is very common"
                    ]
                  },
                  {
                    "text": "Penetrance refers to the number of individuals who develop cancer during their lifetimeHigh penetrance = relative risk [RR] > 10Moderate penetrance = RR 2-3Low penetrance = RR < 1.5Penetrance may be gender dependent for associated cancers (e.g., female carriers are at higher risk for breast cancer than males are)",
                    "sub_points": [
                      "High penetrance = relative risk [RR] > 10",
                      "Moderate penetrance = RR 2-3",
                      "Low penetrance = RR < 1.5",
                      "Penetrance may be gender dependent for associated cancers (e.g., female carriers are at higher risk for breast cancer than males are)"
                    ]
                  },
                  {
                    "text": "Familialpatterns of breast cancer likely to be associated with germline mutationsAffected 1st-degree relatives (mother, sister, daughter)Multiple affected relativesCarcinomas occurring at an early age (premenopausal)Multiple carcinomas (bilateral or ipsilateral)Relatives with nonbreast cancers associated with specific germline mutationsMale breast cancer forBRCA2andBRCA1Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2Sarcomas forTP53Relatives with diseases due to homozygous mutationsAtaxia-telangiectasia forATMFanconi anemia forBRCA2andBRIP1",
                    "sub_points": [
                      "Affected 1st-degree relatives (mother, sister, daughter)",
                      "Multiple affected relatives",
                      "Carcinomas occurring at an early age (premenopausal)",
                      "Multiple carcinomas (bilateral or ipsilateral)",
                      "Relatives with nonbreast cancers associated with specific germline mutationsMale breast cancer forBRCA2andBRCA1Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2Sarcomas forTP53",
                      "Male breast cancer forBRCA2andBRCA1",
                      "Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2",
                      "Sarcomas forTP53",
                      "Relatives with diseases due to homozygous mutationsAtaxia-telangiectasia forATMFanconi anemia forBRCA2andBRIP1",
                      "Ataxia-telangiectasia forATM",
                      "Fanconi anemia forBRCA2andBRIP1"
                    ]
                  }
                ],
                "BRCA1(Hereditary Breast & Ovarian Cancer Syndrome)": [
                  {
                    "text": "FunctionBRCA1andBRCA2code for large proteinsProteins do not have sequence homology but do share many similar functionsBRCA1andBRCA2help maintain genomic stabilityDirect role in regulation of DNA damage responses and repair and cell cycle checkpointsRequired for error-free DNA double-strand break repairCells lackingBRCA1&BRCA2functional activity are prone to replication errors and genomic instabilityAccumulating DNA abnormalities include mutations in genes essential to cell cycle checkpoint activationDrives acquisition of mutations and chromosomal instability, contributing to tumor formationBRCA1function is required for transactivation of the estrogen receptor (ER) gene promoterMay explain why 90% ofBRCA1-associated carcinomas are negative for ER",
                    "sub_points": [
                      "BRCA1andBRCA2code for large proteinsProteins do not have sequence homology but do share many similar functions",
                      "Proteins do not have sequence homology but do share many similar functions",
                      "BRCA1andBRCA2help maintain genomic stabilityDirect role in regulation of DNA damage responses and repair and cell cycle checkpointsRequired for error-free DNA double-strand break repairCells lackingBRCA1&BRCA2functional activity are prone to replication errors and genomic instabilityAccumulating DNA abnormalities include mutations in genes essential to cell cycle checkpoint activationDrives acquisition of mutations and chromosomal instability, contributing to tumor formation",
                      "Direct role in regulation of DNA damage responses and repair and cell cycle checkpoints",
                      "Required for error-free DNA double-strand break repair",
                      "Cells lackingBRCA1&BRCA2functional activity are prone to replication errors and genomic instability",
                      "Accumulating DNA abnormalities include mutations in genes essential to cell cycle checkpoint activation",
                      "Drives acquisition of mutations and chromosomal instability, contributing to tumor formation",
                      "BRCA1function is required for transactivation of the estrogen receptor (ER) gene promoterMay explain why 90% ofBRCA1-associated carcinomas are negative for ER",
                      "May explain why 90% ofBRCA1-associated carcinomas are negative for ER"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1-0.3%More common in some ethnic groups: Ashkenazi Jews, Finns, French CanadiansMutation can be suspected in young patients (35% risk for a patient < 30 years of age with an ER-negative poorly differentiated cancer)",
                    "sub_points": [
                      "More common in some ethnic groups: Ashkenazi Jews, Finns, French Canadians",
                      "Mutation can be suspected in young patients (35% risk for a patient < 30 years of age with an ER-negative poorly differentiated cancer)"
                    ]
                  },
                  {
                    "text": "High penetrance:40-90% lifetime riskMagnitude of risk can vary for different mutations and for different types of cancersResponsible for ~ 1/2 of cancers known to be due to a germline mutation (~ 2% of all breast cancers)",
                    "sub_points": [
                      "Magnitude of risk can vary for different mutations and for different types of cancers",
                      "Responsible for ~ 1/2 of cancers known to be due to a germline mutation (~ 2% of all breast cancers)"
                    ]
                  },
                  {
                    "text": "Breast cancerMean age of onset is 44 years, but age can vary with specific mutationsRisk of subsequent contralateral cancer is higher~ 90% ofBRCA1cancers share same gene expression pattern with basal-type carcinomas defined by gene expression profilingBasal-type carcinomas may also have defectiveBRCA1functionMorphology of invasive carcinomasCircumscribed growth pattern with pushing borders, dense lymphocytic infiltrateHigh nuclear grade and high proliferative rateMedullary carcinomas are overrepresented: 13% of cases vs. < 5% for all womenMajority of women with medullary carcinomas do not haveBRCA1mutationsAdditionalBRCA1carcinomas have \"medullary features\" but not all criteria for classification as classic medullary carcinomaMorphology of DCISNegative for ER, PR, and HER2In general population, this type of DCIS is uncommon: < 10% of casesUsually has a solid pattern with high-grade pleomorphic nucleiInvolved lobules may be associated with a dense lymphocytic infiltrateMay be subtle with little expansion of involved lobular aciniPrecursor lesionsT-cell lobulitis has been described in prophylactic mastectomies forBRCA1mutationsMore common compared to women undergoing the procedure for other reasonsInfiltrate similar to that seen associated with carcinomasTumor markersLack hormone receptor positivityLack overexpression of HER2: BothHER2andBRCA1are on long arm of chromosome 17, and loss of heterozygosity may affect both10-25% of women < 50 years of age with a triple-negative carcinoma will have aBRCA1mutationMajority express p53Majority positive for basal markers such as EGFR (HER1), cytokeratin 5/6, cytokeratin 14",
                    "sub_points": [
                      "Mean age of onset is 44 years, but age can vary with specific mutations",
                      "Risk of subsequent contralateral cancer is higher",
                      "~ 90% ofBRCA1cancers share same gene expression pattern with basal-type carcinomas defined by gene expression profilingBasal-type carcinomas may also have defectiveBRCA1function",
                      "Basal-type carcinomas may also have defectiveBRCA1function",
                      "Morphology of invasive carcinomasCircumscribed growth pattern with pushing borders, dense lymphocytic infiltrateHigh nuclear grade and high proliferative rate",
                      "Circumscribed growth pattern with pushing borders, dense lymphocytic infiltrate",
                      "High nuclear grade and high proliferative rate",
                      "Medullary carcinomas are overrepresented: 13% of cases vs. < 5% for all womenMajority of women with medullary carcinomas do not haveBRCA1mutationsAdditionalBRCA1carcinomas have \"medullary features\" but not all criteria for classification as classic medullary carcinoma",
                      "Majority of women with medullary carcinomas do not haveBRCA1mutations",
                      "AdditionalBRCA1carcinomas have \"medullary features\" but not all criteria for classification as classic medullary carcinoma",
                      "Morphology of DCISNegative for ER, PR, and HER2In general population, this type of DCIS is uncommon: < 10% of casesUsually has a solid pattern with high-grade pleomorphic nucleiInvolved lobules may be associated with a dense lymphocytic infiltrateMay be subtle with little expansion of involved lobular acini",
                      "Negative for ER, PR, and HER2",
                      "In general population, this type of DCIS is uncommon: < 10% of cases",
                      "Usually has a solid pattern with high-grade pleomorphic nuclei",
                      "Involved lobules may be associated with a dense lymphocytic infiltrate",
                      "May be subtle with little expansion of involved lobular acini",
                      "Precursor lesionsT-cell lobulitis has been described in prophylactic mastectomies forBRCA1mutationsMore common compared to women undergoing the procedure for other reasonsInfiltrate similar to that seen associated with carcinomas",
                      "T-cell lobulitis has been described in prophylactic mastectomies forBRCA1mutations",
                      "More common compared to women undergoing the procedure for other reasons",
                      "Infiltrate similar to that seen associated with carcinomas",
                      "Tumor markersLack hormone receptor positivityLack overexpression of HER2: BothHER2andBRCA1are on long arm of chromosome 17, and loss of heterozygosity may affect both10-25% of women < 50 years of age with a triple-negative carcinoma will have aBRCA1mutationMajority express p53Majority positive for basal markers such as EGFR (HER1), cytokeratin 5/6, cytokeratin 14",
                      "Lack hormone receptor positivity",
                      "Lack overexpression of HER2: BothHER2andBRCA1are on long arm of chromosome 17, and loss of heterozygosity may affect both",
                      "10-25% of women < 50 years of age with a triple-negative carcinoma will have aBRCA1mutation",
                      "Majority express p53",
                      "Majority positive for basal markers such as EGFR (HER1), cytokeratin 5/6, cytokeratin 14"
                    ]
                  },
                  {
                    "text": "Other associated cancersOvarian, fallopian tube, primary peritoneal (40-50% lifetime risk)Usually high-grade serous carcinomas~ 80% of women with both breast and ovarian cancer will have aBRCAmutationAverage age of onset: 49-53 years (compared to 63 years in general population)Male breast cancer (1-5% lifetime risk, but ~ 1/2 risk ofBRCA2)Pancreas, cervix, uterus",
                    "sub_points": [
                      "Ovarian, fallopian tube, primary peritoneal (40-50% lifetime risk)Usually high-grade serous carcinomas~ 80% of women with both breast and ovarian cancer will have aBRCAmutationAverage age of onset: 49-53 years (compared to 63 years in general population)",
                      "Usually high-grade serous carcinomas",
                      "~ 80% of women with both breast and ovarian cancer will have aBRCAmutation",
                      "Average age of onset: 49-53 years (compared to 63 years in general population)",
                      "Male breast cancer (1-5% lifetime risk, but ~ 1/2 risk ofBRCA2)",
                      "Pancreas, cervix, uterus"
                    ]
                  }
                ],
                "BRCA2(Hereditary Breast & Ovarian Cancer Syndrome)": [
                  {
                    "text": "FunctionAlthoughBRCA2is not structurally related toBRCA1, both genes have very similar functions and regulatory roles",
                    "sub_points": [
                      "AlthoughBRCA2is not structurally related toBRCA1, both genes have very similar functions and regulatory roles"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1-0.7%More common in some ethnic groups: Ashkenazi Jews, Icelandic populations",
                    "sub_points": [
                      "More common in some ethnic groups: Ashkenazi Jews, Icelandic populations"
                    ]
                  },
                  {
                    "text": "High penetrance: 45-85% lifetime riskMagnitude of risk can vary for different mutations and for different types of cancersResponsible for ~ 1/2 of cancers known to be due to a germline mutation (~ 2% of all breast cancers)",
                    "sub_points": [
                      "Magnitude of risk can vary for different mutations and for different types of cancers",
                      "Responsible for ~ 1/2 of cancers known to be due to a germline mutation (~ 2% of all breast cancers)"
                    ]
                  },
                  {
                    "text": "Breast cancerMean age of onset is 47 years but can vary with specific mutationsGroup with luminal A or B by gene expression profilingMajority are high gradeER positiveHER2 negativeNot strongly associated with a specific morphologic appearanceSome studies suggest higher incidence of cancers belonging to tubular-lobular group (pleomorphic lobular)Other series have not shown significant differences betweenBRCA2tumors & sporadic breast cancer",
                    "sub_points": [
                      "Mean age of onset is 47 years but can vary with specific mutations",
                      "Group with luminal A or B by gene expression profiling",
                      "Majority are high gradeER positiveHER2 negative",
                      "ER positive",
                      "HER2 negative",
                      "Not strongly associated with a specific morphologic appearanceSome studies suggest higher incidence of cancers belonging to tubular-lobular group (pleomorphic lobular)Other series have not shown significant differences betweenBRCA2tumors & sporadic breast cancer",
                      "Some studies suggest higher incidence of cancers belonging to tubular-lobular group (pleomorphic lobular)",
                      "Other series have not shown significant differences betweenBRCA2tumors & sporadic breast cancer"
                    ]
                  },
                  {
                    "text": "Other associated cancersOvary, fallopian tube, primary peritoneal  (10-20% lifetime risk)Usual age of onset: 55-58 years (compared to 63 years in general population)Male breast cancer: 5-10% lifetime risk; ~ 5-15% of cases are associated withBRCA2Also increased risk of early onset aggressive prostate cancerPancreas, gallbladder, stomach, bile duct, melanoma",
                    "sub_points": [
                      "Ovary, fallopian tube, primary peritoneal  (10-20% lifetime risk)Usual age of onset: 55-58 years (compared to 63 years in general population)",
                      "Usual age of onset: 55-58 years (compared to 63 years in general population)",
                      "Male breast cancer: 5-10% lifetime risk; ~ 5-15% of cases are associated withBRCA2Also increased risk of early onset aggressive prostate cancer",
                      "Also increased risk of early onset aggressive prostate cancer",
                      "Pancreas, gallbladder, stomach, bile duct, melanoma"
                    ]
                  }
                ],
                "TP53(Li-Fraumeni Syndrome)": [
                  {
                    "text": "FunctionCentral role in cell cycle control, DNA replication, DNA repair, and apoptosisSomaticTP53mutations are also frequently found inBRCA1-andBRCA2-associated carcinomas",
                    "sub_points": [
                      "Central role in cell cycle control, DNA replication, DNA repair, and apoptosis",
                      "SomaticTP53mutations are also frequently found inBRCA1-andBRCA2-associated carcinomas"
                    ]
                  },
                  {
                    "text": "Incidence: 0.0025%Population in southeastern Brazil has 1/300 incidence",
                    "sub_points": [
                      "Population in southeastern Brazil has 1/300 incidence"
                    ]
                  },
                  {
                    "text": "High penetrance:  >90% lifetime risk of breast cancer for womenPenetrance varies for different mutations",
                    "sub_points": [
                      "Penetrance varies for different mutations"
                    ]
                  },
                  {
                    "text": "Breast cancer1/3 of malignancies in affected familiesEarly onset: Average age at diagnosis is 33 years~ 55% of women will develop breast cancer by age 45~ 2-7% of women with breast cancer were diagnosed at < 30 years of ageRare for breast cancer to be diagnosed after age 50Most common type is ER positive and HER2 positive (~ 55%)Male breast cancer has not been reported",
                    "sub_points": [
                      "1/3 of malignancies in affected familiesEarly onset: Average age at diagnosis is 33 years~ 55% of women will develop breast cancer by age 45~ 2-7% of women with breast cancer were diagnosed at < 30 years of ageRare for breast cancer to be diagnosed after age 50",
                      "Early onset: Average age at diagnosis is 33 years",
                      "~ 55% of women will develop breast cancer by age 45",
                      "~ 2-7% of women with breast cancer were diagnosed at < 30 years of age",
                      "Rare for breast cancer to be diagnosed after age 50",
                      "Most common type is ER positive and HER2 positive (~ 55%)",
                      "Male breast cancer has not been reported"
                    ]
                  },
                  {
                    "text": "Other associated cancersSarcomas: Most occur in children < 10 years of ageHowever, Ewing sarcoma, gastrointestinal stromal tumor (GIST), desmoid tumor, and angiosarcoma have not been reportedAdrenal cortical carcinoma: Most occur in children around 3 years of ageBrain tumors: Occur in children or in 4th-5th decades",
                    "sub_points": [
                      "Sarcomas: Most occur in children < 10 years of ageHowever, Ewing sarcoma, gastrointestinal stromal tumor (GIST), desmoid tumor, and angiosarcoma have not been reported",
                      "However, Ewing sarcoma, gastrointestinal stromal tumor (GIST), desmoid tumor, and angiosarcoma have not been reported",
                      "Adrenal cortical carcinoma: Most occur in children around 3 years of age",
                      "Brain tumors: Occur in children or in 4th-5th decades"
                    ]
                  }
                ],
                "CDH1(Familial Gastric Cancer and Lobular Breast Cancer Syndrome)": [
                  {
                    "text": "FunctionCDH1encodes gene for E-cadherinE-cadherin is a protein involved in cell-to-cell adhesionMutations interfere with function75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletionsLoss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cells",
                    "sub_points": [
                      "CDH1encodes gene for E-cadherin",
                      "E-cadherin is a protein involved in cell-to-cell adhesion",
                      "Mutations interfere with function75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletionsLoss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cells",
                      "75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletions",
                      "Loss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cells"
                    ]
                  },
                  {
                    "text": "Incidence:  0.005%"
                  },
                  {
                    "text": "High penetrance: ~40-50% lifetime risk for women"
                  },
                  {
                    "text": "Breast cancerWomen are at increased risk for lobular carcinomaHowever, majority of women with lobular carcinomas do not haveCDH1germline mutationsLoss of E-cadherin prevents cell adhesion, resulting in single tumor cells with rounded contoursMany tumor cells have intracellular mucin (signet ring cells)Gastric carcinomas and breast carcinomas can resemble each other closelyBreast signet ring cells are more likely to have a single mucin vacuole with a central dotGastric signet ring cells are more likely to have bubbly vacuolated cytoplasmIHC may be helpful in some cases to distinguish primary and metastatic carcinomasBreast carcinomas are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)Gastric carcinomas are typically ER(-), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)",
                    "sub_points": [
                      "Women are at increased risk for lobular carcinomaHowever, majority of women with lobular carcinomas do not haveCDH1germline mutations",
                      "However, majority of women with lobular carcinomas do not haveCDH1germline mutations",
                      "Loss of E-cadherin prevents cell adhesion, resulting in single tumor cells with rounded contoursMany tumor cells have intracellular mucin (signet ring cells)",
                      "Many tumor cells have intracellular mucin (signet ring cells)",
                      "Gastric carcinomas and breast carcinomas can resemble each other closelyBreast signet ring cells are more likely to have a single mucin vacuole with a central dotGastric signet ring cells are more likely to have bubbly vacuolated cytoplasm",
                      "Breast signet ring cells are more likely to have a single mucin vacuole with a central dot",
                      "Gastric signet ring cells are more likely to have bubbly vacuolated cytoplasm",
                      "IHC may be helpful in some cases to distinguish primary and metastatic carcinomasBreast carcinomas are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)Gastric carcinomas are typically ER(-), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)",
                      "Breast carcinomas are typically ER(+), PR(+), GCDFP-15(+), and MUC1(+)",
                      "Gastric carcinomas are typically ER(-), PR(-), GCDFP-15(-), and MUC1(-), while typically CDX-2(+) and Hep-Par1(+)"
                    ]
                  },
                  {
                    "text": "Other associated cancers70-85% lifetime risk of developing gastric signet ring cell carcinoma in majority of familiesGastric carcinomas are more common than breast carcinomas in most affected familiesFamilies developing only breast cancer have also been identified",
                    "sub_points": [
                      "70-85% lifetime risk of developing gastric signet ring cell carcinoma in majority of familiesGastric carcinomas are more common than breast carcinomas in most affected familiesFamilies developing only breast cancer have also been identified",
                      "Gastric carcinomas are more common than breast carcinomas in most affected families",
                      "Families developing only breast cancer have also been identified"
                    ]
                  }
                ],
                "PTEN(Cowden Syndrome)": [
                  {
                    "text": "FunctionDual specificity phosphatase gene involved in control of proliferation signals and apoptosis",
                    "sub_points": [
                      "Dual specificity phosphatase gene involved in control of proliferation signals and apoptosis"
                    ]
                  },
                  {
                    "text": "Incidence: 0.0005%"
                  },
                  {
                    "text": "High penetrance: 25-50% lifetime risk of breast cancer for women"
                  },
                  {
                    "text": "Breast cancerEarly onset; most women diagnosed between 38 and 46 years of ageMen also at increased risk for breast cancer; magnitude of risk not yet determinedOther breast lesions include fibroadenomas and hamartomas",
                    "sub_points": [
                      "Early onset; most women diagnosed between 38 and 46 years of age",
                      "Men also at increased risk for breast cancer; magnitude of risk not yet determined",
                      "Other breast lesions include fibroadenomas and hamartomas"
                    ]
                  },
                  {
                    "text": "Other associated tumorsMultiple hamartomas (including trichilemmomas)Thyroid, and endometrial cancer",
                    "sub_points": [
                      "Multiple hamartomas (including trichilemmomas)",
                      "Thyroid, and endometrial cancer"
                    ]
                  }
                ],
                "ATM(Ataxia-Telangiectasia Carriers)": [
                  {
                    "text": "FunctionSerine threonine kinase that phosphorylatesTP53andBRCA1in response to DNA double-strand breaksHomozygosity results in ataxia-telangiectasiaProgressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma",
                    "sub_points": [
                      "Serine threonine kinase that phosphorylatesTP53andBRCA1in response to DNA double-strand breaks",
                      "Homozygosity results in ataxia-telangiectasiaProgressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma",
                      "Progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma"
                    ]
                  },
                  {
                    "text": "Incidence: 0.5%"
                  },
                  {
                    "text": "High penetrance: 11% by age 50 and 30% by age 70"
                  },
                  {
                    "text": "Breast cancerEarlier onset than sporadic breast cancer",
                    "sub_points": [
                      "Earlier onset than sporadic breast cancer"
                    ]
                  }
                ],
                "CHEK2": [
                  {
                    "text": "FunctionCell cycle checkpoint gene involved in DNA repair",
                    "sub_points": [
                      "Cell cycle checkpoint gene involved in DNA repair"
                    ]
                  },
                  {
                    "text": "Incidence: 0.5%"
                  },
                  {
                    "text": "High penetrance: ~40% lifetime risk for women"
                  },
                  {
                    "text": "Breast cancerLater onsetIncreased risk for malesNo reported specific histologic types; 70-80% are ER positive (similar to sporadic breast cancer)",
                    "sub_points": [
                      "Later onset",
                      "Increased risk for males",
                      "No reported specific histologic types; 70-80% are ER positive (similar to sporadic breast cancer)"
                    ]
                  }
                ],
                "STK11/LKB1(Peutz-Jeghers Syndrome)": [
                  {
                    "text": "FunctionSerine/threonine kinase that regulates how cells respond to proliferation signals depending on ATP availability",
                    "sub_points": [
                      "Serine/threonine kinase that regulates how cells respond to proliferation signals depending on ATP availability"
                    ]
                  },
                  {
                    "text": "Incidence: 0.001%"
                  },
                  {
                    "text": "High penetrance: ~40% lifetime risk for women"
                  },
                  {
                    "text": "Breast cancerEarly onset: 8% by age 40 and 32% by age 60No reported specific histologic types",
                    "sub_points": [
                      "Early onset: 8% by age 40 and 32% by age 60",
                      "No reported specific histologic types"
                    ]
                  },
                  {
                    "text": "Other associated lesionsHamartomatous gastrointestinal polyps (including small intestine) and skin pigmentation (lips and buccal mucosa)Skin pigmentation (lips and buccal mucosa)Ovarian cancer (sex cord stromal tumors are most common): ~ 20% riskIncreased risk of cancer of colon, stomach, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix",
                    "sub_points": [
                      "Hamartomatous gastrointestinal polyps (including small intestine) and skin pigmentation (lips and buccal mucosa)",
                      "Skin pigmentation (lips and buccal mucosa)",
                      "Ovarian cancer (sex cord stromal tumors are most common): ~ 20% risk",
                      "Increased risk of cancer of colon, stomach, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix"
                    ]
                  }
                ],
                "BRIP1(FANCJ or BACH1)": [
                  {
                    "text": "FunctionDNA helicase that interacts with BRCA1 to carry out its functionsMutations result in defects in DNA repair",
                    "sub_points": [
                      "DNA helicase that interacts with BRCA1 to carry out its functionsMutations result in defects in DNA repair",
                      "Mutations result in defects in DNA repair"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1%Heterozygosity increases risk of breast cancerHomozygosity results in Fanconi anemia",
                    "sub_points": [
                      "Heterozygosity increases risk of breast cancer",
                      "Homozygosity results in Fanconi anemia"
                    ]
                  },
                  {
                    "text": "Moderate penetrance: ~20% lifetime risk for women"
                  },
                  {
                    "text": "Breast cancerEarlier onset compared to sporadic cancers (before age 50)No reported specific histologic types",
                    "sub_points": [
                      "Earlier onset compared to sporadic cancers (before age 50)",
                      "No reported specific histologic types"
                    ]
                  },
                  {
                    "text": "Other associated cancersOvary",
                    "sub_points": [
                      "Ovary"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Population to be testedAmerican Society of Clinical Oncology recommends that patients with a > 10% mutation risk undergo testing forBRCA1andBRCA2mutationsThis approach will detect 85% of mutation carriersNational Institute for Health and Clinical Excellence in the United Kingdom recommends testing individuals with a > 20% mutation riskPatients meeting criteria for Li-Fraumeni syndrome or Li-Fraumeni-like syndrome have > 15% risk of having a mutationGroup of genes conferring a low increased risk for breast cancer has been identifiedGenes functionally related toBRCA1andBRCA2:BARD1,CHEK1,MRE11A,NBN,RAD50,RAD51DGenes in the Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51BOther genes:MUTYH,PMS2For many of these genes, the risk of breast cancer is not yet clearLimited information is available for variants of unknown significanceTesting for mutations in these genes may only be of value in selected casesIndividuals may undergo testing for rare genes in the following settingsTesting has excluded mutations inBRCA1,BRCA2, andTP53Clinical setting is suggestive of a specific gene mutationMutation has been identified in the familyCounseling should occur before testing to ensure patient is aware of possible implications for individual and family",
                    "sub_points": [
                      "American Society of Clinical Oncology recommends that patients with a > 10% mutation risk undergo testing forBRCA1andBRCA2mutationsThis approach will detect 85% of mutation carriers",
                      "This approach will detect 85% of mutation carriers",
                      "National Institute for Health and Clinical Excellence in the United Kingdom recommends testing individuals with a > 20% mutation risk",
                      "Patients meeting criteria for Li-Fraumeni syndrome or Li-Fraumeni-like syndrome have > 15% risk of having a mutation",
                      "Group of genes conferring a low increased risk for breast cancer has been identifiedGenes functionally related toBRCA1andBRCA2:BARD1,CHEK1,MRE11A,NBN,RAD50,RAD51DGenes in the Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51BOther genes:MUTYH,PMS2For many of these genes, the risk of breast cancer is not yet clearLimited information is available for variants of unknown significanceTesting for mutations in these genes may only be of value in selected cases",
                      "Genes functionally related toBRCA1andBRCA2:BARD1,CHEK1,MRE11A,NBN,RAD50,RAD51D",
                      "Genes in the Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51B",
                      "Other genes:MUTYH,PMS2",
                      "For many of these genes, the risk of breast cancer is not yet clear",
                      "Limited information is available for variants of unknown significance",
                      "Testing for mutations in these genes may only be of value in selected cases",
                      "Individuals may undergo testing for rare genes in the following settingsTesting has excluded mutations inBRCA1,BRCA2, andTP53Clinical setting is suggestive of a specific gene mutationMutation has been identified in the family",
                      "Testing has excluded mutations inBRCA1,BRCA2, andTP53",
                      "Clinical setting is suggestive of a specific gene mutation",
                      "Mutation has been identified in the family",
                      "Counseling should occur before testing to ensure patient is aware of possible implications for individual and family"
                    ]
                  },
                  {
                    "text": "Predictive modelsNational Comprehensive Cancer Network issues clinical guidelines for identifying individuals with a high risk ofBRCA1,BRCA2,TP53, orPTENmutationsVersion 1.2013 is available at www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdfBRCA1andBRCA2Multiple models availableBRCAPRO (available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html) and BOADICEA (available at http://ccge.medschl.cam.ac.uk/boadicea/model/) are commonly usedTP53Classical Li-Fraumeni criteriaChompret criteriaPTENAvailable at http://www.lerner.ccf.org/gmi/ccscore/index.php",
                    "sub_points": [
                      "National Comprehensive Cancer Network issues clinical guidelines for identifying individuals with a high risk ofBRCA1,BRCA2,TP53, orPTENmutationsVersion 1.2013 is available at www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf",
                      "Version 1.2013 is available at www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf",
                      "BRCA1andBRCA2Multiple models availableBRCAPRO (available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html) and BOADICEA (available at http://ccge.medschl.cam.ac.uk/boadicea/model/) are commonly used",
                      "Multiple models available",
                      "BRCAPRO (available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html) and BOADICEA (available at http://ccge.medschl.cam.ac.uk/boadicea/model/) are commonly used",
                      "TP53Classical Li-Fraumeni criteriaChompret criteria",
                      "Classical Li-Fraumeni criteria",
                      "Chompret criteria",
                      "PTENAvailable at http://www.lerner.ccf.org/gmi/ccscore/index.php",
                      "Available at http://www.lerner.ccf.org/gmi/ccscore/index.php"
                    ]
                  },
                  {
                    "text": "Genetic testingFull genome sequencing is required to detect all mutationsAll testing forBRCA1andBRCA2mutations in the USA is performed by Myriad Genetics (Salt Lake City, Utah)Full genome sequencing (or full exome sequencing) is commercially available and will likely decrease in cost to make testing for all genes possible in many individualsLimited sequence analysis can be used to detect the most likely mutationCommon mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish populationHotspots for mutations within geneDetection of a known mutation in a familyDuplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis18% of genetic changes inBRCA1andBRCA2are not detected by standard testingIf a known mutation is not found in the initial test, additional testing may be performedBRACAnalysis large rearrangement test (BART) detects some rearrangementsAccount for 17% of deleterious mutations in individuals from the Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/CaribbeanNone of the current tests detect every deleterious changeVariants of unknown significance (VUS)Genetic polymorphism that has not yet been associated with an increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations; however, frequency has been decreasing as more individuals are studiedMust be identified in multiple individuals to determine clinical significance",
                    "sub_points": [
                      "Full genome sequencing is required to detect all mutationsAll testing forBRCA1andBRCA2mutations in the USA is performed by Myriad Genetics (Salt Lake City, Utah)Full genome sequencing (or full exome sequencing) is commercially available and will likely decrease in cost to make testing for all genes possible in many individuals",
                      "All testing forBRCA1andBRCA2mutations in the USA is performed by Myriad Genetics (Salt Lake City, Utah)",
                      "Full genome sequencing (or full exome sequencing) is commercially available and will likely decrease in cost to make testing for all genes possible in many individuals",
                      "Limited sequence analysis can be used to detect the most likely mutationCommon mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish populationHotspots for mutations within geneDetection of a known mutation in a family",
                      "Common mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish population",
                      "Hotspots for mutations within gene",
                      "Detection of a known mutation in a family",
                      "Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis18% of genetic changes inBRCA1andBRCA2are not detected by standard testingIf a known mutation is not found in the initial test, additional testing may be performedBRACAnalysis large rearrangement test (BART) detects some rearrangementsAccount for 17% of deleterious mutations in individuals from the Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/CaribbeanNone of the current tests detect every deleterious change",
                      "18% of genetic changes inBRCA1andBRCA2are not detected by standard testing",
                      "If a known mutation is not found in the initial test, additional testing may be performed",
                      "BRACAnalysis large rearrangement test (BART) detects some rearrangements",
                      "Account for 17% of deleterious mutations in individuals from the Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean",
                      "None of the current tests detect every deleterious change",
                      "Variants of unknown significance (VUS)Genetic polymorphism that has not yet been associated with an increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations; however, frequency has been decreasing as more individuals are studiedMust be identified in multiple individuals to determine clinical significance",
                      "Genetic polymorphism that has not yet been associated with an increased risk of cancer",
                      "Found in 3-7% of individuals tested forBRCA1andBRCA2",
                      "> 1,500 identified",
                      "More frequent in minority ethnic populations; however, frequency has been decreasing as more individuals are studied",
                      "Must be identified in multiple individuals to determine clinical significance"
                    ]
                  },
                  {
                    "text": "Testing families with a history of cancerMost useful, begin testing individual with cancerIf multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutationOnce a mutation is detected, other family members without cancer may choose testingAnalysis for specific mutation in other family members is considerably less expensive",
                    "sub_points": [
                      "Most useful, begin testing individual with cancerIf multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutation",
                      "If multiple affected individuals are present within a kindred, testing can establish linkage between cancer(s) and mutation",
                      "Once a mutation is detected, other family members without cancer may choose testing",
                      "Analysis for specific mutation in other family members is considerably less expensive"
                    ]
                  },
                  {
                    "text": "Specific mutations are characteristic of some ethnic groupsAshkenazi Jewish populations (1 in 40 individuals may be a carrier): 90% of mutations are 1 of 3 typesBRCA1: 185delAG and 5382insCBRCA2: 6174delTIcelandic:BRCA2: 999del5 accounts for 7% of cases",
                    "sub_points": [
                      "Ashkenazi Jewish populations (1 in 40 individuals may be a carrier): 90% of mutations are 1 of 3 typesBRCA1: 185delAG and 5382insCBRCA2: 6174delT",
                      "BRCA1: 185delAG and 5382insC",
                      "BRCA2: 6174delT",
                      "Icelandic:BRCA2: 999del5 accounts for 7% of cases"
                    ]
                  }
                ],
                "Cancer Risk Management": [
                  {
                    "text": "ChemopreventionTamoxifen reduces the risk of ER-positive cancer for women with a family history of breast cancerHowever, risk of endometrial cancer and thrombosis is increasedTamoxifen reduces risk of cancers forBRCA2carriers but not forBRCA1carriersHowever, few women have been studiedTamoxifen reduces risk of subsequent ipsilateral and contralateral cancer in breast cancer patients withBRCA1andBRCA2germline mutationsBenefit of chemoprevention forBRCAcarriers without breast cancer is less clear (few studies)",
                    "sub_points": [
                      "Tamoxifen reduces the risk of ER-positive cancer for women with a family history of breast cancerHowever, risk of endometrial cancer and thrombosis is increased",
                      "However, risk of endometrial cancer and thrombosis is increased",
                      "Tamoxifen reduces risk of cancers forBRCA2carriers but not forBRCA1carriersHowever, few women have been studied",
                      "However, few women have been studied",
                      "Tamoxifen reduces risk of subsequent ipsilateral and contralateral cancer in breast cancer patients withBRCA1andBRCA2germline mutations",
                      "Benefit of chemoprevention forBRCAcarriers without breast cancer is less clear (few studies)"
                    ]
                  },
                  {
                    "text": "ScreeningClinical breast examination 2x yearly starting at age 25Patient self-breast awareness with periodic breast examinationsMammography at earlier age (10 years before age at which the youngest relative with cancer was diagnosed) or more frequentlyMR screening more sensitive than mammography in young women with dense breastsHowever, lower specificity leads to greater numbers of biopsies for benign lesionsScreening, mammography, and MR may be staggered every 6 months to decrease the screening interval",
                    "sub_points": [
                      "Clinical breast examination 2x yearly starting at age 25Patient self-breast awareness with periodic breast examinations",
                      "Patient self-breast awareness with periodic breast examinations",
                      "Mammography at earlier age (10 years before age at which the youngest relative with cancer was diagnosed) or more frequently",
                      "MR screening more sensitive than mammography in young women with dense breastsHowever, lower specificity leads to greater numbers of biopsies for benign lesions",
                      "However, lower specificity leads to greater numbers of biopsies for benign lesions",
                      "Screening, mammography, and MR may be staggered every 6 months to decrease the screening interval"
                    ]
                  },
                  {
                    "text": "Prophylactic surgeryWomen withBRCA1&BRCA2mutations are at increased risk for subsequent ipsilateral (~ 2-3% per year) and contralateral (~ 2-6%) cancerRecurrence rates are higher for women with very early onset cancer (< 42 years)Ipsilateral cancers are likely new primary cancers rather than true recurrencesRecurrence does not alter survival, as 2nd cancers are likely found at an early stageBilateral mastectomy reduces risk by 97%Not all breast tissue can be removed in all patients with acceptable cosmetic resultsMajor benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastasesBilateral salpingo-oophorectomy for mutations associated with ovarian cancerReduces risk of ovarian and fallopian tube cancer by 70-96%Reduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone productionReduces risk of ER(-) breast cancers forBRCA1patients to a lesser degree; mechanism is unknown",
                    "sub_points": [
                      "Women withBRCA1&BRCA2mutations are at increased risk for subsequent ipsilateral (~ 2-3% per year) and contralateral (~ 2-6%) cancerRecurrence rates are higher for women with very early onset cancer (< 42 years)Ipsilateral cancers are likely new primary cancers rather than true recurrencesRecurrence does not alter survival, as 2nd cancers are likely found at an early stage",
                      "Recurrence rates are higher for women with very early onset cancer (< 42 years)",
                      "Ipsilateral cancers are likely new primary cancers rather than true recurrences",
                      "Recurrence does not alter survival, as 2nd cancers are likely found at an early stage",
                      "Bilateral mastectomy reduces risk by 97%Not all breast tissue can be removed in all patients with acceptable cosmetic resultsMajor benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastases",
                      "Not all breast tissue can be removed in all patients with acceptable cosmetic results",
                      "Major benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastases",
                      "Bilateral salpingo-oophorectomy for mutations associated with ovarian cancerReduces risk of ovarian and fallopian tube cancer by 70-96%Reduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone productionReduces risk of ER(-) breast cancers forBRCA1patients to a lesser degree; mechanism is unknown",
                      "Reduces risk of ovarian and fallopian tube cancer by 70-96%",
                      "Reduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone production",
                      "Reduces risk of ER(-) breast cancers forBRCA1patients to a lesser degree; mechanism is unknown"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "BRCA1: Hereditary Breast and Ovarian Cancer Syndrome 1": {
            "name": "BRCA1: Hereditary Breast and Ovarian Cancer Syndrome 1",
            "url": "https://app.pathprimer.com/document/22747a24-7907-452f-9e5b-d67a62edf1c0/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "BRCA1 syndrome"
                  },
                  {
                    "text": "Breast cancer 1 syndrome"
                  },
                  {
                    "text": "Early-onset breast/ovarian cancer syndrome"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM) #113705"
                  }
                ]
              },
              "Introduction": {
                "Hereditary Breast/Ovarian Cancer Syndrome": [
                  {
                    "text": "BRCA1andBRCA2were first discovered by Dr. Mary-Claire King and colleagues by recognizing that breast cancers arising in young women were more likely to be associated with a germline mutationBRCA1was localized to chromosomal site in 1990 andBRCA2in 1994",
                    "sub_points": [
                      "BRCA1was localized to chromosomal site in 1990 andBRCA2in 1994"
                    ]
                  },
                  {
                    "text": "These genes confer increased risk for breast cancer as well as other cancers for both women and men"
                  },
                  {
                    "text": "The presence of a germlineBRCA1/BRCA2gene mutation affects screening, surgical procedures, and systemic therapy selection"
                  },
                  {
                    "text": "The majority of cancers associated withBRCA1are both tissue and tumor-type specificBreast: Triple negative breast carcinoma (TNBC): Defined by lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2BRCA1cancers are also typically basal-like carcinomas, which are defined by mRNA expression (this group overlaps with TNBC by ~ 80%)Ovary: High-grade serous carcinoma; the majority are thought to arise from the fimbriated end of the fallopian tube",
                    "sub_points": [
                      "Breast: Triple negative breast carcinoma (TNBC): Defined by lack of expression of estrogen receptor (ER), progesterone receptor (PR), and HER2BRCA1cancers are also typically basal-like carcinomas, which are defined by mRNA expression (this group overlaps with TNBC by ~ 80%)",
                      "BRCA1cancers are also typically basal-like carcinomas, which are defined by mRNA expression (this group overlaps with TNBC by ~ 80%)",
                      "Ovary: High-grade serous carcinoma; the majority are thought to arise from the fimbriated end of the fallopian tube"
                    ]
                  },
                  {
                    "text": "Both cancers share similarities in gene expression and mutation profiles (e.g., frequentTP53mutations,MYCamplification and overexpression, andRB1loss)"
                  },
                  {
                    "text": "The very specific increased risk for these 2 types of cancer is not completely understoodOne proposal is that higher estrogen levels due to diminished BRCA1 protein (which is a negative regulator of estrogen) stimulates growth of progenitor cellsER(-) progenitor cells in breast may have their growth stimulated due to paracrine effects on other ER(+) epithelial cellsOther possibilities are under investigation",
                    "sub_points": [
                      "One proposal is that higher estrogen levels due to diminished BRCA1 protein (which is a negative regulator of estrogen) stimulates growth of progenitor cellsER(-) progenitor cells in breast may have their growth stimulated due to paracrine effects on other ER(+) epithelial cells",
                      "ER(-) progenitor cells in breast may have their growth stimulated due to paracrine effects on other ER(+) epithelial cells",
                      "Other possibilities are under investigation"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "~ 1 in 300 (~ 0.1-0.3%)BRCA2mutations are found in ~ 0.1-0.7%",
                    "sub_points": [
                      "BRCA2mutations are found in ~ 0.1-0.7%"
                    ]
                  },
                  {
                    "text": "Founder mutations are present at increased frequency in specific populationsAshkenazi Jewish population~ 2.5% or ~ 1 in 40 individuals carries 1 of 3BRCA1orBRCA2germline mutationsAccount for 95% ofBRCA1/BRCA2mutations in this populationCurrent Human Genome Variation Society (HGVS) guideline designationsBRCA1: c.68_69delAG (previously referred to as 185delAG or 187delAG)BRCA1: c.5266dupC (previously referred to as 5382insC or 5385insC)BRCA2: c.5946delT (previously referred to as 6174delT)Additional founder mutations are present in families in Sweden, Hungary, Iceland, Netherlands, Italy, Quebec (French Canadians), and other locations",
                    "sub_points": [
                      "Ashkenazi Jewish population~ 2.5% or ~ 1 in 40 individuals carries 1 of 3BRCA1orBRCA2germline mutationsAccount for 95% ofBRCA1/BRCA2mutations in this populationCurrent Human Genome Variation Society (HGVS) guideline designationsBRCA1: c.68_69delAG (previously referred to as 185delAG or 187delAG)BRCA1: c.5266dupC (previously referred to as 5382insC or 5385insC)BRCA2: c.5946delT (previously referred to as 6174delT)",
                      "~ 2.5% or ~ 1 in 40 individuals carries 1 of 3BRCA1orBRCA2germline mutationsAccount for 95% ofBRCA1/BRCA2mutations in this population",
                      "Account for 95% ofBRCA1/BRCA2mutations in this population",
                      "Current Human Genome Variation Society (HGVS) guideline designationsBRCA1: c.68_69delAG (previously referred to as 185delAG or 187delAG)BRCA1: c.5266dupC (previously referred to as 5382insC or 5385insC)BRCA2: c.5946delT (previously referred to as 6174delT)",
                      "BRCA1: c.68_69delAG (previously referred to as 185delAG or 187delAG)",
                      "BRCA1: c.5266dupC (previously referred to as 5382insC or 5385insC)",
                      "BRCA2: c.5946delT (previously referred to as 6174delT)",
                      "Additional founder mutations are present in families in Sweden, Hungary, Iceland, Netherlands, Italy, Quebec (French Canadians), and other locations"
                    ]
                  },
                  {
                    "text": "~ 90% of families with both hereditary breast and ovarian cancer haveBRCA1/BRCA2mutation"
                  }
                ],
                "Modifiers of Risk": [
                  {
                    "text": "Parity decreases risk of breast cancer"
                  },
                  {
                    "text": "Low-dose ionizing radiation to chest before age 20 increases risk"
                  },
                  {
                    "text": "Mutations in other genesNone yet well definedGenome-wide association studies (GWAS) are investigating possible associations",
                    "sub_points": [
                      "None yet well defined",
                      "Genome-wide association studies (GWAS) are investigating possible associations"
                    ]
                  }
                ],
                "Cancer Incidence": [
                  {
                    "text": "Lifetime risk varies depending on specific mutationRanges from 40-90% in femalesSmall increased risk for males (1-5%), but lower than risk associated withBRCA2(7%)",
                    "sub_points": [
                      "Ranges from 40-90% in females",
                      "Small increased risk for males (1-5%), but lower than risk associated withBRCA2(7%)"
                    ]
                  },
                  {
                    "text": "For all breast cancers, ~ 2% occur in women withBRCA1germline mutations~ 50% of all breast cancers related to germline mutation are due toBRCA1germline mutations",
                    "sub_points": [
                      "~ 50% of all breast cancers related to germline mutation are due toBRCA1germline mutations"
                    ]
                  }
                ]
              },
              "Genetics": {
                "BRCA1Gene": [
                  {
                    "text": "Located on 17q21, large 81 kb geneNo sequence homology withBRCA2or other genes",
                    "sub_points": [
                      "No sequence homology withBRCA2or other genes"
                    ]
                  },
                  {
                    "text": "24 exons with 22 coding exons, transcript 7,094 base pairsProtein 1,863 amino acids (210 kDa), no sequence homology with other proteins",
                    "sub_points": [
                      "Protein 1,863 amino acids (210 kDa), no sequence homology with other proteins"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritanceDe novo mutations are rare",
                    "sub_points": [
                      "De novo mutations are rare"
                    ]
                  },
                  {
                    "text": "> 1,000 different mutations identifiedOccur along entire sequenceInclude single nucleotide changes, small insertions or deletions, and large genomic rearrangementsCan affect reading frame, splice sites, binding regions, and other areasMajority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absentLess common are full-length proteins with missense mutationsInactivating mutations impair conservative DNA repair and genomic stability functions",
                    "sub_points": [
                      "Occur along entire sequence",
                      "Include single nucleotide changes, small insertions or deletions, and large genomic rearrangements",
                      "Can affect reading frame, splice sites, binding regions, and other areas",
                      "Majority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absentLess common are full-length proteins with missense mutations",
                      "Results in frameshift mutations, nonsense mutations, or splice site alterations",
                      "Protein may be truncated or absent",
                      "Less common are full-length proteins with missense mutations",
                      "Inactivating mutations impair conservative DNA repair and genomic stability functions"
                    ]
                  }
                ],
                "Protein Function": [
                  {
                    "text": "Classified as tumor suppressor gene2nd event involving wildtype allele occurs in tumorigenesisBiallelic inactivation required for pathogenic phenotype",
                    "sub_points": [
                      "2nd event involving wildtype allele occurs in tumorigenesis",
                      "Biallelic inactivation required for pathogenic phenotype"
                    ]
                  },
                  {
                    "text": "Central role in DNA repair, regulation of cell cycle checkpoints in response to DNA damage, and transcriptionAdditional functions beyond DNA repair may help explain why cancer risk is greater and cancers occur at younger ages, as compared toBRCA2",
                    "sub_points": [
                      "Additional functions beyond DNA repair may help explain why cancer risk is greater and cancers occur at younger ages, as compared toBRCA2"
                    ]
                  },
                  {
                    "text": "Regulation of repair of DNA damageBRCA1 protein is required for repair of DNA double-stranded breaks by homologous recombinationThis repair pathway also requires BRCA2, ATM, CHEK2, BARD1, BRIP1, and other proteinsCells that lack BRCA1 protein rely on other less reliable mechanisms for DNA repairIncreases replication errors and genomic instabilityChromosomal instability contributes to tumor formationBRCA1 protein defects are postulated to be initiating oncogenic event",
                    "sub_points": [
                      "BRCA1 protein is required for repair of DNA double-stranded breaks by homologous recombinationThis repair pathway also requires BRCA2, ATM, CHEK2, BARD1, BRIP1, and other proteins",
                      "This repair pathway also requires BRCA2, ATM, CHEK2, BARD1, BRIP1, and other proteins",
                      "Cells that lack BRCA1 protein rely on other less reliable mechanisms for DNA repairIncreases replication errors and genomic instability",
                      "Increases replication errors and genomic instability",
                      "Chromosomal instability contributes to tumor formationBRCA1 protein defects are postulated to be initiating oncogenic event",
                      "BRCA1 protein defects are postulated to be initiating oncogenic event"
                    ]
                  },
                  {
                    "text": "Cell cycle regulation, checkpoint controlAccumulating DNA abnormalities increase likelihood of additional mutations in genes essential to cell cycle checkpoint activation",
                    "sub_points": [
                      "Accumulating DNA abnormalities increase likelihood of additional mutations in genes essential to cell cycle checkpoint activation"
                    ]
                  },
                  {
                    "text": "Transcriptional regulationBRCA1 protein is required for transactivation of ER promoter",
                    "sub_points": [
                      "BRCA1 protein is required for transactivation of ER promoter"
                    ]
                  },
                  {
                    "text": "Also functional in chromatin remodeling and protein ubiquitination"
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "Antibodies to BRCA1 protein are availableDetected as nuclear immunoreactivity",
                    "sub_points": [
                      "Detected as nuclear immunoreactivity"
                    ]
                  },
                  {
                    "text": "Carcinomas arising in women withBRCA1germline mutations are positive or negative for nuclear BRCA1 in approximately equal proportionsSporadic breast cancers can also be positive or negative for BRCA1 proteinTherefore, immunohistochemical studies are not helpful to detect possible germline mutations",
                    "sub_points": [
                      "Sporadic breast cancers can also be positive or negative for BRCA1 protein",
                      "Therefore, immunohistochemical studies are not helpful to detect possible germline mutations"
                    ]
                  },
                  {
                    "text": "Absence of BRCA1 protein in hereditary and sporadic breast cancers has been reported to be a poor prognostic factor"
                  }
                ]
              },
              "Associated Neoplasms": {
                "Female Breast Cancer": [
                  {
                    "text": "Risk (penetrance)40-90% of women with a germline mutation will develop breast cancer by age 70Varies by mutationAfter diagnosis of 1st cancer, 40% of women develop contralateral cancer within 20 years",
                    "sub_points": [
                      "40-90% of women with a germline mutation will develop breast cancer by age 70Varies by mutation",
                      "Varies by mutation",
                      "After diagnosis of 1st cancer, 40% of women develop contralateral cancer within 20 years"
                    ]
                  },
                  {
                    "text": "PrognosisSome studies have shown lower survival compared to sporadic carcinomas, but this has not been supported by all studiesPrognosis may be related to a higher sensitivity to drugs that cause DNA damage (platinum agents)BRCA1-associated TNBC is more likely to undergo pathologic complete response (pCR) to neoadjuvant chemotherapy (~ 46%) compared to TNBC not associated withBRCA1(~ 27%)Patients who achieved pCR had improved survival compared to patients who did not",
                    "sub_points": [
                      "Some studies have shown lower survival compared to sporadic carcinomas, but this has not been supported by all studies",
                      "Prognosis may be related to a higher sensitivity to drugs that cause DNA damage (platinum agents)",
                      "BRCA1-associated TNBC is more likely to undergo pathologic complete response (pCR) to neoadjuvant chemotherapy (~ 46%) compared to TNBC not associated withBRCA1(~ 27%)Patients who achieved pCR had improved survival compared to patients who did not",
                      "Patients who achieved pCR had improved survival compared to patients who did not"
                    ]
                  },
                  {
                    "text": "Precursor lesionsDefinite precursor lesion has not been identifiedProposed (but not proven) possible precursors includeHistologically normal cells with uniform p53 expression (analogous to \"p53 signature\" associated with fallopian tube serous carcinomas)Histologically normal cells associated with T-cell lymphocytic infiltrate (T-cell lymphocytic lobulitis)RANK(+) cells susceptible to DNA damageMicroglandular adenosis; however, this is more advanced lesion that lacks myoepithelial cells and has an infiltrative pattern",
                    "sub_points": [
                      "Definite precursor lesion has not been identified",
                      "Proposed (but not proven) possible precursors includeHistologically normal cells with uniform p53 expression (analogous to \"p53 signature\" associated with fallopian tube serous carcinomas)Histologically normal cells associated with T-cell lymphocytic infiltrate (T-cell lymphocytic lobulitis)RANK(+) cells susceptible to DNA damageMicroglandular adenosis; however, this is more advanced lesion that lacks myoepithelial cells and has an infiltrative pattern",
                      "Histologically normal cells with uniform p53 expression (analogous to \"p53 signature\" associated with fallopian tube serous carcinomas)",
                      "Histologically normal cells associated with T-cell lymphocytic infiltrate (T-cell lymphocytic lobulitis)",
                      "RANK(+) cells susceptible to DNA damage",
                      "Microglandular adenosis; however, this is more advanced lesion that lacks myoepithelial cells and has an infiltrative pattern"
                    ]
                  },
                  {
                    "text": "Ductal carcinoma in situ (DCIS)BRCA1-associated DCIS is usually negative for ER, PR, and HER2 and has a high nuclear gradeThis type of DCIS is rarely seen in absence of invasive carcinomaCells may fill acini in a clinging pattern without distorting lobules, making DCIS difficult to recognizeA dense lymphocytic infiltrate often surrounds involved lobulesMay be detected as enhancement seen on screening MR for high-risk patients",
                    "sub_points": [
                      "BRCA1-associated DCIS is usually negative for ER, PR, and HER2 and has a high nuclear gradeThis type of DCIS is rarely seen in absence of invasive carcinoma",
                      "This type of DCIS is rarely seen in absence of invasive carcinoma",
                      "Cells may fill acini in a clinging pattern without distorting lobules, making DCIS difficult to recognizeA dense lymphocytic infiltrate often surrounds involved lobules",
                      "A dense lymphocytic infiltrate often surrounds involved lobules",
                      "May be detected as enhancement seen on screening MR for high-risk patients"
                    ]
                  },
                  {
                    "text": "Invasive carcinoma: Histologic featuresInvasive carcinomas typically have pushing circumscribed bordersCan mimic benign lesions on imagingPredominantly poorly differentiatedHigh nuclear grade, high proliferation, foci of geographic tumor necrosis, &/or central fibrotic centerLymphocytic infiltrate commonManyBRCA1-associated cancers are associated with a dense lymphocytic infiltrateLymphocytes are predominantly T cellsLymphocytic infiltrate is associated with a better response to neoadjuvant chemotherapy and improved survivalPrimary carcinoma can be mistaken for lymph node metastasis microscopically when there is a dense lymphocytic infiltrateIdentification of normal breast tissue or DCIS within carcinoma excludes metastasisLymph node metastasis can be determined with confidence when there is definite lymph node capsuleThe combination of a circumscribed border, syncytial growth pattern (sheets of tumor cells at least 7 cells across), and lymphocytic infiltrates are the components of \"medullary features\"60% ofBRCA1-associated cancers have medullary features (13% fulfill prior criteria for medullary carcinoma)In one study, 3 of 18 TNBCs with medullary features were found to haveBRCA1mutations, all thought to be germline mutations",
                    "sub_points": [
                      "Invasive carcinomas typically have pushing circumscribed bordersCan mimic benign lesions on imaging",
                      "Can mimic benign lesions on imaging",
                      "Predominantly poorly differentiatedHigh nuclear grade, high proliferation, foci of geographic tumor necrosis, &/or central fibrotic center",
                      "High nuclear grade, high proliferation, foci of geographic tumor necrosis, &/or central fibrotic center",
                      "Lymphocytic infiltrate commonManyBRCA1-associated cancers are associated with a dense lymphocytic infiltrateLymphocytes are predominantly T cellsLymphocytic infiltrate is associated with a better response to neoadjuvant chemotherapy and improved survivalPrimary carcinoma can be mistaken for lymph node metastasis microscopically when there is a dense lymphocytic infiltrateIdentification of normal breast tissue or DCIS within carcinoma excludes metastasisLymph node metastasis can be determined with confidence when there is definite lymph node capsuleThe combination of a circumscribed border, syncytial growth pattern (sheets of tumor cells at least 7 cells across), and lymphocytic infiltrates are the components of \"medullary features\"60% ofBRCA1-associated cancers have medullary features (13% fulfill prior criteria for medullary carcinoma)In one study, 3 of 18 TNBCs with medullary features were found to haveBRCA1mutations, all thought to be germline mutations",
                      "ManyBRCA1-associated cancers are associated with a dense lymphocytic infiltrateLymphocytes are predominantly T cellsLymphocytic infiltrate is associated with a better response to neoadjuvant chemotherapy and improved survival",
                      "Lymphocytes are predominantly T cells",
                      "Lymphocytic infiltrate is associated with a better response to neoadjuvant chemotherapy and improved survival",
                      "Primary carcinoma can be mistaken for lymph node metastasis microscopically when there is a dense lymphocytic infiltrateIdentification of normal breast tissue or DCIS within carcinoma excludes metastasisLymph node metastasis can be determined with confidence when there is definite lymph node capsule",
                      "Identification of normal breast tissue or DCIS within carcinoma excludes metastasis",
                      "Lymph node metastasis can be determined with confidence when there is definite lymph node capsule",
                      "The combination of a circumscribed border, syncytial growth pattern (sheets of tumor cells at least 7 cells across), and lymphocytic infiltrates are the components of \"medullary features\"60% ofBRCA1-associated cancers have medullary features (13% fulfill prior criteria for medullary carcinoma)In one study, 3 of 18 TNBCs with medullary features were found to haveBRCA1mutations, all thought to be germline mutations",
                      "60% ofBRCA1-associated cancers have medullary features (13% fulfill prior criteria for medullary carcinoma)",
                      "In one study, 3 of 18 TNBCs with medullary features were found to haveBRCA1mutations, all thought to be germline mutations"
                    ]
                  },
                  {
                    "text": "Invasive carcinoma: Biologic typeER(-)/HER2(-)TNBC: 70-80%Majority of these carcinomas group with basal-like carcinomas by gene expression profiling (mRNA)~ 7% (if > 60 years of age) to 30% (if < 30 years of age) of women with TNBC haveBRCA1germline mutations~ 1-17% of women with TNBC haveBRCA2germline mutationsSomaticBRCA1mutations are only detected in ~ 1% of TNBCsTP53mutations common (> 90%); ~ 55% positive by immunohistochemistry> 95% poorly differentiated50-80% positive for CK5/6, CK14, or EGFRER(+)/HER2(-)(\"luminal\"): 20-30%~ 85% show loss of wildtypeBRCA1alleleThis finding supports that these cancers are related to germline mutation and are not incidental sporadic cancers~ 45% poorly differentiated, ~ 50% positive for p53< 20% positive for CK5/6, CK14, or EGFRHER2(+): < 5%",
                    "sub_points": [
                      "ER(-)/HER2(-)TNBC: 70-80%Majority of these carcinomas group with basal-like carcinomas by gene expression profiling (mRNA)~ 7% (if > 60 years of age) to 30% (if < 30 years of age) of women with TNBC haveBRCA1germline mutations~ 1-17% of women with TNBC haveBRCA2germline mutationsSomaticBRCA1mutations are only detected in ~ 1% of TNBCsTP53mutations common (> 90%); ~ 55% positive by immunohistochemistry> 95% poorly differentiated50-80% positive for CK5/6, CK14, or EGFR",
                      "Majority of these carcinomas group with basal-like carcinomas by gene expression profiling (mRNA)",
                      "~ 7% (if > 60 years of age) to 30% (if < 30 years of age) of women with TNBC haveBRCA1germline mutations~ 1-17% of women with TNBC haveBRCA2germline mutationsSomaticBRCA1mutations are only detected in ~ 1% of TNBCs",
                      "~ 1-17% of women with TNBC haveBRCA2germline mutations",
                      "SomaticBRCA1mutations are only detected in ~ 1% of TNBCs",
                      "TP53mutations common (> 90%); ~ 55% positive by immunohistochemistry",
                      "> 95% poorly differentiated",
                      "50-80% positive for CK5/6, CK14, or EGFR",
                      "ER(+)/HER2(-)(\"luminal\"): 20-30%~ 85% show loss of wildtypeBRCA1alleleThis finding supports that these cancers are related to germline mutation and are not incidental sporadic cancers~ 45% poorly differentiated, ~ 50% positive for p53< 20% positive for CK5/6, CK14, or EGFR",
                      "~ 85% show loss of wildtypeBRCA1alleleThis finding supports that these cancers are related to germline mutation and are not incidental sporadic cancers",
                      "This finding supports that these cancers are related to germline mutation and are not incidental sporadic cancers",
                      "~ 45% poorly differentiated, ~ 50% positive for p53",
                      "< 20% positive for CK5/6, CK14, or EGFR",
                      "HER2(+): < 5%"
                    ]
                  }
                ],
                "Male Breast Cancer": [
                  {
                    "text": "1-5% lifetime risk (compared to 0.1% risk in general population)7% lifetime risk for males withBRCA2mutation~ 1% of male breast cancer cases are associated withBRCA1and 8-16% of cases withBRCA2",
                    "sub_points": [
                      "7% lifetime risk for males withBRCA2mutation",
                      "~ 1% of male breast cancer cases are associated withBRCA1and 8-16% of cases withBRCA2"
                    ]
                  },
                  {
                    "text": "Majority are invasive carcinomas that are high grade, ER(+), HER2(-), and stages III-IV"
                  }
                ],
                "Ovarian, Fallopian Tube, and Peritoneal Carcinoma": [
                  {
                    "text": "40-50% lifetime riskLifetime risk associated withBRCA2is ~ 11-18%",
                    "sub_points": [
                      "Lifetime risk associated withBRCA2is ~ 11-18%"
                    ]
                  },
                  {
                    "text": "60-85% involve fimbriated end of fallopian tube"
                  },
                  {
                    "text": "Precursor lesionSerous tubal intraepithelial carcinoma (STIC) is found in ~ 1-2% of prophylactic surgeriesEntire fimbriated end of fallopian tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasiaIf no invasion is seen, risk of recurrence in peritoneum is 4-5%Prophylactic surgery is recommended by 35-40 years of ageHigh-grade serous carcinoma is found in 1-17% (average ~ 2-3%) of prophylactic surgeries and is more common in women > 40 years of age",
                    "sub_points": [
                      "Serous tubal intraepithelial carcinoma (STIC) is found in ~ 1-2% of prophylactic surgeriesEntire fimbriated end of fallopian tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasiaIf no invasion is seen, risk of recurrence in peritoneum is 4-5%",
                      "Entire fimbriated end of fallopian tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasia",
                      "Immunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful to identify early neoplasia",
                      "If no invasion is seen, risk of recurrence in peritoneum is 4-5%",
                      "Prophylactic surgery is recommended by 35-40 years of ageHigh-grade serous carcinoma is found in 1-17% (average ~ 2-3%) of prophylactic surgeries and is more common in women > 40 years of age",
                      "High-grade serous carcinoma is found in 1-17% (average ~ 2-3%) of prophylactic surgeries and is more common in women > 40 years of age"
                    ]
                  },
                  {
                    "text": "Invasive carcinomaMajority are high-grade serous carcinomasMore likely to havesolid, pseudoendometrioid, andtransitional-like patterns compared to sporadic carcinomas (SET pattern)Better prognosis compared to sporadic carcinomas in first 10 yearsMay be due to greater response to therapyPlatinum-based therapy causing purine base cross-links that cells lackingBRCA1cannot repair accuratelyPoly ADP-ribose polymerase (PARP) inhibitors block alternative repair pathway, making cells more susceptible to DNA damage",
                    "sub_points": [
                      "Majority are high-grade serous carcinomas",
                      "More likely to havesolid, pseudoendometrioid, andtransitional-like patterns compared to sporadic carcinomas (SET pattern)",
                      "Better prognosis compared to sporadic carcinomas in first 10 yearsMay be due to greater response to therapyPlatinum-based therapy causing purine base cross-links that cells lackingBRCA1cannot repair accuratelyPoly ADP-ribose polymerase (PARP) inhibitors block alternative repair pathway, making cells more susceptible to DNA damage",
                      "May be due to greater response to therapyPlatinum-based therapy causing purine base cross-links that cells lackingBRCA1cannot repair accuratelyPoly ADP-ribose polymerase (PARP) inhibitors block alternative repair pathway, making cells more susceptible to DNA damage",
                      "Platinum-based therapy causing purine base cross-links that cells lackingBRCA1cannot repair accurately",
                      "Poly ADP-ribose polymerase (PARP) inhibitors block alternative repair pathway, making cells more susceptible to DNA damage"
                    ]
                  }
                ],
                "Other Cancers": [
                  {
                    "text": "Prostate: Possibly increased but lower than forBRCA2"
                  },
                  {
                    "text": "Pancreas: Possibly increased but lower than forBRCA2"
                  }
                ]
              },
              "Screening for BRCA1": {
                "Population to Be Tested": [
                  {
                    "text": "Recommendations for persons to be tested have broadened due to the importance of identifying germline mutationsAffected individuals can take steps to reduce risk of subsequent cancers or to detect them at an early stageCarcinomas associated withBRCA1mutations are being treated with specific therapiesFamily members may also be at riskAffected individuals can choose to not pass mutation to their offspring with assisted reproduction",
                    "sub_points": [
                      "Affected individuals can take steps to reduce risk of subsequent cancers or to detect them at an early stage",
                      "Carcinomas associated withBRCA1mutations are being treated with specific therapies",
                      "Family members may also be at risk",
                      "Affected individuals can choose to not pass mutation to their offspring with assisted reproduction"
                    ]
                  },
                  {
                    "text": "Criteria have been developed to identify individuals with increased likelihood of germline mutation using the following informationPersonal history of cancer, age at diagnosis, number of cancers, member of group with known increased incidence (e.g., Ashkenazi Jewish ancestry)Family history of cancer, age at diagnosis, number of cancers, identified germline mutationsPathologic features of cancers (type, presence ofBRCA1mutation)",
                    "sub_points": [
                      "Personal history of cancer, age at diagnosis, number of cancers, member of group with known increased incidence (e.g., Ashkenazi Jewish ancestry)",
                      "Family history of cancer, age at diagnosis, number of cancers, identified germline mutations",
                      "Pathologic features of cancers (type, presence ofBRCA1mutation)"
                    ]
                  },
                  {
                    "text": "Weighted scoring systems are available to determine risk, including BRCAPRO, Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA), and Manchester Scoring SystemBRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html",
                    "sub_points": [
                      "BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/",
                      "BOADICEA available at http://astor.som.jhmi.edu/BayesMendel/brcapro.html"
                    ]
                  },
                  {
                    "text": "American Society of Clinical Oncology (ASCO), National Comprehensive Cancer Network (NCCN), and others have issued recommendations for testing"
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Multigene panel testing has become more common than testing for single genesFor women meeting NCCN guidelines for testing forBRCA1/BRCA2, ~ 10% will be found to have germline mutationHowever, only ~ 1/3 of tested individuals will have a mutation inBRCA1/BRCA2; the rest have mutations in other genesIn addition, ~ 6% of individuals withBRCA1/BRCA2germline mutations do not meet criteria for testingThus, multigene testing can be helpful to detect major germline mutations conferring increased risk for breast cancer",
                    "sub_points": [
                      "For women meeting NCCN guidelines for testing forBRCA1/BRCA2, ~ 10% will be found to have germline mutationHowever, only ~ 1/3 of tested individuals will have a mutation inBRCA1/BRCA2; the rest have mutations in other genesIn addition, ~ 6% of individuals withBRCA1/BRCA2germline mutations do not meet criteria for testingThus, multigene testing can be helpful to detect major germline mutations conferring increased risk for breast cancer",
                      "However, only ~ 1/3 of tested individuals will have a mutation inBRCA1/BRCA2; the rest have mutations in other genes",
                      "In addition, ~ 6% of individuals withBRCA1/BRCA2germline mutations do not meet criteria for testing",
                      "Thus, multigene testing can be helpful to detect major germline mutations conferring increased risk for breast cancer"
                    ]
                  },
                  {
                    "text": "Comprehensive testing by a certified lab is necessary to detect all current gene variants known to increase cancer riskFull sequencing is required to detect all mutationsAdditional testing required to detect deletions and amplifications",
                    "sub_points": [
                      "Full sequencing is required to detect all mutations",
                      "Additional testing required to detect deletions and amplifications"
                    ]
                  },
                  {
                    "text": "Direct to consumer testing (not comprehensive)Assays for cancer risk marketed directly to individuals are generally not comprehensiveTypically only include most common mutations (e.g., the 3BRCA1/BRCA2mutations common in Ashkenazi Jewish populations)In one study, 40% of results from direct to consumer testing could not be validated by a certified laboratory",
                    "sub_points": [
                      "Assays for cancer risk marketed directly to individuals are generally not comprehensive",
                      "Typically only include most common mutations (e.g., the 3BRCA1/BRCA2mutations common in Ashkenazi Jewish populations)",
                      "In one study, 40% of results from direct to consumer testing could not be validated by a certified laboratory"
                    ]
                  }
                ],
                "Interpretation of Results": [
                  {
                    "text": "Alterations inBRCA1may be a variant with no increased risk, a variant that greatly increases risk, or the significance may currently be unknownIdeally, testing includes both pre- and posttest genetic counseling to help determine the best type of testing and to interpret results",
                    "sub_points": [
                      "Ideally, testing includes both pre- and posttest genetic counseling to help determine the best type of testing and to interpret results"
                    ]
                  },
                  {
                    "text": "Pathogenic variants (true positive)Some mutations are well documented to increase cancer risk in multiple members in affected familiesIt is helpful to test multiple members of families with newly detected variant in order to establish linkage",
                    "sub_points": [
                      "Some mutations are well documented to increase cancer risk in multiple members in affected familiesIt is helpful to test multiple members of families with newly detected variant in order to establish linkage",
                      "It is helpful to test multiple members of families with newly detected variant in order to establish linkage"
                    ]
                  },
                  {
                    "text": "Nonpathogenic variants (true negative)Results show normal sequence or benign polymorphismThese include point mutations that do not alter the type of amino acid",
                    "sub_points": [
                      "Results show normal sequence or benign polymorphismThese include point mutations that do not alter the type of amino acid",
                      "These include point mutations that do not alter the type of amino acid"
                    ]
                  },
                  {
                    "text": "Variants of uncertain significance (VUS) (inconclusive)Some alterations have not yet been linked to individuals with breast or ovarian cancerDetected in 7% of individuals tested (> 1,500 identified)More frequent in populations of non-European origin, as fewer individuals have been studiedVUS is problematic for those without personal or family history of cancer because linkage cannot be determined",
                    "sub_points": [
                      "Some alterations have not yet been linked to individuals with breast or ovarian cancer",
                      "Detected in 7% of individuals tested (> 1,500 identified)",
                      "More frequent in populations of non-European origin, as fewer individuals have been studied",
                      "VUS is problematic for those without personal or family history of cancer because linkage cannot be determined"
                    ]
                  }
                ]
              },
              "Medical Care of Individuals With BRCA1 Germline Mutations": {
                "Overview": [
                  {
                    "text": "Identification ofBRCA1germline mutation can have important implications for medical careNotification of relatives at possible risk, childbearing, chemoprevention, screening systemic therapy, and prophylactic surgery",
                    "sub_points": [
                      "Notification of relatives at possible risk, childbearing, chemoprevention, screening systemic therapy, and prophylactic surgery"
                    ]
                  }
                ],
                "Chemoprevention": [
                  {
                    "text": "Oral contraceptivesReduces risk of ovarian cancer by 50%Breast cancer risk may be increased by some types of oral contraceptives (results of studies have not been consistent)",
                    "sub_points": [
                      "Reduces risk of ovarian cancer by 50%",
                      "Breast cancer risk may be increased by some types of oral contraceptives (results of studies have not been consistent)"
                    ]
                  },
                  {
                    "text": "TamoxifenReduces riskEvidence derives from the observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifenProtective effect observed inBRCA1andBRCA2carriersBRCA1carriers appear to benefit despite predilection to develop ER(-) tumor for reasons that remain unclear",
                    "sub_points": [
                      "Reduces riskEvidence derives from the observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen",
                      "Evidence derives from the observed 50% reduction in risk of contralateral cancer among mutation carriers treated with tamoxifen",
                      "Protective effect observed inBRCA1andBRCA2carriersBRCA1carriers appear to benefit despite predilection to develop ER(-) tumor for reasons that remain unclear",
                      "BRCA1carriers appear to benefit despite predilection to develop ER(-) tumor for reasons that remain unclear"
                    ]
                  }
                ],
                "Breast Screening": [
                  {
                    "text": "Annual mammograms, MR imaging, and clinical breast examination are recommendedHowever, for women withBRCA1/BRCA2mutations undergoing regular screening, 15% of malignancies can be interval cancers (cancers detected as a palpable mass between screens)Compared to screen-detected cancers, interval cancers are larger, present at higher stage, and are more likely to be associated with positive lymph nodes",
                    "sub_points": [
                      "However, for women withBRCA1/BRCA2mutations undergoing regular screening, 15% of malignancies can be interval cancers (cancers detected as a palpable mass between screens)Compared to screen-detected cancers, interval cancers are larger, present at higher stage, and are more likely to be associated with positive lymph nodes",
                      "Compared to screen-detected cancers, interval cancers are larger, present at higher stage, and are more likely to be associated with positive lymph nodes"
                    ]
                  },
                  {
                    "text": "Mammography and MR may alternate every 6 months in order to reduce length of interval between screening"
                  }
                ],
                "Prophylactic Surgery": [
                  {
                    "text": "Bilateral mastectomy reduces breast cancer risk by 97%However, not all breast tissue can be removed and achieve acceptable cosmetic resultsGreatest benefit for patients before diagnosis of cancerAfter cancer has been diagnosed, there may be no benefit if distant metastases are presentClinically and radiologically occult carcinoma is found in 1-15% of patientsCancers are most often DCIS or small invasive carcinomas with negative lymph nodes",
                    "sub_points": [
                      "However, not all breast tissue can be removed and achieve acceptable cosmetic results",
                      "Greatest benefit for patients before diagnosis of cancerAfter cancer has been diagnosed, there may be no benefit if distant metastases are present",
                      "After cancer has been diagnosed, there may be no benefit if distant metastases are present",
                      "Clinically and radiologically occult carcinoma is found in 1-15% of patientsCancers are most often DCIS or small invasive carcinomas with negative lymph nodes",
                      "Cancers are most often DCIS or small invasive carcinomas with negative lymph nodes"
                    ]
                  },
                  {
                    "text": "Bilateral salpingo-oophorectomy reduces breast and ovarian cancer riskBreast cancer risk reduced by 50%Mechanism not well understood but may be due to decreased estrogen productionOvarian and fallopian tube cancer risk reduced by 50-96%4-5% risk of papillary serous carcinoma of peritoneum remains",
                    "sub_points": [
                      "Breast cancer risk reduced by 50%Mechanism not well understood but may be due to decreased estrogen production",
                      "Mechanism not well understood but may be due to decreased estrogen production",
                      "Ovarian and fallopian tube cancer risk reduced by 50-96%4-5% risk of papillary serous carcinoma of peritoneum remains",
                      "4-5% risk of papillary serous carcinoma of peritoneum remains"
                    ]
                  }
                ],
                "Systemic Therapy": [
                  {
                    "text": "For patients with advanced cancer, presence ofBRCA1germline mutation may alter type of treatment recommendedPlatinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitorsPARP inhibitors hinder DNA double-strand repair targeting DNA repair deficits with synthetic lethality effectsOptimal sequencing strategy (PARP inhibitors vs. immune checkpoint blockade) is controversialOlaparib or talazoparibRoutine genetic testing recommended for advanced HER2(-) breast cancer",
                    "sub_points": [
                      "Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitorsPARP inhibitors hinder DNA double-strand repair targeting DNA repair deficits with synthetic lethality effectsOptimal sequencing strategy (PARP inhibitors vs. immune checkpoint blockade) is controversial",
                      "PARP inhibitors hinder DNA double-strand repair targeting DNA repair deficits with synthetic lethality effects",
                      "Optimal sequencing strategy (PARP inhibitors vs. immune checkpoint blockade) is controversial",
                      "Olaparib or talazoparib",
                      "Routine genetic testing recommended for advanced HER2(-) breast cancer"
                    ]
                  }
                ],
                "Childbearing": [
                  {
                    "text": "With assisted reproduction, individuals can choose to not pass mutation on to their children"
                  }
                ],
                "BRCA1/BRCA2Mutation Screening": [
                  {
                    "text": "Detection of mutations helps inform treatments, facilitates evaluation of future risk, and guides interventions for high-risk family members"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "BRCA2: Hereditary Breast and Ovarian Cancer Syndrome 2": {
            "name": "BRCA2: Hereditary Breast and Ovarian Cancer Syndrome 2",
            "url": "https://app.pathprimer.com/document/bf02be90-fe77-420f-9545-218c1510cae1/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "TERMINOLOGY": {
                "Synonyms": [
                  {
                    "text": "BRCA2 syndrome"
                  },
                  {
                    "text": "Breast cancer 2 syndrome"
                  },
                  {
                    "text": "Early-onset breast-ovarian cancer syndrome"
                  },
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM) #600185"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Hereditary breast carcinoma (BC) &/or ovarian carcinoma resulting from inheritance of a germline mutation inBRCA2Deficient DNA repair leads to genomic instability, accumulating mutations, and tumor developmentEarly-onset and multiple primary BCsFamily history of breast or ovarian cancer",
                    "sub_points": [
                      "Deficient DNA repair leads to genomic instability, accumulating mutations, and tumor development",
                      "Early-onset and multiple primary BCs",
                      "Family history of breast or ovarian cancer"
                    ]
                  }
                ]
              },
              "EPIDEMIOLOGY": {
                "Incidence": [
                  {
                    "text": "0.1-0.7% of individualsSlightly more common thanBRCA1mutations",
                    "sub_points": [
                      "Slightly more common thanBRCA1mutations"
                    ]
                  },
                  {
                    "text": "Specific mutations are found at increased frequency in specific populationsAshkenazi Jewish population~ 1-3% of individuals6174delTThere are also 2 commonBRCA1mutationsIcelandic population0.6% of individuals999del5 detected in 38% of male patients and 10.4% of female patients with BCBRCA2mutations found in 90% of families with male and female BCAlso increased in Quebec (French Canadians) and other populations",
                    "sub_points": [
                      "Ashkenazi Jewish population~ 1-3% of individuals6174delTThere are also 2 commonBRCA1mutations",
                      "~ 1-3% of individuals",
                      "6174delT",
                      "There are also 2 commonBRCA1mutations",
                      "Icelandic population0.6% of individuals999del5 detected in 38% of male patients and 10.4% of female patients with BCBRCA2mutations found in 90% of families with male and female BC",
                      "0.6% of individuals",
                      "999del5 detected in 38% of male patients and 10.4% of female patients with BC",
                      "BRCA2mutations found in 90% of families with male and female BC",
                      "Also increased in Quebec (French Canadians) and other populations"
                    ]
                  }
                ],
                "Modifiers of Risk": [
                  {
                    "text": "Parity may increase risk (whereas it decreases risk forBRCA1carriers)"
                  },
                  {
                    "text": "Low-dose ionizing radiation to chest before age 20 increases risk"
                  },
                  {
                    "text": "Mutations in other genesNone yet well definedGenome-wide association studies (GWAS) are investigating possible associations",
                    "sub_points": [
                      "None yet well defined",
                      "Genome-wide association studies (GWAS) are investigating possible associations"
                    ]
                  }
                ],
                "Cancer Incidence": [
                  {
                    "text": "~ 2% of BCs are related toBRCA2germline mutations~ 50% of all BCs related to germline mutation are due toBRCA2Mean age ofBRCA2mutation BC lower than nonmutation BC",
                    "sub_points": [
                      "~ 50% of all BCs related to germline mutation are due toBRCA2",
                      "Mean age ofBRCA2mutation BC lower than nonmutation BC"
                    ]
                  },
                  {
                    "text": "~ 7% of ovarian cancers related toBRCA2germline mutations~ 27% of ovarian cancers due to germline mutation are related toBRCA2",
                    "sub_points": [
                      "~ 27% of ovarian cancers due to germline mutation are related toBRCA2"
                    ]
                  },
                  {
                    "text": "Most families with male and female BCs due toBRCA2"
                  }
                ]
              },
              "Genetics": {
                "BRCA2Gene": [
                  {
                    "text": "Located on 13q13.1"
                  },
                  {
                    "text": "Large 84 kb geneDoes not share sequence homology withBRCA1or other genes",
                    "sub_points": [
                      "Does not share sequence homology withBRCA1or other genes"
                    ]
                  },
                  {
                    "text": "27 coding exons"
                  },
                  {
                    "text": "Transcript is 10,930 base pairsProtein is 3,418 amino acids (390 kDa)No sequence homology with other proteins",
                    "sub_points": [
                      "Protein is 3,418 amino acids (390 kDa)",
                      "No sequence homology with other proteins"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritanceDe novo mutations are rare",
                    "sub_points": [
                      "De novo mutations are rare"
                    ]
                  },
                  {
                    "text": "> 1,000 different mutations identifiedMajority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absent; less common are full-length proteins with missense mutationsInactivating mutations impair conservative DNA repair and genomic stability functions",
                    "sub_points": [
                      "Majority are small deletions or insertionsResults in frameshift mutations, nonsense mutations, or splice site alterationsProtein may be truncated or absent; less common are full-length proteins with missense mutations",
                      "Results in frameshift mutations, nonsense mutations, or splice site alterations",
                      "Protein may be truncated or absent; less common are full-length proteins with missense mutations",
                      "Inactivating mutations impair conservative DNA repair and genomic stability functions"
                    ]
                  },
                  {
                    "text": "Central portion of gene identified as \"ovarian cancer cluster region\"Mutations in this region are 2x as likely to be associated with ovarian cancer, as are mutations in 5' or 3' regionRisk of BC with mutation in this region is lower",
                    "sub_points": [
                      "Mutations in this region are 2x as likely to be associated with ovarian cancer, as are mutations in 5' or 3' region",
                      "Risk of BC with mutation in this region is lower"
                    ]
                  },
                  {
                    "text": "Loss of heterozygosity (LOH) ofRB1frequent in BC withBRCA2germline mutationLOH ofRB1correlates with CDK4/6 inhibitors",
                    "sub_points": [
                      "LOH ofRB1correlates with CDK4/6 inhibitors"
                    ]
                  }
                ],
                "Protein Function": [
                  {
                    "text": "Central role in maintaining genome integrity, DNA repair, transcription, gametogenesis, and centrosome duplication"
                  },
                  {
                    "text": "Regulation of repair of DNA damageRepair of DNA double-stranded breaks through homologous recombination (HR)Promotes assembly of RAD51 on single-stranded DNA rather than double-stranded DNABRCA2interacts directly with RAD51 for transport to nuclear complexWithBRCA2mutations, RAD51 remains sequestered in cytoplasmMediator of core mechanism of HR",
                    "sub_points": [
                      "Repair of DNA double-stranded breaks through homologous recombination (HR)",
                      "Promotes assembly of RAD51 on single-stranded DNA rather than double-stranded DNABRCA2interacts directly with RAD51 for transport to nuclear complexWithBRCA2mutations, RAD51 remains sequestered in cytoplasm",
                      "BRCA2interacts directly with RAD51 for transport to nuclear complex",
                      "WithBRCA2mutations, RAD51 remains sequestered in cytoplasm",
                      "Mediator of core mechanism of HR"
                    ]
                  },
                  {
                    "text": "Deficient DNA repair in tumor withBRCA1/BRCA2mutations leads to genomic instability and potential sensitivity to DNA-damaging agentsTumor cells with HR deficiency; highly dependent on DNA repair pathways for single-stranded breaksThis pathway is regulated by enzyme poly(adenosine diphosphate-ribose) polymerase (PARP)PARP inhibitors (PARPi) have been developed as anticancer therapies and have been tested in clinical trials forBRCA1/BRCA2mutation tumors",
                    "sub_points": [
                      "Tumor cells with HR deficiency; highly dependent on DNA repair pathways for single-stranded breaksThis pathway is regulated by enzyme poly(adenosine diphosphate-ribose) polymerase (PARP)PARP inhibitors (PARPi) have been developed as anticancer therapies and have been tested in clinical trials forBRCA1/BRCA2mutation tumors",
                      "This pathway is regulated by enzyme poly(adenosine diphosphate-ribose) polymerase (PARP)",
                      "PARP inhibitors (PARPi) have been developed as anticancer therapies and have been tested in clinical trials forBRCA1/BRCA2mutation tumors"
                    ]
                  }
                ],
                "Targeting Cancer Cell Vulnerabilities": [
                  {
                    "text": "Cancer cells withBRCA1/BRCA2mutation are deficient in HR DNA repair"
                  },
                  {
                    "text": "PARP is a family of proteins involved in a number of cellular processes, including DNA repair, genomic stabilityIn cells withBRCA1/BRCA2mutation, inhibition of PARP causes cell death due to accumulation of irreparable DNA damage (synthetic lethality)",
                    "sub_points": [
                      "In cells withBRCA1/BRCA2mutation, inhibition of PARP causes cell death due to accumulation of irreparable DNA damage (synthetic lethality)"
                    ]
                  },
                  {
                    "text": "In clinical trials, PARPi demonstrate encouraging efficacy in BRCA-mutated BCs"
                  },
                  {
                    "text": "Based on trials, American Society of Clinical Oncology (ASCO) recommends 1 year of adjuvant PARPi in HER2(-)BRCA1-/BRCA2-mutated BC following initial therapy"
                  }
                ]
              },
              "Clinical Implications and Ancillary Tests": {
                "Population to Be Tested": [
                  {
                    "text": "ASCO recommends that patients with > 10% mutation risk undergo testing85% of carriers will be detected using this 10% cutoff",
                    "sub_points": [
                      "85% of carriers will be detected using this 10% cutoff"
                    ]
                  },
                  {
                    "text": "National Institute for Health and Clinical Excellence in United Kingdom recommends testing individuals with > 20% mutation risk"
                  },
                  {
                    "text": "Counseling should occur before testing to ensure patients are aware of implications for themselves and their families"
                  }
                ],
                "Clinical Criteria": [
                  {
                    "text": "History of BC in women < 40 years of age"
                  },
                  {
                    "text": "BC in 1st-degree relatives (mother, sister, daughter)Risk increased if BC diagnosed at young ageRisk increased if individuals have multiple BCs",
                    "sub_points": [
                      "Risk increased if BC diagnosed at young age",
                      "Risk increased if individuals have multiple BCs"
                    ]
                  },
                  {
                    "text": "Risk increased if male with BC is in family"
                  },
                  {
                    "text": "Risk increased if ovarian cancers are also present in family"
                  },
                  {
                    "text": "Risk increased if relative has known mutation"
                  }
                ],
                "Calculating Risk": [
                  {
                    "text": "There are multiple models to predict probability of an individual carrying a germlineBRCA1orBRCA2mutationEmpiric modelsDo not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute modelGenetic risk prediction modelsMake assumptions about number of genes and allele frequenciesInclude information about relationships among individuals in kindredAccuracy depends on validity of assumptionsExamples include BRCAPRO and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at https://ccge.medschl.cam.ac.uk/boadicea/boadicea-web-application",
                    "sub_points": [
                      "Empiric modelsDo not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute model",
                      "Do not make assumptions about genetic risks (e.g., mutation frequency, mode of inheritance, penetrance)",
                      "Examples include Penn II model, Myriad II (Frank) model, and National Cancer Institute model",
                      "Genetic risk prediction modelsMake assumptions about number of genes and allele frequenciesInclude information about relationships among individuals in kindredAccuracy depends on validity of assumptionsExamples include BRCAPRO and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/BOADICEA available at https://ccge.medschl.cam.ac.uk/boadicea/boadicea-web-application",
                      "Make assumptions about number of genes and allele frequencies",
                      "Include information about relationships among individuals in kindred",
                      "Accuracy depends on validity of assumptions",
                      "Examples include BRCAPRO and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA)",
                      "BRCAPRO available at http://www4.utsouthwestern.edu/breasthealth/cagene/",
                      "BOADICEA available at https://ccge.medschl.cam.ac.uk/boadicea/boadicea-web-application"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "Full sequencing required to detect all mutations"
                  },
                  {
                    "text": "Additional testing required to detect large deletions and amplifications18% of genetic changes are not detected by standard testing",
                    "sub_points": [
                      "18% of genetic changes are not detected by standard testing"
                    ]
                  },
                  {
                    "text": "Testing is performed in reference labs, such as Myriad Genetics"
                  },
                  {
                    "text": "Targeted mutation analysis may be population or family specificIndividuals of some ethnic backgrounds are at higher risk for certain mutationsSpecific mutation may be sought if there is affected relative with known mutation",
                    "sub_points": [
                      "Individuals of some ethnic backgrounds are at higher risk for certain mutations",
                      "Specific mutation may be sought if there is affected relative with known mutation"
                    ]
                  }
                ],
                "Interpretation of Results": [
                  {
                    "text": "Mutation associated with BC in other familiesPatient classified as having BRCA2 syndromeTesting of additional family members should be considered",
                    "sub_points": [
                      "Patient classified as having BRCA2 syndrome",
                      "Testing of additional family members should be considered"
                    ]
                  },
                  {
                    "text": "Mutation linked to relative with BCTesting of additional individuals in family may be helpful to establish definite linkage",
                    "sub_points": [
                      "Testing of additional individuals in family may be helpful to establish definite linkage"
                    ]
                  },
                  {
                    "text": "Mutation known to be benign or have low clinical significanceMutations that do not change amino acid typeMutations known to occur in individuals without cancer",
                    "sub_points": [
                      "Mutations that do not change amino acid type",
                      "Mutations known to occur in individuals without cancer"
                    ]
                  },
                  {
                    "text": "Variant of uncertain significance (VUS)Not yet linked to individual with BCDetected in 7% of individuals (> 1,500 identified)More frequent in populations of non-European ancestry",
                    "sub_points": [
                      "Not yet linked to individual with BC",
                      "Detected in 7% of individuals (> 1,500 identified)",
                      "More frequent in populations of non-European ancestry"
                    ]
                  }
                ],
                "Immunoperoxidase Studies": [
                  {
                    "text": "Majority ofBRCA2-associated carcinomas are positive for estrogen receptor (ER) and negative for HER2Therefore, these studies are not useful for distinguishingBRCA2-related cancers from sporadic cancers",
                    "sub_points": [
                      "Therefore, these studies are not useful for distinguishingBRCA2-related cancers from sporadic cancers"
                    ]
                  },
                  {
                    "text": "BRCA2 protein can be detected by immunohistochemistryNormal tissues express protein in nucleusSome, but not all,BRCA2-related cancers will lack positivityThis study is not generally used clinically",
                    "sub_points": [
                      "Normal tissues express protein in nucleus",
                      "Some, but not all,BRCA2-related cancers will lack positivity",
                      "This study is not generally used clinically"
                    ]
                  }
                ]
              },
              "Associated Neoplasms": {
                "Female Breast Cancer": [
                  {
                    "text": "Risk: ~ 45% lifetime riskGermline BRCA mutation carriers usually develop BC at a younger age and have more aggressive behaviorVaries by mutation; may be modified by mutations in additional genesMean age ofBRCA2-mutation BC lower than nonmutation BC",
                    "sub_points": [
                      "Germline BRCA mutation carriers usually develop BC at a younger age and have more aggressive behavior",
                      "Varies by mutation; may be modified by mutations in additional genes",
                      "Mean age ofBRCA2-mutation BC lower than nonmutation BC"
                    ]
                  },
                  {
                    "text": "HistologyMore likely moderately to poorly differentiatedNo specific histologic typePushing marginsLack of tubule formationSome studies have suggested higher incidence of tubulolobular and pleomorphic lobular carcinomasOther series have not shown significant differences betweenBRCA2carcinomas and sporadic carcinomasCarcinomas are frequently associated with ductal carcinoma in situ",
                    "sub_points": [
                      "More likely moderately to poorly differentiated",
                      "No specific histologic typePushing marginsLack of tubule formationSome studies have suggested higher incidence of tubulolobular and pleomorphic lobular carcinomasOther series have not shown significant differences betweenBRCA2carcinomas and sporadic carcinomasCarcinomas are frequently associated with ductal carcinoma in situ",
                      "Pushing margins",
                      "Lack of tubule formation",
                      "Some studies have suggested higher incidence of tubulolobular and pleomorphic lobular carcinomas",
                      "Other series have not shown significant differences betweenBRCA2carcinomas and sporadic carcinomas",
                      "Carcinomas are frequently associated with ductal carcinoma in situ"
                    ]
                  },
                  {
                    "text": "Majority are positive for estrogen receptor (ER)HER2 overexpression is rare (< 5%), lower than incidence in sporadic BC",
                    "sub_points": [
                      "HER2 overexpression is rare (< 5%), lower than incidence in sporadic BC"
                    ]
                  },
                  {
                    "text": "TP53mutations (30-65%) are less common than inBRCA1-associated cancers (> 90%)"
                  },
                  {
                    "text": "Majority classified as luminal B by gene expression profiling"
                  },
                  {
                    "text": "Mutations inBRCA2are not associated with poorer outcome in 1st-line metastatic setting in multivariate analysis"
                  },
                  {
                    "text": "ER(+), germlineBRCA1-/BRCA2-mutation BC had ODX recurrence score 3x higher than nonmutation BC"
                  }
                ],
                "Male Breast Cancer": [
                  {
                    "text": "Risk: ~ 7% lifetime risk (0.07% in general population)8-16% of male BCs are in individuals withBRCA2mutations60-75% chance thatBRCA2mutation exists in families with ≥ 1 male with BCAssociation withBRCA1is less common (< 4% of all male BCs)",
                    "sub_points": [
                      "8-16% of male BCs are in individuals withBRCA2mutations60-75% chance thatBRCA2mutation exists in families with ≥ 1 male with BCAssociation withBRCA1is less common (< 4% of all male BCs)",
                      "60-75% chance thatBRCA2mutation exists in families with ≥ 1 male with BC",
                      "Association withBRCA1is less common (< 4% of all male BCs)"
                    ]
                  },
                  {
                    "text": "HistologyNo specific histologic features reported",
                    "sub_points": [
                      "No specific histologic features reported"
                    ]
                  }
                ],
                "Ovarian, Fallopian Tube, and Peritoneal Carcinoma": [
                  {
                    "text": "Risk: ~ 11-18% lifetime riskRisk for ovarian cancer lower than that observed inBRCA1mutation carriers (40-50% lifetime risk)",
                    "sub_points": [
                      "Risk for ovarian cancer lower than that observed inBRCA1mutation carriers (40-50% lifetime risk)"
                    ]
                  },
                  {
                    "text": "Age, average onset is 55-58 years (63 years in general population)Young women (< 40) with ovarian/tubal/peritoneal carcinoma unlikely to haveBRCA1orBRCA2mutationThese women tend to have borderline tumors and cancers of more favorable histologic types",
                    "sub_points": [
                      "Young women (< 40) with ovarian/tubal/peritoneal carcinoma unlikely to haveBRCA1orBRCA2mutationThese women tend to have borderline tumors and cancers of more favorable histologic types",
                      "These women tend to have borderline tumors and cancers of more favorable histologic types"
                    ]
                  },
                  {
                    "text": "Fallopian tubeSerous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 5-7% of prophylactic salpingo-oophorectomies60-85% involve fimbriated end of fallopian tubeEntire tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful",
                    "sub_points": [
                      "Serous tubal intraepithelial carcinoma (80%) and endometrioid tubal carcinoma (20%) are found in ~ 5-7% of prophylactic salpingo-oophorectomies60-85% involve fimbriated end of fallopian tubeEntire tube should be examined microscopicallyImmunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful",
                      "60-85% involve fimbriated end of fallopian tube",
                      "Entire tube should be examined microscopically",
                      "Immunohistochemical studies for p53 and MIB-1 (Ki-67) can be helpful"
                    ]
                  },
                  {
                    "text": "OvaryCarcinomas are usually high-grade serous carcinomasOnly ~ 2% of tumors are mucinous or borderlineEndometrioid, clear cell, and papillary carcinomas occur but are rare",
                    "sub_points": [
                      "Carcinomas are usually high-grade serous carcinomasOnly ~ 2% of tumors are mucinous or borderlineEndometrioid, clear cell, and papillary carcinomas occur but are rare",
                      "Only ~ 2% of tumors are mucinous or borderline",
                      "Endometrioid, clear cell, and papillary carcinomas occur but are rare"
                    ]
                  },
                  {
                    "text": "Primary peritoneal carcinomaWomen have ~ 4% risk after bilateral prophylactic salpingo-oophorectomy",
                    "sub_points": [
                      "Women have ~ 4% risk after bilateral prophylactic salpingo-oophorectomy"
                    ]
                  }
                ],
                "Other Cancers": [
                  {
                    "text": "Prostate: Relative risk is 4.6%1-2% of cancers diagnosed before age 65Increased prostate cancer risk is not consistent finding across all studies",
                    "sub_points": [
                      "1-2% of cancers diagnosed before age 65",
                      "Increased prostate cancer risk is not consistent finding across all studies"
                    ]
                  },
                  {
                    "text": "Pancreas, gallbladder, and bile duct: Relative risk is 3.5%Presence of pancreatic cancer in BC family may be a predictor ofBRCA2mutation",
                    "sub_points": [
                      "Presence of pancreatic cancer in BC family may be a predictor ofBRCA2mutation"
                    ]
                  },
                  {
                    "text": "GastrointestinalStomach: Relative risk is 2.6%As withBRCA1, initial reports of increased colon cancer risk have generally not been replicated",
                    "sub_points": [
                      "Stomach: Relative risk is 2.6%",
                      "As withBRCA1, initial reports of increased colon cancer risk have generally not been replicated"
                    ]
                  }
                ]
              },
              "Cancer Risk Management": {
                "Chemoprevention": [
                  {
                    "text": "Oral contraceptivesReduce risk of ovarian cancer by 50%BC risk may be increased by some types of oral contraceptives; studies have not been consistent",
                    "sub_points": [
                      "Reduce risk of ovarian cancer by 50%",
                      "BC risk may be increased by some types of oral contraceptives; studies have not been consistent"
                    ]
                  },
                  {
                    "text": "TamoxifenReduces riskEvidence derives from observed 50% reduction in risk of contralateral BC among mutation carriers treated with tamoxifen",
                    "sub_points": [
                      "Reduces riskEvidence derives from observed 50% reduction in risk of contralateral BC among mutation carriers treated with tamoxifen",
                      "Evidence derives from observed 50% reduction in risk of contralateral BC among mutation carriers treated with tamoxifen"
                    ]
                  }
                ],
                "Screening": [
                  {
                    "text": "MammographyShould begin at 10 years younger than youngest affected family memberMay have limited sensitivity, as young women often have dense breast tissue",
                    "sub_points": [
                      "Should begin at 10 years younger than youngest affected family member",
                      "May have limited sensitivity, as young women often have dense breast tissue"
                    ]
                  },
                  {
                    "text": "Magnetic resonance (MR)MR detects cancers due to blood flow and is more sensitive in detecting BC in dense breastsHighly sensitive but not very specific; false-positive results are frequent",
                    "sub_points": [
                      "MR detects cancers due to blood flow and is more sensitive in detecting BC in dense breasts",
                      "Highly sensitive but not very specific; false-positive results are frequent"
                    ]
                  }
                ],
                "Prophylactic Surgery": [
                  {
                    "text": "Bilateral mastectomy reduces BC risk by 97%However, not all breast tissue can be removed and achieve acceptable cosmetic resultsGreatest benefit for patients prior to BC diagnosisAfter BC has been diagnosed, there may be no benefit if distant metastases are present",
                    "sub_points": [
                      "However, not all breast tissue can be removed and achieve acceptable cosmetic results",
                      "Greatest benefit for patients prior to BC diagnosisAfter BC has been diagnosed, there may be no benefit if distant metastases are present",
                      "After BC has been diagnosed, there may be no benefit if distant metastases are present"
                    ]
                  },
                  {
                    "text": "Bilateral salpingo-oophorectomy reduces breast and ovarian cancer riskBC reduced by 50%Mechanism not well understood but may be due to decreased estrogen productionOvarian and fallopian tube cancer reduced by 70-96%There remains a 4% risk of papillary serous carcinoma of peritoneum",
                    "sub_points": [
                      "BC reduced by 50%Mechanism not well understood but may be due to decreased estrogen production",
                      "Mechanism not well understood but may be due to decreased estrogen production",
                      "Ovarian and fallopian tube cancer reduced by 70-96%There remains a 4% risk of papillary serous carcinoma of peritoneum",
                      "There remains a 4% risk of papillary serous carcinoma of peritoneum"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Hereditary Breast Cancer": {
            "name": "Hereditary Breast Cancer",
            "url": "https://app.pathprimer.com/document/bd673ca0-ba01-4b0f-96e2-bf134b2f21ff/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "KEY FACTS": {
                "Etiology/Pathogenesis": [
                  {
                    "text": "Long recognized that many women with breast cancer also have affected relatives"
                  },
                  {
                    "text": "~ 10-25% of women with breast cancer have 1st-degree relative (parent, sister, daughter) with breast cancer"
                  },
                  {
                    "text": "Increased risk is associated with families with premenopausal breast cancer, multiple affected individuals, individuals with multiple cancers, and certain types of breast and other cancers"
                  },
                  {
                    "text": "Familial cancers associated with germline mutations: ~ 1/2 of familial cases or 5-10% of all breast cancers15 major germline mutations contribute to breast cancer riskHigh-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial riskModerate-risk genes (2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial riskLow-risk genes (differing results in studies):BARD1,BRIP1,NBN, RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial riskFeatures incommonAutosomal dominant inheritanceInherited via females and malesMajority of genes are associated with DNA repair pathwaysBreast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateralRisk of some nonbreast cancers increased",
                    "sub_points": [
                      "15 major germline mutations contribute to breast cancer riskHigh-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial riskModerate-risk genes (2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial riskLow-risk genes (differing results in studies):BARD1,BRIP1,NBN, RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial risk",
                      "High-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial risk",
                      "Together, these genes account for ~ 20% of familial risk",
                      "Moderate-risk genes (2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial risk",
                      "Together, these genes account for ~ 5% of familial risk",
                      "Low-risk genes (differing results in studies):BARD1,BRIP1,NBN, RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial risk",
                      "These genes and numerous other low-risk genes (> 170) account for ~ 18% of familial risk",
                      "Features incommonAutosomal dominant inheritanceInherited via females and malesMajority of genes are associated with DNA repair pathwaysBreast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateralRisk of some nonbreast cancers increased",
                      "Autosomal dominant inheritanceInherited via females and males",
                      "Inherited via females and males",
                      "Majority of genes are associated with DNA repair pathways",
                      "Breast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral",
                      "Risk of some nonbreast cancers increased"
                    ]
                  },
                  {
                    "text": "Familial cancersnotassociated with identified germline mutations: ~ 1/2 of familial cases or 5-10% of all breast cancersSource of risk in these families has not yet been identified",
                    "sub_points": [
                      "Source of risk in these families has not yet been identified"
                    ]
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Hereditary Breast Cancer": [
                  {
                    "text": "Long recognized that many women with breast cancer also have affected relatives~ 10-25% of women with breast cancer have 1st-degree relative (parent, sister, daughter) with breast cancerHaving affected 1st-degree relative increases risk by 2-3xIncreased risk is associated with families with premenopausal breast cancer, multiple affected individuals, individuals with multiple cancers, and certain types of breast and other cancersHowever, most common family history is mother developing breast cancer after menopauseSporadic breast cancer in this age group is very commonDoes not increase risk of breast cancer for daughter",
                    "sub_points": [
                      "~ 10-25% of women with breast cancer have 1st-degree relative (parent, sister, daughter) with breast cancerHaving affected 1st-degree relative increases risk by 2-3x",
                      "Having affected 1st-degree relative increases risk by 2-3x",
                      "Increased risk is associated with families with premenopausal breast cancer, multiple affected individuals, individuals with multiple cancers, and certain types of breast and other cancersHowever, most common family history is mother developing breast cancer after menopauseSporadic breast cancer in this age group is very commonDoes not increase risk of breast cancer for daughter",
                      "However, most common family history is mother developing breast cancer after menopauseSporadic breast cancer in this age group is very commonDoes not increase risk of breast cancer for daughter",
                      "Sporadic breast cancer in this age group is very common",
                      "Does not increase risk of breast cancer for daughter"
                    ]
                  },
                  {
                    "text": "Familial cancers associated with germline mutations: ~ 1/2 of familial cases or 5-10% of all breast cancers15 major germline mutations contribute to breast cancer riskHigh-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial riskModerate-risk genes (2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial riskLow-risk genes (differing results in studies):BARD1,BRIP1,NBN,RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial riskMany of these genes are functionally related to each otherGenes functionally related toBRCA1andBRCA2:BARD1,CHEK2,NBN,RAD51DGenes in Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51BFeatures common to all major germline mutationsAutosomal dominant inheritanceNormal protein function is lost when remaining wild-type allele is rendered nonfunctional or abnormal; however, in some cases, mutated protein interferes with function of normal protein (dominant negative mutations)Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutationsInherited via both females and males: Multiple individuals in family are usually affectedMajority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for breast cancer has not been explainedBreast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutationsRisk of some nonbreast cancers is also increasedFeatures specific to certain germline mutationsType of breast carcinomaBRCA1: Negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 with basal-like gene expression pattern (~ 90%)BRCA2: ER positive, HER2 negative, high-grade, luminal B-type gene expression patternTP53: ER positive, HER2 positive (~ 40-50%)CDH1: Lobular carcinomasATM: ER positive, HER2 negative (~ 80%), ER positive, HER2 positive (~ 15%)Specific tumor types have not been reported for other mutationsRisk of male breast cancer15-20% of males with breast cancer have family history of breast or ovarian cancerIncreased risk for some mutations (BRCA2lifetime risk: 7%;BRCA1lifetime risk: 1.8%;PTENlifetime risk: Unknown)Penetrance (percentage of carriers who develop cancer)> 95% lifetime risk for some mutationsOther genes have lower penetrance (20% or lower lifetime risk)Spectrum of nonbreast cancersTypes of other cancers vary according to gene and sometimes are different for specific mutationsFounder mutations in ethnic populationsSome populations have very high incidences of specific mutationsHomozygosityHomozygosity for some mutations confers disease (e.g.,BRCA2andBRIP1: Fanconi anemia;ATM: Ataxia-telangiectasia)Homozygosity for other mutations is likely lethal (e.g.,BRCA1)Role of somatic mutations in genes responsible for hereditary breast cancerTP53is frequently mutated in sporadic carcinomasBRCA1andBRCA2mutations are rareGenes may be inactivated by other mechanisms, such as methylationCDH1is inactivated by somatic mutations in lobular cancers",
                    "sub_points": [
                      "15 major germline mutations contribute to breast cancer riskHigh-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial riskModerate-risk genes (2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial riskLow-risk genes (differing results in studies):BARD1,BRIP1,NBN,RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial risk",
                      "High-risk genes (≥ 4x increased risk):BRCA1,BRCA2,TP53,CDH1,PALB2,PTEN,STK11Together, these genes account for ~ 20% of familial risk",
                      "Together, these genes account for ~ 20% of familial risk",
                      "Moderate-risk genes (2-4x increased risk):ATM,CHEK2Together, these genes account for ~ 5% of familial risk",
                      "Together, these genes account for ~ 5% of familial risk",
                      "Low-risk genes (differing results in studies):BARD1,BRIP1,NBN,RAD51C,RAD51D,NF1These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial risk",
                      "These genes and numerous other low-risk genes (> 170 genes) account for ~ 18% of familial risk",
                      "Many of these genes are functionally related to each otherGenes functionally related toBRCA1andBRCA2:BARD1,CHEK2,NBN,RAD51DGenes in Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51B",
                      "Genes functionally related toBRCA1andBRCA2:BARD1,CHEK2,NBN,RAD51D",
                      "Genes in Fanconi anemia pathway:PALB2,RAD51C(FANCO),BRIP1,RAD51B",
                      "Features common to all major germline mutationsAutosomal dominant inheritanceNormal protein function is lost when remaining wild-type allele is rendered nonfunctional or abnormal; however, in some cases, mutated protein interferes with function of normal protein (dominant negative mutations)Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutationsInherited via both females and males: Multiple individuals in family are usually affectedMajority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for breast cancer has not been explainedBreast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutationsRisk of some nonbreast cancers is also increased",
                      "Autosomal dominant inheritanceNormal protein function is lost when remaining wild-type allele is rendered nonfunctional or abnormal; however, in some cases, mutated protein interferes with function of normal protein (dominant negative mutations)Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutationsInherited via both females and males: Multiple individuals in family are usually affected",
                      "Normal protein function is lost when remaining wild-type allele is rendered nonfunctional or abnormal; however, in some cases, mutated protein interferes with function of normal protein (dominant negative mutations)",
                      "Specific mutations may vary in degree of risk: Truncating mutations (in general) confer greater risk than missense mutations",
                      "Inherited via both females and males: Multiple individuals in family are usually affected",
                      "Majority of identified genes are associated with DNA repair pathwaysAct as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferationRelative tissue specificity for breast cancer has not been explained",
                      "Act as tumor suppressor genes in normal cells to maintain DNA integrity and control proliferation",
                      "Relative tissue specificity for breast cancer has not been explained",
                      "Breast cancers occur at earlier ages compared to sporadic cancers and are often multiple and bilateral1st mutation present at birthDestabilization of genome increases likelihood of additional mutations",
                      "1st mutation present at birth",
                      "Destabilization of genome increases likelihood of additional mutations",
                      "Risk of some nonbreast cancers is also increased",
                      "Features specific to certain germline mutationsType of breast carcinomaBRCA1: Negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 with basal-like gene expression pattern (~ 90%)BRCA2: ER positive, HER2 negative, high-grade, luminal B-type gene expression patternTP53: ER positive, HER2 positive (~ 40-50%)CDH1: Lobular carcinomasATM: ER positive, HER2 negative (~ 80%), ER positive, HER2 positive (~ 15%)Specific tumor types have not been reported for other mutationsRisk of male breast cancer15-20% of males with breast cancer have family history of breast or ovarian cancerIncreased risk for some mutations (BRCA2lifetime risk: 7%;BRCA1lifetime risk: 1.8%;PTENlifetime risk: Unknown)Penetrance (percentage of carriers who develop cancer)> 95% lifetime risk for some mutationsOther genes have lower penetrance (20% or lower lifetime risk)Spectrum of nonbreast cancersTypes of other cancers vary according to gene and sometimes are different for specific mutationsFounder mutations in ethnic populationsSome populations have very high incidences of specific mutationsHomozygosityHomozygosity for some mutations confers disease (e.g.,BRCA2andBRIP1: Fanconi anemia;ATM: Ataxia-telangiectasia)Homozygosity for other mutations is likely lethal (e.g.,BRCA1)",
                      "Type of breast carcinomaBRCA1: Negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 with basal-like gene expression pattern (~ 90%)BRCA2: ER positive, HER2 negative, high-grade, luminal B-type gene expression patternTP53: ER positive, HER2 positive (~ 40-50%)CDH1: Lobular carcinomasATM: ER positive, HER2 negative (~ 80%), ER positive, HER2 positive (~ 15%)Specific tumor types have not been reported for other mutations",
                      "BRCA1: Negative for estrogen receptor (ER), progesterone receptor (PR), and HER2 with basal-like gene expression pattern (~ 90%)",
                      "BRCA2: ER positive, HER2 negative, high-grade, luminal B-type gene expression pattern",
                      "TP53: ER positive, HER2 positive (~ 40-50%)",
                      "CDH1: Lobular carcinomas",
                      "ATM: ER positive, HER2 negative (~ 80%), ER positive, HER2 positive (~ 15%)",
                      "Specific tumor types have not been reported for other mutations",
                      "Risk of male breast cancer15-20% of males with breast cancer have family history of breast or ovarian cancerIncreased risk for some mutations (BRCA2lifetime risk: 7%;BRCA1lifetime risk: 1.8%;PTENlifetime risk: Unknown)",
                      "15-20% of males with breast cancer have family history of breast or ovarian cancer",
                      "Increased risk for some mutations (BRCA2lifetime risk: 7%;BRCA1lifetime risk: 1.8%;PTENlifetime risk: Unknown)",
                      "Penetrance (percentage of carriers who develop cancer)> 95% lifetime risk for some mutationsOther genes have lower penetrance (20% or lower lifetime risk)",
                      "> 95% lifetime risk for some mutations",
                      "Other genes have lower penetrance (20% or lower lifetime risk)",
                      "Spectrum of nonbreast cancersTypes of other cancers vary according to gene and sometimes are different for specific mutations",
                      "Types of other cancers vary according to gene and sometimes are different for specific mutations",
                      "Founder mutations in ethnic populationsSome populations have very high incidences of specific mutations",
                      "Some populations have very high incidences of specific mutations",
                      "HomozygosityHomozygosity for some mutations confers disease (e.g.,BRCA2andBRIP1: Fanconi anemia;ATM: Ataxia-telangiectasia)Homozygosity for other mutations is likely lethal (e.g.,BRCA1)",
                      "Homozygosity for some mutations confers disease (e.g.,BRCA2andBRIP1: Fanconi anemia;ATM: Ataxia-telangiectasia)",
                      "Homozygosity for other mutations is likely lethal (e.g.,BRCA1)",
                      "Role of somatic mutations in genes responsible for hereditary breast cancerTP53is frequently mutated in sporadic carcinomasBRCA1andBRCA2mutations are rareGenes may be inactivated by other mechanisms, such as methylationCDH1is inactivated by somatic mutations in lobular cancers",
                      "TP53is frequently mutated in sporadic carcinomas",
                      "BRCA1andBRCA2mutations are rareGenes may be inactivated by other mechanisms, such as methylation",
                      "Genes may be inactivated by other mechanisms, such as methylation",
                      "CDH1is inactivated by somatic mutations in lobular cancers"
                    ]
                  },
                  {
                    "text": "Familial cancersnotassociated with identified germline mutations:~ 1/2 of familial cases or 5-10% of all breast cancersSource of risk in these families has not yet been identified",
                    "sub_points": [
                      "Source of risk in these families has not yet been identified"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "BRCA1(Hereditary Breast and Ovarian Cancer Syndrome)": [
                  {
                    "text": "FunctionBreastcancer 1 (BRCA1) encodes for protein with central role in DNA repair, regulation of cell cycle checkpoints in response to DNA damage, and transcriptionRequired for error-free DNA double-strand break repairBRCA1function is required for transactivation of ER gene promoterMay explain why 90% ofBRCA1-associated carcinomas are negative for ER",
                    "sub_points": [
                      "Breastcancer 1 (BRCA1) encodes for protein with central role in DNA repair, regulation of cell cycle checkpoints in response to DNA damage, and transcriptionRequired for error-free DNA double-strand break repair",
                      "Required for error-free DNA double-strand break repair",
                      "BRCA1function is required for transactivation of ER gene promoterMay explain why 90% ofBRCA1-associated carcinomas are negative for ER",
                      "May explain why 90% ofBRCA1-associated carcinomas are negative for ER"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1-0.3%More common in some ethnic groups: Ashkenazi Jews, Finns, French CanadiansMean age of onset is 44 years, but age can vary with specific mutationsMutation can be suspected in young patients (35% risk for patients < 30 years of age with ER-negative poorly differentiated cancer)",
                    "sub_points": [
                      "More common in some ethnic groups: Ashkenazi Jews, Finns, French Canadians",
                      "Mean age of onset is 44 years, but age can vary with specific mutations",
                      "Mutation can be suspected in young patients (35% risk for patients < 30 years of age with ER-negative poorly differentiated cancer)"
                    ]
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F):40-90% (relative risk 11.4)Magnitude of risk can vary for different mutations and for different types of cancersResponsible for ~ 1/2 of cancers known to be due to germline mutation (~ 2% of all breast cancers)",
                    "sub_points": [
                      "Magnitude of risk can vary for different mutations and for different types of cancers",
                      "Responsible for ~ 1/2 of cancers known to be due to germline mutation (~ 2% of all breast cancers)"
                    ]
                  },
                  {
                    "text": "Breast cancer~ 70-80% ofBRCA1cancers share same gene expression pattern with basal-type carcinomas defined by gene expression profilingBasal-type carcinomas overlap with triple negative breast cancer (TNBC) (lack expression of hormone receptors and HER2) by ~ 80%10-25% of women < 50 years of age with TNBC haveBRCA1mutationMajority have somatic mutations in p53Majority positive for basal markers, such as EGFR (HER1), and high molecular weight cytokeratins (e.g., 5/6, 14)Majority (~ 80%) of invasive carcinomas have distinctive morphologyCircumscribed growth pattern with pushing borders, dense lymphocytic infiltrateHigh nuclear grade and high proliferative rate~ 20-30% ofBRCA1cancers are ER positive and HER2 negativeMore common in women developing cancer at age > 50 years~ 85% show loss of wild-typeBRCA1allele supporting that these are not sporadic cancers",
                    "sub_points": [
                      "~ 70-80% ofBRCA1cancers share same gene expression pattern with basal-type carcinomas defined by gene expression profilingBasal-type carcinomas overlap with triple negative breast cancer (TNBC) (lack expression of hormone receptors and HER2) by ~ 80%10-25% of women < 50 years of age with TNBC haveBRCA1mutationMajority have somatic mutations in p53Majority positive for basal markers, such as EGFR (HER1), and high molecular weight cytokeratins (e.g., 5/6, 14)",
                      "Basal-type carcinomas overlap with triple negative breast cancer (TNBC) (lack expression of hormone receptors and HER2) by ~ 80%",
                      "10-25% of women < 50 years of age with TNBC haveBRCA1mutation",
                      "Majority have somatic mutations in p53",
                      "Majority positive for basal markers, such as EGFR (HER1), and high molecular weight cytokeratins (e.g., 5/6, 14)",
                      "Majority (~ 80%) of invasive carcinomas have distinctive morphologyCircumscribed growth pattern with pushing borders, dense lymphocytic infiltrateHigh nuclear grade and high proliferative rate",
                      "Circumscribed growth pattern with pushing borders, dense lymphocytic infiltrate",
                      "High nuclear grade and high proliferative rate",
                      "~ 20-30% ofBRCA1cancers are ER positive and HER2 negativeMore common in women developing cancer at age > 50 years~ 85% show loss of wild-typeBRCA1allele supporting that these are not sporadic cancers",
                      "More common in women developing cancer at age > 50 years",
                      "~ 85% show loss of wild-typeBRCA1allele supporting that these are not sporadic cancers"
                    ]
                  },
                  {
                    "text": "Other associated cancersOvarian, fallopian tube, primary peritoneal (40-50% lifetime risk)Usually high-grade serous carcinomas~ 80% of women with both breast and ovarian cancer have BRCA mutationAverage age of onset: 49-53 years (compared to 63 years in general population)Male breast cancer (1-5% lifetime risk but ~ 1/2 risk ofBRCA2)Possibly pancreatic cancer, colon cancer, and others",
                    "sub_points": [
                      "Ovarian, fallopian tube, primary peritoneal (40-50% lifetime risk)Usually high-grade serous carcinomas~ 80% of women with both breast and ovarian cancer have BRCA mutationAverage age of onset: 49-53 years (compared to 63 years in general population)",
                      "Usually high-grade serous carcinomas",
                      "~ 80% of women with both breast and ovarian cancer have BRCA mutation",
                      "Average age of onset: 49-53 years (compared to 63 years in general population)",
                      "Male breast cancer (1-5% lifetime risk but ~ 1/2 risk ofBRCA2)",
                      "Possibly pancreatic cancer, colon cancer, and others"
                    ]
                  }
                ],
                "BRCA2(Hereditary Breast and Ovarian Cancer Syndrome)": [
                  {
                    "text": "FunctionBreastcancer 2 (BRCA2) is not structurally related toBRCA1, but both genes have very similar functions and regulatory roles",
                    "sub_points": [
                      "Breastcancer 2 (BRCA2) is not structurally related toBRCA1, but both genes have very similar functions and regulatory roles"
                    ]
                  },
                  {
                    "text": "Incidence: 0.1-0.7%More common in some ethnic groups: Ashkenazi Jews, Icelandic populationsMean age of onset is 47 years but can vary with specific mutations",
                    "sub_points": [
                      "More common in some ethnic groups: Ashkenazi Jews, Icelandic populations",
                      "Mean age of onset is 47 years but can vary with specific mutations"
                    ]
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): 45-85% (relative risk 11.7)Magnitude of risk can vary for different mutations and for different types of cancersResponsible for ~ 1/2 of cancers known to be due to germline mutation (~ 2% of all breast cancers)",
                    "sub_points": [
                      "Magnitude of risk can vary for different mutations and for different types of cancers",
                      "Responsible for ~ 1/2 of cancers known to be due to germline mutation (~ 2% of all breast cancers)"
                    ]
                  },
                  {
                    "text": "Breast cancerGroup with luminal A or B by gene expression profilingPositive for hormone receptors and negative for HER2Majority are high grade",
                    "sub_points": [
                      "Group with luminal A or B by gene expression profilingPositive for hormone receptors and negative for HER2",
                      "Positive for hormone receptors and negative for HER2",
                      "Majority are high grade"
                    ]
                  },
                  {
                    "text": "Other associated cancers and diseasesOvary, fallopian tube, primary peritoneal (10-20% lifetime risk)Usual age of onset is 55-58 years (compared to 63 years in general population)Male breast cancer: 5-10% lifetime risk; ~ 5-15% of cases are associated withBRCA2Also increased risk of early-onset aggressive prostate cancerPancreatic cancer, prostate cancerHomozygousBRCA2mutations cause rare form of Fanconi anemia",
                    "sub_points": [
                      "Ovary, fallopian tube, primary peritoneal (10-20% lifetime risk)Usual age of onset is 55-58 years (compared to 63 years in general population)",
                      "Usual age of onset is 55-58 years (compared to 63 years in general population)",
                      "Male breast cancer: 5-10% lifetime risk; ~ 5-15% of cases are associated withBRCA2Also increased risk of early-onset aggressive prostate cancer",
                      "Also increased risk of early-onset aggressive prostate cancer",
                      "Pancreatic cancer, prostate cancer",
                      "HomozygousBRCA2mutations cause rare form of Fanconi anemia"
                    ]
                  }
                ],
                "TP53(Li-Fraumeni Syndrome)": [
                  {
                    "text": "FunctionTumorprotein 53 (TP53) encodes for protein with central role in cell cycle control, DNA replication, DNA repair, and apoptosis",
                    "sub_points": [
                      "Tumorprotein 53 (TP53) encodes for protein with central role in cell cycle control, DNA replication, DNA repair, and apoptosis"
                    ]
                  },
                  {
                    "text": "Incidence: 0.0025%Population in southeastern Brazil has 1/300 incidenceEarly onset: Average age at diagnosis is 33 years~ 55% of women will develop breast cancer by age 45~ 2-7% of women with breast cancer were diagnosed at < 30 years of ageRare for breast cancer to be diagnosed after age 50",
                    "sub_points": [
                      "Population in southeastern Brazil has 1/300 incidenceEarly onset: Average age at diagnosis is 33 years~ 55% of women will develop breast cancer by age 45~ 2-7% of women with breast cancer were diagnosed at < 30 years of ageRare for breast cancer to be diagnosed after age 50",
                      "Early onset: Average age at diagnosis is 33 years",
                      "~ 55% of women will develop breast cancer by age 45",
                      "~ 2-7% of women with breast cancer were diagnosed at < 30 years of age",
                      "Rare for breast cancer to be diagnosed after age 50"
                    ]
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): >90% (relative risk ~ 60-165)Penetrance varies for different mutations",
                    "sub_points": [
                      "Penetrance varies for different mutations"
                    ]
                  },
                  {
                    "text": "Breast cancer1/3 of malignancies in affected familiesMost common type is ER positive and HER2 positive (~ 55%)Male breast cancer is rare",
                    "sub_points": [
                      "1/3 of malignancies in affected families",
                      "Most common type is ER positive and HER2 positive (~ 55%)",
                      "Male breast cancer is rare"
                    ]
                  },
                  {
                    "text": "Other associated cancersSarcomas: Most occur in children < 10 years of ageAdrenal cortical carcinoma: Most occur in children ~ 3 years of ageBrain tumors: Occur in children or in 4th-5th decadesLeukemia",
                    "sub_points": [
                      "Sarcomas: Most occur in children < 10 years of age",
                      "Adrenal cortical carcinoma: Most occur in children ~ 3 years of age",
                      "Brain tumors: Occur in children or in 4th-5th decades",
                      "Leukemia"
                    ]
                  }
                ],
                "CDH1(Familial Gastric Cancer and Lobular Breast Cancer Syndrome)": [
                  {
                    "text": "FunctionCadherin 1 (CDH1) encodes for epithelial cadherin (E-cadherin), which is cell adhesion moleculeMutations interfere with function75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletionsLoss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cellsCytoplasmic mucin creates appearance of signet ring cells",
                    "sub_points": [
                      "Cadherin 1 (CDH1) encodes for epithelial cadherin (E-cadherin), which is cell adhesion molecule",
                      "Mutations interfere with function75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletionsLoss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cellsCytoplasmic mucin creates appearance of signet ring cells",
                      "75-80% are truncating mutations, 20-25% are missense mutations, and 7% are large deletions",
                      "Loss of protein results in cells rounding up and single-cell infiltrative pattern due to lack of adhesion to adjacent cellsCytoplasmic mucin creates appearance of signet ring cells",
                      "Cytoplasmic mucin creates appearance of signet ring cells"
                    ]
                  },
                  {
                    "text": "Incidence: 0.005%"
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): ~40-55% (relative risk ~ 7)"
                  },
                  {
                    "text": "Breast cancerWomen are at increased risk for lobular carcinomaHowever, majority of women with lobular carcinomas do not haveCDH1germline mutations",
                    "sub_points": [
                      "Women are at increased risk for lobular carcinomaHowever, majority of women with lobular carcinomas do not haveCDH1germline mutations",
                      "However, majority of women with lobular carcinomas do not haveCDH1germline mutations"
                    ]
                  },
                  {
                    "text": "Other associated cancers70-85% lifetime risk of developing gastric signet ring cell carcinoma in majority of familiesGastric carcinomas are more common than breast carcinomas in most affected familiesFamilies developing only breast cancer have also been identifiedGastric signet ring cell carcinomas morphologically resemble breast lobular carcinomasThese cancers can be distinguished by protein expressionGastric carcinomas are typically ER positive, PR negative, GCDFP-15 negative, and MUC1 negative, while typically CDX-2 positive and Hep-Par1 positiveBreast carcinomas are typically ER positive, PR positive, GCDFP-15 positive, and MUC1 positive",
                    "sub_points": [
                      "70-85% lifetime risk of developing gastric signet ring cell carcinoma in majority of familiesGastric carcinomas are more common than breast carcinomas in most affected familiesFamilies developing only breast cancer have also been identified",
                      "Gastric carcinomas are more common than breast carcinomas in most affected families",
                      "Families developing only breast cancer have also been identified",
                      "Gastric signet ring cell carcinomas morphologically resemble breast lobular carcinomasThese cancers can be distinguished by protein expressionGastric carcinomas are typically ER positive, PR negative, GCDFP-15 negative, and MUC1 negative, while typically CDX-2 positive and Hep-Par1 positiveBreast carcinomas are typically ER positive, PR positive, GCDFP-15 positive, and MUC1 positive",
                      "These cancers can be distinguished by protein expressionGastric carcinomas are typically ER positive, PR negative, GCDFP-15 negative, and MUC1 negative, while typically CDX-2 positive and Hep-Par1 positiveBreast carcinomas are typically ER positive, PR positive, GCDFP-15 positive, and MUC1 positive",
                      "Gastric carcinomas are typically ER positive, PR negative, GCDFP-15 negative, and MUC1 negative, while typically CDX-2 positive and Hep-Par1 positive",
                      "Breast carcinomas are typically ER positive, PR positive, GCDFP-15 positive, and MUC1 positive"
                    ]
                  }
                ],
                "PTEN(Cowden Syndrome)": [
                  {
                    "text": "FunctionPhosphatase andtensin homolog (PTEN) encodes for dual specificity phosphatase gene involved in control of proliferation signals and apoptosis",
                    "sub_points": [
                      "Phosphatase andtensin homolog (PTEN) encodes for dual specificity phosphatase gene involved in control of proliferation signals and apoptosis"
                    ]
                  },
                  {
                    "text": "Incidence: 0.0005%Early onset; most women diagnosed between 38-46 years of age",
                    "sub_points": [
                      "Early onset; most women diagnosed between 38-46 years of age"
                    ]
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): 25-85%"
                  },
                  {
                    "text": "Breast cancerMen also at increased risk for breast cancer; magnitude of risk not yet determinedOther breast lesions include fibroadenomas and hamartomas",
                    "sub_points": [
                      "Men also at increased risk for breast cancer; magnitude of risk not yet determined",
                      "Other breast lesions include fibroadenomas and hamartomas"
                    ]
                  },
                  {
                    "text": "Other associated tumorsMultiple hamartomas (including trichilemmomas)Thyroid and endometrial cancer",
                    "sub_points": [
                      "Multiple hamartomas (including trichilemmomas)",
                      "Thyroid and endometrial cancer"
                    ]
                  }
                ],
                "STK11/LKB1 (Peutz-Jeghers Syndrome)": [
                  {
                    "text": "FunctionSerine/threoninekinase 11 (a.k.a.liverkinase B1) encodes serine/threonine kinase involved in cell cycle regulation and mediation of apoptosis",
                    "sub_points": [
                      "Serine/threoninekinase 11 (a.k.a.liverkinase B1) encodes serine/threonine kinase involved in cell cycle regulation and mediation of apoptosis"
                    ]
                  },
                  {
                    "text": "Incidence: 0.001%Early onset: 8% by age 40 and 32% by age 60",
                    "sub_points": [
                      "Early onset: 8% by age 40 and 32% by age 60"
                    ]
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): ~40%"
                  },
                  {
                    "text": "Breast cancerNo reported specific histologic types",
                    "sub_points": [
                      "No reported specific histologic types"
                    ]
                  },
                  {
                    "text": "Other associated lesionsHamartomatous gastrointestinal polyps (including small intestine)Mucocutaneous pigmentation (lips and buccal mucosa)Ovarian cancer (sex cord stromal tumors are most common): ~ 20% riskIncreased risk of cancer of colon, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix (adenoma malignum)",
                    "sub_points": [
                      "Hamartomatous gastrointestinal polyps (including small intestine)",
                      "Mucocutaneous pigmentation (lips and buccal mucosa)",
                      "Ovarian cancer (sex cord stromal tumors are most common): ~ 20% risk",
                      "Increased risk of cancer of colon, pancreas, small intestine, thyroid, lung, uterus, ovary, and cervix (adenoma malignum)"
                    ]
                  }
                ],
                "PALB2": [
                  {
                    "text": "FunctionPartnerandlocalizer ofBRCA2(PALPB2) encodes for protein that binds to BRCA2 protein and is part of complex responsible for homologous recombination and double-strand DNA break repair",
                    "sub_points": [
                      "Partnerandlocalizer ofBRCA2(PALPB2) encodes for protein that binds to BRCA2 protein and is part of complex responsible for homologous recombination and double-strand DNA break repair"
                    ]
                  },
                  {
                    "text": "Incidence:0.1%"
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): 35-60% (relative risk ~ 5)"
                  },
                  {
                    "text": "Breast cancerMay increase risk of TNBC",
                    "sub_points": [
                      "May increase risk of TNBC"
                    ]
                  },
                  {
                    "text": "Other associated diseasesPossibly pancreatic cancer and ovarian cancerFanconi anemia when homozygous (PALB2is also termed FANCN)",
                    "sub_points": [
                      "Possibly pancreatic cancer and ovarian cancer",
                      "Fanconi anemia when homozygous (PALB2is also termed FANCN)"
                    ]
                  }
                ],
                "ATM(Ataxia-Telangiectasia Carriers)": [
                  {
                    "text": "FunctionAtaxia-telangiectasiamutated (ATM) codes for serine threonine kinase that phosphorylates p53 and BRCA1 in response to DNA double-strand breaks",
                    "sub_points": [
                      "Ataxia-telangiectasiamutated (ATM) codes for serine threonine kinase that phosphorylates p53 and BRCA1 in response to DNA double-strand breaks"
                    ]
                  },
                  {
                    "text": "Incidence: 0.5%"
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): 25-40% (relative risk ~ 3)Varies with specific mutationEarlier onset than sporadic breast cancer",
                    "sub_points": [
                      "Varies with specific mutation",
                      "Earlier onset than sporadic breast cancer"
                    ]
                  },
                  {
                    "text": "Breast cancerMajority intermediate to high grade~ 80% positive for ER and negative for HER2 and ~ 15% positive for both ER and HER2< 5% are negative for ER and positive for HER2 or negative for both",
                    "sub_points": [
                      "Majority intermediate to high grade",
                      "~ 80% positive for ER and negative for HER2 and ~ 15% positive for both ER and HER2< 5% are negative for ER and positive for HER2 or negative for both",
                      "< 5% are negative for ER and positive for HER2 or negative for both"
                    ]
                  },
                  {
                    "text": "Other associated lesionsHeterozygotes may be more susceptible to DNA damage from radiationPossibly pancreatic cancerHomozygosity results in ataxia-telangiectasiaProgressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma",
                    "sub_points": [
                      "Heterozygotes may be more susceptible to DNA damage from radiation",
                      "Possibly pancreatic cancer",
                      "Homozygosity results in ataxia-telangiectasiaProgressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma",
                      "Progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and increased risk of leukemia and lymphoma"
                    ]
                  }
                ],
                "CHEK2": [
                  {
                    "text": "FunctionCheckpointkinase2(CHEK2) encodes for serine threonine kinase that phosphorylates p53 and BRCA1 to halt cell division in response to DNA damage",
                    "sub_points": [
                      "Checkpointkinase2(CHEK2) encodes for serine threonine kinase that phosphorylates p53 and BRCA1 to halt cell division in response to DNA damage"
                    ]
                  },
                  {
                    "text": "Incidence: 0.2-0.3%0.5-1.0% in eastern and northern European populationsLater onset of breast cancer",
                    "sub_points": [
                      "0.5-1.0% in eastern and northern European populations",
                      "Later onset of breast cancer"
                    ]
                  },
                  {
                    "text": "Lifetime risk of breast cancer (F): ~ 30% (relative risk ~ 2)Varies depending on specific mutation and whether or not there is family history of breast cancer",
                    "sub_points": [
                      "Varies depending on specific mutation and whether or not there is family history of breast cancer"
                    ]
                  },
                  {
                    "text": "Breast cancerIncreased risk for malesCancers are usually ER positive",
                    "sub_points": [
                      "Increased risk for males",
                      "Cancers are usually ER positive"
                    ]
                  },
                  {
                    "text": "Other associated cancersMay be linked to prostate, lung, colon, kidney, and thyroid cancer but degree of risk is unclear",
                    "sub_points": [
                      "May be linked to prostate, lung, colon, kidney, and thyroid cancer but degree of risk is unclear"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Genetic Testing": [
                  {
                    "text": "Population to be testedNational Comprehensive Cancer Network (NCCN), U.S. Preventative Services Task Force, National Institute for Health and Care Excellence, and other organizations recommend testing individuals at high risk for having pathogenic mutation in breast cancer predisposition geneNCCN version 3.2019 is available at www.nccn.orgIn general, high risk is defined as > 10% likelihood of having mutationHowever, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testingIn addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasonsCriteria to identify high-risk individuals generally include (but are not limited to)Personal history of breast cancer at < 50 years, TNBC at < 60 years, multiple breast cancers1st-degree relatives with known germline mutation, breast cancer at < 50 years, male breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer with Gleason score ≥ 7Relatives with nonbreast cancers associated with specific germline mutationsMale breast cancer forBRCA2andBRCA1Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2Sarcomas forTP53Membership in groups at high risk for certain mutations (e.g., Ashkenazi Jewish heritage)Relatives with diseases due to homozygous mutationsAtaxia-telangiectasia forATMFanconi anemia forBRCA2andBRIP1For family, it is most useful to begin testing 1 individual with cancerIf multiple affected individuals are present within kindred, testing can establish linkage between cancer(s) and mutationOnce mutation is detected, other family members without cancer may choose testingCounseling should occur before testing to ensure patient is aware of possible implications for individual and family",
                    "sub_points": [
                      "National Comprehensive Cancer Network (NCCN), U.S. Preventative Services Task Force, National Institute for Health and Care Excellence, and other organizations recommend testing individuals at high risk for having pathogenic mutation in breast cancer predisposition geneNCCN version 3.2019 is available at www.nccn.orgIn general, high risk is defined as > 10% likelihood of having mutationHowever, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testingIn addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasons",
                      "NCCN version 3.2019 is available at www.nccn.org",
                      "In general, high risk is defined as > 10% likelihood of having mutationHowever, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testingIn addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasons",
                      "However, up to 50% of women with germline mutations (particularly in lower risk/lower penetrance genes) may not fulfill criteria for testing",
                      "In addition, some individuals may lack family history due to adoption, sperm donation, very small family size, or other reasons",
                      "Criteria to identify high-risk individuals generally include (but are not limited to)Personal history of breast cancer at < 50 years, TNBC at < 60 years, multiple breast cancers1st-degree relatives with known germline mutation, breast cancer at < 50 years, male breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer with Gleason score ≥ 7Relatives with nonbreast cancers associated with specific germline mutationsMale breast cancer forBRCA2andBRCA1Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2Sarcomas forTP53Membership in groups at high risk for certain mutations (e.g., Ashkenazi Jewish heritage)Relatives with diseases due to homozygous mutationsAtaxia-telangiectasia forATMFanconi anemia forBRCA2andBRIP1",
                      "Personal history of breast cancer at < 50 years, TNBC at < 60 years, multiple breast cancers",
                      "1st-degree relatives with known germline mutation, breast cancer at < 50 years, male breast cancer, ovarian cancer, pancreatic cancer, or prostate cancer with Gleason score ≥ 7",
                      "Relatives with nonbreast cancers associated with specific germline mutationsMale breast cancer forBRCA2andBRCA1Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2Sarcomas forTP53",
                      "Male breast cancer forBRCA2andBRCA1",
                      "Ovarian, fallopian tube, or primary peritoneal cancers forBRCA1andBRCA2",
                      "Sarcomas forTP53",
                      "Membership in groups at high risk for certain mutations (e.g., Ashkenazi Jewish heritage)",
                      "Relatives with diseases due to homozygous mutationsAtaxia-telangiectasia forATMFanconi anemia forBRCA2andBRIP1",
                      "Ataxia-telangiectasia forATM",
                      "Fanconi anemia forBRCA2andBRIP1",
                      "For family, it is most useful to begin testing 1 individual with cancerIf multiple affected individuals are present within kindred, testing can establish linkage between cancer(s) and mutationOnce mutation is detected, other family members without cancer may choose testing",
                      "If multiple affected individuals are present within kindred, testing can establish linkage between cancer(s) and mutation",
                      "Once mutation is detected, other family members without cancer may choose testing",
                      "Counseling should occur before testing to ensure patient is aware of possible implications for individual and family"
                    ]
                  },
                  {
                    "text": "Classification of resultsMutations are classified into 5 groupsBenign or likely benign: Both are considered negative resultPathogenic or likely pathogenic: Both are considered positive resultVariants of unknown significance (VUS): Should not be used for patient managementGenetic polymorphism that has not yet been associated with increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations because they are underrepresented in genetic databasesMust be identified in multiple individuals to determine clinical significance",
                    "sub_points": [
                      "Mutations are classified into 5 groupsBenign or likely benign: Both are considered negative resultPathogenic or likely pathogenic: Both are considered positive resultVariants of unknown significance (VUS): Should not be used for patient managementGenetic polymorphism that has not yet been associated with increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations because they are underrepresented in genetic databasesMust be identified in multiple individuals to determine clinical significance",
                      "Benign or likely benign: Both are considered negative result",
                      "Pathogenic or likely pathogenic: Both are considered positive result",
                      "Variants of unknown significance (VUS): Should not be used for patient managementGenetic polymorphism that has not yet been associated with increased risk of cancerFound in 3-7% of individuals tested forBRCA1andBRCA2> 1,500 identifiedMore frequent in minority ethnic populations because they are underrepresented in genetic databasesMust be identified in multiple individuals to determine clinical significance",
                      "Genetic polymorphism that has not yet been associated with increased risk of cancer",
                      "Found in 3-7% of individuals tested forBRCA1andBRCA2",
                      "> 1,500 identified",
                      "More frequent in minority ethnic populations because they are underrepresented in genetic databases",
                      "Must be identified in multiple individuals to determine clinical significance"
                    ]
                  },
                  {
                    "text": "Extent of testingFull genome sequencing is required to detect all mutationsMay become feasible in near futureDoes not detect all genetic alterationsLimited sequence analysis can be used to detect most likely mutationCommon mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish populationHotspots for mutations within geneDetection of known mutation in familyDuplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis18% of genetic changes inBRCA1andBRCA2are not detected by standard testingAlso underlie pathogenic variants in other breast cancer predisposition mutationsBRACAnalysis Large Rearrangement Test (BART) detects some rearrangementsAccount for 17% of deleterious mutations in individuals from Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean",
                    "sub_points": [
                      "Full genome sequencing is required to detect all mutationsMay become feasible in near futureDoes not detect all genetic alterations",
                      "May become feasible in near future",
                      "Does not detect all genetic alterations",
                      "Limited sequence analysis can be used to detect most likely mutationCommon mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish populationHotspots for mutations within geneDetection of known mutation in family",
                      "Common mutations found in ethnic groups, e.g., 2BRCA1and 1BRCA2mutations comprise 90% of mutations found in Ashkenazi Jewish population",
                      "Hotspots for mutations within gene",
                      "Detection of known mutation in family",
                      "Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis18% of genetic changes inBRCA1andBRCA2are not detected by standard testingAlso underlie pathogenic variants in other breast cancer predisposition mutationsBRACAnalysis Large Rearrangement Test (BART) detects some rearrangementsAccount for 17% of deleterious mutations in individuals from Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean",
                      "18% of genetic changes inBRCA1andBRCA2are not detected by standard testing",
                      "Also underlie pathogenic variants in other breast cancer predisposition mutations",
                      "BRACAnalysis Large Rearrangement Test (BART) detects some rearrangements",
                      "Account for 17% of deleterious mutations in individuals from Near East/Middle East and 22% of deleterious mutations in individuals from Latin America/Caribbean"
                    ]
                  },
                  {
                    "text": "Single gene testingUseful when relative has known germline mutation, individual belongs to group with founder mutation of high frequency, or family history is highly suggestive of mutation in specific geneHowever, mutations in other genes may be missedOf all individuals meeting recommended criteria for testing forBRCA1/BRCA1, ~ 10% will be found to have germline mutationHowever, in only ~ 1/3 will mutation be inBRCA1/BRCA1In addition, ~ 6% of individuals who haveBRCA1/BRCA1germline mutation do not meet criteria for testing for these genesTherefore, multigene testing is required to detect majority of germline mutations",
                    "sub_points": [
                      "Useful when relative has known germline mutation, individual belongs to group with founder mutation of high frequency, or family history is highly suggestive of mutation in specific geneHowever, mutations in other genes may be missed",
                      "However, mutations in other genes may be missed",
                      "Of all individuals meeting recommended criteria for testing forBRCA1/BRCA1, ~ 10% will be found to have germline mutationHowever, in only ~ 1/3 will mutation be inBRCA1/BRCA1In addition, ~ 6% of individuals who haveBRCA1/BRCA1germline mutation do not meet criteria for testing for these genesTherefore, multigene testing is required to detect majority of germline mutations",
                      "However, in only ~ 1/3 will mutation be inBRCA1/BRCA1",
                      "In addition, ~ 6% of individuals who haveBRCA1/BRCA1germline mutation do not meet criteria for testing for these genes",
                      "Therefore, multigene testing is required to detect majority of germline mutations"
                    ]
                  },
                  {
                    "text": "Multigene panel testingCurrently most common method of testingCompanies offer different sets of panels and extent of testingCan offer results on from 5-50 or more genesMay or may not offer evaluation of deletions and duplicationsIncreases number of VUS detected",
                    "sub_points": [
                      "Currently most common method of testing",
                      "Companies offer different sets of panels and extent of testingCan offer results on from 5-50 or more genesMay or may not offer evaluation of deletions and duplications",
                      "Can offer results on from 5-50 or more genes",
                      "May or may not offer evaluation of deletions and duplications",
                      "Increases number of VUS detected"
                    ]
                  },
                  {
                    "text": "Direct to consumer testingTypically only includes most common mutationsIf negative result is obtained, and there is strong likelihood of germline mutation due to personal or family history, more comprehensive testing by certified laboratory should be pursuedIf positive result is obtained, result should be confirmed by certified laboratoryIn one study, 40% of positive results obtained by direct to consumer testing could not be confirmed by certified laboratory",
                    "sub_points": [
                      "Typically only includes most common mutationsIf negative result is obtained, and there is strong likelihood of germline mutation due to personal or family history, more comprehensive testing by certified laboratory should be pursuedIf positive result is obtained, result should be confirmed by certified laboratoryIn one study, 40% of positive results obtained by direct to consumer testing could not be confirmed by certified laboratory",
                      "If negative result is obtained, and there is strong likelihood of germline mutation due to personal or family history, more comprehensive testing by certified laboratory should be pursued",
                      "If positive result is obtained, result should be confirmed by certified laboratoryIn one study, 40% of positive results obtained by direct to consumer testing could not be confirmed by certified laboratory",
                      "In one study, 40% of positive results obtained by direct to consumer testing could not be confirmed by certified laboratory"
                    ]
                  },
                  {
                    "text": "Polygenic risk scores (PRS)Common (> 1% incidence) single nucleotide polymorphisms can slightly increase risk of breast cancer> 170 genes with mutations conferring low risk of breast cancer have been identifiedAlthough of little significance alone, multiple polymorphisms can be combined into PRS to modify risk estimates for individuals with germline mutationsIn combination, these low-risk genes may account for ~ 18% of familial risk of breast cancer",
                    "sub_points": [
                      "Common (> 1% incidence) single nucleotide polymorphisms can slightly increase risk of breast cancer> 170 genes with mutations conferring low risk of breast cancer have been identified",
                      "> 170 genes with mutations conferring low risk of breast cancer have been identified",
                      "Although of little significance alone, multiple polymorphisms can be combined into PRS to modify risk estimates for individuals with germline mutations",
                      "In combination, these low-risk genes may account for ~ 18% of familial risk of breast cancer"
                    ]
                  }
                ],
                "Medical Care of Individuals With Germline Mutations": [
                  {
                    "text": "OverviewIdentification of pathogenic germline mutation may modify medical care in multiple areasNotification of relatives at possible riskChemopreventionProphylactic surgeryScreeningAlterations in cancer therapy targeted to mutation for patients who have cancerAssisted reproduction to avoid passing mutation to next generationBenefit of interventions is greatest for individuals with high-risk mutations and less certain for those with moderate-risk mutations",
                    "sub_points": [
                      "Identification of pathogenic germline mutation may modify medical care in multiple areasNotification of relatives at possible riskChemopreventionProphylactic surgeryScreeningAlterations in cancer therapy targeted to mutation for patients who have cancerAssisted reproduction to avoid passing mutation to next generation",
                      "Notification of relatives at possible risk",
                      "Chemoprevention",
                      "Prophylactic surgery",
                      "Screening",
                      "Alterations in cancer therapy targeted to mutation for patients who have cancer",
                      "Assisted reproduction to avoid passing mutation to next generation",
                      "Benefit of interventions is greatest for individuals with high-risk mutations and less certain for those with moderate-risk mutations"
                    ]
                  },
                  {
                    "text": "ChemopreventionTamoxifen reduces risk of ER-positive cancer for women with family history of breast cancerHowever, risk of endometrial cancer and thrombosis is increasedBenefit of chemoprevention for primary prevention of breast cancer for individuals with germline mutations is not yet clear",
                    "sub_points": [
                      "Tamoxifen reduces risk of ER-positive cancer for women with family history of breast cancerHowever, risk of endometrial cancer and thrombosis is increased",
                      "However, risk of endometrial cancer and thrombosis is increased",
                      "Benefit of chemoprevention for primary prevention of breast cancer for individuals with germline mutations is not yet clear"
                    ]
                  },
                  {
                    "text": "ScreeningClinical breast examination 2x yearly starting at age 25 is recommendedPatient self-breast awareness with periodic breast examinationsMammography at earlier age (10 years before age at which youngest relative with cancer was diagnosed) or more frequentlyMR screening more sensitive than mammography in young women with dense breastsHowever, lower specificity leads to greater numbers of biopsies for benign lesionsScreening by mammography and MR may be staggered every 6 months to decrease screening interval",
                    "sub_points": [
                      "Clinical breast examination 2x yearly starting at age 25 is recommendedPatient self-breast awareness with periodic breast examinations",
                      "Patient self-breast awareness with periodic breast examinations",
                      "Mammography at earlier age (10 years before age at which youngest relative with cancer was diagnosed) or more frequently",
                      "MR screening more sensitive than mammography in young women with dense breastsHowever, lower specificity leads to greater numbers of biopsies for benign lesions",
                      "However, lower specificity leads to greater numbers of biopsies for benign lesions",
                      "Screening by mammography and MR may be staggered every 6 months to decrease screening interval"
                    ]
                  },
                  {
                    "text": "Prophylactic surgeryBilateral mastectomy reduces risk of breast cancer by 97%Not all breast tissue can be removed in all patients with acceptable cosmetic resultsMajor benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastasesBilateral salpingo-oophorectomy reduces risk of ovarian and fallopian tube cancer by 70-95%Relevant for mutations that increase risk of both breast and ovarian cancerWomen remain at risk for primary peritoneal cancersReduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone productionReduces risk of ER-negative breast cancers forBRCA1patients to lesser degree; mechanism is unknown",
                    "sub_points": [
                      "Bilateral mastectomy reduces risk of breast cancer by 97%Not all breast tissue can be removed in all patients with acceptable cosmetic resultsMajor benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastases",
                      "Not all breast tissue can be removed in all patients with acceptable cosmetic results",
                      "Major benefit to women prior to development of breast cancer; limited or no benefit after breast cancer diagnosis with possible distant metastases",
                      "Bilateral salpingo-oophorectomy reduces risk of ovarian and fallopian tube cancer by 70-95%Relevant for mutations that increase risk of both breast and ovarian cancerWomen remain at risk for primary peritoneal cancersReduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone productionReduces risk of ER-negative breast cancers forBRCA1patients to lesser degree; mechanism is unknown",
                      "Relevant for mutations that increase risk of both breast and ovarian cancer",
                      "Women remain at risk for primary peritoneal cancers",
                      "Reduces risk of breast cancer by 50% in premenopausal women, presumably due to decrease in hormone production",
                      "Reduces risk of ER-negative breast cancers forBRCA1patients to lesser degree; mechanism is unknown"
                    ]
                  },
                  {
                    "text": "Alterations in recommendations for systemic therapyFor patients with advanced breast cancer, presence of germline mutation may alter type of therapyBRCA1/BRCA1: Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors (olaparib or talazoparib)BRCA1/BRCA1-associated TNBC: Carboplatin",
                    "sub_points": [
                      "For patients with advanced breast cancer, presence of germline mutation may alter type of therapyBRCA1/BRCA1: Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors (olaparib or talazoparib)BRCA1/BRCA1-associated TNBC: Carboplatin",
                      "BRCA1/BRCA1: Platinum-based chemotherapy and poly ADP-ribose polymerase (PARP) inhibitors (olaparib or talazoparib)",
                      "BRCA1/BRCA1-associated TNBC: Carboplatin"
                    ]
                  },
                  {
                    "text": "ChildbearingAssisted reproduction can be used to prevent germline mutation being passed on to children",
                    "sub_points": [
                      "Assisted reproduction can be used to prevent germline mutation being passed on to children"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "TP53: Li-Fraumeni Syndrome": {
            "name": "TP53: Li-Fraumeni Syndrome",
            "url": "https://app.pathprimer.com/document/f83ecbcf-9a4f-4c0f-bf05-19de7234957e/lesson/ad5cf7d4-7b5b-44cd-9832-ed80654954df",
            "content": {
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Li-Fraumeni syndrome (LFS)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Online Mendelian Inheritance in Man (OMIM) 151623"
                  },
                  {
                    "text": "Sarcoma, breast, leukemia, and adrenal gland (SBLA) syndrome"
                  },
                  {
                    "text": "Sarcoma family syndrome of Li and Fraumeni"
                  }
                ]
              },
              "Introduction": {
                "Li-Fraumeni Syndrome": [
                  {
                    "text": "In 1969, Frederick Li and Joseph Fraumeni recognized unusual pattern of cancers in 4 families with autosomal dominant transmissionFamily members developed a wide variety of different types of cancersSyndrome-related cancers developed at different ages at different frequency0-15 years: Sarcomas, adrenal cortical carcinomas, brain tumors, leukemia16-50 years: Sarcomas, breast carcinomas, brain tumors, leukemia> 50 years: Breast carcinomas, sarcomas, lung carcinomas, prostate carcinomas",
                    "sub_points": [
                      "Family members developed a wide variety of different types of cancers",
                      "Syndrome-related cancers developed at different ages at different frequency0-15 years: Sarcomas, adrenal cortical carcinomas, brain tumors, leukemia16-50 years: Sarcomas, breast carcinomas, brain tumors, leukemia> 50 years: Breast carcinomas, sarcomas, lung carcinomas, prostate carcinomas",
                      "0-15 years: Sarcomas, adrenal cortical carcinomas, brain tumors, leukemia",
                      "16-50 years: Sarcomas, breast carcinomas, brain tumors, leukemia",
                      "> 50 years: Breast carcinomas, sarcomas, lung carcinomas, prostate carcinomas"
                    ]
                  },
                  {
                    "text": "LFS was discovered to be due to pathogenic germline mutations inTP53, a key tumor suppressor gene involved in maintenance of genomic stabilityAutosomal dominant inheritanceLFS is characterized by high phenotypic heterogeneity with a wide spectrum of tumors developing at unusually young agesCumulative cancer risk ~ 50% by age 40, ~ 90% by age 60Broader genetic testing is identifying individuals with germlineTP53mutations without typical family historiesThese individuals generally have mutations of lower penetrance or lower pathogenicity or have de novo mutations",
                    "sub_points": [
                      "Autosomal dominant inheritance",
                      "LFS is characterized by high phenotypic heterogeneity with a wide spectrum of tumors developing at unusually young ages",
                      "Cumulative cancer risk ~ 50% by age 40, ~ 90% by age 60",
                      "Broader genetic testing is identifying individuals with germlineTP53mutations without typical family historiesThese individuals generally have mutations of lower penetrance or lower pathogenicity or have de novo mutations",
                      "These individuals generally have mutations of lower penetrance or lower pathogenicity or have de novo mutations"
                    ]
                  },
                  {
                    "text": "Li-Fraumeni-like syndrome has been used to refer to individuals who do not fulfill all clinical criteria for LFS20-40% have germlineTP53mutations and are classified as having LFSOther individuals may have germline mutations in genes such asBRCA2, Fanconi genes (BRIP1,PALB2, andRAD51C), and DNA mismatch repair genes",
                    "sub_points": [
                      "20-40% have germlineTP53mutations and are classified as having LFS",
                      "Other individuals may have germline mutations in genes such asBRCA2, Fanconi genes (BRIP1,PALB2, andRAD51C), and DNA mismatch repair genes"
                    ]
                  }
                ]
              },
              "Epidemiology": {
                "Incidence ofTP53Germline Mutations": [
                  {
                    "text": "~ 1/5,000 to 1/20,000 individuals have pathogenic mutationsHowever, broader screening has identified germline mutations in up to 1/400 to 1/800 individualsMutations associated with cancers, but not associated with classic LFS history, show lower penetrance and cancers occur at older ageMutations not yet associated with cancer are of uncertain significanceModels are being developed in order to help determine if a newly detected mutation is likely to be pathogenic",
                    "sub_points": [
                      "However, broader screening has identified germline mutations in up to 1/400 to 1/800 individualsMutations associated with cancers, but not associated with classic LFS history, show lower penetrance and cancers occur at older ageMutations not yet associated with cancer are of uncertain significanceModels are being developed in order to help determine if a newly detected mutation is likely to be pathogenic",
                      "Mutations associated with cancers, but not associated with classic LFS history, show lower penetrance and cancers occur at older age",
                      "Mutations not yet associated with cancer are of uncertain significance",
                      "Models are being developed in order to help determine if a newly detected mutation is likely to be pathogenic"
                    ]
                  },
                  {
                    "text": "A population in southeastern Brazil has a 1/300 incidenceDue to a specific mutation R337H (c.1010G > A, p.Arg337His)Lifetime risk for cancer: ~ 50-60%Adrenal cortical carcinoma is the most common cancer to be diagnosed first in all age groupsAdults also develop breast cancer, soft tissue sarcoma (STS), and choroid plexus carcinoma~ 12% of Brazilian women who present with breast cancer at < 45 years have this mutation",
                    "sub_points": [
                      "Due to a specific mutation R337H (c.1010G > A, p.Arg337His)",
                      "Lifetime risk for cancer: ~ 50-60%",
                      "Adrenal cortical carcinoma is the most common cancer to be diagnosed first in all age groups",
                      "Adults also develop breast cancer, soft tissue sarcoma (STS), and choroid plexus carcinoma~ 12% of Brazilian women who present with breast cancer at < 45 years have this mutation",
                      "~ 12% of Brazilian women who present with breast cancer at < 45 years have this mutation"
                    ]
                  }
                ],
                "Incidence Among Women With Breast Carcinoma": [
                  {
                    "text": "TP53germline mutations are associated with ~ 6% of breast carcinomas in women < 31 years of age"
                  },
                  {
                    "text": "Responsible for ~ 3% of all breast cancers due to germline mutation"
                  }
                ],
                "Modifiers of Risk": [
                  {
                    "text": "The type ofTP53germline mutation alters age of onset"
                  },
                  {
                    "text": "Missense mutationsDominant-negative missense mutations result in abnormal protein that interferes with function of normal proteinResults in defect in p53 from the time of conception1st tumor has earlier age of onsetOccurs in the majority of pediatric patientsOther missense mutations result in proteins that gain functions that promote tumors",
                    "sub_points": [
                      "Dominant-negative missense mutations result in abnormal protein that interferes with function of normal proteinResults in defect in p53 from the time of conception1st tumor has earlier age of onsetOccurs in the majority of pediatric patients",
                      "Results in defect in p53 from the time of conception",
                      "1st tumor has earlier age of onset",
                      "Occurs in the majority of pediatric patients",
                      "Other missense mutations result in proteins that gain functions that promote tumors"
                    ]
                  },
                  {
                    "text": "Loss-of-function mutations(e.g., nonsense mutations, frameshift mutations, genomic rearrangements) likely require a 2nd event to alter p53 functionSomatic mutations inTP53&/or inactivation of protein p53 are most common alterations detected in all cancers1st tumor in LFS has later age of onset",
                    "sub_points": [
                      "Somatic mutations inTP53&/or inactivation of protein p53 are most common alterations detected in all cancers",
                      "1st tumor in LFS has later age of onset"
                    ]
                  },
                  {
                    "text": "Type ofTP53mutation alters penetranceDominant-negative missense mutations are more highly penetrant (more individuals develop tumors) than other types of mutations",
                    "sub_points": [
                      "Dominant-negative missense mutations are more highly penetrant (more individuals develop tumors) than other types of mutations"
                    ]
                  },
                  {
                    "text": "Chemotherapy and radiation therapyfor 1st tumor likely contribute to subsequent cancersMultiple primary tumors occur in ~ 40% of LFS patients~ 1/3 of LFS patients develop 2nd tumors in radiation fields",
                    "sub_points": [
                      "Multiple primary tumors occur in ~ 40% of LFS patients",
                      "~ 1/3 of LFS patients develop 2nd tumors in radiation fields"
                    ]
                  },
                  {
                    "text": "SexMedian age of developing 1st cancer is higher in females compared to males (28 years vs. 17 years) due to large number of breast cancersIf breast cancers are excluded, median age of 1st cancer in females is ~ 13 years vs. ~ 17 years for malesAfter age 20, incidence of breast cancer in females results in higher overall cancer rates compared to malesLifetime risk for females is ~ 100%, ~ 75% for males",
                    "sub_points": [
                      "Median age of developing 1st cancer is higher in females compared to males (28 years vs. 17 years) due to large number of breast cancersIf breast cancers are excluded, median age of 1st cancer in females is ~ 13 years vs. ~ 17 years for males",
                      "If breast cancers are excluded, median age of 1st cancer in females is ~ 13 years vs. ~ 17 years for males",
                      "After age 20, incidence of breast cancer in females results in higher overall cancer rates compared to males",
                      "Lifetime risk for females is ~ 100%, ~ 75% for males"
                    ]
                  },
                  {
                    "text": "Other modifying factorsGenomic changes, such asTP53polymorphisms, p53 inhibitorMDM2variants, miR-605 microRNA variants, and telomere length, may influence clinical characteristics (e.g., age of 1st tumor)",
                    "sub_points": [
                      "Genomic changes, such asTP53polymorphisms, p53 inhibitorMDM2variants, miR-605 microRNA variants, and telomere length, may influence clinical characteristics (e.g., age of 1st tumor)"
                    ]
                  }
                ]
              },
              "Genetics": {
                "TP53": [
                  {
                    "text": "Located on 17p13.120 kb, 11 coding exons, 393 amino acids",
                    "sub_points": [
                      "20 kb, 11 coding exons, 393 amino acids"
                    ]
                  },
                  {
                    "text": "Autosomal dominant inheritance"
                  },
                  {
                    "text": "Missense mutations: Majority of cases (~ 75%)Most are within central DNA binding domain: 85% in exons 5-8Alter DNA binding capacity or destabilize 3D structure of proteinAltered protein can have dominant-negative effect: Abnormal protein interferes with function of wildtype proteinOccurs in ~ 1/3 of affected LFS familiesAll cells have abnormal p53 function from birth without need for additional mutationsResults in earlier age of diagnosis of 1st tumorUnlike other germline tumor suppressor genes, 2/3 of tumors in individuals with missense mutations retain wildtype alleleRetention likely due to lower selective pressure to lose wildtype protein",
                    "sub_points": [
                      "Most are within central DNA binding domain: 85% in exons 5-8",
                      "Alter DNA binding capacity or destabilize 3D structure of protein",
                      "Altered protein can have dominant-negative effect: Abnormal protein interferes with function of wildtype proteinOccurs in ~ 1/3 of affected LFS familiesAll cells have abnormal p53 function from birth without need for additional mutationsResults in earlier age of diagnosis of 1st tumor",
                      "Occurs in ~ 1/3 of affected LFS families",
                      "All cells have abnormal p53 function from birth without need for additional mutations",
                      "Results in earlier age of diagnosis of 1st tumor",
                      "Unlike other germline tumor suppressor genes, 2/3 of tumors in individuals with missense mutations retain wildtype alleleRetention likely due to lower selective pressure to lose wildtype protein",
                      "Retention likely due to lower selective pressure to lose wildtype protein"
                    ]
                  },
                  {
                    "text": "Null mutations: Minority of casesMay be due to nonsense or splice site mutations, deletions, or insertionsResults in nonfunctional proteinLoss or inactivation of wildtype allele is necessary to alter normalTP53functionLike other germline tumor suppressor genes, majority of tumors exhibit loss of wildtype allele",
                    "sub_points": [
                      "May be due to nonsense or splice site mutations, deletions, or insertions",
                      "Results in nonfunctional protein",
                      "Loss or inactivation of wildtype allele is necessary to alter normalTP53function",
                      "Like other germline tumor suppressor genes, majority of tumors exhibit loss of wildtype allele"
                    ]
                  },
                  {
                    "text": "TP53mutation database is maintained by International Agency for Research on Cancer (IARC), updated each year> 1,500 germline mutations are currently included",
                    "sub_points": [
                      "> 1,500 germline mutations are currently included"
                    ]
                  }
                ],
                "Function of p53 Protein": [
                  {
                    "text": "Transcription factor with central role to upregulate genes involved in cell cycle arrest, DNA replication, DNA repair, apoptosis, and senescence, in response to DNA damageBinds to double-stranded DNATransactivation function for promoter sequences",
                    "sub_points": [
                      "Binds to double-stranded DNA",
                      "Transactivation function for promoter sequences"
                    ]
                  },
                  {
                    "text": "Activated in response to various stress signalsProtects cells against genomic changes resulting from DNA damage",
                    "sub_points": [
                      "Protects cells against genomic changes resulting from DNA damage"
                    ]
                  },
                  {
                    "text": "p53 provides mechanism of protection against accumulation of genetic alterationsActivates DNA repair proteins when DNA has been damagedCell cycle arrest allows repair of genetic damage prior to DNA replication and fixation of mutationsTerminally damaged cells undergo apoptosis (programmed cell death)",
                    "sub_points": [
                      "Activates DNA repair proteins when DNA has been damaged",
                      "Cell cycle arrest allows repair of genetic damage prior to DNA replication and fixation of mutations",
                      "Terminally damaged cells undergo apoptosis (programmed cell death)"
                    ]
                  },
                  {
                    "text": "Central role of p53 as tumor suppressor has led to its title as \"the guardian of the genome\""
                  }
                ],
                "Immunohistochemistry for p53": [
                  {
                    "text": "p53 protein degrades rapidly with only 20-minute half-lifeSome mutant forms of p53 cannot transcriptionally activate MDM2Loss of this negative feedback loop results in p53 accumulation",
                    "sub_points": [
                      "Some mutant forms of p53 cannot transcriptionally activate MDM2",
                      "Loss of this negative feedback loop results in p53 accumulation"
                    ]
                  },
                  {
                    "text": "Many antibodies to p53 are availableTarget different epitopes on proteinMay detect only wildtype protein, mutant protein, or both",
                    "sub_points": [
                      "Target different epitopes on protein",
                      "May detect only wildtype protein, mutant protein, or both"
                    ]
                  },
                  {
                    "text": "Different patterns of positivity are observed in tumorsAbnormal pattern; complete absence: All cells negativeMay correlate with genomic alterations resulting in absence of p53 expression (e.g., deletions, nonsense, splice site mutations)Wildtype pattern: Mixture of negative cells and weak to strongly staining cellsMay correlate with presence of normalTP53However, some splice site mutations or truncating mutations can result in nonfunctional p53 that mimics normal patternSeen in normal tissuesMay be activated in response to inflammation or other stress signalsAbnormal pattern; overexpression: Diffuse strong positivity in majority of cellsOften correlates with mutations that stabilize protein (~ 96% of missense mutations)Some mutant forms of p53 have half-lives of up to 4 hours",
                    "sub_points": [
                      "Abnormal pattern; complete absence: All cells negativeMay correlate with genomic alterations resulting in absence of p53 expression (e.g., deletions, nonsense, splice site mutations)",
                      "May correlate with genomic alterations resulting in absence of p53 expression (e.g., deletions, nonsense, splice site mutations)",
                      "Wildtype pattern: Mixture of negative cells and weak to strongly staining cellsMay correlate with presence of normalTP53However, some splice site mutations or truncating mutations can result in nonfunctional p53 that mimics normal patternSeen in normal tissuesMay be activated in response to inflammation or other stress signals",
                      "May correlate with presence of normalTP53However, some splice site mutations or truncating mutations can result in nonfunctional p53 that mimics normal pattern",
                      "However, some splice site mutations or truncating mutations can result in nonfunctional p53 that mimics normal pattern",
                      "Seen in normal tissuesMay be activated in response to inflammation or other stress signals",
                      "May be activated in response to inflammation or other stress signals",
                      "Abnormal pattern; overexpression: Diffuse strong positivity in majority of cellsOften correlates with mutations that stabilize protein (~ 96% of missense mutations)Some mutant forms of p53 have half-lives of up to 4 hours",
                      "Often correlates with mutations that stabilize protein (~ 96% of missense mutations)Some mutant forms of p53 have half-lives of up to 4 hours",
                      "Some mutant forms of p53 have half-lives of up to 4 hours"
                    ]
                  },
                  {
                    "text": "Immunohistochemistry is not useful for screening for germline mutations because somatic mutations occur in ~ 50% of tumors"
                  }
                ]
              },
              "Associated Neoplasms": {
                "All Tumors": [
                  {
                    "text": "Risk for malignancy is 100x greater than for unaffected individuals"
                  },
                  {
                    "text": "Cancers arising in children(affecting ~ 30-40% of LFS)Osteosarcoma (~ 30%)Adrenal cortical carcinoma (~ 25%)CNS tumor (~ 26%)STS (~ 23%)Leukemia (~ 10%)Lymphoma, nephroblastoma, others (< 5%)",
                    "sub_points": [
                      "Osteosarcoma (~ 30%)",
                      "Adrenal cortical carcinoma (~ 25%)",
                      "CNS tumor (~ 26%)",
                      "STS (~ 23%)",
                      "Leukemia (~ 10%)",
                      "Lymphoma, nephroblastoma, others (< 5%)"
                    ]
                  },
                  {
                    "text": "Cancers arising in adults(affecting > 90% of LFS patients by age 70)Breast cancer (~ 79% of female patients)STS (~ 27%)Lung, prostate, colorectal, renal, pancreatic carcinoma, CNS tumors (all < 10%)",
                    "sub_points": [
                      "Breast cancer (~ 79% of female patients)",
                      "STS (~ 27%)",
                      "Lung, prostate, colorectal, renal, pancreatic carcinoma, CNS tumors (all < 10%)"
                    ]
                  }
                ],
                "Multiple Tumors": [
                  {
                    "text": "LFS patients have a high risk of developing multiple cancers~ 40% have multiple cancers7-20% of individuals with multiple primary tumors have LFS",
                    "sub_points": [
                      "~ 40% have multiple cancers7-20% of individuals with multiple primary tumors have LFS",
                      "7-20% of individuals with multiple primary tumors have LFS"
                    ]
                  },
                  {
                    "text": "Increased risk if 1st cancer occurred at early age"
                  },
                  {
                    "text": "Chemotherapy and radiation treatment for 1st cancer may elevate riskUsually occurs 6-12 years after 1st cancer2nd cancer may occur in radiation field",
                    "sub_points": [
                      "Usually occurs 6-12 years after 1st cancer",
                      "2nd cancer may occur in radiation field"
                    ]
                  }
                ],
                "Breast Carcinoma": [
                  {
                    "text": "TP53is 3rd most common germline mutation associated with breast carcinoma afterBRCA1andBRCA2"
                  },
                  {
                    "text": "Most common malignancy in LFS (~ 33% of total)"
                  },
                  {
                    "text": "Increased risk for women starts at age 20 and continues into adulthood~ 6% of women diagnosed before age 31 have germlineTP53mutation",
                    "sub_points": [
                      "~ 6% of women diagnosed before age 31 have germlineTP53mutation"
                    ]
                  },
                  {
                    "text": "~ 55% of women will develop breast cancer by age 45 (average age at diagnosis: 33)~ 100% lifetime risk for women~ 2% per year will develop subsequent contralateral breast cancerOverall, ~ 30% will have multiple breast carcinomas (~ 12% present with bilateral synchronous carcinomas)Breast carcinoma in men with LFS is very rare",
                    "sub_points": [
                      "~ 100% lifetime risk for women",
                      "~ 2% per year will develop subsequent contralateral breast cancerOverall, ~ 30% will have multiple breast carcinomas (~ 12% present with bilateral synchronous carcinomas)",
                      "Overall, ~ 30% will have multiple breast carcinomas (~ 12% present with bilateral synchronous carcinomas)",
                      "Breast carcinoma in men with LFS is very rare"
                    ]
                  },
                  {
                    "text": "Histologic typeNo special type (\"ductal\") is most commonOther types (lobular, mucinous, medullary) are also observedDistribution similar to that for sporadic breast tumorsMajority have high nuclear grade, solid growth pattern, and elevated mitotic rateNot associated with syncytial growth pattern, pushing borders, or prominent lymphocytic infiltrateThese are features commonly seen inBRCA1-associated cancers",
                    "sub_points": [
                      "No special type (\"ductal\") is most commonOther types (lobular, mucinous, medullary) are also observedDistribution similar to that for sporadic breast tumors",
                      "Other types (lobular, mucinous, medullary) are also observed",
                      "Distribution similar to that for sporadic breast tumors",
                      "Majority have high nuclear grade, solid growth pattern, and elevated mitotic rate",
                      "Not associated with syncytial growth pattern, pushing borders, or prominent lymphocytic infiltrateThese are features commonly seen inBRCA1-associated cancers",
                      "These are features commonly seen inBRCA1-associated cancers"
                    ]
                  },
                  {
                    "text": "Biologic typeER(+)/HER2(+): ~ 40-50%In contrast, this type is much less common in sporadic cancers (~ 10%)ER(+)/HER2(-) (luminal): ~ 40%Most common type of sporadic breast cancer (50-65%)ER(-)/HER2(+) (HER2): ~ 15%Similar to frequency in sporadic tumors (15-20%)ER(-)/HER2(-) (triple negative breast carcinoma): ~ 5%This type is more frequent in sporadic cancers (~ 15%)GermlineTP53mutations are rare amongst women ≤ 50 years of age with HER2(-) breast cancer (< 2%)",
                    "sub_points": [
                      "ER(+)/HER2(+): ~ 40-50%In contrast, this type is much less common in sporadic cancers (~ 10%)",
                      "In contrast, this type is much less common in sporadic cancers (~ 10%)",
                      "ER(+)/HER2(-) (luminal): ~ 40%Most common type of sporadic breast cancer (50-65%)",
                      "Most common type of sporadic breast cancer (50-65%)",
                      "ER(-)/HER2(+) (HER2): ~ 15%Similar to frequency in sporadic tumors (15-20%)",
                      "Similar to frequency in sporadic tumors (15-20%)",
                      "ER(-)/HER2(-) (triple negative breast carcinoma): ~ 5%This type is more frequent in sporadic cancers (~ 15%)GermlineTP53mutations are rare amongst women ≤ 50 years of age with HER2(-) breast cancer (< 2%)",
                      "This type is more frequent in sporadic cancers (~ 15%)",
                      "GermlineTP53mutations are rare amongst women ≤ 50 years of age with HER2(-) breast cancer (< 2%)"
                    ]
                  },
                  {
                    "text": "Favorable pCR rates observed among patients receiving neoadjuvant HER2-directed therapies (~ 70% pCR)Observed for both ER(+) and ER(-) tumors",
                    "sub_points": [
                      "Observed for both ER(+) and ER(-) tumors"
                    ]
                  }
                ],
                "Other Breast Tumors": [
                  {
                    "text": "Phyllodes tumorIncreased incidence in LFS compared with general population",
                    "sub_points": [
                      "Increased incidence in LFS compared with general population"
                    ]
                  },
                  {
                    "text": "Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)These tumors arise in association with textured breast implants and present as late periimplant effusions5 cases have occurred in LFS patients",
                    "sub_points": [
                      "These tumors arise in association with textured breast implants and present as late periimplant effusions",
                      "5 cases have occurred in LFS patients"
                    ]
                  }
                ],
                "Soft Tissue Sarcoma (STS)": [
                  {
                    "text": "2nd most common malignancy in LFS (~ 20-30% of total)Occurs in both children and adults5-10% of children with STS have germlineTP53mutations",
                    "sub_points": [
                      "Occurs in both children and adults5-10% of children with STS have germlineTP53mutations",
                      "5-10% of children with STS have germlineTP53mutations"
                    ]
                  },
                  {
                    "text": "Histologic typesRhabdomyosarcoma (~ 29% of LFS-associated STS)Most common in individuals < 5 years of age~ 50% of children with rhabdomyosarcoma, but without personal or family history of LFS, have germline mutations inTP53Embryonal rhabdomyosarcoma of anaplastic subtype is most common9% of individuals with this sarcoma have LFSLeiomyosarcoma (~ 25% of LFS-associated STS)Liposarcoma (~ 12% of LFS-associated STS)Fibrohistiocytic tumors (~ 11% of LFS-associated STS)Ewing sarcoma, angiosarcoma, and gastrointestinal stromal tumor (GIST) have not been associated with LFS",
                    "sub_points": [
                      "Rhabdomyosarcoma (~ 29% of LFS-associated STS)Most common in individuals < 5 years of age~ 50% of children with rhabdomyosarcoma, but without personal or family history of LFS, have germline mutations inTP53Embryonal rhabdomyosarcoma of anaplastic subtype is most common9% of individuals with this sarcoma have LFS",
                      "Most common in individuals < 5 years of age~ 50% of children with rhabdomyosarcoma, but without personal or family history of LFS, have germline mutations inTP53",
                      "~ 50% of children with rhabdomyosarcoma, but without personal or family history of LFS, have germline mutations inTP53",
                      "Embryonal rhabdomyosarcoma of anaplastic subtype is most common9% of individuals with this sarcoma have LFS",
                      "9% of individuals with this sarcoma have LFS",
                      "Leiomyosarcoma (~ 25% of LFS-associated STS)",
                      "Liposarcoma (~ 12% of LFS-associated STS)",
                      "Fibrohistiocytic tumors (~ 11% of LFS-associated STS)",
                      "Ewing sarcoma, angiosarcoma, and gastrointestinal stromal tumor (GIST) have not been associated with LFS"
                    ]
                  }
                ],
                "Osteosarcoma": [
                  {
                    "text": "~ 15% of LFS tumors2-3% of individuals with osteosarcoma have LFS",
                    "sub_points": [
                      "2-3% of individuals with osteosarcoma have LFS"
                    ]
                  },
                  {
                    "text": "Most commonly develop during adolescence"
                  },
                  {
                    "text": "10% of individuals with osteosarcoma diagnosed before age 20 have germlineTP53mutations"
                  }
                ],
                "CNS Tumors": [
                  {
                    "text": "~ 13% of LFS tumors"
                  },
                  {
                    "text": "~ 80% of LFS-associated CNS tumors occur in childhood2-10% of children with CNS tumors have LFS",
                    "sub_points": [
                      "2-10% of children with CNS tumors have LFS"
                    ]
                  },
                  {
                    "text": "Smaller 2nd peak in incidence in 4th-5th decades"
                  },
                  {
                    "text": "Histologic typesGlioblastomas and other gliomas (~ 45%)Occur in children and adultsChoroid plexus tumors (~ 30%)Occur in infants and young adults~ 50% of children with these tumors have germlineTP53mutationsMedulloblastoma (~ 20%)Occur in childrenEpendymoma (~ 5-10%)Occur in children",
                    "sub_points": [
                      "Glioblastomas and other gliomas (~ 45%)Occur in children and adults",
                      "Occur in children and adults",
                      "Choroid plexus tumors (~ 30%)Occur in infants and young adults~ 50% of children with these tumors have germlineTP53mutations",
                      "Occur in infants and young adults",
                      "~ 50% of children with these tumors have germlineTP53mutations",
                      "Medulloblastoma (~ 20%)Occur in children",
                      "Occur in children",
                      "Ependymoma (~ 5-10%)Occur in children",
                      "Occur in children"
                    ]
                  }
                ],
                "Adrenal Cortical Carcinoma": [
                  {
                    "text": "~ 13% of LFS tumors"
                  },
                  {
                    "text": "80% of children with this carcinoma have LFSMedian age of onset: 3 yearsSome are due to de novo mutations",
                    "sub_points": [
                      "Median age of onset: 3 years",
                      "Some are due to de novo mutations"
                    ]
                  },
                  {
                    "text": "Cases in adults usually occur before 50 years of age"
                  }
                ],
                "Hematologic Malignancies": [
                  {
                    "text": "Include both lymphoma and leukemia"
                  },
                  {
                    "text": "Children with germlineTP53mutations with acute lymphoblastic leukemia are older (~ 15 years vs. ~ 7 years), have lower survival, and are at greater risk for 2nd malignancies compared to children without germline mutations"
                  }
                ],
                "Other Cancers": [
                  {
                    "text": "Lung cancer (lepidic pattern), gastrointestinal cancers (colon, gastric, pancreatic), prostate cancer"
                  }
                ]
              },
              "Screening for Li-Fraumeni Syndrome": {
                "Population to Be Screened": [
                  {
                    "text": "When strict criteria for LFS are met (e.g., classic or Chompret criteria),TP53mutations are found in 60-80%However, ~ 45-60% of individuals with germlineTP53mutations will not fulfill these criteria",
                    "sub_points": [
                      "However, ~ 45-60% of individuals with germlineTP53mutations will not fulfill these criteria"
                    ]
                  },
                  {
                    "text": "Recommendations for germline screening have broadened due to improvements in genetic testingMajority ofTP53mutations are currently detected by multigene testing in patients not fulfilling strict criteria",
                    "sub_points": [
                      "Majority ofTP53mutations are currently detected by multigene testing in patients not fulfilling strict criteria"
                    ]
                  },
                  {
                    "text": "Classic criteria for screeningMust have all 3 of the followingDiagnosed with sarcoma at age < 451st-degree relative with cancer at age < 45Additional 1st- or 2nd-degree relative in same lineage with cancer at age < 45 or sarcoma at any age70-80% of individuals fulfilling these criteria haveTP53germline mutations",
                    "sub_points": [
                      "Must have all 3 of the followingDiagnosed with sarcoma at age < 451st-degree relative with cancer at age < 45Additional 1st- or 2nd-degree relative in same lineage with cancer at age < 45 or sarcoma at any age",
                      "Diagnosed with sarcoma at age < 45",
                      "1st-degree relative with cancer at age < 45",
                      "Additional 1st- or 2nd-degree relative in same lineage with cancer at age < 45 or sarcoma at any age",
                      "70-80% of individuals fulfilling these criteria haveTP53germline mutations"
                    ]
                  },
                  {
                    "text": "Chompret criteria for screening (2015)Person to be tested must have 1 or more of the followingFamilial presentationMust have tumor belonging to LFS spectrum before age 46 (including premenopausal breast cancer, STS, osteosarcoma, CNS tumor, or adrenal cortical carcinoma)andat least one 1st- or 2nd-degree relative with LFS tumor before age 56 or with multiple tumors (excluding breast cancer if person to be tested has breast cancer)Multiple primary tumorsMust have multiple tumors (excluding multiple breast tumors), 2 of which belong to LFS tumor spectrum and 1st of which occurred before age 46Rare tumorsPerson to be tested has adrenal cortical carcinoma, choroid plexus tumor, or rhabdomyosarcoma of embryonal anaplastic subtype, irrespective of family historyEarly-onset breast cancerPerson to be tested has breast carcinoma before age 31~ 80-90% of individuals fulfilling first 3 criteria have germlineTP53mutationsWomen with breast carcinoma before age 31 have ~ 14% likelihood of germlineTP53mutation",
                    "sub_points": [
                      "Person to be tested must have 1 or more of the followingFamilial presentationMust have tumor belonging to LFS spectrum before age 46 (including premenopausal breast cancer, STS, osteosarcoma, CNS tumor, or adrenal cortical carcinoma)andat least one 1st- or 2nd-degree relative with LFS tumor before age 56 or with multiple tumors (excluding breast cancer if person to be tested has breast cancer)Multiple primary tumorsMust have multiple tumors (excluding multiple breast tumors), 2 of which belong to LFS tumor spectrum and 1st of which occurred before age 46Rare tumorsPerson to be tested has adrenal cortical carcinoma, choroid plexus tumor, or rhabdomyosarcoma of embryonal anaplastic subtype, irrespective of family historyEarly-onset breast cancerPerson to be tested has breast carcinoma before age 31",
                      "Familial presentationMust have tumor belonging to LFS spectrum before age 46 (including premenopausal breast cancer, STS, osteosarcoma, CNS tumor, or adrenal cortical carcinoma)andat least one 1st- or 2nd-degree relative with LFS tumor before age 56 or with multiple tumors (excluding breast cancer if person to be tested has breast cancer)",
                      "Must have tumor belonging to LFS spectrum before age 46 (including premenopausal breast cancer, STS, osteosarcoma, CNS tumor, or adrenal cortical carcinoma)andat least one 1st- or 2nd-degree relative with LFS tumor before age 56 or with multiple tumors (excluding breast cancer if person to be tested has breast cancer)",
                      "Multiple primary tumorsMust have multiple tumors (excluding multiple breast tumors), 2 of which belong to LFS tumor spectrum and 1st of which occurred before age 46",
                      "Must have multiple tumors (excluding multiple breast tumors), 2 of which belong to LFS tumor spectrum and 1st of which occurred before age 46",
                      "Rare tumorsPerson to be tested has adrenal cortical carcinoma, choroid plexus tumor, or rhabdomyosarcoma of embryonal anaplastic subtype, irrespective of family history",
                      "Person to be tested has adrenal cortical carcinoma, choroid plexus tumor, or rhabdomyosarcoma of embryonal anaplastic subtype, irrespective of family history",
                      "Early-onset breast cancerPerson to be tested has breast carcinoma before age 31",
                      "Person to be tested has breast carcinoma before age 31",
                      "~ 80-90% of individuals fulfilling first 3 criteria have germlineTP53mutationsWomen with breast carcinoma before age 31 have ~ 14% likelihood of germlineTP53mutation",
                      "Women with breast carcinoma before age 31 have ~ 14% likelihood of germlineTP53mutation"
                    ]
                  }
                ],
                "Genetic Testing": [
                  {
                    "text": "DNA sequencing is the gold standard for identifyingTP53mutations> 200 different pathogenic mutations have been identifiedSequence analysis of exons 2-11 detects ~ 95% of mutationsDeletions of gene, promoter region, or exon 1 may be present in ~ 1% of familiesDuplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis",
                    "sub_points": [
                      "> 200 different pathogenic mutations have been identified",
                      "Sequence analysis of exons 2-11 detects ~ 95% of mutations",
                      "Deletions of gene, promoter region, or exon 1 may be present in ~ 1% of families",
                      "Duplications, inversions, large deletions, and mutations in noncoding regions may not be detected by standard sequence analysis"
                    ]
                  },
                  {
                    "text": "De novo germline mutations account for ~ 12% of all germline mutationsPathogenic de novo mutations will not have family history, but person and their children are at high risk",
                    "sub_points": [
                      "Pathogenic de novo mutations will not have family history, but person and their children are at high risk"
                    ]
                  },
                  {
                    "text": "When abnormal results are found in individuals without personal or family history of cancer, not all will be found to be pathogenic germline mutationsFalse-positive results~ 40% of results indicating individual has genetic variant associated with cancer risk may be false-positives when direct to consumer testing is usedAbnormal result needs to be confirmed by certified laboratoryGermline mutations that do not increase risk of cancerModels are being developed to separate mutations that confer risk from polymorphic variantsSomatic mutations in hematopoietic cellsAcquired aberrant clonal expansions (ACEs) due to clonal hematopoiesis of indeterminate potential (CHIP) can occur in hematopoietic cellsMore common in older individuals and after chemotherapyTesting of additional tissue samples &/or relatives may be necessary to distinguish ACE from germline mutationMay account for ~ 20% ofTP53-positive testsIncreases risk for hematopoietic malignancy and cardiovascular diseaseRelatives and offspring are not at higher riskSomatic mutations in solid tissueMutations in solid tissue may occur during embryogenesis and result in mosaicismMay increase risk of primary and secondary tumors~ 5% of patients with tumors characteristic of LFS (adrenal cortical carcinoma, choroid plexus tumor, or breast cancer at < 31 years) are mosaic for somaticTP53mutationMay increase risk for secondary tumors after chemotherapy or radiationRelatives and offspring are not at higher risk",
                    "sub_points": [
                      "False-positive results~ 40% of results indicating individual has genetic variant associated with cancer risk may be false-positives when direct to consumer testing is usedAbnormal result needs to be confirmed by certified laboratory",
                      "~ 40% of results indicating individual has genetic variant associated with cancer risk may be false-positives when direct to consumer testing is used",
                      "Abnormal result needs to be confirmed by certified laboratory",
                      "Germline mutations that do not increase risk of cancerModels are being developed to separate mutations that confer risk from polymorphic variants",
                      "Models are being developed to separate mutations that confer risk from polymorphic variants",
                      "Somatic mutations in hematopoietic cellsAcquired aberrant clonal expansions (ACEs) due to clonal hematopoiesis of indeterminate potential (CHIP) can occur in hematopoietic cellsMore common in older individuals and after chemotherapyTesting of additional tissue samples &/or relatives may be necessary to distinguish ACE from germline mutationMay account for ~ 20% ofTP53-positive testsIncreases risk for hematopoietic malignancy and cardiovascular diseaseRelatives and offspring are not at higher risk",
                      "Acquired aberrant clonal expansions (ACEs) due to clonal hematopoiesis of indeterminate potential (CHIP) can occur in hematopoietic cellsMore common in older individuals and after chemotherapyTesting of additional tissue samples &/or relatives may be necessary to distinguish ACE from germline mutationMay account for ~ 20% ofTP53-positive tests",
                      "More common in older individuals and after chemotherapy",
                      "Testing of additional tissue samples &/or relatives may be necessary to distinguish ACE from germline mutation",
                      "May account for ~ 20% ofTP53-positive tests",
                      "Increases risk for hematopoietic malignancy and cardiovascular disease",
                      "Relatives and offspring are not at higher risk",
                      "Somatic mutations in solid tissueMutations in solid tissue may occur during embryogenesis and result in mosaicismMay increase risk of primary and secondary tumors~ 5% of patients with tumors characteristic of LFS (adrenal cortical carcinoma, choroid plexus tumor, or breast cancer at < 31 years) are mosaic for somaticTP53mutationMay increase risk for secondary tumors after chemotherapy or radiationRelatives and offspring are not at higher risk",
                      "Mutations in solid tissue may occur during embryogenesis and result in mosaicism",
                      "May increase risk of primary and secondary tumors~ 5% of patients with tumors characteristic of LFS (adrenal cortical carcinoma, choroid plexus tumor, or breast cancer at < 31 years) are mosaic for somaticTP53mutation",
                      "~ 5% of patients with tumors characteristic of LFS (adrenal cortical carcinoma, choroid plexus tumor, or breast cancer at < 31 years) are mosaic for somaticTP53mutation",
                      "May increase risk for secondary tumors after chemotherapy or radiation",
                      "Relatives and offspring are not at higher risk"
                    ]
                  }
                ]
              },
              "National Comprehensive Cancer Network (NCCN) Guidelines": {
                "Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2025 - November, 2024 (accessed 11/22/2024)": [
                  {
                    "text": "Li-Fraumeni Syndrome Management provides guidelines for diagnosis, adult surveillance, and pediatric surveillance"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      },
      "Other Types of Malignancy": {
        "name": "Other Types of Malignancy",
        "url": "https://app.pathprimer.com/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
        "topics": {
          "Lymphoma": {
            "name": "Lymphoma",
            "url": "https://app.pathprimer.com/document/3c620162-b0cb-4453-9c61-550a1ebeb33d/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Primary breast lymphoma (~ 25%): Restricted to breast parenchyma and regional nodes when initially diagnosed"
                  },
                  {
                    "text": "Secondary breast lymphoma (~ 75%): Breast involvement in patient with known systemic disease"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Rare; < 0.5% of all breast malignancies"
                  },
                  {
                    "text": "Majority of patients present with a breast mass by palpation or imaging"
                  },
                  {
                    "text": "There are no specific features to suggest lymphoma"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Majority of breast lymphomas are derived from B cells (> 90%) with only rare T-cell lymphomas (~ 5%)"
                  },
                  {
                    "text": "> 90% are non-Hodgkin B-cell lymphomas"
                  },
                  {
                    "text": "Diffuse large B-cell lymphoma ~ 60-80%"
                  },
                  {
                    "text": "Marginal zone lymphoma ~ 10-30%"
                  },
                  {
                    "text": "Follicular lymphoma ~ 10-20%"
                  },
                  {
                    "text": "Mantle cell lymphoma < 1%"
                  },
                  {
                    "text": "Chronic lymphocytic leukemia/small lymphocytic lymphoma < 1%"
                  },
                  {
                    "text": "Burkitt lymphoma < 6%"
                  },
                  {
                    "text": "Breast implant-associated large cell lymphoma < 1%"
                  },
                  {
                    "text": "Peripheral T-cell lymphoma < 1%"
                  },
                  {
                    "text": "Hodgkin lymphoma < 1%"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Acute leukemia"
                  },
                  {
                    "text": "Myeloma"
                  },
                  {
                    "text": "Invasive carcinoma"
                  },
                  {
                    "text": "Lymphocytic/diabetic mastopathy"
                  },
                  {
                    "text": "Lupus mastitis"
                  },
                  {
                    "text": "IgG4-related sclerosing mastitis"
                  },
                  {
                    "text": "Rosai-Dorfman disease"
                  },
                  {
                    "text": "Inflammatory myofibroblastic tumor"
                  },
                  {
                    "text": "T-cell lymphocytic lobulitis"
                  },
                  {
                    "text": "Reactive inflammatory infiltrate"
                  },
                  {
                    "text": "Intramammary lymph node"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Non-Hodgkin lymphoma (NHL)"
                  }
                ],
                "Definitions": [
                  {
                    "text": "A clonal population of malignant lymphocytes involving breast"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Overview": [
                  {
                    "text": "Lymphomas occurring at other sites can also involve the breast"
                  },
                  {
                    "text": "Primary breast lymphoma: Restricted to breast parenchyma and regional nodes when initially diagnosed (~ 25% of cases)No prior history of lymphoma involving other sitesSome patients have bilateral breast involvementSome definitions include patients with initial presentation in breast with distant involvement discovered during staging",
                    "sub_points": [
                      "No prior history of lymphoma involving other sitesSome patients have bilateral breast involvement",
                      "Some patients have bilateral breast involvement",
                      "Some definitions include patients with initial presentation in breast with distant involvement discovered during staging"
                    ]
                  },
                  {
                    "text": "Secondary breast lymphoma: Breast involvement in patients with systemic disease (~ 75% of cases)Usually involve breast parenchyma but occasionally involve intramammary lymph node(s)",
                    "sub_points": [
                      "Usually involve breast parenchyma but occasionally involve intramammary lymph node(s)"
                    ]
                  },
                  {
                    "text": "~ 2/3 have a prior history of lymphoma, and for ~ 1/3, the breast biopsy is their 1st diagnosis"
                  },
                  {
                    "text": "Lymphomas of the breast need to be distinguished from normal physiologic infiltrates (e.g., regression after pregnancy), chronic inflammatory reactions, autoimmune disease, and reactions to carcinomas"
                  },
                  {
                    "text": "Lymphomas also need to be distinguished from carcinomas (especially lobular carcinoma) and metastatic melanoma"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare; < 0.5% of all breast malignancies1% of all NHL< 3% of extranodal lymphomas",
                    "sub_points": [
                      "1% of all NHL",
                      "< 3% of extranodal lymphomas"
                    ]
                  }
                ],
                "Age": [
                  {
                    "text": "Ranges from 12-90 years with bimodal peaks in mid 30s and mid 60s"
                  }
                ],
                "Sex": [
                  {
                    "text": "> 98% are females"
                  },
                  {
                    "text": "The majority of cases in males are diffuse large B-cell lymphomas"
                  }
                ],
                "Presentation": [
                  {
                    "text": "80% present as a palpable breast mass"
                  },
                  {
                    "text": "20% present as a mammographic densityThere are no specific features to suggest lymphoma",
                    "sub_points": [
                      "There are no specific features to suggest lymphoma"
                    ]
                  },
                  {
                    "text": "A rare type of presentation mimics inflammatory breast carcinomaBreast is edematous and swollen due to lymphatic blockage by involved axillary lymph nodes",
                    "sub_points": [
                      "Breast is edematous and swollen due to lymphatic blockage by involved axillary lymph nodes"
                    ]
                  },
                  {
                    "text": "B symptoms (fever, night sweats, and weight loss) or diffuse lymphadenopathy are uncommon"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Appropriate treatment is dependent on type of lymphoma"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Prognosis is dependent on type of lymphoma"
                  }
                ]
              },
              "IMAGING": {
                "Mammographic Findings": [
                  {
                    "text": "~ 20% of cases present as mammographic densityBorders may be irregular or circumscribedThere are no specific imaging findings to identify mass as lymphomaCalcifications would be unusual but are rarely associated with foci of necrosis",
                    "sub_points": [
                      "Borders may be irregular or circumscribed",
                      "There are no specific imaging findings to identify mass as lymphoma",
                      "Calcifications would be unusual but are rarely associated with foci of necrosis"
                    ]
                  },
                  {
                    "text": "If patient has systemic lymphoma, bilateral lymph node enlargement may be present"
                  },
                  {
                    "text": "Rare cases present as diffuse breast involvement with trabecular pattern and skin thickening"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Gross mass is usually white to gray with fleshy appearanceMedian size: 4 cm",
                    "sub_points": [
                      "Median size: 4 cm"
                    ]
                  },
                  {
                    "text": "The majority of cases are diagnosed by core needle biopsy and excision is not necessary"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "The majority of breast lymphomas are derived from B cells (> 90%) with only rare T-cell lymphomas (~ 5%)"
                  },
                  {
                    "text": "Diffuse large B-cell lymphoma (~ 60-80%)This is the most common breast lymphoma in both females and malesDiffuse proliferation of large cells (5x size of lymphocyte)Nuclei may have 1 or multiple nucleoliMature B-cell phenotypePositive for CD20, CD79a, and pax-5Relapse often occurs in ipsilateral or contralateral breastAlso occurs in other extranodal sites, including CNSCan closely resemble poorly differentiated carcinoma or melanomaShould be considered in differential diagnosis for high-grade malignancies invading as dyscohesive single cells, negative for hormone receptors and HER2, in absence of ductal carcinoma in situ (DCIS)Broad spectrum and high molecular weight keratins will identify carcinomas> 30% of these lymphomas are p63(+), as are some carcinomas",
                    "sub_points": [
                      "This is the most common breast lymphoma in both females and males",
                      "Diffuse proliferation of large cells (5x size of lymphocyte)Nuclei may have 1 or multiple nucleoli",
                      "Nuclei may have 1 or multiple nucleoli",
                      "Mature B-cell phenotypePositive for CD20, CD79a, and pax-5",
                      "Positive for CD20, CD79a, and pax-5",
                      "Relapse often occurs in ipsilateral or contralateral breastAlso occurs in other extranodal sites, including CNS",
                      "Also occurs in other extranodal sites, including CNS",
                      "Can closely resemble poorly differentiated carcinoma or melanomaShould be considered in differential diagnosis for high-grade malignancies invading as dyscohesive single cells, negative for hormone receptors and HER2, in absence of ductal carcinoma in situ (DCIS)Broad spectrum and high molecular weight keratins will identify carcinomas> 30% of these lymphomas are p63(+), as are some carcinomas",
                      "Should be considered in differential diagnosis for high-grade malignancies invading as dyscohesive single cells, negative for hormone receptors and HER2, in absence of ductal carcinoma in situ (DCIS)",
                      "Broad spectrum and high molecular weight keratins will identify carcinomas> 30% of these lymphomas are p63(+), as are some carcinomas",
                      "> 30% of these lymphomas are p63(+), as are some carcinomas"
                    ]
                  },
                  {
                    "text": "Marginal zone lymphoma (~ 10-30%)Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue [(MALT) lymphoma] can be primary or secondary in breastSome patients have a history of autoimmune diseaseDiffuse proliferation of intermediate-size cells (2-3x size of lymphocyte)Monocytoid or centrocyte-like with round to irregular nuclei or plasmacytoidScattered large immunoblasts with prominent nucleoli can be presentTumor cells may be associated with hyperplastic B-cell folliclesInvolve marginal zone at edge of mantle zone of follicleCan mimic reactive follicles or follicular lymphomaLymphoepithelial lesions may be seen if tumor involves breast epitheliumTumor cells are seen within ducts and lobulesCharacteristic of MALT lymphomas in generalLymphocytes in epithelium can mimic lobular neoplasia or carcinoma in situThese lesions may be absent or inconspicuous in breast tissueTransformation to large B-cell lymphoma can occurLymphomas with a plasmacytoid appearance can resemble invasive lobular carcinoma if there is a single cell infiltrative patternNormal phenotype of marginal zone/memory B cellsPositive for CD20, CD79a, pax-5, BCL2",
                    "sub_points": [
                      "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue [(MALT) lymphoma] can be primary or secondary in breastSome patients have a history of autoimmune disease",
                      "Some patients have a history of autoimmune disease",
                      "Diffuse proliferation of intermediate-size cells (2-3x size of lymphocyte)Monocytoid or centrocyte-like with round to irregular nuclei or plasmacytoidScattered large immunoblasts with prominent nucleoli can be present",
                      "Monocytoid or centrocyte-like with round to irregular nuclei or plasmacytoid",
                      "Scattered large immunoblasts with prominent nucleoli can be present",
                      "Tumor cells may be associated with hyperplastic B-cell folliclesInvolve marginal zone at edge of mantle zone of follicleCan mimic reactive follicles or follicular lymphoma",
                      "Involve marginal zone at edge of mantle zone of follicle",
                      "Can mimic reactive follicles or follicular lymphoma",
                      "Lymphoepithelial lesions may be seen if tumor involves breast epitheliumTumor cells are seen within ducts and lobulesCharacteristic of MALT lymphomas in generalLymphocytes in epithelium can mimic lobular neoplasia or carcinoma in situThese lesions may be absent or inconspicuous in breast tissue",
                      "Tumor cells are seen within ducts and lobules",
                      "Characteristic of MALT lymphomas in general",
                      "Lymphocytes in epithelium can mimic lobular neoplasia or carcinoma in situ",
                      "These lesions may be absent or inconspicuous in breast tissue",
                      "Transformation to large B-cell lymphoma can occur",
                      "Lymphomas with a plasmacytoid appearance can resemble invasive lobular carcinoma if there is a single cell infiltrative pattern",
                      "Normal phenotype of marginal zone/memory B cellsPositive for CD20, CD79a, pax-5, BCL2",
                      "Positive for CD20, CD79a, pax-5, BCL2"
                    ]
                  },
                  {
                    "text": "Follicular lymphoma (~ 10-20%)Can be primary or secondary with involvement of intramammary lymph nodesNeoplastic back-to-back neoplastic folliclesComposed of centrocytes (small cleaved cells without nucleoli) and centroblasts (large noncleaved cells with multiple nucleoli)Can mimic reactive changesGenerally lack tingible body macrophages and mitoses are absent or rareLymphoepithelial lesions are generally not seenB-cell phenotypePositive for CD20 and CD79aInfiltration in collagenous tissue in single-file pattern can mimic invasive lobular carcinoma",
                    "sub_points": [
                      "Can be primary or secondary with involvement of intramammary lymph nodes",
                      "Neoplastic back-to-back neoplastic folliclesComposed of centrocytes (small cleaved cells without nucleoli) and centroblasts (large noncleaved cells with multiple nucleoli)Can mimic reactive changesGenerally lack tingible body macrophages and mitoses are absent or rare",
                      "Composed of centrocytes (small cleaved cells without nucleoli) and centroblasts (large noncleaved cells with multiple nucleoli)",
                      "Can mimic reactive changes",
                      "Generally lack tingible body macrophages and mitoses are absent or rare",
                      "Lymphoepithelial lesions are generally not seen",
                      "B-cell phenotypePositive for CD20 and CD79a",
                      "Positive for CD20 and CD79a",
                      "Infiltration in collagenous tissue in single-file pattern can mimic invasive lobular carcinoma"
                    ]
                  },
                  {
                    "text": "Mantle cell lymphoma(< 1%)Small cells with slightly irregular nuclei",
                    "sub_points": [
                      "Small cells with slightly irregular nuclei"
                    ]
                  },
                  {
                    "text": "Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (< 1%)Typically presents with elevated white blood cell countsDiagnosis usually well known clinicallyConsists of small mature lymphocytes, prolymphocytes, and paraimmunoblastsCan resemble follicular lymphomaA pattern surrounding epithelial elements and blood vessels can closely mimic lymphocytic/diabetic mastopathy or T-cell lymphocytic lobulitisHowever, the lymphoma usually also involves intervening breast stromaThe stroma is usually not densely hyalinized, as is seen in lymphocytic mastopathyCan be seen in breast or lymph nodes as incidental finding in biopsies performed for different lesion",
                    "sub_points": [
                      "Typically presents with elevated white blood cell countsDiagnosis usually well known clinically",
                      "Diagnosis usually well known clinically",
                      "Consists of small mature lymphocytes, prolymphocytes, and paraimmunoblastsCan resemble follicular lymphoma",
                      "Can resemble follicular lymphoma",
                      "A pattern surrounding epithelial elements and blood vessels can closely mimic lymphocytic/diabetic mastopathy or T-cell lymphocytic lobulitisHowever, the lymphoma usually also involves intervening breast stromaThe stroma is usually not densely hyalinized, as is seen in lymphocytic mastopathy",
                      "However, the lymphoma usually also involves intervening breast stroma",
                      "The stroma is usually not densely hyalinized, as is seen in lymphocytic mastopathy",
                      "Can be seen in breast or lymph nodes as incidental finding in biopsies performed for different lesion"
                    ]
                  },
                  {
                    "text": "Burkitt lymphoma (BL) (< 6%)Occurs as endemic BL, sporadic BL, and immunodeficiency-associated BLBL of breast is most common in endemic BLEndemic BL occurs in malaria endemic areas, including equatorial Africa, Brazil, and Papua New GuineaEpstein-Barr virus infection is present in almost all patients (> 95%)Malaria may reduce resistance to viral infectionUsually occurs in young pregnant or lactating women and may be bilateralPresents with breast swelling, rather than discrete massDiffuse proliferation of medium-sized cells with basophilic cytoplasm, round, noncleaved nuclei with multiple nucleoliHigh mitotic rateStarry-sky appearance (\"stars\" are tingible body macrophages)Mature B-cell phenotypePositive for CD20, CD79a, and pax-5Tumors have chromosomal translocations involvingMYCgene and 1 of the immunoglobulin genes",
                    "sub_points": [
                      "Occurs as endemic BL, sporadic BL, and immunodeficiency-associated BL",
                      "BL of breast is most common in endemic BLEndemic BL occurs in malaria endemic areas, including equatorial Africa, Brazil, and Papua New GuineaEpstein-Barr virus infection is present in almost all patients (> 95%)Malaria may reduce resistance to viral infection",
                      "Endemic BL occurs in malaria endemic areas, including equatorial Africa, Brazil, and Papua New Guinea",
                      "Epstein-Barr virus infection is present in almost all patients (> 95%)Malaria may reduce resistance to viral infection",
                      "Malaria may reduce resistance to viral infection",
                      "Usually occurs in young pregnant or lactating women and may be bilateralPresents with breast swelling, rather than discrete mass",
                      "Presents with breast swelling, rather than discrete mass",
                      "Diffuse proliferation of medium-sized cells with basophilic cytoplasm, round, noncleaved nuclei with multiple nucleoliHigh mitotic rateStarry-sky appearance (\"stars\" are tingible body macrophages)",
                      "High mitotic rate",
                      "Starry-sky appearance (\"stars\" are tingible body macrophages)",
                      "Mature B-cell phenotypePositive for CD20, CD79a, and pax-5",
                      "Positive for CD20, CD79a, and pax-5",
                      "Tumors have chromosomal translocations involvingMYCgene and 1 of the immunoglobulin genes"
                    ]
                  },
                  {
                    "text": "Breast implant-associated anaplastic large T-cell lymphoma (BIA-ALCL) (< 1%)This lymphoma was 1st reported in 1997> 600 cases worldwide and 17 deaths as of 2019Risk is ~ 1 in 3,000-30,000 for women with textured implantsStrong association with textured implants, which can be filled with silicone or salineUsually presents 8-11 years after surgery (range < 1 to 44 years)Most common presentation is a late-onset seromaLess common is a palpable mass or lymphadenopathyIt has been hypothesized that the irregular surface promotes bacterial biofilmsA chronic sustained T-cell response to the implant and bacteria may predispose to lymphomaAn association with viral infection/reactivation has also been proposedImportant prognostic feature is the extent of tumorRestricted to seroma cavity and capsule (~ 70% of cases): 5-year survival 100%Mass beyond capsule (~ 30% of cases): 5-year survival 84%Regional lymph node involvement: 5-year survival 75%It is recommended that known or suspected cases have the implant removed with the intact surrounding capsule and tissueBIA-ALCL has distinct features compared to other lymphomasMost have an activated CD4(+) memory T-cell phenotypeUpregulation of genes associated with cell motility, myeloid cell differentiation, and viral gene transcriptionAll cases should be reported to the Federal Drug Association (FDA) MedWatch safety information and adverse event reporting programhttps://www.accessdata.fda.gov/scripts/medwatch/index.dfm?action=reporting.home (accessed September 2, 2020)Cases can also be reported to the BIA-ALCL patient registry and outcomes for breast implants and anaplastic lymphoma etiology and epidemiology (PROFILE) registryCollaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundationhttps://www.thepsf.org/research/registries/profile (accessed September 5, 2020)Guidelines have been issued for the pathologic evaluation of specimensPhotographs are taken to document the implant, capsule, and tissueEffusion fluid is submitted for cytologic evaluation and flow cytometryFluid involved by lymphoma is usually cloudy, viscous, and has membranous strandsThe specimen should be oriented and the margins inkedThe capsule is pinned out and fixed in formalin overnightPerpendicular sections of the capsule are sampled from each margin (at least 2 sections per cassette in 6 cassettes)Lymphoma can be present in grossly normal capsulesAll mass-forming lesions and irregular areas of the capsule are also sampledAnaplastic tumor cells are present in seroma fluid, capsule, &/or surrounding tissueALK1(-)CD30 (membrane and Golgi) strongly positiveT-cell markers: Variably presentMost cases lack T-cell receptors α/β or γ/δ or have gene mutations resulting in a defective T-cell receptor phenotypeSome cases can be positive for EMA and negative for typical T-cell markersTumor cells in tissue are associated with an inflammatory infiltrate with numerous eosinophilsOnly 11 cases of B-cell neoplasms have been reported in association with breast implants7 lymphomas and 4 plasma cell neoplasms",
                    "sub_points": [
                      "This lymphoma was 1st reported in 1997> 600 cases worldwide and 17 deaths as of 2019Risk is ~ 1 in 3,000-30,000 for women with textured implants",
                      "> 600 cases worldwide and 17 deaths as of 2019",
                      "Risk is ~ 1 in 3,000-30,000 for women with textured implants",
                      "Strong association with textured implants, which can be filled with silicone or salineUsually presents 8-11 years after surgery (range < 1 to 44 years)Most common presentation is a late-onset seromaLess common is a palpable mass or lymphadenopathyIt has been hypothesized that the irregular surface promotes bacterial biofilmsA chronic sustained T-cell response to the implant and bacteria may predispose to lymphomaAn association with viral infection/reactivation has also been proposed",
                      "Usually presents 8-11 years after surgery (range < 1 to 44 years)",
                      "Most common presentation is a late-onset seromaLess common is a palpable mass or lymphadenopathy",
                      "Less common is a palpable mass or lymphadenopathy",
                      "It has been hypothesized that the irregular surface promotes bacterial biofilmsA chronic sustained T-cell response to the implant and bacteria may predispose to lymphomaAn association with viral infection/reactivation has also been proposed",
                      "A chronic sustained T-cell response to the implant and bacteria may predispose to lymphoma",
                      "An association with viral infection/reactivation has also been proposed",
                      "Important prognostic feature is the extent of tumorRestricted to seroma cavity and capsule (~ 70% of cases): 5-year survival 100%Mass beyond capsule (~ 30% of cases): 5-year survival 84%Regional lymph node involvement: 5-year survival 75%It is recommended that known or suspected cases have the implant removed with the intact surrounding capsule and tissue",
                      "Restricted to seroma cavity and capsule (~ 70% of cases): 5-year survival 100%",
                      "Mass beyond capsule (~ 30% of cases): 5-year survival 84%",
                      "Regional lymph node involvement: 5-year survival 75%",
                      "It is recommended that known or suspected cases have the implant removed with the intact surrounding capsule and tissue",
                      "BIA-ALCL has distinct features compared to other lymphomasMost have an activated CD4(+) memory T-cell phenotypeUpregulation of genes associated with cell motility, myeloid cell differentiation, and viral gene transcription",
                      "Most have an activated CD4(+) memory T-cell phenotype",
                      "Upregulation of genes associated with cell motility, myeloid cell differentiation, and viral gene transcription",
                      "All cases should be reported to the Federal Drug Association (FDA) MedWatch safety information and adverse event reporting programhttps://www.accessdata.fda.gov/scripts/medwatch/index.dfm?action=reporting.home (accessed September 2, 2020)",
                      "https://www.accessdata.fda.gov/scripts/medwatch/index.dfm?action=reporting.home (accessed September 2, 2020)",
                      "Cases can also be reported to the BIA-ALCL patient registry and outcomes for breast implants and anaplastic lymphoma etiology and epidemiology (PROFILE) registryCollaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundationhttps://www.thepsf.org/research/registries/profile (accessed September 5, 2020)",
                      "Collaborative effort of the FDA, the American Society of Plastic Surgeons, and the Plastic Surgery Foundationhttps://www.thepsf.org/research/registries/profile (accessed September 5, 2020)",
                      "https://www.thepsf.org/research/registries/profile (accessed September 5, 2020)",
                      "Guidelines have been issued for the pathologic evaluation of specimensPhotographs are taken to document the implant, capsule, and tissueEffusion fluid is submitted for cytologic evaluation and flow cytometryFluid involved by lymphoma is usually cloudy, viscous, and has membranous strandsThe specimen should be oriented and the margins inkedThe capsule is pinned out and fixed in formalin overnightPerpendicular sections of the capsule are sampled from each margin (at least 2 sections per cassette in 6 cassettes)Lymphoma can be present in grossly normal capsulesAll mass-forming lesions and irregular areas of the capsule are also sampled",
                      "Photographs are taken to document the implant, capsule, and tissue",
                      "Effusion fluid is submitted for cytologic evaluation and flow cytometryFluid involved by lymphoma is usually cloudy, viscous, and has membranous strands",
                      "Fluid involved by lymphoma is usually cloudy, viscous, and has membranous strands",
                      "The specimen should be oriented and the margins inked",
                      "The capsule is pinned out and fixed in formalin overnight",
                      "Perpendicular sections of the capsule are sampled from each margin (at least 2 sections per cassette in 6 cassettes)Lymphoma can be present in grossly normal capsules",
                      "Lymphoma can be present in grossly normal capsules",
                      "All mass-forming lesions and irregular areas of the capsule are also sampled",
                      "Anaplastic tumor cells are present in seroma fluid, capsule, &/or surrounding tissueALK1(-)CD30 (membrane and Golgi) strongly positiveT-cell markers: Variably presentMost cases lack T-cell receptors α/β or γ/δ or have gene mutations resulting in a defective T-cell receptor phenotypeSome cases can be positive for EMA and negative for typical T-cell markersTumor cells in tissue are associated with an inflammatory infiltrate with numerous eosinophils",
                      "ALK1(-)",
                      "CD30 (membrane and Golgi) strongly positive",
                      "T-cell markers: Variably present",
                      "Most cases lack T-cell receptors α/β or γ/δ or have gene mutations resulting in a defective T-cell receptor phenotype",
                      "Some cases can be positive for EMA and negative for typical T-cell markers",
                      "Tumor cells in tissue are associated with an inflammatory infiltrate with numerous eosinophils",
                      "Only 11 cases of B-cell neoplasms have been reported in association with breast implants7 lymphomas and 4 plasma cell neoplasms",
                      "7 lymphomas and 4 plasma cell neoplasms"
                    ]
                  },
                  {
                    "text": "Peripheral T-cell lymphoma(< 1%)Rare T-cell lymphomas not associated with implants occur in the breastSome have a pattern of involvement surrounding breast lobules that could mimic CLL/SLL, lymphocytic mastopathy, or T-cell lymphocytic lobulitis",
                    "sub_points": [
                      "Rare T-cell lymphomas not associated with implants occur in the breast",
                      "Some have a pattern of involvement surrounding breast lobules that could mimic CLL/SLL, lymphocytic mastopathy, or T-cell lymphocytic lobulitis"
                    ]
                  },
                  {
                    "text": "Hodgkin disease (< 1%)Hodgkin disease of breast is very rare and is usually accompanied by nodal involvementWomen who have been treated for Hodgkin disease with mantle radiation are at increased risk for developing breast carcinoma",
                    "sub_points": [
                      "Hodgkin disease of breast is very rare and is usually accompanied by nodal involvement",
                      "Women who have been treated for Hodgkin disease with mantle radiation are at increased risk for developing breast carcinoma"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Differentiation between lymphoma and other types of lesions with lymphocytic infiltrates can be very difficult on core needle biopsyAn accurate diagnosis is necessary because the majority of patients do not require additional surgeryIn ~ 90% of cases, the diagnosis of lymphoma is made by core needle biopsy aloneMore extensive surgery has been associated with increased morbidity",
                    "sub_points": [
                      "An accurate diagnosis is necessary because the majority of patients do not require additional surgery",
                      "In ~ 90% of cases, the diagnosis of lymphoma is made by core needle biopsy alone",
                      "More extensive surgery has been associated with increased morbidity"
                    ]
                  },
                  {
                    "text": "Lymphomas usually form solid masses of tumor cells that create the clinically detected massThe presence of a prominent component of stroma or normal epithelial cells should suggest other diagnosesDucts and lobules are often absent or only present at the periphery of the lesion",
                    "sub_points": [
                      "The presence of a prominent component of stroma or normal epithelial cells should suggest other diagnoses",
                      "Ducts and lobules are often absent or only present at the periphery of the lesion"
                    ]
                  },
                  {
                    "text": "Presence of lymph node capsule and normal germinal centers help identify intramammary lymph nodes"
                  },
                  {
                    "text": "Documenting the presence of DCIS is helpful to identify carcinomas negative for hormone receptors and HER2 that resemble large cell lymphomasIHC studies may be helpful to confirm DCIS within carcinoma",
                    "sub_points": [
                      "IHC studies may be helpful to confirm DCIS within carcinoma"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Leukocyte common antigen (LCA, CD45), keratins, S100This panel is useful when the differential diagnosis includes lymphoma, carcinoma, and melanoma",
                    "sub_points": [
                      "This panel is useful when the differential diagnosis includes lymphoma, carcinoma, and melanoma"
                    ]
                  },
                  {
                    "text": "Hormone receptorsObservations suggest a possible role of hormone exposure in lymphomaThere are sexual differences in incidence and prognosis of lymphomas in generalAlmost all patients with primary breast lymphoma are womenA very small subset of lymphomas are reported to express estrogen receptor (ER)Both ER-α and ER-β have been reportedSome normal lymphocytes express hormone receptorsEstrogen acting via ER-α stimulates proliferationEstrogen acting via ER-β inhibits proliferation and promotes apoptosisA recent study of 18 breast lymphomas showed only focal weak to moderate ER-α positivity in 4 cases, faint nuclear staining for ER-β in 7 cases, and focal weak positivity for androgen receptor in 4 cases",
                    "sub_points": [
                      "Observations suggest a possible role of hormone exposure in lymphomaThere are sexual differences in incidence and prognosis of lymphomas in generalAlmost all patients with primary breast lymphoma are women",
                      "There are sexual differences in incidence and prognosis of lymphomas in general",
                      "Almost all patients with primary breast lymphoma are women",
                      "A very small subset of lymphomas are reported to express estrogen receptor (ER)Both ER-α and ER-β have been reportedSome normal lymphocytes express hormone receptorsEstrogen acting via ER-α stimulates proliferationEstrogen acting via ER-β inhibits proliferation and promotes apoptosis",
                      "Both ER-α and ER-β have been reportedSome normal lymphocytes express hormone receptors",
                      "Some normal lymphocytes express hormone receptors",
                      "Estrogen acting via ER-α stimulates proliferation",
                      "Estrogen acting via ER-β inhibits proliferation and promotes apoptosis",
                      "A recent study of 18 breast lymphomas showed only focal weak to moderate ER-α positivity in 4 cases, faint nuclear staining for ER-β in 7 cases, and focal weak positivity for androgen receptor in 4 cases"
                    ]
                  },
                  {
                    "text": "p63Many lymphomas are p63(+)Keratins should be used to differentiate lymphoma from carcinoma",
                    "sub_points": [
                      "Many lymphomas are p63(+)",
                      "Keratins should be used to differentiate lymphoma from carcinoma"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Acute Leukemia (Granulocytic Sarcoma, Chloroma)": [
                  {
                    "text": "Can occur 1st in the breast, or the breast can be a site of relapseIf breast is the 1st site, at least 1/2 of patients will eventually develop systemic leukemiaVery rare diagnosis in breast; only 19 reported cases",
                    "sub_points": [
                      "If breast is the 1st site, at least 1/2 of patients will eventually develop systemic leukemiaVery rare diagnosis in breast; only 19 reported cases",
                      "Very rare diagnosis in breast; only 19 reported cases"
                    ]
                  },
                  {
                    "text": "Tumor cells infiltrate around breast epithelium and can closely mimic lobular carcinomaHowever, tumor cells are directly adjacent to epithelium, whereas lobular carcinoma is more commonly seen in concentric rings in stroma",
                    "sub_points": [
                      "However, tumor cells are directly adjacent to epithelium, whereas lobular carcinoma is more commonly seen in concentric rings in stroma"
                    ]
                  },
                  {
                    "text": "Misdiagnosis as lymphoma or sarcoma is commonLeukemia should be considered when B- and T-cell markers are negative in a case suspected to be lymphoma",
                    "sub_points": [
                      "Leukemia should be considered when B- and T-cell markers are negative in a case suspected to be lymphoma"
                    ]
                  },
                  {
                    "text": "Hairy cell leukemia can involve the breast and can mimic alveolar or solid lobular carcinoma or epithelioid myofibroblastoma"
                  }
                ],
                "Myeloma": [
                  {
                    "text": "Myeloma can involve the breast and usually presents as a breast mass"
                  },
                  {
                    "text": "Plasma cells diffusely involve stroma with little involvement of breast epithelium"
                  },
                  {
                    "text": "Some cases are associated with amyloid"
                  },
                  {
                    "text": "Amyloid can also involve the breast in the absence of a monoclonal gammopathy"
                  }
                ],
                "Invasive Carcinoma With Medullary Features: High Grade": [
                  {
                    "text": "These carcinomas are associated with dense, lymphocytic infiltrate consisting predominantly of T cellsIncludes some basal carcinomas, majority ofBRCA1-associated carcinomas",
                    "sub_points": [
                      "Includes some basal carcinomas, majority ofBRCA1-associated carcinomas"
                    ]
                  },
                  {
                    "text": "In some cases, tumor cells can be obscured by lymphocytes"
                  },
                  {
                    "text": "Small or peripheral biopsies could have little or no carcinoma"
                  },
                  {
                    "text": "Lymphoma should be suspected if cells are dyscohesive, and there is no DCISSome high-grade lymphomas are immunoreactive for EMA; keratin is more reliable marker to identify carcinomas",
                    "sub_points": [
                      "Some high-grade lymphomas are immunoreactive for EMA; keratin is more reliable marker to identify carcinomas"
                    ]
                  }
                ],
                "Invasive Carcinoma: Low Grade": [
                  {
                    "text": "Low-grade lymphomas, such as follicular carcinoma, can mimic lobular carcinomasSome lymphomas have cells that mimic signet ring cells; however, mucin is not presentLymphomas can infiltrate in concentric pattern around ducts, similar to lobular carcinomas",
                    "sub_points": [
                      "Some lymphomas have cells that mimic signet ring cells; however, mucin is not present",
                      "Lymphomas can infiltrate in concentric pattern around ducts, similar to lobular carcinomas"
                    ]
                  },
                  {
                    "text": "Important features to support diagnosis of carcinoma are presence of lobular carcinoma in situ and immunoreactivity for keratinER and PR positivity may be unreliable; some lymphocytes are positive for these markersAbsence of ER and PR in carcinoma that appears lobular in type would be clue that malignancy might be lymphoma",
                    "sub_points": [
                      "ER and PR positivity may be unreliable; some lymphocytes are positive for these markersAbsence of ER and PR in carcinoma that appears lobular in type would be clue that malignancy might be lymphoma",
                      "Absence of ER and PR in carcinoma that appears lobular in type would be clue that malignancy might be lymphoma"
                    ]
                  }
                ],
                "Lymphocytic/Diabetic Mastopathy": [
                  {
                    "text": "The predominant component is very dense collagenized stroma, which forms the palpable or imaging massTissue on slides typically looks uniformly pink with punctate blue areasIn contrast, slides from lymphomas are typically blue due to the dense lymphocytic infiltrate",
                    "sub_points": [
                      "Tissue on slides typically looks uniformly pink with punctate blue areas",
                      "In contrast, slides from lymphomas are typically blue due to the dense lymphocytic infiltrate"
                    ]
                  },
                  {
                    "text": "Lymphocytic infiltrate consists predominantly of small, round lymphocytes and clusters around ducts, lobules, and blood vessels"
                  },
                  {
                    "text": "Ducts and lobules typically appear atrophic with thickened basement membranes"
                  }
                ],
                "Lupus Mastitis": [
                  {
                    "text": "Panniculitis involving subcutaneous tissue or breast adipose tissueHyaline fat necrosis has characteristic appearance as homogeneous glassy fibrosis surrounding fat lobulesVasculitis is present",
                    "sub_points": [
                      "Hyaline fat necrosis has characteristic appearance as homogeneous glassy fibrosis surrounding fat lobules",
                      "Vasculitis is present"
                    ]
                  },
                  {
                    "text": "Dense lymphocytic infiltrate surrounds fat lobules as well as septaMixed population of B cells, T cells, and occasional plasma cellsGerminal centers may be present",
                    "sub_points": [
                      "Mixed population of B cells, T cells, and occasional plasma cells",
                      "Germinal centers may be present"
                    ]
                  }
                ],
                "IgG4-Related Sclerosing Mastitis": [
                  {
                    "text": "Presents as breast mass consisting of small lymphocytes and numerous plasma cells"
                  },
                  {
                    "text": "The number of IgG4(+) plasma cells is increased"
                  },
                  {
                    "text": "Stromal fibrosis and obliterative phlebitis are important features but are less commonly seen in breast lesions"
                  }
                ],
                "Rosai-Dorfman Disease": [
                  {
                    "text": "This is a benign proliferation of S100(+) histiocytes and lymphocytes that can form a breast massNumerous plasma cells can be present",
                    "sub_points": [
                      "Numerous plasma cells can be present"
                    ]
                  },
                  {
                    "text": "Emperipolesis (engulfment of lymphocytes and other cells by histiocytes) is a characteristic feature"
                  },
                  {
                    "text": "Stromal sclerosis is usually present and can be prominent"
                  }
                ],
                "Inflammatory Myofibroblastic Tumor (IMT)": [
                  {
                    "text": "Synonyms (or closely related lesions) include pseudolymphoma, inflammatory pseudotumor, plasma cell granuloma, xanthomatous pseudotumor, and pseudosarcomatous myofibrohistiocytic proliferation"
                  },
                  {
                    "text": "Very rare in breastPresents as palpable mass",
                    "sub_points": [
                      "Presents as palpable mass"
                    ]
                  },
                  {
                    "text": "Consists of loose fascicles of plump myofibroblasts intermingled with lymphocytes, plasma cells, eosinophils, and histiocytesMorphologic overlap with IgG4-sclerosing mastitisHowever, increased numbers of IgG4 plasma cells absent in IMTs",
                    "sub_points": [
                      "Morphologic overlap with IgG4-sclerosing mastitisHowever, increased numbers of IgG4 plasma cells absent in IMTs",
                      "However, increased numbers of IgG4 plasma cells absent in IMTs"
                    ]
                  },
                  {
                    "text": "50% of IMTs are positive for ALKVarious fusion genes withALKhave been foundAlso reported in some breast tumors",
                    "sub_points": [
                      "Various fusion genes withALKhave been found",
                      "Also reported in some breast tumors"
                    ]
                  },
                  {
                    "text": "A few cases of breast IMT have recurred locally, and rare tumors have metastasized"
                  }
                ],
                "T-Cell Lymphocytic Lobulitis": [
                  {
                    "text": "Perilobular infiltrate of T cells has been described in patients withBRCA1mutations"
                  },
                  {
                    "text": "Generally incidental finding in biopsies or prophylactic mastectomiesRarely presents as clinically or radiologically evident massAlso seen in benign breast tissue adjacent to carcinomas",
                    "sub_points": [
                      "Rarely presents as clinically or radiologically evident mass",
                      "Also seen in benign breast tissue adjacent to carcinomas"
                    ]
                  }
                ],
                "Chronic Inflammation Associated With Benign Breast Conditions": [
                  {
                    "text": "Lymphocytic infiltrates can be seen in many benign conditionsRegression after pregnancy and breastfeedingAdjacent to ruptured cystsAdjacent to ectatic &/or ruptured lactiferous sinuses (as part of duct ectasia)",
                    "sub_points": [
                      "Regression after pregnancy and breastfeeding",
                      "Adjacent to ruptured cysts",
                      "Adjacent to ectatic &/or ruptured lactiferous sinuses (as part of duct ectasia)"
                    ]
                  },
                  {
                    "text": "Lymphocytic infiltrate should be incidental to clinically or radiologically evident lesion"
                  },
                  {
                    "text": "Infiltrate is generally a mixture of small lymphocytes and occasional plasma cells"
                  }
                ],
                "Intramammary Lymph Node": [
                  {
                    "text": "Most common in upper outer quadrant but may be present at other locations"
                  },
                  {
                    "text": "Imaging features are usually characteristic for lymph node; fatty hilum should be present"
                  },
                  {
                    "text": "These nodes may be biopsied if unusual in size or appearance"
                  },
                  {
                    "text": "On core needle biopsy, it is important to identify lymph node capsule and normal germinal centers"
                  },
                  {
                    "text": "IHC studies may be helpful to document that normal complement of lymphocytes is present"
                  }
                ],
                "Nonspecific Lymphocytic Infiltrates": [
                  {
                    "text": "\"Inflammatory pseudotumor,\" \"pseudolymphoma,\" and \"plasma cell mastitis\" are poorly defined terms without specific pathologic criteria or identified etiologies"
                  },
                  {
                    "text": "They have been used to refer to multiple types of nonneoplastic inflammatory lesions of the breast"
                  },
                  {
                    "text": "If a lesion cannot be given a more specific diagnosis, the case can be signed out descriptively"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "In the absence of a prior history of lymphoma, there are often no clinical or imaging features to suggest this diagnosis"
                  },
                  {
                    "text": "For clearly malignant lesions, the differential diagnosis usually includes carcinoma and melanoma"
                  },
                  {
                    "text": "Lower grade lesions need to be distinguished from many types of benign lymphocytic proliferations in the breast"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Metastases to Breast": {
            "name": "Metastases to Breast",
            "url": "https://app.pathprimer.com/document/fc4b5983-dbe7-4147-a84e-cd952c6c4242/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
            "content": {
              "KEY FACTS": {
                "Clinical Issues": [
                  {
                    "text": "Metastases to breast comprise < 2% of all breast malignancies"
                  },
                  {
                    "text": "Most common presentation is as a palpable breast mass"
                  },
                  {
                    "text": "In 70-80% of cases, patient is known to have another malignancyIn 20-30% of cases, breast metastasis is 1st indication patient has cancer",
                    "sub_points": [
                      "In 20-30% of cases, breast metastasis is 1st indication patient has cancer"
                    ]
                  },
                  {
                    "text": "In majority of cases, breast surgery and lymph node evaluation are not necessaryTherefore, it is very important not to mistake metastasis for primary breast carcinoma",
                    "sub_points": [
                      "Therefore, it is very important not to mistake metastasis for primary breast carcinoma"
                    ]
                  },
                  {
                    "text": "Outcome is generally poor, as metastasis to breast is manifestation of disseminated systemic disease"
                  },
                  {
                    "text": "All types of tumors metastasize to breastCarcinomas most common (~ 60%)Ovary (especially high-grade serous carcinoma), lung, gastrointestinal tract, genitourinary tract, thyroid, skinProstate carcinoma in male patientsMelanoma is 2nd most common type (~ 20%)CarcinoidSarcomaLeiomyosarcoma (most common), rhabdomyosarcoma (primarily in adolescent girls), liposarcoma, others",
                    "sub_points": [
                      "Carcinomas most common (~ 60%)Ovary (especially high-grade serous carcinoma), lung, gastrointestinal tract, genitourinary tract, thyroid, skinProstate carcinoma in male patients",
                      "Ovary (especially high-grade serous carcinoma), lung, gastrointestinal tract, genitourinary tract, thyroid, skin",
                      "Prostate carcinoma in male patients",
                      "Melanoma is 2nd most common type (~ 20%)",
                      "Carcinoid",
                      "SarcomaLeiomyosarcoma (most common), rhabdomyosarcoma (primarily in adolescent girls), liposarcoma, others",
                      "Leiomyosarcoma (most common), rhabdomyosarcoma (primarily in adolescent girls), liposarcoma, others"
                    ]
                  },
                  {
                    "text": "Small panels of IHC markers can usually distinguish between primary breast carcinoma and metastasis"
                  }
                ],
                "Imaging": [
                  {
                    "text": "Majority of metastases are solitary (~ 75%) and unilateral"
                  },
                  {
                    "text": "Most metastases present as circumscribed or ill-defined massesFindings are not specific for metastasis",
                    "sub_points": [
                      "Findings are not specific for metastasis"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Primary breast carcinoma"
                  },
                  {
                    "text": "Lymphoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Definitions": [
                  {
                    "text": "Metastatic tumors to breast from another organ or site"
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Presentation": [
                  {
                    "text": "Metastases to breast comprise < 2% of all breast malignancies"
                  },
                  {
                    "text": "Most common presentation is palpable breast massLess common are a mass on imaging (~ 10% with calcifications) or inflammatory carcinomaAxillary and other regional lymph nodes are often enlarged and involved",
                    "sub_points": [
                      "Less common are a mass on imaging (~ 10% with calcifications) or inflammatory carcinoma",
                      "Axillary and other regional lymph nodes are often enlarged and involved"
                    ]
                  },
                  {
                    "text": "A solitary breast metastasis is present in 80-90% of patients and multiple (unilateral or bilateral) metastases in 10-20%"
                  },
                  {
                    "text": "In 70-80% of cases, patient is known to have another malignancyMetastases to breast typically occur ~ 4-5 years after initial diagnosisSome tumors (especially melanoma and renal cell carcinoma) can metastasize after very long intervalsHowever, this information may not be provided to the pathologistIn many cases, metastases to other sites are also present",
                    "sub_points": [
                      "Metastases to breast typically occur ~ 4-5 years after initial diagnosisSome tumors (especially melanoma and renal cell carcinoma) can metastasize after very long intervals",
                      "Some tumors (especially melanoma and renal cell carcinoma) can metastasize after very long intervals",
                      "However, this information may not be provided to the pathologist",
                      "In many cases, metastases to other sites are also present"
                    ]
                  },
                  {
                    "text": "All types of tumors metastasize to breastCarcinomas most common (~ 60%)Ovary (especially high-grade serous carcinoma), lung, gastrointestinal tract, genitourinary tract, thyroid, skinMelanoma is 2nd most common type (~ 20%)CarcinoidSarcomaLeiomyosarcoma (most common), rhabdomyosarcoma (primarily in adolescent girls), liposarcoma, others",
                    "sub_points": [
                      "Carcinomas most common (~ 60%)Ovary (especially high-grade serous carcinoma), lung, gastrointestinal tract, genitourinary tract, thyroid, skin",
                      "Ovary (especially high-grade serous carcinoma), lung, gastrointestinal tract, genitourinary tract, thyroid, skin",
                      "Melanoma is 2nd most common type (~ 20%)",
                      "Carcinoid",
                      "SarcomaLeiomyosarcoma (most common), rhabdomyosarcoma (primarily in adolescent girls), liposarcoma, others",
                      "Leiomyosarcoma (most common), rhabdomyosarcoma (primarily in adolescent girls), liposarcoma, others"
                    ]
                  },
                  {
                    "text": "In 20-30% of cases, breast metastasis is the 1st indication patient has cancer"
                  },
                  {
                    "text": "Many types of metastases are difficult to distinguish from primary breast cancer"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Breast surgery to remove metastasis and lymph node evaluation generally do not improve outcome and are not performedTherefore, it is very important to distinguish metastases from primary breast carcinomas",
                    "sub_points": [
                      "Therefore, it is very important to distinguish metastases from primary breast carcinomas"
                    ]
                  },
                  {
                    "text": "Systemic treatment depends on type of metastatic cancer"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Outcome is generally poor, as metastasis to breast is manifestation of disseminated systemic diseaseMedian survival is only 15 months",
                    "sub_points": [
                      "Median survival is only 15 months"
                    ]
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "Most metastases present as circumscribed or ill-defined massesFew present as irregular massesCalcifications usually absentMajor exception is papillary serous carcinoma that is associated with psammoma body calcifications in tumorExtensive calcifications outside of tumor favor breast carcinoma associated with ductal carcinoma in situ (DCIS)",
                    "sub_points": [
                      "Few present as irregular masses",
                      "Calcifications usually absentMajor exception is papillary serous carcinoma that is associated with psammoma body calcifications in tumorExtensive calcifications outside of tumor favor breast carcinoma associated with ductal carcinoma in situ (DCIS)",
                      "Major exception is papillary serous carcinoma that is associated with psammoma body calcifications in tumor",
                      "Extensive calcifications outside of tumor favor breast carcinoma associated with ductal carcinoma in situ (DCIS)"
                    ]
                  },
                  {
                    "text": "Metastases may be present in adipose tissue near chest wall"
                  },
                  {
                    "text": "Majority of metastases are solitary (~ 75%) and unilateralLess commonly, multiple masses are present in 1 or both breasts",
                    "sub_points": [
                      "Less commonly, multiple masses are present in 1 or both breasts"
                    ]
                  },
                  {
                    "text": "No specific features distinguish primary carcinoma from metastasis"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Majority of metastases are diagnosed by core needle biopsy and not excised"
                  },
                  {
                    "text": "The only gross feature that would identify metastatic cancer would be black pigmentation in melanoma"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Metastasis should be suspected when the histologic pattern is unusual for breast carcinoma, definite in situ carcinoma is not present, or the ER status is inconsistent with appearanceUnusual histologic patternsClear cellsWell-formed papillaeTall columnar cellsPsammoma body calcificationsDyscohesive cells with high-grade nucleiCarcinoma in situ can be mimicked by metastasesCarcinomas invading as circumscribed nests of cells with solid or cribriform patternsGrowth of metastatic tumor into ductsTumor filling lymphaticsHowever, lymphovascular invasion is only seen in association with ~ 15% of metastasesLow-grade neoplasms negative for ER may beMetastatic tumors, such as carcinoidLymphomaMicroglandular adenosisMetastasis should also be suspected when a tubule-forming, mucinous, or papillary neoplasm is ER(-)",
                    "sub_points": [
                      "Unusual histologic patternsClear cellsWell-formed papillaeTall columnar cellsPsammoma body calcificationsDyscohesive cells with high-grade nuclei",
                      "Clear cells",
                      "Well-formed papillae",
                      "Tall columnar cells",
                      "Psammoma body calcifications",
                      "Dyscohesive cells with high-grade nuclei",
                      "Carcinoma in situ can be mimicked by metastasesCarcinomas invading as circumscribed nests of cells with solid or cribriform patternsGrowth of metastatic tumor into ductsTumor filling lymphaticsHowever, lymphovascular invasion is only seen in association with ~ 15% of metastases",
                      "Carcinomas invading as circumscribed nests of cells with solid or cribriform patterns",
                      "Growth of metastatic tumor into ducts",
                      "Tumor filling lymphaticsHowever, lymphovascular invasion is only seen in association with ~ 15% of metastases",
                      "However, lymphovascular invasion is only seen in association with ~ 15% of metastases",
                      "Low-grade neoplasms negative for ER may beMetastatic tumors, such as carcinoidLymphomaMicroglandular adenosis",
                      "Metastatic tumors, such as carcinoid",
                      "Lymphoma",
                      "Microglandular adenosis",
                      "Metastasis should also be suspected when a tubule-forming, mucinous, or papillary neoplasm is ER(-)"
                    ]
                  },
                  {
                    "text": "Metastatic tumors usually have well-circumscribed borders and lack calcifications"
                  },
                  {
                    "text": "Metastases in childrenEmbryonal rhabdomyosarcoma is the most common type~ 6% of patients with rhabdomyosarcoma develop breast metastasisIn some cases, breast metastasis is diagnosed 1st with occult primary siteSome children have Li-Fraumeni syndromePrimary rhabdomyosarcoma of breast occurs primarily in adults but can also occur in childrenHistologic appearance of tumor is generally sufficient for diagnosisIHC studies for muscle markers may be used to support diagnosisOther tumors occurring in children can metastasize to the breastNeuroblastoma, medulloblastoma, primitive neuroectodermal tumor, medullary carcinoma of the thyroid",
                    "sub_points": [
                      "Embryonal rhabdomyosarcoma is the most common type~ 6% of patients with rhabdomyosarcoma develop breast metastasisIn some cases, breast metastasis is diagnosed 1st with occult primary siteSome children have Li-Fraumeni syndromePrimary rhabdomyosarcoma of breast occurs primarily in adults but can also occur in children",
                      "~ 6% of patients with rhabdomyosarcoma develop breast metastasisIn some cases, breast metastasis is diagnosed 1st with occult primary site",
                      "In some cases, breast metastasis is diagnosed 1st with occult primary site",
                      "Some children have Li-Fraumeni syndrome",
                      "Primary rhabdomyosarcoma of breast occurs primarily in adults but can also occur in children",
                      "Histologic appearance of tumor is generally sufficient for diagnosisIHC studies for muscle markers may be used to support diagnosis",
                      "IHC studies for muscle markers may be used to support diagnosis",
                      "Other tumors occurring in children can metastasize to the breastNeuroblastoma, medulloblastoma, primitive neuroectodermal tumor, medullary carcinoma of the thyroid",
                      "Neuroblastoma, medulloblastoma, primitive neuroectodermal tumor, medullary carcinoma of the thyroid"
                    ]
                  },
                  {
                    "text": "Metastases in adultsMelanomaMelanomas, as well as lymphomas and high-grade lobular breast carcinomas, often have a dyscohesive pattern of rounded cellsPrimary site may be occult (e.g., retinal or visceral) or diagnosed in distant past (> 10 years)Histologic features favoring melanoma are melanin pigment (but only seen rarely), intranuclear inclusions, marked nuclear pleomorphism, and spindle cellsBest markers supporting melanoma over breast: Melan-A (85% vs. 0%), HMB-45 (> 90% vs. < 10%), S100 (95% vs. 30%)A few melanomas can show weak focal staining for keratinBest markers supporting breast over melanoma: Keratin (100% vs. < 5%), GATA3 (85% vs. 0%), ER (75% vs. 0%)Gynecologic carcinomasWomen with gynecologic carcinomas are at higher risk for developing primary breast carcinomaIt is unusual for gynecologic malignancy to be clinically occultOvarian serous carcinomas more commonly metastasize to breast than mucinous or clear cell carcinomasMetastatic ovarian carcinomas may present as a mammographic mass with calcificationsPsammoma bodies may be frequent in ovarian serous carcinomas but are unusual in breast carcinomasImmunoprofiles for gynecologic carcinomas and breast carcinomas overlapBoth are commonly ER(+)Best markers supporting GYN over breast: PAX8 (85% vs. 0%), WT1 (nuclear) (85% vs. 3%)Cytoplasmic immunoreactivity for WT1 is less specific and is seen in a larger number of breast carcinomasBest markers supporting breast over GYN: GATA3 (85% vs. 5%)Lung carcinomaThe 1st presentation of lung carcinoma can be as a metastasis, such as to breastHistologic appearance in lung (e.g., squamous cell carcinoma, adenocarcinoma, small cell carcinoma) should match appearance of metastasis in breastHistologic comparison of carcinoma in lung to carcinoma in breast is best method for identificationBest markers supporting lung adenocarcinoma over breast: TTF-1 (60% vs. 2%), napsin (85% vs. 2%)Results for TTF-1 can vary with antibody usedBest markers supporting breast over lung adenocarcinoma: Mammaglobin (80% vs. < 2%), GCDFP-15 (80% vs. 10%), GATA3 (85% vs. 5%)Some lung carcinomas are positive for ER (primarily ER-β) and PR; frequency varies with antibody used (~ 10%)Prostatic carcinomaMen with prostatic carcinoma undergoing hormonal treatments are at increased risk for primary breast carcinomaMetastatic prostatic carcinoma can closely mimic low-grade breast carcinoma or metastatic carcinoid tumorEpithelial proliferation due to endocrine-related treatment can mimic DCISBest markers supporting prostate over breast: PAP (90% vs. 0%), PSA (90% vs. 20%)Best markers supporting breast over prostate: Cytokeratin 7 (90% vs. 15%), GATA3 (85% vs. 1%), GCDFP-15 (55% vs. 10%), ER (75% vs. 0%)Some prostatic carcinomas (and breast carcinomas) are strongly positive for neuroendocrine markers (including chromogranin)Gastric signet-ring cell carcinomaSignet-ring cell carcinomas are histologically similar (or identical) to some invasive lobular carcinomasDiffuse, foamy cytoplasm is more common in gastric carcinomasDistinct vacuole with central mucin dot is more common in lobular carcinomasBoth tumors occur in patients with germline mutations of E-cadherin; however, gastric carcinomas are more commonBest markers supporting gastric over breast: CDX-2 (75% vs. < 5%), cytokeratin 20 (55% vs. 3%)Best markers supporting breast over gastric: GATA3 (85% vs. 0%), mammaglobin (85% vs. 0%), GCDFP-15 (65% vs. 0%), ER (90% vs. 0%)Carcinoid tumorMetastases can occur from both gastrointestinal and lung primariesA primary carcinoid tumor of breast is not recognizedMetastatic carcinoid may be suspected when a low-grade nested tumor is negative for ER and PRMyoepithelial markers can be helpful to distinguish circumscribed tumor nests from carcinoma in situCarcinoid can also resemble lobular carcinoma in situ (LCIS); carcinoid is positive for E-cadherin and lacks myoepithelial cellsBest markers supporting carcinoid over breast: Chromogranin (85% vs. 20%), synaptophysin (95% vs. 15%)Gastrointestinal carcinoids are often positive for CDX-2 (80%), and lung carcinoids are often positive for TTF-1 (60%)Best markers supporting breast over carcinoid: Cytokeratin 7 (90% vs. 20%), ER (75% vs. 10%), GCDFP-15 (55% vs. 5%)Contralateral breast carcinomaWomen with breast carcinoma are at increased risk for developing a 2nd primary carcinoma in contralateral breast~ 5-10% of breast cancers may be metastases from a current or prior contralateral breast cancerThis is more likely if the primary carcinoma is locally advanced (large size, extensive lymphovascular invasion, multiple metastases to axillary nodes)Lymphatic channels can cross the midline and drain to the contralateral breast and axillaRarely, an axillary metastasis arises from the contralateral breastThe presence of associated DCIS is strong evidence that a breast cancer has arisen in the same breastAdditional evidence supporting 2 separate primaries are different histologic type, different grade, &/or different expression patterns of hormone receptors or HER2However, tumors can change after treatmentIn the absence of in situ carcinoma, it is often difficult or impossible to distinguish metastasis from 2nd carcinomaIn the majority of these cases, there will be extensive lymphovascular invasion and involved axillary lymph nodes",
                    "sub_points": [
                      "MelanomaMelanomas, as well as lymphomas and high-grade lobular breast carcinomas, often have a dyscohesive pattern of rounded cellsPrimary site may be occult (e.g., retinal or visceral) or diagnosed in distant past (> 10 years)Histologic features favoring melanoma are melanin pigment (but only seen rarely), intranuclear inclusions, marked nuclear pleomorphism, and spindle cellsBest markers supporting melanoma over breast: Melan-A (85% vs. 0%), HMB-45 (> 90% vs. < 10%), S100 (95% vs. 30%)A few melanomas can show weak focal staining for keratinBest markers supporting breast over melanoma: Keratin (100% vs. < 5%), GATA3 (85% vs. 0%), ER (75% vs. 0%)",
                      "Melanomas, as well as lymphomas and high-grade lobular breast carcinomas, often have a dyscohesive pattern of rounded cells",
                      "Primary site may be occult (e.g., retinal or visceral) or diagnosed in distant past (> 10 years)",
                      "Histologic features favoring melanoma are melanin pigment (but only seen rarely), intranuclear inclusions, marked nuclear pleomorphism, and spindle cells",
                      "Best markers supporting melanoma over breast: Melan-A (85% vs. 0%), HMB-45 (> 90% vs. < 10%), S100 (95% vs. 30%)A few melanomas can show weak focal staining for keratin",
                      "A few melanomas can show weak focal staining for keratin",
                      "Best markers supporting breast over melanoma: Keratin (100% vs. < 5%), GATA3 (85% vs. 0%), ER (75% vs. 0%)",
                      "Gynecologic carcinomasWomen with gynecologic carcinomas are at higher risk for developing primary breast carcinomaIt is unusual for gynecologic malignancy to be clinically occultOvarian serous carcinomas more commonly metastasize to breast than mucinous or clear cell carcinomasMetastatic ovarian carcinomas may present as a mammographic mass with calcificationsPsammoma bodies may be frequent in ovarian serous carcinomas but are unusual in breast carcinomasImmunoprofiles for gynecologic carcinomas and breast carcinomas overlapBoth are commonly ER(+)Best markers supporting GYN over breast: PAX8 (85% vs. 0%), WT1 (nuclear) (85% vs. 3%)Cytoplasmic immunoreactivity for WT1 is less specific and is seen in a larger number of breast carcinomasBest markers supporting breast over GYN: GATA3 (85% vs. 5%)",
                      "Women with gynecologic carcinomas are at higher risk for developing primary breast carcinomaIt is unusual for gynecologic malignancy to be clinically occult",
                      "It is unusual for gynecologic malignancy to be clinically occult",
                      "Ovarian serous carcinomas more commonly metastasize to breast than mucinous or clear cell carcinomasMetastatic ovarian carcinomas may present as a mammographic mass with calcificationsPsammoma bodies may be frequent in ovarian serous carcinomas but are unusual in breast carcinomas",
                      "Metastatic ovarian carcinomas may present as a mammographic mass with calcifications",
                      "Psammoma bodies may be frequent in ovarian serous carcinomas but are unusual in breast carcinomas",
                      "Immunoprofiles for gynecologic carcinomas and breast carcinomas overlapBoth are commonly ER(+)",
                      "Both are commonly ER(+)",
                      "Best markers supporting GYN over breast: PAX8 (85% vs. 0%), WT1 (nuclear) (85% vs. 3%)Cytoplasmic immunoreactivity for WT1 is less specific and is seen in a larger number of breast carcinomas",
                      "Cytoplasmic immunoreactivity for WT1 is less specific and is seen in a larger number of breast carcinomas",
                      "Best markers supporting breast over GYN: GATA3 (85% vs. 5%)",
                      "Lung carcinomaThe 1st presentation of lung carcinoma can be as a metastasis, such as to breastHistologic appearance in lung (e.g., squamous cell carcinoma, adenocarcinoma, small cell carcinoma) should match appearance of metastasis in breastHistologic comparison of carcinoma in lung to carcinoma in breast is best method for identificationBest markers supporting lung adenocarcinoma over breast: TTF-1 (60% vs. 2%), napsin (85% vs. 2%)Results for TTF-1 can vary with antibody usedBest markers supporting breast over lung adenocarcinoma: Mammaglobin (80% vs. < 2%), GCDFP-15 (80% vs. 10%), GATA3 (85% vs. 5%)Some lung carcinomas are positive for ER (primarily ER-β) and PR; frequency varies with antibody used (~ 10%)",
                      "The 1st presentation of lung carcinoma can be as a metastasis, such as to breast",
                      "Histologic appearance in lung (e.g., squamous cell carcinoma, adenocarcinoma, small cell carcinoma) should match appearance of metastasis in breastHistologic comparison of carcinoma in lung to carcinoma in breast is best method for identification",
                      "Histologic comparison of carcinoma in lung to carcinoma in breast is best method for identification",
                      "Best markers supporting lung adenocarcinoma over breast: TTF-1 (60% vs. 2%), napsin (85% vs. 2%)Results for TTF-1 can vary with antibody used",
                      "Results for TTF-1 can vary with antibody used",
                      "Best markers supporting breast over lung adenocarcinoma: Mammaglobin (80% vs. < 2%), GCDFP-15 (80% vs. 10%), GATA3 (85% vs. 5%)Some lung carcinomas are positive for ER (primarily ER-β) and PR; frequency varies with antibody used (~ 10%)",
                      "Some lung carcinomas are positive for ER (primarily ER-β) and PR; frequency varies with antibody used (~ 10%)",
                      "Prostatic carcinomaMen with prostatic carcinoma undergoing hormonal treatments are at increased risk for primary breast carcinomaMetastatic prostatic carcinoma can closely mimic low-grade breast carcinoma or metastatic carcinoid tumorEpithelial proliferation due to endocrine-related treatment can mimic DCISBest markers supporting prostate over breast: PAP (90% vs. 0%), PSA (90% vs. 20%)Best markers supporting breast over prostate: Cytokeratin 7 (90% vs. 15%), GATA3 (85% vs. 1%), GCDFP-15 (55% vs. 10%), ER (75% vs. 0%)Some prostatic carcinomas (and breast carcinomas) are strongly positive for neuroendocrine markers (including chromogranin)",
                      "Men with prostatic carcinoma undergoing hormonal treatments are at increased risk for primary breast carcinoma",
                      "Metastatic prostatic carcinoma can closely mimic low-grade breast carcinoma or metastatic carcinoid tumor",
                      "Epithelial proliferation due to endocrine-related treatment can mimic DCIS",
                      "Best markers supporting prostate over breast: PAP (90% vs. 0%), PSA (90% vs. 20%)",
                      "Best markers supporting breast over prostate: Cytokeratin 7 (90% vs. 15%), GATA3 (85% vs. 1%), GCDFP-15 (55% vs. 10%), ER (75% vs. 0%)",
                      "Some prostatic carcinomas (and breast carcinomas) are strongly positive for neuroendocrine markers (including chromogranin)",
                      "Gastric signet-ring cell carcinomaSignet-ring cell carcinomas are histologically similar (or identical) to some invasive lobular carcinomasDiffuse, foamy cytoplasm is more common in gastric carcinomasDistinct vacuole with central mucin dot is more common in lobular carcinomasBoth tumors occur in patients with germline mutations of E-cadherin; however, gastric carcinomas are more commonBest markers supporting gastric over breast: CDX-2 (75% vs. < 5%), cytokeratin 20 (55% vs. 3%)Best markers supporting breast over gastric: GATA3 (85% vs. 0%), mammaglobin (85% vs. 0%), GCDFP-15 (65% vs. 0%), ER (90% vs. 0%)",
                      "Signet-ring cell carcinomas are histologically similar (or identical) to some invasive lobular carcinomasDiffuse, foamy cytoplasm is more common in gastric carcinomasDistinct vacuole with central mucin dot is more common in lobular carcinomas",
                      "Diffuse, foamy cytoplasm is more common in gastric carcinomas",
                      "Distinct vacuole with central mucin dot is more common in lobular carcinomas",
                      "Both tumors occur in patients with germline mutations of E-cadherin; however, gastric carcinomas are more common",
                      "Best markers supporting gastric over breast: CDX-2 (75% vs. < 5%), cytokeratin 20 (55% vs. 3%)",
                      "Best markers supporting breast over gastric: GATA3 (85% vs. 0%), mammaglobin (85% vs. 0%), GCDFP-15 (65% vs. 0%), ER (90% vs. 0%)",
                      "Carcinoid tumorMetastases can occur from both gastrointestinal and lung primariesA primary carcinoid tumor of breast is not recognizedMetastatic carcinoid may be suspected when a low-grade nested tumor is negative for ER and PRMyoepithelial markers can be helpful to distinguish circumscribed tumor nests from carcinoma in situCarcinoid can also resemble lobular carcinoma in situ (LCIS); carcinoid is positive for E-cadherin and lacks myoepithelial cellsBest markers supporting carcinoid over breast: Chromogranin (85% vs. 20%), synaptophysin (95% vs. 15%)Gastrointestinal carcinoids are often positive for CDX-2 (80%), and lung carcinoids are often positive for TTF-1 (60%)Best markers supporting breast over carcinoid: Cytokeratin 7 (90% vs. 20%), ER (75% vs. 10%), GCDFP-15 (55% vs. 5%)",
                      "Metastases can occur from both gastrointestinal and lung primariesA primary carcinoid tumor of breast is not recognized",
                      "A primary carcinoid tumor of breast is not recognized",
                      "Metastatic carcinoid may be suspected when a low-grade nested tumor is negative for ER and PRMyoepithelial markers can be helpful to distinguish circumscribed tumor nests from carcinoma in situCarcinoid can also resemble lobular carcinoma in situ (LCIS); carcinoid is positive for E-cadherin and lacks myoepithelial cells",
                      "Myoepithelial markers can be helpful to distinguish circumscribed tumor nests from carcinoma in situ",
                      "Carcinoid can also resemble lobular carcinoma in situ (LCIS); carcinoid is positive for E-cadherin and lacks myoepithelial cells",
                      "Best markers supporting carcinoid over breast: Chromogranin (85% vs. 20%), synaptophysin (95% vs. 15%)Gastrointestinal carcinoids are often positive for CDX-2 (80%), and lung carcinoids are often positive for TTF-1 (60%)",
                      "Gastrointestinal carcinoids are often positive for CDX-2 (80%), and lung carcinoids are often positive for TTF-1 (60%)",
                      "Best markers supporting breast over carcinoid: Cytokeratin 7 (90% vs. 20%), ER (75% vs. 10%), GCDFP-15 (55% vs. 5%)",
                      "Contralateral breast carcinomaWomen with breast carcinoma are at increased risk for developing a 2nd primary carcinoma in contralateral breast~ 5-10% of breast cancers may be metastases from a current or prior contralateral breast cancerThis is more likely if the primary carcinoma is locally advanced (large size, extensive lymphovascular invasion, multiple metastases to axillary nodes)Lymphatic channels can cross the midline and drain to the contralateral breast and axillaRarely, an axillary metastasis arises from the contralateral breastThe presence of associated DCIS is strong evidence that a breast cancer has arisen in the same breastAdditional evidence supporting 2 separate primaries are different histologic type, different grade, &/or different expression patterns of hormone receptors or HER2However, tumors can change after treatmentIn the absence of in situ carcinoma, it is often difficult or impossible to distinguish metastasis from 2nd carcinomaIn the majority of these cases, there will be extensive lymphovascular invasion and involved axillary lymph nodes",
                      "Women with breast carcinoma are at increased risk for developing a 2nd primary carcinoma in contralateral breast~ 5-10% of breast cancers may be metastases from a current or prior contralateral breast cancerThis is more likely if the primary carcinoma is locally advanced (large size, extensive lymphovascular invasion, multiple metastases to axillary nodes)",
                      "~ 5-10% of breast cancers may be metastases from a current or prior contralateral breast cancer",
                      "This is more likely if the primary carcinoma is locally advanced (large size, extensive lymphovascular invasion, multiple metastases to axillary nodes)",
                      "Lymphatic channels can cross the midline and drain to the contralateral breast and axillaRarely, an axillary metastasis arises from the contralateral breast",
                      "Rarely, an axillary metastasis arises from the contralateral breast",
                      "The presence of associated DCIS is strong evidence that a breast cancer has arisen in the same breastAdditional evidence supporting 2 separate primaries are different histologic type, different grade, &/or different expression patterns of hormone receptors or HER2However, tumors can change after treatment",
                      "Additional evidence supporting 2 separate primaries are different histologic type, different grade, &/or different expression patterns of hormone receptors or HER2",
                      "However, tumors can change after treatment",
                      "In the absence of in situ carcinoma, it is often difficult or impossible to distinguish metastasis from 2nd carcinoma",
                      "In the majority of these cases, there will be extensive lymphovascular invasion and involved axillary lymph nodes"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Diagnosis on needle biopsy is important, as unnecessary surgery can be avoided"
                  },
                  {
                    "text": "Metastasis should be considered for any patient with prior history of malignancy"
                  },
                  {
                    "text": "Documentation of carcinoma in situ is helpful, as this finding strongly supports primary breast carcinoma"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Primary Breast Carcinoma": [
                  {
                    "text": "The best method to establish that an invasive carcinoma is primary in the breast is to identify associated DCIS or LCISMyoepithelial cell markers can be used to confirm in situ carcinomaMetastatic neoplasms involving lymphatics, growing into ducts, or with an expansile growth pattern could potentially mimic carcinoma in situER(-) DCIS can be scant in extent and difficult to detectThe neoplastic cells can have a clinging pattern in aciniAn associated prominent lymphocytic infiltrate is helpful to identify involved lobules",
                    "sub_points": [
                      "Myoepithelial cell markers can be used to confirm in situ carcinomaMetastatic neoplasms involving lymphatics, growing into ducts, or with an expansile growth pattern could potentially mimic carcinoma in situ",
                      "Metastatic neoplasms involving lymphatics, growing into ducts, or with an expansile growth pattern could potentially mimic carcinoma in situ",
                      "ER(-) DCIS can be scant in extent and difficult to detectThe neoplastic cells can have a clinging pattern in aciniAn associated prominent lymphocytic infiltrate is helpful to identify involved lobules",
                      "The neoplastic cells can have a clinging pattern in acini",
                      "An associated prominent lymphocytic infiltrate is helpful to identify involved lobules"
                    ]
                  },
                  {
                    "text": "In the absence of carcinoma in situ, pathologists must consider the possibility of metastasisUnusual histologic appearanceDiscordance between ER status and morphologyHistory of another malignancy",
                    "sub_points": [
                      "Unusual histologic appearance",
                      "Discordance between ER status and morphology",
                      "History of another malignancy"
                    ]
                  },
                  {
                    "text": "In questionable cases, IHC is usually helpful to support a primary breast carcinoma or a metastasis"
                  },
                  {
                    "text": "If there is no reason to suspect a metastasis, routine additional studies are rarely indicated, as metastases to the breast are very rare"
                  }
                ],
                "Lymphoma": [
                  {
                    "text": "May be primary in breast, involve an intramammary lymph node, or can involve the breast as part of systemic diseaseDoes not require local surgery and nodal evaluation",
                    "sub_points": [
                      "Does not require local surgery and nodal evaluation"
                    ]
                  },
                  {
                    "text": "Majority form a mass consisting entirely of neoplastic cellsInvolvement of breast epithelium may be absent or only very focal at the periphery",
                    "sub_points": [
                      "Involvement of breast epithelium may be absent or only very focal at the periphery"
                    ]
                  },
                  {
                    "text": "High-grade (anaplastic) lymphomas can mimic breast carcinoma and melanoma"
                  },
                  {
                    "text": "IHC is useful to identify type of lymphoma and to exclude carcinoma and melanoma"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "A high index of suspicion is necessary to detect metastases to breast, as they are very rare compared to primary carcinomas"
                  },
                  {
                    "text": "If a patient has a history of malignancy, a metastasis to the breast should always be consideredThis history may not be provided to the pathologist, particularly if there has been a long time interval",
                    "sub_points": [
                      "This history may not be provided to the pathologist, particularly if there has been a long time interval"
                    ]
                  },
                  {
                    "text": "Carcinoma in situ is most useful histologic finding to strongly support breast primary carcinomaMimics of carcinoma in situ must be considered and excluded",
                    "sub_points": [
                      "Mimics of carcinoma in situ must be considered and excluded"
                    ]
                  },
                  {
                    "text": "Comparison of a possible metastasis to the primary carcinoma is the most useful method to strongly support a metastasis"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Tricholemmoma": {
            "name": "Tricholemmoma",
            "url": "https://app.pathprimer.com/document/786b7c5e-59de-465f-82d0-8da3ab6e677b/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Tricholemmoma (TL)Benign clear cell adnexal proliferation with external root sheath differentiation",
                    "sub_points": [
                      "Benign clear cell adnexal proliferation with external root sheath differentiation"
                    ]
                  },
                  {
                    "text": "Subtype: Desmoplastic tricholemmoma (dTL)"
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Some cases are associated with Cowden syndrome (PTEN hamartoma syndrome)Multiple tricholemmomas, hamartomas, and visceral tumors including breast and thyroid carcinomasMutations inPTENgene on 10q23.31",
                    "sub_points": [
                      "Multiple tricholemmomas, hamartomas, and visceral tumors including breast and thyroid carcinomas",
                      "Mutations inPTENgene on 10q23.31"
                    ]
                  },
                  {
                    "text": "Some have considered TL to be related to HPV infection (\"tricholemmal verrucae\"), but not well-accepted"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Relatively common tumors"
                  },
                  {
                    "text": "Usually occur in adults, although Cowden syndrome patients present at earlier age"
                  },
                  {
                    "text": "Most occur on face, especially nose and upper lip"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Lobular proliferation of mature squamoid cells with pale- to clear-staining cytoplasm"
                  },
                  {
                    "text": "Peripheral palisading of basaloid cells"
                  },
                  {
                    "text": "Cells are surrounded by thickened, glassy-appearing basement membrane"
                  },
                  {
                    "text": "Multiple broad connections to epidermis and follicles"
                  },
                  {
                    "text": "Desmoplastic tricholemmomaVariant with prominent desmoplastic stromaTypically in center of tumor, surrounded by conventional-appearing TL",
                    "sub_points": [
                      "Variant with prominent desmoplastic stroma",
                      "Typically in center of tumor, surrounded by conventional-appearing TL"
                    ]
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Tumor of follicular infundibulum (TFI)"
                  },
                  {
                    "text": "Clear cell acanthoma"
                  },
                  {
                    "text": "Tricholemmal carcinoma"
                  },
                  {
                    "text": "Clear cell squamous cell carcinoma in situ (clear cell Bowen disease)"
                  },
                  {
                    "text": "Clear cell basal cell carcinoma (BCC)"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Tricholemmoma (TL)"
                  },
                  {
                    "text": "Desmoplastic tricholemmoma (DTL)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Trichilemmoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Benign clear cell adnexal proliferation with external root sheath differentiation"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Unknown in Most Cases": [
                  {
                    "text": "Some have considered TL to be related to HPV infection (\"tricholemmal verrucae\")Not generally accepted, and most PCR studies for HPV have been negative",
                    "sub_points": [
                      "Not generally accepted, and most PCR studies for HPV have been negative"
                    ]
                  }
                ],
                "Genetic": [
                  {
                    "text": "Some cases are associated with Cowden syndrome (PTEN hamartoma syndrome)Characterized by multiple tricholemmomas, hamartomas, and visceral tumors including breast and thyroid carcinomasMutations inPTEN, a tumor suppressor gene, on 10q23.31",
                    "sub_points": [
                      "Characterized by multiple tricholemmomas, hamartomas, and visceral tumors including breast and thyroid carcinomas",
                      "Mutations inPTEN, a tumor suppressor gene, on 10q23.31"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Relatively common tumors"
                  }
                ],
                "Age": [
                  {
                    "text": "Usually adults, although Cowden syndrome patients present at earlier age"
                  }
                ],
                "Site": [
                  {
                    "text": "Most occur on face, especially nose and upper lip"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Small papular lesionUsually flesh-coloredOften clinically mimics basal cell carcinoma or verruca",
                    "sub_points": [
                      "Usually flesh-colored",
                      "Often clinically mimics basal cell carcinoma or verruca"
                    ]
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Usually not necessary, as these are benign tumors"
                  },
                  {
                    "text": "Complete conservative excision is curative"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent, no malignant potential"
                  },
                  {
                    "text": "Cowden syndrome patients have high risk of internal malignancies"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Lobular proliferation of mature squamoid cells with pale- to clear-staining cytoplasm"
                  },
                  {
                    "text": "Peripheral palisading of basaloid cellsCells are surrounded by thickened, glassy-appearing basement membrane",
                    "sub_points": [
                      "Cells are surrounded by thickened, glassy-appearing basement membrane"
                    ]
                  },
                  {
                    "text": "Squamous eddies and small foci of tricholemmal (pilar)-type keratinization often present"
                  },
                  {
                    "text": "Multiple broad connections to epidermis and folliclesEarly lesions often surround a follicle, consistent with follicular derivation",
                    "sub_points": [
                      "Early lesions often surround a follicle, consistent with follicular derivation"
                    ]
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Adnexal keratinocyte with external root sheath differentiation"
                  }
                ],
                "Subtype": [
                  {
                    "text": "Desmoplastic tricholemmoma (DTL)Variant with prominent desmoplastic stromaTypically in center of tumorCan mimic invasive carcinomaHowever, infiltrative areas are usually surrounded by conventional-appearing TL",
                    "sub_points": [
                      "Variant with prominent desmoplastic stroma",
                      "Typically in center of tumor",
                      "Can mimic invasive carcinomaHowever, infiltrative areas are usually surrounded by conventional-appearing TL",
                      "However, infiltrative areas are usually surrounded by conventional-appearing TL"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Clear Cell Acanthoma": [
                  {
                    "text": "Psoriasiform epidermal acanthosis"
                  },
                  {
                    "text": "Epidermal cells show prominent clear cell changes, similar to TL, butClear cell acanthoma shows overlying hypogranulosis and parakeratosisLacks lobular configuration and thickened peripheral basement membraneSharp demarcation from adjacent normal epidermis",
                    "sub_points": [
                      "Clear cell acanthoma shows overlying hypogranulosis and parakeratosis",
                      "Lacks lobular configuration and thickened peripheral basement membrane",
                      "Sharp demarcation from adjacent normal epidermis"
                    ]
                  }
                ],
                "Tricholemmal Carcinoma": [
                  {
                    "text": "Shows lobular proliferation of clear cells with peripheral palisading"
                  },
                  {
                    "text": "However, tricholemmal carcinoma also showsSignificant cytologic atypia, mitotic activity, infiltrative features, and may show necrosisTypically lacks symmetry and circumscription of TLDesmoplastic areas at periphery, not in center of tumor (unlike dTL)",
                    "sub_points": [
                      "Significant cytologic atypia, mitotic activity, infiltrative features, and may show necrosis",
                      "Typically lacks symmetry and circumscription of TL",
                      "Desmoplastic areas at periphery, not in center of tumor (unlike dTL)"
                    ]
                  }
                ],
                "Tumor of Follicular Infundibulum (TFI)": [
                  {
                    "text": "Superficial, plate-like growth pattern parallel to epidermis"
                  },
                  {
                    "text": "Peripheral palisading and clear cells present, butTFI is more plate-like, less lobular than TLTFI shows multiple anastomosing connections between tumor cells and with epidermisHair follicles merge with undersurface of TFI, not TL",
                    "sub_points": [
                      "TFI is more plate-like, less lobular than TL",
                      "TFI shows multiple anastomosing connections between tumor cells and with epidermis",
                      "Hair follicles merge with undersurface of TFI, not TL"
                    ]
                  }
                ],
                "Clear Cell Squamous Cell Carcinoma In Situ (Clear Cell Bowen Disease)": [
                  {
                    "text": "Atypical intraepidermal proliferation of clear-staining keratinocytesProminent nuclear atypia with hyperchromasia and large nucleoliMultiple mitotic figures, including atypical forms, typically present",
                    "sub_points": [
                      "Prominent nuclear atypia with hyperchromasia and large nucleoli",
                      "Multiple mitotic figures, including atypical forms, typically present"
                    ]
                  },
                  {
                    "text": "Lacks lobular architecture and peripheral thickened basement membrane of TL"
                  }
                ],
                "Clear Cell Basal Cell Carcinoma (BCC)": [
                  {
                    "text": "Can occasionally show prominent clear cell features"
                  },
                  {
                    "text": "Peripheral palisading seen in both BCC and TL, howeverProminent mitoses, apoptoses, and infiltrative feature characteristic of BCCTumor-stromal retraction artifact and mucinous stroma typical of BCC",
                    "sub_points": [
                      "Prominent mitoses, apoptoses, and infiltrative feature characteristic of BCC",
                      "Tumor-stromal retraction artifact and mucinous stroma typical of BCC"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Invasive Apocrine Carcinoma": {
            "name": "Invasive Apocrine Carcinoma",
            "url": "https://app.pathprimer.com/document/7968e91e-4f98-4e48-b506-39c0442bbbb7/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Invasive apocrine carcinoma (IAC) shows prominent apocrine features"
                  }
                ],
                "Classification": [
                  {
                    "text": "The majority of IACs are positive for AR and GCDFP-15 and negative for ER~ 1/2 are HER2 positive",
                    "sub_points": [
                      "~ 1/2 are HER2 positive"
                    ]
                  },
                  {
                    "text": "Characterized by a gene expression pattern largely driven by expression of AR"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Incidence varies from < 1% up to 4% depending on diagnostic criteria"
                  },
                  {
                    "text": "IAC does not have specific epidemiologic, clinical, or imaging features"
                  },
                  {
                    "text": "Apocrine triple negative breast cancers are more likely to be grade 1 or 2 and have a more favorable prognosis compared to other TNBCs"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Histologic criteria for invasive apocrine carcinoma must be present in > 90% of the cancerAbundant eosinophilic granular or vacuolated cytoplasm with distinct cell bordersLarge, round to oval nuclei with moderate to marked atypia and prominent nucleoli",
                    "sub_points": [
                      "Abundant eosinophilic granular or vacuolated cytoplasm with distinct cell borders",
                      "Large, round to oval nuclei with moderate to marked atypia and prominent nucleoli"
                    ]
                  },
                  {
                    "text": "DCIS with apocrine features is recognized by abnormal architecture and nuclear atypia"
                  },
                  {
                    "text": "Pleomorphic apocrine LCIS can be ER(-) and HER2(+)"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Benign apocrine lesions"
                  },
                  {
                    "text": "Sclerosing adenosis involved by apocrine change"
                  },
                  {
                    "text": "Granular cell tumor"
                  },
                  {
                    "text": "Invasive carcinomas with abundant cytoplasm"
                  },
                  {
                    "text": "Cutaneous apocrine carcinoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Invasive apocrine carcinoma (IAC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Carcinoma with apocrine differentiation or apocrine carcinoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Characterized by cells with large nuclei with prominent nucleoli and abundant eosinophilic granular or vacuolated cytoplasm"
                  }
                ]
              },
              "CLASSIFICATION": {
                "Overview": [
                  {
                    "text": "Invasive apocrine carcinomas (IACs) are recognized by pathologists due to the characteristic cytologic and nuclear features"
                  },
                  {
                    "text": "Various definitions for defining \"apocrine carcinoma\" include morphology, immunoreactivity for certain proteins, and gene expression profiling, as well as combinations of these assays"
                  },
                  {
                    "text": "These multiple methods identify similar and overlapping, but not identical, groups of cancers"
                  }
                ],
                "Biologic Types of Apocrine Carcinoma": [
                  {
                    "text": "Based on the expression of estrogen receptor (ER), androgen receptor (AR), and HER2, IACs can be divided into distinct groups"
                  },
                  {
                    "text": "ER(-)/AR(+)/HER2(-): ~ 55% of IACsThese are \"triple negative breast carcinomas\" (TNBCs) that are not basal-like carcinomas (BLCs) by gene expression profiling due to AR expression~ 75% of TNBCs with apocrine morphology are AR(+)~ 20-40% of all TNBCs are AR(+)> 95% are GCDFP-15(+) and ~ 75% GATA3(+)Only ~ 10% of nonapocrine AR(-) TNBC is GATA3(+) and < 5% are GCDFP-15(+)In 1 study, 6 apocrine TNBCs were positive for claudin 1 and 3 and were negative for claudin 4Compared to AR(-) TNBCs, these IACs are more likely to be grade 1 (~ 10-15% vs. < 2%) or grade 2 (~ 35-55% vs. 15%), and less likely to be grade 3 (~ 30-55% vs. 85%)Compared to nonapocrine TNBCs in the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program, apocrine TNBCs occurred in older women, were smaller, were more likely to be grade 1 or 2, and patients had significantly improved survival (82% vs. 74% at 5 years)",
                    "sub_points": [
                      "These are \"triple negative breast carcinomas\" (TNBCs) that are not basal-like carcinomas (BLCs) by gene expression profiling due to AR expression~ 75% of TNBCs with apocrine morphology are AR(+)~ 20-40% of all TNBCs are AR(+)",
                      "~ 75% of TNBCs with apocrine morphology are AR(+)~ 20-40% of all TNBCs are AR(+)",
                      "~ 20-40% of all TNBCs are AR(+)",
                      "> 95% are GCDFP-15(+) and ~ 75% GATA3(+)Only ~ 10% of nonapocrine AR(-) TNBC is GATA3(+) and < 5% are GCDFP-15(+)",
                      "Only ~ 10% of nonapocrine AR(-) TNBC is GATA3(+) and < 5% are GCDFP-15(+)",
                      "In 1 study, 6 apocrine TNBCs were positive for claudin 1 and 3 and were negative for claudin 4",
                      "Compared to AR(-) TNBCs, these IACs are more likely to be grade 1 (~ 10-15% vs. < 2%) or grade 2 (~ 35-55% vs. 15%), and less likely to be grade 3 (~ 30-55% vs. 85%)",
                      "Compared to nonapocrine TNBCs in the National Cancer Database (NCDB) and the Surveillance, Epidemiology, and End Results (SEER) program, apocrine TNBCs occurred in older women, were smaller, were more likely to be grade 1 or 2, and patients had significantly improved survival (82% vs. 74% at 5 years)"
                    ]
                  },
                  {
                    "text": "ER(-)/AR(+)/HER2(+): ~ 20-55% of IACsThese carcinomas often express HER2 at very high levels~ 80% of cancers that are ER(-) and HER2(+) show apocrine morphology",
                    "sub_points": [
                      "These carcinomas often express HER2 at very high levels",
                      "~ 80% of cancers that are ER(-) and HER2(+) show apocrine morphology"
                    ]
                  },
                  {
                    "text": "ER(+): ~ 24-40% of IACs~ 10-50% of these carcinomas are AR(-) and ~ 1/2 are HER2(+)~ 55% of cancers that are ER(+) and HER2(+) show apocrine morphologyThese cancers may be excluded from studies of IAC if absence of ER is a criterion for diagnosis",
                    "sub_points": [
                      "~ 10-50% of these carcinomas are AR(-) and ~ 1/2 are HER2(+)",
                      "~ 55% of cancers that are ER(+) and HER2(+) show apocrine morphology",
                      "These cancers may be excluded from studies of IAC if absence of ER is a criterion for diagnosis"
                    ]
                  },
                  {
                    "text": "ER(-)/AR(-)/HER2(-): < 5% of IACsThis small group is a rare type of apocrine TNBC that does not express AR",
                    "sub_points": [
                      "This small group is a rare type of apocrine TNBC that does not express AR"
                    ]
                  }
                ],
                "Criteria for Apocrine Carcinoma": [
                  {
                    "text": "A definition of \"pure apocrine carcinoma\" (PAC) has been proposed> 90% of tumor cells show apocrine morphology (this is an essential WHO diagnostic criterion)ER(-) and AR(+) (this is a desirable WHO diagnostic criterion)",
                    "sub_points": [
                      "> 90% of tumor cells show apocrine morphology (this is an essential WHO diagnostic criterion)",
                      "ER(-) and AR(+) (this is a desirable WHO diagnostic criterion)"
                    ]
                  },
                  {
                    "text": "IACs not meeting these criteria have been termed \"apocrine like carcinoma\" (ALC)"
                  },
                  {
                    "text": "Of all IACs, > 1/2 are PAC and the remainder ALC according to this definition"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Benign Apocrine Breast Lesions": [
                  {
                    "text": "Apocrine glands normally occur in skinBreasts evolved from skin appendages and, thus, have many features in common",
                    "sub_points": [
                      "Breasts evolved from skin appendages and, thus, have many features in common"
                    ]
                  },
                  {
                    "text": "Cells with functional apocrine characteristics have been described in fetal breast tissue"
                  },
                  {
                    "text": "Apocrine change is commonly seen in cysts in adult breast tissue and may arise from fetal cells or from metaplasia"
                  },
                  {
                    "text": "Benign apocrine lesions express AR and are negative for ER and PRAlthough these lesions do not show HER2 gene amplification, moderate cytoplasmic and basal/lateral membrane immunoreactivity is often seen",
                    "sub_points": [
                      "Although these lesions do not show HER2 gene amplification, moderate cytoplasmic and basal/lateral membrane immunoreactivity is often seen"
                    ]
                  },
                  {
                    "text": "Some apocrine lesions show loss of heterozygosity and genetic changes, supporting that some are clonal lesions and may be nonobligate precursors of apocrine carcinomasAtypical apocrine proliferations are found more commonly in breasts with apocrine carcinomasGrowth of cutaneous apocrine glands is stimulated by androgens",
                    "sub_points": [
                      "Atypical apocrine proliferations are found more commonly in breasts with apocrine carcinomas",
                      "Growth of cutaneous apocrine glands is stimulated by androgens"
                    ]
                  }
                ],
                "Androgen Metabolism in Breast Cancer": [
                  {
                    "text": "The majority of breast cancers (70-80%) express ARER/PR(+), HER2(+): ~ 80%ER/PR(+), HER2(-): ~ 60%ER/PR(-), HER2(+): ~ 50%ER/PR(-), HER2(-): ~ 35%HER2 may induce AR transactivation through MAP kinase pathway",
                    "sub_points": [
                      "ER/PR(+), HER2(+): ~ 80%",
                      "ER/PR(+), HER2(-): ~ 60%",
                      "ER/PR(-), HER2(+): ~ 50%",
                      "ER/PR(-), HER2(-): ~ 35%HER2 may induce AR transactivation through MAP kinase pathway",
                      "HER2 may induce AR transactivation through MAP kinase pathway"
                    ]
                  },
                  {
                    "text": "IAC is AR(+) in 50-80% of casesEnhanced metabolism of testosterone precursors has been reported in IACAltered androgen metabolism may play a role in pathogenesis and tumor progressionAR is inhibitory and counteracts the oncogenic activity of ER-α in ER(+) breast cancerAR expression is prognostic in ER(+) breast cancer and is correlated with better outcomeOngoing clinical trials are investigating efficacy of antiandrogen drugs in AR(+) breast cancerTherapies that inhibit androgen signaling (e.g., antiandrogen bicalutamide, CYP17 inhibitor abiraterone acetate) are used in prostate cancer",
                    "sub_points": [
                      "Enhanced metabolism of testosterone precursors has been reported in IAC",
                      "Altered androgen metabolism may play a role in pathogenesis and tumor progression",
                      "AR is inhibitory and counteracts the oncogenic activity of ER-α in ER(+) breast cancerAR expression is prognostic in ER(+) breast cancer and is correlated with better outcome",
                      "AR expression is prognostic in ER(+) breast cancer and is correlated with better outcome",
                      "Ongoing clinical trials are investigating efficacy of antiandrogen drugs in AR(+) breast cancerTherapies that inhibit androgen signaling (e.g., antiandrogen bicalutamide, CYP17 inhibitor abiraterone acetate) are used in prostate cancer",
                      "Therapies that inhibit androgen signaling (e.g., antiandrogen bicalutamide, CYP17 inhibitor abiraterone acetate) are used in prostate cancer"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "< 1% up to 4% depending on diagnostic criteria"
                  }
                ],
                "Presentation": [
                  {
                    "text": "There are no characteristic clinical or radiographic features specific to IAC"
                  }
                ],
                "Treatment": [],
                "Adjuvant therapy": [
                  {
                    "text": "Currently no specific treatment based on classification as IAC"
                  },
                  {
                    "text": "Altered androgen metabolism may be therapeutically useful in future"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Some NCDB- and SEER-based studies have shown better overall survival for AR(+) apocrine TNBC compared to AR(-) nonapocrine TNBC"
                  },
                  {
                    "text": "Studies of survival need to control for the different biologic types of IAC"
                  }
                ]
              },
              "IMAGING": {
                "General Features": [
                  {
                    "text": "There are no imaging features specific to IAC"
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "There are no gross features specific to IAC"
                  }
                ]
              },
              "MOLECULAR": {
                "DNA": [
                  {
                    "text": "MutationsThe most common mutations arePIK3CA(~ 70-100%),PTEN(~ 33%), andTP53(~ 30%) in ER(-)/AR(+)/HER2(-) IACSome carcinomas in patients with Cowden syndrome (germlinePTENmutation) show apocrine morphology",
                    "sub_points": [
                      "The most common mutations arePIK3CA(~ 70-100%),PTEN(~ 33%), andTP53(~ 30%) in ER(-)/AR(+)/HER2(-) IAC",
                      "Some carcinomas in patients with Cowden syndrome (germlinePTENmutation) show apocrine morphology"
                    ]
                  },
                  {
                    "text": "Copy number changesChromosomal gains of 1p, 1q, and 2q as well as losses of 1p, 12q, 16q, 17q, and 22qAlso common in other types of breast carcinoma",
                    "sub_points": [
                      "Chromosomal gains of 1p, 1q, and 2q as well as losses of 1p, 12q, 16q, 17q, and 22qAlso common in other types of breast carcinoma",
                      "Also common in other types of breast carcinoma"
                    ]
                  }
                ],
                "mRNA (Gene Expression Profiling)": [
                  {
                    "text": "IACs fall into multiple groups defined by gene expression profilingLargely driven by expression of ER, AR, and HER2 in subsets of these cancers",
                    "sub_points": [
                      "Largely driven by expression of ER, AR, and HER2 in subsets of these cancers"
                    ]
                  },
                  {
                    "text": "Molecular apocrine tumors (MATs)This group shows high expression of AR (~ 60%) and about 50% overexpress HER2The signature also includes increased expression of numerous genes with roles in metabolism and expression of luminal rather than basal keratinsSome MATs do not have apocrine morphology~ 93% overlap with ER(-)/AR(+)/HER2(-) IAC~ 67% overlap with ER(-)/AR(+)/HER2(+) IAC",
                    "sub_points": [
                      "This group shows high expression of AR (~ 60%) and about 50% overexpress HER2",
                      "The signature also includes increased expression of numerous genes with roles in metabolism and expression of luminal rather than basal keratinsSome MATs do not have apocrine morphology",
                      "Some MATs do not have apocrine morphology",
                      "~ 93% overlap with ER(-)/AR(+)/HER2(-) IAC",
                      "~ 67% overlap with ER(-)/AR(+)/HER2(+) IAC"
                    ]
                  },
                  {
                    "text": "Luminal androgen receptor groupThis group includes some IACs that are TNBCs but are AR(+)This group shows low response to neoadjuvant chemotherapy (~ 10%) compared to other molecular basal-like groups (> 50%)However, survival is not diminished, possibly due to lower proliferation",
                    "sub_points": [
                      "This group includes some IACs that are TNBCs but are AR(+)",
                      "This group shows low response to neoadjuvant chemotherapy (~ 10%) compared to other molecular basal-like groups (> 50%)However, survival is not diminished, possibly due to lower proliferation",
                      "However, survival is not diminished, possibly due to lower proliferation"
                    ]
                  },
                  {
                    "text": "HER2-enriched groupSome IACs are in this groupIncludes most pleomorphic lobular carcinomas with apocrine features",
                    "sub_points": [
                      "Some IACs are in this group",
                      "Includes most pleomorphic lobular carcinomas with apocrine features"
                    ]
                  },
                  {
                    "text": "Luminal groupSome IACs cluster with other ER(+) carcinomas",
                    "sub_points": [
                      "Some IACs cluster with other ER(+) carcinomas"
                    ]
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "IAC has characteristic nuclear and cytoplasmic features that should be present in > 90% of tumor cellsNuclei (most commonly nuclear grade 2 or 3)Round &/or pleomorphic, large vesicular nucleiProminent, often multiple, nucleoliHowever, some carcinomas have low nuclear gradeCytoplasmAbundant, nuclear:cytoplasmic ratio 1:2 or greaterEosinophilic and finely granular most common; some may have foamy or clear cytoplasmSharply defined cell bordersCarcinomas with focal apocrine appearance are common (~ 30% of carcinomas of no special type) and should not be classified as IAC",
                    "sub_points": [
                      "Nuclei (most commonly nuclear grade 2 or 3)Round &/or pleomorphic, large vesicular nucleiProminent, often multiple, nucleoliHowever, some carcinomas have low nuclear grade",
                      "Round &/or pleomorphic, large vesicular nuclei",
                      "Prominent, often multiple, nucleoli",
                      "However, some carcinomas have low nuclear grade",
                      "CytoplasmAbundant, nuclear:cytoplasmic ratio 1:2 or greaterEosinophilic and finely granular most common; some may have foamy or clear cytoplasmSharply defined cell borders",
                      "Abundant, nuclear:cytoplasmic ratio 1:2 or greater",
                      "Eosinophilic and finely granular most common; some may have foamy or clear cytoplasm",
                      "Sharply defined cell borders",
                      "Carcinomas with focal apocrine appearance are common (~ 30% of carcinomas of no special type) and should not be classified as IAC"
                    ]
                  },
                  {
                    "text": "Growth patternsSolid/sheet-like without tubule formation: Majority of IACSingle cell \"lobular\": Minority of IAC (E-cadherin negative)Usually poorly differentiatedIncludes some lobular carcinomas described as histiocytoidWell-formed tubules: RareMay be classified as grade 1 due to lack of nuclear pleomorphism and low mitotic rateThis is an unusual type of grade 1 carcinoma that can be TNBC/HER2(+)",
                    "sub_points": [
                      "Solid/sheet-like without tubule formation: Majority of IAC",
                      "Single cell \"lobular\": Minority of IAC (E-cadherin negative)Usually poorly differentiatedIncludes some lobular carcinomas described as histiocytoid",
                      "Usually poorly differentiated",
                      "Includes some lobular carcinomas described as histiocytoid",
                      "Well-formed tubules: RareMay be classified as grade 1 due to lack of nuclear pleomorphism and low mitotic rateThis is an unusual type of grade 1 carcinoma that can be TNBC/HER2(+)",
                      "May be classified as grade 1 due to lack of nuclear pleomorphism and low mitotic rate",
                      "This is an unusual type of grade 1 carcinoma that can be TNBC/HER2(+)"
                    ]
                  },
                  {
                    "text": "Apocrine DCISCan be difficult to recognize in isolation as it can be difficult to distinguish benign metaplasia from a clonal neoplastic proliferationHigh nuclear grade, necrosis, and atypical architectural patterns (e.g., cribriform spaces or micropapillae) are useful diagnostic featuresAll architectural patterns can be seenComedo, solid, cribriform, papillary, and micropapillary",
                    "sub_points": [
                      "Can be difficult to recognize in isolation as it can be difficult to distinguish benign metaplasia from a clonal neoplastic proliferationHigh nuclear grade, necrosis, and atypical architectural patterns (e.g., cribriform spaces or micropapillae) are useful diagnostic featuresAll architectural patterns can be seenComedo, solid, cribriform, papillary, and micropapillary",
                      "High nuclear grade, necrosis, and atypical architectural patterns (e.g., cribriform spaces or micropapillae) are useful diagnostic features",
                      "All architectural patterns can be seenComedo, solid, cribriform, papillary, and micropapillary",
                      "Comedo, solid, cribriform, papillary, and micropapillary"
                    ]
                  },
                  {
                    "text": "Apocrine LCISPleomorphic apocrine LCIS (PALCIS) has high nuclear grade and often has central necrosis~ 60% are ER(-) and > 40% HER2(+)",
                    "sub_points": [
                      "Pleomorphic apocrine LCIS (PALCIS) has high nuclear grade and often has central necrosis~ 60% are ER(-) and > 40% HER2(+)",
                      "~ 60% are ER(-) and > 40% HER2(+)"
                    ]
                  },
                  {
                    "text": "Apocrine encapsulated papillary carcinoma (A-EPC)This is a rare, well-circumscribed tumor that usually presents as a palpable subareolar mass in older womenNo myoepithelial cells are present at the periphery or in fibrovascular cores using multiple IHC markersOf the cases tested, the carcinomas have been ER(-), AR(+), HER2(-), GCDP-15(+)Only 1 has been associated with frankly invasive carcinomaThese cases are distinct from high-grade EPC which show marked nuclear pleomorphism and increased mitosesApocrine features have not been described in this group~ 1/2 are ER(-)",
                    "sub_points": [
                      "This is a rare, well-circumscribed tumor that usually presents as a palpable subareolar mass in older women",
                      "No myoepithelial cells are present at the periphery or in fibrovascular cores using multiple IHC markers",
                      "Of the cases tested, the carcinomas have been ER(-), AR(+), HER2(-), GCDP-15(+)",
                      "Only 1 has been associated with frankly invasive carcinoma",
                      "These cases are distinct from high-grade EPC which show marked nuclear pleomorphism and increased mitosesApocrine features have not been described in this group~ 1/2 are ER(-)",
                      "Apocrine features have not been described in this group",
                      "~ 1/2 are ER(-)"
                    ]
                  }
                ],
                "Core Needle Biopsy": [
                  {
                    "text": "Apocrine lesions may be challenging on limited needle biopsy samples"
                  },
                  {
                    "text": "Apocrine metaplasia or apocrine atypical hyperplasia or carcinoma in situ in sclerosing adenosis can mimic IACRounded or lobulated border by imaging or histologically suggests possible sclerosing adenosisBack-to-back involved spaces with little intervening stroma suggests possible involvement of sclerosing adenosis",
                    "sub_points": [
                      "Rounded or lobulated border by imaging or histologically suggests possible sclerosing adenosis",
                      "Back-to-back involved spaces with little intervening stroma suggests possible involvement of sclerosing adenosis"
                    ]
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Histochemistry": [
                  {
                    "text": "PAS diastaseReactivity: PositiveStaining Pattern: Cytoplasmic (granular pattern)",
                    "sub_points": [
                      "Reactivity: Positive",
                      "Staining Pattern: Cytoplasmic (granular pattern)"
                    ]
                  }
                ],
                "Immunohistochemistry": [
                  {
                    "text": "ER and PR: > 50% negativeMay be positive for ER-β but negative for ER-α",
                    "sub_points": [
                      "May be positive for ER-β but negative for ER-α"
                    ]
                  },
                  {
                    "text": "HER2: ~ 50% positive"
                  },
                  {
                    "text": "AR: 50-80% positiveTypically strong diffuse expression is seen",
                    "sub_points": [
                      "Typically strong diffuse expression is seen"
                    ]
                  },
                  {
                    "text": "Gross cystic disease fluid protein-15 (GCDFP-15): > 75% positiveTypically, > 50% of cells show reactivity for GCDFP-15GCDFP-15 is regulated by AR and is a diagnostic marker for mammary differentiationExpression of both GCDFP-15 and AR are correlated~ 23% of nonapocrine breast carcinomas are also positive for GCDFP-15, including most lobular carcinomasTherefore, GCDFP-15 expression is not specific for apocrine differentiation",
                    "sub_points": [
                      "Typically, > 50% of cells show reactivity for GCDFP-15",
                      "GCDFP-15 is regulated by AR and is a diagnostic marker for mammary differentiationExpression of both GCDFP-15 and AR are correlated",
                      "Expression of both GCDFP-15 and AR are correlated",
                      "~ 23% of nonapocrine breast carcinomas are also positive for GCDFP-15, including most lobular carcinomasTherefore, GCDFP-15 expression is not specific for apocrine differentiation",
                      "Therefore, GCDFP-15 expression is not specific for apocrine differentiation"
                    ]
                  },
                  {
                    "text": "p53: 46-50% positive"
                  },
                  {
                    "text": "Carcinoembryonic antigen (CEA-P): ~ 47% positive"
                  }
                ],
                "Electron Microscopy": [
                  {
                    "text": "Cells from benign and malignant apocrine lesions have numerous mitochondriaSome show incomplete cristaeVarying numbers of osmiophilic secretory granules",
                    "sub_points": [
                      "Some show incomplete cristae",
                      "Varying numbers of osmiophilic secretory granules"
                    ]
                  },
                  {
                    "text": "Secretory granules, empty vesicles, and other intracytoplasmic organelles typically present"
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Benign Apocrine Lesions": [
                  {
                    "text": "Apocrine metaplasia is frequent finding in breast tissueOften associated with calcifications (calcium phosphate and calcium oxalate)Partial involvement of lesions (e.g., papillomas) is an indication of polyclonality supporting a benign diagnosis",
                    "sub_points": [
                      "Often associated with calcifications (calcium phosphate and calcium oxalate)",
                      "Partial involvement of lesions (e.g., papillomas) is an indication of polyclonality supporting a benign diagnosis"
                    ]
                  },
                  {
                    "text": "Rare benign apocrine lesions can lack myoepithelial cellsThe absence of myoepithelial cells alone is not sufficient for classification as invasive carcinoma",
                    "sub_points": [
                      "The absence of myoepithelial cells alone is not sufficient for classification as invasive carcinoma"
                    ]
                  }
                ],
                "Sclerosing Adenosis": [
                  {
                    "text": "Involved by apocrine metaplasia or apocrine DCIS can closely mimic IAC"
                  },
                  {
                    "text": "Usually has circumscribed borders, a back-to-back swirling pattern, and associated dense stroma"
                  },
                  {
                    "text": "Immunoperoxidase studies to demonstrate myoepithelial cells are helpful in problematic casesMany tumor cells in IAC are p63(+) but will not have the basal location and morphology of myoepithelial cells",
                    "sub_points": [
                      "Many tumor cells in IAC are p63(+) but will not have the basal location and morphology of myoepithelial cells"
                    ]
                  }
                ],
                "Granular Cell Tumor": [
                  {
                    "text": "Benign tumor that can form masses with circumscribed or irregular borders"
                  },
                  {
                    "text": "Has small uniform round nuclei and abundant granular eosinophilic cytoplasmIAC typically has large pleomorphic nuclei with nucleoli",
                    "sub_points": [
                      "IAC typically has large pleomorphic nuclei with nucleoli"
                    ]
                  },
                  {
                    "text": "Cytokeratin (-) and S100(+)IAC is strongly cytokeratin (+) and may or may not be S100(+)",
                    "sub_points": [
                      "IAC is strongly cytokeratin (+) and may or may not be S100(+)"
                    ]
                  }
                ],
                "Breast Carcinomas With Abundant Cytoplasm": [
                  {
                    "text": "Several carcinomas are characterized by abundant cytoplasmHistiocytoid (lobular) carcinoma: Foamy, clear cytoplasm due to secretory vacuoles &/or mucinER and HER2 can be positive or negative, the majority are AR and GCDFP-15 (+)Lipid-rich carcinoma: Abundant microvacuolated, foamy, or clear cytoplasm due to lipidsER and AR (-), HER2 and S100 may be (+)Sebaceous carcinoma: Finely vacuolated cytoplasm due to lipidsER, AR, and HER2 may be (+), GCDFP-15(-), S100 (-)Oncocytic carcinoma: Abundant granular eosinophilic cytoplasm due to numerous mitochondriaAntimitochondrial antibodies are positiveER majority (+), AR ~ 1/4 (+), HER2 ~ 1/4 (+), GCDFP-15 ~ 1/3 (+)Glycogen-rich carcinoma: Clear or finely vacuolated cytoplasm due to glycogenER and HER2 may be (+), GCDFP-15(-)Secretory carcinoma: Eosinophilic cytoplasm and extracellular eosinophilic secretionsER and HER2 (-), S100 strongly (+)Acinic cell carcinoma: Amphophilic coarsely granular cytoplasm due to zymogen-like granulesER, AR, and HER2 (-), GCDFP-15 can be focally (+), S100(+)",
                    "sub_points": [
                      "Histiocytoid (lobular) carcinoma: Foamy, clear cytoplasm due to secretory vacuoles &/or mucinER and HER2 can be positive or negative, the majority are AR and GCDFP-15 (+)",
                      "ER and HER2 can be positive or negative, the majority are AR and GCDFP-15 (+)",
                      "Lipid-rich carcinoma: Abundant microvacuolated, foamy, or clear cytoplasm due to lipidsER and AR (-), HER2 and S100 may be (+)",
                      "ER and AR (-), HER2 and S100 may be (+)",
                      "Sebaceous carcinoma: Finely vacuolated cytoplasm due to lipidsER, AR, and HER2 may be (+), GCDFP-15(-), S100 (-)",
                      "ER, AR, and HER2 may be (+), GCDFP-15(-), S100 (-)",
                      "Oncocytic carcinoma: Abundant granular eosinophilic cytoplasm due to numerous mitochondriaAntimitochondrial antibodies are positiveER majority (+), AR ~ 1/4 (+), HER2 ~ 1/4 (+), GCDFP-15 ~ 1/3 (+)",
                      "Antimitochondrial antibodies are positive",
                      "ER majority (+), AR ~ 1/4 (+), HER2 ~ 1/4 (+), GCDFP-15 ~ 1/3 (+)",
                      "Glycogen-rich carcinoma: Clear or finely vacuolated cytoplasm due to glycogenER and HER2 may be (+), GCDFP-15(-)",
                      "ER and HER2 may be (+), GCDFP-15(-)",
                      "Secretory carcinoma: Eosinophilic cytoplasm and extracellular eosinophilic secretionsER and HER2 (-), S100 strongly (+)",
                      "ER and HER2 (-), S100 strongly (+)",
                      "Acinic cell carcinoma: Amphophilic coarsely granular cytoplasm due to zymogen-like granulesER, AR, and HER2 (-), GCDFP-15 can be focally (+), S100(+)",
                      "ER, AR, and HER2 (-), GCDFP-15 can be focally (+), S100(+)"
                    ]
                  },
                  {
                    "text": "Histologic features may overlap with apocrine carcinoma"
                  },
                  {
                    "text": "Prognosis and therapy for these types are based on standard prognostic and predictive markersThese histologic variants need to be distinguished from benign cells and nonbreast tumorsIt is not necessary to perform special tests to attempt to distinguish these special types of carcinoma",
                    "sub_points": [
                      "These histologic variants need to be distinguished from benign cells and nonbreast tumors",
                      "It is not necessary to perform special tests to attempt to distinguish these special types of carcinoma"
                    ]
                  }
                ],
                "Cutaneous Apocrine Carcinoma (Sweat Gland Carcinoma of Skin)": [
                  {
                    "text": "The breast evolved as a modified skin appendage and, therefore, shares many characteristics with skin glands"
                  },
                  {
                    "text": "Sweat gland carcinomas of skin can have the same appearance and immunoprofile as IAC"
                  },
                  {
                    "text": "Important distinguishing features are the location of the carcinoma (i.e., dermis vs. deep in breast tissue) and the presence or absence of DCISSweat gland carcinomas are much less common than IAC of breast",
                    "sub_points": [
                      "Sweat gland carcinomas are much less common than IAC of breast"
                    ]
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "IAC is recognized morphologically by the characteristic histologic appearance"
                  },
                  {
                    "text": "At this time, there is no need to perform additional studies for classification (e.g., GCDFP-15 or AR)"
                  },
                  {
                    "text": "Many TNBC that are IAC express ARClinicians may request AR testing to enroll patients on clinical trials",
                    "sub_points": [
                      "Clinicians may request AR testing to enroll patients on clinical trials"
                    ]
                  },
                  {
                    "text": "Apocrine change in benign sclerosing lesions is a close mimic of IACMyoepithelial markers should be performed in difficult cases",
                    "sub_points": [
                      "Myoepithelial markers should be performed in difficult cases"
                    ]
                  }
                ]
              },
              "REPORTING": {
                "Guidelines": [
                  {
                    "text": "Invasive carcinomas are reported according to the College of American Pathology Invasive Breast Cancer Protocol"
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Apocrine Tubular Adenoma": {
            "name": "Apocrine Tubular Adenoma",
            "url": "https://app.pathprimer.com/document/7e8ae3aa-999e-46b3-b608-cdb9b71aecaf/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
            "content": {
              "Key Facts": {
                "Clinical Issues": [
                  {
                    "text": "Scalp"
                  },
                  {
                    "text": "Nodule measuring < 2 cm"
                  }
                ],
                "Microscopic Features": [
                  {
                    "text": "Intradermal tumor"
                  },
                  {
                    "text": "Sometimes arises in association with nevus sebaceous and syringocystadenoma papilliferum"
                  },
                  {
                    "text": "Tubules of different size and shape"
                  },
                  {
                    "text": "Some cystically dilated"
                  },
                  {
                    "text": "Papillary projections devoid of fibrovascular cores"
                  },
                  {
                    "text": "Outer layer composed of myoepithelial cells"
                  },
                  {
                    "text": "Inner layer composed of apocrine cells"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Syringocystadenoma papilliferum"
                  },
                  {
                    "text": "Papillary eccrine adenoma"
                  },
                  {
                    "text": "Apocrine hamartoma"
                  },
                  {
                    "text": "Apocrine carcinoma"
                  }
                ]
              },
              "Terminology": {
                "Synonyms": [
                  {
                    "text": "Apocrine adenoma, tubulopapillary hidradenoma, papillary tubular adenoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Rare benign adnexal neoplasm with apocrine differentiation"
                  }
                ]
              },
              "Clinical Issues": {
                "Epidemiology": [],
                "Incidence": [
                  {
                    "text": "Rare tumor"
                  }
                ],
                "Age": [
                  {
                    "text": "Wide age distribution (range: 18-78 years)"
                  }
                ],
                "Gender": [
                  {
                    "text": "Female predominance (2:1)"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Scalp noduleOther locations include face, axilla, anogenital area, extremities",
                    "sub_points": [
                      "Other locations include face, axilla, anogenital area, extremities"
                    ]
                  },
                  {
                    "text": "< 2 cm in diameter"
                  }
                ],
                "Treatment": [
                  {
                    "text": "Complete excision is curative"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Excellent"
                  }
                ]
              },
              "Macroscopic Features": {
                "General Features": [
                  {
                    "text": "Well-circumscribed intradermal nodule"
                  }
                ],
                "Size": [
                  {
                    "text": "< 2 cm in diameterLarger lesions are exceptional",
                    "sub_points": [
                      "Larger lesions are exceptional"
                    ]
                  }
                ]
              },
              "Microscopic Pathology": {
                "Histologic Features": [
                  {
                    "text": "Intradermal noduleWell-circumscribedInfiltrative borders should not be seen in apocrine tubular adenomaSubcutaneous tissue may rarely be involvedRarely tumor communicates with epidermis through ducts or infundibula of hair follicles",
                    "sub_points": [
                      "Well-circumscribedInfiltrative borders should not be seen in apocrine tubular adenoma",
                      "Infiltrative borders should not be seen in apocrine tubular adenoma",
                      "Subcutaneous tissue may rarely be involved",
                      "Rarely tumor communicates with epidermis through ducts or infundibula of hair follicles"
                    ]
                  },
                  {
                    "text": "Variable-sized tubulesDouble or multilayeredSome cystically dilatedSome with papillary projectionsUsually without fibrovascular cores",
                    "sub_points": [
                      "Double or multilayered",
                      "Some cystically dilated",
                      "Some with papillary projectionsUsually without fibrovascular cores",
                      "Usually without fibrovascular cores"
                    ]
                  },
                  {
                    "text": "Peripheral (outer) layerFlattened to cuboidal myoepithelial cells",
                    "sub_points": [
                      "Flattened to cuboidal myoepithelial cells"
                    ]
                  },
                  {
                    "text": "Luminal (inner) layerLined by columnar cells with apocrine differentiationEosinophilic cytoplasmOften showing decapitation secretionRegular round to oval nucleiNuclear pleomorphism absent to minimalMitoses are very rare",
                    "sub_points": [
                      "Lined by columnar cells with apocrine differentiation",
                      "Eosinophilic cytoplasm",
                      "Often showing decapitation secretion",
                      "Regular round to oval nuclei",
                      "Nuclear pleomorphism absent to minimal",
                      "Mitoses are very rare"
                    ]
                  },
                  {
                    "text": "Eosinophilic proteinaceous material may be seen in the lumen"
                  },
                  {
                    "text": "Connective tissue stromaScattered blood vessels and few inflammatory cells",
                    "sub_points": [
                      "Scattered blood vessels and few inflammatory cells"
                    ]
                  },
                  {
                    "text": "May arise in a background of nevus sebaceousSometimes associated with syringocystadenoma papilliferum",
                    "sub_points": [
                      "Sometimes associated with syringocystadenoma papilliferum"
                    ]
                  }
                ],
                "Cytologic Features": [
                  {
                    "text": "Apocrine cells with decapitation secretion (apical snouts and secretions)"
                  }
                ]
              },
              "Ancillary Tests": {
                "Immunohistochemistry": [
                  {
                    "text": "Luminal cells are positive forEMA and CEA (surface expression)HMFG-1 and GCDFP-15",
                    "sub_points": [
                      "EMA and CEA (surface expression)",
                      "HMFG-1 and GCDFP-15"
                    ]
                  },
                  {
                    "text": "Myoepithelial cells are positive forS100 and SMA",
                    "sub_points": [
                      "S100 and SMA"
                    ]
                  }
                ]
              },
              "Differential Diagnosis": {
                "Syringocystadenoma Papilliferum": [
                  {
                    "text": "Connects to epidermis"
                  },
                  {
                    "text": "Papillae with true fibrovascular cores"
                  },
                  {
                    "text": "Dense plasma cell-rich inflammatory infiltrate"
                  },
                  {
                    "text": "Some apocrine tubular adenomas arise in association with syringocystadenoma papilliferumEspecially when arising in background of nevus sebaceous",
                    "sub_points": [
                      "Especially when arising in background of nevus sebaceous"
                    ]
                  }
                ],
                "Papillary Eccrine Adenoma": [
                  {
                    "text": "Lacks true apocrine differentiation"
                  },
                  {
                    "text": "Lacks surface decapitation"
                  },
                  {
                    "text": "Rare tumors may have mixed features of eccrine and apocrine tubular adenomasDistinction may be impossible in such cases",
                    "sub_points": [
                      "Distinction may be impossible in such cases"
                    ]
                  }
                ],
                "Apocrine Hamartoma (Apocrine Nevus)": [
                  {
                    "text": "Often affect the axilla"
                  },
                  {
                    "text": "May affect chest, neck, inguinal area"
                  },
                  {
                    "text": "Excess of normal-appearing apocrine glandsUsually located in reticular dermis",
                    "sub_points": [
                      "Usually located in reticular dermis"
                    ]
                  }
                ],
                "Apocrine Carcinoma": [
                  {
                    "text": "Infiltrative tumor"
                  },
                  {
                    "text": "Nuclear pleomorphism"
                  },
                  {
                    "text": "Numerous mitoses usually present"
                  }
                ]
              },
              "Diagnostic Checklist": {
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "2 or more cell layers with outer layer composed of myoepithelial cells"
                  },
                  {
                    "text": "Luminal cells show decapitation secretion"
                  },
                  {
                    "text": "Infiltrative pattern is not a feature of apocrine tubular adenomaShould raise suspicion for apocrine carcinoma",
                    "sub_points": [
                      "Should raise suspicion for apocrine carcinoma"
                    ]
                  }
                ]
              },
              "Selected References": {}
            }
          },
          "Squamous Cell Carcinoma": {
            "name": "Squamous Cell Carcinoma",
            "url": "https://app.pathprimer.com/document/d5f3c07d-da79-4355-9e47-9b317bed9ed2/lesson/dfc7b7c6-986b-4b46-a4ed-0e05e893d0b2",
            "content": {
              "KEY FACTS": {
                "Terminology": [
                  {
                    "text": "Squamous cell carcinoma (SCC)Malignant epithelial tumor of squamous keratinocytes",
                    "sub_points": [
                      "Malignant epithelial tumor of squamous keratinocytes"
                    ]
                  }
                ],
                "Etiology/Pathogenesis": [
                  {
                    "text": "Most cases are related to UV radiation"
                  },
                  {
                    "text": "Previous radiation therapy implicated in some cases; usually associated with more aggressive SCC"
                  }
                ],
                "Clinical Issues": [
                  {
                    "text": "Often arises in sun-damaged skin of elderly patients (usually head and neck)Vast majority of cases associated with preexisting actinic keratosis (AK)",
                    "sub_points": [
                      "Vast majority of cases associated with preexisting actinic keratosis (AK)"
                    ]
                  },
                  {
                    "text": "Complete surgical excision is optimal and definitive therapy"
                  },
                  {
                    "text": "Prognosis usually good in superficial and well-differentiated cases"
                  },
                  {
                    "text": "Worse prognosis with poorly differentiated, deeply invasive, or aggressive subtypes"
                  }
                ],
                "Microscopic": [
                  {
                    "text": "Proliferation of invasive atypical keratinocytes, often with areas of keratinization (keratin pearls) and squamous eddies"
                  },
                  {
                    "text": "Cells are present in nests, sheets, and cords"
                  },
                  {
                    "text": "Cytologically, cells show abundant eosinophilic cytoplasm and large nucleus with vesicular chromatin and prominent nucleoli"
                  },
                  {
                    "text": "Degree of differentiation is variable, ranging from well to moderately to poorly differentiated"
                  },
                  {
                    "text": "Multiple variants of differing malignant potential described"
                  }
                ],
                "Top Differential Diagnoses": [
                  {
                    "text": "Basal cell carcinoma"
                  },
                  {
                    "text": "Atypical fibroxanthoma"
                  },
                  {
                    "text": "Poorly differentiated carcinoma (Including metastatic)"
                  },
                  {
                    "text": "Pseudoepitheliomatous hyperplasia"
                  },
                  {
                    "text": "Keratoacanthoma"
                  }
                ]
              },
              "TERMINOLOGY": {
                "Abbreviations": [
                  {
                    "text": "Squamous cell carcinoma (SCC)"
                  }
                ],
                "Synonyms": [
                  {
                    "text": "Sarcomatoid carcinoma (spindle cell carcinoma/carcinosarcoma/metaplastic carcinoma)"
                  },
                  {
                    "text": "Acantholytic (adenoid/pseudoglandular) SCC"
                  },
                  {
                    "text": "Verrucous carcinoma: Well-differentiated variant"
                  },
                  {
                    "text": "Keratoacanthoma (KA): Very well-differentiated variant, regresses spontaneously"
                  },
                  {
                    "text": "Epidermoid carcinoma"
                  }
                ],
                "Definitions": [
                  {
                    "text": "Malignant tumor of squamous keratinocytes"
                  }
                ]
              },
              "ETIOLOGY/PATHOGENESIS": {
                "Environmental Exposure": [
                  {
                    "text": "Most cases are related to UV radiation"
                  },
                  {
                    "text": "Some cases are likely related to chronic inflammation (i.e., SCC arising in burns, lupus, lichen planus)"
                  },
                  {
                    "text": "Previous radiation therapy is implicated in some cases; usually associated with more aggressive SCC"
                  },
                  {
                    "text": "Chronic wounds and burn scars also can be associated with high-risk SCC"
                  },
                  {
                    "text": "Human papillomavirus is associated with some casesEspecially verrucous carcinoma (low grade) and SCC in immunosuppressed patients (high grade)",
                    "sub_points": [
                      "Especially verrucous carcinoma (low grade) and SCC in immunosuppressed patients (high grade)"
                    ]
                  }
                ]
              },
              "CLINICAL ISSUES": {
                "Epidemiology": [],
                "Age": [
                  {
                    "text": "Usually in elderly, especially solar-related lesions"
                  },
                  {
                    "text": "However, can present in wide age range (34-95 years)Rare cases in children (should prompt genetic studies)",
                    "sub_points": [
                      "Rare cases in children (should prompt genetic studies)"
                    ]
                  }
                ],
                "Sex": [
                  {
                    "text": "Slightly more common in males, overall"
                  }
                ],
                "Presentation": [
                  {
                    "text": "Slow-growing papular, nodular, or plaque lesion"
                  },
                  {
                    "text": "Often arises in sun-damaged skin (head and neck tumors)Vast majority of cases associated with preexisting actinic keratosis (AK)",
                    "sub_points": [
                      "Vast majority of cases associated with preexisting actinic keratosis (AK)"
                    ]
                  },
                  {
                    "text": "May be ulcerated or bleeding"
                  },
                  {
                    "text": "Ear canal and middle ear tumors may present with pain, hearing loss, and discharge"
                  }
                ],
                "Treatment": [],
                "Surgical approaches": [
                  {
                    "text": "Complete surgical excision is optimal and definitive therapyMohs surgery has been shown to be highly effective for most tumors",
                    "sub_points": [
                      "Mohs surgery has been shown to be highly effective for most tumors"
                    ]
                  }
                ],
                "Drugs": [
                  {
                    "text": "If patients are not surgical candidates, topical chemotherapeutics or immunomodulators may be used"
                  }
                ],
                "Radiation": [
                  {
                    "text": "May be used for very advanced cases where surgical therapy is not curative"
                  }
                ],
                "Prognosis": [
                  {
                    "text": "Usually excellent in most cases"
                  },
                  {
                    "text": "Worse prognosis with poorly differentiated, deeply invasive, or rare aggressive subtypes"
                  },
                  {
                    "text": "Site of tumor important for prognosisLip and ear tumors more aggressive, regardless of degree of differentiation",
                    "sub_points": [
                      "Lip and ear tumors more aggressive, regardless of degree of differentiation"
                    ]
                  }
                ]
              },
              "MACROSCOPIC": {
                "General Features": [
                  {
                    "text": "Papular to nodular or plaque-like lesion; can be exophyticMay be ulcerated or hemorrhagic",
                    "sub_points": [
                      "May be ulcerated or hemorrhagic"
                    ]
                  }
                ],
                "Size": [
                  {
                    "text": "Variable; can be small or large lesions"
                  }
                ]
              },
              "MICROSCOPIC": {
                "Histologic Features": [
                  {
                    "text": "Proliferation of atypical keratinocytes invading into dermisCells are present in nests, sheets, and infiltrative cordsOften show areas of keratinization (keratin pearls) and squamous eddiesAttachments to overlying epidermis in most casesAssociated AK is very common; less likely, may be associated with SCC in situ (Bowen disease)Cytologically, cells show abundant eosinophilic cytoplasm and large nucleus with vesicular chromatin and prominent nucleoliIntercellular bridges (desmosomes) should be present on high-power examinationPresence of dyskeratotic cells (apoptotic keratinocytes) is reliable sign of squamous differentiationIf no definite squamous differentiation is present, immunohistochemistry should be used to confirm diagnosis",
                    "sub_points": [
                      "Cells are present in nests, sheets, and infiltrative cords",
                      "Often show areas of keratinization (keratin pearls) and squamous eddies",
                      "Attachments to overlying epidermis in most cases",
                      "Associated AK is very common; less likely, may be associated with SCC in situ (Bowen disease)",
                      "Cytologically, cells show abundant eosinophilic cytoplasm and large nucleus with vesicular chromatin and prominent nucleoli",
                      "Intercellular bridges (desmosomes) should be present on high-power examination",
                      "Presence of dyskeratotic cells (apoptotic keratinocytes) is reliable sign of squamous differentiation",
                      "If no definite squamous differentiation is present, immunohistochemistry should be used to confirm diagnosis"
                    ]
                  },
                  {
                    "text": "Degree of differentiation is variable, ranging from well to moderately to poorly differentiatedAmount of keratinization typically decreases and cytologic atypia increases with higher gradesMitotic figures are usually numerous, and atypical forms are found, especially in moderately to poorly differentiated cases",
                    "sub_points": [
                      "Amount of keratinization typically decreases and cytologic atypia increases with higher grades",
                      "Mitotic figures are usually numerous, and atypical forms are found, especially in moderately to poorly differentiated cases"
                    ]
                  },
                  {
                    "text": "Multiple variants of differing malignant potential describedLow-risk variants include well-differentiated SCC arising in AK, KA, verrucous carcinoma, and tricholemmal (variant of clear cell) carcinomaIntermediate-risk variants include acantholytic (adenoid/pseudoglandular) and lymphoepithelioma-like carcinoma of the skinHigh-risk variants include spindle cell/sarcomatoid, basaloid, adenosquamous, and desmoplasticAlso, radiation, burn scar, and immunosuppression-related SCCsRare variants of uncertain malignant potential include clear cell SCC, signet ring cell SCC, follicular SCC, papillary SCC, pigmented SCC, and SCC arising from adnexal ducts or cysts",
                    "sub_points": [
                      "Low-risk variants include well-differentiated SCC arising in AK, KA, verrucous carcinoma, and tricholemmal (variant of clear cell) carcinoma",
                      "Intermediate-risk variants include acantholytic (adenoid/pseudoglandular) and lymphoepithelioma-like carcinoma of the skin",
                      "High-risk variants include spindle cell/sarcomatoid, basaloid, adenosquamous, and desmoplasticAlso, radiation, burn scar, and immunosuppression-related SCCs",
                      "Also, radiation, burn scar, and immunosuppression-related SCCs",
                      "Rare variants of uncertain malignant potential include clear cell SCC, signet ring cell SCC, follicular SCC, papillary SCC, pigmented SCC, and SCC arising from adnexal ducts or cysts"
                    ]
                  }
                ],
                "Predominant Pattern/Injury Type": [
                  {
                    "text": "Epithelioid/squamoid"
                  }
                ],
                "Predominant Cell/Compartment Type": [
                  {
                    "text": "Squamous cell"
                  }
                ]
              },
              "ANCILLARY TESTS": {
                "Immunohistochemistry": [
                  {
                    "text": "Not necessary in well-/moderately differentiated cases but may be needed in poorly differentiated and spindle cell cases"
                  },
                  {
                    "text": "Cytokeratins are most important markers, especially high molecular weight cytokeratins (HMWCKs)HMWCKs are most sensitive markers for poorly differentiated and spindle cell/sarcomatoid SCCPankeratin can be lost in poorly differentiated and spindle cell tumorsp63 is also very sensitive marker and can be used in addition to HMWCK to confirm diagnosis",
                    "sub_points": [
                      "HMWCKs are most sensitive markers for poorly differentiated and spindle cell/sarcomatoid SCCPankeratin can be lost in poorly differentiated and spindle cell tumors",
                      "Pankeratin can be lost in poorly differentiated and spindle cell tumors",
                      "p63 is also very sensitive marker and can be used in addition to HMWCK to confirm diagnosis"
                    ]
                  },
                  {
                    "text": "Vimentin is very nonspecific and may be positive in spindle cell/sarcomatoid cases"
                  },
                  {
                    "text": "Negative staining for other markers, includingS100, SOX10, MART-1/Melan-A, and HMB-45 (melanoma)CD10, CD68, and CD99 [atypical fibroxanthoma (AFX)]Actin-sm and desmin (leiomyosarcoma)BER-EP4, androgen receptor (AR), and D2-40 [basal cell carcinoma (BCC) and sebaceous carcinoma]",
                    "sub_points": [
                      "S100, SOX10, MART-1/Melan-A, and HMB-45 (melanoma)",
                      "CD10, CD68, and CD99 [atypical fibroxanthoma (AFX)]",
                      "Actin-sm and desmin (leiomyosarcoma)",
                      "BER-EP4, androgen receptor (AR), and D2-40 [basal cell carcinoma (BCC) and sebaceous carcinoma]"
                    ]
                  }
                ]
              },
              "DIFFERENTIAL DIAGNOSIS": {
                "Basal Cell Carcinoma": [
                  {
                    "text": "Cells are typically smaller, more hyperchromatic, and show peripheral palisading, mucinous stroma, and retraction artifact"
                  },
                  {
                    "text": "Cytokeratins do not distinguish basal cell carcinoma (BCC) from SCC, but BER-EP4 and AR are almost always positive in BCC; negative in SCC"
                  }
                ],
                "Atypical Fibroxanthoma": [
                  {
                    "text": "Usually large, nodular lesion in heavily sun-damaged skin (typically head and neck)"
                  },
                  {
                    "text": "Immunohistochemistry is essential in excluding poorly differentiated SCCSCC is typically positive for HMWCKs and p63; atypical fibroxanthoma is negative for these markers and often CD10(+) and CD99(+)",
                    "sub_points": [
                      "SCC is typically positive for HMWCKs and p63; atypical fibroxanthoma is negative for these markers and often CD10(+) and CD99(+)"
                    ]
                  }
                ],
                "Poorly Differentiated Carcinoma (Including Metastatic)": [
                  {
                    "text": "Clinical history and imaging studies are paramount, as immunohistochemistry may not be able to distinguish some cases from primary SCC"
                  },
                  {
                    "text": "Adenocarcinomas may show varying degree of ductal/glandular differentiationIf present, ductal spaces can be highlighted with markers such as EMA and CEA",
                    "sub_points": [
                      "If present, ductal spaces can be highlighted with markers such as EMA and CEA"
                    ]
                  }
                ],
                "Pseudoepitheliomatous Hyperplasia": [
                  {
                    "text": "Can mimic SCC, especially SCC in situ, but does not show infiltrative features or high-grade cytologic atypia"
                  },
                  {
                    "text": "Mitotic figures can be numerous but should be in basilar keratinocytes and not atypical"
                  }
                ],
                "Keratoacanthoma": [
                  {
                    "text": "Essentially, well-differentiated variant of SCC that spontaneously regresses in most cases"
                  },
                  {
                    "text": "Typically composed of large, crateriform (cup-like) lesion filled with abundant keratin debris"
                  },
                  {
                    "text": "Cells are enlarged, with abundant glassy-appearing/hyalinized cytoplasm"
                  },
                  {
                    "text": "Most cases regress, but giant KA and subungual KA can be aggressive; some may metastasize in immunosuppressed patients"
                  }
                ]
              },
              "DIAGNOSTIC CHECKLIST": {
                "Clinically Relevant Pathologic Features": [
                  {
                    "text": "Degree of differentiation"
                  },
                  {
                    "text": "Depth of invasionDeeply invasive tumors have much higher rates of recurrence and metastasis",
                    "sub_points": [
                      "Deeply invasive tumors have much higher rates of recurrence and metastasis"
                    ]
                  },
                  {
                    "text": "Perineural invasionTumors with perineural invasion have high rates of local recurrence and increased risk of metastasis",
                    "sub_points": [
                      "Tumors with perineural invasion have high rates of local recurrence and increased risk of metastasis"
                    ]
                  },
                  {
                    "text": "Location of tumor important (i.e., facial sites, including lip and mucosal lesions, are more aggressive)"
                  }
                ],
                "Pathologic Interpretation Pearls": [
                  {
                    "text": "Invasive proliferation of epithelioid cells, with areas of keratinization (keratin pearls) and squamous eddiesIntercellular bridges (desmosomes) and dyskeratotic cells confirm squamous differentiation in poorly differentiated cases",
                    "sub_points": [
                      "Intercellular bridges (desmosomes) and dyskeratotic cells confirm squamous differentiation in poorly differentiated cases"
                    ]
                  },
                  {
                    "text": "Adjacent or overlying AK often present in external ear cases"
                  }
                ]
              },
              "Selected References": {}
            }
          }
        }
      }
    }
  }
}